<SEC-DOCUMENT>0001193125-21-156414.txt : 20210510
<SEC-HEADER>0001193125-21-156414.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510171235
ACCESSION NUMBER:		0001193125-21-156414
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Millendo Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001544227
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451472564
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255198
		FILM NUMBER:		21908389

	BUSINESS ADDRESS:	
		STREET 1:		110 MILLER AVENUE, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		734-845-9000

	MAIL ADDRESS:	
		STREET 1:		110 MILLER AVENUE, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OvaScience, Inc.
		DATE OF NAME CHANGE:	20120308
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d150774ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on May 10, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-255198</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 2 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">45-1472564</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>incorporation&nbsp;or&nbsp;organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Classification&nbsp;Code&nbsp;Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S.&nbsp;Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Identification&nbsp;Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>110 Miller Avenue, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Ann Arbor, Michigan 48104 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(734) <FONT STYLE="white-space:nowrap">845-9000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Louis J. Arcudi III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer and Director </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>110 Miller Avenue, Suite&nbsp;100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Ann Arbor, Michigan 48104 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">(734)&nbsp;845-9000</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code,
of agent for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>Copies to:</I></B><B> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Stuart M. Falber</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Joseph B. Conahan</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>WilmerHale</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>60 State
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02109 USA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(617) 526 6000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Stephen Brady</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>President&nbsp;and&nbsp;Chief&nbsp;Operating&nbsp;Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>7000&nbsp;Shoreline Court; Suite 275</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, CA 94080</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(415)&nbsp;798-8589</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Asher Rubin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Frank Rahmani</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rob
Carlson</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Istvan A Hajdu</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Sidley Austin LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>1001 Page
Mill Road, Building 1</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA 94304 USA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">565-7000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this registration statement and the
satisfaction or waiver of all other conditions<B> </B>under the Merger Agreement described herein. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If the securities being registered on this Form are
being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box:&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If this Form is
a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth
company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Exchange Act <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman">Exchange Act <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-1(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of<BR>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount<BR>to be<BR>registered(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>maximum<BR>offering price<BR>per share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>maximum<BR>aggregate<BR>offering price(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>registration fee(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Common stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">81,249,860</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$55,464.45</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$6.06(4)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Relates to common stock, $0.001 par value per share, of Millendo Therapeutics, Inc., a Delaware corporation, or
Millendo, issuable to holders of common stock, $0.001 par value per share of Tempest Therapeutics, Inc., a Delaware corporation, or Tempest, in the proposed merger of Mars Merger Corp., a Delaware corporation and a direct, wholly owned subsidiary of
Millendo, with and into Tempest, with Tempest continuing as a wholly owned subsidiary of Millendo and the surviving corporation of the merger. The amount of Millendo common stock to be registered is based on the estimated number of shares of
Millendo common stock that are expected to be issued pursuant to the merger, without taking into account the effect of a reverse stock split of Millendo common stock, assuming a <FONT STYLE="white-space:nowrap">pre-split</FONT> exchange ratio of
approximately 0.4883 shares of Millendo common stock for each outstanding share of Tempest common stock. The estimated exchange ratio contained herein is subject to adjustment prior to the closing of the merger. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the
Securities Act of 1933, as amended. Tempest is a private company, no market exists for its securities, and Tempest has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price is
<FONT STYLE="white-space:nowrap">one-third</FONT> of the aggregate par value of the Tempest securities expected to be exchanged in the proposed merger. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Determined in accordance with Section&nbsp;6(b) of the Securities Act of 1933, as amended, at a rate equal to
$109.10 per $1,000,000 of the proposed maximum aggregate offering price. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="left">Previously paid. </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this proxy statement/prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>SUBJECT TO COMPLETION, DATED MAY 10, 2021 </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em" ALIGN="center">


<IMG SRC="g150774g02o42.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g150774g31c55.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSED MERGER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS VERY IMPORTANT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">To the Stockholders of
Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Millendo Therapeutics, Inc., a Delaware corporation, or Millendo, and
Tempest Therapeutics, Inc., a Delaware corporation, or Tempest, entered into an Agreement and Plan of Merger, or the Merger Agreement, on March&nbsp;29, 2021, pursuant to which a direct, wholly owned subsidiary of Millendo, Mars Merger Corp., or
Merger Sub, will merge with and into Tempest, with Tempest surviving as a wholly owned subsidiary of Millendo, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The surviving corporation following
the merger is referred to herein as the combined company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Immediately prior to the effective time of the merger each share of
Tempest&#146;s preferred stock will be converted into shares of Tempest&#146;s common stock and at the effective time of the merger each share of Tempest&#146;s common stock, including those shares of common stock issued upon conversion of the
preferred stock, will be converted into the right to receive a number of shares of Millendo common stock equal to the exchange ratio described in more detail in the section titled &#147;<I>The Merger Agreement&#151;Exchange Ratio</I>&#148; beginning
on page&nbsp;141 of the accompanying proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">In connection with the merger, each outstanding and unexercised
option to purchase shares of Tempest common stock that, following assumption by Millendo at the effective time, will be eligible to be registered on a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8,</FONT> will be assumed
by Millendo and will be converted into an option to purchase shares of Millendo&#146;s common stock, with necessary adjustments to reflect the exchange ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Each share of Millendo common stock and option to purchase Millendo common stock that is issued and outstanding at the effective time of the
merger will remain issued and outstanding and such shares will be unaffected by the merger. Immediately after the merger, Millendo securityholders as of immediately prior to the merger are expected to own approximately 18.5% of the outstanding
shares of the combined company and former Tempest securityholders, including shares purchased in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing are expected to own approximately 81.5% of the outstanding shares of the
combined company, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest
raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing described in the accompanying proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Shares of Millendo common stock are currently listed on The Nasdaq Capital Market under the symbol &#147;MLND.&#148; Millendo has filed an
initial listing application for the combined company with The Nasdaq Stock Market Inc., or Nasdaq. After completion of the merger, Millendo will be renamed &#147;Tempest Therapeutics, Inc.&#148; and it is expected that the common stock of the
combined company will trade on The Nasdaq Capital Market under the symbol &#147;TPST.&#148; On May 7, 2021, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Millendo common stock was
$1.09 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is conditioned upon the
satisfaction or waiver of the conditions to the closing of the merger as well as certain other conditions. The Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is more fully described in the accompanying proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Millendo stockholders are cordially invited to attend the special meeting of Millendo stockholders. Millendo is
holding its special meeting of stockholders, or the Millendo special meeting, on June 22, 2021, at 11:00 a.m. Eastern </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">
Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the merger and related matters. The Millendo special meeting will be held
entirely online. Millendo stockholders will be able to attend and participate in the Millendo special meeting online by visiting www.virtualshareholdermeeting.com/MLND2021SM where they will be able to listen to the meeting live, submit questions and
vote. At the Millendo special meeting, Millendo will ask its stockholders to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Approve the issuance of shares of common stock of Millendo to stockholders of Tempest, pursuant to the terms
of the Merger Agreement, a copy of which is attached as <I>Annex A</I> to the accompanying proxy statement/prospectus, and the change of control resulting from the merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Approve an amendment to the amended and restated certificate of incorporation of Millendo to effect a reverse
stock split of Millendo&#146;s issued and outstanding common stock within a range, as determined by the Millendo board of directors and agreed to by Tempest, of one new share of Millendo common stock for every 10 to 15 shares (or any number in
between) of outstanding Millendo common stock in the form attached as <I>Annex F</I> to the accompanying proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Approve, on a nonbinding, advisory basis, the compensation that will or may become payable by Millendo to its
named executive officers in connection with the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Consider and vote upon an adjournment of the Millendo special meeting, if necessary, to solicit additional
proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Transact such other business as may properly come before the stockholders at the Millendo special meeting or
any adjournment or postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">As described in the accompanying proxy statement/prospectus, certain Millendo
stockholders who in the aggregate owned approximately 16% of the outstanding shares of Millendo as of March&nbsp;31, 2021, and certain Tempest stockholders who in the aggregate owned approximately 87.4% of the outstanding shares of Tempest capital
stock as of March&nbsp;31, 2021, are parties to stockholder support agreements with Millendo and Tempest, respectively, whereby such stockholders have agreed to vote in favor of the approval of the transactions contemplated therein, including, with
respect to Tempest stockholders, adoption of the Merger Agreement and approval of the merger and, with respect to such Millendo stockholders, the issuance of Millendo common stock in the merger pursuant to the Merger Agreement, subject to the terms
of the support agreements. Following the effectiveness of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement,
Tempest stockholders holding a sufficient number of shares of Tempest capital stock to adopt the Merger Agreement and approve the merger and related transactions will execute written consents providing for such adoption and approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">After careful consideration, each of the Millendo and Tempest boards of directors have approved the Merger Agreement and have determined that
it is advisable to consummate the merger. Millendo&#146;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#147;FOR&#148; the proposals
described in the accompanying proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>More
information about Millendo, Tempest, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. Millendo urges you to read the accompanying proxy
statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#147;<A HREF="#toc150774_18">RISK FACTORS</A>&#148; BEGINNING ON PAGE 17 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:9pt; font-family:Times New Roman">Millendo and Tempest are excited about the opportunities the merger brings to Millendo&#146;s and Tempest&#146;s stockholders and
thank you for your consideration and continued support. Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center">Louis J. Arcudi III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Tom Dubensky, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center"><I>Chief Executive Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>Chief Executive Officer</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" ALIGN="center">Millendo Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Tempest Therapeutics, Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">The accompanying proxy statement/prospectus is
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and is first being mailed to Millendo stockholders on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MILLENDO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>110 Miller Avenue, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ann Arbor, Michigan 48104 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(734) <FONT STYLE="white-space:nowrap">845-9000</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders of Millendo Therapeutics, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE
IS HEREBY GIVEN </B>that a virtual special meeting of stockholders, or the Millendo special meeting, will be held on June&nbsp;22, 2021, at 11:00 a.m. Eastern Time, unless postponed or adjourned to a later date. The Millendo special meeting will be
held entirely online. You will be able to attend and participate in the Millendo special meeting online by visiting www.virtualshareholdermeeting.com/MLND2021SM where you will be able to listen to the meeting live, submit questions and vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Millendo special meeting will be held for the following purposes: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the issuance of shares of common stock of Millendo Therapeutics, Inc., or Millendo, to stockholders
of Tempest Therapeutics, Inc., or Tempest, pursuant to the terms of the Agreement and Plan of Merger among Millendo, Tempest and Mars Merger Corp., or Merger Sub, dated as of March&nbsp;29, 2021, a copy of which is attached as <I>Annex A </I>to the
accompanying proxy statement/prospectus, which is referred to in this Notice as the Merger Agreement, and the change of control resulting from the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the restated certificate of incorporation of Millendo, as amended, to effect a
reverse stock split of Millendo&#146;s issued and outstanding common stock within a range, as determined by the Millendo board of directors and agreed to by Tempest, of one new share of Millendo common stock for every 10 to 15 shares (or any number
in between) of outstanding Millendo common stock in the form attached as <I>Annex F </I>to the accompanying proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on a nonbinding, advisory basis, the compensation that will or may become payable by Millendo to
its named executive officers in connection with the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon an adjournment of the Millendo special meeting, if necessary, to solicit additional
proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the stockholders at the Millendo special meeting or
any adjournment or postponement thereof. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Record Date:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Millendo&#146;s board of directors has fixed May&nbsp;7, 2021 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Millendo special meeting and any adjournment or postponement thereof.
Only holders of record of shares of Millendo common stock at the close of business on the record date are entitled to notice of, and to vote at, the Millendo special meeting. At the close of business on the record date, Millendo had
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding and entitled to vote.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Your vote is important. The affirmative vote of the holders of a majority of shares present in attendance
or represented by proxy at the Millendo special meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal Nos. 1, 3 and 4. The affirmative vote of the holders of a majority of the outstanding
shares of Millendo common stock entitled to vote at the Millendo special meeting is required for approval of Proposal No.&nbsp;2. Approval of each of Proposal No.&nbsp;1, referred to as the merger proposal, and Proposal No.&nbsp;2, referred to as
the reverse stock split proposal, is a condition to the completion of the merger. Therefore, the merger cannot be consummated without the approval of Proposal Nos.&nbsp;1 and 2. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Even if you plan to virtually attend the Millendo special meeting, Millendo requests that you sign and return the enclosed proxy or vote by
mail or online to ensure that your shares will be represented at the </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
Millendo special meeting if you are unable to virtually attend. You may change or revoke your proxy at any time before it is voted at the Millendo special meeting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>MILLENDO&#146;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS
OF, AND ADVISABLE TO MILLENDO AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. MILLENDO&#146;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT MILLENDO STOCKHOLDERS VOTE &#147;FOR&#148; EACH SUCH PROPOSAL. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the
Availability of Proxy Materials for the Stockholders&#146; Meeting to</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Be Held on June 22</B>, <B>2021 at 11:00 a.m. Eastern Time via
the internet</B><B></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The proxy statement/prospectus and annual report to stockholders are available at
www.virtualshareholdermeeting.com/MLND2021SM</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of Millendo&#146;s Board of Directors, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Louis J. Arcudi III </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>Ann Arbor, Michigan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REFERENCES TO ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus incorporates important business and financial information about Millendo Therapeutics, Inc. that is not
included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission website (<I>www.sec.gov</I>) or upon your written or oral request by contacting the Corporate Secretary of
Millendo Therapeutics, Inc., 110 Miller Avenue, Suite&nbsp;100 Ann Arbor, Michigan 48104, by calling (734) <FONT STYLE="white-space:nowrap">845-9000</FONT> or via email to IR@Millendo.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>To ensure timely delivery of these documents, any request should be made no later than June&nbsp;11, 2021 to receive them before the
Millendo special meeting. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details about where you can find information about Millendo, please see the section
titled &#147;<I>Where You Can Find More Information</I>&#148; beginning on page&nbsp;321 of this proxy statement/prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_1">QUESTIONS AND ANSWERS ABOUT THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_3">The Companies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_4">The Merger (see page 105)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_5">Reasons for the Merger (see pages 114 and 117)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_6">Opinion of Millendo&#146;s Financial Advisor (see page 119)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_7">Interests of Certain Directors, Officers and Affiliates of Millendo and Tempest
 (see pages 125 and 131)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_8">Management Following the Merger (see page 283)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_9">Overview of the Merger Agreement and Agreements Related to the Merger Agreement
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_10">Material U.S. Federal Income Tax Consequences of the Merger (see page
133)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_11">Nasdaq Stock Market Listing (see page 136)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_12">Anticipated Accounting Treatment (see page 136)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_13">Appraisal Rights and Dissenters&#146; Rights (see page 136)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_14">Comparison of Stockholder Rights (see page 306)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_15">Risk Factors (see page 17)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_16">MARKET PRICE AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_17">Dividends</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_18">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_19">Risks Related to the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_20">Risks Related to the Proposed Reverse Stock Split</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_21">Risks Related to the Combined Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_21a">Risks Related to Millendo</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_22">Risks Related to Tempest</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_23">Risks Related to Tempest&#146;s Financial Position</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_24">Risks Related to Tempest&#146;s Product Development and Regulatory Approval
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_25">Risks Related to Commercialization and Manufacturing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_26">Risks Related to Government Regulation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_27">Risks Related to Tempest&#146;s Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_28">Risks Related to Employee Matters, Managing Growth and Other Risks Related to
Tempest&#146;s Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_29">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_30">THE SPECIAL MEETING OF MILLENDO STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_31">Date, Time and Place</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_32">Purposes of the Millendo Special Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_33">Recommendation of Millendo&#146;s Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_34">Record Date and Voting Power</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_35">Voting and Revocation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_36">Required Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_37">Solicitation of Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_38">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_39">THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_40">Background of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_41">Millendo Reasons for the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_42">Tempest Reasons for the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_43">Opinion of Millendo&#146;s Financial Advisor</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_45">Interests of Millendo Directors and Executive Officers in the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_46">Interests of Tempest Directors and Executive Officers in the
Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_47">Effective Time of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_48">Regulatory Approvals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_49">Material U.S. Federal Income Tax Consequences of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_50">Anticipated Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_51">Nasdaq Stock Market Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_52">Appraisal Rights and Dissenters&#146; Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_53">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_54">Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_55">Completion and Effectiveness of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_56">Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_57">Exchange Ratio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_58">Calculation of Millendo&#146;s Final Net Cash</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_59">Treatment of Tempest Options</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_60">Treatment of Millendo Common Stock and Millendo Options</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_61">Procedures for Exchanging Tempest Stock Certificates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_62">Directors and Officers of Millendo Following the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_63">Amendment of the Amended and Restated Certificate of Incorporation of Millendo
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_64">Representations and Warranties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_65">Covenants; Conduct of Business Pending the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_66"><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_67">Board Recommendation Change</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_68">Meeting of Millendo&#146;s Stockholders and Written Consent of Tempest&#146;s
 Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_69">Indemnification and Insurance for Directors and Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_70">Additional Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_71">Conditions to the Completion of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_72">Termination and Termination Fees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_73">Amendment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_74">Fees and Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_75">AGREEMENTS RELATED TO THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_76">Support Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_77"><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_78">Funding Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_79">MILLENDO DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_80">MILLENDO EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_81">TEMPEST EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_82">MATTERS BEING SUBMITTED TO A VOTE OF MILLENDO STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_84">PROPOSAL NO. 1: APPROVAL OF THE ISSUANCE OF COMMON STOCK IN THE MERGER AND THE
CHANGE OF CONTROL RESULTING FROM THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_86">PROPOSAL NO. 2: APPROVAL OF THE AMENDMENT TO AMENDED AND RESTATED CERTIFICATE
 OF INCORPORATION OF MILLENDO TO EFFECT THE REVERSE STOCK&nbsp;SPLIT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_87">PROPOSAL NO. 3: ADVISORY, NON-BINDING VOTE ON MERGER-RELATED EXECUTIVE COMPENSATION
 ARRANGEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_88">PROPOSAL NO. 4</A>: APPROVAL OF POSSIBLE ADJOURNMENT OF THE SPECIAL
MEETING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_89">MILLENDO&#146;S BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_90">TEMPEST&#146;S BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_91">MILLENDO MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
 RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_92">MANAGEMENT FOLLOWING THE MERGER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_93">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_94">Tempest Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><A HREF="#toc150774_95">Promissory Note with Tom Dubensky</A></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><A HREF="#toc150774_96">Equity Grants to Executive Officers and Directors</A></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><A HREF="#toc150774_97">Director and Executive Officer Compensation</A></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><A HREF="#toc150774_98">Employment Agreements</A></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><A HREF="#toc150774_99">Indemnification Agreements</A></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_100">Millendo Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_101">PRINCIPAL STOCKHOLDERS OF MILLENDO</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_102">PRINCIPAL STOCKHOLDERS OF TEMPEST</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_103">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_104">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_105">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_106">TRADEMARK NOTICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_107">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_108">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_110">Stockholder Proposals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_111">Householding of Proxy Statement/Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_112a">INDEX TO MILLENDO CONSOLIDATED FINANCIAL STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_112">INDEX TO TEMPEST FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_113">PART II INFORMATION NOT REQUIRED IN PROXY
STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_114">Item 20. <I>Indemnification of Directors and Officers</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_115">Item 21. <I>Exhibits and Financial Statement Schedules</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">II-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc150774_116">Item 22. <I>Undertakings</I></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">II-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_201"><B>Annex A</B>&#151;Agreement and Plan of Merger</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_202"><B>Annex B</B>&#151;Opinion of SVB Leerink LLC</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_203"><B>Annex C</B>&#151;Form of Millendo Stockholder Support Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_204"><B>Annex D</B>&#151;Form of Tempest Stockholder Support Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_205"><B>Annex E</B>&#151;Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_206"><B>Annex F</B>&#151;Certificate of Amendment for the Reverse Stock Split</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><A HREF="#toc150774_207"><B>Annex G</B>&#151;Appraisal Rights (Section&nbsp;262 of the Delaware General Corporation Law)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_1"></A>QUESTIONS AND ANSWERS ABOUT THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not
give effect to the proposed reverse stock split described in Proposal No.</I><I></I><I>&nbsp;2 of this proxy statement/prospectus</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following section provides answers to frequently asked questions about the merger. This section, however, provides only summary
information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo Therapeutics, Inc., or Millendo, and Tempest Therapeutics, Inc., or Tempest, have entered into an
Agreement and Plan of Merger, or the Merger Agreement, dated as of March&nbsp;29, 2021, a copy of which is attached as <I>Annex A </I>to this proxy statement/prospectus<I>. </I>The Merger Agreement contains the terms and conditions of the proposed
business combination of Millendo and Tempest. Pursuant to the Merger Agreement, Mars Merger Corp., or Merger Sub, a direct, wholly owned subsidiary of Millendo, will merge with and into Tempest, with Tempest surviving as a wholly owned subsidiary of
Millendo. This transaction is referred to in this proxy statement/prospectus as the merger. After the completion of the merger, Millendo will change its corporate name to &#147;Tempest Therapeutics, Inc.&#148; Millendo following the merger is
referred to herein as the combined company. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the merger each share of
Tempest preferred stock will be converted into shares of Tempest common stock and at the effective time of the merger each share of Tempest&#146;s common stock will be converted into the right to receive a number of shares of Millendo common stock
equal to the exchange ratio described in more detail in the section titled &#147;<I>The Merger</I> <I>Agreement&#151;Exchange Ratio</I>&#148; beginning on page&nbsp;141 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, each outstanding and unexercised option to purchase shares of Tempest common stock will be assumed by Millendo
and will be converted into an option to purchase shares of Millendo&#146;s common stock, with necessary adjustments to reflect the exchange ratio. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each share of Millendo common stock and option to purchase Millendo common stock that is issued and outstanding at the effective time of the
merger will remain issued and outstanding and such shares will be unaffected by the merger. Immediately after the merger, Millendo securityholders as of immediately prior to the merger are expected to own approximately 18.5% of the outstanding
shares of the combined company and former Tempest securityholders, including shares purchased in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, are expected to own approximately 81.5% of the outstanding shares of the
combined company, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest
raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why are the two companies proposing to merge? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo and Tempest believe that combining the two companies will result in a company with a robust pipeline,
strong leadership team and substantial capital resources, positioning it to become a leading company researching, developing and commercializing therapies for cancer. For a more complete description of the reasons for the merger, please see the
sections titled &#147;<I>The Merger&#151;Millendo Reasons for the</I> <I>Merger</I>&#148; and &#147;<I>The Merger&#151;Tempest Reasons for the Merger</I>&#148; beginning on pages 114 and 117, respectively, of this proxy statement/prospectus.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why am I receiving this proxy statement/prospectus? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Millendo
as of the record date, and you are entitled to vote at the Millendo special meeting to approve the matters set forth herein. This document serves as: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>a proxy statement of Millendo used to solicit proxies for the Millendo special meeting to vote on the
matters set forth herein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>a prospectus of Millendo used to offer shares of Millendo common stock in exchange for shares of Tempest
common stock and preferred stock in the merger. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On March&nbsp;29, 2021, immediately prior to the execution and delivery of the Merger Agreement, Tempest
entered into Funding Agreements with certain investors, pursuant to which the investors agreed to purchase shares of Tempest&#146;s common stock for a per share purchase price of $0.85 and an aggregate purchase price of approximately
$30.0&nbsp;million. The closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger as well as certain other conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What proposals will be voted on at the Millendo special meeting the approval of which are conditions to the
closing of the merger? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite
stockholder vote at the Millendo special meeting in order for the merger to close: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Proposal No.&nbsp;1 to approve the issuance of shares of Millendo common stock to Tempest stockholders
pursuant to the Merger Agreement and the change of control resulting from the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Proposal No.&nbsp;2 to approve an amendment to the amended and restated certificate of incorporation of
Millendo to effect a reverse stock split of Millendo&#146;s issued and outstanding common stock within a range, as determined by the Millendo board of directors and agreed to by Tempest, of one new share of Millendo common stock for every 10 to 15
shares (or any number in between) of outstanding Millendo common stock, which is referred to herein as the reverse stock split, in the form attached as <I>Annex</I><I></I>&nbsp;F to this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Proposal No.&nbsp;1 is referred to herein as the merger proposal. Proposal No.&nbsp;2 is referred to herein as the reverse stock split
proposal. The approval of the merger proposal and the reverse stock split proposal is a condition to completion of the merger. The issuance of Millendo common stock in connection with the merger and the change of control resulting from the merger,
or Proposal No.&nbsp;1, and the amendment to the restated certificate of incorporation of Millendo to effect a reverse stock split of Millendo&#146;s issued and outstanding common stock, or Proposal No.&nbsp;2, will not take place unless approved by
Millendo stockholders and the merger is consummated. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the requirement of obtaining Millendo stockholder approval, each
of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#147;<I>The Merger
Agreement&#151;Conditions to the Completion of the Merger</I>&#148; beginning on page&nbsp;154 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The presence, by accessing online or being represented by proxy, at the Millendo special meeting of the holders of a majority of the shares of
Millendo common stock outstanding and entitled to vote at the Millendo special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the merger proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What proposals are to be voted on at the Millendo special meeting, other than the merger proposal and the
reverse stock split proposal? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Millendo special meeting, the holders of Millendo common stock will also be asked to consider the
following proposals: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Proposal No.&nbsp;3 to approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote
basis, compensation that will or may become payable by Millendo to its named executive officers in connection with the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Proposal No.&nbsp;4 to approve an adjournment of the Millendo special meeting, if necessary, to solicit
additional proxies if there are not sufficient votes in favor of Proposal Nos.&nbsp;1 and 2. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The approval of Proposal
Nos.&nbsp;3 and 4 are not a condition to the merger. Such proposals, together with the merger proposal and the reverse stock split proposal, are referred to collectively in this proxy statement/prospectus as the proposals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The presence, by accessing online or being represented by proxy, at the Millendo special meeting of the holders of a majority of the shares of
Millendo common stock outstanding and entitled to vote at the Millendo special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the proposals. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What stockholder votes are required to approve the proposals at the Millendo special meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The affirmative vote of the holders of a majority of shares present in attendance or represented by proxy at
the Millendo special meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal Nos. 1, 3 and 4. The affirmative vote of the holders of a majority of the outstanding shares of Millendo common stock
entitled to vote at the Millendo special meeting is required for approval of Proposal No.&nbsp;2. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Votes will be counted
by the inspector of election appointed for the meeting, who will separately count &#147;FOR&#148; and &#147;AGAINST&#148; votes, abstentions and any broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the special meeting. Abstentions will be counted towards the vote totals for
each proposal, and will have the same effect as &#147;AGAINST&#148; votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on Proposal Nos.&nbsp;1, 3 and 4, and will have the same effect as &#147;AGAINST&#148; votes for
Proposal No.&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the directors and certain executive officers of Millendo owned or controlled less than 1%
of the outstanding shares of Millendo common stock entitled to vote at the Millendo special meeting. As of March 31, 2021, the Millendo stockholders that are party to support agreements, including the directors and certain executive officers of
Millendo, owned an aggregate of 2,962,292 shares of Millendo common stock representing approximately 16% of the outstanding shares of Millendo common stock. Pursuant to the support agreements, these stockholders, including the directors and certain
executive officers of Millendo, have agreed to vote all shares of Millendo common stock owned by them as of the record date in favor of Proposal Nos.&nbsp;1 and 2. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will Tempest stockholders and optionholders receive in the merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tempest stockholders will receive shares of Millendo common stock, and Tempest optionholders will receive
options to purchase Millendo common stock. Applying the exchange ratio, the former Tempest securityholders immediately before the merger, including shares purchased in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, are
expected to own approximately 81.5% of the aggregate number of shares of the combined company&#146;s common stock following the merger and Millendo securityholders immediately before the merger are expected to own approximately 18.5% of the
aggregate number of shares of the combined company common stock following the merger, in each case subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30,
2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, each outstanding and unexercised option to purchase shares of
Tempest common stock will be converted into an option to purchase Millendo common stock, with the number of shares and exercise price being appropriately adjusted to reflect the exchange ratio between Millendo common stock and Tempest common stock
determined in accordance with the Merger Agreement. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of what Tempest stockholders and optionholders
will receive in the merger, please see the sections titled &#147;<I>The</I> <I>Merger Agreement&#151;Merger Consideration</I>&#148;<I> </I>and &#147;<I>The Merger Agreement&#151;Exchange Ratio</I>&#148; beginning on pages&nbsp;140 and 141,
respectively, of this<I> </I>proxy statement/prospectus. For a description of the effect of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing on Millendo&#146;s and Tempest&#146;s current securityholders, please see the
section titled &#147;<I>Agreements Related to the Merger&#151;Funding Agreements</I> &#147; beginning on page&nbsp;163 of this proxy statement/prospectus. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will the common stock of the combined company trade on an exchange? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of Millendo common stock are currently listed on The Nasdaq Capital Market under the symbol
&#147;MLND.&#148; Millendo has filed an initial listing application for the combined company with Nasdaq. After completion of the merger, Millendo will be renamed &#147;Tempest Therapeutics, Inc.&#148; and it is expected that the common stock of the
combined company will trade on The Nasdaq Capital Market under the symbol &#147;TPST.&#148; On May 7, 2021, the last trading day before the date of this proxy statement/prospectus, the closing sale price of Millendo common stock was $1.09 per share.
</P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will be the directors of the combined company following the merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately following the merger, the combined company&#146;s board of directors will be composed of seven
(7)&nbsp;members, consisting of (i)&nbsp;one director appointed by Millendo, namely Geoff Nichol, and (ii)&nbsp;six directors appointed by Tempest, namely Stephen Brady (who is Tempest&#146;s President and Chief Operating Officer and will serve as
Chief Executive Officer of the combined company), Mike Raab, Thomas Dubensky, Tom Woiwode, and Stella Xu, with one vacancy. The staggered structure of the Millendo board of directors will remain in place for the combined company following the
completion of the merger. </P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will be the executive officers of the combined company immediately following the merger?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately following the merger, the executive management team of the combined company is expected to consist
of members of the Tempest executive management team prior to the merger, including: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>As a Millendo stockholder, how does Millendo&#146;s board of directors recommend that I vote?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After careful consideration, Millendo&#146;s board of directors unanimously recommends that Millendo
stockholders vote &#147;FOR&#148; all of the proposals. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What risks should I consider in deciding whether to vote in favor of the merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You should carefully review the section titled &#147;<I>Risk Factors</I>&#148; beginning on page 17 of this
proxy statement/prospectus and the annexes attached hereto, which set forth certain risks and uncertainties related to the merger, risks and uncertainties to which the combined company&#146;s business will be subject, and risks and uncertainties to
which each of Millendo and Tempest, as independent companies, are subject. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When do you expect the merger to be consummated? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The merger is anticipated to close promptly after the Millendo special meeting scheduled to be held on
June&nbsp;22, 2021, but the exact timing cannot be predicted. For more information, please see the section titled &#147;<I>The Merger Agreement&#151;Conditions to the Completion of the Merger</I>&#148; beginning on page 154 of this proxy
statement/prospectus. </P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo urges you to read this proxy statement/prospectus carefully, including the annexes attached hereto,
and to consider how the merger affects you. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a Millendo stockholder of record, you may provide your proxy
instructions in one of four different ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You can attend the Millendo special meeting online and vote online during the special meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You can mail your signed proxy card in the enclosed return envelope. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You can provide your proxy instructions via telephone by following the instructions on your proxy card.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You can provide your proxy instructions via the internet by following the instructions on your proxy card.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Your signed proxy card, telephonic proxy instructions, or internet proxy instructions must be received by June&nbsp;21,
2021, 11:59&nbsp;p.m. Eastern Time to be counted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares in &#147;street name&#148; (as described below), you may provide
your proxy instructions via telephone or the internet by following the instructions on your vote instruction form. Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy instruction, and as soon as
possible so that your shares can be voted at the Millendo special meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a Millendo stockholder, the failure to return your proxy card or otherwise vote or provide proxy
instructions will reduce the aggregate number of votes required to approve Proposal Nos. 1, 3 and 4 and will have the same effect as a vote &#147;AGAINST&#148; Proposal No.&nbsp;2. Also, your shares will not be counted for purposes of determining
whether a quorum is present at the Millendo special meeting unless your broker has discretionary authority to vote on certain matters. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I attend the Millendo special meeting and vote in person? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In light of the <FONT STYLE="white-space:nowrap">coronavirus/COVID-19</FONT> outbreak and governmental decrees
that <FONT STYLE="white-space:nowrap">in-person</FONT> gatherings be postponed or cancelled, and in the best interests of public health and the health and safety of Millendo&#146;s board of directors and stockholders, the Millendo special meeting
will be held entirely<B> </B>online. Stockholders of record as of May&nbsp;7, 2021 will be able to attend and participate in the Millendo special meeting online by accessing www.virtualshareholdermeeting.com/MLND2021SM. To join the Millendo special
meeting, you will need to have your <FONT STYLE="white-space:nowrap">16-digit</FONT> control number which is included on your Notice of Internet Availability of Proxy Materials and your proxy card. If your shares are held in &#147;street name,&#148;
you should contact your bank, broker or other nominee to obtain your 16-digit control number or otherwise vote through your bank, broker or other nominee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who counts the votes? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Broadridge Financial Solutions, Inc., or Broadridge, will be engaged as Millendo&#146;s independent agent to
tabulate stockholder votes, which Millendo refers to as the inspector of election. If you are a stockholder of record, your executed proxy card is returned directly to Broadridge for tabulation. If you hold your shares through a broker, your broker
returns one proxy card to Broadridge on behalf of all its clients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If my Millendo shares are held in &#147;street name&#148; by my broker, will my broker vote my shares for
me? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless your broker has discretionary authority to vote on certain matters, your broker will not be able to vote
your shares of Millendo common stock on matters requiring discretionary authority without instructions from you. If you do not give instructions to your broker, your broker can vote your Millendo shares with respect to &#147;discretionary,&#148;
routine items but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-discretionary,&#148;</FONT> <FONT STYLE="white-space:nowrap">non-routine</FONT> items. Discretionary items are proposals considered routine under Rule 452 of the New
York Stock Exchange on which your broker may vote shares held in &#147;street name&#148; in the absence of your voting instructions. With respect to <FONT STYLE="white-space:nowrap">non-routine</FONT> items for which you do not give your broker
instructions, your Millendo shares will be treated as broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Proposal Nos. 1, 3 and 4 at the Millendo special meeting will be <FONT STYLE="white-space:nowrap">non-routine.</FONT> It is anticipated
that Proposal No.&nbsp;2 will be routine. To make sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by your broker. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and do they count for determining a
quorum? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Generally, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when shares held by a broker in
&#147;street name&#148; for a beneficial owner are not voted with respect to a particular proposal because the broker (i)&nbsp;has not received voting instructions from the beneficial owner or (ii)&nbsp;lacks discretionary voting power to vote those
shares. A broker is entitled<B> </B>to vote shares held for a beneficial owner on routine matters without instructions from the beneficial owner of those shares. On the other hand, absent instructions from the beneficial owner of such shares, a
broker is not entitled to vote shares held for a beneficial owner on <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for the purpose of determining the presence of a
quorum for the transaction of business at the Millendo special meeting. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not be treated as votes cast for or against a proposal and accordingly will not have any effect with respect to the
outcome of Proposal Nos.&nbsp;1, 3 and 4, and will have the same effect as &#147;AGAINST&#148; votes for Proposal No.&nbsp;2. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I change my vote after I have submitted a proxy or provided proxy instructions?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo stockholders of record, unless such stockholder&#146;s vote is subject to a support agreement, may
change their vote at any time before their proxy is voted at the Millendo special meeting in one of four ways: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You may submit another properly completed proxy with a later date by mail or via the internet.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You can provide your proxy instructions via telephone at a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You may send a written notice that you are revoking your proxy to Millendo&#146;s Corporate Secretary at
110 Miller Avenue, Suite&nbsp;100 Ann Arbor, Michigan 48104. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>You may attend the Millendo special meeting online and vote by following the instructions at
www.virtualshareholdermeeting.com/MLND2021SM. Simply attending the Millendo special meeting will not, by itself, revoke your proxy. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Your signed proxy card, telephonic proxy instructions, internet proxy instructions, or written notice must be received by June&nbsp;21, 2021,
11:59&nbsp;p.m. Eastern Time to be counted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a Millendo stockholder who owns Millendo shares in &#147;street name&#148; has instructed a
broker to vote its shares of Millendo common stock, the stockholder must follow directions received from its broker to change those instructions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who is paying for this proxy solicitation? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo and Tempest will share equally the cost of printing and filing of this proxy statement/prospectus and
the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and fiduciaries who are record holders of Millendo common stock for the forwarding of solicitation materials to the beneficial owners of Millendo common stock. Millendo will reimburse these
brokers, custodians, nominees and fiduciaries for the reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses they incur in connection with the forwarding of solicitation materials. Millendo
will retain Broadridge to assist it in soliciting proxies using the means referred to above. Millendo will pay the fees of Broadridge, which Millendo expects to be approximately $35 thousand, plus reimbursement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the material U.S. federal income tax consequences of the merger to United States holders of Tempest
capital stock? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo and Tempest intend the merger to qualify as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). Assuming the merger constitutes a reorganization, subject to the limitations and qualifications described in the section titled &#147;<I>The
Merger&#151;Material U.S.</I><I></I><I>&nbsp;Federal</I> <I>Income Tax Consequences of the Merger</I>,&#148; holders of Tempest capital stock will not recognize gain or loss for U.S.&nbsp;federal income tax purposes on<I> </I>the receipt of shares
of Millendo common stock issued in connection with the merger, except with respect to cash received in lieu of a fractional share of Millendo common stock. For a more detailed discussion of the material U.S.&nbsp;federal income tax consequences of
the merger, see &#147;<I>The Merger&#151;Material U.S.</I><I></I><I>&nbsp;Federal Income Tax Consequences of the Merger</I>&#148; beginning on page&nbsp;133. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a Millendo stockholder and would like additional copies of this proxy statement/prospectus without
charge or if you have questions about the merger, including the procedures for voting your shares, you should contact: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Millendo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110
Miller Avenue, Suite&nbsp;100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ann Arbor, Michigan 48104, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (734) <FONT STYLE="white-space:nowrap">845-9000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email:
IR@Millendo.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">x </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is
important to you. To better understand the merger and the proposals being considered at the Millendo special meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you
are referred in this proxy statement/prospectus. For more information, please see the section titled </I>&#147;<I>Where You Can Find More Information</I>&#148;<I> beginning on page</I><I></I>&nbsp;<I>321</I><I> of this proxy statement/prospectus.
Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.</I><I></I><I>&nbsp;2 of this proxy
statement/prospectus.</I> </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_3"></A>The Companies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">110
Miller Avenue, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ann Arbor, Michigan 48104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (734) <FONT STYLE="white-space:nowrap">845-9000</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is a biopharmaceutical company that was previously primarily focused on developing novel treatments for endocrine diseases where
current therapies do not exist or are insufficient. The endocrine system is a collection of glands that secrete hormones into the blood stream to regulate a number of functions, including appetite, metabolism, growth, development and reproduction.
Diseases of the endocrine system can cause multiple and varied symptoms, including appetite dysregulation, metabolic dysfunction, obesity, cardiovascular disease, menstrual irregularity, hirsutism, and infertility. In April 2020, Millendo&#146;s
board of directors decided to discontinue the development of livoletide, an unacylated ghrelin analogue, as a potential treatment for Prader-Willi syndrome (&#147;PWS&#148;) based upon results from its Phase 2b trial. In addition, in June 2020, the
Millendo board of directors decided to cease investing in the development of nevanimibe as a potential treatment for classic congenital adrenal hyperplasia, (&#147;CAH&#148;) based on an interim review of data from its Phase 2b trial. Finally, in
January 2021, the Millendo board of directors also decided to discontinue the investment in <FONT STYLE="white-space:nowrap">MLE-301,</FONT> a neurokinin 3 receptor (&#147;NK3R&#148;) antagonist Millendo was developing for the treatment of
menopausal vasomotor symptoms (&#147;VMS&#148;), based on an analysis of the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose portion of the Phase 1 study conducted in healthy male volunteers. Given Millendo&#146;s
limited expected financing options, it began exploring an expanded range of strategic alternatives that included, but was not limited to, the potential sale or merger of Millendo or its assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to streamline costs after discontinuing the PWS program, Millendo eliminated employee positions representing approximately 30% of
its prior headcount, which was completed in the second quarter of 2020. Millendo also began evaluating corporate strategic plans to prioritize and allocate resources to its remaining product candidates at the time and any future pipeline assets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, as a result of Millendo&#146;s decision to discontinue the investment in
<FONT STYLE="white-space:nowrap">MLE-301,</FONT> the Millendo board of directors also approved a corporate restructuring plan (the &#147;Plan&#148;) furthering Millendo&#146;s ongoing efforts to align its resources with its current strategy and
operations. In connection with the Plan, the Millendo board of directors determined to reduce Millendo&#146;s workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April&nbsp;15, 2021. Millendo initiated
this reduction in force in January 2021 and expects to provide severance payments and continuation of group health insurance coverage for a specified period to the affected employees. Millendo has also entered into retention arrangements with
employees who are expected to remain with the Millendo. Millendo estimates that it will incur costs of approximately $5.5&nbsp;million for termination benefits and retention arrangements related to the Plan, substantially all of which will be cash
expenditures. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, Millendo undertook a strategic review process, which was intended to result in an
actionable plan that leverages its assets, capital and capabilities to maximize stockholder value. Following an extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or
other transaction, on March&nbsp;29, 2021, Millendo entered into the Merger Agreement with Tempest, under which the privately held Tempest will merge with a wholly owned subsidiary of Millendo. If the merger is completed, the business of Tempest
will continue as the business of the combined organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7000 Shoreline Court, Suite 275, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">South San Francisco, California 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (415) 798-8689 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is a clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer biology and medicinal chemistry
to develop and advance novel orally available therapies for the treatment of solid tumors. Tempest&#146;s philosophy is to build a company based upon not only good ideas and creative science, but also upon the efficient translation of those ideas
into therapies that will improve patient&#146;s lives. To this end, Tempest is advancing TPST-1495 and TPST-1120, two product candidates in clinical trials that it believes are the first clinical stage molecules designed to treat their respective
targets; and a third program in preclinical studies that could be the first to target <FONT STYLE="white-space:nowrap">TREX-1,</FONT> a key cellular enzyme that regulates the innate immune response in tumors. TPST-1495 is a dual antagonist of EP2
and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. Tempest&#146;s second program, TPST-1120, is a selective antagonist of peroxisome proliferator-activated receptor alpha, or PPAR&#945;, and is also in a
Phase 1 trial in solid tumors. Tempest expects to report initial data from both these programs in the second half of 2021. Additionally, Tempest is advancing a third program targeting the three prime repair exonuclease, or <FONT
STYLE="white-space:nowrap">TREX-1,</FONT> for which Tempest expects to select a development candidate by the end of 2021. Beyond these three ongoing programs, Tempest plans to leverage its drug development and company-building experience along with
academic relationships to identify promising new targets that may feed new programs into Tempest&#146;s pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has developed a
diversified pipeline of small molecule product candidates that are designed to target tumor cells directly, modulate the immune system to kill cancer cells, or a combination of both, in each case that Tempest believes are innovative and target
scientifically validated pathways. Tempest selected targets that are expressed in a diverse set of tumor types, with the intention to address unmet medical needs or improve existing standards of care. Tempest&#146;s product development programs
consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g14u85.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Definitions: </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; CCA: cholangiocarcinoma; CRC: colorectal cancer; FPI: First Patient In; RP2D: Recommended Phase 2
Dose; DC: Development Candidate; ORR: Objective Response Rate. Note that the primary anti-tumor activity readout is ORR by RECIST v. 1.1 criteria, and time on study treatment; additional endpoints include duration of response and progression free
survival, which may be reported at a later timepoint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>Timing is an estimate based on current
projections; <SUP STYLE="font-size:85%; vertical-align:top">2</SUP>Tempest is evaluating whether the first Phase 2 study will be in CRC and/or multiple solid tumors; if multiple histologies, Tempest may elect to open individual studies; <SUP
STYLE="font-size:85%; vertical-align:top">3</SUP>Pursuant to a collaboration with Roche; TPST retains all product rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s
first product candidate is TPST-1495, a novel, oral, small molecule designed to be a dual antagonist of only two of the four prostaglandin E2 (PGE2) receptors, EP2 and EP4, sparing the homologous but differentially active EP1 and EP3 receptors. PGE2
is well understood from the scientific literature to be an important stimulator of tumor growth in diverse cancer types of high need, and to be inhibitory to anti-tumor immune function in the tumor microenvironment. PGE2 signaling through EP2 and
EP4 has been observed both to enhance tumor progression and promote immune suppression. Tempest conducted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical studies comparing TPST-1495 to single
antagonists of EP4 being developed by other companies. Tempest observed in these studies significantly enhanced activity of TPST-1495 in both overcoming PGE2 mediated suppression of human immune cells in vitro as well as significantly increased
anti-tumor activity in mouse models of human colorectal cancer as compared to single antagonists of EP4. Tempest is currently evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and possible anti-tumor activity of
TPST-1495 in a multicenter Phase 1a/1b dose and schedule optimization study in subjects with advanced solid tumors, with a focus on tumor types such as colorectal cancer, or CRC, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or
NSCLC and urothelial, or bladder, cancer, which are all known to be prostaglandin-driven. Tempest is observing dose-proportional exposure, and Tempest is encouraged by early signs of activity of TPST-1495 monotherapy, as shown by <FONT
STYLE="white-space:nowrap">on-target</FONT> pharmacodynamic changes, disease control, and reduction of tumor-specific biomarkers in the ongoing dose optimization clinical study. The TPST-1495 Phase 1 clinical trial is ongoing in the schedule and
dose optimization stage and Tempest expects to establish the RP2D for expansion and the preliminary safety profile and ORR in second half of 2021. Tempest also expects to initiate monotherapy combination studies with an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> immune check point inhibitor, prior to the end of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s second product candidate is TPST-1120, an oral, small molecule designed to be a selective antagonist of PPAR&#945; and is the
first PPAR&#945; antagonist in the clinic. PPAR&#945; is a key transcription factor controlling fatty acid oxidation, or FAO. It is clear from the scientific literature that FAO can serve as a source of energy for tumor cell growth and that the
PPAR&#945; transcriptome is upregulated in many tumor types. It also is published that FAO is a preferred energy source for <FONT STYLE="white-space:nowrap">so-called</FONT> immune suppressor cells such as regulatory
<FONT STYLE="white-space:nowrap">T-cells</FONT> (Treg), myeloid derived suppressor cells, or MDSCs, and M2 macrophages. Tempest&#146;s preclinical data suggest that TPST-1120 can directly kill tumor cells that are dependent upon FAO, alter the tumor
microenvironment immune cell infiltrate away from suppressor immune phenotype, and synergize with immune checkpoint inhibitor therapy in animal models. Tempest is evaluating TPST-1120 in a Phase 1a/b clinical study that has both monotherapy and
combination therapy arms in patients with advanced solid tumors that Tempest&#146;s PPAR&#945;-dependent transcriptome analysis of diverse human cancers revealed favor the usage of FAO. Tempest has been observing dose-dependent exposure and <FONT
STYLE="white-space:nowrap">on-target</FONT> pharmacodynamic changes in both monotherapy and combination TPST-1120 therapy arms. The monotherapy dose escalation phase of the clinical study has been completed, and Tempest observed clinical benefit in
10 of 20 of patients enrolled in this arm in the form of disease stabilization. Three patients with advanced cholangiocarcinoma experienced prolonged stable disease (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>21 weeks) and some reduction of tumor
burden, although not to the extent of a RECIST response. In the TPST-1120 combination arm with nivolumab, Tempest observed a deep RECIST response at eight weeks with 54% </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
overall tumor burden reduction in a fourth-line patient with advanced kidney cancer, which was confirmed in a second on-study assessment at 16 weeks. Tempest is encouraged by this response as a
signal of TPST-1120 clinical activity, as the patient did not have a RECIST response and progressed from prior front-line ipilimumab and nivolumab and two subsequent targeted therapies. Tempest recently announced a clinical collaboration with <FONT
STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd., or Roche, to accelerate the development of TPST-1120 into a frontline, randomized study. Pursuant to the terms of Tempest&#146;s collaboration, Roche will evaluate TPST-1120 in a global
randomized phase 1b/2 clinical study in combination with the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic
hepatocellular carcinoma, or HCC, not previously treated with systemic therapy. The study will include at least 40 and up to 60 patients who will receive the TPST-1120 combination and will be compared to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> atezolizumab and bevacizumab regimen with primary objectives of anti-tumor activity and safety. Under the terms of the collaboration agreement, Roche will manage the study operations for this
global multicenter trial. Tempest will retain global development and commercialization rights to TPST-1120. Tempest expects the first patient in the frontline HCC study to be enrolled in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and for ORR
results of the TPST-1120 Phase 1a/1b dose finding trials to be available prior to the end of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has a third program in its
pipeline against <FONT STYLE="white-space:nowrap">TREX-1,</FONT> a target Tempest believes may be an effective approach to systemically modulate STING, which stands for <B>ST</B>imulator of <B>IN</B>terferon <B>G</B>enes, and is the focus of
clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs at multiple pharmaceutical and biotechnology companies. <FONT STYLE="white-space:nowrap">TREX-1</FONT> is a double-stranded DNA exonuclease that is designed to control
activation of the cGAS/STING pathway, which is an innate immune response pathway that induces the production of <FONT STYLE="white-space:nowrap">IFN-&szlig;,</FONT> a cytokine that is well-established to trigger the development of anti-tumor
immunity. The expression of <FONT STYLE="white-space:nowrap">TREX-1</FONT> is enhanced in tumors and inhibits activation of cGAS/STING to evade immune recognition. Because STING is expressed ubiquitously, but
<FONT STYLE="white-space:nowrap">TREX-1</FONT> expression is increased in tumors, Tempest believes that <FONT STYLE="white-space:nowrap">TREX-1</FONT> may be the optimal approach to target STING with an orally available small molecule inhibitor to
selectively activate this pathway in tumors. Tempest expects to select a TREX1 inhibitor development candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mars Merger Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">110 Miller
Avenue, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ann Arbor, Michigan 48104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (734) <FONT STYLE="white-space:nowrap">845-9000</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Sub is a direct, wholly owned subsidiary of Millendo and was formed solely for the purpose of carrying out the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_4"></A><B>The Merger </B>(see page&nbsp;105) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed Merger Sub will merge with and into Tempest, with Tempest surviving the merger as a wholly owned subsidiary of
Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, at the closing of the merger, (a)&nbsp;each then outstanding share
of Tempest common stock (including shares of Tempest common stock issued upon conversion of Tempest preferred stock and shares of Tempest common stock issued in the <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing transaction described
below) will be converted into the right to receive a number of shares of Millendo common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a reverse stock split of Millendo common stock described below)
calculated in accordance with the exchange ratio set forth in the Merger Agreement; and (b)&nbsp;each then outstanding Tempest stock option and warrant to purchase Tempest common stock will be assumed by Millendo, subject to adjustment as set forth
in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the exchange ratio formula in the Merger Agreement, upon the closing of the merger, on a pro forma basis
and based upon the number of shares of Millendo common stock expected to be issued in the merger, </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">pre-merger</FONT> Millendo shareholders will own approximately 18.5% of the combined company and <FONT STYLE="white-space:nowrap">pre-merger</FONT> Tempest
stockholders (including holders of Tempest common stock issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing) will own approximately 81.5% of the combined company (assuming the financing transaction described below
results in gross proceeds of approximately $30 million). For purposes of calculating the exchange ratio, shares of Millendo common stock underlying Millendo stock options outstanding as of immediately prior to the closing of the merger with an
exercise price of less than $5.00 per share will be deemed to be outstanding and all shares of Tempest common stock underlying outstanding Tempest stock options, warrants and other derivative securities will be deemed to be outstanding. The exchange
ratio will be adjusted to the extent that Millendo&#146;s net cash at the earlier of the closing and June&nbsp;30, 2021 is less than $15.3&nbsp;million or greater than $18.7&nbsp;million and to the extent the proceeds of the financing transaction
described below exceed $25&nbsp;million, as further described in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Millendo common stock issued and
outstanding at the time of the merger will remain issued and outstanding and such shares will be appropriately adjusted to reflect the proposed reverse stock split. In addition, each option to purchase shares of Millendo common stock that is
outstanding immediately prior to the effective time of the merger, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms. The number of shares of Millendo common stock underlying such options, and
the exercise prices for such stock options will be appropriately adjusted to reflect the proposed reverse stock split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more
complete description of the merger and the exchange ratio please see the section titled &#147;<I>The Merger Agreement</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be completed as promptly as practicable after all of the conditions to completion of the merger are satisfied or waived,
including the adoption of the Merger Agreement by the Tempest stockholders and the approval by the Millendo stockholders of the issuance of Millendo common stock and the reverse stock split. Millendo and Tempest are working to complete the merger as
quickly as practicable. The merger is anticipated to close promptly after the Millendo special meeting scheduled to be held on June 22, 2021. However, Millendo and Tempest cannot predict the exact timing of the completion of the merger because it is
subject to the satisfaction of various conditions. After completion of the merger, assuming that Millendo receives the required stockholder approval, Millendo will be renamed &#147;Tempest Therapeutics, Inc.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_5"></A><B>Reasons for the Merger</B> (see pages&nbsp;114 and 117) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After consideration and consultation with its senior management and its financial and legal advisors, the Millendo board of directors
unanimously&nbsp;determined that the Merger Agreement, the merger and other transactions contemplated thereby are advisable and in the best interests of Millendo and its stockholders. The Millendo board of directors considered various reasons to
reach its determination. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial condition and prospects of Millendo and the risks associated with continuing to operate Millendo on
a stand-alone basis, particularly in light of Millendo&#146;s January 2021 decision to discontinue development of <FONT STYLE="white-space:nowrap">MLE-301</FONT> and reduce its workforce; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the Millendo board of directors and its financial advisor undertook a comprehensive and thorough process of
reviewing and analyzing potential strategic alternatives and merger partner candidates to identify the opportunity that would, in the Millendo board of directors&#146; view, create the most value for Millendo stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors&#146; belief, after a thorough review of strategic alternatives and discussions
with Millendo&#146;s senior management, financial advisors and legal counsel, that the Merger is more favorable to Millendo Stockholders than the potential value that might have resulted from other strategic alternatives available to Millendo,
including a liquidation of Millendo and the distribution of any available cash; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors&#146; belief that, as a result of arm&#146;s length negotiations with Tempest,
Millendo and its representatives negotiated the highest exchange ratio to which Tempest was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Millendo in the aggregate to which Tempest was willing
to agree; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic
transaction with Millendo based on the scientific, technical and other due diligence conducted by Millendo management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Millendo stockholders to participate in the growth and value creation of the combined company
following the closing of the Merger by virtue of their continued ownership of Millendo Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors&#146; view that the combined company will be led by an experienced senior
management team from Tempest and a board of directors with representation from each of the current boards of directors of Millendo and Tempest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tempest board of directors has unanimously approved the Merger Agreement, the merger and the transactions contemplated thereby. The
Tempest board of directors reviewed several factors in reaching its decision and believes that the Merger Agreement, the merger and the transactions contemplated thereby are in the best interests of Tempest and its stockholders. Several factors
considered by the Tempest board of directors included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger will provide Tempest&#146;s current stockholders with greater liquidity by owning publicly-traded
stock, and expanding both the access to capital for Tempest and the range of investors potentially available as a public company, compared to the investors Tempest could otherwise gain access to if it continued to operate as a privately-held
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief of the Tempest board of directors that this transaction provides a viable alternate public listing
strategy, and addresses the risk of the lack of an available market for an initial public offering at a later date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected cash resources of the combined organization (including the ability to support the combined
company&#146;s current and planned clinical trials and operations). </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information, please see the
section titled &#147;<I>The Merger&#151;Tempest Reasons for the Merger</I>&#148; beginning on page&nbsp;
117 of this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_6"></A><B>Opinion of Millendo</B><B>&#146;</B><B>s Financial Advisor</B> (see page&nbsp;119)
</P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo retained SVB Leerink LLC (&#147;SVB Leerink&#148;) as its financial advisor in connection with the merger and the other
transactions contemplated by the Merger Agreement. The Millendo board selected SVB Leerink to act as Millendo&#146;s financial advisor based on SVB Leerink&#146;s qualifications, reputation, experience and expertise in the biopharmaceuticals
industry, its knowledge of and involvement in recent transactions in the biopharmaceutical industry, and its relationship and familiarity with Millendo and its business. SVB Leerink is an internationally recognized investment banking firm that has
substantial experience in transactions similar to this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this engagement, Millendo requested that SVB
Leerink evaluate the fairness, from a financial point of view, to Millendo of the exchange ratio to be paid by Millendo pursuant to the terms of the Merger Agreement. On March&nbsp;28, 2021, at a meeting of the Millendo board, SVB Leerink rendered
to the Millendo board its oral opinion, which was subsequently confirmed by delivery of a written opinion dated March&nbsp;28, 2021, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and
limitations upon the review undertaken by SVB Leerink in preparing its opinion, the exchange ratio to be paid by Millendo pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Millendo. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of SVB Leerink&#146;s written opinion, which describes the assumptions made,
and the qualifications and limitations upon the review undertaken by SVB Leerink in preparing its opinion, is attached to this proxy statement/prospectus as <I>Annex B </I>and is incorporated by reference in its entirety to this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SVB Leerink&#146;s financial advisory services and opinion were provided for the information and assistance of
the members of the Millendo board (in their capacity as directors and not in any other capacity) in connection with and for purposes of the Millendo board&#146;s consideration of the merger and the other transactions contemplated by the Merger
Agreement and SVB Leerink&#146;s opinion addressed only the fairness, from a financial point of view, as of the date thereof, to Millendo of the exchange ratio to be paid by Millendo pursuant to the terms of the Merger Agreement. SVB Leerink&#146;s
opinion did not address any other term or aspect of the Merger Agreement or the transactions contemplated thereby and does not constitute a recommendation to any stockholder of Millendo as to whether or how such holder should vote with respect to
the merger or otherwise act with respect to the merger or the other transactions contemplated by the Merger Agreement or any other matter. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of SVB Leerink&#146;s written opinion should be read carefully in its entirety for a description of the assumptions made and
limitations upon the review undertaken by SVB Leerink in preparing its opinion. </B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_7"></A><B>Interests of Certain Directors,
Officers and Affiliates of Millendo and Tempest </B>(see pages&nbsp;125 and 131) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Millendo
board of directors with respect to issuing shares of Millendo common stock in the merger and the other matters to be acted upon by the Millendo stockholders at the Millendo special meeting, Millendo stockholders should be aware that Millendo&#146;s
directors and executive officers have interests in the merger that are different from, or in addition to, the interests of Millendo&#146;s stockholders generally. Interests of the directors and executive officers may be different from or in addition
to the interests of the stockholders for the following reasons, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Geoff Nichol from the Millendo board of directors will continue as a director of the combined company after the
effective time of the merger, and, following the closing of the merger, will be eligible to be compensated as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of Tempest pursuant to the Millendo non-employee director compensation
policy that is expected to remain in place following the effective time of the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the Merger Agreement, Millendo&#146;s directors and executive officers are entitled to continued
indemnification, expense advancement and insurance coverage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the merger, Millendo&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director
options (for directors other than Dr.&nbsp;Owens) were amended to provide that any unvested options will vest in full upon the closing of the merger and to provide that all option grants they hold will be exercisable for the shorter of (i) 18 months
after the closing or (ii)&nbsp;the original duration of the option&#146;s term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The options held by each of Mr.&nbsp;Arcudi and <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> are
expected to accelerate in connection with the closing. Mr.&nbsp;Arcudi&#146;s and <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary&#146;s</FONT> May&nbsp;25, 2020 and February&nbsp;26, 2021 options provide for exercise up to 18 months after the
closing of a change in control. Dr.&nbsp;Owen&#146;s May&nbsp;25, 2020 and March&nbsp;17, 2021 provide for full vesting upon a change of control and would be exercisable for 18&nbsp;months after the closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interests are discussed in more detail in the section titled &#147;<I>The Merger&#151;Interests of Millendo Directors and Executive
Officers in the</I> <I>Merger</I>&#148; beginning on page&nbsp;125 of this proxy statement/prospectus. The members of Millendo&#146;s board of directors were aware of and considered these<I> </I>interests, among other matters, in evaluating and
negotiating the Merger Agreement and the merger, and in recommending to the stockholders that the merger proposal be approved. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Millendo&#146;s executive officers and each of Millendo&#146;s directors has
also entered into a support agreement and a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in connection with the merger. For a more detailed discussion of the support agreements and <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, please see the sections titled &#147;<I>Agreements Related to the Merger&#151;Support Agreements</I>&#148; and &#147;<I>Agreements Related to the <FONT STYLE="white-space:nowrap">Merger&#151;Lock-Up</FONT> Agreements</I>&#148; beginning
on page&nbsp;162 and page&nbsp;163, respectively, of this proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the
Tempest board of directors with respect to approving the merger and related transactions, Tempest stockholders should be aware that certain members of the Tempest board of directors and certain executive officers of Tempest have interests in the
merger that may be different from, or in addition to, interests they have as Tempest stockholders. For example, Tempest&#146;s executive officers have options, subject to vesting, to purchase shares of Tempest common stock, which will convert into
options to purchase a number of shares of Millendo common stock determined by the exchange ratio, rounding any resulting fractional shares down to the nearest whole share, certain of Tempest&#146;s directors and executive officers are expected to
become directors and executive officers of the combined company upon the closing and all of Tempest&#146;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger
Agreement. These interests are discussed in more detail in the section titled &#147;<I>The Merger&#151;Interests of Tempest Directors and Executive</I> <I>Officers in the Merger</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_8"></A><B>Management Following the Merger </B>(see page&nbsp;283) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the closing of the merger, the combined company&#146;s executive officers are expected to be members of the Tempest executive
management team prior to the merger, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Title</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_9"></A><B>Overview of the Merger Agreement and Agreements Related to the Merger Agreement</B> <B><I>
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger Consideration </I></B>(see page&nbsp;140) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger, upon the terms and subject to the conditions set forth in the Merger Agreement each outstanding share of
Tempest common stock (after giving effect to the conversion of all shares of Tempest preferred stock, but excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into
the right to receive a number of shares of Millendo common stock equal to the exchange ratio described in more detail below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the merger, Millendo securityholders as of immediately prior to the merger are expected to own approximately 18.5% of the
outstanding shares of Millendo common stock on a fully-diluted basis, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being between
$15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. For information on the impact of the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, please see the section titled &#147;<I>Agreements</I> <I>Related to the Merger&#151;Funding Agreements</I>&#148; beginning on page&nbsp;163 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Tempest Options </I></B>(see page&nbsp;143) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each option to purchase shares of Tempest common stock that is outstanding and unexercised immediately
prior to the effective time of the merger, whether or not vested, will be converted into a number of options to purchase shares of Millendo common stock to be determined by the exchange ratio, on the same terms and conditions as were applicable
under such Tempest option immediately </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the ffective time of the merger. Millendo will assume Tempest&#146;s stock option plans and other stock or equity-related plans and each such outstanding option to purchase shares of
Tempest common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the effective time of the merger: (i)&nbsp;each outstanding Tempest stock option assumed by Millendo
may be exercised solely for shares of Millendo common stock; (ii)&nbsp;the number of shares of Millendo common stock subject to each outstanding Tempest stock option assumed by Millendo will be determined by multiplying (A)&nbsp;the number of shares
of Tempest common stock that were subject to such Tempest stock option, as in effect immediately prior to the effective time of the merger, by (B)&nbsp;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares
of Millendo common stock; (iii)&nbsp;the per share exercise price of Millendo common stock issuable upon exercise of each Tempest stock option assumed by Millendo will be determined by dividing (A)&nbsp;the per share exercise price of Tempest common
stock subject to such Tempest stock option, as in effect immediately prior to the effective time of the merger, by (B)&nbsp;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv)&nbsp;any restriction on
the exercise, and any provision providing for the acceleration of vesting and/or exercisability, of any Tempest stock option assumed by Millendo will continue in full force and effect and the term, exercisability, vesting schedule, acceleration
rights and other provisions of such Tempest stock option will otherwise remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, to the extent provided under the terms
of a Tempest stock option assumed by Millendo in accordance with the terms of the Merger Agreement, such Tempest stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division
or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Millendo common stock subsequent to the effective time of the merger.
In addition, the Millendo board of directors or a committee thereof will succeed to the authority and responsibility of the Tempest board of directors or any committee thereof with respect to each Tempest option assumed by Millendo in accordance
with the terms of the Merger Agreement. Furthermore, in the case of each Tempest option assumed by Millendo in accordance with the Merger Agreement that is subject to &#147;double-trigger&#148; accelerated vesting, for purposes of such
double-trigger acceleration provisions a &#147;Change of Control&#148; (or term of similar import) of Tempest will refer to a &#147;Change of Control&#148; (or term of similar import) of Millendo following the effective time of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Millendo Common Stock and Millendo Options </I></B>(see page&nbsp;144) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Millendo common stock issued and outstanding at the time of the merger will remain issued and outstanding. In addition, each
option to purchase shares of Millendo common stock that is outstanding immediately prior to the effective time of the merger, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms, except that the
Merger Agreement permits the board of directors of Millendo to accelerate such Millendo options in full, immediately prior to the effective time of the merger. The number of shares of Millendo common stock underlying such options and the exercise
prices for such stock options will be appropriately adjusted to reflect the proposed reverse stock split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo and Tempest have
agreed that the merger constitutes or will be deemed to constitute a &#147;change of control&#148; or &#147;change in control&#148; for purposes of the Millendo stock plans and any awards issued thereunder and for purposes of any employee benefit
plan maintained for current or former employees or directors of or independent contractors to Millendo. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conditions to the Completion of the
Merger </I></B>(see page&nbsp;154) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To complete the merger, Millendo stockholders must approve Proposal No.&nbsp;1 and Tempest
stockholders must adopt the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived (including the closing of the transactions contemplated by the funding agreements). </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> </I></B>(see page&nbsp;150) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains <FONT STYLE="white-space:nowrap">&#147;non-solicitation&#148;</FONT> provisions, pursuant to which, subject to
specified exceptions, each of Millendo and Tempest has agreed that neither it nor its subsidiaries will, and each of Millendo and Tempest will use reasonable best efforts to cause its respective directors, officers, members, employees, agents,
attorneys, consultants, contractors, accountants, financial advisors or other representatives not to, directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>solicit, seek or initiate or knowingly take any action to facilitate or encourage any offers, inquiries or
the making of any proposal or offer that constitutes, or could reasonable be expected to lead to, any Acquisition Proposal (as defined in the section of this proxy statement/prospectus entitled &#147;<I>The Merger</I> <I><FONT
STYLE="white-space:nowrap">Agreement&#151;Non-Solicitation</FONT></I>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>enter into, continue or otherwise participate or engage in any discussions or negotiations regarding any
Acquisition Proposal, or furnish to any person any <FONT STYLE="white-space:nowrap">non-public</FONT> information or afford any person other than Millendo or Tempest, as applicable, access to such party&#146;s property, books or records (except
pursuant to a request by a governmental entity) in connection with any offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, any Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>take any action to make the provisions of any takeover statute inapplicable to any transactions
contemplated by an Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>publicly propose to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Recommendation Change </I></B>(see page&nbsp;151) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to specified exceptions described in the Merger Agreement, Millendo agreed that its board of directors may not take any of the
following actions, each of which are referred to in this proxy statement/prospectus as a Millendo board recommendation change: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>withhold, withdraw or modify (or publicly propose to withhold, withdraw or modify) the approval or
recommendation of the Millendo board of directors with respect to the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>fail to recommend against acceptance of a tender offer within ten business days after commencement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>publicly propose to adopt, approve or recommend any Acquisition Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to specified exceptions described in the Merger Agreement, Tempest agreed that its board of directors may not take any of the
following actions, each of which are referred to in this proxy statement/prospectus as a Tempest board recommendation change: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>withhold, withdraw or modify (or publicly propose to withhold, withdraw or modify) the approval or
recommendation of the Tempest board of directors with respect to the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>fail to recommend against acceptance of a tender offer within ten business days after commencement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>publicly propose to adopt, approve or recommend any Acquisition Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of the Merger Agreement </I></B>(see page&nbsp;158) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Either Millendo or Tempest may terminate the Merger Agreement under certain circumstances, which would prevent the merger from being
consummated. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination Fee </I></B>(see page&nbsp;158) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated under specified circumstances, Millendo will be required to pay Tempest a termination fee of
$1.4&nbsp;million and up to $1.0&nbsp;million in expense reimbursements. If the Merger Agreement is terminated under specified circumstances, Tempest will be required to pay Millendo a termination fee of $2.8&nbsp;million and up to $1.0&nbsp;million
in expense reimbursements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Support Agreements </I></B>(see page&nbsp;162) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce Millendo to enter into the Merger Agreement, certain Tempest stockholders are parties to support agreements with Millendo
pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Tempest stockholder, to vote all of his, her or its shares of Tempest capital stock in favor of the adoption of the Merger Agreement.
These Tempest stockholders also agreed to vote against any competing Acquisition Proposal with respect to Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31,
2021, the Tempest stockholders that are party to a support agreement with Millendo owned an aggregate of 114,604,717 shares of Tempest capital stock, representing approximately 87.4% of the outstanding shares of Tempest capital stock on an as
converted to common stock basis. These stockholders include executive officers and directors of Tempest, as well as certain other stockholders owning a significant portion of the outstanding shares of Tempest capital stock. Following the
effectiveness of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, Tempest stockholders holding a sufficient number of shares
of Tempest capital stock to adopt the Merger Agreement and approve the merger and related transactions will execute written consents providing for such adoption and approval. Therefore, holders of a sufficient number of shares of Tempest capital
stock required to adopt the Merger Agreement and approve the merger and related transactions are contractually obligated to adopt the Merger Agreement are expected to adopt the Merger Agreement via written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to induce Tempest to enter into the Merger Agreement, certain Millendo stockholders have entered into support agreements
with Tempest pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Millendo stockholder, to vote all of his, her or its shares of Millendo common stock in favor of the share issuance and the
reverse stock split. These Millendo stockholders also agreed to vote against any competing Acquisition Proposal with respect to Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the Millendo stockholders that are party to a support agreement owned an aggregate of 2,962,292 shares of Millendo
common stock representing approximately 16% of the outstanding shares of Millendo common stock. These stockholders include certain executive officers and directors of Millendo and certain other Millendo stockholders holding a significant portion of
the outstanding shares of Millendo common stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </I></B>(see page&nbsp;163) </P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Tempest&#146;s executive officers, directors and stockholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, any shares of Millendo&#146;s common stock (other than the shares obtained in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing), until 180&nbsp;days after the effective time of
the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tempest stockholders who have executed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as of March&nbsp;29,
2021 owned, in the aggregate, approximately 87.4% of the shares of Tempest&#146;s outstanding capital stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Agreements </I></B>(see page&nbsp;163) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the execution and delivery of the Merger Agreement, certain investors entered into funding agreements with Tempest, or the
Funding Agreements, pursuant to which such investors have agreed to purchase certain shares of Tempest common stock (representing an aggregate commitment of $30.0 million) in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing,
immediately prior to the closing of the merger. The merger is conditioned upon the closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing in an amount of at least $25&nbsp;million. The shares of Tempest common stock
that are issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing will be converted into shares of Millendo common stock in the merger. Accordingly, by approving Proposal No.&nbsp;1 relating to the merger, Millendo
stockholders will also be approving the issuance of shares of Millendo common stock to be issued in exchange for all shares of Tempest common stock that are sold in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is subject to certain conditions, including the
satisfaction or waiver of each of the conditions to the consummation of the merger set forth in the Merger Agreement (other than those conditions which, by their nature, are to be satisfied at the closing of the merger pursuant to the Merger
Agreement, and the condition regarding the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_10"></A><B>Material U.S.</B><B></B><B>&nbsp;Federal Income Tax Consequences of the Merger </B>(see page&nbsp;133) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in detail in the section titled &#147;<I>The Merger&#151;Material U.S.</I><I></I><I>&nbsp;Federal Income Tax Consequences of the
Merger</I>,&#148; Millendo and Tempest intend the merger to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. In general, and subject to the qualifications and limitations set forth in the section titled
&#147;<I>The Merger&#151;Material U.S.</I><I></I><I>&nbsp;Federal Income Tax Consequences of the Merger</I>,&#148; if the merger qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, the material
U.S.&nbsp;federal income tax consequences to a U.S.&nbsp;holder of Tempest capital stock will be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>such Tempest stockholder will not recognize gain or loss upon the exchange of Tempest capital stock for
Millendo common stock pursuant to the merger, except with respect to cash received in lieu of a fractional share of Millendo common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>such Tempest stockholder&#146;s aggregate tax basis for the shares of Millendo common stock received in
the merger will equal the stockholder&#146;s aggregate tax basis in the shares of Tempest capital stock surrendered in the merger reduced by the basis allocable to any fractional share of Millendo common stock for which cash is received; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>the holding period of the shares of Millendo common stock received by such Tempest stockholder in the
merger will include the holding period of the shares of Tempest capital stock surrendered in exchange therefor. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
merger does not qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, then each U.S.&nbsp;holder of Tempest capital stock would recognize gain or loss on the exchange of Tempest shares for Millendo common
stock in the merger equal to the difference between such Tempest stockholder&#146;s adjusted tax basis in the shares of Tempest capital stock surrendered and the fair market value of the shares of Millendo common stock received in exchange therefor.
Determining the actual tax consequences of the merger to you may be complex and will depend on the facts of your own situation. You should consult your tax advisors to fully understand the tax consequences to you of the merger, including estate,
gift, state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the merger. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_11"></A><B>Nasdaq Stock
Market Listing </B>(see page&nbsp;136) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has filed an initial listing application for the combined company common stock with
Nasdaq. If such application is accepted, Millendo anticipates that the common stock of the combined company will be listed on The Nasdaq Capital Market following the closing of the merger under the trading symbol &#147;TPST.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_12"></A><B>Anticipated Accounting Treatment </B>(see page&nbsp;136) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles, or GAAP. Under
this method of accounting, Tempest will be deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the merger: (i)&nbsp;Tempest stockholders will
own substantial majority of the voting rights; (ii)&nbsp;Tempest will designate a majority (six of seven) of the initial members of the board of directors of the combined company; and (iii)&nbsp;Tempest&#146;s executive management team will become
the management of the combined company; and (iv)&nbsp;the combined company will be named Tempest Therapeutics, Inc. and be headquartered in South San Francisco, California. Accordingly, for accounting purposes, the merger will be treated as the
equivalent of Tempest issuing stock to acquire the net assets of Millendo. As a result of the merger, the net assets of Millendo will be recorded at their acquisition-date fair value in the financial statements of Tempest and the reported operating
results prior to the merger will be those of Tempest. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_13"></A><B>Appraisal Rights and Dissenters</B><B>&#146;</B><B> Rights
</B>(see page&nbsp;136) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Millendo common stock are not entitled to appraisal rights in connection with the merger under
Delaware law. Holders of Tempest capital stock are entitled to appraisal rights in connection with the merger under Delaware law. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_14">
</A><B>Comparison of Stockholder Rights </B>(see page&nbsp;306) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Millendo and Tempest are incorporated under the laws of the State of
Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law, or the DGCL. If the merger is completed, Tempest stockholders will become Millendo
stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of Millendo and the amended and restated certificate of incorporation of Millendo, as may be further amended by Proposal No.&nbsp;2 if approved by the
Millendo stockholders at the Millendo special meeting. The rights of Millendo stockholders contained in the amended and restated certificate of incorporation, as amended, and amended and restated bylaws, as amended, of Millendo differ from the
rights of Tempest stockholders under the amended and restated certificate of incorporation and amended and restated bylaws of Tempest, as more fully described under the section titled &#147;<I>Comparison of Rights of Holders of Millendo Capital
Stock and Tempest Capital Stock</I>&#148; beginning on page&nbsp;306 of this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_15"></A><B>Risk Factors
</B>(see page&nbsp;17) </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Millendo and Tempest are subject to various risks associated with their businesses and their industries.
In addition, the merger, including the possibility that the merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>The exchange ratio will not be adjusted based on the market price of Millendo common stock so the merger
consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Failure to complete the merger may result in Millendo or Tempest paying a termination fee to the other
party which could harm the common stock price of Millendo and the future business and operations of each company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>If the conditions to the merger are not satisfied or waived, the merger may not occur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>The merger may be completed even though material adverse effects may result from the announcement of the
merger, industry-wide changes and other causes; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>If Millendo and Tempest complete the merger, the combined company will need to raise additional capital by
issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#146;s stockholders or restrict the combined company&#146;s operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Some Millendo and Tempest executive officers and directors have interests in the merger that are different
from yours and that may influence them to support or approve the merger without regard to your interests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Millendo&#146;s stockholders may not realize a benefit from the merger commensurate with the ownership
dilution they will experience in connection with the merger, including the conversion of Tempest common stock issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>If the merger is not completed, Millendo&#146;s stock price may fluctuate significantly.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks and other risks are discussed in greater detail under the section titled &#147;<I>Risk
Factors</I>&#148; beginning on page&nbsp;17 of this proxy statement/prospectus. Millendo and Tempest both encourage you to read and consider all of these risks carefully. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_16"></A>MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of Millendo common stock on March&nbsp;26, 2021, the last trading day prior to the public announcement of the merger, was
$2.18 per share and the closing price of Millendo common stock on May 7, 2021 was $1.09 per share, in each case as reported on The Nasdaq Capital Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the market price of Millendo common stock is subject to fluctuation, the market value of the shares of Millendo common stock that
Tempest stockholders will be entitled to receive in the merger may increase or decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is a private company and its shares of
common stock and preferred stock are not publicly traded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_17"></A>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has never declared or paid cash dividends on its capital stock and does not anticipate paying any cash dividends in the foreseeable
future. Tempest has never paid or declared any cash dividends on its capital stock. Tempest intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on
its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the merger will be at the discretion of the combined company&#146;s board of directors and will depend upon a number of
factors, including the combined company&#146;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#146;s board of directors deems
relevant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary
Unaudited Cash and Cash Equivalents as of March&nbsp;31, 2021 and Net Loss for the Three-Month Period Ended March&nbsp;31, 2021. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Millendo has not finalized its full financial results for the fiscal quarter ended March&nbsp;31, 2021, Millendo expects to report
that it had (a) cash, cash equivalents, restricted cash and marketable securities of approximately $27.3&nbsp;million as of March&nbsp;31, 2021 and (b)&nbsp;a net loss of approximately $8.4 million for the three-month period ended March&nbsp;31,
2021. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated cash, cash equivalents, restricted cash and marketable securities and net loss
figures are preliminary and unaudited, and represent Millendo management&#146;s estimates as of the date of this proxy statement/prospectus. The financial information is subject to the completion of Millendo&#146;s financial closing procedures with
respect to the interim consolidated financial statements, as of and for the three-month period ended March 31, 2021, which will be filed on Form&nbsp;10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Tempest has not finalized its full financial results for the fiscal quarter ended March&nbsp;31, 2021, Tempest expects to report that
it had (a) cash and cash equivalents of approximately $27.4 million as of March&nbsp;31, 2021 and (b)&nbsp;a net loss of approximately $5.4 million for the three-month period ended March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated cash and cash equivalents, and net loss figures are preliminary and unaudited, and represent Tempest management&#146;s estimates
as of the date of this proxy statement/prospectus. The financial information is subject to the completion of Tempest&#146;s financial closing procedures with respect to the interim financial statements, as of and for the three-month period ended
March&nbsp;31, 2021. Tempest&#146;s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to interim financial statements, as of and for the
three-month period ended March&nbsp;31, 2021. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 23, 2021 a complaint was filed against the Company and each of its directors in the United States District Court for the Southern
District of New York. The lawsuit, captioned <I>Nakkhumpun&nbsp;v. Millendo Therapeutics, Inc.,</I> alleges violations of Sections&nbsp;14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule&nbsp;14a-9 promulgated thereunder, as well as for
breach of fiduciary duty of candor, against the defendants for allegedly disseminating a materially incomplete and misleading registration statement with the SEC in connection with the proposed merger. The plaintiff seeks to enjoin the defendants
from proceeding with a shareholder vote on the proposed merger until the Company discloses the material. The plaintiff also seeks damages and an award of costs, expert fees and attorneys&#146; fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 27, 2021, a second complaint was filed against the Company and each of its directors in the United States District Court for the
Southern District of New York. The lawsuit, captioned <I>Klaus&nbsp;v. Millendo Therapeutics Inc.,</I> alleges violations of Sections&nbsp;14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule&nbsp;14a-9 promulgated thereunder against the
defendants for allegedly disseminating a materially incomplete and misleading registration statement with the SEC in connection with the proposed merger. The plaintiff seeks to enjoin the defendants from proceeding with or consummating the proposed
merger, or, in the event the proposed merger is consummated, the plaintiff seeks to rescind it or recover damages. The plaintiff also seeks an award of costs, expert fees and attorneys&#146; fees. Finally, the plaintiff seeks to direct the Company
to disseminate a registration statement that does not contain any alleged misstatements of material fact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 29, 2021, a third
complaint was filed against the Company and each of its directors in the United States District Court for the Eastern District of New York. The lawsuit, captioned <I>Campbell&nbsp;v. Millendo Therapeutics Inc.,</I> alleges the same violations and
demands the same relief as in <I>Klaus&nbsp;v. Millendo Therapeutics Inc</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;30, 2021, a complaint was filed against the
Company and each of its directors in the United States District Court for the Southern District of New York. The lawsuit, captioned <I>Schmidt&nbsp;v. Millendo Therapeutics, Inc.</I>, alleges the same violations as <I>Campbell&nbsp;v. Millendo
Therapeutics, Inc. </I>and <I>Klaus&nbsp;v. Millendo Therapeutics, Inc</I>. It also demands the same relief. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 4, 2021, a complaint was filed against the Company and each of its directors in
the United States District Court for the Southern District of New York. The lawsuit, captioned <I>Colthurst v. Millendo Therapeutics, Inc.</I>, alleges the same violations as <I>Campbell v. Millendo Therapeutics, Inc.</I>, <I>Klaus v. Millendo
Therapeutics, Inc.</I>, and <I>Schmidt v. Millendo Therapeutics, Inc</I>. It also demands the same relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 7, 2021, a complaint
was filed against the Company and each of its directors in the United States District Court for the Eastern District of Michigan. The lawsuit, captioned <I>Wilhelm v. Millendo Therapeutics, Inc.</I>, alleges the same violations as <I>Colthurst v.
Millendo Therapeutics, Inc.</I>, <I>Campbell v. Millendo Therapeutics, Inc.</I>, <I>Klaus v. Millendo Therapeutics, Inc.</I>, and <I>Schmidt v. Millendo Therapeutics, Inc. </I>It also demands the same relief. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_18"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which
will be beyond its control. In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Millendo common stock. You
should also read and consider the other information in this proxy statement/prospectus and additional information about Millendo set forth in its Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended
December&nbsp;31, 2020, which is filed with the Securities and Exchange Commission, or the SEC, as updated by its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Please see the section titled &#147;Where You Can Find More
Information&#148; beginning on page&nbsp;321 of this proxy statement/prospectus for further information. </I></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Merger </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exchange ratio will not be adjusted based on the market price of Millendo common stock so the merger
consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Failure to complete the merger may result in either Millendo or Tempest paying a termination fee to the other
party, which could harm the common stock price of Millendo and future business and operations of each company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the conditions to the merger are not satisfied or waived, the merger may not occur. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The merger may be completed even though a material adverse effect may result from the announcement of the merger,
industry-wide changes or other causes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Proposed Reverse Stock Split </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The reverse stock split may not increase the combined company&#146;s stock price over the long-term.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The reverse stock split may decrease the liquidity of the combined company&#146;s common stock.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The reverse stock split may lead to a decrease in the combined company&#146;s overall market capitalization.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Combined Company </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The combined company will need substantial additional funding before it can complete the development of its
product candidates. If the combined company is unable to obtain such additional capital in favorable terms, or at all, it would be forced to delay, reduce or eliminate its product development and clinical programs and may not have the capital
required to otherwise operate its business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The combined company may be exposed to increased litigation, including stockholder litigation, which could have
an adverse effect on the combined company&#146;s business and operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Millendo </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s merger with Tempest may not be consummated or may not deliver the anticipated benefits Millendo
expects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain provisions of the Merger Agreement may discourage third-parties from submitting alternative acquisition
proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Millendo does not successfully consummate the transaction with Tempest, Millendo&#146;s board of directors may
dissolve or liquidate its assets to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to Millendo&#146;s stockholders will depend heavily on the timing of such transaction or liquidation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a result of Millendo&#146;s decision to discontinue further investment in
<FONT STYLE="white-space:nowrap">MLE-301</FONT> and the reductions in Millendo&#146;s workforce, Millendo has only 10 employees remaining as of the date of this proxy statement/prospectus. If Millendo is unable to retain certain of its remaining
employees, the ability to consummate the planned merger transaction may be delayed or seriously jeopardized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the merger is not completed, Millendo would need to raise substantial additional funding to the extent it
resumes drug development efforts, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force delays, limit or terminate its drug development efforts or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product liability lawsuits against Millendo could cause it to incur substantial liabilities and could limit
commercialization of any future product candidate that Millendo may develop. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo has recently reduced the size of its organization, and it may encounter difficulties in managing its
business as a result of this reduction, or the attrition that may occur following this reduction, which could disrupt Millendo&#146;s operations. In addition, Millendo may not achieve anticipated benefits and savings from the reduction.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trading price of the shares of Millendo&#146;s common stock has been and is likely to continue to be
volatile, and purchasers of its common stock could incur substantial losses. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Tempest </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest and its auditors have substantial doubt about Tempest&#146;s ability to continue as a going concern,
which may hinder its ability to obtain further financing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest has a history of operating losses, and Tempest may not achieve or sustain profitability. Tempest
anticipates that it will continue to incur losses for the foreseeable future. If Tempest fails to obtain additional funding to conduct its planned research and development efforts, Tempest could be forced to delay, reduce or eliminate Tempest&#146;s
product development programs or commercial development efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest expects that it will need to raise additional funding before Tempest can expect to become profitable from
any potential future sales of Tempest&#146;s product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force Tempest to delay, limit or terminate its
product development efforts or other operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Tempest is unable to develop, obtain regulatory approval for and commercialize TPST-1495 and TPST-1120 and its
future product candidates, or if Tempest experiences significant delays in doing so, Tempest&#146;s business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Success in preclinical studies and earlier clinical trials for Tempest&#146;s product candidates may not be
indicative of the results that may be obtained in later clinical trials, which may delay or prevent obtaining regulatory approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The commercial success of Tempest&#146;s product candidates, including TPST-1495 and TPST-1120, will depend upon
their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest faces significant competition in an environment of rapid technological change, and it is possible that
Tempest&#146;s competitors may achieve regulatory approval before Tempest or develop therapies that are more advanced or effective than Tempest&#146;s, which may harm Tempest&#146;s business, financial condition and Tempest&#146;s ability to
successfully market or commercialize TPST-1495, TPST-1120, and Tempest&#146;s other product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Tempest is unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell Tempest&#146;s product candidates, Tempest may be unable to generate any revenues. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FDA regulatory approval process is lengthy and time-consuming, and Tempest may experience significant delays
in the clinical development and regulatory approval of Tempest&#146;s product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest expects to expand its development and regulatory capabilities, and as a result, Tempest may encounter
difficulties in managing its growth, which could disrupt Tempest&#146;s operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="toc150774_19"></A>Risks Related to
the Merger </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exchange ratio will not be adjusted based on the market price of Millendo common stock so the merger consideration at the
closing may have a greater or lesser value than at the time the Merger Agreement was signed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger,
outstanding shares of Tempest capital stock will be converted into shares of Millendo common stock. Applying the exchange ratio, the former Tempest securityholders immediately before the merger, including shares purchased in the Tempest <FONT
STYLE="white-space:nowrap">pre-closing</FONT> financing, are expected to own approximately 81.5% of the aggregate number of shares of Millendo common stock following the merger, and Millendo securityholders immediately before the merger are expected
to own approximately 18.5% of the aggregate number of shares of Millendo common stock following the merger, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and
June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. To the extent that Millendo&#146;s net cash is
greater than $18.7&nbsp;million, Millendo securityholders immediately before the merger would own a greater percentage of the aggregate shares of Millendo common stock following the merger than stated above and, accordingly, the former Tempest
securityholders immediately before the merger, including securityholders that purchased shares in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, would own a lesser percentage of the aggregate shares of Millendo common
stock following the merger than stated above. Conversely, to the extent that Millendo&#146;s net cash is less than $15.3&nbsp;million, Millendo securityholders immediately before the merger would own a lesser percentage of the aggregate shares of
Millendo common stock following the merger than stated above and, accordingly, the former Tempest securityholders immediately before the merger, including securityholders that purchased shares in the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, would own a greater percentage of the aggregate shares of Millendo common stock following the merger than stated above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the market price of Millendo stock before the completion of the merger will not affect the number of shares Tempest
stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the merger, the market price of Millendo common stock increases from the market price on the date of the Merger Agreement, then Tempest
stockholders could receive merger consideration with substantially more value for their shares of Tempest capital stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the merger the
market price of Millendo common stock declines from the market price on the date of the Merger Agreement, then Tempest stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a
price-based termination right. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to complete the merger may result in either Millendo or Tempest paying a termination fee to the other party,
which could harm the common stock price of Millendo and future business and operations of each company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is not
completed, Millendo and Tempest are subject to the following risks: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Merger Agreement is terminated under specified circumstances, Millendo will be required to pay Tempest a
termination fee of $1.4&nbsp;million and up to $1.0&nbsp;million in expense reimbursements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Merger Agreement is terminated under specified circumstances, Tempest will be required to pay Millendo a
termination fee of $2.8&nbsp;million and up to $1.0&nbsp;million in expense reimbursements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price of Millendo common stock may decline and could fluctuate significantly; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the merger, such as financial advisor, legal and accounting fees, which Millendo estimates will
total approximately $2.0&nbsp;million, $1.0&nbsp;million, and $0.2&nbsp;million, respectively, a majority of which must be paid even if the merger is not completed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated and the board of directors of Millendo or Tempest determines to seek another business combination, there
can be no assurance that either Millendo or Tempest will be able to find a partner with whom a business combination would yield greater benefits than the benefits to be provided under the Merger Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the conditions to the merger are not satisfied or waived, the merger may not occur. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the Merger Agreement is adopted by the stockholders of Tempest and Proposal Nos. 1 and 2 as described in this proxy
statement/prospectus are approved by the Millendo stockholders, specified conditions must be satisfied or waived to complete the merger. These conditions are set forth in the Merger Agreement and described in the section titled &#147;<I>The Merger
Agreement&#151;Conditions to the Completion of the Merger</I>&#148; beginning on page&nbsp;154 of this proxy statement/prospectus. Millendo and Tempest cannot assure you that all of the conditions to the consummation of the merger will be satisfied
or waived. If the conditions are not satisfied or waived, the merger may not occur or the closing may be delayed, and Millendo and Tempest each may lose some or all of the intended benefits of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The merger may be completed even though a material adverse effect may result from the announcement of the merger, industry-wide changes or other causes.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, neither Millendo nor Tempest is obligated to complete the merger if there is a material adverse effect affecting
the other party between March&nbsp;29, 2021, the date of the Merger Agreement, and the closing of the merger. However, certain types of changes are excluded from the concept of a &#147;material adverse effect.&#148; Such exclusions include but are
not limited to changes in general economic or market conditions, industry wide changes, changes in GAAP, changes in laws, rules or regulations of general applicability or interpretations thereof, natural disasters, pandemics (including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic), outbreaks of hostilities or acts of terrorism, changes resulting from the announcement or pendency of the merger, and failures to meet internal guidance, budgets, plans or forecasts. Therefore,
if any of these events were to occur impacting Millendo or Tempest, the other party would still be obliged to consummate the closing of the merger. If any such adverse changes occur and Millendo and Tempest consummate the closing of the merger, the
stock price of the combined company may suffer. This in turn may reduce the value of the merger to the stockholders of Millendo, Tempest or both. For a more complete discussion of what constitutes a material adverse effect on Millendo or Tempest,
see the section titled &#147;<I>The Merger Agreement&#151;Representations</I> <I>and Warranties</I>&#148; beginning on page&nbsp;145 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Millendo and Tempest complete the merger, the combined company will need to raise additional capital by issuing equity securities or additional debt
or through licensing arrangements, which may cause significant dilution to the combined company&#146;s stockholders or restrict the combined company&#146;s operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2021, Tempest entered into Funding Agreements with certain investors, including existing investors of Tempest, pursuant to
which the investors agreed to purchase, in the aggregate, approximately $30&nbsp;million in shares of common stock of Tempest immediately prior to the closing of the merger, referred to as the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. The closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger as
well as certain other conditions. The Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is more fully described under the section titled &#147;<I>Agreements Related to the Merger&#151;Funding Agreements</I>&#148; beginning on
page&nbsp;163 of this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional financing may not be available to the combined company when it is needed or may
not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including
Millendo&#146;s <FONT STYLE="white-space:nowrap">pre-merger</FONT> securityholders and Tempest&#146;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#146;s
common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined
company&#146;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to
grant licenses on terms that are not favorable to the combined company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some Millendo and Tempest directors and executive officers have interests
in the merger that are different from yours and that may influence them to support or approve the merger without regard to your interests. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors and executive officers of Millendo and Tempest may have interests in the merger that are different from, or in addition to, the
interests of other Millendo stockholders generally. These interests with respect to Millendo&#146;s directors and executive officers may include, among others, acceleration of stock option vesting, retention bonus payments, extension of
exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the merger and rights to continued indemnification, expense advancement and insurance
coverage. A current member of the Millendo board of directors will continue as a director of the combined company after the effective time of the merger, and, following the closing of the merger, will be eligible to be compensated as <FONT
STYLE="white-space:nowrap">non-employee</FONT> director of the combined company pursuant to the Millendo <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that is expected to remain in place following the effective
time of the merger. These interests with respect to Tempest&#146;s directors and executive officers may include, among others, that certain of Tempest&#146;s directors and executive officers have options, subject to vesting, to purchase shares of
Tempest common stock which, after the effective time of the merger, will be converted into and become options to purchase shares of the common stock of the combined company; Tempest&#146;s executive officers are expected to continue as executive
officers of the combined company after the effective time of the merger; and all of Tempest&#146;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger
Agreement. Further, certain current members of Tempest&#146;s board of directors will continue as directors of the combined company after the effective time of the merger, and, following the closing of the merger, will be eligible to be compensated
as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the combined company pursuant to the Millendo <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that is expected to remain in place following the
effective time of the merger. The directors and executive officers own options to purchase the shares of their respective companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Millendo and Tempest boards of directors were aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the merger, and recommend the approval of the Merger Agreement
to Millendo and Tempest stockholders. These interests, among other factors, may have influenced the directors and executive officers of Millendo and Tempest to support or approve the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding the interests of Millendo and Tempest directors and executive officers in the merger, please see the sections
titled &#147;<I>The Merger&#151;Interests of Millendo Directors and Executive Officers in the Merger</I>&#148; beginning on page&nbsp;125 and &#147;<I>The Merger&#151;Interests of Tempest</I> <I>Directors and Executive Officers in the
Merger</I>&#148; beginning on page&nbsp;131 of this proxy statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo stockholders may not realize a benefit from the
merger commensurate with the ownership dilution they will experience in connection with the merger, including the conversion of Tempest common stock issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the merger, Millendo
stockholders will have experienced substantial dilution of their ownership interests </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial
benefits currently anticipated from the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the merger is not completed, Millendo&#146;s stock price may fluctuate significantly.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Millendo common stock is subject to significant fluctuations. During the
<FONT STYLE="white-space:nowrap">12-month</FONT> period ended May 7, 2021, the closing sales price of Millendo&#146;s common stock on The Nasdaq Capital Market ranged from a high of $3.28 on June 17, 2020 to a low of $0.93 on April&nbsp;21, 2021.
Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Millendo common stock will likely be volatile based on whether stockholders
and other investors believe that Millendo can complete the merger or otherwise raise additional capital to support Millendo&#146;s operations if the merger is not consummated and another strategic transaction cannot be identified, negotiated and
consummated in a timely manner, if at all. The volatility of the market price of Millendo common stock is exacerbated by low trading volume. Additional factors that may cause the market price of Millendo common stock to fluctuate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation of, material developments in, or conclusion of litigation to enforce or defend its intellectual
property rights or defend against claims involving the intellectual property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into, or termination of, key agreements, including commercial partner agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by commercial partners or competitors of new commercial products, clinical progress or lack
thereof, significant contracts, commercial relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of technological innovations or new therapies that compete with its future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the loss of key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future sales of its common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general and industry-specific economic conditions that may affect its research and development expenditures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to meet industry analyst expectations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in
financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been
unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Millendo common stock. In the past, following periods of volatility in the market price of a
company&#146;s securities, stockholders have often instituted class action securities litigation against such companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo and Tempest
securityholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the merger as compared to their current ownership and voting interests in
the respective companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of the merger, the current stockholders of Millendo and Tempest will own a smaller
percentage of the combined company than their ownership of their respective companies prior to the merger. Immediately after the merger, Millendo securityholders as of immediately prior to the merger are expected to own approximately 18.5% of the
outstanding shares of the combined company and former Tempest securityholders, including shares purchased in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing are expected to own approximately 81.5% of the outstanding shares
of the combined company, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and
(b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. The President and Chief Operating Officer of Tempest will serve as the Chief Executive Officer of the combined company following
the completion of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>During the pendency of the merger, Millendo and Tempest may not be able to enter into a business
combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Covenants in the Merger Agreement impede the ability of Millendo and Tempest to make acquisitions during the pendency of the merger, subject to
specified exceptions. As a result, if the merger is not completed, the parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from
soliciting, proposing, seeking or knowingly encouraging, facilitating or supporting any inquiries, indications of interest, proposals or offers that constitute or may reasonably be expected to lead to certain transactions involving a third party,
including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such party&#146;s stockholders, but the parties may be unable to pursue them. For more information, see
the section titled &#147;<I>The Merger</I> <I><FONT STYLE="white-space:nowrap">Agreement&#151;Non-Solicitation</FONT></I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions
of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Merger Agreement prohibit each of Millendo and Tempest from soliciting competing proposals or cooperating with persons making
unsolicited takeover proposals, except in limited circumstances as described in further detail in the section titled &#147;<I>The Merger <FONT STYLE="white-space:nowrap">Agreement&#151;Non-Solicitation</FONT></I>.&#148; In addition, if the Merger<I>
</I>Agreement is terminated under specified circumstances, Millendo would be required to pay Tempest a termination fee of $1.4 million and reimburse up to $1.0 million of expenses. This termination fee may discourage third parties from submitting
competing proposals to Millendo or its stockholders, and may cause the Millendo board of directors to be less inclined to recommend a competing proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the lack of a public market for Tempest&#146;s capital stock makes it difficult to evaluate the fair market value of Tempest&#146;s capital
stock, Millendo may pay more than the fair market value of Tempest&#146;s capital stock and/or the stockholders of Tempest may receive consideration in the merger that is less than the fair market value of Tempest&#146;s capital stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding capital stock of Tempest is privately held and is not traded in any public market. The lack of a public market makes it
difficult to determine the fair market value of Tempest&#146;s capital stock. Because the percentage of Millendo equity to be issued to Tempest stockholders was determined based on negotiations between the parties, it is possible that the value of
the Millendo common stock to be received by Tempest stockholders will be less than the fair market value of Tempest&#146;s capital stock, or Millendo may pay more than the aggregate fair market value for Tempest&#146;s capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The merger may fail to qualify as a &#147;reorganization&#148; for U.S. federal income tax purposes, resulting in recognition of taxable gain or loss by
Tempest stockholders in respect of their Tempest capital stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo and Tempest intend for the merger to qualify as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, as described in the section titled &#147;<I>The Merger&#151;Material U.S. Federal Income Tax Consequences of the Merger</I>&#148; in this proxy statement/prospectus.
In the event that the merger does not qualify as a &#147;reorganization,&#148; the merger would result in taxable gain or loss for each Tempest stockholder, with the amount of such gain or loss determined by the amount that each Tempest
stockholder&#146;s adjusted tax basis in the Tempest capital stock surrendered is less or more than the fair market value of the Millendo common stock and any cash in lieu of a fractional share received in exchange therefor. Each holder of Tempest
capital stock is urged to consult with his, her or its own tax advisor with respect to the tax consequences of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="toc150774_20"></A>Risks Related to the Proposed Reverse Stock Split </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reverse stock split may not increase the combined company&#146;s stock price over the long-term. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purpose of the reverse stock split is to increase the <FONT STYLE="white-space:nowrap">per-share</FONT> market price of
Millendo&#146;s common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of Millendo and the shares of Millendo common stock being issued in the merger on Nasdaq will be approved. It cannot be assured, however,
that the reverse stock split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of
Millendo&#146;s common stock, it cannot be assured that the reverse stock split will increase the market price of its common stock by a multiple of the reverse stock split ratio mutually agreed by Millendo and Tempest, or result in any permanent or
sustained increase in the market price of Millendo&#146;s common stock, which is dependent upon many factors, including Millendo&#146;s business and financial performance, general market conditions and prospects for future success. Thus, while the
stock price of Millendo might meet the listing requirements for Nasdaq initially, it cannot be assured that it will continue to do so. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reverse
stock split may decrease the liquidity of the combined company&#146;s common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Millendo board of directors
believes that the anticipated increase in the market price of the combined company&#146;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its
stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market
makers for the combined company&#146;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#146;s stock price necessary to satisfy Nasdaq&#146;s initial listing requirements for the combined
company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The reverse stock split may lead to a decrease in the combined company&#146;s overall market capitalization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the market price of the combined company&#146;s common stock decline after the reverse stock split, the percentage decline may be
greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined
company&#146;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some
cases, the <FONT STYLE="white-space:nowrap">per-share</FONT> stock price of companies that have effected reverse stock splits subsequently declined back to <FONT STYLE="white-space:nowrap">pre-reverse</FONT> split levels, and accordingly, it cannot
be assured that the total market value of the combined company&#146;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#146;s stock
price due to the reduced number of shares outstanding after the reverse stock split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="toc150774_21"></A>Risks Related to the Combined
Company </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether you should approve the issuance of shares of Millendo common stock, the change of control resulting
from the merger and other matters related to the merger, as applicable, you should carefully read the following risk factors in addition to the risks described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of the combined company&#146;s common stock is expected to be volatile, and the market price of the common stock may drop following the
merger. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of the combined company&#146;s common stock following the merger could be subject to significant
fluctuations. Some of the factors that may cause the market price of the combined company&#146;s common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials and preclinical studies of the combined company&#146;s product candidates, or those of
the combined company&#146;s competitors or the combined company&#146;s existing or future collaborators; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial and development projections the combined company may provide to the public;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed the financial and development projections of the investment community;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent
anticipated by financial or industry analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the
combined company or its competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions taken by regulatory agencies with respect to the combined company&#146;s product candidates, clinical
studies, manufacturing process or sales and marketing terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the
combined company&#146;s ability to obtain patent protection for its technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts do not publish research or reports about the combined company&#146;s business,
or if they issue adverse or misleading opinions regarding its business and stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of securities by the combined company or its securityholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the combined company fails to raise an adequate amount of capital to fund its operations and continued
development of its product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of the combined company&#146;s common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by competitors of new commercial products, clinical progress or lack thereof, significant
contracts, commercial relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity relating to precision medicine product candidates, including with respect to other products in
such markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of technological innovations or new therapies that compete with the products and services of the
combined company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in
the combined company&#146;s financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial
volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#146;s common stock. In addition, a recession,
depression or other sustained adverse market event resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or otherwise could materially and adversely affect the combined company&#146;s business and the value of its common
stock. In the past, following periods of volatility in the market price of a company&#146;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to
increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#146;s strategic direction
or seek changes in the composition of its board of directors could have an adverse effect on its operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following the merger, the combined company may be unable to integrate successfully and realize the
anticipated benefits of the merger. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger involves the combination of two companies which currently operate as independent
companies. The combined company may fail to realize some or all of the anticipated benefits of the merger if the integration process takes longer than expected or is more costly than expected. In addition, Millendo and Tempest have operated and,
until the completion of the merger, will continue to operate, independently. It is possible that the integration process also could result in the diversion of each company&#146;s management&#146;s attention, the disruption or interruption of, or the
loss of momentum in, each company&#146;s ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect the combined company&#146;s ability to maintain relationships with customers,
suppliers and employees or the ability to achieve the anticipated benefits of the merger, or could otherwise adversely affect the business and financial results of the combined company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company will need substantial additional funding before it can complete the development of its product candidates. If the combined company
is unable to obtain such additional capital on favorable terms, on a timely basis or at all, it would be forced to delay, reduce or eliminate its product development and clinical programs and may not have the capital required to otherwise operate
its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing cancer therapies, including conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials and establishing manufacturing capabilities, is expensive. The combined company has not generated any revenues from the commercial sale of products and will not be able to generate any product revenues until, and only if, the
combined company receives approval to sell its product candidates from the FDA or other regulatory authorities. The cash expected from both Millendo and Tempest at closing, including the net proceeds of the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, are expected to fund the further development of the combined company&#146;s three oncology programs and operate the combined company into early 2023. However, as the combined company has
not generated any revenue from commercial sales to date and does not expect to generate any revenue for several years, if ever, the combined company will need to raise substantial additional capital in order to fund its general corporate activities
and to fund its research and development, including its currently planned clinical trials and plans for new clinical trials and product development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may seek to raise additional funds through various potential sources, such as equity and debt financings, or through
strategic collaborations and license agreements. The combined company can give no assurances that it will be able to secure such additional sources of funds to support its operations or, if such funds are available, that such additional financing
will be sufficient to meet its needs. Moreover, to the extent that the combined company raises additional funds by issuing equity securities, its stockholders may experience additional significant dilution, and debt financing, if available, may
involve restrictive covenants. To the extent that the combined company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant
licenses on terms that may not be favorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the combined company&#146;s capital constraints, it will need to prioritize spending on its clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs. If the combined company is unable to raise sufficient funds to support its current and planned operations, it may elect to discontinue certain of its ongoing activities or programs.
The combined company&#146;s inability to raise additional funds could also prevent it from taking advantage of opportunities to pursue promising new or existing programs in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#146;s forecasts regarding its beliefs in the sufficiency of its financial resources to support its current and planned
operations are forward-looking statements and involve significant risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. These
estimates are based on assumptions that may prove to be wrong, and the combined company could utilize its available capital resources sooner than currently expected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company will incur additional costs and increased demands upon management as a result of
complying with the laws and regulations affecting public companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will incur significant legal, accounting
and other expenses as a public company that Tempest did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act. The combined
company&#146;s management team will consist of the executive officers of Tempest prior to the merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting
requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it
to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it
more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#146; and
officers&#146; insurance, on acceptable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies
for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#146;s costs and the demands on management and could harm the combined
company&#146;s operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will be subject to the reporting requirements of the Exchange Act, which
requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#146;s business and financial condition as well as other disclosure and corporate governance
requirements. However, as a &#147;smaller reporting company&#148; the combined company may take advantage of some of exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in the combined company&#146;s periodic reports and proxy statements. Once the combined company is no longer a smaller reporting company
or otherwise qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do
so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#146;s financial condition or the market price of the combined company&#146;s common stock may be harmed. For example, if the
combined company or its independent auditor identifies deficiencies in the combined company&#146;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those
deficiencies, the market price of the combined company&#146;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and
management resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited pro&nbsp;forma condensed combined financial data for Millendo and Tempest included in this proxy
statement/prospectus is preliminary, and the combined company&#146;s actual financial position and operations after the merger may differ materially from the unaudited pro&nbsp;forma financial data included in this proxy statement/prospectus.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro&nbsp;forma financial data for Millendo and Tempest included in this proxy statement/prospectus is presented for
illustrative purposes only and is not necessarily indicative of the combined company&#146;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had
the entities been combined during the periods presented. The unaudited pro forma financial statements have been derived from the historical financial statements of Millendo and Tempest Therapeutics and adjustments and assumptions have been made
regarding the combined company after giving effect to the transaction. The information upon which these adjustments and assumptions have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made is preliminary, and these kinds of adjustments and assumptions are difficult to make with accuracy. Moreover, the unaudited pro forma financial statements do not reflect all costs that are
expected to be incurred by the combined company in connection with the transactions or that have been incurred since the date of such unaudited pro forma financial statements. The assumptions used in preparing the unaudited pro forma financial
information may not prove to be accurate, and other factors may affect the combined company&#146;s financial condition following the transaction. For more information see the section titled &#147;<I>Unaudited Pro</I><I></I><I>&nbsp;Forma Condensed
Combined Financial Information</I>&#148; beginning on page 294. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions that will be in the combined company&#146;s certificate of
incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> and provisions under Delaware law could make an acquisition of the combined company, which may be beneficial to its stockholders, more difficult and may prevent attempts by its
stockholders to replace or remove its management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions that will be included in the combined company&#146;s certificate of
incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its
common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#146;s common stock, thereby depressing
the market price of its common stock. In addition, because the combined company&#146;s board of directors will be responsible for appointing the members of the combined company&#146;s management team, these provisions may frustrate or prevent any
attempts by the combined company&#146;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#146;s board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that not all members of the combined company board of directors
are elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of the combined company&#146;s directors to be changed only by resolution of its
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from the combined company&#146;s board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
for nominations to the combined company&#146;s board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit actions by the combined company&#146;s stockholders by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions be effected at a duly called stockholders meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the combined company&#146;s board of directors to issue preferred stock without stockholder approval,
which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#146;s board of
directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 75&nbsp;percent of the votes that all combined company
stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, because the combined company is incorporated in Delaware, it is governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, or the DGCL, which prohibits a person who owns 15&nbsp;percent or more of the combined company&#146;s outstanding voting stock from merging or combining with the combined company for a period of three&nbsp;years after the date of the
transaction in which the person acquired 15&nbsp;percent or more of the combined company&#146;s outstanding voting stock, unless the merger or combination is approved in a manner prescribed by the statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The certificate of incorporation and bylaws of the combined company will provide that the Court of
Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the combined company and its stockholders, which could limit its stockholders&#146; ability to obtain a favorable judicial forum for disputes with the
combined company or its directors, officers or other employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The bylaws of the combined company will provide that the Court of
Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on the combined company&#146;s behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against it arising
pursuant to any provisions of the DGCL, its certificate of incorporation or its bylaws, or any action asserting a claim against it that is governed by the internal affairs doctrine. The provision may limit a stockholder&#146;s ability to bring a
claim in a judicial forum that it finds favorable for disputes with the combined company or its directors, officers or other employees, which may discourage such lawsuits against the combined company and its directors, officers and other employees.
Alternatively, if a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other
jurisdictions, which could materially and adversely affect its business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company&#146;s
ability to utilize its net operating loss carryforwards and tax credit carryforwards may be subject to limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined
company&#146;s ability to use its federal and state net operating losses (&#147;NOLs&#148;) to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon the combined company&#146;s generation of
future taxable income, and Millendo and Tempest cannot predict with certainty when, or whether, the combined company will generate sufficient taxable income to use all of its NOLs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 and Section&nbsp;383 of the Code and corresponding provisions of state law, if a corporation undergoes an
&#147;ownership change,&#148; its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset its
post-change income may be limited. A Section&nbsp;382 &#147;ownership change&#148; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. Millendo
believes that it has experienced an ownership change in the past, and may experience ownership changes in the future due to subsequent shifts in its stock ownership (some of which are outside of its control). Tempest may have experienced ownership
changes in the past, may experience an ownership change as a result of the merger, and may experience ownership changes in the future due to subsequent shifts in the combined company&#146;s stock ownership (some of which are outside of its control).
Furthermore, the merger, if consummated, will constitute an ownership change (within the meaning of Section&nbsp;382 of the Code) of Millendo which could eliminate or otherwise substantially limit the combined company&#146;s ability to use
Millendo&#146;s federal and state NOLs to offset its future taxable income. Consequently, even if the combined company achieves profitability, it may not be able to utilize a material portion of Tempest&#146;s, Millendo&#146;s or the combined
company&#146;s NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit the combined company&#146;s use of accumulated
state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, the combined company&#146;s existing NOLs could expire or otherwise be unavailable to offset future
income tax liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or regulations could materially adversely affect the combined company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is
adverse to the combined company, which could adversely affect its business and financial condition. For example, legislation enacted in 2017, informally titled the Tax Act, enacted many significant changes to the U.S. tax laws, including changes in
corporate tax rates, the utilization of NOLs and other deferred tax assets, the deductibility of expenses, and the taxation of foreign earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may affect the combined company, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or
CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. The impact of changes under the Tax
Act, the CARES Act, or future reform legislation could increase the combined company&#146;s future U.S. tax expense and could have a material adverse impact on its business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo and Tempest do not anticipate that the combined company will pay any cash dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#146;s
business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for the combined company&#146;s common stock may not develop and its stockholders may not be able to resell their shares of
common stock for a profit, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the merger, there had been no public market for shares of Tempest capital stock. An
active trading market for the combined company&#146;s shares of common stock may never develop or be sustained. If an active market for the combined company&#146;s common stock does not develop or is not sustained, it may be difficult for its
stockholders to sell their shares at an attractive price or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares by existing stockholders could cause the combined
company&#146;s stock price to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If existing securityholders of Millendo and Tempest sell, or indicate an intention to sell,
substantial amounts of the combined company&#146;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline.
Based on shares outstanding as of March 31, 2021, the shares to be issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing and shares expected to be issued upon completion of the merger the combined company is expected to
have outstanding a total of approximately 111,559,188 shares of common stock immediately following the completion of the merger. Of the shares of common stock, approximately 55,961,483 shares will be available for sale in the public market beginning
180&nbsp;days after the closing of the merger as a result of the expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between Millendo and Tempest on the one hand and certain securityholders of Millendo and Tempest on the other
hand. All other outstanding shares of common stock, other than shares held by affiliates of the combined company, will be freely tradable, without restriction, in the public market. In addition, shares of common stock that are subject to outstanding
options of Tempest will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined
company&#146;s common stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After completion of the merger, the combined company&#146;s executive officers, directors and principal
stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#146;s stockholders for approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the merger, and giving effect to the issuance of the shares of common stock of Tempest prior to the closing of the
merger pursuant to the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, it is anticipated that the combined company&#146;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own
approximately 54.4% of the combined company&#146;s outstanding shares of common stock, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being
between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. As a result, if these stockholders were to choose to act together, they
would be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control or significantly influence all matters submitted to the combined company&#146;s stockholders for approval, as well as the combined company&#146;s management and affairs. For example,
these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#146;s assets. This concentration
of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company may
be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on the combined company&#146;s business and operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may be exposed to increased litigation from stockholders, customers, suppliers, consumers and other third parties due to
the combination of Millendo&#146;s business and Tempest&#146;s business following the merger. Such litigation may have an adverse impact on the combined company&#146;s business and results of operations or may cause disruptions to the combined
company&#146;s operations. In addition, in the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if
instituted against the combined company, could cause the combined company to incur substantial costs and divert management&#146;s attention and resources, which could have a material adverse effect on the combined company&#146;s business, financial
condition and results of operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company may be exposed to continued litigation resulting from the four complaints
described above in the section titled &#147;Recent Developments - Litigation&#148; beginning on page 15 of this proxy statement/prospectus. Such lawsuits, if remaining outstanding following the closing, could cause the combined company to incur
substantial costs and divert management&#146;s attention and resources, which could have a material adverse effect on the combined company&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or
its market, its stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the combined company&#146;s common stock will
be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company&#146;s common stock after the completion of the
merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and
opinions included in their reports. The price of the combined company&#146;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research
analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Tempest <FONT
STYLE="white-space:nowrap">pre-closing</FONT> financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the
Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. You may not agree with the combined company&#146;s decisions, and its use of the proceeds may not yield any return on your investment. The combined company&#146;s failure to
apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity
to influence its decisions on how to use the combined company&#146;s cash resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The combined company&#146;s internal control over financial reporting may not meet the standards
required by Section&nbsp;404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section&nbsp;404 of the Sarbanes-Oxley Act, could have a material adverse effect on
the combined company&#146;s business and share price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a privately held company, Tempest was not required to evaluate its
internal control over financial reporting in a manner that meets the standards of publicly traded companies required by Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404. Following the merger, the combined company&#146;s management
will be required to report on the effectiveness of the combined company&#146;s internal control over financial reporting. The rules governing the standards that must be met for the combined company&#146;s management to assess the combined
company&#146;s internal control over financial reporting are complex and require significant documentation, testing and possible remediation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing Tempest&#146;s financial statements as of and for the year ended December&nbsp;31, 2020, management of Tempest identified
material weaknesses in its internal control over financial reporting. See &#147;<I>Tempest has identified material weaknesses in its internal control over financial reporting. Failure to achieve and</I> <I>maintain effective internal control over
financial reporting could harm its business and negatively impact the value of its common stock</I>.&#148; The combined<I> </I>company cannot assure you that the material weaknesses identified at Tempest will be remediated by the combined company on
the timelines currently anticipated by Tempest, or at all, and/or that there will not be additional material weaknesses or significant deficiencies in the combined company&#146;s internal control over financial reporting in the future. Any failure
to maintain effective internal control over financial reporting could severely inhibit the combined company&#146;s ability to accurately report its financial condition, results of operations or cash flows. If the combined company is unable to
conclude that its internal control over financial reporting is effective, or if the combined company&#146;s independent registered public accounting firm determines the combined company has a material weakness or significant deficiency in the
combined company&#146;s internal control over financial reporting once that firm begins its reporting on internal control over financial reporting, investors may lose confidence in the accuracy and completeness of the combined company&#146;s
financial reports, the market price of the combined company&#146;s common stock could decline, and the combined company could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any
material weakness in the combined company&#146;s internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict the combined company&#146;s future access to
the capital markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="toc150774_21a"></A>Risks Related to Millendo </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Proposed Merger and Millendo&#146;s Retention of Key Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s merger with Tempest may not be consummated or may not deliver the anticipated benefits Millendo expects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, Millendo undertook a strategic review process, which was intended to result in an actionable plan that leverages its assets, capital
and capabilities to maximize stockholder value. Following an extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, on March&nbsp;29, 2021, Millendo
entered into a merger agreement with Tempest, under which the privately held Tempest will merge with a wholly owned subsidiary of Millendo. <FONT STYLE="white-space:nowrap">Pre-merger</FONT> Millendo shareholders will own approximately 18.5% of the
combined company and <FONT STYLE="white-space:nowrap">pre-merger</FONT> Tempest stockholders will own approximately 81.5% of the combined company (assuming the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing results in gross
proceeds of approximately $30 million). Millendo is devoting substantially all of its time and resources to consummating this transaction, however, there can be no assurance that such activities will result in the consummation of this transaction or
that such transaction will deliver the anticipated benefits or enhance stockholder value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions of the Merger Agreement may discourage third-parties from submitting alternative
acquisition proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
terms of the Merger Agreement prohibit each party from soliciting or engaging in discussions with third parties regarding alternative acquisition proposals, except in limited circumstances when such party&#146;s board of directors determines in good
faith that an unsolicited acquisition proposal constitutes or could reasonably be expected to lead to a superior proposal and that failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable
law. In addition, if the Merger Agreement is terminated by Millendo or Tempest under certain circumstances, including because of a decision of Millendo&#146;s board of directors to accept a superior proposal, Millendo would be required to pay
Tempest a termination fee of $1.4&nbsp;million or reimburse Tempest&#146;s expenses up to a maximum of $1.0&nbsp;million. This termination fee may discourage third parties from submitting alternative takeover proposals to Millendo or its
stockholders, and may cause Millendo&#146;s board of directors to be less inclined to recommend an alternative proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The announcement and
pendency of the merger, whether or not consummated, may adversely affect the trading price of Millendo&#146;s common stock and its business prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The announcement and pendency of the merger, whether or not consummated, may adversely affect the trading price of Millendo&#146;s common stock
and its business prospects. In the event that the merger is not completed, the announcement of the termination of the Merger Agreement may also adversely affect the trading price of Millendo&#146;s common stock and its business prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to consummate the merger may result in Millendo paying a termination fee to Tempest and could harm Millendo&#146;s common stock price and its
future business and operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will not be consummated if the conditions precedent to the consummation of the
transaction are not satisfied or waived, or if the Merger Agreement is terminated in accordance with its terms. If the merger is not consummated, Millendo is subject to the following risks: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Merger Agreement is terminated under certain circumstances, Millendo will be required to pay Tempest a
termination fee of $1.4&nbsp;million or reimburse Tempest&#146;s expenses up to a maximum of $1.0&nbsp;million; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price of Millendo&#146;s common stock may decline and remain volatile. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger does not close for any reason, Millendo&#146;s board of directors may elect to, among other things, attempt to complete another
strategic transaction, attempt to sell or otherwise dispose of Millendo&#146;s various assets, dissolve or liquidate its assets, declare bankruptcy or seek to continue to operate its business. If Millendo seeks another strategic transaction or
attempts to sell or otherwise dispose of its various assets, there is no assurance that it will be able to do so, that the terms would be equal to or superior to the terms of the merger or as to the timing of such transaction. If Millendo decides to
dissolve and liquidates its assets, Millendo would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount or timing of available
cash left to distribute to stockholders after paying its debts and other obligations and setting aside funds for reserves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo
was to seek to continue its business, it would need to determine whether to acquire one or more other product candidates. Millendo would also need to raise funds to support continued operations and <FONT STYLE="white-space:nowrap">re-assess</FONT>
its workforce requirements in consideration of its reduced workforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is not consummated, Millendo may be unable to retain
the services of key remaining members of its management team and, as a result, may be unable to seek or consummate another strategic transaction, properly dissolve and liquidate its assets or continue its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Millendo does not successfully consummate the transaction with Tempest, Millendo&#146;s board of
directors may dissolve or liquidate its assets to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to Millendo&#146;s stockholders will depend heavily on the timing of such transaction or
liquidation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger does not close for any reason, Millendo&#146;s board of directors may elect to, among other things,
dissolve or liquidate its assets, which may include seeking protection from creditors in a bankruptcy proceeding. If Millendo decides to dissolve and liquidate its assets, Millendo would be required to pay all of its debts and contractual
obligations, and to set aside certain reserves for potential future claims, and there can be no assurances as to the amount or timing of available cash left to distribute to stockholders after paying its debts and other obligations and setting aside
funds for reserves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a dissolution and liquidation, the amount of cash available for distribution to Millendo&#146;s
stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as Millendo funds its operations in preparation for the consummation of the
merger. Further, the Merger Agreement contains certain termination rights for each party, and provides that, upon termination under specified circumstances, Millendo may be required to pay Tempest a termination fee of $1.4&nbsp;million or reimburse
Tempest&#146;s expenses up to a maximum of $1.0&nbsp;million, which would further decrease Millendo&#146;s available cash resources. If Millendo&#146;s board of directors were to approve and recommend, and its stockholders were to approve, a
dissolution and liquidation, Millendo would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation
to its stockholders. Millendo&#146;s commitments and contingent liabilities may include (i)&nbsp;regulatory and clinical obligations remaining under its clinical trials; (ii)&nbsp;obligations under its employment, separation and retention agreements
with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of Millendo; and (iii)&nbsp;potential litigation against Millendo, and other
various claims and legal actions arising in the ordinary course of business. As a result of this requirement, a portion of Millendo&#146;s assets may need to be reserved pending the resolution of such obligations. In addition, Millendo may be
subject to litigation or other claims related to a dissolution and liquidation of Millendo. If a dissolution and liquidation were pursued, Millendo&#146;s board of directors, in consultation with its advisors, would need to evaluate these matters
and make a determination about a reasonable amount to reserve. Accordingly, holders of Millendo common stock could lose all or a significant portion of their investment in the event of its liquidation, dissolution or winding up. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a result of Millendo&#146;s decision to discontinue further investment in <FONT STYLE="white-space:nowrap">MLE-301</FONT> and the reductions in
Millendo&#146;s workforce, Millendo has only 10 employees remaining as of the date of this proxy statement/prospectus. If Millendo is unable to retain certain of its remaining employees, the ability to consummate the planned merger transaction may
be delayed or seriously jeopardized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;28, 2021, Millendo announced workforce reductions, and current headcount has
been reduced to 10 employees as of the date of this proxy statement/prospectus. Millendo&#146;s cash conservation activities may yield unintended consequences, such as attrition beyond the planned workforce reductions and reduced employee morale,
which may cause the remaining employees to seek alternate employment. Competition among biotechnology companies for qualified employees is intense, and the ability to retain the remaining employees is critical to Millendo&#146;s ability to
effectively manage its business and to consummate the planned merger transaction. Additional attrition could have a material adverse effect on its business and ability to consummate the merger. In addition, as a result of the reduction in the
workforce, Millendo may face an increased risk of employment litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Millendo&#146;s Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo has incurred significant operating losses since inception and anticipates that it will continue to incur substantial operating losses for the
foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Millendo has incurred significant operating
losses and negative operating cash flows and there is no assurance that Millendo will ever achieve or sustain profitability. Millendo&#146;s net loss was $36.4&nbsp;million and $44.6&nbsp;million and for the years ended December&nbsp;31, 2020 and
2019, respectively. As of December&nbsp;31, 2020, Millendo had an accumulated deficit of $245.1&nbsp;million and expects to continue to incur significant expenses and increasing operating losses for the foreseeable future. Millendo has devoted
substantially all of its efforts to the acquisition of and preclinical and clinical development of <FONT STYLE="white-space:nowrap">MLE-301,</FONT> in which it decided to discontinue its investment in January 2021, nevanimibe, in which Millendo
ceased investing in June 2020, and livoletide, of which Millendo discontinued development in April 2020, as well as to building its management team and infrastructure. The net losses Millendo incurs may fluctuate significantly from quarter to
quarter and year to year. Millendo anticipates that expenses may increase if it resumes drug development activities. Millendo&#146;s failure to become and remain profitable would decrease its value and could impair its ability to raise capital,
continue its operations. A decline in its value also could cause Millendo stockholders to lose all or part of their investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo has a
limited operating history and has never generated any revenue from product sales, which may make it difficult to assess its future viability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is a biopharmaceutical company with a limited operating history. Its operations to date, with respect to the development of its
product candidates, has been limited to organizing and staffing its business, business planning, raising capital, acquiring its product candidates and other assets and conducting preclinical and clinical development of its product candidates.
Millendo has not demonstrated an ability to successfully complete clinical development of a product candidate, obtain marketing approval, manufacture a commercial-scale drug (or arrange for a third-party to do so on Millendo&#146;s behalf), or
conduct sales and marketing activities necessary for successful commercialization. Consequently, Millendo&#146;s predictions about the future success or viability may not be as accurate as they could be if it had more experience developing product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the merger is not completed, Millendo would need to raise substantial additional funding to the extent it resumes drug development
efforts, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force delays, limit or terminate its drug development efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is not completed, Millendo may require substantial additional capital to fund any research and development and expenses related
to its business. Millendo had cash, cash equivalents and restricted cash of $38.7&nbsp;million at December&nbsp;31, 2020. In the event that the merger is not completed, Millendo may pursue a liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up,</FONT> or may seek to complete an alternate strategic transaction or may elect to resume investment in other product candidates. Based on the current operating plan, Millendo believe that its existing
cash, cash equivalents and restricted cash will be sufficient to allow it to fund its current operating plan for at least the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo cannot predict to what extent it will resume drug development activities for any other drug product candidates. If Millendo resumes
drug development activities, only a small minority of all research and development programs ultimately result in commercially successful drugs. Clinical failure can occur at any stage of clinical development and clinical trials may produce negative
or inconclusive results, and Millendo may decide, or regulators may require Millendo, to conduct additional clinical or preclinical trials. In addition, data obtained from trials are susceptible to varying interpretations, and regulators may not
interpret the data as favorably as Millendo does, which may delay, limit or prevent regulatory approval. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise
provide adequate data to demonstrate the efficacy and safety of a drug candidate. Further, even if Millendo completes the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development for a drug product candidate and gains marketing approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory authorities in a timely manner, it
cannot be sure that such drug product candidate will be commercially successful in the pharmaceutical market. If the results of clinical trials, the anticipated or actual timing of marketing approvals, or the market acceptance of any drug product
candidate, if approved, do not meet the expectations of investors or public market analysts, the market price of Millendo&#146;s common stock would likely decline. Further, if Millendo resumes drug development activities, it will need substantial
additional financing to complete the development of any other drug product candidates it may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects to incur losses
for the foreseeable future. Millendo&#146;s ability to achieve profitability in the future is dependent upon achieving a level of revenues adequate to support its cost structure. Millendo may never achieve profitability, and unless and until it
does, it will continue to need to raise additional capital. If Millendo raises additional capital through the sale of equity or convertible debt securities, the issuance of those securities could result in substantial dilution for current Millendo
stockholders and the terms may include liquidation or other preferences that adversely affect the rights of current stockholders, further diminishing current stockholders&#146; ability to realize any value for their stock holdings. Furthermore, the
issuance of additional securities, whether equity or debt, by Millendo, or the possibility of such issuance, may cause the market price of Millendo&#146;s common stock to decline further and existing stockholders may not agree with its financing
plans or the terms of such financings. There can be no assurances, however, that additional funding will be available on terms acceptable to Millendo, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo will require additional capital to finance its operations, which may not be available on acceptable terms, if at all. Failure to obtain capital
when needed may force Millendo to delay, limit or terminate certain of its development programs, future commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects its expenses to increase in connection with ongoing activities and expects to continue to incur additional costs associated
with operating as a public company. As of December&nbsp;31, 2020, Millendo&#146;s cash, cash equivalents and restricted cash were $38.7&nbsp;million. Millendo&#146;s existing cash, cash equivalents and restricted cash are currently expected to be
sufficient to fund its current operating plans through at least the next 12 months. This cash runway guidance is based on Millendo&#146;s current operational plans and excludes any additional funding that may be received and business development
activities that may be undertaken. In addition, the operating plans may change as a result of many factors currently unknown to Millendo, including the short- and long-term effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
and Millendo may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, and marketing and distribution arrangements, as well as other collaborations, strategic alliances and
licensing arrangements, or a combination of these approaches. In any event, Millendo will require additional capital to pursue preclinical and clinical activities, regulatory approval and the commercialization of its current and future product
candidates. Even if Millendo believes it has sufficient capital for its current operating plans, Millendo may seek additional capital if market conditions are favorable or if it has specific strategic considerations. If Millendo elects to do so,
additional capital may not be available to it on acceptable terms, if at all. Millendo&#146;s ability to access additional capital, and as a result its operating results and liquidity needs, could be negatively affected by market fluctuations and
economic downturn. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, Millendo could experience an inability to access
additional capital, which could negatively affect its business. Any additional capital raising efforts may divert its management from its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which
may adversely affect Millendo&#146;s ability to develop and commercialize its current and future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital by
issuing equity or debt securities may cause dilution to Millendo&#146;s existing stockholders, and raising funds through lending and licensing arrangements may restrict Millendo&#146;s operations or require Millendo to relinquish proprietary rights.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time as Millendo can generate substantial revenue from product sales, if ever, Millendo expects to finance its cash
needs through a combination of equity and debt financings, strategic alliances and license and development agreements in connection with any future collaborations. To the extent that Millendo raises </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional capital by issuing equity securities, its existing stockholders&#146; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other
preferences that adversely affect an investor in Millendo&#146;s rights as a stockholder. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting Millendo&#146;s ability to take specific
actions, such as redeeming Millendo&#146;s shares, making investments, incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incurrence of indebtedness could result in increased fixed payment obligations and Millendo may be required to agree to certain
restrictive covenants therein, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely affect its ability
to conduct its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo raises additional capital through collaborations, strategic alliances or third-party licensing
arrangements, it may have to relinquish valuable rights to its intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to it. If Millendo is unable to raise
additional capital through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts, or grant rights to develop and market product candidates that it
would otherwise develop and market itself. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Development and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo has never obtained marketing approval for a product candidate and may be unable to obtain, or may be delayed in obtaining, marketing approval
for any future product candidates that it may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has never obtained marketing approval for a product candidate. It
is possible that the FDA may refuse to accept for substantive review any NDAs that Millendo submits for any future candidates Millendo may choose to develop or may conclude after review of the data that Millendo&#146;s application is insufficient to
obtain marketing approval of its product candidates. If the FDA does not accept or approve Millendo&#146;s NDAs for any of Millendo&#146;s future product candidates, it may require that Millendo conduct additional clinical trials, preclinical
studies or manufacturing validation studies and submit that data before it will reconsider Millendo&#146;s applications. Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT> trials or studies, approval
of any New Drug Application, or NDA, or application that Millendo submits may be delayed by several&nbsp;years or may require Millendo to expend more resources than it has available. It is also possible that additional trials or studies, if
performed and completed, may not be considered sufficient by the FDA to approve Millendo&#146;s NDAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining, or an
inability to obtain, marketing approvals would prevent Millendo from commercializing its product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occurs, Millendo may be forced to abandon its
development efforts for its product candidates, which could significantly harm its business, prospects, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo is exposed to a variety of risks associated with its international operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the closing date of the merger Millendo completed with OvaScience, Inc. or OvaScience in 2018 (&#147;the OvaScience Merger&#148;),
Millendo has been engaged in the process of winding up various subsidiaries of OvaScience, some or all of which are in foreign jurisdictions. Millendo is also in the process of closing all other international subsidiaries. Millendo expects to incur
additional costs to complete these processes. Moreover, even if Millendo successfully winds up these entities, Millendo may be exposed to liability in these foreign jurisdictions as a result of their historical operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in December&nbsp;2017, Millendo acquired Aliz&eacute; Pharma SAS (&#147;Aliz&eacute;&#148;), a biopharmaceutical company based in
Lyon, France. As of March&nbsp;31, 2021, Millendo had 11 employees located in the United States and one employee located in France. Millendo&#146;s past and current global operations expose it to numerous and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sometimes conflicting legal, tax and regulatory requirements, and violations or unfavorable interpretation by the respective authorities of these regulations could harm its business. Risks
associated with international operations include the following, and these risks may be more pronounced if Millendo seeks to commercialize any future product candidates outside of the United States: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in diplomatic and trade relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anti-corruption laws, including the Foreign Corrupt Practices Act, or FCPA, and its equivalent in foreign
jurisdictions, such as the UK Bribery Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from pandemics and public health emergencies, including those related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are complex regulatory, tax, labor, and other legal requirements imposed by both the European Union and many of the
individual countries in and outside of the European Union, with which Millendo may need to comply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against Millendo
could cause it to incur substantial liabilities and could limit commercialization of any future product candidate that Millendo may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo faces an inherent risk of product liability exposure related to its historical testing of product candidates. If Millendo cannot
successfully defend itself against claims that any such product candidates caused injuries, Millendo could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidate that Millendo may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidate that it may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to its reputation and significant negative media attention; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased marketing costs to attempt to overcome any injury to its reputation or negative media attention.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Millendo faces an inherent risk of product liability exposure related to
OvaScience&#146;s prior use of fertility treatments in humans. Product liability claims involving OvaScience&#146;s activities may be brought for significant amounts because OvaScience&#146;s potential fertility treatments involved mothers and
children. For example, it is possible that Millendo will be subject to product liability claims that assert that OvaScience&#146;s potential fertility treatments have caused birth defects in children or that such defects are inheritable. These
claims could be made many&nbsp;years into the future based on effects that were not observed or observable at the time of birth. If Millendo cannot successfully defend against claims that OvaScience&#146;s potential fertility treatments caused
injuries, Millendo will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in, among other things, significant costs to defend the related litigation; substantial monetary awards or payments to trial
participants or patients; loss of revenue; and the diversion of management&#146;s resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Millendo maintains product
liability insurance coverage, such insurance may not be adequate to cover all liabilities that it may incur. Millendo anticipates that it will need to increase its insurance coverage each time it commences a clinical trial and if it successfully
commercializes any product candidate. Insurance coverage is increasingly expensive. Millendo may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If OvaScience failed to comply with environmental, health and safety laws and regulations, Millendo could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OvaScience was subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. OvaScience&#146;s prior operations involved the use of hazardous and
flammable materials, including chemicals and biological materials. OvaScience&#146;s prior operations also produced hazardous waste products. OvaScience generally contracted with third-parties for the disposal of these materials and wastes. In the
event of contamination or injury resulting from OvaScience&#146;s use of hazardous materials, Millendo could be held liable for any resulting damages, and any liability could exceed Millendo&#146;s resources. Millendo also could incur significant
costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo does not maintain insurance for environmental liability or toxic
tort claims that may be asserted against it in connection with OvaScience&#146;s storage or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory,
legislative or self-regulatory/standard developments regarding privacy and data security matters could adversely affect Millendo&#146;s ability to conduct its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is subject to and affected by laws, rules, regulations and industry standards related to data privacy and security, and restrictions
or technological requirements regarding the collection, use, storage, security, retention or transfer of data. In the United States, the rules&nbsp;and regulations to which Millendo may be subject include federal laws and regulations enforced by the
Federal Trade Commission, HHS, and state privacy, data security, and breach notification laws, as well as regulator enforcement positions and expectations. Internationally, governments and agencies have adopted and could in the future adopt, modify,
apply or enforce additional laws, policies, regulations, and standards covering privacy and data security that may apply to Millendo&#146;s business. New regulation or legislative actions regarding data privacy and security (together with applicable
industry standards) may increase its costs of doing business. In addition to privacy and data security regulations currently in force in the jurisdictions where Millendo operates, the European Union General Data Protection Regulation
(&#147;GDPR&#148;), went into effect in May&nbsp;2018. The GDPR contains numerous requirements and changes from existing European Union (&#147;EU&#148;), law, including more robust obligations on data processors and data controllers and heavier
documentation requirements for data protection compliance programs. Specifically, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the GDPR will introduce numerous privacy-related changes for companies operating in the EU, including greater control over personal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">data-by-data</FONT></FONT> subjects (e.g., the &#147;right to be forgotten&#148;), increased data portability for EU consumers, data breach notification requirements, and increased
fines. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between Millendo and its subsidiaries, including employee information. However, despite the ongoing efforts to bring Millendo&#146;s
practices into compliance before the effective date of the GDPR, Millendo may not be successful either due to various factors within its control, such as limited financial or human resources, or other factors outside its control. It is also possible
that local data protection authorities may have different interpretations of the GDPR, leading to potential inconsistencies amongst various EU member states. Any failure or alleged failure (including as a result of deficiencies in its policies,
procedures, or measures relating to privacy, data security, marketing, or communications) by Millendo to comply with laws, regulations, policies, legal or contractual obligations, industry standards, or regulatory guidance relating to privacy or
data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties, additional regulatory oversight and reporting obligations or adverse publicity. Further, because of the work-from-home policies
Millendo implemented due to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> information that is normally protected, including company confidential information, may be less secure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection
in the United States, the European Union, and in other jurisdictions, and cannot determine the impact such future laws, regulations and standards may have on its business. Future laws, regulations, standards and other obligations or any changed
interpretation of existing laws or regulations could impair its ability to operate its business and negatively impact its results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Millendo&#146;s Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Millendo is unable to obtain and maintain patent protection for its technology and products,
or if the scope of the patent protection obtained is not sufficiently broad, Millendo may not be able to compete effectively in its markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent Millendo resumes drug development activities, it will rely upon a combination of patents, trade secret protection and
confidentiality agreements to protect the intellectual property related to its product candidates. The patent prosecution process is expensive and time-consuming, and Millendo may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is
highly uncertain, involves complex legal and factual questions and has in recent&nbsp;years been the subject of much litigation. In addition, the laws of foreign countries may not protect Millendo&#146;s rights to the same extent as the laws of the
United States, or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Further, Millendo may not be aware of all third-party intellectual property rights
potentially relating to its product candidates. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically published 18&nbsp;months
after filing, or in some cases, not at all. Therefore, Millendo cannot know with certainty whether it was the first to make the inventions claimed in its owned or licensed patents or pending patent applications, or that it was the first to file for
patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of Millendo&#146;s patent rights are highly uncertain. The pending and future patent applications may not result in patents being
issued which protect Millendo&#146;s technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the
patent laws in the United States and other countries may diminish the value of Millendo&#146;s patents or narrow the scope of its patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of Millendo patent applications and
the enforcement or defense of its issued patents. On September&nbsp;16, 2011, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Leahy-Smith America Invents Act (the &#147;Leahy-Smith Act&#148;), was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include
provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent and Trademark Office (&#147;USPTO&#148;), recently developed new regulations and procedures to govern administration of
the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any,
impact the Leahy-Smith Act will have on the operation of Millendo&#146;s business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Millendo&#146;s patent applications and
the enforcement or defense of its issued patents, all of which could have a material adverse effect on its business and financial condition. Any further changes in either the patent laws or interpretation of the patent laws in the United States and
other countries may diminish the value of Millendo&#146;s patents and patent applications or narrow the scope of its potential patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, Millendo may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO
or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, Millendo&#146;s patent rights, allow third-parties to commercialize its technology or product candidates and compete directly with Millendo, without payment to Millendo, or result in
Millendo&#146;s inability to manufacture or commercialize product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by Millendo&#146;s patents and patent applications is
threatened, it could dissuade companies from collaborating with Millendo to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and Millendo&#146;s owned and licensed
patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in
part, which could limit its ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection of Millendo&#146;s technology and product candidates. Moreover,
patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&nbsp;years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Various extensions
may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for Millendo&#146;s current or future product candidates, it may be open to competition from generic versions of such drugs. Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, Millendo&#146;s owned
and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing drugs similar or identical to that of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo jointly owns patents and patent applications with third-parties. Millendo&#146;s ability to exploit or enforce these patent rights, or to
prevent the third-party from granting licenses to others with respect to these patent rights, may be limited in some circumstances. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo jointly owns certain patents and patent applications with third-parties. In the absence of an agreement with each <FONT
STYLE="white-space:nowrap">co-owner</FONT> of jointly owned patent rights, Millendo will be subject to default rules&nbsp;pertaining to joint ownership. Some countries require the consent of all joint owners to exploit, license or assign jointly
owned patents, and if Millendo is unable to obtain that consent from the joint owners, it may be unable to exploit the invention or to license or assign its rights under these patents and patent applications in those countries. For example, Millendo
secured exclusive rights from the University of Michigan for certain patents and patent applications that they jointly own with Millendo related to nevanimibe. Additionally, in the United States, each <FONT STYLE="white-space:nowrap">co-owner</FONT>
may be required to be joined as a party to any claim or action Millendo may wish to bring to enforce these patent rights, which may limit its ability to pursue third-party infringement claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo has <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications from
third-parties. Its ability to exploit or enforce these patent rights, or to prevent the third-party from granting licenses to others with respect to these patent rights, may be limited in some circumstances. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has <FONT STYLE="white-space:nowrap">in-licensed</FONT> certain patents and patent applications from third-parties. In the absence of
an agreement with each patent rights owner, Millendo will be subject to default rules pertaining to ownership. Some countries require the consent of all owners to exploit, license or assign owned patents, and if Millendo is unable to obtain that
consent from the owners, it may be unable to exploit the invention or to license or assign its rights under these patents and patent applications in those countries. For example, Millendo secured exclusive rights from Roche for certain patents and
patent applications that Roche owns related to <FONT STYLE="white-space:nowrap">MLE-301.</FONT> Additionally, in the United States, each owner may be required to be joined as a party to any claim or action Millendo may wish to bring to enforce these
patent rights, which may limit its ability to pursue third-party infringement claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining Millendo&#146;s patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and Millendo&#146;s patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity
fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States in several stages over the lifetime of Millendo&#146;s owned and licensed
patents and/or applications and any patent rights it may own or license in the future. Millendo relies on its outside counsel or its licensing partners to pay these fees due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The
USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. Millendo employs
reputable law firms and other professionals to help it comply and is also dependent on its licensors to take the necessary action to comply with these requirements with respect to its licensed intellectual property. In many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are situations, however, in
which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such an event, potential competitors might be able to enter the market and this circumstance would have a material adverse effect on
Millendo&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect Millendo&#146;s competitive position on its product candidates for an adequate
amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. Millendo has in the past sought, and in the future may seek, extensions of patent terms in the United States and, if available, in other
countries where it is prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits extension of the term of one U.S. patent that includes at least one claim covering the composition of matter
of an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> method of treatment using the drug. The extended patent term cannot exceed the shorter of five&nbsp;years beyond the <FONT
STYLE="white-space:nowrap">non-extended</FONT> expiration of the patent or 14&nbsp;years from the date of the FDA approval of the drug. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent
regulatory authority in other countries, may not agree with Millendo&#146;s assessment of whether such extensions are available, and may refuse to grant extensions to Millendo&#146;s patents, or may grant more limited extensions than it requests.
Further, Millendo may not elect to extend the most beneficial patent to it or the claims underlying the patent that it chooses to extend could be invalidated. If any of the foregoing occurs, Millendo&#146;s competitors may be able to take advantage
of Millendo&#146;s investment in development and clinical trials by referencing its clinical and preclinical data and launch their drug earlier than might otherwise be the case. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to Millendo&#146;s
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by Millendo&#146;s intellectual property rights is uncertain because
intellectual property rights have limitations and may not adequately protect its business. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds or formulations that are similar to Millendo&#146;s formulation but that are
not covered by the claims of the patents that it owns or controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo or any strategic partners might not have been the first to make the inventions covered by the issued
patents or pending patent applications that it owns or controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo might not have been the first to file patent applications covering certain of its inventions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of Millendo&#146;s
technologies without infringing its intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that Millendo&#146;s pending patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that Millendo owns or controls may not provide it with any competitive advantages, or may be held
invalid or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s competitors might conduct research and development activities in the United States and other
countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where Millendo does not have patent rights and then use the information learned from such activities to
develop competitive drugs for sale in Millendo&#146;s major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on Millendo&#146;s business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-parties may initiate legal proceedings, which are expensive and time consuming, alleging that Millendo is infringing their intellectual property
rights, the outcome of which would be uncertain and could have a material adverse impact on the success of Millendo&#146;s business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual
property rights. Millendo may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to any future product candidates and technology, including interference
proceedings, post grant review and inter partes review before the USPTO. Third-parties may assert infringement claims against Millendo based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk
that third-parties may choose to engage in litigation with Millendo to enforce or to otherwise assert their patent rights against Millendo. Even if Millendo believes such claims are without merit, a court of competent jurisdiction could hold that
these third-party patents are valid, enforceable and infringed, which could have a material adverse effect on its ability to commercialize any future product candidates. In order to successfully challenge the validity of any such U.S. patent in
federal court, Millendo would need to overcome a presumption of validity. As this burden is a high one requiring Millendo to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court
of competent jurisdiction would invalidate the claims of any such U.S. patent. If Millendo is found to infringe a third-party&#146;s valid and enforceable intellectual property rights, Millendo could be required to obtain a license from such
third-party to continue developing, manufacturing and marketing its product candidate and technology. However, Millendo may not be able to obtain any required license on commercially reasonable terms or at all. Even if Millendo was able to obtain a
license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving its competitors and other third-parties access to the same technologies licensed to Millendo, and it could require Millendo to make substantial licensing and
royalty payments. Millendo could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, Millendo could be found liable for monetary damages, including
treble damages and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attorneys&#146; fees, if it is found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent Millendo from manufacturing and
commercializing any future product candidates or force it to cease some or all of its business operations, which would have a material adverse effect on its business. Claims that Millendo has misappropriated the confidential information or trade
secrets of third-parties could have a similar material adverse effect on its business. Even if Millendo prevails in such infringement claims, patent litigation can be expensive and time consuming, which would harm its business, financial condition
and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may become involved in lawsuits to protect or enforce its patents, the patents of its licensors or its other
intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise
violate Millendo&#146;s patents, the patents of its licensors or its other intellectual property rights. To counter infringement or unauthorized use, Millendo may be required to file legal claims, which can be expensive and time-consuming. In
addition, in an infringement proceeding, a court may decide that a patent of Millendo or its licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that its patents do not
cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of Millendo&#146;s patents at risk of being invalidated or interpreted narrowly and could put Millendo&#146;s patent applications at
risk of not issuing. The initiation of a claim against a third-party may also cause the third-party to bring counter claims against Millendo such as claims asserting that Millendo&#146;s patents are invalid or unenforceable. In patent litigation in
the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT
STYLE="white-space:nowrap">non-enablement</FONT> or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from
the USPTO, or made a materially misleading statement, during prosecution. Third-parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or
oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Millendo cannot be
certain that there is no invalidating prior art, of which Millendo and the patent examiner were unaware during prosecution. For the patents and patent applications that it has licensed, it may have a limited or no right to participate in the defense
of any licensed patents against challenge by a third-party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, Millendo would lose at least part, and perhaps all, of any future patent protection on its current or
future product candidates. Such a loss of patent protection could have material adverse effect on its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo may not be able
to prevent, alone or with its licensors, misappropriation of its intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any litigation or other proceedings to enforce its
intellectual property rights may fail, and even if successful, may result in substantial costs and distract its management and other employees. Even if Millendo prevails in such infringement claims, patent litigation can be expensive and time
consuming, which would harm its business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of Millendo&#146;s confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of Millendo&#146;s common stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the
value of patents in general, thereby impairing Millendo&#146;s ability to protect its product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States has
recently enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent&nbsp;years, either narrowing the scope of patent protection available in certain circumstances or weakening
the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Millendo&#146;s ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on actions by the U.S. Congress, federal courts, USPTO, and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable
ways that would weaken Millendo&#146;s ability to obtain new patents or to enforce patents that it has licensed or that it might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in
the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken Millendo&#146;s ability to obtain new patents or to enforce patents that it has licensed or that it may
obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may not be able to protect its intellectual property rights throughout the world, which could have a material
adverse effect on its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents covering any future product candidates throughout the
world would be prohibitively expensive. Competitors may use Millendo&#146;s technologies in jurisdictions where it has not obtained patent protection to develop its own drugs and, further, may export otherwise infringing drugs to territories where
Millendo may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with Millendo&#146;s drugs in jurisdictions where Millendo does not have any issued or licensed patents and
any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may
be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third-parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Millendo&#146;s employees, consultants or advisors are currently, or were previously, employed at universities or other
biotechnology or pharmaceutical companies, including Millendo&#146;s competitors or potential competitors. Although Millendo tries to ensure that its employees, consultants and advisors do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for Millendo, Millendo may be subject to claims that these individuals or Millendo has used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If Millendo fails in defending any such claims, in addition to paying monetary damages Millendo may lose valuable
intellectual property rights or personnel. Even if Millendo is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is Millendo&#146;s approach to require its employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to Millendo, it may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that
Millendo regards as its own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and Millendo may be forced to bring claims against third-parties, or defend claims that they may
bring against Millendo, to determine the ownership of what Millendo regards as its intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Millendo&#146;s Dependence on Third-Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may in the future enter into collaborations with third-parties to develop its product candidates. If these collaborations are not successful,
its business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo may enter into collaborations with third-parties in the future. It may in the future
determine to collaborate with other pharmaceutical and biotechnology companies for development and potential commercialization of its product candidates. These relationships, or those like them, may require Millendo to incur <FONT
STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase Millendo&#146;s near- and long-term expenditures, issue securities that dilute Millendo&#146;s existing stockholders or disrupt its management and business. In addition,
Millendo could face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Millendo&#146;s ability to reach a definitive collaboration agreement will depend, among other things, upon
its assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of several factors. If Millendo licenses rights to its product candidates, it
may not be able to realize the benefit of such transactions if it is unable to successfully integrate them with its existing operations and company culture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such potential future collaborations do not result in the successful development and commercialization of product candidates, or if one
of Millendo&#146;s future collaborators terminates its agreement with Millendo, Millendo may not receive any future research funding or milestone or royalty payments under the collaboration. If Millendo does not receive the funding its expects under
these agreements, the development of its product candidates could be delayed and it may need additional resources to develop its product candidates. In addition, if one of Millendo&#146;s future collaborators terminates its agreement with Millendo,
Millendo may find it more difficult to attract new collaborators and the perception of Millendo in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and
commercialization apply to the activities of Millendo&#146;s potential future collaborators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Millendo&#146;s Business Operations and
Employee Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s business, preclinical studies and clinical development programs and timelines, its financial condition and
results of operations could be materially and adversely affected by the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A novel strain of coronavirus, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> causing <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> has been declared a pandemic by the World Health Organization. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in travel and other restrictions in order to reduce the spread of
the disease, including state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease
<FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibit certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings, and order cessation of <FONT STYLE="white-space:nowrap">non-essential</FONT>
travel. In response to these public health directives and orders, Millendo has implemented work-from-home policies for certain employees. The effects of the executive orders, the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders and the work-from-home policies may negatively impact productivity, disrupt Millendo&#146;s business and delay its clinical programs and
timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on Millendo&#146;s ability to conduct its business in the ordinary course. These and similar, and perhaps more severe,
disruptions in Millendo&#146;s operations could negatively impact its business, operating results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> may adversely impact Millendo&#146;s business operations and the
business operations of its contract research organizations conducting its clinical trials and its third-party manufacturing facilities in the United States and other countries. In particular, some of Millendo&#146;s third-party manufacturers which
it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical studies and clinical trials are located in countries affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
and should they experience disruptions, such as temporary closures or suspension of services, Millendo would likely experience delays in advancing these tests and trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad
impact globally, may materially affect Millendo economically. While the potential economic impact brought by, and the duration of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, a widespread pandemic could
result in significant disruption of global financial markets, reducing Millendo&#146;s ability to access capital, which could in the future negatively affect Millendo&#146;s liquidity. In addition, a recession or market correction resulting from the
spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect Millendo&#146;s business and the value of its common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global pandemic of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to rapidly evolve. The extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts Millendo&#146;s business, Millendo&#146;s clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence,
such as the duration of the outbreak, travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries, and business disruptions, and the effectiveness of actions taken in the United
States and other countries to contain and treat the disease. Accordingly, Millendo does not yet know the full extent of potential delays or impacts on its business, its clinical and regulatory activities, healthcare systems or the global economy as
a whole. However, these impacts could adversely affect Millendo&#146;s business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects Millendo&#146;s business
and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#145;&#145;Risk Factors&#146;&#146; section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo has recently reduced the size of its organization, and it may encounter difficulties in managing its business as a result of this reduction, or
the attrition that may occur following this reduction, which could disrupt Millendo&#146;s operations. In addition, Millendo may not achieve anticipated benefits and savings from the reduction. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, Millendo began the implementation of a reduction in force that will reduce the number of its employees by up to
85&nbsp;percent. The reduction in force, and the attrition thereafter, resulted in the loss of longer-term employees, the loss of institutional knowledge and expertise and the reallocation and combination of certain of roles and responsibilities
across the organization, all of which could adversely affect Millendo&#146;s operations. Millendo anticipates that its <FONT STYLE="white-space:nowrap">pre-closing</FONT> workforce will no longer be employed at the closing of the merger. However, if
the merger is not consummated, given the complexity and nature of Millendo&#146;s business, it must continue to implement and improve its managerial, operational and financial systems, manage its facilities and continue to recruit and retain
qualified personnel. This will be made more challenging given the reduction in force described above and additional measures Millendo may take to reduce costs. As a result, Millendo&#146;s management may need to divert a disproportionate amount of
its attention away from its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> strategic and operational activities, and devote a substantial amount of time to managing these organizational changes. Further,
the restructuring and possible additional cost containment measures may yield unintended consequences, such as attrition beyond Millendo&#146;s intended reduction in force and reduced employee morale. In addition, employees who were not affected by
the reduction in force may seek alternate employment which would result in Millendo seeking contract support at unplanned additional expense. In addition, Millendo may not achieve anticipated benefits from the reduction in force. Due to
Millendo&#146;s limited resources, it may not be able to effectively manage its operations or recruit and retain qualified personnel, which may result in weaknesses in its infrastructure and operations, risks that it may not be able to comply with
legal and regulatory requirements, loss of business opportunities, loss of employees and reduced productivity among remaining employees. If Millendo&#146;s management is unable to effectively manage this transition and reduction in force and
additional cost containment measures, Millendo&#146;s expenses may be more than expected, and it may not be able to implement its business strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s employees, independent contractors, principal investigators, consultants, commercial
collaborators, service providers and other vendors may engage in misconduct or other improper activities, including historical noncompliance with regulatory standards and requirements, which could have an adverse effect on its results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is exposed to the risk of fraud or other misconduct by its employees, principal investigators, consultants and commercial
partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with
healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to Millendo. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or
other regulatory authorities, which could result in regulatory sanctions and cause serious harm to Millendo&#146;s reputation. It is not always possible to identify and deter employee misconduct, and the precautions Millendo takes to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting it from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any
such actions are instituted against Millendo and it is not successful in defending itself or asserting its rights, those actions could have a negative impact on Millendo&#146;s business, financial condition and results of operations, including the
imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may be delayed in its receipt of certain tax benefits that Aliz&eacute; historically
received as a French technology company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a French technology company, Aliz&eacute; historically benefited from certain tax
advantages, including the French research tax credit (<I>credit d&#146;impot recherche</I>) (&#147;CIR&#148;). The CIR is a French tax credit aimed at stimulating research and development and can offset French corporate income tax due. Aliz&eacute;
has historically received CIR reimbursements promptly following filing for such reimbursements with applicable French taxing authorities. For the year ended December&nbsp;31, 2018, claims were made totaling $1.3&nbsp;million, which Millendo received
in the third quarter of 2019. For the year ended December&nbsp;31, 2019, claims were made totaling $1.3&nbsp;million, which Millendo received in the second quarter of 2020. In the future, Millendo may no longer qualify as a French small or medium
size enterprise, and, accordingly, it may be subject to a three-year waiting period for reimbursement of CIRs, which could adversely affect the combined business&#146;s results of operations and cash flows. In addition, the amount of CIR received
is, among other factors, dependent upon incurring qualified research and development expenses and maintaining a certain level of employee salaries and other personnel costs in France. The number of Millendo&#146;s research and development employees
in France decreased during the year ended December&nbsp;31, 2020 and it experienced a decrease in qualified research and development expenses for the year ended December&nbsp;31, 2020 due to the discontinuation of its livoletide program. Millendo
plans to dissolve its subsidiary in France. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s internal computer systems, or those of its collaborators or other contractors or
consultants, may fail or suffer security breaches, which could result in a material disruption of its product development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s internal computer systems and those of its current and any future collaborators and other contractors or consultants are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While Millendo is not aware of any such material system failure, accident or security breach to date,
if such an event were to occur and cause interruptions in its operations, it could result in a material disruption of Millendo&#146;s development programs and business operations, whether due to a loss of Millendo&#146;s trade secrets or other
proprietary information or other similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in Millendo&#146;s regulatory approval efforts and significantly increase
its costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, Millendo&#146;s data or applications, or inappropriate disclosure of confidential or proprietary information,
Millendo could incur liability, its competitive position could be harmed and the further development and commercialization of its product candidates could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo may be exposed to significant foreign exchange risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo incurs portions of its expenses, and may in the future derive revenue, in currencies other than the U.S. dollar, in particular, the
euro. As a result, it is exposed to foreign currency exchange risk as its results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Any fluctuation in the exchange rate of these foreign currencies may
negatively impact Millendo&#146;s business, financial condition and operating results. Global economic events, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, have and may continue to significantly impact local economies and
the foreign exchange markets, which may increase the risks associated with sales denominated in foreign currencies. Millendo currently does not engage in hedging transactions to protect against uncertainty in future exchange rates between particular
foreign currencies and the euro. Therefore, for example, an increase in the value of the euro against the U.S. dollar could be expected to have a negative impact on its operating expenses as euro denominated expenses, if any, would be translated
into U.S. dollars at an increased value. Millendo cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect its financial condition, results of operations and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The risks arising with respect to the historic OvaScience business and operations may be different from what Millendo anticipates, which could lead to
significant, unexpected costs and liabilities and could materially and adversely affect Millendo&#146;s business going forward. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It
is possible that Millendo may not have fully anticipated the extent of the risks associated with the OvaScience Merger Millendo completed with OvaScience in 2018. After the OvaScience Merger, OvaScience&#146;s historic business was discontinued, but
prior to the transaction OvaScience had a significant operating history. As a consequence, Millendo may be subject to claims, demands for payment, regulatory issues, costs and liabilities that were not and are not currently expected or anticipated.
Notwithstanding Millendo&#146;s exercise of due diligence <FONT STYLE="white-space:nowrap">pre-transaction</FONT> and winding down of the OvaScience business post-transaction, the risks involved with taking over a business with a significant
operating history and the costs and liabilities associated with these risks may be greater than anticipated. Millendo may not be able to contain or control the costs or liabilities associated with OvaScience&#146;s historic business, which could
materially and adversely affect its business, liquidity, capital resources or results of operation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Millendo&#146;s
Common Stock and Its Status as a Public Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of Millendo&#146;s common stock has been and is likely to
continue to be volatile, and purchasers of its common stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Millendo&#146;s
common stock has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in price in response to various factors. A number of factors could influence the volatility in the trading price of Millendo&#146;s
common stock, including changes in the economy or in the financial markets, including recently in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, industry-related developments, and the impact of material events
and changes in its operations, including as a result of its recent announcements that Millendo has discontinued its livoletide program in PWS and ceased investing in its nevanimibe program and its <FONT STYLE="white-space:nowrap">MLE-301</FONT>
program. Worsening economic conditions and other adverse effects or developments relating to Millendo&#146;s business or the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may negatively affect the market price of its common
stock. The market price for Millendo&#146;s common stock is likely to continue to be volatile, particularly due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and subject to significant price and volume fluctuations in
response to market, industry and other factors, including the risk factors described in this &#147;Risk Factors&#148; section. As a result of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for Millendo&#146;s common stock may be influenced by many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements and market perceptions related to the merger with Tempest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by Millendo or by any securities analysts who might cover Millendo&#146;s stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in Millendo&#146;s industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the
biopharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about Millendo or its industry or positive or negative recommendations or
withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by Millendo or its competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of Millendo&#146;s operations or lawsuits filed against
it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of Millendo and its business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of Millendo&#146;s common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and
Millendo&#146;s ability to obtain patent protection for its technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond Millendo&#146;s control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following
periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against Millendo, could cause it to incur substantial costs and divert management&#146;s attention and resources from its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of Millendo&#146;s common stock in the public market could cause its share price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of Millendo&#146;s common stock in the public market could occur at any time, subject to the
restrictions and limitations described below. If Millendo stockholders sell, or the market perceives that its stockholders intend to sell, substantial amounts of Millendo&#146;s common stock in the public market, the market price of Millendo&#146;s
common stock could decline significantly&nbsp;and could impair Millendo&#146;s ability to raise capital through the sale of additional equity securities. Millendo is unable to predict the effect that sales, particularly sales by its directors,
executive officers, and significant stockholders, may have on the prevailing market price of its common stock. As of March&nbsp;31, 2021, Millendo had 19,043,034 shares of common stock outstanding. All of the outstanding shares of Millendo common
stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act. In addition, the shares of common stock subject to outstanding options under Millendo&#146;s equity incentive plans and the
shares reserved for future issuance under those equity incentive plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. In addition, certain holders of Millendo&#146;s common
stock have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the right, subject to various conditions and limitations, to request Millendo include their shares of Millendo&#146;s common stock in registration statements Millendo may file relating to its
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in Millendo&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> and under Delaware law
could make an acquisition of Millendo, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in Millendo&#146;s certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> may discourage, delay or prevent
a merger, acquisition or other change in control of Millendo that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also
limit the price that investors might be willing to pay in the future for shares of Millendo&#146;s common stock, thereby depressing the market price of its common stock. In addition, because the Millendo board of directors is responsible for
appointing the members of Millendo&#146;s management team, these provisions may frustrate or prevent any attempts by Millendo stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of
the Millendo board of directors. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that not all members of the Millendo board of directors are
elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of Millendo&#146;s directors to be changed only by resolution of its board of
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from the Millendo board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
for nominations to Millendo&#146;s board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit actions by Millendo stockholders by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions be effected at a duly called stockholders meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize Millendo&#146;s board of directors to issue preferred stock without stockholder approval, which could
be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by Millendo&#146;s board of directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 75&nbsp;percent of the votes that all Millendo stockholders would
be entitled to cast to amend or repeal certain provisions of Millendo&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because Millendo is incorporated in Delaware, it is governed by the provisions of Section&nbsp;203 of the Delaware General
Corporation Law, which prohibits a person who owns 15&nbsp;percent or more of Millendo&#146;s outstanding voting stock from merging or combining with Millendo for a period of three&nbsp;years after the date of the transaction in which the person
acquired 15&nbsp;percent or more of Millendo&#146;s outstanding voting stock, unless the merger or combination is approved in a manner prescribed by the statute. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo is at risk of securities class action and similar litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of
Millendo&#146;s securities. This risk is especially relevant for Millendo because biopharmaceutical companies have experienced significant stock price volatility in recent&nbsp;years. Millendo remains the subject of various securities class action
lawsuits and shareholder derivative lawsuits that were filed against OvaScience and certain of its officer and directors, as described in more detail in the section titled &#147;<I>Millendo&#146;s Business&#151;Legal Proceedings</I>&#148; of this
proxy statement/prospectus. These lawsuits, as well as any similar lawsuits initiated in the future, could result in substantial cost and a diversion of management&#146;s attention and resources, which could harm Millendo&#146;s business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above in the section titled &#147;Recent Developments - Litigation&#148;
beginning on page 14 of this proxy statement/prospectus, four complaints have been filed against Millendo and each of its directors in connection with the transaction. These lawsuits, as well as any similar lawsuits initiated in the future, could
result in substantial cost and a diversion of management&#146;s attention and resources, which could harm Millendo&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Millendo
fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is subject to the reporting requirements of the Exchange Act, The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer
Protection Act, and the rules and regulations of the stock market on which Millendo&#146;s common stock is listed. The Sarbanes-Oxley Act requires, among other things, that Millendo maintains effective disclosure controls and procedures and internal
control over financial reporting and that it furnish a report by management on, among other things, the effectiveness of its internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by
Millendo&#146;s management in its internal control over financial reporting. However, due to recent changes in SEC rules related to smaller reporting companies, Millendo is not required to have its auditors formally attest to the effectiveness of
its internal control over financial reporting. For the year ended December&nbsp;31, 2018, Millendo was unable to conduct the required assessment primarily due to the OvaScience Merger occurring in the fourth quarter of 2018 and the substantial
change in operational focus, management and the internal control environment following the OvaScience Merger. As a result, Millendo provided its first internal control assessment with its Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo may identify weaknesses in its system of
internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. its internal control over financial reporting will not prevent or detect all errors and all fraud. A control system,
no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo is not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if it is unable
to maintain proper and effective internal controls, it may not be able to produce timely and accurate financial statements. If that were to happen, the market price of Millendo&#146;s stock could decline and it could be subject to sanctions or
investigations by the stock exchange on which Millendo&#146;s common stock is listed, the SEC, or other regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo expects to
continue to incur increased costs as a result of operating as a public company, and its management is required to devote substantial time to compliance with its public company responsibilities and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a relatively new public company, Millendo continues to incur significant legal, accounting and other expenses that it did not incur as a
private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq and other applicable securities rules&nbsp;and regulations impose various requirements on public
companies. Millendo&#146;s management and other personnel need to devote a substantial amount of time to compliance with these requirements. Moreover, these rules&nbsp;and regulations increase its legal and financial compliance costs and will make
some activities more time-consuming and costly. For example, Millendo expects that these rules&nbsp;and regulations may make it more difficult and more expensive for it to obtain directors&#146; and officers&#146; liability insurance, compared to
when it was a private company, which could make it more difficult for it to attract and retain qualified members of its board of directors. Millendo cannot predict or estimate the amount of additional costs it will continue to incur as a public
company or the timing of such costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s effective tax rate may fluctuate, and it may incur obligations in tax jurisdictions in
excess of accrued amounts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is subject to taxation in more than one tax jurisdiction. As a result, its effective tax rate
is derived from a combination of applicable tax rates in the various places that it operates. In preparing financial statements, Millendo estimates the amount of tax that will become payable in each of such places. Nevertheless, its effective tax
rate may be different than experienced in the past due to numerous factors, including changes to the federal corporate income tax laws, changes in the mix of its profitability from jurisdiction to jurisdiction, the results of examinations and audits
of its tax filings, its inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes, cash repatriation restrictions and possible withholding taxes and other changes in tax laws. Any of these
factors could cause Millendo to experience an effective tax rate significantly different from previous periods or its current expectations and may result in tax obligations in excess of amounts accrued in its financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo&#146;s ability to use net operating loss carryforwards and tax credit carryforwards may be subject to limitations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Millendo had federal and state NOLs of $330.8&nbsp;million and $280.9&nbsp;million, respectively. Its NOLs could
expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Millendo&#146;s federal and state NOL carryforwards will begin to expire, if not utilized, by
2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 and Section&nbsp;383 of the Code and corresponding provisions of state law, if a corporation undergoes an
&#147;ownership change,&#148; its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset its
post-change income may be limited. A Section&nbsp;382 &#147;ownership change&#148; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. Millendo
believes that it has experienced an ownership change in the past, and may experience ownership changes in the future due to subsequent shifts in its stock ownership (some of which are outside of its control). Furthermore, the merger, if consummated,
will constitute an ownership change (within the meaning of Section&nbsp;382 of the Code) of Millendo which could eliminate or otherwise substantially limit the combined company&#146;s ability to use its federal and state NOLs to offset its future
taxable income. Consequently, even if the combined company achieves profitability, it may not be able to utilize a material portion of Millendo&#146;s NOL carryforwards and other tax attributes, which could have a material adverse effect on cash
flow and results of operations. Similar provisions of state tax law may also apply to limit Millendo&#146;s use of accumulated state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or
other unforeseen reasons, Millendo&#146;s existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Millendo
does not anticipate paying any cash dividends on its common stock in the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors should not rely on an
investment in Millendo&#146;s common stock to provide dividend income. Millendo has not declared or paid cash dividends on its common stock to date. Millendo currently intends to retain its future earnings, if any, to fund the development and growth
of its business. In addition, the terms of any existing or future debt agreements may preclude Millendo from paying dividends. As a result, capital appreciation, if any, of its common stock will be a Millendo stockholder&#146;s sole source of gain
for the foreseeable future. Investors seeking cash dividends should not purchase Millendo common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><A NAME="toc150774_22"></A>Risks Related to
Tempest </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_23"></A>Risks Related to Tempest&#146;s Financial Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest and its auditors have substantial doubt about Tempest&#146;s ability to continue as a going concern, which may hinder its ability to obtain
further financing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s recurring losses from operations raise substantial doubt about its ability to continue as a
going concern. As a result, management has included disclosures in Note 1 of the financial statements and Tempest&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independent registered public accounting firm included an explanatory paragraph in its report on its financial statements for the year ended December&nbsp;31, 2020 with respect to this
uncertainty. Tempest&#146;s 2020 financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the
outcome of this uncertainty. Tempest&#146;s ability to continue as a going concern will require Tempest to obtain additional funding. If Tempest is unable to raise capital when needed or on acceptable terms, it would be forced to delay, reduce or
eliminate its research and development programs, and Tempest&#146;s stockholders could lose all, or a significant portion, of their investment in Tempest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest has a history of operating losses, and Tempest may not achieve or sustain profitability. Tempest anticipates that it will continue to incur
losses for the foreseeable future. If Tempest fails to obtain additional funding to conduct its planned research and development efforts, Tempest could be forced to delay, reduce or eliminate Tempest&#146;s product development programs or commercial
development efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is a clinical-stage biotechnology company with a limited operating history. Biotechnology product
development is a highly speculative undertaking and involves a substantial degree of risk. Tempest&#146;s operations to date have been limited primarily to organizing and staffing Tempest, business planning, raising capital, acquiring and developing
product and technology rights, manufacturing, and conducting research and development activities for Tempest&#146;s product candidates. Tempest has never generated any revenue from product sales. Tempest has not obtained regulatory approvals for any
of its product candidates, and has funded its operations to date through proceeds from sales of its preferred stock and common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has incurred net losses in each year since its inception. Tempest incurred net losses of $14.4&nbsp;million and $19.2&nbsp;million for
the year ended December&nbsp;31, 2019 and the year ended December&nbsp;31, 2020, respectively. As of December&nbsp;31, 2020, Tempest had an accumulated deficit of $71.8&nbsp;million. Substantially all of Tempest&#146;s operating losses have resulted
from costs incurred in connection with Tempest&#146;s research and development programs and from general and administrative costs associated with Tempest&#146;s operations. Tempest expects to continue to incur significant expenses and operating
losses over the next several years and for the foreseeable future as Tempest intends to continue to conduct research and development, clinical testing, regulatory compliance activities, manufacturing activities, and, if any of Tempest&#146;s product
candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in Tempest incurring significant losses for the foreseeable future. Tempest&#146;s prior losses, combined
with expected future losses, have had and will continue to have an adverse effect on Tempest&#146;s stockholders&#146; equity and working capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest expects that it will need to raise additional funding before Tempest can expect to become profitable from any potential future sales of
Tempest&#146;s product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force Tempest to delay, limit or terminate its product development efforts or
other operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest will require substantial future capital in order to complete planned and future preclinical and clinical
development for its product candidates and potentially commercialize these product candidates. Based upon Tempest&#146;s current operating plan, Tempest believes that its existing cash and cash equivalents as of December&nbsp;31, 2020, along with
the net cash held by Millendo upon consummation of the transaction, including the expected proceeds from the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, will enable Tempest to fund its operating expenses and capital
expenditure requirements through into early 2023. Tempest expects Tempest&#146;s spending levels to increase in connection with Tempest&#146;s preclinical studies and clinical trials of Tempest&#146;s product candidates. In addition, if Tempest
obtains marketing approval for any of Tempest&#146;s product candidates, Tempest expects to incur significant expenses related to commercial launch, product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, Tempest
expects to incur additional costs associated with operating as a public company. Accordingly, Tempest will need to obtain substantial additional funding in connection with its continuing operations before any commercial revenue may occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional capital might not be available when Tempest needs it and Tempest&#146;s actual
cash requirements might be greater than anticipated. If Tempest requires additional capital at a time when investment in its industry or in the marketplace in general is limited, Tempest might not be able to raise funding on favorable terms, if at
all. If Tempest is not able to obtain financing when needed or on terms favorable to Tempest, Tempest may need to delay, reduce or eliminate certain research and development programs or other operations, sell some or all of Tempest&#146;s assets or
merge with another entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s operations have consumed significant amounts of cash since inception. Tempest&#146;s future
capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with the scope, progress and results of discovery, preclinical development, laboratory
testing and clinical trials for Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with the manufacturing of Tempest&#146;s product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs related to the extent to which Tempest enters into partnerships or other arrangements with third
parties to further develop Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and fees associated with the discovery, acquisition or
<FONT STYLE="white-space:nowrap">in-license</FONT> of product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s ability to establish collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of future commercialization activities, if any, including product sales, marketing, manufacturing and
distribution, for any of Tempest&#146;s product candidates for which Tempest receives marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue, if any, received from commercial sales of Tempest&#146;s product candidates, should any of
Tempest&#146;s product candidates receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing Tempest&#146;s
intellectual property rights and defending intellectual property-related claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s product candidates, if
approved, may not achieve commercial success. Tempest&#146;s commercial revenues, if any, will be derived from sales of product candidates that Tempest does not expect to be commercially available for many years, if at all. Accordingly, Tempest will
need to continue to rely on additional financing to achieve Tempest&#146;s business objectives, which may not be available to Tempest on acceptable terms, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest has identified material weaknesses in its internal control over financial reporting. Failure to achieve and maintain effective internal control
over financial reporting could harm its business and negatively impact the value of its common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has identified
material weaknesses in its internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of Tempest&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. In preparing Tempest&#146;s financial statements as of and for the year ended December&nbsp;31, 2020, management of Tempest
identified the following material weaknesses in its internal control over financial reporting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest did not have sufficient resources with appropriate knowledge and expertise to design, implement, document
and operate effective internal controls over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest did not design and implement controls surrounding review of clinical trial expenses, including the
evaluation of the terms of its clinical trial contracts. Specifically, Tempest failed to properly review and evaluate the progress of expenses incurred in its clinical trial contracts that resulted in the inaccurate accrual of clinical trial
expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These material weaknesses resulted in adjustments to Tempest&#146;s financial statements.
Additionally, these material weaknesses could result in a misstatement of Tempest&#146;s accounts or disclosures that would result in a material misstatement of its annual or interim financial statements that would not be prevented or detected, and
accordingly, Tempest determined that these control deficiencies constitute material weaknesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is actively recruiting additional
accounting personnel with appropriate experience, certification, education and training as a component of its plans to remediate the material weaknesses. Tempest also plans to design and implement controls related to review of clinical trial
expenses to properly evaluate progress of expense incurred in clinical trial contracts. To the extent that Tempest is not able to hire and retain such<I> </I>individuals, or is unable to successfully design and implement such controls, the material
weaknesses identified may not be remediated and management may be required to record additional adjustments to its financial statements in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s limited operating history may make it difficult for you to evaluate the success of Tempest&#146;s business to date and to assess
Tempest&#146;s future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is a clinical-stage biotechnology company formed in February 2011 and renamed Tempest
Therapeutics in August 2017. Tempest&#146;s operations to date have been limited to organizing and staffing Tempest, business planning, raising capital, acquiring Tempest&#146;s technology, identifying potential product candidates, undertaking
research and preclinical studies of Tempest&#146;s product candidates, manufacturing, and establishing licensing arrangements. Tempest has not yet demonstrated the ability to complete clinical trials of Tempest&#146;s product candidates, obtain
marketing approvals, manufacture a commercial scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about Tempest&#146;s future success or viability may not be as
accurate as they could be if Tempest had a longer operating history. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a new business, Tempest may encounter unforeseen
expenses, difficulties, complications, delays and other known and unknown factors. Tempest will need to transition from a company with a licensing and research focus to a company that is also capable of supporting clinical development and commercial
activities. Tempest may not be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_24"></A>Risks Related to Tempest&#146;s Product Development and
Regulatory Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest is unable to develop, obtain regulatory approval for and commercialize TPST-1495 and TPST-1120 and its future
product candidates, or if Tempest experiences significant delays in doing so, Tempest&#146;s business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest plans to invest a substantial amount of its efforts and financial resources in its current lead product candidates, TPST-1495, a dual
EP2/EP4 prostaglandin (PGE2) receptor antagonist, and TPST-1120, a peroxisome proliferator-activated receptor alpha (PPAR&#945;) antagonism for the treatment of various cancers. Tempest has initiated phase 1 clinical trials of TPST-1495 and
TPST-1120 for the treatment of advanced solid tumors. In addition, Tempest plans to advance its <FONT STYLE="white-space:nowrap">TREX-1</FONT> inhibitor program and select a development candidate for this program by the end of 2021. Tempest&#146;s
ability to generate product revenue will depend heavily on the successful development and eventual commercialization of TPST-1495 and TPST-1120 and Tempest&#146;s other product candidates, which may never occur. Tempest currently generates no
revenue from sales of any product and Tempest may never be able to develop or commercialize a marketable product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Tempest&#146;s
programs and product candidates will require further clinical and/or preclinical development, regulatory approval in multiple jurisdictions, obtaining preclinical, clinical and commercial manufacturing supply, capacity and expertise, building of a
commercial organization, substantial investment and significant marketing efforts before Tempest generates any revenue from product sales. TPST-1495 and TPST-1120 and Tempest&#146;s other product candidates must be authorized for marketing by the
U.S.&nbsp;Food and Drug Administration, or FDA, the Health Products and Food Branch of Health Canada, or HPFB, the European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicines Agency, or EMA, and certain other foreign regulatory agencies before Tempest may commercialize any of its product candidates in the United States, Canada, EU, or other jurisdictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of TPST-1495 and TPST-1120 and Tempest&#146;s other product candidates depends on multiple factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies, including those compliant with Good Laboratory Practices, or GLP,
or GLP toxicology studies, biodistribution studies and minimum effective dose studies in animals, and successful enrollment and completion of clinical trials compliant with current Good Clinical Practices, or GCPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effective Investigational New Drug applications, or INDs or other regulatory applications, that allow
commencement of Tempest&#146;s planned clinical trials or future clinical trials for Tempest&#146;s product candidates in relevant territories; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for
the clinical development of Tempest&#146;s product candidates, both in the United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of arrangements with third-party contract manufacturing organizations, or CMOs, for key materials
used in Tempest&#146;s manufacturing processes and to establish backup sources for clinical and large-scale commercial supply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive results from Tempest&#146;s clinical programs that are supportive of safety and efficacy and provide an
acceptable risk-benefit profile for Tempest&#146;s product candidates in the intended patient populations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities, including those necessary for pricing and
reimbursement of its product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment and maintenance of patent and trade secret protection and regulatory exclusivity for Tempest&#146;s
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercial launch of Tempest&#146;s product candidates, if and when approved, whether alone or in collaboration
with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of Tempest&#146;s product candidates, if and when approved, by patients, patient advocacy groups,
third-party payors and the general medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s effective competition against other therapies available in the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment and maintenance of adequate reimbursement from third-party payors for Tempest&#146;s product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s ability to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prosecution, maintenance, enforcement and defense of intellectual property rights and claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintenance of a continued acceptable safety profile of Tempest&#146;s product candidates following approval,
including meeting any post-marketing commitments or requirements imposed by or agreed to with applicable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">political factors surrounding the approval process, such as government shutdowns, political instability or global
pandemics such as the outbreak of the novel strain of coronavirus, <FONT STYLE="white-space:nowrap">COVID-19;</FONT> or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions in enrollment of Tempest&#146;s clinical trials due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest does not succeed in one or more of these factors
in a timely manner or at all, Tempest could experience significant delays or an inability to successfully commercialize its product candidates, which would materially harm Tempest&#146;s business. If Tempest does not receive regulatory approvals for
Tempest&#146;s product candidates, Tempest may not be able to continue its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in preclinical studies and earlier clinical trials for Tempest&#146;s product candidates may
not be indicative of the results that may be obtained in later clinical trials, which may delay or prevent obtaining regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. Success in preclinical studies and early clinical trials may not be predictive of results in later-stage clinical trials, and successful results from early or small clinical trials may not be replicated or show as
favorable an outcome in later-stage or larger clinical trials, even if successful. Tempest will be required to demonstrate through adequate and well-controlled clinical trials that Tempest&#146;s product candidates are safe and effective for their
intended uses before Tempest can seek regulatory approvals for their commercial sale. The conduct of phase 3 trials and the submission of an NDA is a complicated process. Tempest has not previously completed any clinical trials, has limited
experience in preparing, submitting and supporting regulatory filings, and has not previously submitted an NDA. Consequently, Tempest may be unable to successfully and efficiently execute and complete necessary clinical trials and other requirements
in a way that leads to NDA submission and approval of any product candidate Tempest is developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although TPST-1495 and TPST-1120 are
being evaluated in clinical trials, Tempest&#146;s other product candidates, such as <FONT STYLE="white-space:nowrap">TREX-1,</FONT> have not been evaluated in human clinical trials, and Tempest may experience unexpected or negative results in the
future if and when <FONT STYLE="white-space:nowrap">TREX-1</FONT> or Tempest&#146;s other product candidates are evaluated in clinical trials. Any positive results Tempest observes for <FONT STYLE="white-space:nowrap">TREX-1</FONT> in preclinical
animal models may not be predictive of Tempest&#146;s future clinical trials in humans, as animal models carry inherent limitations relevant to all preclinical studies. Tempest&#146;s product candidates, including
<FONT STYLE="white-space:nowrap">TREX-1,</FONT> may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials. Even if Tempest&#146;s clinical trials
demonstrate acceptable safety and efficacy of TPST-1495, TPST-1120 or <FONT STYLE="white-space:nowrap">TREX-1</FONT> or any other product candidates and such product candidates receive regulatory approval, the labeling Tempest obtains through
negotiations with the FDA or foreign regulatory authorities may not include data on secondary endpoints and may not provide Tempest with a competitive advantage over other products approved for the same or similar indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving positive results
in early-stage development, and there is a high failure rate for product candidates proceeding through clinical trials. In addition, different methodologies, assumptions and applications Tempest utilizes to assess particular safety or efficacy
parameters may yield different statistical results. Even if Tempest believes the data collected from clinical trials of Tempest&#146;s product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign
regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from Tempest or Tempest&#146;s partners, which could
delay, limit or prevent regulatory approval. If Tempest&#146;s study data do not consistently or sufficiently demonstrate the safety or efficacy of any of Tempest&#146;s product candidates, including TPST-1495 and TPST-1120, to the satisfaction of
the FDA or foreign regulatory authorities, then the regulatory approvals for such product candidates could be significantly delayed as Tempest works to meet approval requirements, or, if Tempest is not able to meet these requirements, such approvals
could be withheld or withdrawn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest encounters difficulties enrolling patients in Tempest&#146;s clinical trials, Tempest&#146;s clinical
development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may experience difficulties in patient enrollment
in Tempest&#146;s clinical trials for a variety of reasons, including, without limitation, the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The timely completion of clinical trials in accordance with their protocols
depends, among other things, on Tempest&#146;s ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of
Tempest&#146;s product candidates or trial completion. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest intends to conduct a number of clinical trials for
product candidates in the fields of cancer in geographies which are affected by <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Tempest believes that the coronavirus pandemic could have an impact on various aspects of its future clinical
trials. For example, investigators may not want to take the risk of exposing cancer patients to <FONT STYLE="white-space:nowrap">COVID-19</FONT> since the dosing of patients is conducted within an <FONT STYLE="white-space:nowrap">in-patient</FONT>
setting. Other potential impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Tempest&#146;s future various clinical trials include patient dosing and study monitoring, which may be paused or delayed due to changes in policies
at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians
serving as Tempest&#146;s clinical trial investigators and reduced availability of site staff supporting the conduct of its clinical trials, interruption or delays in the operations of the government regulators, or other reasons related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. It is unknown how long these pauses or disruptions could continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
Tempest&#146;s clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as Tempest&#146;s product candidates, and this competition will reduce the number and types of patients available to
Tempest because some patients who might have opted to enroll in Tempest trials may instead opt to enroll in a trial being conducted by one of Tempest&#146;s competitors. Since the number of qualified clinical investigators is limited, some of
Tempest&#146;s clinical trial sites are also being used by some of Tempest&#146;s competitors, which may reduce the number of patients who are available for Tempest&#146;s clinical trials in that clinical trial site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because Tempest&#146;s product candidates represent unproven methods for cancer treatment, potential patients and their doctors may
be inclined to use existing therapies rather than enroll patients in Tempest&#146;s clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in patient enrollment may
result in increased costs or may affect the timing or outcome of Tempest&#146;s ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect Tempest&#146;s ability to advance the development
of Tempest&#146;s product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim &#147;top line&#148; and preliminary data from Tempest&#146;s clinical trials that Tempest may
announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, Tempest may publish interim &#147;top line&#148; or preliminary data from Tempest&#146;s clinical studies. Interim data from clinical trials
that Tempest may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary or &#147;top line&#148; data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data Tempest previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could
significantly harm Tempest&#146;s business prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if Tempest completes the necessary preclinical studies and clinical trials, Tempest cannot
predict when, or if, Tempest will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than Tempest seeks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to commercialization, TPST-1495, TPST-1120 and Tempest&#146;s other product candidates must be approved by the FDA pursuant to an NDA in
the United States and pursuant to similar marketing applications by the HPFB, EMA and similar regulatory authorities outside the United States. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and
takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate
will prevent Tempest from commercializing the product candidate. Tempest has not received approval to market TPST-1495, TPST-1120 or any of Tempest&#146;s other product candidates from regulatory authorities in any jurisdiction. Tempest has no
experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that Tempest may submit such applications, Tempest may be unable to do so as quickly and efficiently as
desired. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and
efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Tempest&#146;s product candidates may not be
effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Tempest&#146;s obtaining marketing approval or prevent or limit commercial use. Regulatory
authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that Tempest&#146;s data are insufficient for approval and require additional preclinical, clinical or other studies. In
addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of TPST-1495 and TPST-1120 and Tempest&#146;s other product candidates may be delayed or refused for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of
Tempest&#146;s clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory
authorities, that Tempest&#146;s product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the populations studied in clinical trials may not be sufficiently broad or representative to assure efficacy and
safety in the populations for which Tempest seeks approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may be unable to demonstrate that Tempest&#146;s product candidates&#146; clinical and other benefits
outweigh their safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of Tempest&#146;s product candidates may not be sufficient to support the
submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the facilities of third-party manufacturers with which Tempest contracts or procures certain service or raw
materials, may not be adequate to support approval of Tempest&#146;s product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering Tempest&#146;s clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Tempest&#146;s product
candidates meet their <FONT STYLE="white-space:nowrap">pre-specified</FONT> safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner and may not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consider such the clinical trial results sufficient to grant, or Tempest may not be able to obtain, regulatory approval. Additional delays may result if an FDA Advisory Committee or other
regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, Tempest may experience delays or rejections based upon additional government regulation from future legislation or
administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant
limitations in the form of narrow indications, warnings, contraindications or Risk Evaluation and Mitigation Strategies, or REMS.&nbsp;These regulatory authorities may also grant approval subject to the performance of costly post-marketing clinical
trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of Tempest&#146;s product candidates. Any of the foregoing scenarios could materially harm the
commercial prospects for Tempest&#146;s product candidates and adversely affect Tempest&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or similar public health crises, could have a material adverse impact on
Tempest&#146;s business, financial condition and results of operations, including the execution of Tempest&#146;s planned clinical trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT>
was identified. This virus has since spread globally, including within the United States and while cases and hospitalization are currently on the decline in the US, there can be no assurances they will not continue at the current rate or increase in
the future especially in light of the number of variants that are emerging across the world. Governments in the United States and elsewhere have taken and are continuing to take severe measures to slow the spread of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> including requiring that certain businesses close or conduct only the minimum necessary operations. The pandemic and government measures taken in response have also had a significant impact, both
direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical services and supplies,
has spiked, while demand for other goods and services, such as travel, has fallen. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> will continue to impact Tempest&#146;s business and operating results will depend on future
developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19</FONT> and government measures taken in response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and
data analysis for Tempest&#146;s planned clinical trials may be delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to
the pandemic. Additionally, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement,
affect sponsor access to study sites, or interrupt healthcare services, and Tempest may be unable to conduct its planned clinical trials. If the global effort to control the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and treat <FONT
STYLE="white-space:nowrap">COVID-19</FONT> patients continues for an extended period of time, Tempest risks a delay in activating sites and enrolling subjects as previously projected. Any such delays to Tempest&#146;s planned clinical trials for
TPST-1495 and TPST-1120 and the planned clinical trials for its other product candidates could impact the use and sufficiency of its existing cash reserves, and it may be required to raise additional capital earlier than it had previously planned.
Tempest may be unable to raise additional capital if and when needed, which may result in further delays or suspension of its development plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, infections and deaths related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> are disrupting certain healthcare and healthcare
regulatory systems globally. Such disruptions could divert healthcare resources away from, or materially delay review by, the FDA and comparable foreign regulatory agencies. It is unknown how long these disruptions could continue, were they to
occur. Any elongation or <FONT STYLE="white-space:nowrap">de-prioritization</FONT> of Tempest&#146;s clinical trials or delay in regulatory review resulting from such disruptions could materially adversely affect the development and study of its
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest currently utilizes third parties to, among other things, manufacture raw materials
and its product candidates, components, parts, and consumables, and to perform quality testing. If either Tempest or any third-party in the supply chain for materials used in the production of its product candidates are adversely impacted by
restrictions resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, its supply chain may be disrupted, limiting Tempest&#146;s ability to manufacture product candidates for its clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Tempest complied with applicable regulation and limited required
<FONT STYLE="white-space:nowrap">on-site</FONT> staff to essential workers, with the balance of its employees continuing their work primarily outside of Tempest&#146;s offices. Due to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders or other mandated local travel restrictions, third parties conducting clinical or manufacturing activities may not be able to access laboratory
or manufacturing space, and Tempest&#146;s core activities may be significantly limited or curtailed, possibly for an extended period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused,
and is likely to result in further, significant disruption of global financial markets and the trading prices of biopharmaceutical companies have been highly volatile as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
which may reduce Tempest&#146;s ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the global effort to control
<FONT STYLE="white-space:nowrap">COVID-19</FONT> infections could materially and adversely affect Tempest&#146;s business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ultimate
impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. Tempest does not yet know the full extent of potential delays or impacts on its business, its planned clinical trials, healthcare systems or the
global economy as a whole. However, these effects could have a material adverse impact on Tempest&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TPST-1495, TPST-1120 and Tempest&#146;s other product candidates may cause undesirable and/or unforeseen side effects or be perceived by the public as
unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with Tempest&#146;s
product candidates&#146; use. Results of Tempest&#146;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. As Tempest continues developing its product candidates and initiate
clinical trials of its additional product candidates, serious adverse events (SAEs), undesirable side effects, relapse of disease or unexpected characteristics may emerge causing Tempest to abandon these product candidates or limit their development
to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such adverse events occur, Tempest&#146;s clinical trials could be suspended or terminated and the FDA, the HPFB, the European
Commission, the EMA or other regulatory authorities could order Tempest to cease further development of, or deny approval of, Tempest&#146;s product candidates for any or all targeted indications. Even if Tempest can demonstrate that all future
serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if Tempest elects, or is required, to not initiate, delay, suspend or terminate
any future clinical trial of any of Tempest&#146;s product candidates, the commercial prospects of such product candidates may be harmed and Tempest&#146;s ability to generate product revenues from any of these product candidates may be delayed or
eliminated. Any of these occurrences may harm Tempest&#146;s ability to develop other product candidates, and may adversely affect Tempest&#146;s business, financial condition, results of operations and prospects significantly. Other treatments for
cancers that utilize a dual EP2/EP4 antagonist or a PPAR&#945; antagonist or similar mechanism of action could also generate data that could adversely affect the clinical, regulatory or commercial perception of TPST-1495 and TPST-1120 and
Tempest&#146;s other product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if any of Tempest&#146;s product candidates receives marketing approval, the
FDA could require Tempest to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, for example, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to
health care practitioners, or other elements to assure safe use of the product. Furthermore, if Tempest or others later identify undesirable side effects caused by Tempest&#146;s product candidates, several potentially significant negative
consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings in the labeling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may be required to change the way a product candidate is administered or conduct additional clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these occurrences may harm Tempest&#146;s business, financial condition, results of operations and prospects significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may not be successful in its efforts to expand its pipeline of product candidates and develop marketable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Tempest has limited financial and managerial resources, Tempest focuses on research programs and product candidates that Tempest
identifies for specific indications. Tempest&#146;s business depends on its successful development and commercialization of the limited number of internal product candidates Tempest is researching or has in preclinical development. Even if Tempest
is successful in continuing to build its pipeline, development of the potential product candidates that Tempest identifies will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing
activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before Tempest generates any revenue from product sales. Furthermore, such
product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval
and achieve market acceptance. If Tempest cannot develop further product candidates, Tempest may not be able to obtain product revenue in future periods, which would adversely affect Tempest&#146;s business, prospects, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Tempest&#146;s pipeline includes multiple programs, Tempest is primarily focused on its lead product
candidates, TPST-1495 and TPST-1120, and Tempest may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Tempest&#146;s resource allocation decisions
may cause Tempest to fail to capitalize on viable commercial products or profitable market opportunities. Tempest&#146;s spending on current and future research and development programs and product candidates for specific indications may not yield
any commercially viable products. Tempest&#146;s understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical
development. If Tempest does not accurately evaluate the commercial potential or target market for a particular product candidate, Tempest may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for Tempest to retain sole development and commercialization rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate for which Tempest obtains marketing approval will be subject to extensive
post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and Tempest may be subject to penalties if it fails to comply with regulatory requirements or if it experiences unanticipated
problems with its product candidates, when and if any of them are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s product candidates and the activities
associated with their development and potential commercialization, including their testing, manufacturing, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA
and other U.S.&nbsp;and international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, including
current Good Manufacturing Practices, or cGMPs, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the
distribution of samples to providers and recordkeeping. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance
with cGMPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the
safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed in a manner consistent with the provisions of the approved labeling. The FDA imposes stringent
restrictions on manufacturers&#146; communications regarding use of their products. If Tempest promotes its product candidates in a manner inconsistent with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling or otherwise not in compliance
with FDA regulations, Tempest may be subject to enforcement action. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare
fraud and abuse laws, as well as state consumer protection laws and similar laws in international jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later
discovery of previously unknown adverse events or other problems with Tempest&#146;s product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such product candidates, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of any approved product from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that Tempest submits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of Tempest&#146;s product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit Tempest&#146;s ability to commercialize its product candidates and generate
revenue and could require Tempest to expend significant time and resources in response and could generate negative publicity. The FDA&#146;s and other regulatory authorities&#146; policies may change, and additional government regulations may be
enacted that could prevent, limit or delay regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of Tempest&#146;s product candidates. If Tempest is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Tempest is not able
to maintain regulatory compliance, it may lose any marketing approval that it has obtained, and Tempest may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> with Canadian and European requirements regarding safety monitoring or
pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with Canada&#146;s or Europe&#146;s requirements regarding
the protection of personal information can also lead to significant penalties and sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s failure to obtain regulatory approval
in international jurisdictions would prevent Tempest from marketing its product candidates outside the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To market
and sell TPST-1495, TPST-1120 and Tempest&#146;s other product candidates in other jurisdictions, Tempest must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among
countries and can involve additional testing. The time and data required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the
risks associated with obtaining FDA approval. In addition, in many countries outside the United States, Tempest must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to
obtain foreign regulatory approvals or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with foreign regulatory requirements could result in significant delays, difficulties and costs for Tempest and could delay or prevent the introduction of
Tempest&#146;s product candidates in certain countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest fails to comply with the regulatory requirements in international
markets and receive applicable marketing approvals, Tempest&#146;s target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Tempest may
not obtain foreign regulatory approvals on a timely basis, if at all. Tempest&#146;s failure to obtain approval of any of its product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that
product candidate and Tempest&#146;s business prospects could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_25"></A>Risks Related to Commercialization and Manufacturing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of Tempest&#146;s product candidates, including TPST-1495 and TPST-1120, will depend upon their degree of market
acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the
requisite approvals from the FDA, the HPFB, the EMA and other regulatory authorities internationally are obtained, the commercial success of Tempest&#146;s product candidates will depend, in part, on the acceptance of providers, patients and
third-party payors of drugs designed to act as a dual antagonist of EP2 and EP4 and PPAR&#945; antagonists in general, and Tempest&#146;s product candidates in particular, as medically necessary, cost-effective and safe. In addition, Tempest may
face challenges in seeking to establish and grow sales of TPST-1495 and TPST-1120 or its other product candidates. Any product that Tempest commercializes may not gain acceptance by providers, patients, patient advocacy groups, third-party payors
and the general medical community. If these products do not achieve an adequate level of acceptance, Tempest may not generate significant product revenue and may not become profitable. The degree of market acceptance of TPST-1495, TPST-1120 and
Tempest&#146;s other product candidates, if approved for commercial sale, will depend on several factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, durability and safety of such product candidates as demonstrated in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages of product candidates over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment relative to alternative treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by the FDA, the HPFB or the European
Commission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of providers to prescribe new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, the HPFB, EMA or other regulatory authorities,
including any limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality of Tempest&#146;s relationships with patient advocacy groups; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning Tempest&#146;s product candidates or competing products and treatments; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient third-party payor coverage and adequate reimbursement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of
the product will not be fully known until after it is launched. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pricing, insurance coverage and reimbursement status of newly approved products
is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for Tempest&#146;s product candidates, if approved, could limit Tempest&#146;s ability to market those products and decrease Tempest&#146;s ability to generate product
revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of Tempest&#146;s product candidates, if approved, depend on the availability of coverage and adequate
reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement
status of any product candidates for which Tempest obtains regulatory approval. In addition, because Tempest&#146;s product candidates represent new approaches to the treatment of cancer, Tempest cannot accurately estimate the potential revenue from
Tempest&#146;s product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest expects that coverage and reimbursement by third-party payors will be essential for most
patients to be able to afford these treatments. Accordingly, sales of Tempest&#146;s product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of Tempest&#146;s product candidates will be
paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government payors, private health coverage insurers and other third-party payors. Even if coverage is provided, the
established reimbursement amount may not be high enough to allow Tempest to establish or maintain pricing sufficient to realize a sufficient return on Tempest&#146;s investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States,
third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered and reimbursed. The Medicare program covers certain
individuals aged 65 or older, disabled or suffering from <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease. The Medicaid program, which varies from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-to-state,</FONT></FONT> covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how
private payors and other government payors develop their coverage and reimbursement policies for drugs. One payor&#146;s determination to provide coverage for a drug product, however, does not assure that other payors will also provide coverage for
the drug product. Further, a payor&#146;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to government and private payors, professional organizations such as the
American Medical Association, or the AMA, can influence decisions about coverage and reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide
guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit compared to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of
Tempest&#146;s product candidates, if approved. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which Tempest&#146;s collaborators receive regulatory approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to
extensive governmental price controls and other market regulations, and Tempest believes the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of
therapeutics such as Tempest&#146;s product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries,
pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, Tempest may be required to conduct a clinical trial
that compares the cost-effectiveness of Tempest&#146;s product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix
their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that Tempest is able to charge for its product candidates. Accordingly, in
markets outside the United States, the reimbursement for Tempest&#146;s product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by government and other third-party payors, in the United States and internationally, to cap or reduce healthcare
costs may cause such payors to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for Tempest&#146;s product candidates. Tempest expects to experience pricing
pressures in connection with the sale of any of Tempest&#146;s product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional
legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry
of new products into the healthcare market. Recently there have been instances in which third-party payors have refused to reimburse treatments for patients for whom the treatment is indicated in the
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> product labeling. Even if Tempest is successful in obtaining FDA approval to commercialize Tempest&#146;s product candidates, Tempest cannot guarantee that Tempest will be able to secure
reimbursement for all patients for whom treatment with Tempest&#146;s product candidates is indicated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third parties on which Tempest depends to
conduct its planned preclinical studies or clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, Tempest&#146;s development program could be delayed with adverse
effects on Tempest&#146;s business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest relies on third party CROs,
CMOs, consultants and others to design, conduct, supervise and monitor key activities relating to, discovery, manufacturing, preclinical studies and clinical trials of Tempest&#146;s product candidates, and Tempest intends to do the same for future
activities relating to existing and future programs. Because Tempest relies on third parties and does not have the ability to conduct all required testing, discovery, manufacturing, preclinical studies or clinical trials independently, Tempest has
less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than Tempest would if Tempest conducted them on its own. These investigators, CROs, CMOs and consultants are not
Tempest&#146;s employees, and Tempest has limited control over the amount of time and resources that they dedicate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Tempest&#146;s programs. These third parties may have contractual relationships with other entities, some of which may be Tempest&#146;s competitors, which may draw time and resources from
Tempest&#146;s programs. The third parties Tempest contracts with might not be diligent, careful or timely in conducting Tempest&#146;s discovery, manufacturing, preclinical studies or clinical trials, resulting in testing, discovery, manufacturing,
preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest cannot contract with acceptable
third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected
deadlines, Tempest&#146;s clinical development programs could be delayed and otherwise adversely affected. In all events, Tempest is responsible for ensuring that each of Tempest&#146;s preclinical studies and clinical trials is conducted in
accordance with the general investigational plan and protocols for the trial, as well as in accordance with GLP, GCP and other applicable laws, regulations and standards. Tempest&#146;s reliance on third parties that it does not control does not
relieve Tempest of these responsibilities and requirements. The FDA and other regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If Tempest or any of these third parties fails
to comply with applicable GCPs, the clinical data generated in its clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Tempest to perform additional clinical trials before approving its
marketing applications. Tempest cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Tempest&#146;s clinical trials have complied with GCPs. In addition, Tempest&#146;s clinical
trials must be conducted with product produced in accordance with cGMPs. Tempest&#146;s failure to comply with these regulations may require it to repeat clinical trials, which could delay or prevent the receipt of regulatory approvals. Any such
event could have an adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest faces significant
competition in an environment of rapid technological change, and it is possible that Tempest&#146;s competitors may achieve regulatory approval before Tempest or develop therapies that are more advanced or effective than Tempest&#146;s, which may
harm Tempest&#146;s business, financial condition and Tempest&#146;s ability to successfully market or commercialize TPST-1495, TPST-1120, and Tempest&#146;s other product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation.
Tempest is aware of other companies focused on developing cancer therapies in various indications. Tempest may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government
agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Tempest&#146;s potential competitors, alone or with their strategic partners, may have substantially greater financial, technical and
other resources than Tempest does, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being
concentrated among a smaller number of competitors. Tempest&#146;s commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are
more convenient or are less expensive than any product candidates that Tempest may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than Tempest may obtain approval for its products, which could
result in Tempest&#146;s competitors establishing a strong market position before Tempest is able to enter the market, if ever. Additionally, new or advanced technologies developed by Tempest&#146;s competitors may render Tempest&#146;s current or
future product candidates uneconomical or obsolete, and Tempest may not be successful in marketing its product candidates against competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, Tempest must develop and eventually commercialize product candidates with significant market potential, which
will require Tempest to be successful in a range of challenging activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These activities include, among other things, completing preclinical studies and initiating and completing clinical trials of Tempest&#146;s product candidates, obtaining marketing approval for
these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any post marketing requirements. Tempest may never succeed in any or all of these activities and, even if Tempest does, Tempest may never
generate revenues that are significant or large enough to achieve profitability. If Tempest does achieve profitability, Tempest may not be able to sustain or increase profitability on a quarterly or annual basis. Tempest&#146;s failure to become and
remain profitable would decrease the value of Tempest and could impair Tempest&#146;s ability to raise capital, maintain Tempest&#146;s research and development efforts, expand Tempest&#146;s business or continue operations. A decline in the value
of Tempest also could cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may rely on third parties to manufacture Tempest&#146;s clinical
product supplies, and Tempest may have to rely on third parties to produce and process Tempest&#146;s product candidates, if approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest must currently rely on outside vendors to manufacture supplies and process Tempest&#146;s product candidates. Tempest has not yet
caused its product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> product to satisfy demands for any of Tempest&#146;s product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest
does not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of Tempest&#146;s product candidates, and the actual cost to manufacture and process Tempest&#146;s product candidates could
materially and adversely affect the commercial viability of its product candidates. As a result, Tempest may never be able to develop a commercially viable product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Tempest anticipates reliance on a limited number of third-party manufacturers exposes it to the following risks: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may be unable to identify manufacturers on acceptable terms or at all because the number of potential
manufacturers is limited, and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially
equivalent processes for, production of Tempest&#146;s products after receipt of FDA questions, if any. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s third-party manufacturers might be unable to timely formulate and manufacture Tempest&#146;s
product or produce the quantity and quality required to meet Tempest&#146;s clinical and commercial needs, if any. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contract manufacturers may not be able to execute Tempest&#146;s manufacturing procedures appropriately.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s future contract manufacturers may not perform as agreed or may not remain in the contract
manufacturing business for the time required to supply Tempest&#146;s clinical trials or to successfully produce, store and distribute Tempest&#146;s products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement
Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. Tempest does not have control over third-party manufacturers&#146; compliance with these
regulations and standards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may not own, or may have to share, the intellectual property rights to any improvements made by
Tempest&#146;s third-party manufacturers in the manufacturing process for Tempest&#146;s products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s third-party manufacturers could breach or terminate their agreement(s) with Tempest.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s contract manufacturers would also be subject to the same risks Tempest faces in developing its own
manufacturing capabilities, as described above. Each of these risks could delay Tempest&#146;s clinical trials, the approval, if any, of Tempest&#146;s product candidates by the FDA or the commercialization of Tempest&#146;s product candidates or
result in higher costs or deprive Tempest of potential product revenue. In addition, Tempest will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rely on third parties to perform release tests on Tempest&#146;s product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable,
patients could be put at risk of serious harm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of drugs is complex, and Tempest&#146;s third-party manufacturers may encounter
difficulties in production. If any of Tempest&#146;s third-party manufacturers encounter such difficulties, Tempest&#146;s ability to provide adequate supply of its product candidates for clinical trials, Tempest&#146;s ability to obtain marketing
approval, or Tempest&#146;s ability to provide supply of Tempest&#146;s product candidates for patients, if approved, could be delayed or stopped. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest intends to establish manufacturing relationships with a limited number of suppliers to manufacture raw materials, the drug substance
and finished product of any product candidate for which Tempest is responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the
public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to regulatory approval. If supply from the approved vendor is interrupted, there could be a significant disruption in
commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new
supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in Tempest&#146;s desired clinical and commercial timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing drugs is complex, highly-regulated and subject to multiple risks. Manufacturing drugs is highly susceptible to
product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even
minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of Tempest&#146;s
manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm Tempest&#146;s business. Moreover, if the FDA determines that
Tempest&#146;s CMOs are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny NDA approval until the deficiencies are corrected or Tempest replaces the manufacturer in Tempest&#146;s NDA with a
manufacturer that is in compliance. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies,
including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, Tempest&#146;s CMOs are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although Tempest
does not have <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> control over the operations of its CMOs, it is responsible for ensuring compliance with applicable laws and regulations, including cGMPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost
overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if
Tempest&#146;s collaborators obtain regulatory approval for any of Tempest&#146;s product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other
regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If Tempest&#146;s manufacturers are unable to produce sufficient quantities for
clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest believes that it will rely upon on a limited number of manufacturers for its product candidates, which may include single-source
suppliers for the various steps of manufacture. This reliance on a limited number of manufacturers and the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory
submissions, required approvals or commercialization of Tempest&#146;s product candidates, cause Tempest to incur higher costs and prevent Tempest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from commercializing Tempest&#146;s product candidates successfully. Furthermore, if Tempest&#146;s suppliers fail to deliver the required commercial quantities of materials on a timely basis and
at commercially reasonable prices, and Tempest is unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, Tempest&#146;s clinical trials may be delayed or Tempest could lose
potential revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and
sell Tempest&#146;s product candidates, Tempest may be unable to generate any revenues. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest currently does not have an
organization for the sales, marketing and distribution of TPST-1495, TPST-1120, <FONT STYLE="white-space:nowrap">TREX-1</FONT> and Tempest&#146;s other product candidates, and the cost of establishing and maintaining such an organization may exceed
the cost-effectiveness of doing so. To market any products that may be approved, Tempest must build its sales, marketing, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties
to perform these services. With respect to certain of Tempest&#146;s current programs as well as future programs, Tempest may rely completely on an alliance partner for sales and marketing. In addition, although Tempest intends to establish a sales
organization if Tempest is able to obtain approval to market any product candidates, Tempest may enter into strategic alliances with third parties to develop and commercialize TPST-1495, TPST-1120 and other product candidates, including in markets
outside of the United States or for other large markets that are beyond Tempest&#146;s resources. This will reduce the revenue generated from the sales of these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future strategic alliance partners may not dedicate sufficient resources to the commercialization of Tempest&#146;s product candidates or
may otherwise fail in their commercialization due to factors beyond Tempest&#146;s control. If Tempest is unable to establish effective alliances to enable the sale of Tempest&#146;s product candidates to healthcare professionals and in geographical
regions, including the United States, that will not be covered by Tempest&#146;s marketing and sales force, or if Tempest&#146;s potential future strategic alliance partners do not successfully commercialize the product candidates, Tempest&#146;s
ability to generate revenues from product sales will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest is unable to establish adequate sales, marketing
and distribution capabilities, whether independently or with third parties, Tempest may not be able to generate sufficient product revenue and may not become profitable. Tempest will be competing with many companies that currently have extensive and
well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, Tempest may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may not be successful in finding strategic collaborators for continuing development of certain of Tempest&#146;s future product candidates or
successfully commercializing or competing in the market for certain indications. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, Tempest may decide to collaborate
with <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations, universities and pharmaceutical and biotechnology companies for the development and potential commercialization of existing and new product candidates. Tempest faces significant
competition in seeking appropriate collaborators. Whether Tempest reaches a definitive agreement for a collaboration will depend, among other things, upon Tempest&#146;s assessment of the collaborator&#146;s resources and expertise, the terms and
conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory
authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of
uncertainty with respect to Tempest&#146;s ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also
consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with Tempest for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest&#146;s product candidate. The terms of any additional collaborations or other arrangements that Tempest may establish may not be favorable to Tempest. Collaborations are complex and
time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If Tempest is unable to do so, Tempest
may have to curtail the development of the product candidate for which Tempest is seeking to collaborate, reduce or delay its development program or one or more of Tempest&#146;s other development programs, delay its potential commercialization or
reduce the scope of any sales or marketing activities, or increase Tempest&#146;s expenditures and undertake development or commercialization activities at Tempest&#146;s expense. If Tempest elects to increase Tempest&#146;s expenditures to fund
development or commercialization activities on Tempest&#146;s product candidates, Tempest may need to obtain additional capital, which may not be available to Tempest on acceptable terms or at all. If Tempest does not have sufficient funds, Tempest
may not be able to further develop Tempest&#146;s product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of
any potential collaboration arrangements will depend heavily on the efforts and activities of Tempest&#146;s collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these
collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some
cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third
parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect Tempest financially and could harm Tempest&#146;s business reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_26"></A>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA regulatory approval process is lengthy and time-consuming, and Tempest may experience significant delays in the clinical development and
regulatory approval of Tempest&#146;s product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining FDA approval is unpredictable, typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data
necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities
have substantial discretion in the approval process and may refuse to accept any application or may decide that Tempest&#146;s data are insufficient for approval and require additional preclinical, clinical or other data. Even if Tempest eventually
completes clinical testing and receive approval for its product candidates, the FDA may approve its product candidates for a more limited indication or a narrower patient population than originally requested or may impose other prescribing
limitations or warnings that limit the product&#146;s commercial potential. Tempest has not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of its product candidates will ever obtain regulatory
approval. Further, development of Tempest&#146;s product candidates and/or regulatory approval may be delayed for reasons beyond its control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may also experience delays in obtaining regulatory approvals, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory authorization to begin a trial, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesigning its study protocols and need to conduct additional studies as may be required by a regulator;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governmental or regulatory delays and changes in regulation or policy relating to the development and
commercialization of its product candidate by the FDA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable
foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of financial resources to commence and complete the planned trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating the terms of any collaboration agreements Tempest may choose to initiate or conclude;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party contractors, such as CROs, or investigators to comply with regulatory requirements,
including good clinical practice standards (GCPs); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in
order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inability to recruit and enroll suitable patients to participate in a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial
before the product candidate is manufactured and returned to the site, or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in having patients complete a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any patient safety concerns that arise during the course of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to add new clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of the data generated from its preclinical or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third
parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of establishing, expanding and scaling manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to manufacture, or obtain from third parties, sufficient quantities of qualified materials under cGMPs,
for the completion in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">problems with biopharmaceutical product candidate storage, stability and distribution resulting in global supply
chain disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which
Tempest may receive regulatory approval in regions where Tempest chooses to commercialize its products on its own; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential unforeseen business disruptions or market fluctuations that delay its product development or clinical
trials and increase its costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import
or export restrictions, or public health crises, such as the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of
Tempest&#146;s product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical
trial in accordance with regulatory requirements or Tempest clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or
adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data
Safety Monitoring Committee. If Tempest experiences termination of, or delays in the completion of, any clinical trial of Tempest&#146;s product candidates, the commercial prospects for Tempest&#146;s product candidates will be harmed, and
Tempest&#146;s ability to generate product revenue will be delayed. In addition, any delays in completing Tempest&#146;s clinical trials will increase Tempest&#146;s costs, slow down Tempest&#146;s product development and approval process and
jeopardize Tempest&#146;s ability to commence product sales and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the factors that cause, or lead to, a delay in
the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of Tempest&#146;s product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of its product candidates, but may not receive
such designation. Even if Tempest secures such designation, it may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that Tempest&#146;s product candidates will receive marketing
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may seek Breakthrough Therapy or Fast Track designation for some of its product candidates. If a product
candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the product candidate may be eligible for Fast Track
designation. The benefits of Fast Track designation include more frequent meetings with FDA to discuss the drug&#146;s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written communication
from FDA about such things as the design of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and rolling review, which means that a drug company can submit
completed sections of its NDA for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. NDA review usually does not begin until the entire application has been submitted to the
FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biologics, to
treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drugs designated as breakthrough therapies by the FDA may be eligible for all features of Fast Track designation, intensive guidance on an efficient drug development program, beginning as
early as Phase 1, and organizational commitment involving senior managers at FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has broad discretion whether or not to grant
these designations, so even if Tempest believes a particular product candidate is eligible, it cannot assure that the FDA would decide to grant the designation. Even if Tempest obtains Fast Track designation and/or Breakthrough Therapy designation
for one or more of Tempest&#146;s product candidates, it may not experience a faster development process, review or approval compared to <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures. In addition, the FDA may withdraw
Fast Track designation or Breakthrough Therapy designation if it believes that the designation is no longer supported. These designations do not guarantee qualification for the FDA&#146;s priority review procedures or a faster review or approval
process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may attempt to secure FDA approval of its product candidates through the accelerated approval
pathway. If Tempest is unable to obtain accelerated approval, Tempest may be required to conduct additional preclinical studies or clinical trials beyond those that Tempest currently contemplates, which could increase the expense of obtaining, and
delay the receipt of, necessary marketing approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is developing certain product candidates for the treatment of serious
conditions, and therefore may decide to seek approval of such product candidates under the FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease
or condition and provides a meaningful therapeutic benefit over existing treatments based upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical
endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence
of the condition and the availability of or lack of alternative treatments. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is
thought to predict clinical benefit, but is not itself a measure of clinical benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway may be used in
cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually
contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug&#146;s anticipated effect on irreversible morbidity or mortality or other clinical benefit. In
some cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. If the sponsor fails to conduct such studies in a timely manner, or if such post-approval studies fail to verify the drug&#146;s
predicted clinical benefit, or if other evidence demonstrates that Tempest&#146;s product candidate is not shown to be safe and effective under the conditions of use, the FDA may withdraw its approval of the drug on an expedited basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest decides to submit an NDA seeking accelerated approval or receives an expedited regulatory designation for any of its product
candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. If any of Tempest&#146;s competitors were to receive full
approval on the basis of a confirmatory trial for an indication for which Tempest is seeking accelerated approval before Tempest receives accelerated approval, the indication Tempest is seeking may no longer qualify as a condition for which there is
an unmet medical need and accelerated approval of its product candidate would be more difficult or may not occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain
accelerated approval or any other form of expedited development, review or approval for Tempest&#146;s product candidates would result in a longer time period to commercialization of such product candidate, if any, and could increase the cost of
development of such product candidate harm Tempest&#146;s competitive position in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may be unsuccessful in obtaining Orphan
Drug Designation for its product candidates or transfer of designations obtained by others for future product candidates, and, even if Tempest obtains such designation, it may be unable to maintain the benefits associated with Orphan Drug
Designation, including the potential for market exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA may designate drugs intended to treat relatively small patient
populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United
States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for
that drug. Orphan drug designation must be requested before submitting an NDA. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for tax credits for qualified clinical research costs and
exemption from prescription drug user fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a drug with an Orphan Drug Designation subsequently receives the first
marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes FDA from approving another marketing application for the same drug and indication for that time
period, except in limited circumstances. If a competitor is able to obtain orphan drug exclusivity prior to Tempest for a product that constitutes the same active moiety and treats the same indications as Tempest&#146;s product candidates, Tempest
may not be able to obtain approval of its drug by the applicable regulatory authority for a significant period of time unless Tempest is able to show that its drug is clinically superior to the approved drug. The applicable period is seven years in
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may seek Orphan Drug Designation for one or more of its product candidates in the United States as part of its
business strategy. However, Orphan Drug Designation does not guarantee future orphan drug marketing exclusivity. Even after an orphan drug is approved, the FDA can also subsequently approve a later application for the same drug for the same
condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. In addition, a designated
orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the
FDA later determines that the request for designation was materially defective or if Tempest is unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan Drug Designation
neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for Tempest to commercialize and obtain marketing approval of Tempest&#146;s product
candidates and may affect the prices Tempest may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change, and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of Tempest&#146;s product candidates. Tempest cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action, either in the United States or abroad. If Tempest is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Tempest is not able to maintain regulatory compliance,
Tempest may lose any marketing approval that Tempest may have obtained, and Tempest may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March
2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, or ACA, was enacted to broaden access to health insurance, reduce or constrain the
growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.
The ACA contains provisions that may potentially affect the profitability of Tempest&#146;s product candidates, if approved, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid
managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs, and expansion of the entities eligible for discounts under the
340B Drug Pricing Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Congress has not passed legislation to comprehensively repeal the ACA, legislation affecting the ACA has
been signed into law, including the Tax Cuts and Jobs Act of 2017, which eliminated, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who
fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#147;individual mandate.&#148; In December 2018, a federal district court in Texas ruled that the ACA&#146;s individual mandate, without the
penalty that was eliminated effective January&nbsp;1, 2019, was unconstitutional and could not be severed from the ACA. As a result, the court ruled the remaining provisions of the ACA were also invalid. The Fifth Circuit Court of Appeals affirmed
the district court&#146;s ruling that the individual mandate was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unconstitutional, but it remanded the case back to the district court for further analysis of whether the mandate could be severed from the ACA (i.e., whether the entire ACA was therefore also
unconstitutional). The Supreme Court of the United States granted certiorari on March&nbsp;2, 2020 and heard oral argument in November 2020. The Supreme Court is expected to issue its decision in 2021. While Congress continues to amend the ACA, the
law appears likely to continue the downward pressure on pharmaceutical pricing, and may also increase Tempest&#146;s regulatory burdens and operating costs. In the future, there may be other efforts to challenge, repeal or replace the ACA. Tempest
is continuing to monitor any changes to the ACA that, in turn, may potentially impact its business in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other
legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&nbsp;1, 2013, which, due to subsequent legislative
amendments, will stay in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021 due to the coronavirus pandemic, unless additional Congressional action is taken. While there is currently
legislation pending that would extend this suspension through the end of 2021, passage of the law is not certain. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to
several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, effective January&nbsp;1, 2019, the Bipartisan Budget Act of 2018, among other things,
further amended portions of the Social Security Act implemented as part of the ACA to increase from 50% to 70% the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that pharmaceutical
manufacturers participating in the Coverage Gap Discount Program must provide to eligible Medicare Part D beneficiaries during the coverage gap phase of the Part D benefit, commonly referred to as the &#147;donut hole,&#148; and to reduce standard
beneficiary cost sharing in the coverage gap from 30% to 25% in most Medicare Part D plans. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for
Tempest&#146;s drugs, if approved, and accordingly, Tempest&#146;s financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been
proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&nbsp;1, 2013, which, due to subsequent legislative amendments, will stay in effect
through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020 implemented under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which was signed into law on March&nbsp;27, 2020,
unless additional Congressional action is taken. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers
for Tempest&#146;s drugs, if approved, and accordingly, Tempest&#146;s financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on May&nbsp;30, 2018, the
Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients who have been diagnosed with life-threatening diseases
or conditions to access certain investigational new drug products that have completed a phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law. Tempest may
choose to seek an expanded access program for Tempest&#146;s product candidates, or to utilize comparable rules in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, the cost of prescription pharmaceuticals has been the subject of considerable discussion in the United States at both the federal
and state levels. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the new Biden administration have each indicated that it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will seek new legislative and/or administrative measures to address prescription drug costs. Since the Presidential inauguration, the Biden administration has taken several executive actions that
signal changes in policy from the prior administration. For example, on January&nbsp;20, 2021, the Biden administration directed all federal departments and agencies to consider taking steps to withdraw or delay certain regulations and guidance
issued by the Trump administration that had not become effective as of January&nbsp;20, 2021 to permit the Biden administration to review such actions for questions of fact, law, and policy. At the state level, legislatures and agencies are
increasingly passing legislation and implementing regulations designed to control spending on and patient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs for drug products. These measures include
constraints on pricing, discounting and reimbursement; restrictions on certain product access and marketing; cost disclosure and transparency measures that require detailed reporting of drug pricing and marketing information both at product launch
and in the event of a price increase; and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest expects that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and in additional downward pressure on the price that Tempest receives for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent Tempest from being able to generate revenue, attain profitability, or commercialize Tempest&#146;s product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products. Tempest cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of
Tempest&#146;s product candidates, if any, may be. In addition, increased scrutiny by the U.S.&nbsp;Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject Tempest to more stringent
product labeling and post-marketing testing and other requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA&#146;s ability to review and approve new products may be hindered by a
variety of factors, including budget and funding levels, ability to hire and retain key personnel, statutory, regulatory and policy changes and global health concerns. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. In
addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the
time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect Tempest&#146;s business. For example, over the last several years the U.S.&nbsp;government has shut down several times and
certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the
FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions
could significantly impact the ability of the FDA and other agencies to fulfill their functions, and could greatly impact healthcare and the pharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its
intention to postpone most foreign inspections of manufacturing facilities and, subsequently, on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside
the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Subsequently, on July&nbsp;10, 2020 the FDA announced its intention to resume certain <FONT
STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of
all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other
regulatory authorities to timely review and process Tempest&#146;s regulatory submissions, which could have a material adverse effect on Tempest&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of Tempest&#146;s product candidates in one jurisdiction does not mean that Tempest will be successful in
obtaining regulatory approval of Tempest&#146;s product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory
approval of Tempest&#146;s product candidates in one jurisdiction does not guarantee that Tempest will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one
jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the
manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United
States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product
candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Tempest intends to charge for Tempest&#146;s products is also subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have
requirements for approval of product candidates with which Tempest must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays,
difficulties and costs for Tempest and could delay or prevent the introduction of Tempest&#146;s products in certain countries. If Tempest fails to comply with the regulatory requirements in international markets and/or receive applicable marketing
approvals, Tempest&#146;s target market will be reduced and Tempest&#146;s ability to realize the full market potential of Tempest&#146;s product candidates will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s operations and relationships with future customers, providers and third-party payors will be subject to applicable anti-kickback, fraud
and abuse and other healthcare laws and regulations, which could expose Tempest to penalties including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which
Tempest obtains marketing approval. Tempest&#146;s future arrangements with providers, third-party payors and customers will subject Tempest to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the
business or financial arrangements and relationships through which Tempest markets, sells and distributes any product candidates for which Tempest obtains marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restrictions under applicable U.S.&nbsp;federal and state healthcare laws and regulations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, a criminal law that prohibits, among other things, persons and entities from
knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or
service, for which payment may be made under </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order
to have committed a violation. Violations of the federal Anti-Kickback Statute can result in significant civil monetary penalties and criminal fines, as well as imprisonment and exclusion from participation in federal health care programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil False Claims Act, imposes significant civil penalties and treble damages, including through
civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease
or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S.&nbsp;federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Criminal Statute on False Statements Relating to Health Care Matters makes it a crime to knowingly
and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially
false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties
against an entity that engages in activities including, among others (1)&nbsp;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&nbsp;arranging for
or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3)&nbsp;violations of the federal Anti-Kickback Statute; or
(4)&nbsp;failing to report and return a known overpayment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil
liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute,
a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs, devices,
biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, among others, to track and report payments and other transfers of value provided during the previous year to
U.S. licensed physicians, teaching hospitals, and for reports submitted on or after January&nbsp;1, 2022, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives, as well as
certain ownership and investment interests held by physicians and their immediate family; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers
or marketing expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that Tempest&#146;s business arrangements with third parties will comply
with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that Tempest&#146;s business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If Tempest&#146;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to Tempest,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and
Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of Tempest&#146;s operations. If any of the physicians or other healthcare providers or entities with whom
Tempest expects to do business is found to be not in compliance with applicable laws, it may be costly to Tempest in terms of money, time and resources, and Tempest may be subject to criminal, civil or administrative sanctions, including exclusion
from government-funded healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_27"></A>Risks Related to Tempest&#146;s Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s success depends in part on its ability to obtain, maintain and protect its intellectual property. It is difficult and costly to protect
Tempest&#146;s proprietary rights and technology, and Tempest may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s
commercial success will depend in large part on obtaining and maintaining patent, trademark, trade secret and other intellectual property protection of Tempest&#146;s proprietary technologies and product candidates, which include TPST-1495,
TPST-1120 and the other product candidates Tempest has in development, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending Tempest&#146;s
patents and other intellectual property rights against third-party challenges. Tempest&#146;s ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing Tempest&#146;s product
candidates is dependent upon the extent to which Tempest has rights under valid and enforceable patents or trade secrets that cover these activities. If Tempest is unable to secure and maintain patent protection for any product or technology Tempest
develops, or if the scope of the patent protection secured is not sufficiently broad, Tempest&#146;s competitors could develop and commercialize products and technology similar or identical to Tempest&#146;s, and Tempest&#146;s ability to
commercialize any product candidates Tempest may develop may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patenting process is expensive and
time-consuming, and Tempest may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, Tempest may not pursue or obtain patent protection in all relevant markets. It
is also possible that Tempest will fail to identify patentable aspects of Tempest&#146;s research and development activities before it is too late to obtain patent protection. Moreover, in some circumstances, Tempest may not have the right to
control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that Tempest licenses from or licenses to third parties and may be reliant on Tempest&#146;s licensors or licensees to do so.
Tempest&#146;s pending and future patent applications may not result in issued patents. Even if patent applications Tempest licenses or owns currently or in the future issue as patents, they may not issue in a form that will provide Tempest with any
meaningful protection, prevent competitors or other third parties from competing with Tempest, or otherwise provide Tempest with any competitive advantage. Any patents that Tempest holds or <FONT STYLE="white-space:nowrap">in-licenses</FONT> may be
challenged, narrowed, circumvented or invalidated by third parties. Consequently, Tempest does not know whether any of Tempest&#146;s platform advances and product candidates will be protectable or remain protected by valid and enforceable patents.
In addition, Tempest&#146;s existing patents and any future patents Tempest obtains may not be sufficiently broad to prevent others from using Tempest&#146;s technology or from developing competing products and technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the future, Tempest may depend on intellectual property licensed from third parties, and its licensors may not always act in Tempest&#146;s best
interest. If Tempest fails to comply with its obligations under its intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, Tempest could lose significant rights that may be important to its
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is currently not the case, Tempest may in the future depend on patents,
<FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology licensed from third parties. Tempest&#146;s licenses to such patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology may not provide exclusive
rights in all relevant fields of use and in all territories in which Tempest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may wish to develop or commercialize Tempest&#146;s products in the future. The agreements under which Tempest licenses patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary
technology from others may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest
may need to obtain licenses from third parties to advance Tempest&#146;s research or allow commercialization of product candidates Tempest may develop. It is possible that Tempest may be unable to obtain any licenses at a reasonable cost or on
reasonable terms, if at all. In either event, Tempest may be required to expend significant time and resources to redesign Tempest&#146;s technology, product candidates, or the methods for manufacturing them or to develop or license replacement
technology, all of which may not be feasible on a technical or commercial basis. If Tempest is unable to do so, Tempest may be unable to develop or commercialize the affected technology or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest&#146;s future licensors fail to adequately protect Tempest&#146;s licensed intellectual property, Tempest&#146;s ability to
commercialize product candidates could suffer. Tempest may not have complete control over the maintenance, prosecution and litigation of Tempest&#146;s future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. For
example, Tempest cannot be certain that activities such as the maintenance and prosecution by Tempest&#146;s future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable
patents and other intellectual property rights. It is possible that future Tempest&#146;s licensors&#146; infringement proceedings or defense activities may be less vigorous than had Tempest conducted them itself or may not be conducted in
accordance with Tempest&#146;s best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the resolution of any contract interpretation disagreement that may arise
could narrow what Tempest might believe to be the scope of Tempest&#146;s rights to the relevant patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, or increase what Tempest believes to be Tempest&#146;s financial
or other obligations under the relevant agreement. Disputes that may arise between Tempest and Tempest&#146;s future licensors regarding intellectual property subject to a license agreement could include disputes regarding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which Tempest&#146;s technology and processes infringe on intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s right to sublicense patent and other rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s diligence obligations with respect to the use of the licensed technology in relation to
Tempest&#146;s development and commercialization of Tempest&#146;s product candidates and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">royalty, milestone or other payment obligations that may result from the advancement or commercial sale of any of
Tempest&#146;s product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by Tempest&#146;s licensors and Tempest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual
property that Tempest licenses in the future prevent or impair Tempest&#146;s ability to maintain Tempest&#146;s licensing arrangements on acceptable terms, Tempest may be unable to successfully develop and commercialize the affected technology or
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may not provide
sufficient protection of Tempest&#146;s product candidates or result in any competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of
biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of
Tempest&#146;s patent rights is highly uncertain. Tempest&#146;s pending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and future patent applications and those of its licensors may not result in patents being issued which protect its product candidates or which effectively prevent others from commercializing
competitive product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and
scientific questions and can be uncertain. The patent applications that Tempest owns or, in the future, <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover Tempest&#146;s product candidates
or uses thereof in the United States or in other foreign countries. For example, while Tempest&#146;s patent applications are pending, Tempest may be subject to a third party preissuance submission of prior art to the United States Patent and
Trademark Office, or USPTO, or become involved in interference or derivation proceedings, or equivalent proceedings in foreign jurisdictions. Even if patents do successfully issue, third parties may challenge their inventorship, validity,
enforceability or scope, including through opposition, revocation, reexamination, post-grant and <I>inter partes</I> review proceedings. An adverse determination in any such submission, proceeding or litigation may result in loss of patent rights,
loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit Tempest&#146;s ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of
the patent protection of Tempest&#146;s technology and product candidates. Furthermore, even if they are unchallenged, Tempest&#146;s patents and patent applications may not adequately protect Tempest&#146;s intellectual property or prevent others
from designing around Tempest&#146;s claims. Moreover, some of Tempest&#146;s owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties.
If Tempest is unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able
to license their rights to other third parties, including Tempest&#146;s competitors, and Tempest&#146;s competitors could market competing products and technology. In addition, Tempest may need the cooperation of any such <FONT
STYLE="white-space:nowrap">co-owners</FONT> of Tempest&#146;s patents in order to enforce such patents against third parties, and such cooperation may not be provided to Tempest. If the breadth or strength of protection provided by the patent
applications Tempest holds with respect to Tempest&#146;s product candidates is threatened, it could dissuade companies from collaborating with Tempest to develop, and threaten Tempest&#146;s ability to commercialize, Tempest&#146;s product
candidates. Further, if Tempest encounters delays in development, testing, and regulatory review of new product candidates, the period of time during which Tempest could market Tempest&#146;s product candidates under patent protection would be
reduced or eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since patent applications in the United States and other countries are confidential for a period of time after
filing or until issuance, at any moment in time, Tempest cannot be certain that it was in the past or will be in the future the first to file any patent application related to Tempest&#146;s product candidates. In addition, some patent applications
in the United States may be maintained in secrecy until the patents are issued. As a result, there may be prior art of which Tempest is not aware that may affect the validity or enforceability of a patent claim, and Tempest may be subject to
priority disputes. Tempest may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There also may be prior art of which Tempest is aware, but which Tempest does not believe affects
the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, Tempest&#146;s patents would be declared by a court, patent
office or other governmental authority to be valid or enforceable or that even if found valid and enforceable, a competitor&#146;s technology or product would be found by a court to infringe Tempest&#146;s patents. Tempest may analyze patents or
patent applications of Tempest&#146;s competitors that Tempest believes are relevant to Tempest&#146;s activities, and consider that Tempest is free to operate in relation to Tempest&#146;s product candidates, but Tempest&#146;s competitors may
achieve issued claims, including in patents Tempest considers to be unrelated, that block Tempest&#146;s efforts or potentially result in Tempest&#146;s product candidates or Tempest&#146;s activities infringing such claims. It is possible that
Tempest&#146;s competitors may have filed, and may in the future file, patent applications covering Tempest&#146;s products or technology similar to Tempest&#146;s. Those patent applications may have priority over Tempest&#146;s owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent applications or patents, which could require Tempest to obtain rights to issued patents covering such technologies. The possibility also exists that others will develop products that have the same
effect as Tempest&#146;s product candidates on an independent basis that do not infringe Tempest&#146;s patents or other intellectual property rights, or will design around the claims of patents that Tempest has had issued that cover Tempest&#146;s
product candidates or their use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, Tempest&#146;s currently owned patents and patent applications, if issued as
patents, directed to Tempest&#146;s proprietary technologies and Tempest&#146;s product candidates are expected to expire from 2033 through 2041, without taking into account any possible patent term adjustments or extensions. Tempest&#146;s earliest
patents may expire before, or soon after, Tempest&#146;s first product achieves marketing approval in the United States or foreign jurisdictions. Additionally, Tempest cannot be assured that the USPTO or relevant foreign patent offices will grant
any of the pending patent applications Tempest owns or <FONT STYLE="white-space:nowrap">in-licenses</FONT> currently or in the future. Upon the expiration of Tempest&#146;s current patents, Tempest may lose the right to exclude others from
practicing these inventions. The expiration of these patents could also have a similar material adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for Tempest&#146;s proprietary rights is uncertain because legal means afford only limited protection and may
not adequately protect Tempest&#146;s rights or permit Tempest to gain or keep Tempest&#146;s competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make or use compounds that are similar to the active compositions of Tempest&#146;s product
candidates but that are not covered by the claims of Tempest&#146;s patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the APIs in Tempest&#146;s current product candidates will eventually become commercially available in generic
drug products, and no patent protection may be available with regard to formulation or method of use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest or Tempest&#146;s future licensors, as the case may be, may fail to meet its or Tempest&#146;s
obligations to the U.S. government regarding any patents and patent applications funded by U.S.&nbsp;government grants, leading to the loss or unenforceability of patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest or Tempest&#146;s future licensors, as the case may be, might not have been the first to file patent
applications for certain inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of Tempest&#146;s
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that Tempest&#146;s pending patent applications will not result in issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate Tempest&#146;s owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, as the case may be, or parts of Tempest&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that others may circumvent Tempest&#146;s owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may
later issue with claims covering Tempest&#146;s product candidates or technology similar to Tempest&#146;s; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the laws of foreign countries may not protect Tempest&#146;s or Tempest&#146;s future licensors&#146;, as the
case may be, proprietary rights to the same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of Tempest&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or
patent applications, if and when issued, may not adequately cover Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents may not provide
Tempest with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventors of Tempest&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications may become involved with competitors, develop products or processes that design around Tempest&#146;s patents, or become hostile to Tempest or the patents or patent applications on which they are named as inventors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that Tempest&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications may omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or
unenforceable or such omitted individuals may grant licenses to third parties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest has engaged in scientific collaborations in the past and will continue to do so in the future and
Tempest&#146;s collaborators may develop adjacent or competing products that are outside the scope of Tempest&#146;s patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest may not develop additional proprietary technologies for which Tempest can obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that product candidates or diagnostic tests Tempest develops may be covered by third parties&#146;
patents or other exclusive rights; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on Tempest&#146;s business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the foregoing could have a material adverse effect on Tempest&#146;s business, financial conditions, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s strategy of obtaining rights to key technologies through
<FONT STYLE="white-space:nowrap">in-licenses</FONT> may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future growth of Tempest&#146;s business may depend
in part on Tempest&#146;s ability to <FONT STYLE="white-space:nowrap">in-license</FONT> or otherwise acquire the rights to additional product candidates and technologies. Tempest cannot assure you that Tempest will be able to <FONT
STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, Tempest&#146;s agreements with certain of its third-party research partners provide that improvements developed in the course of
its relationship may be owned solely by either Tempest or its third-party research partner, or jointly between Tempest and the third party. If Tempest determines that exclusive rights to such improvements owned solely by a research partner or other
third party with whom Tempest collaborates are necessary to commercialize Tempest&#146;s drug candidates or maintain Tempest&#146;s competitive advantage, Tempest may need to obtain an exclusive license from such third party in order to use the
improvements and continue developing, manufacturing or marketing Tempest&#146;s drug candidates. Tempest may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent Tempest from
commercializing its drug candidates or allow Tempest&#146;s competitors or others the opportunity to access technology that is important to Tempest&#146;s business. Tempest also may need the cooperation of any
<FONT STYLE="white-space:nowrap">co-owners</FONT> of Tempest&#146;s intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to Tempest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of these technologies is a highly competitive area, and
a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that Tempest may consider attractive. These established companies may have a competitive advantage over Tempest due to their
size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Tempest to be a competitor may be unwilling to license rights to Tempest. Furthermore, Tempest may be unable to identify
suitable product candidates or technologies within Tempest&#146;s area of focus. If Tempest is unable to successfully obtain rights to suitable product candidates or technologies, Tempest&#146;s business and prospects could be materially and
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest is unable to protect the confidentiality of its trade secrets, Tempest&#146;s business and competitive position
would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, Tempest relies upon <FONT STYLE="white-space:nowrap">know-how</FONT> and trade
secret protection, as well as <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements and invention assignment agreements with Tempest&#146;s employees, consultants and third-parties, to protect Tempest&#146;s confidential and proprietary
information, especially where Tempest does not believe patent protection is appropriate or obtainable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is Tempest&#146;s policy to
require Tempest&#146;s employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment or consulting relationships with Tempest. These agreements provide that all confidential information concerning Tempest&#146;s business or financial affairs developed or made known to
the individual or entity during the course of the party&#146;s relationship with Tempest is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that
all inventions conceived by the individual, and that are related to Tempest&#146;s current or planned business or research and development or made during normal working hours, on Tempest&#146;s premises or using Tempest&#146;s equipment or
proprietary information (or as otherwise permitted by applicable law), are Tempest&#146;s exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services
provided are Tempest&#146;s exclusive property. However, Tempest cannot guarantee that Tempest has entered into such agreements with each party that may have or have had access to Tempest&#146;s trade secrets or proprietary technology and processes.
Tempest has also adopted policies and conducts training that provides guidance on Tempest&#146;s expectations, and Tempest&#146;s advice for best practices, in protecting its trade secrets. Despite these efforts, any of these parties may breach the
agreements and disclose Tempest&#146;s proprietary information, including its trade secrets, and Tempest may not be able to obtain adequate remedies for such breaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, Tempests tries to protect the confidential nature of Tempest&#146;s proprietary information through other
appropriate precautions, such as physical and technological security measures. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. These measures may not, for example, in the case of
misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for Tempest&#146;s proprietary information. Tempest&#146;s security measures may not prevent an employee or consultant from
misappropriating Tempest&#146;s trade secrets and providing them to a competitor, and any recourse Tempest might take against this type of misconduct may not provide an adequate remedy to protect Tempest&#146;s interests fully. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent
Tempest from receiving legal recourse. If any of Tempest&#146;s confidential or proprietary information, such as its trade secrets, were to be disclosed or misappropriated, such as through a data breach, or if any of that information was
independently developed by a competitor, Tempest&#146;s competitive position could be harmed. Additionally, certain trade secret and proprietary information may be required to be disclosed in submissions to regulatory authorities. If such
authorities do not maintain the confidential basis of such information or disclose it as part of the basis of regulatory approval, Tempest&#146;s competitive position could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If Tempest chooses to go to court to stop a
third party from using any of Tempest&#146;s trade secrets, Tempest may incur substantial costs. Even if Tempest is successful, these types of lawsuits may result in substantial cost and require significant time from our scientists and management.
Although Tempest takes steps to protect Tempest&#146;s proprietary information and trade secrets, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to Tempest&#146;s
trade secrets or disclose Tempest&#146;s technology, through legal or illegal means. As a result, Tempest may not be able to meaningfully protect its trade secrets. Any of the foregoing could have a material adverse effect on Tempest&#146;s
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent, delay or
otherwise interfere with Tempest&#146;s product discovery and development efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s commercial success depends in
part on Tempest&#146;s ability to develop, manufacture, market and sell Tempest&#146;s product candidates and use Tempest&#146;s proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or other
proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging
patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or oppositions and other comparable proceedings in foreign jurisdictions. Tempest may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual
property rights alleging that Tempest&#146;s product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S.&nbsp;and foreign issued patents and pending patent
applications that are owned by third parties exist in the fields in which Tempest is developing Tempest&#146;s product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that
Tempest&#146;s product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including Tempest, which patents cover various types of drugs, products or their
methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in Tempest&#146;s field, third parties may allege they have patent rights encompassing Tempest&#146;s product candidates, technologies
or methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third-party claims that Tempest infringes, misappropriates or otherwise violates its intellectual property rights,
Tempest may face a number of issues, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">infringement and other intellectual property claims that, regardless of merit, may be expensive and
time-consuming to litigate and may divert Tempest&#146;s management&#146;s attention from its core business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial damages for infringement, which Tempest may have to pay if a court decides that the product candidate
or technology at issue infringes on or violates the third party&#146;s rights, and, if the court finds that the infringement was willful, Tempest could be ordered to pay treble damages plus the patent owner&#146;s attorneys&#146; fees;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a court prohibiting Tempest from developing, manufacturing, marketing or selling Tempest&#146;s product
candidates, or from using Tempest&#146;s proprietary technologies, unless the third-party licenses its product rights or proprietary technology to Tempest, which it is not required to do, on commercially reasonable terms or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a license is available from a third party, Tempest may have to pay substantial royalties, upfront fees and
other amounts, and/or grant cross-licenses to intellectual property rights for Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that Tempest redesign its product candidates or processes so they do not infringe, which may not
be possible or may require substantial monetary expenditures and time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there could be public announcements of the results of hearings, motions, or other interim proceedings or
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Tempest&#146;s common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of Tempest&#146;s competitors may be able to sustain the costs of complex patent litigation more effectively than Tempest can because
they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Tempest&#146;s ability to raise the funds necessary to continue
Tempest&#146;s operations or could otherwise have a material adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that Tempest is employing their proprietary technology without authorization, including by enforcing its patents
against Tempest by filing a patent infringement lawsuit against Tempest. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#147;clear and convincing,&#148; a
heightened standard of proof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which Tempest is currently unaware with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of Tempest&#146;s product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that
may later result in issued patents that Tempest&#146;s product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of Tempest&#146;s technologies infringes upon these patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any third-party patents were held by a court of competent jurisdiction to cover the
manufacturing process of Tempest&#146;s product candidates, or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able to block Tempest&#146;s ability to commercialize
Tempest&#146;s product candidate unless Tempest obtains a license under the applicable patents, or until those patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were
held by a court of competent jurisdiction to cover aspects of Tempest&#146;s formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of that patent may be able to block
Tempest&#146;s ability to develop and commercialize the product candidate unless Tempest obtains a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, a license may not be available on
commercially reasonable terms, or at all, particularly if such patent is owned or controlled by one of Tempest&#146;s primary competitors. If Tempest is unable to obtain a necessary license to a third-party patent on commercially reasonable terms,
or at all, Tempest&#146;s ability to commercialize Tempest&#146;s product candidates may be impaired or delayed, which could significantly harm Tempest&#146;s business. Even if Tempest obtains a license, it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving Tempest&#146;s competitors access to the same technologies licensed to Tempest. In addition, if the breadth or strength of protection provided by Tempest&#146;s patents and patent
applications is threatened, it could dissuade companies from collaborating with Tempest to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against Tempest may seek and obtain injunctive or other equitable relief, which could effectively block Tempest&#146;s
ability to further develop and commercialize Tempest&#146;s product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee time and resources from
Tempest&#146;s business. In the event of a successful claim of infringement against Tempest, Tempest may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from
third parties, pay royalties or redesign Tempest&#146;s infringing products, which may be impossible or require substantial time and monetary expenditure. Tempest cannot predict whether any license of this nature would be available at all or whether
it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, Tempest may need to obtain licenses from third parties to advance Tempest&#146;s research or allow commercialization of Tempest&#146;s product
candidates and Tempest may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, Tempest would be unable to further develop and commercialize Tempest&#146;s product candidates, which could
significantly harm Tempest&#146;s business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may be involved in lawsuits to protect or enforce its patents or the patents of its licensors,
which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe Tempest&#146;s patents or the patents of its future licensors. To counter infringement or unauthorized use, Tempest
may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of Tempest&#146;s patents is not valid or is unenforceable, or may refuse to stop
the other party from using the technology at issue on the grounds that Tempest&#146;s patents do not cover the technology in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a
validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type double patenting.
Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise
similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review,
interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). These types of proceedings could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in revocation or amendment to Tempest&#146;s patents such that they no longer cover Tempest&#146;s product candidates. The outcome for any particular patent following legal assertions of
invalidity and unenforceability is unpredictable. With respect to the validity question, for example, Tempest cannot be certain that there is no invalidating prior art, of which Tempest, Tempest&#146;s patent counsel and the patent examiner were
unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if Tempest is otherwise unable to adequately protect Tempest&#146;s rights, Tempest would lose at least part, and perhaps all,
of the patent protection on Tempest&#146;s product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from Tempest&#146;s
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conversely, Tempest may choose to challenge the patentability of claims in a third party&#146;s U.S.&nbsp;patent by requesting
that the USPTO review the patent claims in <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,
opposition proceedings), or Tempest may choose to challenge a third party&#146;s patent in patent opposition proceedings in the Canadian Intellectual Property Office, or CIPO, the European Patent Office, or EPO, or another foreign patent office.
Even if successful, the costs of these opposition proceedings could be substantial, and may consume Tempest&#146;s time or other resources. If Tempest fails to obtain a favorable result at the USPTO, CIPO, EPO or other patent office then Tempest may
be exposed to litigation by a third party alleging that the patent may be infringed by Tempest&#146;s product candidates or proprietary technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of Tempest&#146;s confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of Tempest&#146;s common stock. Any of the foregoing could have a material adverse effect on Tempest&#146;s
business financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may not be able to protect its intellectual property rights throughout
the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be
prohibitively expensive, and Tempest&#146;s intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as federal and state laws in the United States. For example, patents covering <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">methods-of-use</FONT></FONT> are not available in certain foreign
countries. Consequently, Tempest may not be able to prevent third parties from practicing Tempest&#146;s inventions in all countries outside the United States, or from selling or importing products made using Tempest&#146;s inventions in and into
the United States or other jurisdictions. Competitors may use Tempest&#146;s technologies in jurisdictions where Tempest does not have or has not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where Tempest has patent protection but where enforcement is not as strong as that in the United States. These products may compete with Tempest&#146;s product candidates in jurisdictions where Tempest does not have any
issued patents and Tempest&#146;s patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could
make it difficult for Tempest to stop the infringement of Tempest&#146;s patents or marketing of competing products against third parties in violation of Tempest&#146;s proprietary rights generally. The initiation of proceedings by third parties to
challenge the scope or validity of Tempest&#146;s patent rights in foreign jurisdictions could result in substantial cost and divert management&#146;s efforts and attention from other aspects of Tempest&#146;s business. Proceedings to enforce
Tempest&#146;s patent rights in foreign jurisdictions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could result in substantial costs and divert management&#146;s efforts and attention from other aspects of Tempest&#146;s business, could put Tempest&#146;s patents at risk of being invalidated
or interpreted narrowly and Tempest&#146;s patent applications at risk of not issuing and could provoke third parties to assert claims against Tempest. Tempest may not prevail in any lawsuits that Tempest initiates and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, Tempest&#146;s efforts to enforce Tempest&#146;s intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that Tempest develops or licenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that Tempest&#146;s employees or consultants have wrongfully used or disclosed
confidential information or misappropriated trade secrets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries,
Tempest employs individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including Tempest&#146;s competitors or potential competitors. Although Tempest tries to ensure that Tempest&#146;s
employees and consultants do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for Tempest, Tempest may be subject to claims that Tempest&#146;s employees, consultants or independent
contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Tempest may then have to pursue litigation to defend against
these claims. If Tempest fails in defending any claims of this nature, in addition to paying monetary damages, Tempest may lose valuable intellectual property rights or personnel. Even if Tempest is successful in defending against these types of
claims, litigation or other legal proceedings relating to intellectual property claims may cause Tempest to incur significant expenses, and could distract Tempest&#146;s technical and management personnel from their normal responsibilities. In
addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial
adverse effect on the price of Tempest&#146;s common stock. This type of litigation or proceeding could substantially increase Tempest&#146;s operating losses and reduce Tempest&#146;s resources available for development activities, and Tempest may
not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of Tempest&#146;s competitors may be able to sustain the costs of this type of litigation or proceedings more
effectively than Tempest can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings
could adversely affect Tempest&#146;s ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining Tempest&#146;s patent protection depends on
compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and Tempest&#146;s patent protection could be reduced or eliminated for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are
due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable laws and rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or
lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit
formal documents. Were a noncompliance event to occur, Tempest&#146;s competitors might be able to enter the market, which would have a material adverse effect on Tempest&#146;s business financial condition, results of operations and prospects. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States and in <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdictions could diminish the value of patents in general, thereby impairing Tempest&#146;s ability to protect its product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, Tempest&#146;s success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of Tempest&#146;s patent
applications and the enforcement or defense of Tempest&#146;s issued patents. For example, in March 2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a &#147;first to invent&#148; to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> patent system. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the
other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act
includes a number of other significant changes to U.S.&nbsp;patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes
continue to evolve as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act. In addition, the courts have yet to address many of these provisions and the applicability of the act and new
regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. Moreover, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of
Tempest&#146;s patent applications and the enforcement or defense of Tempest&#146;s issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, recent
U.S.&nbsp;Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Tempest&#146;s
ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S.&nbsp;Congress, the federal courts and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that would weaken Tempest&#146;s ability to obtain new patents or to enforce Tempest&#146;s existing patents and patents that Tempest might obtain or license in the future. For
example, in the case, <I>Assoc. for</I> <I>Molecular Pathology v. Myriad Genetics, Inc.</I>, the U.S.&nbsp;Supreme Court held that certain claims to DNA molecules are not patent-eligible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, other cases by the U.S.&nbsp;Supreme Court have held that certain methods of treatment or diagnosis are not patent-eligible.
U.S.&nbsp;law regarding patent-eligibility continues to evolve. While Tempest does not believe that any of Tempest&#146;s patents will be found invalid based on these changes to US patent law, Tempest cannot predict how future decisions by the
courts, the U.S.&nbsp;Congress or the USPTO may impact the value of Tempest&#146;s patents and patent applications. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on Tempest&#146;s
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect Tempest&#146;s competitive position
on its product candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all
maintenance fees are timely paid, the natural expiration of a patent is generally 20&nbsp;years from its earliest <FONT STYLE="white-space:nowrap">U.S.&nbsp;non-provisional</FONT> filing date. Various extensions may be available, but the life of a
patent, and the protection it affords, is limited. Even if patents covering Tempest&#146;s product candidates are obtained, once the patent life has expired, Tempest may be open to competition from competitive products, including generics. Given the
amount of time required for the development, testing and regulatory review of new product candidates, patents protecting Tempest&#146;s product candidates might expire before or shortly after Tempest or Tempest&#146;s partners commercialize those
candidates. As a result, Tempest&#146;s owned and licensed patent portfolio may not provide Tempest with sufficient rights to exclude others from commercializing products similar or identical to Tempest&#146;s. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest does not obtain patent term extension for any product candidates it may develop,
Tempest&#146;s business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval
of any product candidates Tempest may develop, one or more of Tempest&#146;s U.S.&nbsp;patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of
a patent beyond a total of 14&nbsp;years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended.
U.S.&nbsp;and <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> law concerning patent term extensions and foreign equivalents continue to evolve. Even if Tempest were to seek a patent term extension, it may not be granted because of, for example, the
failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable
requirements. Moreover, the applicable time period of extension or the scope of patent protection afforded could be less than Tempest requests. If Tempest is unable to obtain patent term extension or term of any such extension is less than it
requests, Tempest&#146;s competitors may obtain approval of competing products following Tempest&#146;s patent expiration sooner than expected, and Tempest&#146;s business, financial condition, results of operations and prospects could be materially
harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property discovered through government funded programs may be subject to federal regulations such as </I></B>&#147;<B><I><FONT
STYLE="white-space:nowrap">march-in</FONT></I></B>&#148;<B><I> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit Tempest&#146;s exclusive rights and limit its ability to
contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers.</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Tempest does not currently own issued
patents or pending patent applications that have been generated through the use of U.S. government funding, Tempest may acquire or license in the future intellectual property rights that have been generated through the use of U.S. government funding
or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT
STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive,
partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (1)&nbsp;adequate steps have not been taken to commercialize the invention; (2)&nbsp;government
action is necessary to meet public health or safety needs; or (3)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT>
rights&#148;). If the U.S. government exercised its <FONT STYLE="white-space:nowrap">march-in</FONT> rights in Tempest&#146;s future intellectual property rights that are generated through the use of U.S. government funding or grants, Tempest could
be forced to license or sublicense intellectual property developed by Tempest or that Tempest licenses on terms unfavorable to Tempest, and there can be no assurance that Tempest would receive compensation from the U.S. government for the exercise
of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified
time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require Tempest to expend substantial resources. In addition, the U.S. government requires
that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the
funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United
States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit Tempest&#146;s ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for
products covered by such intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_28"></A>Risks Related to Employee Matters, Managing Growth and Other Risks Related to
Tempest&#146;s Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest expects to expand its development and regulatory capabilities, and as a result, Tempest may encounter
difficulties in managing its growth, which could disrupt Tempest&#146;s operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest expects to experience significant
growth in the number of Tempest&#146;s employees and the scope of Tempest&#146;s operations, particularly in the areas of product candidate development, growing Tempest&#146;s capability to conduct clinical trials, and, if approved, through
commercialization of Tempest&#146;s product candidates. To manage its anticipated future growth, Tempest must continue to implement and improve its managerial, operational and financial systems, expand its facilities and continue to recruit and
train additional qualified personnel, or contract with third parties to provide these capabilities for Tempest. Due to Tempest&#146;s limited financial resources and the limited experience of Tempest&#146;s management team in managing a company with
such anticipated growth, Tempest may not be able to effectively manage the expansion of Tempest&#146;s operations or recruit and train additional qualified personnel. The expansion of Tempest&#146;s operations may lead to significant costs and may
divert Tempest&#146;s management and business development resources. Any inability to manage growth could delay the execution of Tempest&#146;s business plans or disrupt Tempest&#146;s operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest must attract and retain highly skilled employees to succeed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To succeed, Tempest must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and Tempest
faces significant competition for experienced personnel. If Tempest does not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect Tempest&#146;s ability to execute its business
plan, harm Tempest&#146;s results of operations and increase Tempest&#146;s capabilities to successfully commercialize its product candidates. In particular, Tempest believes that its future success is highly dependent upon the contributions of its
senior management, particularly its Chief Executive Officer, Tom Dubensky and its President and Chief Operating Officer, Stephen Brady. The loss of services of Messrs.&nbsp;Dubensky or Brady, or any of Tempest&#146;s senior management, could delay
or prevent the successful development of Tempest&#146;s product pipeline, completion of Tempest&#146;s planned clinical trials or the commercialization of Tempest&#146;s product candidates, if approved. The competition for qualified personnel in the
biotechnology field is intense and as a result, Tempest may be unable to continue to attract and retain qualified personnel necessary for the development of Tempest&#146;s business or to recruit suitable replacement personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other biotechnology companies that Tempest competes against for qualified personnel have greater financial and other resources,
different risk profiles and a longer history in the industry than Tempest does. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality
candidates than what Tempest has to offer. If Tempest is unable to continue to attract and retain high-quality personnel, the rate and success at which Tempest can discover and develop product candidates and Tempest&#146;s business will be limited.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future acquisitions or strategic alliances could disrupt Tempest&#146;s business and harm Tempest&#146;s financial condition and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third
parties that Tempest believes will complement or augment Tempest&#146;s existing business. If Tempest acquires businesses with promising markets or technologies, Tempest may not be able to realize the benefit of acquiring such businesses if Tempest
is unable to successfully integrate them with Tempest&#146;s existing operations and company culture. Tempest may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or
acquisition that delay or prevent Tempest from realizing their expected benefits or enhancing Tempest&#146;s business. Tempest cannot assure you that, following any such acquisition, Tempest will achieve the expected synergies to justify the
transaction. The risks Tempest faces in connection with acquisitions, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management time and focus from operating Tempest&#146;s business to addressing acquisition
integration challenges; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordination of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees from the acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning
resulting from the acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural challenges associated with integrating employees from the acquired company into Tempest&#146;s
organization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition
may have lacked sufficiently effective controls, procedures and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liability for activities of the acquired company before the acquisition, including intellectual property
infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated write-offs or charges; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation or other claims in connection with the acquired company, including claims from terminated employees,
customers, former stockholders or other third parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s failure to address these risks or other problems
encountered in connection with its past or future acquisitions or strategic alliances could cause Tempest to fail to realize the anticipated benefits of these transactions, cause Tempest to incur unanticipated liabilities and harm the business
generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm Tempest&#146;s financial condition or results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Tempest fails to comply with environmental, health, and safety laws and regulations, Tempest could become subject to fines or
penalties or incur costs that could harm Tempest&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is subject to numerous environmental, health, and safety
laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Tempest&#146;s operations involve the use of hazardous and flammable materials, including
chemicals and biological materials. Tempest&#146;s operations also may produce hazardous waste products. Tempest generally contracts with third parties for the disposal of these materials and wastes. Tempest will not be able to eliminate the risk of
contamination or injury from these materials. In the event of contamination or injury resulting from any use by Tempest of hazardous materials, Tempest could be held liable for any resulting damages, and any liability could exceed Tempest&#146;s
resources. Tempest also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Tempest maintains workers&#146; compensation insurance to cover Tempest for costs and expenses Tempest may incur due to injuries to
Tempest&#146;s employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Tempest may incur substantial costs in order to comply with current or future environmental, health, and safety laws and
regulations. These current or future laws and regulations may impair Tempest&#146;s research, development or production efforts. Tempest&#146;s failure to comply with these laws and regulations also may result in substantial fines, penalties or
other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect Tempest&#146;s business, financial condition, stock price and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s results of operations could be adversely affected by general conditions in the global
economy and in the global financial markets. For example, a global economic downturn that could result from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could cause extreme volatility and disruptions in the capital and credit
markets. A severe or prolonged economic downturn could result in a variety of risks to Tempest&#146;s business, including, weakened demand for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest&#146;s product candidates and Tempest&#146;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain Tempest&#146;s
suppliers, possibly resulting in supply disruption, or cause Tempest&#146;s customers to delay making payments for Tempest&#146;s services. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more
difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on Tempest&#146;s growth strategy, financial performance and stock price and could
require Tempest to delay or abandon clinical development plans. In addition, there is a risk that one or more of Tempest&#146;s current service providers, manufacturers and other partners may not survive such difficult economic times, which could
directly affect Tempest&#146;s ability to attain Tempest&#146;s operating goals on schedule and on budget. Any of the foregoing could harm Tempest&#146;s business and Tempest cannot anticipate all of the ways in which the current economic climate
and financial market conditions could adversely impact Tempest&#146;s business. Furthermore, the combined company&#146;s stock price may decline due in part to the volatility of the stock market and any general economic downturn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest or the third parties upon whom Tempest depends may be adversely affected by natural disasters and other calamities, including pandemics, such as
the global outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and Tempest&#146;s business continuity and disaster recovery plans may not adequately protect Tempest from a serious disaster. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Natural disasters could severely disrupt Tempest&#146;s operations and have a material adverse effect on Tempest&#146;s business, results of
operations, financial condition and prospects. If a natural disaster, fire, hurricane, power outage or other event occurred that prevented Tempest from using all or a significant portion of Tempest&#146;s headquarters, that damaged critical
infrastructure, such as Tempest&#146;s suppliers&#146; manufacturing facilities, or that otherwise disrupted operations, such as data storage, it may be difficult or, in certain cases, impossible for Tempest to continue Tempest&#146;s business for a
substantial period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Occurrences of epidemics or pandemics, depending on their scale, may cause different degrees of damage to the
national and local economies within Tempest&#146;s geographic focus. Global economic conditions may be disrupted by widespread outbreaks of infectious or contagious diseases, and such disruption may adversely affect clinical development plans. For
example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could have an adverse effect on the coordination of research and development, Tempest&#146;s capital raising efforts, and the financial condition of Tempest&#146;s business, as
well as the ability of Tempest to retain key personnel and continue to expand product candidate development and conduct clinical trials. In addition, the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> is likely to continue to cause
substantial changes in consumer behavior and has caused restrictions on business and individual activities, which are likely to lead to reduced economic activity. Extraordinary actions taken by international, federal, state and local public health
and governmental authorities to contain and combat the outbreak and spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in regions throughout the world, including travel bans, quarantines, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;stay-at-home&#148;</FONT></FONT> orders and similar mandates for many individuals and businesses to substantially restrict daily activities could have an adverse effect on Tempest&#146;s financial condition and
ability to raise financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disaster recovery and business continuity plans Tempest has in place may prove inadequate in the event of
a serious disaster or similar event. Tempest may incur substantial expenses as a result of the limited nature of Tempest&#146;s disaster recovery and business continuity plans, which could have a material adverse effect on Tempest&#146;s business.
As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Tempest may experience reduction in research and development, clinical testing, regulatory compliance activities, and manufacturing activities, and is unable at this time
to estimate the extent of the effect of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on its business. The extent and duration of the economic slowdown attributable to <FONT STYLE="white-space:nowrap">COVID-19</FONT> remains uncertain at this
time. A continued significant economic slowdown could have a substantial adverse effect on Tempest&#146;s financial condition, liquidity, and results of operations. If these conditions persist for an extended term, it could have a material adverse
effect on Tempest&#146;s future revenue and sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s internal computer and information systems, or those used by its CROs, CMOs or other
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of Tempest&#146;s development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of appropriate security measures, Tempest&#146;s internal computer and information systems and those of
Tempest&#146;s current and any future CROs, CMOs and other contractors or consultants may become vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If
such an event were to occur and cause interruptions in Tempest&#146;s operations, it could result in a material disruption of Tempest&#146;s development programs and Tempest&#146;s business operations, whether due to a loss of Tempest&#146;s trade
secrets or other proprietary information or other similar disruptions. For example, the loss of data from completed or future preclinical studies or clinical trials could result in significant delays in Tempest&#146;s regulatory approval efforts and
significantly increase Tempest&#146;s costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, Tempest&#146;s data or applications, or inappropriate disclosure of
confidential or proprietary information, Tempest could incur liability, Tempest&#146;s competitive position could be harmed and the further development and commercialization of Tempest&#146;s product candidates could be significantly delayed.
Tempest&#146;s internal information technology systems and infrastructure are also vulnerable to damage from natural disasters, terrorism, war, telecommunication and electrical failures. System failures or outages, including any potential
disruptions due to significantly increased global demand on certain cloud-based systems during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could compromise Tempest&#146;s ability to perform its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations, which could harm its ability to conduct business or delay its financial reporting. Such failures could materially adversely affect Tempest&#146;s operating results and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest is subject to a variety of privacy and data security laws, and Tempest&#146;s failure to comply with them could harm
Tempest&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest maintains a large quantity of sensitive information, including confidential business and patient
health information in connection with Tempest&#146;s preclinical and clinical studies, and is subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy
and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including health information privacy laws, security breach notification laws, and consumer protection laws. Each of these laws
is subject to varying interpretations and constantly evolving. In addition, Tempest may obtain health information from third parties (including research institutions from which it obtains clinical trial data) that are subject to privacy and security
requirements under HIPAA. Depending on the facts and circumstances, Tempest could be subject to criminal penalties if it knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA covered entity in a
manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain states have also adopted comparable privacy and security laws and
regulations, some of which may be more stringent than HIPAA. For example, California enacted the California Consumer Privacy Act, or the CCPA, which took effect on January&nbsp;1, 2020. The CCPA gives California residents expanded rights to access
and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right
of action for data breaches that is expected to increase data breach litigation. The CCPA may increase Tempest&#146;s compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more
stringent privacy legislation in the United States, which could increase Tempest&#146;s potential liability and adversely affect Tempest&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Canada, the Personal Information Protection and Electronic Documents Act, or PIPEDA, and similar provincial laws may impose obligations
with respect to processing personal information, including health-related information. PIPEDA requires companies to obtain an individual&#146;s consent when collecting, using or disclosing that individual&#146;s personal information. Individuals
have the right to access and challenge the accuracy of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for
another purpose, it must again obtain that individual&#146;s consent. Failure to comply with PIPEDA could result in significant fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, the General Data Protection Regulation, or the GDPR, took effect in the European Economic Area, the EEA. The GDPR governs the
collection, use, disclosure, transfer or other processing of personal data of natural persons. Among other things, the GDPR imposes strict obligations on the ability to process health-related and other personal data of data subjects in the EEA,
including in relation to use, collection, analysis and transfer (including cross-border transfer) of such personal data. The GDPR includes requirements relating to the consent of the individuals to whom the personal data relates, including detailed
notices for clinical trial subjects and investigators. The GDPR also includes certain requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection
authorities or data subjects as well as requirements for establishing a lawful basis on which personal data can be processed. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to
the United States and other jurisdictions that the European Commission does not recognize as having &#147;adequate&#148; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or
4% of Tempest&#146;s annual worldwide gross revenue). Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of information from the EEA to the United States. For example, on
June&nbsp;16, 2020, the Court of Justice of the European Union, or the CJEU, declared the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield framework, or the Privacy Shield, to be invalid. As a result, Privacy Shield is no longer a
valid mechanism for transferring personal data from the EEA to the United States. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature, which seems possible given the
rationale behind the CJEU&#146;s concerns about U.S.&nbsp;law and practice on government surveillance. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek
judicial remedies and obtain compensation for damages resulting from violations of the GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these and any other
applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and Tempest may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If Tempest fails to comply
with any such laws or regulations, Tempest may face significant fines and penalties that could adversely affect Tempest&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest may be unable to adequately protect its information systems from cyberattacks, which could result in the disclosure of confidential information,
damage Tempest&#146;s reputation, and subject Tempest to significant financial and legal exposure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyberattacks are increasing in
their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the
deployment of harmful malware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service,</FONT></FONT> social engineering fraud or other means to threaten data confidentiality, integrity and availability. A successful
cyberattack could cause serious negative consequences for Tempest, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss
and the disclosure of corporate strategic plans. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is generally increasing the attack surface available to criminals, as more companies and individuals work online and work remotely, and as
such, the risk of a cybersecurity incident potentially occurring, and Tempest&#146;s investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social
engineering attempts from &#147;hackers&#148; hoping to use the recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to their advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Tempest devotes resources to protect its information systems, Tempest realizes that cyberattacks are a threat, and there can be no
assurance that Tempest&#146;s efforts will prevent information security breaches that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would result in business, legal, financial or reputational harm to Tempest, or would have a material adverse effect on Tempest&#146;s results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the computer systems of various third parties on which Tempest relies, including its CROs, CMOs and other contractors,
consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication
and electrical failures. Tempest relies on its third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is
exposed to the risk of fraud or other misconduct by Tempest&#146;s employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulators, to provide accurate information to the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulators, to comply with healthcare fraud and abuse laws and regulations in the United States
and abroad, to report financial information or data accurately or disclose unauthorized activities to Tempest. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and could cause serious harm to Tempest&#146;s
reputation. It is not always possible to identify and deter employee misconduct, and the precautions Tempest takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Tempest
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against Tempest, and Tempest is not successful in defending or asserting
Tempest&#146;s rights, those actions could have a significant impact on Tempest&#146;s business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s business entails a significant risk of product liability and Tempest&#146;s ability to obtain sufficient insurance coverage could have a
material and adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest will
face an inherent risk of product liability exposure related to the testing of its product candidates in clinical trials and will face an even greater risk if Tempest commercializes any of Tempest&#146;s product candidates. Any such product liability
claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in a product, negligence, strict liability or breach of warranty. Claims could also be asserted under U.S.&nbsp;state consumer
protection acts. If Tempest cannot successfully defend Tempest&#146;s against claims that Tempest&#146;s product candidates caused injuries, Tempest could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may
result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates that Tempest may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to Tempest&#146;s reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of Tempest&#146;s collaboration relationships or disputes with its collaborators;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voluntary product recalls, withdrawals or labeling restrictions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidates that Tempest may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Tempest currently has insurance that Tempest believes is appropriate for Tempest&#146;s stage of development, Tempest may need to obtain
higher levels prior to clinical development or marketing any of its future product candidates. Any insurance Tempest has or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product
liability insurance is becoming increasingly expensive. As a result, Tempest may be unable to obtain sufficient insurance at a reasonable cost to protect Tempest against losses caused by product liability claims that could have a material and
adverse effect on Tempest&#146;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tempest&#146;s ability to use net operating
loss carryforwards and tax credit carryforwards may be subject to limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Tempest had federal
and state NOLs of approximately $80.9 million and $80.3&nbsp;million, respectively. To the extent that Tempest&#146;s taxable income exceeds any current year operating losses, Tempest plans to use its carryforwards to offset income that would
otherwise be taxable. Its NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Tempest&#146;s federal and state NOL carryforwards will
begin to expire, if not utilized, in 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 and Section&nbsp;383 of the Code and corresponding provisions of state
law, if a corporation undergoes an &#147;ownership change,&#148; its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as
research tax credits) to offset its post-change income or taxes may be limited. A Section&nbsp;382 &#147;ownership change&#148; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain
stockholders over a three-year period. Tempest may have experienced ownership changes in the past, may experience an ownership change as a result of the merger, and may experience ownership changes in the future due to subsequent shifts in the
combined company&#146;s stock ownership (some of which are outside of its control). Consequently, even if the combined company achieves profitability, it may not be able to utilize a material portion of Tempest&#146;s NOL carryforwards and other tax
attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit Tempest&#146;s use of accumulated state tax attributes. There is also a risk that due to
regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, Tempest&#146;s existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_29"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains forward-looking statements relating to Millendo, Tempest, the merger and the other proposed
transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on current expectations and beliefs and involve numerous
risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions of future events as Millendo and Tempest cannot assure you that the events or
circumstances reflected in these statements will be achieved or will occur. You can identify forward-looking statements by the use of forward-looking terminology including &#147;believes,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;seeks,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;pro&nbsp;forma,&#148; &#147;estimates&#148; or &#147;anticipates&#148; or the negative of these words and phrases or other variations of these words and phrases or
comparable terminology. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, forward-looking statements include any statements regarding the strategies, prospects,
plans, expectations or objectives of management of Millendo or Tempest for future operations of the combined company, the progress, scope or timing of the development of the combined company&#146;s product candidates, the benefits that may be
derived from any future products or the commercial or market opportunity with respect to any future products of the combined company, the ability of the combined company to protect its intellectual property rights, the anticipated operations,
financial position, ability to raise capital to fund operations, revenues, costs or expenses of Millendo, Tempest or the combined company, statements regarding future economic conditions or performance, statements of belief and any statement of
assumptions underlying any of the foregoing. Forward-looking statements may also include any statements regarding the approval and closing of the merger, including the timing of the consummation of the merger, Millendo&#146;s ability to solicit a
sufficient number of proxies to approve the change of control resulting from the merger, satisfaction of conditions to the completion of the merger, the expected benefits of the merger, the ability of Millendo and Tempest to complete the merger,
Tempest&#146;s ability to complete the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing immediately prior to the merger and any statement of assumptions underlying any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the factors that may cause Millendo, Tempest or the combined company&#146;s actual results, performance or achievements to
differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or for a discussion of risk associated with the ability of Millendo and Tempest to complete the merger and the effect of
the merger on the business of Millendo, Tempest and the combined company, please see the section titled &#147;<I>Risk Factors</I>&#148; beginning on page&nbsp;17 of this proxy statement/prospectus. Additional factors that could cause actual results
to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by Millendo. Please see the section titled &#147;<I>Where You Can Find More Information</I>&#148; beginning on page&nbsp;321 of
this proxy statement/prospectus. There can be no assurance that the merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the merger will be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of Millendo, Tempest or the
combined company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus are current only as of the date on which the statements were made. Millendo and Tempest do not undertake
any obligation to (and expressly disclaim any such obligation to) publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_30"></A>THE SPECIAL MEETING OF MILLENDO STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_31"></A>Date, Time and Place </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Millendo special meeting will be held on June&nbsp;22, 2021, commencing at 11:00 a.m. Eastern Time, unless postponed or adjourned to a
later date. The Millendo special meeting will be held entirely online. Millendo is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by Millendo&#146;s board of directors for use at the
Millendo special meeting and any adjournments or postponements of the Millendo special meeting. This proxy statement/prospectus is first being furnished to Millendo stockholders on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_32"></A>Purposes of the Millendo Special
Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes of the Millendo special meeting are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the issuance of shares of common stock of Millendo Therapeutics, Inc., or Millendo, to stockholders
of Tempest Therapeutics, Inc., or Tempest, pursuant to the terms of the Agreement and Plan of Merger among Millendo, Tempest and Mars Merger Corp., or Merger Sub, dated as of March&nbsp;29, 2021, a copy of which is attached as <I>Annex A </I>to this
proxy statement/prospectus, and the change of control resulting from the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the restated certificate of incorporation of Millendo, as amended, to effect a
reverse stock split of Millendo&#146;s issued and outstanding common stock within a range, as determined by the Millendo board of directors and agreed to by Tempest, of one new share of Millendo common stock for every 10 to 15 shares (or any number
in between) of outstanding Millendo common stock in the form attached as <I>Annex F</I> to this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on a nonbinding, advisory basis, the compensation that will or may become payable by Millendo to
its named executive officers in connection with the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon an adjournment of the Millendo special meeting, if necessary, to solicit additional
proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the stockholders at the Millendo special meeting or
any adjournment or postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposal No.&nbsp;1 is referred to herein as the merger proposal and Proposal
No.&nbsp;2 is referred to herein as the reverse stock split proposal. Each of Proposal Nos.&nbsp;1 and 2 is a condition to completion of the merger. The issuance of Millendo common stock in connection with the merger, or Proposal No.&nbsp;1, and the
amendment to the restated certificate of incorporation of Millendo to effect a reverse stock split of Millendo&#146;s issued and outstanding common stock, or Proposal No.&nbsp;2, will not take place unless approved by Millendo stockholders and the
merger is consummated. Therefore, the merger cannot be consummated without the approval of Proposal Nos.&nbsp;1 and 2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_33"></A>Recommendation of Millendo&#146;s Board of Directors </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors has determined and believes that the issuance of shares of Millendo&#146;s
common stock pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, Millendo and its stockholders and has approved such issuance. Millendo&#146;s board of directors unanimously recommends that Millendo stockholders
vote &#147;FOR&#148; Proposal No.&nbsp;1 to approve the issuance of shares of Millendo common stock pursuant to the Merger Agreement and the change of control resulting from the merger. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors has determined and believes that it is fair to, in the best interests of, and
advisable to, Millendo and its stockholders to approve the amendment to the amended and restated </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
certificate of incorporation of Millendo as amended to effect the reverse stock split, as described in this proxy statement/prospectus. Millendo&#146;s board of directors unanimously recommends
that Millendo stockholders vote &#147;FOR&#148; Proposal No.&nbsp;2 to approve the reverse stock split. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors and has determined and believes that it is fair to, in the best interests of,
and advisable to, Millendo and its stockholders to approve, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote basis, comensation that will or may become payable by Millendo to its named executive officers in connection with the
merger. Millendo&#146;s board of directors unanimously recommends that Millendo stockholders vote &#147;FOR&#148; Proposal No.&nbsp;3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors has determined and believes that adjourning the Millendo special meeting, if
necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2 is fair to, in the best interests of, and advisable to, Millendo and its stockholders and has approved and adopted the proposal.
Millendo&#146;s board of directors unanimously recommends that Millendo stockholders vote &#147;FOR&#148; Proposal No.&nbsp;4 to adjourn the Millendo special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in
favor of Proposal Nos. 1 and 2. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_34"></A>Record Date and Voting Power </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of Millendo common stock at the close of business on the record date May&nbsp;7, 2021, are entitled to notice of, and to
vote at, the Millendo special meeting. At the close of business on the record date, there were 76 registered holders of record of Millendo common stock and there were 19,043,034 shares of Millendo common stock issued and outstanding. Each share of
Millendo common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_35"></A>Voting and Revocation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy accompanying this proxy statement/prospectus is solicited on behalf of Millendo&#146;s board of directors for use at the Millendo
special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, as of the record date referred to above, your shares were registered directly in your name with the transfer agent
for Millendo common stock, Computershare Trust Company, N.A., then you are a stockholder of record. Whether or not you plan to attend the Millendo special meeting online, Millendo urges you to fill out and return the proxy card or vote by proxy over
the telephone or on the internet as instructed below to ensure your vote is counted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The procedures for voting are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote at the Millendo special meeting. Alternatively, you may vote by proxy by using the
accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the Millendo special meeting, Millendo encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the
Millendo special meeting, you may still attend the Millendo special meeting and vote in person. In such case, your previously submitted proxy will be disregarded. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote at the Millendo special meeting, attend the Millendo special meeting online and follow the instructions
posted at www.virtualshareholdermeeting.com/MLND2021SM. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly
in the envelope provided. If you return your signed proxy card before the Millendo special meeting, Millendo will vote your shares in accordance with the proxy card. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote by proxy over the internet, follow the instructions provided on the Notice of Internet Availability.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote by telephone, you may vote by proxy by calling the toll free number found on the Notice of Internet
Availability. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you
should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from us. Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote in person
at the Millendo special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to
request a proxy form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure
the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not give instructions to your broker, your broker can vote your Millendo shares with respect to &#147;discretionary,&#148; routine
items but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-discretionary,&#148;</FONT> <FONT STYLE="white-space:nowrap">non-routine</FONT> items. Discretionary items are proposals considered routine under Rule 452 of the New York Stock
Exchange on which your broker may vote shares held in &#147;street name&#148; in the absence of your voting instructions. On <FONT STYLE="white-space:nowrap">non-routine</FONT> items for which you do not give your broker instructions, Millendo
shares will be treated as broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> It is anticipated that Proposal Nos. 1, 3, and 4 will be <FONT STYLE="white-space:nowrap">non-routine.</FONT> It is anticipated that Proposal No.&nbsp;2 will be
routine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All properly executed proxies that are not revoked will be voted at the Millendo special meeting and at any adjournments or
postponements of the Millendo special meeting in accordance with the instructions contained in the proxy. <B>If a holder of Millendo common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will
be voted &#147;FOR&#148; all of the proposals in accordance with the recommendation of Millendo&#146;s board of directors.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are
a stockholder of record of Millendo and you have not executed a support agreement, you may change your vote at any time before your proxy is voted at the Millendo special meeting in any one of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit another properly completed proxy with a later date by mail or via the internet.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You can provide your proxy instructions via telephone at a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a written notice that you are revoking your proxy to Millendo&#146;s Corporate Secretary at 110
Miller Avenue, Suite 100, Ann Arbor, Michigan 48104. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend the Millendo special meeting online and vote by following the instructions at
www.virtualshareholdermeeting.com/MLND2021SM. Simply attending the Millendo special meeting will not, by itself, revoke your proxy. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_36"></A>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence, in person or represented by proxy, at the Millendo special meeting of the holders of a majority of the shares of Millendo common
stock outstanding and entitled to vote at the Millendo special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards a quorum. The affirmative
vote of the holders of a majority of the shares present in attendance or represented by proxy at the Millendo special meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal Nos. 1, 3, and 4.
The affirmative vote of the holders of a majority of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the outstanding shares of Millendo common stock entitled to vote at the Millendo special meeting is required for approval of Proposal No.&nbsp;2. Proposal No.&nbsp;1 is referred to herein as the
merger proposal and Proposal No.&nbsp;2 is referred to herein as the reverse stock split proposal. Each of Proposal Nos.&nbsp;1 and 2 is a condition to the completion of the merger. Therefore, the merger cannot be consummated without the approval of
Proposal Nos.&nbsp;1 and 2. The issuance of Millendo common stock in connection with the merger and the change of control resulting from the merger, or Proposal No.&nbsp;1, and the amendment to the restated certificate of incorporation of Millendo
to effect a reverse stock split of Millendo&#146;s issued and outstanding common stock, or Proposal No.&nbsp;2, will not take place unless approved by Millendo stockholders and the merger is consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#147;FOR&#148; and
&#147;AGAINST&#148; votes, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will also be treated as shares present for the purpose of determining the
presence of a quorum for the transaction of business at the special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect as &#147;AGAINST&#148; votes. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on Proposal Nos. 1, 3, and 4, and will have the same effect as &#147;AGAINST&#148; votes for Proposal No.&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the directors and certain executive officers of Millendo owned or controlled less than 1% of the outstanding shares
of Millendo common stock entitled to vote at the Millendo special meeting. As of March 31, 2021, the Millendo stockholders that are party to a support agreement, including the directors and certain executive officers of Millendo, owned an aggregate
of 2,962,292 shares of Millendo common stock representing approximately 16% of the outstanding shares of Millendo common stock. Each stockholder that entered into a support agreement, including the directors and certain executive officers of
Millendo, has agreed to vote all shares of Millendo common stock owned by him or her as of the record date in favor of Proposal Nos. 1, 2, 3, and 4 and against any competing &#147;Acquisition Proposal&#148; (as defined in the Merger Agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_37"></A>Solicitation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to solicitation by mail, the directors, officers, employees and agents of Millendo may solicit proxies from Millendo stockholders
by personal interview, telephone, email, fax or otherwise. Millendo and Tempest will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other
custodians, nominees and fiduciaries who are record holders of Millendo common stock for the forwarding of solicitation materials to the beneficial owners of Millendo common stock. Millendo will reimburse these brokers, custodians, nominees and
fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. Millendo has retained Morrow Sodali, or Morrow, to assist it in soliciting proxies using the means referred to above.
Millendo will pay the fees of Morrow, which Millendo expects to be approximately $20,000, plus reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_38"></A>Other Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, Millendo&#146;s board of directors does not know of any business to be presented at the
Millendo special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Millendo special meeting, it is intended that the shares represented by proxies will be
voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_39"></A>THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This section and the section titled </I>&#147;<I>The Merger Agreement</I>&#148;<I> beginning on page</I><I></I><I>&nbsp;</I><I></I><I>140
of this proxy statement/prospectus describe the material aspects of the merger and the Merger Agreement. While Millendo and Tempest believe that this description covers the material terms of the merger and the Merger Agreement, it may not contain
all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the merger and the Merger Agreement and the other documents to which you are referred in this
proxy statement/prospectus. See the section titled </I>&#147;<I>Where You Can Find More Information</I>&#148;<I> beginning on page</I><I></I><I>&nbsp;</I><I></I><I>321 of this proxy statement/prospectus.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_40"></A>Background of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In an effort to enhance stockholder value, the Millendo board of directors and Millendo executive management regularly review and discuss
Millendo&#146;s near and long-term operating and strategic priorities. Among other things, these reviews and discussions focus on the opportunities and risks associated with Millendo&#146;s development programs, financial condition and its strategic
relationships and potential long-term strategic options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On April&nbsp;6, 2020, Millendo announced it was discontinuing the development
of its livoletide product candidate as a potential treatment for Prader-Willi Syndrome. The decision to discontinue development was based on topline data from the pivotal Phase 2b trial in patients with Prader-Willi Syndrome which showed that
treatment with livoletide did not result in a statistically significant improvement in the primary endpoint of change in hyperphagia and food-related behaviors relative to the placebo. In the same announcement, Millendo announced that it would shift
its development focus and resources to nevanimibe for congenital adrenal hyperplasia and <FONT STYLE="white-space:nowrap">MLE-301,</FONT> a selective neurokinin 3 receptor antagonist, for menopausal vasomotor symptoms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On May&nbsp;8, 2020, Millendo announced that it was evaluating its business strategy, taking into consideration its existing pipeline assets,
assessing the evolving impact of the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and leveraging the deep development expertise of its leadership team to investigate potential strategic additions to its portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2020, the Millendo board of directors held a meeting by videoconference at which members of Millendo management and
representatives of SVB Leerink LLC (&#147;SVB Leerink&#148;), an investment bank specializing in representing healthcare and life sciences companies, were present. At the meeting, representatives of SVB Leerink reviewed potential strategic
alternatives for Millendo. Following discussion, the Millendo board of directors authorized and directed Millendo management and SVB Leerink to contact 12 potential strategic counterparties to gauge their interest in pursuing a potential acquisition
of Millendo or its programs. It was the consensus of Millendo&#146;s board of directors that these 12 parties were the parties to be most likely to have an interest in pursuing an acquisition of Millendo and to have the financial and other resources
necessary to complete a transaction on terms that the Millendo board of directors would find acceptable. The Millendo board of directors discussed whether other parties should be contacted as part of the process and, taking into account the
recommendations of Millendo management and SVB Leerink, concluded that the potential benefit of contacting additional parties at that time was outweighed by the risk that contacting additional parties would adversely affect Millendo&#146;s business
and operations, including by distracting management and/or resulting in leaks or market rumors that could harm Millendo, and that, therefore, additional parties should not be contacted at that time. Based on, among other factors, SVB Leerink&#146;s
qualifications, professional reputation and industry expertise, the Millendo board of directors also authorized the engagement of SVB Leerink to serve as Millendo&#146;s financial advisor in connection with a potential strategic transaction arising
from the authorized outreach. This engagement was memorialized in an engagement letter, dated June&nbsp;9, 2020, between Millendo and SVB Leerink. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From <FONT STYLE="white-space:nowrap">mid-May</FONT> 2020 through early June 2020, SVB Leerink contacted the 12 strategic counterparties
identified by the Millendo board of directors at its May&nbsp;15, 2020 meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On June&nbsp;17 and 18, 2020, the Millendo board of directors held a meeting by
videoconference at which members of Millendo management and representatives of SVB Leerink were present. During the meeting, the Millendo board of directors reviewed interim data from an open-label Phase 2b trial of nevanimibe, determined to
discontinue investment in nevanimibe based on the observed level of nevanimibe activity and the changing competitive environment and determined to focus Millendo&#146;s development efforts and resources on
<FONT STYLE="white-space:nowrap">MLE-301.</FONT> In addition, at the meeting, the representatives of SVB Leerink reviewed strategic considerations with respect to <FONT STYLE="white-space:nowrap">MLE-301</FONT> and reported that none of the 12
parties contacted by SVB Leerink at the request of the Millendo board of directors expressed an interest in pursuing an acquisition of Millendo. Following discussion, and based on the recommendations of Millendo management and SVB Leerink, the
Millendo board of directors directed Millendo management and SVB Leerink to solicit interest from potential counterparties in a strategic transaction with Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2020, Millendo announced the discontinuation of investment in nevanimibe and that
<FONT STYLE="white-space:nowrap">MLE-301</FONT> would be advanced into <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human-trials</FONT></FONT> in the third quarter of 2020. Millendo also announced that it was engaged in
a strategic review process and the engagement of SVB Leerink to support the strategic review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During late June and July 2020, at
the direction of the Millendo board of directors, SVB Leerink contacted 107 potential strategic counterparties to gauge their interest in a potential strategic transaction with Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2020, the Millendo board of directors held a meeting by videoconference at which members of Millendo management,
representatives of SVB Leerink and a representative of Cooley LLP, Millendo&#146;s outside corporate counsel (&#147;Cooley&#148;), were present. At the meeting, representatives of SVB Leerink updated the Millendo board of directors on SVB
Leerink&#146;s outreach to potential counterparties to gauge interest in a potential strategic transaction with Millendo. Following discussion, the Millendo board of directors established a transaction committee (the &#147;Transaction
Committee&#148;) composed of James Hindman, Mary Lynne Hedley, Ph.D., Habib J. Dable and Julia C. Owens, Ph.D. with authority to oversee Millendo management in connection with and evaluate any potential strategic transaction involving Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From July 2020 until November 2020, at the direction and under the supervision of the Transaction Committee, members of Millendo management
and representatives of SVB Leerink engaged in discussions and due diligence activities with multiple potential counterparties in connection with a potential strategic transaction involving Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On November&nbsp;11, 2020, the Transaction Committee held a meeting by videoconference at which other members of the Millendo board of
directors, members of Millendo management and representatives of SVB Leerink were present. Following discussion, the Millendo board of directors authorized Millendo&#146;s execution of a <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of
intent with a company referred to as Party A (the &#147;Party A Letter of Intent&#148;), which was entered into on November&nbsp;15, 2020. The Party A Letter of Intent contemplated a merger transaction with an ownership interest in the combined
company of 33% for existing Millendo equity holders, a contingent value right potentially payable to existing Millendo stockholders equal to up to $60&nbsp;million in the aggregate in the event of a partnership or asset sale with respect to <FONT
STYLE="white-space:nowrap">MLE-301</FONT> or the commencement by the combined company of a Phase 3 trial of <FONT STYLE="white-space:nowrap">MLE-301,</FONT> a private placement to be conducted by Millendo and intended to raise proceeds of
$89&nbsp;million (at least $39&nbsp;million of which was to be invested by Party A&#146;s Series A investors) (the &#147;Proposed 2020 PIPE Financing&#148;) and a period of 30 days during which Millendo and Party would negotiate exclusively with
each other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020, the Transaction Committee held a meeting by videoconference at which other members of the Millendo
board of directors, members of Millendo management, representatives of SVB Leerink and representatives of Cooley were present. During the meeting, representatives of SVB Leerink reviewed the timeline for the Proposed 2020 PIPE Financing, and the
Transaction Committee authorized the engagement of SVB Leerink to serve as lead financial advisor in connection with the Proposed 2020 PIPE Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;11, 2020, the Millendo board of directors held a meeting by videoconference
at which members of Millendo management, representatives of SVB Leerink and a representative of Cooley were present. At the meeting, representatives of SVB Leerink gave a status report on the Proposed 2020 PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;12, 2020, Millendo received a letter from Party A indicating that Party A had decided not to pursue a transaction with
Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2021, the Millendo board of directors held a meeting by videoconference at which members of Millendo
management were present. During the meeting, the Millendo board of directors reviewed the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose portion of the Phase 1 trial of <FONT STYLE="white-space:nowrap">MLE-301</FONT>
being conducted in healthy male volunteers. Following discussion, the Millendo board of directors determined that Millendo should discontinue further investment in <FONT STYLE="white-space:nowrap">MLE-301</FONT> and explore an expanded range of
strategic alternatives, including a potential sale or merger of Millendo or sale of its assets. The Millendo board of directors directed management to work with SVB Leerink to contact potential counterparties to a strategic transaction involving
Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2021, Millendo announced that it was discontinuing further investment in the development of <FONT
STYLE="white-space:nowrap">MLE-301</FONT> based on an analysis of the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose portion of the Phase 1 trial being conducted in healthy male volunteers. Millendo also announced
that, given Millendo&#146;s limited expected financing options, it was exploring an expanded range of strategic alternatives to maximize the value of its assets and that SVB Leerink would continue to assist in Millendo&#146;s ongoing strategic
process. Millendo also announced that it intended to review its operating costs and may plan for a reduction in its workforce in order to focus its resources on essential business activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Between January&nbsp;15, 2021 and February&nbsp;18, 2021, SVB Leerink contacted 102 potential counterparties to a strategic transaction
involving Millendo and requested <FONT STYLE="white-space:nowrap">non-binding</FONT> indications of interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2021,
the Millendo board of directors held a meeting at which members of Millendo management and representatives of SVB Leerink were present. At the meeting, representatives of SVB Leerink reviewed the potential counterparties that had been contacted by
SVB Leerink and the responses received to date. The Millendo board discussed and agreed upon the proposed criteria that would be used to evaluate any potential indications of interest, consisting of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inherent attractiveness of the counterparty&#146;s technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upcoming catalysts within the pro forma cash runway that drive value creation in a reasonable timeframe;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">readiness to be a US publicly traded company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposed valuation and ownership split. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Also at the January&nbsp;22, 2021 meeting of the Millendo board of directors, Dr.&nbsp;Owens was appointed as Millendo&#146;s executive chair
effective February&nbsp;1, 2021, Louis J. Arcudi III was appointed as Millendo&#146;s president and chief executive officer effective February&nbsp;1, 2021, each of Dr.&nbsp;Hedley and Mr.&nbsp;Dable indicated their intention to resign from the
Millendo board of directors effective January&nbsp;31, 2021, and Mr.&nbsp;Arcudi was appointed to the Millendo board of directors effective February&nbsp;1, 2021. In addition, the Transaction Committee was reconstituted with Dr.&nbsp;Owens, Geoffrey
Nichol, M.B., Ch.B., M.B.A. and Mr.&nbsp;Hindman as the members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On January&nbsp;29, 2021, SVB Leerink received on behalf of Millendo <FONT
STYLE="white-space:nowrap">non-binding</FONT> indications of interest from 26 potential counterparties, including indications of interest from Tempest and the companies referred to as Party B, Party C, Party D, Party E and Party F, as described
below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Tempest proposed a reverse merger transaction with an ascribed value of Millendo
of $33&nbsp;million (assuming closing net cash of $25 million) and an ascribed value </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of Tempest of $153.4&nbsp;million (assuming a concurrent financing of $25&nbsp;million that had been committed by existing Tempest investors), with an implied ownership interest in the combined
company of approximately 17.7% for existing Millendo equity holders. The indication of interest from Tempest also proposed that the combined company would have a board of directors composed of seven directors, six of whom would be designated by
Tempest and one of whom would be designated by Millendo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Party B, a privately held company, proposed a reverse merger transaction with an
ascribed value of Millendo of $45&nbsp;million (assuming closing net cash of $22.5 million) and an ascribed value of Party B of $155&nbsp;million, with an implied ownership interest in the combined company of approximately 22.5% for existing
Millendo equity holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Party C, a publicly traded company, proposed a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> acquisition of Millendo by Party C with an ownership interest in the combined company of 25% to 28% for existing Millendo equity holders, assuming closing net cash of at least
$25&nbsp;million. The indication of interest from Party C indicated that Party C also proposed that Millendo could designate one or two directors from the Millendo board of directors, as mutually agreed, to the Party C board of directors upon
closing of the transaction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Party D, a publicly traded company, proposed a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> acquisition of Millendo by Party D with an ascribed value of Millendo equal to 125% of Millendo&#146;s closing net cash and a deemed value of Party D&#146;s common stock equal to 140% of the
volume-weighted average price of Party D&#146;s common stock over the five trading days prior to closing. The indication of interest from Party D also proposed that Millendo could designate one board member to the Party D board of directors upon
closing of the transaction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Party E, a privately held company, proposed a reverse merger transaction in which
Party E would be valued at $82&nbsp;million, with an ownership interest in the combined company of 20% to 25% for existing Millendo equity holders. The indication of interest from Party E also proposed that the combined company would have a board of
directors composed of six directors, four of whom would be designated by Party E and two of whom would be designated by Millendo. Party E&#146;s indication of interest also indicated a willingness to pursue an alternative transaction structure that
would permit the transaction to sign and close simultaneously. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Party F, a privately held company, proposed a reverse merger transaction in which
Millendo would be valued at $41&nbsp;million (assuming net cash at closing of $25 million) and Party F would be valued at $220&nbsp;million, with an ownership interest in the combined company of approximately 15.7% for existing Millendo equity
holders. The indication of interest from Party F also proposed that the combined company would have a board of directors composed of seven directors, six of whom would be designated by Party F and one of whom would be designated by Millendo and
indicated that Party F would be willing to pursue a financing that would target $50&nbsp;million in proceeds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From
January&nbsp;30, 2021 through February&nbsp;5, 2021, members of Millendo management and representatives of SVB Leerink analyzed the 26 indications of interest using the criteria that were agreed to by the Millendo board of directors at its
January&nbsp;22, 2021 meeting along with additional criteria that SVB Leerink and Millendo management considered relevant for a complete evaluation. The full list of criteria was: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality of the underlying technology and potential for commercialization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing potential public company infrastructure and readiness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to achieve milestones; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">concurrent financing considerations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality of management, board and investor base; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposed ownership split and premium applied over Millendo&#146;s expected closing net cash.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on this analysis, members of Millendo management and representatives of SVB Leerink identified ten potential counterparties,
including Tempest, Party B, Party C, Party D, Party E and Party F, to present to Millendo management and the Transaction Committee. Also during this period, Millendo executed nondisclosure agreements with each of the ten identified potential
counterparties, including in certain cases a mutual <FONT STYLE="white-space:nowrap">two-year</FONT> standstill provision (which, in each case, Millendo waived with respect to the counterparty on April 12, 2021). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2021, the Transaction Committee held a meeting by video conference at which members of Millendo management and
representatives of SVB Leerink were present. During the meeting, representatives of SVB Leerink reviewed the criteria used by Millendo management and SVB Leerink to analyze the 26 indications of interest received by Millendo, reviewed the terms of
the indications of interest received from the ten potential counterparties identified to present to Millendo management and the Transaction Committee, provided perspectives on each of the ten potential counterparties and discussed the timeline for a
potential strategic transaction. Also during the meeting, the Transaction Committee authorized Millendo management to engage Wilmer Cutler Pickering Hale and Dorr LLP (&#147;WilmerHale&#148;) to serve as Millendo&#146;s special M&amp;A counsel in
connection with a strategic transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the week of February&nbsp;7, 2021, each of the ten identified potential counterparties
presented to Millendo management about its business, and SVB Leerink informed the other potential counterparties that they had not advanced to the next stage of discussions. Following the presentations, Millendo management and SVB Leerink identified
Tempest, Party B, Party C, Party D, Party E and Party F as warranting further consideration by the Millendo board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;10 and 11, 2021, at the direction of Millendo management, SVB Leerink informed the potential counterparties other than Tempest, Party B, Party C, Party D, Party E and Party F that they had not advanced to the next stage of discussions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the week of February&nbsp;14, 2021, each of Tempest, Party B, Party C, Party D, Party E and Party F presented to Transaction
Committee about its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the week of February&nbsp;22, 2021, at the direction of Millendo management, SVB Leerink contacted
each of the six remaining counterparties to advise them to assume closing net cash of Millendo of approximately $19&nbsp;million, which at the time reflected Millendo management&#146;s best estimate of closing net cash in light of adjustments to
Millendo&#146;s anticipated cash needs through the closing of a potential transaction, rather than closing net cash of $25&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2021, the Transaction Committee held a meeting by videoconference at which other members of the Millendo board of
directors, members of Millendo&#146;s management, representatives of SVB Leerink and representatives of WilmerHale were present. At the meeting, representatives of SVB Leerink reviewed the indications of interest received from the six remaining
potential counterparties (as adjusted by SVB Leerink to reflect Millendo&#146;s updated estimate of closing net cash) and related considerations, and Millendo&#146;s management reviewed the due diligence conducted to date on each of the potential
counterparties, including their respective science and technology, their respective management teams, their respective upcoming value inflection points and their respective public company readiness. Following discussion, the Transaction Committee
directed management to request a proposed term sheet from each of Tempest, Party B, Party C, Party D and Party E. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the period from
February&nbsp;17, 2021 through February&nbsp;25, 2021, members of Millendo management engaged in due diligence activities with each of<B><I> </I></B>Tempest, Party B, Party C, Party D and Party E<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the week of February&nbsp;21, 2021, SVB Leerink received on behalf of Millendo the
following <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheets: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term sheet from Tempest proposed a reverse merger transaction with an ascribed value of Millendo of
$36&nbsp;million (assuming closing net cash of $21&nbsp;million and subject to adjustment if closing net cash were less than $20 million) and an ascribed value of Tempest of $153.4&nbsp;million (assuming a concurrent financing of $25 million), with
an implied ownership interest in the combined company of approximately 19.0% for existing Millendo equity holders. The term sheet also proposed that the combined company would have a board of directors composed of seven directors, six of whom would
be designated by Tempest and one of whom would be designated by Millendo. Tempest&#146;s term sheet contemplated a <FONT STYLE="white-space:nowrap">30-day</FONT> exclusive negotiations period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term sheet from Party B proposed a reverse merger transaction with an ascribed value of Millendo of
$45&nbsp;million (assuming closing net cash of $19.0&nbsp;million and subject to adjustment if closing net cash were greater or less than $19 million) and an ascribed value of Party B of $155&nbsp;million, with an implied ownership interest in the
combined company of approximately 22.5% for existing Millendo equity holders. The term sheet from Party B also contemplated that the combined company would have a board of directors composed of nine directors, seven of whom would be designated by
Party B and two of whom would be designated by Millendo, and that Millendo and Party B would pay a termination fee of $3&nbsp;million, or reimburse the other for expenses up to $1&nbsp;million, if the merger agreement were terminated in certain
circumstances. Party B&#146;s term sheet also provided that Millendo would not have the right to terminate a merger agreement with Party B to accept a superior proposal and contemplated a <FONT STYLE="white-space:nowrap">45-day</FONT> exclusive
negotiations period (subject to an automatic <FONT STYLE="white-space:nowrap">15-day</FONT> extension so long as the parties were continuing to have good faith discussions regarding the proposed transaction). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term sheet from Party C proposed a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> acquisition of Millendo by Party C with an ascribed value of Millendo of $39.5&nbsp;million (assuming closing net cash of $19.5 million) and an ascribed
value of $130&nbsp;million for Party C, with an ownership interest in the combined company of 23% to 26% for existing Millendo equity holders. The term sheet from Party C indicated that Party C would be willing to discuss post-closing board
representation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term sheet from Party D proposed a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> acquisition of Millendo by Party D with an ascribed value of Millendo equal to $25&nbsp;million (assuming closing net cash of $19 million) and a deemed
value of Party D&#146;s common stock equal to (a)&nbsp;the greater of (i) $2.275 and (ii)&nbsp;the volume-weighted average price of Party D&#146;s common stock over the five consecutive trading days ending on the trading day immediately prior to the
closing multiplied by (b)&nbsp;an adjustment factor (ranging from 1.275x to 1.225x) based on Millendo&#146;s closing net cash, except that the number of shares of Party D&#146;s common stock issuable in the transaction would be limited to 19.99% of
the number of shares of Party D common stock issued and outstanding as of the date of the definitive agreement. The term sheet from Party D provided that Party D&#146;s obligation to complete the transaction would be conditioned on, among other
things, Millendo&#146;s closing net cash being at least $17.5&nbsp;million. Party D also indicated that Party D would offer Millendo the ability to add one board member to Party D&#146;s current board of directors. Party D&#146;s term sheet
contemplated an exclusive negotiations period until March&nbsp;31, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The term sheet from Party E proposed a reverse merger transaction in which Millendo would be valued at
$25&nbsp;million (assuming closing net cash of $20 million) and Party E would be valued at $82&nbsp;million, with an implied ownership interest in the combined company of 23% for existing Millendo equity holders. The term sheet from Party E also
proposed that the combined company would have a board of directors composed of six directors, four of whom would be designated by Party E and two of whom would be designated by Millendo. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On February&nbsp;25, 2021, the Transaction Committee held a meeting by videoconference at
which other members of the Millendo board of directors, members of Millendo management, representatives of SVB Leerink and representatives of WilmerHale were present. During the meeting, representatives of SVB Leerink and members of Millendo
management reviewed the discussions and scientific and other due diligence activities that had taken place with the remaining potential counterparties since the meeting of the Transaction Committee held on February&nbsp;17, 2021, and representatives
of SVB Leerink reviewed the term sheets received from the remaining potential counterparties, focusing on the term sheet received from each of Tempest, Party B, Party C and Party D. After discussion, the Transaction Committee directed management and
SVB Leerink to prioritize discussions with Tempest, Party B and Party C based on the scientific and other due diligence activities to date and the terms proposed in their respective term sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From February&nbsp;25, 2021 through March&nbsp;4, 2021, members of Millendo management engaged in scientific and other due diligence
activities with each of Tempest, Party B and Party C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;4, 2021, the Transaction Committee held a meeting by videoconference
at which other members of the Millendo board of directors, members of Millendo management, representatives of SVB Leerink and representatives of WilmerHale were present. During the meeting, representatives of SVB Leerink and members of Millendo
management reviewed the discussions and scientific and other due diligence activities that had taken place with the remaining potential counterparties since the meeting of the Transaction Committee held on February&nbsp;25, 2021. In addition,
management presented an updated calculation of estimated net cash, which reflected management&#146;s best estimate of closing net cash in light of adjustments to Millendo&#146;s anticipated cash needs through the closing of a potential transaction.
The Transaction Committee directed management and SVB Leerink to prioritize discussions with Tempest and Party B. In addition, the Transaction Committee instructed management to provide a draft merger agreement to each of Tempest and Party B and
request revised proposals from each of Tempest and Party reflecting management&#146;s most recent estimate of closing net cash. The Transaction Committee determined to prioritize discussions with Tempest and Party B primarily due to concerns
identified in due diligence with respect to Party C, including concerns over Party C&#146;s ability to obtain financing necessary to fund its operations and potential delay and execution risk associated with Party C&#146;s proposed transaction
structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;4, 2021, a representative of SVB Leerink informed a representative of Party D that Millendo was prioritizing
discussions with other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2021, SVB Leerink sent a draft merger agreement prepared by WilmerHale to each of
Tempest and Party B and instructed each party to respond with their best and final proposal by March&nbsp;10, 2021 in the form of a markup to the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;10, 2021, the Transaction Committee held a meeting by videoconference at which members of management, representatives of SVB
Leerink and representatives of WilmerHale were present. During the meeting, representatives of SVB Leerink and members of Millendo management reviewed the discussions and scientific and other due diligence activities that had taken place with the
remaining potential counterparties since the meeting of the Transaction Committee held on March&nbsp;4, 2021 and provided their perspectives on each of the remaining potential counterparties. Following discussion, the Transaction Committee
determined to focus on clinical data, timing and cash resources as it continued to consider a potential strategic transaction with each of the potential remaining counterparties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Later on March&nbsp;10, 2021, a member of Millendo management received from Tempest in response to the draft merger agreement that had been
provided to Tempest on March&nbsp;5, 2021 an issues list that revised the terms of Tempest&#146;s proposal. Tempest&#146;s revised proposal contemplated a reverse merger transaction with an ascribed value of Millendo of $36&nbsp;million (subject to
adjustment to the extent Millendo&#146;s closing net cash were less than $15.3&nbsp;million or greater than $18.7 million) and an ascribed value of Tempest of $153.4&nbsp;million (assuming a concurrent financing of $25 million), with an implied
ownership interest in the combined company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of approximately 19.0% for existing Millendo equity holders. Tempest&#146;s revised proposal also proposed that the combined company would have a board of directors composed of seven directors,
six of whom would be designated by Tempest and one of whom would be designated by Millendo and indicated that Tempest expected to enter into exclusive negotiations with Millendo by early the week of March&nbsp;14, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2021, a representative of SVB Leerink informed a representative of Party C that Millendo was prioritizing discussions with
other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, representatives of WilmerHale and representatives of Sidley Austin LLP, counsel for Tempest
(&#147;Sidley&#148;), discussed aspects of the draft merger agreement that had been provided to Tempest on March&nbsp;5, 2021, including the calculation of net cash, the net cash collar, the treatment of Millendo options, closing conditions, the
definition of superior offer and termination fee and expense reimbursement provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Also on March&nbsp;12, 2021, a member of Millendo
management received from Party B in response to the draft merger agreement that had been provided to Party B on March&nbsp;5, 2021 a revised term sheet. Party B&#146;s revised term sheet contemplated a reverse merger transaction with an ascribed
value of Millendo of $45&nbsp;million (subject to adjustment to the extent Millendo&#146;s closing net cash were less than $16&nbsp;million or greater than $18 million) and an ascribed value of Party B of $155&nbsp;million, with an implied ownership
interest in the combined company of approximately 22.5% for existing Millendo equity holders. Party B&#146;s revised term sheet also contemplated that the combined company would have a board of directors composed of nine directors, seven of whom
would be designated by Party B and two of whom would be designated by Millendo and that Millendo and Party B would pay a termination fee of $3&nbsp;million, or reimburse the other for expenses up to $1&nbsp;million, if the merger agreement were
terminated in certain circumstances. Party B&#146;s revised term sheet also provided that Millendo would not have the right to terminate a merger agreement with Party B to accept a superior proposal and contemplated a
<FONT STYLE="white-space:nowrap">45-day</FONT> exclusive negotiations period (subject to an automatic <FONT STYLE="white-space:nowrap">15-day</FONT> extension so long as the parties were continuing to have good faith discussions regarding the
proposed transaction), provided that Millendo would have the right to terminate exclusivity if Party B failed to deliver to Millendo a term sheet with a third party that involved a financing of at least $10&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the evening of March&nbsp;12, 2021, representatives of WilmerHale sent representatives of Sidley a revised merger agreement, along with
a proposed form of exclusivity agreement to be entered into in the event that the Transaction Committee authorized Millendo to enter into exclusive negotiations with Tempest. The exclusivity agreement contemplated that Tempest and Millendo would
negotiate exclusively with each other through March&nbsp;22, 2021. Later in the evening of March&nbsp;12, 2021, a representative of Sidley sent representatives of WilmerHale a revised draft of the exclusivity agreement which contemplated that the
exclusivity period would continue through March&nbsp;28, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;13, 2021, a representative of Sidley sent to representatives
of WilmerHale a markup of the merger agreement, reflecting the terms set forth in Tempest&#146;s March&nbsp;10, 2021 proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;14, 2021, Millendo held a Transaction Committee meeting by videoconference at which other members of the Millendo board of directors, members of Millendo management, representatives of SVB Leerink and representatives of WilmerHale were
present. During the meeting, representatives of WilmerHale reviewed the fiduciary duties of the Transaction Committee and the Millendo board of directors in connection with a potential strategic transaction involving Millendo, the representatives of
SVB Leerink reviewed the process conducted to date by Millendo management and SVB Leerink to solicit interest in a strategic transaction involving Millendo and the terms of the most recent proposals submitted by each of Tempest and Party B, and
Millendo management reviewed the scientific and other due diligence activities undertaken to date by Millendo management and Millendo&#146;s advisors on each of Tempest and Party B. Millendo&#146;s management then recommended, based on its belief
that the most recent proposal submitted by each party was its best and final proposal, concerns raised in the scientific due diligence of Party B, the uncertainty surrounding Party B&#146;s ability to obtain additional financing and statements by
representatives of Tempest that Tempest would be unwilling to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue discussions with Millendo in the absence of an exclusive negotiation period, that the Transaction Committee authorize Millendo to enter into exclusive negotiations with Tempest through
March&nbsp;28, 2021. At the request of the Transaction Committee, representatives of WilmerHale expressed their view that the merger agreement submitted by Tempest was capable of being negotiated in a matter of days and that it would be difficult to
estimate how long it would take to negotiate a definitive merger agreement with Party B because Party B had not submitted a markup of the merger agreement, as had been requested by SVB Leerink. Following discussion and after taking into account the
advantages and disadvantages of entering into exclusive negotiations with Tempest, the Transaction Committee authorized Millendo management, on behalf of Millendo, to enter into an exclusivity agreement with Tempest pursuant to which Millendo and
Tempest would negotiate exclusively with each other through March&nbsp;28, 2021. During the evening of March&nbsp;14, 2021, Millendo and Tempest executed an exclusivity agreement on the terms approved by the Transaction Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2021, a member of Millendo management and a representative of SVB Leerink advised a representative of Party B that Millendo
had entered into exclusivity with another party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March 17, 2021, the Millendo board of directors held a regular meeting by
videoconference at which members of Millendo management and representatives of SVB Leerink were present. At the meeting, the members of management and representatives of SVB Leerink reviewed Millendo&#146;s net cash model prepared in connection with
the proposed strategic transaction and the status of Millendo&#146;s discussions with Tempest. Also at the meeting, the Millendo board of directors granted to Dr.&nbsp;Owens, in connection with Dr.&nbsp;Owens&#146; appointment as executive chair of
the Millendo board of directors, an option to purchase 24,000 shares of Millendo common stock at an exercise price per share of $2.29, which is equal to the closing price per share of Millendo common stock as reported on the Nasdaq Stock Market LLC
on March&nbsp;17, 2021. Upon a change in control of Millendo, the option granted to Dr.&nbsp;Owens will vest in full and have an 18-month post-termination exercise period. In addition, the Millendo board of directors amended the option awards held
by independent directors to provide that, upon a change in control of Millendo, the option awards will vest in full and have an 18-month post-termination exercise period. For more information, see &#147;&#151;Interest of Millendo Directors and
Executive Officers in the Merger.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the period from March&nbsp;14, 2021 through March&nbsp;28, 2021, representatives of
Millendo and representatives of Tempest completed confirmatory due diligence on each other and representatives of WilmerHale and Sidley negotiated the remaining terms of the merger agreement, including the definition of net cash, the calculation of
the exchange ratio, the representations and warranties and operating covenants of each party, the ratio of the reverse stock split, the treatment of Millendo options, the financing condition for Millendo&#146;s benefit, the amount of the termination
fees and the expense reimbursement cap, and the terms of the forms of support agreement and the form of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. Also during this period, Piper Sandler&nbsp;&amp; Co. marketed to potential investors
a financing in Tempest that would close immediately prior to the closing of Millendo&#146;s transaction with Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;28,
2021, the Millendo board of directors held a meeting at which members of Millendo management, representatives of SVB Leerink and representatives of WilmerHale were present. During the meeting, the representatives of WilmerHale reviewed the duties of
the Millendo board of directors in connection with the proposed transaction with Tempest and the terms of the merger agreement and forms of support agreement and form of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. The Millendo board
of directors then discussed various considerations with respect to the proposed transaction, as summarized under &#147;Millendo Reasons for the Merger&#148;. Representatives of SVB Leerink then reviewed the process conducted to solicit potential
interest in a strategic transaction involving Millendo and reviewed SVB Leerink&#146;s financial analyses of the relative valuations of Millendo and Tempest and the number of shares of Millendo common stock to be issued to holders of Tempest common
stock in the merger. Representatives of SVB Leerink noted that a discounted cash flow analysis had not been performed because a discounted cash flow analysis would not be informative, in SVB Leerink&#146;s professional judgement, in light of the
early stage of Tempest and the absence of any projections by Millendo or Tempest, other than expense projections prepared by Millendo. Following discussion with the directors, SVB Leerink then rendered to the Millendo board of directors its oral
opinion, which was subsequently confirmed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery of a written opinion dated March&nbsp;28, 2021, that, as of such date and based upon and subject to the assumptions made, and the qualifications and limitations upon the review
undertaken by SVB Leerink in preparing its opinion, the exchange ratio to be paid by Millendo pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Millendo. Following discussion, the members of the Transaction
Committee unanimously recommended to the Millendo board of directors that the Millendo board of directors approve the merger agreement and the transactions contemplated by the merger agreement. Thereafter, taking into account the opinion of SVB
Leerink, the recommendation of the Transaction Committee and other factors, the Millendo board of directors unanimously approved the merger agreement and the transactions contemplated by the merger agreement and authorized Millendo management to
execute the merger agreement on behalf of Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2021 prior to the open of trading on the Nasdaq Stock Market,
Millendo and Tempest executed the merger agreement and issued a joint press release announcing execution of the merger agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_41">
</A>Millendo Reasons for the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">During the course of its evaluation of the Merger Agreement and the transactions contemplated by
the Merger Agreement, the Millendo Board of Directors and the Transaction Committee held numerous meetings, consulted with Millendo&#146;s senior management, legal counsel and financial advisor, and reviewed and assessed a significant amount of
information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the Millendo Board of Directors considered a number of factors that it viewed as supporting its decision to approve the
Merger Agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the financial condition and prospects of Millendo and the risks associated with continuing to operate Millendo on
a stand-alone basis, particularly in light of Millendo&#146;s January 2021 decision to discontinue development of <FONT STYLE="white-space:nowrap">MLE-301</FONT> and reduce its workforce; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the Millendo Board of Directors and its financial advisor undertook a comprehensive and thorough process of
reviewing and analyzing potential strategic alternatives and merger partner candidates to identify the opportunity that would, in the Millendo Board of Directors&#146; view, create the most value for Millendo stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; belief, after a thorough review of strategic alternatives and discussions
with Millendo&#146;s senior management, financial advisors and legal counsel, that the Merger is more favorable to Millendo Stockholders than the potential value that might have resulted from other strategic alternatives available to Millendo,
including a liquidation of Millendo and the distribution of any available cash; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; belief that, as a result of arm&#146;s length negotiations with Tempest,
Millendo and its representatives negotiated the highest exchange ratio to which Tempest was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Millendo in the aggregate to which Tempest was willing
to agree; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; view, based on the scientific, regulatory and technical due diligence
conducted by Millendo management, of the regulatory pathway for, and market opportunity of, Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; consideration of the expected cash balances of the combined company as of
the closing of the Merger resulting from the approximately $17 million of net cash expected to be held by Millendo upon completion of the Merger together with the cash Tempest currently holds and the $30 million of expected gross proceeds from the
Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; view, following a review with Millendo&#146;s management of Tempest&#146;s
current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Tempest&#146;s product candidates through upcoming value inflection
points; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic
transaction with Millendo based on the scientific, technical and other due diligence conducted by Millendo management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of Millendo stockholders to participate in the growth and value creation of the combined company
following the closing of the Merger by virtue of their continued ownership of Millendo Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; view that the combined company will be led by an experienced senior
management team from Tempest and a board of directors with representation from each of the current boards of directors of Millendo and Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current financial market conditions and historical market prices, volatility and trading information with
respect to Millendo Common Stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo Board of Directors&#146; consideration of the financial analyses of SVB Leerink, including its
opinion to the Millendo Board of Directors as to the fairness, from a financial point of view and as of the date of the opinion, to Millendo of the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement, as more fully
described below under the caption &#147;<I>The Merger&#151;Opinion of Millendo&#146;s Financial Advisor</I>,&#148; beginning on page 119 in this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Millendo Board of Directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described
below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the calculation of the Exchange Ratio, closing net cash and the estimated number of shares of Millendo Common
Stock to be issued in the Merger, including that the valuation of Millendo under the Merger Agreement would be reduced only to the extent that Millendo&#146;s closing net cash is less than $15.3&nbsp;million, the valuation of Millendo under the
Merger Agreement would be increased to the extent Millendo&#146;s closing net cash exceeds $18.7&nbsp;million and the determination time for calculating Millendo&#146;s closing net cash would be no later than June&nbsp;30, 2021 unless the failure to
close the Merger on or before July&nbsp;1, 2021 is solely a result of a material breach by Millendo of its obligations under the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and nature of the conditions to Tempest&#146;s and Millendo&#146;s respective obligations to complete
the Merger and the likelihood that the Merger will be completed on a timely basis, including the fact that Tempest&#146;s obligation to complete the Merger would not be conditioned on Millendo having a specified level of closing net cash and the
fact that Millendo&#146;s obligation to complete the Merger would be conditioned on Tempest having completed at least $25&nbsp;million of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, as more fully described below under
the caption &#147;<I>The Merger Agreement &#151;Conditions to the Completion of the Merger</I>,&#148; beginning on page 154 in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the respective rights of, and limitations on, Millendo and Tempest under the Merger Agreement to consider and
engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the merger, as more fully described below under the
caption &#147;<I>The Merger Agreement <FONT STYLE="white-space:nowrap">&#151;Non-Solicitation</FONT></I>,&#148; beginning on page 150 in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right of each party to terminate the Merger Agreement to accept an unsolicited Acquisition Proposal in
certain circumstances, subject to payment of a termination fee, as more fully described below under the caption &#147;<I>The Merger Agreement &#151;Termination and Termination Fees</I>,&#148; beginning on page 158 in this proxy statement/prospectus;
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential termination fee of $1.4&nbsp;million, in the case of the fee payable by Millendo, or
$2.8&nbsp;million, in the case of the fee payable by Tempest, and related reimbursement of certain transaction expenses of up to $1.0 million, which could become payable by either Millendo or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Tempest to the other party if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#147;<I>The Merger Agreement &#151;Termination and
Termination Fees</I>,&#148; beginning on page 158 in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, pursuant to which certain Tempest stockholders
have, subject to certain exceptions, agreed not to transfer their shares of Millendo Common Stock during the period of 180 days following the completion of the Merger, as more fully described below under the caption &#147;<I>Agreements Related to
the Merger <FONT STYLE="white-space:nowrap">&#151;Lock-Up</FONT> Agreements</I>,&#148; beginning on page 163 in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the support agreements, pursuant to which certain stockholders of Millendo and Tempest, respectively, have
agreed, solely in their capacities as stockholders, to vote all of their shares of Millendo Common Stock or Tempest Capital Stock in favor of the proposals submitted to them in connection with the Merger and against any alternative acquisition
proposals, as more fully described below under the caption &#147;<I>Agreements Related to the Merger &#151;Support Agreements</I>,&#148; beginning on page 162 in this proxy statement/prospectus; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the Merger will qualify as a reorganization within the meaning of Section&nbsp;368(a) of the
Internal Revenue Code of 1986, as amended, and will constitute a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-2(g),</FONT> with the result that Tempest stockholders
will generally not recognize taxable gain or loss for U.S. federal income tax purposes upon the exchange of Tempest Common Stock for Millendo Common Stock pursuant to the Merger, as more fully described below under the caption &#147;<I>The Merger
&#151;Tax Characterization of the Merger</I>,&#148; beginning on page 134 in this proxy statement/prospectus. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In
the course of its deliberations, the Millendo Board of Directors also considered a variety of risks and other countervailing factors related to entering into the Merger, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential effect of the $1.4&nbsp;million termination fee payable by Millendo and Millendo&#146;s expense
reimbursement obligations upon the occurrence of certain events in deterring other potential acquirors from proposing an alternative acquisition proposal that may be more advantageous to Millendo stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prohibition on Millendo to solicit alternative acquisition proposals during the pendency of the Merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substantial expenses to be incurred by Millendo in connection with the Merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible volatility of the trading price of the Millendo Common Stock resulting from the announcement,
pendency or completion of the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the Merger might not be consummated in a timely manner or at all, including as a result of an
inability to complete the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scientific, technical, regulatory and other risks and uncertainties associated with development and
commercialization of Tempest&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the combined company may not have available sources of financing necessary to fund development of
Tempest&#146;s product candidates through upcoming value inflection points; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the various other risks associated with the combined company and the transaction, including those described in
the sections entitled &#147;<I>Risk Factors</I>&#148; and &#147;<I>Cautionary Statement Concerning Forward-Looking Statements</I>&#148; in this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing information and factors considered by the Millendo Board of Directors are not intended to be exhaustive but are believed to include all of the
material factors considered by the Millendo Board of Directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Millendo Board of Directors did not find it
useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual members of the Millendo Board of Directors may have given different weight to different factors. The Millendo Board of Directors conducted an overall analysis of the factors described
above, including thorough discussions with, and questioning of, the Millendo management team and the legal and financial advisors of Millendo, and considered the factors overall to be favorable to, and to support, its determination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_42"></A>Tempest Reasons for the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the merger, the Tempest board of directors held numerous meetings, consulted with
Tempest&#146;s senior management, its financial advisors and legal counsel, and considered a wide variety of factors including, among others, the following material factors (which factors are not necessarily presented in any order of relative
importance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the merger will provide Tempest&#146;s current stockholders with greater liquidity by owning publicly-traded
stock, and expanding both the access to capital for Tempest and the range of investors potentially available as a public company, compared to the investors Tempest could otherwise gain access to if it continued to operate as a privately-held
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits from increased public market awareness of Tempest and its pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical and current information concerning Tempest&#146;s business, including its financial performance
and condition, operations, management and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive nature of the industry in which Tempest operates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Tempest board of directors&#146; fiduciary duties to Tempest&#146;s stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the board&#146;s belief that this transaction provides a viable alternate public listing strategy, and addresses
the risk of the lack of an available market for an initial public offering at a later date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected cash resources of the combined organization (including the ability to support the combined
company&#146;s current and planned clinical trials and operations); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions of the Merger Agreement, including the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the determination that the expected relative percentage ownership of Millendo&#146;s stockholders and
Tempest&#146;s stockholders in the combined organization was appropriate, based on the Tempest board of directors&#146; judgment and assessment of the approximate valuations of Millendo (including the value of the net cash Millendo is expected to
provide to the combined organization) and Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the merger will be treated as a reorganization for U.S.&nbsp;federal income tax purposes,
with the result that in the merger the Tempest stockholders will generally not recognize taxable gain or loss for U.S.&nbsp;federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited number and nature of the conditions of the obligation of Millendo to consummate the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights of Tempest under the Merger Agreement to consider certain unsolicited acquisition proposals under
certain circumstances should Tempest receive a superior proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conclusion of the Tempest board of directors that the potential termination fees of $1,400,000, payable by
Millendo to Tempest and of $2,800,000, payable by Tempest to Millendo, and the circumstances when such fees may be payable, were reasonable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conclusion of the Tempest board of directors that the potential expense reimbursement of up to $1,000,000,
payable by Millendo to Tempest, and the circumstances when such fee may be payable, were reasonable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the other terms of the Merger Agreement, including the parties&#146; representations, warranties
and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of Millendo&#146;s common stock issued to Tempest&#146;s stockholders will be registered on a <FONT
STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> registration statement and will become freely tradable for Tempest&#146;s stockholders who are not affiliates of Tempest and who are not parties to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the support agreements, pursuant to which certain directors, officers and stockholders of Tempest and Millendo,
respectively, have agreed, solely in their capacity as stockholders of Tempest and Millendo, respectively, to vote all of their shares of Tempest capital stock or Millendo common stock in favor of the adoption or approval, respectively, of the
Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain a Nasdaq listing and the change of the combined organization&#146;s name to Tempest
Therapeutics, Inc. upon the closing of the merger; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood that the merger will be consummated on a timely basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tempest board of directors also considered a number of uncertainties and risks in its deliberations concerning the merger and the other transactions
contemplated by the Merger Agreement, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the merger might not be completed and the potential adverse effect of the public
announcement of the merger on the reputation of Tempest and the ability of Tempest to obtain financing in the future in the event the merger is not completed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that future sales of common stock by existing Millendo stockholders may cause the price of Millendo
common stock to fall, thus reducing the potential value of Millendo common stock received by Tempest stockholders following the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exchange ratio used to establish the number of shares of Millendo&#146;s common stock to be issued to
Tempest&#146;s stockholders in the merger is fixed, except for adjustments due to Millendo&#146;s cash balance and outstanding capital stock at closing (subject to certain limitations)and under the facts and circumstances, that the relative
percentage ownership of Millendo&#146;s stockholders and Tempest&#146;s stockholders in the combined organization immediately following the completion of the merger is expected to not change materially; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination fee of $2,800,000, payable by Tempest to Millendo upon the occurrence of certain events, and the
potential effect of such termination fee in deterring other potential acquirers from proposing an alternative transaction that may be more advantageous to Tempest&#146;s stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential reduction of Millendo&#146;s net cash prior to the closing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Millendo could, under certain circumstances, consider unsolicited acquisition proposals if
superior to the merger or change its recommendation to approve the merger upon certain events; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the merger might not be completed in a timely manners or at all, for a variety of reasons,
such as the failure of Millendo to obtain the required stockholder vote, and the potential adverse effect on the reputation of Tempest and the ability of Tempest to obtain financing in the future in the event the merger is not completed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in connection with completing the merger, the time and effort of Tempest senior management
required to complete the merger, the related disruptions or potential disruptions to Tempest&#146;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may
do business in the future with Tempest, and related administrative challenges associated with combining the companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the additional expenses and obligations to which Tempest&#146;s business will be subject following the merger
that Tempest has not previously been subject to, and the operational changes to Tempest&#146;s business, in each case that may result from being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the merger
and the potential risk of liabilities that may arise post-closing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">various other risks associated with the combined organization and the merger, including the risks described in
the section entitled &#147;<I>Risk</I> <I>Factors</I>&#148; in this proxy statement/prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information is not intended to be exhaustive, but summarizes the material
factors considered by the Tempest board of directors in its consideration of the Merger Agreement and the transactions contemplated. The Tempest board of directors concluded that the benefits, advantages and opportunities of a potential transaction
outweighed the uncertainties and risks described above. After considering these and other factors, the Tempest board of directors unanimously approved the Merger Agreement, the merger and the other transactions contemplated by the Merger Agreement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_43"></A>Opinion of Millendo&#146;s Financial Advisor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Introduction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo retained SVB
Leerink LLC as its financial advisor in connection with the merger and the other transactions contemplated by the Merger Agreement, which are, collectively, referred to as the &#147;Transaction&#148; throughout this section. In connection with this
engagement, Millendo requested that SVB Leerink evaluate the fairness, from a financial point of view, to Millendo of the Exchange Ratio proposed to be paid by Millendo pursuant to the terms of the Merger Agreement. On March&nbsp;28, 2021, SVB
Leerink rendered to the Millendo board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated March&nbsp;28, 2021 that, as of such date and based upon and subject to the various assumptions made, and
the qualifications and limitations upon the review undertaken by SVB Leerink in preparing its opinion, the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to Millendo. In
providing its opinion, SVB Leerink noted that the Exchange Ratio is intended to result in holders of Tempest Therapeutics, Inc. capital stock and Millendo common stock immediately prior to the effective time of the merger holding, on a fully-diluted
basis, approximately 81.5% and 18.5% of the outstanding Millendo common stock, respectively, on a pro forma basis immediately following the effective time of the merger and that the Exchange Ratio and, accordingly, such percentages are subject to
adjustment based upon Millendo&#146;s net cash as of the closing of the Transaction. SVB Leerink expressed no opinion with respect to such adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the SVB Leerink written opinion, dated March&nbsp;28, 2021, which describes the assumptions made and the qualifications and
limitations upon the review undertaken by SVB Leerink in preparing its opinion, is attached as Annex B to this proxy statement/prospectus and is incorporated herein by reference. The summary of the written opinion of SVB Leerink set forth below is
qualified in its entirety by the full text of the written opinion attached as Annex B to this proxy statement/prospectus. <B>SVB Leerink&#146;s financial advisory services and opinion were provided for the information and assistance of the Millendo
board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction and the SVB Leerink opinion addressed only the fairness, from a financial point of view, as
of the date thereof, to Millendo of the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement. The SVB Leerink opinion did not address any other term or aspect of the Merger Agreement or the Transaction and does not
constitute a recommendation to any stockholder of Millendo as to whether or how such holder should vote with respect to the merger or otherwise act with respect to the Transaction or any other matter.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The full text of SVB Leerink&#146;s written opinion should be read carefully in its entirety for a description of the assumptions made and
limitations upon the review undertaken by SVB Leerink in preparing its opinion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering the opinion described
above and performing its related financial analyses, SVB Leerink reviewed, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a draft of the Merger Agreement, dated March&nbsp;27, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2020, in the form to be filed by Millendo with the SEC on March&nbsp;29, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as filed by Millendo with, or
furnished by Millendo to, the SEC; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain internal information, primarily related to expense forecasts, furnished to SVB Leerink by the managements
of Millendo and Tempest, respectively, and approved for SVB Leerink&#146;s use by Millendo </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink also conducted
discussions with members of the senior management of Millendo and Tempest and their respective advisors and representatives regarding the internal information referred to above as well as the past and current business, operations, financial
condition and prospects of each of Millendo and Tempest. In addition, SVB Leerink reviewed the historical trading prices and trading activity for the Millendo common stock. Furthermore, SVB Leerink reviewed publicly available market capitalization
data regarding companies in the biopharmaceutical industry that SVB Leerink believed to be comparable in certain respects to Tempest; and SVB Leerink reviewed publicly available financial terms of certain initial public offerings involving companies
in the biopharmaceutical industry that SVB Leerink believed to be comparable in certain respects to Tempest. SVB Leerink also conducted such other financial studies and analyses and took into account such other information as it deemed appropriate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial,
legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by it for purposes of the opinion and, with the consent of the Millendo board of directors, relied upon such information as being complete and
accurate. In addition, with the consent of the Millendo board of directors, SVB Leerink did not make any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative,
<FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> or otherwise) of Millendo or Tempest, nor was SVB Leerink furnished with any such evaluation or appraisal, and SVB Leerink was not asked to conduct, and did not conduct, a physical inspection
of the properties or assets of Millendo or Tempest. SVB Leerink assumed, with the consent of the Millendo board of directors, that the final executed Merger Agreement would not differ in any respect material to SVB Leerink&#146;s analysis or the
opinion from the last draft of the Merger Agreement reviewed by SVB Leerink. SVB Leerink also assumed, with the consent of the Millendo board of directors, that the Transaction would be consummated on the terms set forth in the Merger Agreement and
in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to SVB Leerink&#146;s analysis or
its opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change would be imposed, the
effect of which would be material to such analysis or opinion. SVB Leerink did not evaluate and did not express any opinion as to the solvency or fair value of Millendo or Tempest, or their respective abilities to pay their obligations when they
come due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. SVB Leerink are not legal, regulatory, tax or accounting advisors, and SVB Leerink
expressed no opinion as to any legal, regulatory, tax or accounting matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink expressed no view as to, and its opinion did not
address, Millendo&#146;s underlying business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to Millendo or in
which Millendo might engage. The opinion was limited to and addressed only the fairness, from a financial point of view, as of the date thereof, to Millendo of the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement.
SVB Leerink was not asked to, nor did SVB Leerink express any view on, and its opinion did not address, any other term or aspect of the Merger Agreement or the Transaction, including, without limitation, the structure or form of the Transaction, or
any other agreements or arrangements contemplated by the Merger Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or aspect of
the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any class of securities, creditors or other constituencies of Millendo or any other party. In addition, SVB
Leerink expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Millendo or any other party,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or class of such persons in connection with the Transaction, whether relative to the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement or otherwise. The SVB
Leerink opinion was necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to SVB Leerink as of, the date thereof, and SVB Leerink does not have
any obligation or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events occurring after the date of the opinion. The SVB Leerink opinion does not constitute a recommendation to any stockholder of
Millendo as to whether or how such holder should vote with respect to the merger or otherwise act with respect to the Transaction or any other matter. SVB Leerink provided its financial services and rendered its opinion for the information and
assistance of the Millendo board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. The issuance of the SVB Leerink opinion was approved by the SVB
Leerink LLC Fairness Opinion Review Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Financial Analyses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material financial analyses prepared by SVB Leerink and reviewed with the Millendo board of directors in
connection with the rendering by SVB Leerink of its opinion on March&nbsp;28, 2021. The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion
of, SVB Leerink, nor does the order of the financial analyses described represent the relative importance or weight given to those financial analyses by SVB Leerink. SVB Leerink may have deemed various assumptions more or less probable than other
assumptions, so the reference ranges resulting from any particular portion of the analyses summarized below should not be taken to be the view of SVB Leerink as to the actual value of Millendo. Some of the summaries of the financial analyses set
forth below include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the
financial analyses performed by SVB Leerink. Considering the data in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions
underlying such analyses or factors, could create a misleading or incomplete view of the processes underlying SVB Leerink&#146;s financial analyses and its opinion. In performing its analyses, SVB Leerink made numerous assumptions with respect to
industry performance, general business and economic conditions and other matters, many of which are beyond the control of Millendo or any other parties to the Transaction. None of Millendo, Tempest, Merger Sub, SVB Leerink or any other person
assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly
more or less favorable than as set forth below. In addition, analyses relating to the value of Millendo or Tempest do not purport to be appraisals or reflect the prices at which these companies may actually be sold. Accordingly, the assumptions and
estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on
market data as it existed on or before March&nbsp;24, 2021 and is not necessarily indicative of current market conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing
its analysis, SVB Leerink took into account that the Exchange Ratio contained in the Merger Agreement is calculated by attributing equity values of $36,000,000 and $158,400,000 to Millendo and Tempest, respectively, subject to an adjustment based
upon Millendo&#146;s net cash as of the closing of the merger. Tempest&#146;s equity value is inclusive of $30,000,000 in committed concurrent financing by new and existing investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the board of directors of Millendo was aware, neither Millendo&#146;s nor Tempest&#146;s management provided SVB Leerink with, and SVB
Leerink did not otherwise have access to, financial forecasts regarding Millendo&#146;s or Tempest&#146;s businesses, other than the expense forecasts described above. Accordingly, SVB Leerink did not perform either discounted cash flow analyses or
any multiples-based analyses with respect to Millendo or Tempest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tempest Therapeutics Valuation Analysis &#150; Selected Biopharma Initial Public Offering <FONT
STYLE="white-space:nowrap">Step-Ups</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink reviewed publicly available information relating to <FONT
STYLE="white-space:nowrap">step-up</FONT> multiples for U.S.-listed initial public offerings since 2018 for biopharmaceutical companies whose lead product at the time of its IPO was a small molecule in Phase 1 or Phase 2 of clinical development,
focused on oncology indications. The <FONT STYLE="white-space:nowrap">step-up</FONT> multiple was derived by dividing the fully-diluted <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation at time of IPO by the post-money valuation of the
financing round prior to IPO. These initial public offerings, which are referred to as the Selected Initial Public Offering <FONT STYLE="white-space:nowrap">Step-Ups,</FONT> are listed below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pricing Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issuer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead&nbsp;Relevant<BR>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication at IPO</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Development<BR>Stage at IPO</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Money</FONT><BR>Equity&nbsp;Value&nbsp;(in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Step-up</FONT><BR>Multiple&nbsp;to<BR>IPO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">11/18/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>Olema Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">OP-1250</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">ER+ / HER2- Metastatic Breast Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">$</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">1.9x</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">7/23/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>iTeos Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">EOS-850</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">5/7/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>Ayala Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">AL101</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">R/M ACC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">4/23/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>ORIC Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">ORIC-101</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Prostate Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">10/30/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>RAPT Therapeutics, INc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">FLX475</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&#147;Charged&#148; Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">3/14/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP>Arcus Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">AB928</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">536</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD NOWRAP VALIGN="middle" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink noted that although such companies had certain financial and operating characteristics that could
be considered similar to those of Tempest Therapeutics, none of the companies had the same <FONT STYLE="white-space:nowrap">management&nbsp;make-up,&nbsp;technology,</FONT> size or mix of businesses as Tempest Therapeutics and, accordingly, there
were inherent limitations on the applicability of such companies to the valuation analysis of Tempest Therapeutics. SVB Leerink also noted that market conditions have varied over the precedent time periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink calculated <FONT STYLE="white-space:nowrap">the&nbsp;step-up</FONT> multiple of each of these companies and applied these
multiples to Tempest Therapeutics&#146; valuation of $158.4&nbsp;million (pro forma for the $30&nbsp;million committed concurrent offering, less underwriting expenses) to arrive at a comparable <FONT STYLE="white-space:nowrap">pre-money</FONT>
valuation for Tempest Therapeutics. SVB Leerink compared <FONT STYLE="white-space:nowrap">these&nbsp;pre-money</FONT> valuations to the proposed Tempest Therapeutics valuation of $158.4&nbsp;million based on the proposed valuation and ownership
ratio in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Step-up&nbsp;Multiple&nbsp;to&nbsp;IPO</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Implied&nbsp;Tempest&nbsp;Post-Money</FONT><BR>Valuation (in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tempest Therapeutics Valuation Analysis &#150; Selected Biopharma Initial Public Offerings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink reviewed publicly available information relating to the U.S.-listed initial public offerings completed since January&nbsp;1, 2018
for biopharmaceutical companies whose lead product at the time of its IPO was a small molecule in Phase 1 or Phase 2 of clinical development, focused on oncology indications. These initial public offerings, which are referred to as the Selected
Oncology IPOs, are listed below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pricing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issuer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead&nbsp;Relevant<BR>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication&nbsp;at<BR>IPO</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Development<BR>Stage&nbsp;at&nbsp;IPO</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Money</FONT><BR>Equity&nbsp;Value<BR>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Money</FONT><BR>Enterprise&nbsp;Value<BR>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Post-Money</FONT><BR>Equity&nbsp;Value<BR>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">11/18/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">Olema Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><FONT STYLE="white-space:nowrap">OP-1250</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">ER+ / HER2- Metastatic Breast Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">7/23/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">iTeos Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><FONT STYLE="white-space:nowrap">EOS-850</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">709</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">5/7/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">Ayala Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">AL101</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">R/M ACC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">4/23/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">ORIC Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><FONT STYLE="white-space:nowrap">ORIC-101</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Prostate Cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">10/30/2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">RAPT Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">FLX475</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#147;Charged&#148; Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">3/14/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">Arcus Biosciences, INc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">AB928</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Phase 1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">536</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink noted that although such companies had certain financial and operating characteristics that could
be considered similar to those of Tempest Therapeutics, none of the companies had the same <FONT STYLE="white-space:nowrap">management&nbsp;make-up,&nbsp;technology,</FONT> size or mix of businesses as Tempest Therapeutics and, accordingly, there
were inherent limitations on the applicability of such companies to the valuation analysis of Tempest Therapeutics. SVB Leerink also noted that market conditions have varied over the precedent time periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink calculated a <FONT STYLE="white-space:nowrap">pre-money</FONT> enterprise valuation for the companies and added Tempest
Therapeutics&#146; estimated net cash at closing of $48.2&nbsp;million (pro forma for the $30&nbsp;million committed concurrent offering, less underwriting expenses) to reach an adjusted <FONT STYLE="white-space:nowrap">pre-money</FONT> equity value
for Tempest Therapeutics. SVB Leerink compared these&nbsp;adjusted <FONT STYLE="white-space:nowrap">pre-money</FONT> equity values to the proposed Tempest Therapeutics valuation of $158.4&nbsp;million based on the proposed valuation and ownership
ratio in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Adj.&nbsp;Pre-Money&nbsp;Enterprise</FONT><BR>Value (in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Adj.&nbsp;Pre-Money&nbsp;Equity&nbsp;Value</FONT><BR>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tempest Therapeutics Valuation Analysis &#150; Selected Biopharma Public Companies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink reviewed publicly available information relating to the market capitalization of U.S.-listed publicly-traded biopharmaceutical
companies whose lead product was a small molecule in Phase 1 or Phase 2 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical development, focused in oncology. The companies meeting these criteria, which are referred to as the Selected Companies, were: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Lead&nbsp;Relevant<BR>Compound</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Development&nbsp;Stage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Value&nbsp;(in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Enterprise&nbsp;Value&nbsp;(in<BR>millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Olema Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">OP-1250</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">ER+,&nbsp;HER2-MBC</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase&nbsp;1/2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">iTeos Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Inupadenant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase&nbsp;1b/2a</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals Inc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">ORIC-101</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Prostate Cancer and Solid Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 1b</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RAPT Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">FLX475</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#147;Charged&#148; Tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Zandelisib</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Follicular Lymphoma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infinity Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Eganelisib</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Urothelial Cancer / TNBC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ayala Pharmaceuticals Inc</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">AL101</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">R/M ACC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink noted that although such companies had certain financial and operating characteristics that could
be considered similar to those of Tempest Therapeutics, none of the companies had the same <FONT STYLE="white-space:nowrap">management,&nbsp;make-up,&nbsp;technology,</FONT> size or mix of businesses as Tempest Therapeutics and, accordingly, there
were inherent limitations on the applicability of such companies to the valuation analysis of Tempest Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink
calculated the aggregate enterprise value of each of the Selected Companies based upon the closing price of the common stock of each Selected Company on March&nbsp;24, 2021 and the fully-diluted number of shares outstanding, using the treasury stock
method. SVB Leerink then added Tempest&#146;s estimated net cash at closing of $48.2&nbsp;million (pro forma for the $30&nbsp;million committed concurrent offering, less underwriting expenses) and applied a 25% liquidity discount to reach an
adjusted equity value for Tempest Therapeutics. SVB Leerink compared these&nbsp;adjusted equity valuations to the proposed Tempest Therapeutics valuation of $158.4&nbsp;million based on the proposed valuation and ownership ratio in the Merger
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this analysis are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Enterprise&nbsp;Value&nbsp;(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adj.&nbsp;Equity&nbsp;Value<BR>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adj. Equity Value with 25%<BR>Liquidity&nbsp;Discount&nbsp;(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75th Percentile</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of a fairness opinion is a complex analytical process involving various determinations as to the most appropriate and relevant
methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a fairness opinion is not readily susceptible to summary description. In arriving at its opinion, SVB Leerink did not draw, in
isolation, conclusions from or with regard to any factor or analysis that it considered. Rather, SVB Leerink made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the
analyses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink&#146;s financial analyses and opinion were only one of many factors taken into
consideration by the Millendo board of directors in its evaluation of the Transaction. Consequently, the analyses described above should not be viewed as determinative of the views of the Millendo board of directors or management of Millendo with
respect to the Exchange Ratio or as to whether the Millendo board of directors would have been willing to determine that a different Exchange Ratio was fair. The Exchange Ratio was determined through
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between Millendo and Tempest and was approved by the Millendo board of directors. SVB Leerink provided advice to Millendo during these negotiations. However, SVB Leerink did not
recommend any specific Exchange Ratio or other financial terms to Millendo or the Millendo board of directors or that any specific Exchange Ratio or other financial terms constituted the only appropriate consideration for the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and
financial advisory services. SVB Leerink has provided certain investment banking services to Millendo from time to time, for which it has received compensation. In the ordinary course of business, SVB Leerink and its affiliates may, in the future,
provide commercial and investment banking services to Millendo, Tempest or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the ordinary course of their trading and brokerage activities,
SVB Leerink or its affiliates have in the past and may in the future hold positions, for their own account or the accounts of their customers, in equity, debt or other securities of Millendo, Tempest or their respective affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with applicable legal and regulatory requirements, SVB Leerink has adopted policies and procedures to establish and maintain the
independence of its research departments and personnel. As a result, SVB Leerink&#146;s research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Millendo and the Transaction and
other participants in the Transaction that differ from the views of SVB Leerink&#146;s investment banking personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Millendo
Therapeutics Board selected SVB Leerink to act as Millendo&#146;s financial advisor based on SVB Leerink&#146;s qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent
transactions in the biopharmaceutical industry and its relationship and familiarity with Millendo and its business. SVB Leerink is an internationally recognized investment banking firm that has substantial experience in transactions similar to the
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_44"></A>In connection with SVB Leerink&#146;s services as financial advisor to Millendo, Millendo has agreed to pay SVB
Leerink an aggregate fee of $2.0&nbsp;million, $500,000 of which became payable upon the rendering by SVB Leerink of its opinion on March&nbsp;28, 2021 and the remainder of which is payable contingent upon consummation of the Transaction. In
addition, Millendo has agreed to reimburse certain of SVB Leerink&#146;s expenses arising, and to indemnify SVB Leerink against certain liabilities that may arise, out of SVB Leerink&#146;s engagement. The terms of the fee arrangement between SVB
Leerink and Millendo, which are customary in transactions of this nature, were negotiated at arm&#146;s length between SVB Leerink and Millendo Therapeutics, and the Millendo board of directors was aware of the arrangement, including the fact that a
significant portion of the fee payable to SVB Leerink is contingent upon the completion of the Transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_45"></A>Interests of
Millendo Directors and Executive Officers in the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Millendo board of directors with
respect to issuing shares of Millendo common stock in the merger and the other matters to be acted upon by the Millendo stockholders at the Millendo special meeting, the Millendo stockholders should be aware that Millendo&#146;s directors and
executive officers have interests in the merger that are different from, or in addition to, the interests of Millendo&#146;s stockholders generally. These interests may present them with actual or potential conflicts of interest, and these
interests, to the extent material, are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Millendo board of directors was aware of these potential conflicts of
interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the merger, and to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recommend that the Millendo stockholders approve the proposals to be presented to the Millendo stockholders for consideration at the Millendo special meeting as contemplated by this proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership Interests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, Millendo&#146;s current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and executive officers
beneficially owned, in the aggregate, less than 1% of the shares of Millendo common stock, which for purposes of this subsection&nbsp;excludes any Millendo shares issuable upon exercise of Millendo stock options held by such individuals. The
affirmative vote of the holders of a majority of the shares present in attendance or represented by proxy at the Millendo special meeting and entitled to vote on the matter, assuming a quorum is present, is required for approval of Proposal Nos. 1,
3, and 4. The affirmative vote of the holders of a majority of the outstanding shares of Millendo common stock entitled to vote at the Millendo special meeting is required for approval of Proposal No.&nbsp;2. Each of Millendo&#146;s <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors have also entered into a support agreement in connection with the merger. For a more detailed discussion of the support agreements, please see the section&nbsp;titled &#147;<I>Agreements
Related to the Merger&#151;Support Agreements</I>&#148; beginning on page&nbsp;162 of this proxy statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Millendo
Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the merger, the Millendo board of directors will have the right, in its sole discretion, to adopt
appropriate resolutions and take all other actions necessary and appropriate to provide that each Millendo option, whether vested or unvested, be accelerated in full effective as of immediately prior to the effective time of the merger. At the
effective time of the merger, each Millendo option that is outstanding and unexercised immediately prior to the effective time of the merger, whether or not vested, will survive the closing and remain outstanding in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo estimates that the aggregate amount that would be payable, net of exercise price,
to Millendo&#146;s executive officers as a group and Millendo&#146;s current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group if they exercised their Millendo options, whether vested or unvested, and immediately sold the
common stock of Millendo acquired upon exercise is $0 and $10,000, respectively. The amounts above are determined using a per share Millendo stock price of $1.24, which is the average closing trading price of Millendo common stock over the first
five business days following the first public announcement of the transactions contemplated by the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets
forth information regarding the Millendo stock options held as of March&nbsp;31, 2021 by each of the individuals who are or were at any point on or after January&nbsp;1, 2020 Millendo&#146;s executive officers and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The number of shares of Millendo common stock underlying such options will be adjusted appropriately to reflect the proposed reverse stock split. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Vested<BR>Options&nbsp;Held</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted <BR>Average <BR>Exercise <BR>Price&nbsp;of <BR>Vested&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of <BR>Unvested <BR>Options&nbsp;Held</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price of<BR>Unvested<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Arcudi III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer L. <FONT STYLE="white-space:nowrap">Minai-Azary</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christophe Arbet-Engels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Zeidan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamara Joseph</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia C. Owens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">691,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">466,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Habib J. Dable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lynne Hedley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James M. Hindman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Howe, III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geoff Nichol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carole L. Nuechterlein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Positions Following the Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Geoff Nichol is currently a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of Millendo and will continue as a director of the
combined company after the effective time of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification and Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the indemnification and insurance provisions related to the Millendo directors and officers under the Merger Agreement,
please see the section&nbsp;titled &#147;<I>The Merger Agreement&#151;Indemnification and Insurance for Officers and Directors</I>&#148; beginning on page&nbsp;153 below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo
compensates its <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (including Dr.&nbsp;Owens, when she ceased to be chief executive officer) for their service on the Millendo board of directors pursuant to its <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy but does not provide compensation to Mr.&nbsp;Arcudi other than for his service as an employee of Millendo. <FONT STYLE="white-space:nowrap">Non-employee</FONT> members of
the Millendo board of directors receive cash compensation, payable in equal quarterly installments, in arrears following the end of each quarter in which service occurred, prorated for any months of partial service. Pursuant to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are also eligible to receive initial and annual grants of stock options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Merger Agreement, each outstanding option of the <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors (other than Dr.&nbsp;Owens) that have not previously vested will fully vest, and the options will be exercisable for 18 months after the closing; provided, however, that no option shall remain
exercisable following the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Executive Chair Advisory Agreement Millendo entered into with
Dr.&nbsp;Owens in connection with her becoming Executive Chair of the Millendo board of directors and ceasing to be chief executive officer, Dr.&nbsp;Owens earns a monthly stipend payable on a quarterly basis, in addition to any cash and equity
compensation provided to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Millendo board of directors plus cash and equity compensation provided to the individual acting as the chair of the Millendo board of directors, all
pursuant to Millendo&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy. The Millendo board of directors amended Dr.&nbsp;Owen&#146;s May&nbsp;25, 2020 option to provide and provided in her March&nbsp;17, 2021
option (granted to her in connection with her becoming Executive Chair) that such options would fully vest on a Change in Control and would be exercisable for 18 months after the closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing, Geoff Nichol will be eligible to be compensated as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of
Tempest pursuant to the Millendo non-employee director compensation policy that is expected to remain in place following the effective time of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Employment Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has entered into amended and restated retention agreements with Mr.&nbsp;Arcudi and
<FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary,</FONT> pursuant to which each are eligible to receive certain severance payments and benefits in lieu of any prior severance arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amended employment agreement Millendo entered into with Mr.&nbsp;Arcudi upon his becoming Chief Executive Officer and
President (the &#147;Arcudi Employment Agreement&#148;), if Mr.&nbsp;Arcudi is terminated by Millendo without &#147;Cause&#148; or he resigns employment for &#147;Good Reason&#148; (each, as defined below), and subject to delivery to Millendo of a
separation agreement including a general release of claims in favor of Millendo, Mr.&nbsp;Arcudi will be entitled to payment of his COBRA health insurance premiums for a twelve (12)&nbsp;month period. If such a termination without Cause or
resignation for Good Reason takes place within three (3)&nbsp;months prior to or twelve (12)&nbsp;months following the effective date of a &#147;Change in Control&#148; (as defined in the Arcudi Employment Agreement), Mr.&nbsp;Arcudi will be
entitled to: (a)&nbsp;payment of his COBRA health insurance premiums for an eighteen (18)&nbsp;month period and (b)&nbsp;accelerated vesting of all unvested equity awards such that all unvested equity awards shall become immediately vested and
exercisable. In addition, Mr.&nbsp;Arcudi is eligible to earn retention bonuses of up to a total of $630,000 in the aggregate and paid in two equal installments (one of which has already been paid and is subject to repayment if he is not employed by
Millendo through June 30, 2021), and, with respect to the second installment, will be paid on the earlier of December&nbsp;31, 2021 or the closing of a Change in Control of Millendo (as defined in the Arcudi Employment Agreement), and his execution
of release agreements in favor of Millendo. Mr.&nbsp;Arcudi will also be eligible for a transaction bonus of $250,000 if Millendo undergoes a Change in Control during Mr.&nbsp;Arcudi&#146;s employment term. In February 2021, the Millendo board of
directors provided in Mr.&nbsp;Arcudi&#146;s February&nbsp;26, 2021 option (the option granted to him in connection with his promotion to chief executive officer) that such option would fully vest on a Change in Control and would be exercisable for
18 months after the closing and amended his May&nbsp;25, 2020 option to extend it to 18 months after the closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amended
employment agreement Millendo entered into with <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> upon her becoming Chief Financial Officer (the <FONT STYLE="white-space:nowrap">&#147;Minai-Azary</FONT> Employment Agreement&#148;), if <FONT
STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> is terminated by Millendo without &#147;Cause&#148; or she resigns employment for &#147;Good Reason&#148; (each, as defined below), and subject to delivery to Millendo of a separation agreement
including a general release of claims in favor of Millendo, <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> will be entitled to: (a)&nbsp;payment of her COBRA health insurance premiums for a twelve (12)&nbsp;month period and
(b)&nbsp;twelve (12) months of professional services outplacement assistance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an outplacement vendor funded by Millendo. If such a termination without Cause or resignation for Good Reason takes place within three (3)&nbsp;months prior to or twelve (12)&nbsp;months
following the effective date of a &#147;Change in Control&#148; (as defined in the <FONT STYLE="white-space:nowrap">Minai-Azary</FONT> Employment Agreement), <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> will also be entitled to
accelerated vesting of all unvested equity awards such that all unvested equity awards shall become immediately vested and exercisable. In addition, <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary</FONT> is eligible to earn retention bonuses
of up to a total of $403,000 in the aggregate and paid in two equal installments (one of which has already been paid and is subject to repayment if she is not employed by Millendo through June 30, 2021), and, with respect to the second installment,
will be paid on the earlier of December&nbsp;31, 2021 or the closing of a Change in Control of Millendo (as defined in the <FONT STYLE="white-space:nowrap">Minai-Azary</FONT> Employment Agreement), and her execution of release agreements in favor of
Millendo. In February 2021, the Millendo board of directors provided in <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary&#146;s</FONT> February&nbsp;26, 2021 option (the option granted to her in connection with her promotion to chief financial
officer) that such option would fully vest on a Change in Control and would be exercisable for 18 months after the closing and amended her May&nbsp;25, 2020 option to extend it to 18 months after the closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Mr.&nbsp;Arcudi&#146;s and <FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary&#146;s</FONT> employment agreements,
&#147;cause&#148; means Millendo (or its designee) has determined in its sole discretion that the executive has engaged in any of the following: (i)&nbsp;a material breach of any covenant or condition under the applicable employment agreement or any
other agreement between the parties; (ii)&nbsp;any act constituting dishonesty, fraud, immoral or disreputable conduct; (iii)&nbsp;any conduct which constitutes a felony under applicable law; (iv)&nbsp;material violation of any policy of Millendo
Therapeutics, Inc. or Millendo Therapeutics US, Inc. or any act of misconduct; (v)&nbsp;refusal to follow or implement a clear and reasonable directive of Millendo Therapeutics US, Inc. or, if applicable, Millendo Therapeutics, Inc.; (vi) negligence
or incompetence in the performance of the executive&#146;s duties or failure to perform such duties in a manner satisfactory to Millendo Therapeutics US, Inc. after the expiration of ten (10)&nbsp;days without cure after written notice of such
failure; or (vii)&nbsp;breach of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Mr.&nbsp;Arcudi&#146;s and
<FONT STYLE="white-space:nowrap">Ms.&nbsp;Minai-Azary&#146;s</FONT> employment agreements, &#147;good reason&#148; means the occurrence of any of the following without the executive&#146;s consent: (i)&nbsp;a material reduction of the
executive&#146;s base salary of at least 10%; (ii) a material reduction in the executive&#146;s duties, authority and responsibilities relative to the executive&#146;s duties, authority, and responsibilities in effect immediately prior to such
reduction; or (iii)&nbsp;the relocation of the executive&#146;s principal place of employment, without the executive&#146;s consent, in a manner that lengthens the executive&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute distance by
fifty (50)&nbsp;or more miles from the executive&#146;s then-current principal place of employment immediately prior to such relocation, subject in all cases to customary notice and cure provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Liability and Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification obligations required by the restated certificate of incorporation and third amended and restated bylaws of
Millendo, Millendo has entered into indemnification agreements with each of its directors and officers. These agreements provide for the indemnification of Millendo&#146;s directors and executive officers for all reasonable expenses and liabilities
incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were agents of Millendo. Millendo believes that these restated certificate of incorporation provisions, third amended and restated bylaw
provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Golden Parachute
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section sets forth the information required by Item&nbsp;402(t) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> regarding the compensation that is based on or otherwise relates to the merger that may become payable to each of Millendo&#146;s named executive officers, in accordance with SEC rules.
This compensation is referred to as &#147;golden parachute&#148; compensation by the applicable SEC disclosure rules, and in this section Millendo uses this term to describe this merger-related compensation payable to Millendo&#146;s named executive
officers for fiscal year 2020, who are Millendo&#146;s current Chief Executive Officer&nbsp;and President, its former Chief Executive Officer and current Executive Chair of the Millendo board of directors, and its former Chief Medical Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the potential golden parachute compensation, if any, that each
named executive officer received from Millendo (in the case of Dr.&nbsp;Arbet-Engels) or could be entitled to receive from Millendo (in the case of Mr.&nbsp;Arcudi and Dr.&nbsp;Owens) if the merger is completed. It is currently expected that
Mr.&nbsp;Arcudi will not continue to be employed by Millendo following the closing and, accordingly, will be entitled to receive the severance and/or other benefits described above and below, which are contingent upon the occurrence of a change in
control or qualifying termination of employment or other event. Please note that the amounts indicated below are estimates based on multiple assumptions that may or may not actually occur, including assumptions described herein. Accordingly, the
actual amounts, if any, to be received may differ in material respects from the amounts set forth below. Furthermore, the amounts set forth in the table below do not reflect any reductions in payments or benefits that would result from a cutback of
such amounts under applicable agreements or otherwise in light of the adverse tax consequences under Sections 280G and 4999 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts set forth below represent an estimate of each named executive officer&#146;s golden parachute compensation, assuming the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that consummation of the merger constitutes a change of control for purposes of the applicable compensation plan,
arrangement or agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the merger was consummated on March 31, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mr.&nbsp;Arcudi&#146;s employment is terminated by Millendo without &#147;cause&#148; or by him with &#147;good
reason&#148; immediately following the merger; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value of the vesting acceleration of the named executive officers&#146; equity awards is calculated assuming
a price per share of Millendo common stock of $1.24, which represents the average closing market price of Millendo&#146;s securities over the first five business days following the first public announcement of the transaction. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Golden&nbsp;Parachute&nbsp;Compensation(6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>COBRA<BR>Benefits(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Arcudi III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">914,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia C. Owens(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christophe Arbet-Engels(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Owens is Millendo&#146;s former Chief Executive Officer and ceased to be employed in connection with
becoming Executive Chair of the Millendo board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Arbet-Engels is Millendo&#146;s former Chief Medical Officer and is no longer an employee of Millendo.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the total cash to be paid to Mr.&nbsp;Arcudi upon a termination of
employment without &#147;cause&#148; or a termination for &#147;good reason&#148; within three months before or 12 months following the closing of a change in control. Included in the amount is $0 for severance, $630,000 in a retention bonus (50% of
which has been paid and the other 50% of which will be due upon continued employment but will be accelerated upon the closing of the change in control and paid to the extent not previously paid), and $250,000 as a transaction bonus upon the closing
of a change of control. Dr.&nbsp;Owens and Dr.&nbsp;Arbet-Engels received severance but not in connection with the pending change of control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the value attributable to accelerated vesting of Millendo equity awards as
set forth below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. Amounts attributable to Millendo stock options represent the value of accelerated vesting of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> stock options, which will become vested in full as described above in &#147;<I>Treatment of Millendo Common Stock and Millendo Options&#148;</I> pursuant to the
existing terms of the options. The Millendo board of directors has not determined whether to accelerate the vesting of any additional unvested options. Additional options are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-the-money</FONT></FONT></FONT> and are attributed no value above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted to Mr.&nbsp;Arcudi, other than
his February&nbsp;26, 2021 grant, will, to the extent unvested, fully vest in connection with the closing of a change in control assuming he then ceases to be employed, while the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
February&nbsp;26, 2021 grant would fully vest at the closing of a change in control, irrespective of whether he remains employed thereafter. Stock options granted to Dr.&nbsp;Owens granted on
May&nbsp;25, 2020 and March&nbsp;17, 2021 that have not then previously vested will become fully vested in connection with a change in control. Stock options granted to Mr.&nbsp;Arcudi on May&nbsp;25, 2020 and on February&nbsp;26, 2021 will be
exercisable until the 18 month anniversary of the closing of the change in control, as will options granted to Dr.&nbsp;Owens on May&nbsp;25, 2020 and March&nbsp;17, 2021. The value reflected above is based on the extent, if any, to which the
assumed Millendo Common Stock price of $1.24 exceeds the exercise price of those options. Because certain options may be exercised up to 18 months following the closing, the payment Mr.&nbsp;Arcudi or Dr.&nbsp;Owens would receive as a result of the
exercise of such options could vary significantly based on the price of Millendo common stock on the date of exercise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent COBRA premiums to which Mr.&nbsp;Arcudi would be entitled upon a
qualifying termination. Drs. Owens and Arbet-Engels began receiving COBRA payments on their separations from employment, and those payments are not affected by a change in control. The amount shown in the table is not reduced for any payments with
respect to COBRA that Millendo may be required to make pursuant to the American Rescue Plan Act of 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The named executive officers are not entitled to receive pension or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation benefits or enhancements or any tax reimbursements in connection with the merger. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_46"></A>Interests of Tempest Directors and Executive Officers in the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Tempest board of directors with respect to approving the merger, stockholders should be aware that
Tempest&#146;s directors and executive officers have interests in the merger that are different from, or in addition to, the interests of Tempest stockholders generally. These interests may present them with actual or potential conflicts of
interest, and these interests, to the extent material, are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors of Tempest was aware of these potential conflicts of
interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the merger, and to recommend that the Tempest stockholders approve the merger as contemplated by this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership Interests </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
March&nbsp;31, 2021, Tempest&#146;s current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and executive officers beneficially owned, in the aggregate approximately 70.9% of the shares of Tempest capital stock, which for purposes of
this subsection excludes any Tempest shares issuable upon exercise or settlement of Tempest stock options held by such individual. Each of Tempest&#146;s officers, directors and affiliated stockholders have also entered into a support agreement in
connection with the merger. For a more detailed discussion of the support agreements, please see the section titled &#147;<I>Agreements Related to</I> <I>the Merger&#151;Support Agreements</I>&#148; beginning on page&nbsp;162 of this proxy
statement/prospectus. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Tempest Options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each option to purchase shares of Tempest common stock that is outstanding and unexercised
immediately prior to the effective time of the merger, whether vested or unvested, and all stock option plans or other stock or equity-related plans of Tempest will be assumed by Millendo at the effective time and will be converted into an option to
acquire shares of Millendo common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth information regarding the Tempest stock options held as of March
31, 2021 by each of Tempest&#146;s current executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The number of shares of common stock underlying such options will be adjusted appropriately to reflect the proposed
reverse stock split. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>of&nbsp;Vested<BR>Options<BR>Held</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted<BR>Average<BR>Exercise<BR>Price of<BR>Vested<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number&nbsp;of<BR>Unvested<BR>Options<BR>Held</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Weighted<BR>Average<BR>Exercise<BR>Price of<BR>Unvested<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,984,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,417,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,023,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Grayson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peppi Prasit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Raab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">363,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">607,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Weisskoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tom Woiwode</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stella Xu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek Yuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Following the Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described elsewhere in this proxy statement/prospectus, including in the section captioned &#147;<I>Management Following the
Merger</I>,&#148; certain of Tempest&#146;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification and Insurance </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a
discussion of the indemnification and insurance provisions related to the Tempest directors and officers under the Merger Agreement, please see the section titled &#147;<I>The Merger Agreement&#151;Indemnification and Insurance for Directors and
Officers</I>&#148; beginning on page&nbsp;153 below. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_47"></A>Effective Time of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement requires the parties to consummate the merger as promptly as practicable (and in any event within two business days unless
any conditions remain unsatisfied or unwaived) after all of the conditions to the consummation of the merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Tempest stockholders and
the approval by the Millendo stockholders of the issuance of Millendo common stock, the reverse stock split, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the
closing of the merger. The merger will become effective upon the filing of a certificate of merger with the Secretary of State of the State of Delaware or at such later time as is agreed by Millendo and Tempest and specified in the certificate of
merger. Neither Millendo nor Tempest can predict the exact timing of the consummation of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_48"></A>Regulatory Approvals
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, Millendo must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq
in connection with the issuance of shares of Millendo common stock to Tempest&#146;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. Millendo does
not intend to seek any regulatory approval from antitrust authorities to consummate the transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_49"></A>Material U.S.&nbsp;Federal Income Tax Consequences of the
Merger </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S.&nbsp;federal income tax consequences of the merger that are applicable
to U.S.&nbsp;holders (as defined below) who exchange shares of Tempest capital stock for shares of Millendo common stock in the merger, assuming that the merger is consummated in the manner described in the Merger Agreement and in this proxy
statement/prospectus. This discussion does not purport to be a complete analysis of all potential tax consequences and is based upon current provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and
administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax
consequences to Tempest stockholders as described in this summary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all U.S.&nbsp;federal income tax
consequences relevant to a Tempest stockholder. In addition, it does not address consequences relevant to Tempest stockholders that are subject to particular U.S.&nbsp;or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including, without
limitation to Tempest stockholders that are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold their Tempest capital stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual
funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; regulated investment companies; <FONT STYLE="white-space:nowrap">tax-exempt</FONT>
organizations or governmental organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes
and limited liability companies (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to the alternative minimum tax provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other
integrated transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have a functional currency other than the U.S.&nbsp;dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold shares of Tempest capital stock that may constitute &#147;qualified small business stock&#148;
under Section&nbsp;1202 of the Code or as &#147;Section&nbsp;1244 stock&#148; for purposes of Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired their shares of Tempest capital stock in a transaction subject to the gain rollover
provisions of Section&nbsp;1045 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to Tempest
capital stock being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell Tempest capital stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding Tempest capital stock who exercise dissenters&#146; rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired their shares of Tempest capital stock pursuant to the exercise of options or otherwise as
compensation or through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expatriates or former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest stockholders subject to particular U.S.&nbsp;or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including those that are
described in this paragraph, are urged to consult their own tax advisors regarding the consequences to them of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is treated as a partnership for U.S.&nbsp;federal income tax purposes
holds Tempest capital stock, the U.S.&nbsp;federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the partnership or other pass-through entity
and certain determinations made at the partner level. If you are a partner of a partnership or other pass-through entity holding Tempest capital stock, you should consult your tax advisors regarding the tax consequences of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the following discussion does not address: (a)&nbsp;the tax consequences of transactions effectuated before, after or at the same
time as the merger, whether or not they are in connection with the merger, including, without limitation, transactions in which shares of Tempest capital stock are acquired or disposed of other than in exchange for shares of Millendo common stock in
the merger; (b)&nbsp;the tax consequences to holders of Tempest convertible notes, or options or warrants issued by Tempest which are assumed in connection with the merger; (c)&nbsp;the tax consequences of the ownership of shares of Millendo common
stock following the merger; (d)&nbsp;any U.S.&nbsp;federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences of the merger, including estate, gift or other tax consequences; (e)&nbsp;any state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the merger; or (f)&nbsp;the Medicare contribution tax on net investment income. No ruling from the Internal Revenue Service, or the IRS, has been or will be requested in connection with
the merger. Tempest stockholders should be aware that the IRS could adopt a position which could be sustained by a court contrary to that set forth in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR
SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE MERGER ARISING UNDER THE U.S.&nbsp;FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY
APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Definition of </I></B>&#147;<B><I>U.S. Holder</I></B>&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;U.S. holder&#148; is a beneficial owner of Tempest capital stock that is, for U.S.&nbsp;federal income
tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any other entity taxable as a corporation created or organized in or under the laws of the
United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if either (i)&nbsp;a court within the United States is able to exercise primary supervision over the
administration of such trust, and one or more United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) are authorized or has the authority to control all substantial decisions of such trust, or (ii)&nbsp;the trust was in
existence on August&nbsp;20, 1996 and has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S.&nbsp;federal income tax purposes; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S.&nbsp;federal income tax regardless of its source.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Characterization of the Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo and Tempest intend for the merger to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code.
However, no opinion of counsel has been obtained or will be obtained regarding the treatment of the merger as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger does not qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code (including if the IRS
successfully challenges the qualification of the merger as such), then each U.S.&nbsp;holder would recognize gain or loss on the exchange of Tempest capital stock for Millendo common stock in the merger equal to the difference between such Tempest
stockholder&#146;s adjusted tax basis in the shares of Tempest capital stock surrendered and the fair market value of the shares of Millendo common stock received in exchange therefor and any cash received in lieu of a fractional share. The
remainder of this discussion assumes that the merger will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Treatment of Tempest Stockholders in the Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, except as described below with
respect to the receipt of cash in lieu of a fractional share of Millendo common stock, U.S.&nbsp;holders generally will not recognize gain or loss upon the exchange of their Tempest capital stock for Millendo common stock. A U.S.&nbsp;holder
generally will obtain an aggregate tax basis in the Millendo common stock such holder receives in the merger equal to the holder&#146;s aggregate adjusted tax basis in the Tempest capital stock exchanged therefor reduced by the basis allocable to
any fractional share of Millendo common stock for which cash is received. The holding period of the shares of Millendo common stock received by a U.S. holder in the merger will include the holding period of the shares of Tempest capital stock
surrendered in exchange therefor. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Tempest capital stock surrendered to the shares of Millendo common stock received. U.S. holders of shares
of Tempest capital stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. <B>Holders of Tempest capital stock are urged to consult
their tax advisors regarding the U.S.</B><B></B><B>&nbsp;federal income tax consequences of the merger in light of their personal circumstances and the consequences to them under state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax
laws and other federal tax laws.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash in Lieu of Fractional Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder that receives cash in lieu of a fractional share of Millendo common stock will generally be treated as having received such
fractional share and then as having received such cash in redemption of the fractional share. Gain or loss will generally be recognized based on the difference between the amount of cash received in lieu of the fractional share of Millendo common
stock and the portion of the U.S. holder&#146;s aggregate adjusted tax basis in the shares of Tempest capital stock exchanged therefor which is allocable to the fractional share. Such gain or loss will generally be capital gain or loss and will
generally be long-term capital gain or loss if the U.S. holder&#146;s holding period for its Tempest capital stock surrendered in the merger exceeds one year at the effective time. Long-term capital gains of certain
<FONT STYLE="white-space:nowrap">non-corporate</FONT> holders of Tempest capital stock, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reporting Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
merger is a reorganization within the meaning of Section&nbsp;368(a) of the Code, each U.S.&nbsp;holder who receives shares of Millendo common stock in the merger is required to retain permanent records pertaining to the merger, and make such
records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of the Tempest capital stock exchanged and the amount of Millendo common stock
and cash received in exchange therefor. U.S.&nbsp;holders who owned immediately before the merger at least one percent (by vote or value) of the total outstanding stock of Tempest are required to attach a statement to their tax returns for the year
in which the merger is consummated that contains the information listed in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-3(b).</FONT> Such statement must include the U.S. holder&#146;s tax basis in such holder&#146;s
Tempest capital stock surrendered in the merger, the fair market value of such stock, the date of the merger and the name and employer identification number of each of Tempest and Millendo. U.S.&nbsp;holders are urged to consult with their tax
advisors to comply with these rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and Information Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. holder may, under certain circumstances, be subject to information reporting and backup withholding (currently, at a rate of 24%) on any
payments of cash in lieu of fractional shares, unless such holder properly establishes an exemption or provides its correct tax identification number and otherwise complies with the applicable equirements of the backup withholding rules. Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or credited against a payee&#146;s U.S. federal income tax liability, if any, so long as such payee furnishes the required information to
the IRS in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The foregoing summary is of a general nature only and is not intended to be, and should
not be construed to be, legal, business or tax advice to any particular Tempest stockholder. This summary does not take into account your particular circumstances and does not address consequences that may be particular to you. Therefore, you should
consult your tax advisor regarding the particular consequences of the merger to you. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_50"></A>Anticipated Accounting Treatment
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Tempest
will be deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the merger: (i)&nbsp;Tempest stockholders will own substantial majority of the
voting rights; (ii)&nbsp;Tempest will designate a majority (six of seven) of the initial members of the board of directors of the combined organization; and (iii)&nbsp;Tempest&#146;s executive management team will become the management of the
combined company; and (iv)&nbsp;the combined company will be named Tempest Therapeutics, Inc. and be headquartered in South San Francisco, California. Accordingly, for accounting purposes, the Merger will be treated as the equivalent of Tempest
issuing stock to acquire the net assets of Millendo. As a result of the merger, the net assets of Millendo will be recorded at their acquisition-date fair value in the financial statements of Tempest and the reported operating results prior to the
merger will be those of Tempest. See the &#147;<I>Unaudited Pro</I><I></I><I>&nbsp;Forma Condensed Combined Financial Information</I>&#148; elsewhere in this proxy statement/prospectus for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_51"></A>Nasdaq Stock Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Millendo common stock are currently listed on The Nasdaq Capital Market under the symbol &#147;MLND.&#148; Millendo has agreed to use
commercially reasonable efforts to cause the shares of Millendo common stock being issued in the merger to be approved for listing (subject to notice of issuance) on The Nasdaq Capital Market at or prior to the effective time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Merger Agreement, each of Millendo&#146;s and Tempest&#146;s obligation to complete the merger is subject to the
satisfaction or waiver by each of the parties, at or prior to the merger, of various conditions, including that the shares of Millendo common stock to be issued in the merger have been approved for listing (subject to official notice of issuance) on
Nasdaq as of the closing of the merger. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Nasdaq listing application is accepted, Millendo anticipates that the common stock of
the combined company will be listed on The Nasdaq Capital Market following the closing of the merger under the trading symbol &#147;TPST.&#148; In order for the Nasdaq listing application to be accepted, among other requirements, the combined
company must maintain a bid price of $4 or higher for a certain period of time following the proposed reverse stock split. As of May&nbsp;7, 2021, the bid price of Millendo&#146;s common stock was $1.09. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_52"></A>Appraisal Rights and Dissenters&#146; Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, Millendo stockholders are not entitled to appraisal rights in connection with the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest stockholders who do not deliver a written consent approving the merger are entitled to appraisal rights in connection with the merger
under Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below is not a complete summary regarding Tempest stockholders&#146; appraisal rights
under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <I>Annex&nbsp;G</I> to this proxy statement/prospectus. Stockholders intending to exercise appraisal
rights should carefully review <I>Annex</I><I></I><I>&nbsp;G</I> to this proxy statement/prospectus<I>. </I>Failure to follow precisely any of the statutory procedures set forth in <I>Annex</I><I></I><I>&nbsp;G</I> may result in a termination or
waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Tempest stockholders exercise their appraisal rights under Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;262, where a merger is adopted by stockholders by written consent in lieu
of a meeting of stockholders pursuant to Section&nbsp;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten days after the effective date of such merger, must notify
each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, within ten days after the effective date of the merger, Tempest will notify its stockholders that the merger has
been approved, the effective date of the merger and that appraisal rights are available to any stockholder who has not delivered a written consent approving the merger. Holders of shares of Tempest capital stock who desire to exercise their
appraisal rights must deliver a written demand for appraisal to Tempest within 20&nbsp;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the merger. A demand for appraisal must
reasonably inform Tempest of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Tempest capital stock held by such stockholder. Failure to deliver a written consent approving the merger
will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&nbsp;262. All demands for appraisal should be addressed to Tempest Therapeutics, Inc., c/o Sidley Austin LLP, 1001 Page Mill Road, Building 1,
Palo Alto, California 94304, Attn: Rob R. Carlson, and should be executed by, or on behalf of, the record holder of shares of Tempest capital stock. ALL DEMANDS MUST BE RECEIVED BY TEMPEST WITHIN 20 DAYS AFTER THE DATE TEMPEST MAILS A NOTICE TO ITS
STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of Tempest capital stock fails to deliver a written demand for appraisal within the time period specified above, such holder will
be entitled to receive the merger consideration for your shares of Tempest capital stock as provided for in the Merger Agreement, but will have no appraisal rights with respect to such holder&#146;s shares of Tempest capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be effective, a demand for appraisal by a holder of shares of Tempest capital stock must be made by, or in the name of, the registered
stockholder, fully and correctly, as the stockholder&#146;s name appears on the stockholder&#146;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Tempest. The beneficial
owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or
custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint
owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact
that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#146;s right of appraisal with respect to the shares held
for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the
demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of shares of Tempest capital stock holds such shares in a brokerage account or in other custodian form and such holder wishes to
exercise appraisal rights, such holder should consult with such holder&#146;s bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time within 60&nbsp;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an
appraisal proceeding or joined an appraisal proceeding as a named party, has the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withdraw such stockholder&#146;s demand and accept the terms of the merger by delivering a written withdrawal to Tempest. If, following a demand for appraisal, a holder of Tempest capital stock
has withdrawn such holder&#146;s demand for appraisal in accordance with Section&nbsp;262, such holder will have the right to receive the merger consideration for such holder&#146;s shares of Tempest capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120&nbsp;days after the effective date of the merger, any stockholder who has delivered a demand for appraisal in accordance with
Section&nbsp;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for
appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within ten days after the stockholder&#146;s written request is received by the surviving
corporation or within ten days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&nbsp;days after the effective date of the merger, either the surviving corporation or any stockholder who has
delivered a demand for appraisal in accordance with Section&nbsp;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a
stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Tempest,
which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the
stockholder&#146;s previously written demand for appraisal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a petition for appraisal is duly filed by a stockholder and a copy of the
petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&nbsp;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list
containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting
stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&nbsp;262 and who have become entitled to the
appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the
appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#147;fair
value&#148; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the merger, but may include a fair rate of interest, if any, upon the amount determined to
be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the
stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to
appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of
Chancery and (ii)&nbsp;interest theretofore accrued, unless paid at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining fair value, and, if applicable, a fair rate
of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP, Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal
proceeding, stating that &#147;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#148; should be considered, and that &#147;fair price obviously
requires consideration of all relevant factors involving the value of a company.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;262 provides that fair value is to be &#147;exclusive of any element of value
arising from the accomplishment or expectation of the merger.&#148; In Cede&nbsp;&amp; Co. v. Technicolor, Inc., the Delaware Supreme Court stated that this exclusion is a &#147;narrow exclusion [that] does not encompass known elements of
value,&#148; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&nbsp;262 to mean that &#147;elements of future value,
including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest stockholders should be aware that the fair value of such holder&#146;s shares as determined under Section&nbsp;262 could be more than,
the same as, or less than the value that such holder is entitled to receive under the terms of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of the
appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a
stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#146; fees and the fees and expenses
of experts, to be charged pro&nbsp;rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after
the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the
effective time; however, if no petition for appraisal is filed within 120&nbsp;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the merger within
60&nbsp;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Tempest capital stock pursuant to the Merger
Agreement. Any withdrawal of a demand for appraisal made more than 60&nbsp;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be
dismissed as to any stockholder without the approval of the court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to follow the steps required by Section&nbsp;262 for
perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&nbsp;262, stockholders who may wish to dissent from the merger and pursue appraisal rights should consult their legal advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_53"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement, is attached to this proxy
statement/prospectus as Annex&nbsp;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not
intended to provide any other factual information about Millendo, Tempest or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full
text of the Merger Agreement for details of the merger and the terms and conditions of the Merger Agreement. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Merger Agreement
contains representations and warranties that Millendo and Merger Sub, on the one hand, and Tempest, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other
parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and
warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Millendo and Tempest do not believe that these disclosure schedules contain information
required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations
and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Millendo or Tempest, because they were made as of specific
dates, may be intended merely as a risk allocation mechanism between Millendo, Merger Sub and Tempest and are modified by the disclosure schedules. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_54"></A>Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the completion of the merger, Merger Sub,
a wholly owned subsidiary of Millendo formed by Millendo in connection with the merger, will merge with and into Tempest, with Tempest surviving as a wholly owned subsidiary of Millendo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_55"></A>Completion and Effectiveness of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The merger will be completed as promptly as practicable after all of the conditions to completion of the merger are satisfied or waived,
including the approval by the stockholders of Millendo and Tempest. Millendo and Tempest are working to complete the merger as quickly as practicable and expect that the merger will be completed soon after the Millendo special meeting of
stockholders scheduled to be held on June&nbsp;22, 2021. However, Millendo and Tempest cannot predict the completion of the merger or the exact timing of the completion of the merger because it is subject to various conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_56"></A>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the merger, upon the terms and subject to the conditions set forth in the Merger Agreement, each outstanding share of
Tempest common stock (including shares of Tempest common stock issued upon conversion of Tempest preferred stock and including shares of Tempest common stock sold in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, but
excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of Millendo common stock equal to the exchange ratio described in
more detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of Millendo common stock will be issued in connection with the merger, and no certificates or
scrip for any such fractional shares will be issued and such fractional share interests shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitle the owner thereof to vote or to any other rights of a stockholder of Millendo. Any fractional shares of Millendo common stock resulting from the conversion of Tempest capital stock into
the right to receive a number of shares of Millendo common stock equal to the exchange ratio or from the settlement of Tempest options pursuant to the Merger Agreement (after aggregating all fractional shares of Millendo common stock issuable to
such holder) will be rounded down to the nearest whole share of Millendo common stock, with cash being paid in lieu of such fractional shares of Millendo common stock eliminated by such rounding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_57"></A>Exchange Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange ratio is calculated using a formula intended to allocate existing Millendo and Tempest securityholders a percentage of the
combined company. Based on Millendo&#146;s and Tempest&#146;s capitalization as of March 31, 2021, the exchange ratio is estimated to be equal to approximately 0.4883 shares of Millendo common stock. This estimate is subject to adjustment prior to
closing of the merger for net cash at the cash determination time and the aggregate amount of Tempest capital stock sold in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing (and as a result, Millendo securityholders could
own more, and Tempest securityholders could own less, or vice versa, of the combined company). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the estimates set forth
above, without giving effect to the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, and certain other assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and
June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, Millendo securityholders would own approximately
18.5% of the common stock of the combined company and Tempest securityholders, including shares purchased in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, would own approximately 81.5% of the common stock of the combined
company. For more information on the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, please see the section titled &#147;<I>Agreements Related to the Merger&#151;Funding Agreements</I>&#148; <I>beginning on
page</I><I></I><I>&nbsp;</I><I></I><I>163 in this proxy statement/prospectus.</I> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange ratio formula is the quotient
obtained (rounded down to four decimal places) by dividing the number of Tempest merger shares (defined below) by the Tempest outstanding shares (defined below), in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Millendo allocation percentage&#148; means the quotient (rounded down to four decimal places) determined by
dividing (i)&nbsp;the Millendo valuation by (ii)&nbsp;the aggregate valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Millendo outstanding shares&#148; means, subject to certain adjustments pursuant to the terms of the Merger
Agreement, the sum of (i)&nbsp;the total number of shares of Millendo common stock outstanding immediately prior to the effective time of the mergerand (ii)&nbsp;the total number of shares of Millendo common stock that are issuable upon exercise of
options with a per share exercise price that is less than or equal to $5.00 (as adjusted for the reverse stock split) that are outstanding immediately prior to the effective time of the merger. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Millendo valuation&#148; means $36&nbsp;million, except that (i)&nbsp;if Millendo&#146;s final net cash is
greater than $18.7&nbsp;million, the Millendo valuation will be increased by such excess, and (ii)&nbsp;if Millendo&#146;s final net cash is less than $15.3&nbsp;million, the Millendo valuation will be decreased by such shortfall.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;aggregate valuation&#148; means the sum of the (i)&nbsp;Tempest valuation plus (ii)&nbsp;the Millendo
valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Tempest allocation percentage&#148; means the quotient (rounded down to four decimal places) determined by
dividing (i)&nbsp;the Tempest valuation by (ii)&nbsp;the aggregate valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Tempest merger shares&#148; means the product determined by multiplying (i)&nbsp;the post-closing Millendo
shares by (ii)&nbsp;the Tempest allocation percentage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Tempest outstanding shares&#148; means the total number of shares of Tempest common stock outstanding
immediately prior to the effective time of the merger (after giving effect to the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing and the conversion of Tempest preferred stock into Tempest common stock) expressed on a
fully-diluted and <FONT STYLE="white-space:nowrap">as-converted</FONT> to Tempest common stock basis and assuming, without duplication, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(i)&nbsp;the exercise of all Tempest options and warrants outstanding as of immediately prior to the effective time of the merger and (ii)&nbsp;the issuance of shares of Tempest common stock in
respect of all other options, warrants or rights to receive such shares that will be outstanding immediately after the effective time of the merger, but excluding any shares of Tempest common stock reserved for issuance other than with respect to
outstanding Tempest options under the Tempest equity incentive plans as of immediately prior to the effective time of the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Tempest valuation&#148; means $153.4&nbsp;million, except that the Tempest valuation will be increased by
the amount of proceeds received from the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing in excess of $25&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Post-closing Millendo shares&#148; mean the quotient (rounded down to the nearest whole share) determined
by dividing (i)&nbsp;the Millendo outstanding shares by (ii)&nbsp;the Millendo allocation percentage. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_58"></A>Calculation of Millendo&#146;s Final Net Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, Millendo&#146;s &#147;final net cash&#148; means, as of the cash determination time (which is as
of the close of business on the last business day prior to the anticipated closing date, unless the closing date has not occurred on or prior to July&nbsp;1, 2021, in which case the cash determination time means the close of business on
June&nbsp;30, 2021) the sum (without duplication) of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s cash, cash equivalents, restricted cash and marketable securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s accounts receivable, interest and other receivables (including amounts payable to Millendo under
insurance policies); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s deposits and prepaid expenses; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I><U>minus</U></I><I> </I>the sum (without duplication) of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s accrued and unpaid accounts payable and accrued and unpaid expenses (other than transaction
expenses and rent); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s unpaid transaction expenses (including the cash cost of any change of control, bonus, severance
(voluntary or otherwise) (including a reasonable estimate of payment or reimbursement for continued coverage under any employee benefit plan), retention or similar payments (whether &#147;single trigger&#148; or &#147;double trigger&#148;) that
become due and payable at or prior to the effective time of the merger or as a result of the merger or the transactions contemplated by the Merger Agreement, and subject limited exceptions, all costs, fees and expenses incurred by Millendo at or
prior to the effective time of the merger in connection with the negotiation, preparation and execution of the Merger Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s unpaid indebtedness for borrowed money, liabilities evidenced by bonds, debentures, notes or
similar instruments, liabilities upon which interest charges are customarily paid (other than obligations accepted in connection with the purchase of products or services), liabilities in respect of liabilities of others that are secured by any lien
or security interest on Millendo&#146;s property, liabilities under capital leases, liabilities for any &#147;applicable employment taxes&#148; (as defined in Section&nbsp;2302(d)(1) of the CARES Act) elected to be deferred pursuant to
Section&nbsp;2302 of the CARES Act, and guarantees relating to any of the foregoing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s unpaid rent to the extent owed by Millendo under its real estate lease, net of any right to
receive rent from a third party under any sublease or similar arrangement, for the period prior to March&nbsp;31, 2022 in an amount not to exceed $576,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not more than seven nor less than five calendar days prior to the anticipated closing date, Millendo will deliver to Tempest a net cash
schedule setting forth, in reasonable detail, Millendo&#146;s good faith estimated calculation of its net cash at the cash determination time, prepared and certified by Millendo&#146;s Chief Financial Officer (or if there is no Chief Financial
Officer, the Chief Executive Officer) together with the relevant work </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
papers and <FONT STYLE="white-space:nowrap">back-up</FONT> materials used or useful in preparing the net cash schedule. Within three calendar days after delivery of such net cash schedule (the
last day of such period referred to as the response date), Tempest will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to Millendo (referred to herein as a dispute notice). Any dispute
notice will identify in reasonable detail each item in dispute and Tempest&#146;s proposed revisions to Millendo&#146;s net cash schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest disputes the net cash schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon
determination of net cash. If the parties are unable to negotiate an agreed-upon determination of net cash or any component thereof within three calendar days after the delivery of Tempest&#146;s notice, any remaining disagreements will be referred
to an independent auditor of recognized national standing jointly selected by Millendo and Tempest which is not serving as auditor of either Millendo or Tempest. The determination of the amount of net cash made by such accounting firm shall be final
and binding on Millendo and Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s net cash balance is subject to numerous factors, some of which are outside of
Millendo&#146;s control. The actual amount of net cash will depend significantly on the timing of the closing of the merger. In addition, the closing of the merger could be delayed if Millendo and Tempest are not able to agree upon the amount of
Millendo&#146;s net cash as of the cash determination time. In the event the closing of the merger is delayed past July&nbsp;1, 2021, the cash determination time for calculation of Millendo&#146;s net cash will be June&nbsp;30, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_59"></A>Treatment of Tempest Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each option to purchase shares of Tempest common stock that is outstanding and unexercised immediately
prior to the effective time of the merger, whether or not vested, will be converted into a number of options to purchase shares of Millendo common stock as determined by the exchange ratio, on the same terms and conditions as were applicable under
such Tempest option immediately prior to the effective time of the merger. Millendo will assume Tempest&#146;s stock option plans and other stock or equity-related plans and each such outstanding option to purchase shares of Tempest common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the effective time of the merger: (i)&nbsp;each outstanding Tempest stock option assumed by Millendo may be
exercised solely for shares of Millendo common stock; (ii)&nbsp;the number of shares of Millendo common stock subject to each outstanding Tempest stock option assumed by Millendo will be determined by multiplying (A)&nbsp;the number of shares of
Tempest common stock that were subject to such Tempest stock option, as in effect immediately prior to the effective time of the merger, by (B)&nbsp;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of
Millendo common stock; (iii)&nbsp;the per share exercise price of Millendo common stock issuable upon exercise of each Tempest stock option assumed by Millendo will be determined by dividing (A)&nbsp;the per share exercise price of Tempest common
stock subject to such Tempest stock option, as in effect immediately prior to the effective time of the merger, by (B)&nbsp;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv)&nbsp;any restriction on
the exercise, and any provision providing for the acceleration of vesting and/or exercisability, of any Tempest stock option assumed by Millendo will continue in full force and effect and the term, exercisability, vesting schedule, acceleration
rights and other provisions of such Tempest stock option will otherwise remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, to the extent provided under the terms
of a Tempest stock option assumed by Millendo in accordance with the terms of the Merger Agreement, such Tempest stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division
or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Millendo common stock subsequent to the effective time of the merger.
In addition, the Millendo board of directors or a committee thereof will succeed to the authority and responsibility of the Tempest board of directors or any committee thereof with respect to each Tempest option assumed by Millendo in accordance
with the terms of the Merger Agreement. Furthermore, in the case of each Tempest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option assumed by Millendo in accordance with the Merger Agreement that is subject to &#147;double-trigger&#148; accelerated vesting, for purposes of such double-trigger acceleration provisions a
&#147;Change of Control&#148; (or term of similar import) of Tempest will refer to a &#147;Change of Control&#148; (or term of similar import) of Millendo following the effective time of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_60"></A>Treatment of Millendo Common Stock and Millendo Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Millendo common stock issued and outstanding at the time of the merger will remain issued and outstanding. In addition, each
option to purchase shares of Millendo common stock that is outstanding immediately prior to the effective time of the merger, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms, except that the
Merger Agreement permits the board of directors of Millendo to accelerate such Millendo options in full, immediately prior to the effective time of the merger. The number of shares of Millendo common stock underlying such options and the exercise
prices for such stock options will be appropriately adjusted to reflect the proposed reverse stock split. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo and Tempest have
agreed that the merger constitutes or will be deemed to constitute a &#147;change of control&#148; or &#147;change in control&#148; for purposes of the Millendo stock plans and any awards issued thereunder and for purposes of any employee benefit
plan maintained for current or former employees or directors of or independent contractors to Millendo. Immediately after the merger, Millendo securityholders as of immediately prior to the merger are expected to own approximately 18.5% of the
outstanding shares of Millendo common stock on a fully-diluted basis, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the earlier of the closing and June&nbsp;30, 2021 being between
$15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. For more information on the impact of the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, please see the section titled &#147;<I>Agreements</I> <I>Related to the Merger&#151;Funding Agreements</I>&#148; beginning on page&nbsp;163 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_61"></A>Procedures for Exchanging Tempest Stock Certificates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the effective time of the merger, Millendo will deposit with Computershare Trust Company, N.A. or another bank or
trust company designated by Millendo and reasonably acceptable to Tempest, as the exchange agent, (i)&nbsp;certificates representing the shares of Millendo common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of
Tempest common stock, (ii)&nbsp;cash payable in lieu of fractional shares of Millendo common stock otherwise issuable pursuant to the terms of the Merger Agreement, and (iii)&nbsp;any dividends or distributions to which <FONT
STYLE="white-space:nowrap">pre-closing</FONT> holders of Tempest common stock may be entitled to under the terms of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as reasonably practicable after the effective time of the merger, the exchange agent will mail to each record holder of Tempest common
stock (i)&nbsp;a letter of transmittal and (ii)&nbsp;instructions for surrendering the record holder&#146;s stock certificates in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in
accordance with the exchange agent&#146;s instructions, the surrender of the record holder&#146;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or
Millendo, the record holder of such Tempest common stock will be entitled to receive in exchange therefor a stock certificate or book-entry shares representing the number of whole shares of Millendo common stock issuable to such holder pursuant to
the merger. The surrendered certificates representing shares of Tempest common stock or Tempest preferred stock will be canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After
the effective time of the merger, each certificate representing Tempest common stock or Tempest preferred stock that has not been surrendered will represent only the right to receive shares of Millendo common stock issuable pursuant to the merger to
which the holder of any such certificate is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>HOLDERS OF TEMPEST COMMON STOCK OR TEMPEST PREFERRED STOCK SHOULD NOT SEND IN
THEIR TEMPEST STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF TEMPEST STOCK CERTIFICATES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_62"></A>Directors and Officers of Millendo Following the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, each of the directors and officers of Millendo who will not continue as directors or officers of Millendo
following the consummation of the merger will resign effective as of the closing of the merger. Effective as of the effective time of the merger, the combined company board of directors will consist of a total of seven directors, one of whom will be
designated by Millendo (who qualifies as an &#147;independent director&#148; under Nasdaq listing standards and the applicable rules of the SEC as of the effective time of the merger) and six of whom will be designated by Tempest (at least three
(3)&nbsp;out of six (6)&nbsp;of whom qualify as an &#147;independent director&#148; under Nasdaq listing standards and the applicable rules of the SEC as of the effective time of the merger). Millendo has designated Geoff Nichol to serve as a member
of the Millendo board of directors and Tempest has designated Stephen Brady, Mike Raab, Thomas Dubensky, Tom Woiwode, Stella Xu and to serve as members of the Millendo board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the closing of the merger, Stephen Brady, will serve as Chief Executive Officer, Thomas Dubensky will serve as President,
and Samuel Whiting will serve as Chief Medical Officer of the combined company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_63"></A>Amendment of the Amended and Restated
Certificate of Incorporation of Millendo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo agreed to amend its amended and restated certificate of incorporation to effect the
proposed reverse stock split at a ratio of between 1 to 10 and 1 to 15 (inclusive) as determined by a committee of the board of directors of Millendo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_64"></A>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Millendo and Tempest for a transaction of this type relating to,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate organization, standing and power, and similar corporate matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to enter into the Merger Agreement and the related agreements and the absence of certain conflicts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial statements and, with respect to Millendo, documents filed with the SEC and the accuracy of information
contained in those documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material changes or events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real property and leaseholds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">environmental matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee benefit plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permits and regulatory matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Millendo, matters related to the opinion of Millendo&#146;s financial advisor;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Millendo, matters related Section&nbsp;203 of the DGCL; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Millendo, the operations of merger sub; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, fees and expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain transactions or relationships with affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal controls and procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">books and records; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Tempest, ownership of Millendo stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governmental subsidies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Tempest, the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Millendo, the valid issuance in the merger of Millendo common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the merger, but their
accuracy forms the basis of one of the conditions to the obligations of Millendo and Tempest to complete the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_65"></A>Covenants; Conduct of Business Pending the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has agreed that, except as permitted by the Merger Agreement or unless Tempest has provided written consent, during the period
commencing on the date of the Merger Agreement and continuing until the earlier to occur of the effective time and the termination of the Merger Agreement, Millendo and its subsidiaries will use commercially reasonable efforts to conduct their
business and operations in the ordinary course of business consistent in all material respects with past practice taking into account any acts or omissions that have been taken to comply with any quarantine, &#147;shelter in place&#148;, &#147;stay
at home&#148;, workforce reduction, social distancing, shutdown, closure, sequester or any other law, order, guideline or recommendation by any governmental authority in connection with or in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or in the Ordinary Course of Business, and in compliance with all applicable laws, regulations and certain contracts, and to maintain and preserve its and each of its subsidiaries&#146;
business organization, assets and properties, keep available the services of its present officers and certain key employees, and preserve its advantageous business relationships with customers, strategic partners, suppliers, distributors and others
to the extent consistent with Millendo&#146;s corporate restructuring plan. Millendo has also agreed that, subject to certain limited exceptions, without the consent of Tempest, it will not, and will not cause or permit any of its subsidiaries to,
during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the effective time and the termination of the Merger Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) subject to certain exceptions, declare, set aside or pay any dividends on, or make any other distributions in
respect of, any of its capital stock; (ii)&nbsp;except as contemplated by the reverse stock split, split, combine or reclassify any of its capital stock or issue or authorize the issuance of any other
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities; or (iii)&nbsp;subject to certain exceptions, purchase, redeem or otherwise
acquire any shares of its capital stock or any other of its securities or any rights, warrants or options to acquire any such shares or other securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any shares
of its capital stock, any other voting securities or any securities convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting securities or convertible or exchangeable securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as contemplated by the reverse stock split, amend its certificate of incorporation, bylaws or other
comparable charter or organizational documents or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split or reverse stock split or form any new subsidiary or
acquire any equity interest or other interest in any other person ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, acquire (i)&nbsp;by merging or consolidating with, or by purchasing all or a
substantial portion of the assets or any stock of, or by any other manner, any business or any corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof or (ii)&nbsp;any assets
that are material, in the aggregate, to Millendo and its subsidiaries, taken as a whole ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in the Ordinary Course of Business, sell, lease, license, pledge, or otherwise dispose of or encumber any
properties or assets of Millendo or any of its subisidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, sell, dispose of or otherwise transfer any assets material to Millendo and its
subsidiaries, taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) incur or suffer to exist any indebtedness for borrowed money or guarantee any such indebtedness of another
person, (ii)&nbsp;issue, sell or amend any debt securities or warrants or other rights to acquire any debt securities of Millendo or any of its subsidiaries, guarantee any debt securities of another person, enter into any &#147;keep well&#148; or
other agreement to maintain any financial statement condition of another person or enter into any arrangement having the economic effect of any of the foregoing, (iii)&nbsp;make any loans, advances (other than routine advances to employees of
Millendo in the Ordinary Course of Business) or capital contributions to, or investment in, any other person, other than Millendo or any of its direct or indirect wholly owned subsidiaries or (iv)&nbsp;enter into any hedging agreement or other
financial agreement or arrangement designed to protect Millendo or its subsidiaries against fluctuations in commodities prices or exchange rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, make any capital expenditures or other expenditures with respect to property,
plant or equipment for Millendo and its subsidiaries, taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any changes in accounting methods, principles or practices, except insofar as may have been required by the
SEC or a change in GAAP or, except as so required, change any assumption underlying, or method of calculating, any bad debt, contingency or other reserve; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, (i)&nbsp;modify or amend in any material respect, or terminate, any material
contract or agreement to which Millendo or any of its subsidiaries is party, or (ii)&nbsp;knowingly waive, release or assign any material rights or claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) enter into any material contract or agreement relating to the rendering of services or the distribution, sale
or marketing by third parties of the products, of, or products licensed by, Millendo or any of its subsidiaries or (ii)&nbsp;license any material intellectual property rights to or from any third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, (i)&nbsp;take any action with respect to, adopt, enter into, terminate or amend
any employment, severance or similar agreement or benefit plan for the benefit or welfare of any current or former director, officer, employee or consultant or any collective bargaining agreement,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(ii)&nbsp;increase in any material respect the compensation or fringe benefits of, or pay any material bonus to, any director, officer, employee or consultant, (iii)&nbsp;amend or accelerate the
payment, right to payment or vesting of any compensation or benefits, including any outstanding options or restricted stock awards, (iv)&nbsp;pay any material benefit not provided for as of the date of the Merger Agreement under any benefit plan,
(v)&nbsp;grant any awards under any bonus, incentive, performance or other compensation plan or arrangement or benefit plan, (vi)&nbsp;hire any additional officers or other employees, or any consultants or independent contractors, or (vii)&nbsp;take
any action to fund or in any other way secure the payment of compensation or benefits under any employee plan, agreement, contract or arrangement or benefit plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or change any material tax election, change an annual accounting period, enter into any closing agreement,
waive or extend any statute of limitations with respect to taxes, settle or compromise any material tax liability, claim or assessment, surrender any right to claim a refund of material taxes, or amend any income or other material tax return;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commence any offering of shares of Millendo common stock pursuant to any employee stock purchase plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate, compromise or settle any litigation or arbitration proceeding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">open or close any facility or office; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to use commercially reasonable efforts to maintain insurance at levels substantially comparable to levels
existing as of the date of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to pay accounts payable and other obligations in the Ordinary Course of Business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend or otherwise fail to take all actions within its reasonable control to perform in any material respect
Millendo&#146;s corporate restructuring plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or any
action that would make any representation or warranty of Millendo in the Agreement untrue or incorrect in any material respect, or would materially impair, delay or prevent the satisfaction of any conditions to obligations of the parties to effect
the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has agreed that, except as permitted by the Merger Agreement, as required by law, or unless
Millendo shall have provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the effective time and the termination of the Merger Agreement, Tempest will use commercially
reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in compliance with all applicable laws, regulations and certain contracts, and to maintain and preserve its and each of its subsidiaries&#146; business
organization, assets and properties, keep available the services of its present officers and certain key employees, and preserve its advantageous business relationships with customers, strategic partners, suppliers, distributors and others. Tempest
has also agreed that, subject to certain limited exceptions, without the consent of Millendo, it will not, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the effective time and the
termination of the Merger Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) declare, set aside or pay any dividends on, or make any other distributions in respect of, any of its capital
stock; (ii)&nbsp;split, combine or reclassify any of its capital stock or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities; or
(iii)&nbsp;subject to certain exceptions, purchase, redeem or otherwise acquire any shares of its capital stock or any other of its securities or any rights, warrants or options to acquire any such shares or other securities ; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any shares
of its capital stock, any other voting securities or any securities convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting securities or convertible or exchangeable securities;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend its certificate of incorporation, bylaws or other comparable charter or organizational documents or effect
or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split or reverse stock split or form any new subsidiary or acquire any equity interest or other interest in any
other person ; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, acquire (i)&nbsp;by merging or consolidating with, or by purchasing all or a
substantial portion of the assets or any stock of, or by any other manner, any business or any corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof or (ii)&nbsp;any assets
that are material, in the aggregate, to Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in the Ordinary Course of Business, sell, lease, license, pledge, or otherwise dispose of or encumber any
properties or assets of Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, sell, dispose of or otherwise transfer any assets material to Tempest;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) subject to certain exceptions, incur or suffer to exist any indebtedness for borrowed money or guarantee any
such indebtedness of another person, (ii)&nbsp;issue, sell or amend any debt securities or warrants or other rights to acquire any debt securities of Tempest, guarantee any debt securities of another person, enter into any &#147;keep well&#148; or
other agreement to maintain any financial statement condition of another person or enter into any arrangement having the economic effect of any of the foregoing, (iii)&nbsp;make any loans, advances (other than routine advances to employees of
Tempest in the Ordinary Course of Business) or capital contributions to, or investment in, any other person, other than Tempest or (iv)&nbsp;enter into any hedging agreement or other financial agreement or arrangement designed to protect Tempest
against fluctuations in commodities prices or exchange rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, make any capital expenditures or other expenditures with respect to property,
plant or equipment for Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any changes in accounting methods, principles or practices, except insofar as may have been required change
in GAAP or, except as so required, change any assumption underlying, or method of calculating, any bad debt, contingency or other reserve; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, (i)&nbsp;modify or amend in any material respect, or terminate, any material
contract or agreement to which Tempest is party, or (ii)&nbsp;knowingly waive, release or assign any material rights or claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except in the Ordinary Course of Business, (i)&nbsp;enter into any material contract or agreement relating to the
rendering of services or the distribution, sale or marketing by third parties of the products, of, or products licensed by, Tempest or (ii)&nbsp;license any material intellectual property rights to or from any third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required to comply with applicable law and subject to certain exceptions, (i)&nbsp;other than in the
Ordinary Course of Business, adopt, enter into, terminate or amend any employment, severance or similar agreement or benefit plan for the benefit or welfare of any current or former director, officer, employee or consultant or any collective
bargaining agreement, (ii)&nbsp;increase in any material respect the compensation or fringe benefits of, or pay any material bonus to, any director, officer, employee or consultant, (iii)&nbsp;amend or accelerate the payment, right to payment or
vesting of any compensation or benefits, including any outstanding options or restricted stock awards, (iv)&nbsp;pay any material benefit not provided for as of the date of the Merger Agreement under any benefit plan, (v)&nbsp;grant any awards under
any bonus, incentive, performance or other compensation plan or arrangement or benefit plan, or (vi)&nbsp;take any action other than in the Ordinary Course of Business to fund or in any other way secure the payment of compensation or benefits under
any employee plan, agreement, contract or arrangement or benefit plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or change any material tax election, change an annual accounting period, enter into any closing agreement,
waive or extend any statute of limitations with respect to taxes, settle or compromise any material tax liability, claim or assessment, surrender any right to claim a refund of material taxes, or amend any income or other material tax return;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commence any offering of shares of Tempest common stock pursuant to any employee stock purchase plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate, compromise or settle any litigation or arbitration proceeding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">open or close any facility or office; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to use commercially reasonable efforts to maintain insurance at levels substantially comparable to levels
existing as of the date of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to pay accounts payable and other obligations in the Ordinary Course of Business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Tempest, suspend any clinical trials sponsored by Tempest or involving any products marketed or
in development by Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Millendo, amend or otherwise fail to take all actions within its reasonable control to perform in
any material respect the corporate restructuring plan; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or any
action that would make any representation or warranty of Tempest in the Agreement untrue or incorrect in any material respect, or would materially impair, delay or prevent the satisfaction of any conditions to obligations of the parties to effect
the Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_66"></A><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Millendo and Tempest have agreed that, except as described below, Millendo and Tempest and any of their respective subsidiaries will
not, and each party and its subsidiaries will use reasonable best efforts to cause their respective directors, officers, members, employees, agents, attorneys, consultants, contractors, accountants, financial advisors or other representatives
retained by it or any of its subsidiaries to not, directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, seek or initiate or knowingly take any action to facilitate or encourage any offers, inquiries or the
making of any proposal or offer that constitutes, or could reasonably be expected to lead to,any Acquisition Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, continue or otherwise participate or engage in any discussions or negotiations regarding any
Acquisition Proposal, or furnish to any person any <FONT STYLE="white-space:nowrap">non-public</FONT> information or afford any person other than Millendo or Tempest, as applicable, access to such party&#146;s property, books or records (except
pursuant to a request by a governmental entity) in connection with any offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, any Acquisition Proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any action to make the provisions of any takeover statute inapplicable to any transactions contemplated by
an Acquisition Proposal; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;Acquisition Proposal&#148; means, with respect to Millendo or Tempest, (a)&nbsp;any inquiry, proposal or offer for a merger,
consolidation, dissolution, sale of substantial assets, recapitalization, share exchange, tender offer or other business combination involving such party and its subsidiaries, other than mergers, consolidations, recapitalizations, share exchanges or
other business combinations involving solely such party and/or one or more subsidiaries of such party, (b)&nbsp;any proposal for the issuance by such party of 15% or more of its equity securities, or (c)&nbsp;any proposal or offer to acquire in any
manner, directly or indirectly, 15% or more of the equity securities or consolidated total assets of such party and its subsidiaries, in each case other than the transactions contemplated by the Merger Agreement, other than, with respect to Tempest,
the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, before the earlier of the
effective time of the merger and either party obtaining the applicable approvals of the Millendo stockholders or Tempest stockholders required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consummate the merger, each party may furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding such party and its subsidiaries to, and may engage in discussions or
negotiations with, any third party making an unsolicited Acquisition Proposal, which such party&#146;s board of directors determines in good faith, after consultation with such party&#146;s outside financial advisors and outside legal counsel,
constitutes or is reasonably expected to result in a Superior Proposal and which Acquisition Proposal has not resulted from a material breach by such party of its obligations under Sections 6.1(a) or 6.1(e) of the Merger Agreement, if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither such party nor any representative of such party has materially breached the <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> provisions of the Merger Agreement described above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such party&#146;s board of directors has determined, after consultation with outside legal counsel, that the
failure to take such actions would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable legal requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such party receives from the third party an executed confidentiality agreement containing provisions at least as
favorable to such party as those contained in the confidentiality agreement between Millendo and Tempest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
&#147;Superior Proposal&#148; means, with respect to Millendo or Tempest, any bona fide, unsolicited written proposal made by a third party to acquire 50% or more of the equity securities or consolidated total assets of such party and its
subsidiaries, pursuant to a tender or exchange offer, a merger, a consolidation, business combination or recapitalization or a sale or exclusive license of its assets, (a)&nbsp;on terms which the board of directors of such party determines in its
good faith judgment to be more favorable, from a financial point of view, to the holders of such party&#146;s capital stock than the transactions contemplated by the Merger Agreement, after consultation with its financial and legal advisors, taking
into account all the terms and conditions of such proposal and the Merger Agreement (including any termination or <FONT STYLE="white-space:nowrap">break-up</FONT> fees and conditions to consummation, as well as any written, binding offer by the
other party hereto to amend the terms of this Agreement, which offer is not revocable for at least four Business Days) that the board of directors of such party determines to be relevant, and (b)&nbsp;which board of directors of such party has
determined to be reasonably capable of being completed on the terms proposed, taking into account all financial, regulatory, legal and other aspects of such proposal that board of directors of such party determines to be relevant (including the
likelihood and timing of consummation as compared to the transactions contemplated by the Merger Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also
provides that each party will promptly advise the other of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or any material change or proposed material change to that Acquisition
Proposal. In addition to the foregoing, each party must provide the other party with written notice of any determination by its board of directors to consider any Acquisition Proposal, to enter into discussions or negotiations concerning any
Acquisition Proposal, to provide <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to such to any person, or that such Acquisition Proposal constitutes a Superior Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_67"></A>Board Recommendation Change </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, Millendo agreed that its board of directors may not take any of the
following actions, each of which are referred to in this proxy statement/prospectus as a Millendo board recommendation change: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold, withdraw or modify (or publicly propose to withhold, withdraw or modify) the approval or recommendation
of the Millendo board of directors with respect to the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to recommend against acceptance of a tender offer within ten business days after commencement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to adopt, approve or recommend any Acquisition Proposal. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, notwithstanding the foregoing, at any time prior to the approval of the proposals
to be considered at the Millendo special meeting by the necessary vote of Millendo stockholders, with respect to a Superior Proposal or in response to an Intervening Event, the Millendo board of directors may make a Millendo board recommendation
change if, but only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors determines, after consultation with outside legal counsel, that the failure to
make a Millendo board recommendation change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo has provided at least four business days&#146; prior written notice to Tempest that it intends to effect
a Millendo board recommendation change, including a description in reasonable detail of the reasons for such Millendo board recommendation change, and written copies of any relevant proposed transactions agreements with any party making a potential
Superior Proposal, including the identity of the person making such Superior Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo has complied in all material respects with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
provisions of the Merger Agreement in connection with any potential Superior Proposal or Intervening Event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if after Tempest has delivered to Millendo a written, binding and irrevocable offer to alter the terms or
conditions of the Merger Agreement during the required four business day notice period, the Millendo board of directors has determined after consultation with outside legal counsel and after considering the terms of such offer by Tempest, that the
failure to effect a Millendo board recommendation change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, Tempest agreed that its board of directors may not take any of the
following actions, each of which are referred to in this proxy statement/prospectus as a Tempest board recommendation change: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold, withdraw or modify (or publicly propose to withhold, withdraw or modify) the approval or recommendation
of the Tempest board of directors with respect to the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to recommend against acceptance of a tender offer within ten business days after commencement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to adopt, approve or recommend any Acquisition Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, notwithstanding the foregoing, at any time prior to the approval of the merger by the necessary vote of Tempest stockholders, with
respect to a Superior Proposal or in response to an Intervening Event, the Tempest board of directors may make an Tempest board recommendation change if, but only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Tempest board of directors determines, after consultation with outside legal counsel, that the failure to
make an Tempest board recommendation change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest has provided at least four business days&#146; prior written notice to Millendo that it intends to effect
a Tempest board recommendation change, including a description in reasonable detail of the reasons for such Tempest board recommendation change, and written copies of any relevant proposed transactions agreements with any party making a potential
Superior Proposal, including the identity of the person making such Superior Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest has complied in all material respects with the <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
provisions of the Merger Agreement in connection with any potential Superior Proposal or Intervening Event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if after Millendo has delivered to Tempest a written, binding and irrevocable offer to alter the terms or
conditions of the Merger Agreement during the required four business day notice period, the Tempest board of directors has determined after consultation with outside legal counsel and after considering the terms of such offer by Millendo, that the
failure to effect a Tempest board recommendation change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;Intervening Event&#148; means a material change, effect, event, circumstance or
development (other than any change, effect, event, circumstance or development resulting from a material breach of the Merger Agreement by the party seeking to claim an Intervening Event) that (a)&nbsp;is materially adverse to Millendo or Tempest,
as applicable), (b) was not known to or reasonably foreseeable by the Millendo board of directors (with respect to Millendo) or the Tempest board of directors (with respect to Tempest) and (c)&nbsp;does not relate to an Acquisition Proposal. The
receipt, existence or terms of an Acquisition Proposal or Superior Proposal or any matter relating thereto shall not constitute an Intervening Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_68">
</A>Meeting of Millendo&#146;s Stockholders and Written Consent of Tempest&#146;s Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is obligated under the Merger
Agreement to take all action necessary under applicable law, its certificate of incorporation and bylaws, and Nasdaq rules to duly call, give notice of, convene and hold a meeting of the holders of Millendo common stock for the purpose of
considering and voting to approve the proposals. The Millendo special meeting will be held as promptly as practicable after the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> is declared effective under the
Securities Act, and in any event no later than 45&nbsp;days after the effective date of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> has been declared effective under the
Securities Act, and in any event no later than two business days thereafter, Tempest will solicit and obtain the consent of Tempest&#146;s stockholders for purposes of (i)&nbsp;adopting and approving the Merger Agreement and the transactions
contemplated therein, (ii)&nbsp;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&nbsp;262 of the DGCL, a copy of which will be
attached thereto, and that such stockholder has received and read a copy of Section&nbsp;262 of the DGCL and (iii)&nbsp;acknowledging that by its approval of the merger it is not entitled to appraisal rights with respect to its shares in connection
with the merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_69"></A>Indemnification and Insurance for Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the effective time of the merger through the sixth anniversary of the date on which the effective time of the
merger occurs, Millendo and the surviving corporation in the merger agreed to indemnify and hold harmless each person who was at the time of the execution of the Merger Agreement, or has been at any time prior to the date of the Merger Agreement, or
who becomes prior to the effective time of the merger, a director or officer of Millendo or Tempest or any of their respective subsidiaries, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses,
including attorneys&#146; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the
indemnified officer or director is or was a director or officer of Millendo or of Tempest or any of ther respective subsidiaries, whether asserted or claimed prior to, at or after the effective time of the merger, to the fullest extent permitted by
applicable law. From and after the effective time of the merger, Millendo and the surviving corporation in the merger will also fulfill Millendo&#146;s and Tempest&#146;s indemnity obligations, respectively, to each person who is, has been, or who
becomes prior to the effective time of the merger, a director or officer of Millendo or Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that
the provisions of the amended and restated certificate of incorporation and amended and restated bylaws of Millendo with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Millendo
that are presently set forth in the amended and restated certificate of incorporation and amended and restated bylaws of Millendo will not be amended modified or repealed for a period of six years from the effective time of the merger in a manner
that would adversely affect the rights thereunder of individuals who, at or prior to the effective time of the merger, were officers or directors of Millendo, unless such modification is required by applicable law. The amended and restated
certificate of incorporation and amended and restated bylaws of the surviving corporation will contain, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Millendo will cause the amended and restated certificate of incorporation and amended and restated bylaws of the surviving corporation to so contain, provisions no less favorable with respect
to indemnification, advancement of expenses and elimination of liability for monetary damages as those presently set forth in the amended and restated certificate of incorporation and amended and restated bylaws of Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Millendo and Tempest will secure and purchase a six year &#147;tail policy&#148; on their respective existing directors&#146; and
officers&#146; liability insurance policies with an effective date as of the date of the closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_70"></A>Additional Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Millendo and Tempest has agreed to use its commercially reasonable efforts to cause to be taken all actions necessary to
consummate the merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to use reasonable best efforts to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other
parties in doing, all things necessary, proper or advisable to consummate and make effective the transactions contemplated by the Merger Agreement as promptly as practicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as promptly as practicable, obtain from any governmental entity or any other third party any consents, licenses,
permits, waivers, approvals, authorizations, or orders required to be obtained or made by Millendo or Tempest or any of their subsidiaries in connection with the authorization, execution and delivery of the Merger Agreement and the consummation of
the transactions contemplated by the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as promptly as practicable, make all necessary filings, and thereafter make any other required submissions, with
respect to the Merger Agreement and the merger required under applicable law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execute or deliver any additional instruments necessary to consummate the transactions contemplated by, and to
fully carry out the purposes of, the Merger Agreement . </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Millendo and Tempest have
further agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo will use its commercially reasonable efforts to continue the listing of Millendo common stock on Nasdaq
during the term of the Merger Agreement and to cause the shares of Millendo common stock being issued in the merger to be approved for listing (subject to notice of issuance) on Nasdaq at or prior to the effective time of the merger.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest will cooperate with Millendo with respect to the listing application for the Millendo common stock and
promptly furnish to Millendo all information concerning Tempest and its stockholders that may be required or reasonably requested in connection with the Nasdaq listing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_71"></A>Conditions to the Completion of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party&#146;s obligation to complete the merger is subject to the satisfaction or waiver by each of the parties, at or prior to the
closing, of various conditions, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adoption of the Merger Agreement shall have been approved by means of written consents by the requisite vote
of the stockholders of Tempest under applicable law and Tempest&#146;s certificate of incorporation. The share issuance and the reverse stock split shall have been approved at a meeting of Millendo&#146;s stockholders, at which a quorum is present,
by the requisite vote of the stockholders of Millendo under applicable law and stock market regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than the filing of the certificate of merger, all authorizations, consents, orders or approvals of, or
declarations or filings with, or expirations of waiting periods imposed by, any governmental entity in connection with the merger and the consummation of the other transactions contemplated by the Merger Agreement, the failure of which to file,
obtain or occur is reasonably likely to have a material </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
adverse effect on Millendo or Tempest, shall have been filed, been obtained or occurred on terms and conditions that would not reasonably be likely to have a material adverse effect on Millendo
or Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this proxy
statement/prospectus is a part shall have become effective under the Securities Act and no stop order suspending the effectiveness of the registration statement shall have been issued and no proceeding for that purpose, and no similar proceeding
with respect to this proxy statement/prospectus, shall have been initiated or threatened in writing by the SEC or its staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No governmental entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any
order, executive order, stay, decree, judgment or injunction (preliminary or permanent) or statute, rule or regulation which is in effect and which has the effect of making the merger illegal or otherwise prohibiting consummation of the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the listing of the additional shares of Millendo common stock on Nasdaq will have been obtained
and the shares of Millendo common stock to be issued in the merger pursuant to the Merger Agreement will have been approved for listing (subject to official notice of issuance) on Nasdaq; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s final net cash shall have been finally determined in accordance with the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the obligation of Millendo and Merger Sub to complete the merger is further subject to the satisfaction or
waiver of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties regarding certain matters related to corporate organization and power, and
similar corporate matters, capitalization, authority to enter into the Merger Agreement and the related agreements and lack of certain conflicts, and material changes or events must be true and correct on the date of the Merger Agreement and on the
closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address matters as of a particular date, then as of that particular date;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties regarding certain capitalization matters of Tempest in the Merger Agreement
must be true and correct on the date of the Merger Agreement and on the closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address
matters as of a particular date, then as of that particular date, except for such inaccuracies which are de&nbsp;minimis, in the aggregate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remaining representations and warranties of the other party in the Merger Agreement must be true and correct
on the date of the Merger Agreement and on the closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address matters as of a particular
date, then as of that particular date, except in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a material adverse effect on Tempest (without giving effect to any references
therein to materiality qualifications); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest must have performed in all material respects all obligations required to be performed by it under the
Merger Agreement on or prior to the closing date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no material adverse effect on Tempest shall have occurred since the date of the Merger Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest must have obtained certain specified consents and approvals of third parties, and any other required
consents or approvals of third parties (other than a governmental entity) the failure of which to obtain, individually or in the aggregate, is reasonably likely to have a material adverse effect on Tempest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo must have received copies of the resignations, effective as of the effective time of the merger, of each
director of Tempest and its subsidiaries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of dissenting shares must not exceed 5% of the number of outstanding shares of Tempest outstanding as
of the effective time of the merger, after giving effect to the conversion of Tempest preferred stock into Tempest common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the funding agreements must be in full force and effect and the Tempest
<FONT STYLE="white-space:nowrap">pre-closing</FONT> financing must have been completed in accordance with its terms and Tempest must have received the proceeds therefrom; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest must have effected a conversion of all Tempest preferred stock into Tempest common stock as of
immediately prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain specified contracts must have been terminated; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo must have received an officers&#146; certificate duly executed by Tempest&#146;s chief executive officer
and chief financial officer to the effect that certain closing conditions have been satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
obligation of Tempest to complete the merger is further subject to the satisfaction or waiver of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties regarding certain matters related to corporate organization and power, and
similar corporate matters, capitalization, authority to enter into the Merger Agreement and the related agreements and lack of certain conflicts, and material changes or events must be true and correct on the date of the Merger Agreement and on the
closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address matters as of a particular date, then as of that particular date;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties regarding certain capitalization matters of Millendo in the Merger Agreement
must be true and correct on the date of the Merger Agreement and on the closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address
matters as of a particular date, then as of that particular date, except for such inaccuracies which are de&nbsp;minimis, in the aggregate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remaining representations and warranties of the other party in the Merger Agreement must be true and correct
on the date of the Merger Agreement and on the closing date of the merger with the same force and effect as if made on the date on which the merger is to be completed or, if such representations and warranties address matters as of a particular
date, then as of that particular date, except in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a material adverse effect on Millendo (without giving effect to any references
therein to materiality or material adverse effect qualifications); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo must have performed in all material respects all obligations required to be performed by it under the
Merger Agreement on or prior to the closing date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no material adverse effect on Millendo shall have occurred since the date of the Merger Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo must have obtained certain specified consents and approvals of third parties, and any other consents or
approvals of third parties (other than a governmental entity) the failure of which to obtain, individually or in the aggregate, is reasonably likely to have a material adverse effect on Millendo; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest must have received an officers&#146; certificate duly executed by Millendo&#146;s chief executive officer
and chief financial officer to the effect that certain closing conditions have been satisfied. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Tempest,
a &#147;material adverse effect&#148; for purposes of the Merger Agreement means any change, effect, event, circumstance or development, or an Effect, that, individually or in the aggregate with all other Effects that have occurred through the date
of determination, has had, or is reasonably likely to have, a material adverse effect on the business, assets, liabilities, financial condition or results of operations of Tempest and its subsidiaries, taken as a whole; <U>provided</U>,
<U>however</U>, that no Effect, to the extent resulting from or arising </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
out of any of the following, shall be deemed to be a material adverse effect or be taken into account for purposes of determining whether a material adverse effect has occurred or is reasonably
likely to occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in prevailing economic or market conditions in the United States
or any other jurisdiction in which such entity has substantial business operations (except to the extent those changes have a disproportionate effect on Tempest and its subsidiaries relative to the other participants in their industries);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or events after the date of the Merger Agreement affecting the industry or industries in which Tempest
and its subsidiaries operate generally (except to the extent those changes or events have a disproportionate effect on Tempest and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in GAAP or requirements (except to the extent those changes have a
disproportionate effect on Tempest and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in laws, rules or regulations of general applicability or
interpretations thereof by any governmental entity (except to the extent those changes have a disproportionate effect on Tempest and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any natural disaster, epidemic, pandemic or other disease outbreak (including the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or any outbreak of major hostilities in which the United States is involved or any act of terrorism within the United States or directed against its facilities or citizens wherever located
(except to the extent those changes or events have a disproportionate effect on Tempest and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the announcement of the Merger Agreement or the pendency of the transactions contemplated by the Merger
Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure by Tempest to meet any internal guidance, budgets, plans or forecasts of its revenues, earnings or
other financial performance or results of operations (but not the underlying cause of such changes or failures, unless such changes or failures would otherwise be excepted from the definition of material adverse effect). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Millendo, a &#147;material adverse effect&#148; for purposes of the Merger Agreement means any Effect that, individually or in
the aggregate with all other Effects that have occurred through the date of determination, has had, or is reasonably likely to have, a material adverse effect on the business, assets, liabilities, financial condition or results of operations of
Millendo and its subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, that no Effect, to the extent resulting from or arising out of any of the following, shall be deemed to be a material adverse effect or be taken into account for
purposes of determining whether a material adverse effect has occurred or is reasonably likely to occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in prevailing economic or market conditions in the United States
or any other jurisdiction in which such entity has substantial business operations (except to the extent those changes have a disproportionate effect on Millendo and its subsidiaries relative to the other participants in their industries);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or events after the date of the Merger Agreement affecting the industry or industries in Millendo and its
subsidiaries operate generally (except to the extent those changes or events have a disproportionate effect on Millendo and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in GAAP or requirements (except to the extent those changes have a
disproportionate effect on Millendo and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes after the date of the Merger Agreement in laws, rules or regulations of general applicability or
interpretations thereof by any governmental entity (except to the extent those changes have a disproportionate effect on Millendo and its subsidiaries relative to the other participants in their industries); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any natural disaster, epidemic, pandemic or other disease outbreak (including the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or any outbreak of major hostilities in which the United States is involved or any act of terrorism within the United States or directed against its facilities or citizens wherever located
(except to the extent those changes or events have a disproportionate effect on Millendo and its subsidiaries relative to the other participants in the industry or industries in which Millendo and its subsidiaries operate); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a change in the public trading price of Millendo&#146;s common stock (but not the underlying cause of such
change, unless such changes or failures would otherwise be excepted from the definition of material adverse effect); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a change in the trading volume of Millendo&#146;s common stock following the announcement of the Merger Agreement
or during the pendency of the transactions contemplated by the Merger Agreement (but not the underlying cause of such change, unless such changes or failures would otherwise be excepted from the definition of material adverse effect);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure by Millendo to meet any public estimates or expectations of Millendo&#146;s revenue, earnings or
other financial performance or results of operations for any period (but not the underlying cause of such failure, unless such changes or failures would otherwise be excepted from the definition of material adverse effect); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure by Millendo to meet any internal guidance, budgets, plans or forecasts of its revenues, earnings or
other financial performance or results of operations (but not the underlying cause of such failure, unless such changes or failures would otherwise be excepted from the definition of material adverse effect). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_72"></A>Termination and Termination Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of the Merger Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated at any time before the effective time of the merger, whether before or (subject to the terms of the
Merger Agreement) after the required stockholder approvals to complete the merger have been obtained, as set forth below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by mutual written consent of Millendo and Tempest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Millendo or Tempest, if the merger has not been consummated by September&nbsp;30, 2021;
<I>provided</I>, <I>however</I>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of or resulted in the failure of the merger to occur on or before
September&nbsp;30, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Millendo or Tempest, if a court of competent jurisdiction or governmental entity has issued a final
and <FONT STYLE="white-space:nowrap">non-appealable</FONT> order, decree or ruling or taken any other action that permanently restrains, enjoins or otherwise prohibits the merger;<I> provided</I>, <I>however</I>, that this right to terminate the
Merger Agreement will not be available to any party if the issuance of any such order, decree, ruling or other action is attributable to the failure of such party, or any affiliate of such party, to perform in any material respect any covenant in
the Merger Agreement required to be performed by such party, or any affiliate of such party, at or prior to the effective time of the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Millendo or Tempest, if at the Millendo special meeting (including any adjournment or postponement)
at which and Millendo stockholders have taken a vote on the share issuance and the reverse stock split, and such proposals have not been approved by the Millendo stockholders; <I>provided</I>,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
that Millendo may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of Millendo<I> </I>stockholders was caused by the action or failure to act of
Millendo and such action or failure to act constitutes a material and willful breach by Millendo of the Merger Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Millendo, at any time prior to the approval by Tempest stockholders of the adoption of the Merger Agreement,
if any of the following circumstances shall occur: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s board of directors has failed to give its recommendation to the approval of the adoption of the
Merger Agreement or has withdrawn or modified its recommendation in a manner adverse to Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if after the receipt by Tempest of an Acquisition Proposal, Millendo requests in writing that Tempest reconfirm
its recommendation of the share issuance and the reverse stock split and Millendo&#146;s board of directors fails to do so within ten business days after receipt of the request; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest&#146;s board of directors has approved or recommended to the stockholders of Tempest an Acquisition
Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a tender offer or exchange offer for outstanding shares of Tempest common stock is commenced, other than by
Millendo or an affiliate of Millendo, and Tempest&#146;s board of directors recommends that the stockholders of Tempest tender their shares in such tender or exchange offer or, within ten business days of the commencement of such tender offer or
exchange offer, Tempest&#146;s board of directors fails to recommend against acceptance of such officer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest has materially breached certain of its <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
obligations under the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Tempest, at any time prior to the approval by Millendo stockholders of the share issuance and the reverse
stock split, if any of the following circumstances shall occur: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors has failed to give its recommendation to the approval of the share issuance
and the reverse stock split or has withdrawn or modified its recommendation in a manner adverse to Tempest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if after the receipt by Millendo of an Acquisition Proposal, Tempest requests in writing that Millendo reconfirm
its recommendation of the share issuance and the reverse stock split and Millendo&#146;s board of directors fails to do so within ten business days after receipt of the request; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s board of directors has approved or recommended to the stockholders of Millendo an Acquisition
Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a tender offer or exchange offer for outstanding shares of Millendo common stock is commenced, other than by
Tempest or an affiliate of Tempest, and Millendo&#146;s board of directors recommends that the stockholders of Millendo tender their shares in such tender or exchange offer or, within five business days of the commencement of such tender offer or
exchange offer, Millendo&#146;s board of directors fails to recommend against acceptance of such officer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo has materially breached certain of its <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
obligations under the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Millendo, if Tempest has breached or failed to perform any of its representations, warranties, covenants or
agreements contained in the Merger Agreement (other than those referred to in Section&nbsp;8.1 (Termination) of the Merger Agreement) such that the conditions to the closing would not be satisfied; <I>provided</I> that Millendo is not then in
material breach of any representation, warranty, or covenant under the Merger Agreement; <I>provided, further,</I> if such breach or inaccuracy is curable, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a
particular breach or inaccuracy until the earlier of the expiration of a <FONT STYLE="white-space:nowrap">30-day</FONT> period after delivery of written notice of such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
breach or inaccuracy from Millendo to Tempest (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if
such breach by Tempest is cured prior to such termination becoming effective); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Tempest, if Millendo has breached or failed to perform any of its representations, warranties, covenants or
agreements contained in the Merger Agreement (other than those referred to in Section&nbsp;8.1 (Termination) of the Merger Agreement) such that the conditions to the closing would not be satisfied; <I>provided</I> that Tempest is not then in
material breach of any representation, warranty, or covenant under the Merger Agreement; <I>provided, further,</I> if such breach or inaccuracy is curable, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a
particular breach or inaccuracy until the earlier of the expiration of a <FONT STYLE="white-space:nowrap">30-day</FONT> period after delivery of written notice of such breach or inaccuracy from Tempest to Millendo (it being understood that the
Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Millendo is cured prior to such termination becoming effective); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Millendo, if the written consent of Tempest stockholders necessary to adopt the Merger Agreement and approve
the merger and related matters has not been obtained on or prior to 5:00 p.m., New York City time, on the date that is two business days after the registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this proxy
statement/prospectus is a part, is declared effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Tempest if, at any time prior to the receipt of the approval of the Tempest stockholders of the adoption of
the Merger Agreement, each of the following occur: (A)&nbsp;Tempest shall have received a Superior Proposal; (B)&nbsp;Tempest shall have complied in all material respects with its obligations under Section&nbsp;6.1 of the Merger Agreement;
(C)&nbsp;Tempest&#146;s board of directors approves, and Tempest concurrently with the termination of the Merger Agreement enters into, a definitive agreement with respect to such Superior Proposal; and (D)&nbsp;prior to or concurrently with such
termination, Tempest pays to Millendo $2.8&nbsp;million; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Millendo if, at any time prior to the receipt of the approval of the Millendo stokcholders of the share
issuance and the reverse stock split, each of the following occur: (A)&nbsp;Millendo shall have received a Superior Proposal; (B)&nbsp;Millendo shall have complied in all material respects with its obligations under Section&nbsp;6.1 of the Merger
Agreement; (C)&nbsp;Millendo&#146;s board of directors approves, and Millendo concurrently with the termination of the Merger Agreement enters into, a definitive agreement with respect to such Superior Proposal; and (D)&nbsp;prior to or concurrently
with such termination, Millendo pays to Tempest $1.4&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The party desiring to terminate the Merger Agreement
will give the other party written notice of such termination, specifying the provisions hereof pursuant to which such termination is made and the basis for termination described in reasonable detail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination Fees Payable by Millendo </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo must pay Tempest a termination fee of $1.4&nbsp;million if the Merger Agreement is terminated by (i)&nbsp;Millendo or Tempest pursuant
to clause&nbsp;(b) or (h)&nbsp;above so long as (A)&nbsp;prior to the termination of the Merger Agreement, any person makes an Acquisition Proposal or amends an Acquisition Proposal made prior to the date of the Merger Agreement with respect to
Millendo; and (B)&nbsp;within 12 months after such termination Millendo enters into a definitive agreement to consummate, or consummates, any Acquisition Proposal, regardless of whether made before or after the termination of this Agreement,
(ii)&nbsp;Tempest pursuant to clause (f)&nbsp;above, or (iii)&nbsp;Millendo pursuant to clause&nbsp;(k) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo must reimburse
Tempest for expenses incurred by Tempest in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $1.0&nbsp;million, if (i)&nbsp;Tempest terminates the Merger Agreement pursuant to clause&nbsp;(h) above,
solely as a result of a willful and material breach, or (ii)&nbsp;either Millendo or Tempest terminates the Merger Agreement pursuant to clause&nbsp;(d) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination Fees Payable by Tempest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest must pay Millendo a termination fee of $2.8&nbsp;million if the Merger Agreement is terminated by (i)&nbsp;Millendo or Tempest pursuant
to clause&nbsp;(b) or (g)&nbsp;above so long as (A)&nbsp;prior to the termination of the Merger Agreement, any person makes an Acquisition Proposal or amends an Acquisition Proposal made prior to the date of the Merger Agreement with respect to
Tempest; and (B)&nbsp;within 12 months after such termination Tempest enters into a definitive agreement to consummate, or consummates, any Acquisition Proposal, regardless of whether made before or after the termination of this Agreement,
(ii)&nbsp;Millendo pursuant to clause (e)&nbsp;above, or (iii)&nbsp;Tempest pursuant to clause (j)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest must reimburse
Millendo for expenses incurred by Millendo in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $1.0&nbsp;million, if (i)&nbsp;Millendo terminates the Merger Agreement pursuant to clause&nbsp;(g)
above, solely as a result of a willful and material breach, or pursuant to clause&nbsp;(i) above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_73"></A>Amendment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of Tempest, Merger Sub and Millendo. Such
amendment requires the approval of the respective boards of directors of Tempest, Merger Sub and Millendo at any time, except that after the Merger Agreement has been adopted and approved by the Tempest stockholders or Millendo stockholders, no
amendment which by law requires further approval by the Tempest stockholders or Millendo stockholders, as the case may be, may be made without such further approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_74"></A>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby
shall be paid by the party incurring such expenses, except as described above in the section titled &#147;<I> &#151;Termination and Termination Fees</I>&#148; beginning on page&nbsp;158 of this proxy statement/prospectus, and except that Tempest and
Millendo will share equally in any fees and expenses of the exchange agent and in any fees and expenses, other than attorneys&#146; and accountants&#146; fees and expenses, incurred in relation to the printing, filing and mailing of this proxy
statement/prospectus and the registration statement of which this proxy statement/prospectus is part, and any amendments or supplements thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_75"></A>AGREEMENTS RELATED TO THE MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_76"></A>Support Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to induce Millendo to enter into the Merger Agreement, certain Tempest stockholders are parties to support agreements with Millendo
pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Tempest stockholder, to vote all of his, her or its shares of Tempest capital stock in favor of the adoption of the Merger Agreement.
These Tempest stockholders also agreed to vote against any competing Acquisition Proposal with respect to Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Tempest
stockholders have also granted Millendo an irrevocable proxy to vote their respective shares of Tempest common stock or Tempest preferred stock in accordance with the support agreements. The Tempest stockholders may vote their shares of Tempest
common stock or Tempest preferred stock on all other matters not referred to in such proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the Tempest
stockholders that are party to a support agreement with Millendo owned an aggregate of 114,604,717 shares of Tempest capital stock, representing approximately 87.4% of the outstanding shares of Tempest capital stock on an as converted to common
stock basis. These stockholders include executive officers and directors of Tempest, as well as certain other stockholders owning a significant portion of the outstanding shares of Tempest capital stock. Following the effectiveness of the
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, Tempest stockholders holding a sufficient number of shares of Tempest capital
stock to adopt the Merger Agreement and approve the merger and related transactions will execute written consents providing for such adoption and approval. Therefore, holders of a sufficient number of shares of Tempest capital stock required to
adopt the Merger Agreement and approve the merger and related transactions are contractually obligated to adopt the Merger Agreement are expected to adopt the Merger Agreement via written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these support agreements, subject to certain exceptions, such stockholders have also agreed not to sell or transfer their shares of
Tempest capital stock and securities convertible into shares of Tempest capital stock held by them, or any voting rights with respect thereto, until the earlier of the termination of the Merger Agreement and the completion of the merger, subject to
certain exceptions. To the extent that any such sale or transfer is permitted pursuant to the exceptions included in the support agreement, each person to which any shares of Tempest capital stock or securities convertible into shares of Tempest
capital stock are so sold or transferred must agree in writing to be bound by the terms and provisions of the support agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, in order to induce Tempest to enter into the Merger Agreement, certain Millendo stockholders have entered into support agreements with Tempest pursuant to which, among other things, each such stockholder has agreed, solely in his, her or
its capacity as a Millendo stockholder, to vote all of his, her or its shares of Millendo common stock in favor of the share issuance and the reverse stock split. These Millendo stockholders also agreed to vote against any competing Acquisition
Proposal with respect to Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Millendo stockholders have also granted Tempest an irrevocable proxy to vote their respective
shares of Millendo common stock in accordance with the support agreements. Millendo stockholders may vote their shares of Millendo common stock on all other matters not referred to in such proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, the Millendo stockholders that are party to a support agreement owned an aggregate of 2,962,292 shares of Millendo
common stock representing approximately 16% of the outstanding shares of Millendo common stock. These stockholders include certain executive officers and directors of Millendo and certain other Millendo stockholders holding a significant portion of
the outstanding shares of Millendo common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these support agreements, subject to certain exceptions, such stockholders have
also agreed not to sell or transfer their shares of Millendo common stock and securities convertible into shares of Millendo common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock held by them until the earlier of the termination of the Merger Agreement and the completion of the merger, subject to certain exceptions. To the extent that any such sale or transfer is
permitted pursuant to the exceptions included in the support agreements, each person to which any shares of Millendo common stock or securities convertible into shares of Millendo common stock are so sold or transferred must agree in writing to be
bound by the terms and provisions of the support agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the support agreements does not purport to be
complete and is qualified in its entirety by the full text of the forms of support agreements, which are attached hereto as <I>Annex</I><I></I><I>&nbsp;C</I> and <I>Annex D</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_77"></A><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Tempest&#146;s executive officers, directors and stockholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, any shares of Millendo&#146;s common stock, until 180&nbsp;days after the effective time of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tempest stockholders who have executed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as of March&nbsp;31, 2021, owned in the
aggregate, approximately 87.4% of the shares of Tempest&#146;s outstanding capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements does not purport to be complete and is qualified in its entirety by the full text of the form of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, which is attached hereto as <I>Annex
E</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_78"></A>Funding Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the execution and delivery of the Merger Agreement, certain investors entered into funding agreements with Tempest, or the
Funding Agreements, pursuant to which such investors have agreed to purchase certain shares of Tempest common stock (representing an aggregate commitment of $30.0 million) in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing,
immediately prior to the closing of the merger. The merger is conditioned upon the closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing in an amount of at least $25&nbsp;million. The shares of Tempest common stock
that are issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing will be converted into shares of Millendo common stock in the merger. Accordingly, by approving Proposal No.&nbsp;1 relating to the merger, Millendo
stockholders will also be approving the issuance of shares of Millendo common stock to be issued in exchange for all shares of Tempest common stock that are sold in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Funding Agreements contain customary representations and warranties of Tempest. The Funding Agreements also contain customary
representations and warranties of the investors party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each investor&#146;s obligation to purchase shares of Tempest&#146;s
common stock from Tempest pursuant to the Funding Agreements are subject to the satisfaction or waiver of certain conditions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the satisfaction or waiver of each of the conditions to the consummation of the merger set forth in the Merger
Agreement (other than those conditions which, by their nature, are to be satisfied at the closing of the merger pursuant to the Merger Agreement, and the condition regarding the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order, law,
rule or regulation which is then in effect and has the effect of making the consummation of the transactions contemplated by the Funding Agreements illegal or otherwise restraining or prohibiting consummation of the transactions contemplated by the
Funding Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all representations and warranties of Tempest contained in the applicable Funding Agreement shall be true and
correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true in all respects) at and as of the date of the closing of the Tempest <FONT
STYLE="white-space:nowrap">pre-closing</FONT> financing; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tempest shall have performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by the applicable Funding Agreement to be performed, satisfied or complied with by it at or prior to the closing of the Tempes <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s obligation to sell shares of Tempest common stock to each investor pursuant to the Funding Agreements are subject to the
satisfaction or waiver of certain conditions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the satisfaction or waiver of each of the conditions to the consummation of the merger set forth in the Merger
Agreement (other than those conditions which, by their nature, are to be satisfied at the closing of the merger pursuant to the Merger Agreement, and the condition regarding the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order, law,
rule or regulation which is then in effect and has the effect of making the consummation of the transactions contemplated by the Funding Agreements illegal or otherwise restraining or prohibiting consummation of the transactions contemplated by the
Funding Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all representations and warranties of the investor contained in the applicable Funding Agreement shall be true
and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true in all respects) at and as of the date of the closing of the Tempest <FONT
STYLE="white-space:nowrap">pre-closing</FONT> financing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the investor shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the applicable Funding Agreement to be performed, satisfied or complied with by it at or prior to the closing of the Tempes <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Funding Agreements may be amended, modified or waived only with the written consent of Tempest and the applicable investors party thereto,
except that the Funding Agreements may be amended, modified or waived, subject to certain exceptions, with the written consent of Tempest and the investors holding a majority of the aggregate shares to be issued in the Tempest <FONT
STYLE="white-space:nowrap">pre-closing</FONT> financing. The Funding Agreements terminate upon the terminaton of the Merger Agreement, the mutual written consent of Tempest and the applicable investor, if on the closing date of the merger, the
closing conditions under the Funding Agreement have not be satisified and accordingly the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing is not consummated, or on September&nbsp;30, 2021. Millendo is an express third-party
beneficiary of certain provisions of the Funding Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_79"></A>MILLENDO DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independence of Millendo&#146;s Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required under Nasdaq listing rules, a majority of the members of a listed company&#146;s board of directors must qualify as
&#147;independent,&#148; as affirmatively determined by the company&#146;s board. The Millendo board of directors consults with Millendo&#146;s counsel to ensure that the determinations made by the Millendo board of directors are consistent with
relevant securities and other laws and regulations regarding the definition of &#147;independent,&#148; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Millendo&#146;s board of directors has undertaken a review of the independence of the directors and considered
whether any director has a material relationship with Millendo that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director
concerning such director&#146;s background, employment and affiliations, including family relationships, Millendo&#146;s board of directors determined that all of the directors, other than Dr.&nbsp;Owens, were &#147;independent directors&#148; as
defined under current rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, the Millendo board of directors considered the current and prior relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with Millendo and all other facts and circumstances that Millendo&#146;s board of directors deemed relevant in determining their independence, including the beneficial ownership of
Millendo&#146;s capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions involving them described &#147;<I>Certain Relationships and Related Party Transactions of the Combined Company&#151;Millendo
Transactions</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of Millendo&#146;s Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Millendo&#146;s board of directors had an independent Chair, Carol G. Gallagher, Pharm.D., with authority, among
other things, to call and preside over Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to Millendo&#146;s board of directors. Accordingly, the Chair has substantial
ability to shape the work of Millendo&#146;s board of directors. Millendo believes that separation of the positions of Chair and Chief Executive Officer reinforces the independence of Millendo&#146;s board of directors in its oversight of
Millendo&#146;s business and affairs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Millendo&#146;s Board of Directors in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of Millendo&#146;s board of directors is informed oversight of Millendo&#146;s risk management process.
Millendo&#146;s board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various board standing committees that
address risks inherent in their respective areas of oversight. In particular, Millendo&#146;s board of directors is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk
appropriate for Millendo. Millendo&#146;s audit committee has the responsibility to consider and discuss Millendo&#146;s major financial risk exposures and the steps Millendo&#146;s management has taken to monitor and control these exposures,
including guidelines and policies to govern the process by which risk assessment and risk management is undertaken. Millendo&#146;s audit committee also monitors compliance with legal and regulatory requirements. Its nominating and corporate
governance Committee monitors the effectiveness of Millendo&#146;s Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Millendo&#146;s compensation committee assesses
and monitors whether any of Millendo&#146;s compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the chairperson of each committee to report findings regarding material risk exposures
to Millendo&#146;s board of directors as quickly as possible. Millendo&#146;s board of directors has delegated to the Chair the responsibility of coordinating between Millendo&#146;s board of directors and management with regard to the determination
and implementation of responses to any problematic risk management issues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of Millendo&#146;s Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s board of directors met seven times during 2020. Each member of Millendo&#146;s board of directors attended 75% or more of the
aggregate number of meetings of the Millendo board of directors and of the committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_80"></A>MILLENDO EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information regarding compensation earned with respect to the years ended December&nbsp;31, 2020 and 2019 by Millendo&#146;s named executive officers, which include its principal executive officer and the next two most highly
compensated executive officers in 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive&nbsp;Plan</B><br><B>Compensation</B><br><B>($)<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia C. Owens</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">526,300</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,483,928</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,150</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,281,928</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478,900</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,679,077</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,505</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,381,882</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis Arcudi III</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,400</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">437,930</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,360</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976,240</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,609</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,003,401</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christophe Arbet-Engels</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380,730</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">752,560</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,314,132</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect discretionary bonuses for all named executive officers. Dr.&nbsp;Arbet-Engels&#146; bonus
amount reflects a $20,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus paid in 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards
granted during the applicable year computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (&#147;ASC 718&#148;). Assumptions used in the calculation of
these amounts are included in Note 9 to Millendo&#146;s audited financial statements included in this proxy statement/prospectus. These amounts do not reflect the actual economic value that may be realized by the named executive officer upon the
vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#147;&#151;Employment arrangements&#151;2020 Bonus Opportunity&#148; below for a description of the
material terms of the programs pursuant to which this compensation to Millendo&#146;s named executive officers was awarded. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount includes a $11,392 <FONT STYLE="white-space:nowrap">tax-gross</FONT> up on taxable commuting benefits.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information about equity awards granted to Millendo&#146;s named executive officers that remained
outstanding as of December&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia C. Owens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/30/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,179</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/28/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,600</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.44</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/27/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/24/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,991</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,848</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.40</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,427</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,900</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,944</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,722</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,505</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.59</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/24/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis Arcudi III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/7/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,650</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.40</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/6/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/15/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,958</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,042</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,625</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.59</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/24/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christophe Arbet-Engels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/10/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.90</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/9/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/24/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards were granted under the Millendo Therapeutics 2012 Stock Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards were granted under the OvaScience, Inc. 2012 Stock Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards were granted under the Millendo Therapeutics 2019 Equity Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards represent an inducement grant outside of but subject to the terms of the OvaScience, Inc. 2012
Stock Incentive Plan and in compliance with Nasdaq Listing Rule 5634(c)(4). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option awards represent an inducement grant outside of but subject to the terms of the Millendo Therapeutics,
Inc. 2019 Stock Incentive Plan and in compliance with Nasdaq Listing Rule 5634(c)(4). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option vest and become exercisable over a four year period, with 25%
of the option vested on August&nbsp;20, 2019 and the remaining shares underlying the option vesting in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through each vesting date.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option vest and become exercisable over a four year period, with 25%
of the option vested on January&nbsp;15, 2020 and the remaining shares underlying the option vesting in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through each vesting date.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option vest and become exercisable over a four year period, with 25%
of the option vested on June&nbsp;20, 2020 and the remaining shares underlying the option vesting in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through each vesting date.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option vest and become exercisable over a four year period, with 25%
of the option vested on November 5, 2019 and the remaining shares underlying the option vesting in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through each vesting date.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option vest and become exercisable over a four year period, with 25%
of the option vested on January 31, 2021 and the remaining shares underlying the option vesting in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through each vesting date.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% of the shares of common stock underlying this option vest and become exercisable on the earlier of:
(i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the Millendo board of director&#146;s approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares underlying the option vesting in equal monthly
installments thereafter, subject to the recipient&#146;s continued service through each vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares of common stock underlying this option were eligible to vest and become exercisable over a four year
period, with 25% of the option eligible to vest on February 10, 2021 and the remaining shares underlying the option eligible to vest in equal monthly installments over 36 months thereafter, subject to the recipient&#146;s continued service through
each vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;&#151;Potential Payments upon Termination or Change of Control&#148; for a description of vesting
acceleration applicable to stock options held by Millendo&#146;s named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment, Severance and Change in Control Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Arrangements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
of Millendo&#146;s named executive officers&#146; employment is &#147;at will&#148; and may be terminated at any time. Below is a description of Millendo&#146;s employment agreements with each of its named executive officers, for the fiscal year
ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Julia C. Owens, Ph.D.</I> Millendo entered into an amended and restated employment agreement with
Dr.&nbsp;Owens in June 2019, setting forth the terms of her employment. Under the terms of the employment agreement, Dr.&nbsp;Owens was entitled to an initial annual base salary of $478,900, which was subsequently increased to $526,300 in January
2020. The employment agreement also provides that Dr.&nbsp;Owens was eligible to receive an annual performance bonus, with a target bonus percentage of 50% of her then-current annual base salary, with the actual amount of any such bonus to be
determined at the sole discretion of Millendo&#146;s board of directors based upon its assessment of Dr.&nbsp;Owens&#146; performance and company performance. In addition, Dr.&nbsp;Owens&#146; employment agreement provided for certain severance and
change in control-related payments and benefits, the terms of which are described below under &#147;&#151;Potential Payments upon Termination or Change of Control.&#148; In connection with Mr.&nbsp;Arcudi&#146;s appointment as Chief Executive
Officer, Dr.&nbsp;Owens stepped down from her role as Chief Executive Officer, President and Principal Executive Officer, effective January&nbsp;31, 2021, pursuant to a Separation Agreement entered into between Millendo and Dr.&nbsp;Owens on
January&nbsp;27, 2021 (the &#147;Owens Separation Agreement&#148;). Pursuant to the Owens Separation Agreement, Dr.&nbsp;Owens received the following severance benefits: (a)&nbsp;a lump sum payment in the amount of $789,450.12, less applicable
deductions and withholdings and (b)&nbsp;a lump sum payment of Dr.&nbsp;Owens&#146;s annual bonus for 2021 in the amount of $394,725, less applicable deductions and withholdings and is receiving and will receive continuation of COBRA health
insurance premiums for an eighteen (18)&nbsp;month period that is funded by Millendo. The Owens Separation Agreement contains release covenants that are binding upon Dr.&nbsp;Owens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Louis J. Arcudi, III.</I> Millendo entered into an amended and restated employment agreement with Mr.&nbsp;Arcudi in June 2019, setting
forth the terms of his employment as Chief Financial Officer. Under the terms of the employment agreement, Mr.&nbsp;Arcudi was entitled to an initial annual base salary of $350,000, which was subsequently increased to $378,400 in January 2020. The
employment agreement also provides that Mr.&nbsp;Arcudi is eligible to receive an annual performance bonus, with a target bonus percentage of 40% of his then-current annual base salary, with the actual amount of any such bonus to be determined at
the sole discretion of Millendo&#146;s board of directors based upon its assessment of Mr.&nbsp;Arcudi&#146;s performance and company performance. In connection with his appointment to Chief Executive Officer and President in January 2021, Millendo
entered into an amended and restated employment agreement under which Mr.&nbsp;Arcudi&#146;s annual base salary was increased to $447,600 and he will continue to be eligible to receive an annual performance bonus, targeted at 40% of his annual base
salary. Further, if Mr.&nbsp;Arcudi is terminated by Millendo without &#147;Cause&#148; or he resigns employment for &#147;Good Reason&#148; (each as defined in his employment agreement), and subject to delivery to Millendo of a separation agreement
including a general release of claims in favor of Millendo, Mr.&nbsp;Arcudi will be entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment of his COBRA health insurance premiums for a twelve (12)&nbsp;month period. In addition, Mr.&nbsp;Arcudi&#146;s employment agreement provides for certain severance and change in
control-related payments and benefits, the terms of which are described below under &#147;&#151;Potential Payments upon Termination or Change of Control.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Christophe Arbet-Engels, M.D., Ph.D.</I> Millendo entered into an employment agreement with Dr.&nbsp;Arbet-Engels in February 2020, setting forth the terms
of his employment. Under the terms of the employment agreement, Dr.&nbsp;Arbet-Engels was entitled to an annual base salary of $425,000. The employment agreement also provided that Dr.&nbsp;Arbet-Engles was eligible to receive an annual performance
bonus, with a target bonus percentage of 40% of his then-current annual base salary, with the actual amount of any such bonus to be determined at the sole discretion of Millendo&#146;s board of directors based upon its assessment of
Dr.&nbsp;Arbet-Engels&#146;s performance and company performance. In addition, Dr.&nbsp;Arbet-Engels&#146;s employment agreement provides for certain severance and change in control-related payments and benefits, the terms of which are described
below under &#147;&#151;Potential Payments upon Termination or Change of Control.&#148; Dr.&nbsp;Arbet-Engels stepped down from his position, effective January&nbsp;29, 2021. In connection with his departure, Millendo entered into a separation
agreement with <FONT STYLE="white-space:nowrap">Dr.&nbsp;Arbet-Engels,</FONT> under which he received (a)&nbsp;a lump sum payment in the amount of $407,291.67, less applicable deductions and withholdings and (b)&nbsp;a lump sum payment of
Dr.&nbsp;Arbet-Engel&#146;s annual bonus for 2021 in the amount of $170,000, less applicable deductions and withholdings and began receiving continuation of COBRA health insurance premiums for a twelve (12)&nbsp;month period that is funded Millendo.
The Separation Agreement contains release covenants that are binding upon Dr.&nbsp;Arbet-Engels. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2020 Bonus Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Owens and each of Millendo&#146;s other named executive officers were eligible to receive a bonus in 2020. The bonus opportunity was
designed to motivate and reward Millendo&#146;s named executive officers for the attainment of company-wide performance goals. The 2020 target bonus amounts were set as a percentage of the named executive officer&#146;s annual base salary for 2020
as follows: (1)&nbsp;Dr.&nbsp;Owens&#146; target bonus percentage was set at 50%, (2) Mr.&nbsp;Arcudi&#146;s and Dr.&nbsp;Arbet-Engels&#146; target bonus percentage were each set at 40%. Payment of 100% of the target bonus amount was subject to the
achievement of company objectives as determined by Millendo&#146;s board of directors. Millendo&#146;s named executive officers for 2020 were eligible to receive more than 100% of their target bonuses in the discretion of Millendo&#146;s board of
directors. In addition, to remain eligible to receive a bonus, the named executive officers were required to remain employees in good standing on the date bonuses were paid. Bonuses were measured as of December&nbsp;31, 2020, and Millendo&#146;s
compensation committee determined that performance goals under the 2020 bonus plan were achieved at a 100% level. The bonuses were paid in the first quarter of 2021. For 2020, Dr.&nbsp;Owens&#146; actual bonus amount was $263,150,
Mr.&nbsp;Arcudi&#146;s actual bonus amount was $151,360, and Dr.&nbsp;Arbet-Engels&#146; actual bonus amount was $152,292. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Bonus Opportunity
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, Mr.&nbsp;Arcudi is eligible for a target bonus set at 40% of his base salary but with the eligibility to earn more than 100%
of the target bonus in the discretion of Millendo&#146;s board of directors. Target-level compensation is dependent upon Millendo&#146;s achievement of 2021 business objectives. In addition, to remain eligible to receive a bonus, Mr.&nbsp;Arcudi
must remain an employee in good standing on the date bonuses are paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Payments upon Termination or Change of Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Julia C. Owens, Ph.D.</I> Pursuant to Dr.&nbsp;Owens&#146; employment agreement, if Dr.&nbsp;Owens&#146; employment with Millendo (or any
parent or subsidiary or successor of Millendo, including the combined company) ended within three months prior to or within 12 months following a change in control of Millendo (a &#147;Change in Control Period&#148;), due to her resignation for
&#147;good reason&#148; or her termination by Millendo other than for &#147;cause,&#148; death or &#147;disability&#148; (each, as defined in her employment agreement), then the vesting and exercisability of her existing option awards, as of the
date of her employment agreement, as well as all equity awards granted to her after the date of her employment agreement that are subject to a time-based vesting schedule, will accelerate in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pursuant to the terms of the option agreement for Dr.&nbsp;Owens&#146; August 2018 options, if Dr.&nbsp;Owens&#146; employment with Millendo (or any parent or subsidiary or successor of Millendo,
including the combined company) ended within six months prior to or within 12 months following a change in control of Millendo due to her resignation for &#147;good reason&#148; or her termination by Millendo other than for &#147;cause,&#148; death
or disability, then her August 2018 options will accelerate in full. Pursuant to her employment agreement, if, within a Change in Control Period, Dr.&nbsp;Owens&#146; employment with Millendo ended due to her resignation for good reason, her
termination by Millendo other than for cause or as a result of her death or disability, then Millendo will pay (i)&nbsp;her base salary then in effect for 18 months following her termination, (ii) 100% of the health insurance premiums for
Dr.&nbsp;Owens and her covered dependents for up to 18 months following her termination, and (iii)&nbsp;an additional amount equivalent to 150% of Dr.&nbsp;Owens&#146; target annual bonus for the year in which her termination occurs, payable when
bonuses for that year are paid to similarly situated employees. Pursuant to Dr.&nbsp;Owens&#146; employment agreement, if Dr.&nbsp;Owens&#146; employment with Millendo (or any parent or subsidiary or successor of Millendo, including the combined
company) ended outside of a Change in Control Period due to her resignation for good reason or her termination by Millendo other than for cause, death or disability, then Millendo will pay (i)&nbsp;her base salary then in effect for 12 months
following her termination and (ii) 100% of the health insurance premiums for Dr.&nbsp;Owens and her covered dependents for up to 12 months following her termination. Dr.&nbsp;Owens&#146; severance and change in control benefits are conditioned,
among other things, on her complying with her post-termination obligations under her employment agreement, executing and not revoking a general release of claims in Millendo&#146;s favor and resigning from all positions that she holds with us. As
described above with respect to her employment agreement and separation agreement, these provisions, other than the August 2018 option treatment and the option changes described under &#147;<I>The Merger&#151;Interests of the Millendo Directors and
Executive Officers in the Merger</I>&#148; are no longer effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Louis J. Arcudi, III.</I> Pursuant to Mr.&nbsp;Arcudi&#146;s
employment agreement, if Mr.&nbsp;Arcudi&#146;s employment with Millendo (or any parent or subsidiary or successor of Millendo, including the combined company) ends within a Change in Control Period due to his resignation for &#147;good reason&#148;
or his termination by Millendo other than for &#147;cause,&#148; death or &#147;disability&#148; (each, as defined in his employment agreement), then the vesting and exercisability of his existing option awards, as of the date of his employment
agreement, as well as all equity awards granted to him after the date of his employment agreement that are subject to a time-based vesting schedule, will accelerate in full. Pursuant to his employment agreement, if, within a Change in Control
Period, Mr.&nbsp;Arcudi&#146;s employment with Millendo ends due to his resignation for good reason, his termination by Millendo other than for cause or as a result of his death or disability, then Millendo will pay (i)&nbsp;his base salary then in
effect for 12 months following his termination, (ii) 100% of the health insurance premiums for Mr.&nbsp;Arcudi and his covered dependents for up to 12 months following his termination, and (iii)&nbsp;an additional amount equivalent to 100% of
Mr.&nbsp;Arcudi&#146;s target annual bonus for the year in which his termination occurs, payable when bonuses for that year are paid to similarly situated employees. Pursuant to Mr.&nbsp;Arcudi&#146;s employment agreement, if Mr.&nbsp;Arcudi&#146;s
employment with Millendo (or any parent or subsidiary or successor of Millendo, including the combined company) ends outside of a Change in Control Period due to his resignation for good reason or his termination by Millendo other than for cause,
death or disability, then Millendo will pay (i)&nbsp;his base salary then in effect for 12 months following his termination and (ii) 100% of the health insurance premiums for Mr.&nbsp;Arcudi and his covered dependents for up to 12 months following
his termination. Mr.&nbsp;Arcudi&#146;s severance and change in control benefits are conditioned, among other things, on his complying with his post-termination obligations under his employment agreement, executing and not revoking a general release
of claims in Millendo&#146;s favor and resigning from all positions that he holds with Millendo. Under the amended terms and in replacement for the terms described above, if such a termination without Cause or resignation for Good Reason takes place
within a Change in Control Period, Mr.&nbsp;Arcudi will be entitled to: (a)&nbsp;payment of his COBRA health insurance premiums for an eighteen (18)&nbsp;month period; and (b)&nbsp;accelerated vesting of all unvested equity awards such that all
unvested equity awards shall become immediately vested and exercisable. In addition, Mr.&nbsp;Arcudi became eligible to earn retention bonuses of up to a total of $630,000 in the aggregate and paid in two equal installments (one of which has already
been paid and is subject to repayment if he is not employed by Millendo through June 30, 2021), and, with respect to the second installment, will be paid on the earlier of December&nbsp;31, 2021 or the closing of a Change in Control of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Millendo, and his execution of release agreements in favor of Millendo. Mr.&nbsp;Arcudi will also be eligible for a transaction bonus of $250,000 if Millendo undergoes a Change in Control during
Mr.&nbsp;Arcudi&#146;s employment term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Christophe Arbet-Engels M.D., Ph.D.</I> Pursuant to Dr.&nbsp;Arbet-Engels&#146; employment
agreement, if Dr.&nbsp;Arbet-Engels&#146; employment with Millendo (or any parent or subsidiary or successor of Millendo, including the combined company) ended within a Change in Control Period due to his resignation for &#147;good reason&#148; or
his termination by Millendo other than for &#147;cause,&#148; death or &#147;disability&#148; (each, as defined in his employment agreement), then the vesting and exercisability of his existing option awards, as of the date of his employment
agreement, as well as all equity awards granted to him after the date of his employment agreement that are subject to a time-based vesting schedule, will accelerate in full. Pursuant to his employment agreement, if, within a Change in Control
Period, Dr.&nbsp;Arbet-Engels&#146; employment with Millendo ended due to his resignation for good reason, his termination by Millendo other than for cause or as a result of his death or disability, then Millendo will pay (i)&nbsp;his base salary
then in effect for 12 months following his termination, (ii) 100% of the health insurance premiums for Dr.&nbsp;Arbet-Engels and his covered dependents for up to 12 months following his termination, and (iii)&nbsp;an additional amount equivalent to
100% of Dr.&nbsp;Arbet-Engels&#146; target annual bonus for the year in which his termination occurs, payable when bonuses for that year are paid to similarly situated employees. Pursuant to Dr.&nbsp;Arbet-Engels&#146; employment agreement, if
Dr.&nbsp;Arbet-Engels&#146; employment with Millendo (or any parent or subsidiary or successor of Millendo, including the combined company) ended outside of a Change in Control Period due to his resignation for good reason or his termination by
Millendo other than for cause, death or disability, then Millendo will pay (i)&nbsp;his base salary then in effect for 12 months following his termination and (ii) 100% of the health insurance premiums for Dr.&nbsp;Arbet-Engels and his covered
dependents for up to 12 months following his termination. Dr.&nbsp;Arbet-Engels severance and change in control benefits are conditioned, among other things, on his complying with his post-termination obligations under his employment agreement,
executing and not revoking a general release of claims in Millendo&#146;s favor and resigning from all positions that he holds with us. As described above with respect to his separation agreement, these provisions are no longer effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo maintains a defined
contribution retirement plan (the &#147;401(k) plan&#148;), that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees may defer eligible compensation on a <FONT
STYLE="white-space:nowrap">pre-tax</FONT> basis, up to the statutorily prescribed annual limits on contributions under the Code. Contributions are allocated to each participant&#146;s individual account and are then invested in selected investment
alternatives according to the participants&#146; directions. Millendo contributes a safe harbor minimum contribution equivalent to 3% of employees&#146; eligible compensation. Employees are immediately and fully vested in their contributions. The
401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with the 401(k) plan&#146;s related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT>
retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. In anticipation of the closing of the merger, the Millendo board of directors has
terminated the 401(k) plan effective May 1, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation earned for service on Millendo&#146;s board of directors during the year
ended December&nbsp;31, 2020 by Millendo&#146;s directors who were not also its employees. Julia C. Owens, Ph.D., Millendo&#146;s President and Chief Executive Officer, is also a member of Millendo&#146;s board of directors, but did not receive any
additional compensation for service as a director in 2020. The compensation for Dr.&nbsp;Owens as an executive officer is set forth above under &#147;Executive Compensation- Summary Compensation Table.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid&nbsp;in&nbsp;Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Howe, III, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,792</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carole L. Nuechterlein, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,792</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James M. Hindman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Habib J. Dable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lynne Hedley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geoff Nichol, M.B., Ch.B., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards
granted during 2020 computed in accordance with FASB ASC Topic 718. The assumptions Millendo used in valuing the option awards are described in Note 9 to Millendo&#146;s consolidated financial statements included in this proxy statement/prospectus.
The aggregate grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. These amounts do not reflect the actual economic value that will be realized by director upon the vesting of the stock
options, the exercise of the stock options or the sale of the common stock underlying such stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table below shows the aggregate number of option awards and stock awards outstanding for each of
Millendo&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as of December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Awards</B><br><B>(#)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Howe, III, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">33,776</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carole L. Nuechterlein, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">30,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James M. Hindman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51,229</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Habib J. Dable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">44,880</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lynne Hedley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48,600</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geoff Nichol, M.B., Ch.B., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">36,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash compensation for Dr.&nbsp;Gallagher&#146;s service on Millendo&#146;s board of directors and compensation
committee is paid to NEA Management Company, LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director receives an annual board service retainer of $40,000. The <FONT
STYLE="white-space:nowrap">non-executive</FONT> chairperson receives an additional service retainer of $30,000. The chairperson of each of Millendo&#146;s audit committee, compensation committee and nominating and corporate governance committee
receives additional annual committee chair service retainers of $15,000, $10,000 and $8,000, respectively. Other members of Millendo&#146;s audit committee, compensation committee and nominating and corporate governance committee receive additional
annual cash retainers of $7,500, $5,000 and $4,000, respectively, for each such committee of which they are a member. The annual cash compensation amounts set forth above are payable in equal quarterly installments, payable in arrears following the
end of each calendar quarter in which the board service occurs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prorated for any partial months of service. Millendo also reimburses all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses
incurred by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of Millendo&#146;s board of directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to cash compensation, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director is eligible to receive options to
purchase Millendo common stock. Upon each <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial appointment to Millendo&#146;s board of directors, he or she is granted an option to purchase 24,000 shares of Millendo common
stock, with a <FONT STYLE="white-space:nowrap">per-share</FONT> exercise price equal to 100% of the fair market value of a share of Millendo common stock on the grant date. This initial stock option award vests over three years, with <FONT
STYLE="white-space:nowrap">one-third</FONT> of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service through each vesting date. On the date of each annual meeting, each continuing <FONT STYLE="white-space:nowrap">non-employee</FONT> director is granted an option
to purchase 12,000 shares of Millendo&#146;s common stock, with a <FONT STYLE="white-space:nowrap">per-share</FONT> exercise price equal to 100% of the fair market value of a share of Millendo common stock on the grant date. This annual stock option
award fully vests on the earlier to occur of the first anniversary of the grant date and the date of the first annual meeting following the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous
service through such vesting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s board of directors has undertaken a review of the independence of the directors and considered whether any director has a
material relationship with Millendo that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning such
director&#146;s background, employment and affiliations, including family relationships, Millendo&#146;s board of directors determined that all of the directors, other than Dr.&nbsp;Owens, are &#147;independent directors&#148; as defined under
current rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, Millendo&#146;s board of directors considered the current and prior relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with Millendo and all other facts and circumstances that it deemed relevant in determining their independence, including the beneficial ownership of Millendo capital stock by each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director and the transactions involving them described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides certain information with respect to Millendo&#146;s equity compensation plans in effect as of December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Securities&nbsp;to&nbsp;be</B><br><B>Issued&nbsp;upon</B><br><B>Exercise&nbsp;
of</B><br><B>Outstanding</B><br><B>Options,<BR>Warrants&nbsp;and</B><br><B>Rights&nbsp;(a)(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise&nbsp;Price</B><br><B>of&nbsp;Outstanding</B><br><B>Options,</B><br><B>Warrants&nbsp;and</B><br><B>Rights&nbsp;
(b)($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities</B><br><B>Remaining&nbsp;Available</B><br><B>for&nbsp;Future&nbsp;Issuance</B><br><B>Under&nbsp;
Equity</B><br><B>Compensation&nbsp;Plans</B><br><B>(Excluding&nbsp;Securities</B><br><B>Reflected&nbsp;in</B><br><B>Column&nbsp;(a))(c)(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Plan Category</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,271,378</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545,699</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)&nbsp;(4)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477,724</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,749,102</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545,699</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the Millendo Therapeutics 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan, the
OvaScience, Inc. 2012 and 2011 Stock Incentive Plans and the Millendo Therapeutics, Inc. 2012 Stock Plan. Does not include 48,265 shares of common stock issuable upon the exercise of warrants at a weighted-average exercise price of $7.85 per share,
which are related to <FONT STYLE="white-space:nowrap">non-employee</FONT> (BSA) warrants and employee (BSPCE) warrants previously granted by Aliz&eacute; and assumed by Private Millendo in connection with Private Millendo&#146;s acquisition of
Aliz&eacute; in December 2017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes an option to purchase 71,324 shares of common stock at a
<FONT STYLE="white-space:nowrap">per-share</FONT> exercise price of $21.90 granted to Dr.&nbsp;Kroeger (OvaScience&#146;s former Chief Executive Officer), an option to purchase 74,400 shares of common stock at a
<FONT STYLE="white-space:nowrap">per-share</FONT> exercise price of $10.40 granted to Louis Arcudi III (then Chief Financial Officer, now Chief Executive Officer), and options to purchase a total of 62,000 shares of common stock, at a
weighted-average per share exercise price of $9.34 per share, granted to two of Millendo&#146;s employees who are not executive officers, in each case, that were granted outside of, but subject to the terms of, the OvaScience, Inc. 2012 Stock
Incentive Plan as an inducement material to the grantee entering into an employment relationship with Millendo (the &#147;2012 Plan Inducement Grants&#148;). Also includes an option to purchase 130,000 shares of common stock at a <FONT
STYLE="white-space:nowrap">per-share</FONT> exercise price of $7.27 granted to Tamara Joseph (Millendo&#146;s now former General Counsel) and an option to purchase 140,000 shares of common stock at a <FONT STYLE="white-space:nowrap">per-share</FONT>
exercise price of $6.90 granted to Christophe Arbet-Engels (Millendo&#146;s now former Chief Medical Officer), in each case, that were granted outside of, but subject to the terms of, Millendo&#146;s 2019 Equity Incentive Plan as an inducement
material to the grantee entering into an employment relationship with Millendo (together with the 2012 Plan Inducement Grants, the &#147;Inducement Grants&#148;). Each Inducement Grant other than the Inducement Grant awarded to Dr.&nbsp;Kroeger has
a term of ten years and is subject to a vesting over four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in equal monthly installments over 36 months following the
first anniversary of the vesting commencement date, subject to the grantee&#146;s continued employment with Millendo through each vesting date. The Inducement Grant awarded to Dr.&nbsp;Kroeger vested in full on December&nbsp;7, 2018, the date of his
separation with us, and may be exercised by Dr.&nbsp;Kroeger until December&nbsp;7, 2021, which is the three year anniversary of his separation date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 278,539 shares reserved for issuance under the 2019 Equity Incentive Plan as of December&nbsp;31,
2020. The number of shares of common stock reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2020 and continuing through and including January&nbsp;1,
2029, by 4% of the total number of shares of Millendo capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by Millendo&#146;s board
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of directors. Pursuant to the terms of the 2019 Equity Incentive Plan, an additional 759,988 shares were added to the number of available shares effective January&nbsp;1, 2021. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 267,160 shares reserved for issuance under the 2019 Employee Stock Purchase Plan as of
December&nbsp;31, 2020. The number of shares of common stock reserved for issuance under the 2019 Employee Stock Purchase Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2020 and continuing through and
including January&nbsp;1, 2029, by the lesser of (i) 1% of the total number of shares of Millendo capital stock outstanding on December&nbsp;31 of the preceding calendar year, or (ii) 133,580 shares of Millendo common stock; unless a lesser number
of shares is determined by Millendo&#146;s board of directors. Pursuant to the terms of the 2019 Employee Stock Purchase Plan, an additional 133,580 shares were added to the number of available shares effective January&nbsp;1, 2021.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_81"></A>TEMPEST EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following section discusses the material components of the executive compensation program for Tempest&#146;s named executive officers who
are identified in the Summary Compensation Table below. This discussion may contain forward-looking statements that are based on Tempest&#146;s current plans, considerations, expectations, and determinations regarding future compensation programs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a &#147;smaller
reporting company,&#148; as such term is defined in the rules promulgated under the Securities Act, Tempest has opted to comply with the reduced disclosure obligations applicable to smaller reporting companies. These rules require compensation
disclosure for Tempest&#146;s principal executive officer and the two most highly compensated executive officers other than the principal executive officer whose total compensation for 2020 exceeded $100,000 and who were serving as executive
officers as of December&nbsp;31, 2020. Tempest refers to these individuals as &#147;named executive officers.&#148; For 2020, Tempest&#146;s named executive officers were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Thomas Dubensky,<I> </I>Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stephen Brady, President and Chief Operating Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sam Whiting, Executive Vice President and Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Compensation of Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Base
salaries are intended to provide a level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of Tempest&#146;s executive compensation program. The relative levels of
base salary for the named executive officers are designed to reflect each executive officer&#146;s scope of responsibility and accountability. Please see the &#147;Salary&#148; column in the Summary Compensation Table for the base salary amount
received by each named executive officer during the years ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, cash bonuses have been provided through an annual cash bonus program. Bonus compensation is designed to hold executives
accountable, reward the executives based on actual business results and help create a &#147;pay for performance&#148; culture. The target amount of cash bonus that each named executive officer may be eligible to earn in a given year is set forth in
each named executive officer&#146;s offer letter, as described in the section titled &#147;Additional Narrative Disclosure&#148;. Please see the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column in the
Summary Compensation Table for the annual cash bonus amount received by each named executive officer during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
further focus Tempest&#146;s executive officers on Tempest&#146;s long-term performance, Tempest has granted equity compensation in the form of stock options. In the year ended December&nbsp;31, 2020, the Board awarded Drs. Dubensky, and Whiting and
Mr.&nbsp;Brady stock options representing the right to purchase 1,428,207, 1,923,779, and 2,181,868 shares of Tempest common stock, respectively. The shares subject to Dr.&nbsp;Dubensky&#146;s and Mr.&nbsp;Brady&#146;s stock options vest in a series
of 48 successive equal monthly installments measured from the vesting commencement date, February&nbsp;20, 2020, subject to each award recipient&#146;s continued service through the applicable vesting date. On March&nbsp;10, 2021, the Board modified
the vesting schedules of the stock options granted to Dr.&nbsp;Dubensky and Mr.&nbsp;Brady in 2020 by providing for vesting acceleration upon a termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment in connection with a change in control, which is required under each of Dr.&nbsp;Dubensky&#146;s and Mr.&nbsp;Brady&#146;s offer letter agreement.
<FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to Dr.&nbsp;Whiting&#146;s stock option vest on the first anniversary of the vesting commencement date, November&nbsp;16, 2020, with the remaining shares vesting in a series of
36 successive equal monthly installments thereafter, subject to Dr.&nbsp;Whiting&#146;s continued service through each applicable vesting date. In addition, Dr.&nbsp;Whiting&#146;s stock option is subject to vesting acceleration upon a termination
of employment in connection with a change in control. The vesting acceleration provisions that apply to each named executive officer&#146;s equity awards are described in more detail below in the section titled &#147;Additional Narrative
Disclosure.&#148; For the avoidance of doubt, the merger is not a change in control for purposes of the Tempest compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see
&#147;Outstanding Equity Awards at Fiscal 2020 <FONT STYLE="white-space:nowrap">Year-End&#148;</FONT> below for a summary of the outstanding equity awards held by each of the named executive officers as of the 2020
<FONT STYLE="white-space:nowrap">year-end.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding the compensation of Tempest&#146;s named executive officers for services performed during the
year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)
</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">816,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">895,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief Medical Officer <B><SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the dollar value of base salary earned by the named executive officer as of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount disclosed represents a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus paid to
Dr.&nbsp;Whiting pursuant to his offer letter in connection with his service as Tempest&#146;s Executive Vice President and Chief Medical Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation listed for each named
executive officer represents the cash bonus paid to each named executive officer in 2021 for performance in fiscal year 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the stock options awarded in 2020
subject to time-based vesting conditions, computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation (ASC 718) using the Black-Scholes option-pricing model and based on the following assumptions: risk-free interest rate of
0.5%; expected volatility of 66%; expected term of 6.1 years and expected dividend rate of 0%. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Whiting joined Tempest as the Executive Vice President and Chief Medical Officer effective
November&nbsp;16, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal 2020 <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the outstanding equity awards held by each of the named executive officers as of
December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="24" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Shares<BR>or Units<BR>of Stock<BR>That<BR>Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares or<BR>Units of<BR>Stock That<BR>Have Not<BR>Vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/27/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/5/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">648,354</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213,957</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10/3/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,126,183</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10/2/2028</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/30/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2/20/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,130,664</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/29/2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/16/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/9/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,071,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,357,839</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/15/2029</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/30/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2/20/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,636,313</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/29/2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Samuel Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/16/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/16/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,923,779</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/15/2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This number represents shares purchased by Dr.&nbsp;Dubensky pursuant to Tempest&#146;s 2017 Equity Incentive
Plan, which are subject to repurchase rights in favor of Tempest, with the repurchase right lapsing upon continued service or in connection with a change in control. The repurchase right lapsed with respect to 25% of the purchased shares on
September&nbsp;5, 2018, and lapses with respect to 1/48 of the total purchased shares in equal monthly installments thereafter, subject to Dr.&nbsp;Dubensky&#146;s continued service. Notwithstanding the foregoing, the repurchase right lapses with
respect to 100% of the purchased shares on the earliest of (i)&nbsp;the date that is nine months following a change in control, (ii)&nbsp;the date Tempest terminates Dr.&nbsp;Dubensky&#146;s status as a service provider upon or following the closing
of the change in control for any reason other than cause or Dr.&nbsp;Dubensky&#146;s death or disability, and (iii)&nbsp;the date Dr.&nbsp;Dubensky terminates his status as a service provider for good reason upon or following the closing of the
change in control (&#147;the Dubensky Double-Trigger&#148;). If the successor corporation in a change in control does not assume the Dubensky Double-Trigger obligation, the repurchase right will lapse immediately with respect to 100% of the
purchased shares still subject to such repurchase right. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2020, Tempest&#146;s equity was not publicly traded and, therefore, there was no
ascertainable public market value for the equity on such date. The market value reported in this table is based upon the Section&nbsp;409A valuation analysis of Tempest&#146;s equity as of December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the shares underlying this option vest upon the earlier of (i)&nbsp;the closing of a change in control,
or (b)&nbsp;the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offering and sale of Tempest common stock, subject to Dr.&nbsp;Dubensky&#146;s continued
service. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement
date, subject to each award recipient&#146;s continued service. On March&nbsp;10, 2021, the Board modified the vesting schedules of these stock options to include the following vesting acceleration provisions: if, within three months prior to or 12
months following a change in control, Tempest terminates the executive officer&#146;s employment without cause or the executive officer resigns for good reasons, then the vesting of all of the shares subject to such executive officer&#146;s option
will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the executive officer&#146;s last day of employment, provided that the executive officer satisfies certain severance
conditions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares underlying this option vested on
September&nbsp;9, 2020, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to Mr.&nbsp;Brady&#146;s continued service. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Notwithstanding the foregoing, 100% of the unvested shares subject to this option vest immediately on the earliest of (i)&nbsp;the date that is 12 months following a change in control,
(ii)&nbsp;the date Tempest terminates Mr.&nbsp;Brady&#146;s status as a service provider upon or following the closing of the change in control for any reason other than cause or Mr.&nbsp;Brady&#146;s death or disability, in each case within the
period beginning three months before and ending 12 months after the closing of the change in control, and (iii)&nbsp;the date Mr.&nbsp;Brady terminates his status as a service provider for good reason within the period beginning three months before
and ending 12 months after the closing of the change in control (the &#147;Brady Double-Trigger&#148;). If the successor corporation in a change in control does not assume the Brady Double-Trigger obligation, 100% of the unvested shares subject to
this option will vest immediately prior to such change in control. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares underlying this option vest on
November&nbsp;16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to Dr.&nbsp;Whiting&#146;s continued service. Notwithstanding the foregoing, if within three months prior to or 12 months
following a change in control Tempest terminates Dr.&nbsp;Whiting&#146;s employment without cause or Dr.&nbsp;Whiting resigns for good reason, then the vesting of all of the shares subject to this option will be immediately accelerated such that all
shares will be deemed fully vested and exercisable as of Dr.&nbsp;Whiting&#146;s last day of employment, provided that Dr.&nbsp;Whiting satisfies certain severance conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Narrative Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dubensky Offer Letter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Dubensky and Tempest entered into an amended and restated offer letter agreement, dated October&nbsp;31, 2020 and effective as of
January&nbsp;1, 2020 (the &#147;Dubensky Offer Letter&#148;). Under the terms of the Dubensky Offer Letter, Dr.&nbsp;Dubensky is entitled to a base salary of $448,000 annually and is eligible for an annual discretionary performance bonus with a
target amount of up to 40% of his base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Dr.&nbsp;Dubensky is entitled to certain severance benefits in the event that
his employment with Tempest is terminated without Cause or that he resigns for Good Reason (&#147;Cause&#148; and &#147;Good Reason&#148; each as defined in the Dubensky Offer Letter). The severance benefits consist of (i)&nbsp;a cash severance
benefit paid in a lump sum in an amount equal to the sum of 12 months of Dr.&nbsp;Dubensky&#146;s then current base salary plus a prorated portion of Dr.&nbsp;Dubensky&#146;s target annual bonus for the calendar year in which he is terminated, less
applicable deductions and withholdings, and (ii)&nbsp;if Dr.&nbsp;Dubensky timely elects healthcare continuation coverage under COBRA, Company-paid COBRA premiums (including in respect of coverage for eligible dependents) for a maximum of 12 months,
subject to earlier termination if Dr.&nbsp;Dubensky obtains health coverage from another source unless otherwise provided by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if, within three months prior to or 12 months following a Change in Control (as defined in Tempest&#146;s 2017 Equity Incentive
Plan), Dr.&nbsp;Dubensky is terminated by Tempest without Cause or he resigns for Good Reason, then the vesting of his equity awards will accelerate such that all shares subject to the awards will be deemed fully vested and exercisable as of his
last day of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Dubensky is terminated without Cause or he resigns for Good Reason after Tempest has become a
publicly-traded entity, and the termination is effective within three months prior to or 12 months following a Change in Control, then in lieu of the severance benefits described above, he is entitled to receive (i)&nbsp;a cash severance benefit in
an amount equal to the sum of 18 months of his then current base salary plus an amount equal to Dr.&nbsp;Dubensky&#146;s target annual bonus for the calendar year in which he is terminated, less applicable deductions and withholdings, and
(ii)&nbsp;if Dr.&nbsp;Dubensky timely elects healthcare continuation coverage under COBRA, Company-paid COBRA premiums (including in respect of coverage for eligible dependents) for a maximum of 18 months, subject to earlier termination if
Dr.&nbsp;Dubensky obtains health coverage from another source unless otherwise provided by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Dubensky&#146;s
receipt of the severance benefits described above is conditioned upon (x)&nbsp;his continued compliance with his obligations under his confidentiality, invention assignment, and arbitration agreement with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest, and (y)&nbsp;his timely execution, delivery and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of an effective release of all claims against Tempest and its affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Brady Offer Letter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Brady and Tempest entered into an offer letter agreement, dated September&nbsp;2, 2019 (the &#147;Brady Offer Letter&#148;). Under the
terms of the Brady Offer Letter, Mr.&nbsp;Brady is entitled to a base salary of $448,000 annually and to a target bonus equal to 40% of his base salary. Pursuant to the Brady Offer Letter, Mr.&nbsp;Brady was granted an option to purchase
approximately 3.5% of Tempest&#146;s fully-diluted equity as of the date on which his employment commenced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event
that Mr.&nbsp;Brady&#146;s employment with Tempest is terminated by Tempest without Cause or that he resigns for Good Reason (&#147;Cause&#148; and &#147;Good Reason&#148; each as defined in the Brady Offer Letter), he is entitled to receive
(i)&nbsp;a cash severance benefit in an amount equal to the sum of 12 months of his base salary plus a prorated portion of his target annual bonus for the calendar year in which he is terminated and (ii) 12 months of health coverage following the
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if Mr.&nbsp;Brady&#146;s employment is terminated by Tempest without Cause or he resigns for Good Reason within
three months prior to or 12 months following a Change in Control (as defined in Tempest&#146;s 2017 Equity Incentive Plan and applicable option agreement), then in lieu of the severance benefits described above (i)&nbsp;the vesting of his equity
awards will accelerate, and (ii)&nbsp;Mr.&nbsp;Brady will be entitled to receive (x)&nbsp;a cash severance benefit in an amount equal to the sum of 12 months of his base salary and his full target bonus and (y) 12 months of health benefits following
the termination. If the Company is a publicly-traded entity at the time of such termination, then the cash severance benefit is increased to 18 months of his base salary and 150% of his target annual bonus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Brady&#146;s receipt of the severance benefits is subject to the execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT>
of a separation agreement containing, among other things a general release of claims in favor of Tempest and related persons and entities, confidentiality, return of property and <FONT STYLE="white-space:nowrap">non-disparagement.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Whiting Offer Letter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Whiting and Tempest entered into an offer letter agreement, dated October&nbsp;7, 2020 (the &#147;Whiting Offer Letter&#148;). Under
the terms of the Whiting Offer Letter, Dr.&nbsp;Whiting is entitled to a base salary of $33,333 per month, and is eligible for an annual discretionary bonus equal to 35% of his base salary. Dr.&nbsp;Whiting is also entitled to a <FONT
STYLE="white-space:nowrap">sign-on</FONT> bonus of $50,000; provided, however, if Dr.&nbsp;Whiting voluntarily terminates employment other than for Good Reason or is terminated for Cause (&#147;Good Reason&#148; and &#147;Cause&#148; each as defined
in the Whiting Offer Letter) prior to the first anniversary of his start date, he will repay the <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus to Tempest. Tempest will also reimburse Dr.&nbsp;Whiting for reasonable travel costs when business
returns to a more standard mode of operations and Dr.&nbsp;Whiting is expected to work a portion of time from the office in San Francisco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Whiting offer Letter, subject to Board approval, Tempest will grant Dr.&nbsp;Whiting an option to purchase 1.2% of
Tempest&#146;s common stock on a fully-diluted basis. The option will be subject to the following vesting schedule: (i) 1/4 of the total shares will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement
date, and 1/48 of the total shares will vest each month thereafter subject to Dr.&nbsp;Whiting&#146;s continuous service as of each vesting date; and (ii)&nbsp;if, within three months prior to or 12 months following a Change in Control (as defined
in the 2017 Equity Incentive Plan), Tempest terminates Dr.&nbsp;Whiting&#146;s employment without Cause or Dr.&nbsp;Whiting resigns for Good Reason, the vesting of his equity awards will accelerate such that all shares subject to the awards will be
deemed fully vested and exercisable as of his last day of employment, provided that certain conditions are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Dr.
Whiting&#146;s employment with Tempest is terminated without Cause or he resigns for Good Reason, he is entitled to receive (i)&nbsp;a cash severance benefit in an amount equal to the sum of nine months of his then current
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
base salary plus a <FONT STYLE="white-space:nowrap">pro-rated</FONT> amount of Dr. Whiting&#146;s target annual bonus for the calendar year in which he is terminated, less applicable deductions
and withholdings, and (ii)&nbsp;if Dr.&nbsp;Whiting timely elects healthcare continuation coverage under COBRA, Company-paid COBRA premiums (including in respect of coverage for eligible dependents) for a maximum of nine months, subject to earlier
termination if Dr.&nbsp;Whiting obtains health coverage from another source unless otherwise provided by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Whiting&#146;s receipt of the severance benefits described above is conditioned upon (x)&nbsp;his continued compliance with his
obligations under his Proprietary Information and Inventions Agreement, and (y)&nbsp;his timely execution, delivery and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of an effective release of all claims against Tempest and its affiliates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest participates in a multiple employer <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) savings plan which allows participants
to defer eligible compensation up to the maximum amount allowed under Internal Revenue Service guidelines. Tempest does not make any discretionary or employer matching contributions under the plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board and stockholders of Tempest approved the Tempest 2017 Plan, which replaced the Inception 2 Plan, as described below. The purposes of
the Tempest 2017 Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors and consultants, and to promote the success of Tempest&#146;s business.
The Tempest 2017 Plan will be assumed by Millendo upon the closing of the merger. The material terms of the Tempest 2017 Plan are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Subject to the Plan</I>. The number of shares reserved for future grant under the Tempest 2017 Plan as of December&nbsp;31, 2020 was
14,890,925. Up to 34,471,728 shares of Tempest common stock that may be issued under the Tempest 2017 Plan may be issued in satisfaction of incentive stock option awards. The number of shares reserved under the Tempest 2017 Plan also includes
(i)&nbsp;any shares that, as of the date of stockholder approval of the Tempest 2017 Plan, have been reserved but not issued pursuant to any awards granted under the Inception 2 Plan, and (ii)&nbsp;any shares subject to stock options or similar
awards granted under the Inception 2 Plan that, after the date of stockholder approval of the Tempest 2017 Plan, are forfeited to or repurchased by Tempest, subject to a maximum limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent an equity award granted under the Tempest 2017 Plan expires or becomes unexercisable without having been exercised in full, is
surrendered pursuant to an Exchange Program, as defined under the Tempest 2017 Plan, is forfeited to or repurchased by Tempest due to failure to vest, or is settled in cash, the shares subject to such award will become available for future grant or
sale under the Tempest 2017 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#146;s tax withholding obligation relating to an award or to pay the exercise price of an award, such shares will become
available for future grant or sale under the Tempest 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Tempest employees, directors and
consultants hold outstanding stock options granted under the Tempest 2017 Plan for the purchase of up to 13,560,841 shares of Tempest common stock, with 3,323,982 of the shares subject to outstanding stock options vested as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Tempest&#146;s Board or a committee appointed or duly authorized by the Board administers the Tempest 2017 Plan.
The Board has the authority to amend and modify the plan, subject to any stockholder approval required by law or stock exchange rules. Subject to the terms of the Tempest 2017 Plan, the Board also has the authority to determine the eligibility for
awards and the terms, conditions, and restrictions, including vesting terms, the number of shares subject to an award, and any performance goals applicable to grants made under the Tempest 2017 Plan, to construe and interpret the Tempest 2017 Plan
and awards, and amend outstanding awards at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation Rights</I>. Tempest&#146;s Board may grant incentive
stock options, nonstatutory stock options, and stock appreciation rights under the Tempest 2017 Plan, provided that incentive stock options are granted only to employees. The exercise price of stock options and stock appreciation rights under the
Tempest 2017 Plan is determined by the Board, but must equal to at least 100% of the fair market value of Tempest&#146;s common stock on the date of grant. The term of an option or stock appreciation right may not exceed ten years; provided,
however, that an incentive stock option held by an employee who owns more than 10% of all classes of Tempest&#146;s stock, or of certain Tempest affiliates, may not have a term in excess of five years, and must have an exercise price of at least
110% of the fair market value of Tempest common stock on the grant date. Subject to the provisions of the Tempest 2017 Plan, the Board will determine the remaining terms of the options and stock appreciation rights, including the number of shares
subject to the award, vesting, and the nature of any performance measures. Upon a participant&#146;s termination of service, the participant may exercise his or her option or stock appreciation right, to the extent vested (unless the Tempest
compensation committee permits otherwise), as specified in the award agreement. The Tempest 2017 Plan prohibits the payment of dividends with respect to options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Awards.</I> The Board will decide at the time of grant whether an award will be in the form of restricted stock or restricted stock
units. The Board will determine the terms of the awards, including the number of shares subject to the award, vesting, and the nature of any performance measures. Unless the Board determines otherwise, the recipient of restricted stock will have
voting rights and be entitled to receive dividends and other distributions with respect to his or her shares of restricted stock. If any such dividends or distributions are paid in shares, the shares will be subject to the same restrictions on
transferability and forfeitability as the shares of restricted stock with respect to which they are paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of
Awards</I>. The Tempest 2017 Plan does not allow awards to be transferred other than by will or the laws of decent and distribution. Awards may be exercised, during the lifetime of the participant, only by the participant. Further, until Tempest
becomes subject to the reporting requirements of section 13 or 15(d) of the Exchange Act, or after the Board determines that it is, will or may no longer be relying upon the exemption from registration under the Exchange Act, an option, or prior to
exercise, the shares subject to the option, may be transferred to a family member by gift or pursuant to a domestic relations order, or to an executor or guardian of the participant upon the death or disability of the participant, in each case, to
the extent required for continued reliance on the exemption from registration under the Exchange Act. The Board may in its sole discretion determine to permit transfers to Tempest or in connection with a change in control or other acquisition
transactions involving Tempest to the extent permitted by the Tempest 2017 Plan or the Exchange Act. A participant may also designate a beneficiary who will receive outstanding awards upon the participant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. In the event that any dividend or other distribution, recapitalization, stock split, reverse stock split,
reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase or exchange of shares or other securities of Tempest, or other change in
Tempest&#146;s corporate structure affecting the shares occurs, the Board, in order to prevent diminution or enlargement of the benefits, will adjust the number, class, and price of shares subject to each outstanding award and the number and class
of shares that may be delivered under the Tempest 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control</I>. In the event of a merger or a Change in
Control (as defined in the Tempest 2017 Plan), each outstanding award will be treated as Tempest&#146;s Board determines without participant consent, including, without limitation, (i)&nbsp;awards will be assumed or substantially equivalent awards
be substituted by the acquiring or succeeding corporation; (ii)&nbsp;upon written notice to a participant, awards will terminate upon or immediately prior to the consummation of such merger or Change in Control; (iii)&nbsp;outstanding awards will
vest and become exercisable, or restrictions applicable to an award will lapse, in whole or in part prior to or upon consummation of such merger or Change in Control, and to the extent the Board determines, terminate; (iv)&nbsp;awards will terminate
in exchange for an amount of cash and/or property, or will be replaced with other rights or property selected by the Board in its sole discretion, or (v)&nbsp;any combination of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback</I>. Awards granted under the Tempest 2017 Plan may be subject to reduction,
cancellation, forfeiture or recoupment upon the occurrence of certain specified events pursuant to applicable award agreement, and will be subject to Tempest&#146;s clawback policy as may be established and amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. Tempest&#146;s Board has the authority to amend, alter, suspend or terminate the Tempest 2017 Plan, subject
to any stockholder approval required by law or stock exchange rules. Unless terminated by earlier by the Board, the Tempest 2017 Plan will terminate on the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the later of its adoption by
the Board, or (b)&nbsp;the earlier of the most recent Board or stockholder approval of an increase in the number of shares reserved for issuance under the Tempest 2017 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2011 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2011, the Board and stockholders of Tempest (then known as Inception 2, Inc.) approved the Inception 2, Inc. 2011 Equity
Incentive Plan (the &#147;Incentive 2 Plan&#148;). The Inception 2 Plan will be assumed by Millendo upon the closing of the merger. The material terms of the Inception 2 Plan are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Inception 2 Plan is to help secure and retain persons performing services to Tempest, provide incentives for such persons
to exert maximum efforts for the success of Tempest and any affiliate, and provide a means by which such persons may benefit from increases in value of Tempest&#146;s common stock. The Inception 2 Plan provides for the grant of incentive stock
options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock awards. Only directors, employees and consultants who provide services to Tempest are eligible to receive such awards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares.</I> As of December&nbsp;31, 2020, Tempest employees, directors and consultants hold outstanding stock options
granted under the Inception 2 Plan for the purchase of up to 481,588 shares of Tempest common stock, all of which were vested as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration. </I>Tempest&#146;s Board, or a committee or committees delegated by the Board, administers the Inception 2 Plan.
Subject to the terms of the Inception 2 Plan, The Board will have the authority to determine the eligibility for awards and the terms, conditions, and restrictions, including vesting terms, the number of shares subject to an award, and any
performance goals applicable to awards made under the Inception 2 Plan. The Board also will have the authority, subject to the terms of the Inception 2 Plan, to construe and interpret the Inception 2 Plan and awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types and Terms of Awards. </I>Under the Inception 2 Plan, the Board may grant stock options, stock appreciation rights, restricted stock
awards, RSUs, and other stock awards. Stock options and stock appreciation rights may not be exercised beyond a <FONT STYLE="white-space:nowrap">ten-year</FONT> term (or such shorter period as required with respect to incentive stock options held by
certain holders). The terms of the awards are specified in an underlying award agreement approved by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards. </I>The Inception 2 Plan does not allow options or stock appreciation rights to be transferred other than by
will or the laws of descent and distribution. Options and stock appreciation rights may be exercisable during the lifetime of a participant only by the participant; provided, however, that the Board may, in its sole discretion, permit transfer of an
option or stock appreciation right to the extent permitted by applicable law upon a participant&#146;s request. Restricted stock awards may be transferable by the participant only upon such terms and conditions as set forth in the award agreement,
as the Board determines in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments. </I>If any change is made in Tempest&#146;s common stock, without
the receipt of consideration, such as through a merger, consolidation, reorganization, reincorporation, recapitalization, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split,
liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, appropriate and proportionate adjustments will be made in the number, class, and price of shares subject
to each outstanding award and the number and kind of shares subject to the Inception 2 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> In the event Tempest experiences a corporate transaction
under the terms of the Inception 2 Plan, subject to the terms of the applicable award agreement or any other written agreement between the participant and Tempest or any affiliate, or unless otherwise expressly provided by the Board at the time of
grant of an award, the Board may (i)&nbsp;arrange for the surviving or acquiring corporation to assume or continue the stock awards, or to substitute stock awards; (ii)&nbsp;arrange for the assignment of any reacquisition or repurchase rights held
by Tempest in respect of common stock issued pursuant to stock awards to the surviving or acquiring corporation; (iii)&nbsp;accelerate the vesting, in whole or in part, of stock awards, and terminate such awards if not exercised; (iv)&nbsp;arrange
for the lapse, in whole or in part, of any reacquisition or repurchase rights held by Tempest with respect to stock awards; (v)&nbsp;cancel or arrange for the cancellation of stock awards in exchange for such cash consideration or no consideration
as the Board, in its sole discretion, may consider appropriate; or (vi)&nbsp;make a payment (in the form determined by the Board) equal to the excess, if any, of the value of the property a participant would have received upon the exercise of a
stock award immediately prior to the effective time of the corporate transaction over any exercise price payable by such participant in connection with such exercise, which payments may be made subject to conditions or contingencies applicable to
shareholders of common stock in the transaction. The Board is not required to take the same action or actions with respect to all stock awards or portions thereof with respect to all participants, and may take different actions with respected to
vested and unvested portions of stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control. </I>In the event Tempest experience a change in control under the
terms of the Inception 2 Plan, an award may be subject to additional acceleration of vesting and exercisability as may be provided in the award agreement or in any other written agreement between Tempest or any affiliate and the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. The Board has the authority to amend or terminate the Inception 2 Plan, subject to any stockholder approval
required by law. No amendment or termination may impair the rights of a holder of an outstanding award without the consent of such holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2020 Director Compensation Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for the year ended December&nbsp;31, 2020 regarding the compensation awarded to or earned by certain
of <FONT STYLE="white-space:nowrap">Tempest&#146;s&nbsp;non-employee&nbsp;directors.</FONT> Dr.&nbsp;Dubensky, Tempest&#146;s Chief Executive Officer, does not receive any additional compensation for his service as a member of Tempest&#146;s Board.
Please see the Summary Compensation Table above for the compensation paid or awarded to Dr.&nbsp;Dubensky for 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or&nbsp;Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Michael Raab</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>40,000</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>31,830</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>71,830</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The amount disclosed represents the aggregate grant date fair value of the stock option awarded in 2020
subject to time-based vesting conditions, computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation (ASC 718) using the Black-Scholes option-pricing model and based on the following assumptions: risk-free interest rate of
0.5%; expected volatility of 66%; expected term of 6.1 years and expected dividend rate of 0%. The amount does not correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>As of December&nbsp;31, 2020, Mr.&nbsp;Raab held outstanding options to acquire Tempest common stock
with respect to 821,250 shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_82"></A>MATTERS BEING SUBMITTED TO A VOTE OF MILLENDO STOCKHOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_83"></A>PROPOSAL NO.&nbsp;1: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_84"></A>APPROVAL OF THE ISSUANCE OF COMMON STOCK IN THE MERGER AND THE CHANGE OF CONTROL RESULTING FROM THE MERGER
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Millendo special meeting, Millendo stockholders will be asked to approve the issuance of Millendo common stock in the merger.
Immediately following the merger, it is expected that the former Tempest securityholders, including shares issued in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, will own approximately 81.5% of the common stock of
Millendo and the Millendo securityholders as of immediately prior to the merger will own approximately 18.5% of the common stock of Millendo, subject to certain assumptions, including, but not limited to, (a)&nbsp;Millendo&#146;s net cash as of the
earlier of closing and June&nbsp;30, 2021 being between $15.3&nbsp;million and $18.7&nbsp;million, and (b)&nbsp;Tempest raising $30&nbsp;million in the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the Merger Agreement, the merger and the issuance of Millendo common stock in the merger are
described in detail in the other sections in this proxy statement/prospectus. A copy of the Merger Agreement is attached as <I>Annex A </I>to this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common
stock, among other things, in connection with the acquisition of another company&#146;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance
of the shares of Millendo common stock in the merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 81.5% of Millendo&#146;s common stock following the merger. Accordingly, in order to ensure compliance
with Nasdaq Listing Rule 5635(a)(1), Millendo must obtain the approval of Millendo stockholders for the issuance of these shares of common stock in the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that
will result in a &#147;change of control&#148; of the listed company. Nasdaq has determined that the merger constitutes a &#147;change of control&#148; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule
5635(b), Millendo must obtain the approval of Millendo stockholders of the change of control resulting from the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required
Vote </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares present in attendance or represented by proxy at the Millendo
special meeting and entitled to vote on the matter, assuming a quorum is present, is required to approve the issuance of Millendo common stock in the merger and the change of control of Millendo resulting from the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>MILLENDO&#146;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THIS PROPOSAL NO. 1 TO APPROVE THE ISSUANCE OF MILLENDO
COMMON STOCK IN THE MERGER AND THE CHANGE OF CONTROL OF MILLENDO RESULTING FROM THE MERGER. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the
intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#147;FOR&#148; the approval of the issuance of Millendo common stock in the merger and the change of control of Millendo
resulting from the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_85"></A>PROPOSAL NO.&nbsp;2: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_86"></A>APPROVAL OF THE AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MILLENDO TO EFFECT THE REVERSE
STOCK SPLIT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the Millendo special meeting, Millendo stockholders will be asked to approve a series of amendments to the restated certificate of incorporation of Millendo as amended that will implement a reverse stock split of the issued and outstanding shares of
Millendo common stock, at a reverse stock ratio in the range of between one new share for every 10 shares and one new share for every 15 shares outstanding (or any number in between). The effectiveness of any one of these amendments and the
abandonment of the other amendments, or the abandonment of all of these amendments, will be determined by the Millendo board of directors in its discretion and subject to agreement by Tempest in connection with the merger. Upon the effectiveness of
such amendment to the restated certificate of incorporation of Millendo as amended to effect the reverse stock split, or the reverse stock split effective time, the issued and outstanding shares of Millendo common stock immediately prior to the
reverse stock split effective time will be reclassified into a smaller number of shares such that a Millendo stockholder will own one new share of Millendo common stock for each two to five (or any number in between) shares of issued common stock
held by such stockholder immediately prior to the reverse stock split effective time, as specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Millendo board of directors may
determine to effect the reverse stock split, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the issuance of Millendo common stock pursuant to the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By approving this Proposal No.&nbsp;2, Millendo stockholders will: (a)&nbsp;approve a series of alternate amendments to the restated
certificate of incorporation of Millendo as amended pursuant to which any whole number of issued and outstanding shares of common stock between and including 10 to 15 and could be combined and reclassified into one share of common stock; and
(b)&nbsp;authorize the Millendo board of directors to file only one such amendment, as determined by the Millendo board of directors in its sole discretion, and to abandon each amendment not selected by the Millendo board of directors. Should
Millendo receive the required stockholder approval for this Proposal No.&nbsp;2, and following such stockholder approval, the Millendo board of directors, subject to agreement by Tempest, determines that effecting the reverse stock split is in the
best interests of Millendo and its stockholders, the reverse stock split will become effective as specified in the amendment filed with the Secretary of State of the State of Delaware. The amendment filed thereby will contain the number of shares
selected by the Millendo board of directors within the limits set forth in this Proposal No.&nbsp;2 to be combined and reclassified into one share of Millendo common stock. Accordingly, upon the effectiveness of the amendment to the restated
certificate of incorporation of Millendo as amended to effect the reverse stock split, or the split effective time, every 10 to 15 shares (or any number in between) of Millendo common stock outstanding immediately prior to the split effective time
will be combined and reclassified into one share of Millendo common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposed form of certificate of amendment to the restated
certificate of incorporation of Millendo as amended to effect the reverse stock split, as more fully described below, will affect the reverse stock split but<B><I></I></B><B><I>&nbsp;will not</I></B>&nbsp;change the number of authorized shares of
Millendo common stock or preferred stock, or the par value of Millendo common stock or preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the proposed form of
certificate of amendment to the restated certificate of incorporation of Millendo as amended to effect the reverse stock split is attached as<I></I><I>&nbsp;Annex</I><I></I><I>&nbsp;F </I>to this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding approval of this Proposal No.&nbsp;2 by Millendo stockholders, the Millendo board of directors may, in its sole discretion,
abandon the proposed amendments and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under Section&nbsp;242(c) of the Delaware General
Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Purpose </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Millendo board of directors approved the proposal approving the amendment to the Millendo restated certificate of incorporation as amended
effecting the reverse stock split for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors believes effecting the reverse stock split will result in an increase in the
minimum bid price of Millendo&#146;s common stock and reduce the risk of a delisting of Millendo common stock from Nasdaq in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Millendo board of directors believes a higher stock price may help generate investor interest in Millendo and
ultimately the combined company and help Millendo attract and retain employees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the reverse stock split successfully
increases the per share price of Millendo common stock, Millendo&#146;s board of directors also believes this increase may increase trading volume in Millendo common stock and facilitate future financings by Millendo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq Requirements for Listing on Nasdaq </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo common stock is listed on The Nasdaq Capital Market under the symbol &#147;MLND.&#148; Millendo has filed an initial listing
application pursuant to the terms of the Merger Agreement for the combined company with Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Nasdaq rules, an issuer
must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a <FONT STYLE="white-space:nowrap">non-Nasdaq</FONT> entity, resulting in a change of control of the issuer and potentially allowing
the <FONT STYLE="white-space:nowrap">non-Nasdaq</FONT> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Millendo to have, among other things, a $4.00 per share minimum bid price for a certain number of
trading days preceding the closing of the merger. Therefore, the reverse stock split may be necessary in order to consummate the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, it is a condition to the closing of the merger that the shares of Millendo common stock to be issued in the merger pursuant to
the Merger Agreement having been approved for listing on Nasdaq. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the effects of the reverse stock split will be to effectively
increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in Millendo&#146;s management being able to issue more shares without further stockholder approval. The reverse stock split will
not affect the number of authorized shares of Millendo capital stock which will continue to be authorized pursuant to the restated certificate of incorporation of Millendo, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Increased Investor Interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;7, 2021, Millendo common stock closed at $1.09 per share. An investment in Millendo common stock may not appeal to brokerage firms
that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such
stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the Millendo board of directors believes that most investment funds are reluctant to
invest in lower priced stocks. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks associated with the reverse stock split, including that the reverse stock split may
not result in an increase in the per share price of Millendo common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo cannot predict whether the reverse stock split will
increase the market price for Millendo common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price per share of Millendo common stock after the reverse stock split will rise in proportion to the
reduction in the number of shares of Millendo common stock outstanding before the reverse stock split; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade
in lower priced stocks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reverse stock split will result in a per share price that will increase the ability of Millendo to attract
and retain employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by
Nasdaq for continued listing; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient
period of time for the combined company&#146;s common stock to be approved for listing by Nasdaq. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of
Millendo common stock will also be based on the performance of Millendo, and after the merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split
is effected and the market price of Millendo common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of Millendo may be greater than would occur in the absence of a reverse stock
split.&nbsp;Furthermore, the liquidity of Millendo common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Principal Effects of the Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split will be realized simultaneously for all shares of Millendo common stock, options to purchase shares of Millendo common
stock outstanding immediately prior to the effective time of the reverse stock split.&nbsp;The reverse stock split will affect all holders of shares of Millendo common stock outstanding immediately prior to the effective time of the reverse stock
split uniformly and each such stockholder will hold the same percentage of Millendo common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for immaterial
adjustments that may result from the treatment of fractional shares as described below. The reverse stock split will not change the par value of Millendo common stock or preferred stock and will not reduce the number of authorized shares of Millendo
common stock or preferred stock. Millendo common stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. The reverse stock split will not affect Millendo continuing to be subject to the periodic reporting
requirements of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Millendo stockholders approve the amendment to the Millendo restated certificate of incorporation as amended effecting the reverse stock
split, and if the Millendo board of directors still believes that a reverse stock split is in the best interests of Millendo and its stockholders, Millendo will file the amendment to the restated certificate of incorporation as amended with the
Secretary of State of the State of Delaware at such time as the Millendo board of directors has determined to be the appropriate split effective time. The Millendo board of directors may delay effecting the reverse stock split without resoliciting
stockholder approval. Beginning at the split effective time, each stock certificate representing <FONT STYLE="white-space:nowrap">pre-split</FONT> shares will be deemed for all corporate purposes to evidence ownership of post-split shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the split effective time, stockholders will be notified that the reverse stock split has been effected. Millendo
expects that the Millendo transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of <FONT STYLE="white-space:nowrap">pre-split</FONT> shares will be asked to surrender to the exchange agent
stock certificates representing <FONT STYLE="white-space:nowrap">pre-split</FONT> shares in exchange for stock certificates (or book-entry </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
positions) representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by Millendo. No new certificates (or book-entry positions) will
be issued to a stockholder until such stockholder has surrendered such stockholder&#146;s outstanding certificate(s) together with the properly completed and executed letter of transmittal to the exchange agent. Shares held in book-entry form will
be automatically exchanged. Any <FONT STYLE="white-space:nowrap">pre-split</FONT> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares. <B>Stockholders
should not destroy any stock certificate(s) and should not submit any certificate(s) unless and until requested to do so.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fractional Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued in connection with the reverse stock split.&nbsp;Stockholders of record who otherwise would be entitled to
receive fractional shares because they hold a number of <FONT STYLE="white-space:nowrap">pre-split</FONT> shares not evenly divisible by the number of <FONT STYLE="white-space:nowrap">pre-split</FONT> shares for which each post-split share is to be
reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the
closing price of the common stock on Nasdaq on the date of the filing of the amendment to the restated certificate of incorporation as amended effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder
will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Millendo is
domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence
has been received by Millendo or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from
the state to which they were paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Anti-Takeover Effect </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover
effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Millendo board of directors or contemplating a tender offer or other transaction for the combination
of Millendo with another company, the reverse stock split proposal is not being proposed in response to any effort of which Millendo is aware to accumulate shares of Millendo common stock or obtain control of Millendo, other than in connection with
the merger, nor is it part of a plan by management to recommend a series of similar amendments to the Millendo board of directors and stockholders. Other than the proposals being submitted to the Millendo stockholders for their consideration at the
Millendo special meeting, the Millendo board of directors does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of Millendo. For
more information, please see the section&nbsp;titled &#147;<I>Risk Factors&#151;Risks Related to the Combined Company</I>&#148; beginning on page&nbsp;24. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Material U.S.&nbsp;Federal Income Tax Consequences of the Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S.&nbsp;federal income tax consequences of the reverse stock split that are applicable to
U.S. holders (as defined below) of Millendo common stock. This discussion does not purport to be a complete analysis of all potential tax consequences and is based upon current provisions of the Code, existing Treasury regulations, judicial
decisions and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be
retroactive, could alter the tax consequences to holders of Millendo common stock as described in this summary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all U.S.&nbsp;federal income tax consequences relevant to
holders of Millendo common stock. In addition, it does not address consequences relevant to holders of Millendo common stock that are subject to particular U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including, without
limitation, to holders of Millendo common stock that are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold their Millendo common stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual
funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; regulated investment companies; <FONT STYLE="white-space:nowrap">tax-exempt</FONT>
organizations or governmental organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes
and limited liability companies (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to the alternative minimum tax provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other
integrated transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have a functional currency other than the U.S.&nbsp;dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold shares of Millendo common stock that may constitute &#147;qualified small business stock&#148;
under Section&nbsp;1202 of the Code or as &#147;Section&nbsp;1244 stock&#148; for purposes of Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired their shares of Millendo stock in a transaction subject to the gain rollover provisions of
Section&nbsp;1045 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to Millendo
stock being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell Millendo common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired their shares of Millendo common stock pursuant to the exercise of options or otherwise as
compensation or through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expatriates or former citizens or long-term residents of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Holders of Millendo common stock subject to particular U.S.&nbsp;or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax rules, including
those that are described in this paragraph, are urged to consult their own tax advisors regarding the consequences to them of the reverse stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If an entity that is treated as a partnership for U.S.&nbsp;federal income tax purposes holds Millendo stock, the U.S.&nbsp;federal income tax
treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the partnership or other pass-through entity and certain determinations made at the partner level. If you
are a partner of a partnership or other pass-through entity holding Millendo common stock, you should consult your tax advisors regarding the tax consequences of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the following discussion does not address the tax consequences of the reverse stock split under state, local and foreign tax
laws. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE
U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S.&nbsp;FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited
to holders of Millendo common stock that are U.S.&nbsp;Holders. For purposes of this discussion, a &#147;U.S.&nbsp;Holder&#148; is a beneficial owner of Millendo common stock that, for U.S.&nbsp;federal income tax purposes, is or is treated as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any other entity taxable as a corporation created or organized in or under the laws of the
United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S.&nbsp;federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if either (i)&nbsp;a court within the United States is able to exercise primary supervision over the
administration of such trust, and one or more United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) is authorized or has the authority to control all substantial decisions of such trust, or (ii)&nbsp;the trust was in
existence on August&nbsp;20, 1996 and has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S.&nbsp;federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences of the Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposed reverse stock split should constitute a &#147;recapitalization&#148; for U.S.&nbsp;federal income tax purposes pursuant to
Section&nbsp;368(a)(1)(E) of the Code. As a result, a U.S.&nbsp;Holder generally should not recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of Millendo common stock, as
discussed below. A U.S.&nbsp;Holder&#146;s aggregate adjusted tax basis in the shares of Millendo common stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted tax basis of the shares of the Millendo common
stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Millendo common stock), and such U.S.&nbsp;Holder&#146;s holding period in the shares of Millendo common stock received should include the holding
period in the shares of Millendo common stock surrendered. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Millendo common stock surrendered to the shares of Millendo common stock
received in a recapitalization pursuant to the proposed reverse stock split.&nbsp;U.S.&nbsp;Holders of shares of Millendo common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of
the tax basis and holding period of such shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash in Lieu of Fractional Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S.&nbsp;Holder that receives cash in lieu of a fractional share of Millendo common stock pursuant to the proposed reverse stock split
should recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S.&nbsp;Holder&#146;s tax basis in the shares of Millendo common stock surrendered that is allocated to such fractional share of
Millendo common stock. Such capital gain or loss should be long-term capital gain or loss if the U.S.&nbsp;Holder&#146;s holding period for Millendo common stock surrendered exceeded one year at the effective time of the reverse stock split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of cash made in lieu of a fractional share of Millendo common stock may, under certain circumstances, be subject to information
reporting and backup withholding. To avoid backup withholding, each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder of Millendo common stock that does not otherwise establish an exemption should furnish its taxpayer identification number and comply with the applicable certification procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld will be allowed as a credit against the holder&#146;s U.S. federal income
tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Millendo common stock should consult their tax advisors regarding their qualification for an exemption from backup
withholding and the procedures for obtaining such an exemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the outstanding shares of Millendo common stock entitled to vote at the Millendo special
meeting is required to approve the amendment to the restated certificate of incorporation of Millendo as amended to effect a reverse stock split of Millendo common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>MILLENDO&#146;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THIS PROPOSAL NO. 2 TO APPROVE THE AMENDMENT TO THE
RESTATED CERTIFICATE OF INCORPORATION OF MILLENDO AS AMENDED TO EFFECT THE REVERSE STOCK SPLIT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is
the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#147;FOR&#148; the approval of the amendment to the restated certificate of incorporation of Millendo as amended to effect
the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_87"></A>PROPOSAL NO.&nbsp;3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY, <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> VOTE ON MERGER-RELATED EXECUTIVE COMPENSATION ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14A of the Exchange Act, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010,
requires that Millendo provide stockholders with the opportunity to vote to approve, on <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the payment of certain compensation that will or may become payable by Millendo to its named
executive officers in connection with the Merger, as disclosed in the section titled &#147;<I>The Merger&#151;Interests of the Millendo Directors and Executive Officers in the Merger&#151;Golden Parachute Compensation.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the consummation of the merger, each of the Millendo named executive officers will resign with good reason. Therefore, Millendo is asking
stockholders to indicate their approval of the compensation that will or may become payable by Millendo to its named executive officers in connection with the merger and the associated termination by the named executive officers for good reason upon
the consummation of the merger. These payments are set forth in the section titled &#147;<I>The Merger&#151;Interests of the Millendo Directors and Executive Officers in the Merger&#151;Golden Parachute Compensation,</I>&#148; and the accompanying
footnotes. In general, the employment agreements, equity awards and other arrangements pursuant to which these compensation payments may be made have previously formed a part of Millendo&#146;s overall compensation program for its named executive
officers and previously have been disclosed to stockholders as part of Millendo&#146;s annual proxy statements or its other reports filed with the SEC. These historical employment agreements, equity awards and other arrangements were adopted and
approved by the compensation committee of the Millendo board of directors, which is composed solely of <FONT STYLE="white-space:nowrap">non-management</FONT> directors, and are believed to be reasonable and in line with marketplace norms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, Millendo is seeking approval of the following resolution at the Millendo special meeting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the stockholders of Millendo Therapeutics, Inc. approve, on a nonbinding, advisory basis, the compensation that will or
may become payable by Millendo to its named executive officers that is based on or otherwise relates to the merger as disclosed pursuant to Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in the section titled &#147;<I>The
Merger&#151;Interests of the Millendo Directors and Executive Officers in the Merger&#151; Golden Parachute Compensation.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of Millendo should note that this proposal is not a condition to&nbsp;the closing of the Merger, and as an advisory vote, the
result will not be binding on Millendo, its board of directors or the named executive officers. Further, the underlying employment agreements, equity awards and other arrangements are contractual in nature and not, by their terms, subject to
stockholder approval. Accordingly, regardless of the outcome of the advisory vote, if the Merger is consummated and Millendo&#146;s&nbsp;named executive officers are terminated in connection with the Merger, the named executive officers will be
eligible to receive the compensation that is based on or otherwise relates to the Merger in accordance with the terms and conditions applicable to the underlying employment agreements, equity awards and other arrangements Millendo entered into with
these named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares present in attendance or represented by proxy at the Millendo special meeting
and entitled to vote on the matter, assuming a quorum is present, is required to approve the <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on compensation that will or may become payable by Millendo to its named executive
officers in connection with the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>MILLENDO&#146;S BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THIS PROPOSAL
NO. 3 TO APPROVE, ON A <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE BASIS,</B> <B>COMPENSATION THAT WILL OR MAY BECOME PAYABLE BY MILLENDO TO ITS NAMED EXECUTIVE OFFICERS IN CONNECTION WITH THE MERGER</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_88"></A>PROPOSAL NO.&nbsp;4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF POSSIBLE ADJOURNMENT OF THE SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo fails to receive a sufficient number of votes to approve Proposal Nos. 1 and 2, Millendo may propose to adjourn the Millendo
special meeting, for a period of not more than 60 days, for the purpose of soliciting additional proxies to approve Proposal Nos. 1 and 2. Millendo currently does not intend to propose adjournment at the Millendo special meeting if there are
sufficient votes to approve Proposal Nos. 1 and 2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Required Vote </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares present in attendance or represented by proxy at the Millendo special meeting
and entitled to vote on the matter, assuming a quorum is present, is required to approve the adjournment of the Millendo special meeting for the purpose of soliciting additional proxies to approve Proposal Nos. 1 and 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>MILLENDO&#146;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THIS PROPOSAL NO. 4 TO ADJOURN THE MILLENDO SPECIAL MEETING, IF
NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSAL NOS.&nbsp;1 AND 2. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
instructed, it is the intention of the persons named in the accompanying proxy to vote shares &#147;FOR&#148; the ratification to adjourn the Millendo special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in
favor of Proposal Nos. 1 and 2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_89"></A>MILLENDO&#146;S BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is a biopharmaceutical company that was previously primarily focused on developing novel treatments for endocrine diseases where
current therapies do not exist or are insufficient. The endocrine system is a collection of glands that secrete hormones into the blood stream to regulate a number of functions, including appetite, metabolism, growth, development and reproduction.
Diseases of the endocrine system can cause multiple and varied symptoms, including appetite dysregulation, metabolic dysfunction, obesity, cardiovascular disease, menstrual irregularity, hirsutism, and infertility. In April 2020, Millendo&#146;s
board of directors decided to discontinue the development of livoletide, an unacylated ghrelin analogue, as a potential treatment for Prader-Willi syndrome (&#147;PWS&#148;) based upon results from its Phase 2b trial. In addition, in June 2020, the
Millendo board of directors decided to cease investing in the development of nevanimibe as a potential treatment for classic congenital adrenal hyperplasia, (&#147;CAH&#148;) based on an interim review of data from its Phase 2b trial. Finally, in
January 2021, the Millendo board of directors also decided to discontinue the investment in <FONT STYLE="white-space:nowrap">MLE-301,</FONT> a neurokinin 3 receptor (&#147;NK3R&#148;) antagonist Millendo was developing for the treatment of
menopausal vasomotor symptoms (&#147;VMS&#148;), based on an analysis of the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose portion of the Phase 1 study conducted in healthy male volunteers. Given Millendo&#146;s
limited expected financing options, it began exploring an expanded range of strategic alternatives that included, but was not limited to, the potential sale or merger of Millendo or its assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to streamline costs after discontinuing the PWS program, Millendo eliminated employee positions representing approximately 30% of
its prior headcount, which was completed in the second quarter of 2020. Millendo also began evaluating corporate strategic plans to prioritize and allocate resources to its remaining product candidates at the time and any future pipeline assets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, as a result of Millendo&#146;s decision to discontinue the investment in
<FONT STYLE="white-space:nowrap">MLE-301,</FONT> the Millendo board of directors also approved a corporate restructuring plan (the &#147;Plan&#148;) furthering Millendo&#146;s ongoing efforts to align its resources with its current strategy and
operations. In connection with the Plan, the Millendo board of directors determined to reduce Millendo&#146;s workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April&nbsp;15, 2021. Millendo initiated
this reduction in force in January 2021 and expects to provide severance payments and continuation of group health insurance coverage for a specified period to the affected employees. Millendo has also entered into retention arrangements with
employees who are expected to remain with the Millendo. Millendo estimates that it will incur costs of approximately $5.5&nbsp;million for termination benefits and retention arrangements related to the Plan, substantially all of which will be cash
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, Millendo undertook a strategic review process, which was intended to result in an actionable plan that leverages
its assets, capital and capabilities to maximize stockholder value. Following an extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, on
March&nbsp;29, 2021, Millendo entered into the Merger Agreement with Tempest, under which the privately held Tempest will merge with a wholly owned subsidiary of Millendo. If the merger is completed, the business of Tempest will continue as the
business of the combined organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects to devote significant time and resources to completion of this merger. However,
there can be no assurance that such activities will result in the completion of the merger. Further, the completion of the merger may ultimately not deliver the anticipated benefits or enhance shareholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is not completed, Millendo will reconsider its strategic alternatives. In this case, Millendo considers one of the following
courses of action to be the most likely alternatives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dissolve and liquidate its assets.</I> If, for any reason, the merger does not close, the Millendo board of
directors may conclude that it is in the best interest of its stockholders to dissolve Millendo and liquidate its assets, which may include seeking protections from creditors in a bankruptcy proceeding.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
In that event, Millendo would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims. There would be no assurances as to
the amount or timing of available cash remaining to distribute to stockholders after paying its obligations and setting aside funds for reserves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue another strategic transaction.</I> Millendo may resume the process of evaluating a potential strategic
transaction in order to attempt another strategic transaction like the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Operate its business.</I> Although less likely than the alternatives above, the Millendo board of directors
may elect to seek new product candidates for development. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Historical Business and Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, Millendo advanced three product candidates. Livoletide <FONT STYLE="white-space:nowrap">(AZP-531),</FONT> was a potential treatment
for PWS, a rare and complex genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger, that contributes to serious complications, a significant burden on patients and caregivers, and early mortality. In a randomized,
double-blind, placebo-controlled Phase 2a clinical trial in 47 patients with PWS, Millendo observed that administration of livoletide once daily was associated with a clinically meaningful improvement in hyperphagia, as well as a reduction in
appetite. In a <FONT STYLE="white-space:nowrap">pre-specified</FONT> analysis of 38 home-resident patients with PWS from the Phase 2a trial, Millendo observed a larger and statistically significant decrease in hyperphagia following administration of
livoletide as compared to placebo. In March 2019, Millendo initiated a Phase 2b/3 clinical trial of livoletide in patients with PWS. In April 2020, Millendo discontinued the PWS program based on topline data from the Phase 2b ZEPHYR study which
showed that treatment with livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors as measured by the Hyperphagia Questionnaire for Clinical Trials
<FONT STYLE="white-space:nowrap">(HQ-CT)</FONT> compared to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo was developing nevanimibe
<FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment for patients with CAH, a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses. These chronic high doses of cortisol
can result in side effects that include diabetes, obesity, hypertension and psychological problems. When on suboptimal doses of cortisol, female patients with CAH can experience hirsutism, infertility and menstrual irregularity, and male patients
with CAH can experience testicular atrophy, infertility and testicular tumors. It is often difficult for physicians to appropriately treat CAH without causing adverse consequences. Millendo reported results from its Phase 2a clinical trial of
nevanimibe in patients with CAH in March 2018 and initiated a Phase 2b trial in the third quarter of 2018. In June 2020, Millendo elected to cease investing in the development of nevanimibe as a potential treatment for CAH. The decision to cease
investment in the CAH program was based on the interim review of results from the Phase 2b clinical study and the changing competitive environment. Results from 10 subjects, nine from cohort 1 and one from cohort 2, with at least 12 weeks of
treatment with nevanimibe in this open-label, continuous dose escalation study showed that one patient (10%) met the primary endpoint of achieving <FONT STYLE="white-space:nowrap">17-hydroxyprogesterone</FONT>
<FONT STYLE="white-space:nowrap">(17-OHP)</FONT> levels less than or equal to <FONT STYLE="white-space:nowrap">2-times</FONT> the upper limit of normal. Treatment under the amended protocol with dose titration starting at 500 mg BID improved
tolerability of nevanimibe. Millendo is no longer developing nevanimibe for the treatment of CAH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo was also developing a NK3R
antagonist <FONT STYLE="white-space:nowrap">(MLE-301)</FONT> as a potential treatment of vasomotor symptoms (&#147;VMS&#148;), commonly known as hot flashes and night sweats, in menopausal women. The sensations of heat and/or perspiration associated
with VMS can occur frequently, generally lasting several minutes, and are often preceded or followed by sensations of cold and/or shivering. VMS interfere with the lives of affected women in a number of ways, including disrupting patients&#146;
ability to sleep and concentrate and causing anxiety and depression. VMS is experienced by up to 70% of women as they advance through menopause. Millendo believes that over 20&nbsp;million women in the United States experience VMS at any given time
and that these patients are motivated to seek medical treatment for relief. In September 2020, Millendo initiated its Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">MLE-301.</FONT> The Phase 1 clinical trial was supported by preclinical
studies in which Millendo observed potency and selectivity for the NK3R, the potential for once-daily dosing, and testosterone lowering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent with the expected activity of an NK3R antagonist. In January 2021, Millendo discontinued further investment in the development of <FONT STYLE="white-space:nowrap">MLE-301</FONT> for
the treatment of VMS based on an analysis of the pharmacokinetic and pharmacodynamic data from the single ascending dose portion of the Phase 1 study and the competitive NK3R antagonist market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo had also been investigating nevanimibe <FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment for patients with
endogenous Cushing&#146;s syndrome (&#147;CS&#148;), a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. As a result of slower than anticipated enrollment in its CS Phase 2 clinical trial, Millendo
elected to discontinue the trial in August 2019 and is no longer developing nevanimibe for the treatment of CS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is not currently conducting sales and marketing efforts with respect to any of its previous programs and is in the process of
terminating the license agreements pursuant to which it had development and commercialization rights with respect to livoletide, nevanimibe and <FONT STYLE="white-space:nowrap">MLE-301.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is not
currently conducting research and development of any of its previous programs and its plans for future research and development are dependent on the results of its ongoing strategic evaluation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assignment Agreement with Erasmus University Medical Center and the University of Turin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has an assignment agreement (the &#147;Assignment Agreement&#148;) with Erasmus University Medical Center, the University of Turin and
certain individuals, which it refers to collectively as the assignors, for certain patents and patent applications relating to livoletide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Assignment Agreement, Millendo agreed to pay the assignors a flat, low single digit royalty on net commercial sales of
products containing livoletide that are covered by the claims of the assigned intellectual property. Further, upon approval of livoletide by the FDA or the European Medicines Agency or EMA, Millendo is required to pay the assignors CDN$100,000,
which amount will be deducted from any future royalty payments due to the assignors. Millendo also agreed to pay the assignors a low single digit percentage of any amounts received in connection with its license of the assigned intellectual property
or products containing livoletide that are covered by the claims of the assigned intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assignors have a right to
repurchase the assigned intellectual property at a certain price in the event Millendo does not, upon receiving notice, use reasonable efforts to develop, introduce for sale and promote products derived from the assigned intellectual property. Such
reasonable efforts involve spending an annual amount of at least CDN$100,000 in research and development related to livoletide, actively pursuing the registration, licenses and permits necessary to market livoletide, and the actual commercialization
of livoletide, if approved. In addition, pursuant to the assignment agreement, certain individuals at the Erasmus University Medical Center and the University of Turin were granted <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights to use
the assigned intellectual property for <FONT STYLE="white-space:nowrap">non-commercial</FONT> research with Millendo&#146;s prior written consent. In March 2021, Millendo notified the assignors that it had discontinued the PWS program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with the University of Michigan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, Millendo entered into a license agreement with the University of Michigan, or the UM License Agreement, for a worldwide,
exclusive, sublicensable license to the University of Michigan&#146;s interest in certain patent rights jointly owned with Millendo, covering, among other things, the use of nevanimibe to treat CAH. Such license rights allowed Millendo to make, have
made, import, export, use, market, offer for sale and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell products containing nevanimibe for such use in the United States. Due to Millendo&#146;s decision to cease investing in the nevanimibe program, effective on March&nbsp;5, 2021, Millendo
notified the University of Michigan of its decision to terminate the UM License Agreement, which termination shall be effective April&nbsp;30, 2021, as agreed to by the University of Michigan </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with Roche </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;16, 2018, Millendo entered into a license agreement with F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Inc. (collectively, &#147;Roche&#148;), for a
worldwide, exclusive license to Roche&#146;s interest in certain patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> covering, among other things, the use of a neurokinin 3 receptor antagonist (the &#147;Roche License
Agreement&#148;). Such license rights have allowed Millendo to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed,
distribute, have distributed, sell and have sold an NK3R antagonist for use in all countries in the world and for all other uses other than diagnostic use. Due to Millendo&#146;s decision to discontinue investing in the <FONT
STYLE="white-space:nowrap">MLE-301</FONT> program, in March 2021, Millendo notified Roche that it was terminating the Roche License Agreement effective three months from the date of such notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When applicable to
Millendo&#146;s development programs, Millendo seeks to obtain and maintain patent and other intellectual property and proprietary protection for its drug candidates in the United States and internationally, including
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter,</FONT></FONT> dosage and formulation patents, as well as patent and other intellectual property and proprietary protection for its novel biological discoveries
and other important technology inventions and <FONT STYLE="white-space:nowrap">know-how.</FONT> In addition to patents, Millendo relies upon unpatented trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and continuing technological
innovation to develop and maintain its intellectual property rights. Millendo protects its proprietary information, in part, using confidentiality agreements with its commercial partners, collaborators, employees and consultants and invention
assignment agreements with its employees as well as selected commercial partners and consultants. Despite these measures, any of its intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or
misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit Millendo to take advantage of current market trends or otherwise to provide competitive advantages. In addition, such confidentiality agreements
and invention assignment agreements can be breached and Millendo may not have adequate remedies for any such breach. For more information, please see &#147;<I>Risk Factors</I><I>&#151;</I><I>Risks Related to Millendo&#151;Risks Related to
Millendo</I><I>&#146;</I><I>s Intellectual Property</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo seeks patent protection in significant markets and/or countries
for each drug in development. Millendo also seeks to maximize patent term. The patent exclusivity period for a drug will prevent generic drugs from entering the market. Patent exclusivity depends on a number of factors including the strength of the
claims, the initial patent term, patent term adjustments and available patent term extensions based upon delays caused by the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies like Millendo are generally uncertain and involve complex legal, scientific and factual
questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, Millendo may not obtain or maintain adequate patent
protection for any of its product candidates. As of March&nbsp;31, 2021, with respect to livoletide patent rights, Millendo owned four issued U.S. patents, one pending U.S. patent application, and a number of patents and pending patent applications
in other jurisdictions. As of March&nbsp;31, 2021, with respect to nevanimibe patent rights, Millendo owned two issued U.S. patents, two pending U.S. patent applications, and a number of pending patent applications in other jurisdictions, and
jointly owned, with University of Michigan, three issued U.S. patents, one pending U.S. patent application, and a number of patent applications in other jurisdictions. As of March 31, 2021, with respect to
<FONT STYLE="white-space:nowrap">MLE-301</FONT> patent rights, Millendo owned one pending U.S. patent application, and it exclusively licensed from Roche one issued U.S. patent and a number of patents and pending patent applications in other
jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo cannot predict whether the patent applications it pursues will issue as patents in
any particular jurisdiction or whether the claims of any issued patents will provide any proprietary protection from competitors. The patent portfolios for its leading product candidates as of March 31, 2021 are summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Livoletide </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
respect to livoletide patent rights, as of March 31, 2021 Millendo owned four issued U.S. patents, which are not due to expire before 2028, 2028, 2029, and 2032, respectively, excluding any additional term for patent term extension pursuant to the
Hatch-Waxman Act; one pending U.S. patent application, which is not due to expire before 2034, excluding any additional term for patent term adjustment or extension; and a number of patent applications in other jurisdictions. The foregoing patents
and patent applications cover a form of and methods of making and using livoletide or its analogs. Related international patent applications have issued in Australia, Canada, China, Europe, Japan, and Mexico and are pending in a number of other
countries, including Canada, Europe, and India. In March 2021, in connection with the discontinuation of its livoletide program, Millendo notified the assignors of its decision to discontinue development of livoletide. Millendo does not expect its
livoletide patents to enable development of livoletide apart from the intellectual property licensed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nevanimibe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to nevanimibe patent rights, as of March 31, 2021, Millendo owned two issued U.S. patents, which are not due to expire before
2035, excluding any additional term for patent term adjustment or extension; two pending U.S. patent applications, which, if issued, are not due to expire before 2035 and 2036, respectively, excluding any additional term for patent term adjustment
or extension; and a number of patent applications in other jurisdictions. As of March 31, 2021, Millendo jointly owned, with University of Michigan, three issued U.S. patents, which are each not due to expire before 2033, excluding any additional
term for patent term adjustments or extensions; one pending U.S. patent application, which, if issued, is not due to expire before 2033, excluding any additional term for patent term adjustment or extension; and a number of patent applications in
other jurisdictions. The foregoing patents and patent applications cover a form of and methods of making and using nevanimibe or its analogs. Related international patent applications have issued in Australia, China, Japan, Mexico, and New Zealand
and are pending in a number of other countries, including Australia, Brazil, Canada, China, Europe, and Mexico. Due to Millendo&#146;s decision to discontinue the development of its nevanimibe program, in March 2021, it notified the University of
Michigan of its decision to terminate the UM License Agreement, which termination shall be effective as of April&nbsp;30, 2021, as agreed with the University of Michigan. Millendo does not expect its nevanimibe patents to enable development of
nevanimibe apart from the intellectual property licensed pursuant to the UM License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">MLE-301</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to <FONT STYLE="white-space:nowrap">MLE-301</FONT> patent rights, as of March 31, 2021, Millendo owned one pending Patent
Cooperation Treaty patent application, which, if issued, is not due to expire before 2040, excluding any additional term for patent term adjustment or extension. As of March 31, 2021, Millendo exclusively licensed from Roche one issued U.S. patent,
which is not due to expire before 2031, excluding any additional term for patent term adjustment or extension. The foregoing patents and patent applications cover a form of and methods of making and using
<FONT STYLE="white-space:nowrap">MLE-301</FONT> or its analogs. Related international patent applications have issued in China, Europe, Japan, South Korea, and Mexico, and are pending in a number of other countries, including Brazil, Canada, India,
and Russia. Due to Millendo&#146;s decision to discontinue developing the <FONT STYLE="white-space:nowrap">MLE-301</FONT> program in March 2021, it notified Roche that it was terminating the Roche License Agreement effective three months from the
date of such notice. Millendo does not expect its <FONT STYLE="white-space:nowrap">MLE-301</FONT> patents to enable development of <FONT STYLE="white-space:nowrap">MLE-301</FONT> apart from the intellectual property licensed pursuant to the Roche
License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo relied on contract manufacturing organizations, or CMOs, to produce drug candidates in accordance with the FDA&#146;s current Good
Manufacturing Practices, or cGMP, regulations for use in its prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials. The manufacture of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all areas of record
keeping, production processes and controls, personnel and quality control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>United <FONT STYLE="white-space:nowrap">States-FDA</FONT> process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs. The Federal Food, Drug, and Cosmetic Act, or FDCA, and other federal and state statutes and
regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of
drugs. To obtain regulatory approvals in the United States and in foreign countries, and subsequently comply with applicable statutes and regulations, Millendo will need to spend substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Approval process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA must approve any new drug or a drug with certain changes to a previously approved drug before a manufacturer can market it in the
United States. If a company does not comply with applicable United States requirements it may be subject to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending applications, warning or untitled letters, clinical
holds, drug recalls, drug seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. The steps Millendo must complete before it can market a drug include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies, and formulation studies, all performed in accordance
with the FDA&#146;s good laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical
studies start. The sponsor must update the IND annually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of the study by an independent institutional review board, or IRB, or ethics committee representing each
clinical site before each clinical study begins; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the
drug for each indication to the FDA&#146;s satisfaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential review of the drug application by an FDA advisory committee, where appropriate and if applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities to assess compliance
with current good manufacturing practices, cGMP, or regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It generally takes companies many years to satisfy the FDA approval requirements, but this varies substantially based upon the type,
complexity, and novelty of the drug or disease. Preclinical tests include laboratory evaluation of a drug&#146;s chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the
drug. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. Millendo submits the results of the preclinical testing to the FDA as part of an IND along with other information, including information
about the product drug&#146;s chemistry, manufacturing and controls, and a proposed clinical study protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, are generally conducted after submitting the
initial IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA requires a <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the submission of each IND before
Millendo can begin clinical testing in humans in the United States. The FDA may, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raise concerns or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
questions relating to one or more proposed clinical studies and place the study on a clinical hold. In such a case, Millendo and the FDA must resolve any outstanding concerns before Millendo
begins the clinical study. Accordingly, the content of an IND submission may or may not be sufficient for the FDA to permit the sponsor to start a clinical study. Millendo must also make a separate submission to an existing IND for each successive
clinical study conducted in the U.S. during drug development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies involve administering the investigational new drug to healthy volunteers or patients under the supervision of a qualified
investigator. Millendo must conduct clinical studies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in compliance with federal regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and
health of patients and to define the roles of clinical study sponsors, administrators, and monitors; as well as </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under protocols detailing the objectives of the trial, the safety monitoring parameters, and the effectiveness
criteria. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo must submit each protocol involving testing on United States patients and subsequent protocol
amendments to the FDA as part of the IND. The FDA may order the temporary, or permanent, discontinuation of a clinical study at any time, or impose other sanctions, if it believes that the sponsor is not conducting the clinical study in accordance
with FDA requirements or presents an unacceptable risk to the clinical study patients. The sponsor must also submit the study protocol and informed consent information for patients in clinical studies to an institutional review board for approval.
An IRB may halt the clinical study, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies generally divide the clinical investigation of a drug into three or four phases. While companies usually conduct these phases
sequentially, they are sometimes overlapped or combined. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1.</I> Millendo evaluates the drug in healthy human subjects or patients with the target disease or
condition. These studies typically evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational new drug in humans, the side effects associated with increasing doses, and if possible, gain early evidence on
effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2.</I> Millendo administers the drug to a limited patient population to evaluate dosage tolerance and
optimal dosage, identify possible adverse side effects and safety risks, and preliminarily evaluate efficacy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3.</I> Millendo administers the drug to an expanded patient population, generally at geographically
dispersed clinical study sites, to generate enough data to statistically evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug, and to provide an adequate basis for product
approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 4.</I> In some cases, the FDA may condition approval of an NDA for a drug on Millendo&#146;s agreement
to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the drug. Millendo typically refers to such post-approval studies as
Phase 4 clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A pivotal study is a clinical study that adequately meets regulatory agency requirements to
evaluate a drug&#146;s efficacy and safety to justify the approval of the drug. Generally, pivotal studies are Phase 3 studies, but the FDA may accept results from Phase 2 studies if the study design provides a well controlled and reliable
assessment of clinical benefit, particularly in situations in which there is an unmet medical need and the results are sufficiently robust. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, the IRB, or the clinical study sponsor may suspend or terminate a clinical study at
any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, an independent group of qualified experts organized by the clinical study sponsor, known as a data safety
monitoring board or committee, may oversee some clinical studies. This group provides authorization for whether or not a study may move forward at designated checkpoints based on access to certain data from the study. Millendo may also suspend or
terminate a clinical study based on evolving business objectives and the competitive climate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Submission of an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a company completes the required clinical testing, it can prepare and submit an NDA to the FDA, who must approve the NDA before it can
start marketing the drug in the United States. An NDA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information
relating to the drug&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company- sponsored clinical studies on a drug, or from a number of alternative sources, including studies initiated by
investigators or studies not conducted under a U.S. IND. To support marketing authorization, the data a company submits must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug to the
FDA&#146;s satisfaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject
to a substantial application user fee, and the manufacturer and/or sponsor under an approved new drug application are also subject to annual program user fees. The FDA typically increases these fees annually. Orphan drug designation entitles a party
to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of an NDA to determine whether it will accept the application for filing based on the agency&#146;s
threshold determination that the application is sufficiently complete to permit substantive review. Once the FDA accepts the filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review. The FDA has agreed to certain performance
goals in the review of NDAs. Under the Prescription Drug User Fee Act, the FDA has a goal of responding to standard review NDAs within ten months after the <FONT STYLE="white-space:nowrap">60-day</FONT> filing review period, but this timeframe may
be extended. The FDA reviews most applications for standard review drugs within ten to 12 months and most applications for priority review drugs within six to eight months. Priority review can be applied to drugs that the FDA determines offer major
advances in treatment, or provide a treatment where no adequate therapy exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also refer applications for novel drugs that
present difficult questions of safety or efficacy, to an advisory committee. This is typically a panel that includes clinicians and other experts that will review, evaluate, and recommend whether the FDA should approve the application. The FDA is
not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP, and will inspect the facility
or the facilities at which the drug is manufactured. The FDA will not approve the drug unless compliance with cGMP is satisfactory and the NDA contains data that provide evidence that the drug is safe and effective in the indication studied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA&#146;s decision on an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter indicates that the FDA has completed its review of the application, and the agency has determined that it will not approve the application in its present form. A complete response letter generally outlines the deficiencies in the
submission and may require substantial additional clinical data and/or other significant, expensive, and time-consuming requirements related to clinical studies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preclinical studies and/or manufacturing. The FDA has committed to reviewing resubmissions of the NDA addressing such deficiencies in two or six months, depending on the type of information
included. Even if Millendo submits such data, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Also, the government may establish additional requirements, including those resulting from new legislation, or the
FDA&#146;s policies may change, which could delay or prevent regulatory approval of Millendo&#146;s drugs under development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the
benefits of the drug outweigh the potential risks. REMS can include communication plans for healthcare professionals, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring,
and the use of patient registries. The requirement for REMS can materially affect the potential market and profitability of the drug. Moreover, the FDA may condition approval on substantial post-approval testing and surveillance to monitor the
drug&#146;s safety or efficacy. Once granted, the FDA may withdraw drug approvals if Millendo fails to comply with regulatory standards or identifies problems following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing
processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before Millendo can implement the change. An NDA supplement for a new indication typically requires clinical data similar to that in the original
application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing new NDAs. As with new NDAs, the FDA often significantly extends the review process with requests for additional information or
clarification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA regulates drugs that are manufactured or distributed pursuant to FDA approvals and has specific requirements pertaining to
recordkeeping, periodic reporting, drug sampling and distribution, advertising and promotion and reporting of adverse experiences with the drug. After approval, the FDA must provide review and approval for most changes to the approved drug, such as
adding new indications or other labeling claims. There also are continuing, annual user fee requirements for any marketed drugs and the establishments who manufacture its drugs, as well as new application fees for supplemental applications with
clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP
requirements. There are strict regulations regarding changes to the manufacturing process, and, depending on the significance of the change, it may require prior FDA approval before Millendo can implement it. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon Millendo and any third-party manufacturers that Millendo may decide to use. Accordingly, manufacturers must continue to expend time,
money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if a company does not comply with regulatory requirements and maintain standards or if problems occur after the
drug reaches the market. If a company or the FDA discovers previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, issues with manufacturing processes, or Millendo&#146;s failure to comply with
regulatory requirements, the FDA may revise the approved labeling to add new safety information; impose post-marketing studies or other clinical studies to assess new safety risks; or impose distribution or other restrictions under a REMS program.
Other potential consequences may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the drug, complete withdrawal of the drug from the market or
drug recalls; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA refusing to approve pending NDAs or supplements to approved NDAs, or suspending or revoking of drug
license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug seizure or detention, or refusal to permit the import or export of drugs; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising, and promotion of drugs that are placed on the market. Drugs may be promoted only
for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#146;s FDA approved labeling. The FDA and
other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Millendo could be subject to significant liability if it violated these laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent term (as extended by the Hatch-Waxman Act), the holder of the NDA for a listed drug may be entitled to a period of
marketing exclusivity, during which the FDA cannot approve an abbreviated new drug application, or ANDA, or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#147;active moiety&#148; is defined
as the molecule or ion responsible for the drug substance&#146;s physiological or pharmacological action. During the five year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any
505(b)(2) NDA for the same active moiety and that relies on the FDA&#146;s findings regarding that drug, except that FDA may accept an application for filing after four years if the <FONT STYLE="white-space:nowrap">follow-on</FONT> applicant makes a
paragraph IV certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A drug, including one approved under Section&nbsp;505(b)(2), may obtain a three-year period of exclusivity
for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the
approval of the application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year exclusivity period
has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant orphan drug designation to sponsors of drugs intended to treat a rare disease or condition that affects fewer than 200,000
individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from
sales in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding
towards clinical study costs, tax advantages, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a drug receives FDA approval for the indication for which it has orphan designation, the drug may be entitled to orphan drug
exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the drug with orphan
exclusivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the
drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals,
for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which the FDA has granted an orphan designation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and foreign jurisdictions, the legislative landscape continues to evolve. There have been a number of legislative and
regulatory changes to the healthcare system that could affect the future results of Millendo&#146;s operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to
reform the way in which healthcare is funded and reduce healthcare costs. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively PPACA, was enacted, which
included measures that have significantly changed health care financing by both governmental and private insurers. The provisions of PPACA of importance to the pharmaceutical and biotechnology industry are, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs
agents, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the
average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations, unless the drug is subject to discounts under the 340B drug discount program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal
Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements under the federal Physician Payments Sunshine Act for drug manufacturers to report information
related to payments and other transfers of value made to physicians, as defined by such law, and teaching hospitals as well as ownership or investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirement to annually report certain drug samples that manufacturers and distributors provide to licensed
practitioners, or to pharmacies of hospitals or other healthcare entities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been executive, judicial and
Congressional challenges to certain aspects of the PPACA.While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision that repealed, effective January&nbsp;1, 2019, the tax based shared
responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; In addition, the 2020 federal spending
package permanently eliminated, effective January&nbsp;1, 2020, the PPACA mandated &#147;Cadillac&#148; tax on high cost employer sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminated the health
insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the PPACA, effective January&nbsp;1, 2019, to increase from 50% to 70% the point of sale discount that is owed by pharmaceutical manufacturers who participate in
Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety
because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was
unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. The United States Supreme Court is currently reviewing this case, but it is unknown when a decision
will be reached. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the PPACA, on January&nbsp;28, 2021, President Biden issued an executive order to initiate a special enrollment period from February&nbsp;15, 2021 through
May&nbsp;15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to
healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or
the PPACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the PPACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the President signed into
law the Budget Control Act of 2011, as amended, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and, following passage of subsequent legislation, including the
BBA, will continue through 2030 with the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, unless additional Congressional action is taken. In
January 2013, the American Taxpayer Relief Act of 2012 was enacted and, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there has been increasing legislative and enforcement interest in the United States with respect to drug
pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through
federal budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to
implement several of the administration&#146;s proposals. As a result, the FDA also released a final rule on September&nbsp;24, 2020, effective November&nbsp;30, 2020, implementing a portion of the importation executive order providing guidance for
states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D,
either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&nbsp;1, 2022 to January&nbsp;1, 2023 in response to ongoing
litigation. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a new safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March&nbsp;22, 2021. On November&nbsp;20, 2020, CMS issued an interim final rule implementing
the Trump administration&#146;s Most Favored Nation executive order, which would tie Medicare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January&nbsp;1, 2021. On December&nbsp;28, 2020, the United
States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy
initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It also possible that governmental action will be taken
in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>European
<FONT STYLE="white-space:nowrap">Union-EMA</FONT> process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, Millendo&#146;s product candidates are also
subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a marketing authorization, or MA, from the competent regulatory agencies has been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant
regulatory controls. Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on Good Clinical
Practices, or GCP. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the European Union clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the European
Union, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the Member State regimes. To improve the current system, Regulation (EU) No 536/2014 on clinical trials on
medicinal products for human use, which repealed Directive 2001/20/EC, was adopted on April&nbsp;16, 2014 and published in the European Official Journal on May&nbsp;27, 2014. The Regulation aims to harmonize and streamline the clinical trials
authorization process, simplify adverse event reporting procedures, improve the supervision of clinical trials, and increase their transparency. Although the Regulation entered into force on June&nbsp;16, 2014, it will not be applicable until six
months after the full functionality of the IT portal and database envisaged in the Regulation is confirmed by an independent audit, and the European Commission publishes a notice of this confirmation. This is not expected to occur until before 2021
as an audit of the system is intended to commence in December 2020. Until then the Clinical Trials Directive 2001/20/EC will still apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the transitory provisions of the new Regulation offer the sponsors the possibility to choose between the requirements of the
Directive and the Regulation for one year from the entry into application of the Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the current regime, before a clinical
trial can be initiated it must be approved in each of the EU Member States where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all
suspected unexpected serious adverse reactions, or SUSARs, to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred and would also be reported in all countries where
the drug is being used in a clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, after the EMA issues an opinion, the European Commission issues a single marketing authorization valid across
the European Union, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: derived from biotechnology processes, such as genetic engineering; contain a new active substance indicated for the
treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders diseases or autoimmune diseases and other immune dysfunctions; advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medicines; and officially designated orphan drugs. For drugs that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing
authorization to the EMA, as long as the drug concerned contains a new active substance; is a significant therapeutic, scientific or technical innovation; or if its authorization would be in the interest of public health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also three other possible routes to authorize medicinal products in the European Union, which are available for products that fall
outside the scope of the centralized procedure: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">National procedure. National MAs, issued by the competent authorities of the Member States of the EEA, are
available however these only cover their respective territory; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization
in more than one European Union country of a medicinal product that has not yet been authorized in any European Union country; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one European
Union Member State, in accordance with the national procedures of that country. Thereafter, further marketing authorizations can be sought from other European Union countries in a procedure whereby the countries concerned agree to recognize the
validity of the original, national marketing authorization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Regulation (EC) No 1901/2006, all applications
for marketing authorization for new medicines must include the results of all studies performed and details of all information collected in compliance with as described in a pediatric investigation plan, or PIP, agreed between regulatory
authorities, the EMA&#146;s Pediatric Committee, and the applicant, unless the medicine is exempt because of a deferral or waiver (e.g., because the relevant disease or condition occurs only in adults). Applicants are encouraged to submit pediatric
investigation plans early during product development, in time for studies to be conducted in the pediatric population, where appropriate, before marketing authorization applications are submitted.&nbsp;Before the EMA is able to begin its assessment
of a centralized procedure MA application, it will validate that the applicant has complied with an agreed pediatric investigation plan, or an application for a waiver has been submitted. The applicant and the EMA may, where such a step is
adequately justified, agree to modify a pediatric investigation plan to assist validation. Modifications are not always possible; may take longer to agree than the period of validation permits; and may still require the applicant to withdraw its
marketing authorization application, or MA, and to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies.&nbsp;Products that are granted a MA on the basis of the pediatric clinical trials conducted in
accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate or a patent qualifying for a supplementary protection (if any is in effect at the time of approval) or certificate or, in
the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and
submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, Regulation (EC) No 141/2000, as amended, states that a drug will be designated as an orphan drug if its sponsor can
establish: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in ten thousand persons in the European Union when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic
condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that
has been authorized in the European Union or, if such method exists, that the drug will be of significant benefit to those affected by that condition. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 847/2000 sets out further provisions for implementation of the criteria
for designation of a drug as an orphan drug. An application for the designation of a drug as an orphan drug may be submitted at any stage of development of the drug before submission of a MA application.&nbsp;However, an application for designation
as an orphan drug may be submitted for a new therapeutic indication for an already authorized medicinal product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a centralized
procedure MA in respect of an orphan drug is granted pursuant to Regulation (EC) No 726/2004, regulatory authorities will not, for a period of 10 years, accept another application for a MA, or grant a MA or accept an application to extend an
existing MA, for the same therapeutic indication, in respect of a similar drug. This period may however be reduced to six years if, at the end of the fifth year, it is established, in respect of the drug concerned, that the criteria for orphan drug
designation are no longer met, for example, when it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. The exclusivity period may increase to 12 years if, among
other things, the MA includes the results of studies from an agreed pediatric investigation plan. Notwithstanding the foregoing, a MA may be granted for the same therapeutic indication to a similar drug if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan drug has given its consent to the second applicant;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder of the MA for the original orphan drug is unable to supply sufficient quantities of the drug; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish in the application that the second drug, although similar to the orphan drug
already authorized, is safer, more effective or otherwise clinically superior. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No 847/2000 lays down
definitions of the concepts &#145;similar drug&#146; and &#145;clinical superiority&#146;. Other incentives available to orphan drugs in the European Union include financial incentives such as a reduction of fees or fee waivers and protocol
assistance. Orphan drug designation does not shorten the duration of the regulatory review and approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Good manufacturing
practices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Like the FDA, the EMA, the competent authorities of the European Union Member States and other regulatory agencies
regulate and inspect equipment, facilities and processes used in the manufacturing of drugs intended for the EU market to ensure that certain minimum standards are met. These requirements apply, no matter where in the world the manufacturing process
takes place and are designed to ensure that products intended for the EU market are of consistent high quality, are appropriate for their intended use and meet the requirements of the marketing authorization or clinical trial authorization.&nbsp;If,
after receiving clearance from regulatory agencies, a company makes a material change in manufacturing equipment, location, or process, additional regulatory review and approval may be required. A company and its partners will be required to
continue to comply with cGMP, and drug-specific regulations enforced by, the European Commission, the EMA and the competent authorities of European Union Member States following drug approval. Also like the FDA, the EMA, the competent authorities of
the European Union Member States and other regulatory agencies also conduct regular, periodic visits to reinspect equipment, facilities, and processes following the initial approval of a drug. If, as a result of these inspections, the regulatory
agencies determine that a company or its partners&#146; equipment, facilities, or processes do not comply with applicable regulations and conditions of drug approval, they may seek civil, criminal or administrative sanctions and/or remedies against
Millendo, including the suspension of its manufacturing operations or the withdrawal of its drug from the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval
Controls </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a European MA must establish and maintain a pharmacovigilance system and appoint an individual qualified
person for pharmacovigilance, or QPPV, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAs must include a risk management plan, or RMP, describing the risk management
system that Millendo will put in place, recording the product&#146;s safety profile and documenting the effectiveness of risk-minimization measures. The regulatory authorities may also impose specific obligations as a condition of the MA. Such
risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely
available to third-parties requesting access, subject to limited redactions. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is also prohibited in the European Union.
Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each EU Member State and can differ from one country to another. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Data and market exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, there is a process to authorize generic versions of innovative drugs in the European Union. Generic competitors
can, where data exclusivity has expired, submit abridged applications to authorize generic versions of drugs authorized by the EMA through the centralized procedure referencing the innovator&#146;s data and demonstrating bioequivalence to the
reference drug, among other things. If a marketing authorization is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity, during which generic marketing authorization
applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic products may not be placed on the market. The <FONT
STYLE="white-space:nowrap">two-year</FONT> period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. This system is usually referred to
as &#147;8+2&#148;. There is also a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of
differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for
different types of biological product.&nbsp;In addition, there are certain circumstances, such as where the innovator company is granted a marketing authorization for a significant new indication for the relevant medicinal product, where an
additional one year of marketing exclusivity may be granted.&nbsp;&nbsp;&nbsp;&nbsp;As referenced above, orphan medicinal products are subject to separate marketing exclusivity arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other international markets-drug approval process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some international markets (such as China or Japan), although data generated in United States or European Union trials may be submitted in
support of a marketing authorization application, regulators may require additional clinical studies conducted in the host territory, or studying people of the ethnicity of the host territory, prior to the filing or approval of marketing
applications within the country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pricing and reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any drugs for which companies may obtain regulatory approval. In
the United States and markets in other countries, sales of any drugs for which companies receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party
payors include government authorities, managed care plans, private health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a drug may be separate from the process for setting the
reimbursement rate that the payor will pay for the drug. Third-party payors may limit coverage to specific drugs on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs for a
particular indication. Moreover, a third-party payor&#146;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Additionally, coverage and reimbursement for drugs can differ significantly from
payor to payor. One </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third-party payor&#146;s decision to cover a particular drug does not ensure that other payors will also provide coverage for the drug, or will provide coverage at an adequate reimbursement rate.
Adequate third-party reimbursement may not be available to enable Millendo to maintain price levels sufficient to realize an appropriate return on its investment in drug development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of drugs and services, in
addition to their safety and efficacy. To obtain coverage and reimbursement for any drug that might be approved for sale, Millendo may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of
its drug. These studies will be in addition to the studies required to obtain regulatory approvals. If third-party payors do not consider a drug to be cost-effective compared to other available therapies, they may not cover the drug after approval
as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its drugs at a profit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to
limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs for branded prescription drugs. By way of example, PPACA contains provisions that may
reduce the profitability of drugs, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual
fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit
payments for Millendo&#146;s drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Community, governments influence the price of drugs through their pricing and
reimbursement rules and control of national health care systems that fund a large part of the cost of those drugs to consumers. Some jurisdictions operate positive and negative list systems under which drugs may only be marketed once a reimbursement
price has been agreed to by the government. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical studies that compare the cost effectiveness of a particular drug candidate to currently available
therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a
result, increasingly high barriers are being erected to the entry of new drugs. In addition, in some countries, cross border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a
country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any drugs for which companies receive regulatory approval for commercial sale may suffer if government and
other third-party payors fail to provide coverage and adequate reimbursement. In addition, the focus on cost containment measures in the United States and other countries has increased and Millendo expects will continue to increase the pressure on
pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other healthcare laws
impacting sales, marketing, and other company activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous regulatory authorities in addition to the FDA, including, in the
United States, CMS, other divisions of the U.S. Department of Health and Human Services, or HHS, the U.S. Department of Justice, and similar foreign, state, and local government authorities, regulate and enforce laws and regulations applicable to
sales, promotion and other activities of pharmaceutical manufacturers. These laws and regulations may impact, among other things, Millendo&#146;s clinical research programs, proposed sales and marketing and education activities, and financial and
business relationships with future prescribers of its product candidates, once approved. These laws and regulations include U.S. federal, U.S. state and foreign anti-kickback, false claims, and data privacy and security laws, which are described
below, among other legal requirements that may affect Millendo&#146;s current and future operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA regulates all advertising and promotion activities for drugs under its jurisdiction
both prior to and after approval. Only those claims relating to safety and efficacy that the FDA has approved may be used in labeling once the drug is approved. Physicians may prescribe legally available drugs for uses that are not described in the
drug&#146;s labeling and that differ from those Millendo tested and the FDA approved. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties, and often reflect a physician&#146;s belief that the <FONT
STYLE="white-space:nowrap">off-label</FONT> use is the best treatment for the patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers&#146;
communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> uses. If Millendo does not comply with applicable FDA requirements it may face adverse publicity, enforcement action by the FDA, corrective advertising, consent decrees and
the full range of civil and criminal penalties available to the FDA. Promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses of drugs can also implicate the false claims laws described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-kickback laws including, without limitation, the federal Anti-Kickback Statute that applies to items and services reimbursable under
governmental healthcare programs such as Medicare and Medicaid, make it illegal for a person or entity to, among other things, knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, to induce, or in return for,
purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service reimbursable, in whole or in part, under a federal healthcare program. Due to the breadth of the statutory
provisions and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that Millendo&#146;s practices might be challenged under anti-kickback or similar laws. Moreover, recent healthcare reform legislation
has strengthened these laws. For example, PPACA among other things, amends the intent requirement of the federal Anti-Kickback Statute and certain other criminal healthcare fraud statutes to clarify that a person or entity does not need to have
actual knowledge of these statutes or specific intent to violate them in order to have committed a crime. In addition, PPACA clarifies that the government may assert that a claim that includes items or services resulting from a violation of the
federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">False claims
laws, including, without limitation, the federal civil False Claims Act, and civil monetary penalty laws prohibit, among other things, anyone from knowingly and willingly presenting, or causing to be presented for payment, to the federal government
(including Medicare and Medicaid) claims for reimbursement for, among other things, drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.
Millendo&#146;s activities relating to the sales and marketing of its drugs may be subject to scrutiny under these laws, as well as civil monetary penalties laws and the criminal healthcare fraud provisions enacted as part of the federal Health
Insurance Portability and Accountability Act of 1996, or HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection
with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to
have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and
their implementing regulations governs the conduct of certain electronic healthcare transactions and imposes requirements with respect to safeguarding the security and privacy of protected health information on HIPAA covered entities and their
business associates who provide services involving HIPAA protected health information to such covered entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Physician
Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report
annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to
CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician
assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives provided during the previous year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies may be subject to state law equivalents of each of the above federal laws, such as anti-kickback, self-referral, and
false claims laws which may apply to Millendo&#146;s business practices, including but not limited to, research, distribution, sales and marketing arrangements and submitting claims involving healthcare items or services reimbursed by any
third-party payor, including commercial insurers; state laws that require pharmaceutical manufacturers to comply with the industry&#146;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government
that otherwise restricts payments that may be made to healthcare providers; state laws that require pharmaceutical manufacturers to file reports with states regarding marketing information, such as the tracking and reporting of gifts, compensation
and other remuneration and items of value provided to healthcare professionals and entities; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales
representatives; and state laws governing the privacy and security of personal data and protected health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violations of these laws may result in significant criminal, civil and administrative sanctions, including fines and civil monetary penalties,
the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement, contractual damages, reputational harm and the imposition of corporate integrity agreements or other similar agreements with governmental
entities, which may impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees, including criminal
sanctions against executive officers under the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;responsible corporate officer&#148; doctrine, even in situations where the executive officer did not intend to violate the law and was unaware of
any wrongdoing. Given the significant penalties and fines that can be imposed on companies and individuals if convicted, allegations of such violations often result in settlements even if the company or individual being investigated admits no
wrongdoing. Settlements often include significant civil sanctions and additional corporate integrity obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar rigorous
restrictions are imposed on the promotion and marketing of drugs in the European Union and other countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, Millendo had 12 employees, 11 of whom were full-time employees and one of whom was a part-time employee. As of
March&nbsp;31, 2021, none of its employees was engaged in research and development activities and 12 of its employees were engaged in business development, finance, information systems, facilities, human resources or administrative support. As of
March&nbsp;31, 2021, Millendo had 12 employees located in the United States and one employee located in France. None of its U.S. employees are represented by any collective bargaining agreements. Its French employee is represented by a collective
bargaining agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Plan, the Millendo board of directors determined to reduce Millendo&#146;s workforce by up
to 85%, with the majority of the reduction in personnel expected to be completed by April&nbsp;15, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OvaScience Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2018, OvaScience, Inc., or OvaScience, now known as Millendo Therapeutics, Inc., completed its reverse merger or, the
OvaScience Merger, with what was then known as &#147;Millendo Therapeutics, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inc.,&#148; or Private Millendo, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of August&nbsp;8, 2018, as amended on September&nbsp;25, 2018 and
November&nbsp;1, 2018. OvaScience&#146;s shares of common stock listed on Nasdaq, previously trading through the close of business on Friday, December&nbsp;7, 2018 under the ticker symbol &#147;OVAS,&#148; commenced trading on The Nasdaq Capital,
under the ticker symbol &#147;MLND,&#148; on Monday, December&nbsp;10, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the OvaScience Merger, Private
Millendo became a wholly-owned subsidiary of OvaScience.&nbsp;Upon consummation of the OvaScience Merger, OvaScience adopted the business plan of Private Millendo and discontinued the pursuit of OvaScience&#146;s business plan <FONT
STYLE="white-space:nowrap">pre-closing.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s corporate headquarters are located at 110 Miller Avenue, Suite 100, Ann Arbor, Michigan, 48104, where it occupy approximately
21,000 square feet of office space under two separate leases. Millendo leases approximately 10,000 square feet of third floor office space pursuant to a lease entered into in October 2018, which began on July&nbsp;1, 2019 and is set to expire on
June&nbsp;30, 2024. In addition, Millendo leases approximately 11,000 square feet of first floor office space pursuant to a lease entered into in February 2019, which began on April&nbsp;1, 2019 and is set to expire on March&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9,
2016, a purported shareholder derivative action was filed in the Business Litigation Session of the Suffolk County Superior Court in the Commonwealth of Massachusetts (Cima v. Dipp, No. <FONT STYLE="white-space:nowrap">16-3443-BLS1</FONT> (Mass.
Sup. Ct.)) against certain former officers and directors of OvaScience and one current director of Millendo (a former director of OvaScience) and OvaScience as a nominal defendant alleging breach of fiduciary duties, unjust enrichment, abuse of
control, gross mismanagement and waste of corporate assets for purported actions related to OvaScience&#146;s January 2015 <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering. On February&nbsp;22, 2017, the court approved the
parties&#146; joint stipulation to stay all proceedings in the action until further notice. Following a status conference in December 2017, the stay was lifted. On January&nbsp;25, 2018, at the parties&#146; request, the court entered a second order
staying all proceedings in the action until further order of the court. On March&nbsp;2, 2020, the parties submitted a status report requesting that the court continue the stay. On March&nbsp;5, 2020, the court entered an order continuing the stay
and requiring that the parties file a further status report on or before June&nbsp;30, 2020. On June&nbsp;30, 2020, the parties filed a further status report requesting that the court continue the stay. The court continued the stay until at least
January&nbsp;7, 2021. On January&nbsp;7, 2021, the parties filed a further status report requesting that the court continue the stay until at least April&nbsp;30, 2021. The case remains stayed until at least April&nbsp;30, 2021, when the parties are
due to file a further status report. Millendo believes that the complaint is without merit and intends to defend against the litigation. There can be no assurance, however, that Millendo will be successful. At present, Millendo is unable to estimate
potential losses, if any, related to the lawsuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2017, a purported shareholder class action lawsuit was filed in the
U.S. District Court for the District of Massachusetts (Dahhan v. OvaScience, Inc., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-cv-10511-IT</FONT></FONT></FONT> (D. Mass.)) against
OvaScience and certain former officers of OvaScience alleging violations of Sections 10(b) and 20(a) of the Exchange Act (the &#147;Dahhan Action&#148;). On July&nbsp;5, 2017, the court entered an order approving the appointment of Freedman Family
Investments LLC as lead plaintiff, the firm of Robins Geller Rudman&nbsp;&amp; Dowd LLP as lead counsel and the Law Office of Alan L. Kovacs as local counsel. Plaintiff filed an amended complaint on August&nbsp;25, 2017. Millendo filed a motion to
dismiss the amended complaint, which the court denied on July&nbsp;31, 2018. On August&nbsp;14, 2018, Millendo answered the amended complaint. On December&nbsp;9, 2019, the court granted leave for the lead plaintiff to file a second amended
complaint under seal and permitted the defendants to file a motion to strike the second amended complaint. On December&nbsp;30, 2019, the court granted the parties&#146; joint motion to stay all proceedings in the case pending mediation. On
March&nbsp;3, 2020, the parties conducted a mediation session. The mediation was unsuccessful. Millendo filed a motion to strike the second amended complaint on May&nbsp;1, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo believes that the amended complaint and the second amended complaint are without
merit. On August&nbsp;17, 2020, the court granted the parties&#146; joint motion to stay all proceedings in the case pending mediation. The parties agreed to participate in a second mediation session on November&nbsp;10, 2020. On October&nbsp;16,
2020, the court granted the parties&#146; joint request to extend the stay until November&nbsp;16, 2020. On November&nbsp;16, 2020, the parties filed a joint status report seeking to extend the stay for an additional thirty days. On
November&nbsp;17, 2020, the court ordered the parties to file a supplemental joint status report clarifying whether they sought a continuance of the stay of all proceedings or instead, a partial lifting of the stay. On November&nbsp;19, 2020, the
parties filed a joint status report seeking to continue a partial stay of the case while the parties engaged in additional settlement discussions, and a partial lifting of the stay to the extent required for the court to rule on Millendo&#146;s
pending motion to strike and motions to dismiss filed by other defendants. Those motions remain pending. A resolution of this lawsuit adverse to Millendo or the other defendants could have a material effect on Millendo&#146;s consolidated financial
position and results of operations. At present, Millendo is unable to estimate potential losses, if any, related to the lawsuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;27, 2017, a purported shareholder derivative complaint was filed in the U.S. District Court for the District of Massachusetts (Chiu v. Dipp, No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1:17-cv-11382-IT</FONT></FONT></FONT> (D. Mass.)) against OvaScience as a nominal defendant, certain former officers and directors of OvaScience and one current director of Millendo (a former director of OvaScience)
alleging breach of fiduciary duties, unjust enrichment and violations of Section&nbsp;14(a) of the Exchange Act alleging that compensation awarded to the director defendants was excessive and seeking redress for purported actions related to
OvaScience&#146;s January 2015 <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering and other public statements concerning OvaScience&#146;s AUGMENT treatment. On September&nbsp;26, 2017, the plaintiff filed an amended complaint which
eliminated all claims regarding allegedly excessive director pay and additionally alleged claims of abuse of control and waste of corporate assets. On October&nbsp;27, 2017, the defendants filed a motion to dismiss the amended complaint. The court
heard oral argument on the motion to dismiss on April&nbsp;5, 2018. On April&nbsp;13, 2018, the court granted the defendants&#146; motion to dismiss the amended complaint for failure to state a claim for relief under Section&nbsp;14(a). The court
also dismissed the plaintiffs&#146; pendent state law claims without prejudice, based on lack of subject matter jurisdiction. On April&nbsp;25, 2018, the plaintiffs moved for leave to amend the complaint and to stay this case pending the outcome of
the Dahhan Action. Millendo does not believe that the proposed amended complaint cures the defects in the current complaint, but informed plaintiffs&#146; counsel that, in the interest of judicial economy, defendants would not oppose the proposed
amendment if the court would consider staying the case pending the resolution of the Dahhan Action. On April&nbsp;27, 2018, the court granted the plaintiffs&#146; motion for leave to amend the complaint and for a stay. On April&nbsp;30, 2018, the
plaintiffs filed their second amended complaint. On May&nbsp;23, 2018, the court entered an order staying this case pending the resolution of the Dahhan Action. Millendo believes that the complaint is without merit and intends to defend against the
litigation. There can be no assurance, however, that Millendo will be successful. At present, Millendo is unable to estimate potential losses, if any, related to the lawsuit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the matters described above, Millendo may be a party to litigation and subject to claims incident to the ordinary course of
business from time to time. Regardless of the outcome, litigation can have an adverse impact on Millendo because of defense and settlement costs, and diversion of management resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_90"></A>TEMPEST&#146;S BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest is a clinical-stage
oncology company focused on leveraging its deep scientific understanding of cancer biology and medicinal chemistry to develop and advance novel orally available therapies for the treatment of solid tumors. Tempest&#146;s philosophy is to build a
company based upon not only good ideas and creative science, but also upon the efficient translation of those ideas into therapies that will improve patient&#146;s lives. To this end, Tempest is advancing TPST-1495 and TPST-1120, two product
candidates in clinical trials that it believes are the first clinical stage molecules designed to treat their respective targets; and a third program in preclinical studies that could be the first to target
<FONT STYLE="white-space:nowrap">TREX-1,</FONT> a key cellular enzyme that regulates the innate immune response in tumors. TPST-1495 is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid
tumors. Tempest&#146;s second program, TPST-1120, is a selective antagonist of peroxisome proliferator-activated receptor alpha, or PPAR&#945;, and is also in a Phase 1 trial in solid tumors. Tempest expects to report initial data from both these
programs in the second half of 2021. Additionally, Tempest is advancing a third program targeting the three prime repair exonuclease, or <FONT STYLE="white-space:nowrap">TREX-1,</FONT> for which Tempest expects to select a development candidate by
the end of 2021. Beyond these three ongoing programs, Tempest plans to leverage its drug development and company-building experience along with academic relationships to identify promising new targets that may feed new programs into Tempest&#146;s
pipeline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tempest&#146;s Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest has developed a diversified pipeline of small molecule product candidates that are designed to target tumor cells directly, modulate
the immune system to kill cancer cells, or a combination of both, in each case that Tempest believes are innovative and target scientifically validated pathways. Tempest selected targets that are expressed in a diverse set of tumor types, with the
intention to address unmet medical needs or improve existing standards of care. Tempest&#146;s product development programs consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g14u85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Definitions: </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; CCA: cholangiocarcinoma; CRC: colorectal cancer; FPI: First Patient In; RP2D: Recommended Phase 2
Dose; DC: Development Candidate; ORR: Objective Response Rate. Note that the primary anti-tumor activity readout is ORR by RECIST v. 1.1 criteria, and time on study treatment; additional endpoints include duration of response and progression free
survival, which may be reported at a later timepoint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Timing is an estimate based on current projections;
<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>Tempest is evaluating whether the first Phase 2 study will be in CRC and/or multiple solid tumors; if multiple histologies, Tempest may elect to open individual studies; 3Pursuant to a
collaboration with Roche; TPST retains all product rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s first product candidate is TPST-1495, a
novel, oral, small molecule designed to be a dual antagonist of only two of the four prostaglandin E2 (PGE2) receptors, EP2 and EP4, sparing the homologous but differentially active EP1 and EP3 receptors. PGE2 is well understood from the scientific
literature to be an important stimulator of tumor growth in diverse cancer types of high need, and to be inhibitory to anti-tumor immune function in the tumor microenvironment. PGE2 signaling through EP2 and EP4 has been observed both to enhance
tumor progression and promote immune suppression. Tempest conducted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical studies comparing TPST-1495 to single antagonists of EP4 being developed by
other companies. Tempest observed in these studies significantly enhanced activity of TPST-1495 in both overcoming PGE2 mediated suppression of human immune cells in vitro as well as significantly increased anti-tumor activity in mouse models of
human colorectal cancer as compared to single antagonists of EP4. Tempest is currently evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and possible anti-tumor activity of TPST-1495 in a multicenter Phase 1a/1b dose
and schedule optimization study in subjects with advanced solid tumors, with a focus on tumor types such as colorectal cancer, or CRC, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or NSCLC and urothelial, or bladder, cancer,
which are all known to be prostaglandin-driven. Tempest is observing dose-proportional exposure, and Tempest is encouraged by early signs of activity of TPST-1495 monotherapy, as shown by <FONT STYLE="white-space:nowrap">on-target</FONT>
pharmacodynamic changes, disease control, and reduction of tumor-specific biomarkers in the ongoing dose optimization clinical study. The TPST-1495 Phase 1 clinical trial is ongoing in the schedule and dose optimization stage and Tempest expects to
establish the RP2D for expansion and the preliminary safety profile and ORR in second half of 2021. Tempest also expects to initiate monotherapy combination studies with an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> immune check point inhibitor, prior to the end of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s second product candidate is TPST-1120, an oral, small molecule designed to be a selective antagonist of PPAR&#945; and is the
first PPAR&#945; antagonist in the clinic. PPAR&#945; is a key transcription factor controlling fatty acid oxidation, or FAO. It is clear from the scientific literature that FAO can serve as a source of energy for tumor cell growth and that the
PPAR&#945; transcriptome is upregulated in many tumor types. It also is published that FAO is a preferred energy source for <FONT STYLE="white-space:nowrap">so-called</FONT> immune suppressor cells such as regulatory
<FONT STYLE="white-space:nowrap">T-cells</FONT> (Treg), myeloid derived suppressor cells, or MDSCs, and M2 macrophages. Tempest&#146;s preclinical data suggest that TPST-1120 can directly kill tumor cells that are dependent upon FAO, alter the tumor
microenvironment immune cell infiltrate away from suppressor immune phenotype, and synergize with immune checkpoint inhibitor therapy in animal models. Tempest is evaluating TPST-1120 in a Phase 1a/b clinical study that has both monotherapy and
combination therapy arms in patients with advanced solid tumors that Tempest&#146;s PPAR&#945;-dependent transcriptome analysis of diverse human cancers revealed favor the usage of FAO. Tempest has been observing dose-dependent exposure and <FONT
STYLE="white-space:nowrap">on-target</FONT> pharmacodynamic changes in both monotherapy and combination TPST-1120 therapy arms. The monotherapy dose escalation phase of the clinical study has been completed, and Tempest observed clinical benefit in
10 of 20 of patients enrolled in this arm in the form of disease stabilization. Three patients with advanced cholangiocarcinoma experienced prolonged stable disease (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>21 weeks) and some reduction of tumor
burden, although not to the extent of a RECIST response. In the TPST-1120 combination arm with nivolumab, Tempest observed a deep RECIST response at eight weeks with 54% overall tumor burden reduction in a fourth-line patient with advanced kidney
cancer, which was confirmed in a second on-study assessment at 16 weeks. Tempest is encouraged by this response as a signal of TPST-1120 clinical activity, as the patient did not have a RECIST response and progressed from prior front-line ipilimumab
and nivolumab and two subsequent targeted therapies. Tempest recently announced a clinical collaboration with <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd., or Roche, to accelerate the development of TPST-1120 into a frontline,
randomized study. Pursuant to the terms of Tempest&#146;s collaboration, Roche will evaluate TPST-1120 in a global randomized phase 1b/2 clinical study in combination with the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma, or HCC, not previously treated with
systemic therapy. The study will include at least 40 and up to 60 patients who will receive the TPST-1120 combination and will be compared to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
atezolizumab and bevacizumab regimen with primary objectives of anti-tumor activity and safety. Under the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the collaboration agreement, Roche will manage the study operations for this global multicenter trial. Tempest will retain global development and commercialization rights to TPST-1120. Tempest
expects the first patient in the frontline HCC study to be enrolled in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and for ORR results of the TPST-1120 Phase 1a/1b dose finding trials to be available prior to the end of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest has a third program in its pipeline against <FONT STYLE="white-space:nowrap">TREX-1,</FONT> a target Tempest believes may be an
effective approach to systemically modulate STING, which stands for <B>ST</B>imulator of <B>IN</B>terferon <B>G</B>enes, and is the focus of clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs at multiple pharmaceutical and
biotechnology companies. <FONT STYLE="white-space:nowrap">TREX-1</FONT> is a double-stranded DNA exonuclease that is designed to control activation of the cGAS/STING pathway, which is an innate immune response pathway that induces the production of <FONT
STYLE="white-space:nowrap">IFN-&szlig;,</FONT> a cytokine that is well-established to trigger the development of anti-tumor immunity. The expression of <FONT STYLE="white-space:nowrap">TREX-1</FONT> is enhanced in tumors and inhibits activation of
cGAS/STING to evade immune recognition. Because STING is expressed ubiquitously, but <FONT STYLE="white-space:nowrap">TREX-1</FONT> expression is increased in tumors, Tempest believes that <FONT STYLE="white-space:nowrap">TREX-1</FONT> may be the
optimal approach to target STING with an orally available small molecule inhibitor to selectively activate this pathway in tumors. Tempest expects to select a TREX1 inhibitor development candidate for
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Internal Discovery Capability and Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest built an internal discovery team at Tempest to create and advance small-molecule product candidates with the ideal pharmacological
properties to target the tumor micro-environment and the immune system. This discovery capability has enabled what Tempest believes is the rapid and efficient generation of a broad pipeline of innovative orally available therapies, that if approved
by the FDA, will be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class.</FONT></FONT> Tempest&#146;s small molecule product candidates target pathways that have been validated in the scientific literature to play key
roles in promoting tumor growth and suppressing development of anti-tumor immunity across a diverse set of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tempest leveraged its
deep scientific knowledge, long-term established relationships with key opinion leaders along with its extensive medicinal chemistry and drug development expertise to develop its current portfolio. Dr.&nbsp;Peppi Prasit, a Tempest founder, serves a
continuing role for Tempest in the design of Tempest&#146;s small molecule therapeutics. Dr.&nbsp;Peppi Prasit (see also under Scientific Advisors), directs both Tempest&#146;s medicinal chemistry activities and synthetic chemistry activities
conducted by contract research organizations. Dr.&nbsp;Peppi Prasit has played a pivotal role in the discovery of multiple marketed drugs, including Vioxx&reg; and <I>Arcoxia</I>&reg; while at Merck Frosst, and led the medicinal chemistry of several
drugs still under clinical development. Tempest designs its molecules to have the ideal pharmacological properties for the targeted pathway and the desired clinical effect. Small-molecule drugs against the same biological target can be highly
differentiated from each other based on their respective pharmacokinetic, pharmacodynamic and biophysical properties. For example, many small-molecule drugs are potent when tested in buffer solution but lose a significant amount of this potency in
physiologically relevant media such as blood or tumor tissue. Tempest rigorously tests its molecules in whole blood or other physiologically relevant systems and only advances molecules that retain a high degree of activity when tested under such
&#147;real world&#148; conditions. Tempest believes that the expertise that Dr.&nbsp;Prasit imparts on the development of its small molecule drugs is a differentiating factor of the potential activity of its product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Prasit leveraged his scientific insights gained from developing approved prostaglandin signaling pathway targeted drugs together with
the published literature to hypothesize that optimal anti-tumor inhibition and immune activation might result from blocking both EP2 and EP4 receptor signaling pathways. Tempest designed TPST-1495 to be a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> dual selective inhibitor of prostaglandin receptors EP2 and EP4, based on this scientific hypothesis. Dr.&nbsp;Prasit continues to be a Scientific Advisor for Tempest and leads medicinal
chemistry for Tempest&#146;s existing drugs in development and for targets Tempest is considering. Tempest established the scientific rationale for developing TPST-1120 after discussions with several academic investigators, including Dr.&nbsp;David
Spaner, MD, PhD (Sunnybrook Research Institute, Toronto), who found that patients with selected advanced cancers had comparatively elevated levels of long-chain fatty acid amides in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
peripheral blood, that were reduced after responding to approved therapies. These findings along with the published literature demonstrating the role of lipid metabolism on metastasis,
angiogenesis and immune evasion led Tempest to establish an internal program to develop selective antagonists of PPAR&#945;, a transcription factor that regulates lipid metabolism. This pathway is known to be druggable, with the decades-long
clinical use of fenofibrates, a class of small molecule PPAR&#945; agonists, in patients with dyslipidemia. Several members of the team at Tempest developed the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> STING small molecule agonists at a prior company. The Tempest president, Dr.&nbsp;Tom Dubensky is recognized as a thought leader in drugging the STING
pathway. The insights and experience of the Tempest team, together with the rapidly expanding scientific understanding of the role of innate immunity in developing effective tumor-specific immunity, led Tempest to the scientific hypothesis that the
optimal approach to localize activation of the STING pathway to the tumor microenvironment in metastatic disease with an orally available small molecule is through a specific inhibitor of TREX1, a dsDNA exonuclease known to have elevated expression
in tumors. Tempest is actively considering other innovative oncology targets that Tempest believes have strong scientific rationale and would address specific unmet medical needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Tempest management team comprised of Steve Brady, CEO, Tom Dubensky, PhD, President and Sam Whiting, MD, PhD, CMO comprise a deeply
experienced group, gained over many years in both private and public biotechnology companies, in the selection of new targets, discovery of molecules to modulate pathways of interest, and the evolution of program candidates through the full range of
clinical development. The Tempest management team also has substantial financing and strategic transaction experience, including private and public equity and debt financings, product and licensing collaborations, and both private and public
M&amp;A. Tempest believes the collective and diverse experience of the team, along with Tempest&#146;s view that a company should be run in accordance with a foundational set of guiding principles, positions Tempest for success in developing
therapies to benefit patients living with cancer. While Tempest believes that its experienced management team represents an important competitive advantage, the historical results, past performance and/or acquisition of companies with which members
of its management team have been affiliated do not necessarily predict or guarantee similar results for its company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our scientific and
clinical advisors includes thought leaders in oncology, immunology and clinical development, including: Toni K. Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and <FONT
STYLE="white-space:nowrap">Co-Leader,</FONT> Kidney Cancer Program, Dana-Farber/Harvard Cancer Center; Drew M. Pardoll, MD, PhD, Abeloff Professor of Oncology, Director, Bloomberg&#150;Kimmel Institute for Cancer Immunotherapy, Director, Cancer
Immunology Program, Johns Hopkins University School of Medicine; Jason Luke, MD, FACP, Associate Professor of Medicine, Hematology/Oncology, and Director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Immunology and
Immunotherapy Program; Raymond N. Dubois, MD, PhD, Dean of the College of Medicine at the Medical University of South Carolina; Peppi Prasit, PhD, CEO Emeritus Inception Sciences; and, Benjamin F. Cravatt, PhD, Professor and Gilula Chair of Chemical
Biology, Department of Chemistry, The Scripps Research Institute. Tempest additionally has extensive established relationships with key opinion leaders, or KOLs, with whom Tempest has sponsored research agreements and/or frequently consult to both
gain insights on Tempest&#146;s existing pipeline and clinical development strategy and to discuss potential new target opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As
of March&nbsp;31, 2021, Tempest had 14 employees, including eight holding Ph.D., M.D., JD, and/or LL.M. degrees, and have established internal expertise in chemistry, biochemistry, molecular biology, immunology, pharmacology, toxicology, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development, regulatory and quality, translational medicine, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-late-stage</FONT></FONT> clinical development, as well as
finance, business development and strategic transactions. An important element of Tempest&#146;s strategy to date has been to utilize consultants with whom Tempest has established relationships over several companies and in the development of
multiple innovative oncology therapies, including those skilled in medicinal chemistry, pharmacology and toxicology, translational sciences, clinical operations and medical affairs. Tempest will continue to maintain internal capabilities in R&amp;D
and clinical development areas as noted and add experienced and talented scientists in areas, such as medicinal chemistry, that Tempest believes are critical for the discovery of highly differentiated small-molecule compounds. Additionally, while
Tempest&#146;s current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pipeline consists of orally available small molecules, the Tempest team is also experienced in the conception, translation and clinical development of simple and complex biologics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Since its inception, Tempest has raised approximately $100&nbsp;million in equity capital from high-tier investors with significant experience
in healthcare that share Tempest&#146;s vision to create a leading development organization advancing targeted innovative therapies that may provide benefit to patients with cancer, including: Eight Roads,
<FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital, Foresight Ventures, Lilly Asia Ventures, Lyfe Capital, Quan Capital, Rock Springs Capital and Versant Ventures. Tempest has also secured commitments from a premier syndicate of healthcare
investors comprised of Versant Ventures, Rock Springs Capital, <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital, Monashee Investment Management, Quan Capital, Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads for
a $30&nbsp;million <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing that is expected to close concurrent with the completion of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tempest&#146;s Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Tempest team
has come together to build an integrated company that delivers meaningful therapies to cancer patients, through leveraging its team&#146;s capabilities and research and development engine. Tempest expects to build value for the Tempest shareholders
with the following over-arching strategy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Effectively advance TPST-1495, </I><I>its </I><I>dual EP2/4 antagonist, through clinical development to
meaningful data</I>. Tempest plans to complete the TPST-1495 monotherapy dose and optimization stage of the ongoing Phase 1 study in the second of half of 2021, followed by the initiation of a monotherapy dose expansion cohorts in tumor histologies
of interest, as well as cohorts combining TPST-1495 with an immune checkpoint inhibitor. Tempest expects to have ORR data from these cohorts beginning in second half of 2021 and through 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Facilitate </I><I>Tempest</I><I>&#146;</I><I>s </I><I>Roche collaboration evaluating TPST-1120 in a
randomized, frontline HCC study</I>. Pursuant to the terms of its agreement with Roche, Tempest expects Roche to commence enrollment of patients in <FONT STYLE="white-space:nowrap">mid-2021,</FONT> and for enrollment to be complete by the end of
2022. Because TPST-1120 is being combined with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> first line treatment, and randomized against that same <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> Tempest believes that positive study results may provide multiple strategic opportunities for Tempest. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance </I><I>its </I><I>TREX1 inhibitor into clinical studies</I>. The Tempest team developed the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> STING agonists in a prior company and are widely acknowledged to be leaders in the field. Tempest believes that a highly selective TREX1 inhibitor given orally
is an innovative approach to selectively engage the STING pathway broadly in the tumor microenvironment of metastatic disease. Tempest&#146;s medicinal chemists have developed a series of compounds with low nanomolar potency against human TREX1,
which Tempest is actively optimizing towards selecting a development candidate for IND enabling activities by the end of 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Explore business development opportunities to maximize the potential of </I><I>its </I><I>pipeline and extend
financial resources</I>. Tempest believes that its pipeline has broad potential reach and partnerships that bring in additional expertise and/or geographic presence could be important aspects of its progress. Tempest established a clinical
collaboration with Roche to evaluate TPST-1120 in a global frontline randomized study in HCC patients, which Tempest believes accelerated the program by years without the risk of the associated global infrastructure build, while retaining global
development and commercialization rights. Tempest intends to become a fully integrated biopharmaceutical company and build a targeted sales force in the United States to support the commercialization of its drug candidates, if approved.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Enhance Tempest</I><I>&#146;</I><I>s pipeline by identifying novel oncology targets and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> promising product candidates for oncology.</I><B><I> </I></B>Tempest is actively evaluating and pursuing novel targets, intellectual property and product candidates for acquisition and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> to supplement Tempest&#146;s internal </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
research efforts and continue to build its pipeline of targeted molecules for oncology. Through the Tempest team&#146;s focus and expertise in oncology and immunology, as well as established
relationships with oncology and immunology thought leaders, Tempest is positioning the company as a partner of choice for innovative oncology drug candidate development. Tempest believes continued advances in the biological understanding of diseases
will provide opportunities to further expand its portfolio with preclinical and/or clinical product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our programs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>TPST-1495: Dual EP2/EP4 Prostaglandin Receptor Antagonist </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Program Summary </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first clinical molecule is TPST-1495, a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> oral, small molecule dual antagonist of the PGE2 receptors, EP2 and EP4. TPST-1495 is engineered to inhibit only the EP2 and EP4 receptors while sparing
the homologous but differentially active EP1 and EP3 receptors. There is extensive literature demonstrating that PGE2 both enhances tumor proliferation and inhibits anti-cancer immune function; it is known from the scientific literature that many
tumors express elevated levels of the cyclooxygenase enzymes that produce PGE2. The literature supports that PGE2 predominantly drives tumor proliferation by autocrine signaling through EP2 and EP4 receptors on tumor cells and immune suppression
through EP2 and EP4 receptors on lymphoid and myeloid immune cells in the tumor microenvironment. Tempest has conducted extensive preclinical studies to test and compare the anti-tumor activities and immune activation of <FONT
STYLE="white-space:nowrap">EP2-</FONT> and <FONT STYLE="white-space:nowrap">EP4-specific</FONT> inhibition by TPST-1495 to alternative mechanisms of PGE2 inhibition, supporting the improved activity of the TPST-1495 approach. Tempest additionally
conducted <FONT STYLE="white-space:nowrap">IND-enabling</FONT> pharmacology and toxicology studies to support initiation of Tempest&#146;s ongoing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase
1/1b study of TPST-1495 monotherapy in patients with advanced solid tumors. Tempest currently is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of TPST-1495 in this multicenter
study conducted at Phase 1 units in the United States. Tempest has observed dose-dependent TPST-1495 exposure, <FONT STYLE="white-space:nowrap">on-target</FONT> pharmacodynamic changes and reduction of tumor-specific biomarkers in the ongoing dose
optimization stage of the clinical study. Tempest expects to establish the monotherapy RP2D and schedule for TPST-1495, initiate dose expansion studies with TPST-1495 as monotherapy in selected cancer indications, and initiate dose-finding
combination studies with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L1)</FONT></FONT> immune checkpoint inhibitor therapy in the second half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Prostaglandin E2 enhances tumor progression of diverse cancers </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elevated expression of <FONT STYLE="white-space:nowrap">COX-2</FONT> and overproduction of PGE2 is correlated with progression
of diverse malignancies by stimulating tumor cell proliferation, survival, evasion and metastasis as well as host angiogenesis. In addition, PGE2 suppresses anti-tumor immunity by inhibiting the function of critical anti-tumor immune effector cell
populations such as dendritic cells, natural killer, or NK cells, T cells, and M1 macrophages, while promoting the activity of suppressive immune cell populations including myeloid-derived suppressor cells, or MDSCs, M2 macrophages, and regulatory T
cells. Additionally, recent studies have shown that increased expression of <FONT STYLE="white-space:nowrap">COX-2</FONT> and production of PGE2 can play a role in the effectiveness of immune checkpoint inhibitor therapy and in the development of
adaptive resistance to therapy. This body of literature provides the scientific rationale for developing therapeutics that maximally inhibit the prostaglandin pathway. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">How PGE2 signals through each of its four homologous <FONT STYLE="white-space:nowrap">E-prostanoid</FONT> <FONT
STYLE="white-space:nowrap">G-protein</FONT> coupled receptor targets, known as EP1, EP2, EP3 and EP4, informed the development of TPST-1495. PGE2 signaling through each of these receptors activates distinct signal transduction pathways. In general,
signaling through EP2 and EP4 receptors increases the activity of suppressive immune cell populations found in the tumor microenvironment of metastatic tumors, including myeloid derived suppressor cells, M2 macrophages, regulatory T cells, and
exhausted CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells. In contrast, EP3 signaling is generally <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
inhibits the activity of EP2 and EP4 receptor signaling. Decreased EP1 and EP3 receptor expression levels has been associated with numerous progressing malignancies. The differential modulation
of anti-tumor immune responses by the four individual EP receptors provides the scientific rationale that selective antagonism of EP2 and EP4 receptors to the exclusion of EP1 and EP3 receptors provide enhanced anti-tumor immunity and improved
therapeutic effect, as compared to selective EP4 antagonists or <FONT STYLE="white-space:nowrap">COX-1</FONT> or <FONT STYLE="white-space:nowrap">COX-2</FONT> inhibitors. Tempest does not believe that preventing signaling through all four EP
receptors by inhibiting the production of PGE2 (e.g., with nonsteroidal anti-inflammatory drugs, or NSAIDs, which target both <FONT STYLE="white-space:nowrap">COX-1</FONT> and <FONT STYLE="white-space:nowrap">COX-2</FONT> or with drugs that target
only <FONT STYLE="white-space:nowrap">COX-2)</FONT> is an optimal therapeutic approach for cancer treatment for two reasons. First, these agents have multiple effects beyond just inhibiting PGE2 production and are associated with renal and cardio
toxicities with long-term use, particularly at high doses. Second, and perhaps more importantly, by preventing PGE2 production, these agents prevent PGE2-mediated signaling through EP1 and EP3. Tempest has demonstrated in human immune cell culture
systems in vitro that signaling through EP1 and EP3 is required for optimal functional activation of critical immune cell populations required for mounting anti-tumor immunity, such as dendritic cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Rationale for Clinical Evaluation of TPST-1495 in Solid Tumors </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is strong evidence in the literature that indicates a role of both EP2 and EP4 in regulating <FONT
STYLE="white-space:nowrap">PGE2-mediated</FONT> immune suppression in the tumor microenvironment, or TME, indicating that effective anti-tumor immunity might be best achieved with a dual EP2/EP4 antagonist. Overall, as a dual antagonist targeting
both EP2 and EP4, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> offers the potential for unique therapeutic properties as compared to either broad inhibition of PGE2 signaling via COX inhibitors or
<FONT STYLE="white-space:nowrap">EP4-specific</FONT> single antagonists that are currently in clinical development. The Figure below provides a schematic representation for selectively antagonizing both EP2 and EP4 receptors with TPST-1495 and
preserving PGE2 signaling through EP1 and EP3 to maintain functional immunity. Increased levels of EP2 and EP4 receptor expression is correlated with tumor progression, most notably in colorectal carcinoma; EP2 and EP4 receptor signaling has also
been associated with enhanced tumorigenesis. Subjects with all histologic types of solid tumors are eligible for Tempest&#146;s ongoing Phase 1/1b study of <FONT STYLE="white-space:nowrap">TPST-1495.</FONT> However, enrollment of subjects with
colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, squamous cell carcinoma of the head and neck, urothelial cancer, endometrial cancer, and gastroesophageal junction or gastric cancer are specified in the protocol
as being preferred histologies, as the data from preclinical studies evaluating EP2 and EP4 antagonists in vivo as well as gene expression profiling from primary human tumors (data from the Cancer Genome Atlas) indicate that these tumor types may be
particularly susceptible to an <FONT STYLE="white-space:nowrap">anti-EP2</FONT> and <FONT STYLE="white-space:nowrap">anti-EP4</FONT> dual antagonist. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Mechanism of Action </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g15d63.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">TPST-1495</FONT> Antagonist Activity is Selective and
Specific to EP2 and EP4 </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest evaluated <FONT STYLE="white-space:nowrap">TPST-1495</FONT> as a competitive
antagonist to PGE2 signaling in a calcium flux assay against human EP1, EP2, EP3 and EP4 using commercially available cell lines that individually express a single designated EP receptor. PGE2 binding to four related EP receptors (EP1, EP2, EP3 and
EP4) leads to distinct downstream signaling events due to the different G protein coupling status of each receptor. EP1 and EP3 signaling activates calcium flux and EP2 and EP4 signaling stimulates the production of immune suppressive cAMP. In order
to use calcium flux as a consistent readout for the binding of all four EP receptors to PGE2, cell lines stably expressing EP2 or EP4 were also transfected with a promiscuous G protein. This enabled the activation of the calcium signaling pathway in
response to binding of PGE2 to EP2 and EP4. <FONT STYLE="white-space:nowrap">TPST-1495did</FONT> not achieve 50% inhibition of EP1 or EP3 at concentrations up to 30&nbsp;&micro;M, and the IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>
values in two independent experiments were calculated to be 134,200&nbsp;nM and 108,800&nbsp;nM for EP1 and EP3, respectively. In contrast, the calculated IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> for EP2 was 17.21&nbsp;nM (14
independent experiments) and 3.24&nbsp;nM for EP4 (15&nbsp;independent experiments). Tempest believes that these experimental results indicate that <FONT STYLE="white-space:nowrap">TPST-1495</FONT> is a highly selective and specific dual antagonist
of EP2 and EP4 PGE2 receptors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest evaluated the <FONT STYLE="white-space:nowrap">TPST-1495</FONT> selectivity in
vitro in a broad Eurofins Cerep screen of 75 targets, supplemented by additional adenosine transporter binding and uptake assays. In the presence of 10&nbsp;&micro;M <FONT STYLE="white-space:nowrap">TPST-1495,</FONT> mean inhibition of specific
binding for all binding targets was less than 50% with the exception of the adenosine transporter assay. Tempest believes that these results suggest that <FONT STYLE="white-space:nowrap">TPST-1495</FONT> is highly selective and does not
significantly bind or affect the activity of a broad range of targets. Tempest subsequently determined that the IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> for inhibition of adenosine uptake was 0.26&nbsp;&micro;M, which is
approximately <FONT STYLE="white-space:nowrap">16-fold</FONT> higher than the observed maximum unbound concentration of 0.016&nbsp;&micro;M TPST-1495 at a clinical dose of 25&nbsp;mg. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Summary of TPST-1495 Preclinical Results </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest conducted an extensive series of in vitro and in vivo experiments to assess the activity of TPST-1495 to support the
rationale for its clinical evaluation. In this section Tempest shows some of its experimental results which Tempest believes collectively indicate that dual antagonism of the EP2 and EP4 PGE2 receptors is an innovative approach to overcome PGE2
immune suppression in human immune cell culture systems in vitro and inhibits tumor development in several mouse tumor models. Additionally, Tempest believes that these results demonstrate that TPST-1495 has significantly increased anti-tumor
activity in these experimental systems as compared to single EP4 antagonist molecules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>TPST-1495 Reverses <FONT
STYLE="white-space:nowrap">PGE2-Mediated</FONT> Suppression of Monocyte to Dendritic Cell Differentiation and Activation </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest conducted experiments to evaluate the ability of <FONT STYLE="white-space:nowrap">TPST-1495</FONT> to reverse
PGE2-mediated suppression of primary human monocyte to dendritic cell differentiation and activation in vitro. Shown in the Figure below, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> induced a dose-dependent reversal of <FONT
STYLE="white-space:nowrap">PGE2-mediated</FONT> inhibition of CD1a<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>/CD16<SUP STYLE="font-size:85%; vertical-align:top">-</SUP> DC differentiation, with a composite IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50 </SUB>value for the restoration of DC differentiation under PGE2 suppression of 332&nbsp;nM (calculated from pooled normalized data from 21 independent experiments; 95% confidence interval <FONT
STYLE="white-space:nowrap">251-439&nbsp;nM)</FONT> (Panel A). Cells differentiated in the presence of <FONT STYLE="white-space:nowrap">TPST-1495</FONT> also exhibited a <FONT STYLE="white-space:nowrap">dose-dependent</FONT> increase in expression of
CD86<SUP STYLE="font-size:85%; vertical-align:top">+</SUP>, a <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> marker known to be expressed on mature activated DCs (Panel B), and a converse effect on expression of CD163<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>, a marker for immunosuppressive M2 macrophages (Panel C). <FONT STYLE="white-space:nowrap">TPST-1495</FONT> also demonstrated a dose-dependent reversal of PGE2-mediated inhibition of the
proinflammatory cytokines interleukin (IL)-12p70 and TNF&#945; (see second Figure below). Additionally, this series of experiments indicates that TPST-1495 targeting both EP2 and EP4 receptors is more potent at overcoming PGE2 immune suppression
compared to a single EP4 receptor antagonist. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Appears to Reverse PGE2-Mediated Immune Suppression in Human Monocytes </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g16q32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest also evaluated the comparative capacity for TPST-1495 and the single EP4 antagonist
E7046 (TPST-7317) to reverse prostaglandin-mediated immune suppression in conditions of both high and low PGE2 concentrations in human monocyte cultures in vitro. The literature indicates that plasma PGE2 levels in healthy individuals range from 30
to 336 pM, but PGE2 levels in the TME can be elevated up to 3 nM. However, the actual level in the TME is likely much higher than reported due to the short half-life of PGE2. The rationale for conducting this experiment was to test the capacity of
TPST-1495 to reverse immune suppression in a broad range of PGE2 levels that may encompass the range in the TME. Shown in the Figure below, in the presence of 500nM PGE2 (blue curves), the observed concentration of TNF&#945; was significantly lower
than with 10nM PGE2 (green curves) which is likely due to increased suppression of PGE2 signaling through EP receptors. In both low and high PGE2 conditions, TPST-1495 rescued the production of TNF&#945; by monocytes. In contrast, the single EP4
antagonist E7046 was only able to partially rescue TNF&#945; production when PGE2 concentrations were below the Kd for EP2 (green curve, right graph). When PGE2 concentrations were above the EP2 Kd (blue curve, right graph), the single EP4
antagonist was unable to rescue TNF&#945; production due to the redundancy of inhibition by PGE2 signaling through the EP2 receptor. These results suggest that at appropriate dose levels, TPST-1495 may completely block signaling through both EP2 and
EP4 pathways in the TME and that this dual blockade is more effective than EP4 blockade alone to reverse PGE2-mediated immune suppression. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Antagonism of Both EP2 and EP4 Receptors with TPST-1495 is Required to Reverse Immune Suppression in Human Monocytes at High and Low
Prostaglandin Levels </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g17p79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>TPST-1495 Activity in Mouse Tumor Models </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest conducted extensive experiments in several tumor mouse models to evaluate the anti-tumor activity of TPST-1495 and to
compare its potency to a single EP4 antagonist E7046, developed by Eisai Co. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Ltd., or Eisai. Tempest believes that these experimental results demonstrate that TPST-1495 has increased therapeutic activity in tumor-bearing mouse models and has significantly improved
anti-tumor activity compared to single EP4 antagonists. As shown in the Figure below, TPST-1495 demonstrated significant efficacy as monotherapy when given to Balb/c mice bearing established flank CT26 colon tumors. In these experiments, Tempest
analyzed immune compartments in the TME using flow analysis and immunohistochemistry, or IHC, to evaluate whether the <FONT STYLE="white-space:nowrap">anti-tumor</FONT> effects observed in this model correlated with changes in tumor-infiltrating
lymphocytes, or TILs. Administration of TPST-1495 at 100 mg/kg BID significantly increased the total T cell number and percentage of CD4<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> and
CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells within the tumor compared to vehicle control. Specifically, immunodominant AH1 tumor antigen specific CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells (AH1 tetramer<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP>) were significantly elevated (p = 0.035). Mice treated with TPST-1495 demonstrated immune activation, with increased effector to Treg cell ratio (p=0.0001). Consistent with increased T cells in the
TME, the absolute number and frequency of AH1 tetramer<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells was also significantly elevated in the tumor draining lymph node. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Anti-Tumor Response in Mice Correlates with Increased CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells and
Reduced Tregs in the TME </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g18f63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the Figure below, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> anti-tumor
efficacy in the CT26 colon tumor model was significantly diminished when CD8+ T cells were depleted from the mouse with <FONT STYLE="white-space:nowrap">anti-CD8</FONT> antibodies. Additionally, treatment with
<FONT STYLE="white-space:nowrap">anti-CD8</FONT> antibody reversed the effects of <FONT STYLE="white-space:nowrap">TPST-1495</FONT> on tumor infiltration, with a large reduction of CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells
and AH1 rejection antigen specific CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells (data not shown). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells are Required for the
TPST-1495 Mediated Anti-Tumor Response in the CT26 Colon Tumor Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g67q07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The published literature indicates that blockade of the prostaglandin pathway in mice
bearing <FONT STYLE="white-space:nowrap">non-inflamed</FONT> or &#147;cold&#148; tumors leads to the recruitment of IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> expressing NK cells, the development of tumor-specific CD8<SUP
STYLE="font-size:85%; vertical-align:top">+</SUP> T cell immunity and tumor reduction. To support the rationale for combination of TPST-1495 with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> immune
checkpoint inhibitors in patients, Tempest tested the possible increased anti-tumor activity in the CT26 model by combining TPST-1495 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monoclonal antibody
therapies. Shown in the Figure below, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> alone exhibited a 35% reduction in tumor growth compared to vehicle-treated animals (n&nbsp;=&nbsp;10 per group). A 31% reduction in tumor growth was observed in
mice given <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy. When combined, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> decreased tumor growth by 73%, a significant reduction when compared to either the <FONT STYLE="white-space:nowrap">TPST-1495</FONT> (p&nbsp;=&nbsp;0.036) or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy cohorts (p&nbsp;=&nbsp;0.004). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Synergistic Activity with <FONT STYLE="white-space:nowrap">anti-PD1</FONT> Combination in CT26 Tumor Bearing Mice </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g61u20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest also evaluated the anti-tumor activity of TPST 1495 in a spontaneous mouse model
which recapitulates many aspects of human CRC. The <FONT STYLE="white-space:nowrap">so-named</FONT> Apc<SUP STYLE="font-size:85%; vertical-align:top">Min/+</SUP> mice harbor one copy of the multiple intestinal neoplasia (Min) mutant allele of the
Apc locus and spontaneously develop multiple tumors primarily in the small intestine. Both humans and mice bearing Apc mutations are predisposed to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
spontaneous formation of adenomas and adenocarcinomas; humans with Apc mutations typically develop tumors throughout the small and large intestine. To test the impact of TPST-1495 therapy on
small intestine tumor development in the Apc<SUP STYLE="font-size:85%; vertical-align:top">Min/+</SUP> model, mice were treated, starting at the age of six&nbsp;weeks, with 100&nbsp;mg/kg <FONT STYLE="white-space:nowrap">TPST-1495</FONT>
(n&nbsp;=&nbsp;12) or methylcellulose (MC)&nbsp;vehicle (n&nbsp;=&nbsp;12) by twice daily gavage for the duration of eight&nbsp;weeks. The anti-tumor efficacy of dual antagonism of EP2 and EP4 receptors by
<FONT STYLE="white-space:nowrap">TPST-1495</FONT> was compared to a single <FONT STYLE="white-space:nowrap">EP4-specific</FONT> receptor antagonist, <FONT STYLE="white-space:nowrap">TPST-7317,</FONT> which corresponds to E7046, the molecule
developed by Eisai and is in clinical development by Adlai Nortye Biopharma. 24, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">six-week-old</FONT></FONT> Apc<SUP STYLE="font-size:85%; vertical-align:top">Min/+</SUP> mice were
randomly divided into three groups and treated with methylcellulose vehicle control, or MC, <FONT STYLE="white-space:nowrap">MC-containing</FONT> <FONT STYLE="white-space:nowrap">TPST-1495</FONT> (100&nbsp;mg/kg) or
<FONT STYLE="white-space:nowrap">TPST-7317</FONT> (100&nbsp;mg/kg) by twice-daily gavage for eight&nbsp;weeks. The EP4 antagonist IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> was comparable for both compounds. As shown in the Figure
below, <FONT STYLE="white-space:nowrap">TPST-7317</FONT> did not significantly inhibit the number and/or size of small intestine tumors (33.83&nbsp;&plusmn;&nbsp;3.95 tumors in control mice compared to 30.67&nbsp;&plusmn;&nbsp;3.63 tumors in <FONT
STYLE="white-space:nowrap">TPST-7317</FONT> treated mice, p&nbsp;=&nbsp;0.5683). In contrast, treatment of mice with <FONT STYLE="white-space:nowrap">TPST-1495</FONT> resulted in an approximately five-fold reduction in tumors compared to control
mice (6.33&nbsp;&plusmn;&nbsp;1.65 tumors per small intestine; p&nbsp;&lt;&nbsp;0.0001). Tempest believes that these results demonstrate that <FONT STYLE="white-space:nowrap">TPST-1495&nbsp;has</FONT> potent
<FONT STYLE="white-space:nowrap">anti-tumor</FONT> activity as monotherapy and that antagonizing both EP2 and EP4 is significantly more effective at reducing tumor lesions in Apc<SUP STYLE="font-size:85%; vertical-align:top">Min/+</SUP> mice
compared to single EP4 antagonists. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dual EP2 and EP4 Antagonism with TPST-1495 has Significantly Increased Anti-Tumor Potency Compared
to a Single EP4 Antagonist in the APC Mouse Model of Human CRC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g21d92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Significance: *&nbsp;p&nbsp;&lt;&nbsp;0.05, ***&nbsp;=&nbsp;p&nbsp;&lt;&nbsp;0.001,
****&nbsp;=&nbsp;p&nbsp;&lt;&nbsp;0.0001; TPST-7317 is E7046 single EP4 antagonist developed by Eisai </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U><FONT
STYLE="white-space:nowrap">IND-Enabling</FONT> Toxicology Studies </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The toxicology program for TPST-1495 was
designed to evaluate the toxicity profile of <FONT STYLE="white-space:nowrap">TPST-1495,</FONT> enable selection of an appropriate clinical starting dose, and support the oral administration of TPST-1495 to advanced cancer patients. Potential
toxicity was characterized in <FONT STYLE="white-space:nowrap">28-day</FONT> repeated-dose good-laboratory-practice (GLP) studies conducted in two relevant species, rats and monkeys. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary microscopic target organ in the TPST-1495 toxicology program, common to both species, was the gastrointestinal (GI)
tract. In monkeys, liquid or nonformed feces was noted. Microscopic findings of erosion/ulceration and inflammation in the GI tract were the main observations, which were reversible after a <FONT STYLE="white-space:nowrap">28-day</FONT> recovery
period. In the rat, the locations of the findings were primarily in the stomach and duodenum, while in the monkey, the locations of findings were the stomach, cecum, and colon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the <FONT STYLE="white-space:nowrap">28-day</FONT> GLP repeat-dose study conducted in rats, since GI tract microscopic
findings were adverse at all doses tested, a <FONT STYLE="white-space:nowrap">no-observed-adverse-effect-level</FONT> (NOAEL) was not established. However, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
highest <FONT STYLE="white-space:nowrap">non-severely</FONT> toxic dose (HNSTD) was 300&nbsp;mg/kg/day. Clinical pathology findings were limited to animals given
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;30&nbsp;mg/kg/day and were consistent with inflammation and blood loss with a regenerative response. Glandular stomach ulcers and/or erosions were observed microscopically in animals at all doses
and were associated with inflammatory infiltrates and/or hemorrhage, but the findings were of low incidence and lacked a dose response. Stomach ulcers and erosions were considered adverse at all <FONT STYLE="white-space:nowrap">TPST-1495</FONT>
doses. At the end of the <FONT STYLE="white-space:nowrap">28-day</FONT> drug-free recovery period, there were no ulcers or erosions apparent in animals in any dose group. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the <FONT STYLE="white-space:nowrap">28-day</FONT> GLP repeat-dose study conducted in monkeys, the NOAEL was 100 mg/kg/day.
In addition to the GI tract, target organs identified in the monkey included the kidney and liver. Findings in these two organs were only observed at higher doses in initial <FONT STYLE="white-space:nowrap">non-GLP</FONT> monkey repeat-dose studies.
At high doses, moderate to marked increases in urea nitrogen and creatinine were noted, with increased inorganic phosphorus concentrations. Microscopically, kidney findings were characterized as renal tubular degeneration/necrosis, with associated
mixed cell inflammation in two animals given 500 mg/kg/day. Clinical chemistry parameters that were increased included total bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Histologic liver
findings consisted of hepatocellular hypertrophy, hepatocyte vacuolation, periportal inflammation, and/or Kupffer cell hyperplasia of animals administered <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;150&nbsp;mg/kg/day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">TPST-1495 was not mutagenic in a <FONT STYLE="white-space:nowrap">non-GLP</FONT> bacterial mutation assay. TPST-1495 was found
to be not phototoxic in a GLP study conducted in rats. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Ongoing TPST-1495 Phase 1a/1b Clinical study: Overview </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest initiated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1
study in May 2020 to evaluate the safety, tolerability, PK, PD and preliminary anti-tumor activity of TPST-1495 in a multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study in subjects with advanced solid
tumors. Subjects with all histologic types of solid tumors are eligible for the <FONT STYLE="white-space:nowrap">dose-escalation</FONT> and schedule and dose optimization stages. However, the preferred tumor types for enrollment are CRC, NSCLC,
squamous cell carcinoma of the head and neck, or SCCHN, urothelial cancer, endometrial cancer, and gastroesophageal junction, or GEJ, or gastric adenocarcinoma. To be eligible for study, subjects must have no remaining standard therapy known to
confer clinical benefit. The study is composed of three stages. First, the dose-escalation stage will determine the maximum tolerated dose, or MTD, and/or RP2D of single-agent TPST-1495 administered twice daily, or BID. Second, the schedule and dose
optimization stage will evaluate alternative TPST-1495 administration schedules and determine a RP2D for the selected schedule. Third, an expansion stage will evaluate the activity of TPST-1495 in disease-specific cohorts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dose escalation stage of the Phase 1a/1b clinical trial was completed in Q1 2021 and patients currently are enrolling in
the schedule and dose optimization stage. During the dose escalation stage, <FONT STYLE="white-space:nowrap">TPST-1495</FONT> was initially administered on a BID schedule. However, higher than predicted exposure, i.e., greater than IC<SUB
STYLE="font-size:85%; vertical-align:bottom">90</SUB> of the EP2 and EP4 receptors at trough exposure, was associated with reduced gastrointestional, or GI, tolerability that limited chronic dosing by subjects on the BID schedule. On the current
schedule and dose optimization stage of the trial, TPST-1495 is administered once daily, or QD, and is being evaluated on a continuous dosing and an intermittent dosing schedule of days <FONT STYLE="white-space:nowrap">1-5,</FONT> every 7 days.
Tempest&#146;s hypothesis is that the trough exposure levels achieved with QD dosing will improve gut homeostasis and tolerability for chronic dosing while maintaining the Cmax drug levels that Tempest believes block EP2/EP4 receptor signaling in
the TME, thereby providing clinical benefit to subjects during chronic dosing. Both the QD continuous and intermittent administration schedules will be tested at the 25 mg dose level, and possibly higher and lower dose levels. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;23, 2021, 22 subjects have enrolled into the <FONT STYLE="white-space:nowrap">TPST-1495-001</FONT> study,
three subjects discontinued study before initiating treatment and 19 patients received at least one dose of TPST-1495 and are included in the safety database.&nbsp;The safety profile of TPST-1495 has been characterized by predominantly Grade <FONT
STYLE="white-space:nowrap">1-2</FONT> treatment related adverse events, or TRAE, with 26.3% of the 19 safety subjects </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
experiencing a Grade 3 TRAE and no subjects experiencing Grade 4 or Grade 5 AEs. The most common TRAEs of any grade have been diarrhea (32%), abdominal pain (26%), dyspepsia (26%), anemia (21%),
fatigue (21%), nausea (16%) and vomiting (16%), while the only Grade 3 TRAEs reported have been anemia (16%), GI hemorrhage (6%), and lymphopenia (6%). A solitary dose limiting toxicity (DLT) was reported at the highest dose (100 mg) tested on the
BID administration schedule and this same event (Grade 3 GI hemorrhage) was the only related Serious Adverse Event (SAE) reported. No dose-limiting toxicities, or DLTs, have been reported on the QD administration schedule with six subjects treated
at the 25 mg QD dose level and two at the 25 mg QD intermittent dose level. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Treatment-Related Adverse Events </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g34o59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>No Grade 4 or Grade 5 AEs have been reported. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Overview of Clinical Pharmacology </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">PK analyses indicated that the drug exposure at steady state in subjects who received the BID dosing schedule remained well
above the human whole blood IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> values for the EP2 and EP4 receptors at 50 mg and 25&nbsp;mg dose levels. The Figure below shows the TPST-1495 concentration-time profiles following a single
dose on Day&nbsp;1 and steady state concentrations with BID or QD dosing on Day&nbsp;8. The PK profiles on Days 1 and 8 of study subjects treated at 25 mg on the QD schedule demonstrated that once daily dosing of TPST-1495 reduced the minimum
observed plasma concentration, or C<SUB STYLE="font-size:85%; vertical-align:bottom">min</SUB>, and steady state exposure levels in those patients compared to the BID schedule. The PK profiles of the six subjects Tempest has treated to date with the
25 mg QD dose schedule have been remarkably similar and indicate TPST-1495 exposure levels at trough at 24 hours are beneath the EP2 receptor IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> value and comparable to the EP4 receptor IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> value, to facilitate intestinal mucosal homeostasis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Mean Concentration-Time Profiles by Dose Level for TPST-1495 for 25 mg and 50 mg BID and
QD Dosing Schedules </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g97h86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Abbreviations: BID&nbsp;=&nbsp;twice a day; D&nbsp;=&nbsp;day; h&nbsp;=&nbsp;hour; IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;=&nbsp;half maximal inhibitory concentration. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>For BID administration,
Day&nbsp;1 PK is following a single dose, Day 8 is BID, and Day 22 is BID. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Error bars are standard deviations around the mean.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PD assessment in subjects treated with TPST-1495 includes both the PGE2 whole blood immune suppression assay
conducted with patient blood discussed in the nonclinical section and measurements of a stable metabolite of PGE2 known as PGEM in the urine. Shown in the Figure below, the first PD results indicate target engagement in subjects dosed with 25 mg
TPST-1495, as indicated by the reversal of PGE2 immune suppression in the whole blood assay, as shown by the increase of TNF&#945; production in whole blood monocytes due to TPST-1495 exposure. Tempest has also observed increased levels of PGEM in
the urine, resulting from TPST-1495 antagonism of EP2 and EP4 receptors (inferred through measurement of the PGEM metabolite). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recovery of <FONT STYLE="white-space:nowrap">TNF-a</FONT> Production in Whole Blood on the First Day Following Dosing with 25 mg and 50 mg
TPST-1495 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g21j92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Percent increase of <FONT STYLE="white-space:nowrap">TNF-</FONT></I>&#945;<I></I><I> measured in
subjects&#146; whole blood as indicated by ELISA following stimulation with LPS alone with and without exogenously added PGE2 sampled at the times indicated in the legend post dosing. The values expressed reflect the percent recovery of <FONT
STYLE="white-space:nowrap">TNF-</FONT></I>&#945;<I></I><I> production observed in the presence of PGE2 and TPST-1495 in subject plasma as compared to the level <FONT STYLE="white-space:nowrap">TNF-</FONT></I>&#945;<I></I><I> production in subject
plasma stimulated with LPS alone (without PGE2).</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;23, 2021, 22 subjects have enrolled into the study, three
subjects discontinued the study before initiating treatment and 19 patients received at least one dose of TPST-1495 and are included in the safety and efficacy database.&nbsp;The Swimmer&#146;s plot shown below summarizes the TPST-1495 treatment
duration (in some cases ongoing) of the 19 treated patients on study and is annotated with the Best Overall Response, or BOR, for subjects who achieved 0% tumor growth or reduction of target lesions on treatment. Of note, these emerging data
indicate that subjects starting on (or reduced to) the QD schedule at the current 25 mg dose have a generally increased duration of treatment and improved objective tumor response compared to the BID schedule, consistent with improved tolerability
and more prolonged dosing with the QD schedule. In addition, four patients on the 25 mg QD dose schedule experienced a reduction in disease specific tumor marker, i.e., PSA and CEA in prostate and colon cancer subjects respectively. With 3/19
subjects ongoing before first tumor assessment, a best response of stable disease, or SD, has been observed in 25% (4/16) of study subjects, conservatively defining <FONT STYLE="white-space:nowrap">non-evaluable</FONT> subjects as <FONT
STYLE="white-space:nowrap">non-responders,</FONT> including tumor shrinkage in some subjects not meeting RECIST criteria of at least 30% tumor reduction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1495 Treatment Duration and Best Overall Response </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g20o06.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Asterisk denotes a dose reduction during course of study; asterisked 25mg BID patients changed schedule to
25mg QD. Data source are electronic data capture and site clinical site communications and are preliminary partially-unmonitored data. For ongoing patients, last dose of TPST-1120 assumed to be March 23rd, 2021. Subjects shown in the Figure were
enrolled into the Dose Escalation or the schedule and dose optimization arms of the Phase 1a/1b clinical study. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the TPST-1495 RP2D and schedule are identified, expansion cohorts will be opened to further evaluate TPST-1495 in selected
cancer indications that are strongly associated with prostaglandin signaling and high expression of EP2 and EP4 receptors, including colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, squamous cell cancer of the
head and neck, and urothelial carcinoma. The <FONT STYLE="white-space:nowrap">co-primary</FONT> objectives of the expansion stage cohorts are to further characterize the safety profile of TPST-1495 and to assess the preliminary anti-tumor activity
of TPST-1495 as monotherapy treatment in these key indications.&nbsp;Additional exploratory objectives in the expansion cohorts focus upon characterizing the immunomodulatory activity of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
TPST-1495 in treated subjects in blood and in the tumor microenvironment, as well as characterization of potential predictive biomarkers for patient selection, for example the PGE2 metabolite
known as PGEM.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest expects to identify the RP2D dose and schedule for TPST-1495 and initiate the dose expansion phase
in the second half of 2021. Additionally, once Tempest has identified the monotherapy RP2D dose level and schedule, Tempest plans to initiate combination studies with an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> immune checkpoint inhibitor antibody, focusing on the same prostaglandin-driven cancers. Tempest expects to initiate this TPST-1495 combination study in H2
2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>TPST-1120: PPAR</B>&#945;<B></B><B> Transcription Factor Antagonist </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Overall Program Summary </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">TPST-1120 is potentially a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> oral,
small molecule antagonist of Peroxisome Proliferator-Activated Receptor-alpha, or PPAR&#945;, currently in multicenter, open-label, dose-escalation, Phase 1a/1b clinical studies as both monotherapy and in combination with nivolumab in patients with
advanced solid tumors. The dose escalation phase of the clinical study has been completed, and the combination arm is ongoing. Tempest has observed evidence of TPST-1120 clinical activity in the dose escalation arms, and Tempest plans to disclose
the results of the monotherapy and combination therapy dose escalation studies in the second half of 2021. Tempest expects to initiate a multicenter global randomized Phase 1b/2 clinical study in collaboration with
<FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd. in the first half of 2021 that will evaluate TPST-1120 in combination with atezolizumab (Tecentriq&reg;) and bevacizumab (Avastin&reg;) in previously untreated patients with advanced
hepatocellular carcinoma, or HCC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As illustrated in the Figure below, tumors evolve to modulate metabolism to promote
their own survival, promote angiogenesis and to evade immune recognition. PPAR&#945; is a transcription factor that is activated through binding of long-chain fatty acid ligands, which in turn regulates the expression of &gt;100 genes that control
glucose and lipid homeostasis, inflammation, proliferation, differentiation and cell death. Included among these regulated genes are those that enable FAO and <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>-oxidation metabolic pathways in cellular
peroxisomes and in mitochondria. An FAO metabolic profile is associated with tumor proliferation, induction of angiogenesis and immune suppression. Published studies and internal Tempest analyses of over 9,000 primary or metastatic tumor samples in
the TCGA public database reveal a metabolic gene expression profile characterized by increased PPAR&#945;, FAO genes and lipogenesis associated with increased metastatic potential and reduced survival enrichment among multiple cancers, including
hepatocellular carcinoma (HCC), cholangiocarcinoma, breast carcinoma, colorectal adenocarcinoma, RCC, lung adenocarcinoma, and prostate adenocarcinoma. TPST-1120 is designed to collectively block the pathways that support tumor cell proliferation,
angiogenesis and immune suppression, resulting in reduced disease and patient benefit. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1120 Mechanism of Action </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g20e07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Rationale for Clinical Evaluation of TPST-1120 in Solid Tumors: The Role of
PPAR</U></I>&#945;<I></I><I> in Cancer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Peroxisome Proliferator-Activated Receptors, or PPARs, are ligand-activated
transcription factors involved in the regulation of glucose and lipid metabolism homeostasis, inflammation, proliferation, differentiation and cell death. The three PPAR subtypes, PPAR&#945;, PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and
PPAR&szlig;/<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>, are activated in tumors, where they appear to modulate cell proliferation, differentiation and survival, supporting an important role of PPARs in cancer biology. PPAR&#945; regulates the
expression of about 100 genes, including those that produce enzymes that enable metabolic processes in cellular peroxisomes and mitochondria known as fatty acid oxidation, or FAO, or &szlig;-oxidation. PPAR&#945; expression levels and FAO metabolism
is increased in selected healthy, including liver, heart, skeletal muscle, brown adipose tissue, and kidney. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">It has been
published that multiple human hematologic and solid tumor malignancies demonstrate comparatively increased expression levels of the PPAR&#945; transcription factor, its activating ligands including long-chain fatty acids, and PPAR&#945; induced
genes. This metabolic profile has been observed in hypoxic metastases and extends to immune suppressor cell populations also including myeloid- and lymphoid-derived effector cell populations in the tumor microenvironment such as dendritic cells and
CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells which are rendered <FONT STYLE="white-space:nowrap">non-functional,</FONT> or exhausted, by virtue of utilizing FAO. These published findings indicate that the FAO metabolic pathway
enables both tumor cell proliferation and evasion of tumor-specific immune recognition. Tempest interrogated the TCGA public data base to determine which human cancers expressed the highest levels of PPAR&#945; and 30 of its targeted genes.
Interestingly, Tempest found that FAO is a favored metabolic pathway in hepatocellular carcinoma (HCC), cholangiocarcinoma, breast carcinoma, colorectal adenocarcinoma, RCC, lung adenocarcinoma, and prostate adenocarcinoma. This analysis has served
as a primary rationale along with the published literature to guide Tempest&#146;s TPST-1120 clinical strategy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In support
of Tempest&#146;s clinical strategy to evaluate TPST-1120 in patients with HCC, it has been shown in published preclinical studies that therapeutic benefit is observed in mice bearing activated <FONT STYLE="white-space:nowrap">&szlig;-catenin</FONT>
pathway liver tumors&#151;also common in human HCC&#151;given a small molecule drug known as etomoxir which targets an FAO pathway protein known as CPT1. In a separate line of investigations, PPAR&#945;-deficient mice have been shown to be
refractory to the liver carcinogenic effects of an activated <FONT STYLE="white-space:nowrap">&szlig;-catenin</FONT> pathway or by treatment with the PPAR&#945; fibrate agonist WY14643, which is carcinogenic in wild-type mice. The foundational
scientific rationale for targeting PPAR&#945; with an antagonist was demonstrated in a published study describing a series of experiments conducted in PPAR&#945; deficient mice. When these mice were implanted with tumors&#151;which also lacked a
functional PPAR&#945; gene&#151;the tumors initially established, grew, but then spontaneously completely regressed, due to an inability to convert to FAO metabolism to support continued tumor proliferation. These reports and others support the
scientific rationale for targeting the PPAR&#945; for the treatment of cancer. Although there have been a few PPAR&#945; antagonists that have exerted beneficial effects in preclinical cancer models, to date, no selective PPAR&#945; antagonists have
been tested in human trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Summary of TPST-1120 Preclinical Results </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has conducted <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmacology studies along with PK and toxicology
studies with <FONT STYLE="white-space:nowrap">TPST-1120</FONT> to support its ongoing evaluation for the treatment of patients with advanced solid tumors. The combined results of the preclinical studies that Tempest has performed indicate that the
TPST-1120 anti-tumor response mechanism of action involves both directly inhibiting tumor proliferation and targeting suppressive immune response pathways to promote effective tumor-specific immunity. Tempest&#146;s preclinical results support the
large body of published literature that the PPAR&#945; target genes play an integral role in tumor growth, angiogenesis and evasion of immune recognition and provide the scientific rationale for targeting this pathway with TPST-1120. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Specifically, TPST-1120 has shown the following properties in <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potent human PPAR&#945; binding (time-resolved fluorescence resonance energy transfer <FONT
STYLE="white-space:nowrap">[TR-Fret]</FONT> reporter EC50 = 0.011 &micro;M) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potent human PPAR&#945; inhibition (luciferase reporter
IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> = 0.052 &micro;M) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Direct and dose-dependent inhibition of cultured primary tumor cells from 14 patients with chronic lymphocytic
leukemia </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promotion of macrophage repolarization (increase in M1/M2 ratio) in PancOH7 syngeneic tumor model
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Therapeutic benefit of TPST-1120 in syngeneic mouse MC38 colorectal cancer model in parental C57BL/6 mice, but
not in Goldenticket (STING<SUP STYLE="font-size:85%; vertical-align:top">-/-</SUP>) or in BatF3 gene knockout mice, indicating an immunomodulatory mechanism, operating through Stimulator of INterferon Genes (STING) and CD8&#945; dendritic cells
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restoration of <FONT STYLE="white-space:nowrap">thrombospondin-1</FONT>
<FONT STYLE="white-space:nowrap">(TSP-1)</FONT> to homeostatic levels in B16F10 and PancOH7 models, suggesting <FONT STYLE="white-space:nowrap">TSP-1</FONT> plays a role in TPST-1120 anti-tumor activity. <FONT STYLE="white-space:nowrap">TSP-1</FONT>
has been shown to be a potent endogenous inhibitor of angiogenesis </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inhibition of growth of melanoma (B16F10), colon (MC38) and Lewis lung syngeneic carcinoma models with TPST-1120
monotherapy at a dose of 30 mg/kg twice daily </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Significant synergistic inhibition of growth of syngeneic mouse MC38 colorectal and ID8 ovarian cancer models in
combination with anti-programmed cell death protein 1 <FONT STYLE="white-space:nowrap">(PD-1)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Induction of anti-tumor immune memory in an orthotopic ID8 ovarian and syngeneic MC38 colorectal cancer models
when combined with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Synergistic response with chemotherapies including gemcitabine in PancOH7 model and paclitaxel in Lewis lung
carcinoma </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Figure below shows experimental results that are illustrative of the TPST-1120 dual
mechanism of action, or MOA, targeting both tumor cells and suppressive immune cell populations. The left upper panel demonstrates that TPST-1120 can directly kill three different HCC human tumor cell lines in vitro in a dose-dependent fashion,
consistent with Tempest&#146;s findings from the Human Cancer Genome, or TCGA, database that HCC had the highest level of PPAR&#945;-induced genes of all malignancies. Tempest&#146;s TCGA analysis also demonstrated that renal cell cancer, or RCC, is
an <FONT STYLE="white-space:nowrap">FAO-reliant</FONT> malignancy. Shown in the lower left panel in the Figure below, TPST-1120 monotherapy inhibited tumor growth in immune deficient mice implanted with <FONT STYLE="white-space:nowrap">Caki-1</FONT>
human RCC tumor cells. The experimental results shown in the right panel below were conducted in C57BL/6 mice bearing syngeneic MC38 colon tumors and treated TPST-1120. Tempest analyzed two immune cell populations in the MC38 TME to test whether
TPST-1120 therapy inhibited suppressive or <FONT STYLE="white-space:nowrap">non-functional</FONT> immune cell populations. Using BODIPY flow cytometry, which is a method to measure cellular uptake of long chain fatty acids, Tempest found that
TPST-1120 therapy inhibited uptake of the PPAR&#945; transcription factor activating ligand in toleragenic dendritic cells, thus inhibiting the preferred metabolic pathway of this suppressive immune cell population. Shown in the right panel of the
Figure, TPST-1120 treatment of MC38 tumor-bearing mice also reduced the expression of <FONT STYLE="white-space:nowrap">PD-1,</FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> and <FONT STYLE="white-space:nowrap">TIM-3</FONT> exhaustion markers on
tumor infiltrating CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1120 Directly Inhibits Tumor Cell Proliferation and Immune Suppression in the TME
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g99q79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immune checkpoint blockade enhances anti-tumor immunity by restoring the activity of
cytotoxic T (Teff) cells. Emerging experimental results suggest that inhibiting FAO with a PPAR&#945; antagonist may target resistance mechanisms to both <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1/PD-1</FONT></FONT></FONT> and anti-VEGF therapies. Upon ligation between <FONT STYLE="white-space:nowrap">PD-1</FONT> on tumor infiltrating T cells with <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressed on
tumor cells, metabolic <FONT STYLE="white-space:nowrap">T-cell</FONT> <FONT STYLE="white-space:nowrap">re-programming</FONT> occurs, which is characterized by a shift from glycolysis to FAO, thereby restricting
<FONT STYLE="white-space:nowrap">T-effector</FONT> cell differentiation and promoting suppressive <FONT STYLE="white-space:nowrap">T-regulatory</FONT> cells. The rationale for targeting PPAR&#945; is to inhbit suppressive immune cells in the tumor
microenvironment and promote the function and/or recruitment of cytotoxic T effector cells, thus enhancing the efficacy of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> blockade. In this context,
inhibiting FAO metabolism has the combined effect of inhibiting tumor cell growth directly and also the metabolism of suppressive immune cell populations, markedly improving the success of immunotherapies. These observations support both the
scientific rationale and provide insights into clinical evaluation of combining TPST-1120 with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-(L)-1</FONT></FONT> immune checkpoint inhibitor antibodies. Shown in panel A in the
Figure below, while both TPST-1120 or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy inhibited outgrowth of established flank MC38 tumors, the combination of these two agents resulted in
synergistic anti-tumor activity. Shown in panel B, MC38 tumor-bearing mice cured by the combination therapy, unlike <FONT STYLE="white-space:nowrap">age-matched</FONT> na&iuml;ve control mice, were completely refractory to tumor growth when
rechallenged with autologous MC38 tumor cells. These results demonstrate that TPST-1120 in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> induced lasting tumor-specific immune memory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Significant Anti-Tumor Activity and Induction of Tumor-Specific Immune Memory is Observed
in MC38 Colon Tumor Bearing Mice Given with TPST-1120 + <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> mAb Combination Therapy </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g150774g44t35.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">PPAR&#945; orchestrates the metabolic
<FONT STYLE="white-space:nowrap">re-programming</FONT> to utilize FAO as the main energy source in mice with <FONT STYLE="white-space:nowrap">&szlig;-catenin&#045;activated</FONT> HCC. PPAR&#945; deficient mice are refractory to the liver
carcinogenic effects of the activated <FONT STYLE="white-space:nowrap">&szlig;-catenin</FONT> pathway and the PPAR&#945; fenofibrate agonist WY14643. Since a significant proportion (up to 50%) of HCC cancers have
<FONT STYLE="white-space:nowrap">Wnt-&szlig;-catenin</FONT> pathway activation, Tempest tested the activity of TPST-1120 in the Hepa <FONT STYLE="white-space:nowrap">1-6</FONT> tumor cells, which are a syngeneic &szlig;-catenin driven HCC tumor.
Shown in panel A of the Figure below, Tempest observed a synergistic reduction in established tumor volume and long-term durable cures when <FONT STYLE="white-space:nowrap">TPST-1120</FONT> therapy was combined with an
<FONT STYLE="white-space:nowrap">anti&#045;PD-1</FONT> antibody. Additionally, tumor resistance to anti-angiogenic drugs is associated with elevated lipogenesis and FAO, primarily through the vascular regression and hypoxic environment that this
class of therapies engenders. In response, tumor cells can switch to FAO as a mechanism of resistance against anti-angiogenic therapy. The published literature indicates that in the MC38 CRC model inhibiting FAO is highly effective in overcoming
this resistance when administered in combination with anti-VEGF therapy. Tempest confirmed that combination of TPST-1120 with anti-angiogenesis therapy confers potent anti-tumor activity. Shown in panel B of the Figure below, Tempest&#146;s
preliminary results show complete reduction of established MC38 tumors in mice given a combined therapy of TPST-1120 with the approved VEGF receptor tyrosine kinase inhibitor cabozantinib. Taken together, the experimental results shown in this
Figure provide the scientific rationale for the planned clinical evaluation of TPST-1120 therapy in front-line HCC in combination with atezolizumab and bevacizumab, and evaluation of TPST-1120 in combination with cabozantinib in <FONT
STYLE="white-space:nowrap">FAO-reliant</FONT> malignancies such as HCC and RCC. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-Tumor Activity of TPST-1120 Combination Therapy
with Immune Checkpoint or Angiogenesis Inhibitors </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g36k70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Toxicology Studies </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The toxicology program for TPST-1120 was designed to evaluate the toxicity profile of TPST-1120, enable selection of an
appropriate clinical starting dose, and support the oral administration of TPST-1120 to advanced cancer patients. Potential toxicity was characterized in <FONT STYLE="white-space:nowrap">28-day</FONT> repeated-dose good-laboratory-practice (GLP)
studies conducted in two relevant species, rats and dogs. In the GLP study conducted in rats, audible respiration with labored respiration caused the early sacrifice of one rat at 1000&nbsp;mg/kg/day. A similar finding had been noted in a <FONT
STYLE="white-space:nowrap">non-GLP</FONT> <FONT STYLE="white-space:nowrap">14-day</FONT> repeated-dose study, where there were five deaths and wheezing was reported as a clinical sign at 1000&nbsp;mg/kg/day. There was no pathologic cause of death
for this finding. In the GLP study, a dose of 750&nbsp;mg/kg/day was considered to be the severely toxic dose in 10% of animals (STD10), while the <FONT STYLE="white-space:nowrap">no-observed-adverse-effect</FONT> level (NOAEL) was 250 mg/kg/day
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the <FONT STYLE="white-space:nowrap">28-day</FONT> GLP repeat-dose toxicity study conducted in dogs, the highest <FONT
STYLE="white-space:nowrap">non-severely</FONT> toxic dose (HNSTD) was 1000&nbsp;mg/kg/day due to the lack of severely toxic findings at that dose. The NOAEL in dogs was 300&nbsp;mg/kg/day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The two primary microscopic target organs identified in both species were
the liver and kidney. The findings were different in the two species and were adverse in dogs at the high dose of 1000 mg/kg/day. Conversely, microscopic findings were not found to be adverse in rats. The third target organ based on clinical signs,
which was also common to both species, was the gastrointestinal (GI) tract. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">TPST-1120 was not mutagenic in a <FONT
STYLE="white-space:nowrap">non-GLP</FONT> bacterial mutation assay. TPST-1120 was not found to be phototoxic in a GLP study conducted in rats. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Ongoing TPST-1120 Phase 1a/1b Clinical study: Overview, Status&nbsp;&amp; Safety </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is sponsoring an ongoing,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> open-label, <FONT STYLE="white-space:nowrap">dose-escalation</FONT> and <FONT STYLE="white-space:nowrap">dose-expansion</FONT> Phase 1/1b study
evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TPST-1120 alone and in combination with systemic anti-cancer therapies in patients with advanced solid tumors. Part 1 of the study is designed to determine the
MTD and/or RP2D of TPST-1120 monotherapy. Part 2 is designed to determine the MTD and/or RP2D of TPST-1120 in combination with the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monoclonal antibody,
nivolumab. Parts 3 and 4 (not yet open) are designed to evaluate the anti-tumor activity of TPST-1120 monotherapy and in combination with nivolumab at the MTD or RP2D in tumor-specific expansion cohorts, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a data cutoff date of March&nbsp;23, 2021, 20 subjects have been dosed on the Phase 1 study with TPST-1120 at escalating
doses from 100 mg BID to 600 mg BID. No DLTs have been reported and the MTD not reached at the highest dose level tested. The RP2D of monotherapy TPST-1120 for further development is 600 mg BID. The majority of TPST-1120 related adverse events,
including at the 600 mg BID dose, have been Grade 1-2 in severity and manageable without requiring dose hold or dose reduction. The most common related adverse events reported have been nausea, fatigue, and diarrhea, all <FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> Grade 2 in severity. Only one Grade 3 related adverse event (Grade 3 hypertension) considered by the investigator to be possibly/probably related to <FONT STYLE="white-space:nowrap">TPST-1120</FONT> has been
reported, and no &gt; Grade 3 AEs have been reported. No subjects have had <FONT STYLE="white-space:nowrap">TPST-1120</FONT> discontinued due to a <FONT STYLE="white-space:nowrap">drug-related</FONT> toxicity. In the preliminary combination cohorts
with nivolumab, 8 subjects have been dosed with escalating doses of TPST-1120 from 100 mg BID to 400 mg BID and the dose escalation continues with the highest dose to be tested being the monotherapy RP2D of 600 mg BID. No DLTs have been reported for
the combination regimen to the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, and the safety profile of the combination appears consistent with the individual profiles of the two drugs. Pharmacokinetic analysis of TPST-1120 in study
subjects has demonstrated dose-proportional exposure with increasing dose up to the highest dosed level tested. Additionally, pharmacodynamic (PD) assessment of <FONT STYLE="white-space:nowrap">on-target</FONT> activity in patients has demonstrated
modulation of triglycerides and PPAR&#945; controlled gene expression in TPST-1120 treated subjects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the primary
objective of the dose escalation is to characterize the TPST-1120 safety profile and determine the recommended dose for development, Tempest is encouraged by the observations of prolonged disease control in some patients as well as RECIST stable
disease with tumor shrinkage (up to <FONT STYLE="white-space:nowrap">-15%)</FONT> achieved with monotherapy TPST-1120 during the dose escalation stage. Extended time on study has occurred in subjects with late-line treatment refractory cancers,
including cholangiocarcinoma which is known to have particularly short <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-progression</FONT></FONT> with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> in the late-line treatment setting. Shown below, one subject with late line cholangiocarcinoma had a 15% tumor shrinkage and was on study for over 9
months of treatment while also demonstrating <FONT STYLE="white-space:nowrap">on-target</FONT> inhibition of expression of PPAR&#945; target genes on PD assessment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1120 Monotherapy Treatment Duration and Best Overall Response </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g11a65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Long-Term Tumor Control and PPAR</B>&#945;<B></B><B> Target Gene Modulation in Late-Line
Cholangiocarcinoma Patients Treated with TPST-1120 Monotherapy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g12r65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dose escalation of TPST-1120 in combination with nivolumab is continuing and has not
reached a MTD or RP2D. However, Tempest is encouraged by preliminary signs of activity with a deep RECIST partial response (PR) with an overall reduction of <FONT STYLE="white-space:nowrap">-54%</FONT> in tumor burden observed in a subject with 4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> line RCC who had already progressed on the combination of nivolumab and ipilimumab. Shown below, this subject had extensive metastatic disease at study entry including large-burden pulmonary
metastases, multiple soft tissue metastases and bone metastases. Her prior therapies included (best response and reason for discontinuation): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First-line: ipilimumab + nivolumab (SD, PD) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Second-line: cabozantinib (SD, PD) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-line: everolimus (SD, PD) </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notably, this subject had been treated with the combination of nivolumab and ipilimumab without experiencing an objective
response and then had experienced progression of cancer on this IO doublet, followed by progression of cancer on both cabozantinib and everolimus before initiating treatment with TPST-1120 and nivolumab. The initial RECIST PR was seen at the first <FONT
STYLE="white-space:nowrap">on-study</FONT> assessment at 8 weeks and included a response in all target lesions as well as complete radiographic resolution of multiple sites of metastatic disease (see CT scan), and was confirmed in a second on-study
assessment at 16&nbsp;weeks. Tempest feels that induction of an objective response despite resistance to nivolumab could reflect either monotherapy activity of TPST-1120 on an <FONT STYLE="white-space:nowrap">FAO-dependent</FONT> tumor or, based
upon the mechanism of action and the extensive supporting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, reduction of immune suppressive cells and release of the subject&#146;s own anti-cancer immune response. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Partial Response in Late-Line RCC Patient Treated with TPST-1120 and Nivolumab Combination Therapy </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g12b68.jpg" ALT="LOGO">
&nbsp;


<IMG SRC="g150774g12b69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TPST-1120 Monotherapy and Nivolumab Combination Therapy Waterfall Plot </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g13k66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Planned TPST-1120 Phase 1b/2 Clinical study in Front Line HCC </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the TPST-1120 mechanism of action, preclinical data demonstrating synergy with both
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and anti-angiogenesis agents, and the encouraging safety profile and early signs of anti-tumor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
activity, Tempest and Roche entered into a clinical collaboration with Roche to evaluate TPST-1120 in combination with atezolizumab and bevacizumab in patients with advanced/metastatic HCC <FONT
STYLE="white-space:nowrap">not-previously</FONT> treated with systemic therapy. This global, randomized, open-label, Phase 1b/2 trial will be operationalized by Roche and will evaluate the triplet regimen of TPST-1120 + atezolizumab + bevacizumab
randomized against the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> doublet of atezolizumab + bevacizumab in the first-line systemic treatment of patients with hepatocellular carcinoma. The primary
objective of this study is to evaluate the anti-tumor efficacy of the combination as determined by confirmed ORR by RECIST 1.1. Additional efficacy endpoints include progression free survival, or PFS, overall survival. or OS, and duration of
response, or DOR, while a key exploratory objective is to identify biomarkers that are predictive of response to the experimental treatment, including an assessment activation of the <FONT STYLE="white-space:nowrap">&szlig;-catenin</FONT> pathway,
which is predicted to be present in approximately 50% of patients with HCC. Tempest anticipates that enrollment to this clinical coloration will initiate in the second half of 2021. Tempest is considering the additional development of TPST-1120 as
either monotherapy in selected indications, or in combination immunotherapy and/or anti-angiogenesis therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">TREX-1</FONT> Inhibitor Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest believes that the exonuclease <FONT STYLE="white-space:nowrap">TREX-1</FONT> may be the optimal approach to drug the
STING pathway (<B>ST</B>imulator of <B>IN</B>terferon <B>G</B>enes) with an orally available small molecule inhibitor. Extensive genetic evidence from human disease that has been confirmed in numerous mouse
<FONT STYLE="white-space:nowrap">knock-out</FONT> investigations point to the STING pathway as a critical innate immune sensor for the development of anti-tumor immunity. Although the STING pathway has significant scientific validation, the clinical
trials sponsored by several groups utilizing synthetic cyclic dinucleotide STING agonists have been somewhat disappointing. The underlying scientific hypothesis for these clinical trials was that localized T cell priming in the lymph nodes draining
from the injected tumor would have activity against <FONT STYLE="white-space:nowrap">non-injected</FONT> distal tumors, sometimes referred to as the abscopal effect. It is well-known that metastatic tumors have unique antigenic repertoires,
indicating a need for global innate activation in the TME of all metastases in order to prime T cells that can recognize and broadly eradicate distinct tumors. However, it would be likely difficult to achieve a therapeutic index with systemically
delivered STING- agonists due to the ubiquitous expression of this central innate immune receptor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shown in the Figure
below, <FONT STYLE="white-space:nowrap">TREX-1</FONT> is a cytosolic exonuclease that inhibits activation of the cGAS/STING pathway by degrading double-stranded (ds) DNA. <FONT STYLE="white-space:nowrap">TREX-1</FONT> expression is increased across
diverse malignancies, due to, for example DNA repair mutation, selected therapeutic interventions such as <FONT STYLE="white-space:nowrap">DNA-modifying</FONT> chemotherapeutic agents or radiation. The increased expression of <FONT
STYLE="white-space:nowrap">TREX-1</FONT> in tumors serves as the foundational scientific evidence that tumors can hijack this pathway to prevent activation of the STING pathway and avoid immune recognition. The underlying scientific hypothesis for
the program is that systemic oral dosing with a potent and specific inhibitor will activate the STING pathway selectively in the tumor microenvironment (TME) and prime cytolytic CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells
broadly in tumor draining lymph nodes serving distinct metastatic lesions having unique antigenic repertoires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TREX-1</FONT> DNA Exonuclease Modulates cGAS/STING
Pathway and Innate Immunity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g14a65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown by the Figure below, Tempest is currently advancing a lead series with a &gt;1000-fold increase in
SAR with an IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> inhibitory value as low as 8 nM in human <FONT STYLE="white-space:nowrap">TREX-1</FONT> inhibitor biochemical assays. The lead series is also active against mouse <FONT
STYLE="white-space:nowrap">TREX-1,</FONT> which will facilitate development of the molecule. In addition, as shown below, this lead series enhances STING activation in a dsDNA-stimulated reporter cell line. Tempest expects to select a Development
Candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities by the end of 2021, followed by an IND for evaluation in patients with advanced solid tumors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lead Series Compound-Mediated Inhibition of TREX1 Activity in Biochemical Assay and Enhancement of STING Activation in a Reporter Cell line
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g14b44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, Tempest entered into a collaboration agreement with Roche to accelerate the development of TPST-1120 into a frontline,
randomized study. Under the terms of the collaboration agreement, Roche will evaluate TPST-1120 in a global randomized phase 1b/2 clinical study in combination with the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carcinoma, or HCC, not previously treated with systemic therapy. Pursuant to the terms of the collaboration agreement, Roche will manage the study operations for the trial, and Tempest will
retain global development and commercialization rights to TPST-1120. According to the agreement, Roche will provide Tempest with notice of the amount of TPST-1120 required for a study and the delivery timeline, and Tempest will supply the TPST-1120
to Roche for the study. All rights to invention and discoveries relating solely to TPST-1120 or biomarkers solely related to TPST-1120 made during any study will be the exclusive property of Tempest. All data generated in the performance of any
study under the collaboration agreement will be the property of Roche, but Tempest is entitled to use the data for any lawful purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collaboration agreement is effective from February&nbsp;23, 2021 and continues to be in force on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">study-by-study</FONT></FONT> basis until the last treatment of the last patient in a study receiving TPST-1120 in accordance with the protocol for such study or until the termination of this collaboration agreement by
either party. Each party has the right to terminate the collaboration agreement upon sixty days prior written notice to the other party. Upon any termination of the agreement, neither Tempest nor Roche will be entitled to any compensation, damages
or other payment. If any individual study supplement is terminated, Roche must return all unused TPST-1120 to Tempest free of charge or destroy such product at Tempest&#146;s request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest intends to
retain significant development and commercial rights to its product candidates and, if marketing approval is obtained, to commercialize its product candidates on its own, or potentially with a partner, in the United States and other regions. Tempest
currently has no sales, marketing or commercial product distribution capabilities. Tempest intends to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement
of its product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter its commercialization plans. If Tempest builds a commercial
infrastructure to support marketing in North America, such commercial infrastructure could be expected to include a targeted sales force supported by sales management, internal sales support, an internal marketing group and distribution support. To
develop the appropriate commercial infrastructure internally, Tempest would have to invest financial and management resources, some of which would have to be deployed prior to any confirmation that one of its product candidate will be approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest does not own or operate, and currently has no plans to establish, any manufacturing facilities. Tempest relies and expects to continue
to rely, on third parties for the manufacture of its product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of its product candidates obtain marketing approval. Tempest also relies, and expects to
continue to rely, on third parties to package, label, store and distribute its investigational product candidates, as well as for its commercial products if marketing approval is obtained. Tempest has internal personnel and utilizes consultants with
extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities. Tempest will continue to expand and strengthen its network of third-party providers but may also consider investing in
internal manufacturing capabilities in the future if there is a technical need, or a strategic or financial benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing is
subject to extensive regulations that impose procedural and documentation requirements. At a minimum these regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Tempest&#146;s
systems, procedures and contractors are required to be in compliance with these regulations and are assessed through regular monitoring and formal audits.&nbsp;&nbsp;&nbsp;&nbsp;<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and
immune-oncology industries are characterized by intense competition and rapid innovation. Any product candidates that Tempest successfully develops and commercializes will have to compete </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with existing and future new therapies. While Tempest believes that its technology, development experience and scientific knowledge provide it with competitive advantages, Tempest faces potential
competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions that conduct research, seek patent
protection, and establish collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tempest&#146;s
TPST-1495, TPST-1120, or its other product candidates are approved for the treatment of tumors, they may compete with other products used to treat such diseases. There are a variety of treatments used for cancerous tumors that include chemotherapy
drugs, small molecules, monoclonal antibodies, antibody-drug conjugates, bi-specific&nbsp;antibodies, cell therapies, oncolytic viruses and vaccines, as well as other approaches.&nbsp;In addition, there are several competitors in clinical
development for the treatment of HCC, RCC, cholangiocarcinoma, CRC and other indications that Tempest may be targeting with TPST-1495 and TPST-1120, including companies such as Agios, Ikena, Ono, Adlai Nortye, Merck, Roche, Exelixis, and
AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For TPST-1495, Tempest&#146;s small molecule designed to be a dual antagonist of the EP2 and EP4 receptor, Tempest is aware
of other clinical-stage EP-4-only antagonists being developed by Adlai Nortye, Ikena, and Ono. TPST-1120, Tempest&#146;s small molecule designed to be a selective antagonist of PPAR&#945;, is the first PPAR&#945; antagonist in the clinic. Tempest is
not aware of other companies developing such an antagonist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Tempest&#146;s competitors, either alone or with strategic partners,
have substantially greater financial, technical and human resources than Tempest does. Accordingly, Tempest&#146;s competitors may be more successful than it in research and development, manufacturing, preclinical testing, conducting clinical
trials, obtaining approval for treatments and achieving widespread market acceptance, rendering Tempest&#146;s treatments obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Merger and acquisition activity in the biotechnology and
biopharmaceutical industries may result in even more resources being concentrated among a smaller number of Tempest&#146;s competitors. These companies also compete with Tempest in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, Tempest&#146;s programs. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. Tempest&#146;s commercial opportunity could be substantially limited if Tempest&#146;s competitors develop and commercialize products that are more
effective, safer, less toxic, more convenient or less expensive than Tempest&#146;s comparable products. In geographies that are critical to Tempest&#146;s commercial success, competitors may also obtain regulatory approvals before it, resulting in
Tempest&#146;s competitors building a strong market position in advance of the entry of its products. The key competitive factors affecting the success of all of Tempest&#146;s programs are likely to be their efficacy, safety, convenience and
availability of reimbursement. In addition, Tempest&#146;s ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs.&nbsp;&nbsp;&nbsp;&nbsp;<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest strives to
protect and enhance the proprietary technology, inventions and improvements that are commercially important to its business, including obtaining, maintaining and defending its patent rights. Tempest&#146;s policy is to seek to protect its
proprietary position by, among other methods, filing patent applications and obtaining issued patents in the United States and in markets outside of the United States directed to its proprietary technology, inventions, improvements and product
candidates that are important to the development and implementation of its business. Tempest also relies on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to its proprietary technology and product candidates and
continuing innovation to develop, strengthen and maintain its proprietary position in the field of oncology. Tempest also plans to rely on data exclusivity, market exclusivity and patent term extensions when available. Tempest&#146;s commercial
success will depend in part on its ability to obtain and maintain patent and other proprietary protection for its technology, inventions, improvements, and product candidates; to preserve the confidentiality of its trade secrets; to defend and
enforce its proprietary rights, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including any patents that Tempest may own or license in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;28, 2021, Tempest&#146;s patent portfolio consisted of issued patents and pending patent applications that Tempest owns
related to TPST-1120, TPST-1495 and various other compounds and programs. In total, as of that date, Tempest owned two issued United States patents, six pending United States patent applications, 23 issued patents and 32 pending patent applications
in various markets outside of the United States, including Europe, China and Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to TPST-1120, Tempest owns issued and
pending patent applications in the United States, Europe, China, Japan and other markets outside of the United States. The issued United States patents covering TPST-1120 as composition of matter, pharmaceutical compositions, and related methods of
use are expected to expire in December 2033, absent any patent term extensions for regulatory delay. Any patents that may issue from its pending patent applications are expected to expire in December 2033, absent any patent term adjustments or
patent term extensions for regulatory delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to TPST-1495, Tempest owns pending patent applications in the United States,
Europe, China, Japan and other markets outside of the United States. Any patents that may issue from its pending patent applications are expected to expire between April 2038 and April 2039, absent any patent term adjustments or patent term
extensions for regulatory delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest also possesses substantial <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets
relating to the development and commercialization of its product candidates, including related manufacturing processes and technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to Tempest&#146;s product candidates and processes that Tempest intends to develop and commercialize in the normal course of
business, Tempest intends to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. Tempest may also pursue patent protection with respect to manufacturing and drug development processes and
technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent
application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for patent applications filed in the United States can provide exclusionary rights for 20 years from the
earliest effective filing date. The term of United States patents may be extended by delays encountered during prosecution that are caused by the USPTO, also known as patent term adjustment. In addition, in certain instances, the term of an issued
United States patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period
cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign
jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT>
basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country</FONT></FONT> and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions,
the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of
companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology has emerged in the United States. The relevant patent laws
and their interpretation outside of the United States are also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish Tempest&#146;s ability to protect its technology or product
candidates and could affect the value of such intellectual property. In particular, Tempest&#146;s ability to stop third parties from making, using, selling, offering to sell or importing products that infringe Tempest&#146;s intellectual property
will depend in part on Tempest&#146;s success in obtaining and enforcing patent claims that cover its technology, inventions and improvements. Tempest cannot </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guarantee that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications Tempest may file in the future, nor can Tempest be sure
that any patents that may be granted to Tempest in the future will be commercially useful in protecting its products, the methods of use or manufacture of those products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, even its issued patents may not guarantee Tempest the right to practice its technology in relation to the commercialization of its
products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent Tempest
from commercializing its product candidates and practicing its proprietary technology, and its issued patents may be challenged, invalidated or circumvented, which could limit Tempest&#146;s ability to stop competitors from marketing related
products or could limit the term of patent protection that otherwise may exist for its product candidates. In addition, the scope of the rights granted under any issued patents may not provide Tempest with protection or competitive advantages
against competitors with similar technology. Furthermore, Tempest&#146;s competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, Tempest may face
competition with respect to its product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be
commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government regulation&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and
export and import of pharmaceutical products, such as Tempest&#146;s investigational medicines and any future investigational medicines. Generally, before a new pharmaceutical product can be marketed, considerable data demonstrating its quality,
safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Approval Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, pharmaceutical products are subject to extensive regulation by the Food and Drug Administration, or FDA, the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and other federal and state statutes and regulations govern, among
other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products.
Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending New Drug Applications, or NDAs, warning or untitled letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a NDA before they
may be legally marketed in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations,
including studies conducted in accordance with Good Laboratory Practice, or GLP, requirements </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an Investigational New Drug application, or IND, which must become effective before
human clinical trials may begin; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by an Institutional Review Board (IRB) or independent ethics committee at each clinical trial site
before each clinical trial may be commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
Good Clinical Practice (GCP) requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Payment of any user fees for FDA review of the NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A determination by the FDA within 60 days of its receipt of a NDA to accept the filing for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of
the manufacturing facility or facilities where the drug, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in
support of the NDA to assure compliance with GCPs and integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with any post-approval requirements, including REMS, where applicable, and post- approval studies
required by the FDA as a condition of approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical and clinical testing and approval process requires
substantial time, effort and financial resources, and Tempest cannot be certain that any approvals for its product candidates will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before
testing any drug product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as in vitro and animal studies to
assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. An IND sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a
request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND
automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials
involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator, generally a physician not employed by or under the trial sponsor&#146;s control. Clinical trials must be
conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and
monitors; as well as (iii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing
on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, each clinical trial must be reviewed and approved by an IRB for each
institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent
form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.
Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of
investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two
years after the date of completion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but
need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will accept a
well- designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who
are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the
product candidate, and, if possible, early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept
and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary
evaluation of efficacy is conducted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most
cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose expansion
stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in
selected subpopulation(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are
disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for <FONT STYLE="white-space:nowrap">non-oncology</FONT> therapies. A single Phase
3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies). The manufacturer of an
investigational drug in a phase 2 or 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The
FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on various grounds, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to
patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a
trial may move forward at designated checkpoints based on access to certain data from the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials,
companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and
purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Review Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical and
other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture and controls. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and
efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a NDA must be obtained before a drug may be marketed in the United States. The cost of preparing and submitting an NDA is substantial. Under the PDUFA, each NDA
must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a
small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The applicant under an approved NDA is also
subject to an annual program fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews each submitted NDA before it determines whether to file it and may request additional
information. The FDA must make a decision on whether to file an NDA within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is filed, the FDA begins an
<FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. The FDA has agreed to certain performance goals in the review of NDAs. Most applications for standard review drug products are reviewed within ten to twelve months; most
applications for priority review drugs are reviewed in six to eight months. Priority review can be applied to drugs that the FDA determines may offer significant improvement in safety or effectiveness compared to marketed products or where no
adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided
in the submission. The FDA does not always meet its goal dates for standard and priority NDAs, and the review process can be extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an
outside advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by
the recommendation of an advisory committee, but it generally follows such recommendations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will conduct
a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. The FDA also typically inspects clinical trial sites to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A
complete response letter, or CRL, generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application, such as additional clinical data, additional
pivotal clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may resubmit the NDA addressing all of the deficiencies
identified in the letter, withdraw the application, engage in formal dispute resolution or request an opportunity for a hearing. The FDA has committed to reviewing resubmissions in two or six months depending on the type of information included.
Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
potential condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks to patients. A REMS can include medication guides, communication
plans for healthcare professionals and elements to assure a product&#146;s safe use (ETASU). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under
certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval
testing and surveillance to monitor the product&#146;s safety or efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to some of the conditions established in an approved
application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of an NDA supplement or, in some case, a new NDA, before the change can be implemented. An NDA supplement for a
new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000
individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the drug and
its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for
the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in
instances of drug supply issues. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Other benefits of orphan drug designation
include tax credits for certain research and an exemption from the NDA user fee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fast Track Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which
there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being
studied. The sponsor of an investigational drug product may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the submission of the IND for the drug candidate. The FDA must
determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of
a fast track product&#146;s NDA before the application is complete. This rolling review is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The
sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. At the time of NDA filing, the FDA will determine whether to grant priority review
designation. Additionally, fast track designation may be withdrawn if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Breakthrough Therapy Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to
treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the
breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the drug candidate. The
FDA must determine if the drug product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with
the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and
taking other steps to design the clinical studies in an efficient manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Priority Review </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide
a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accelerated
approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval
may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a
measurement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used
in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus,
accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical
disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct additional post-approval confirmatory studies to
verify and describe the product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to
conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved
under accelerated regulations are subject to prior review by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the
FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and
accelerated approval do not change the standards for approval, but may expedite the development or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric Information
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial
waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted, with certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of any
exclusivity&#151;patent or nonpatent&#151;for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#146;s determination that information relating to the use of a new drug in the pediatric population may produce health
benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority
applications, with all of the benefits that designation confers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the
post-approval marketing and promotion of drugs, including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT>
promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in a manner consistent with the approved labeling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. The FDA also may require
post-marketing testing, known as phase 4 testing, risk evaluation and mitigation strategies, or REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution
or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their
establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the Agency inspects manufacturing facilities to assess compliance with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may
withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of
the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fines, warning or other enforcement-related letters or holds on post-approval clinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Hatch-Waxman Act </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orange Book Listing
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments, NDA
applicants are required to identify to the FDA each patent whose claims cover the applicant&#146;s drug or approved method of using the drug. Upon approval of a drug, the applicant must update its listing of patents to the NDA in timely fashion and
each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug
application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient(s), strength, route of administration, and dosage form as the listed drug and has been shown through bioequivalence testing to be
therapeutically equivalent to the listed drug. An approved ANDA product is considered to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit
results of, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved under the ANDA pathway are commonly referred to as &#147;generic equivalents&#148; to the
listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug pursuant to each state&#146;s laws on drug substitution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ANDA applicant is required to certify to the FDA concerning any patents identified for the reference listed drug in the Orange Book.
Specifically, the applicant must certify to each patent in one of the following ways: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired but will expire
on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s
listed patents, or that such patents are invalid, is called a Paragraph IV certification. For patents listed that claim an approved method of use, under certain circumstances the ANDA applicant may also elect to submit a section viii statement
certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than certify to a listed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. If the applicant does not challenge the listed patents through a Paragraph IV certification,
the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV
certification to the <FONT STYLE="white-space:nowrap">NDA-holder</FONT> and patentee(s) once the ANDA has been accepted for filing by the FDA (referred to as the &#147;notice letter&#148;). The NDA and patent holders may then initiate a patent
infringement lawsuit in response to the notice letter. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months
from the date the notice letter is received, expiration of the patent, the date of a settlement order or consent decree signed and entered by the court stating that the patent that is the subject of the certification is invalid or not infringed, or
a decision in the patent case that is favorable to the ANDA applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ANDA application also will not be approved until any
applicable <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity listed in the Orange Book for the referenced product has expired. In some instances, an ANDA applicant may receive approval prior to expiration of certain <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity if the applicant seeks, and the FDA permits, the omission of such exclusivity-protected information from the ANDA prescribing information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon NDA approval of
a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot receive any ANDA seeking approval of
a generic version of that drug unless the application contains a Paragraph IV certification, in which case the application may be submitted one year prior to expiration of the NCE exclusivity. If there is no listed patent in the Orange Book, there
may not be a Paragraph IV certification, and, thus, no ANDA for a generic version of the drug may be filed before the expiration of the exclusivity period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain changes to an approved drug, such as the approval of a new indication, the approval of a new strength, and the approval of a new
condition of use, are associated with a three-year period of exclusivity from the date of approval during which the FDA cannot approve an ANDA for a generic drug that includes the change. In some instances, an ANDA applicant may receive approval
prior to expiration of the three-year exclusivity if the applicant seeks, and the FDA permits, the omission of such exclusivity-protected information from the ANDA package insert. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Extension </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hatch
Waxman Amendments permit a patent term extension as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the
product&#146;s approval date. After NDA approval, owners of relevant drug patents may apply for the extension. The allowable patent term extension is calculated as half of the drug&#146;s testing phase (the time between IND application and NDA
submission) and all of the review phase (the time between NDA submission and approval) up to a maximum of five years. The time can be reduced for any time the FDA determines that the applicant did not pursue approval with due diligence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent
term extension or restoration. However, the USPTO may not grant an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to
apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total patent term after the extension may not exceed 14 years, and only one patent can be extended. The application for the extension must
be submitted prior to the expiration of the patent, and for patents that might </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four
times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is
likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to
restrict certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes and other healthcare laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This
statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and
regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or
recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly
presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government
reimburses, such as Medicare and Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have been
prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with
the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, may also violate false claims laws. Additionally, the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Most states also have statutes
or regulations similar to the federal Anti-Kickback Statute and civil False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other
things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offerer or payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier,
and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud
any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for
healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to commit a violation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, pursuant to the ACA, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
has issued a final rule that requires manufacturers of prescription drugs to collect and report information on certain payments or transfers of value to physicians and teaching hospitals, as well as investment interests held by physicians (defined
to include doctors, dentists, optometrists, podiatrists and chiropractors) and their immediate family members. The first reports were due in 2014 and must be submitted on an annual basis. The reported data is made available in searchable form on a
public website on an annual basis. Failure to submit required information may result in civil monetary penalties. Effective January&nbsp;1, 2022, reporting on transfers of value to physician assistants, nurse practitioners or clinical nurse
specialists, certified registered nurse anesthetists, and certified nurse-midwives will also be required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, several states now
require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various
marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain drug pricing
information, including information pertaining to and justifying price increases. In addition, states such as California, Connecticut, Nevada and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes.
Several additional states are considering similar proposals. Certain states and local jurisdictions also require the registration of pharmaceutical sales and medical representatives. Compliance with these laws is difficult and time consuming, and
companies that do not comply with these state laws face civil penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that business arrangements with third parties
comply with applicable healthcare laws and regulations involve substantial costs. If a drug company&#146;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare
reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk
of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#146;s
attention from the operation of the business, even if such action is successfully defended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party
payors to control or manage the increased costs of health care and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major
legislative initiatives. For example, in March 2010, the ACA was enacted, which intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency
requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, substantially changed the way healthcare is financed by both governmental and private
insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (i)&nbsp;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for <FONT
STYLE="white-space:nowrap">follow-on</FONT> biologic products, (ii)&nbsp;proscribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled,
infused, instilled, implanted or injected, (iii)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations,
(iv)&nbsp;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, apportioned among these entities according to their market share in certain government healthcare programs,
(v)&nbsp;established a new Medicare Part D coverage gap discount program, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in which manufacturers must agree to offer 50% (now 70%) point <FONT STYLE="white-space:nowrap">of-sale</FONT> discounts off negotiated prices of applicable brand drugs and therapeutic biologics
to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs and therapeutic biologics to be covered under Medicare Part D, (vi)&nbsp;expanded eligibility criteria for Medicaid programs by,
among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing
manufacturers&#146; Medicaid rebate liability, (vii)&nbsp;expanded the entities eligible for discounts under the Public Health program, (viii)&nbsp;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and
conduct comparative clinical effectiveness research, along with funding for such research, and (ix)&nbsp;established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid
spending, potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current U.S. presidential administration and Congress have, and Tempest
expects they will continue to, seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. By way of example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, was enacted and included, among other things, a provision
that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year
that is commonly referred to as the &#147;individual mandate&#148;. There have been subsequent challenges to the constitutionality of the ACA following the repeal of the individual mandate. The case is currently pending before the U.S. Supreme
Court, although it is unclear when a decision will be made or how the Supreme Court will rule. It is also unclear how other efforts to repeal, replace or challenge the ACA will impact the ACA. Tempest cannot predict the ultimate content, timing or
effect of any healthcare reform legislation or the impact of potential legislation on its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. United States federal government agencies also currently face potentially significant spending reductions, which may further
impact healthcare expenditures. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&nbsp;1,
2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020, unless additional Congressional action is taken.
Moreover, on January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of
relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay Tempest&#146;s ability to develop, market and sell any products Tempest may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. While the MMA only applies to
drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a
similar reduction in payments from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drug products. At the federal level, the current U.S. presidential administration&#146;s budget proposal for fiscal year 2021 includes a $135&nbsp;billion allowance to support legislative
proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic and
biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place
limits on pharmaceutical price increases. In addition, the Trump administration previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition,
increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS, has solicited feedback on some of
these measures and has implemented others under existing authority. Although a number of these, and other potential, proposals will require additional authorization to become effective, Congress and the current U.S. presidential administration have
each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and
Matthew Bellina Right to Try Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a phase 1 clinical trial and that
are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program; however,
manufacturers are not obligated to provide investigational new drug products under the current federal right to try law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s corporate headquarters are located at 7000 Shoreline Court, Suite 275, South San Francisco, California 94080 where it occupies
approximately 9,780 square feet of research and development laboratory and related office space under a lease that ends in February 2024 . Tempest believes that its existing facilities meet its current needs. Tempest may need additional office space
in the future as it continues to build its development, commercial and support teams. Tempest believes that it can find suitable additional space in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021,
Tempest had 14 employees, including eight holding Ph.D., M.D., JD, and/or LL.M. degrees, Tempest&#146;s employees have established internal expertise in chemistry, biochemistry, molecular biology, immunology, pharmacology, toxicology, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development, regulatory and quality, translational medicine, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-late-stage</FONT></FONT> clinical development, as well as
finance, business development and strategic transactions. None of Tempest&#146;s employees are represented by a labor union or covered by collective bargaining agreements. Tempest will continue to add experienced and talented scientists in areas,
such as medicinal chemistry, that Tempest believes are critical for the discovery of highly differentiated small-molecule compounds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest may from time to time be involved in various legal proceedings and other matters arising in the normal course of business. In the future
Tempest may also institute additional legal proceedings to enforce its rights and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seek remedies, such as monetary damages, injunctive relief and declaratory relief. Tempest cannot predict the results of any such disputes, and despite the potential outcomes, the existence
thereof may have an adverse material impact on Tempest because of diversion of management time and attention as well as the financial costs related to resolving such disputes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_91"></A>MILLENDO MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of Millendo&#146;s financial condition
and results of operations in conjunction with the financial statements and the related notes, each included elsewhere in this proxy statement/prospectus. In addition to historical financial information, the following discussion contains
forward-looking statements that reflect Millendo&#146;s plans, estimates, beliefs and expectations that involve risks and uncertainties. Millendo&#146;s actual results and the timing of events could differ materially from those discussed in these
forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in &#147;Risk Factors&#148; and &#147;Cautionary Statement
Concerning Forward-Looking Statement.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is a biopharmaceutical company that was previously primarily focused on developing novel treatments for endocrine diseases where
current therapies do not exist or are insufficient. The endocrine system is a collection of glands that secrete hormones into the blood stream to regulate a number of functions, including appetite, metabolism, growth, development and reproduction.
Diseases of the endocrine system can cause multiple and varied symptoms, including appetite dysregulation, metabolic dysfunction, obesity, cardiovascular disease, menstrual irregularity, hirsutism, and infertility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo had been developing livoletide <FONT STYLE="white-space:nowrap">(AZP-531)</FONT> as a potential treatment for Prader-Willi syndrome,
or PWS, a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. As previously announced, Millendo discontinued the development of livoletide as a potential treatment for PWS in April 2020, including the <FONT
STYLE="white-space:nowrap">9-month</FONT> extension study and the initiation of the Phase 3 ZEPHYR trial. The decision to discontinue the PWS program was based on results from the Phase 2b ZEPHYR study, which showed that treatment with livoletide
did not result in a statistically significant improvement in hyperphagia and food-related behaviors as measured by the Hyperphagia Questionnaire for Clinical Trials <FONT STYLE="white-space:nowrap">(HQ-CT)</FONT> compared to placebo. Millendo does
not expect to incur future material expenses related to its livoletide program for the treatment of PWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to streamline costs
after discontinuing its PWS program, Millendo eliminated employee positions representing approximately 30% of its prior headcount, which were completed in the second quarter of 2020. Millendo also began evaluating corporate strategic plans to
prioritize and allocate resources to its remaining product candidates at the time and any future pipeline assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo had also been
developing nevanimibe <FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment for patients with classic congenital adrenal hyperplasia, or CAH, a rare, monogenic adrenal disease that requires lifelong treatment with exogenous
cortisol, often at high doses. As Millendo previously announced, it elected to cease investing in the development of nevanimibe as a potential treatment for CAH in June 2020. The decision to cease investment in the CAH program was based on the
interim review of results from the Phase 2b clinical study and the changing competitive environment. Results from 10 subjects, nine from cohort 1 and one from cohort 2, with at least 12 weeks of treatment with nevanimibe in this open-label,
continuous dose escalation study showed that one patient (10%) met the primary endpoint of achieving <FONT STYLE="white-space:nowrap">17-hydroxyprogesterone</FONT> <FONT STYLE="white-space:nowrap">(17-OHP)</FONT> levels less than or equal to <FONT
STYLE="white-space:nowrap">2-times</FONT> the upper limit of normal. Treatment under the amended protocol with dose titration starting at 500 mg BID improved tolerability of nevanimibe. Millendo does not expect to incur future material expenses
related to its nevanimibe program for the treatment of CAH as it is no longer developing this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo had also been developing
a selective neurokinin <FONT STYLE="white-space:nowrap">3-receptor</FONT> (NK3R) antagonist <FONT STYLE="white-space:nowrap">(MLE-301)</FONT> as a potential treatment of vasomotor symptoms, or VMS, commonly known as hot flashes and night sweats, in
menopausal women. As previously announced, in January 2021, Millendo discontinued further investment in <FONT STYLE="white-space:nowrap">MLE-301</FONT> for the treatment of VMS based on an analysis of the pharmacokinetic and pharmacodynamic data
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from the single ascending dose portion of the Phase 1 study. Given Millendo&#146;s limited expected financing options, it began exploring an expanded range of strategic alternatives that
included, but was not limited to, the potential sale or merger of Millendo or its assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2021, as a result of its decision to
discontinue Millendo&#146;s investment in <FONT STYLE="white-space:nowrap">MLE-301,</FONT> Millendo&#146;s board of directors also approved a corporate restructuring plan, or the Plan, furthering Millendo&#146;s ongoing efforts to align its
resources with its current strategy and operations. In connection with the Plan, Millendo plans to reduce its workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April&nbsp;15, 2021. Millendo initiated
this reduction in force in January 2021 and expects to provide severance payments and continuation of group health insurance coverage for a specified period to the affected employees. Millendo has also entered into retention arrangements with
employees who are expected to remain with Millendo. Millendo estimates that it will incur costs of approximately $5.5&nbsp;million for termination benefits and retention arrangements related to the Plan, substantially all of which will be cash
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo had also been investigating nevanimibe <FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment
for patients with endogenous Cushing&#146;s syndrome, or CS, a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. As a result of slower than anticipated enrollment in its CS Phase 2 clinical trial,
Millendo elected to discontinue the trial in August 2019 and is no longer developing nevanimibe for the treatment of CS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020,
Millendo undertook a strategic review process, which was intended to result in an actionable plan that leverages its assets, capital and capabilities to maximize stockholder value. Following an extensive process of evaluating strategic alternatives,
including identifying and reviewing potential candidates for a strategic acquisition or other transaction, on March&nbsp;29, 2021, Millendo entered into the Merger Agreement with Tempest under which the privately held Tempest will merge with a
wholly owned subsidiary of Millendo. If the merger with Tempest is completed, the business of Tempest will continue as the business of the combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects to devote significant time and resources to the completion of the merger. However, there can be no assurances that such
activities will result in the completion of the merger. Further, the completion of the merger may ultimately not deliver the anticipated benefits or enhance shareholder value. If the merger is not completed, Millendo will reconsider its strategic
alternatives. Millendo considers one of the following courses of action to be the most likely alternatives if the merger is not completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dissolve and liquidate its assets</I>. If, for any reason, the merger does not close, Millendo&#146;s board of
directors may conclude that it is in the best interest of stockholders to dissolve Millendo and liquidate its assets. In that event, Millendo would be required to pay all of its debts and contractual obligations, and to set aside certain reserves
for potential future claims. There would be no assurances as to the amount or timing of available cash remaining to distribute to stockholders after paying its obligations and setting aside funds for reserves. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue another strategic transaction</I>. Millendo may resume the process of evaluating a potential strategic
transaction in order to attempt another strategic transaction like the merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Operate its business. </I>Although less likely than the alternatives above, Millendo&#146;s board of directors
may elect to seek new product candidates for development. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Historical Business and Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since Millendo&#146;s inception in January 2012, its operations have focused on conducting preclinical studies and clinical trials, acquiring
technology and assets, organization and staffing, business planning, and raising capital. Millendo has devoted substantial effort and resources to acquiring its previous four product candidates, livoletide, nevanimibe, and <FONT
STYLE="white-space:nowrap">MLE-301,</FONT> as well as MLE4901, which Millendo ceased developing in 2017. Millendo acquired livoletide in connection with its acquisition of Aliz&eacute; Pharma SAS, or Aliz&eacute;, in December
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2017. Millendo <FONT STYLE="white-space:nowrap">in-licensed</FONT> nevanimibe from the Regents of the University of Michigan, or the University of Michigan, in June 2013. Millendo licensed <FONT
STYLE="white-space:nowrap">MLE-301</FONT> from F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Inc. (collectively, &#147;Roche&#148;), in October 2018. Millendo does not
have any product candidates approved for sale and has not generated any revenue from product sales. Millendo has funded its operations primarily through the sale and issuance of common stock, preferred stock and convertible promissory notes,
proceeds received from the OvaScience Merger as well as borrowings under term loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, Millendo has incurred significant
operating losses and negative operating cash flows and there is no assurance that it will ever achieve or sustain profitability. Millendo&#146;s net losses were $36.4&nbsp;million and $44.6&nbsp;million for the years ended December&nbsp;31, 2020 and
2019, respectively. As of December&nbsp;31, 2020, it had an accumulated deficit of $245.1&nbsp;million. Millendo expects to continue to incur significant expenses and operating losses for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After conducting a
diligent and extensive process of evaluating strategic alternatives for Millendo and identifying and reviewing potential candidates for a strategic acquisition or other transaction, which included the careful evaluation and consideration of
proposals from interested parties, and following extensive negotiation with Tempest, on March&nbsp;29, 2021, Millendo, Merger Sub, a wholly owned subsidiary of Millendo, and Tempest entered into the Merger Agreement. More information regarding the
merger and the terms of the Merger Agreement are discussed throughout this proxy statement/prospectus, particularly in &#147;<I>The Merger</I>&#148; and &#147;<I>The Merger Agreement</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019,
Millendo sold 4,791,667 shares of common stock pursuant to an underwriting agreement, or the Underwriting Agreement, with Citigroup Global Markets Inc. and SVB Leerink LLC, as representatives of the several underwriters named therein, or the
Underwriters, for net proceeds to Millendo of approximately $26.5&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses payable by Millendo. The price to the public in this offering was $6.00 per share and
resulted in the sale of 4,166,667 shares of Millendo&#146;s common stock for net proceeds to Millendo of approximately $23.0&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses. In addition, the
Underwriters purchased an additional 625,000 shares of Millendo&#146;s common stock at the public offering price of $6.00 per share pursuant to a purchase option granted to them under the Underwriting Agreement, resulting in net proceeds to Millendo
of approximately $3.5&nbsp;million, after deducting underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering was made pursuant to
Millendo&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-230749),</FONT> which was declared effective by the Securities and Exchange Commission
on April&nbsp;18, 2019, and a prospectus supplement thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Equity Distribution Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, Millendo entered into an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;,</FONT></FONT> or ATM, equity distribution agreement with Citigroup Global Markets Inc., acting as sole agent with an aggregate offering value of up to
$50.0&nbsp;million. Subject to the terms of the ATM equity distribution agreement, Millendo is able to determine, at its sole discretion, the timing and number of shares to be sold under this ATM facility. In March 2020, Millendo amended and
restated the equity distribution agreement to include SVB Leerink LLC as an additional sales agent for the ATM. In March 2020, Millendo sold 719,400 shares of its common stock under its ATM equity distribution agreement for net proceeds of
approximately $5.5&nbsp;million. Millendo does not expect to sell additional shares under this ATM facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of Millendo&#146;s
common stock pursuant to the ATM equity distribution agreement have been made pursuant to its registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration Statement
<FONT STYLE="white-space:nowrap">No.&nbsp;333-230749),</FONT> which was declared effective by the Securities and Exchange Commission on April&nbsp;18, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> Business Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the global impacts of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continuing in the fourth quarter of 2020,
Millendo is maintaining the business continuity plans it established and implemented in the first quarter of 2020, which are designed to address and mitigate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on it
employees, operations and business. While Millendo is experiencing limited financial impacts from the pandemic at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and
uncertainties associated with the pandemic, its business, financial condition, and results of operations, could be materially adversely affected. Millendo continues to closely monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation as
it evolves its business continuity plans and response strategy. In March 2020, Millendo&#146;s global workforce transitioned to working remotely. Throughout the fourth quarter of 2020, Millendo continued its plan to allow some employees to return to
the office voluntarily, which was based on a phased approach that is principles-based, flexible and local in design, with a focus on employee safety and optimal work environment. Millendo&#146;s current plans remain fluid as federal, state and local
guidelines, rules and regulations continue to evolve. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OvaScience Merger </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2018, OvaScience, Inc., or OvaScience, now known as Millendo Therapeutics, Inc. completed its reverse merger (the
&#147;OvaScience Merger&#148;), with what was then known as &#147;Millendo Therapeutics, Inc.,&#148; or Private Millendo, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of August&nbsp;8, 2018, as amended
on September&nbsp;25, 2018 and November&nbsp;1, 2018 (the &#147;OvaScience Merger Agreement&#148;).&nbsp;OvaScience&#146;s shares of common stock listed on The Nasdaq Capital Market, previously trading through the close of business on Friday,
December&nbsp;7, 2018 under the ticker symbol &#147;OVAS,&#148; commenced trading on The Nasdaq Capital Market, under the ticker symbol &#147;MLND,&#148; on Monday, December&nbsp;10, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, Private Millendo issued convertible promissory notes (the &#147;Notes&#148;), to several of its existing investors and
received cash proceeds of $8.0&nbsp;million. The Notes accrued simple interest of 6.0% per annum.&nbsp;Additionally, immediately prior to the OvaScience Merger, Private Millendo issued and sold an aggregate of 1,320,129 shares of Private Millendo
common stock for total net proceeds of approximately $20.1&nbsp;million, or the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing, to certain existing stockholders of Private Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the OvaScience Merger, each outstanding share of Private Millendo capital stock converted into shares of OvaScience&#146;s
common stock, and each outstanding option or warrant to purchase Private Millendo capital stock converted into the right to receive shares of OvaScience&#146;s common stock.&nbsp;At the Closing of the OvaScience Merger, Private Millendo stockholders
received an aggregate of 8,789,628 shares of OvaScience common stock, which includes 1,320,129 shares of common stock issued to the investors in the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing, Private Millendo option holders
received options to purchase 1,874,158 shares of OvaScience common stock and Private Millendo warrant holders received warrants to purchase 17,125 shares of OvaScience common stock.&nbsp;In addition, upon the Closing of the OvaScience Merger, all
principal and interest underlying the Notes converted into 499,504 shares of OvaScience common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the
OvaScience Merger, Private Millendo became a wholly-owned subsidiary of OvaScience.&nbsp;Upon consummation of the OvaScience Merger, or the Closing, OvaScience adopted the business plan of Private Millendo and discontinued the pursuit of
OvaScience&#146;s business plan <FONT STYLE="white-space:nowrap">pre-Closing.&nbsp;The</FONT> OvaScience Merger was accounted for as a reverse recapitalization with Private Millendo as the accounting acquirer. On the OvaScience Merger date, the
primary <FONT STYLE="white-space:nowrap">pre-combination</FONT> assets of OvaScience was cash, cash equivalents and marketable securities.&nbsp;At the time of the OvaScience Merger, OvaScience had net assets of $38.0&nbsp;million, which was
comprised primarily of cash, cash equivalents and marketable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the OvaScience Merger, on
December&nbsp;7, 2018, Millendo issued and sold an aggregate of 1,230,158 shares of common stock to an institutional investor for $16.258065 per share, for total net proceeds of approximately&nbsp;$18.7&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Integration of OvaScience </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leading up to the closing date of the OvaScience Merger, OvaScience had agreed to terminate, assign or otherwise fully discharge substantially
all obligations under all contracts to which OvaScience or its subsidiaries were a party, wind-down the operations, and dissolve certain subsidiaries. OvaScience has closed their offices and all employees were terminated or resigned prior to or at
the closing. All operations are drawing to a close that were not already wound down prior to closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Aliz&eacute; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, Private Millendo entered into agreements to acquire 100% of the outstanding ownership interests of Aliz&eacute;, a privately
held biotechnology company based in Lyon, France focused on the development of a treatment for patients with PWS, through its lead product candidate, livoletide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, Millendo acquired 83.6% of the issued and outstanding share capital of Aliz&eacute; pursuant to a Share Sale and
Contribution Agreement. The consideration included an upfront payment of $1.0&nbsp;million, and the issuance of Private Millendo&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock, and <FONT STYLE="white-space:nowrap">common-1</FONT> stock, which upon consummation of the OvaScience Merger were converted to shares of Milledno common stock. In December 2018, Millendo
acquired the remaining 16.4% of Aliz&eacute;&#146;s issued and outstanding share capital from Otonnale SAS, or Otonnale. The consideration included a cash payment of $0.8&nbsp;million and the issuance of the 442,470 shares of Millendo common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Share and Contribution Agreement with Aliz&eacute; was accounted for as an asset acquisition as substantially all of the fair value
of the gross assets acquired was concentrated in the livoletide development program. The $63.8&nbsp;million in estimated fair value allocated to livoletide was expensed, as Millendo determined the asset has no alternative future use. The total
consideration given, net of cash acquired was $63.1&nbsp;million. The assets acquired and liabilities assumed as of the acquisition date were $65.3&nbsp;million and $2.2&nbsp;million, respectively, for net assets acquired of $63.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
development expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consist primarily of costs incurred in connection with the development of
Millendo&#146;s product candidates. Millendo expenses research and development costs as incurred. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits and stock-based compensation expense; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of funding research performed by third-parties, including pursuant to agreements with contract research
organizations, or CROs, as well as investigative sites and consultants that conduct Millendo&#146;s preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing <FONT
STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made under Millendo&#146;s third-party licensing agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consultant fees and expenses associated with outsourced professional scientific development services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses for regulatory activities, including filing fees paid to regulatory agencies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone payment obligations incurred prior to regulatory approval of a product candidate, which are accrued when the
event requiring payment of the milestone occurs are included in research and development expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo typically uses its employee, consultant and infrastructure resources across its
development programs. Millendo tracks certain outsourced development costs by product candidate, but does not allocate all personnel costs or other internal costs to specific product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Millendo&#146;s research and development expenses by product candidate, personnel expense and other expenses
for the years ended December&nbsp;31, 2020 and 2019, respectively: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Livoletide expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,086</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,702</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nevanimibe expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">965</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,899</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MLE-301</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,211</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,723</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,559</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,843</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s research and development costs related to livoletide and nevanimibe have decreased
significantly due to its decision to discontinue the livoletide and nevanimibe programs based on results from the Phase 2b ZEPHYR study in PWS and the Phase 2b clinical study in CAH, respectively. All costs, including estimated program closeout
costs associated with these programs, were primarily recognized during the second quarter of 2020. Any revisions to estimated program closeout costs have been recognized as of December&nbsp;31, 2020. Future expenses may be recorded as a result of
changes to these estimated costs as closeout activities continue. Millendo&#146;s research and development costs related to <FONT STYLE="white-space:nowrap">MLE-301</FONT> increased significantly due to preclinical studies and clinical trials during
2020, however, Millendo expects future costs to decrease significantly due to its decision in January 2021 to discontinue the <FONT STYLE="white-space:nowrap">MLE-301</FONT> program based on the data from the single ascending dose portion of the
Phase 1 study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo decides to resume product candidate development, the successful development of any future product candidates
would be highly uncertain. Millendo is also unable to predict when, if ever, material net cash inflows would commence from sales of any future product candidates that it may develop due to the numerous risks and uncertainties associated with
clinical development, including risks and uncertainties related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including the potential impact on various
aspects and stages of the clinical development process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll suitable patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that ultimately participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient <FONT STYLE="white-space:nowrap">follow-up</FONT> and number of patient visits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of Millendo&#146;s clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of commercial manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt of marketing approvals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo may never succeed in obtaining regulatory approval for any future product candidates it may develop. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense consists primarily of personnel expenses, including salaries, benefits and stock-based compensation expense,
for employees in executive, finance, accounting, business development, legal and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, not
otherwise included in research and development expense, as well as legal fees related to intellectual property and corporate matters and fees for accounting, recruiting and consulting services. Millendo expects its general and administrative
expenses to increase during the first half of 2021 due to its corporate restructuring plan and the proposed merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest income, net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income represents amounts earned on Millendo&#146;s cash, cash equivalents and restricted cash balances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the
years ended December&nbsp;31, 2020 and 2019 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,843</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,598</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,556</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,972</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,399</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,406</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,568</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense decreased by $7.5&nbsp;million to $20.4&nbsp;million for the year ended December&nbsp;31, 2020 from
$27.8&nbsp;million for the year ended December&nbsp;31, 2019. The following table summarizes Millendo&#146;s research and development expenses for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and clinical development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,262</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,324</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense, other than stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,524</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,299</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,843</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in total research and development expense is attributable to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $6.1&nbsp;million decrease in preclinical and clinical development expense primarily related to decrease spend
due to discontinuing the development of the livoletide and nevanimibe programs offset by increased spend on <FONT STYLE="white-space:nowrap">MLE-301;</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.1&nbsp;million decrease in compensation and stock-based compensation expenses primarily due to the reduction
in force completed in the second quarter of 2020, as a result of the discontinuance of the livoletide program; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million decrease in other expenses mainly related to a reduction in travel in connection with the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and allocated overhead due to fewer research and development personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense decreased by $2.0&nbsp;million to $15.6&nbsp;million for the year ended December&nbsp;31, 2020 from
$17.6&nbsp;million for the year ended December&nbsp;31, 2019. The decrease was primarily due to lower professional fees and travel costs. Professional fees decreased $2.9&nbsp;million mainly as a result of lower legal, accounting and consulting fees
incurred as compared to the prior period. The decrease in these fees was due to lower expenditures on preparations for certain public reporting requirements in 2020 as compared to 2019, as well as lower consulting fees incurred related to assessing
market opportunities for previous product candidates. Travel costs decreased $0.3&nbsp;million as a result of a reduction in business travel in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. These decreases were
partially offset by increases in compensation expenses, including stock-based compensation, as well as increases in insurance, rent and facility related expenses. Compensation and stock-based compensation increased by $0.8&nbsp;million as a result
of termination benefits paid in connection with Millendo&#146;s reduction in force in the second quarter of 2020 and additional options granted in 2020. Insurance, rent and facility related expenses increased $0.4&nbsp;million. These increases were
due to higher insurance premiums and costs for additional leased office space compared to the prior period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest income, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income, net decreased by $0.9&nbsp;million to $0.2&nbsp;million net interest income for the year ended December&nbsp;31, 2020 from
$1.0&nbsp;million net interest income for the year ended December&nbsp;31, 2019. The change was primarily due to lower interest income received as a result of lower cash, cash equivalent and restricted cash balances and lower interest rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other loss increased
by $0.4&nbsp;million to $0.6&nbsp;million for the year ended December&nbsp;31, 2020 from $0.2&nbsp;million for the year ended December&nbsp;31, 2019. The increase was due to higher foreign currency losses as a result of exchange rate fluctuations on
transactions denominated in a currency other than Millendo&#146;s functional currency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the primary uses of cash and cash equivalents for each year set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,988</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,386</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,943</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign currency exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$(24,854)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$(10,258)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uses of funds </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year
ended December&nbsp;31, 2020, Millendo used $30.4&nbsp;million of cash to fund operating activities. During the year ended December&nbsp;31, 2020, cash used in operating activities reflected Millendo&#146;s net loss of $36.4&nbsp;million offset by <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $5.7&nbsp;million, principally related to stock-based compensation, amortization of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and the
foreign currency remeasurement loss and a net change in operating assets and liabilities of $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2019, Millendo used $41.2&nbsp;million of cash to fund operating activities. During the year ended December&nbsp;31, 2019, cash used in operating activities reflected its net loss of $44.6&nbsp;million and a net change in operating
assets and liabilities of $2.0&nbsp;million, offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $5.4&nbsp;million, principally related to stock-based compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year
ended December&nbsp;31, 2020, Millendo paid $26,000 in purchases of property and equipment. During the year ended December&nbsp;31, 2019, Millendo received $4.4&nbsp;million in net proceeds from the sale of marketable securities offset by
$0.4&nbsp;million in purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2020, Millendo received proceeds of $5.5&nbsp;million received from the issuance of common stock, net
of issuance costs paid. See Note 1 of Millendo&#146;s Consolidated Financial Statements in this proxy statement/prospectus for additional information related to the issuance of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, Millendo received proceeds of $0.5&nbsp;million from the exercise of options and warrants, and
$26.7&nbsp;million in proceeds received from the issuance of common stock, net of issuance costs paid. See Note 1 of Millendo&#146;s Consolidated Financial Statements in this proxy statement/prospectus for additional information related to the
issuance of common stock. These proceeds were offset by $0.2&nbsp;million for the repayment of debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo expects its expenses to decrease as a result of its discontinuing the development of livoletide, nevanimibe and <FONT
STYLE="white-space:nowrap">MLE-301</FONT> as compared to previous operations. However, Millendo expects to continue to incur costs associated with operating as a public company. Accordingly, it will need to obtain substantial additional funding in
connection with its continuing operations. If Millendo is unable to raise capital when needed or on attractive terms, it may be forced to liquidate its assets. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve
and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, Millendo could experience an inability to access additional capital, which could in the future negatively affect its
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, Millendo entered into an ATM equity distribution agreement with Citigroup Global Markets Inc. acting as sole
agent with an aggregate offering value of up to $50.0&nbsp;million. Subject to the terms of the ATM equity distribution agreement, Millendo is able to determine, at its sole discretion, the timing and number of shares to be sold under this ATM
facility. In March 2020, Millendo amended and restated the equity distribution agreement to include SVB Leerink LLC as an additional sales agent for the ATM. In March 2020, Millendo sold 719,400 shares of its common stock under its ATM equity
distribution agreement for net proceeds of approximately $5.5&nbsp;million. Millendo does not expect to sell additional shares under this ATM facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Millendo had cash, cash equivalents and restricted cash of
$38.7&nbsp;million, which it believes are sufficient to fund its planned operations through at least the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s
future capital requirements will depend on the results of its ongoing strategic evaluation, including whether it completes the merger with Tempest. If the merger is not completed, Millendo will reconsider its strategic alternatives which may include
a dissolution of Millendo, pursuit of another strategic transaction or the continued operation of product development. In the event Millendo resumes product candidate development, its future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of any future preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, prioritization and number of any future research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Millendo&#146;s ability to establish and maintain any future collaborations on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which Millendo is obligated to reimburse, or entitled to reimbursement of, clinical trial costs
under future collaboration agreements, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing any future
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which Millendo acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other product
candidates and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of securing manufacturing arrangements for commercial production; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing or contracting for sales and marketing capabilities if Millendo obtains regulatory
approvals to market any future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical
studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and Millendo may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In
addition, any future product candidates, if approved, may not achieve commercial success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo elects to resume product candidate
development, it expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that Millendo raises additional capital through the sale of
equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available,
may involve agreements that include covenants limiting or restricting Millendo&#146;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Millendo raises funds through additional collaborations, strategic alliances or licensing arrangements with third-parties, Millendo may
have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to Millendo. If Millendo is unable to raise additional funds through
equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market product candidates that Millendo would otherwise prefer
to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Millendo&#146;s commitments to settle contractual obligations at December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31, 2020,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1</B><br><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than</B><br><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating leases <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,651</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing arrangements <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$1,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$1,650</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$302</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$2,971</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects obligations pursuant to Millendo&#146;s office leases in Ann Arbor, Michigan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects obligations pursuant to Millendo&#146;s advance agreement with Bpifrance Financing. In December 2017,
in connection with Millendo&#146;s acquisition of Aliz&eacute;, it assumed &#128;0.7&nbsp;million of debt that Aliz&eacute; had outstanding with Bpifrance Financing. No interest is charged or accrued with respect to the debt. Millendo is required to
make quarterly principal payments between &#128;17,500 to &#128;50,000 per quarter through maturity. In addition to the quarterly payments, Millendo could be obligated to pay, if applicable, no later than March&nbsp;31 of each year starting from
January&nbsp;1, 2016, a reimbursement annuity equal to 20% of the proceeds generated by Millendo from license, assignment or revenue-generating use of the livoletide program. Millendo is permitted to repay the debt at any time.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects obligations pursuant to Millendo&#146;s license agreements with the University of Michigan, other than
contingent obligations to make milestone and royalty payments where the amount, likelihood and timing of such payments are not fixed or determinable. Contingent payments pursuant to Millendo&#146;s license agreements with Erasmus University Medical
Center and Roche are also excluded from the above table. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Millendo is obligated to pay the University of Michigan minimum royalties of $20,000 per year from 2020 to 2023
and $0.2&nbsp;million per year beginning in 2024 through expiration of the term of the license agreement. All such amounts due after December&nbsp;31, 2023 are excluded from the table above because the duration of the license agreement is not
determinable. On March&nbsp;5, 2021, Millendo notified the University of Michigan of its decision to terminate the UM License Agreement, which termination shall be effective as of April&nbsp;30, 2021, as agreed with the University of Michigan. As a
result, Millendo expects its expenditures under this agreement to decrease in the year ending December&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all
significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include obligations under agreements that Millendo can
cancel without a significant penalty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo does not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as
structured finance or special purpose entities that were established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements or other contractually narrow or limited purposes. Millendo does not engage
in <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements. In addition, Millendo does not engage in trading activities involving <FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts. Millendo therefore
believes that it is not materially exposed to any financing, liquidity, market or credit risk that could arise if it had engaged in these relationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s Consolidated Financial Statements are prepared in accordance with U.S. GAAP. The preparation of Millendo&#146;s Consolidated
Financial Statements requires it to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported
amounts of expenses during the reported period. Millendo bases its estimates on historical experience, known trends and events and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Millendo evaluates its estimates and assumptions on an ongoing basis. Millendo&#146;s actual results may differ from these
estimates under different assumptions and conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consists primarily of costs incurred in connection with the development of Millendo&#146;s product candidates.
Millendo expenses research and development costs as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of each reporting period, Millendo compares payments made to
third-party service providers to the estimated progress toward completion of the applicable research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to
the service providers and the progress that it estimates has been made as a result of the service provided, Millendo may record net prepaid or accrued expense relating to these costs. As of December&nbsp;31, 2020, Millendo had not made any material
adjustments to its prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo measures expense for all stock options based on the estimated fair market value of the award on the grant date. Millendo uses the
Black-Scholes option pricing model to value its stock option awards. Millendo recognizes compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Millendo has issued awards
where vesting is subject to a performance condition and the recognition is based on the derived service period. Expense for awards with performance conditions would be estimated and adjusted on a quarterly basis based upon Millendo&#146;s assessment
of the probability that the performance condition will be met. Millendo has not issued awards where vesting is subject to a market condition. The fair market value of Millendo&#146;s common stock is determined based on the closing price of its
common stock on The Nasdaq Capital Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to Millendo&#146;s Consolidated Financial Statements for a description of recent accounting pronouncements applicable to its
Consolidated Financial Statement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEMPEST MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of Tempest&#146;s financial condition and results of operations
together with Tempest&#146;s financial statements and related notes included elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy statement/prospectus contain forward-looking statements that involve risks and
uncertainties, such as its plans, objectives, expectations, intentions, and beliefs. Tempest&#146;s actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, those identified below and those discussed in the section titled &#147;Risk Factors&#151;Risks Related to Tempest&#146;s Financial Position&#148; included elsewhere in this proxy statement/prospectus.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is a
clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer biology and medicinal chemistry to develop and advance novel orally available therapies for the treatment of solid tumors. Tempest&#146;s philosophy is
to build a company based upon not only good ideas and creative science, but also upon the efficient translation of those ideas into therapies that will improve patient&#146;s lives. To this end, Tempest is advancing TPST-1495 and TPST-1120, two
product candidates in clinical trials that it believes are the first clinical stage molecules designed to treat their respective targets; and a third program in preclinical studies that could be the first to target
<FONT STYLE="white-space:nowrap">TREX-1,</FONT> a key cellular enzyme that regulates the innate immune response in tumors. TPST-1495 is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid
tumors. Tempest&#146;s second program, TPST-1120, is a selective antagonist of peroxisome proliferator-activated receptor alpha, or PPAR&#945;, and is also in a Phase 1 trial in solid tumors. Tempest expects to report initial data from both these
programs in the second half of 2021. Additionally, Tempest is advancing a third program targeting the three prime repair exonuclease, or <FONT STYLE="white-space:nowrap">TREX-1,</FONT> for which Tempest expects to select a development candidate by
the end of 2021. Beyond these three ongoing programs, Tempest plans to leverage its drug development and company-building experience along with academic relationships to identify promising new targets that may feed new programs into Tempest&#146;s
pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has no products approved for commercial sale and has not generated any revenue from product sales. From inception to
December&nbsp;31, 2020, Tempest has raised $100&nbsp;million, through sales of convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has never been
profitable and has incurred operating losses in each period since inception. Tempest&#146;s net losses were $19.2&nbsp;million and $14.4&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31, 2020,
Tempest had an accumulated deficit of $71.8&nbsp;million. Substantially all of its operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with
its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest expects to incur significant expenses and increasing operating losses for at least the next several years as it
initiates and continues the clinical development of, and seeks regulatory approval for, its product candidates and adds personnel necessary to advance its pipeline of clinical-stage product candidates. In addition, operating as a publicly traded
company will involve the hiring of additional financial and other personnel, upgrading its financial information and other systems, and incurring substantial costs associated with operating as a public company. Tempest expects that its operating
losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Tempest had cash and cash equivalents of $18.8&nbsp;million. Tempest&#146;s current capital resources are not
sufficient to fund its planned operations for a <FONT STYLE="white-space:nowrap">12-month</FONT> period without the merger and <FONT STYLE="white-space:nowrap">pre-closing</FONT> common stock financing transaction. These matters raise substantial
doubt about its ability to continue as a going concern. Tempest will continue to require substantial additional capital to continue its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical development and potential commercialization activities. Accordingly, Tempest will need to raise substantial additional capital to continue to fund its operations. The amount and timing
of its future funding requirements will depend on many factors, including the pace and results of its clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on its
financial condition and its ability to develop its product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Events &#151; Proposed Merger with Millendo </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following extensive negotiation with Millendo, on March&nbsp;29, 2021, Tempest, Merger Sub, a wholly owned subsidiary of Millendo, and Millendo
entered into the Merger Agreement. More information regarding the merger and the terms of the Merger Agreement are discussed throughout this proxy statement/prospectus, particularly in &#147;<I>The Merger</I>&#148; and &#147;<I>The Merger
Agreement</I>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of
accounting, Tempest will be deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the Merger: (1)&nbsp;Tempest stockholders will own substantial
majority of the voting rights; (2)&nbsp;Tempest will designate a majority of the initial members of the board of directors of the combined organization; and (3)&nbsp;Tempest&#146;s senior management will hold key positions in senior management of
the combined organization. In addition, Millendo has ceased all research and development activities and substantially reduced its workforce. Accordingly, for accounting purposes, the Merger will be treated as the equivalent of Tempest issuing stock
to acquire the net assets of Millendo. As a result of the Merger, the net assets of Millendo will be recorded at their acquisition-date fair value in the financial statements of Tempest and the reported operating results prior to the merger will be
those of Tempest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution and delivery of the Merger Agreement, Tempest entered into Funding Agreements with
certain investors named therein, pursuant to which the investors agreed to purchase, in the aggregate, $30.0&nbsp;million of Tempest common stock convertible into securities of Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Tempest concurrent financing is subject to certain conditions, including the satisfaction or waiver of each of the
conditions to the consummation of the merger set forth in the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses represent costs incurred to conduct research and development, such as the development of Tempest&#146;s
product candidates. Tempest recognizes all research and development costs as they are incurred. Research and development expenses consist primarily of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries, benefits and stock-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">licensing costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated occupancy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">materials and supplies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contracted research and manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consulting arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other expenses incurred to advance Tempest&#146;s research and development activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The largest component of Tempest&#146;s operating expenses has historically been the investment in research and development activities. Tempest
expects research and development expenses will increase in the future as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest advances its product candidates into and through clinical trials and pursues regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory
support and contract manufacturing and inventory <FONT STYLE="white-space:nowrap">build-up.</FONT> In addition, Tempest continues to evaluate opportunities to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies, which may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. Tempest may never succeed in
timely developing and achieving regulatory approval for its product candidates. The probability of success of Tempest&#146;s product candidates may be affected by numerous factors, including clinical data, competition, manufacturing capability and
commercial viability. As a result, Tempest is unable to determine the duration and completion costs of Tempest&#146;s development projects or when and to what extent Tempest will generate revenue from the commercialization and sale of any of its
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of employee-related expenses, including salaries, benefits, travel and noncash stock-based
compensation, for the Tempest personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research
and development expense. Legal costs include general corporate legal fees and patent costs. Tempest expects to incur additional expenses as a result of becoming a public company following completion of the merger, including expenses related to
compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income (expense), net consists primarily of changes in carrying value of the convertible preferred stock tranche liability, interest income, and various income or expense items of a <FONT STYLE="white-space:nowrap">non-recurring</FONT> nature. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of the years ended
December&nbsp;31, 2020 and 2019 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s research and development expenses for the years ended December&nbsp;31, 2020 and 2019 were primarily incurred in connection with
Tempest&#146;s most advanced product candidates, TPST-1120 and TPST-1495. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tempest has not historically tracked research and development expense by program other than direct external expenses in conducting clinical trials for TPST-1120 and TPST-1495. Tempest typically
has various early-stage research and drug discovery projects, as well as various potential product candidates undergoing clinical trials. Tempest&#146;s internal resources, employees and infrastructure are not directly tied to any one research and
drug discovery project and Tempest&#146;s resources are typically deployed across multiple projects. As such Tempest does not maintain information regarding these costs incurred for these early-stage research and drug discovery programs on a project
specific basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense decreased by $3.5&nbsp;million to $14.3&nbsp;million for the year ended
December&nbsp;31, 2020 from $17.8&nbsp;million for the year ended December&nbsp;31, 2019. The following table summarizes Tempest&#146;s research and development expenses for the years ended December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,612</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,281</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense, other than stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,070</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,038</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,867</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in total research and development expense is attributable to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $4.7&nbsp;million decrease in research and development outside services expense primarily related to a decline
in TPST-1120 related contract manufacturing of active pharmaceutical ingredient (API) and contract research associated with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in stock-based compensation expense primarily due to vesting acceleration of certain
stock options related to termination of <FONT STYLE="white-space:nowrap">non-employee</FONT> service agreements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in consulting and professional services primarily due to increases in clinical
consulting support in 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.9&nbsp;million increase in other expenses primarily related to increase in facilities-related expenses which
were allocated to research and development departments. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased by $0.6&nbsp;million to $4.9&nbsp;million for the year ended December&nbsp;31, 2020 from
$5.5&nbsp;million for the year ended December&nbsp;31, 2019. The decrease was primarily due to a decline in overhead expenses, offset by increases in compensation and benefits expenses. Travel and entertainment expense also declined year over year
due to COVID19-related travel restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of convertible preferred stock tranche liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of convertible preferred stock tranche liability of $8.7&nbsp;million was recognized as other income for the year
ended December&nbsp;31, 2019 compared to nil for the year ended December&nbsp;31, 2020. The decrease was due to recognition of the change in fair value of the convertible preferred stock liability associated with the issuance of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> convertible preferred stock in January 2020. Such change in fair value resulted in a liability balance of nil as of December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception through December&nbsp;31, 2020, Tempest&#146;s operations have been financed primarily by net cash proceeds from the sale of its convertible preferred stock and issuance of debt. As of December&nbsp;31, 2020, Tempest had $18.8&nbsp;million
in cash and cash equivalents and an accumulated deficit of $71.8&nbsp;million. Tempest expects that its research and development and general and administrative expenses will increase, and, as a result, Tempest anticipates that it will continue to
incur increasing losses in the foreseeable future. Therefore, Tempest will need to raise additional capital to fund its operations, which may be through the issuance of additional equity or through borrowings, including in connection with the
merger, or through business development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January2021, Tempest entered into a loan agreement with a lender to borrow a term
loan amount of $35.0&nbsp;million to be funded in three tranches. Tranche A of $15.0&nbsp;million was funded to Tempest on January&nbsp;15, 2021. Tranche B of $10.0&nbsp;million will be available through March&nbsp;31, 2022 contingent upon
achievement of each of the following: i) receipt of at least $50.0&nbsp;million in Series C equity capital, ii) initiation of the Phase 1 combination study of TPST-1495 or monotherapy expansion study, and iii) initiation of Phase 2 trial of
TPST-1120 or the 1L Triplet Collaboration study. Tranche C of $10.0&nbsp;million is available at lender&#146;s option. The term loan matures on August&nbsp;1, 2025 and has an annual floating interest rate of 7.15% which is an Index Rate plus 7%.
Index Rate is the greater of (i) <FONT STYLE="white-space:nowrap">30-day</FONT> US LIBOR or (ii) 0.15%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above under the
section titled &#147;<I>Recent Events</I>,&#148; on March&nbsp;29, 2021, Tempest entered into the Merger Agreement with Millendo, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger
Agreement, a wholly owned subsidiary of Millendo will merge with and into Tempest, with Tempest becoming a wholly-owned subsidiary of Millendo and the surviving corporation of the merger. At the closing of the merger, each outstanding share of
Tempest&#146;s capital stock (including preferred stock) will be converted into the right to receive shares of common stock of Millendo pursuant to an exchange ratio calculation set forth in the Merger Agreement, and the equity holders of Tempest
will become the majority owners (approximately 81.5%) of Millendo&#146;s outstanding common stock on a fully-diluted basis upon the close of the merger. The exchange ratio may be adjusted pursuant to the terms of the Merger Agreement. At the closing
of the merger, Millendo will be renamed Tempest Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution and delivery of the Merger Agreement,
Tempest entered into Funding Agreements with certain investors named therein, pursuant to which the investors agreed to purchase Tempest common stock at a purchase price of $0.85 per share for an aggregate purchase price of approximately
$30.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Tempest&#146;s cash flows for the years indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from operating activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&nbsp;31, 2020 was $19.0&nbsp;million, consisting of a net loss of
$19.2&nbsp;million, add back of <FONT STYLE="white-space:nowrap">non-cash</FONT> adjustments for depreciation, stock-based compensation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense totaling $1.3&nbsp;million, less changes in operating assets and liabilities of $1.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&nbsp;31, 2019 was $21.6&nbsp;million consisting of a net loss of
$14.4&nbsp;million, add back of <FONT STYLE="white-space:nowrap">non-cash</FONT> adjustments for depreciation, stock-based compensation and <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense totaling $0.8&nbsp;million, which
was offset by change in fair value of convertible preferred stock tranche liability of $8.7&nbsp;million, plus changes in operating assets and liabilities of $0.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The year over year decrease in cash used in operating activities was primarily related to the decline in TPST-1120 outside services costs,
especially costs related to API production and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology and safety pharmacology studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from investing activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for all periods presented was related to purchases of property and equipment, primarily related to office,
laboratory and computer equipment. In 2020, cash provided from investing activities was due to a repayment of a promissory note. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash flows from
financing activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for all periods presented was primarily related to proceeds from the
issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock, net of issuance costs and the issuance of common stock through exercise of stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has not generated any revenue from product sales, and does not know when, or if, it will generate any revenue from product sales.
Tempest does not expect to generate any revenue from product sales unless and until it obtains regulatory approval of and commercializes any of its product candidates. At the same time, Tempest expects its expenses to increase in connection with its
ongoing development activities, particularly as Tempest continues the research, development and clinical trials of, and seeks regulatory approval for, its product candidates. In addition, subject to obtaining regulatory approval of any of its
product candidates, Tempest anticipates that it will need substantial additional funding in connection with its continuing operations. Tempest plans to continue to fund its operations and capital requirements through equity financing, debt financing
and/or business development activities, but there are no assurances that Tempest will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, Tempest had cash and cash equivalents of $18.8&nbsp;million. On January&nbsp;15, 2021, Tempest entered into a
loan agreement with a lender to borrow a term loan amount of $35.0&nbsp;million to be funded in three tranches. Tranche A of $15.0&nbsp;million was funded to Tempest on January&nbsp;15, 2021. Tranche B of $10.0&nbsp;million will be available through
March&nbsp;31, 2022 contingent upon achievement of each of the following: i) receipt of at least $50.0&nbsp;million in Series C equity capital, ii) initiation of the Phase 1 combination study of TPST-1495 or monotherapy expansion study, and iii)
initiation of Phase 2 trial of TPST-1120 or the 1L Triplet Collaboration study. Tranche C of $10.0&nbsp;million is available at lender&#146;s option. The term loan matures on August&nbsp;1, 2025 and has an annual floating interest rate of 7.15%
which is an Index Rate plus 7%. Index Rate is the greater of (i) <FONT STYLE="white-space:nowrap">30-day</FONT> US LIBOR or (ii) 0.15%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, Tempest entered into the Merger Agreement with Millendo. Tempest&#146;s present capital resources are not sufficient to fund
its planned operations for a <FONT STYLE="white-space:nowrap">12-month</FONT> period without the merger and the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing transaction, and therefore, raise substantial doubt about
Tempest&#146;s ability to continue as a going concern. However, the cash expected from both Millendo and Tempest at closing, including the net proceeds of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing, are expected to
fund the further development of the combined company&#146;s three oncology programs and operate the combined company into early 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until Tempest can generate a sufficient amount of product revenue to finance its cash
requirements, it expects to finance its future cash needs primarily through the issuance of additional equity, borrowings and strategic alliances with partner companies. To the extent that Tempest raises additional capital through the issuance of
additional equity or convertible debt securities, the ownership interest of Tempest&#146;s stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing
stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting Tempest&#146;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If Tempest raises additional funds through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, Tempest may have to relinquish valuable rights to its technologies, future
revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to Tempest. If Tempest is unable to raise additional funds through equity or debt financings when needed, Tempest may be required to delay,
limit, reduce or terminate its product development or commercialization efforts or grant rights to develop and market product candidates to third parties that Tempest would otherwise prefer to develop and market itself. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Contracts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest enters into
contracts in the normal course of business with various third parties for preclinical research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and therefore Tempest believes that
its <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements and does not have any holdings in
variable interest entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is exposed to market risks in the ordinary course of its business. These risks primarily include interest rate fluctuation. As of
December&nbsp;31, 2020, and December&nbsp;31, 2019, Tempest had cash and cash equivalents of approximately $18.8 million and $3.2&nbsp;million, respectively, which consisted primarily of bank deposit and money market funds. Such interest-earning
instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting
Polices and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest&#146;s management&#146;s discussion and analysis of financial condition and results of operations is based on its
financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires Tempest to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an
ongoing basis, Tempest evaluates these estimates and judgments. Tempest bases its estimates on historical experience and on various assumptions that Tempest believes to be reasonable under the circumstances. These estimates and assumptions form the
basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. Tempest believes that the
accounting policies discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest records accrued expenses for estimated costs of its research and development activities conducted by third-party service providers,
which include the conduct of preclinical studies and clinical trials and contract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing activities. Tempest records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and Tempest
includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statement of operations. These costs are a significant component of Tempest&#146;s research and development expense. Tempest records
accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest estimates the amount of work completed through discussions with internal personnel and external service providers as to the progress
or stage of completion of the services and the agreed-upon fee to be paid for such services. Tempest makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, Tempest adjusts
its accrued estimates. Although Tempest does not expect its estimates to be materially different from amounts actually incurred, Tempest&#146;s understanding of the status and timing of services performed, the number of patients enrolled and the
rate of patient enrollment may vary from its estimates and could result in Tempest reporting amounts that are too high or too low in any particular period. Tempest&#146;s accrued expenses are dependent, in part, upon the receipt of timely and
accurate reporting from clinical research organizations and other third-party service providers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair values of the shares of common stock underlying the share-based awards were estimated on each grant date by the board of directors.
Tempest used the option-pricing method (OPM). Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the
preferred and common stock are inferred by analyzing these options. Tempest applied a discount for lack of marketability to account for a lack of access to an active public market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application of this approach involves the use of estimates, judgment, and assumptions that are complex and subjective, such as those regarding
the expected future revenue, expenses, and cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships
between those assumptions, impact the valuation and may have a material impact on the valuation of common stock which is the key input into the calculation of stock-based compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest
recognizes noncash stock-based compensation expense related to stock-based awards to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and directors, including stock options, based on the fair value on the grant date using the
Black-Scholes option pricing model. The related stock-based compensation is recognized as expense on a straight line-basis over the employee&#146;s, <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> or director&#146;s requisite service
period (generally the vesting period). Noncash stock compensation expense is based on awards ultimately expected to vest and is reduced by an estimate for future forfeitures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of stock options, Tempest uses the Black-Scholes option-pricing model and assumptions discussed below. Each of
these inputs is subjective and generally requires significant judgment to determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Common Stock</I>&#151;The fair value
of the shares of common stock underlying stock options has historically been determined by Tempest&#146;s board of directors. Because there has been no public market for its common stock, the board of directors exercises reasonable judgment and
considers a number of objective and subjective factors to determine the best estimate of the fair value of Tempest&#146;s common stock, including important developments in its operations, sales of redeemable convertible preferred stock, actual
operating results and financial performance, the conditions in the life sciences industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of its common stock, among
other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>&#151;Tempest&#146;s expected term represents the period that the
stock-based awards are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term) for employee options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>&#151;Since Tempest is privately held and does not have any trading history for its common stock, the expected
volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, or
stage in the product development life cycle. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury
zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected
Dividend</I>&#151;Tempest has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, Tempest uses an expected dividend yield of zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2020 and 2019, stock-based compensation expense was $0.5&nbsp;million and $0.3&nbsp;million,
respectively. Of the amount of $0.5&nbsp;million in stock-based compensation expense, $0.4&nbsp;million was recorded in research and development and $0.1&nbsp;million was recorded in general and administrative for the year ended December&nbsp;31,
2020. Of the amount of $0.3&nbsp;million in stock-based compensation expense, $0.2&nbsp;million was recorded in research and development and $0.1&nbsp;million was recorded in general and administrative for the year ended December&nbsp;31, 2019. As
of December&nbsp;31, 2020, Tempest had $1.0&nbsp;million of total unrecognized stock-based compensation costs, net of estimated forfeitures, which it expects to recognize over a weighted-average period of 1.6 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See
Note 2 to Tempest&#146;s financial statements included elsewhere in this proxy statement/prospectus for information about recent accounting pronouncements, the timing of their adoption and Tempest&#146;s assessment, to the extent it has made one
yet, of their potential impact on Tempest&#146;s financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with generally accepted accounting principles. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of Tempest&#146;s annual or interim financial statements will not be prevented or detected and corrected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing Tempest&#146;s financial statements as of and for the year ended December 31, 2020, management of Tempest identified material
weaknesses in its internal control over financial reporting. The material weaknesses identified were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There was a material weakness in Tempest&#146;s internal control environment over financial reporting as a
result of insufficient resources with appropriate knowledge and expertise to design, implement, document and operate effective internal controls over financial reporting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There was a material weakness in Tempest&#146;s internal control activities due to a failure in the design and
implementation of controls to review clinical trial expenses, including the evaluation of the terms of clinical trial contracts. Specifically, Tempest failed to properly review and evaluate progress of expense incurred in clinical trial contracts
which resulted in the inaccurate accrual of its clinical trial expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remediation of Material Weaknesses in Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s management, under the supervision of its Chief Executive Officer, has undertaken a plan to remediate the material weaknesses
identified above. The remediation efforts summarized below, which are in the process of being implemented, are intended to address the identified material weaknesses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tempest will seek to recruit and hire additional accounting personnel with appropriate experience,
certification, education and training to help design, implement, document and operate effective internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tempest will design and implement controls related to review of clinical trial expenses to properly evaluate
progress of expense incurred in clinical trial contracts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company cannot assure you that the material
weaknesses identified at Tempest will be remediated by the combined company on the timelines currently anticipated by Tempest, or at all, and/or that there will not be additional material weaknesses or significant deficiencies in the combined
company&#146;s internal control over financial reporting in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_92"></A>MANAGEMENT FOLLOWING THE MERGER </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive
Officers and Directors of the Combined Company Following the Merger </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined company&#146;s board of directors will initially
be fixed at seven members, consisting of (i)&nbsp;one (1)&nbsp;current Millendo board member, namely Geoff Nichol, (ii)&nbsp;five (5)&nbsp;current Tempest board members, namely Stephen Brady, Mike Raab, Thomas Dubensky, Tom Woiwode, and Stella Xu,
and (iii)&nbsp;one (1)&nbsp;member to be appointed by Tempest. The staggered structure of the current Millendo board of directors will remain in place for the combined company following the completion of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists the names and ages, as of March&nbsp;31, 2021, and positions of the individuals who are expected to serve as
executive officers and directors of the combined company upon completion of the merger: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Dubensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Whiting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geoff Nichol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Raab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tom Woiwode</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stella Xu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stephen Brady </B>was appointed president and chief operating officer of Tempest Therapeutics in September 2019.<B> </B>Before Tempest, he
served as executive vice president, strategy and finance at Immune Design, a biopharmaceutical company that was acquired by Merck in 2019. At Immune Design, Mr.&nbsp;Brady led the general and administrative functions at the company, including
strategy, corporate development, finance and investor and public relations, and was instrumental in the company&#146;s successful IPO, financings and eventual sale to Merck. Prior to Immune Design, he held roles of increasing responsibility in
multiple biopharmaceutical companies, including as vice president of corporate development at Proteolix, where he had primary responsibility for the company&#146;s business development activities and sale to Onyx Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Thomas Dubensky, Ph.D.</B> became the CEO of Tempest Therapeutics in 2017 and has served as a member of the board of directors of Tempest
since September 2017. Prior to Tempest, Tom was the Chief Scientific Officer of Aduro Biotech, where he led the development of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> STING agonists.
Additionally, Tom has served executive and principal roles in leading discovery biology, development and clinical translation of multiple <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> agents in cancer
immunotherapy and infectious disease indications at several biotech companies, including Viagene, Chiron, Onyx, Cerus and Immune Design. Tom has an extensive publication and patent record. He received his BA in Bacteriology and Immunology from the
University of California, Berkeley, his Ph.D. at the University of Colorado Health Sciences Center, conducted his post-doctoral studies at Harvard Medical School in the Department of Pathology, and received executive training at the University of
California, San Diego, in the Executive Program for Scientist and Engineers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Samuel Whiting, M.D., Ph.D. </B>has served as Tempest
Therapeutic&#146;s Chief Medical Officer since November 2020. Before Tempest, he was Senior Vice President of Clinical Development at Calithera Biosciences where he oversaw the clinical development of the oral small molecule glutaminase inhibitor
teleglenastat and the clinical development of the Calithera&#146;s pipeline CD73 inhibitor and served on Calithera&#146;s Senior Management Team. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prior to joining Calithera in 2016, Dr.&nbsp;Whiting held positions of increasing responsibility developing small molecule, targeted, immunotherapy, and cancer vaccine therapies (Medical
Director, Senior Medical Director and Vice President of Research and Development) at Oncothyreon (subsequently Cascadian), VentiRx, and Gradalis Inc. Prior to his positions in the biotech industry, Dr.&nbsp;Whiting was an assistant professor of
medical oncology at the University of Washington, assistant member of clinical research at the Fred Hutchinson Cancer Research Center, and clinical director of gastrointestinal (GI) oncology at the Seattle Cancer Care Alliance, where
Dr.&nbsp;Whiting also maintained a clinical practice in GI oncology.&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Geoff</B><B><I></I></B><B>&nbsp;Nichol</B><B><I>, M.B., Ch.B., M.B.A.,</I></B><B></B>&nbsp;was appointed to
Millendo&#146;s board of directors in December 2019. Dr.&nbsp;Nichol has nearly 30 years&#146; experience in drug development. He has served as Chief Medical Officer at BioMarin Pharmaceutical Inc., where he manages an active portfolio of clinical
development programs, since November 2016. From July 2011 to November 2016, he was Executive Vice President, Research and Development at Sangamo BioSciences, where he managed the preclinical development of several IND candidates. From September 2002
to January 2010, he was Senior Vice President of Development at Medarex, where he was responsible for a portfolio of clinical development programs. From February 1996 to September 2002, he was Vice President at Novartis, where he managed a clinical
development therapeutic area, United States Medical Affairs, and Global Project and Portfolio Management. From December 1989 to February 1996, he held various positions up to Group Medical Director, Clinical Development at SmithKline Beecham, where
he was responsible for anti-infective development and medical affairs. Dr.&nbsp;Nichol received a B.Med.Sc., M.B., Ch.B., or the equivalent of an M.D. in the U.S., from Otago University Medical School in New Zealand and an M.B.A. from Warwick
University in the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mike Raab </B>has served as a member of the board of directors of Tempest since December 2018. Mr.
Raab has served as Ardelyx&#146;s president and chief executive officer since March 2009. Before Ardelyx, he was a partner at New Enterprise Associates (NEA), one of the world&#146;s largest and most successful venture capital firms, where he
specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA in 2002, Mr.&nbsp;Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He
was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. In this position, he launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of
hyperphosphatemia, with over $1.0&nbsp;billion in worldwide sales in 2013. Mr.&nbsp;Raab was also instrumental in the worldwide launch of Genzyme&#146;s therapies for Gaucher disease, Ceredase and Cerezyme. Mike also spent two years with
Genzyme&#146;s diagnostic products and services division. Previous to Genzyme, he held business development and sales and marketing positions at Repligen and Bristol-Myers. Mr.&nbsp;Raab received his B.A. from DePauw University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Tom Woiwode, Ph.D. </B>has served as a member of the board of directors of Tempest since March 2018. Dr.&nbsp;Woiwode has been working with
Versant since 2002, and has served in both operational and investment roles during that time. He was the <FONT STYLE="white-space:nowrap">start-up</FONT> CBO for Amira (sale), Synosia (sale) and Flexion (2014 IPO), and was the COO of Okairos where
he led the process that culminated in the acquisition by GSK. Since being promoted to Managing Director in 2014, Dr.&nbsp;Woiwode has assumed the lead role in multiple investments including Crispr (2016 IPO), Audentes (2016 IPO), Annapurna (merged
to form Adverum), Gritstone (2018 IPO), Crinetics (2018 IPO), Jecure (sale) Anokion, Therachon, Vividion, Tempest, Aligos, CODA and Passage. Prior to joining Versant, he was a medicinal chemist at XenoPort, a
<FONT STYLE="white-space:nowrap">start-up</FONT> biotech company that completed an IPO in 2005. Dr.&nbsp;Woiwode earned his Ph.D. in chemistry from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Stella Xu, Ph.D. </B>has served as a member of the board of directors of Tempest since March 2018. Dr. Xu is a Managing Director of Quan
Capital, a life sciences venture fund with deep expertise in cross-board value creation and global investments, and a Board Director of ARMO Biosciences and Centrexion Therapeutics. Prior to Quan, she was a core member of the global management team
for Roche&#146;s Immunology, Inflammation&nbsp;&amp; Infectious Diseases Areas, and VP/Site Head of Roche Innovation Center Shanghai. From 2012-2017, she led the integrated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research&nbsp;&amp; early development site of approximately 200 scientists, successfully delivered a world-class innovative pipeline from Discovery to global Clinical Development in 3 years, and
pioneered novel development strategies in China. In addition, Dr.&nbsp;Xu had extensive global business development and licensing leadership experiences across deal types and disease areas in the US and Asia with Roche Partnering. She joined Roche
from McKinsey US where she led management consulting engagements in diverse healthcare sectors from R&amp;D to commercialization. Earlier in her career, Dr.&nbsp;Xu worked in biotech R&amp;D in oncology and inflammation. Dr.&nbsp;Xu received her
Ph.D. in Immunology from Northwestern University, and B.S. in Biophysics from Peking University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest&#146;s executive officers are appointed by, and serve at the discretion of, Tempest&#146;s board of directors. There are no family
relationships among any of Tempest&#146;s directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors of the Combined Company Following the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s board of directors currently consists of eight directors divided into three staggered classes, with one class to be elected at
each annual meeting to serve for a three-year term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the merger. It is anticipated that the incoming directors will be
appointed to applicable vacant director seats of the combined company board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of
the proposed combined company directors and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committees of the Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s board of directors currently has the following standing committees: audit committee, compensation committee and nominating and
corporate governance committee. Following the completion of the merger the combined company will continue to have the following standing committees: audit committee, compensation committee and nominating and corporate governance committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s audit committee oversees its corporate accounting and financial reporting process. Among other matters, the audit committee:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoints its independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluates the independent registered public accounting firm&#146;s qualifications, independence and performance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determines the engagement of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and approves the scope of the annual audit and the audit fee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discusses with management and the independent registered public accounting firm the results of the annual audit
and the review of Millendo&#146;s quarterly consolidated financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approves the retention of the independent registered public accounting firm to perform any proposed permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitors the rotation of partners of the independent registered accounting firm on Millendo&#146;s engagement
team in accordance with requirements established by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is responsible for reviewing Millendo&#146;s consolidated financial statements and its management&#146;s
discussion and analysis of financial condition and results of operations to be included in its annual and quarterly reports to be filed with the SEC; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews Millendo&#146;s critical accounting policies and estimates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews, with Millendo&#146;s independent registered public accounting firm and management, significant issues
that may arise regarding Millendo&#146;s accounting principles and financial statement presentation, as well as matters concerning the scope, adequacy and effectiveness of Millendo&#146;s financial controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considers and approves or disapproves all related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews the audit committee charter and the committee&#146;s and its member&#146;s performance at least annually;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishes procedures for the receipt, retention and treatment of complaints received by Millendo regarding
financial controls, accounting or auditing matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee of the combined company is expected to retain
these duties and responsibilities following the completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the merger, the combined
company&#146;s board of directors is expected to select members of the audit committee. To qualify as independent to serve on the combined company&#146;s audit committee, listing standards of Nasdaq and the applicable SEC rules require that a
director not accept any consulting, advisory or other compensatory fee from the combined company, other than for service as a director, or be an affiliated person of the combined company. Millendo and Tempest believe that, following the completion
of the merger, the composition of the audit committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s compensation committee oversees policies relating to compensation and benefits of its officers and employees. Among other
matters, the compensation committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and approves corporate performance goals and objectives relevant to the compensation of executive
officers and other senior management, as appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and recommends to the board the type and amount of compensation to be paid or awarded to board members;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluates and approves the compensation plans and programs advisable for Millendo, as well as evaluating and
approving the modification or termination of existing plans and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishes policies with respect to equity compensation arrangements with the objective of appropriately
balancing the perceived value of equity compensation and the dilutive and other costs of that compensation to Millendo; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews compensation practices and trends to assess the adequacy and competitiveness of Millendo&#146;s
compensation programs among comparable companies in its industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and approves the terms of any employment agreements, severance arrangements, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements (including, without limitation, perquisites and any other form of compensation) for Millendo&#146;s
executive officers and, as appropriate, other senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approves any loans by Millendo (i)&nbsp;to its executive officers and (ii)&nbsp;to its employees who are <FONT
STYLE="white-space:nowrap">non-executive</FONT> officers where the amount of any such loan exceeds $10,000; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administers equity compensation plans, pension and profit-sharing plans, stock purchase plans, bonus plans,
deferred compensation plans and other similar plan and programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee of the combined company is
expected to retain these duties and responsibilities following completion of the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the merger, the combined company&#146;s board of directors
is expected to select members of the compensation committee. Each member of the combined company&#146;s compensation committee is expected to be a <FONT STYLE="white-space:nowrap">&#147;non-employee&#148;</FONT> director within the meaning of <FONT
STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. Millendo and Tempest believe that, following the completion of the
merger, the composition of the compensation committee will comply with the applicable requirements of the rules and regulations of Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s nominating and corporate governance committee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interviews, evaluates, nominates and recommends to the board of directors candidates for directorships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performs periodic reviews of the performance of each member of the entire board of directors and its committees
and recommends areas for improvement to the board and Millendo&#146;s management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">oversees the corporate governance policies and reporting and makes recommendations to the board of directors
concerning governance matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviews and evaluates, at least annually, the performance of the nominating and corporate governance committee
and its members, including compliance by the nominating and corporate governance committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
nominating and corporate governance committee of the combined company is expected to retain these duties and responsibilities following completion of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the merger, the combined company&#146;s board of directors is expected to select members of the nominating
and corporate governance committee. Millendo and Tempest believe that, after the completion of the merger, the composition of the nominating and corporate governance committee will meet the requirements for independence under, and the functioning of
such nominating and corporate governance committee will comply with, any applicable requirements of the rules and regulations of Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks and Insider Participation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the merger, the combined company&#146;s board of directors is expected to select members of the compensation
committee. Each member of the compensation committee is expected to be a <FONT STYLE="white-space:nowrap">&#147;non-employee&#148;</FONT> director within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> of the rules promulgated
under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed combined company&#146;s executive officers serves as a member of the board of directors or compensation committee of any
entity that has one or more executive officers who is proposed to serve on the combined company&#146;s board of directors or compensation committee following the completion of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the merger, Tempest did not have a formal policy to provide any cash or equity compensation to its
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service on its board of directors or committees of its board of directors, nor did any <FONT STYLE="white-space:nowrap">non-employee</FONT> director receive any compensation
for serving on Tempest&#146;s board of directors. In connection with closing of the merger, it is expected that the combined company will provide compensation to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that is consistent with
Millendo&#146;s current practices, however, these director compensation policies may be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> by the combined company and the compensation committee following the completion of the merger and may be
subject to change. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are expected to receive an annual retainer fee and equity compensation in the form of a stock option grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s board of directors has adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy pursuant to
which Millendo compensates <FONT STYLE="white-space:nowrap">non-employee</FONT> directors with a combination of cash and equity. The annual cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation contained in this policy, set forth below, is payable in equal quarterly installments, in arrears following the end of each quarter in which service occurred, prorated for any months
of partial service. Eligible directors may annually elect, in writing, to receive their annual cash compensation in the form of stock options. Such stock options are granted on the date of the annual meeting of stockholders and vest monthly over one
year from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual Board Service Retainer: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors other than the <FONT STYLE="white-space:nowrap">non-executive</FONT>
chairperson: $40,000 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-executive</FONT> chairperson: $70,000 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual Committee Service Retainer (Chair): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chair of the Audit Committee: $15,000 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chair of the Compensation Committee: $10,000 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chair of the Nominating and Corporate Governance Committee: $8,000 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual Committee Service Retainer <FONT STYLE="white-space:nowrap">(Non-Chair):</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Audit Committee: $7,500 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Compensation Committee: $5,000 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee: $4,000 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy also provides for equity compensation to
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Initial&nbsp;Grant:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the time he or she joins Millendo&#146;s board of directors, each new
<FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an initial stock option grant to purchase 24,000 shares of Millendo&#146;s common stock. <FONT STYLE="white-space:nowrap">One-third</FONT> of the shares subject to the
initial grant vest on the first anniversary of the grant date and the remainder vest in equal monthly installments thereafter such that the initial grant is fully vested on the third anniversary of the date of grant, subject to the director&#146;s
continuous service on each applicable vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Annual&nbsp;Grant:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will also be granted an option to purchase
12,000 shares of Millendo&#146;s common stock on the date of each annual meeting of stockholders. The annual stock option award fully vests on the earlier to occur of the first anniversary of the grant date and the date of the first annual meeting
following the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service on each applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All options granted to Millendo&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under the policy will vest in full upon
the completion of a change in control, including the merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_93"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE
COMBINED COMPANY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control
arrangements, with Tempest&#146;s and Millendo&#146;s directors and executive officers, including those discussed in the sections titled &#147;<I>Management Following the Merger</I>,&#148; &#147;<I>Tempest</I> <I>Executive Compensation</I>&#148; and
&#147;<I>Millendo Executive Compensation</I>,&#148; the following is a description of each transaction involving Millendo since January&nbsp;1,<I> </I>2018, each transaction involving Tempest since January&nbsp;1, 2018 and each currently proposed
transaction in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either Tempest or Millendo has been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Tempest&#146;s or
Millendo&#146;s total assets at year end for the last two completed fiscal years, as applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of Tempest&#146;s or Millendo&#146;s directors, executive officers or holders of more than 5% of
Tempest&#146;s or Millendo&#146;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_94"></A>Tempest Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed
elsewhere in this proxy statement/prospectus, on March&nbsp;29, 2021, immediately prior to the delivery of the Merger Agreement, Tempest entered into Funding Agreements with certain investors, pursuant to which the investors agreed to purchase an
aggregate of 35,305,882 shares of Tempest&#146;s common stock at a purchase price of $0.85 per share for an aggregate purchase price of approximately $30.0&nbsp;million. The closing of the Tempest <FONT STYLE="white-space:nowrap">pre-closing</FONT>
financing contemplated by the Funding Agreements is conditioned upon the satisfaction or waiver of the conditions to the closing of the merger as well as certain other conditions, as set forth in the Funding Agreements. The following table
summarizes the shares of Tempest common stock that members of Tempest&#146;s board of directors or their affiliates and holders of more than 5% of Tempest&#146;s outstanding capital stock agreed to purchase under the Funding Agreements. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Venture Capital IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,352,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,949,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Side Fund IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,352,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,235,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LYFE Capital Fund III (Phoenix), L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,705,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LAV Regulus Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ERVC Healthcare IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,070,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">910,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two closings in February 2019 and January, 2020, Tempest sold an aggregate of 72,499,993 shares of its
<FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> convertible preferred stock at a purchase price of $0.80 per share for an aggregate purchase price of approximately $58.0&nbsp;million. Each share of Tempest
<FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> convertible preferred stock will convert automatically into one share of Tempest common stock immediately prior to the completion of the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> convertible preferred stock purchased by members of
Tempest&#146;s board of directors or their affiliates and holders of more than 5% of Tempest&#146;s outstanding capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock. The terms of these purchases were the same for all purchasers of Tempest&#146;s <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> convertible preferred stock. Please refer to the
section titled &#147;<I>Principal Stockholders of Tempest</I>&#148; for more details regarding the shares held by these entities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchased&nbsp;Shares<BR>of Series <FONT STYLE="white-space:nowrap">B-1</FONT><BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Venture Capital VI, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,959,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,967,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LYFE Capital Fund III (Phoenix), L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,340,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,072,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,340,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,072,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LAV Regulus Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,804,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,443,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ERVC Healthcare IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,268,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,814,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series&nbsp;B Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, Tempest sold an aggregate of 25,186,738 shares of its Series&nbsp;B convertible preferred stock at a purchase price of $1.00
per share for an aggregate purchase price of approximately $25.2&nbsp;million, inclusive of the conversion of certain outstanding indebtedness. Each share of Tempest Series&nbsp;B convertible preferred stock will convert automatically into one share
of Tempest common stock immediately prior to the completion of the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series&nbsp;B convertible
preferred stock purchased by members of Tempest&#146;s board of directors or their affiliates and holders of more than 5% of Tempest&#146;s outstanding capital stock. The terms of these purchases were the same for all purchasers of Tempest&#146;s
Series&nbsp;B convertible preferred stock. Please refer to the section titled &#147;<I>Principal Stockholders of Tempest</I>&#148; for more details regarding the shares held by these entities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchased&nbsp;Shares<BR>of Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Venture Capital IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,135,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,135,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Venture Capital VI, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,032,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,032,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Side Fund IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LAV Regulus Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,056,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ERVC Healthcare IV, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">685,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">685,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A NAME="toc150774_95"></A>Promissory Note with Tom Dubensky </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest is party to a Full Recourse Promissory Note, dated as of November&nbsp;29, 2017 (the &#147;Dubensky Note&#148;), with Thomas Dubensky,
Tempest&#146;s Chief Executive Officer, who will serve as the President of the combined company following the merger. The Dubensky Note was issued in connection with a loan from Tempest to Dr.&nbsp;Dubensky in the amount of $259,341. The Dubensky
Note bears interest at a rate of 2% per year. As of December&nbsp;31, 2020, Dr.&nbsp;Dubensky owes Tempest $226,707 in principal and interest under the Dubensky Note. No amounts have been paid under the Dubensky Note to date, but Dr.&nbsp;Dubensky
will pay off the Dubensky Note in full prior to the consummation of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investor Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, Tempest entered into an amended and restated investor rights agreement (the &#147;IRA&#148;) with certain holders of its
preferred stock and common stock, including certain holders of 5% of its capital stock, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including certain members of, and affiliates of, its directors and certain of its executive officers. The IRA provides the holders of Tempest&#146;s convertible preferred stock with certain
registration rights, including the right to demand that Tempest files a registration statement or request that their shares be covered by a registration statement that Tempest is otherwise filing. The IRA also provides certain major stockholders
with information rights, which will terminate upon the closing of the merger, and a right of first refusal with regard to certain issuances of Tempest&#146;s capital stock, which will also terminate upon the closing of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February
2018, Tempest entered into an amended and restated voting agreement (the &#147;Voting Agreement&#148;) with certain holders of its preferred stock and common stock, including certain holders of 5% of its capital stock, and including certain members
of, and affiliates of, its directors and certain of its executive officers. Pursuant to the Voting Agreement, certain holders of its preferred stock and common stock have agreed to vote their shares in favor of the election of certain directors and
specified transactions approved by the requisite supermajority of the shares of its voting capital stock held by investors party thereto. The Voting Agreement will terminate upon the closing of the merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, Tempest entered into an amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT>
agreement (the <FONT STYLE="white-space:nowrap">&#147;Co-Sale</FONT> Agreement&#148;) with certain holders of its preferred stock and common stock, including certain holders of 5% of its capital stock, and including certain members of, and
affiliates of, its directors and certain of its executive officers. Pursuant to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, Tempest has a right of first refusal in respect of certain sales of securities by certain holders of its
capital stock. To the extent Tempest does not exercise such right in full, certain holders of its preferred stock are granted certain rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sales. The <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement will terminate upon the closing of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A NAME="toc150774_96"></A>Equity Grants to
Executive Officers and Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has granted stock options to its executive officers and certain directors, as more fully
described in the sections titled &#147;<I>Tempest Executive</I> <I>Compensation</I>&#148; and &#147;<I>Management Following the <FONT STYLE="white-space:nowrap">Merger&#151;Non-Employee</FONT> Director Compensation,</I>&#148; respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A NAME="toc150774_97"></A>Director and Executive Officer Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the sections titled &#147;<I>Management Following the <FONT STYLE="white-space:nowrap">Merger&#151;Non-Employee</FONT> Director
Compensation</I>&#148; and &#147;<I>Tempest Executive</I> <I>Compensation</I>&#148; for information regarding the compensation of Tempest&#146;s directors and executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A NAME="toc150774_98"></A>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has entered into employment agreements with certain of its executive officers. For more information regarding these agreements, see the
section titled &#147;<I>Tempest Executive Compensation&#151;Employment Arrangements</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><A NAME="toc150774_99"></A>Indemnification
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the merger, the combined company intends to enter into new indemnification agreements with each of
the combined company&#146;s directors and executive officers. The indemnification agreements, Millendo&#146;s amended and restated certificate of incorporation and Millendo&#146;s amended and restated bylaws will require the combined company to
indemnify its directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, Millendo&#146;s amended and restated bylaws also require it to advance expenses incurred by the combined company&#146;s directors and
officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_100"></A>Millendo Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roche License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;16, 2018, Millendo entered into a license agreement with F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Inc. or collectively, Roche, for a worldwide,
exclusive license to Roche&#146;s interest in certain patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> covering, among other things, the use of a neurokinin 3 receptor antagonist, or the Roche License Agreement. Carole L.
Nuechterlein, who is currently a member of Millendo&#146;s board of directors and who was a member of Private Millendo&#146;s board of directors from March 2017 until the closing of the OvaScience Merger, serves as a Deputy Director and head of
Roche Venture Fund, an affiliate of Roche. Roche Finance Ltd, an affiliate of Roche, is a beneficial owner of 5% or more of Millendo capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the rights granted to Millendo under the Roche License Agreement, it agreed to pay Roche an <FONT
STYLE="white-space:nowrap">up-front</FONT> payment. Under the terms of the Roche License Agreement, Millendo is also obligated to make significant milestone and royalty payments in connection with the attainment of certain development steps and the
sale of resulting products with respect to the neurokinin <FONT STYLE="white-space:nowrap">3-receptor</FONT> (NK3R) antagonist. No amounts were paid in 2019 or 2020 related to the achievement of development or commercial milestones. In addition,
Millendo is required to share a portion of any net proceeds received in connection with certain agreements that it may enter into with third parties to develop and commercialize the NK3R antagonist. Due to Millendo&#146;s decision to discontinue
developing its <FONT STYLE="white-space:nowrap">MLE-301</FONT> program, in March 2021, Millendo notified Roche that it was terminating the Roche License Agreement effective three months from the date of such notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>E</I><B><I>mployment Arrangements</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has entered into employment agreements or offer letter agreements with certain of its executive officers. For more information
regarding these agreements with its named executive officers, see &#147;<I>Millendo Executive Compensation&#151;Employment, Severance and Change in Control Arrangements&#151;Employment Arrangements</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Grants to Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has granted stock options to certain of its directors and executive officers. For more information regarding the stock options and
stock awards granted to its directors and named executive officers, see &#147;<I>Millendo Executive Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Separation Pay
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has entered into separation pay agreements with certain of its executive officers. For more information
regarding these arrangements with its named executive officers, see &#147;<I>Millendo Executive Compensation&#151;Employment, Severance and Change in Control Arrangements&#151;Potential Payments Upon Termination or Change of Control</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>December 2019 Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
December 2019, Millendo sold 4,166,667 shares of its common stock to the public pursuant to an underwriting agreement with Citigroup Global Markets Inc. and SVB Leerink LLC, as representatives of the several underwriters named therein, for net
proceeds to Millendo of approximately $23.0&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses payable by Millendo. The price to the public in this offering was $6.00 per share and investors included
Great Point Partners, LLC and its affiliates and Roche. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has entered into indemnification agreements with each of its directors and executive officers. The indemnification agreements and its
amended and restated certificate of incorporation and amended and restated bylaws require Millendo to indemnify its directors and executive officers to the fullest extent permitted by Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2021, Millendo Therapeutics, Inc., a Delaware corporation (&#147;Millendo&#148;), Tempest Therapeutics, Inc., a Delaware
corporation (&#147;Tempest&#148;), and Mars Merger Sub, a Delaware corporation and a wholly-owned subsidiary of Millendo (&#147;Merger Sub&#148;) entered into an agreement and plan of merger (the &#147;Merger Agreement&#148;). Upon the terms and
subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, including approval of the transaction by Millendo&#146;s stockholders and Tempest&#146;s stockholders, Merger Sub will merge with and into Tempest, with
Tempest becoming a wholly-owned subsidiary of Millendo and the surviving corporation of the merger (the &#147;Merger&#148;). At the effective time of the Merger, or the Effective Time, Millendo will change its name to Tempest Therapeutics,&nbsp;Inc.
(&#147;Public Tempest&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger (&#147;Effective Time&#148;), each share of Tempest&#146;s common stock
outstanding immediately prior to the Effective Time, including shares of Tempest&#146;s common stock that are issued pursuant to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing will be converted into the right to receive a number
of shares of Millendo&#146;s common stock based on agreed upon ratio by the parties (&#147;the Exchange Ratio&#148;). The Exchange Ratio was initially estimated to be 0.488 shares of Millendo&#146;s common stock for each share of Tempest&#146;s
common stock, and is subject to change to account for, among other things, Millendo&#146;s net cash as of the business day prior to the closing (the &#147;Closing&#148;) of the Merger. The Exchange Ratio also does not give effect to the proposed
Millendo Reverse Stock Split (as defined below) because the proposed reverse stock split is a range and is not final. Each share of Tempest&#146;s convertible preferred stock outstanding immediately prior to the Effective Time is expected to be
converted into shares of Tempest&#146;s common stock in accordance with its terms, which would then convert into the right to receive shares of Millendo&#146;s common stock along with all other shares of Tempest&#146;s common stock as described
above. Under the Exchange Ratio formula in the Merger Agreement, the former Tempest equity holders immediately before the Effective Time are expected to own approximately 81.5% of the outstanding capital stock of Millendo on a fully-diluted basis,
and the stockholders of Millendo immediately before the Effective Time are expected to own approximately 18.5% of the outstanding capital stock of Millendo on a fully-diluted basis, subject to adjustment based upon whether Millendo&#146;s net cash
at the closing of the Merger is greater than $18.7&nbsp;million or less than $15.3&nbsp;million and other potential adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
reverse stock split of Millendo&#146;s common stock will be effectuated prior to the Closing at a ratio of between 1 to 10 and 1 to 15 (&#147;Millendo Reverse Stock Split&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because, among other things, the number of shares of Millendo&#146;s common stock issuable to Tempest&#146;s securityholders is determined
based on Millendo&#146;s net cash balance on the business day prior to the Closing and the capitalization of Tempest and Millendo at the Closing, Millendo&#146;s securityholders cannot be certain of the exact number of shares that will be issued to
(or reserved for issuance to) Tempest&#146;s securityholders when Millendo&#146;s stockholders vote on the proposals. The Exchange Ratio referenced above is an estimate only and the final Exchange Ratio will be determined pursuant to a formula
described in more detail in the Merger Agreement and in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of
the Merger Agreement, certain parties have entered into agreements with Tempest, pursuant to which they have agreed, subject to terms and conditions of such agreements, to purchase prior to the consummation of the Merger shares of Tempest common
stock for an aggregate purchase price of approximately $28.1&nbsp;million, net of issuance costs of $1.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
unaudited pro forma condensed combined financial information gives effect to the (i)&nbsp;Merger and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing, but does not give effect to the proposed Millendo Reverse Stock Split
because the proposed reverse stock split is a range and is not final. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the unaudited pro forma combined financial statements, the
Merger has been accounted for as a reverse recapitalization under U.S. GAAP because the assets of Millendo at the Effective Date are expected to be primarily cash and <FONT STYLE="white-space:nowrap">non-operating</FONT> assets. Tempest was
determined to be the accounting acquirer based upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of the Merger and other factors including: (1)&nbsp;Tempest stockholders will own a substantial majority of the voting rights of the combined company; (2)&nbsp;Tempest will designate a
majority (six of seven) of the initial members of the board of directors of the combined company; and (3)&nbsp;Tempest&#146;s senior management will hold all key positions in senior management of the combined company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of Tempest being treated as the accounting acquirer, Tempest&#146;s assets and liabilities will be recorded at their
precombination carrying amounts and the historical operations that are reflected in the unaudited pro forma condensed combined financial information will be those of Tempest. Millendo&#146;s assets and liabilities will be measured and recognized at
their fair values as of the effective date of the Merger, and combined with the assets, liabilities, and results of operations of Tempest after the consummation of the Merger. As a result, upon consummation of the Merger, the historical financial
statements of Tempest will become the historical consolidated financial statements of the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma
combined balance sheet data as of December&nbsp;31, 2020 assumes that the Merger took place on December&nbsp;31, 2020 and combines the Millendo and Tempest historical balance sheets as of December&nbsp;31, 2020. The unaudited pro forma condensed
combined statements of operations assumes that the Merger took place on January&nbsp;1, 2020 and combines the historical results of Millendo and Tempest for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical financial statements of Millendo and Tempest have been adjusted to give pro forma effect to reflect the accounting for the
transaction in accordance with U.S. GAAP. The adjustments presented on the unaudited pro forma condensed combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding of the
combined company upon consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is based on
assumptions and adjustments that are described in the accompanying notes. The unaudited pro forma condensed combined financial information is for illustrative purposes only. The financial results may have been different had the companies always been
combined. The unaudited pro forma condensed combined financial information should not be relied upon as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the
combined company will experience. The actual amounts recorded as of the completion of the Merger may differ materially from the information presented in these unaudited pro forma combined financial information as a result, if any, of the amount of
capital raised by Tempest between the signing of the Merger Agreement and Closing, the amount of cash used by Millendo&#146;s operations between the signing of the Merger Agreement and the Closing, the timing of Closing of the Merger, and other
changes in Millendo&#146;s assets and liabilities that occur prior to the completion of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed
combined financial statements, including the notes thereto, should be read in conjunction with the separate historical consolidated financial statements of Millendo and Tempest and the sections of this proxy statement/prospectus titled
&#147;<I>Millendo Management&#146;s Discussion and Analysis of Financial Condition and Results of</I> <I>Operations</I>&#148; and &#147;<I>Tempest Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148;
Both Millendo&#146;s historical audited consolidated financial statements for the year ended December&nbsp;31, 2020 and Tempest&#146;s historical audited financial statements for the year ended December&nbsp;31, 2020 appear elsewhere in this proxy
statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Condensed Combined Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tempest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Millendo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;Combined<BR>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,050</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,050</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>E</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LIABILITIES, CONVERTIBLE PREFERRED STOCK&nbsp;&amp; STOCKHOLDERS&#146; EQUITY (DEFICIT)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B,&nbsp;C,&nbsp;D</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early option exercise liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>F</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>G</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(245,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Condensed Combined Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tempest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Millendo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction&nbsp;Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>H,&nbsp;I,&nbsp;J</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(589</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(589</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,539,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,862,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>K</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,902,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.65</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Pro Forma Combined Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of the Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Merger </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;29,
2021, Millendo, Tempest and Merger Sub entered into the Merger Agreement. At the Effective Time of the Merger, each share of Tempest common stock outstanding immediately prior to the Effective Time, including shares of Tempest&#146;s convertible
preferred stock that is expected to be converted into common stock as described above, will be converted into the right to receive a number of shares of Millendo&#146;s common stock equal to the Exchange Ratio. The Exchange Ratio is initially
estimated to be 0.488 of Millendo&#146;s Common Stock for each share of Tempest&#146;s Common Stock. Under the Exchange Ratio formula in the Merger Agreement, the former Tempest equity holders immediately before the Effective Time are expected to
own approximately 81.5% of the outstanding capital stock of Millendo on a fully-diluted basis, and the stockholders of Millendo immediately before the Effective Time are expected to own approximately 18.5% of the outstanding capital stock of
Millendo on a fully-diluted basis, subject to adjustment based upon whether Millendo&#146;s net cash at the closing of the Merger is greater than $18.7&nbsp;million or less than $15.3&nbsp;million and other potential adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because, among other things, the number of shares of Millendo&#146;s common stock issuable to Tempest&#146;s securityholders is determined
based on Millendo&#146;s net cash balance on the business day prior to the Closing and the capitalization of Tempest and Millendo at the Closing, Millendo&#146;s securityholders cannot be certain of the exact number of shares that will be issued to
(or reserved for issuance to) Tempest&#146;s securityholders when Millendo&#146;s stockholders vote on the proposals at the Board Meeting. The Exchange Ratio referenced above is an estimate only and the final Exchange Ratio will be determined
pursuant to a formula described in detail in the Merger Agreement and in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as of the
Effective time, each Millendo stock option that is outstanding and unexercised immediately prior to the effective time of the Merger, will remain outstanding in accordance with its terms including certain Millendo stock options that will accelerate
and vest in accordance with its terms on Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Effective Time, each option to purchase shares of Tempest&#146;s common stock
(a &#147;Tempest Option&#148;) that is outstanding and unexercised immediately prior to the Effective Time granted under the Tempest 2011 and 2017 Equity Incentive Plans (&#147;Tempest Plan&#148;), or otherwise, whether or not vested, will be, along
with the Tempest Plan, assumed by Millendo and will become an option to purchase solely that number of shares of Millendo&#146;s common stock equal to the product obtained by multiplying (i)&nbsp;the number of shares of Tempest&#146;s common stock
that were subject to such Tempest Option immediately prior to the Effective Time by (ii)&nbsp;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Millendo&#146;s common stock. The per share exercise
price for Millendo&#146;s common stock issuable upon exercise of each Tempest Option assumed by Millendo shall be determined by dividing (a)&nbsp;the per share exercise price of Tempest&#146;s common stock subject to such Tempest Option, as in
effect immediately prior to the Effective Time, by (b)&nbsp;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Any restriction on the exercise of any Tempest Option assumed by Millendo will continue in full
force and effect and the term, exercisability, vesting schedule and other provisions of such Tempest Option shall otherwise remain unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, each warrant to purchase Tempest&#146;s common stock (&#147;Tempest Warrant&#148;) that is outstanding and unexercised
immediately prior to the Effective Time, whether or not vested, will be converted into and become a warrant to purchase (and Millendo shall assume each such Tempest Warrant in accordance with its terms) solely that number of shares of
Millendo&#146;s common stock equal to the product obtained by multiplying (i)&nbsp;the number of shares of Tempest Common Stock that were subject to such Tempest Warrant immediately prior to the Effective Time by (ii)&nbsp;the Exchange Ratio, and
rounding the resulting number down to the nearest whole number of shares of Millendo&#146;s common stock. The per share exercise price for Millendo&#146;s common stock issuable upon exercise of each Tempest Warrant assumed by Millendo shall be
determined by dividing (a)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per share exercise price of Tempest&#146;s common stock subject to such Millendo Warrant, as in effect immediately prior to the Effective Time, by (b)&nbsp;the Exchange Ratio, and rounding the
resulting exercise price up to the nearest whole cent. Any restriction on the exercise of any Tempest Warrant assumed by Millendo will continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such
Tempest Warrant shall otherwise remain unchanged. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into agreements with Tempest pursuant to
which they have agreed, subject to the terms and conditions of such agreements, to purchase prior to the consummation of the Merger shares of Tempest common stock for an aggregate purchase price of approximately $28.1&nbsp;million, net of issuance
costs of $1.9&nbsp;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement. Shares of Tempest common stock issued pursuant to this
financing transaction will be converted into shares of Millendo common stock in the Merger in accordance with the Exchange Ratio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of
Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro forma condensed combined financial information was prepared in accordance with Article 11
of <FONT STYLE="white-space:nowrap">SEC&nbsp;Regulation&nbsp;S-X.&nbsp;The&nbsp;unaudited</FONT> pro forma condensed combined balance sheet as of December&nbsp;31, 2020 was prepared using the historical balance sheets of Tempest and Millendo as of
December&nbsp;31, 2020 and gives effect to the Merger as if it occurred on December&nbsp;31, 2020. The unaudited pro forma combined statements of operations for the year ended December&nbsp;31, 2020 give effect to the Merger as if it occurred on
January&nbsp;1, 2020 and were prepared using the historical consolidated statement of operations and comprehensive income of Millendo and Tempest for the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, Tempest is considered to be the acquiring company and the Merger is expected to be accounted for as a reverse
recapitalization of Millendo by Tempest because on the Merger date, the <FONT STYLE="white-space:nowrap">pre-combination&nbsp;assets</FONT> of Millendo are expected to be primarily cash and other <FONT STYLE="white-space:nowrap">non-operating</FONT>
assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of these pro forma financial statements, this estimated purchase price consideration consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated number of shares of the combined company to be owned by Millendo
stockholders&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,043,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by the assumed price per share of Millendo common stock (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of shares of combined company to be owned by Millendo stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,709,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of assumed Millendo equity awards based on precombination
service&nbsp;(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of assumed Millendo warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,890,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the number of shares of common stock of the combined company that Millendo equity holders would own as
of the Closing pursuant to the Merger Agreement. This amount is calculated, for purposes of this unaudited pro forma condensed combined financial information, based on shares of Millendo&#146;s common stock outstanding as of April&nbsp;29, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the assumed price per share of Millendo common stock, which is the closing trading price of
Millendo&#146;s common stock on April&nbsp;29, 2021. The actual purchase price will fluctuate until the effective date </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the transaction. A 10% increase (decrease) to the Millendo share price would increase (decrease) the purchase price by $2.2&nbsp;million. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the estimated acquisition-date fair value of the assumed Millendo&#146;s equity awards attributable to
precombination service (which amount will be determined based on the closing trading price of Millendo common stock on April&nbsp;29, 2021, the number of Millendo equity awards outstanding on this date, and the period of service provided by the
holders of the awards prior to the Merger closing date in 2021). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase consideration for the net assets of
Millendo will be determined based on a net cash calculation prior to Closing and will be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">adjusted&nbsp;dollar-for-dollar&nbsp;by</FONT></FONT> the amount that the net cash amount is
greater than $18.7&nbsp;million or less than $15.3&nbsp;million. The actual purchase consideration will vary based on the net cash calculation prior to Closing, the Exchange Ratio, and Millendo share price at Closing as described above and that
difference could be material. As such, the estimated purchase consideration reflected in these unaudited pro forma condensed combined financial information does not purport to represent what the actual purchase consideration will be when the Merger
is completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under reverse recapitalization accounting, the assets and liabilities of Millendo will be recorded, as of the completion of
the Merger, at their fair value. No goodwill or intangible assets are expected to be recognized and any excess consideration transferred over the fair value of the net assets of Millendo following determination of the actual purchase consideration
for Millendo will be reflected as a reduction to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. Consequently, the financial statements of Tempest reflect the operations of the acquirer for accounting purposes together with a
deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. The accompanying unaudited proforma condensed combined financial information
is derived from the historical financial statements of Millendo and Tempest, and include adjustments to give pro forma effect to reflect the accounting for the transaction in accordance with U.S. GAAP. The historical financial statements of Tempest
shall become the historical financial statements of the combined company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial
information does not include the impact of any revenue, cost or other operating synergies that may result from the Merger or any related restructuring costs that may be contemplated and does not give effect to the proposed Millendo Reverse Stock
Split because the proposed reverse stock split is a range, is not definitive and is subject to approval by Millendo&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent there are significant changes to the business following completion of the Merger, the assumptions and estimates set forth in the
unaudited pro forma condensed consolidated financial information could change significantly. Accordingly, the pro forma adjustments are subject to further adjustments as additional information becomes available and as additional analyses are
conducted following the completion of the Merger. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Shares of Millendo Common Stock Issued to Tempest Stockholders upon Closing of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, all outstanding shares of Tempest&#146;s convertible preferred stock are expected to be converted into Tempest common
stock, which will be exchanged for shares of Millendo common stock based on the Exchange Ratio determined in accordance with the Merger Agreement. The estimated Exchange Ratio for purposes of the unaudited pro forma condensed combined financial
information was derived on a fully-diluted basis as of April&nbsp;29, 2021 using a stipulated value of Tempest of approximately $158.4&nbsp;million (including the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing discussed above) and of
Millendo of approximately $36.0&nbsp;million. The estimated number of shares of common stock that Millendo expects to issue to Tempest&#146;s common and preferred stockholders as of April&nbsp;29, 2021 (ignoring rounding of fractional shares) is
determined as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Tempest&#146;s common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,769,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Tempest&#146;s convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,686,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,456,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated shares of Millendo common stock expected to be issued to Tempest stockholders upon
Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,230,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the reverse stock split is a range and is not definitive and will occur immediately prior to the
consummation of the Merger, the Exchange Ratio and estimated shares of Millendo&#146;s common stock issued to Tempest&#146;s security holders have not been adjusted to give retrospective effect to the reverse stock split.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Proforma Adjustments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X&nbsp;as</FONT> amended by the final rule, Release
<FONT STYLE="white-space:nowrap">No.&nbsp;33-10786&nbsp;&#147;Amendments</FONT> to Financial Disclosures about Acquired and Disposed Businesses.&#148; Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786&nbsp;replaces</FONT> the existing pro
forma adjustment criteria with simplified requirements to depict the accounting for the transaction (&#147;Transaction Accounting Adjustments&#148;) and present the reasonably estimable synergies and other transaction effects that have occurred or
are reasonably expected to occur (&#147;Management&#146;s Adjustments&#148;). Millendo has elected not to present Management&#146;s Adjustments and will only be presenting Transaction Accounting Adjustments in the following unaudited pro forma
condensed combined financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on Tempest management&#146;s review of Millendo&#146;s summary of significant accounting
policies, the nature and amount of any adjustments to the historical financial statements of Millendo to conform to the accounting policies of Tempest are not expected to be significant. The pro forma adjustments, based on preliminary estimates that
could change materially as additional information is obtained, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect $28.1&nbsp;million, net of issuance costs of $1.9&nbsp;million, in proceeds to be received by
Tempest, in connection with the consummation the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing. The Merger is contingent upon the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing, which is expected to close concurrent
with the Merger, at or prior to the Closing. If the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing does not close, Tempest and Millendo are not required to complete the Merger. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect preliminary estimated transaction costs of $3.3&nbsp;million in connection with the Merger, such as
adviser fees, legal, and accounting expenses that are expected to be incurred by Tempest as an increase in accrued liabilities and a reduction to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital in the unaudited proforma condensed
combined balance sheet. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect preliminary estimated transaction costs of $5.5&nbsp;million in connection with the Merger, such as
adviser fees, legal, directors and officers liability insurance, and accounting expenses, that are expected to be incurred by Millendo as an increase in accrued liabilities and accumulated deficit in the unaudited proforma condensed combined balance
sheet. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Compensation expense of $2.2&nbsp;million related to severance, retention and transaction bonuses resulting
from preexisting employment agreements that will be payable in connection with the Merger is reflected as an increase to accumulated deficit and accrued liabilities in the unaudited pro forma condensed combined balance sheet. The pro forma
adjustments exclude certain termination benefits incurred in connection with Millendo&#146;s January 2021 corporate restructuring plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the adjustments to account for operating lease liabilities and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets at their fair values as of December&nbsp;31, 2020 in the unaudited pro forma condensed combined balance sheet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the conversion of 114,686,731 shares of Tempest&#146;s convertible preferred stock into shares of
Tempest&#146;s common stock immediately prior to the Merger. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record (i)&nbsp;the conversion of Tempest&#146;s convertible preferred stock into 114,686,731 shares of
common stock, (ii)&nbsp;issuance of 35,258,582 shares in connection with the consummation the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing (iii)&nbsp;the accrual of transaction costs associated with the Merger, (iv)&nbsp;the payment
of severance and retention bonuses in connection with the Merger, (v)&nbsp;post combination compensation expense of $0.3&nbsp;million related to Millendo options recognized upon the Closing, (vi)&nbsp;the elimination of Millendo&#146;s historical
equity, including 18,999,701 outstanding shares of common stock at their par value of $0.001&nbsp;million, $0.4&nbsp;million of accumulated other comprehensive income and $277.7&nbsp;million additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital, (vii)&nbsp;the exchange of outstanding Tempest&#146;s common stock into 81,230,783 shares of Millendo&#146;s common stock based on the assumed Exchange Ratio for purposes of these pro forma condensed combined financial information, and
(viii)&nbsp;the effect of the reverse recapitalization of Millendo for a total of $33.1&nbsp;million, which is the net assets of Millendo as of December&nbsp;31, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(amounts in thousands, except<BR>share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Paid-In-</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acccumulated</B><br><B>other<BR>comprehensive</B><br><B>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tempest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Millendo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of outstanding Tempest&#146;s convertible preferred stock into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,686,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of D&amp;O insurance tail</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment of severance and retention bonuses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Post combination stock-based compensation costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of Millendo&#146;s historical equity carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,043,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(277,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange of outstanding Tempest&#146;s common stock into Millendo&#146;s common stock based on the
assumed Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,456,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,230,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reverse recapitalization of Millendo</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,043,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pre-Closing Financing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,258,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value remeasurement of right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,511,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,230,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">H.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The preliminary estimated transaction cost of $5.5&nbsp;million in connection with the Merger, such as adviser
fees, legal, directors&#146; and officers&#146; liability insurance, and accounting expenses that are expected to be incurred by Millendo are reflected as if incurred on January&nbsp;1, 2020, the date the Merger occurred for the purposes of the
unaudited pro forma condensed combined statement of operations. This is a <FONT STYLE="white-space:nowrap">non-recurring</FONT> item. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Compensation expense of $2.2&nbsp;million related to severance, retention and transaction bonuses resulting
from preexisting employment agreements that will be payable in connection with the Merger is reflected as if incurred on January&nbsp;1, 2020, the date the Merger occurred for the purposes of the unaudited pro forma condensed combined statement of
operations. This is a <FONT STYLE="white-space:nowrap">non-recurring</FONT> item. The pro forma adjustments exclude certain termination benefits incurred in connection with Millendo&#146;s January 2021 corporate restructuring plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">J.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the post combination compensation expense of $0.3&nbsp;million related to Millendo&#146;s options
recognized upon the Closing for the purposes of the unaudited pro forma condensed combined statement of operations. This is a <FONT STYLE="white-space:nowrap">non-recurring</FONT> item. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">K.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net
loss for the year ended December&nbsp;31, 2020. In addition, the weighted average shares outstanding for the period have been adjusted to give effect to the issuance of Millendo&#146;s common stock in connection with the Merger as of April&nbsp;29,
2021. As the combined company is in a net loss position, any adjustment for potentially dilutive shares would be anti-dilutive, and as such basic and diluted loss per share are the same. The following table presents the calculation of the pro forma
weighted average number of common stock outstanding without giving effect to the proposed reverse stock split: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average Tempest shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,539,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of Tempest redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,169,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued upon <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,258,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,967,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average Tempest shares outstanding adjusted for the Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,040,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average Millendo shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,862,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma combined weighted average number of shares of common stock&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,902,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Milendo common stock is currently listed on The Nasdaq Capital Market under the symbol &#147;MLND.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of the Millendo common stock on March&nbsp;26, 2021, the last day of trading prior to the announcement of the Merger, as
reported on The Nasdaq Capital Market, was $2.18 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the market price of the Millendo common stock is subject to
fluctuation, the market value of the shares of the Millendo common stock that Merger Partner stockholders will be entitled to receive in the Merger may increase or decrease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming approval of Proposal Nos. 1, 2 and 3 and successful application for initial listing with The Nasdaq Capital Market, following the
consummation of the merger, the Millendo common stock will trade on The Nasdaq Capital Market under Millendo&#146;s new name, &#147;Tempest Therapeutics, Inc.,&#148; and new trading symbol &#147;TPST.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;7, 2021, the Record Date for the Special Meeting, there were approximately 76 registered holders of record of the Millendo
common stock. As of May&nbsp;7, Tempest had 79 holders of record of Tempest common stock and 10 holders of record of Tempest Preferred Stock. For detailed information regarding the beneficial ownership of certain Millendo and Tempest stockholders,
see the sections of this proxy statement/prospectus titled &#147;<I>Principal Stockholders of Millendo</I>&#148; and &#147;<I>Principal Stockholders of Tempest</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has never declared or
paid any cash dividends on the Millendo common stock and does not anticipate paying cash dividends on the Millendo common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the
merger will be at the discretion of the combined organization&#146;s then-current board of directors and will depend upon a number of factors, including the combined organization&#146;s results of operations, financial condition, future prospects,
contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. Tempest has never paid or declared any cash dividends on the Tempest capital stock. If the merger does not occur,
Tempest does not anticipate paying any cash dividends on the Tempest capital stock in the foreseeable future, and Tempest intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future
determination to pay dividends will be at the discretion of the Tempest board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and
restrictions imposed by applicable laws and other factors the Tempest board of directors deems relevant. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF MILLENDO
CAPITAL STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of Millendo capital stock and provisions of Millendo&#146;s restated certificate of
incorporation and amended and restated bylaws are summaries and are qualified by reference to such restated certificate of incorporation and amended and restated bylaws and applicable provisions of Delaware corporate law. Millendo has filed copies
of these documents with the SEC as exhibits to its periodic filings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s authorized capital stock consists of 100,000,000 shares of Millendo common stock, par value $0.001 per share, and 5,000,000
shares of Millendo preferred stock, par value $0.001 per share, all of which preferred stock is undesignated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Millendo common stock are entitled to one vote for each share held on all matters submitted to a vote of Millendo stockholders and
do not have cumulative voting rights. Each election of directors by Millendo stockholders will be determined by a plurality of the votes cast by Millendo stockholders entitled to vote on the election. Holders of Millendo common stock are entitled to
receive any dividends as may be declared by the Millendo board of directors, subject to any preferential dividend or other rights of any then outstanding preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of Millendo&#146;s liquidation or dissolution, the holders of Millendo common stock are entitled to receive all assets available
for distribution to Millendo stockholders after the payment of all debts and other liabilities and subject to the prior rights of any then outstanding Millendo preferred stock. Holders of Millendo common stock have no
<FONT STYLE="white-space:nowrap">pre-emptive,</FONT> subscription, redemption or conversion rights. The rights, preferences and privileges of holders of Millendo common stock are subject to and may be adversely affected by the rights of the holders
of shares of any series of Millendo preferred stock that Millendo may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of Millendo&#146;s restated certificate of incorporation, the Millendo board of directors is authorized to issue shares of
preferred stock in one or more series without stockholder approval by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General
Corporation Law of the State of Delaware. The Millendo board of directors has the discretion to determine the designations, rights, preferences, privileges and restrictions, including voting powers (full or limited), dividend rights, conversion
rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of authorizing the Millendo
board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of Millendo outstanding
voting stock. As of the date of this proxy statement/prospectus, there are no shares of preferred stock outstanding, and Millendo has no present plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021,
Millendo had (i)&nbsp;outstanding warrants to purchase an aggregate of 17,125 shares of Millendo common stock, at a weighted average exercise price of $16.93 per share and (ii)&nbsp;outstanding warrants to purchase an aggregate of 48,265 shares of
Millendo common stock, at a weighted average exercise price of $7.50 per share.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">These warrants provide for adjustments in the event of
specified reclassifications, stock dividends, stock splits or other changes in Millendo&#146;s corporate structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2021, Millendo had outstanding options to purchase an aggregate of 3,520,359 shares of Millendo common stock, at a
weighted average exercise price of $11.28 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPARISON OF RIGHTS OF HOLDERS OF MILLENDO CAPITAL STOCK AND TEMPEST CAPITAL STOCK
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the merger is completed, Tempest stockholders will receive shares of Millendo common stock, pursuant to the terms of the Merger
Agreement. Immediately prior to the closing of the merger, Millendo&#146;s amended and restated certificate of incorporation will be amended to effect the reverse stock split, as set forth in the form of certificate of amendment attached as
<I>Annex</I><I></I><I>&nbsp;F</I> to this proxy statement/prospectus. In addition, after the completion of the merger, Millendo&#146;s amended and restated certificate of incorporation will be amended to change its corporate name to &#147;Tempest
Therapeutics, Inc.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo and Tempest are both incorporated under the laws of the State of Delaware. The rights of Millendo
stockholders and Tempest stockholders are generally governed by the DGCL. Upon completion of the merger, Tempest stockholders will become Millendo stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of
Millendo and the amended and restated certificate of incorporation of Millendo, as amended. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material differences between the
current rights of Tempest stockholders under the Tempest amended and restated certificate of incorporation and amended and restated bylaws and their rights as Millendo stockholders, after the merger, under the Millendo amended and restated
certificate of incorporation and the amended and restated bylaws, both as will be in effect immediately following the completion of the merger, are summarized below. The summary below does not purport to be complete and is subject to, and qualified
in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the
governing corporate instruments, for a more complete understanding of the differences between being a stockholder of Millendo or Tempest before the merger and being a stockholder of the combined company following the completion of the merger. For
more information on how to obtain these documents, see the section titled &#147;<I>Where You Can Find More Information</I>&#148; beginning on page&nbsp;321 of this proxy statement/prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><I>Organizational Documents</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The rights of Millendo stockholders are governed by Millendo&#146;s amended and restated certificate of incorporation, Millendo&#146;s amended and restated bylaws and the DGCL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The rights of Tempest stockholders are governed by Tempest&#146;s amended and restated certificate of incorporation, Tempest&#146;s amended and restated bylaws and the DGCL.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Authorized Capital Stock</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo is authorized to issue two classes of capital stock which are designated, respectively, &#147;common stock&#148; and &#147;preferred stock.&#148; The total number of shares that Millendo is authorized to issue is
105,000,000, of which 100,000,000 shares are common stock, par value $0.001 per share, and 5,000,000 shares are preferred stock, par value $0.001 per share. The number of authorized shares of Millendo preferred stock may be increased or decreased
(but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the
provisions of Section&nbsp;242(b)(2)&nbsp;of the General Corporation Law of the State of Delaware. The number of authorized shares of</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tempest is authorized to issue two classes of capital stock which are designated, respectively, &#147;common stock&#148; and &#147;preferred stock.&#148; The total number of shares that Tempest is authorized to issue is 331,936,731,
of which 196,000,000 shares are common stock, par value $0.001 per share, and 135,936,731 shares are preferred stock, par value $0.001 per share. The number of authorized shares of Tempest preferred stock may be increased or decreased (but not below
the number of shares thereof then outstanding) by the affirmative vote of holders of the capital stock, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Tempest
preferred stock. The number of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of common stock entitled to vote, subject to the provisions of
Section&nbsp;242(b)(2) of the DGCL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of capital stock, irrespective of the provisions of
Section&nbsp;242(b)(2) of the DGCL.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Common Stock</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo&#146;s authorized common stock consists of 100,000,000 shares of common stock.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Millendo common stock is entitled to one vote for each such
share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tempest&#146;s authorized common stock consists of 196,000,000 shares of common stock.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Tempest common stock is entitled to one vote for each such
share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Preferred Stock</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo&#146;s authorized preferred stock consists of 5,000,000 shares of preferred stock. No shares of Millendo preferred stock are currently outstanding.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tempest&#146;s authorized preferred stock consists of 135,936,731 shares of preferred stock, 17,000,000 of which is designated &#147;Series&nbsp;A Preferred Stock,&#148; 25,186,738 of which is designated &#147;Series B Preferred
Stock&#148; and 93,749,993 of which is designated &#147;Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock.&#148; 21,250,000 shares of Tempest preferred stock are currently outstanding.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Number and Qualification of Directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Millendo board of directors consists of one or more members, and the number of directors is fixed from time to time by resolution of the Millendo board of directors. The Millendo board of directors currently consists of eight
members. No decrease in the authorized number of directors constituting the Millendo board of directors will shorten the term of any incumbent director. Directors of Millendo need not be stockholders of Millendo.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Tempest board of directors consists of one or more members, and the number of directors is fixed from time to time by resolution of the Tempest board of directors. The Tempest board of directors currently consists of seven
members. No decrease in the authorized number of directors constituting the Tempest board of directors will shorten the term of any incumbent director. Directors of Tempest need not be stockholders of Tempest.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Structure of Board of Directors; Term of Directors; Election of Directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other than any directors elected by the separate vote of the holders of any series of Millendo preferred stock, the Millendo board of directors is divided into three classes, designated as Class&nbsp;I, Class&nbsp;II and
Class&nbsp;III, respectively. Directors are assigned to each class in accordance with a resolution or resolutions adopted by the Millendo board of directors. At the first annual meeting of stockholders following the effectiveness of Millendo&#146;s
initial public offering, the term of office of the Class&nbsp;I directors expired and Class&nbsp;I directors were elected for a full term of three years. At the second annual meeting of stockholders following Millendo&#146;s initial public offering,
the term of office of the Class&nbsp;II directors expired and Class&nbsp;II directors were elected for</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As long as 2,000,000 shares of Series A Preferred Stock remain outstanding, the holders of Series A Preferred Stock, voting as a separate class, are entitled to elect one director of the Tempest board of directors. As long as
2,000,000 shares of Series B Preferred Stock remain outstanding, the holders of record of shares of Series B Preferred Stock, voting as a separate class, are entitled to elect four directors of the Tempest board of directors. The holders of record
of shares of Common Stock, as a separate class, are entitled to elect one director of the Tempest board of directors. If the holders of shares of Series&nbsp;A Preferred Stock, Series B Preferred Stock or Common Stock, as the case may be, fail to
elect a</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a full term of three years. At the third annual meeting of stockholders following Millendo&#146;s initial public offering, the term of office of the Class&nbsp;III directors expired and Class&nbsp;III directors were elected for a
full term of three years. At each succeeding annual meeting of stockholders, directors are elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Series&nbsp;A Preferred Stock,
Series B Preferred Stock or Common Stock, as the case may be, elect a person to fill such directorship. Directors are elected at each annual meeting of stockholders. Each director holds office until such director&#146;s successor is elected and
qualified or until such director&#146;s death, resignation or removal.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Removal of Directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subject to the special rights of the holders of one or more series of Millendo preferred stock to elect directors, or except as otherwise provided by the DGCL, the Millendo board of directors or any individual director may be
removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least sevety-five percent (75%) of the voting power of all the then outstanding shares of voting stock of Millendo entitled to vote at an
election of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the special rights of the holders of one or more series of Tempest preferred stock to elect directors, or except as otherwise provided by the DGCL or the Tempest amended and restated certificate of incorporation, the
Tempest board of directors or any individual director may be removed from office at any time, with or without cause by the holders of a majority of the shares entitled to vote at an election of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Vacancies on the Board of Directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice in writing or electronic transmission to Millendo&#146;s Chairman of the Board, the Chief
Executive Officer, the President or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one or more directors resigns from the Millendo board of directors, effective at a
future date, a majority of the directors then in office, including those who have so resigned, will have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations will become effective, and
each director so chosen will hold office for the unexpired portion of the term of the director whose place will be vacated and until his successor is duly elected and qualified.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to any limitations imposed by applicable law and subject to the rights of the
holders of any series of Millendo preferred stock, any vacancies resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, will, unless
the Millendo board of directors determines by resolution that any such vacancies or newly created</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice in writing or electronic transmission to Tempest&#146;s Secretary. Such resignation will
specify whether it will be effective at a particular time. If no such specification is made, the Secretary, in his or her discretion, may either require confirmation from the director prior to deeming the resignation effective, in which case the
resignation will be deemed effective upon receipt of such confirmation, or deem the resignation effective at the time of delivery of the resignation to the Secretary.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one or more directors resigns from the Tempest board of directors, effective at a future date, a majority of the directors then in office, including those
who have so resigned, will have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations will become effective, and each director so chosen will hold office for the unexpired portion of the
term of the director whose place will be vacated and until his successor is duly elected and qualified.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Tempest preferred stock, any vacancies resulting
from death, resignation, disqualification, removal or</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">directorships will be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a sole
remaining director, and not by the stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such
director&#146;s successor is elected and qualified.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">other causes and any newly created directorships resulting from any increase in the number of directors, will, unless the Tempest board of directors determines by resolution that any such vacancies or newly created directorships
will be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum, and not by the stockholders. Any director
elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor is elected and qualified.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Stockholder Action by Written Consent</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No action may be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with Millendo&#146;s amended and restated bylaws, and no action may be taken by the stockholders by written
consent or by electronic transmission.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Action may be taken by the stockholders at an annual or special meeting of stockholders called in accordance with Tempest&#146;s amended and restated bylaws, or by the written consent or electronic transmission of the Tempest
stockholders entitled to vote thereon.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Quorum</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless otherwise provided by law, Millendo&#146;s amended and restated certificate of incorporation, or Millendo&#146;s amended and restated bylaws, at each meeting of stockholders the holders of a majority of the shares of stock
entitled to vote at the meeting, present in person, by remote communication, if applicable, or represented by proxy, will constitute a quorum for the transaction of business. If a quorum fails to attend any meeting, the chairperson of the meeting or
the holders of a majority of the shares entitled to vote who are present, in person, by remote communication, if applicable, or by proxy, at the meeting may adjourn or recess the meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unless otherwise provided by law, Tempest&#146;s amended and restated certificate of incorporation, or Tempest&#146;s amended and restated bylaws, at each meeting of stockholders the holders of a majority of the shares of stock
entitled to vote at the meeting, present in person, by remote communication, if applicable, or represented by proxy, will constitute a quorum for the transaction of business. If a quorum fails to attend any meeting, the chairperson of the meeting or
the holders of a majority of the shares entitled to vote who are present, in person, by remote communication, if applicable, or by proxy, at the meeting may adjourn or recess the meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Special Meetings of Stockholders</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Special meetings of stockholders for any purpose or purposes may be called at any time by the board of directors, the Chairperson of the Millendo board of directors, or the Chief Executive Officer.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Special meetings of stockholders for any purpose or purposes may be called at any time by the Chairperson of the Tempest board of directors, the Chief Executive Officer, the President, the Secretary or any two directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Millendo board of directors will determine the time and place, if any, of such special meeting. Special meetings may not be called by any other person or persons.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Tempest board of directors will determine the time and place, if any, of such special meeting. Special meetings may not be called by any other person or persons.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Notice of Stockholder Meetings</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of all meetings of stockholders is to be given in writing or by electronic transmission in the manner provided by law and Millendo&#146;s amended and restated bylaws, stating the place, if any, date and hour, of the meeting
and, in the case of a special meeting, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. Unless
otherwise required by applicable law, such notice is to be given not less than ten nor more than 60&nbsp;days before the date of the meeting to each stockholder of record entitled to vote at such meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notice of all meetings of stockholders is to be given in writing or by electronic transmission in the manner provided by law and Tempest&#146;s amended and restated bylaws, stating the place, if any, date and hour, of the meeting
and, in the case of a special meeting, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. Unless
otherwise required by applicable law or Tempest&#146;s amended and restated certificate of incorporation, such notice is to be given not less than ten nor more than 60&nbsp;days before the date of the meeting to each stockholder of record entitled
to vote at such meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Advance Notice Requirements for Stockholder Proposals</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nominations of persons for election to the Millendo board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders
only&nbsp;&nbsp;&nbsp;&nbsp;(i) pursuant to Millendo&#146;s notice of such meeting, (ii)&nbsp;by or at the direction of the Millendo board of directors or (iii)&nbsp;by any stockholder of Millendo who is a stockholder of record at the time the
written notice provided is delivered to the Secretary of Millendo, who is entitled to vote at the meeting and who complies with the notice procedures set forth in Millendo&#146;s amended and restated bylaws. For the avoidance of doubt, the foregoing
clause&nbsp;(iii) is the exclusive means for a stockholder to make director nominations and submit other business before an annual meeting of stockholders.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nominations of persons for election to the Tempest board of directors and the proposal of business other than nominations to be considered by the stockholders may be made at an annual meeting of stockholders only (i)&nbsp;pursuant
to Tempest&#146;s notice of such meeting, (ii)&nbsp;by or at the direction of the Tempest board of directors or (iii)&nbsp;by any stockholder of Tempest who is a stockholder of record at the time the notice provided is delivered to the Secretary of
Tempest, who is entitled to vote at the meeting and who complies with the notice procedures set forth in Tempest&#146;s amended and restated bylaws.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Amendment of Certificate of Incorporation</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of holders of at least seventy-five percent (75%) of the voting power of all of the then outstanding shares of voting
stock, voting as a single class, will be required to amend certain provisions of Millendo&#146;s amended and restated certificate of incorporation, including provisions relating to the size of the board, removal of directors, actions by written
consent, forum selection and indemnification of directors, officers and agents of Millendo.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of Millendo&#146;s amended and restated certificate of incorporation, Millendo&#146;s amended and restated bylaws, or any
provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend Millendo&#146;s amended and restated certificate of incorporation pursuant to Section&nbsp;242 of the DGCL.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of holders of at least a majority of the then-outstanding shares of voting stock will be required to amend certain
provisions of Tempest&#146;s amended and restated certificate of incorporation, including provisions relating to the size of the board and authorizing the creation of additional series of capital stock.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of Tempest&#146;s amended and restated certificate
of incorporation, Tempest&#146;s amended and restated bylaws, or any provision of law which might otherwise permit a lesser vote or no vote, stockholders may vote to amend Tempest&#146;s amended and restated certificate of incorporation pursuant to
Section&nbsp;242 of the DGCL.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Amendment of Bylaws</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The affirmative vote of holders of at least seventy-five percent (75%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal Millendo&#146;s amended and
restated bylaws. The Millendo board of directors also has the power to adopt, amend or repeal Millendo&#146;s amended and restated bylaws by the approval of a majority of the authorized number of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of holders of at least a majority of the voting power of all of the then outstanding voting capital stock is required to amend or repeal certain provisions of Tempest&#146;s amended and restated bylaws. The
Tempest board of directors also has the power to adopt, amend or repeal Tempest&#146;s amended and restated bylaws by the approval of a majority of the authorized number of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Limitation on Director Liability</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The liability of the Millendo directors for monetary damages is and will be eliminated to the fullest extent under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the
personal liability of directors, then the liability of a director to Millendo will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The liability of the Tempest directors for monetary damages is and will be eliminated to the fullest extent under applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the
personal liability of directors, then the liability of a director to Tempest will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Indemnification</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To the fullest extent permitted by applicable law, Millendo is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of Millendo (and any other persons to which applicable law
permits Millendo to provide indemnification) through provisions of Millendo&#146;s amended and restated bylaws, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the
indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Millendo
will be eliminated or limited to the fullest extent permitted by applicable law as so amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To the fullest extent permitted by applicable law, Tempest is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of Tempest (and any other persons to which applicable law permits
Tempest to provide indemnification) through provisions of Tempest&#146;s amended and restated bylaws, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and
advancement otherwise permitted by such applicable law. If applicable law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to Tempest will be eliminated or
limited to the fullest extent permitted by applicable law as so amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Conversion Rights</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo does not have any outstanding shares of preferred stock.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tempest&#146;s amended and restated certificate of incorporation provides that holders of Tempest preferred stock have the right to convert such shares into shares of common stock at any time at a conversion rate in accordance with
the terms of Tempest&#146;s amended and restated certificate of incorporation.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Right of First Refusal</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo does not have a right of first refusal in place.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Any stockholder wishing to transfer any shares of Tempest Common Stock must first provide Tempest with the right to purchase such shares. In such an event, if Tempest does not elect to exercise its right of first refusal in full,
any major investor has a right of first refusal with respect to certain sales of equity securities as defined in the Investor Rights Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Right of <FONT STYLE="white-space:nowrap">Co-Sale</FONT></I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo does not have a right of <FONT STYLE="white-space:nowrap">co-sale</FONT> in place.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tempest does not have a right of <FONT STYLE="white-space:nowrap">co-sale</FONT> in place.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Preemptive Rights</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo stockholders do not have preemptive rights. Thus, if additional shares of Millendo common stock are issued, the current holders of Millendo common stock will own a proportionately smaller interest in a larger number of
outstanding shares of common stock to the extent that they do not participate in the additional issuance.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Amended and Restated Investor Rights Agreement, dated July&nbsp;3, 2019, or the IRA, if Tempest proposes to offer or sell new equity securities, Tempest shall first offer such securities to certain holders of
preferred stock of Tempest, or the Tempest Major Investors. Each of the Tempest Major Investors will then have the right to purchase securities in such new offering equal to the proportion of the ownership interest of such Tempest Major Investor
prior to such offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Distributions to Stockholders</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dividends upon Millendo capital stock, subject to the provisions of Millendo&#146;s amended and restated certificate of incorporation and applicable law, if any, may be declared by the Millendo board of directors pursuant to law at
any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of Millendo&#146;s amended and restated certificate of incorporation and applicable law. The Millendo board of
directors may fix a record date for the determination of holders of Millendo common stock entitled to receive payment of a dividend or distribution declared thereon, which record date is to be not to precede the date upon which the resolution fixing
the record date is adopted, and which record date may not be more than 60&nbsp;days prior to the date fixed for the payment thereof.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dividends upon Tempest capital stock, subject to the provisions of Tempest&#146;s amended and restated certificate of incorporation and applicable law, if any, may be declared by the Tempest board of directors pursuant to law at any
regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of Tempest&#146;s amended and restated certificate of incorporation and applicable law. The Tempest board of
directors may fix a record date for the determination of holders of Tempest common stock entitled to receive payment of a dividend or distribution declared thereon, which record date is to be not to precede the date upon which the resolution fixing
the record date is adopted, and which record date may not be more than 60&nbsp;days prior to the date fixed for the payment thereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Exclusive Forum</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless Millendo consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware, to the fullest extent permitted by law, will be the sole and exclusive forum for (i)&nbsp;any derivative
action or proceeding brought on behalf of Millendo;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unless Tempest consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of
Tempest; (ii)&nbsp;any action</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Millendo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tempest</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Millendo to Millendo or Millendo stockholders; (iii)&nbsp;any action asserting a claim against Millendo arising
pursuant to any provision of the DGCL, Millendo&#146;s amended and restated certificate of incorporation or Millendo&#146;s amended and restated bylaws; or (iv)&nbsp;any action asserting a claim against Millendo governed by the internal affairs
doctrine.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Tempest to Tempest or Tempest stockholders; (iii)&nbsp;any action asserting a claim against Tempest arising pursuant to any provision
of the DGCL, Tempest&#146;s amended and restated certificate of incorporation or Tempest&#146;s amended and restated bylaws; or (iv)&nbsp;any action asserting a claim against Tempest governed by the internal affairs doctrine.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Registration Rights</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Millendo does not have registration rights in place.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under the IRA, certain holders of Tempest preferred stock that are party to the IRA, have certain registration rights, including the right to demand that Tempest file a registration statement, so called &#147;demand&#148;
registration rights, or request that their shares be covered by a registration statement that Tempest is otherwise filing, <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;piggyback&#148; registration rights.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Stock Transfer Restrictions Applicable to Stockholders</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shares of Millendo are transferable in the manner prescribed by the DGCL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of Tempest are transferable in the manner prescribed by the DGCL.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_101"></A>PRINCIPAL STOCKHOLDERS OF MILLENDO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to
the proposed reverse stock split. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth certain information with respect to the
beneficial ownership of Millendo common stock at March&nbsp;31, 2021<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by Millendo to beneficially own more than 5% of
Millendo&#146;s common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of Millendo&#146;s named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of Millendo&#146;s directors as of December 31, 2020; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of Millendo&#146;s executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership prior to the completion of the merger is based on 19,043,034 shares of Millendo common stock outstanding as of
March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has determined beneficial ownership in accordance with the rules of the SEC. These rules generally
attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, these rules require that Millendo includes shares of common stock issuable pursuant to
the vesting of restricted stock units and the exercise of stock options and warrants that are either immediately exercisable or exercisable within 60 days of March&nbsp;31, 2021. These shares are deemed to be outstanding and beneficially owned by
the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise
indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for persons listed in the table is c/o Millendo Therapeutics, Inc., 110 Miller Avenue, Suite 100,
Ann Arbor, Michigan 48104. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Name of Beneficial Owner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Number of<BR>Shares<BR>Beneficially<BR>Owned</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Percentage<BR>of Shares<BR>Beneficially<BR>Owned (%)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or greater stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with New Enterprise Associates (1)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o New Enterprise Associates, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1954 Greenspring Drive, Suite 600</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timonium, MD 21093</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,766,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ikarian Capital, LLC (2)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Crescent Court, Suite 1620</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dallas, TX 75201</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,348,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roche Finance Ltd (3)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grenzacherstrasse 122 4070</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basel, Switzerland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,089,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fonds InnoBio FPCI (4)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">27-31</FONT> Avenue du G&eacute;n&eacute;ral Leclerc</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">94700 Maisons-Alfort, France</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attention: Bpifrance Investissement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,078,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Name of Beneficial Owner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Number of<BR>Shares<BR>Beneficially<BR>Owned</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Percentage<BR>of Shares<BR>Beneficially<BR>Owned (%)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named executive officers and directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia C. Owens, Ph.D. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">799,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Arcudi, III (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christophe Arbet-Engels (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D. (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James M. Hindman (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Lynne Hedley, Ph.D. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Howe, III, M.D. (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carole L. Nuechterlein, J.D. (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Habib J. Dable (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geoff Nichol, M.B., Ch.B., M.B.A. (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and all directors as of December 31, 2020 as a group (10 persons)
(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,204,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 372 shares held by NEA Ventures 2015, L.P. (&#147;NEA Ventures&#148;) and (ii) 1,766,407 shares
held by New Enterprise Associates 15, L.P. (&#147;NEA 15&#148;). The shares directly held by NEA 15 are indirectly held by each of (a)&nbsp;NEA Partners 15, L.P. (&#147;NEA Partners 15&#148;), the sole general partner of NEA 15, (b) NEA 15 GP, LLC
(&#147;NEA 15 LLC&#148;), the sole general partner of NEA Partners 15, and (c)&nbsp;each of the individual Managers of NEA 15 LLC. The individual managers of NEA 15 LLC (collectively, the &#147;NEA 15 Managers&#148;) are Forest Baskett, Anthony A.
Florence, Jr., Joshua Makower, Scott D. Sandell, Peter Sonsini and Mohamad Makhzoumi. The shares directly held by NEA Ventures are indirectly held by Karen P. Welsh, the general partner of NEA Ventures. NEA 15, NEA Partners 15, NEA 15 LLC and the
NEA 15 Managers share voting and dispositive power with regard to the shares held by NEA 15. Karen P. Welsh, the general partner of NEA Ventures, shares voting and dispositive power with regard to the shares held by NEA Ventures. Dr.&nbsp;Gallagher,
a member of the Millendo board of directors, has no voting or dispositive power with regard to any shares held by NEA 15 or NEA Ventures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G jointly filed with the SEC on April&nbsp;7, 2021 by and on behalf of each of
Ikarian Capital, LLC, a Delaware limited liability company (&#147;Ikarian Capital&#148;), Ikarian Healthcare Master Fund, L.P, a Cayman Islands exempted limited partnership (the &#147;Fund&#148;), Ikarian Healthcare Fund GP, L.P., a Delaware limited
partnership (&#147;Ikarian GP&#148;), Chart Westcott and Neil Shahrestani. Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be
deemed to indirectly beneficially own securities owned by, the Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP. Ikarian Capital is a <FONT
STYLE="white-space:nowrap">sub-advisor</FONT> for certain separate managed accounts (collectively, the &#147;Managed Accounts&#148;) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is
ultimately owned and controlled by Chart Westcott Living Trust, of which Mr.&nbsp;Westcott serves as the sole trustee (the &#147;Trust&#148;), and indirectly by Mr.&nbsp;Shahrestani. Accordingly, each of Mr.&nbsp;Westcott, as sole trustee of the
Trust, and Mr.&nbsp;Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this
statement. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on a Schedule 13G/A filed with the SEC on February&nbsp;16, 2021. Roche Finance Ltd is a wholly
owned subsidiary of Roche Holding Ltd, a publicly held corporation, and has sole voting and investment power with respect to such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The general partner of Fonds InnoBio FPCI (&#147;InnoBio&#148;) is Bpifrance Investissement, a French
simplified joint-stock company (soci&eacute;t&eacute; par actions simplifi&eacute;e). InnoBio has the sole voting and investment power with respect to such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 725,085 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 163,243 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 40,000 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 23,684 shares held by the Gallagher Revocable Trust, (ii) 8,249 shares held by
Dr.&nbsp;Gallagher, and (iii) 18,000 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 38,068 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 36,213 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 21,776 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 18,000 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 26,680 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 11,333 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 1,098,398 shares issuable pursuant to stock options exercisable within 60 days of March&nbsp;31,
2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_102"></A>PRINCIPAL STOCKHOLDERS OF TEMPEST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of Tempest common stock
at March&nbsp;31, 2021 for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>each of Tempest&#146;s current directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>each of Tempest&#146;s named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>all of Tempest&#146;s current directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>each person, or group of affiliated persons, who beneficially owned more than 5% of Tempest&#146;s
outstanding shares of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership prior to the completion of the merger is based on 16,400,711
shares of Tempest common stock and 114,686,731 shares of Tempest preferred stock, in each case outstanding as of March&nbsp;31, 2021. The Tempest preferred stock will be converted into Tempest common stock prior to the consummation of the merger and
the following table and accompanying footnotes assume such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest has determined beneficial ownership in accordance with the
rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, these rules require that Tempest includes
shares of common stock issuable pursuant to the vesting of restricted stock units and the exercise of stock options and warrants that are either immediately exercisable or exercisable within 60 days of March&nbsp;31, 2021. These shares are deemed to
be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership
of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for persons listed in the table is c/o Tempest Therapeutics, Inc., 7000 Shoreline Court,
Suite 275, South San Francisco, CA 94090. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership<BR>Prior to this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Brady(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,121,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas W. Dubensky(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,914,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Grayson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peppi Prasit(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,722,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Raab(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Weisskoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel H. Whiting(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tom Woiwode(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,178,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stella Xu(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,768,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek Yuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (10 persons)(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,013,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Versant Entities(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,178,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,768,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, LP(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,768,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LYFE Capital Fund III (Phoenix), L.P. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LAV Regulus Limited(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,860,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">*</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 2,121,242 shares of common stock subject to options that are exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 3,457,880 shares of common stock and (ii) 456,730 shares of common stock subject to options
that are exercisable within 60 days of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 1,622,500 shares of common stock held by Dr.&nbsp;Prasit, and (ii) 100,000 shares of common stock
held by Kef K. Prasit Separate Property Trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 404,062 shares of common stock subject to options that are exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 4,166 shares of common stock subject to options that are exercisable within 60 days of
March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 30,991,934 shares of common stock held by Versant Venture Capital VI, L.P., (ii) 27,016,545
shares of common stock held by Versant Venture Capital IV, L.P., and (iii) 170,193 shares of common stock held by Versant Side Fund IV, L.P. Versant Ventures IV, LLC, is the general partner of each of Versant Venture Capital IV, L.P. and Versant
Side Fund IV, L.P. Dr.&nbsp;Woiwode, a member of Tempest&#146;s board of directors, Kirk Nielsen, Bradley Bolzon, Robin Praeger, William Link, Samuel Colella, Rebecca Robertson, Brian Atwood, Ross Jaffe and Charles Warden, the managing members of
Versant Ventures IV, LLC may be deemed to possess voting and dispositive control over the shares held by Versant Venture Capital IV, L.P. and Versant Side Fund IV, L.P., and may be deemed to have indirect beneficial ownership of the shares held by
such entities but disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interest therein, if any. Versant Ventures VI GP, L.P. is the general partner of Versant Venture Capital VI, L.P. and Versant
Ventures VI <FONT STYLE="white-space:nowrap">GP-GP,</FONT> LLC is the general partner of Versant Ventures VI GP, L.P. and has voting and dispositive control over the shares held by Versant Venture Capital VI, L.P. Dr.&nbsp;Woiwode, Bradley Bolzon,
Jerel Davis, Kirk Nielsen, Clare Ozawa and Robin Praeger, the managing directors of Versant Ventures VI <FONT STYLE="white-space:nowrap">GP-GP,</FONT> LLC, may be deemed to possess voting and dispositive control over the shares held by Versant
Venture Capital VI, L.P. and may be deemed to have indirect beneficial ownership of the shares held by such entity but disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interest therein, if any.
The address of Dr.&nbsp;Woiwode and each of these persons and entities is One Sansome, Suite 3630, San Francisco, CA 94104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 14,768,145 shares of common stock held by Quan Venture Fund I, L.P. The general partner of Quan
Venture Fund I, L.P. is Quan Venture Partners I, L.L.C. Dr.&nbsp;Xu, a member of Tempest&#146;s board of directors, is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture
Fund I, L.P. Dr.&nbsp;Xu disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest, if any. The address of Dr.&nbsp;Xu and Quan Venture Fund I, L.P. is c/o Maples Corporate Services Ltd., PO
Box 309, Ugland House Grand Cayman, Cayman Islands KY1-1104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents (i)&nbsp;all shares of common stock beneficially owned by Tempest&#146;s directors and three
current executive officers, and (ii)&nbsp;all shares of common stock issuable upon exercise of options held by Tempest&#146;s directors and three current executive officers that are vested and exercisable as of March&nbsp;31, 2021 or will become
vested and exercisable within 60 days of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 14,768,145 shares of common stock held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital
Partners Healthcare Fund V LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund V LP is the general partner of <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Fund V LP. <FONT
STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Healthcare Advisors Fund V LP is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or
indirectly, by various shareholders and employees of FMR LLC. Each the entities listed above expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein, if any. The address of these
entities is 245 Summer Street, Boston, Massachusetts 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 12,500,000 shares of common stock held by LYFE Capital Fund III (Phoenix), L.P. LYFE Capital
Management (Phoenix) LLC is the general partner of LYFE Capital Fund III (Phoenix), L.P. Mr.&nbsp;Yao Li Ho is the sole member of LYFE Capital Management (Phoenix) LLC and has the voting and investment power with respect to all of the shares held by
LYFE Capital Fund III (Phoenix), L.P. The address of the foregoing entities is 1209 Orange Street, Wilmington, DE 19801, USA. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman; " ALIGN="left">Represents 8,860,886 shares of common stock held by LAV Regulus Limited which is wholly owned by LAV
Biosciences Fund IV, L.P.. Dr. Yi Shi is the managing partner of LAV Corporate IV GP, Ltd., the general partner of LAV GP IV, L.P., which is the general partner of LAV Biosciences Fund IV, L.P.. The voting and investment power of shares held by LAV
Regulus Limited is exercised by Dr. Yi Shi. The registered address of LAV Regulus Limited is PO Box 4301, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_103"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wilmer Cutler Pickering Hale and Dorr LLP will pass upon the validity of Millendo&#146;s common stock offered by this proxy
statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_104"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Millendo Therapeutics, Inc. at December 31, 2020 and 2019, and for each of the two years in the
period ended December 31, 2020, included in the Proxy Statement of Millendo Therapeutics, Inc., which is referred to and made a part of this Prospectus and Registration Statement, have been audited by Ernst &amp; Young LLP, independent registered
public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Tempest Therapeutics, Inc. as of and for the year ended December&nbsp;31, 2020, and as of and for the year ended
December&nbsp;31, 2019 included in this proxy statement/prospectus have been so included in reliance on the report of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm, given on the authority of said firm as experts in
auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_105"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current
reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains Millendo&#146;s filings as well as reports, proxy and information statements, and other information issuers file
electronically with the SEC at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo also makes available free of charge on or through its website at
<I>www.millendo.com</I>, its Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and
amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Millendo electronically files such material with or otherwise furnishes it to the SEC. The website
addresses for the SEC and Millendo are inactive textual references and information on those websites is not part of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this proxy
statement/prospectus is a part, under the Securities Act to register the shares of Millendo common stock to be issued to Tempest stockholders in the merger. This proxy statement/prospectus is a part of that registration statement and constitutes a
prospectus of Millendo, as well as a proxy statement of Millendo for its special meeting, and it will also serve as an information statement for the stockholders of Tempest. The registration statement, including the attached annexes, exhibits and
schedules, contains additional relevant information about Millendo and Millendo common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration
statement are omitted in accordance with the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has supplied all the information contained in
this proxy statement/prospectus relating to Millendo, and Tempest has supplied all information contained in this proxy statement/prospectus relating to Tempest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to request documents from Millendo or Tempest, please send a request in writing or by telephone to either Millendo or
Tempest at the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Millendo Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Tempest Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">110 Miller Avenue, Suite 100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7000 Shoreline Court, Suite 275</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Ann Arbor, MI 48104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">South San Francisco, CA 94080</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Attn: Investor Relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Attn: Investor Relations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Tel: (734) <FONT STYLE="white-space:nowrap">845-9000</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Tel: (415) 798-8589</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">Email: IR@millendo.com</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Email: info@Tempesttx.com</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a Millendo stockholder and would like additional copies, without charge, of this proxy
statement/prospectus or if you have questions about the merger, including the procedures for voting your shares, you should contact Millendo&#146;s proxy solicitor, Morrow Sodali, at the following address and telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Morrow Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">509 Madison Avenue,
Suite 1206 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call Collect: (203) 561-6945 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Call
Toll Free: (800) 662-5200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: MLND@investor.morrowsodali.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_106"></A>TRADEMARK NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Millendo
Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Millendo&#146;s (logo)<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> are trademarks of Millendo Therapeutics, Inc. in the United States. Tempest Therapeutics<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> and Tempest&#146;s logo<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> are trademarks of Tempest Therapeutics, Inc. Other third-party logos and product/trade names are registered
trademarks or trade names of their respective companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_107"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_108"></A>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="toc150774_109"></A>Section&nbsp;16(a) of the Exchange Act requires Millendo&#146;s executive officers, directors and persons who own
more than 10% of Millendo common stock to file reports of ownership and reports of changes in ownership of common stock and other equity securities of Millendo with the SEC. Executive officers, directors and greater than 10% stockholders are
required by SEC regulations to furnish Millendo with copies of all Section&nbsp;16(a) forms they file. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To Millendo&#146;s knowledge,
based solely on a review of the copies of reports furnished to Millendo, Millendo believes that during the year ended December&nbsp;31, 2020, Millendo&#146;s executive officers, directors and greater than 10% stockholders complied with all
Section&nbsp;16(a) filing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_110"></A>Stockholder Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders may submit proposals for consideration at a forthcoming annual meeting of Millendo stockholders, provided such proposal is based
on a proper subject for stockholders&#146; action. In order for a stockholder proposal to be considered for inclusion in the proxy statement in reliance on Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> of the Exchange Act and presented at
Millendo&#146;s 2021 annual meeting of stockholders, such proposal must be received by Millendo a reasonable time before Millendo begins to print and send its proxy materials to stockholders (in the case where Millendo will have changed the date of
its annual meeting by more than 30 days from the prior year), in such form as is required by the rules and regulations promulgated by the SEC. Stockholder proposals must be submitted in writing, to Millendo&#146;s Corporate Secretary at 110 Miller
Avenue, Suite 100, Ann Arbor, Michigan 48104. A proposal submitted by a stockholder outside of the process of Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> for Millendo&#146;s 2021 annual meeting of stockholders will not be considered timely
unless such proposal is received by Millendo a reasonable time before Millendo begins to print and send its proxy materials to stockholders. The proxy to be solicited on behalf of Millendo&#146;s board of directors for its 2021 annual meeting of
stockholders may confer discretionary authority to vote on any such proposal considered to have been received on a <FONT STYLE="white-space:nowrap">non-timely</FONT> basis that nonetheless properly comes before Millendo&#146;s 2021 annual meeting of
stockholders. Stockholders are also advised to review the Millendo bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Submissions for director nomination must include (1)&nbsp;the full name, age, business address and, if known, residence address of such
nominee, (2)&nbsp;the principal occupation or employment of such nominee, (3)&nbsp;the class and number of shares of each class of capital stock of Millendo which are owned of record and beneficially by such nominee, (4)&nbsp;ta description of all
direct and indirect compensation and other material monetary agreements, arrangement and understandings during the past three years, and any other material relationships between or among (x)&nbsp;the stockholder, the beneficial owner, if any, on
whose behalf the nomination is being made and the respective affiliates and associates of, or others acting in concert with, such stockholder and such beneficial owner, on the one hand, and (y)&nbsp;each proposed nominee, and his or her respective
affiliates and associates, or others acting in concert with such nominee(s), on the other hand, including all information that would be required to be disclosed pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if the
stockholder making the nomination and any beneficial owner on whose behalf the nomination is made or any affiliate or associate thereof or person acting in concert therewith were the &#147;registrant&#148; for purposes of such Item and the proposed
nominee were a director or executive officer of such registrant, and (5)&nbsp;any other information concerning such person that must be disclosed as to nominees in proxy solicitations pursuant to Regulation 14A under the Securities Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the full text of the provisions of the Millendo&#146;a bylaws dealing with stockholder nominations and proposals will be made
available to stockholders from Millendo&#146;s Corporate Secretary upon written request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communication with the Millendo Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s stockholders may communicate with the Millendo board of directors by writing to Millendo&#146;s Corporate Secretary at 110
Miller Avenue, Suite 100, Ann Arbor, Michigan 48104. Millendo&#146;s Corporate Secretary will review these communications and will determine whether they should be presented to the Millendo board of directors. The purpose of this screening is to
allow the Millendo board of directors to avoid having to consider irrelevant or inappropriate communications. All communications directed to the audit committee of the Millendo board of directors in accordance with Millendo&#146;s Whistleblower
Policy that relate to questionable accounting or auditing matters involving Millendo will be promptly and directly forwarded to the audit committee of the Millendo board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_111"></A>Householding of Proxy Statement/Prospectus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet
Availability of Proxy Materials or other special meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other special meeting materials
addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Millendo special meeting, a number of brokers with account holders who are Millendo stockholders will be
&#147;householding&#148; Millendo&#146;s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected
stockholders. Once the stockholder has received notice from his or her broker that the broker will be &#147;householding&#148; communications to the stockholder&#146;s address, &#147;householding&#148; will continue until the stockholder are
notified otherwise or until the stockholder revokes his or her consent. If, at any time, the stockholder no longer wishes to participate in &#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy
Materials, please notify the broker or Millendo. Direct the written request to Millendo Therapeutics, Inc., Attn: Corporate Secretary, 110 Miller Avenue, Suite 100, Ann Arbor, Michigan 48104. Stockholders who currently receive multiple copies of the
Notices of Internet Availability of Proxy Materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_112a"></A>MILLENDO THERAPEUTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_4">Consolidated Statements of Stockholders&#146; Equity
(Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#finb150774_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><A NAME="toc150774_112"></A>TEMPEST THERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_1">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER&nbsp;31, 2020 AND
2019:</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="bottom"></TD>
<TD ROWSPAN="2" VALIGN="bottom"></TD>
<TD ROWSPAN="2" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_4">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc150774_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Millendo Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Millendo Therapeutics, Inc. (the Company) as of December&nbsp;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#146; equity (deficit) and cash flows
for each of the two years in the period ended December&nbsp;31, 2020, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2020, in conformity with U.S. generally
accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Audit Matter </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to
be communicated to the audit committee and that: (1)&nbsp;relates to accounts or disclosures that are material to the financial statements and (2)&nbsp;involved our especially challenging, subjective, or complex judgments. The communication of the
critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on
the accounts or disclosures to which it relates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><I>Accrued preclinical and clinical costs</I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Description of the Matter</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As described in Note 2 to the consolidated financial statements under the caption &#147;Research and development expenses&#148;, and within Note 6, the Company records the cost of research and development activities as they are
incurred. These include, among others, costs of funding research performed by third parties, amounts due under agreements with contract manufacturing organizations and outsourced professional scientific development services. The amounts recorded
include an estimate of progress toward the completion of the applicable research or development objectives. The Company compares payments made to third-party service providers to the estimated progress toward completion of the applicable research or
development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the
service provided, the Company may record net prepaid or accrued expense relating to these costs. As of December&nbsp;31, 2020, the Company&#146;s accrual for preclinical and clinical costs was $1&nbsp;million.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Auditing the Company&#146;s accrual for preclinical and clinical costs was challenging because information necessary to estimate the accruals was accumulated from multiple sources. In addition, in certain circumstances, the
determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing did not correspond to the level of services provided and invoicing from
clinical study sites and other vendors may not yet be available to management.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>How We Addressed the Matter in Our Audit</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To test the accrued preclinical and clinical costs, our audit procedures included, among others, testing the completeness and accuracy of the underlying data used in the estimate, including, but not limited to, estimated project
duration, research and manufacturing services incurred to date and terms of contractual arrangements. To assess the reasonableness of the data, we corroborated the progress of the clinical trials with Company research and development personnel and
obtained third-party evidence supporting the activities performed to date. We recalculated the accrual based on executed contracts with the clinical research organizations, contract manufacturing organizations and clinical study sites. We also
tested subsequent invoicing received from third parties and any pending change orders to assess the impact to the accrual through the balance sheet date and compared that to the Company&#146;s estimates.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand
Rapids, Michigan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;29, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value: 100,000,000 shares authorized; 18,999,701 shares and 18,266,545
shares issued and outstanding at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(245,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(208,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity attributable to Millendo Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of common stock, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,862,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,706,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_4"></A>Consolidated Statements of Stockholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>(Deficit)<BR>attributable<BR>to Millendo<BR>Therapeutics,<BR>Inc.</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Equity<BR>Attributable to<BR>Noncontrolling<BR>Interests</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>(Deficit)<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Balance at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,357,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(164,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock to board of directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,791,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise/forfeiture of BSPCE warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,266,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(208,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">719,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Exercise/forfeiture of BSPCE warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,999,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(245,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying Notes to Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency remeasurement loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-cash</FONT> items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of private placement, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of principal on finance lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from option and BSPCE warrant exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign currency exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental schedule of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets acquired under operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">See accompanying Notes to Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Millendo Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="finb150774_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Description of Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics,
Inc. (the &#147;Company&#148;), a Delaware corporation, together with its subsidiaries, is a biopharmaceutical company that was previously primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not
exist or are insufficient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had been developing livoletide <FONT STYLE="white-space:nowrap">(AZP-531),</FONT> as a potential treatment for
Prader-Willi syndrome, (&#147;PWS&#148;), a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. The Company discontinued the development of livoletide as a potential treatment for PWS in April 2020 based
upon results from its Phase 2b trial. All costs, including estimated closeout costs associated with the livoletide program were recognized during the second quarter, which resulted in the Company recording $3.1&nbsp;million in the second quarter of
2020. The Company recorded additional expense in the second half of 2020 related to the livoletide program, which reflects changes to estimated closeout costs. The Company does not expect to incur future material expenses related to this program.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In an effort to streamline costs after discontinuing the PWS program, the Company eliminated employee positions representing approximately 30% of its
prior headcount, which were completed in the second quarter of 2020. The Company recorded <FONT STYLE="white-space:nowrap">one-time</FONT> costs of $1.1&nbsp;million in the form of termination benefits to this plan in the second quarter of 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had also been developing nevanimibe <FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment for patients with classic
congenital adrenal hyperplasia, (&#147;CAH&#148;), a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses. The Company elected to cease investing in the development of nevanimibe as a
potential treatment for CAH in June 2020 based on an interim review of data from its Phase 2b trial. All costs, including estimated closeout costs associated with the nevanimibe program for the treatment of CAH were recognized during the second
quarter of 2020. The Company recorded additional expense in the second half of 2020 related to the nevanimibe program, which reflects changes to estimated close out costs. The Company does not expect to incur future material expenses related to its
nevanimibe program for the treatment of CAH as it is no longer developing this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had also been developing a selective neurokinin <FONT
STYLE="white-space:nowrap">3-receptor</FONT> (NK3R) antagonist <FONT STYLE="white-space:nowrap">(MLE-301)</FONT> as a potential treatment of vasomotor symptoms (&#147;VMS&#148;), commonly known as hot flashes and night sweats, in menopausal women.
In January 2021, the Company discontinued further investment in <FONT STYLE="white-space:nowrap">MLE-301</FONT> for the treatment of VMS based on an analysis of the pharmacokinetic and pharmacodynamic data from the single ascending dose portion of
the Phase 1 study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2021, as a result of its decision to discontinue its investment in <FONT STYLE="white-space:nowrap">MLE-301,</FONT> the
Company&#146;s Board of Directors (the &#147;Board&#148;) also approved a corporate restructuring plan (the &#147;Plan&#148;) furthering the Company&#146;s ongoing efforts to align its resources with its current strategy and operations. In
connection with the Plan, the Company plans to reduce its workforce by up to 85%, with the majority of the reduction in personnel expected to be completed by April&nbsp;15, 2021. The Company initiated this reduction in force in January 2021 and
expects to provide severance payments and continuation of group health insurance coverage for a specified period to the affected employees. The Company has also entered into retention arrangements with employees who are expected to remain with the
Company. The Company estimates that it will incur costs of approximately $5.5&nbsp;million for termination benefits and retention arrangements related to the Plan, substantially all of which will be cash expenditures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the Company undertook a strategic review process, which was intended to result in an actionable
plan that leverages its assets, capital and capabilities to maximize stockholder value. Following an extensive process of evaluating strategic alternatives, including identifying and reviewing potential candidates for a strategic acquisition or
other transaction, on March&nbsp;29, 2021, the Company entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;), with Tempest Therapeutics, Inc. (&#147;Tempest&#148;) under which the privately held Tempest will merge with a
wholly owned subsidiary of Millendo (the &#147;Merger&#148;). If the Merger is completed, the business of Tempest will continue as the business of the combined company (see Note 12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had also been investigating nevanimibe <FONT STYLE="white-space:nowrap">(ATR-101)</FONT> as a potential treatment for patients with endogenous
Cushing&#146;s syndrome (&#147;CS&#148;), a rare endocrine disease characterized by excessive cortisol production from the adrenal glands. As a result of slower than anticipated enrollment in its CS Phase 2 clinical trial, the Company elected to
discontinue this trial in August 2019, suspend development of nevanimibe for the treatment of CS, and focus its resources on other programs in its research and development pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred net losses
since inception and it expects to generate losses from operations for the foreseeable future primarily due to the ongoing review of corporate strategic alternatives that include, but are not limited to, the potential sale or merger of the Company or
its assets. As of December&nbsp;31, 2020, the Company had cash, cash equivalents and restricted cash of $38.7&nbsp;million and an accumulated deficit of $245.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the Company sold a total of 4,791,667 shares of its common stock pursuant to an underwriting agreement (the &#147;Underwriting
Agreement&#148;) with Citigroup Global Markets Inc. and SVB Leerink LLC, as representatives of the several underwriters named therein (the &#147;Underwriters&#148;), for total net proceeds of approximately $26.5&nbsp;million, after deducting
underwriting discounts and commissions and other offering expenses payable by the Company. The price to the public in this offering was $6.00 per share and resulted in the sale of 4,166,667 shares of the Company&#146;s common stock for net proceeds
of approximately $23.0&nbsp;million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Underwriters purchased an additional 625,000 shares of the Company&#146;s common stock
at the public offering price of $6.00 per share pursuant to a purchase option granted to them under the Underwriting Agreement, resulting in net proceeds of approximately $3.5&nbsp;million, after deducting underwriting discounts and commissions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT>
(&#147;ATM&#148;) equity distribution agreement with Citigroup Global Markets Inc. acting as sole agent with an aggregate offering value of up to $50.0&nbsp;million, which allows the Company to sell its common stock through the facilities of the
Nasdaq Capital Market. Subject to the terms of the ATM equity distribution agreement, the Company is able to determine, at its sole discretion, the timing and number of shares to be sold under this ATM facility. In March 2020, the Company amended
the equity distribution agreement to include SVB Leerink LLC as an additional sales agent for the ATM. In March 2020, the Company sold 719,400 shares of its common stock under our ATM equity distribution agreement for net proceeds of approximately
$5.5&nbsp;million. The Company does not expect to sell additional shares of common stock under the equity distribution agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given its limited
expected financing options, the Company is currently exploring an expanded range of strategic alternatives that include, but are not limited to, the potential sale or merger of the Company or its assets. In the event that the Company does not
complete the Merger with Tempest, the Company (i)&nbsp;may elect to pursue a dissolution and liquidation of the Company, (ii)&nbsp;pursue another strategic transaction or (iii)&nbsp;may resume research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes its cash, cash equivalents and restricted cash at December&nbsp;31, 2020 are sufficient to fund its current operations for at least 12
months following the issuance of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Presentation and Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of presentation and consolidation principles </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying Consolidated Financial Statements include the accounts of Millendo Therapeutics, Inc. and its subsidiaries, and all intercompany amounts have
been eliminated. The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in
the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). The Consolidated Financial Statements include the accounts of the
Company&#146;s subsidiaries in which the Company holds a controlling financial interest as of the financial statement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of estimates
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those
estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the Consolidated Financial Statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically
reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant
Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the global spread of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in 2020, the Company has
implemented business continuity plans designed to address and mitigate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its business. The Company anticipates that the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic will continue to have an impact on clinical and preclinical development activities. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts the Company&#146;s business, its preclinical and clinical
development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The
global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#146;s business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on
its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product
candidates, loss of single source suppliers or failure to comply with manufacturing regulations, identifying, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional products or product candidates; pharmaceutical product
development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects its business and results of operations, the Company may also have the effect of heightening many of the other risks and uncertainties discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of credit risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and restricted cash. The Company generally invests its cash in deposits with high credit quality financial institutions. Deposits
at banks may exceed the insurance provided on such deposits. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents as of
December&nbsp;31, 2020 and 2019 consisted of money market funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash relates to amounts used to secure the Company&#146;s credit card facility balances held on deposit with major financial institutions, to
collateralize a letter of credit in the name of the Company&#146;s landlord pursuant to a certain operating lease agreement, and to fund an escrow arrangement in connection with a sublease agreement also pursuant to that same operating lease
agreement. The escrow agreement ended in connection with the expiration of the Company&#146;s Waltham, Massachusetts lease agreement in November 2020 (see Note 7). The following table provides a reconciliation of the components of cash, cash
equivalents, and restricted cash reported in the Company&#146;s consolidated balance sheets to the total of the amount presented in the Consolidated Statements of Cash Flows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash
Flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Refundable tax credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company earns French research tax credits (cr&eacute;dit d&#146;imp&ocirc;t recherche) or (&#147;CIR&#148;) in connection with its research efforts through
its wholly owned subsidiary in Lyon, France. CIR earned are refundable or they can offset French corporate income tax due. Since the French research tax credit can be recovered in cash, the Company has elected to treat this as a grant. During the
year ended December&nbsp;31, 2020 and 2019, the Company recognized a reduction of research and development expenses of $0.5&nbsp;million and $1.2&nbsp;million, respectively, and had a research tax credit receivable of $0.3&nbsp;million and
$1.3&nbsp;million at December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use
of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1)&nbsp;there is an identified asset in the contract that is land or a depreciable asset (i.e.,
property, plant, and equipment), and (2)&nbsp;the customer has the right to control the use of the identified asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease liabilities are initially
and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. When readily determinable, the Company uses the implicit rate in determining the present value of lease payments. When leases do not provide
an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, including the lease term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease
commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Refer to Note 7 for further details.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair value of financial instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first
two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets
for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The asset&#146;s or liability&#146;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is
significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying value of the Company&#146;s debt approximates fair value as of December&nbsp;31, 2020 and 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other assets includes property
and equipment and other assets. Property and equipment, less accumulated depreciation, are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives which range from three to five years except for leasehold
improvements which are amortized over the shorter of the asset life or lease term. Repairs and maintenance costs are expensed as incurred. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. The Company has not recognized any impairment of long-lived assets through December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development costs are expensed as incurred and consist primarily of personnel expenses, costs of funding research performed by third-parties, expenses incurred under agreements with contract manufacturing organizations, payments under third-party
licensing agreements, consultant fees and expenses associated with outsourced professional scientific development services, expenses related to regulatory activities and allocated expense for facility costs. Milestone payment obligations incurred
prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs, are included in research and development expenses. Upfront milestone payments made to third-parties who perform research and
development services on the Company&#146;s behalf are expensed as services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the end of each reporting period, the Company compares
payments made to third-party service providers to the estimated progress toward completion of the applicable research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the
timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. As of December&nbsp;31, 2020
and 2019, the Company has not made any material adjustments to its prior estimates of accrued research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes compensation expense for all stock options awarded to employees and nonemployees based on the estimated fair market value
of the award on the grant date. The Company uses the Black-Scholes option pricing model to value its stock option awards. The Company recognizes compensation expense on a straight-line basis over the requisite service period, which is generally the
vesting period of the award. The Company accounts for forfeitures of stock options as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimating the fair market value of options requires
the input of subjective assumptions, including the estimated fair value of the Company&#146;s common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the
Company&#146;s Black-Scholes option-pricing model represent management&#146;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#146;s judgment, as they are inherently subjective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax
assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#146;s assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates
and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company&#146;s financial statements in the period of enactment. The measurement of deferred tax assets is
reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&nbsp;31, 2020 and 2019, the Company has concluded that a full valuation
allowance is necessary for all of its net deferred tax assets. The Company had no material amounts recorded for uncertain tax positions, interest or penalties in the accompanying Consolidated Financial Statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net loss per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share of common
stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the
potential exercise or conversion of securities, such as restricted stock, and stock options, which would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted-average number
of shares of common stock remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they
would be anti-dilutive (amounts shown as common stock equivalents): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,749,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,498,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BSA and BSPCE warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,814,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,611,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating
decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of foreign operations are translated from their functional currency into U.S. dollars (reporting currency) using average exchange rates in effect
during the year, while assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. The resulting translation adjustments are recorded in accumulated other comprehensive loss. Transaction gains
and losses resulting from exchange rate changes on transactions denominated in currencies other than the functional currency are included in income in the period in which the change occurs and reported within other expenses in the consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-01,</FONT> <I>Investments-Equity Securities (Topic 321), Investments-Equity Method
and Joint Ventures (Topic 323),</I> <I>and Derivatives and Hedging (Topic 815). </I>ASU <FONT STYLE="white-space:nowrap">2020-01</FONT> states any equity security transitioning from the alternative method of accounting under Topic 321<I> </I>to the
equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain <FONT STYLE="white-space:nowrap">non-derivative</FONT> forward contracts
or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December&nbsp;15,
2020, and will be applied on a prospective basis. Early adoption is permitted. The Company adopted ASU <FONT STYLE="white-space:nowrap">2020-01</FONT> on January&nbsp;1, 2021, which did not have a material effect on the consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740)&#151;Simplifying the
Accounting for Income Taxes.</I> ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities,
the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating
tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The ASU is
effective for fiscal years beginning after December&nbsp;15, 2020, and will be applied either retrospectively or prospectively based upon the applicable amendments. Early adoption is permitted. The Company adopted ASU
<FONT STYLE="white-space:nowrap">2019-01</FONT> on January&nbsp;1, 2021, which did not have a material effect on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-13,</FONT> <I>Fair Value Measurement (Topic 820) Disclosure Framework&#151;Changes
to the Disclosure Requirements</I> <I>for Fair Value Measurement</I>. ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> resulted in certain modifications to fair value measurement disclosures, primarily related to level 3 fair value<I>
</I>measurements. The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2019, and early adoption was permitted. The adoption of ASU
<FONT STYLE="white-space:nowrap">2018-13</FONT> did not have a material impact on the Company&#146;s consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments &#150; Credit Losses (Topic 326) Measurement of
Credit Losses on Financial Instruments</I>, which replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable
information to inform credit loss estimates. Additionally, ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> requires a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected through the use of
an allowance of expected credit losses. In May 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-05,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326) Targeted Transition Relief</I>, which amends ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> by providing entities with an option to irrevocably elect the fair value option to be applied on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">instrument-by-instrument</FONT></FONT>
basis for eligible financial instruments that are within the scope of Topic 326. The fair value option election does not apply to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> debt securities. In
November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and</I> <I>Leases (Topic 842)</I>, which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
finalized effective date delays for private companies, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> organizations, and certain smaller reporting
companies applying the credit losses, leases, and hedging standards. Also in November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-11,</FONT> <I>Codification Improvements to Topic 326, Financial Instruments&#151;Credit</I>
<I>Losses</I>, which provides clarity about certain aspects of the amendments in ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> as amended, is effective for fiscal years beginning<I>
</I>after December&nbsp;15, 2022, including interim periods within those fiscal years, and requires a modified retrospective approach. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial
statements and related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent events were evaluated through the filing date of this Annual Report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents
the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds (included in cash and cash equivalents)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical and clinical costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Debt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bpifrance
Reimbursable Advance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017, in connection with its acquisition of Aliz&eacute;, a privately held biotechnology company based in Lyon,
France, the Company assumed &#128;0.7&nbsp;million of debt that Aliz&eacute; had outstanding with Bpifrance Financing (&#147;Bpifrance&#148;). The original advance amount of &#128;0.8&nbsp;million (&#147;the Bpifrance Advance&#148;) was provided to
Aliz&eacute; as an innovation aid that required Aliz&eacute; to carry out certain activities related to its livoletide clinical development program and incur a certain level of program expenditures. No interest is charged or accrued under the
advance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to make quarterly principal payments, which began in December 2016 and continue
through September 2021. The quarterly principal payments escalate over the repayment period beginning with &#128;17,500 per quarter and increasing to &#128;50,000 through maturity. In addition to the quarterly payments, beginning January&nbsp;1,
2016, Bpifrance may require the Company to pay, by no later than March&nbsp;31 of each year, a reimbursement annuity equal to 20% of the proceeds generated by the Company from license, assignment or use of livoletide. Under no circumstance, however,
would the Company be required to reimburse to Bpifrance principal amounts greater than the original advance it received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is permitted to
repay the Bpifrance Advance at any time, at which point it would be released from all commitments and obligations under the Bpifrance Advance agreement. The Bpifrance Advance Agreement does not contain any ongoing financial covenants. For the year
ending December&nbsp;31, 2020 the Company made $0.1&nbsp;million in principal payments under the Bpifrance Advance agreement due to the fact that in April 2020, Bpifrance provided a six month deferral of principal payments to support businesses as a
result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. During the third quarter the Company resumed normal principal payments under the Bpifrance Advance agreement. For the year ending December&nbsp;31, 2019, the Company made
principal payments of $0.2&nbsp;million. At December&nbsp;31, 2020, the balance outstanding was $0.3&nbsp;million (&#128;0.2 million). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. License
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>University of Michigan License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, the Company entered into a license agreement with the Regents of the University of Michigan (the &#147;University of Michigan&#148;) for a
worldwide, exclusive, sublicensable license to the University of Michigan&#146;s interest in certain patent rights jointly owned with the Company, covering the use of <FONT STYLE="white-space:nowrap">ATR-101</FONT> for the treatment of certain
indications (the &#147;UM License Agreement&#148;). Due to the Company&#146;s decision to cease investing in the nevanimibe program, effective on March&nbsp;5, 2021, the Company notified the University of Michigan of its decision to terminate the UM
License Agreement, which termination shall be effective April&nbsp;30, 2021, as agreed to by the University of Michigan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company would have been
obligated to make payments to the University of Michigan totaling up to $2.5&nbsp;million upon the achievement of certain development and commercial milestones. No amounts were paid in 2018 or 2019 related to the achievement of development or
commercial milestones. During the year ended December&nbsp;31, 2019, $0.1&nbsp;million was paid in order to extend the milestone achievement date of certain development milestones. The Company would have also been required to pay the University of
Michigan a <FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty percentage on net sales of applicable products, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, $20,000
in annual minimum royalties would have been due under the UM License Agreement for each of 2021 through 2023. Further, beginning in 2024, the Company would have been required to pay an annual fee of $0.2&nbsp;million which would have been creditable
against royalties due, if any, until the expiration or termination of the UM License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignment agreement with Erasmus University
Medical Center and the University of Turin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of Aliz&eacute;, the Company assumed Aliz&eacute;&#146;s obligations
under an assignment agreement with Erasmus University Medical Center, the University of Turin and certain individuals (collectively &#147;the Assignors&#148;), for certain patents and patent applications relating to livoletide. In March 2021, the
Company notified the assignors that it had discontinued its PWS program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the assignment, the Company agreed to pay the Assignors a
flat, low single digit royalty on net commercial sales of products containing livoletide that are covered by the claims of the assigned intellectual property. Further, upon approval of livoletide by the FDA or EMA, the Company would have been
required to pay the Assignors CDN $100,000, which amount would have been deducted from any future royalty payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due to the Assignors. The Company also agreed to pay the Assignors a low single digit percentage of any amounts received in connection with its license of the assigned intellectual property or
products containing livoletide that are covered by the claims of the assigned intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Roche </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2018, the Company entered into a license agreement with F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT
STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Inc. (collectively, &#147;Roche&#148;), for a worldwide, exclusive license to Roche&#146;s interest in certain patent rights and <FONT STYLE="white-space:nowrap">know-how</FONT> covering, among
other things, the use of a neurokinin 3 receptor antagonist (the &#147;Roche License Agreement&#148;). Due to the Company&#146;s decision to discontinue developing the <FONT STYLE="white-space:nowrap">MLE-301</FONT> program, in March 2021, the
Company notified Roche that it was terminating the Roche License Agreement effective three months from the date of such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the
rights granted to the Company under the Roche License Agreement, the Company agreed to pay Roche an <FONT STYLE="white-space:nowrap">up-front</FONT> payment. Under the terms of the Roche License Agreement, the Company would have also been obligated
to make significant milestone and royalty payments in connection with the attainment of certain development steps and the sale of resulting products with respect to the neurokinin 3 receptor antagonist. In addition, the Company would have been
required to share a portion of any net proceeds received in connection with certain agreements that it may enter into with third-parties to develop and commercialize the neurokinin 3 receptor antagonist. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating leases
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has noncancelable operating leases for office space which have remaining lease terms of approximately 3.5 years. In connection with
the OvaScience Merger, the Company assumed a sublease agreement for office and laboratory space located in Waltham, Massachusetts. The sublease commenced on January&nbsp;15, 2019 and expired on November&nbsp;30, 2020. The total minimum sublease
rentals received under the Waltham, Massachusetts agreement was $0.6&nbsp;million. In February 2019 and October 2018, the Company entered into two additional noncancelable operating leases for office space in Ann Arbor, Michigan for the
Company&#146;s headquarters; one that the Company took possession of in April 2019, and the other that the Company took possession of in July 2019, respectively. One of its leases in Ann Arbor, Michigan expires in June 2024 and the other expires in
March 2024. In April 2019, the Company entered into a lease agreement for office space in Lexington, Massachusetts. This lease was scheduled to expire on September&nbsp;30, 2020; however, in June 2020 the Company exercised its right to terminate the
lease early such that the lease terminated on August&nbsp;11, 2020. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants. In January 2020, the Company terminated its office
lease agreement in Lyon, France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the operating lease ROU asset and the operating lease liabilities were $2.2&nbsp;million
and $2.4&nbsp;million, respectively. The weighted average discount rate used to account for the Company&#146;s operating leases is the Company&#146;s estimated incremental borrowing rate of 7.0%. The Company has options to extend certain of its
leases for another five to ten years. These options to extend were not recognized as part of the Company&#146;s measurement of the ROU assets and operating lease liabilities for the year ended December&nbsp;31, 2020. The weighted average remaining
term of the Company&#146;s noncancelable operating leases is 3.38 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rent expense related to the Company&#146;s operating leases was approximately
$0.9&nbsp;million and $0.7&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. The Company recognizes rent expense on a straight-line basis over the lease period. Cash paid for amounts included in the measurement of the
lease liabilities was approximately $1.8&nbsp;million and $1.5&nbsp;million during the years ended December&nbsp;31, 2020 and 2019, respectively. The Company received approximately $0.3&nbsp;million in sublease payments related to its Waltham,
Massachusetts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lease during each of the years ended December&nbsp;31, 2020 and 2019. Future minimum rental payments under the Company&#146;s noncancelable operating leases at December&nbsp;31, 2020 is as
follows (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Year Ending December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present Value Adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease liability at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment benefit plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum
contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to 3% of employees&#146; compensation. The Company generally assumes all administrative costs of the plan. For the years ended December&nbsp;31, 2020 and
2019, the expense relating to the contributions made was $0.2&nbsp;million and $0.2&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a
liability has been incurred and the amount can be reasonably estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2016, a purported shareholder derivative action was filed in
the Business Litigation Session of the Suffolk County Superior Court in the Commonwealth of Massachusetts (Cima v. Dipp, No. <FONT STYLE="white-space:nowrap">16-3443-BLS1</FONT> (Mass. Sup. Ct.)) against certain former officers and directors of
OvaScience and one current director of the Company (a former director of OvaScience) and OvaScience as a nominal defendant alleging breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and waste of corporate assets
for purported actions related to OvaScience&#146;s January 2015 <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering. On February&nbsp;22, 2017, the court approved the parties&#146; joint stipulation to stay all proceedings in the
action until further notice. Following a status conference in December 2017, the stay was lifted. On January&nbsp;25, 2018, at the parties&#146; request, the court entered a second order staying all proceedings in the action until further order of
the court. On March&nbsp;2, 2020, the parties submitted a status report requesting that the court continue the stay. On March&nbsp;5, 2020, the court entered an order continuing the stay and requiring that the parties file a further status report on
or before June&nbsp;30, 2020. On June&nbsp;30, 2020, the parties filed a further status report requesting that the court continue the stay. The court continued the stay until at least January&nbsp;7, 2021. On January&nbsp;7, 2021, the parties filed
a further status report requesting that the court continue the stay until at least April&nbsp;30, 2021. The case remains stayed until at least April&nbsp;30, 2021, when the parties are due to file a further status report. The Company believes that
the complaint is without merit and intends to defend against the litigation. There can be no assurance, however, that the Company will be successful. At present, the Company is unable to estimate potential losses, if any, related to the lawsuit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2017, a purported shareholder class action lawsuit was filed in the U.S. District Court for the District of Massachusetts (Dahhan v.
OvaScience, Inc., No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-cv-10511-IT</FONT></FONT></FONT> (D. Mass.)) against OvaScience and certain former officers of OvaScience alleging
violations of Sections 10(b) and 20(a) of the Exchange Act (the &#147;Dahhan Action&#148;). On July&nbsp;5, 2017, the court entered an order approving the appointment of Freedman Family Investments LLC as lead plaintiff, the firm of Robins Geller
Rudman&nbsp;&amp; Dowd LLP as lead counsel and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Law Office of Alan L. Kovacs as local counsel. Plaintiff filed an amended complaint on August&nbsp;25, 2017. The Company filed a motion to dismiss the amended complaint, which the court
denied on July&nbsp;31, 2018. On August&nbsp;14, 2018, the Company answered the amended complaint. On December&nbsp;9, 2019, the court granted leave for the lead plaintiff to file a second amended complaint under seal and permitted the defendants to
file a motion to strike the second amended complaint. On December&nbsp;30, 2019, the court granted the parties&#146; joint motion to stay all proceedings in the case pending mediation. On March&nbsp;3, 2020, the parties conducted a mediation
session. The mediation was unsuccessful. The Company filed a motion to strike the second amended complaint on May&nbsp;1, 2020. The Company believes that the amended complaint and the second amended complaint are without merit. On August&nbsp;17,
2020, the court granted the parties&#146; joint motion to stay all proceedings in the case pending mediation. The parties agreed to participate in a second mediation session on November&nbsp;10, 2020. On October&nbsp;16, 2020, the court granted the
parties&#146; joint request to extend the stay until November&nbsp;16, 2020. On November&nbsp;16, 2020, the parties filed a joint status report seeking to extend the stay for an additional thirty days. On November&nbsp;17, 2020, the court ordered
the parties to file a supplemental joint status report clarifying whether they sought a continuance of the stay of all proceedings or instead, a partial lifting of the stay. On November&nbsp;19, 2020, the parties filed a joint status report seeking
to continue a partial stay of the case while the parties engaged in additional settlement discussions, and a partial lifting of the stay to the extent required for the court to rule on the Company&#146;s pending motion to strike and motions to
dismiss filed by other defendants. Those motions remain pending. A resolution of this lawsuit adverse to the Company or the other defendants could have a material effect on the Company&#146;s consolidated financial position and results of
operations. At present, the Company is unable to estimate potential losses, if any, related to the lawsuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2017, a purported
shareholder derivative complaint was filed in the U.S. District Court for the District of Massachusetts (Chiu v. Dipp, No.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1:17-cv-11382-IT</FONT></FONT></FONT> (D. Mass.)) against OvaScience as a nominal defendant, certain former officers and directors of OvaScience and
one current director of the Company (a former director of OvaScience) alleging breach of fiduciary duties, unjust enrichment and violations of Section&nbsp;14(a) of the Exchange Act alleging that compensation awarded to the director defendants was
excessive and seeking redress for purported actions related to OvaScience&#146;s January 2015 <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering and other public statements concerning OvaScience&#146;s AUGMENT treatment. On
September&nbsp;26, 2017, the plaintiff filed an amended complaint which eliminated all claims regarding allegedly excessive director pay and additionally alleged claims of abuse of control and waste of corporate assets. On October&nbsp;27, 2017, the
defendants filed a motion to dismiss the amended complaint. The court heard oral argument on the motion to dismiss on April&nbsp;5, 2018. On April&nbsp;13, 2018, the court granted the defendants&#146; motion to dismiss the amended complaint for
failure to state a claim for relief under Section&nbsp;14(a). The court also dismissed the plaintiffs&#146; pendent state law claims without prejudice, based on lack of subject matter jurisdiction. On April&nbsp;25, 2018, the plaintiffs moved for
leave to amend the complaint and to stay this case pending the outcome of the Dahhan Action. The Company does not believe that the proposed amended complaint cures the defects in the current complaint, but informed plaintiffs&#146; counsel that, in
the interest of judicial economy, defendants would not oppose the proposed amendment if the court would consider staying the case pending the resolution of the Dahhan Action. On April&nbsp;27, 2018, the court granted the plaintiffs&#146; motion for
leave to amend the complaint and for a stay. On April&nbsp;30, 2018, the plaintiffs filed their second amended complaint. On May&nbsp;23, 2018, the court entered an order staying this case pending the resolution of the Dahhan Action. The Company
believes that the complaint is without merit and intends to defend against the litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance, however, that the Company will be
successful. At present, the Company is unable to estimate potential losses, if any, related to the lawsuit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the matters described above,
the Company may be a party to litigation and subject to claims incident to the ordinary course of business from time to time. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs,
and diversion of management resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Common Stock and Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles
the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the
Company&#146;s board of directors may declare out of funds legally available for that purpose on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis. No dividends had been declared through December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common stock warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2020, there were 17,125 common stock warrants outstanding with a weighted average exercise price of $16.93 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock-Based Compensation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2019, the Company held its 2019 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;). At the Annual Meeting, the
Company&#146;s stockholders approved the Company&#146;s 2019 Equity Incentive Plan (the &#147;2019 Plan&#148;) and the Company&#146;s 2019 Employee Stock Purchase Plan (the &#147;2019 ESPP,&#148; and together with the 2019 Plan, the
&#147;Plans&#148;). The 2019 Plan is the successor to the Private Millendo 2012 Stock Plan and the OvaScience 2012 Stock Incentive Plan (each, as amended, the &#147;Prior Plans&#148;) and allows the Company to grant stock options, restricted stock
unit awards and other awards at levels determined appropriate by the Company&#146;s Board of Directors (the &#147;Board&#148;) or the Compensation Committee of the Board. No additional awards will be granted under either of the Prior Plans. The 2019
ESPP enables employees to purchase shares of the Company&#146;s common stock through offerings of rights to purchase the Company&#146;s common stock to all eligible employees. The Plans were adopted by the Board on April&nbsp;29, 2019, subject to
approval by the Company&#146;s stockholders, and became effective with such stockholder approval on June&nbsp;11, 2019. Outstanding awards under the Prior Plans continue to be subject to the terms and conditions of the Prior Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate number of shares of the Company&#146;s common stock initially reserved for issuance under the 2019 Plan was 2,919,872 shares, which is the sum
of (i) 534,320 shares, (ii)&nbsp;the number of unallocated shares remaining available for grant under the Prior Plans as of the effective date of the 2019 Plan, and (iii)&nbsp;the Prior Plans&#146; Returning Shares (as defined below), as such shares
become available from time to time. The number of shares of the Company&#146;s common stock reserved for issuance under the 2019 Plan will automatically increase on January&nbsp;1 of each year, for a period of ten years, from January&nbsp;1, 2020
continuing through January&nbsp;1, 2029, by 4% of the total number of shares of the Company&#146;s common stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. Pursuant
to the terms of the 2019 Plan, an additional 4% of the total number of shares of the Company&#146;s common stock outstanding on December&nbsp;31, 2019 were added to the number of available shares effective January&nbsp;1, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Prior Plans&#146; Returning Shares&#148; refers to the following shares of the Company&#146;s common stock subject to any outstanding stock
award granted under either of the Prior Plans: shares of common stock subject to awards that (i)&nbsp;expire or terminate for any reason prior to exercise or settlement; (ii)&nbsp;are forfeited because of the failure to meet a contingency or
condition required to vest such shares or otherwise return to the Company; or (iii)&nbsp;are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price
of a stock award. The foregoing includes shares subject to outstanding awards under the OvaScience 2011 Stock Incentive Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original
issuance price pursuant to a contractual repurchase right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following shares of the Company&#146;s common stock (collectively, the &#147;2019 Plan
Returning Shares&#148;) will also become available again for issuance under the 2019 Plan: (i)&nbsp;any shares subject to a stock award that are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to a stock award that are
not issued because such stock award is settled in cash; (iii)&nbsp;any shares issued pursuant to a stock award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the
vesting of such shares; and (iv)&nbsp;any shares reacquired by the Company in satisfaction of tax withholding obligations on a stock award or as consideration for the exercise or purchase price of a stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate number of shares of the Company&#146;s common stock that may be issued under the 2019 ESPP is 133,580 shares, plus the number of shares of the
Company&#146;s common stock that are automatically added on January 1st of each year, for a period of up to ten years, from January&nbsp;1, 2020 continuing through January&nbsp;1, 2029, by 1% of the total number of shares of the Company&#146;s
common stock outstanding on December&nbsp;31 of the preceding calendar year, (ii)&nbsp;&nbsp;&nbsp;&nbsp;133,580 shares of the Company&#146;s common stock, unless a lesser number of shares is determined by the Board. Pursuant to the terms of the
2019 Employee Stock Purchase Plan, an additional 133,580 shares were added to the number of available shares effective January&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded stock-based compensation expense in the following expense categories of its accompanying consolidated statements of operations and
comprehensive loss for the years ended December&nbsp;31, 2020 and 2019 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options issued may have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Board. Vesting generally occurs
over a period of not greater than four years. In May 2020, the Company granted 840,450 stock options to its employees in connection with the PWS and CAH program changes that occurred during the second quarter of 2020 (see Note 1). The vesting was as
follows: 1) 50&nbsp;percent of the shares subject to this option grant will vest on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the Board&#146;s approval of the achievement of certain performance criteria, and 2) one twelfth (1/12th)
of the remaining shares subject to this option grant will vest in equal monthly installments thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity related to stock option grants to employees and nonemployees for
the years ended December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise<BR>price&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>remaining<BR>contractual life<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,225,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(394,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,498,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,864,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(612,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,749,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,819,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,749,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the unrecognized compensation cost related to 1,929,703 unvested stock options expected to vest
was $8.1&nbsp;million. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.3 years. The aggregate intrinsic value of options exercised during the year ended December&nbsp;31, 2020 was $1,000.
The aggregate intrinsic value of options exercised during the year ended December&nbsp;31, 2019 was $0.7&nbsp;million. The aggregate intrinsic value of options outstanding and options exercisable as of December&nbsp;31, 2020 was $0.2&nbsp;million
and $0.1&nbsp;million, respectively. The options granted during the years ended December&nbsp;31, 2020 and 2019, had an estimated weighted average grant date fair value of $3.13 and $6.74, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the value of
the underlying common stock at the grant date, expected term, expected volatility, risk-free interest rate and dividend yield. The fair value of each grant of options during the years ended December&nbsp;31, 2020 and 2019 was determined using the
methods and assumptions discussed below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected term of employee options with service-based vesting is determined using the &#147;simplified&#148;
method, as prescribed in SEC&#146;s Staff Accounting Bulletin (&#147;SAB&#148;) No.&nbsp;107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#146;s lack
of sufficient historical data. The expected term of nonemployee options is equal to the contractual term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected volatility is based on historical volatilities of similar entities within the Company&#146;s
industry which were commensurate with the expected term assumption as described in SAB No.&nbsp;107. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the
time of grant for a period that is commensurate with the assumed expected term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the
foreseeable future to pay, a dividend on its common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prior to the OvaScience Merger, the Company&#146;s common stock was not publicly traded. The Company&#146;s board
of directors periodically estimated the fair value of the Company&#146;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm in accordance with the guidance
provided by the American </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Institute of Certified Public Accountants 2013 Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</I> Following the OvaScience Merger, the fair market
value of the Company&#146;s common stock is determined based on the closing price of its common stock on the Nasdaq Capital Market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the following assumptions for the Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended,</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended,</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of the Aliz&eacute; acquisition, Aliz&eacute; had 6,219 <FONT STYLE="white-space:nowrap">non-employee</FONT> (BSA)
warrants and 5,360 employee (BSPCE) warrants outstanding, which have weighted-average exercise prices of &#128;80.06 and &#128;83.40, respectively. As of December&nbsp;31, 2020, all BSAs and BSPCEs were vested. During the year ended
December&nbsp;31, 2020, 910 BSPCE warrants were exercised resulting in the issuance of 12,307 shares of the Company&#146;s common stock. In addition, during the year ended December&nbsp;31, 2020, a total of 2,586 BSA and BSPCE warrants were
forfeited. As of December&nbsp;31, 2020, there were an aggregate of 48,265 shares of common stock issuable upon the exercise of the warrants with a weighted-average exercise price of $7.85 per share. These instruments are included in the equity
attributable to noncontrolling interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company had approximately $330.8&nbsp;million and $280.9&nbsp;million of federal and state net operating loss carryforwards,
respectively, which begin to expire in 2031. As of December&nbsp;31, 2020, the Company had approximately $5.3&nbsp;million and $1.1&nbsp;million of federal and state research and development tax credit carryforwards, respectively, that begin to
expire in 2031 and 2029, respectively. As of December&nbsp;31, 2020, the Company had approximately $7.4&nbsp;million of federal orphan drug tax credit carryforwards that begin to expire in 2032. As of December&nbsp;31, 2020, the Company had foreign
net operating loss carryforwards of approximately $20.7&nbsp;million which can be carried forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;382 of the Internal Revenue
Code of 1986, as amended (the &#147;Code&#148;) provides for limitation on the use of net operating loss and research and development tax credit carryforwards following certain ownership changes (as defined in Code) that could limit the
Company&#146;s ability to utilize these carryforwards. Pursuant to Section&nbsp;382 of the Code, an ownership change occurs when the stock ownership of a 5% stockholder increases by more than 50% over a three-year testing period. The Company may
have experienced various ownership changes, as defined by the Code, as a result of past financing and may in the future experience an ownership change. Accordingly, the Company&#146;s ability to utilize the aforementioned carryforwards may be
limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the net deferred income tax asset as of December&nbsp;31, 2020 and 2019 are as follows
(amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized <FONT STYLE="white-space:nowrap">start-up</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(109,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, the Company considers whether it is
<FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against its net
deferred tax assets as of December&nbsp;31, 2020 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The valuation allowance decreased by
$5.6&nbsp;million during the year ended December&nbsp;31, 2020, primarily due to the <FONT STYLE="white-space:nowrap">write-off</FONT> of net operating loss carryforwards related to a wholly owned foreign subsidiary that filed for liquidation during
the year ended December&nbsp;31, 2020, offset by the generation of net operating losses and credit carryforwards during 2020. In addition to the deferred taxes listed in the above table, an income tax reduction of $83.4&nbsp;million <FONT
STYLE="white-space:nowrap">(tax-effected</FONT> $19.5&nbsp;million deferred tax asset with a full valuation allowance) resulting from the foreign subsidiary liquidation may be available as capital loss carryforwards, net operating loss carryforwards
or a combination of both in the U.S., however, a detailed analysis of these losses is required to make this determination and has not yet been initiated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;31, 2020 and 2019, the Company had no unrecognized tax benefits. The Company&#146;s policy is to record interest and penalties related to
income taxes as a component of income tax expense. As of December&nbsp;31, 2020 and 2019, the Company had no accrued interest or penalties related to income taxes and no amounts have been recognized in the Company&#146;s statement of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes
as reflected in the financial statements is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal income tax benefit at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22.5</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. Federal, various state, and foreign jurisdictions. The statute of limitations
for assessment by the Internal Revenue Service (IRS) and state tax authorities is open for the Company&#146;s tax years from 2017 to present. Federal and state carryforward attributes that were generated prior to the tax year ended December&nbsp;31,
2017 may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in a period for which the statute of limitations remains open. The statute of limitations for assessment by the authorities in
the various foreign jurisdictions in which the Company files ranges from one to three years and is open for the Company&#146;s tax years from 2017 to present. There are currently no federal, state or foreign income tax audits in progress. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 1,
the Company sold shares of its common stock in December 2019. Roche invested in the Company&#146;s December 2019 financing. One of the Company&#146;s Board members is affiliated with Roche. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following an extensive process of
evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, on March&nbsp;29, 2021, the Company entered into a Merger Agreement with Tempest. If the Merger is completed, the
business of Tempest will continue as the business of the combined organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing of the Merger, (a)&nbsp;each then outstanding share of
Tempest common stock (including shares of Tempest common stock issued upon conversion of Tempest preferred stock and shares of Tempest common stock issued in the financing transaction described in the Merger Agreement) will be converted into the
right to receive a number of shares of Millendo common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a reverse stock split of Millendo common stock) calculated in accordance with the Merger Agreement
and (b)&nbsp;each then outstanding Tempest stock option and warrant to purchase Tempest common stock will be assumed by Millendo, subject to adjustment as set forth in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains certain termination rights of each of Millendo and Tempest, including, subject to compliance with the applicable terms of the
Merger Agreement, the right of each party to terminate the Merger Agreement to enter into a definitive agreement for a superior proposal. Upon termination of the Merger Agreement under specified circumstances, Millendo may be required to pay Tempest
a termination fee of $1.4&nbsp;million or reimburse Tempest&#146;s expenses up to a maximum of $1.0&nbsp;million and Tempest may be required to pay Millendo a termination fee of $2.8&nbsp;million or reimburse Millendo&#146;s expenses up to a maximum
of $1.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the shareholders and the Board of Directors of Tempest Therapeutics Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying balance sheets of Tempest Therapeutics Inc. (the &#147;Company&#148;) as of December&nbsp;31, 2020 and 2019, the related statements of operations, convertible preferred stock and stockholders&#146; deficit, and cash flows, for the years
then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31,
2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred losses since inception and has forecasted cash needs in excess of current liquidity, which raises
substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note&nbsp;1. The financial statements do not include any adjustments that might result from the outcome of
this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits
included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Audit Matter </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to
be communicated to the audit committee and that (1)&nbsp;relates to accounts or disclosures that are material to the financial statements and (2)&nbsp;involved our especially challenging, subjective, or complex judgments. The communication of
critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
accounts or disclosures to which it relates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses, Accrued Clinical Trial Liability, and Prepaid Research and
Development Costs -Refer to Note 2 and Note 5 to the financial statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Critical Audit Matter Description </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes research and development expenses as incurred. Advance payments for future research and development activities are deferred and expensed
as the goods are delivered or the related services are performed. The Company recognizes its preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research
organizations (collectively, &#147;CRO&#148;) that conduct and manage preclinical studies and clinical trials on the Company&#146;s behalf. Service fees are accrued based on the Company&#146;s estimates of the time period over which services will be
performed and the level of effort to be expended in each period. Total research and development expenses for the year ended December&nbsp;31, 2020 was $14.4&nbsp;million. Prepaid research and development costs as of December&nbsp;31, 2020 was
$0.4&nbsp;million and the accrued clinical trial liability as of December&nbsp;31, 2020 was $0.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each balance sheet date, the Company
estimates prepaid research and development costs and the accrued clinical trial liability by obtaining reporting from CROs, discussing progress or stage of completion of services with internal personnel and external service providers, and comparing
this information to payments made, invoices received, and the agreed-upon fee to be paid for such services in the applicable contract, statements of work, or purchase orders. The estimate of the amount of work completed is primarily based on the
status and timing of services performed, the number of patients enrolled, and the rate of patient enrollment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We identified research and development
expenses, accrued clinical trial liability, and prepaid research and development costs as a critical audit matter given the estimation involved in accounting for research and development expenses, accrued clinical trial liability, and prepaid
research and development costs, as well as the material weaknesses identified by the Company in its internal controls over financial reporting. This required extensive audit effort related to the estimation of research and development expenses,
accrued clinical trial liability and prepaid research and development costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>How the Critical Audit Matter Was Addressed in the Audit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit procedures related to research and development expenses, accrued clinical trial liability and prepaid research and development costs included the
following, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We selected a sample of amounts recognized as research and development expense, the accrued clinical trial
liability and prepaid research development expenses and performed the following procedures for each item selected: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We obtained and read related master service agreements, statements of work, purchase orders or other supporting
agreements with the CRO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We performed corroborating inquiries with Company&#146;s clinical operations personnel responsible for the
oversight of the activities regarding the nature and status of work performed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We inspected evidence from the third-party vendor regarding the payments made and the status and timing of
services performed, the number of patients enrolled, and the rate of patient enrollment incurred to date as well as payment information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We compared the data and evidence obtained from internal and external sources to the inputs used in the
Company&#146;s analysis and recalculated the related research and development expense, prepaid research and development expense, and the accrued clinical liability balances. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We tested the completeness and accuracy of the underlying data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We evaluated management&#146;s judgments regarding status and timing of services performed, the number of
patients enrolled, and the rate of patient enrollment compared to the evidence obtained. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We examined a selection of subsequent payments and the related invoices to determine whether the related research
and development expenses were appropriately recorded. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the material weaknesses, we increased the number of selections we
would have otherwise made if the Company&#146;s controls were effective. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_2"></A>BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AS OF
DECEMBER&nbsp;31, 2020 AND 2019 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands except share and per share amounts)</B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT ASSETS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PROPERTY AND EQUIPMENT&#151;Net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OPERATING LEASE RIGHT OF USE ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OTHER NONCURRENT ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT LIABILITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early option exercise liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LONG TERM LIABILITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMMITMENTS AND CONTINGENCIES (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONVERTIBLE PREFERRED STOCK, $0.001 PAR VALUE, 135,936,731 AND 147,231,000 SHARES AUTHORIZED AT
DECEMBER&nbsp;31, 2020 AND 2019, RESPECTIVELY; 114,686,731 and 70,936,735 SHARES ISSUED AND OUTSTANDING AT DECEMBER&nbsp;31, 2020 AND 2019, RESPECTIVELY, LIQUIDATION PREFERENCE OF $100,186,732 and $65,186,736 AT DECEMBER&nbsp;31, 2020 AND 2019,
RESPECTIVELY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS&#146; EQUITY (DEFICIT):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 196,000,000 and 185,007,408 shares authorized;
16,374,711 and 15,939,555 issued and outstanding, 900,509 and 3,193,307 subject to repurchase at December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top">&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top" ALIGN="right">15</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top">&nbsp;</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top" ALIGN="right">13</TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_3"></A>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands except share and per share amounts)</B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXPENSES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 14,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 17,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OPERATING LOSS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OTHER INCOME:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PROVISION FOR INCOME TAXES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NET LOSS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,539,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,578,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_4"></A>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands except share amounts) </B></P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B1 Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deficit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stockholders&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Equity&nbsp;(Deficit)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BALANCE&#151;January 1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;12,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,935,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of options&#151;net of repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of preferred stock for cash&#151;net of issuance costs of $245</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,749,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of early exercised stock options and restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,522,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BALANCE&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,749,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,746,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of options&#151;net of repurchase liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of preferred stock for cash&#151;net of issuance costs of $265</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,749,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of early exercised stock options and restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,280,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">BALANCE&#151;December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,499,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,474,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEMPEST THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_5"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2020 AND 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands)</B></P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OPERATING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash related party interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INVESTING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of related party note receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINANCING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of preferred stock issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of non vested options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NET INCREASE IN CASH AND CASH EQUIVALENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS &#151;Beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS &#151;End of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SUPPLEMENTAL DISCLOSURE FOR CASH FLOW ACTIVITIES&#151;Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NON-CASH</FONT> OPERATING ACTIVITIES&#151;Operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset recorded on adoption of ASC 842</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING ACTIVITIES&#151;Property and equipment
in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NON-CASH</FONT> FINANCING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs for issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock
in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt issuance costs related to financing in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of early exercise stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEMPEST THERAPEUTICS,&nbsp;INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc150774_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AS OF AND FOR THE YEARS ENDED DECEMBER&nbsp;31, 2020 AND 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS) </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DESCRIPTION OF THE BUSINESS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Nature of Business</B>&#151;Tempest Therapeutics (the Company)&nbsp;was incorporated in the state of Delaware on February&nbsp;10, 2011
originally as Next Beta,&nbsp;Inc., and then changed its name to Inception 2,&nbsp;Inc. on October&nbsp;4, 2011 and then finally to Tempest Therapeutics,&nbsp;Inc. on August&nbsp;14, 2017.&nbsp;The Company is a privately held, small
biopharmaceutical company focused on the discovery and development of small molecule drugs to treat cancers such as hepatocellular carcinoma and colorectal cancer. The Company is headquartered in South San Francisco, California. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Management Plans</B>&#151;The accompanying financial statements have been prepared assuming the Company will continue as a
going concern. In the course of its development activities, the Company has incurred significant losses since inception, including a net loss of approximately $19.2&nbsp;million and $14.4&nbsp;million for the years ended December&nbsp;31, 2020 and
2019, respectively, and expects such losses to continue for the foreseeable future. As of December&nbsp;31, 2020, and 2019, the Company had cash and cash equivalents of approximately $18.8&nbsp;million and $3.2&nbsp;million, respectively, and
accumulated deficit of approximately $71.8&nbsp;million and has forecasted cash needs in excess of current liquidity. To date, the Company has funded its operations primarily with the net proceeds from the sale of convertible preferred stock and
convertible preferred notes. As a result of these conditions, substantial doubt is raised about the Company&#146;s ability to continue as a going concern within one year after the date that the financial statements are available to be issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is continuing to develop its drug candidates, which is the primary use of funds for the Company. The Company&#146;s ability to fund
continued development will require additional capital, and the Company intends to raise such capital through the issuance of additional debt or equity including in connection with potential merger opportunities, or through business development
activities. As described in Note 14, on March&nbsp;29, 2021, Tempest entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Millendo Therapeutics, Inc. Concurrent with the execution and delivery of the Merger Agreement,
Tempest entered into funding agreements with certain investors named therein, pursuant to which the investors agreed to purchase, in the aggregate, $30.0&nbsp;million of Tempest common stock convertible into securities of Millendo. However, if such
financing is not approved, does not occur, or alternative financing is not available at adequate levels or on acceptable terms, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some
of its development programs, enter into a collaboration or other similar arrangement with respect to commercialization rights to any of its product candidates, <FONT STYLE="white-space:nowrap">out-license</FONT> intellectual property rights to its
product candidates and sell unsecured assets, or a combination of the above. Any of these actions could have a material adverse effect on the Company&#146;s business, results of operations, financial condition and/or its ability to fund its
scheduled obligations on a timely basis or at all. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish these plans and secure sources of financing and ultimately attain profitable
operations. If the Company is unable to obtain adequate capital, it could be forced to cease operations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These plans are intended to
mitigate the relevant conditions or events that raise substantial doubt about the Company&#146;s ability to continue as a going concern; however, as the plans are not entirely within the Company&#146;s control, management has determined it is not
probable they will be effectively implemented.<I> </I>The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation</B>&#151;The financial statements have been prepared in accordance with accounting principles generally accepted in
the United States of America (GAAP). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates</B>&#151;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the
reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, lease obligations, fair value of convertible preferred stock tranche liability, fair value of common stock <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation and income
taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Segment Information &#150; </B>The Company operates and manages its business as one reportable and operating segment, which is the business
of discovery and development of small molecule drugs to treat cancers. All assets and operations are in the U.S. The Company&#146;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate
basis for purposes of allocating resources and evaluating financial performance.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks and Uncertainties &#150; </B>The Company
is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key
personnel, reliance on single-source vendors, availability of raw materials, patentability of the Company&#146;s products and processes and clinical efficacy and safety of the Company&#146;s products under development, compliance with government
regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials
and regulatory approval, prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company&#146;s product candidates are still in
development and, to date, none of the Company&#146;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company&#146;s research and
development will be successfully completed, that adequate protection for the Company&#146;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved
products will be commercially viable. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid
technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Moreover, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> (coronavirus) pandemic, which is impacting worldwide economic activity,
poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by
governmental authorities. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will impact the Company&#146;s business will depend on future developments that are highly uncertain and cannot be predicted at this time.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk</B>&#151;Financial instruments, which potentially subject the Company to concentration of risk, consist
principally of cash and money market fund. All of the Company&#146;s cash and money market fund are deposited in accounts with a major financial institution, and amounts may exceed federally insured limits. Management believes that the Company is
not exposed to significant credit risk due to the financial strength of the depository institution in which the cash and money market fund are held. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company has no <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging
arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents</B>&#151;The Company considers all highly liquid investments purchased with original maturities
of 90 days or less at acquisitions to be cash equivalents. As of December&nbsp;31, 2020, and 2019, the Company&#146;s cash and cash equivalents consisted of bank deposits and a money market fund. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment</B>&#151;Property and equipment is recorded at cost and depreciated over the estimated useful lives of the related
assets using the straight-line method. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the asset accounts and any resulting gain or loss is included in the statement of operations. Repair and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment. The estimated useful lives of the Company&#146;s respective assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Shorter of the useful life of the asset or the life of the
lease</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets</B>&#151;Long-lived assets are reviewed for impairment if events or
circumstances indicate the carrying amount of these assets may not be recoverable. If this review indicates that these assets will not be recoverable, based on the forecasted undiscounted future operating cash flows expected to result from the use
of long-lived assets and their eventual disposition, the Company&#146;s carrying value of the long-lived assets is reduced to fair value based on a discounted future cash flow approach or quoted market values. During 2020 and 2019, there were no
events or circumstances which required an impairment test of long-lived assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Leases</B>&#151;The Company elected to early adopt
Accounting Standard Update (ASU) <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I>&nbsp;Leases </I>(ASC&nbsp;842) and its associated amendments as of January&nbsp;1, 2019 using the modified retrospective transition approach. There was no
cumulative-effect adjustment recorded to accumulated deficit upon adoption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under ASC&nbsp;842, the Company determines if an arrangement
is a lease at inception. In addition, the Company determines whether leases&nbsp;meet the classification criteria of a finance or operating&nbsp;lease at the lease commencement date considering: (1)&nbsp;whether the lease transfers ownership of the
underlying asset to the lessee at the end of the lease term, (2)&nbsp;whether the lease contains a bargain purchase option, (3)&nbsp;whether the lease term is for a major part of the remaining economic life of the underlying asset, (4)&nbsp;whether
the&nbsp;present value of the sum of the lease payments and residual value guaranteed by the lessee&nbsp;equals or exceeds substantially all of the fair value of the underlying asset, and (5)&nbsp;whether the underlying asset is of such a
specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December&nbsp;31, 2020 and 2019, the Company&#146;s lease population consisted only of an office lease. As of the date of adoption of
ASC&nbsp;842 and December&nbsp;31, 2019, the Company did not have finance leases. Operating leases are included in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets
and operating lease liabilities in the balance sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ROU assets represent the right to use an underlying asset for the lease term, and
lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The
Company uses the implicit rate when readily determinable. If the Company&#146;s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at commencement dates in determining the present value
of lease payments. The determination of the Company&#146;s incremental borrowing rate requires management judgment including the development of a synthetic credit rating and cost of debt as the Company currently does not carry any debt. The
incremental borrowing rate is estimated on a collateralized basis with similar terms and economic considerations under a recovery rate approach utilizing the historical recoverability rate of secured versus unsecured senior corporate debt to reflect
a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
recoverability-adjusted spread and overall rate on a lease by lease basis. The operating lease ROU assets also include any lease payments made and exclude lease incentives when paid by the
Company or on the Company&#146;s behalf. The Company&#146;s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company elected the practical expedient option that allows the Company to not need to
reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and the initial direct costs for any existing leases. The Company elected the practical expedient to adopt the
policy to not separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for its real estate leases. Operating leases are included in operating lease ROU assets and operating lease liabilities on the Company&#146;s balance
sheets. The Company also made an accounting policy election to recognize lease expense for leases with a term of 12&nbsp;months or less on a straight-line basis over the lease term and not recognize ROU assets or lease liabilities for such leases.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has a lease for its office facility, which is classified as an operating lease. This lease has a lease term of five years,
which includes an option to extend the lease. The Company has determined that it is not reasonably certain to exercise the option. The lease for the office includes costs for common area maintenance expenditures which are variable and not included
in lease payments measured at lease inception. Differences between lease payments as measured at lease inception and variations in monthly payments will be recognized as operating expenses in the period in which the obligation is incurred. Please
refer to Note&nbsp;7&nbsp;Commitments and Contingencies for details. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock</B>&#151;The Company records
convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&#146; deficit because the shares contain liquidation features that are not solely within
the Company&#146;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate
the Company to pay the liquidation preferences to holders of shares of convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a liquidation event
will occur. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock Liability</B>&#151;The obligation to issue additional shares of the Company&#146;s <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> convertible preferred stock at a future date was determined to be a freestanding financial instrument that should be accounted for as a liability. At initial recognition, the Company recorded the
convertible preferred stock liability on the balance sheet at its estimated fair value. The liability is subject to remeasurement at each balance sheet date, with changes in fair value recognized as a gain or (loss)&nbsp;on remeasurement of
convertible preferred stock liability on the statement of operations. The Company recognized a gain of $8.7&nbsp;million associated with the change in fair value of preferred stock liability for the period ended December&nbsp;31, 2019. In 2020,
there was no such gain or loss. The convertible preferred stock liability balance was zero as of December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss</B>&#151;Comprehensive loss includes net loss as well as other changes in stockholders&#146; deficit that results from
transactions and economic events other than those with stockholders. There was no other comprehensive income or loss for the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses and Accrued Research and Development</B>&#151;Research and development expenses are charged to expense as
incurred. Research and development expenses include certain payroll and personnel expenses, laboratory supplies, consulting costs, external contract research and development expenses. <FONT STYLE="white-space:nowrap">In-licensing</FONT> fees and
other costs to acquire technologies that are utilized in research and development, and that are not expected to have alternative future use, are expensed when incurred. Advance payments for goods or services for future research and development
activities are deferred and expensed as the goods are delivered or the related services are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company estimates preclinical studies and clinical trial expenses based on the services
performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company&#146;s behalf. In accruing service fees, the Company estimates the time
period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the <FONT STYLE="white-space:nowrap">third-party</FONT> service providers, the Company&#146;s
estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The
estimates are trued up to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#146;s
estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Patent
Costs &#150; </B>Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These patent related legal costs are reported as a component of general and administrative
expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expense &#150; </B>General and administrative costs are expensed as incurred and include
employee-related expenses including salaries, benefits, travel and stock-based compensation for the Company&#146;s personnel in executive, finance and accounting, and other administrative functions, as well as fees paid for legal, accounting and tax
services, consulting fees and facilities costs not otherwise included in research and development expense. Legal costs include general corporate legal fees and patent costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurements</B>&#151;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As such, fair value is a <FONT STYLE="white-space:nowrap">market-based</FONT> measurement that should be determined based on assumptions that market participants would
use in pricing an asset or liability. The carrying amounts of the Company&#146;s financial instruments, including cash, prepaid and other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their <FONT
STYLE="white-space:nowrap">short-term</FONT> maturities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock</B><B><FONT STYLE="white-space:nowrap">-Based</FONT> Compensation
Expense</B>&#151;The Company accounts for <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation by measuring and recognizing compensation expense for all <FONT STYLE="white-space:nowrap">share-based</FONT> payments made to employees,
directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> based on estimated <FONT STYLE="white-space:nowrap">grant-date</FONT> fair values. The Company uses the <FONT STYLE="white-space:nowrap">straight-line</FONT> method to allocate
compensation cost to reporting periods over each optionee&#146;s requisite service period, which is generally the vesting period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company estimates the fair value of stock options to employees, directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT>
<FONT STYLE="white-space:nowrap">option-valuation</FONT> model. The <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, <FONT
STYLE="white-space:nowrap">risk-free</FONT> rate of return, and the estimated fair value of the underlying common stock on the date of grant. Due to the lack of company-specific historical and implied volatility data, the Company has based its
estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of
representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses the simplified method to calculate the expected term for options granted to
employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The simplified method is based on the vesting period and the contractual term for each grant, or for each
vesting tranche for awards with graded vesting. The <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple
vesting-tranches, the times from grant until the <FONT STYLE="white-space:nowrap">mid-points</FONT> for each of the tranches may be averaged to provide an overall expected term. The risk-free interest rate is based on a treasury instrument whose
term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for forfeitures as they occur. The fair value of restricted stock
awards granted to employees are valued as of the grant date using the estimated fair value of the Company&#146;s common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Net Loss
per Share Attributable to Common Stockholders</B>&#151;The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net loss per share as the Company has issued shares that meet the definition of participating
securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed
earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive
dividends as if all income for the period had been distributed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed
by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common
stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders
by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purpose of this calculation, outstanding stock options, convertible preferred stock and warrants to purchase shares of
convertible preferred stock are considered potential dilutive common shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Income Taxes</B>&#151;The Company accounts for income
taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and
liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence,
including its operating results, ongoing tax planning and forecasts of future taxable income on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis. In the event the Company determines
that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event
that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&nbsp;31, 2020, and
2019, the Company has recorded a full valuation allowance on its deferred tax assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tax benefits related to uncertain tax positions are
recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B>&#151;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties
and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements</B>&#151;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards
Board, or FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the
Company&#146;s financial position or results of operations upon adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation
(Topic</I><I></I><I>&nbsp;718): Improvements to Nonemployees Share-Based Payment Accounting</I> <FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2018-07&#148;).</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07</FONT> expands the scope of
Topic&nbsp;718 (which currently only includes share-based payments to employees)&nbsp;to include share-based payments issued to nonemployees for goods or services. With the adoption of <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,</FONT> the
accounting for share-based payments for <FONT STYLE="white-space:nowrap">non-employees</FONT> and employees will be substantially the same. <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07</FONT> is effective for fiscal years beginning after
December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020, with early adoption permitted. The adoption of ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> on January&nbsp;1, 2020 did not have a
material impact on the Company&#146;s financial statements and related disclosures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2018-13,</FONT> <I>Fair Value Measurement (Topic 820) Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</I>. ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> resulted in certain
modifications to fair value measurement disclosures, primarily related to level 3 fair value measurements. The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2019, and early
adoption was permitted. The adoption of ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> on January&nbsp;1, 2020 did not have a material impact on the Company&#146;s financial statements and related disclosures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> Income Taxes (Topic 740), <I>Simplifying the
Accounting for Income Taxes</I>, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after
December&nbsp;15, 2021. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> is effective for the Company beginning January&nbsp;1, 2022. Early adoption is permitted. The Company has early adopted this guidance on January&nbsp;1, 2020 and the impact
on the Company&#146;s financial statements was not material. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2020-01,</FONT> <I>Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).</I> ASU <FONT STYLE="white-space:nowrap">2020-01</FONT>
states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU
clarifies the accounting for certain <FONT STYLE="white-space:nowrap">non-derivative</FONT> forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic
321 before settlement or exercise. The ASU is effective for fiscal years beginning after December&nbsp;15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company adopted ASU
<FONT STYLE="white-space:nowrap">2020-01</FONT> on January&nbsp;1, 2021, which did not have a material effect on the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-06</FONT><I>, Debt-Debt With Conversations and Other Options
(Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging-Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40)</FONT></I>. The ASU simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. Under the new ASU, convertible instruments will now more frequently accounted for as a single unit of
account. That is, a conversion feature and the host instrument in which it is embedded now generally will be treated as a single unit of account unless the conversion feature requires bifurcation under Topic 815. The ASU is effective for fiscal
years beginning after December&nbsp;15, 2021 for public business entities, and for fiscal years beginning after December&nbsp;15, 2023 for all other entities. Early adoption is permitted. The Company is in the process of evaluating the impact of
this new guidance on its financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Correction of Errors</B> &#150; Subsequent to the issuance of the financial statements as
of and for the year ended December&nbsp;31, 2019, the Company determined that the following disclosures were incorrect, and accordingly the Company has corrected the amounts as of December&nbsp;31, 2019 in the respective sections referenced as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convertible preferred stock number of shares authorized were overstated by 5,000,000 shares from amount
previously reported of 152,231,000 as disclosed on the face of the balance sheet. The Company corrected the convertible preferred stock number of shares authorized as disclosed on the face of the accompanying balance sheet as of December&nbsp;31,
2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common stock number of shares issued and outstanding were overstated by 190,383 shares from amount previously
reported of 16,129,938 on the face of the balance sheet. The Company corrected the common stock number of shares issued and outstanding as disclosed on the face of the accompanying balance sheet as of December&nbsp;31, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common stock number of shares outstanding subject to repurchase were overstated by 3,001,183 shares from amount
previously reported of 6,194,490 on the face of the balance sheet. The Company corrected the common stock number of shares outstanding subject to repurchase on the face of the accompanying balance sheet as of December&nbsp;31, 2019.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Options available for grant under stock plan number of shares were understated by 115,962 shares from amount
previously reported of 2,990,912 in footnote 9 in the table of reserved common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis for future issuance. The Company corrected the options available for grant number of shares as of
December&nbsp;31, 2019 within the referenced table in footnote 9. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares available for grant Balance as of December&nbsp;31, 2019 number of shares were understated by 115,962
shares from amount previously reported of 2,990,912 in footnote 10 in the table of Stock option activity under the plan. The Company corrected the shares available for issuance balance as of December&nbsp;31, 2019 within the referenced table in
footnote 10.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares available for grant - Restricted stock repurchased for the period ended December&nbsp;31, 2019 were
understated by 115,963 shares from amount previously reported of 359,205 in footnote 10 in the table of Stock option activity under the plan. The Company corrected the shares available for grant-restricted stock repurchased for the period ended
December&nbsp;31, 2019 within the referenced table in footnote 10. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unvested shares related to early option exercise liability as of December&nbsp;31, 2019 were overstated by 20,412
shares from amount previously reported of 3,213,719 in footnote 6 and footnote 10. The Company corrected the unvested shares as of December&nbsp;31, 2019 within footnote 6 and footnote 10. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company believes the corrections of the disclosure errors noted above are immaterial to the previously issued financial statements as a
whole. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FAIR VALUE MEASUREMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The authoritative guidance on fair value measurements establishes a <FONT STYLE="white-space:nowrap">three-tier</FONT> fair value hierarchy for
disclosure of fair value measurements as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;1</I></B>&#151;Quoted prices in active
markets for identical assets or liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;2</I></B>&#151;Observable inputs other than
Level&nbsp;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the
assets or liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Level</I></B><B><I></I></B><B><I>&nbsp;3</I></B>&#151;Unobservable inputs that are supported by little or no
market activity and that are significant to the fair value of the assets or liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities measured at fair value are
classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#146;s assessment of the significance of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments consist of Level&nbsp;1 assets and Level&nbsp;3 liabilities. Level&nbsp;1 assets are measured at fair
value on a recurring basis and consist of a money market fund. Level&nbsp;3 liabilities that are measured at fair value on a recurring basis consist of convertible preferred stock tranche liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, the Company has not changed the manner in which it values assets and liabilities that are measured at estimated
fair value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. The Company&#146;s fair
value hierarchy for its assets and financial liabilities that are carried at fair value was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities&#151;convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities&#151;convertible preferred stock tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, the Company recognized $8.7&nbsp;million in realized gains on the
preferred stock liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The changes in the carrying value of the liability were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of convertible preferred stock tranche liability change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of the redeemable convertible preferred stock tranche liability is based on significant
unobservable inputs, which represent Level&nbsp;3 measurements within the fair value hierarchy. In determining the fair value of the convertible preferred stock tranche liability, the Company used the Probability-Weighted Expected Return Method,
&#147;PWERM&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There were no transfers within the hierarchy during the years ended December&nbsp;31, 2020 and 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSACTIONS WITH RELATED PARTIES (AMOUNTS IN THOUSANDS) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Inception Sciences Service Agreements</B>&#151;Inception Sciences is wholly owned by Versant which is a majority shareholder of the Company.
The Company has service agreements with Inception Sciences US, and Inception Sciences Canada whereby research and support services are provided to the Company. On June&nbsp;30, 2020, the Company terminated these Inception Sciences service
agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total expenses under the service agreements consist of charges for services, equipment usage, lab supplies and other out of
pocket expenses as incurred. For the years ended December&nbsp;31, 2020 and 2019, the Company incurred $1,315 and $4,770, respectively, in expenses under the Inception Sciences service agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Related Party Notes Receivable</B>&#151;On November&nbsp;29, 2017, three officers of the Company issued promissory notes to the Company
totaling $353 related to the early exercise of their stock options which had a total exercise cost of $652. Two officers paid $298 which represents 50% of the exercise cost and the other 50% totaling $298 was recorded as notes receivable. The other
officer did not pay any portion of the exercise cost and $55 was recorded as note receivable. The three notes receivable accrue interest at 2% per year and will mature on November&nbsp;29, 2022. The notes receivable vest over time until maturity in
conjunction with the vesting of the early-exercised stock options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2020, one of the officers left the Company and repaid $44
of which $43 was the vested portion of the note receivable and $1 was accrued interest. As of December&nbsp;31, 2020 and 2019, the balance of the vested notes receivable and accrued interest was $260 and $200, respectively. For the years ended
December&nbsp;31, 2020 and 2019, total related party interest income was $6 and $7, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BALANCE SHEET ITEMS (AMOUNTS IN THOUSANDS) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current asset consist of the following as of December&nbsp;31, 2020 and 2019 : </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes and interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following as of December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold Improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense related to property and equipment was $339 and $104 for the years ended
December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities as of December&nbsp;31, 2020 and 2019 consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, accrued other liabilities include primarily accrual for legal services related to
intellectual properties, debt issuance and corporate legal, and research and development activities totaling $352. As of December&nbsp;31, 2019, accrued other liabilities include primarily accrual for legal services related to intellectual
properties and preferred stock issuance, and research and development activities totaling $271. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EARLY OPTION EXERCISE LIABILITY (AMOUNTS IN THOUSANDS) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The recorded amount of the early option exercise liability relates to restricted stock awards and stock options granted to certain employees
and contractors that were early-exercised before they became vested. The early option exercise liability decreases as the restricted stock awards and stock options vest over time or if the Company decides to repurchase them, and the amount of
decrease is recorded in common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. During 2020, certain early-exercised unvested stock options of 32,635 were repurchased by the Company for $1. As of December&nbsp;31, 2020
and 2019, the early option exercise liability was $79 and $241, respectively, which represents unvested shares of 900,509 and 3,193,307. The unvested shares purchased by the employees are not deemed, for accounting purposes, to be issued and
outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMITMENTS AND CONTINGENCIES (AMOUNTS IN THOUSANDS) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Facility Lease Agreement</B>&#151;In February 2019, the Company entered into a <FONT STYLE="white-space:nowrap">5-year</FONT> office lease
agreement for a 9,780 square feet facility in South San Francisco, California. The remaining lease term of the office lease is three years and two months as of December&nbsp;31, 2020, and the discount rate used to calculate the Company&#146;s right
of use asset and lease liability is 4.25%. There are no other leases as of December&nbsp;31, 2020 and 2019. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020
and 2019, the balance of the operating lease right of use assets were $1,877 and $2,353, respectively, and the related operating lease liability were $2,439 and $2,364, respectively, as shown in the accompanying balance sheets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Related to the facility lease agreement, the Company entered into a letter of credit with a bank to deposit $51 as security rent deposit for
the South San Francisco office. This amount is shown as other noncurrent assets in the accompanying balance sheets as of December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rent expense was $665 for the year ended December&nbsp;31, 2020 and $623 for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2020 and 2019 the Company paid a total of $734 and $529, respectively for the operating lease liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Future minimum annual lease payments under the Company&#146;s operating lease liabilities as
of December&nbsp;31, 2020 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ending</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Commitment</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Guarantees and Indemnifications</B>&#151;In the normal course of business, the Company enters into
agreements that contain a variety of representations and provide for general indemnification. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the
Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of December&nbsp;31, 2020, and 2019, the Company does not have any material indemnification claims that were probable or reasonably
possible and consequently has not recorded related liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings &#150; </B>From time to time, the Company may become
involved in litigation relating to claims arising from the ordinary course of business. Management believes that there are no actions pending against the Company currently, the ultimate disposition of which would have a material adverse effect on
the Company&#146;s results of operations, financial condition or cash flows. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONVERTIBLE PREFERRED STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company was authorized to issue up to 135,936,731&nbsp;shares of preferred stock at a par value of $0.001.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences at December&nbsp;31, 2020 and
2019 were as follows (in thousands except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Series</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares Issued</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per Share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation<BR>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proceeds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Net of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issuance&nbsp;Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Net<BR>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,749,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,499,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,936,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,686,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Series</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares&nbsp;Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Per Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Aggregate<BR>Liquidation<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proceeds</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Net of<BR>Issuance&nbsp;Cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Net<BR>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,293,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,938,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,749,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,231,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,936,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2011, the Company received a commitment from its venture investor for a Series A Preferred Stock
financing totaling $10&nbsp;million to be taken down in two tranches of $5&nbsp;million each. Upon execution of the stock purchase agreement, the Company received the first tranche of $5&nbsp;million, which included $2,399 in cash proceeds and the
conversion of notes payable and accrued interest totaling $2,601 for issuing 5,000,000 shares of its Series A Preferred Stock. In June 2012, the Company received cash proceeds of $5&nbsp;million related to the second tranche of the Series A
Preferred Stock financing from the issuance of 5,000,000 shares of Series A Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2015, the Company issued an
additional 2,000,000 shares of Series A Preferred Stock to its venture investor for cash proceeds of $2&nbsp;million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In September 2016,
the Company issued an additional 5,000,000 shares of Series A Preferred Stock to its venture investor for cash proceeds of $5&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the Company issued 25,186,738&nbsp;shares of Series&nbsp;B Preferred Stock for $1.00 per share in connection with the closing
of the Series&nbsp;B Preferred Stock Purchase Agreement. The Company&#146;s convertible notes of $8.0&nbsp;million and accrued interest was converted as part of the Series&nbsp;B offering. Investors in the Series&nbsp;B convertible preferred stock
financing also received freestanding rights to purchase additional shares of Series&nbsp;B convertible preferred stock on the same terms as the first closing upon completion of certain defined milestones or waiver of the milestones by the holders of
at least 67% of the outstanding convertible preferred stock, voting as a single class on an as converted basis. In August 2018, the terms of the Series&nbsp;B Agreement were amended. The amendment allowed for the purchase of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1&nbsp;shares</FONT> at a price of $0.80 per share based upon the completion of certain amended milestones. These milestones are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Second Tranche Milestones: </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clearance by the U.S. Food and Drug Administration of the filing by the Company of an investigational new drug
application (IND) for PPAR&#945; antagonist. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selection of an EP2/EP4 dual antagonist DC. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Third Tranche Milestones: </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstration of safety/tolerability and clinical Proof of Mechanism with PPAR&#945; antagonist.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Single additional program having a data package that is sufficient for submitting an IND. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The investors&#146; rights to purchase Series&nbsp;B and <FONT STYLE="white-space:nowrap">B-1</FONT> convertible preferred stock represent a
freestanding financial instrument accounted for as a liability measured at fair value at inception and remeasured at fair value each reporting date. Based on the probability vs. 100% of the milestones for the purchase of Series <FONT
STYLE="white-space:nowrap">B-1&nbsp;shares</FONT> as of December&nbsp;31, 2019, this resulted in a fair value of $0 at such date. Changes in fair value are recognized in the statement of operations. The proceeds from the initial closing of the
Series&nbsp;B convertible preferred stock of $25.2&nbsp;million were allocated to the convertible preferred stock tranche liability at its initial fair value of $12.7&nbsp;million with the remaining amount allocated to the carrying value of the
Series&nbsp;B convertible preferred stock. The fair value of the convertible preferred stock tranche liability was determined using an option pricing model approach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company issued 28,749,997&nbsp;shares of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> preferred stock for $0.80 per share for total cash proceeds of $23&nbsp;million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
January 2020, the Company issued 43,749,996&nbsp;shares of <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> preferred stock for $0.80 per share for total cash proceeds of $35&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The significant rights, preferences, and privileges of the convertible preferred stock as of December&nbsp;31, 2020 were as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends</I></B>&#151;The holders of the Company&#146;s convertible preferred stock are entitled to receive noncumulative dividends of
8% per share (as adjusted for stock splits, combinations, and reorganizations)&nbsp;per annum on each outstanding share of Series convertible preferred stock. Such dividends shall be payable only when and if declared by the Board of Directors. As of
December&nbsp;31, 2020, and 2019, the Company&#146;s Board of Directors had not declared any dividends. Dividends on convertible preferred stock shall be payable in preference to and prior to any payments of any dividends on common stock. No
dividends have been declared to date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion</I></B>&#151;The Company&#146;s preferred stock is convertible, at the option of
the holder into an equal number of shares of common stock, at the option of the holder, subject to certain <FONT STYLE="white-space:nowrap">anti-dilution</FONT> adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each share of preferred stock is automatically converted into common stock immediately upon (i)&nbsp;the Company&#146;s sale of its common
stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, in which per share price is at least $3.00 (as adjusted), and the gross cash proceeds are at least
$50&nbsp;million or (ii)&nbsp;the affirmative vote of the requisite preferred holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The conversion of Series&nbsp;B shares, either at
the option of the holder or automatically, requires the prior vote or consent of the holders of at least 70% of the Series&nbsp;B preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights</I></B>&#151;The holders of preferred stock are entitled to one vote for each share of common stock into which such
preferred stock could then be converted; and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation</I></B>&#151;The holders of preferred stock are entitled to receive liquidation preferences at an amount per share of
preferred stock equal to the original price plus all declared and unpaid dividends on the preferred stock. Liquidation payments to the holders of preferred stock have priority and are made in preference to any payments to the holders of common
stock. After full payment of the liquidation preference to the holders of the preferred stock, the remaining assets, if any, will be distributed ratably to the holders of the common stock and preferred stock on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-if-converted</FONT></FONT> to common stock basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption and Balance Sheet
Classification</I></B>&#151; The convertible preferred stock is recorded within mezzanine equity because while it is not mandatorily redeemable, it will become redeemable at the option of the stockholders upon the occurrence of certain deemed
liquidation events that are considered not solely within the Company&#146;s control. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMON STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company was authorized to issue 196,000,000&nbsp;shares of common stock at a par value of $0.001.&nbsp;Of the
196,000,000 common stock shares authorized, 16,374,711 are legally issued and outstanding at December&nbsp;31, 2020, with 900,509&nbsp;shares subject to repurchase due to remaining vesting requirements. Common stockholders are entitled to dividends
as declared by the Board of Directors, subject to rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holders of each share of common stock are entitled to
one vote. Except for effecting or validating certain specific actions intended to protect the preferred stockholders, the holders of common stock vote together with preferred stockholders and have the right to elect one member of the Company&#146;s
Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of the shares of common stock has historically been determined by management
and approved by the Board of Directors. Because there has been no public market for the Company&#146;s common stock, the Board of Directors has determined the fair value of the common stock by considering a number of objective and subjective
factors, including contemporaneous valuations performed by an unrelated <FONT STYLE="white-space:nowrap">third-party</FONT> specialist, important developments in the Company&#146;s operations, the prices at which the Company sold shares of
convertible preferred common stock, the rights, privileges, and preferences of the Company&#146;s convertible preferred stock relative to the Company&#146;s common stock, valuations of comparable public companies, operating and financial
performance, the lack of liquidity of capital stock, and general and <FONT STYLE="white-space:nowrap">industry-specific</FONT> economic outlook. Valuations performed by the <FONT STYLE="white-space:nowrap">third-party</FONT> valuation specialist
used the methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Privately-Held-Company</FONT></FONT> Equity Securities Issued as Compensation (AICPA Accounting and Valuation Guide). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company had reserved common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis for future issuance as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,499,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,749,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options available for grant under stock plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,211,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,106,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options under stock plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,042,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,227,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,940,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,271,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>STOCK COMPENSATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2011 the Company adopted the 2011 Equity Incentive Plan, and in 2017, the Company adopted the 2017 Equity Incentive Plan, together &#147;the
Plans&#148;. Upon adoption of the 2017 Equity Incentive Plan, the 2011 Equity Incentive Plan was terminated. Both the Plans provide for the granting of stock awards to employees, directors and consultants of the Company. Awards issuable under the
Plans include incentive stock options (ISO), nonqualified stock options (NSO), stock appreciation rights (SAR), restricted stock awards, restricted stock unit awards and other stock awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Options to purchase the Company&#146;s common stock may be granted at a price not less than the fair market value in the case of both NSOs and
ISOs, except for an employee or <FONT STYLE="white-space:nowrap">non-employee</FONT> with options who owns more than 10&nbsp;percent of the voting power of all classes of stock of the Company, in which case the exercise price shall be no less than
110&nbsp;percent of the fair market value per share on the grant date. Stock options granted under the Plans generally vest over four years and expire no later than ten (10)&nbsp;years from the date of grant. Vested options can be exercised at any
time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The grant date fair market value of the shares of common stock underlying stock options has historically been determined by the
Company&#146;s Board of Directors. Because there has been no public market for the Company&#146;s common stock, the Board of Directors exercises reasonable judgment and considers a number of objective and subjective factors to determine the best
estimate of the fair market value, which include valuations performed by an independent <FONT STYLE="white-space:nowrap">third-party,</FONT> important developments in the Company&#146;s operations, sales of convertible preferred stock, actual
operating results, financial performance, the conditions in the life sciences industry, the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#146;s common stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock option activity under the Plan is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Available</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>for
Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total&nbsp;Options</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;January 1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,959,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,190,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,049,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,049,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(290,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,721,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,721,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,106,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,227,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional shares authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,366,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,971,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,971,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(447,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">709,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(709,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,211,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,042,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes information about stock options outstanding at December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Contractual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Life&nbsp;(In&nbsp;Years)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Intrinsic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,042,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;2,214,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,911,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,022,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,805,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 646,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of options exercised during 2020 and 2019 was $16,408 and zero, respectively, and is
calculated based on the difference between the exercise price and the fair value of the Company common stock as of the exercise date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Employee Stock Options</B>&#151;During the years ended December&nbsp;31, 2020 and 2019, the Company granted stock options to employees to
purchase 6,524,854 and 4,722,063, shares of common stock with a <FONT STYLE="white-space:nowrap">weighted-average</FONT> grant date fair value of $0.11 and $0.09 per share, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was total unrecognized compensation costs related to unvested employee stock options of $942. These costs
are expected to be recognized over a <FONT STYLE="white-space:nowrap">weighted-average</FONT> period of approximately 1.6&nbsp;years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company estimated the fair value of stock options using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing valuation model. The fair value of employee stock options is being amortized on the
<FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following range of assumptions during 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0&#150;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62%&#150;66%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4%&#150;0.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expected Term</I></B>&#151;The expected term of options granted represents the period of time that the
options are expected to be outstanding. Due to the lack of historical exercise history, the expected term of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company&#146;s employee stock options has been determined utilizing the simplified method for awards that qualify as <FONT STYLE="white-space:nowrap">plain-vanilla</FONT> options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expected Volatility</I></B>&#151;The expected stock price volatility assumption was determined by examining the historical volatilities
for industry peers, as the Company did not have any trading history for the Company&#146;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the
Company&#146;s common stock becomes available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risk</I></B><B><I><FONT STYLE="white-space:nowrap">-Free</FONT> Interest
Rate</I></B>&#151;The <FONT STYLE="white-space:nowrap">risk-free</FONT> interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#146;s stock options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends</I></B>&#151;The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any
dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Non</B><B><FONT
STYLE="white-space:nowrap">-Employee</FONT> Stock Options</B>&#151;During the years ended December&nbsp;31, 2020 and 2019, the Company granted stock options to <FONT STYLE="white-space:nowrap">non-employees</FONT> to purchase 446,900 and
327,500&nbsp;shares of common stock, respectively. During 2019 the fair value of stock options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> was calculated at each vesting date. Upon the Company&#146;s adoption of ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> all unvested shares were valued as of January&nbsp;1, 2020 and all subsequent options were valued at the grant date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, there was total unrecognized compensation costs related to unvested
<FONT STYLE="white-space:nowrap">non-employee</FONT> stock options of $33. These costs are expected to be recognized over a <FONT STYLE="white-space:nowrap">weighted-average</FONT> period of approximately 0.7&nbsp;years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of stock options using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing valuation
model. The fair value of <FONT STYLE="white-space:nowrap">non-employee</FONT> stock options is being amortized on the <FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the requisite service period of the awards. The fair value of <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock options was estimated using the following range of assumptions during 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64%&#150;65%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expected Term</I></B>&#151;The expected term of options granted represents the period of time that the
options are expected to be outstanding. The Company has valued its <FONT STYLE="white-space:nowrap">non-employee</FONT> stock options using the contractual term as the expected term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expected Volatility</I></B>&#151;The expected stock price volatility assumption was determined by examining the historical volatilities
for industry peers, as the Company did not have any trading history for the Company&#146;s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the
Company&#146;s common stock becomes available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risk</I></B><B><I><FONT STYLE="white-space:nowrap">-Free</FONT> Interest
Rate</I></B>&#151;The <FONT STYLE="white-space:nowrap">risk-free</FONT> interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#146;s stock options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends</I></B>&#151;The Company has not paid any cash dividends on common stock since inception and does not anticipate paying any
dividends in the foreseeable future. Consequently, an expected dividend yield of zero was used. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock</B>&#151;In 2011 the
Company sold 2,440,000&nbsp;shares of common stock to founders at $0.001 per share, that were subject to certain vesting restrictions. During 2017 the Company modified the vesting schedules of 1,406,673 of these shares, 666,667 of which affected one
employee and 740,006 affected 21 <FONT STYLE="white-space:nowrap">non-employees.</FONT> The modifications provided for a <FONT STYLE="white-space:nowrap">four-year</FONT> vesting schedule for shares that were not previously expected to vest. The
modifications were accounted for as cancellations and <FONT STYLE="white-space:nowrap">re-issuance</FONT> of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The shares to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> are valued
based on an estimate of the Company&#146;s common stock price on the grant date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The activity of the unvested restricted stock during 2020
and 2019 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance&#151;January 1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">853,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(288,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">486,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(486,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All stock-based compensation related to restricted stock has been recognized as of December&nbsp;31, 2020.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Stock</B><B><FONT STYLE="white-space:nowrap">-Based</FONT> Compensation Expense</B>&#151;The following table summarizes the components
of <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense recognized in the Company&#146;s statement of operations during 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Share Based Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Early Exercise Liability</B>&#151;Stock options may be exercised, and restricted stock may be purchased
prior to the time that the awards have vested, provided that such shares shall remain subject to repurchase until such time as they have vested. The right to repurchase these shares generally lapses over three to four years. As of December&nbsp;31,
2020 and 2019, there were 900,509 and 3,193,307 unvested shares representing an early exercise liability of $79 and $241, respectively. The unvested shares purchased by the employees are not deemed, for accounting purposes, to be issued and
outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RETIREMENT PLAN </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company participates in a qualified 401(k)&nbsp;Plan sponsored by its professional service organization. The retirement plan is a defined
contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. There was no contribution from the Company in 2020 and 2019.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TAXES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has no provision for income taxes in 2020. This differs from the amounts computed by applying the statutory income tax rate of 21%
to <FONT STYLE="white-space:nowrap">pre-tax</FONT> loss primarily due to research credits generated and changes in the valuation allowance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provision (benefit) for income taxes consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;<BR>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;<BR>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision (Benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;<BR>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Income tax provision (benefit) related to continuing operations differ from the amounts computed by applying
the statutory income tax rate of 21% to pretax loss as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>U.S. Federal provision (benefit)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;(4,033)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;(3,017)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mark-to-market</FONT></FONT>
adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred tax assets at December&nbsp;31, 2020 and 2019 are shown
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has recorded a full valuation allowance against its net deferred tax assets due
to the uncertainty as to whether such assets will be realized. The valuation allowance increased by $6.4&nbsp;million from December&nbsp;31, 2019 to December&nbsp;31, 2020 due primarily to the generation of net operating losses and research and
development credits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company has net operating loss carryforwards for federal and California income tax
purposes of approximately $80.9&nbsp;million and $80.3&nbsp;million, respectively. As of December 31, 2019, the Company has net operating loss carryforwards for federal and California income tax purposes of approximately $62.9 million and $63.3
million, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The federal and state net operating loss carryforwards begin to expire in 2031, if not utilized. Federal net
operating losses of $40.0&nbsp;million are not subject to expiration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company also has federal and state
research and development carryforwards of approximately $3.9&nbsp;million and $1.9&nbsp;million, respectively. As of December 31, 2019, the Company also has federal and state research and development carryforwards of approximately $3.1 million and
$1.6 million, respectively. The federal credits begin to expire in 2031 and the state credits can be carried forward indefinitely. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Utilization of some of the federal and state net operating loss and credit carryforwards may be subject to annual limitations due to the
&#147;change in ownership&#148; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company has not performed a
Section&nbsp;382 study as of December&nbsp;31, 2020. State net operating losses are being computed based on an alternate apportionment methodology.&nbsp;Amounts reported can change accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, the Company has approximately $1.3&nbsp;million in unrecognized tax benefits, excluding indirect tax effects. Of
the total unrecognized tax benefits at December&nbsp;31, 2020, $1.3&nbsp;million was recorded as a reduction to deferred tax assets, which caused a corresponding reduction in the Company&#146;s valuation allowance of $1.3&nbsp;million. The Company
does not anticipate that the amount of unrecognized tax benefits as of December&nbsp;31, 2020 will change materially within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following December&nbsp;31, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has the following activity relating to unrecognized tax benefits: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross increase - tax positions in prior periods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross decreases - tax positions in prior periods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross increases - tax position in current period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lapses in statutes of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s practice is to recognize interest and/or penalties related to income tax matters in income
tax expense. The Company had no accrual for interest and penalties on the accompanying balance sheet as of December&nbsp;31, 2020 and has not recognized penalties and/or interest in the accompanying statement of operations for the year ended
December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and various states. The
Company&#146;s tax years from inception are subject to examination by the IRS and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NET LOSS PER SHARE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the Company&#146;s basis in diluted net loss per share for the years ended December&nbsp;31,
2020 and 2019 (in thousands except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (19,208)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (14,365)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,184,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,924,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Weighted-average unvested restricted shares and shares subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,645,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,346,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,539,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,578,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to common stockholders - basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (1.32)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (1.14)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020 and 2019, the Company&#146;s potentially dilutive securities included preferred
stock, unvested restricted stock and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. Based on the amounts outstanding as of
December&nbsp;31, 2020 and 2019, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,186,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,499,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,749,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,042,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,227,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,193,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,629,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,357,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBSEQUENT EVENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events occurring through May&nbsp;10, 2021, the date when these financial statements are available to be
issued. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Term Loan</B>&#151;On January&nbsp;15, 2021, the Company entered into a loan agreement with a lender to borrow a term loan
amount of $35.0&nbsp;million to be funded in three tranches. Tranche A of $15.0&nbsp;million was wired to the Company on January&nbsp;15, 2021. Tranche B of $10.0&nbsp;million will be available through March&nbsp;31, 2022 contingent upon achievement
of each of the following: i) receipt of at least $50,000,000 in Series C equity capital, ii) initiation of the Phase 1 combination study of TPST-1495 or monotherapy expansion study, and iii) initiation of Phase 2 trial of TPST-1120 or the 1L Triplet
Collaboration study. And Tranche C of $10.0&nbsp;million is available at lender&#146;s option. The term loan matures on August&nbsp;1, 2025 and has an annual floating interest rate of 7.15% which is an Index Rate plus 7%. Index Rate is the greater
of (i) <FONT STYLE="white-space:nowrap">30-day</FONT> US LIBOR or (ii) 0.15%. Concurrent with the funding of an amount under each Tranche, the Company will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
grant the lender a warrant to purchase shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock equal to 1% of the funded amount. For Tranche A, the Company issued 187,500
Series <FONT STYLE="white-space:nowrap">B-1</FONT> stock warrants. No Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock warrants have been issued for Trances B and C since those tranches have not been funded yet. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Reverse Merger</B>&#151;On March&nbsp;29, 2021, Tempest entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with
Millendo Therapeutics, Inc., or (&#147;Millendo&#148;), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly owned subsidiary of Millendo will merge with and into
Tempest, with Tempest becoming a wholly-owned subsidiary of Millendo and the surviving corporation of the merger. At the closing of the merger, each outstanding share of Tempest&#146;s capital stock (including preferred stock) will be converted into
the right to receive shares of common stock of Millendo at a ratio whereby the equity holders of Tempest will become the majority owners (81.5%) of Millendo&#146;s outstanding common stock on a full-diluted basis upon the close of the merger (the
&#147;Merger&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under
this method of accounting, Tempest will be deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the expectations that, immediately following the Merger: (1)&nbsp;Tempest stockholders will
own substantial majority of the voting rights; (2)&nbsp;Tempest will designate a majority of the initial members of the board of directors of the combined organization; and (3)&nbsp;Tempest&#146;s senior management will hold key positions in senior
management of the combined organization. Accordingly, for accounting purposes, the Merger will be treated as the equivalent of Tempest issuing stock to acquire the net assets of Millendo. As a result of the Merger, the net assets of Millendo will be
recorded at their acquisition-date fair value in the financial statements of Tempest and the reported operating results prior to the Merger will be those of Tempest. Any excess in consideration paid will be presented as cost of equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution and delivery of the Merger Agreement, Tempest entered into Funding Agreements with certain
investors named therein, pursuant to which the investors agreed to purchase, in the aggregate, $30.0&nbsp;million of Tempest common stock convertible into securities of Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_201"></A>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION COPY </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MILLENDO
THERAPEUTICS, INC., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARS MERGER CORP., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEMPEST
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of March&nbsp;29, 2021 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">THE MERGER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time of the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and Officers of the Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;II</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONVERSION OF SECURITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Capital Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Stock Plans and Merger Partner Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dissenting Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES OF MERGER PARTNER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organization, Standing and Power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authority; No Conflict; Required Filings and Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements; Information Provided</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Undisclosed Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Certain Changes or Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Owned and Leased Real Properties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Benefit Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance With Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permits and Regulatory Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokers; Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain Business Relationships With Affiliates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controls and Procedures, Certifications and Other Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Books and Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Public Company Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Data Protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Other Representations or Warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;IV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REPRESENTATIONS AND WARRANTIES OF PUBLIC COMPANY AND THE MERGER SUB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Organization, Standing and Power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authority; No Conflict; Required Filings and Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Filings; Financial Statements; Information Provided</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Undisclosed Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Certain Changes or Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Owned and Leased Real Properties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Benefit Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance With Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permits and Regulatory Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opinion of Financial Advisor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokers; Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operations of Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain Business Relationships With Affiliates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controls and Procedures, Certifications and Other Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Books and Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Data Protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Other Representations or Warranties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;V</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONDUCT OF BUSINESS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covenants of Merger Partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Covenants of Public Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;VI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADDITIONAL AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Solicitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Statement/Prospectus; Registration Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Listing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Access to Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Conditions to Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;368(a) Reorganization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate Legends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of Certain Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FIRPTA Tax Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Takeover Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security Holder Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;16 Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calculation of Public Company Net Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">401(k) Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE VII</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONDITIONS TO MERGER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-65</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions to Each Party&#146;s Obligation To Effect the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Conditions to the Obligations of Public Company and Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Conditions to the Obligations of Merger Partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE&nbsp;VIII</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TERMINATION AND AMENDMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extension; Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Procedure for Termination, Amendment, Extension or Waiver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman; ">ARTICLE IX</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonsurvival of Representations, Warranties and Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Third Party Beneficiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts and Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remedies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Submission to Jurisdiction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WAIVER OF JURY TRIAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Exhibit&nbsp;A-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Merger Partner Support Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">A-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Public Company Support Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Surviving Corporation Certificate of Incorporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Surviving Corporation Bylaws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annex A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Illustration of Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annex B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Illustration of Public Company Net Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF DEFINED TERMS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cross&nbsp;Reference</B><br><B>in Agreement</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting Firm</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.3(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aggregate Valuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alternative Acquisition Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;6.1(b)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticipated Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankruptcy and Equity Exception</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization Reference Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CARES Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.8(q)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash Determination Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;6.17(d)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Code</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 5.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.11(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.3(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DGCL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dissenting Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Benefit Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.14(i)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Environmental Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.13(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ERISA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.14(i)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ERISA Affiliate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.14(i)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Families First Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.8(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Funding Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governmental Entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hazardous Substance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.13(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IND</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(d)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnified Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.10(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Designees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.5(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual Property Registrations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(ii)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cross&nbsp;Reference</B><br><B>in Agreement</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intervening Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.14(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.10(l)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liens</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Allocation Percentage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Authorizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.16(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Board Recommendation Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Capital Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Disclosure Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Article III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Employee Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.14(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Insurance Policies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.9(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Licensed Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Material Adverse Effect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Merger Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2,1(c)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Outstanding Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Owned Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(vi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2 (a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Registrations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.10(l)(vii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Stock Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Stockholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Support Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Tail Policy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.10(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 8.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Valuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Voting Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Partner Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Most Recent Balance Sheet Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Application</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(d)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Course of Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.3(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outside Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 8.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.10(l)(viii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Closing Public Company Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(vi)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Statement/Prospectus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company 401(k) Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Allocation Percentage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(vii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Authorizations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.16(a)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cross&nbsp;Reference</B><br><B>in Agreement</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Balance Sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Board Recommendation Change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(b)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Disclosure Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Article IV</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Employee Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.14(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Financial Advisor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Insurance Policies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.18</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.10(l)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.9(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Licensed Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.10(l)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Material Adverse Effect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Net Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Net Cash Schedule</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.17(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Outstanding Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;2.1(c)(viii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Owned Intellectual Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.10(l)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Registrations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.10(l)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company SEC Reports</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Stock Plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Stockholder Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Support Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Tail Policy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.10(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Termination Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 8.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Valuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 2.1(c)(ix)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Voting Proposals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Company Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 4.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualified Person</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recommendation Change Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulating Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.16(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reverse Stock Split</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.5(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rule 145 Affiliates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.2(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specified Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Superior Proposal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 6.1(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surviving Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 1.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Returns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.8(r)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.8(r)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;3.10(l)(ix)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;6.17(d)(iv)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Worker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.10(l)(x)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Written Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 3.4(d)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;), dated as of March&nbsp;29, 2021, is entered into by and among Millendo
Therapeutics, Inc., a Delaware corporation (&#147;<U>Public Company</U>&#148;); Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company (the &#147;<U>Merger Sub</U>&#148;); and Tempest Therapeutics, Inc., a Delaware
corporation (&#147;<U>Merger Partner</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of Public Company (the &#147;<U>Public Company
Board</U>&#148;) and the Board of Directors of Merger Partner (the &#147;<U>Merger Partner Board</U>&#148;) have each (i)&nbsp;determined that the Merger is fair to, and in the best interests of, their respective corporations and stockholders,
(ii)&nbsp;approved and declared advisable this Agreement, the Merger and the actions contemplated by this Agreement and (iii)&nbsp;determined to recommend that the stockholders of their respective corporations vote to approve such matters as are
contemplated by this Agreement, including, in the case of Merger Partner, the adoption of this Agreement and, in the case of Public Company, the approval of the issuance of shares of Public Company Common Stock pursuant to this Agreement (the
&#147;<U>Share Issuance</U>&#148;) and the Reverse Stock Split (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the combination of Public Company and Merger
Partner shall be effected through a merger (the &#147;<U>Merger</U>&#148;) of Merger Sub with and into Merger Partner in accordance with the terms of this Agreement and the General Corporation Law of the State of Delaware (the
&#147;<U>DGCL</U>&#148;), as a result of which Merger Partner will become a wholly owned subsidiary of Public Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery of this Agreement and as a condition and inducement to Public Company&#146;s willingness to enter into this Agreement, each of the stockholders of Merger Partner named in <U>Section A</U> of the Merger
Partner Disclosure Schedule has entered into (i)&nbsp;a support agreement, dated as of the date of this Agreement, in the form attached hereto as <U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT></U> (the &#147;<U>Merger Partner Support
Agreements</U>&#148;) and (ii)&nbsp;a lock-up agreement in the form attached hereto as <U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></U> (the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to Merger Partner&#146;s willingness
to enter into this Agreement, each of the stockholders of Public Company named in <U>Section A</U> of the Public Company Disclosure Schedule have entered into a support agreement, dated as of the date of this Agreement, in the form attached hereto
as <U>Exhibit <FONT STYLE="white-space:nowrap">A-3</FONT></U> (the &#147;<U>Public Company Support Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, for
United States federal income tax purposes, it is intended that (i)&nbsp;the Merger shall qualify as a reorganization within the meaning of Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), and
(ii)&nbsp;this Agreement shall constitute a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.368-2(g);</FONT> and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the Merger Partner shall have entered into one or more Funding
Agreements (each, a &#147;<U>Funding Agreement</U>&#148; and collectively, the &#147;<U>Funding Agreements</U>&#148;), pursuant to which Merger Partner will, at or prior to the Closing, receive gross proceeds of approximately $30,000,000 (the
&#147;<U>Financing</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties,
covenants and agreements set forth below, Public Company, Merger Sub and Merger Partner agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE MERGER </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Effective Time of the Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement, on the Closing Date the parties hereto will cause the Merger to be consummated by executing and filing a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificate of merger (the &#147;<U>Certificate of Merger</U>&#148;) in accordance with the relevant provisions of the DGCL. The Merger shall become effective upon the due filing of the
Certificate of Merger with the Secretary of State of the State of Delaware or at such subsequent time or date as Public Company and Merger Partner shall agree and specify in the Certificate of Merger (the &#147;<U>Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Closing</U>. Subject to the satisfaction or (to the extent permitted by Law) waiver of the conditions set forth in <U>Article VII</U>,
the closing of the Merger (the &#147;<U>Closing</U>&#148;) will take place at 10:00 a.m., Eastern time, on a date to be specified by Public Company and Merger Partner (the &#147;<U>Closing Date</U>&#148;), which shall be no later than the second
Business Day after satisfaction or (to the extent permitted by Law) waiver of the conditions set forth in <U>Article VII</U> (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or (to
the extent permitted by law) waiver of such conditions), at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109 (or by remote exchange of electronic documents), unless another date, place or time is
agreed to in writing by Public Company and Merger Partner. For the purposes of this Agreement, the term &#147;<U>Business</U> <U>Day</U>&#148; shall mean any day other than a Saturday, Sunday or other day on which commercial banking institutions in
New York, New York, Boston, Massachusetts or Wilmington, Delaware are required or permitted by Law to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Effects of the
Merger</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, (i)&nbsp;the separate existence of Merger Sub shall cease and Merger Sub shall be merged with and
into Merger Partner (Merger Partner as the surviving corporation following the Merger is sometimes referred to herein as the &#147;<U>Surviving</U> <U>Corporation</U>&#148;) and (ii)&nbsp;the certificate of incorporation of Merger Partner as in
effect as of immediately prior to the Effective Time shall be amended and restated in its entirety to read as set forth on <U>Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></U>, and, as so amended and restated, shall be the certificate of
incorporation of the Surviving Corporation. In addition, the bylaws of Merger Partner, as in effect immediately prior to the Effective Time, shall be amended and restated to read as set forth on <U>Exhibit
<FONT STYLE="white-space:nowrap">B-2</FONT></U>, and, as so amended, shall be the bylaws of the Surviving Corporation. The Merger shall have the effects set forth in Section&nbsp;259 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At and after the Effective Time, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in
the name and on behalf of the Surviving Corporation, Merger Sub or Merger Partner, any deeds, bills of sale, assignments or assurances and to take and do, in the name and on behalf of the Surviving Corporation, Merger Sub or Merger Partner, any
other actions and things necessary to vest, perfect or confirm of record or otherwise in the Surviving Corporation any and all right, title and interest in, to and under any of the rights, properties or assets acquired or to be acquired by the
Surviving Corporation as a result of, or in connection with, the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Directors and Officers of the Surviving Corporation.</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The individuals named on <U>Section</U><U></U><U>&nbsp;1.4(a)</U> of the Merger Partner Disclosure Schedule shall be the initial
directors of the Surviving Corporation as of the Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The individuals named on <U>Section</U><U></U><U>&nbsp;1.4(b)</U> of the Merger Partner Disclosure Schedule shall be the initial officers
of the Surviving Corporation as of the Effective Time, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Public Company Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Board of Directors</U>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or
removal of any directors on the Public Company Board as of the Effective Time) so </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that, as of immediately after the Effective Time, the number of directors that comprise the full Public Company Board shall be seven (7)) and initially consist of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) six (6)&nbsp;directors designated by Merger Partner and reasonably acceptable to Public Company, at least three (3)&nbsp;out of six
(6)&nbsp;of whom qualify as an &#147;independent director&#148; under Nasdaq listing standards and the applicable rules of the SEC as of the Effective Time (an &#147;<U>Independent Designee</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) one (1)&nbsp;director, designated by Public Company and reasonably acceptable to Merger Partner, who qualifies, and is designated, as an
Independent Designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Officers</U>. The parties shall take all action necessary (including, to the extent necessary, procuring the
resignation or removal of any executive officer as of the Effective Time) to cause each individual designated by Merger Partner and identified in <U>Section</U><U>&nbsp;1.5(b)</U> of the Merger Partner Disclosure Schedule to be appointed to the
office of Public Company indicated next to such individual&#146;s name thereon as of immediately after the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Replacement of Designees</U>. In the event that, prior to the Effective Time, any individual initially designated pursuant to <U>Section</U><U></U><U>&nbsp;1.5(a)</U> or <U>Section</U><U></U><U>&nbsp;1.5(b)</U> is unable or unwilling to serve in
the capacity so designated (it being agreed that no designee who is designated as an Independent Designee and who fails, as of or prior to the Effective Time, to qualify as an Independent Designee shall be permitted to serve on the Public Company
Board), the party who designated such person shall select a replacement for such initial designee to serve in such initial designee&#146;s place; <U>provided</U> that (A)&nbsp;such replacement shall be reasonably acceptable to Public Company and
Merger Partner, and (B)&nbsp;if such replacement is designated to replace an Independent Designee, such replacement must qualify as an Independent Designee as of the Effective Time. The parties shall take all actions necessary to ensure that any
such replacement is duly appointed to serve as a director or officer of Public Company, as applicable, as of immediately after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</U>. Public Company and Merger Partner shall use reasonable best efforts to
have each individual who will serve as a director or officer of Public Company following the Closing to execute and deliver a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement prior to Closing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONVERSION OF SECURITIES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Conversion of Capital Stock</U>. As of the Effective Time (and after giving effect to the Merger Partner Preferred Stock Conversion),
by virtue of the Merger and without any action on the part of the holder of any shares of Merger Partner Capital Stock or any shares of capital stock of Merger Sub: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Capital Stock of Merger Sub</U>. Each share of the common stock, par value $0.001 per share, of Merger Sub issued and outstanding
immediately prior to the Effective Time shall be converted into and become one fully paid and nonassessable share of common stock, $0.001 par value per share, of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Cancellation of Treasury Stock and Public Company Owned Stock</U>. All shares of common stock, par value $0.001 per share of Merger
Partner (&#147;<U>Merger Partner</U> <U>Common Stock</U>&#148;) that are held in treasury or by any Subsidiary of Merger Partner and any shares of Merger Partner Common Stock owned by Public Company, Merger Sub or any other Subsidiary of Public
Company immediately prior to the Effective Time shall be cancelled and shall cease to exist and no stock of Public Company or other consideration shall be delivered in exchange therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Conversion of Merger Partner Common Stock</U>. Subject to
<U>Section</U><U></U><U>&nbsp;2.2</U>, each share of Merger Partner Common Stock (including any shares of Merger Partner Common Stock issued in the Financing, including any Excess Financing Shares) (other than shares to be cancelled in accordance
with <U>Section</U><U></U><U>&nbsp;2.1(b)</U> and any Dissenting Shares) shall be automatically converted into the right to receive a number of shares of common stock, par value $0.001 per share, of Public Company (&#147;<U>Public Company Common
Stock</U>&#148;) equal to the Exchange Ratio.<B> </B>As of the Effective Time, all such shares of Merger Partner Common Stock shall cease to be outstanding and shall automatically be cancelled and shall cease to exist, and each holder of a
certificate representing any such shares of Merger Partner Common Stock shall cease to have any rights with respect thereto, except the right to receive the shares of Public Company Common Stock pursuant to this
<U>Section</U><U></U><U>&nbsp;2.1(c)</U> and any cash in lieu of fractional shares of Public Company Common Stock to be issued or paid in consideration therefor and any amounts payable pursuant to <U>Section</U><U></U><U>&nbsp;2.2(d)</U> upon the
surrender of such certificate in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U>, without interest. For purposes of this Agreement, &#147;<U>Exchange Ratio</U>&#148; means, subject to <U>Section</U><U>&nbsp;2.1(d)</U>, the quotient (rounded
down to four decimal places) obtained by dividing (x)&nbsp;the number of Merger Partner Merger Shares by (y)&nbsp;the number of Merger Partner Outstanding Shares, in which: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Aggregate Valuation</U>&#148; means the sum of (a)&nbsp;the Merger Partner Valuation, plus (b)&nbsp;the Public Company
Valuation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Excess Financing Shares</U>&#148; means Merger Partner Common Stock issued in the Financing, to the extent the
Financing results in the Merger Partner receiving proceeds in excess of Twenty-Five Million Dollars ($25,000,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Merger
Partner Allocation Percentage</U>&#148; the quotient (rounded down to four decimal places) determined by dividing (i)&nbsp;the Merger Partner Valuation by (ii)&nbsp;the Aggregate Valuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Merger Partner Merger Shares</U>&#148; means the product (rounded down to the nearest whole share) determined by multiplying
(i)&nbsp;the Post-Closing Public Company Shares by (ii)&nbsp;the Merger Partner Allocation Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Merger Partner
Outstanding Shares</U>&#148; means the total number of shares of Merger Partner Common Stock outstanding immediately prior to the Effective Time (after giving effect to the Financing, including the Excess Financing Shares, and the Merger Partner
Preferred Stock Conversion) expressed on a fully-diluted and <FONT STYLE="white-space:nowrap">as-converted</FONT> to Merger Partner Common Stock basis and assuming, without limitation or duplication, (i)&nbsp;the exercise of all Merger Partner
Options and Merger Partner Warrants outstanding as of immediately prior to the Effective Time and (ii)&nbsp;the issuance of shares of Public Company Common Stock in respect of all other options, warrants or rights to receive such shares that will be
outstanding immediately after the Effective Time (but excluding any shares of Merger Partner Common Stock reserved for issuance other than with respect to outstanding Merger Partner Options under the Merger Partner Plans as of immediately prior to
the Effective Time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) &#147;<U>Merger Partner Valuation</U>&#148; means $153,400,000; provided, however, that if the Merger Partner
issues any Excess Financing Shares, then the Merger Partner Valuation shall be increased by the amount of proceeds received from the issuance and sale of such Excess Financing Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) &#147;<U>Post-Closing Public Company Shares</U>&#148; means the quotient (rounded down to the nearest whole share) determined by
dividing (i)&nbsp;the Public Company Outstanding Shares by (ii)&nbsp;the Public Company Allocation Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) &#147;<U>Public
Company Allocation Percentage</U>&#148; means the quotient (rounded down to four decimal places) determined by dividing (i)&nbsp;the Public Company Valuation by (ii)&nbsp;the Aggregate Valuation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) &#147;<U>Public Company Outstanding Shares</U>&#148;<B><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B>means the sum of (A)&nbsp;the total number of shares of Public Company Common Stock that are issued and outstanding immediately prior to the Effective Time and (B)&nbsp;the total number of shares
of Public Company Common Stock that are issuable upon exercise of then outstanding options with a per share exercise price that is less than or equal to $5.00 (as adjusted for the Reverse Stock Split) and, for the avoidance of doubt, excluding other
shares of Public Company Common Stock issuable upon exercise of all other outstanding options, warrants or other derivative securities (in each case of the foregoing clauses (A)&nbsp;and (B) after giving effect to the Reverse Stock Split). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Public Company Valuation</U>&#148; means $36,000,000; <U>provided</U>, <U>however</U>, that (i)&nbsp;if Public Company Net Cash
is greater than $18,700,000, the Public Company Valuation shall be increased by the amount by which Public Company Net Cash is greater than $18,700,000 and (ii)&nbsp;if Public Company Net Cash is less than $15,300,000, the Public Company Valuation
shall be decreased by the amount by which Public Company Net Cash is less than $15,300,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt and for illustrative purposes
only, a sample Exchange Ratio calculation is attached hereto as <U>Annex A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Unvested Stock</U>. At the Effective Time, any
shares of Public Company Common Stock issued in accordance with <U>Section</U><U></U><U>&nbsp;2.1(c)</U> with respect to any unvested shares of Merger Partner Common Stock awarded to employees, directors or consultants pursuant to any of Merger
Partner&#146;s plans or arrangements and outstanding immediately prior to the Effective Time shall remain subject to the same terms, restrictions and vesting schedule as in effect immediately prior to the Effective Time, except to the extent by
their terms such unvested shares of Merger Partner Common Stock vest at the Effective Time. Merger Partner shall not take or permit any action which would accelerate vesting of any unvested shares, except to the extent required by their terms as in
effect on the date hereof. Copies of the relevant agreements governing such shares and the vesting thereof have been made available to Public Company. All outstanding rights that Merger Partner may hold immediately prior to the Effective Time to
repurchase unvested shares of Merger Partner Common Stock shall be assigned to Public Company in the Merger and shall thereafter be exercisable by Public Company upon the same terms and conditions in effect immediately prior to the Effective Time,
except that the shares purchasable pursuant to such rights and the purchase price payable per share shall be appropriately adjusted to reflect the Exchange Ratio. Merger Partner shall, prior to the Closing, take all steps necessary to cause the
foregoing provisions of this <U>Section</U><U></U><U>&nbsp;2.1(d)</U> to occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Exchange of Certificates</U>. The procedures for
exchanging outstanding shares of Merger Partner Common Stock for Public Company Common Stock pursuant to the Merger are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Exchange Agent</U>. At or immediately prior to the Effective Time, Public Company shall deposit with Computershare Trust Company, N.A. or another bank or trust company designated by Public Company and reasonably acceptable to Merger Partner (the
&#147;<U>Exchange Agent</U>&#148;), for the benefit of the holders of shares of Merger Partner Common Stock, for exchange in accordance with this <U>Section</U><U></U><U>&nbsp;2.2</U>, through the Exchange Agent, (i)&nbsp;certificates representing
the shares of Public Company Common Stock (such shares of Public Company Common Stock, together with any dividends or distributions with respect thereto with a record date after the Effective Time, being hereinafter referred to as the
&#147;<U>Exchange Fund</U>&#148;) issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> in exchange for outstanding shares of Merger Partner Common Stock, (ii)&nbsp;cash in an amount sufficient to make payments for fractional shares required
pursuant to <U>Section</U><U>&nbsp;2.2(c)</U> and <U>(iii)</U>&nbsp;any dividends or distributions to which holders of certificates that, as of immediately prior to the Effective Time, represented outstanding shares of Merger Partner Common Stock
(the &#147;<U>Certificates</U>&#148;), whose shares were converted pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U> into the right to receive shares of Public Company Common Stock, may be entitled pursuant to
<U>Section</U><U></U><U>&nbsp;2.2(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange Procedures</U>. As soon as reasonably practicable after the Effective Time, the
Exchange Agent shall mail to each holder of record of a Certificate (i)&nbsp;a letter of transmittal in customary form specifying that delivery shall be effected, and risk of loss and title to the Certificates shall pass, only upon delivery of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certificates to the Exchange Agent, and (ii)&nbsp;instructions for use in effecting the surrender of the Certificates in exchange for certificates representing shares of Public Company Common
Stock (plus cash in lieu of fractional shares, if any, of Public Company Common Stock and any dividends or distributions as provided below). Upon surrender of a Certificate for cancellation to the Exchange Agent or to such other agent or agents as
may be appointed by Public Company, together with such letter of transmittal, duly executed, and such other documents as may reasonably be required by the Exchange Agent and Public Company, the holder of such Certificate shall be entitled to receive
in exchange therefor a certificate or book entry account representing that number of whole shares of Public Company Common Stock which such holder has the right to receive pursuant to the provisions of this <U>Article II</U> plus cash in lieu of
fractional shares pursuant to <U>Section</U><U></U><U>&nbsp;2.2(c)</U> and any dividends or distributions then payable pursuant to <U>Section</U><U></U><U>&nbsp;2.2(d)</U>, and the Certificate so surrendered shall immediately be cancelled. In the
event of a transfer of ownership of Merger Partner Common Stock which is not registered in the transfer records of Merger Partner, a certificate representing the proper number of whole shares of Public Company Common Stock plus cash in lieu of
fractional shares pursuant to <U>Section</U><U></U><U>&nbsp;2.2(c)</U> and any dividends or distributions pursuant to <U>Section</U><U></U><U>&nbsp;2.2(d)</U> may be issued or paid to a person other than the person in whose name the Certificate so
surrendered is registered, only if such Certificate is presented to the Exchange Agent, accompanied by all documents required to evidence and effect such transfer and by evidence that any applicable stock transfer taxes have been paid. Until
surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;2.2</U>, each Certificate shall be deemed at any time after the Effective Time to represent only the right to receive shares of Public Company Common Stock pursuant to the provisions
of this <U>Article II</U> plus cash in lieu of fractional shares pursuant to <U>Section</U><U></U><U>&nbsp;2.2(c)</U> and any dividends or distributions then payable pursuant to <U>Section</U><U></U><U>&nbsp;2.2(d)</U> as contemplated by this
<U>Section</U><U></U><U>&nbsp;2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Fractional Shares</U>. No certificate or scrip representing fractional shares of Public
Company Common Stock shall be issued upon the surrender for exchange of Certificates, and such fractional share interests shall not entitle the owner thereof to vote or to any other rights of a stockholder of Public Company. Notwithstanding any
other provision of this Agreement, each holder of shares of Merger Partner Common Stock converted pursuant to the Merger who would otherwise have been entitled to receive a fraction of a share of Public Company Common Stock (after taking into
account all Certificates delivered by such holder and the aggregate number of shares of Merger Partner Common Stock represented thereby) shall receive, in lieu thereof, cash (without interest and subject to applicable Tax withholding) in an amount
equal to such fractional part of a share of Public Company Common Stock multiplied by the last reported sale price of Public Company Common Stock at the 4:00 p.m., Eastern time, end of regular trading hours on The Nasdaq Stock Market, Inc.
(&#147;<U>Nasdaq</U>&#148;) on the last trading day prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Distributions with Respect to Unexchanged
Shares</U>. No dividends or other distributions declared or made after the Effective Time with respect to Public Company Common Stock with a record date after the Effective Time shall be paid to the holder of any unsurrendered Certificate until the
holder of record of such Certificate shall surrender such Certificate in accordance with this <U>Section</U><U></U><U>&nbsp;2.2</U>. Subject to the effect of applicable laws, following surrender of any such Certificate, there shall be issued and
paid to the record holder of the Certificate, at the time of such surrender the amount of dividends or other distributions with a record date after the Effective Time previously paid with respect to such whole shares of Public Company Common Stock,
without interest, and at the appropriate payment date, the amount of dividends or other distributions having a record date after the Effective Time but prior to surrender and a payment date subsequent to surrender that are payable with respect to
such whole shares of Public Company Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>No Further Ownership Rights in Merger Partner Common Stock</U>. All shares of
Public Company Common Stock issued upon the surrender for exchange of Certificates in accordance with the terms hereof (including any cash or dividends or other distributions paid pursuant to <U>Section</U><U></U><U>&nbsp;2.2(c)</U> or
<U>2.2(d)</U>) shall be deemed to have been issued (and paid) in full satisfaction of all rights pertaining to such shares of Merger Partner Common Stock, and from and after the Effective Time there shall be no further registration of transfers on
the stock transfer books of the Surviving Corporation of the shares of Merger Partner Common Stock that were outstanding immediately prior to the Effective Time. If, after the Effective Time, Certificates are presented to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Surviving Corporation or the Exchange Agent for any reason, they shall be cancelled and exchanged as provided in this <U>Article II</U>, subject to applicable Law in the case of Dissenting
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Termination of Exchange Fund</U>. Any portion of the Exchange Fund that remains undistributed to the holders of Merger
Partner Common Stock for one year after the Effective Time shall be delivered to Public Company, upon demand, and any holder of Merger Partner Common Stock immediately prior to the Effective Time who has not previously complied with this
<U>Section</U><U></U><U>&nbsp;2.2</U> shall thereafter look only to Public Company, as a general unsecured creditor, for payment of its claim for Public Company Common Stock, any cash in lieu of fractional shares of Public Company Common Stock and
any dividends or distributions with respect to Public Company Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>No Liability</U>. To the extent permitted by
applicable law, none of Public Company, Merger Sub, Merger Partner, the Surviving Corporation or the Exchange Agent shall be liable to any holder of shares of Merger Partner Common Stock or Public Company Common Stock, as the case may be, for such
shares or any cash amounts required to be delivered to a public official pursuant to any applicable abandoned property, escheat or similar law. If any Certificate shall not have been surrendered immediately prior to such date on which any shares of
Public Company Common Stock, and any cash payable to the holder of such Certificate or any dividends or distributions payable to the holder of such Certificate pursuant to this <U>Article II</U> would otherwise escheat to or become the property of
any Governmental Entity, such Certificate and any such shares of Public Company Common Stock or cash, dividends or distributions in respect of such Certificate shall, to the maximum extent permitted by applicable law, become the property of the
Surviving Corporation, free and clear of all claims or interest of any person previously entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Withholding Rights</U>.
Each of the Exchange Agent, Public Company and the Surviving Corporation shall be entitled to deduct and withhold from the amounts otherwise payable pursuant to this Agreement to any holder of shares of Merger Partner Common Stock and any other
recipient of payments hereunder such amounts as it reasonably determines that it is required to deduct and withhold with respect to the making of such payment under the Code, or any other applicable provision of law. To the extent that amounts are
so withheld and paid to the appropriate taxing authority by the Surviving Corporation or Public Company, as the case may be, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of the shares of
Merger Partner Common Stock or other recipient of payments hereunder in respect of which such deduction and withholding was made by the Surviving Corporation or Public Company, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Lost Certificates</U>. If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact and
an indemnity (without the requirement of posting a bond) by the person claiming such Certificate to be lost, stolen or destroyed, the Exchange Agent shall issue in exchange for such lost, stolen or destroyed Certificate the shares of Public Company
Common Stock and any cash in lieu of fractional shares, and unpaid dividends and distributions on shares of Public Company Common Stock deliverable in respect thereof pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Merger Partner Stock Plans and Merger Partner Warrants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, each outstanding option to purchase Merger Partner Common Stock (each, a &#147;<U>Merger Partner Stock
Option</U>&#148; and collectively, the &#147;<U>Merger Partner</U> <U>Stock Options</U>&#148;), whether vested or unvested, and all stock option plans or other stock or equity-related plans of Merger Partner (the &#147;<U>Merger Partner Stock
Plans</U>&#148;) themselves, insofar as they relate to outstanding Merger Partner Stock Options, shall be assumed by Public Company and shall become an option to acquire, on the same terms and conditions as were applicable under such Merger Partner
Stock Option immediately prior to the Effective Time, such number of shares of Public Company Common Stock as is equal to the number of shares of Merger Partner Common Stock subject to the unexercised portion of such Merger Partner Stock Option
immediately prior to the Effective Time multiplied by the Exchange Ratio (rounded down to the nearest whole share number), at an exercise price per share equal to the exercise price per share of such Merger Partner Stock Option immediately prior to
the Effective Time divided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Exchange Ratio (rounded up to the nearest whole cent); <U>provided</U> that the assumption of each Merger Partner Stock Option pursuant to this <U>Section</U><U></U><U>&nbsp;2.3(a)</U>
shall comply with all requirements of Sections 424 and 409A of the Code and the Treasury regulations issued thereunder, as applicable. Such Merger Partner Stock Options shall continue in effect on the same terms and conditions to which they are
currently subject (subject to the adjustments required by this <U>Section</U><U>&nbsp;2.3</U> after giving effect to the Merger). Merger Partner shall, prior to the Effective Time, take all actions necessary or desirable in connection with the
treatment of Merger Partner Stock Options contemplated by this <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, including obtaining the consent from each holder of any Merger Partner Stock Options (unless such consent is not required under the terms of the
applicable agreement, instrument or plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As soon as practicable after the Effective Time, Public Company shall deliver to the
participants in the Merger Partner Stock Plans an appropriate notice setting forth such participants&#146; rights pursuant to Merger Partner Stock Options, as provided in this <U>Section</U><U>&nbsp;2.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the Effective Time, Public Company shall assume each of the Merger Partner Stock Plans, and Public Company thereafter shall be
entitled to grant equity-based compensation awards, to the extent permissible under applicable Law, using the share reserves of such Merger Partner Stock Plans as of the Effective Time (including any shares returned to such share reserves as a
result of the termination of Merger Partner Stock Options that are assumed by Public Company pursuant to <U>Section</U><U></U><U>&nbsp;2.3(a)</U>), except that: (i)&nbsp;the stock subject to such awards shall be shares of Public Company Common
Stock; (ii)&nbsp;all references in such Merger Partner Stock Plans to a number of shares of Merger Partner Common Stock shall be deemed amended to refer instead to a number of shares of Public Company Common Stock determined by multiplying the
number of referenced shares of Merger Partner Common Stock by the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Public Company Common Stock; and (iii)&nbsp;the Public Company Board or a committee
thereof shall succeed to the authority and responsibility of the Merger Partner Board or any committee thereof with respect to the administration of such Merger Partner Stock Plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company shall take all corporate action necessary to reserve for issuance a sufficient number of shares of Public Company Common
Stock for delivery upon exercise of Merger Partner Stock Options assumed in accordance with <U>Section</U><U></U><U>&nbsp;2.3(a)</U> and the shares of Public Company Common Stock reserved for future grant under the Merger Partner Stock Plans assumed
by Public Company pursuant to <U>Section</U><U></U><U>&nbsp;2.3(c)</U>. As promptly as practicable after the Effective Time, Public Company shall file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor
form) with respect to the shares of Public Company Common Stock subject to such options and reserved for future grants under the Merger Partner Stock Plans, to the extent so registrable, and shall use commercially reasonable efforts to maintain the
effectiveness of such registration statement or registration statements (and maintain the current status of the prospectus or prospectuses contained therein) for so long as any awards granted under the Merger Partner Stock Plans remain outstanding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) At the Effective Time, by virtue of the Merger, each Merger Partner Warrant outstanding immediately prior to the Effective Time shall
be automatically assumed by Public Company and shall become a warrant to acquire, on the same terms and conditions as were applicable under such Merger Partner Warrant, such number of shares of Public Company Common Stock as is equal to the number
of shares of Merger Partner Common Stock subject to the unexercised portion of such Merger Partner Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio (rounded down to the nearest whole share number), at an exercise
price per share equal to the exercise price per share of such Merger Partner Warrant immediately prior to the Effective Time divided by the Exchange Ratio (rounded up to the nearest whole cent) (each, as so adjusted, an &#147;<U>Adjusted
Warrant</U>&#148;). Merger Partner shall, prior to the Effective Time, take all actions necessary or desirable in connection with the treatment of Merger Partner Stock Warrants contemplated by this <U>Section</U><U></U><U>&nbsp;2.3(e)</U>. Public
Company shall take all corporate actions necessary to reserve for issuance of shares of Public Company Common Stock that will be subject to the Adjusted Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Dissenting Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, &#147;<U>Dissenting Shares</U>&#148; shall mean shares of Merger Partner Common Stock issued and
outstanding immediately prior to the Effective Time that are held as of the Effective Time by a holder who has not voted in favor of the Merger or consented thereto in writing and who has made a proper demand for appraisal of such shares in
accordance with Section&nbsp;262 of the DGCL (until such time as such holder fails to perfect or otherwise loses such holder&#146;s appraisal rights under the DGCL with respect to such shares, at which time such shares shall cease to be Dissenting
Shares). Dissenting Shares will only entitle the holder thereof to such rights as are granted by the DGCL to a holder thereof and shall not be converted into or represent the right to receive Public Company Common Stock unless the stockholder
holding such Dissenting Shares shall have forfeited his, her or its right to appraisal under the DGCL or properly withdrawn his, her or its demand for appraisal. If such stockholder has so forfeited or withdrawn his, her or its right to appraisal of
Dissenting Shares, then (i)&nbsp;as of the occurrence of such event, such holder&#146;s Dissenting Shares shall cease to be Dissenting Shares and shall be deemed to have been converted, as of the Effective Time, into and represent the right to
receive Public Company Common Stock issuable in respect of such Merger Partner Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;2.1(c)</U> or <U>Section</U><U></U><U>&nbsp;2.1(d)</U>, as the case may be, without interest, and
(ii)&nbsp;promptly following the occurrence of such event, Public Company shall deliver to the Exchange Agent a certificate representing Public Company Common Stock to which such stockholder is entitled pursuant to
<U>Section</U><U></U><U>&nbsp;2.1(c)</U> or <U>Section</U><U></U><U>&nbsp;2.1(d)</U>, as well as any cash or other distributions to which such holder of Merger Partner Common Stock may be entitled under this <U>Article II</U> if not previously
delivered to the Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner shall give Public Company prompt notice of any written demands for appraisal of any
Merger Partner Common Stock, withdrawals of such demands and any other instruments that relate to such demands received by Merger Partner. Merger Partner shall have the right to direct all negotiations and proceedings with respect to demands for
appraisal under the DGCL. Merger Partner shall not, except with the prior written consent of Public Company (not to be unreasonably withheld), make any payment with respect to any demands for appraisal of Merger Partner Common Stock or settle or
offer to settle any such demands. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS AND WARRANTIES OF MERGER PARTNER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Partner represents and warrants to Public Company and Merger Sub that the statements contained in this <U>Article III</U> are true and
correct, except as expressly set forth herein or in the disclosure schedule delivered or made available by Merger Partner to Public Company and Merger Sub on the date of this Agreement (the &#147;<U>Merger Partner Disclosure Schedule</U>&#148;). For
purposes hereof, the phrase &#147;to the knowledge of Merger Partner&#148; and similar expressions mean the actual knowledge of the persons identified on Section K of the Merger Partner Disclosure Schedule for this purpose, and such knowledge as
such persons would reasonably be expected to have obtained in the course of their performance of their duties to Merger Partner (after due inquiry). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Organization, Standing and Power</U>. Merger Partner is a corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction of its incorporation, has all requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as currently conducted, and is duly qualified to do business and is in
good standing as a foreign corporation in each jurisdiction listed on <U>Section</U><U></U><U>&nbsp;3.1</U> of the Merger Partner Disclosure Schedule, which jurisdictions constitute the only jurisdictions in which the character of the properties it
owns, operates or leases or the nature of its activities makes such qualification necessary, except for such failures to be so qualified or in good standing, individually or in the aggregate, that have not had, and are not reasonably likely to have,
a Merger Partner Material Adverse Effect. For purposes of this Agreement, the term &#147;<U>Merger Partner Material Adverse Effect</U>&#148; means any change, effect, event, circumstance or development (an &#147;<U>Effect</U>&#148;) that,
individually or in the aggregate with all other Effects that have occurred through the date of determination, has had, or is reasonably likely to have, a material adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect on the business, assets, liabilities, financial condition or results of operations of Merger Partner and its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, that no
Effect, to the extent resulting from or arising out of any of the following, shall be deemed to be a Merger Partner Material Adverse Effect or be taken into account for purposes of determining whether a Merger Partner Material Adverse Effect has
occurred or is reasonably likely to occur: (A)&nbsp;changes after the date of this Agreement in prevailing economic or market conditions in the United States or any other jurisdiction in which such entity has substantial business operations (except
to the extent those changes have a disproportionate effect on Merger Partner and its Subsidiaries relative to the other participants in the industry or industries in which Merger Partner and its Subsidiaries operate), (B) changes or events after the
date of this Agreement affecting the industry or industries in which Merger Partner and its Subsidiaries operate generally (except to the extent those changes or events have a disproportionate effect on Merger Partner and its Subsidiaries relative
to the other participants in the industry or industries in which Merger Partner and its Subsidiaries operate), (C) changes after the date of this Agreement in generally accepted accounting principles or requirements (except to the extent those
changes have a disproportionate effect on Merger Partner and its Subsidiaries relative to the other participants in the industry or industries in which Merger Partner and its Subsidiaries operate), (D) changes after the date of this Agreement in
laws, rules or regulations of general applicability or interpretations thereof by any Governmental Entity (except to the extent those changes have a disproportionate effect on Merger Partner and its Subsidiaries relative to the other participants in
the industry or industries in which Merger Partner and its Subsidiaries operate), (E) any natural disaster, epidemic, pandemic or other disease outbreak (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or any outbreak of
major hostilities in which the United States is involved or any act of terrorism within the United States or directed against its facilities or citizens wherever located (except to the extent those changes or events have a disproportionate effect on
Merger Partner and its Subsidiaries relative to the other participants in the industry or industries in which Merger Partner and its Subsidiaries operate), (F) the announcement of this Agreement or the pendency of the transactions contemplated
hereby or (G)&nbsp;any failure by Merger Partner to meet any internal guidance, budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (but not, in the case of this clause (G), the underlying
cause of such changes or failures, unless such changes or failures would otherwise be excepted from this definition). For the avoidance of doubt, the parties agree that the terms &#147;material,&#148; &#147;materially&#148; and
&#147;materiality&#148; as used in this Agreement with an initial lower case &#147;m&#148; shall have their respective customary and ordinary meanings, without regard to the meanings ascribed to Merger Partner Material Adverse Effect or Public
Company Material Adverse Effect, in each case as defined in this Agreement. Merger Partner has made available to Public Company complete and accurate copies of its certificate of incorporation and bylaws and is not in material default under or in
material violation of any provision of either such document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Merger Partner consists of 196,000,000 shares of Merger Partner Common Stock and 135,936,731 shares of
preferred stock, par value $0.001 per share, of Merger Partner (&#147;<U>Merger Partner Preferred Stock</U>&#148; and, collectively with Merger Partner Common Stock, &#147;<U>Merger Partner Capital Stock</U>&#148;), of which shares of Merger Partner
Preferred Stock 17,000,000 shares are designated as Series A Preferred Stock, 25,186,738 shares are designated as Series B Preferred Stock, and 93,749,993 shares are designated as Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock.
The rights and privileges of each class of Merger Partner&#146;s capital stock are as set forth in Merger Partner&#146;s certificate of incorporation. As of the close of business on March&nbsp;24, 2021 (the &#147;<U>Capitalization Reference
Time</U>&#148;), (i) 16,388,711 shares of Merger Partner Common Stock were issued and outstanding, (ii)&nbsp;no shares of Merger Partner Common Stock were held in the treasury of Merger Partner or by Subsidiaries of Merger Partner, (iii) 17,000,000
shares of Series A Preferred Stock were issued or outstanding, (iv) 25,186,738 shares of Series B Preferred Stock were issued or outstanding, and (v) 72,499,993 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock were issued
or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Merger Partner Disclosure Schedule sets forth a complete and accurate
list, as of the Capitalization Reference Time, of the holders of Merger Partner Capital Stock, showing the number of shares of capital stock, and the class or series of such shares, held by each stockholder and (for shares other than
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Partner Common Stock) the number of shares of Merger Partner Common Stock (if any) into which such shares are convertible. <U>Section</U><U></U><U>&nbsp;3.2(b)</U> of the Merger Partner
Disclosure Schedule also sets forth a complete and accurate list of all issued and outstanding shares of Merger Partner Common Stock that constitute restricted stock or that are otherwise subject to a repurchase or redemption right or right of first
refusal in favor of Merger Partner, indicating the name of the applicable stockholder, the vesting schedule for any such shares, including the extent to which any such repurchase or redemption right or right of first refusal has lapsed as of the
date of this Agreement, whether (and to what extent) the vesting will be accelerated in any way by the transactions contemplated by this Agreement or by termination of employment or change in position following consummation of the Merger, and
whether such holder has the sole power to vote and dispose of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section</U><U></U><U>&nbsp;3.2(c)</U> of the Merger
Partner Disclosure Schedule sets forth a complete and accurate list, as of the Capitalization Reference Time, of: (i)&nbsp;all Merger Partner Stock Plans, indicating for each Merger Partner Stock Plan, the number of shares of Merger Partner Common
Stock subject to outstanding options under such Plan and the number of shares of Merger Partner Common Stock available for future issuance under such Plan; and (ii)&nbsp;all outstanding Merger Partner Stock Options, indicating with respect to each
such Merger Partner Stock Option the name of the holder thereof, the Merger Partner Stock Plan under which it was granted, the number of shares of Merger Partner Common Stock subject to such Merger Partner Stock Option, the exercise price, the date
of grant and the vesting schedule, including whether (and to what extent) the vesting will be accelerated in any way by the transactions contemplated by this Agreement or by termination of employment or change in position following consummation of
the Merger, and whether such Merger Partner Stock Option is intended to be an incentive stock option. Merger Partner has made available to Public Company complete and accurate copies of all Merger Partner Stock Plans and the forms of all stock
option agreements evidencing Merger Partner Stock Options. With respect to each Merger Partner Stock Option (whether outstanding or previously exercised), (i)&nbsp;each such Merger Partner Stock Option intended to qualify as an &#147;incentive stock
option&#148; under Section&nbsp;422 of the Code so qualifies, (ii)&nbsp;each grant of a Merger Partner Stock Option was duly authorized no later than the date on which the grant of such Merger Partner Stock Option was by its terms to be effective by
all necessary corporate action, including, as applicable, approval by the Merger Partner&#146;s Board of Directors (or a duly constituted and authorized committee thereof), or a duly authorized delegate thereof, and any required stockholder approval
by the necessary number of votes or written consents, (iii)&nbsp;each such grant was made in material compliance with the terms of the applicable Merger Partner Stock Plan, the Securities Act, the Exchange Act, to the extent applicable, and all
other applicable Laws and are not and have not been the subject of any internal investigation, review or inquiry, and (iv)&nbsp;each such grant was properly accounted for in all material respects in accordance with GAAP in the financial statements
(including the related notes) of the Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Section</U><U></U><U>&nbsp;3.2(d)</U> of the Merger Partner Disclosure
Schedule sets forth the number of shares of Merger Partner Common Stock and Merger Partner Preferred Stock reserved for future issuance pursuant to warrants or other outstanding rights (other than Merger Partner Stock Options) to purchase shares of
Merger Partner Common Stock and Merger Partner Preferred Stock outstanding as of the Capitalization Reference Time (such outstanding warrants or other rights, the &#147;<U>Merger Partner Warrants</U>&#148;) and the agreement or other document under
which such Merger Partner Warrants were granted and sets forth a complete and accurate list of all holders of Merger Partner Warrants indicating the number and type of shares of Merger Partner Capital Stock subject to each Merger Partner Warrant,
and the exercise price, the date of grant and the expiration date thereof. Merger Partner has made available to Public Company complete and accurate copies of the forms of agreements evidencing all Merger Partner Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except (i)&nbsp;as set forth in this <U>Section</U><U></U><U>&nbsp;3.2</U> and <U>(ii)</U>&nbsp;as reserved for future grants under Merger
Partner Stock Plans, (A)&nbsp;there are no equity securities of any class of Merger Partner, or any security exchangeable into or exercisable for such equity securities, issued, reserved for issuance or outstanding and (B)&nbsp;there are no options,
warrants, equity securities, calls, rights, commitments or agreements of any character to which Merger Partner is a party or by which Merger Partner or any of its Subsidiaries is bound obligating Merger Partner or any of its Subsidiaries to issue,
exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other equity interests of Merger Partner or any security or rights
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible into or exchangeable or exercisable for any such shares or other equity interests, or obligating Merger Partner or any of its Subsidiaries to grant, extend, accelerate the vesting of,
otherwise modify or amend or enter into any such option, warrant, equity security, call, right, commitment or agreement. Merger Partner does not have any outstanding stock appreciation rights, phantom stock, performance based rights or similar
rights or obligations. Other than the Merger Partner Support Agreement, neither Merger Partner nor any of its Affiliates is a party to or is bound by any, and to the knowledge of Merger Partner, there are no, agreements or understandings with
respect to the voting (including voting trusts and proxies) or sale or transfer (including agreements imposing transfer restrictions) of any shares of capital stock or other equity interests of Merger Partner. For purposes of this Agreement, the
term &#147;<U>Affiliate</U>&#148; when used with respect to any party shall mean any person who is an &#147;affiliate&#148; of that party within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended (the
&#147;<U>Securities Act</U>&#148;). Except as contemplated by this Agreement or described in this <U>Section</U><U></U><U>&nbsp;3.2(e)</U>, there are no registration rights to which Merger Partner or any of its Subsidiaries is a party or by which it
or they are bound with respect to any equity security of any class of Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) All outstanding shares of Merger Partner
Capital Stock are, and all shares of Merger Partner Common Stock subject to issuance as specified in <U>Sections 3.2(c)</U>, <U>3.2(d)</U>, and <U>3.2(e)</U> upon issuance on the terms and conditions specified in the instruments pursuant to which
they are issuable, will be, duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar
right under any provision of the DGCL, Merger Partner&#146;s certificate of incorporation or bylaws or any agreement to which Merger Partner is a party or is otherwise bound. There are no obligations, contingent or otherwise, of Merger Partner or
any of its Subsidiaries to repurchase, redeem or otherwise acquire any shares of Merger Partner Capital Stock. All outstanding shares of Merger Partner Capital Stock have been offered, issued and sold by Merger Partner in compliance with all
applicable federal and state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No consent of the holders of Merger Partner Stock Options or Merger Partner Warrants is
required in connection with the actions contemplated by <U>Section</U><U></U><U>&nbsp;2.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Subsidiaries</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner does not have, and has not had since its formation, any Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner does not control directly or indirectly or have any direct or indirect equity participation or similar interest in any
corporation, partnership, limited liability company, joint venture, trust or other business association or entity. There are no obligations, contingent or otherwise, of Merger Partner to repurchase, redeem or otherwise acquire any shares of capital
stock of any Person or to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise) in any Person, other than guarantees of bank obligations of Persons entered into in the ordinary course of business
consistent in all material respects with past practice taking into account any acts or omissions that have been taken to comply with any quarantine, &#147;shelter in place&#148;, &#147;stay at home&#148;, workforce reduction, social distancing,
shutdown, closure, sequester or any other Law, order, guideline or recommendation by any Governmental Authority in connection with or in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (&#147;<U><FONT
STYLE="white-space:nowrap">COVID-19</FONT> Measures</U>&#148;) (as applicable to a party, the &#147;<U>Ordinary Course of Business</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Authority; No Conflict; Required Filings and Consents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has all requisite corporate power and authority to enter into this Agreement and, subject only to the adoption of this
Agreement (the &#147;<U>Merger Partner</U> <U>Voting Proposal</U>&#148;) by Merger Partner&#146;s stockholders under the DGCL and the certificate of incorporation of Merger Partner (the &#147;<U>Merger Partner Stockholder Approval</U>&#148;), to
consummate the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, the Merger Partner Board, at a meeting duly called and held, by the unanimous vote of all directors (i)&nbsp;determined that the Merger is
fair to, and in the best interests of, Merger Partner and its stockholders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;approved this Agreement, the Merger and the actions contemplated by this Agreement in accordance with the provisions of the DGCL, (iii)&nbsp;declared this Agreement advisable, and
(iv)&nbsp;determined to recommend that the stockholders of Merger Partner vote to adopt this Agreement and thereby approve the Merger and such other actions as contemplated hereby. The execution and delivery of this Agreement and the consummation of
the transactions contemplated by this Agreement by Merger Partner have been duly authorized by all necessary corporate action on the part of Merger Partner, subject only to the required receipt of the Merger Partner Stockholder Approval. This
Agreement has been duly executed and delivered by Merger Partner and, assuming the due execution and delivery of this Agreement by Public Company, constitutes the valid and binding obligation of Merger Partner, enforceable against such party in
accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles (the
&#147;<U>Bankruptcy and Equity</U> <U>Exception</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of this Agreement by Merger Partner does not,
and the consummation by Merger Partner of the transactions contemplated by this Agreement shall not, (i)&nbsp;conflict with, or result in any violation or breach of, any provision of the certificate of incorporation or bylaws of Merger Partner,
(ii)&nbsp;conflict with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any
material benefit) under, or require a consent or waiver under, constitute a change in control under, require the payment of a penalty under or result in the imposition of any mortgage, security interest, pledge, lien, charge or encumbrance of any
nature (&#147;<U>Liens</U>&#148;) on Merger Partner&#146;s assets under any of the terms, conditions or provisions of any Contract required to be disclosed in <U>Section</U><U>&nbsp;3.11(d)</U> of the Merger Partner Disclosure Schedules, or
(iii)&nbsp;subject to obtaining the Merger Partner Stockholder Approval and compliance with the requirements specified in clauses (i)&nbsp;through (iv) of <U>Section</U><U></U><U>&nbsp;3.4(c)</U>, conflict with or violate any permit, concession,
franchise, license, judgment, injunction, order, decree, statute, law, ordinance, rule or regulation applicable to Merger Partner or any of its properties or assets, except in the case of clauses (ii)&nbsp;and (iii) of this
<U>Section</U><U></U><U>&nbsp;3.4(b)</U> for any such conflicts, violations, breaches, defaults, terminations, cancellations, accelerations or losses that, individually or in the aggregate, have not had, and are not reasonably likely to result in,
the loss of a material benefit to, or in the creation of any material liability for, Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent, approval, license,
permit, order or authorization of, or registration, declaration, notice or filing with, any court, arbitrational tribunal, administrative agency or commission or other governmental or regulatory authority or Regulating Authority, agency or
instrumentality (a &#147;<U>Governmental Entity</U>&#148;) is required by or with respect to Merger Partner in connection with the execution and delivery of this Agreement by Merger Partner or the consummation by Merger Partner of the transactions
contemplated by this Agreement, except for (i)&nbsp;(i) the filing of the Certificate of Merger with the Delaware Secretary of State and appropriate corresponding documents with the appropriate authorities of other states in which Merger Partner is
qualified as a foreign corporation to transact business, (ii)&nbsp;the filing of the Proxy Statement/Prospectus with the U.S. Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) in accordance with the Securities Exchange Act of 1934, as
amended (the &#147;<U>Exchange Act</U>&#148;), (iii) such consents, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable state securities laws and the laws of any foreign country and
(iv)&nbsp;such other consents, authorizations, orders, filings, approvals and registrations that, individually or in the aggregate, if not obtained or made, would not result in a loss of a material benefit to, or the creation of any material
liability for, Merger Partner, Public Company or the Surviving Corporation as a result of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The affirmative vote in favor
of the Merger Partner Voting Proposal by the holders of (i)&nbsp;a majority of the votes represented by the outstanding shares of Merger Partner Capital Stock, <FONT STYLE="white-space:nowrap">(ii)&nbsp;two-thirds</FONT> of the votes represented by
the outstanding shares of Merger Partner Preferred Stock, and <FONT STYLE="white-space:nowrap">(iii)&nbsp;two-thirds</FONT> of the votes represented by the outstanding shares of Merger Partner Series B Preferred Stock, which is to be delivered
pursuant to written consents of stockholders in lieu of a meeting (collectively, the &#147;<U>Written Consents</U>&#148;), is the only vote of the holders of any class or series of Merger Partner&#146;s capital stock or other securities necessary to
adopt this Agreement and for consummation by Merger Partner of the other transactions contemplated by this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement. There are no bonds, debentures, notes or other indebtedness of Merger Partner having the right to vote (or convertible into, or exchangeable for, securities having the right to vote)
on any matters on which stockholders of Merger Partner may vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Financial Statements; Information Provided</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has made available to Public Company correct and complete copies of the Financial Statements. The Financial Statements
(i)&nbsp;comply as to form in all material respects with all applicable accounting requirements, (ii)&nbsp;were prepared in accordance with United States generally accepted accounting principles (&#147;<U>GAAP</U>&#148;) applied on a consistent
basis throughout the periods covered thereby (except as may be indicated in the notes to such financial statements) and (iii)&nbsp;fairly present in all material respects the consolidated financial position of Merger Partner as of the dates thereof
and the consolidated assets, liabilities, business, financial condition, results of its operations and cash flows for the periods indicated, consistent with the books and records of Merger Partner, except that the unaudited interim financial
statements are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments which will not be material in amount or effect. For purposes of this Agreement,<B><I> </I></B>&#147;<U>Financial Statements</U>&#148; means
(i)&nbsp;the audited consolidated balance sheets and statements of income, changes in stockholders&#146; equity and cash flows of Merger Partner as of the end of and for each of the years ended December&nbsp;31, 2018 and December&nbsp;31, 2019, and
(ii)&nbsp;the unaudited consolidated balance sheet of Merger Partner (the &#147;<U>Merger Partner Balance Sheet</U>&#148;) as of December&nbsp;31, 2020 (the &#147;<U>Most</U> <U>Recent Balance Sheet Date</U>&#148;) and the unaudited consolidated
statements of income, changes in stockholders&#146; equity and cash flows for the year ended as of the Most Recent Balance Sheet Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Deloitte Touche Tohmatsu Limited, the auditor of Merger Partner from 2017 to the date of this Agreement, is and has been at all times
during its engagement by Merger Partner (i) &#147;independent&#148; with respect to Merger Partner within the meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and (ii)&nbsp;in compliance with subsections (g)&nbsp;through (l) of
Section&nbsp;10A of the Exchange Act (to the extent applicable) and the related rules of the SEC. Deloitte Touche Tohmatsu Limited, Merger Partner&#146;s current auditor, is and has been at all times since its engagement by the Merger Partner as of
(x) &#147;independent&#148; with respect to Merger Partner within the meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and (y)&nbsp;in compliance with subsections (g)&nbsp;through (l) of Section&nbsp;10A of the Exchange Act (to the
extent applicable) and the related rules of the SEC and Public Company Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The information to be supplied by
or on behalf of Merger Partner for inclusion or incorporation by reference in the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to be filed by Public Company pursuant to which shares of Public Company Common Stock issued
in connection with the Merger shall be registered under the Securities Act (the &#147;<U>Registration</U> <U>Statement</U>&#148;), or to be included or supplied by or on behalf of Merger Partner for inclusion in any filing pursuant to Rule 165 and
Rule 425 under the Securities Act or Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (each a &#147;<U>Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing</U>&#148;), shall not at the time the Registration
Statement or any such Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing is filed with the SEC, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the SEC, as applicable, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. The information to be supplied by or on behalf of Merger Partner for
inclusion in the proxy statement/prospectus/information statement (the &#147;<U>Proxy Statement/Prospectus</U>&#148;) to be sent to the stockholders of Public Company in connection with the meeting of Public Company&#146;s stockholders (the
&#147;<U>Public Company Meeting</U>&#148;) to consider the Share Issuance and a reverse stock split of Public Company Common Stock to be effectuated prior to the Effective Time at a ratio of between 1 to 10 and 1 to 15 (inclusive), as determined by
the Public Company Board (the &#147;<U>Reverse Stock Split</U>&#148;) (the &#147;<U>Public Company Voting Proposals</U>&#148;) under Nasdaq rules (the &#147;<U>Public Company Stockholder Approval</U>&#148;), which information shall be deemed to
include all information about or relating to Merger Partner and/or the Merger Partner Voting Proposal, shall not, on the date the Proxy Statement/Prospectus is first mailed to stockholders of Public Company, or at the time of the Public Company
Meeting or as of the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state any material fact necessary in order to make the statements made in the Proxy Statement/Prospectus not false or misleading; or omit to state any material fact necessary to correct any
statement in any earlier communication with respect to the solicitation of proxies for the Public Company Meeting that has become false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>No Undisclosed Liabilities</U>. Merger Partner does not have any material liability, except for (a)&nbsp;liabilities shown on the Most
Recent Balance Sheet, (b)&nbsp;liabilities of a type shown on the Most Recent Balance Sheet that have arisen since the Most Recent Balance Sheet Date in the Ordinary Course of Business, (c)&nbsp;liabilities for transaction expenses incurred in
connection with the transactions contemplated by this Agreement and (d)&nbsp;contractual and other liabilities incurred in the Ordinary Course of Business that are not required by GAAP to be reflected on a balance sheet (and which have not resulted
from a breach of contract, breach of warranty, tort, infringement or violation of Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <U>Absence of Certain Changes or Events</U>.
During the period beginning on the Most Recent Balance Sheet Date and ending on the date hereof, Merger Partner has conducted its businesses only in the Ordinary Course of Business and, since such date, there has not been (i)&nbsp;any change, event,
circumstance, development or effect that, individually or in the aggregate, has had, or is reasonably likely to have, a Merger Partner Material Adverse Effect; or (ii)&nbsp;any other action or event that would have required the consent of Public
Company pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U> (other than clause (A)&nbsp;of paragraph (j)&nbsp;or paragraphs (k)&nbsp;or (l) thereof) had such action or event occurred after the date of this Agreement.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.8 <U>Taxes</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger
Partner has properly filed on a timely basis all income and other material Tax Returns that it was required to file, and all such Tax Returns were true, correct and complete in all material respects. Merger Partner has paid on a timely basis all
material Taxes, whether or not shown on any Tax Return, that were due and payable. The unpaid Taxes of Merger Partner for Tax periods (or portions thereof) through the Most Recent Balance Sheet Date do not materially exceed the accruals and reserves
for Taxes (excluding accruals and reserves for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the Merger Partner Balance Sheet and all unpaid Taxes of Merger Partner for all Tax periods commencing
after the Most Recent Balance Sheet Date arose in the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner is not nor has it ever been a
member of an affiliated group with which it has filed (or been required to file) consolidated, combined, unitary or similar Tax Returns, other than a group of which the common parent is Merger Partner. With the exception of customary commercial
leases or contracts that are not primarily related to Taxes entered into in the Ordinary Course of Business and liabilities thereunder, Merger Partner (i)&nbsp;does not have any actual or potential liability under Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any comparable or similar provision of federal, state, local or foreign law), as a transferee or successor, pursuant to any contractual obligation, or otherwise for any Taxes of any person
other than Merger Partner, and (ii)&nbsp;is not a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All material Taxes that Merger Partner was required by Law to withhold or collect have been duly withheld or collected and, to the extent
required, have been properly paid to the appropriate Governmental Entity, and Merger Partner has complied with all information reporting and backup withholding requirements, including the maintenance of required records with respect thereto, in
connection with amounts paid to any employee, independent contractor, creditor, or other third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Merger Partner has delivered or
made available to Public Company (i)&nbsp;complete and correct copies of all material Tax Returns of Merger Partner relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii)&nbsp;complete and
correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any
similar documents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitted by, received by, or agreed to by or on behalf of Merger Partner relating to Taxes for all taxable periods for which the statute of limitations has not yet expired, and
(iii)&nbsp;complete and correct copies of all material agreements, rulings, settlements or other Tax documents with or from any Governmental Entity relating to Tax incentives of Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No examination or audit of any Tax Return of Merger Partner by any Governmental Entity is currently in progress or, to the knowledge of
Merger Partner, threatened or contemplated. No deficiencies for Taxes of Merger Partner have been claimed, proposed or assessed by any Governmental Entity. Merger Partner has not been informed in writing by any jurisdiction in which Merger Partner
does not file a Tax Return that the jurisdiction believes that Merger Partner was required to file any Tax Return that was not filed or is subject to Tax in such jurisdiction. Merger Partner has not (i)&nbsp;waived any statute of limitations with
respect to Taxes or agreed to extend the period for assessment or collection of any Taxes, which waiver or extension is still in effect, (ii)&nbsp;requested any extension of time within which to file any Tax Return, other than routine extensions
available as a matter of right which Tax Return has not yet been filed, or (iii) executed or filed any power of attorney with any taxing authority, which is still in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;Merger Partner has not made any payment, is not obligated to make any payment, and is not a party to any agreement that could
obligate it to make any payment that may be treated as an &#147;excess parachute payment&#148; under Section&nbsp;280G of the Code (without regard to Sections 280G(b)(4) and 280G(b)(5) of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Merger Partner has not been a United States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code
during the applicable period specified in Section&nbsp;897(c)(l)(A)(ii) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Merger Partner has not distributed to its
stockholders or security holders stock or securities of a controlled corporation, nor has stock or securities of Merger Partner been distributed, in a transaction to which Section&nbsp;355 of the Code applies in the two years prior to the date of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) There are no Liens with respect to Taxes upon any of the assets or properties of Merger Partner, other than with
respect to Taxes not yet due and payable or being contested in good faith by appropriate proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Merger Partner will not be
required to include any material item of income in, or exclude any material item of deduction from, taxable income for any period (or any portion thereof) ending after the Closing Date as a result of any (i)&nbsp;adjustments under Section&nbsp;481
of the Code (or any similar adjustments under any provision of the Code or the corresponding foreign, state or local Tax laws) made on or prior to the Closing Date, (ii)&nbsp;installment sale or other open transaction disposition made on or prior to
the Closing Date, or (iii)&nbsp;prepaid amount or deferred revenue received on or prior to the Closing Date outside the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Merger Partner has not participated in any &#147;reportable transaction&#148; as defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)</FONT> of the Treasury Regulations or a &#147;listed transaction&#148; as set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;301.6111-2(b)(2)</FONT> of the Treasury Regulations or any
analogous provision of state or local law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Merger Partner (i)&nbsp;is not a party to any joint venture, partnership, or other
arrangement that is treated as a partnership for federal income Tax purposes and (ii)&nbsp;has not made an entity classification <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;check-the-box&#148;)</FONT></FONT> election
under Section&nbsp;7701 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Merger Partner (i)&nbsp;is not a stockholder of a &#147;specified foreign corporation&#148;
(other than the Subsidiaries of Merger Partner) as defined in Section&nbsp;965(e) of the Code (or any similar provision of state, local or foreign Law), and (ii)&nbsp;is not a stockholder in a &#147;passive foreign investment company&#148; as
defined in Section&nbsp;1297 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Merger Partner is not subject to Tax in any country other than its country of
incorporation, organization or formation by virtue of having employees, a permanent establishment or other place of business in that country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Merger Partner has not taken or agreed to take any action, has not omitted to take any
action, and has no knowledge of any fact or circumstance, the taking, omission, or existence of which, as the case may be, could reasonably be expected to prevent the Merger from constituting a transaction qualifying as a reorganization under
Section&nbsp;368(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) Merger Partner is not an investment company as defined in Section&nbsp;368(a)(2)(F)(iii) and
(iv)&nbsp;of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) Merger Partner (i)&nbsp;did not defer any amount of the employer&#146;s share of any &#147;applicable
employment taxes&#148; under Section&nbsp;2302 of the Coronavirus Aid, Relief and Economic Security Act (the &#147;<U>CARES Act</U>&#148;) (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), (ii) did
not request any available Tax credits under Sections 7001 through 7005 of the Families First Coronavirus Response Act (the &#147;<U>Families First Act</U>&#148;) and Section&nbsp;2301 of the CARES Act, (iii)&nbsp;did not seek (nor has any affiliate
that would be aggregated with Merger Partner and treated as one employer for purposes of Section&nbsp;2301 of the CARES Act sought) a covered loan under paragraph (36)&nbsp;of Section&nbsp;7(a) of the Small Business Act (15 U.S.C. 636(a)), as added
by Section&nbsp;1102 of the CARES Act, and (iv)&nbsp;did not defer any payroll Tax obligations (including those imposed by Code Sections 3101(a) and 3201) pursuant to or in connection with the Memorandum on Deferring Payroll Tax Obligations in Light
of the Ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> Disaster, dated August&nbsp;8, 2020, or any other provision of the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) For purposes of this Agreement, (i) &#147;<U>Taxes</U>&#148; shall mean any and all taxes, charges, fees, duties, contributions, levies or
other similar assessments or liabilities in the nature of a tax, including, without limitation, income, gross receipts, corporation, ad valorem, premium, value-added, net worth, capital stock, capital gains, documentary, recapture, alternative or <FONT
STYLE="white-space:nowrap">add-on</FONT> minimum, disability, estimated, registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment, insurance,
social security, national insurance, business license, business organization, environmental, workers compensation, payroll, profits, severance, stamp, occupation, windfall profits, customs duties, franchise and other taxes of any kind whatsoever
imposed by the United States of America or any state, local or foreign government, or any agency or political subdivision thereof, and any interest, fines, penalties, assessments or additions to tax imposed with respect to such items, and (ii)
&#147;<U>Tax Returns</U>&#148; shall mean any and all reports, returns (including information returns), declarations, or statements relating to Taxes, including any schedule or attachment thereto and any amendment thereof, filed with or submitted
to, or required to be filed with or submitted to, a Governmental Entity in connection with the determination, assessment, collection or payment of Taxes or in connection with the administration, implementation or enforcement of or compliance with
any legal requirement relating to any Tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.9 <U>Owned and Leased Real Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner does not own nor has ever owned any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;3.9(b) </U>of the Merger Partner Disclosure Schedule sets forth a complete and accurate list of all real
property leased, subleased or licensed by Merger Partner as of the date of this Agreement (collectively, the &#147;<U>Merger Partner Leases</U>&#148;) and the location of the premises of such real property. Neither Merger Partner nor, to the
knowledge of Merger Partner, any other party is in breach or default and no event has occurred, is pending or, to the knowledge of Merger Partner, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would constitute
any such breach or default under any of Merger Partner Leases, except where the existence of such breaches or defaults, individually or in the aggregate, has not had, and is not reasonably likely to result in, the loss of a material right or in a
material liability of Merger Partner. Merger Partner does not lease, sublease or license any real property to any person. Merger Partner has made available to Public Company complete and accurate copies of all Merger Partner Leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.10 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.10(a) </U>of the Merger Partner Disclosure Schedule lists all Merger Partner Registrations that have not
been abandoned, expired or cancelled, in each case enumerating specifically the applicable filing or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration number, title, jurisdiction in which filing was made or from which registration issued, date of filing or issuance, and names of all current registered owners(s), as applicable. All
assignments of Merger Partner Registrations to Merger Partner have been properly executed and recorded, and all issuance, renewal, maintenance and other payments that are or have become due with respect thereto have been timely paid by or on behalf
of the Merger Partner. Except as would not be, individually or in the aggregate, material to Merger Partner, to the knowledge of Merger Partner, all Merger Partner Registrations are valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There are no inventorship challenges, <I>inter partes</I> proceedings, opposition or nullity proceedings or interferences pending, or, to
the knowledge of Merger Partner, threatened in writing, with respect to any Patent Rights included in the Merger Partner Registrations. Merger Partner has complied with its duty of candor and disclosure to the United States Patent and Trademark
Office and, to the extent required, any relevant foreign patent office with respect to all patent and trademark applications filed by or on behalf of Merger Partner and has made no material misrepresentation in such applications that would be
material to Merger Partner. Merger Partner has no actual knowledge of any information that would preclude Merger Partner from having clear title to the Merger Partner Registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner is the sole and exclusive owner of all Merger Partner Owned Intellectual Property, free and clear of any Liens, other than
(i)&nbsp;any joint owners of the Merger Partner Owned Intellectual Property that are listed in <U>Section</U><U></U><U>&nbsp;3.10(c)</U> of the Merger Partner Disclosure Schedule and (ii)&nbsp;any license, covenant or other agreement that is listed
in <U>Section</U><U></U><U>&nbsp;3.10(h)</U> of the Merger Partner Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To Merger Partner&#146;s knowledge, the
Merger Partner Intellectual Property constitutes the Intellectual Property necessary to conduct Merger Partner&#146;s business in the manner currently conducted by Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Merger Partner has taken commercially reasonable measures to protect the proprietary nature of each item of Merger Partner Owned
Intellectual Property, and to maintain in confidence all trade secrets and confidential information comprising a part thereof. To Merger Partner&#146;s knowledge and except as would not be, individually or in the aggregate, material to Merger
Partner, there has been no unauthorized disclosure of any third party proprietary or confidential information in the possession, custody or control of Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of Merger Partner and except as would not be, individually or in the aggregate, material to Merger Partner, the
operations of Merger Partner as currently conducted do not and have not in the past three years infringe(d) or misappropriate(d) the Intellectual Property rights of any individual or entity. To Merger Partner&#146;s knowledge and except as would not
be, individually or in the aggregate, material to Merger Partner, no individual or entity has infringed, misappropriated or otherwise violated the Merger Partner Owned Intellectual Property or any rights under the Merger Partner Licensed
Intellectual Property that are exclusively licensed to Merger Partner, and Merger Partner has not filed or threatened in writing any claims alleging that a third party or Worker has infringed, misappropriated or otherwise violated any Merger Partner
Intellectual Property. No individual or entity has filed and served upon Merger Partner or, to Merger Partner&#146;s knowledge, threatened in writing any action or proceeding alleging that Merger Partner has infringed, misappropriated or otherwise
violated any individual&#146;s or entity&#146;s Intellectual Property rights nor has Merger Partner received any written notification that a license under any other individual&#146;s or entity&#146;s Intellectual Property is or may be required to
the conduct of Merger Partner&#146;s business in the manner currently conducted by Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Merger Partner has made available
copies of all correspondence, legal opinions, complaints, claims, notices or threats in writing concerning the infringement, violation or misappropriation of any Merger Partner Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Section</U><U></U><U>&nbsp;3.10(h)</U> of the Merger Partner Disclosure Schedule identifies each license, covenant or other agreement
pursuant to which Merger Partner has assigned, transferred, licensed, distributed or otherwise granted any right or access to any individual or entity, or covenanted not to assert any right, with respect to any past, existing or future Merger
Partner Intellectual Property that is material to the conduct of Merger Partner&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business in the manner currently conducted by Merger Partner, other than <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
licenses entered into in the ordinary course of Merger Partner&#146;s business, and agreements with current and former employees, officers, contractors, and consultants for providing services to the Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Section</U><U></U><U>&nbsp;3.10(i)</U> of the Merger Partner Disclosure Schedule identifies (i)&nbsp;each license or agreement pursuant
to which Merger Partner has obtained rights to any Merger Partner Licensed Intellectual Property (excluding generally available, off the shelf software programs that are licensed by Merger Partner pursuant to &#147;shrink wrap&#148; licenses, the
total fees associated with which are less than $10,000) and (ii)&nbsp;each agreement, contract, assignment or other instrument pursuant to which Merger Partner has obtained any joint or sole ownership interest in or to each item of Merger Partner
Owned Intellectual Property; in each case of the foregoing clauses (i)&nbsp;and (ii), other than <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses entered into in the
ordinary course of Merger Partner&#146;s business, and agreements with current and former employees, officers, contractors, and consultants for providing services to the Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) To Merger Partner&#146;s knowledge, no Worker of Merger Partner is in material default or breach of any term of any employment Contract, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> Contract, assignment of invention Contract or similar Contract between such Worker and Merger Partner relating to the protection, ownership, development, use or transfer of Merger Partner Intellectual
Property. To the extent that any Merger Partner Owned Intellectual Property has been conceived, developed or created for Merger Partner by any individual while a Worker, Merger Partner has obtained the entire and unencumbered right, title and
interest therein and thereto by operation of Law or by valid written assignment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To Merger Partner&#146;s knowledge and except as
would not be, individually or in the aggregate, material to Merger Partner, neither the negotiation, execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated hereby, will result in (i)&nbsp;a breach
of or default under any agreement governing any Merger Partner Intellectual Property, (ii)&nbsp;the grant or transfer to any third party of any new license or other interest under, the abandonment, assignment to any third party, or modification or
loss of any right with respect to, or the creation of any Lien on, any Merger Partner Intellectual Property that is material to the conduct of Merger Partner&#146;s business in the manner currently conducted by Merger Partner, or (iii)&nbsp;Merger
Partner, Public Company or any of their respective Affiliates being obligated to pay any penalty or new or increased royalty or fee to any individual or entity under any agreement governing any Merger Partner Intellectual Property that is material
to the conduct of Merger Partner&#146;s business in the manner currently conducted by Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) For purposes of this Agreement,
the following terms shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Intellectual Property</U>&#148; shall mean the following subsisting
throughout the world: (i)&nbsp;Patent Rights; (ii)&nbsp;Trademarks and all goodwill in the Trademarks; (iii) copyrights, designs, data and database rights and registrations and applications for registration thereof, including moral rights of
authors; (iv)&nbsp;mask works and registrations and applications for registration thereof and any other rights in semiconductor topologies under the Laws of any jurisdiction; (v)&nbsp;inventions, invention disclosures, statutory invention
registrations, trade secrets and confidential business information, <FONT STYLE="white-space:nowrap">know-how,</FONT> scientific and technical information, data and technology, including medical, clinical, toxicological and other scientific data,
manufacturing and product processes, algorithms, techniques and analytical methodology, research and development information, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and
supplier lists and information, whether patentable or nonpatentable, whether copyrightable or noncopyrightable and whether or not reduced to practice; and (vi)&nbsp;other proprietary rights relating to any of the foregoing (including remedies
against infringement thereof and rights of protection of interest therein under the Laws of all jurisdictions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
&#147;<U>Intellectual Property Registrations</U>&#148; shall mean Patent Rights, applications and registrations for Trademarks, applications and registrations for copyrights and designs, mask work registrations and applications for each of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Law</U>&#148; shall mean each applicable transnational, domestic or foreign
federal, state or local law (statutory, common or otherwise) law, order, judgment, rule, code, statute, regulation, requirement, variance, decree, writ, injunction, award, ruling, Permit or ordinance of any Governmental Entity, including any
applicable stock exchange rule or requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Merger Partner Intellectual Property</U>&#148; shall mean the Merger
Partner Owned Intellectual Property and the Merger Partner Licensed Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Merger Partner Licensed
Intellectual Property</U>&#148; shall mean all Intellectual Property that is licensed to Merger Partner by any individual or entity other than Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) &#147;<U>Merger Partner Owned Intellectual Property</U>&#148; shall mean all Intellectual Property owned or purported to be owned by
Merger Partner, in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) &#147;<U>Merger Partner Registrations</U>&#148; shall mean Intellectual Property
Registrations that are owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by the Merger Partner, alone or jointly with others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) &#147;<U>Patent Rights</U>&#148; shall mean all patents, patent applications, utility models, design registrations and certificates of
invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals,
reissues and reexaminations). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) &#147;<U>Trademarks</U>&#148; shall mean all registered trademarks and service marks, logos, Internet
domain names, social media accounts and identifiers, corporate names and doing business designations and all registrations and applications for registration of the foregoing, common Law trademarks and service marks and trade dress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Worker</U>&#148; means any individual who is an officer, director, employee (regular, temporary, part-time or otherwise),
consultant or independent contractor of Merger Partner or Public Company or any of its Subsidiaries, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11
<U>Contracts</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As of the date of this Agreement, there are no Contracts that are material contracts (as defined in Item 601(b)(10)
of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> with respect to Merger Partner (assuming Merger Partner was subject to the requirements of the Exchange Act), other than those Contracts identified in
<U>Section</U><U></U><U>&nbsp;3.11(a)</U> of the Merger Partner Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner has not entered into any
transaction that would be subject to proxy statement disclosure pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> (assuming Merger Partner was subject to the requirements of the Exchange Act), other than as disclosed in
<U>Section</U><U></U><U>&nbsp;3.11(b)</U> of the Merger Partner Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner is not a party to any agreement
under which a third party would be entitled to receive a license or any other right to Merger Partner Intellectual Property as a result of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Section</U><U></U><U>&nbsp;3.11(d)</U> of the Merger Partner Disclosure Schedule lists the following Contracts of Merger Partner in
effect as of the date of this Agreement to the extent Merger Partner has material continuing obligations thereunder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Contract
(or group of related Contracts) for the purchase or sale of products or for the furnishing or receipt of services (A)&nbsp;which calls for performance over a period of more than 180 days from the date of this Agreement and is expected to involve an
aggregate of more than $250,000, (B) which involved an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate of more than $250,000 over the 12 months prior to the date of this Agreement, or (C)&nbsp;in which Merger Partner has granted manufacturing rights, &#147;most favored nation&#148;
pricing provisions or marketing or distribution rights relating to any products or territory or has agreed to purchase a minimum quantity of goods or services or has agreed to purchase goods or services exclusively from a particular party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Contract under which the consequences of a default or termination would reasonably be likely to have a Merger Partner Material
Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any Contract that could reasonably be expected to have the effect of prohibiting or impairing the conduct of the
business of Merger Partner, or Public Company or any of its Subsidiaries, as currently conducted; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Contract under which Merger
Partner is restricted from selling, licensing or otherwise distributing any of its technology or products, or providing services to, customers or potential customers or any class of customers, in any geographic area, during any period of time or any
segment of the market or line of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any dealer, distribution, joint marketing, joint venture, joint development, partnership,
strategic alliance, collaboration, development agreement or outsourcing arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Contract for the conduct of research
studies, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical studies, manufacturing, distribution, supply, marketing or <FONT STYLE="white-space:nowrap">co-promotion</FONT> of any products in development by or which has been or which is
being marketed, distributed, supported, sold or licensed out, in each case by or on behalf of Merger Partner that involved an aggregate of more than $250,000 over the 12 months prior to the date of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any Contract that would entitle any third party to receive a license or any other right to Intellectual Property of Public Company or
any of Public Company&#146;s Affiliates following the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Merger Partner has made available to Public Company a complete and
accurate copy of each Contract listed in <U>Sections 3.10(a)</U>, <U>3.10(h)</U>, <U>3.10(i)</U>, <U>3.11(a)</U>, <U>3.11(b)</U> and <U>3.11(d)</U> of the Merger Partner Disclosure Schedule. With respect to each Contract so listed: (i)&nbsp;the
Contract is legal, valid, binding and enforceable and in full force and effect against Merger Partner, as applicable, and, to the knowledge of Merger Partner, against each other party thereto, as applicable, subject to the Bankruptcy and Equity
Exception; (ii)&nbsp;the Contract will continue to be legal, valid, binding and enforceable and in full force and effect against Merger Partner and, to the knowledge of Merger Partner, against each other party thereto, immediately following the
Closing in accordance with the terms thereof as in effect immediately prior to the Closing (other than any such Contracts that expire or terminate before such time in accordance with their terms and not as a result of a breach or default by Merger
Partner), in each such case subject to the Bankruptcy and Equity Exception; and (iii)&nbsp;none of Merger Partner nor, to the knowledge of Merger Partner, any other party, is in breach or violation of, or default under, any such Contract, and no
event has occurred, is pending or, to the knowledge of Merger Partner, is threatened, which, with or without notice or lapse of time, or both, would constitute a breach or default by Merger Partner or, to the knowledge of Merger Partner, any other
party under such Contract, except for such breaches, violations or defaults that, individually or in the aggregate, have not had, and are not reasonably likely to have, a Merger Partner Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) For purposes of this Agreement, the term &#147;<U>Contract</U>&#148; shall mean, with respect to any person, any written, oral or other
agreement, contract, subcontract, lease (whether for real or personal property), mortgage, understanding, arrangement, instrument, note, option, warranty, license, sublicense, insurance policy, benefit plan or commitment or undertaking of any nature
to which such person is a party or by which such person or any of its assets are bound under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12 <U>Litigation</U>. There is no action, suit, proceeding, claim, arbitration or
investigation before any Governmental Entity or before any arbitrator that is pending or has been threatened in writing against Merger Partner that (a)&nbsp;seeks either damages in excess of $250,000 or equitable relief or (b)&nbsp;in any manner
challenges or seeks to prevent, enjoin, alter or delay the transactions contemplated by this Agreement, except for such actions, suits, proceedings, claims, arbitrations or investigations first arising after the date of this Agreement that,
individually or in the aggregate, have not had, and are not reasonably likely to have, a Merger Partner Material Adverse Effect. There are no material judgments, orders or decrees outstanding against Merger Partner or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.13 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except for such matters that, individually or in the aggregate, have not had, and are not reasonably likely to have, a Merger Partner
Material Adverse Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Merger Partner has complied with all applicable Environmental Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the properties currently or formerly owned, leased or operated by Merger Partner (including soils, groundwater, surface water, buildings
or other structures) are and were not contaminated with any Hazardous Substances; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Merger Partner is not subject to liability for
any Hazardous Substance disposal or contamination on the property of any third party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Merger Partner has not released any
Hazardous Substance into the environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, Merger Partner has not received any written notice,
demand, letter, claim or request for information alleging that Merger Partner may be in violation of, liable under or have obligations under, any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner is not subject to any orders, decrees, injunctions or other arrangements with any Governmental Entity or is subject to any
indemnity or other agreement with any third party relating to liability under any Environmental Law or relating to Hazardous Substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Agreement, the term &#147;<U>Environmental Law</U>&#148; means any law, regulation, order, decree, permit,
authorization, opinion, common Law or agency requirement of any jurisdiction relating to: (i)&nbsp;the protection, investigation or restoration of the environment, human health and safety or natural resources, (ii)&nbsp;the handling, use, storage,
treatment, presence, disposal, release or threatened release of any Hazardous Substance or (iii)&nbsp;noise, odor, wetlands, pollution, contamination or any injury or threat of injury to persons or property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Agreement, the term &#147;<U>Hazardous Substance</U>&#148; means any substance that is: (i)&nbsp;listed, classified,
regulated or which falls within the definition of a &#147;hazardous substance,&#148; &#147;hazardous waste&#148; or &#147;hazardous material&#148; pursuant to any Environmental Law; (ii)&nbsp;any petroleum product or
<FONT STYLE="white-space:nowrap">by-product,</FONT> asbestos-containing material, lead-containing paint or plumbing, polychlorinated biphenyls, radioactive materials or radon; or (iii)&nbsp;any other substance that is the subject of regulatory
action by any Governmental Entity pursuant to any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.14 <U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;3.14(a) </U>of the Merger Partner Disclosure Schedule sets forth a complete and accurate list of all
material Employee Benefit Plans maintained, or contributed to, by Merger Partner or any of its ERISA Affiliates for the benefit of, or relating to, any current or former employee or other service provider of Merger Partner (collectively, the
&#147;<U>Merger Partner</U> <U>Employee Plans</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Merger Partner Employee Plan has been administered in all material respects in
accordance with ERISA, the Code and all other applicable laws and the regulations thereunder and in accordance with its terms. Merger Partner and each of its ERISA Affiliates and each Merger Partner Employee Plan are in compliance in all material
respects with the currently applicable provisions of ERISA and the Code and the regulations thereunder (including Section&nbsp;4980B of the Code, Subtitle K, Chapter 100 of the Code and Sections 601 through 608 and Section&nbsp;701 et seq. of
ERISA). All filings and reports as to each Merger Partner Employee Plan required to have been submitted to the U.S Internal Revenue Service (the &#147;<U>IRS</U>&#148;) or to the United States Department of Labor have been timely submitted. There is
no audit, investigation or other proceeding (including any voluntary correction application) pending against or involving any Merger Partner Employee Plan. There have been no events with respect to any Merger Partner Employee Plan that could result
in payment or assessment by or against the Merger Partner of any material Taxes, including (but without limitation) any material excise Taxes under Sections 4972, 4975, 4976, 4977, 4979, 4980B, 4980D, 4980E, 4980H or 5000 of the Code. With respect
to Merger Partner Employee Plans, no event has occurred, and to the knowledge of Merger Partner, there exists no condition or set of circumstances in connection with which Merger Partner or any of its Subsidiaries could be subject to any liability
that is reasonably likely, individually or in the aggregate, to have a Merger Partner Material Adverse Effect under ERISA, the Code or any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) With respect to Merger Partner Employee Plans, there are no benefit obligations for which contributions have not been properly made or
properly accrued and there are no benefit obligations that have not been properly accounted for by reserves, or otherwise properly footnoted in accordance with GAAP, on the financial statements of Merger Partner, which obligations are reasonably
likely, individually or in the aggregate, to have a Merger Partner Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All Merger Partner Employee Plans that
are intended to be qualified under Section&nbsp;401(a) of the Code have received determination letters, or may rely on an opinion letter, from the IRS to the effect that such Merger Partner Employee Plans are qualified and the plans and trusts
related thereto are exempt from federal income taxes under Sections 401(a) and 501(a), respectively, of the Code, no such determination letter has been revoked and revocation has not been threatened, and no such Merger Partner Employee Plan has been
amended or operated since the date of its most recent determination letter or application therefor in any respect, and no act or omission has occurred, that would reasonably be expected to adversely affect its qualification or materially increase
its cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither Merger Partner nor any of its ERISA Affiliates has (i)&nbsp;ever maintained an Employee Benefit Plan that was ever
subject to Section&nbsp;412 of the Code or Title IV of ERISA or (ii)&nbsp;ever been obligated to contribute to a &#147;multiemployer plan&#148; (as defined in Section&nbsp;4001(a)(3) of ERISA). No Merger Partner Employee Plan is funded by,
associated with or related to a &#147;voluntary employees&#146; beneficiary association&#148; within the meaning of Section 501(c)(9) of the Code. No Merger Partner Employee Plan holds securities issued by Merger Partner or any of its ERISA
Affiliates. No Merger Partner Employee Plan is a &#147;multiple employer plan&#148; within the meaning of Section&nbsp;413(c) of the Code or a &#147;multiple employer welfare arrangement&#148; as defined in Section&nbsp;3(40) of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There are no loans or extensions of credit by the Merger Partner or any ERISA Affiliate of Merger Partner to any employee or any other
service provider to Merger Partner, other than routine advances to employees of Merger Partner in the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
Merger Partner is and has been in compliance in all material respects with all applicable provisions of the Affordable Care Act, including reporting requirements and all requirements relating to eligibility waiting periods and the offer of or
provision of minimum essential coverage that is compliant with Section&nbsp;36B(c)(2)(C) of the Code and the regulations issued thereunder to full-time employees as defined in Section&nbsp;4980H(b)(4) of the Code and the regulations issued
thereunder. No material excise tax or penalty under the Affordable Care Act, including Section&nbsp;4980H of the Code, is outstanding, has accrued, or has arisen and there has been no change in health plan terms or coverage that would reasonably be
expected to attract an excise tax under Section&nbsp;4980H of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Code for the current year. Merger Partner has not received any notification from any Governmental Entity concerning potential liability under the Affordable Care Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Each Merger Partner Employee Plan that is a &#147;nonqualified deferred compensation plan&#148; (as defined in Section&nbsp;409A(d)(1) of
the Code) complies and has complied in all material respects in form and operation with Section&nbsp;409A of the Code and all IRS regulations and other guidance promulgated thereunder. No stock option or equity unit option granted under any Merger
Partner Employee Plan has an exercise price that has been or may be less than the fair market value of the underlying stock or equity units (as the case may be) as of the date such option was granted or has any feature for the deferral of
compensation other than the deferral of recognition of income until the later of exercise or disposition of such option. No nonqualified deferred compensation plan has been administered in a manner that would reasonably be expected to cause an
excise tax to apply to payments to plan participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) For purposes of this Agreement, the following terms shall have the following
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Employee Benefit Plan</U>&#148; means any &#147;employee pension benefit plan&#148; (as defined in
Section&nbsp;3(2) of ERISA), any &#147;employee welfare benefit plan&#148; (as defined in Section&nbsp;3(1) of ERISA) and any other written or oral plan, agreement or arrangement involving direct or indirect compensation, including insurance
coverage, severance benefits, disability benefits, fringe benefits, perquisites, change in control benefits, deferred compensation, bonuses, stock options, stock purchase, phantom stock, stock appreciation or other forms of incentive compensation or
post-retirement compensation and all unexpired severance agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>ERISA</U>&#148; means the Employee Retirement Income
Security Act of 1974, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>ERISA Affiliate</U>&#148; means any entity (whether or not incorporated) that is, or at
any applicable time was, treated as a &#147;single employer&#148; with the Merger Partner or the Public Company, as applicable, or with any of such Person&#146;s Subsidiaries within the meaning of Section&nbsp;414 of the Code or Section&nbsp;4001 of
ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.15 <U>Compliance With Laws</U>. Merger Partner has complied in all material respects with, is not in material violation of, and,
as of the date of this Agreement, has not received any notice alleging any material violation with respect to, any applicable provisions of any statute, Law or regulation with respect to the conduct of its business, or the ownership or operation of
its properties or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.16 <U>Permits and Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has all permits, licenses, registrations, authorizations, certificates, orders, approvals, franchises, variances and other
similar rights issued by or obtained from any Governmental Entities (collectively, &#147;<U>Permits</U>&#148;) that are material to the conduct of its business as currently conducted, including all such Permits required by the U.S. Food and Drug
Administration (the &#147;<U>FDA</U>&#148;), such as a study may proceed letter for an Investigational New Drug application (&#147;<U>IND</U>&#148;), and any other federal, state or foreign agencies or bodies (together with the FDA, the
&#147;<U>Regulating Authority</U>&#148;) engaged in the regulation of pharmaceuticals or biohazardous materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Permits that are
necessary for the conduct of the business of Merger Partner as currently conducted (&#147;<U>Merger Partner Authorizations</U>&#148;) are in full force and effect, and to the knowledge of Merger Partner, no violations or notices of failure to comply
have been issued or recorded by any Regulating Authority in respect of any such Merger Partner Authorization. No such Merger Partner Authorization shall cease to be effective as a result of the consummation of the transactions contemplated by this
Agreement. Merger Partner is in compliance in all material respects under any of such Merger Partner Authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge
of Merger Partner, all applications, reports, notices and other documents required to be filed by Merger Partner with all Governmental Entities have been timely filed and are complete and correct in all material respects as filed or as amended prior
to the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) None of Merger Partner and to Merger Partner&#146;s knowledge, any officer, employee or
agent of Merger Partner has been convicted of any crime or engaged in any conduct that has previously caused or would reasonably be expected to result in (A)&nbsp;disqualification or debarment by the FDA under 21 U.S.C. Sections&nbsp;335a(a) or (b),
or any similar law, rule or regulation of any other Governmental Entity, or (B)&nbsp;exclusion under 42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7</FONT> or any similar law, rule or regulation of any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of the date of this Agreement and for the three years prior to the date of this Agreement, Merger Partner: (i)&nbsp;is and has been in
material compliance, to the extent applicable, with all applicable Laws, including the Federal Food, Drug, and Cosmetic Act (&#147;<U>FDCA</U>&#148;) and such applicable requirements relating to Good Manufacturing Practices, Good Clinical Practices
and Good Laboratory Practices, and with all applicable orders lawfully administered or issued by the FDA or any other Governmental Entity exercising comparable authority, applicable to the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product tested, developed, promoted, marketed, manufactured or distributed by Merger Partner; and (ii)&nbsp;has not
received any written notice or correspondence from any Governmental Entity alleging or asserting any material noncompliance with any such Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Merger Partner nor, to the knowledge of Merger Partner, any of its officers, employees or agents, have made an untrue statement of
a material fact or fraudulent statement to any Governmental Entity relating to the Merger Party Authorizations or failed to disclose a material fact required to be disclosed to any Government Entity relating to the Merger Partner Authorizations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To Merger Partner&#146;s knowledge, all preclinical and clinical investigations and trials sponsored by Merger Partner are being and
have for the three years prior to the date of this Agreement been conducted in compliance in all material respects with applicable laws, including, as applicable, Good Manufacturing Practices, Good Clinical Practices and Good Laboratory Practices
requirements and privacy laws. Merger Partner has not received any written notices from any Government Entity, institutional review board, independent ethics committee, data and safety monitoring board, or other oversight body with respect to any
clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or tests, or chemistry, manufacturing, and control quality issues requiring the termination, suspension or material modification of such studies or tests and, to Merger
Partner&#146;s knowledge, there are no facts that would reasonably give rise to such an action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) There are no seizures, recalls,
market withdrawals, field notifications or corrective actions, notifications of misbranding or adulteration, destruction orders, safety alerts or similar actions relating to the safety or efficacy of any products marketed or sold by Merger Partner
being conducted, requested in writing or, to the knowledge of Merger Partner, that have been threatened by the FDA or any other Governmental Entity. Merger Partner has not, either voluntarily or as requested or required by a Governmental Entity,
initiated, conducted or issued or caused to be initiated, conducted or issued any recall, market withdrawal, safety alert or other similar notice or action relating to the alleged lack of safety or efficacy of any products marketed or sold by Merger
Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.17 <U>Employees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All current and past key employees of Merger Partner have entered into confidentiality and assignment of inventions agreements with Merger
Partner, a copy or form of which has previously been made available to Public Company. To the knowledge of Merger Partner, as of the date of this Agreement, no employee of Merger Partner is in violation of any term of any patent disclosure
agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, or any restrictive covenant to a former employer relating to the right of any such employee to be employed by Merger Partner because of the nature of the business
currently conducted by Merger Partner or to the use of trade secrets or proprietary information of others. To the knowledge of Merger Partner, as of the date of this Agreement, no key employee or group of key employees has any plans to terminate
employment with Merger Partner within the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner is not and has not been a party to or otherwise bound by any collective
bargaining agreement, contract or other agreement or understanding with a labor union or labor organization. Merger Partner is not and has not been the subject of any proceeding asserting that Merger Partner has committed an unfair labor practice or
is seeking to compel it to bargain with any labor union or labor organization, nor is there or has there been pending or, to the knowledge of Merger Partner, threatened, any labor strike, dispute, walkout, work stoppage, slow-down or lockout
involving Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner is and has been in material compliance with all applicable Laws related to employment
(including verification of employment eligibility), employment practices, terms and conditions of employment and wages and hours (including, without limitation, classification of employees) with respect to any employee (as defined by, or determined
in accordance with, applicable Laws). To the knowledge of Merger Partner, all employees of Merger Partner are citizens or lawful permanent residents of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Merger Partner has not received written notice of any charge or complaint pending before the Equal Employment Opportunity Commission or
other Governmental Entity alleging unlawful discrimination, harassment, retaliation or any other violation of or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable Law relating to the employment, treatment, or termination of any
employees of Merger Partner nor, to the knowledge of Merger Partner, has any such charge been threatened. No current or former employee of Merger Partner has, pursuant to internal complaint procedures, made a written complaint of discrimination,
retaliation or harassment, nor to Merger Partner&#146;s knowledge, has an oral complaint of any of the foregoing been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Merger
Partner has not caused a plant closing as defined in the Worker Adjustment and Retraining Notification Act (the &#147;<U>WARN Act</U>&#148;) affecting any site of employment or one or more operating units within any site of employment, or a mass
layoff as defined in the WARN Act, nor have any of the foregoing been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.18 <U>Insurance</U>. Merger Partner maintains insurance policies (the &#147;<U>Merger Partner</U> <U>Insurance Policies</U>&#148;),
including insurance covering directors and officers for securities Law and other customary liabilities, with reputable insurance carriers against all risks of a character and in such amounts as are usually insured against by similarly situated
companies in the same or similar businesses. Each Merger Partner Insurance Policy is in full force and effect. None of the Merger Partner Insurance Policies shall terminate or lapse (or be affected in any other adverse manner) by reason of any of
the transactions contemplated by this Agreement. Merger Partner has complied in all material respects with the provisions of each Merger Partner Insurance Policy under which it is the insured party. No insurer under any Merger Partner Insurance
Policy has cancelled or generally disclaimed liability under any such policy or indicated any intent to do so or not to renew any such policy. All claims under the Merger Partner Insurance Policies have been filed in a timely fashion. The Merger
Partner has delivered to Public Company accurate and complete copies of all Merger Partner Insurance Policies relating to the business, assets, liabilities and operations of the Merger Partner. The Company has provided timely written notice to the
appropriate insurance carrier(s) of each legal proceeding pending against Merger Partner for which Merger Partner has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such legal
proceeding, or informed Merger Partner of its intent to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.19 <U>Brokers; Fees and Expenses</U>. No agent, broker, investment
banker, financial advisor or other firm or person is or shall be entitled, as a result of any action, agreement or commitment of Merger Partner or any of its Affiliates, to any broker&#146;s, finder&#146;s, financial advisor&#146;s or other similar
fee or commission in connection with any of the transactions contemplated by this Agreement, except Piper Sandler&nbsp;&amp; Co., whose fees and expenses shall be the responsibility of Merger Partner. Merger Partner is not a party to any agreements
with any agent, broker, investment banker, financial advisor or other similar firm or person which grant to such person rights after the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.20 <U>Certain Business Relationships With Affiliates</U>. No Affiliate of Merger Partner (a)&nbsp;owns any property or right, tangible or
intangible, which is used in the business of Merger Partner, (b)&nbsp;has any claim or cause of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action against Merger Partner or (c)&nbsp;owes any money to, or is owed any money by, Merger Partner. <U>Section</U><U></U><U>&nbsp;3.20</U> of the Merger Partner Disclosure Schedule describes
any material Contracts between Merger Partner and any Affiliate thereof which were entered into or have been in effect at any time since January&nbsp;1, 2019, other than (i)&nbsp;any employment Contracts, invention assignment agreements and other
Contracts entered into in the Ordinary Course of Business relating to employment, or (ii)&nbsp;Contracts relating to stock purchases and awards, stock options and other equity arrangements, in each case relating to compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.21 <U>Controls and Procedures, Certifications and Other Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner maintains accurate books and records reflecting its assets and liabilities and maintains proper and adequate internal
control over financial reporting that provide assurance that (i)&nbsp;transactions are executed with management&#146;s authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the consolidated financial statements of
Merger Partner and to maintain accountability for Merger Partner&#146;s consolidated assets, (iii)&nbsp;access to assets of Merger Partner is permitted only in accordance with management&#146;s authorization, (iv)&nbsp;the reporting of assets of
Merger Partner is compared with existing assets at regular intervals and (v)&nbsp;accounts, notes and other receivables and inventory were recorded accurately, and proper and adequate procedures are implemented to effect the collection thereof on a
current and timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in <U>Section</U><U></U><U>&nbsp;3.21(b)</U> of the Merger Partner Disclosure Schedule,
Merger Partner has not extended or maintained credit, arranged for the extension of credit, modified or renewed an extension of credit, in the form of a personal loan or otherwise, to or for any director or executive officer of Merger Partner.
<U>Section</U><U></U><U>&nbsp;3.21(b)</U> of the Merger Partner Disclosure Schedule identifies any loan or extension of credit maintained by Merger Partner to which the second sentence of Section&nbsp;13(k)(1) of the Exchange Act applies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner either (i)&nbsp;satisfies the conditions to qualification as a &#147;smaller reporting company&#148; set forth in 17 C.F.R.
229.10(f)(1), or (ii)&nbsp;if shares of Merger Partner Common Stock were traded on any regulated market or stock exchange, would qualify as a &#147;smaller reporting company,&#148; as defined by 17&nbsp;C.F.R.&nbsp;229.10(f)(1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.22 <U>Books and Records</U>. The minute books and other similar records of Merger Partner contain complete and accurate records of all
actions taken at any meetings of Merger Partner&#146;s stockholders, Board of Directors or any committee thereof and of all written consents executed in lieu of the holding of any such meeting. The books and records of Merger Partner have been
maintained in accordance with good business and bookkeeping practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.23 <U>Ownership of Public Company Common Stock</U>. None of
Merger Partner nor any of Merger Partner&#146;s &#147;Affiliates&#148; or &#147;Associates&#148; directly or indirectly &#147;owns,&#148; beneficially or otherwise, and at all times during the three-year period prior to the date of this Agreement,
none of Merger Partner&#146;s &#147;Affiliates&#148; or &#147;Associates&#148; directly or indirectly has &#147;owned,&#148; beneficially or otherwise, any of the outstanding Public Company Common Stock, as those terms are defined in
Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.24 <U>Subsidies</U>. All governmental, state or regional subsidies granted to Merger Partner were used in
accordance with applicable provisions of any statute, Law or regulation or any other public orders or conditions imposed or related to them in conjunction with their granting and, in particular, all conditions imposed by the respective Governmental
Entities have been fulfilled and observed. Merger Partner is not under any further obligation to perform any services with regard to such subsidies and no such subsidies have to be repaid by Merger Partner as a result of the negotiation, execution,
delivery or performance of this Agreement, or the consummation of the transactions contemplated hereby or any other reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.25 <U>Data
Protection</U>. Merger Partner currently fully complies in all material respects with any data protection and privacy legislation applicable to their businesses including (i)&nbsp;the requirements relating to notification and/or registration of
processing of personal data with any applicable national data protection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulator, (ii)&nbsp;all subject information requests from data subjects, (iii)&nbsp;where necessary, the obtaining of consent to data processing and/or direct marketing activity, and
(iv)&nbsp;where necessary, the obtaining of any approval, consultation and/or agreement of any applicable works councils or such similar worker representation bodies. Merger Partner has not received any notice or complaint from any individual, third
party and/or regulatory authority alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable data protection and privacy legislation (including any prohibition or restriction on the transfer of data to any jurisdiction) or
claiming compensation for or an injunction in respect of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable data protection and privacy legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.26 <U>Financing</U>. Merger Partner has made available to Public Company a true, correct and complete copy of each of the Funding
Agreements. No Funding Agreement has been amended or modified in any manner. Neither Merger Partner nor, to the knowledge of Merger Partner, any of its Affiliates has entered into any agreement, side letter or other arrangement relating to the
Financing other than as set forth in the Funding Agreements. The respective obligations and agreements contained in the Funding Agreements have not been withdrawn or rescinded in any respect. Each of the Funding Agreements is in full force and
effect and represents a valid, binding and enforceable obligation of Merger Partner and, to the knowledge of Merger Partner, of each party thereto (except to the extent that enforceability may be limited by the Bankruptcy and Equity Exception). No
event has occurred which, with or without notice, lapse of time or both, would constitute a breach or default on the part of Merger Partner or, to the knowledge of Merger Partner, any other party thereto and assuming the accuracy of the
representations and warranties of Public Company hereunder, under any Funding Agreement. There are no conditions precedent related to the consummation of the Financing contemplated by any Funding Agreement, other than the satisfaction or waiver of
the conditions expressly set forth in such Funding Agreement. To the knowledge of Merger Partner, the proceeds of the Financing will be made available to Merger Partner immediately prior to or concurrently with the consummation of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.27 <U>No Other Representations or Warranties</U>. Merger Partner hereby acknowledges and agrees that, except for the representations and
warranties contained in this Agreement, none of Public Company, Merger Sub nor any other person on behalf of Public Company or Merger Sub makes any express or implied representation or warranty with respect to Public Company, Merger Sub or with
respect to any other information provided to Merger Partner or any of its Affiliates in connection with the transactions contemplated hereby, and (subject to the express representations and warranties of Public Company and Merger Sub set forth in
<U>Article IV</U> (in each case as qualified and limited by the Public Company Disclosure Schedule)) none of Merger Partner or any of its Affiliates, stockholders, directors, officers, employees, agents, representatives or advisors, or any other
person, has relied on any such information (including the accuracy or completeness thereof). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS AND WARRANTIES OF PUBLIC COMPANY AND THE MERGER SUB </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Company and Merger Sub represent and warrant to Merger Partner that the statements contained in this <U>Article IV</U> are true and
correct, except (a)&nbsp;as disclosed in the Public Company SEC Reports filed or furnished prior to the date of this Agreement (but excluding any disclosures under the heading &#147;Risk Factors&#148; and any disclosure of risks included in any
&#147;forward looking statements&#148; disclaimers or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature) or (b)&nbsp;as expressly set forth herein or in the disclosure
schedule delivered by Public Company and Merger Sub to Merger Partner on the date of this Agreement (the &#147;<U>Public Company Disclosure Schedule</U>&#148;). For purposes hereof, the phrase &#147;to the knowledge of Public Company&#148; and
similar expressions mean the actual knowledge of the persons identified on <U>Section K</U> of the Public Company Disclosure Schedule for this purpose, and such knowledge as such persons would reasonably be expected to have obtained in the course of
their performance of their duties to the Public Company (after due inquiry). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization, Standing and Power</U>. Each of Public
Company and Merger Sub is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, has all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as currently conducted, and is duly qualified to do business and is in
good standing as a foreign corporation in each jurisdiction listed on <U>Section</U><U></U><U>&nbsp;4.1</U> of the Public Company Disclosure Schedule, which jurisdictions constitute the only jurisdictions in which the character of the properties it
owns, operates or leases or the nature of its activities makes such qualification necessary, except for such failures to be so qualified or in good standing, individually or in the aggregate, that have not had, and are not reasonably likely to have,
a Public Company Material Adverse Effect. For purposes of this Agreement, the term &#147;<U>Public Company Material Adverse Effect</U>&#148; means any Effect that, individually or in the aggregate with all other Effects that have occurred through
the date of determination, has had, or is reasonably likely to have, a material adverse effect on the business, assets, liabilities, financial condition or results of operations of Public Company and its Subsidiaries, taken as a whole;
<U>provided</U>, <U>however</U>, that no Effect, to the extent resulting from or arising out of any of the following, shall be deemed to be a Public Company Material Adverse Effect or be taken into account for purposes of determining whether a
Public Company Material Adverse Effect has occurred or is reasonably likely to occur: (A)&nbsp;changes after the date of this Agreement in prevailing economic or market conditions in the United States or any other jurisdiction in which such entity
has substantial business operations (except to the extent those changes have a disproportionate effect on Public Company and its Subsidiaries relative to the other participants in the industry or industries in which Public Company and its
Subsidiaries operate), (B) changes or events after the date of this Agreement affecting the industry or industries in which Public Company and its Subsidiaries operate generally (except to the extent those changes or events have a disproportionate
effect on Public Company and its Subsidiaries relative to the other participants in the industry or industries in which Public Company and its Subsidiaries operate), (C) changes after the date of this Agreement in generally accepted accounting
principles or requirements (except to the extent those changes have a disproportionate effect on Public Company and its Subsidiaries relative to the other participants in the industry or industries in which Public Company and its Subsidiaries
operate), (D) changes after the date of this Agreement in laws, rules or regulations of general applicability or interpretations thereof by any Governmental Entity (except to the extent those changes have a disproportionate effect on Public Company
and its Subsidiaries relative to the other participants in the industry or industries in which Public Company and its Subsidiaries operate), (E) any natural disaster, epidemic, pandemic or other disease outbreak (including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic) or any outbreak of major hostilities in which the United States is involved or any act of terrorism within the United States or directed against its facilities or citizens wherever located (except
to the extent those changes or events have a disproportionate effect on Public Company and its Subsidiaries relative to the other participants in the industry or industries in which Public Company and its Subsidiaries operate), (F) a change in the
public trading price of Public Company Common Stock, (G)&nbsp;a change in the trading volume of Public Company Common Stock following the announcement of the Agreement or during the pendency of the transactions contemplated hereby or (H)&nbsp;any
failure by Public Company to meet any public estimates or expectations of Public Company&#146;s revenue, earnings or other financial performance or results of operations for any period, or (I)&nbsp;any failure by Public Company to meet any internal
guidance, budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (but not, in the case of clauses (F), (G), (H) or this clause (I), the underlying cause of such changes or failures, unless such
changes or failures would otherwise be excepted from this definition). Public Company has made available to Merger Partner complete and accurate copies of its certificate of incorporation and bylaws and is not in material default under or in
material violation of any provision of any such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Public Company consists of 100,000,000 shares of Public Company Common Stock and 5,000,000 shares of
preferred stock, $0.001 par value per share (&#147;<U>Public Company Preferred Stock</U>&#148;). The rights and privileges of each class of Public Company&#146;s capital stock are as set forth in Public Company&#146;s certificate of incorporation.
As of the Capitalization Reference Time, (i) 19,043,034 shares of Public Company Common Stock were issued or outstanding, (ii)&nbsp;no shares of Public Company Common Stock were held in the treasury of Public Company or by Subsidiaries of Public
Company, and (iii)&nbsp;no shares of Public Company Preferred Stock were issued or outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;4.2(b)</U> of the Public Company Disclosure Schedule sets
forth a complete and accurate list, as of the Capitalization Reference Time, of: (i)&nbsp;all stock option plans or other stock or equity-related plans of Public Company (each, a &#147;<U>Public Company Stock Plan</U>,&#148; and collectively,
&#147;<U>Public Company Stock Plans</U>&#148;), indicating for each Public Company Stock Plan, the number of shares of Public Company Common Stock subject to outstanding options under such plan (such outstanding options, &#147;<U>Public Company
Stock Options</U>&#148;) and the number of shares of Public Company Common Stock reserved for future issuance under such plan; and (ii)&nbsp;all outstanding Public Company Stock Options, indicating with respect to each Public Company Stock Option
the name of the holder thereof, the Public Company Stock Plan under which it was granted, the number of shares of Public Company Common Stock subject to such Public Company Stock Option, the exercise price, the date of grant and the vesting
schedule, including whether (and to what extent) the vesting will be accelerated in any way by the transactions contemplated by this Agreement or by termination of employment or change in position following consummation of the Transaction, and
whether such Public Company Stock Option is intended to be an incentive stock option. As of the Capitalization Reference Time, Public Company has reserved 400,740 shares of Public Company Common Stock for issuance to employees pursuant to Public
Company&#146;s 2019 Employee Stock Purchase Plan (the &#147;<U>Public</U> <U>Company ESPP</U>&#148;), all of which shares remain available for issuance thereunder as of the date hereof and no shares are expected to be purchased under the Public
Company ESPP. Public Company has not granted, issued or authorized the grant or issuance of any Public Company Stock Options on the Business Day prior to the date of this Agreement or on the date of this Agreement. Public Company has made available
to Merger Partner accurate and complete copies of all Public Company Stock Plans and the forms of all stock option agreements evidencing Public Company Stock Options. With respect to each Public Company Stock Option (whether outstanding or
previously exercised), (i) each such Public Company Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code so qualifies, (ii)&nbsp;each grant of a Public Company Stock Option was duly authorized
no later than the date on which the grant of such Public Company Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the Public Company&#146;s Board of Directors (or a duly
constituted and authorized committee thereof), or a duly authorized delegate thereof, and any required stockholder approval by the necessary number of votes or written consents, (iii)&nbsp;each such grant was made in material compliance with the
terms of the applicable Public Company Stock Plan, the Securities Act, the Exchange Act, to the extent applicable, and all other applicable Laws and are not and have not been the subject of any internal investigation, review or inquiry, and
(iv)&nbsp;each such grant was properly accounted for in all material respects in accordance with GAAP in the financial statements (including the related notes) of the Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section</U><U></U><U>&nbsp;4.2(c)</U> of the Public Company Disclosure Schedule lists the number of shares of Public Company Common
Stock reserved for future issuance pursuant to warrants or other outstanding rights (other than Public Company Stock Options) to purchase shares of Public Company Common Stock outstanding as of the Capitalization Reference Time (such outstanding
warrants or other rights, the &#147;<U>Public Company Warrants</U>&#148;) and the agreement or other document under which such Public Company Warrants were granted, and the exercise price, the date of grant and the expiration date thereof. Public
Company has made available to Merger Partner accurate and complete copies of the forms of agreements evidencing all Public Company Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except (i)&nbsp;as set forth in this <U>Section</U><U></U><U>&nbsp;4.2</U> or in <U>Article II</U>, (ii)&nbsp;as reserved for future
grants under Public Company Stock Plans, outstanding as of the Capitalization Reference Time and (iii)&nbsp;for the rights to acquire shares pursuant to the Public Company ESPP, (A)&nbsp;there are no equity securities of any class of Public Company,
or any security exchangeable into or exercisable for such equity securities, issued, reserved for issuance or outstanding and (B)&nbsp;there are no options, warrants, equity securities, calls, rights, commitments or agreements of any character to
which Public Company or any of its Subsidiaries is a party or by which Public Company or any of its Subsidiaries is bound obligating Public Company or any of its Subsidiaries to issue, exchange, transfer, deliver or sell, or cause to be issued,
exchanged, transferred, delivered or sold, additional shares of capital stock or other equity interests of Public Company or any security or rights convertible into or exchangeable or exercisable for any such shares or other equity interests, or
obligating Public Company or any of its Subsidiaries to grant, extend, accelerate the vesting of, otherwise modify or amend or enter into any such option, warrant, equity security, call, right, commitment or agreement. Public Company does not have
any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding stock appreciation rights, phantom stock, performance based rights or similar rights or obligations. Other than the Public Company Support Agreement, neither Public Company nor any of
its Affiliates is a party to or is bound by any, and to the knowledge of Public Company, there are no, agreements or understandings with respect to the voting (including voting trusts and proxies) or sale or transfer (including agreements imposing
transfer restrictions) of any shares of capital stock or other equity interests of Public Company. Except as contemplated by this Agreement or described in this <U>Section</U><U></U><U>&nbsp;4.2(d)</U>, there are no registration rights to which
Public Company or any of its Subsidiaries is a party or by which it or they are bound with respect to any equity security of any class of Public Company. Stockholders of Public Company are not entitled to dissenters&#146; or appraisal rights under
applicable state Law in connection with the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Public Company Common Stock are, and all shares of
Public Company Common Stock subject to issuance as specified in <U>Sections 4.2(b)</U> and <U>4.2(c)</U> or pursuant to <U>Article II</U>, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable,
will be, duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any
provision of the DGCL, Public Company&#146;s certificate of incorporation or bylaws or any agreement to which Public Company is a party or is otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Subsidiaries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Section</U><U></U><U>&nbsp;4.3(a) </U>of the Public Company Disclosure Schedule sets forth, for each Subsidiary of Public Company: (i)&nbsp;its name; (ii)&nbsp;the number and type of outstanding equity securities and a list of the holders
thereof; and (iii)&nbsp;the jurisdiction of organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Subsidiary of Public Company is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation, has all requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as currently conducted, and is
duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction where the character of its properties owned, operated or leased or the nature of its activities makes such qualification necessary, except for such
failures to be so organized, qualified or in good standing, individually or in the aggregate, that have not had, and are not reasonably likely to have, a Public Company Material Adverse Effect. All of the outstanding shares of capital stock and
other equity securities or interests of each Subsidiary of Public Company are duly authorized, validly issued, fully paid, nonassessable and free of preemptive rights and all such shares (other than directors&#146; qualifying shares in the case of <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Subsidiaries, all of which Public Company has the power to cause to be transferred for no or nominal consideration to Public Company or Public Company&#146;s designee) are owned, of record and beneficially,
by Public Company or another of its Subsidiaries free and clear of all Liens, claims, pledges, agreements or limitations in Public Company&#146;s voting rights. There are no outstanding or authorized options, warrants, rights, agreements or
commitments to which Public Company or any of its Subsidiaries is a party or which are binding on any of them providing for the issuance, disposition or acquisition of any capital stock of any Subsidiary of Public Company. There are no outstanding
stock appreciation, phantom stock or similar rights with respect to any Subsidiary of Public Company. There are no voting trusts, proxies or other agreements or understandings with respect to the voting of any capital stock of any Subsidiary of
Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company has made available to Merger Partner complete and accurate copies of the charter, bylaws or other
organizational documents of each Subsidiary of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company does not control directly or indirectly or have any
direct or indirect equity participation or similar interest in any corporation, partnership, limited liability company, joint venture, trust or other business association or entity which is not a Subsidiary of Public Company. There are no
obligations, contingent or otherwise, of Public Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any shares of capital stock of any Subsidiary of Public Company or to provide funds to or make any material
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment (in the form of a loan, capital contribution or otherwise) in any Subsidiary of Public Company or any other entity, other than guarantees of bank obligations of Subsidiaries of Public
Company entered into in the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Authority; No Conflict; Required Filings and Consents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Public Company and Merger Sub has all requisite corporate power and authority to enter into this Agreement and, subject only to
the Public Company Stockholder Approval and the adoption of this Agreement by Public Company in its capacity as the sole stockholder of Merger Sub, to consummate the transactions contemplated by this Agreement. Without limiting the generality of the
foregoing, Public Company Board, at a meeting duly called and held, by the unanimous vote of all directors, (i)&nbsp;determined that the Merger is fair to, and in the best interests of Public Company and its stockholders and (ii)&nbsp;directed that
the Public Company Voting Proposals be submitted to the stockholders of Public Company for their approval and resolved to recommend that the stockholders of Public Company vote in favor of the approval of Public Company Voting Proposals. The
execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement by Public Company and Merger Sub have been duly authorized by all necessary corporate action on the part of each of Public Company and
Merger Sub, subject only to the required receipt of the Public Company Stockholder Approval and the adoption of this Agreement by Public Company in its capacity as the sole stockholder of Merger Sub. This Agreement has been duly executed and
delivered by each of Public Company and Merger Sub and, assuming the due execution and delivery of this Agreement by Merger Partner, constitutes the valid and binding obligation of each of Public Company and Merger Sub, enforceable against Public
Company and Merger Sub in accordance with its terms, subject to the Bankruptcy and Equity Exception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of
this Agreement by each of Public Company and Merger Sub do not, and the consummation by Public Company and Merger Sub of the transactions contemplated by this Agreement shall not, (i)&nbsp;conflict with, or result in any violation or breach of, any
provision of the certificate of incorporation or bylaws of Public Company or Merger Sub or of the charter, bylaws or other organizational document of any other Subsidiary of Public Company, (ii)&nbsp;conflict with, or result in any violation or
breach of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any material benefit) under, or require a consent or waiver
under, constitute a change in control under, require the payment of a penalty under or result in the imposition of any Lien on Public Company&#146;s or any of its Subsidiaries&#146; assets under any of the terms, conditions or provisions of any
Contract required to be disclosed in <U>Section</U><U></U><U>&nbsp;4.11(d)</U> of the Public Company Disclosure Schedule, or (iii)&nbsp;subject to obtaining the Public Company Stockholder Approval and compliance with the requirements specified in
clauses (i)&nbsp;through (vii) of <U>Section</U><U></U><U>&nbsp;4.4(c)</U>, conflict with or violate any permit, concession, franchise, license, judgment, injunction, order, decree, statute, law, ordinance, rule or regulation applicable to Public
Company or any of its Subsidiaries or any of its or their properties or assets, except in the case of clauses (ii)&nbsp;and (iii) of this <U>Section</U><U></U><U>&nbsp;4.4(b)</U>, for any such conflicts, violations, breaches, defaults, terminations,
cancellations, accelerations or losses that, individually or in the aggregate have not had, and are not reasonably likely to result in, the loss of a material benefit to, or in the creation of a material liability for, Public Company.
<U>Section</U><U></U><U>&nbsp;4.4(b)</U> of the Public Company Disclosure Schedule lists all consents, waivers and approvals under any of Public Company&#146;s or any of its Subsidiaries&#146; agreements, licenses or leases required to be obtained
in connection with the consummation of the transactions contemplated by this Agreement, which, if individually or in the aggregate were not obtained, would result in a loss of a material benefit to, or the creation of any material liability for,
Public Company, Merger Partner or the Surviving Corporation as a result of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No consent, approval, license, permit, order
or authorization of, or registration, declaration, notice or filing with, any Governmental Entity or any stock market or stock exchange on which shares of Public Company Common Stock are listed for trading is required by or with respect to Public
Company or any of its Subsidiaries in connection with the execution and delivery of this Agreement or the consummation by Public Company or Merger Sub of the transactions contemplated by this Agreement, except for (i)&nbsp;the filing of the
Certificate of Merger with the Delaware Secretary of State, (ii)&nbsp;the filing of the Registration Statement with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SEC in accordance with the Securities Act, (iii)&nbsp;the filing of the Proxy Statement/Prospectus with the SEC in accordance with the Exchange Act, (iv)&nbsp;the filing of such reports,
schedules or materials under Section&nbsp;13 of or Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act and materials under Rule 165 and Rule 425 under the Securities Act as may be required in connection with this Agreement and
the transactions contemplated hereby and thereby, (v)&nbsp;such consents, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable state securities laws and the laws of any foreign country,
(vi)&nbsp;the filing of an initial listing application for the Public Company Common Stock on Nasdaq with respect to the shares of Public Company Common Stock to be issued pursuant to this Agreement (the &#147;<U>Nasdaq Listing
Application</U>&#148;) and (vii)&nbsp;such other consents, authorizations, orders, filings, approvals and registrations that, individually or in the aggregate, if not obtained or made, would not result in a loss of a material benefit to, or the
creation of any material liability for, Public Company or Merger Partner as a result of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The affirmative vote in favor of
Public Company Voting Proposals by the holders of a majority of the shares of Public Company Common Stock present or represented by proxy and voting at the Public Company Meeting is the only vote of the holders of any class or series of Public
Company&#146;s capital stock or other securities of Public Company necessary to approve the Public Company Voting Proposals. There are no bonds, debentures, notes or other indebtedness of Public Company having the right to vote (or convertible into,
or exchangeable for, securities having the right to vote) on any matters on which stockholders of Public Company may vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>SEC
Filings; Financial Statements; Information Provided</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company has filed all registration statements, forms, reports,
certifications and other documents required to be filed by Public Company with the SEC for a period of at least twelve calendar months immediately preceding the execution of this Agreement. All registration statements, forms, reports and other
documents, as amended prior to the date hereof, which have been filed by Public Company since January&nbsp;1, 2019, and those that Public Company may file after the date hereof until the Closing, are referred to herein as the &#147;<U>Public Company
SEC Reports</U>.&#148; All of the Public Company SEC Reports (A)&nbsp;were or will be filed on a timely basis, (B)&nbsp;at the time filed (or if amended prior to the date hereof, when so amended), complied, or will comply when filed, as to form in
all<B> </B>material respects with the requirements of the Securities Act and the Exchange Act applicable to such Public Company SEC Reports and (C)&nbsp;did not or will not at the time they were filed (or if amended prior to the date hereof, when so
amended) or are filed contain any untrue statement of a material fact or omit to state a material fact required to be stated in such Public Company SEC Reports or necessary in order to make the statements in such Public Company SEC Reports, in the
light of the circumstances under which they were made, not misleading, in any material respect. For the avoidance of doubt, &#147;<U>Public Company SEC Reports</U>&#148; shall include the Public Company&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2020 in the form made available to Merger Partner prior to the execution of this Agreement (the &#147;<U>Public Company 2020 Form
<FONT STYLE="white-space:nowrap">10-K</FONT></U>&#148;), which shall be filed with the SEC in accordance with Section&nbsp;5.4 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the consolidated financial statements (including, in each case, any related notes and schedules) contained or to be contained in
the Public Company SEC Reports at the time filed (or if amended prior to the date hereof, when so amended)&nbsp;(i) complied or will comply as to form in all material respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto, (ii)&nbsp;were or will be prepared in accordance with GAAP applied on a consistent basis throughout the periods involved and at the dates involved (except as may be indicated in the notes to such
financial statements or, in the case of unaudited interim financial statements, as permitted by the SEC on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> under the Exchange Act) and (iii)&nbsp;fairly presented or will fairly present in all
material respects the consolidated financial position of Public Company and its Subsidiaries as of the dates indicated and the consolidated results of its operations and cash flows for the periods indicated, except that the unaudited interim
financial statements were or are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments. The consolidated balance sheet of Public Company as of December&nbsp;31, 2020 is referred to herein as the &#147;<U>Public
Company Balance Sheet</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Ernst&nbsp;&amp; Young LLP, Public Company&#146;s current auditors, is and has been at all times
since its engagement by Public Company (i) &#147;independent&#148; with respect to Public Company within the meaning of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and (ii)&nbsp;in compliance with subsections (g)&nbsp;through (l) of Section&nbsp;10A of the Exchange Act (to the extent applicable) and the
related rules of the SEC and the Public Company Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The information in the Registration Statement to be
supplied by or on behalf of Public Company for inclusion or incorporation by reference in the Registration Statement or to be included or supplied by or on behalf of Public Company for inclusion in any Regulation
<FONT STYLE="white-space:nowrap">M-A</FONT> Filing, shall not at the time the Registration Statement or any such Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> filing is filed with the SEC, at any time it is amended or supplemented or at the
time the Registration Statement is declared effective by the SEC, as applicable, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein
not misleading. The information to be supplied by or on behalf of Public Company for inclusion in the Proxy Statement/Prospectus to be sent to the stockholders of Public Company and Merger Partner in connection with the Public Company Meeting, which
information shall be deemed to include all information about or relating to Public Company, the Public Company Voting Proposals or the Public Company Meeting, shall not, on the date the Proxy Statement/Prospectus is first mailed to stockholders of
Public Company or Merger Partner, or at the time of the Public Company Meeting or at the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to
any material fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement/Prospectus not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier
communication with respect to the solicitation of proxies for the Public Company Meeting that has become false or misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>No
Undisclosed Liabilities</U>. Public Company does not have any material liability, except for (a)&nbsp;liabilities shown on the Public Company Balance Sheet, (b)&nbsp;liabilities of a type shown on the Public Company Balance Sheet that have arisen
since the date of the Public Company Balance Sheet in the Ordinary Course of Business, (c)&nbsp;liabilities for transaction expenses incurred in connection with the transactions contemplated by this Agreement and (d)&nbsp;contractual and other
liabilities incurred in the Ordinary Course of Business that are not required by GAAP to be reflected on a balance sheet (and which have not resulted from a breach of contract, breach of warranty, tort, infringement or violation of Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Absence of Certain Changes or Events</U>. During the period beginning on the date of the Public Company Balance Sheet and ending on the
date hereof, Public Company and its Subsidiaries have conducted their respective businesses only in the Ordinary Course of Business and, since such date, there has not been (i)&nbsp;any change, event, circumstance, development or effect that,
individually or in the aggregate, has had, or is reasonably likely to have, a Public Company Material Adverse Effect or (ii)&nbsp;any other action or event that would have required the consent of Merger Partner pursuant to
<U>Section</U><U></U><U>&nbsp;5.2</U> (other than clause (A)&nbsp;of paragraph (j)&nbsp;or paragraphs (k)&nbsp;or (l) thereof) had such action or event occurred after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>Taxes</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of
Public Company and its Subsidiaries has properly filed on a timely basis all income and other material Tax Returns that it was required to file, and all such Tax Returns were true, correct and complete in all material respects. Each of Public
Company and its Subsidiaries has paid on a timely basis all material Taxes, whether or not shown on any Tax Return, that were due and payable. The unpaid Taxes of Public Company and each of its Subsidiaries for Tax periods (or portions thereof)
through the date of the Public Company Balance Sheet do not materially exceed the accruals and reserves for Taxes (excluding accruals and reserves for deferred Taxes established to reflect timing differences between book and Tax income) set forth on
the Public Company Balance Sheet, and all unpaid Taxes of Public Company and each of its Subsidiaries for all Tax periods commencing after the date of the Public Company Balance Sheet arose in the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Public Company nor any of its Subsidiaries is or has ever been a member of an affiliated group with which it has filed (or been
required to file) consolidated, combined, unitary or similar Tax Returns, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other than a group of which the common parent is Public Company. With the exception of customary commercial leases or contracts that are not primarily related to Taxes entered into in the
Ordinary Course of Business and liabilities thereunder, neither Public Company nor any of its Subsidiaries (i)&nbsp;has any actual or potential liability under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or
any comparable or similar provision of federal, state, local or foreign law), as a transferee or successor, pursuant to any contractual obligation, or otherwise for any Taxes of any person other than Public Company or any of its Subsidiaries, or
(ii)&nbsp;is a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All material Taxes that
Public Company or any of its Subsidiaries was required by Law to withhold or collect have been duly withheld or collected and, to the extent required, have been properly paid to the appropriate Governmental Entity, and each of Public Company and its
Subsidiaries has complied with all information reporting and backup withholding requirements, including the maintenance of required records with respect thereto, in connection with amounts paid to any employee, independent contractor, creditor, or
other third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company has delivered or made available to Merger Partner (i)&nbsp;complete and correct copies of all
material Tax Returns of Public Company and any of its Subsidiaries relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii)&nbsp;complete and correct copies of all private letter rulings,
revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by,
or agreed to by or on behalf of Public Company or any of its Subsidiaries relating to Taxes for all taxable periods for which the statute of limitations has not yet expired, and (iii)&nbsp;complete and correct copies of all material agreements,
rulings, settlements or other Tax documents with or from any Governmental Entity relating to Tax incentives of Public Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No examination or audit of any Tax Return of Public Company or any of its Subsidiaries by any Governmental Entity is currently in progress
or, to the knowledge of Public Company, threatened or contemplated. No deficiencies for Taxes of Public Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Entity. Neither Public Company nor any of its
Subsidiaries has been informed in writing by any jurisdiction in which Public Company or any of its Subsidiaries does not file a Tax Return that the jurisdiction believes that Public Company or any of its Subsidiaries was required to file any Tax
Return that was not filed or is subject to Tax in such jurisdiction. Neither Public Company nor any of its Subsidiaries has (i)&nbsp;waived any statute of limitations with respect to Taxes or agreed to extend the period for assessment or collection
of any Taxes, which waiver or extension is still in effect, (ii)&nbsp;requested any extension of time within which to file any Tax Return, other than routine extensions available as a matter of right which Tax Return has not yet been filed, or
(iii)&nbsp;executed or filed any power of attorney with any taxing authority, which is still in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Public Company nor
any of its Subsidiaries has made any payment, is obligated to make any payment, or is a party to any agreement that could obligate it to make any payment that may be treated as an &#147;excess parachute payment&#148; under Section&nbsp;280G of the
Code (without regard to Sections 280G(b)(4) and 280G(b)(5) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither Public Company nor any of its Subsidiaries has been
a United States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period specified in Section&nbsp;897(c)(l)(A)(ii) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither Public Company nor any of its Subsidiaries has distributed to its stockholders or security holders stock or securities of a
controlled corporation, nor has stock or securities of Public Company or any of its Subsidiaries been distributed, in a transaction to which Section&nbsp;355 of the Code applies in the two years prior to the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) There are no Liens with respect to Taxes upon any of the assets or properties of Public
Company or any of its Subsidiaries, other than with respect to Taxes not yet due and payable or being contested in good faith by appropriate proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Neither Public Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material
item of deduction from, taxable income for any period (or any portion thereof) ending after the Closing Date as a result of any (i)&nbsp;adjustments under Section&nbsp;481 of the Code (or any similar adjustments under any provision of the Code or
the corresponding foreign, state or local Tax laws) made on or prior to the Closing Date, (ii)&nbsp;installment sale or other open transaction disposition made on or prior to the Closing Date, or (iii)&nbsp;prepaid amount or deferred revenue
received on or prior to the Closing Date outside the Ordinary Course of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Neither Public Company nor any of its Subsidiaries
has participated in any &#147;reportable transaction&#148; as defined in <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)</FONT> of the Treasury Regulations or a &#147;listed transaction&#148; as set forth in
<FONT STYLE="white-space:nowrap">Section&nbsp;301.6111-2(b)(2)</FONT> of the Treasury Regulations or any analogous provision of state or local law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Neither Public Company nor any of its Subsidiaries (i)&nbsp;is a party to any joint venture, partnership, or other arrangement that is
treated as a partnership for federal income Tax purposes or (ii)&nbsp;has made an entity classification <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;check-the-box&#148;)</FONT></FONT> election under Section&nbsp;7701 of
the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Neither Public Company nor any of its Subsidiaries (i)&nbsp;is a stockholder of a &#147;specified foreign corporation&#148;
(other than the Subsidiaries of Public Company) as defined in Section&nbsp;965(e) of the Code (or any similar provision of state, local or foreign Law), or (ii)&nbsp;is a stockholder in a &#147;passive foreign investment company&#148; as defined in
Section&nbsp;1297 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Neither Public Company nor any of its Subsidiaries is subject to Tax in any country other than its
country of incorporation, organization or formation by virtue of having employees, a permanent establishment or other place of business in that country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Neither Public Company nor any of its Affiliates has taken or agreed to take any action, has omitted to take any action, or has any
knowledge of any fact or circumstance, the taking, omission, or existence of which, as the case may be, could reasonably be expected to prevent the Merger from constituting a transaction qualifying as a reorganization under Section&nbsp;368(a) of
the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) Public Company has (i)&nbsp;properly complied with all legal requirements in order to defer the amount of the
employer&#146;s share of any &#147;applicable employment taxes&#148; under Section&nbsp;2302 of the Cares Act (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), (ii) to the extent applicable, properly
complied with all legal requirements and duly accounted for any available Tax credits under Sections 7001 through 7005 of the Families First Act and Section&nbsp;2301 of the CARES Act, (iii)&nbsp;not sought (nor has any affiliate that would be
aggregated with Merger Partner and treated as one employer for purposes of Section&nbsp;2301 of the CARES Act sought) a covered loan under paragraph (36)&nbsp;of Section&nbsp;7(a) of the Small Business Act (15 U.S.C. 636(a)), as added by
Section&nbsp;1102 of the CARES Act, and (iv)&nbsp;not deferred any payroll Tax obligations (including those imposed by Code Sections 3101(a) and 3201) pursuant to or in connection with the Memorandum on Deferring Payroll Tax Obligations in Light of
the Ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> Disaster, dated August&nbsp;8, 2020, or any other provision of the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Owned and Leased Real Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Public Company nor any of its Subsidiaries owns or has ever owned any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;4.9(b)</U> of the Public Company Disclosure Schedule sets forth a complete and accurate list of all real
property leased, subleased or licensed by Public Company or any of its Subsidiaries as of the date of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement (collectively, the &#147;<U>Public Company</U> <U>Leases</U>&#148;) and the location of the premises of such real property. Neither Public Company nor any of its Subsidiaries nor, to
the knowledge of Public Company, any other party is in breach or default and no event has occurred, is pending or, to the knowledge of Public Company, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would
constitute any such breach or default under any of under any of the Public Company Leases, except where the existence of such defaults, individually or in the aggregate, has not had, and is not reasonably likely to result in, the loss of a material
right or in a material liability of Public Company or any of its Subsidiaries. Neither Public Company nor any of its Subsidiaries leases, subleases or licenses any real property to any person other than Public Company and its Subsidiaries. Public
Company has made available to Merger Partner complete and accurate copies of all Public Company Leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10 <U>Intellectual
Property</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.10(a) </U>of the Public Company Disclosure Schedule lists all Public Company
Registrations that have not otherwise been abandoned, expired or cancelled, in each case enumerating specifically the applicable filing or registration number, title, jurisdiction in which filing was made or from which registration issued, date of
filing or issuance, and names of all current registered owners(s), as applicable. All assignments of Public Company Registrations to Public Company have been properly executed and recorded, and all issuance, renewal, maintenance and other payments
that are or have become due with respect thereto have been timely paid by or on behalf of the Public Company. Except as would not be, individually or in the aggregate, material to Public Company, to the knowledge of Public Company, all Public
Company Registrations are valid and enforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There are no inventorship challenges, <I>inter partes</I> proceedings, opposition or
nullity proceedings or interferences pending, or, to the knowledge of Public Company, threatened in writing, with respect to any Patent Rights included in the Public Company Registrations. Public Company has complied with its duty of candor and
disclosure to the United States Patent and Trademark Office and, to the extent required, any relevant foreign patent office with respect to all patent and trademark applications filed by or on behalf of Public Company and has made no material
misrepresentation in such applications that would have a Public Company Material Adverse Effect. Public Company has no actual knowledge of any information that would preclude Public Company from having clear title to the Public Company
Registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company is the sole and exclusive owner of all Public Company Owned Intellectual Property, free and clear of
any Liens, other than (i)&nbsp;any joint owners of the Public Company Owned Intellectual Property are listed in <U>Section</U><U></U><U>&nbsp;4.10(c)</U> of the Public Company Disclosure Schedule and (ii)&nbsp;any license, covenant or other
agreement that is listed in <U>Section</U><U></U><U>&nbsp;4.10(h)</U> of the Public Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To Public
Company&#146;s knowledge, the Public Company Intellectual Property constitutes the Intellectual Property necessary to conduct Public Company&#146;s business in the manner currently conducted and by Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Public Company has taken commercially reasonable measures to protect the proprietary nature of each item of Public Company Owned
Intellectual Property, and to maintain in confidence all trade secrets and confidential information comprising a part thereof. To Public Company&#146;s knowledge and except as would not be, individually or in the aggregate, material to Public
Company, there has been no unauthorized disclosure of any third party proprietary or confidential information in the possession, custody or control of Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of Public Company and except as would not be, individually or in the aggregate, material to Public Company, the
operations of Public Company and its Subsidiaries as currently conducted do not and have not in the past five years infringe(d) or misappropriate(d) the Intellectual Property rights of any individual or entity. To Public Company&#146;s knowledge and
except as would not have, individually or in the aggregate, a Public Company Material Adverse Effect, no individual or entity has infringed, misappropriated or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise violated the Public Company Owned Intellectual Property or any rights under the Public Company Licensed Intellectual Property that are exclusively licensed to Public Company or any of
its Subsidiaries, and neither Public Company nor any of its Subsidiaries has filed or threatened in writing any claims alleging that a third party or Worker has infringed, misappropriated or otherwise violated any Public Company Intellectual
Property. No individual or entity has filed and served upon Public Company or any of its Subsidiaries or, to Public Company&#146;s knowledge, threatened in writing any action or proceeding alleging that Public Company or any of its Subsidiaries has
infringed, misappropriated or otherwise violated any individual&#146;s or entity&#146;s Intellectual Property rights nor has Public Company or any of its Subsidiaries received any written notification that a license under any other individual&#146;s
or entity&#146;s Intellectual Property is or may be required to the conduct of Public Company&#146;s business in the manner currently conducted by Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Public Company has made available copies of all correspondence, legal opinions, complaints, claims, notices or threats in writing
concerning the infringement, violation or misappropriation of any Public Company Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
<U>Section</U><U></U><U>&nbsp;4.10(h)</U> of the Public Company Disclosure Schedule identifies each license, covenant or other agreement pursuant to which Public Company has assigned, transferred, licensed, distributed or otherwise granted any right
or access to any individual or entity, or covenanted not to assert any right, with respect to any past, existing or future Public Company Intellectual Property that is material to the conduct of Public Company&#146;s business in the manner currently
conducted by Public Company, other than <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses entered into in the ordinary course of Public Company&#146;s business, and
agreements with current and former employees, officers, contractors, and consultants for providing services to the Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
<U>Section</U><U></U><U>&nbsp;4.10(i)</U> of the Public Company Disclosure Schedule identifies (i)&nbsp;each license or agreement pursuant to which Public Company has obtained rights to any Public Company Licensed Intellectual Property (excluding
generally available, off the shelf software programs that are licensed by Public Company pursuant to &#147;shrink wrap&#148; licenses, the total fees associated with which are less than $10,000) and (ii)&nbsp;each agreement, contract, assignment or
other instrument pursuant to which Public Company has obtained any joint or sole ownership interest in or to each item of Public Company Owned Intellectual Property; in each case of the foregoing clauses (i)&nbsp;and (ii), other than <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses entered into in the ordinary course of Public Company&#146;s business, and agreements with current and former employees,
officers, contractors, and consultants for providing services to the Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) To Public Company&#146;s knowledge, no Worker of
Public Company or any of its Subsidiaries is in material default or breach of any term of any employment Contract, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> Contract, assignment of invention Contract or similar Contract between such
Worker and Public Company or its Subsidiary, as applicable, relating to the protection, ownership, development, use or transfer of Public Company Intellectual Property. To the extent that any Public Company Owned Intellectual Property has been
conceived, developed or created for Public Company or any of its Subsidiaries by any individual while a Worker, Public Company or such Subsidiary has obtained the entire and unencumbered right, title and interest therein and thereto by operation of
Law or by valid written assignment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To Public Company&#146;s knowledge and except as would not be, individually or in the aggregate,
material to Public Company, neither the negotiation, execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated hereby, will result in (i)&nbsp;a breach of or default under any agreement governing any
Merger Partner Intellectual Property, (ii)&nbsp;the grant or transfer to any third party of any new license or other interest under, the abandonment, assignment to any third party, or modification or loss of any right with respect to, or the
creation of any Lien on, any Merger Partner Intellectual Property that is material to the conduct of Merger Partner&#146;s business in the manner currently conducted by Merger Partner, or (iii)&nbsp;Merger Partner, Public Company or any of their
respective Affiliates being obligated to pay any penalty or new or increased royalty or fee to any individual or entity under any agreement governing any Merger Partner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Intellectual Property that is material to the conduct of Merger Partner&#146;s business in the manner currently conducted by Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Public Company Intellectual Property</U>&#148; shall mean the Public Company Owned Intellectual Property and the Public Company
Licensed Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Public Company Licensed Intellectual Property</U>&#148; shall mean all Intellectual
Property that is licensed to Public Company or any of its Subsidiaries by any individual or entity other than Public Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Public Company Owned Intellectual Property</U>&#148; shall mean all Intellectual Property owned or purported to be owned by
Public Company or any of its Subsidiaries, in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Public Company Registrations</U>&#148; shall mean
Intellectual Property Registrations that are owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Public Company, alone or jointly with others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11 <U>Contracts</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As
of the date of this Agreement, there are no Contracts that are material contracts (as defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> with respect to Public Company, other than those Contracts identified or
described in the Public Company SEC Reports filed prior to the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company has not entered into any transaction that
would be subject to proxy statement disclosure pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> other than as disclosed in an SEC Report filed prior to the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Public Company nor any of its Subsidiaries is a party to any agreement under which a third party would be entitled to receive a
license or any other right to Public Company Intellectual Property as a result of the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Section</U><U></U><U>&nbsp;4.11(d)</U> of the Public Company Disclosure Schedule lists the following Contracts of Public Company and its Subsidiaries in effect as of the date of this Agreement to the extent Public Company or any of its
Subsidiaries has material continuing obligations thereunder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Contract (or group of related Contracts) for the purchase or sale
of products or for the furnishing or receipt of services (A)&nbsp;which calls for performance over a period of more than 180 days from the date of this Agreement and is expected to involve an aggregate of more than $250,000, (B) which involved an
aggregate of more than $250,000 over the 12 months prior to the date of this Agreement, or (C)&nbsp;in which Public Company or any of its Subsidiaries has granted manufacturing rights, &#147;most favored nation&#148; pricing provisions or marketing
or distribution rights relating to any products or territory or has agreed to purchase a minimum quantity of goods or services or has agreed to purchase goods or services exclusively from a particular party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Contract under which the consequences of a default or termination would reasonably be likely to have a Public Company Material
Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any Contract that could reasonably be expected to have the effect of prohibiting or impairing the conduct of the
business of Merger Partner or any of its Subsidiaries or Public Company or any of its Subsidiaries as currently conducted; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Contract under which Public Company or any of its Subsidiaries is restricted from
selling, licensing or otherwise distributing any of its technology or products, or providing services to, customers or potential customers or any class of customers, in any geographic area, during any period of time or any segment of the market or
line of business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any dealer, distribution, joint marketing, joint venture, joint development, partnership, strategic alliance,
collaboration, development agreement or outsourcing arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Contract for the conduct of research studies, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical studies, manufacturing, distribution, supply, marketing or <FONT STYLE="white-space:nowrap">co-promotion</FONT> of any products in development by or which has been or which is being
marketed, distributed, supported, sold or licensed out, in each case by or on behalf of Public Company or any of its Subsidiaries that involved an aggregate of more than $250,000 over the 12 months prior to the date of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any Contract that would entitle any third party to receive a license or any other right to Intellectual Property of Merger Partner or
any of Merger Partner&#146;s Affiliates following the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Public Company has made available to Merger Partner a complete and
accurate copy of each Contract listed in <U>Sections 4.10(a)</U>, <U>4.10(h)</U>, <U>4.10(i)</U> and <U>4.11(d)</U> of the Public Company Disclosure Schedule. With respect to each Contract so listed and those Contracts identified or described in the
Public Company SEC Reports filed prior to the date hereof: (i)&nbsp;the Contract is legal, valid, binding and enforceable and in full force and effect against Public Company and/or its Subsidiaries, as applicable, and, to the knowledge of Public
Company, against each other party thereto, as applicable, subject to the Bankruptcy and Equity Exception; (ii)&nbsp;the Contract will continue to be legal, valid, binding and enforceable and in full force and effect against Public Company and/or its
Subsidiaries, as applicable, and, to the knowledge of Public Company, against each other party thereto, immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing (other than any such
Contracts that expire or terminate before such time in accordance with their terms and not as a result of a breach or default by Public Company or any of its Subsidiaries), in each case subject to the Bankruptcy and Equity Exception; and
(iii)&nbsp;none of Public Company, its Subsidiaries nor, to the knowledge of Public Company, any other party, is in breach or violation of, or default under, any such Contract, and no event has occurred, is pending or, to the knowledge of Public
Company, is threatened, which, with or without notice or lapse of time, or both, would constitute a breach or default by Public Company, its Subsidiaries or, to the knowledge of Public Company, any other party under such Contract, except for such
breaches, violations or defaults that, individually or in the aggregate, have not had, and are not reasonably likely to have, a Public Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12 <U>Litigation</U>. There is no action, suit, proceeding, claim, arbitration or investigation before any Governmental Entity or before any
arbitrator that is pending or has been threatened in writing against Public Company or any of its Subsidiaries that (a)&nbsp;seeks either damages in excess of $250,000 or equitable relief or (b)&nbsp;in any manner challenges or seeks to prevent,
enjoin, alter or delay the transactions contemplated by this Agreement, except for such actions, suits, proceedings, claims, arbitrations or investigations first arising after the date of this Agreement that, individually or in the aggregate, have
not had, and are not reasonably likely to have, a Public Company Material Adverse Effect. There are no material judgments, orders or decrees outstanding against Public Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13 <U>Environmental Matters</U>. Except for such matters that, individually or in the aggregate, have not had, and are not reasonably likely
to have, a Public Company Material Adverse Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Public Company and its Subsidiaries have complied with all applicable
Environmental Laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the properties currently or formerly owned, leased or operated by Public Company and its Subsidiaries
(including soils, groundwater, surface water, buildings or other structures) are or were not contaminated with any Hazardous Substances; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) neither Public Company nor any of its Subsidiaries are subject to liability for any
Hazardous Substance disposal or contamination on the property of any third party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) neither Public Company nor any of its
Subsidiaries have released any Hazardous Substance into the environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, neither Public Company nor
any of its Subsidiaries has received any written notice, demand, letter, claim or request for information alleging that Public Company or any of its Subsidiaries may be in violation of, liable under or have obligations under, any Environmental Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Public Company nor any of its Subsidiaries is subject to any orders, decrees, injunctions or other arrangements with any
Governmental Entity or is subject to any indemnity or other agreement with any third party relating to liability under any Environmental Law or relating to Hazardous Substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14 <U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section</U><U></U><U>&nbsp;4.14(a) </U>of the Public Company Disclosure Schedule sets forth a complete and accurate list of all
material Employee Benefit Plans maintained, or contributed to, by Public Company or any of its Subsidiaries or any of their respective ERISA Affiliates for the benefit of, or relating to, any current or former employee or other service provider of
the Public Company or any of its Subsidiaries (together, the &#147;<U>Public Company Employee Plans</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Public Company
Employee Plan has been administered in all material respects in accordance with ERISA, the Code and all other applicable laws and the regulations thereunder and in accordance with its terms. Public Company and its Subsidiaries and each of their
respective ERISA Affiliates and each Public Company Employee Plan are in compliance in all material respects with the currently applicable provisions of ERISA and the Code and the regulations thereunder (including Section&nbsp;4980B of the Code,
Subtitle K, Chapter 100 of the Code and Sections 601 through 608 and Section&nbsp;701 et seq. of ERISA). All filings and reports as to each Public Company Employee Plan required to have been submitted to the IRS or to the United States Department of
Labor have been timely submitted. There is no audit, investigation or other proceeding (including any voluntary correction application) pending against or involving any Public Company Employee Plan. There have been no events with respect to any
Public Company Employee Plan that could result in payment or assessment by or against Public Company or any of its Subsidiaries of any material Taxes, including (but without limitation) any material excise Taxes under Sections 4972, 4975, 4976,
4977, 4979, 4980B, 4980D, 4980E, 4980H or 5000 of the Code. With respect to the Public Company Employee Plans, no event has occurred, and to the knowledge of Public Company, there exists no condition or set of circumstances in connection with which
Public Company or any of its Subsidiaries could be subject to any liability that is reasonably likely, individually or in the aggregate, to have a Public Company Material Adverse Effect under ERISA, the Code or any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) With respect to the Public Company Employee Plans, there are no benefit obligations for which contributions have not been properly made or
properly accrued and there are no benefit obligations that have not been properly accounted for by reserves, or otherwise properly footnoted in accordance with GAAP, on the financial statements of Public Company, which obligations are reasonably
likely, individually or in the aggregate, to have a Public Company Material Adverse Effect. The assets of each Public Company Employee Plan that is funded are reported at their fair market value on the books and records of such Public Company
Employee Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All Public Company Employee Plans that are intended to be qualified under Section&nbsp;401(a) of the Code have
received determination letters, or may rely on an opinion letter, from the IRS to the effect that such Public Company Employee Plans are qualified and the plans and trusts related thereto are exempt from federal income taxes under Sections 401(a)
and 501(a) of the Code, respectively, of the Code, no such determination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
letter has been revoked and revocation has not been threatened, and no such Public Company Benefit Plan has been amended or operated since the date of its most recent determination letter or
application therefor in any respect, and no act or omission has occurred, that would reasonably be expected to adversely affect its qualification or materially increase its cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither Public Company nor any of its Subsidiaries nor any of their respective ERISA Affiliates has (i)&nbsp;ever maintained a Public
Company Employee Plan that was ever subject to Section&nbsp;412 of the Code or Title&nbsp;IV of ERISA or (ii)&nbsp;ever been obligated to contribute to a &#147;multiemployer plan&#148; (as defined in Section&nbsp;4001(a)(3) of ERISA). No Public
Company Employee Plan is funded by, associated with or related to a &#147;voluntary employees&#146; beneficiary association&#148; within the meaning of Section&nbsp;501(c)(9) of the Code. No Public Company Employee Plan holds securities issued by
Public Company or any of its Subsidiaries or any of their respective ERISA Affiliates. No Public Company Employee Plan is a &#147;multiple employer plan&#148; within the meaning of Section&nbsp;413(c) of the Code or a &#147;multiple employer welfare
arrangement&#148; as defined in Section&nbsp;3(40) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) There are no loans or extensions of credit by Public Company, any of its
Subsidiaries or any of their respective ERISA Affiliate to any employee or any other service provider to Public Company or any of its Subsidiaries, other than routine advances to employees of Public Company in the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Public Company and its Subsidiaries are and have been in material compliance with all applicable provisions of the Affordable Care Act,
including reporting requirements and all requirements relating to eligibility waiting periods and the offer of or provision of minimum essential coverage that is compliant with Section&nbsp;36B(c)(2)(C) of the Code and the regulations issued
thereunder to full-time employees as defined in Section&nbsp;4980H(b)(4) of the Code and the regulations issued thereunder. No material excise tax or penalty under the Affordable Care Act, including Section&nbsp;4980H of the Code, is outstanding,
has accrued, or has arisen and there has been no change in health plan terms or coverage that would reasonably be expected to attract an excise tax under Section&nbsp;4980H of the Code for the current year. None of Public Company nor its
Subsidiaries has received any notification from any Governmental Entity concerning potential liability under the Affordable Care Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
Each Public Company Employee Plan that is a &#147;nonqualified deferred compensation plan&#148; (as defined in Section&nbsp;409A(d)(1) of the Code) materially complies and has complied in all material respects in form and operation with
Section&nbsp;409A of the Code and all IRS regulations and other guidance thereunder. No stock option or equity unit option granted under any Public Company Employee Plan has an exercise price that has been or may be less than the fair market value
of the underlying stock or equity units (as the case may be) as of the date such option was granted or has any feature for the deferral of compensation other than the deferral of recognition of income until the later of exercise or disposition of
such option. No nonqualified deferred compensation plan has been administered in a manner that would reasonably be expected to cause an excise tax to apply to payments to plan participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Section</U><U></U><U>&nbsp;4.14(i)</U> of the Public Company Disclosure Schedule sets forth a complete and accurate list of the
severance, termination or similar pay or benefits to which each current or former employee of, or service provider to, Public Company or its Subsidiaries would be entitled, assuming that each current employee or service provider is terminated
involuntarily by Public Company without cause immediately following the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15 <U>Compliance With Laws</U>. Public Company
and each of its Subsidiaries has complied in all material respects with, is not in material violation of, and, as of the date of this Agreement, has not received any notice alleging any material violation with respect to, any applicable provisions
of any statute, Law or regulation with respect to the conduct of its business, or the ownership or operation of its properties or assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16 <U>Permits and Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company and each of its Subsidiaries have all Permits that are material to the conduct of its business as currently conducted,
including all such Permits required by the <U>FDA</U>, such as a study may proceed letter for an <U>IND</U>, and any other <U>Regulating Authority</U> engaged in the regulation of pharmaceuticals or biohazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Permits that are necessary for the conduct of the business of Public Company and each of its Subsidiaries as currently conducted (the
&#147;<U>Public Company</U> <U>Authorizations</U>&#148;) are in full force and effect, and to the knowledge of Public Company, no violations or notices of failure to comply have been issued or recorded by any Regulating Authority in respect of any
such Public Company Authorization. No such Public Company Authorization shall cease to be effective as a result of the consummation of the transactions contemplated by this Agreement. Public Company and each of its Subsidiaries are in compliance in
all material respects under any of such Public Company Authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of Public Company, all applications, reports,
notices and other documents required to be filed by Public Company and its Subsidiaries with all Governmental Entities have been timely filed and are complete and correct in all material respects as filed or as amended prior to the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) None of Public Company, any Subsidiary of Public Company, and to Public Company&#146;s knowledge, any officer, employee or
agent of Public Company or any of its Subsidiaries has been convicted of any crime or engaged in any conduct that has previously caused or would reasonably be expected to result in (A)&nbsp;disqualification or debarment by the FDA under 21 U.S.C.
Sections 335a(a) or (b), or any similar law, rule or regulation of any other Governmental Entity, or (B)&nbsp;exclusion under 42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7</FONT> or any similar law, rule or regulation of any
Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of the date of this Agreement and for the three years prior to the date of this Agreement, Public Company and
each of its Subsidiaries: (i)&nbsp;is and has been in material compliance, to the extent applicable, with all applicable Laws, including the FDCA and such applicable requirements relating to Good Manufacturing Practices, Good Clinical Practices and
Good Laboratory Practices, and with all applicable orders lawfully administered or issued by the FDA or any other Governmental Entity exercising comparable authority, applicable to the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product tested, developed, promoted, marketed, manufactured or distributed by Public Company and each of its
Subsidiaries; and (ii)&nbsp;has not received any written notice or correspondence from any Governmental Entity alleging or asserting any material noncompliance with any such Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Public Company nor, to the knowledge of Public Company, any of its Subsidiaries, or any of the respective officers, employees or
agents of Public Company or its Subsidiaries, have made an untrue statement of a material fact or fraudulent statement to any Governmental Entity relating to the Public Company Authorizations or failed to disclose a material fact required to be
disclosed to any Government Entity relating to the Public Company Authorizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To Public Company&#146;s knowledge, all preclinical
and clinical investigations and trials sponsored by Public Company are being and have for the three years prior to the date of this Agreement been conducted in compliance in all material respects with applicable laws, including, as applicable, Good
Manufacturing Practices, Good Clinical Practices and Good Laboratory Practices requirements and privacy laws. Public Company has not received any written notices from any Government Entity, institutional review board, independent ethics committee,
data and safety monitoring board, or other oversight body with respect to any clinical or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or tests, or chemistry, manufacturing, and control quality issues requiring the termination,
suspension or material modification of such studies or tests and, to Public Company&#146;s knowledge, there are no facts that would reasonably give rise to such an action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) There are no seizures, recalls, market withdrawals, field notifications or corrective
actions, notifications of misbranding or adulteration, destruction orders, safety alerts or similar actions relating to the safety or efficacy of any products marketed or sold by Public Company tner or any of its Subsidiaries being conducted,
requested in writing or, to the knowledge of Merger Partner, that have been threatened by the FDA or any other Governmental Entity. Public Company has not, either voluntarily or as requested or required by a Governmental Entity, initiated, conducted
or issued or caused to be initiated, conducted or issued any recall, market withdrawal, safety alert or other similar notice or action relating to the alleged lack of safety or efficacy of any products marketed or sold by Public Company or any of
its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17 <U>Employees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All current and past key employees of Public Company or any of its Subsidiaries have entered into confidentiality and assignment of
inventions agreements with Public Company, a copy or form of which has previously been made available to Merger Partner. To the knowledge of Public Company, as of the date of this Agreement, no employee of Public Company or any Subsidiary of Public
Company is in violation of any term of any patent disclosure agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, or any restrictive covenant to a former employer relating to the right of any such employee to be employed by
Public Company or any of its Subsidiaries because of the nature of the business currently conducted by Public Company or any of its Subsidiaries or to the use of trade secrets or proprietary information of others. To the knowledge of Public Company,
as of the date of this Agreement and other than as contemplated by the Corporate Restructuring Plan, no key employee or group of employees has any plans to terminate employment with Public Company or its Subsidiaries within the <FONT
STYLE="white-space:nowrap">12-month</FONT> period following the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Public Company nor any of its
Subsidiaries is or has been a party to or otherwise bound by any collective bargaining agreement, contract or other agreement or understanding with a labor union or labor organization. Neither Public Company nor any of its Subsidiaries is or has
been the subject of any proceeding asserting that Public Company or any of its Subsidiaries has committed an unfair labor practice or is seeking to compel it to bargain with any labor union or labor organization, nor is there or has there been
pending or, to the knowledge of Public Company, threatened, any labor strike, dispute, walkout, work stoppage, slow-down or lockout involving Public Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company and its Subsidiaries are and have been in material compliance with all applicable Laws related to employment (including
verification of employment eligibility), employment practices, terms and conditions of employment and wages and hours (including, without limitation, classification of employees) with respect to any employee (as defined by, or determined in
accordance with, applicable Laws). To the knowledge of Public Company, all employees of Public Company and its Subsidiaries are citizens or lawful permanent residents of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Public Company nor any of its Subsidiaries has received written notice of any charge or complaint pending before the Equal
Employment Opportunity Commission or other Governmental Entity alleging unlawful discrimination, harassment, retaliation or any other violation of or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with applicable Law relating to the
employment, treatment, or termination of any employees of Public Company or any of its Subsidiaries, nor, to the knowledge of Public Company, has any such charge been threatened. No current or former employee of Public Company or any of its
Subsidiaries has, pursuant to internal complaint procedures, made a written complaint of discrimination, retaliation or harassment, nor to Public Company&#146;s knowledge, has an oral complaint of any of the foregoing been made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither Public Company nor any of its Subsidiaries has caused a plant closing as defined in the Worker Adjustment and Retraining
Notification Act (the &#147;<U>WARN Act</U>&#148;) affecting any site of employment or one or more operating units within any site of employment, or a mass layoff as defined in the WARN Act, nor have any of the foregoing been affected by any
transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.18 <U>Insurance</U>. Public Company and its Subsidiaries maintain insurance policies (the
&#147;<U>Public Company Insurance Policies</U>&#148;), including insurance covering directors and officers for securities Law and other customary liabilities, with reputable insurance carriers against all risks of a character and in such amounts as
are usually insured against by similarly situated companies in the same or similar businesses. Each Public Company Insurance Policy is in full force and effect. None of the Public Company Insurance Policies shall terminate or lapse (or be affected
in any other adverse manner) by reason of any of the transactions contemplated by this Agreement. Public Company and each of its Subsidiaries have complied in all material respects with the provisions of each Public Company Insurance Policy under
which it is the insured party. No insurer under any Public Company Insurance Policy has cancelled or generally disclaimed liability under any such policy or indicated any intent to do so or not to renew any such policy. All claims under the Public
Company Insurance Policies have been filed in a timely fashion. Public Company has delivered to Merger Sub accurate and complete copies of all Public Company Insurance Policies relating to the business, assets, liabilities and operations of Public
Company and each of its Subsidiaries. Public Company and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each legal proceeding pending against Public Company or any of its Subsidiaries for
which Public Company or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such legal proceeding, or informed Public Company or any of its Subsidiaries of its
intent to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.19 <U>Opinion of Financial Advisor</U>. The financial advisor of Public Company, SVB Leerink LLC (the &#147;<U>Public
Company Financial Advisor</U>&#148;), has delivered to Public Company an opinion dated the date of this Agreement to the effect that, as of such date and subject to the assumptions, qualifications and limitations set forth therein, the Exchange
Ratio is fair, from a financial point of view, to Public Company, a signed copy of which opinion will be delivered to Merger Partner within one Business Day following the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.20 <U>Section</U><U></U><U>&nbsp;203 of the DGCL</U>. Assuming the accuracy of the representations and warranties of Merger Partner in
<U>Section</U><U></U><U>&nbsp;3.23</U>, Public Company Board has taken all actions so that the restrictions contained in Section&nbsp;203 of the DGCL applicable to a &#147;business combination&#148; (as defined in Section&nbsp;203) shall not apply
to the execution, delivery or performance of this Agreement, the Public Company Support Agreement or the consummation of the Merger or the other transactions contemplated by this Agreement or the Public Company Support Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.21 <U>Brokers; Fees and Expenses</U>. No agent, broker, investment banker, financial advisor or other firm or person is or shall be
entitled, as a result of any action, agreement or commitment of Public Company or any of its Subsidiaries, to any broker&#146;s, finder&#146;s, financial advisor&#146;s or other similar fee or commission in connection with any of the transactions
contemplated by this Agreement, except the Public Company Financial Advisor. Public Company has made available to Merger Partner a complete and accurate copy of all agreements pursuant to which the Public Company Financial Advisor is entitled to any
fees and expenses in connection with any of the transactions contemplated by this Agreement. Public Company is not a party to any agreements with the Public Company Financial Advisor providing the Public Company Financial Advisor with any rights
after the Closing that have not been made available to Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.22 <U>Operations of Merger Sub</U>. Merger Sub was formed solely
for the purpose of engaging in the transactions contemplated by this Agreement, has engaged in no other business activities and has conducted its operations only as contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.23 <U>Certain Business Relationships With Affiliates</U>. No Affiliate of Public Company (other than a wholly owned Subsidiary of Public
Company)&nbsp;(a) owns any property or right, tangible or intangible, which is used in the business of Public Company or any of its Subsidiaries, (b)&nbsp;has any claim or cause of action against Public Company or any of its Subsidiaries or
(c)&nbsp;owes any money to, or is owed any money by, Public Company or any of its Subsidiaries. <U>Section</U><U></U><U>&nbsp;4.23</U> of the Public Company Disclosure Schedule describes any material Contracts between Public Company and any
Affiliate thereof (other than a wholly owned Subsidiary of Public Company) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which were entered into or have been in effect at any time since January&nbsp;1, 2019, other than (i)&nbsp;any employment Contracts, invention assignment agreements and other Contracts entered
into in the Ordinary Course of Business relating to employment, or (ii)&nbsp;Contracts relating to stock purchases and awards, stock options and other equity arrangements, in each case relating to compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.24 <U>Controls and Procedures, Certifications and Other Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company and each of its Subsidiaries maintains accurate books and records reflecting its assets and liabilities and maintains
proper and adequate internal control over financial reporting designed to provide assurance that (i)&nbsp;transactions are executed with management&#146;s authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the
consolidated financial statements of Public Company and to maintain accountability for Public Company&#146;s consolidated assets, (iii)&nbsp;access to assets of Public Company and its Subsidiaries is permitted only in accordance with
management&#146;s authorization, (iv)&nbsp;the reporting of assets of Public Company and its Subsidiaries is compared with existing assets at regular intervals and (v)&nbsp;accounts, notes and other receivables and inventory were recorded
accurately, and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public
Company maintains disclosure controls and procedures required by Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> or <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act, and such controls and procedures are effective to ensure
that all material information concerning Public Company and its Subsidiaries is made known on a timely basis to the individuals responsible for the preparation of Public Company&#146;s filings with the SEC and other public disclosure documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Public Company nor any of its Subsidiaries has, since Public Company became subject to the reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act, extended or maintained credit, arranged for the extension of credit, modified or renewed an extension of credit, in the form of a personal loan or otherwise, to or for any director or
executive officer of Public Company. <U>Section</U><U></U><U>&nbsp;4.24(c)</U> of the Public Company Disclosure Schedule identifies any loan or extension of credit maintained by Public Company to which the second sentence of Section&nbsp;13(k)(1) of
the Exchange Act applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.25 <U>Books and Records</U>. The minute books and other similar records of Public Company contain complete
and accurate records of all actions taken at any meetings of Public Company&#146;s stockholders, Board of Directors or any committee thereof and of all written consents executed in lieu of the holding of any such meeting. The books and records of
Public Company accurately reflect in all material respects the assets, liabilities, business, financial condition and results of operations of Public Company and have been maintained in accordance with good business and bookkeeping practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.26 <U>Subsidies</U>. All governmental, state or regional subsidies granted to Public Company or any of its Subsidiaries were used in
accordance with applicable provisions of any statute, Law or regulation or any other public orders or conditions imposed or related to them in conjunction with their granting and, in particular, all conditions imposed by the respective Governmental
Entities have been fulfilled and observed. Neither Public Company nor any of its Subsidiaries is under any further obligation to perform any services with regard to such subsidies and no such subsidies have to be repaid by Public Company or any of
its Subsidiaries as a result of the negotiation, execution, delivery or performance of this Agreement, or the consummation of the transactions contemplated hereby or any other reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.27 <U>Data Protection</U>. Public Company and its Subsidiaries currently fully comply with any data protection and privacy legislation
applicable to their businesses including (i)&nbsp;the requirements relating to notification and/or registration of processing of personal data with any applicable national data protection regulator, (ii)&nbsp;all subject information requests from
data subjects, (iii)&nbsp;where necessary, the obtaining of consent to data processing and/or direct marketing activity, and (iv)&nbsp;where necessary, the obtaining of any approval, consultation and/or agreement of any applicable works councils or
such similar worker representation bodies. Neither Public Company nor any of its Subsidiaries has received any notice or complaint from any individual, third party and/or regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authority alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable data protection and privacy legislation (including any prohibition or restriction on the transfer of
data to any jurisdiction) or claiming compensation for or an injunction in respect of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any applicable data protection and privacy legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.28 <U>No Other Representations or Warranties</U>. Each of Public Company and Merger Sub hereby acknowledges and agrees that, except for the
representations and warranties contained in this Agreement, none of Merger Partner nor any other person on behalf of Merger Partner makes any express or implied representation or warranty with respect to Merger Partner or with respect to any other
information provided to Public Company, Merger Sub or any of their Affiliates in connection with the transactions contemplated hereby, and (subject to the express representations and warranties of Merger Partner set forth in <U>Article III</U> (in
each case as qualified and limited by the Merger Partner Disclosure Schedule)) none of Public Company, Merger Sub or any of their respective Affiliates, stockholders, directors, officers, employees, agents, representatives or advisors, or any other
person, has relied on any such information (including the accuracy or completeness thereof). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDUCT OF BUSINESS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Covenants of Merger Partner</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;5.1</U> of the Merger Partner Disclosure Schedule
or as expressly provided herein or as consented to in writing by Public Company (which consent shall not be unreasonably withheld, conditioned or delayed), or to the extent necessary to comply with any
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, from and after the date of this Agreement until the earlier of the termination of this Agreement in accordance with its terms and the Effective Time, Merger Partner shall act and carry on
its business in the Ordinary Course of Business, pay its debts and Taxes and perform its other obligations when due (subject to good faith disputes over such debts, Taxes or obligations), comply with applicable laws, rules and regulations, and use
commercially reasonable efforts to maintain and preserve its business organization, assets and properties, keep available the services of its present officers and key employees and preserve its advantageous business relationships with customers,
strategic partners, suppliers, distributors and others having business dealings with it. Without limiting the generality of the foregoing, except as set forth in <U>Section</U><U></U><U>&nbsp;5.1</U> of the Merger Partner Disclosure Schedule or as
expressly provided herein, or to the extent necessary to comply with any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, from and after the date of this Agreement until the earlier of the termination of this Agreement in accordance with
its terms and the Effective Time, Merger Partner shall not, directly or indirectly, do any of the following without the prior written consent of Public Company (which consent shall not, in the case of the actions set forth in clauses (k)&nbsp;and
(l) of this <U>Section</U><U></U><U>&nbsp;5.1</U>, be unreasonably withheld, conditioned or delayed): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) declare, set aside or
pay any dividends on, or make any other distributions (whether in cash, securities or other property) in respect of, any of its capital stock; (ii)&nbsp;split, combine or reclassify any of its capital stock or issue or authorize the issuance of any
other securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities; or (iii)&nbsp;purchase, redeem or otherwise acquire any shares of its capital stock or any other of its securities or any
rights, warrants or options to acquire any such shares or other securities, other than, in the case of this clause (iii), the withholding of shares of Merger Partner Common Stock to pay the exercise price or withholding taxes upon the exercise of
Merger Partner Stock Options or from former employees, directors and consultants in accordance with agreements in effect on the date of this Agreement providing for the repurchase of shares at no or nominal consideration in connection with any
termination of services to Merger Partner; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) except as permitted by <U>Section</U><U></U><U>&nbsp;5.1(l)</U>, and except as
contemplated by the Financing, issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any shares of its capital stock, any other voting securities or any securities convertible into or exchangeable for, or any rights, warrants or
options to acquire, any such shares, voting securities or convertible or exchangeable securities (other than the issuance of shares of Merger Partner Common Stock pursuant to the Financing or the Merger Partner Preferred Stock Conversion or upon the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of Merger Partner Stock Options or Merger Partner Warrants outstanding on the date of this Agreement and set forth in <U>Section</U><U></U><U>&nbsp;3.2(c)</U> or
<U>Section</U><U></U><U>&nbsp;3.2(d)</U> of the Merger Partner Disclosure Schedule in accordance with their present terms (including cashless exercises), or Merger Partner Stock Options granted as contemplated by
<U>Section</U><U></U><U>&nbsp;5.1(l))</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) amend its certificate of incorporation, bylaws or other comparable charter or
organizational documents or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split or reverse stock split or form any new Subsidiary or acquire any equity
interest or other interest in any other person;<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) except for purchases of
inventory, raw materials and, to the extent the cost thereof is not in excess of $250,000 in the aggregate, equipment, in each case in the Ordinary Course of Business, acquire (i)&nbsp;by merging or consolidating with, or by purchasing all or a
substantial portion of the assets or any stock of, or by any other manner, any business or any corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof or (ii)&nbsp;any assets
that are material, in the aggregate, to Merger Partner; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) except in the Ordinary Course of Business, sell, lease, license, pledge, or
otherwise dispose of or encumber any properties or assets of Merger Partner; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) whether or not in the Ordinary Course of Business, sell,
dispose of or otherwise transfer any assets material to Merger Partner (including any accounts, leases, contracts or Intellectual Property or any assets, but excluding the sale or license of products in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;(i) incur or suffer to exist any indebtedness for borrowed money other than such indebtedness that existed as of the date of the
Merger Partner Balance Sheet to the extent reflected on the Merger Partner Balance Sheet or guarantee any such indebtedness of another person, (ii)&nbsp;issue, sell or amend any debt securities or warrants or other rights to acquire any debt
securities of Merger Partner, guarantee any debt securities of another person, enter into any &#147;keep well&#148; or other agreement to maintain any financial statement condition of another person or enter into any arrangement having the economic
effect of any of the foregoing, (iii)&nbsp;make any loans, advances (other than routine advances to employees of Merger Partner in the Ordinary Course of Business) or capital contributions to, or investment in, any other person, other than Merger
Partner or (iv)&nbsp;enter into any hedging agreement or other financial agreement or arrangement designed to protect Merger Partner against fluctuations in commodities prices or exchange rates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) make any capital expenditures or other expenditures with respect to property, plant or equipment in excess of $250,000 in the aggregate
for Merger Partner, other than as set forth in Merger Partner&#146;s budget for capital expenditures previously made available to Public Company or the specific capital expenditures disclosed and set forth in <U>Section</U><U></U><U>&nbsp;5.1(h)</U>
of the Merger Partner Disclosure Schedule; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) make any changes in accounting methods, principles or practices, except insofar as may
have been required by a change in GAAP or, except as so required, change any assumption underlying, or method of calculating, any bad debt, contingency or other reserve; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) except (i)&nbsp;in the Ordinary Course of Business or (ii)&nbsp;for terminations as a result of the expiration of any contract that
expires in accordance with terms, (A)&nbsp;modify or amend in any material respect, or terminate, any material contract or agreement to which Merger Partner is party, or (B)&nbsp;knowingly waive, release or assign any material rights or claims
(including any <FONT STYLE="white-space:nowrap">write-off</FONT> or other compromise of any accounts receivable of Merger Partner); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)
except in the Ordinary Course of Business, (i)&nbsp;enter into any material contract or agreement relating to the rendering of services or the distribution, sale or marketing by third parties of the products, of, or products licensed by, Merger
Partner or (ii)&nbsp;license any material Intellectual Property rights to or from any third party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) except as required to comply with applicable Law or agreements, plans or arrangements
existing on the date hereof and either disclosed in the Merger Partner Disclosure Schedules or not required by this Agreement to be so disclosed, (i)&nbsp;other than in the Ordinary Course of Business, adopt, enter into, terminate (other than
terminations for cause) or amend any employment, severance or similar agreement or benefit plan for the benefit or welfare of any current or former director, officer, employee or consultant or any collective bargaining agreement, (ii)&nbsp;increase
in any material respect the compensation or fringe benefits of, or pay any material bonus to, any director, officer, employee or consultant (except for annual increases of the salaries of <FONT STYLE="white-space:nowrap">non-officer</FONT> employees
in the Ordinary Course of Business, or increases relating to the promotion of an employee to fill a vacancy), (iii) amend or accelerate the payment, right to payment or vesting of any compensation or benefits, including any outstanding options or
restricted stock awards, (iv)&nbsp;pay any material benefit not provided for as of the date of this Agreement under any benefit plan, (v)&nbsp;grant any awards under any bonus, incentive, performance or other compensation plan or arrangement or
benefit plan (including the grant of stock options, stock appreciation rights, stock based or stock related awards, performance units or restricted stock, or the removal of existing restrictions in any benefit plans or agreements or awards made
thereunder), except for the grant of stock options, stock appreciation rights, stock based or stock related awards in the Ordinary Course of Business, which, in the case of stock options shall have an exercise price equal to the fair market value of
Merger Partner Common Stock on the date of grant (determined in a manner consistent with Merger Partner&#146;s existing practice for establishing fair market value for option grants and which awards shall otherwise be upon Merger Partner&#146;s
customary terms) or (vi)&nbsp;take any action other than in the Ordinary Course of Business to fund or in any other way secure the payment of compensation or benefits under any employee plan, agreement, contract or arrangement or benefit plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) make or change any material Tax election, change an annual accounting period, enter into any closing agreement, waive or extend any
statute of limitations with respect to Taxes, settle or compromise any material Tax liability, claim or assessment, surrender any right to claim a refund of material Taxes, or amend any income or other material Tax Return; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) commence any offering of shares of Merger Partner Common Stock pursuant to any Employee Stock Purchase Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) initiate, compromise or settle any material litigation or arbitration proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) open or close any facility or office; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) fail to use commercially reasonable efforts to maintain insurance at levels substantially comparable to levels existing as of the date of
this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) fail to pay accounts payable and other obligations in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) suspend any clinical trials sponsored by Merger Partner or involving any products marketed or in development by Merger Partner; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) authorize any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or any action that would make any
representation or warranty of Merger Partner in this Agreement untrue or incorrect in any material respect, or would materially impair, delay or prevent the satisfaction of any conditions in <U>Article VII</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Covenants of Public Company</U>. Except as set forth in <U>Section</U><U></U><U>&nbsp;5.2</U> of the Public Company Disclosure Schedule
or as expressly provided herein or as consented to in writing by Merger Partner (which consent shall not be unreasonably withheld, conditioned or delayed), or to the extent necessary to comply with any
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, from and after the date of this Agreement until the earlier of the termination of this Agreement in accordance with its terms and the Effective Time, Public Company shall, and shall cause
each of its Subsidiaries </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, act and carry on its business in the Ordinary Course of Business, pay its debts and Taxes and perform its other obligations when due (subject to good faith disputes over such debts, Taxes or
obligations), comply with applicable laws, rules and regulations, and with respect to the Public Company, use commercially reasonable efforts to maintain and preserve its and each of its Subsidiaries&#146; business organization, assets and
properties, keep available the services of its present officers and key employees listed on Section&nbsp;5.2 of the Public Company Disclosure Schedule and preserve its advantageous business relationships with customers, strategic partners,
suppliers, distributors and others having business dealings with it to the extent consistent with the corporate restructuring plan previously announced by the Public Company, as disclosed in Item 2.05 of the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> as filed with the SEC on January&nbsp;28, 2021 (the &#147;<U>Corporate Restructuring Plan</U>&#148;). Without limiting the generality of the foregoing, except as set forth in
<U>Section</U><U></U><U>&nbsp;5.2</U> of the Public Company Disclosure Schedule or as expressly provided herein, or to the extent necessary to comply with any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, from and after the date of this
Agreement until the earlier of the termination of this Agreement in accordance with its terms and the Effective Time, Public Company shall not, and shall not permit any of its Subsidiaries to, directly or indirectly, do any of the following without
the prior written consent of Merger Partner (which consent shall not, in the case of the actions set forth in clauses (k)&nbsp;and (l) of this <U>Section</U><U>&nbsp;5.2</U>, be unreasonably withheld, conditioned or delayed): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, securities or other property) in
respect of, any of its capital stock (other than dividends and distributions by a direct or indirect wholly owned Subsidiary of Merger Partner to its parent); (ii) except as contemplated by the Reverse Stock Split, split, combine or reclassify any
of its capital stock or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or any of its other securities; or (iii)&nbsp;purchase, redeem or otherwise acquire any
shares of its capital stock or any other of its securities or any rights, warrants or options to acquire any such shares or other securities, other than, in the case of this clause (iii), from former employees, directors and consultants in
accordance with agreements in effect on the date of this Agreement providing for the repurchase of shares at no or nominal consideration in connection with any termination of services to Public Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any shares of its capital stock, any other voting securities or
any securities convertible into or exchangeable for, or any rights, warrants or options to acquire, any such shares, voting securities or convertible or exchangeable securities (in each case other than the issuance of shares of Public Company Common
Stock upon the exercise of Public Company Stock Options or Public Company Warrants outstanding on the date of this Agreement and set forth in <U>Section</U><U></U><U>&nbsp;4.2(b)</U> or <U>Section</U><U></U><U>&nbsp;4.2(c)</U> of the Public Company
Disclosure Schedule in accordance with their present terms (including cashless exercises)); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) except as contemplated by the Reverse
Stock Split, amend its certificate of incorporation, bylaws or other comparable charter or organizational documents or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of
shares, stock split or reverse stock split or form any new Subsidiary or acquire any equity interest or other interest in any other person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) acquire (i)&nbsp;by merging or consolidating with, or by purchasing all or a substantial portion of the assets or any stock of, or by any
other manner, any business or any corporation, partnership, joint venture, limited liability company, association or other business organization or division thereof or (ii)&nbsp;any assets that are material, in the aggregate, to Public Company and
its Subsidiaries, taken as a whole; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) except in the Ordinary Course of Business, sell, lease, license, pledge, or otherwise dispose of
or encumber any properties or assets of Public Company or of any of its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) whether or not in the Ordinary Course of
Business, sell, dispose of or otherwise transfer any assets material to Public Company and its Subsidiaries, taken as a whole (including any accounts, leases, contracts or Intellectual Property or any assets or the stock of any of its Subsidiaries,
but excluding the sale or license of products in the Ordinary Course of Business); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;(i) incur or suffer to exist any indebtedness for borrowed money or guarantee any
such indebtedness of another person, (ii)&nbsp;issue, sell or amend any debt securities or warrants or other rights to acquire any debt securities of Public Company or any of its Subsidiaries, guarantee any debt securities of another person, enter
into any &#147;keep well&#148; or other agreement to maintain any financial statement condition of another person or enter into any arrangement having the economic effect of any of the foregoing, (iii)&nbsp;make any loans, advances (other than
routine advances to employees of Public Company in the Ordinary Course of Business) or capital contributions to, or investment in, any other person, other than Public Company or any of its direct or indirect wholly owned Subsidiaries or
(iv)&nbsp;enter into any hedging agreement or other financial agreement or arrangement designed to protect Public Company or its Subsidiaries against fluctuations in commodities prices or exchange rates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) make any capital expenditures or other expenditures with respect to property, plant or equipment for Public Company and its Subsidiaries,
taken as a whole, other than as set forth in Public Company&#146;s budget for capital expenditures previously made available to Merger Partner or the specific capital expenditures disclosed and set forth in <U>Section</U><U></U><U>&nbsp;5.2</U> of
the Public Company Disclosure Schedule; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) make any changes in accounting methods, principles or practices, except insofar as may have
been required by the SEC or a change in GAAP or, except as so required, change any assumption underlying, or method of calculating, any bad debt, contingency or other reserve; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) except (i)&nbsp;in the Ordinary Course of Business or (ii)&nbsp;for terminations as a result of the expiration of any contract that
expires in accordance with its terms, (A)&nbsp;modify or amend in any material respect, or terminate, any material contract or agreement to which Public Company or any of its Subsidiaries is party, or (B)&nbsp;knowingly waive, release or assign any
material rights or claims (including any <FONT STYLE="white-space:nowrap">write-off</FONT> or other compromise of any accounts receivable of Public Company of any of its Subsidiaries); <U>provided</U>, <U>however</U>, that the Public Company shall,
to the extent not delivered prior to the date hereof, deliver a notice of termination under each of the licenses for Intellectual Property set forth in Section&nbsp;5.2 of the Public Company Disclosure Schedule; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;(i) enter into any material contract or agreement relating to the rendering of services or the distribution, sale or marketing by
third parties of the products, of, or products licensed by, Public Company or any of its Subsidiaries or (ii)&nbsp;license any material Intellectual Property rights to or from any third party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) except as required to comply with applicable Law or agreements, plans or arrangements existing on the date hereof and disclosed in the
Public Company Disclosure Schedules, (i)&nbsp;take any action with respect to, adopt, enter into, terminate (other than terminations for cause) or amend any employment, severance or similar agreement or benefit plan for the benefit or welfare of any
current or former director, officer, employee or consultant or any collective bargaining agreement, (ii)&nbsp;increase in any material respect the compensation or fringe benefits of, or pay any material bonus to, any director, officer, employee or
consultant, (iii)&nbsp;amend or accelerate the payment, right to payment or vesting of any compensation or benefits, including any outstanding options or restricted stock awards, (iv)&nbsp;pay any material benefit not provided for as of the date of
this Agreement under any benefit plan, (v)&nbsp;grant any awards under any bonus, incentive, performance or other compensation plan or arrangement or benefit plan (including the grant of stock options, stock appreciation rights, stock based or stock
related awards, performance units or restricted stock, or the removal of existing restrictions in any benefit plans or agreements or awards made thereunder), (vi) hire any additional officers or other employees, or any consultants or independent
contractors, or (vii)&nbsp;take any action to fund or in any other way secure the payment of compensation or benefits under any employee plan, agreement, contract or arrangement or benefit plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) make or change any material Tax election, change an annual accounting period, enter into any closing agreement, waive or extend any
statute of limitations with respect to Taxes, settle or compromise any material Tax liability, claim or assessment, surrender any right to claim a refund of material Taxes, or amend any income or other material Tax Return; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) commence any offering of shares of Public Company Common Stock pursuant to any Employee
Stock Purchase Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) initiate, compromise or settle any litigation or arbitration proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) open or close any facility or office; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) fail to use commercially reasonable efforts to maintain insurance at levels substantially comparable to levels existing as of the date of
this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) fail to pay accounts payable and other obligations in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) amend or otherwise fail to take all actions within its reasonable control to perform in any material respect the Corporate Restructuring
Plan; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) authorize any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or any action that
would make any representation or warranty of Public Company in this Agreement untrue or incorrect in any material respect, or would materially impair, delay or prevent the satisfaction of any conditions in <U>Article VII</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Confidentiality</U>. The parties acknowledge that Public Company and Merger Partner have previously executed a confidentiality
agreement, dated as of January&nbsp;20, 2021 (the &#147;<U>Confidentiality Agreement</U>&#148;), which Confidentiality Agreement shall continue in full force and effect in accordance with its terms, except as expressly modified by this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Public Company 2020 Form <FONT STYLE="white-space:nowrap">10-K</FONT></U>. The Public Company shall file the Public Company 2020
Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC in the form made available to Merger Partner prior to the execution of this Agreement no later than 9:00 A.M. Eastern Time on the date of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ADDITIONAL AGREEMENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>No Solicitation</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>No Solicitation or Negotiation</U>. Except as set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>, until the Effective Time, each of Merger Partner, Public Company and their respective Subsidiaries shall not, and each of Merger Partner and
Public Company shall use reasonable best efforts to cause their respective directors, officers, members, employees, agents, attorneys, consultants, contractors, accountants, financial advisors and other authorized representatives
(&#147;<U>Representatives</U>&#148;) not to, directly or indirectly: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) solicit, seek or initiate or knowingly take any action to
facilitate or encourage any offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, any Acquisition Proposal; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) enter into, continue or otherwise participate or engage in any discussions or negotiations regarding any Acquisition Proposal, or
furnish to any person any <FONT STYLE="white-space:nowrap">non-public</FONT> information or afford any person other than Public Company or Merger Partner, as applicable, access to such party&#146;s property, books or records (except pursuant to a
request by a Governmental Entity) in connection with any offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, any Acquisition Proposal; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) take any action to make the provisions of any takeover statute inapplicable to any
transactions contemplated by an Acquisition Proposal; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) publicly propose to do any of the foregoing described in clauses
(i)&nbsp;through (iii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, subject to compliance with
<U>Section</U><U></U><U>&nbsp;6.1(c)</U>, prior to the Specified Time, each of Public Company and Merger Partner may (A)&nbsp;furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to Public Company and its Subsidiaries
or Merger Partner and its Subsidiaries, as the case may be, to any Qualified Person (and the Representatives of such Qualified Person), or (B)&nbsp;engage in discussions or negotiations (including solicitation of revised Acquisition Proposals) with
any Qualified Person (and the Representatives of such Qualified Person) regarding any such Acquisition Proposal; provided, (x)&nbsp;that either Merger Partner or Public Company (as applicable) receives from the Qualified Person an executed
confidentiality agreement on the terms not less restrictive than exist in the Confidentiality Agreement and continuing additional provisions that expressly permit such party to comply with this terms of this <U>Section</U><U></U><U>&nbsp;6.1</U> (a
copy of which shall be provided to the other party), (y) the party seeking to make use of this proviso has not otherwise materially breached this <U>Section</U><U></U><U>&nbsp;6.1</U> with respect to such Acquisition Proposal or the person making
such Acquisition Proposal, and (z)&nbsp;the Merger Partner Board or Public Company Board (as applicable) has determined (after consultation with outside legal counsel) that the failure to take such actions would reasonably be expected to be
inconsistent with its fiduciary duties under applicable Law. It is understood and agreed that any violation of the restrictions in this <U>Section</U><U></U><U>&nbsp;6.1</U> (or action that, if taken by Public Company or Merger Partner, as
applicable, would constitute such a violation) by any Representatives of Public Company or Merger Partner shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;6.1</U> by Public Company or Merger Partner, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Change in Recommendation or Alternative Acquisition Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Effective Time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;(A)
Merger Partner Board shall not, except as set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>, withhold, withdraw or modify, or publicly propose to withhold, withdraw or modify, the approval or recommendation by the Merger Partner Board with
respect to the Merger, fail to recommend against acceptance of a tender offer within ten (10)&nbsp;Business Days after commencement or propose publicly to approve, adopt or recommend any Acquisition Proposal (a &#147;<U>Merger Partner Board
Recommendation Change</U>&#148;) and (B)&nbsp;the Public Company Board shall not, except as set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>, withhold, withdraw or modify, or publicly propose to withhold, withdraw or modify, the approval or
recommendation by the Public Company Board with respect to the Share Issuance, fail to recommend against acceptance of a tender offer within ten (10)&nbsp;Business Days after commencement or propose publicly to approve, adopt or recommend any
Acquisition Proposal (a &#147;<U>Public Company Board Recommendation Change</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) each of Public Company and Merger Partner
shall not enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement or similar agreement (an &#147;<U>Alternative Acquisition</U> <U>Agreement</U>&#148;) providing for the
consummation of a transaction contemplated by any Acquisition Proposal (other than a confidentiality agreement referred to in <U>Section</U><U></U><U>&nbsp;6.1(a)</U> entered into in the circumstances referred to in
<U>Section</U><U></U><U>&nbsp;6.1(a)</U>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) each of the Public Company Board and the Merger Partner Board, and each committee
thereof, shall not, except as set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>, adopt, approve or recommend, or publicly propose to adopt, approve or recommend, any Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or anything to the contrary set forth in this Agreement (including the provisions of this
<U>Section</U><U></U><U>&nbsp;6.1</U>), at any time prior to the Specified Time, the Public Company Board or the Merger Partner Board, as the case may be (<U>provided</U>, that the applicable party has not materially breached its obligations as set
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth in this Agreement), may effect a Public Company Board Recommendation Change or Merger Partner Board Recommendation Change, as the case may be, (A)&nbsp;with respect to a Superior Proposal
or (B)&nbsp;in response to an Intervening Event (in the case of either clause (A)&nbsp;or clause (B)) if: (i)&nbsp;such board of directors shall have determined (after consultation with outside legal counsel) that the failure to effect such Public
Company Board Recommendation Change or Merger Partner Board Recommendation Change, as applicable, would reasonably be expected to be inconsistent with its fiduciary obligations under applicable law; (ii)&nbsp;such party has provided at least four
Business Days prior written notice to the other party that it intends to effect a Public Company Board Recommendation Change or Merger Partner Board Recommendation Change, as applicable, including a description in reasonable detail of the reasons
for such recommendation change, and written copies of any relevant proposed transactions agreements with any party making a potential Superior Proposal (including the identity of the person making such Superior Proposal) (a
&#147;<U>Recommendation</U> <U>Change Notice</U>&#148;) (it being understood that the Recommendation Change Notice shall not constitute a Public Company Board Recommendation Change or Merger Partner Board Recommendation Change for purposes of this
Agreement); (iii) such party has complied in all material respects with the requirements of this <U>Section</U><U></U><U>&nbsp;6.1</U> in connection with any potential Superior Proposal or Intervening Event; and (iv)&nbsp;if the other party shall
have delivered to such party a written, binding and irrevocable offer to alter the terms or conditions of this Agreement during the four Business Day period referred to in clause (ii)&nbsp;above, such party&#146;s board of directors shall have
determined (after consultation with outside legal counsel), after considering the terms of such offer by the other party, that the failure to effect a Public Company Board Recommendation Change or Merger Partner Board Recommendation Change, as the
case may be, would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law. In the event of any material amendment to any Superior Proposal (including any revision in the amount, form or mix of consideration such
party&#146;s stockholders would receive as a result of such potential Superior Proposal), such party shall be required to provide the other party with notice of such material amendment and there shall be a new two Business Day period following such
notification during which the parties shall comply again with the requirements of this <U>Section</U><U></U><U>&nbsp;6.1(b)</U> and the board of directors of such party shall not make a Public Company Board Recommendation Change or Merger Partner
Board Recommendation Change, as applicable, prior to the end of any such period as so extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Notices of Proposals</U>. Each
party will as promptly as reasonably practicable (and in any event within twenty four (24)&nbsp;hours after receipt)&nbsp;(i) notify the other party of its receipt of any Acquisition Proposal and (ii)&nbsp;provide to the other party a copy of such
Acquisition Proposal (if written), or a summary of the material terms and conditions of such Acquisition Proposal (if oral), including the identity of the person making such Acquisition Proposal, and copies of all written communications with such
person with respect to such actual or potential Acquisition Proposal. Such party in receipt of an Acquisition Proposal shall notify the other party, in writing, of any decision of its board of directors as to whether to consider any Acquisition
Proposal or to enter into discussions or negotiations concerning any Acquisition Proposal or to provide <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to such to any person, which notice shall be given as promptly as
practicable after such determination was reached (and in any event no later than 24 hours after such determination was reached). Such party in receipt of an Acquisition Proposal will (A)&nbsp;provide the other party with written notice setting forth
such information as is reasonably necessary to keep such other party informed of the material terms of any such Acquisition Proposal and of any material amendments or modifications thereto, (B)&nbsp;keep such other party informed as promptly as
practicable with respect to any changes to the material terms of an Acquisition Proposal submitted to such party (and in any event within 24 hours following any such changes), including by providing a copy of all written proposals and a summary of
all oral proposals or material oral modifications to an earlier written proposal, in each case relating to any Acquisition Proposal, (C)&nbsp;prior to, or substantially concurrently with, the provision of any
<FONT STYLE="white-space:nowrap">non-public</FONT> information of such party to any such person, provide such information to the other party (including by posting such information to an electronic data room), to the extent such information has not
previously been made available the other party, and (D)&nbsp;promptly (and in any event within 24 hours of such determination) notify the other party of any determination by such party&#146;s board of directors that such Acquisition Proposal
constitutes a Superior Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Certain Permitted Disclosure</U>. Nothing contained in this Agreement shall prohibit
Merger Partner or Public Company or their respective Boards of Directors from complying with Rules <FONT STYLE="white-space:nowrap">14d-9</FONT> and <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange Act;
<U>provided</U>, <U>however</U>, that any disclosure made by Merger Partner or Public Company or their respective Boards of Directors pursuant to Rules <FONT STYLE="white-space:nowrap">14d-9</FONT> and
<FONT STYLE="white-space:nowrap">14e-2(a)</FONT> shall be limited to a statement that Merger Partner or Public Company, as applicable, is unable to take a position with respect to the bidder&#146;s tender offer unless the applicable Board of
Directors determines after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; <U>provided</U>, <U>further</U>, that any such disclosures
(other than a &#147;stop, look and listen&#148; communication or similar communication of the type contemplated by <FONT STYLE="white-space:nowrap">Section&nbsp;14d-9(f)</FONT> under the Exchange Act) shall be deemed to be a Merger Partner Board
Recommendation Change or Public Company Board Recommendation Change, as applicable, unless the respective Board of Directors expressly publicly reaffirms its recommendation for the Merger and the other transactions contemplated hereby within five
(5)&nbsp;Business Days after being requested in writing to do so by the other party, it being understood that any such request in writing by the other party may only be made once by each party with respect to a particular disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Cessation of Ongoing Discussions</U>. Each of Public Company and Merger Partner shall, and shall direct its Representatives to, cease
immediately all discussions and negotiations that commenced prior to the date of this Agreement regarding any proposal that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal; <U>provided</U>, <U>however</U>, that the
foregoing shall not in any way limit or modify the rights of any party hereto under the other provisions of this <U>Section</U><U></U><U>&nbsp;6.1</U>. Public Company and Merger Partner will each immediately revoke or withdraw access of any person
(other than Public Company, Merger Partner and their respective Representatives) to any data room (virtual or actual) containing any <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to Public Company and request from each
third party (other than Public Company, Merger Partner and their Representatives) the prompt return or destruction of all <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to Public Company or Merger Partner, as applicable,
previously provided to such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Definitions</U>. For purposes of this Agreement, the following terms shall have the following
meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Proposal</U>&#148; means, with respect to Public Company or Merger Partner, (a)&nbsp;any inquiry, proposal
or offer for a merger, consolidation, dissolution, sale of substantial assets, recapitalization, share exchange, tender offer or other business combination involving such party and its Subsidiaries (other than mergers, consolidations,
recapitalizations, share exchanges or other business combinations involving solely such party and/or one or more Subsidiaries of such party), (b) any proposal for the issuance by such party of 15% or more of its equity securities or (c)&nbsp;any
proposal or offer to acquire in any manner, directly or indirectly, 15% or more of the equity securities or consolidated total assets of such party and its Subsidiaries, in each case other than the transactions contemplated by this Agreement, other
than, with respect to the Merger Partner, the Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intervening Event</U>&#148; means a material Effect (other than any
Effect resulting from a material breach of this Agreement by the party seeking to claim an Intervening Event) that (a)&nbsp;is materially adverse to Public Company or Merger Partner (as applicable), (b) was not known to or reasonably foreseeable by
the Public Company Board (with respect to Public Company) or the Merger Partner Board (with respect to Merger Partner) and (c)&nbsp;does not relate to an Acquisition Proposal; provided, however, the receipt, existence or terms of an Acquisition
Proposal or Superior Proposal or any matter relating thereto shall not constitute an Intervening Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Qualified
Person</U>&#148; means any person making an unsolicited Acquisition Proposal that the Public Company Board or the Merger Partner Board, as applicable, determines in good faith (after consultation with outside counsel and its financial advisors) is,
or could reasonably be expected to lead to, a Superior Proposal, and such Acquisition Proposal has not resulted from a material breach by Public Company or Merger Partner, as applicable, of its obligations under
<U>Section</U><U></U><U>&nbsp;6.1(a)</U> or <U>Section</U><U></U><U>&nbsp;6.1(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Specified Time</U>&#148; means the
earliest to occur of (a)&nbsp;the Effective Time, (b)&nbsp;in the case of Public Company, the date on which the stockholders of Public Company shall have approved the Public Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Voting Proposals, (c)&nbsp;in the case of Merger Partner, the date on which the stockholders of Merger Partner shall have approved the Merger Partner Voting Proposal and (d)&nbsp;the time at
which this Agreement is terminated in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Superior Proposal</U>&#148; means, with respect to
Public Company or Merger Partner, any <I>bona fide</I>, unsolicited written proposal made by a third party to acquire 50% or more of the equity securities or consolidated total assets of such party and its Subsidiaries, pursuant to a tender or
exchange offer, a merger, a consolidation, business combination or recapitalization or a sale or exclusive license of its assets, (a)&nbsp;on terms which the board of directors of such party determines in its good faith judgment to be more
favorable, from a financial point of view, to the holders of such party&#146;s capital stock than the transactions contemplated by this Agreement (after consultation with its financial and legal advisors), taking into account all the terms and
conditions of such proposal and this Agreement (including any termination or <FONT STYLE="white-space:nowrap">break-up</FONT> fees and conditions to consummation, as well as any written, binding offer by the other party hereto to amend the terms of
this Agreement, which offer is not revocable for at least four Business Days) that the board of directors of such party determines to be relevant, and (b)&nbsp;which board of directors of such party has determined to be reasonably capable of being
completed on the terms proposed, taking into account all financial, regulatory, legal and other aspects of such proposal that board of directors of such party determines to be relevant (including the likelihood and timing of consummation (as
compared to the transactions contemplated hereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Proxy Statement/Prospectus; Registration Statement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practical after the execution of this Agreement, Public Company, with the cooperation of Merger Partner, shall prepare and
file with the SEC the Registration Statement, in which the Proxy Statement/Prospectus will be included as a prospectus. Merger Partner, Merger Sub and Public Company shall (i)&nbsp;provide to the other parties as promptly as practical all
information, including financial statements and descriptions of its business and financial condition, as Public Company as such other parties may reasonably request for preparation of the Registration Statement and the Proxy Statement/Prospectus and
(ii)&nbsp;use reasonable best efforts to cause the timely cooperation of its independent public accountants in connection with the preparation and filing of the Registration Statement and the Proxy Statement/Prospectus, including by causing such
accountants to provide a consent to the inclusion of such accountant&#146;s reports in respect of the financial statements of the applicable party in the Registration Statement and/or in the Proxy Statement/Prospectus (as applicable) and to the
reference to such accountant firm as an &#147;expert&#148; therein. Public Company shall respond to any comments of the SEC and shall use reasonable best efforts to have the Registration Statement declared effective under the Securities Act as
promptly as practicable after such filing, and Public Company shall cause the Proxy Statement/Prospectus to be mailed to its stockholders at the earliest practicable time after the Registration Statement is declared effective under the Securities
Act. Public Company shall notify Merger Partner promptly upon the receipt of any comments from the SEC or its staff and of any request by the SEC or its staff for amendments or supplements to the Registration Statement, the Proxy
Statement/Prospectus or any filing pursuant to <U>Section</U><U></U><U>&nbsp;6.2(b)</U> or for additional information and shall supply Merger Partner with copies of all correspondence between Public Company or any of its representatives, on the one
hand, and the SEC, or its staff, on the other hand, with respect to the Registration Statement, the Proxy Statement/Prospectus, the Merger or any filing pursuant to <U>Section</U><U></U><U>&nbsp;6.2(b)</U>. Public Company shall use commercially
reasonable efforts to cause all documents that it is responsible for filing with the SEC under this <U>Section</U><U></U><U>&nbsp;6.2</U> to comply in all material respects with all applicable requirements of Law and the rules and regulations
promulgated thereunder. Whenever either Public Company or Merger Partner shall become aware of the occurrence of any event which is required to be set forth in an amendment or supplement to the Proxy Statement/Prospectus, the Registration Statement
or any filing pursuant to <U>Section</U><U></U><U>&nbsp;6.2(b)</U>, Public Company or Merger Partner, as the case may be, shall promptly inform the other of such occurrence and cooperate in filing with the SEC or its staff, and/or mailing to
stockholders of Public Company and Merger Partner, such amendment or supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary stated
above, prior to filing and mailing, as applicable, the Registration Statement or Proxy Statement/Prospectus (or any amendment or supplement thereto) or responding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any comments of the SEC with respect thereto, Public Company shall provide Merger Partner a reasonable opportunity to review and comment on such document or response and shall consider in good
faith any such comments proposed by Merger Partner. No filing of, or amendment or supplement to, the Registration Statement or Proxy Statement/Prospectus will be made by Public Company, without the prior consent of Merger Partner, which shall not be
unreasonably withheld, conditioned or delayed. Public Company will advise Merger Partner, promptly after Merger Partner receives notice thereof, of the time when the Registration Statement has become effective or any supplement or amendment has been
filed, of the issuance of any stop order or the suspension of the qualification of Public Company Common Stock for offering or sale in any jurisdiction, of the initiation or threat of any proceeding for any such purpose, or of any request by the SEC
for the amendment or supplement of the Registration Statement or for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company and Merger Partner shall
promptly make all necessary filings with respect to the Merger and the Share Issuance under the Securities Act, the Exchange Act, applicable state blue sky laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Nasdaq Listing</U>. Public Company agrees to use its commercially reasonable efforts to continue the listing of Public Company Common
Stock on Nasdaq during the term of this Agreement and to cause the shares of Public Company Common Stock being issued in connection with the Merger to be approved for listing (subject to notice of issuance) on Nasdaq at or prior to the Effective
Time, including by filing the Nasdaq Listing Application. Merger Partner will cooperate with Public Company to cause the Nasdaq Listing Application to be approved and shall promptly furnish to Public Company all information concerning Merger Partner
and its equityholders that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Access to Information</U>. Subject to compliance with applicable confidentiality obligations owed to third parties in effect as of the
date of this Agreement, each of Public Company and Merger Partner shall (and shall cause each of its Subsidiaries to) afford to the other party&#146;s officers, employees, accountants, counsel and other representatives, reasonable access, during
normal business hours during the period prior to the Effective Time, to all its properties, books, contracts, commitments, personnel and records and, during such period, each of Public Company and Merger Partner shall (and shall cause each of its
Subsidiaries to) furnish promptly to the other party all information concerning its business, properties, assets and personnel as the other party may reasonably request. Each of Public Company and Merger Partner will hold any such information which
is nonpublic in confidence in accordance with the Confidentiality Agreement. No information or knowledge obtained in any investigation pursuant to this <U>Section</U><U></U><U>&nbsp;6.4</U> or otherwise shall affect or be deemed to modify any
representation or warranty contained in this Agreement or the conditions to the obligations of the parties to consummate the Merger. Without limiting the generality of the foregoing, from the date of this Agreement until the Effective Time, each of
Public Company and Merger Partner shall promptly provide the other party with copies of: (a)&nbsp;unaudited monthly financial statements or management accounts, when available; (b)&nbsp;any written materials or communications sent by or on behalf of
such party to its stockholders; (c)&nbsp;any notice, report or other document filed with or sent to, or received from, any Governmental Entity in connection with the Merger or any of the other transactions contemplated by this Agreement; and
(d)&nbsp;any material notice, report or other document received from any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Stockholder Approval</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Not later than the second Business Day after the Registration Statement is declared effective under the Securities Act (but in no event
before (1)&nbsp;the information statement contained in the Proxy Statement/Prospectus shall have been delivered to Merger Partner&#146;s stockholders and (2)&nbsp;the Registration Statement shall have been declared effective), Merger Partner shall
solicit and obtain the Merger Partner Stockholder Approval by the Written Consents (in a form reasonably acceptable to Public Company) to be executed and delivered by Merger Partner&#146;s stockholders for the purposes of (i)&nbsp;evidencing the
adoption of this Agreement and the approval of the Merger and the other transactions contemplated hereby, (ii)&nbsp;acknowledging that the approval given thereby </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&nbsp;262 of the DGCL, a copy of which was attached to the Written Consent,
and that such stockholder has received and read a copy of Section&nbsp;262 of the DGCL and (iii)&nbsp;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger
and thereby waives any rights to receive payment in cash of the fair value of its Merger Partner Capital Stock under Section&nbsp;262 the DGCL. In connection with the Merger Partner Stockholder Approval, Merger Partner shall comply with all
disclosure and other obligations to its stockholders under the DGCL and any other applicable laws. Merger Partner shall take all action that is both reasonable and lawful to obtain the Merger Partner Stockholder Approval, subject to compliance with
<U>Section</U><U></U><U>&nbsp;6.1(b)</U>. Without limiting the generality of the foregoing, Merger Partner agrees that its obligations under this <U>Section</U><U></U><U>&nbsp;6.5(a)</U> shall not be affected by the commencement, public proposal,
public disclosure or communication to Merger Partner of any Acquisition Proposal or a Merger Partner Board Recommendation Change. Any solicitation or similar disclosure circulated to Merger Partner&#146;s stockholders in connection with this
Agreement and the Merger shall be in form and substance reasonably satisfactory to Public Company and, except in the case of a Merger Partner Board Recommendation Change, any solicitation or similar disclosure, if the Merger Partner Stockholder
Approval has not already been obtained, shall include the recommendation of Merger Partner Board that Merger Partner&#146;s stockholders consent to the adoption of this Agreement and approval of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company, acting through the Public Company Board, shall take all actions in accordance with applicable law, its certificate of
incorporation and bylaws and Nasdaq rules to duly call, give notice of, convene and hold as promptly as practicable, after the declaration of effectiveness of the Registration Statement, the Public Company Stockholders Meeting for the purpose of
considering and voting upon the Public Company Voting Proposals. Subject to <U>Section</U><U></U><U>&nbsp;6.1(b)</U>, the Public Company Board shall include in the Proxy Statement/Prospectus the recommendation of the Public Company Board in favor of
approval of the Public Company Voting Proposals. Subject to <U>Section</U><U></U><U>&nbsp;6.1(b)</U>, Public Company shall take all action that is both reasonable and lawful to solicit from its stockholders proxies in favor of the Public Company
Voting Proposals. The Public Company Meeting shall be held as promptly as practicable after the effective date of the Registration Statement (on a date selected by Public Company in consultation with Merger Partner) but in no event later than
forty-five (45)&nbsp;days after the effective date of the Registration Statement. If sufficient votes to obtain the Public Company Voting Proposals have not been obtained as of the close of business on the Business Day prior to the scheduled date of
the Public Company Meeting, Public Company shall have the right to adjourn or postpone the Public Company Meeting to a later date or dates, such later date or dates not to exceed thirty (30)&nbsp;days in the aggregate from the original date that the
Public Company Meeting was scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Unless the Public Company Board has effected a Public Company Board Recommendation Change in
accordance with <U>Section</U><U></U><U>&nbsp;6.1</U> and terminated this Agreement to enter into a definitive agreement with respect to a Superior Proposal pursuant to <U>Section</U><U></U><U>&nbsp;8.1</U>, Public Company&#146;s obligation to call,
give notice of and hold the Public Company Meeting in accordance with <U>Section</U><U></U><U>&nbsp;6.5(b)</U> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Acquisition Proposal, or by
any Public Company Board Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except in the case of a Public Company Board Recommendation Change made in compliance
with <U>Section</U><U></U><U>&nbsp;6.1</U>, Public Company agrees that the Public Company Board shall recommend that the Public Company Stockholders approve the Public Company Voting Proposals and Public Company shall include such recommendation in
the Proxy Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except in the case of a Public Company Board Recommendation Change made in compliance with
<U>Section</U><U></U><U>&nbsp;6.1</U>, Public Company shall use its reasonable best efforts to solicit from the Public Company Stockholders proxies in favor of the Public Company Voting Proposals and shall take all other action necessary or
advisable to secure the approvals of the stockholders of Public Company. Public Company shall ensure that all proxies solicited in connection with the Public Company Meeting are solicited in material compliance with all applicable laws. Public
Company, in its capacity as the sole stockholder of Merger Sub, shall approve the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding the foregoing, nothing herein shall limit a party&#146;s right to
terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Legal Conditions to Merger</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms hereof, Merger Partner and Public Company shall each use reasonable best efforts to (i)&nbsp;take, or cause to be
taken, all actions, and do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective the transactions contemplated hereby as promptly as practicable,
(ii)&nbsp;as promptly as practicable, obtain from any Governmental Entity or any other third party any consents, licenses, permits, waivers, approvals, authorizations, or orders required to be obtained or made by Merger Partner or Public Company or
any of their Subsidiaries in connection with the authorization, execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, (iii)&nbsp;as promptly as practicable, make all necessary filings, and thereafter
make any other required submissions, with respect to this Agreement and the Merger required under (A)&nbsp;the Securities Act and the Exchange Act, and any other applicable federal or state securities laws, and (B)&nbsp;any other applicable law and
(iv)&nbsp;execute or deliver any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement. Merger Partner and Public Company shall reasonably cooperate with each other in
connection with the making of all such filings. Merger Partner and Public Company shall use their respective commercially reasonable efforts to furnish to each other all information required for any application or other filing to be made pursuant to
the rules and regulations of any applicable Law (including all information required to be included in the Proxy Statement/Prospectus and the Registration Statement) in connection with the transactions contemplated by this Agreement. Without limiting
the foregoing, Merger Partner shall take all actions within its reasonable control to cause (x)&nbsp;the conditions in Section&nbsp;2 of the Funding Agreements to be satisfied or waived as promptly as practicable after the date hereof and
(y)&nbsp;the Financing to be completed as promptly as practicable after the satisfaction or waiver of such conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Merger
Partner and Public Company shall give (or shall cause their respective Subsidiaries to give) any notices to third parties, and use, and cause their respective Subsidiaries to use, their reasonable best efforts to obtain any third party consents
related to or required in connection with the Merger that are (i)&nbsp;necessary to consummate the transactions contemplated hereby, (ii)&nbsp;disclosed or required to be disclosed in the Merger Partner Disclosure Schedule or the Public Company
Disclosure Schedule, as the case may be, or (iii)&nbsp;required to prevent the occurrence of an event that may have a Merger Partner Material Adverse Effect or a Public Company Material Adverse Effect from occurring prior to or after the Effective
Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Public Disclosure</U>. (i)&nbsp;The press release announcing the execution of this Agreement shall be issued only in such
form as shall be mutually agreed upon by Public Company and Merger Partner, and (ii)&nbsp;each party shall use commercially reasonable efforts to consult with the other party before issuing any press release or otherwise making any public statement
with respect to the Merger or this Agreement and shall not issue any such press release or make any such public statement prior to using such efforts (<U>provided</U>, <U>however</U>, that these restrictions shall not apply to any communications by
either party with respect to any Acquisition Proposal, Superior Proposal, Recommendation Change Notice or Board Recommendation Change). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Section</U><U></U><U>&nbsp;368(a) Reorganization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Public Company, Merger Sub and Merger Partner shall use commercially reasonable efforts to cause the Merger to qualify, and agree
not to, and not to permit or cause any of their Affiliates or Subsidiaries to, take any action or cause any action to be taken which could reasonably be expected to prevent or impede the Merger from qualifying, as a &#147;reorganization&#148; within
the meaning of Section&nbsp;368(a) of the Code. This Agreement is intended to constitute, and the parties hereto hereby adopt this Agreement as, a &#147;plan of reorganization&#148; within the meaning of Treasury Regulation Sections <FONT
STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> Each of Public Company, Merger Sub and Merger Partner shall report the Merger as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Code unless otherwise required pursuant to a &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code, including attaching the statement described in Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-3(a)</FONT> on or with its Tax Return for the taxable year of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If, in
connection with the preparation and filing of the Proxy Statement/Prospectus, the SEC requires that tax opinions be prepared and submitted with respect to the treatment of the Merger as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368(a) of the Code, Public Company and Merger Partner shall use commercially reasonable efforts to deliver to Wilmer Cutler Pickering Hale and Dorr LLP and Sidley Austin LLP, respectively, customary Tax representation letters reasonably
satisfactory to such counsel, dated and executed as of the date the Proxy Statement/Prospectus shall have been declared effective by the SEC or such other date(s) as determined reasonably necessary by such counsel in connection with the preparation
and filing of the Proxy Statement/Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Affiliate Legends</U>. <U>Section</U><U></U><U>&nbsp;6.9</U> of the Merger Partner
Disclosure Schedule sets forth a list of those persons who are, in Merger Partner&#146;s reasonable judgment, &#147;affiliates&#148; of Merger Partner within the meaning of Rule 145 promulgated under the Securities Act (&#147;<U>Rule 145
Affiliates</U>&#148;). Merger Partner shall notify Public Company in writing regarding any change in the identity of its Rule 145 Affiliates prior to the Closing Date. Public Company shall be entitled to place appropriate legends on the certificates
evidencing any shares of Public Company Common Stock to be received by Rule 145 Affiliates of Merger Partner in the Merger reflecting the restrictions set forth in Rule 145 promulgated under the Securities Act and to issue appropriate stop transfer
instructions to the transfer agent for Public Company Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Public Company and the
Surviving Corporation shall, jointly and severally, indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Merger Partner, Public
Company or any of their respective Subsidiaries (the &#147;<U>Indemnified</U> <U>Persons</U>&#148;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146; fees and
disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the Indemnified Person is or was an officer,
director, employee or agent of Merger Partner, Public Company or any of their respective Subsidiaries, or, while a director or officer of Merger Partner, Public Company or any of their respective Subsidiaries, is or was serving at the request of
Merger Partner, Public Company or any of their respective Subsidiaries as a director, officer, employee or agent of another person, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted by applicable
law. Each Indemnified Person will be entitled to advancement of expenses (including attorneys&#146; fees) incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Public Company and the Surviving Corporation
following receipt by Public Company or the Surviving Corporation from the Indemnified Party of a request therefor; <U>provided</U> that any person to whom expenses are advanced provides an undertaking, to the extent then required by the DGCL, to
repay such advances if it is ultimately determined that such person is not entitled to indemnification. From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, the certificate of incorporation and bylaws
of the Surviving Corporation will contain provisions at least as favorable as the provisions relating to the indemnification, advance of expenses and elimination of liability for monetary damages set forth in the certificate of incorporation and
bylaws of Merger Partner and Public Company immediately prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to the Effective Time, Public Company
shall purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> prepaid &#147;D&amp;O tail policy&#148; (the &#147;<U>Public Company Tail Policy</U>&#148;) for the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> extension of the
directors&#146; and officers&#146; liability coverage of Public Company&#146;s existing directors&#146; and officers&#146; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with
respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, retentions and limits of liability that are no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
less favorable than the coverage provided under Public Company&#146;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading
statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Public Company by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in
connection with this Agreement or the Merger). The cost of the Public Company Tail Policy shall be included in the Public Company&#146;s Transaction Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to the Effective Time, Merger Partner shall purchase a <FONT STYLE="white-space:nowrap">six-year</FONT> prepaid &#147;D&amp;O tail
policy&#148; (the &#147;<U>Merger Partner Tail Policy</U>&#148;) for the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> extension of the directors&#146; and officers&#146; liability coverage of Merger Partner&#146;s existing directors&#146;
and officers&#146; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms,
conditions, retentions and limits of liability that are no less favorable than the coverage provided under Merger Partner&#146;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading
statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Merger Partner by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in
connection with this Agreement or the Merger). The cost of the Merger Partner Tail Policy shall be included in the Merger Partner&#146;s Transaction Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company shall pay all expenses, including reasonable attorneys&#146; fees, that may be incurred by a person in successfully
enforcing such person&#146;s rights provided in this <U>Section</U><U></U><U>&nbsp;6.10.</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Public Company and Merger Partner agree
that all rights to exculpation, indemnification and advancement of expenses for acts or omissions occurring at or prior to the Effective Time, whether asserted or claimed prior to, at or after the Effective Time, now existing in favor of the current
or former directors, officers or employees, as the case may be, of Public Company, Merger Partner or any of their respective Subsidiaries as provided in their respective certificates of incorporation or bylaws or other organization documents or in
any agreement in existence immediately prior to the Effective Time shall survive the Merger and shall continue in full force and effect. The provisions of this <U>Section</U><U></U><U>&nbsp;6.10</U> are intended to be in addition to the rights
otherwise available to the current officers and directors of Public Company, Merger Partner or any of their respective Subsidiaries by law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each
of the Indemnified Persons, their heirs and their representatives. The obligations set forth in this <U>Section</U><U></U><U>&nbsp;6.10</U> shall not be terminated, amended or otherwise modified in any manner that adversely affects any Indemnified
Person, or any person who is a beneficiary under the policies referred to in this <U>Section</U><U></U><U>&nbsp;6.10</U> and their heirs and representatives, without the prior written consent of such affected Indemnified Person or other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If the Surviving Corporation or Public Company or any of their respective successors or assigns shall (i)&nbsp;consolidate with or merge
into any other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfer all or substantially all of its properties and assets to any person, then, and in each such case, proper
provisions shall be made so that the successors and assigns of such person shall assume all of the obligations of such person set forth in this <U>Section</U><U></U><U>&nbsp;6.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Nothing in this Agreement is intended to, shall be construed to or shall release, waive or impair any rights to directors&#146; and
officers&#146; insurance claims under any policy that is or has been in existence with respect to Merger Partner, Public Company or any of their respective Subsidiaries for any of their respective directors, officers or other employees, it being
understood and agreed that the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;6.10</U> is not prior to or in substitution for any such claims under such policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Notification of Certain Matters</U>. Public Company shall give prompt notice to Merger Partner, and Merger Partner shall give prompt
notice to Public Company, upon becoming aware of the occurrence, or failure to occur, of any event, which occurrence or failure to occur would be reasonably likely to cause (a)&nbsp;(i) any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representation or warranty of such party contained in this Agreement that is qualified as to materiality to be untrue or inaccurate in any respect or (ii)&nbsp;any other representation or
warranty of such party contained in this Agreement to be untrue or inaccurate in any material respect, in each case, at any time from and after the date of this Agreement until the Effective Time, or (b)&nbsp;any material failure of Public Company
and Merger Sub or Merger Partner, as the case may be, or of any officer, director, employee or agent thereof, to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Employee Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company and Merger Partner will consult with each other, and will consider in good faith each other&#146;s advice, prior to sending
any notices or other communication materials to its employees regarding this Agreement, the Merger or the effects thereof on the employment, compensation or benefits of its employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner shall make available group health plan coverage satisfying the requirements of COBRA to any employee or former employee of
Public Company (and their respective dependents) whose &#147;qualifying event&#148; (within the meaning of COBRA) occurred prior to or in connection with the Merger, and Merger Partner shall otherwise discharge and be responsible for all liabilities
related to COBRA. With respect to any current employee of Public Company, Merger Partner and Merger Partner&#146;s group health plans shall treat the termination of employment in connection with the Merger as involuntary for purposes of the
applicable provisions of the American Rescue Plan Act of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner and Public Company agree that the Merger shall
constitute or be deemed to constitute a &#147;change of control&#148; or &#147;change in control&#148; for purposes of the Public Company Stock Plans and any awards issued thereunder and for purposes of any Employee Benefit Plan maintained for
current or former employees or directors of or independent contractors to the Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Merger Partner shall cause each
promissory note set forth in Section&nbsp;3.11(d)(i) of the Merger Partner Disclosure Schedule to be settled and terminated in full prior to Closing to the extent necessary for Public Company to comply with applicable Law as of and following the
Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>FIRPTA Tax Certificates</U>. On or prior to the Closing, Merger Partner shall deliver to Public Company a
properly executed certification that shares of Merger Partner Capital Stock are not &#147;U.S. real property interests&#148; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS
(which shall be filed by Public Company with the IRS following the Closing) in accordance with the provisions of <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2)</FONT> of the Treasury Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14 <U>State Takeover Laws</U>. If any &#147;fair price,&#148; &#147;business combination&#148; or &#147;control share acquisition&#148;
statute or other similar statute or regulation is or may become applicable to any of the transactions contemplated by this Agreement, the parties hereto shall use their respective commercially reasonable efforts to (a)&nbsp;take such actions as are
reasonably necessary so that the transactions contemplated hereunder may be consummated as promptly as practicable on the terms contemplated hereby and (b)&nbsp;otherwise take all such actions as are reasonably necessary to eliminate or minimize the
effects of any such statute or regulation on such transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15 <U>Security Holder Litigation</U>. Notwithstanding anything to the
contrary herein, (a)&nbsp;Public Company shall have the right to control the defense and settlement of any litigation related to this Agreement, the Merger or the other transactions contemplated by this Agreement brought by any stockholder or any
holder of other securities of Public Company against Public Company and/or its directors or officers, provided that Public Company shall give Merger Partner the opportunity to participate in the defense of any such litigation and shall not settle
any such litigation (other than any settlement not requiring the payment of any amount to any third party in excess of the retentions or deductibles under any applicable insurance policies of Public Company) without the prior written consent of
Merger Partner (which consent shall not be unreasonably withheld, conditioned or delayed), and (b)&nbsp;Merger Partner shall have the right to control the defense and settlement of any litigation related to this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, the Merger or the other transactions contemplated by this Agreement brought by any stockholder or any holder of other securities of Merger Partner against Merger Partner and/or its
directors or officers, provided that Merger Partner shall give Public Company the opportunity to participate in the defense of any such litigation and shall not settle any such litigation (other than any settlement not requiring the payment of any
amount to any third party in excess of the retentions or deductibles under any applicable insurance policies of Merger Partner) without the prior written consent of Public Company (which consent shall not be unreasonably withheld, conditioned or
delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.16 <U>Section</U><U></U><U>&nbsp;16 Matters</U>. Prior to the Effective Time, Public Company shall take all such steps as may
be required to cause any acquisitions of Public Company Common Stock (and any options to purchase the same) in connection with this Agreement and the transactions contemplated hereby, by each individual who is reasonably expected to become subject
to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to Public Company following the Merger, to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.17 <U>Calculation of Public Company Net Cash</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Not less than five (but no more than seven (7)) calendar days prior to the anticipated date for Closing (the &#147;<U>Anticipated Closing
Date</U>&#148;), Public Company will deliver to Merger Partner a schedule (the &#147;<U>Public Company Net Cash Schedule</U>&#148;) setting forth, in reasonable detail, Public Company&#146;s good faith, estimated calculation of its Net Cash
(&#147;<U>Public</U> <U>Company Net Cash</U>&#148;) prepared and certified by Public Company&#146;s Chief Financial Officer (or if there is no Chief Financial Officer, the Chief Executive Officer of Public Company). Public Company shall make
available to Merger Partner, as requested by Merger Partner, the work papers and <FONT STYLE="white-space:nowrap">back-up</FONT> materials used or useful in preparing the Public Company Net Cash Schedule and, if requested by Merger Partner, Public
Company&#146;s accountants and counsel at reasonable times and upon reasonable notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On the fourth (4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) calendar day following Public Company&#146;s delivery of the Public Company Net Cash Schedule pursuant to <U>Section</U><U></U><U>&nbsp;6.17(a)</U>, such Public Company Net Cash Schedule shall
become final and binding on all parties to this agreement unless on or prior to the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) calendar day following such delivery Merger Partner disputes such Public Company Net Cash Schedule
by delivering a written notice to Public Company describing in reasonable detail each item in dispute and Merger Partner&#146;s proposed revisions to such Public Company Net Cash Schedule (a &#147;<U>Dispute Notice</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If representatives of Public Company and Merger Partner are unable to negotiate an agreed-upon determination of any items timely disputed
in a Dispute Notice within three (3)&nbsp;days after delivery of such Dispute Notice, then any such disputed items shall be referred to an independent auditor of recognized national standing jointly selected by Public Company and Merger Partner
which is not serving as auditor of either Public Company or Merger Partner (the &#147;<U>Accounting Firm</U>&#148;). Public Company shall promptly deliver to the Accounting Firm the work papers and <FONT STYLE="white-space:nowrap">back-up</FONT>
materials used in preparing the Public Company Net Cash Schedule, and Public Company and Merger Partner shall use reasonable best efforts to cause the Accounting Firm to make its determination within ten (10)&nbsp;calendar days of accepting its
selection. Merger Partner and Public Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; <U>provided</U>, <U>however</U>,
that no such presentation or discussion shall occur without the presence of a representative of each of Merger Partner and Public Company. The determination of the Accounting Firm shall be limited to the items in dispute submitted to the Accounting
Firm. Any determination of Public Company Net Cash made by the Accounting Firm shall be made in writing delivered to each of Public Company and Merger Partner, shall be final and binding on the parties hereto and shall be deemed to have been finally
determined for purposes of this Agreement and to represent the Public Company Net Cash for all purposes of this Agreement. The parties shall delay the Closing until the resolution of the matters described in this
<U>Section</U><U></U><U>&nbsp;6.17(c)</U>. The fees and expenses of the Accounting Firm shall be allocated between Public Company and Merger Partner in the same proportion that the disputed amount of Public Company Net Cash that was unsuccessfully
disputed by such party (as finally determined by the Accounting Firm) bears to the total disputed amount of Public Company Net Cash. If this <U>Section</U><U></U><U>&nbsp;6.17(c)</U> applies as to the determination of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Company Net Cash, upon resolution of the matter in accordance with this <U>Section</U><U></U><U>&nbsp;6.17(c)</U>, the parties shall not be required to determine Public Company Net Cash
again even though the Closing Date may occur later than the Anticipated Closing Date, except that either Public Company or Merger Partner may request a redetermination of Public Company Net Cash if the Closing Date is more than fifteen
(15)&nbsp;calendar days after the Anticipated Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Cash Determination Time</U>&#148; means the close of business as of the Business Day immediately prior to the Anticipated
Closing Date; provided, however, that, notwithstanding the foregoing or anything else to the contrary herein, if the Closing Date shall not have occurred on or prior to July&nbsp;1, 2021 (other than solely as a result of a material breach by Public
Company of its obligations under this Agreement), the Cash Determination Time for purposes of determining Public Company Net Cash shall be the close of business as of June&nbsp;30, 2021.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Indebtedness</U>&#148; shall mean, with respect to any person, any liabilities of such person or its Subsidiaries (A)&nbsp;for
borrowed money, (B)&nbsp;evidenced by bonds, debentures, notes or similar instruments, (C)&nbsp;upon which interest charges are customarily paid (other than obligations accepted in connection with the purchase of products or services in the ordinary
course of business), (D) in respect of liabilities of others that are secured by (or which the holder of such liabilities has an existing right, contingent or otherwise, to be secured by) any Lien or security interest on property owned or acquired
by the person in question whether or not the obligations secured thereby have been assumed, (E)&nbsp;under leases required to be accounted for as capital leases under GAAP (but excluding for the avoidance of doubt obligations under the Public
Company Leases), (F) for any &#147;applicable employment taxes&#148; (as defined in Section 2302(d)(1) of the CARES Act) elected to be deferred pursuant to Section&nbsp;2302 of the CARES Act, or (G)&nbsp;guarantees relating to any such
liabilities.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Net Cash</U>&#148; shall mean, with respect to Public Company as of the Cash Determination Time and
without duplication, (A)&nbsp;the sum of (1)&nbsp;the cash, cash equivalents, restricted cash and marketable securities of such person and its Subsidiaries, (2)&nbsp;accounts receivable, interest and other receivables (including amounts payable to
Public Company under insurance policies), and (3)&nbsp;deposits and prepaid expenses of such person and its Subsidiaries, <I>minus</I> (B)&nbsp;the sum of (1)&nbsp;accrued and unpaid accounts payable and accrued and unpaid expenses of such person
and its Subsidiaries (other than Transaction Expenses and rent), (2) any unpaid Transaction Expenses of such person or its Subsidiaries, (3)&nbsp;unpaid Indebtedness of such person and its Subsidiaries and (4)&nbsp;unpaid rent (if any) to the extent
owed by Public Company under Public Company&#146;s real estate lease, net of any right to receive rent from a third party under any sublease or similar arrangement, for the period prior to March&nbsp;31, 2022 in an amount not to exceed $576,000.
Each component of Public Company Net Cash shall be determined in accordance with GAAP applied on a basis consistent with the application of GAAP in the preparation of such person&#146;s most recent audited financial statements (except as otherwise
provided in <U>Annex B</U>). For purposes of determining Public Company Net Cash, the Surviving Corporation and its Subsidiaries shall not constitute Subsidiaries of Public Company and Public Company Net Cash shall be calculated excluding the
effects of any payments or liabilities (including attorney&#146;s fees and settlement costs) in respect of Dissenting Shares or any security holder litigation by any actual or purported holder of securities of Public Company. A sample calculation of
Public Company Net Cash and its components is set forth in <U>Annex B</U> for illustrative purposes only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Transaction
Expenses</U>&#148; shall mean, with respect to any person as of the Cash Determination Time and without duplication, the sum of (A)&nbsp;the cash cost of any change of control, bonus, severance (voluntary or otherwise) (including a reasonable
estimate of payment or reimbursement for continued coverage under any employee benefit plan), retention or similar payments (whether &#147;single trigger&#148; or &#147;double trigger&#148;) that become due and payable by such person or any of its
Subsidiaries at or prior to the Effective Time or as a result of the Merger or the transactions contemplated hereby, and (B)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;8.3(a)</U>, all costs, fees and expenses incurred by such person or its
Subsidiaries at or prior to the Effective Time in connection with the negotiation, preparation and execution of this Agreement or any agreements, documents, certificates, opinions or other items </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby and the consummation of the Merger or the other transactions contemplated hereby and that are unpaid as of the Effective Time, including brokerage fees and commissions,
finders&#146; fees or financial advisory fees payable by such person at or prior to the Effective Time. <I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.18 <U>Public Company
Stock Options</U>. Prior to the Closing, the Public Company Board shall have the right, in its sole discretion, to adopt appropriate resolutions and take all other actions necessary and appropriate to provide that each Public Company Stock Option,
whether vested or unvested, be accelerated in full effective as of immediately prior to the Effective Time. At the Effective Time, each Public Company Stock Option that is outstanding and unexercised immediately prior to the Effective Time, whether
or not vested, shall survive the Closing and remain outstanding in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.19 <U>401(k) Plan</U>. Unless otherwise
requested by Merger Partner in writing at least five business days prior to the Closing Date, the Public Company Board shall take (or cause to be taken) all actions to adopt such resolutions as may be necessary or appropriate to terminate, effective
no later than the day prior to the Closing Date, any Public Company Employee Plan that contains a cash or deferred arrangement intended to qualify under Section&nbsp;401(k) of the Code (a &#147;<U>Public Company 401(k) Plan</U>&#148;). If Public
Company is required to terminate any Public Company 401(k) Plan, then Public Company shall provide to Merger Partner prior to the Closing Date written evidence of the adoption by the Public Company Board of resolutions authorizing the termination of
such Public Company 401(k) Plan (the form and substance of which shall be subject to the prior review and approval of Merger Partner). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDITIONS TO MERGER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Conditions to Each Party&#146;s Obligation To Effect the Merger</U>. The respective obligations of each party to this Agreement to
effect the Merger shall be subject to the satisfaction prior to the Closing Date of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stockholder
Approvals</U>. The Merger Partner Voting Proposal shall have been approved by means of the Written Consents by the requisite vote of the stockholders of Merger Partner under applicable Law and Merger Partner&#146;s certificate of incorporation. The
Public Company Voting Proposals shall have been approved at the Public Company Meeting, at which a quorum is present, by the requisite vote of the stockholders of Public Company under applicable Law and stock market regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Governmental Approvals</U>. Other than the filing of the Certificate of Merger, all authorizations, consents, orders or approvals of,
or declarations or filings with, or expirations of waiting periods imposed by, any Governmental Entity in connection with the Merger and the consummation of the other transactions contemplated by this Agreement, the failure of which to file, obtain
or occur is reasonably likely to have a Public Company Material Adverse Effect or a Merger Partner Material Adverse Effect, shall have been filed, been obtained or occurred on terms and conditions that would not reasonably be likely to have a Public
Company Material Adverse Effect or a Merger Partner Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Registration Statement; Proxy
Statement/Prospectus</U>. The Registration Statement shall have become effective under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceeding for that purpose, and no
similar proceeding with respect to the Proxy Statement/Prospectus, shall have been initiated or threatened in writing by the SEC or its staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Injunctions</U>. No Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any
order, executive order, stay, decree, judgment or injunction (preliminary or permanent) or statute, rule or regulation which is in effect and which has the effect of making the Merger illegal or otherwise prohibiting consummation of the Merger. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Nasdaq Notification</U>. (i)&nbsp;The Nasdaq Listing Application shall have been
approved, and (ii)&nbsp;the shares of the Public Company Common Stock to be issued pursuant to the Share Issuance shall have been approved for listing (subject to official notice of issuance) on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Net Cash</U>. Public Company Net Cash shall have been finally determined in accordance with <U>Section</U><U></U><U>&nbsp;6.17</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Additional Conditions to the Obligations of Public Company and Merger Sub</U>. The obligations of Public Company and Merger Sub to
effect the Merger shall be subject to the satisfaction on or prior to the Closing Date of each of the following additional conditions, any of which may be waived in writing exclusively by Public Company and Merger Sub: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of Merger Partner set forth in this Agreement and in any
certificate or other writing delivered by Merger Partner pursuant hereto shall be true and correct (i)&nbsp;as of the date of this Agreement (except in the case of this clause (i), (A) to the extent such representations and warranties are
specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date and (B)&nbsp;where the failure to be true and correct (without regard to any materiality or Merger Partner
Material Adverse Effect qualifications contained therein), individually or in the aggregate, has not had, and is not reasonably likely to have, a Merger Partner Material Adverse Effect) and (ii)&nbsp;as of the Closing Date as though made on and as
of the Closing Date (except in the case of this clause (ii), (A) to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such
date, (B)&nbsp;for changes expressly provided for in this Agreement and (C)&nbsp;where the failure to be true and correct (without regard to any materiality or Merger Partner Material Adverse Effect qualifications contained therein), individually or
in the aggregate, has not had, and is not reasonably likely to have, a Merger Partner Material Adverse Effect); <U>provided</U>, <U>however</U>, that the representations and warranties made by Merger Partner in <U>Sections 3.1</U>, <U>3.2</U>,
<U>3.4(a)</U>, <U>3.4(d)</U> and <U>3.7(i)</U> shall not be subject to the qualifications set forth in clauses (i)(B) and (ii)(C) above; <U>provided</U>, <U>further</U>, that the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.2(a)</U> shall be true and correct except for such inaccuracies as are in the aggregate <U>de minimis</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of Merger Partner</U>. Merger Partner shall have performed in all material respects all obligations required
to be performed by it under this Agreement on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Merger Partner Material Adverse Effect</U>. No
Merger Partner Material Adverse Effect shall have occurred since the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Third Party Consents</U>. Merger
Partner shall have obtained (i)&nbsp;all consents and approvals of third parties listed in <U>Section</U><U></U><U>&nbsp;7.2(d)(i)</U> of the Merger Partner Disclosure Schedule and (ii)&nbsp;any other required consent or approval of any third party
(other than a Governmental Entity) the failure of which to obtain, individually or in the aggregate, is reasonably likely to have a Merger Partner Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Resignations</U>. Public Company shall have received copies of the resignations, effective as of the Effective Time, of each director
of Merger Partner and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Dissenting Shares</U>. The number of Dissenting Shares shall not exceed 5% of the number
of outstanding shares of Merger Partner Common Stock as of the Effective Time (after giving effect to Merger Partner Preferred Stock Conversion). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Financing</U>. Each of the Funding Agreements shall be in full force and effect and the Financing shall have been completed in
accordance with the terms thereof and Merger Partner shall have received the proceeds therefrom; provided, that for the avoidance of doubt, it shall not be a condition to closing that any Excess Financing Shares be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Merger Partner Preferred Stock Conversion</U>. Merger Partner shall have effected a
conversion of all Merger Partner Preferred Stock into Merger Partner Common Stock as of immediately prior to the Effective Time (the &#147;<U>Merger Partner Preferred Stock</U> <U>Conversion</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Termination of Investor Agreements</U>. The agreements listed in <U>Section</U><U>&nbsp;7.2(i)</U> of the Merger Partner Disclosure
Letter shall have been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Officers&#146; Certificate</U>. Public Company shall have received an officers&#146;
certificate duly executed by each of the Chief Executive Officer and Chief Financial Officer of Merger Partner to the effect that the conditions of <U>Sections 7.2(a)</U>, <U>(b)</U> and <U>(c)</U>&nbsp;have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Additional Conditions to the Obligations of Merger Partner</U>. The obligation of Merger Partner to effect the Merger shall be subject
to the satisfaction on or prior to the Closing Date of each of the following additional conditions, any of which may be waived, in writing, exclusively by Merger Partner: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. The representations and warranties of Public Company and Merger Sub set forth in this Agreement and
in any certificate or other writing delivered by Public Company or Merger Sub pursuant hereto shall be true and correct (i)&nbsp;as of the date of this Agreement (except in the case of this clause (i), (A) to the extent such representations and
warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date and (B)&nbsp;where the failure to be true and correct (without regard to any materiality or Public
Company Material Adverse Effect qualifications contained therein), individually or in the aggregate, has not had, and is not reasonably likely to have, a Public Company Material Adverse Effect) and (ii)&nbsp;as of the Closing Date as though made on
and as of the Closing Date (except in the case of this clause (ii), (A) to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as
of such date, (B)&nbsp;for changes contemplated by this Agreement and (C)&nbsp;where the failure to be true and correct (without regard to any materiality or Public Company Material Adverse Effect qualifications contained therein), individually or
in the aggregate, has not had, and is not reasonably likely to have, a Public Company Material Adverse Effect); <U>provided</U>, <U>however</U>,<I> </I>that the representations and warranties made by Public Company and Merger Sub in
<U>Sections&nbsp;4.1</U>, <U>4.2</U>, <U>4.4(a)</U>, <U>4.4(d)</U> and <U>4.7(i)</U> shall not be subject to the qualifications set forth in clauses (i)(B) and (ii)(C) above; <U>provided</U>, <U>further</U>, that the representations and warranties
set forth in <U>Section</U><U></U><U>&nbsp;4.2(a)</U> shall be true and correct except for such inaccuracies as are in the aggregate <U>de minimis</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance of Obligations of Public Company and Merger Sub</U>. Public Company and Merger Sub shall have performed in all material
respects all obligations required to be performed by them under this Agreement on or prior to the Closing Date; <U>provided</U>, <U>that</U> Public Company shall have performed the obligations in <U>Section</U><U></U><U>&nbsp;5.4</U> in all
respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Public Company Material Adverse Effect</U>. No Public Company Material Adverse Effect shall have occurred since the
date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Third Party Consents</U>. Public Company shall have obtained (i)&nbsp;all consents and approvals of third
parties listed in <U>Section</U><U></U><U>&nbsp;7.3(d)(i)</U> of the Public Company Disclosure Schedule and (ii)&nbsp;any other consent or approval of any third party (other than a Governmental Entity) the failure of which to obtain, individually or
in the aggregate, is reasonably likely to have a Public Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Officers&#146; Certificate</U>. Merger
Partner shall have received an officers&#146; certificate duly executed by each of the Chief Executive Officer and Chief Financial Officer of Public Company to the effect that the conditions of <U>Sections 7.3(a)</U>, <U>(b)</U>, and
<U>(c)</U>&nbsp;have been satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERMINATION AND AMENDMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Termination</U>. This Agreement may be terminated at any time prior to the Effective Time (with respect to <U>Sections 8.1(b)
</U>through<U> 8.1(k)</U>, by written notice by the terminating party to the other party), whether before or, subject to the terms hereof, after approval of the Merger Partner Voting Proposal by the stockholders of Merger Partner or approval of the
Public Company Voting Proposals by the stockholders of Public Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Public Company and Merger
Partner; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by either Public Company or Merger Partner if the Merger shall not have been consummated by September&nbsp;30, 2021 (the
&#147;<U>Outside Date</U>&#148;) (provided that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;8.1(b)</U> shall not be available to any party whose failure to fulfill any obligation under this Agreement has been a
principal cause of or resulted in the failure of the Merger to occur on or before the Outside Date); provided, that, if as of such date all conditions set forth in Article VII (other than the condition set forth in
<U>Section</U><U></U><U>&nbsp;7.1(f)</U>) have been satisfied or waived, the Outside Date shall automatically be extended until the date that is two (2)&nbsp;Business Days following the final determination of Public Company Net Cash in accordance
with <U>Section</U><U></U><U>&nbsp;6.17</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by either Public Company or Merger Partner if a Governmental Entity of competent
jurisdiction shall have issued a nonappealable final order, decree or ruling or taken any other nonappealable final action, in each case having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger; <U>provided</U>,
<U>however</U>, that a party hereto shall not be permitted to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;8.1(c)</U> if the issuance of any such order, decree, ruling or other action is attributable to the failure of such
party (or any Affiliate of such party) to perform in any material respect any covenant in this Agreement required to be performed by such party (or any Affiliate of such party) at or prior to the Effective Time; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by either Public Company or Merger Partner if at the Public Company Meeting (including any adjournment or postponement), at which a vote
on the Public Company Voting Proposals is taken, the requisite vote of the stockholders of Public Company in favor of the Public Company Voting Proposals shall not have been obtained; provided, however, that the right to terminate this Agreement
under this <U>Section</U><U></U><U>&nbsp;8.1(d)</U> shall not be available to Public Company where the failure to obtain the requisite vote of the stockholders of Public Company shall have been caused by the action or failure to act of Public
Company and such action or failure to act constitutes a material and willful breach by Public Company of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by Public
Company, if at any time prior to the receipt of the Merger Partner Stockholder Approval: (i)&nbsp;the Merger Partner Board shall have failed to give its recommendation to the approval of the Merger Partner Voting Proposal or shall have withdrawn or
modified in a manner adverse to Public Company its recommendation of the Merger Partner Voting Proposal; (ii)&nbsp;after the receipt by Merger Partner of an Acquisition Proposal, Public Company requests in writing that Merger Partner Board reconfirm
its recommendation of this Agreement or the Merger and Merger Partner Board fails to do so within ten Business Days after its receipt of Public Company&#146;s request; (iii)&nbsp;the Merger Partner Board (or any committee thereof) shall have
approved or recommended to the stockholders of Merger Partner an Acquisition Proposal; (iv)&nbsp;a tender offer or exchange offer for outstanding shares of Merger Partner Capital Stock is commenced (other than by Public Company or an Affiliate of
Public Company), and Merger Partner Board (or any committee thereof) recommends that the stockholders of Merger Partner tender their shares in such tender or exchange offer or, within ten Business Days after the commencement of such tender offer or
exchange offer, Merger Partner Board fails to recommend against acceptance of such offer; or (v)&nbsp;Merger Partner shall have materially breached its obligations under <U>Section</U><U></U><U>&nbsp;6.1</U> or
<U>Section</U><U></U><U>&nbsp;6.5(a)</U> of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by Merger Partner, at any time prior to the receipt of the Public Company
Stockholder Approval, if: (i)&nbsp;Public Company Board shall have failed to include its recommendation to the approval of the Public Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Voting Proposals in the Proxy Statement/Prospectus or shall have withdrawn or modified in a manner adverse to Merger Partner its recommendation of the Public Company Voting Proposals;
(ii)&nbsp;after the receipt by Public Company of an Acquisition Proposal, Merger Partner requests in writing that Public Company Board reconfirm its recommendation of the Public Company Voting Proposals and Public Company Board fails to do so within
ten Business Days after its receipt of Merger Partner&#146;s request; (iii)&nbsp;Public Company Board (or any committee thereof) shall have approved or recommended to the stockholders of Public Company an Acquisition Proposal; (iv)&nbsp;a tender
offer or exchange offer for outstanding shares of Public Company Common Stock is commenced (other than by Merger Partner or an Affiliate of Merger Partner), and Public Company Board (or any committee thereof) recommends that the stockholders of
Public Company tender their shares in such tender or exchange offer or, within five Business Days after the commencement of such tender offer or exchange offer, Public Company Board fails to recommend against acceptance of such offer; or
(v)&nbsp;Public Company shall have materially breached its obligations under <U>Section</U> 6.1 or <U>Section</U><U></U><U>&nbsp;6.5(b) </U>of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by Public Company, if there has been a breach of or failure to perform any representation, warranty, covenant or agreement set forth in
this Agreement (other than those referred to elsewhere in this <U>Section</U><U></U><U>&nbsp;8.1</U>) on the part of Merger Partner, which breach would cause the conditions set forth in <U>Section</U><U></U><U>&nbsp;7.2(a)</U> or <U>(b)</U>&nbsp;not
to be satisfied; <U>provided</U> that neither Public Company nor Merger Sub is then in material breach of any representation, warranty or covenant under this Agreement and <U>provided</U><I>, </I>further, that if such breach or failure to perform is
curable by Merger Partner, as applicable, then this Agreement shall not terminate pursuant to this <U>Section</U><U></U><U>&nbsp;8.1(g)</U> as a result of such particular breach or failure until the expiration of a thirty (30)&nbsp;day period
commencing upon delivery of written notice from Public Company to Merger Partner of such breach or failure and it being understood that this Agreement shall not terminate pursuant to this <U>Section</U><U></U><U>&nbsp;8.1(g)</U> as a result of such
particular breach or failure if such breach or failure is cured prior to such termination becoming effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) by Merger Partner, if
there has been a breach of or failure to perform any representation, warranty, covenant or agreement set forth in this Agreement (other than those referred to elsewhere in this <U>Section</U><U></U><U>&nbsp;8.1</U>) on the part of Public Company,
which breach would cause the conditions set forth in <U>Section</U><U></U><U>&nbsp;7.3(a)</U> or <U>(b)</U>&nbsp;not to be satisfied; <U>provided</U> that Merger Partner is not then in material breach of any representation, warranty or covenant
under this Agreement and <U>provided</U><I>, </I>further, that if such breach or failure to perform is curable by Public Company, then this Agreement shall not terminate pursuant to this <U>Section</U><U></U><U>&nbsp;8.1(h)</U> as a result of such
particular breach or failure until the expiration of a thirty (30)&nbsp;day period commencing upon delivery of written notice from Merger Partner to Public Company of such breach or failure and it being understood that this Agreement shall not
terminate pursuant to this <U>Section</U><U></U><U>&nbsp;8.1(h)</U> as a result of such particular breach or failure if such breach or failure is cured prior to such termination becoming effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by Public Company, if the Merger Partner Stockholder Approval is not obtained by delivery of the Written Consents on or prior to 5:00
p.m., New York City time, on the date that is two Business Days after the Registration Statement is declared effective under the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) by Merger Partner if, at any time prior to the receipt of the Merger Partner Stockholder Approval, each of the following occur:
(A)&nbsp;Merger Partner shall have received a Superior Proposal; (B)&nbsp;Merger Partner shall have complied in all material respects with its obligations under <U>Section</U><U></U><U>&nbsp;6.1</U>, including with respect to making a Merger Partner
Board Recommendation Change with respect to such Superior Proposal; (C)&nbsp;the Merger Partner Board approves, and Merger Partner concurrently with the termination of this Agreement enters into, a definitive agreement with respect to such Superior
Proposal; and (D)&nbsp;prior to or concurrently with such termination, Merger Partner pays to the Public Company the amount contemplated by <U>Section</U><U></U><U>&nbsp;8.3(b)</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) by Public Company if, at any time prior to the receipt of the Public Company Stockholder Approval, each of the following occur:
(A)&nbsp;Public Company shall have received a Superior Proposal; (B)&nbsp;Public Company shall have complied in all material respects with its obligations under <U>Section</U><U></U><U>&nbsp;6.1</U>, including with respect to making a Public Company
Board Recommendation Change with respect to such Superior Proposal; (C)&nbsp;the Public Company Board approves, and Public Company concurrently with the termination of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement enters into, a definitive agreement with respect to such Superior Proposal; and (D)&nbsp;prior to or concurrently with such termination, Public Company pays to Merger Partner the amount
contemplated by <U>Section</U><U></U><U>&nbsp;8.3(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Effect of Termination</U>. In the event of termination of this Agreement
as provided in <U>Section</U><U></U><U>&nbsp;8.1</U>, this Agreement shall immediately become void and there shall be no liability or obligation on the part of Public Company, Merger Partner, Merger Sub or their respective officers, directors,
stockholders or Affiliates; <U>provided</U> that (a)&nbsp;any such termination shall not relieve any party from liability for any willful and intentional breach of this Agreement, fraud or intentional misconduct and (b)&nbsp;the provisions of
<U>Section</U><U></U><U>&nbsp;5.3</U> (Confidentiality), this <U>Section</U><U></U><U>&nbsp;8.2</U> (Effect of Termination), <U>Section</U><U></U><U>&nbsp;8.3</U> (Fees and Expenses) and <U>Article IX</U> (Miscellaneous) of this Agreement and the
Confidentiality Agreement shall remain in full force and effect and survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Fees and
Expenses</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in this <U>Section</U><U></U><U>&nbsp;8.3</U>, all fees and expenses incurred in connection with
this Agreement and the transactions contemplated hereby shall be paid by the party incurring such expenses, whether or not the Merger is consummated; <U>provided,</U> <U>however</U>, that Merger Partner and Public Company shall share equally
(i)&nbsp;all fees and expenses of the Exchange Agent, and (ii)&nbsp;all fees and expenses, other than accountant&#146;s and attorneys&#146; fees, incurred with respect to the printing, filing and mailing of the Proxy Statement/Prospectus (including
any related preliminary materials) and the Registration Statement and any amendments or supplements thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner shall pay
Public Company a termination fee of $2,800,000 (the &#147;<U>Merger Partner Termination Fee</U>&#148;) in the event of the termination of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by Public Company pursuant to <U>Sections 8.1(e)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) by Merger Partner pursuant to <U>Section</U><U></U><U>&nbsp;8.1(j)</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) by Public Company or Merger Partner, as applicable, pursuant to <U>Sections 8.1(b)</U> or <U>8.1(g)</U>, so long as (A)&nbsp;prior to
the termination of this Agreement, any person makes an Acquisition Proposal or amends an Acquisition Proposal made prior to the date of this Agreement with respect to Merger Partner; and (B)&nbsp;within 12&nbsp;months after such termination Merger
Partner enters into a definitive agreement to consummate (which is consummated, whether or not within or after the 12 month period), or consummates, any Acquisition Proposal (regardless of whether made before or after the termination of this
Agreement); <U>provided</U> that for purposes of this <U>Section</U><U></U><U>&nbsp;8.3(b)(iii)</U>, the references to 15% in the definition of Acquisition Proposal shall be deemed to be 50%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company shall pay Merger Partner a termination fee of $1,400,000 (the &#147;<U>Public Company Termination Fee</U>&#148;) in the
event of the termination of this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by Merger Partner pursuant to <U>Section</U><U></U><U>&nbsp;8.1(f)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) by Public Company pursuant to <U>Section</U><U></U><U>&nbsp;8.1(k)</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) by Public Company or Merger Partner, as applicable, pursuant to <U>Sections</U> <U>8.1(b)</U> or <U>8.1(h)</U>, so long as
(A)&nbsp;prior to the termination of this Agreement, any person makes an Acquisition Proposal or amends an Acquisition Proposal made prior to the date of this Agreement with respect to Public Company; and (B)&nbsp;within 12 months after such
termination Public Company enters into a definitive agreement to consummate, or consummates, any Acquisition Proposal (regardless of whether made before or after the termination of this Agreement); <U>provided</U> that for purposes of this
<U>Section</U><U></U><U>&nbsp;8.3(c)(iii)</U>, the references to 15% in the definition of Acquisition Proposal shall be deemed to be 50%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If this Agreement is terminated by Merger Partner pursuant to
<U>Section</U><U>&nbsp;8.1(h)</U> (solely as a result of a willful and material breach), or by either party pursuant to <U>Section</U><U>&nbsp;8.1(d)</U>, then Public Company shall reimburse Merger Partner for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses incurred by Merger Partner in connection with this Agreement and the transactions contemplated hereby, up to a maximum of $1,000,000, by wire
transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within two (2)&nbsp;Business Days following the date on which Merger Partner submits to Public Company true and correct copies of reasonable documentation supporting such expenses.
If Merger Partner becomes entitled to receive a Public Company Termination Fee under this Agreement, any amount paid by Public Company under this <U>Section</U><U></U><U>&nbsp;8.3(d)</U> will be credited against the Public Company Termination Fee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If this Agreement is terminated by Public Company pursuant to <U>Section</U><U>&nbsp;8.1(g)</U> (solely as a result of a willful and
material breach) or <U>Section</U><U></U><U>&nbsp;8.1(i)</U>, then Merger Partner shall reimburse Public Company for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses
incurred by Public Company in connection with this Agreement and the transactions contemplated hereby, up to a maximum of $1,000,000, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within two (2)&nbsp;Business Days
following the date on which Public Company submits to Merger Partner true and correct copies of reasonable documentation supporting such expenses. If Public Company becomes entitled to receive a Merger Partner Termination Fee under this Agreement,
any amount paid by Merger Partner under this <U>Section</U><U></U><U>&nbsp;8.3(e)</U> will be credited against the Merger Partner Termination Fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any fee due under <U>Section</U><U></U><U>&nbsp;8.3(b)(i)</U> or <U>8.3(c)(i)</U> shall be paid by wire transfer of same day funds within
one Business Day of the date of termination of this Agreement. Any fee due under <U>Section</U><U></U><U>&nbsp;8.3(b)(ii)</U> or <U>8.3(c)(ii)</U> shall be paid by wire transfer of same day funds on the date of termination of this Agreement (and
shall be a condition to the effectiveness of such termination). Any fee due under <U>Section</U><U></U><U>&nbsp;8.3(b)(iii)</U> or <U>8.3(c)(iii)</U> shall be paid by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds within two
Business Days after the date on which the transaction referenced in clause (B)&nbsp;of such <U>Section</U><U></U><U>&nbsp;8.3(b)(iii)</U> or <U>Section</U><U></U><U>&nbsp;8.3(c)(iii)</U>, as applicable, is consummated. If one party fails to promptly
pay to the other any expense reimbursement or fee due pursuant to this <U>Section</U><U></U><U>&nbsp;8.3</U>, the defaulting party shall pay the costs and expenses (including legal fees and expenses) in connection with any action, including the
filing of any lawsuit or other legal action, taken to collect payment, together with interest on the amount of any unpaid fee at the publicly announced prime rate of Bank of America, N.A. plus five percent per annum, compounded quarterly, from the
date such expense reimbursement or fee was required to be paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The parties hereto acknowledge that the agreements contained in this
<U>Section</U><U></U><U>&nbsp;8.3</U> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the parties hereto would not enter into this Agreement. Notwithstanding
<U>Section</U><U></U><U>&nbsp;8.2</U> or any other provision of this Agreement, payment of the termination fees described in, and under the circumstances provided for in, this <U>Section</U><U></U><U>&nbsp;8.3</U> shall constitute the sole and
exclusive remedy of Public Company or Merger Partner, as applicable in connection with any termination of this Agreement in the circumstances in which such fees became payable. In the event that Public Company or Merger Partner shall receive the
payment of a termination fee under the circumstances provided for in this <U>Section</U><U></U><U>&nbsp;8.3</U>, the receipt of such fee shall be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Public
Company and any of its Affiliates or Merger Partner and any of its Affiliates, as applicable, or any other person in connection with this Agreement (and the termination hereof), the transactions contemplated hereby (and the abandonment thereof) or
any matter forming the basis for such termination, and none of the Public Company, Merger Sub any of their respective Affiliates or Merger Partner or any of its Affiliates, as applicable, or any other person, shall be entitled to bring or maintain
any other claim, action or proceeding against Public Company or Merger Partner, as applicable, or any of their respective Affiliates arising out of this Agreement, any of the transactions contemplated hereby or any matters forming the basis for such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The parties hereto acknowledge and agree that (i)&nbsp;in no event shall Merger Partner be required to pay Merger
Partner Termination Fee on more than one occasion, nor shall Public Company be required to pay Public Company Termination Fee on more than one occasion and (ii)&nbsp;in each case whether or not such fee may be payable under more than one provision
of this Agreement at the same or at different times and the occurrence of different events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Amendment</U>. This Agreement may be amended by the parties hereto, by action taken
or authorized by their respective Boards of Directors, at any time before or after approval of the matters presented in connection with the Merger by the stockholders of any of the parties, but, after any such approval, no amendment shall be made
which by Law requires further approval by such stockholders without such further approval. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>Extension; Waiver</U>. At any time prior to the Effective Time, the parties hereto, by action taken or authorized by their respective
Boards of Directors, may, to the extent legally allowed, (a)&nbsp;extend the time for the performance of any of the obligations or other acts of the other parties hereto, (b)&nbsp;waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (c)&nbsp;waive compliance with any of the agreements or conditions contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if
set forth in a written instrument signed on behalf of such party. Such extension or waiver shall not be deemed to apply to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any agreement or condition, as
the case may be, other than that which is specified in the extension or waiver. The failure of any party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6 <U>Procedure for Termination, Amendment, Extension or Waiver</U>. A termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;8.1</U>, an amendment, modification or supplement of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.4</U> or an extension or waiver of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;8.5</U> shall,
in order to be effective, require action by the respective boards of directors of the applicable parties. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1
<U>Nonsurvival of Representations, Warranties and Agreements</U>. None of the representations, warranties, covenants and agreements in this Agreement shall survive the Effective Time, except for the agreements contained in <U>Article I</U>,
<U>Article II</U>, <U>Section</U><U></U><U>&nbsp;6.10</U>, <U>6.13</U> and <U>6.14</U> and this <U>Article IX</U>. This <U>Section</U><U></U><U>&nbsp;9.1</U> shall have no effect upon any other obligations of the parties hereto, whether to be
performed before or after the consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Notices</U>. All notices and other communications hereunder shall be in
writing and shall be deemed duly delivered (i)&nbsp;three Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (ii)&nbsp;one Business Day after being sent for next Business Day delivery, fees
prepaid, via a reputable overnight courier service, in each case to the intended recipient as set forth below or (iii)&nbsp;on the same Business Day if sent by <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:00 p.m. Eastern Time or on the
following Business Day if sent after 5:00 p.m. Eastern Time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if to Public Company or Merger Sub, to </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">110 Miller Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ann Arbor, Michigan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Louis J. Arcudi III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> arcudi@millendo.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wilmer Cutler Pickering Hale and Dorr LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">60 State Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston,&nbsp;MA 02109 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stuart M. Falber, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Joseph B. Conahan, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;stuart.falber@wilmerhale.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:15%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;joseph.conahan@wilmerhale.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if to Merger Partner, to </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tempest Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7000 Shoreline Court, Suite 275 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Stephen Brady </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> sbrady@Tempesttx.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2850 Quarry Lake Drive, Suite 301 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Baltimore, MD 21209 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Asher Rubin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> arubin@sidley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1001 Page Mill Road, Building 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Rob Carlson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> rob.carlson@sidley.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party to this Agreement may give any notice or other communication hereunder using any other means (including personal delivery, messenger service,
telecopy or ordinary mail), but no such notice or other communication shall be deemed to have been duly given unless and until it actually is received by the party for whom it is intended. Any party to this Agreement may change the address to which
notices and other communications hereunder are to be delivered by giving the other parties to this Agreement notice in the manner herein set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Entire Agreement</U>. This Agreement (including the Schedules, Annexes and Exhibits hereto and the documents and instruments referred
to herein that are to be delivered at the Closing) constitutes the entire agreement among the parties to this Agreement and supersedes any prior understandings, agreements or representations by or among the parties hereto, or any of them, written or
oral, with respect to the subject matter hereof and the parties hereto expressly disclaim reliance on any such prior understandings, agreements or representations to the extent not embodied in this Agreement. Notwithstanding the foregoing, the
Confidentiality Agreement shall remain in effect in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>No Third Party Beneficiaries</U>. This Agreement is
not intended to, and shall not, confer upon any other person any rights or remedies hereunder, except as set forth in or contemplated by the terms and provisions of <U>Section</U><U></U><U>&nbsp;6.10</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Assignment</U>. No party may assign any of its rights or delegate any of its
performance obligations under this Agreement, in whole or in part, by operation of Law or otherwise without the prior written consent of the other parties, and any such assignment without such prior written consent shall be null and void. Subject to
the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns. Any purported assignment of rights or delegation of performance
obligations in violation of this <U>Section</U><U></U><U>&nbsp;9.5</U> is void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 <U>Severability</U>. Any term or provision of this
Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any
other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall
have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such
invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 <U>Counterparts and Signature</U>. This Agreement may be executed in two or more counterparts (including by facsimile or by an electronic
scan delivered by electronic mail), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and
delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile or by an electronic scan delivered by electronic mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 <U>Interpretation</U>. When reference is made in this Agreement to an Article or a Section, such reference shall be to an Article or
Section of this Agreement, unless otherwise indicated. The table of contents, table of defined terms and headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this
Agreement. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Whenever the context may require,
any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or foreign
statute or Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this
Agreement, they shall be deemed to be followed by the words &#147;without limitation.&#148; Where this Agreement refers to information that was &#147;made available&#148;, that means that such information was either (i)&nbsp;provided directly to the
Public Company or Merger Partner, as applicable, by the other party, (ii)&nbsp;included in the virtual data rooms established by Public Company and Merger Partner created for the purposes of providing information to the other party in connection
with this Agreement at least three Business Days prior to the execution and delivery of this Agreement or (iii)&nbsp;solely with respect to information made available by Public Company, filed with and publicly available on the SEC&#146;s EDGAR
system prior to the date of this Agreement. When used in the agreement, &#147;person&#148; shall mean any natural person, corporation, exempted company, limited liability company, partnership, exempted limited partnership, association, trust or
other entity, including a Governmental Entity, as applicable. No summary of this Agreement prepared by any party shall affect the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 <U>Governing Law</U>. All matters arising out of or relating to this Agreement and the transactions contemplated hereby (including its
interpretation, construction, performance and enforcement) shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of Law provision or rule (whether of the
State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10 <U>Remedies</U>. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other
remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the
parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at Law or
in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.11 <U>Submission to Jurisdiction</U>. Each of the parties to this Agreement (a)&nbsp;consents to submit itself to the
exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or
relating to this Agreement or any of the transactions contemplated by this Agreement, (b)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court, (c)&nbsp;agrees that it shall not attempt
to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (d)&nbsp;agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the transaction contemplated by
this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party
with respect thereto. Any party may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in <U>Section</U><U></U><U>&nbsp;9.2</U>.
Nothing in this <U>Section</U><U></U><U>&nbsp;9.11</U>, however, shall affect the right of any party to serve legal process in any other manner permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.12 <U>WAIVER OF JURY TRIAL</U>. EACH OF PUBLIC COMPANY, THE MERGER SUB AND MERGER PARTNER HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY
JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF PUBLIC COMPANY, THE MERGER SUB OR MERGER PARTNER IN
THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.13 <U>Disclosure Schedule</U>. Each of the Merger
Partner Disclosure Schedule and the Public Company Disclosure Schedule shall be arranged in sections corresponding to the numbered sections contained in this Agreement, and the disclosure in any section shall qualify only (a)&nbsp;the corresponding
section of this Agreement and (b)&nbsp;the other sections of this Agreement, to the extent that it is reasonably apparent from a reading of such disclosure that it also qualifies or applies to such other sections. The inclusion of any information in
the Merger Partner Disclosure Schedule or the Public Company Disclosure Schedule, as applicable, shall not be deemed to be an admission or acknowledgment, in and of itself, that such information is required by the terms hereof to be disclosed, is
material, has resulted in or would result in a Merger Partner Material Adverse Effect or a Public Company Material Adverse Effect, as applicable, or is outside the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MILLENDO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Louis J. Arcudi III</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Louis J. Arcudi III</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">CEO &amp; President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MARS MERGER CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Louis J. Arcudi III</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Louis J. Arcudi III</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">President</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Agreement and Plan of Merger] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MERGER PARTNER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEMPEST THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tom Dubensky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tom Dubensky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Agreement and Plan of Merger] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_202"></A>ANNEX B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g150774g83o77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;28, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Board of Directors</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 Miller
Avenue, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ann Arbor, Michigan </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested our opinion as to the fairness, from a financial point of view, to Millendo Therapeutics, Inc., a Delaware
corporation (&#147;Millendo&#148;), of the Exchange Ratio (as defined below) proposed to be paid by Millendo pursuant to the terms of the Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) to be entered into by and among Millendo,
Millendo Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Millendo (&#147;Merger Sub&#148;), and Tempest Therapeutics, Inc., a Delaware corporation (&#147;Tempest&#148;). The Merger Agreement provides for the acquisition by
Millendo of Tempest through the merger of Merger Sub with and into Tempest (the &#147;Merger&#148;), with Tempest continuing as the surviving entity of the Merger and as a wholly owned subsidiary of Millendo. At the effective time of the Merger (the
&#147;Effective Time&#148;), by virtue of the Merger and without any further action on the part of Millendo, Merger Sub, Tempest or any stockholder of Tempest, among other things, each share of common stock, par value $0.0001 of Tempest, and each
share of preferred stock, par value $0.0001, of Tempest (collectively, the &#147;Tempest Capital Stock&#148;) issued and outstanding immediately prior to the Effective Time (other than Excluded Shares (as defined below) will, by virtue of the Merger
Agreement (and subject to the terms and conditions thereof) and without any action on the part of the holder thereof, be converted into and thereafter represent the right to receive a number of shares of the common stock, par value $0.0001 per
share, of Millendo (the &#147;Millendo Common Stock&#148;), equal to the Exchange Ratio, without interest. As used herein, (i)&nbsp;the &#147;Exchange Ratio&#148; is the number of shares of Millendo Common Stock to be received by holders of Tempest
Capital Stock (other than Excluded Shares) in the Merger, which is derived from the agreed relative percentage ownership of the combined company by holders of Tempest Capital Stock (referred to in the Merger Agreement as the &#147;Merger Partner
Allocation Percentage&#148;) and Millendo Common Stock (referred to in Merger Agreement as the &#147;Public Company Allocation Percentage&#148;) following the consummation of the Merger, which is, subject to certain adjustments set forth in the
Merger Agreement (as to which adjustments we express no opinion), equal to 81.5% and 18.5%, respectively, on a fully diluted basis; and (ii) &#147;Excluded Shares&#148; means (a)&nbsp;shares of Tempest Capital Stock that are held in treasury and any
shares of Tempest Capital Stock owned by Millendo, Tempest or any of their respective wholly owned subsidiaries immediately prior to the Effective Time and (b)&nbsp;any shares of Tempest Capital Stock held by a holder who is entitled to and properly
demands appraisal rights in accordance with Section&nbsp;262 of the Delaware General Corporation Law. The Merger and the other transactions summarized above are collectively referred to herein as the &#147;Transaction.&#148; The terms and conditions
of the Transaction are more fully set forth in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been engaged by Millendo to act as its financial advisor in
connection with the proposed Transaction and we will receive a fee from Millendo for providing such services, a portion of which is payable upon delivery of this opinion and the principal portion of which is contingent upon consummation of the </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g150774g84f41.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction. In addition, Millendo
has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and
financial advisory services. We have provided certain investment banking services to Millendo from time to time, for which we have received compensation. In the ordinary course of business, we and our affiliates may, in the future, provide
commercial and investment banking services to Millendo, Tempest or their respective affiliates and would expect to receive customary fees for the rendering of such services. In the ordinary course of our trading and brokerage activities, we or our
affiliates have in the past and may in the future hold positions, for our own account or the accounts of our customers, in equity, debt or other securities of Millendo, Tempest or their respective affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with applicable legal and regulatory requirements, we have adopted policies and procedures to establish and maintain the
independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to Millendo or the proposed Transaction and other
participants in the Transaction that differ from the views of our investment banking personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have
reviewed, among other things: (i)&nbsp;a draft of the Merger Agreement, dated March&nbsp;27, 2021; (ii) Millendo&#146;s Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31,
2020, in the form to be filed by Millendo with the Securities and Exchange Commission (the &#147;SEC&#148;) on March&nbsp;29, 2021; (iii)&nbsp;certain Current Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K,&nbsp;as</FONT> filed by
Millendo with, or furnished by Millendo to, the SEC; and (iv)&nbsp;certain internal information, primarily related to expense forecasts, furnished to us by the managements of Millendo and Tempest, respectively, and approved for our use by Millendo.
We have also conducted discussions with members of the senior management of Millendo and Tempest and their respective advisors and representatives regarding such internal information as well as the past and current business, operations, financial
condition and prospects of each of Millendo and Tempest. In addition, we reviewed the historical trading prices and trading activity for the Millendo Common Stock. Furthermore, we reviewed (i)&nbsp;publicly available market capitalization data
regarding companies in the biotechnology industry that we believed to be comparable in certain respects to Tempest; and (ii)&nbsp;publicly available financial terms of certain initial public offerings involving companies in the biotechnology
industry that we believed to be comparable in certain respects to Tempest. We also conducted such other financial studies and analyses and took into account such other information as we deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal,
regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied upon such information as being complete and accurate. As you are aware, neither
Millendo&#146;s nor Tempest&#146;s management provided us with, and we did not otherwise have access to, financial forecasts regarding Millendo&#146;s or Tempest&#146;s businesses, other than the expense forecasts described above. Accordingly, we
did not perform either discounted cash flow analyses or any multiples-based analyses with respect to Millendo or Tempest. In addition, with your consent, we have not made any independent evaluation or appraisal of any of the assets or liabilities
(contingent, <FONT STYLE="white-space:nowrap">derivative,&nbsp;off-balance-sheet&nbsp;or</FONT> otherwise) of Millendo or Tempest, nor have we been furnished with any such evaluation or appraisal, and we have not been asked to conduct, and did not
conduct, a physical inspection of the properties or assets of Millendo or Tempest. We have assumed, with your consent, that the final executed Merger Agreement will not differ in any respect material to our analysis or this opinion from the last
draft of the Merger Agreement reviewed by us. We have also assumed,&nbsp;with your consent, that the Transaction will be consummated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the terms set forth in the Merger
Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to our analysis or
this opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change will be imposed, the
effect of which would be material to our analysis or this opinion. We have not evaluated and do not express any opinion as to the solvency or fair value of Millendo or Tempest, or their respective abilities to pay their obligations when they come
due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. We are not legal, regulatory, tax or accounting advisors, and we express no opinion as to any
legal, regulatory, tax or accounting matters.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no view as to, and our opinion does not address, Millendo&#146;s underlying
business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to Millendo or in which Millendo might engage. This
opinion is limited to and addresses only the fairness, from a financial point of view, as of the date hereof, to Millendo of the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement. We have not been asked to, nor do
we express any view on, and our opinion does not address, any other term or aspect of the Merger Agreement or the Transaction, including, without limitation, the structure or form of the Transaction, or any other agreements or arrangements
contemplated by the Merger Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or aspect of the Transaction to, or any
consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any class of securities, creditors or other constituencies of Millendo or any other party. In addition, we express no view or opinion as to
the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Millendo or any other party, or class of such persons in connection with the
Transaction, whether relative to the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement or otherwise. Our opinion is necessarily based on financial, economic, monetary, currency, market and other conditions and
circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or responsibility to update, revise or reaffirm this opinion based on circumstances, developments or events occurring
after the date hereof. Our opinion does not constitute a recommendation to any stockholder of Millendo as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Transaction or any other matter.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial advisory services and the opinion expressed herein are provided for the information and assistance of the Board of Directors of
Millendo (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. This opinion has been authorized by our Fairness Opinion Review Committee.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, including the various assumptions, qualifications and limitations set forth herein, it is our opinion
that, as of the date hereof, the Exchange Ratio to be paid by Millendo pursuant to the terms of the Merger Agreement is fair, from a financial point of view, to Millendo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SVB LEERINK LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_203"></A>ANNEX C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-3</FONT> &#150; FORM OF PUBLIC COMPANY SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Support Agreement (this &#147;<U>Agreement</U>&#148;) is made and entered into as of [&#9679;], 2021, by and among Tempest Therapeutics,
Inc. a Delaware corporation (&#147;<U>Merger Partner</U>&#148;), Millendo Therapeutics, Inc., a Delaware corporation (&#147;<U>Public Company</U>&#148;), and the undersigned stockholder (the &#147;<U>Stockholder</U>&#148;) of Public Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery hereof, Public Company, Merger Partner and Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company (the &#147;<U>Merger Sub</U>&#148;), have entered into an agreement and
plan of merger (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#147;<U>Merger Agreement</U>&#148;), pursuant to which Merger Sub will merge with and into Merger Partner, with Merger Partner
surviving the merger as the surviving corporation and a wholly owned subsidiary of Public Company (the &#147;<U>Merger</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Stockholder is the beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-1</FONT> under the Exchange Act) of
such number of shares of Public Company Common Stock as indicated in <U>Appendix A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as an inducement to the willingness of
Merger Partner to enter into the Merger Agreement, Merger Partner has required that Stockholder enter into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, intending to be legally bound, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Certain Definitions</U>. Capitalized terms used but
not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Constructive Sale</U>&#148; means, with respect to any security, a short sale with respect to such security, entering into or
acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either
directly or indirectly materially changing the economic benefits or risks of ownership of such security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Shares</U>&#148;
means (i)&nbsp;all shares of Public Company Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii)&nbsp;all additional shares of Public Company Common Stock acquired by the Stockholder, beneficially or of
record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
&#147;<U>Transfer</U>&#148; or &#147;Transferred&#148; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest
or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or
otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial
ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Transfer and Voting Restrictions</U>. The Stockholder covenants to Merger Partner as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as
defined below), the Stockholder shall not Transfer any of the Stockholder&#146;s Shares, or publicly announce its intention to Transfer any of its Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise permitted by this Agreement or by order of a court of competent jurisdiction, the Stockholder will not commit any act
that would restrict the Stockholder&#146;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement.
Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the
Stockholder&#146;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any
person or entity limiting or affecting the Stockholder&#146;s legal power, authority or right to vote the Stockholder&#146;s Shares in favor of the Public Company Voting Proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i)&nbsp;by will or other
testamentary document or by intestacy, (ii)&nbsp;to any investment fund or other entity controlled or managed by the Stockholder, (iii)&nbsp;to any member of the Stockholder&#146;s immediate family or (iv)&nbsp;to any trust for the direct or
indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes; <U>provided</U>, that (x)&nbsp;such Transferred Shares shall continue to be bound by this Agreement and (y)&nbsp;the applicable
transferee shall have executed and delivered to Public Company and Merger Partner a support agreement substantially identical to this Agreement upon consummation of such Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Agreement to Vote Shares</U>. The Stockholder covenants to Merger Partner as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Until the Expiration Date (as defined below), at any meeting of the stockholders of Public Company, however called, and at every
adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Public Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all
Shares held by the Stockholder (A)&nbsp;in favor of the Public Company Voting Proposals and (B)&nbsp;against any Acquisition Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder shall cause the record holder and any
nominees to be present (in person or by proxy) and vote all the Stockholder&#146;s Shares in accordance with this <U>Section</U><U></U><U>&nbsp;3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Public Company by reason of any <FONT
STYLE="white-space:nowrap">split-up,</FONT> reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#147;Shares&#148; shall be deemed to refer to and include such shares as
well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Action in Stockholder Capacity Only</U>. The Stockholder is entering into this Agreement solely in the Stockholder&#146;s capacity as a
record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#146;s capacity as a director or officer of Public Company. Nothing herein shall limit or affect the Stockholder&#146;s ability to act as an officer or
director of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Documentation and Information</U>. The Stockholder shall permit and hereby authorizes Public Company
and Merger Partner to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Public Company or Merger Partner reasonably determines to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary in connection with the transactions contemplated by the Merger Agreement, such Stockholder&#146;s identity and ownership of the Share and the nature of such Stockholder&#146;s
commitments and obligations under this Agreement. Each of Public Company and Merger Partner is an intended third-party beneficiary of this Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Irrevocable Proxy</U>. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore
granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <U>Section</U><U></U><U>&nbsp;3</U> at any applicable meeting of the stockholders of Public Company or pursuant to
any applicable written consent of the stockholders of Public Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Merger Partner, and any individual designated in writing by Merger Partner, and each of them
individually, as his, her or its proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in
any action by written consent of Public Company stockholders or at any meeting of the Public Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, <U>Section</U><U></U><U>&nbsp;3</U> of
this Agreement. Merger Partner agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is
coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall
automatically terminate upon the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Solicitation</U>. Subject to
<U>Section</U><U></U><U>&nbsp;4</U>, the Stockholder agrees not to, directly or indirectly, including through any of its officers, directors or agents, (a)&nbsp;solicit, seek or initiate or knowingly take any action to facilitate or encourage, any
offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, any Acquisition Proposal or (b)&nbsp;enter into, continue or otherwise participate or engage in any discussions or negotiations
regarding any Acquisition Proposal, or furnish to any person any <FONT STYLE="white-space:nowrap">non-public</FONT> information or afford any person, other than Public Company or Merger Partner, as applicable, access to such party&#146;s property,
books or records (except pursuant to a request by a Governmental Entity) in connection with, any Acquisition Proposal; <U>provided</U>, <U>however</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;7</U> shall prevent the Stockholder from
referring a person to this <U>Section</U><U></U><U>&nbsp;7 </U>or to the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Representations and Warranties of the
Stockholder</U>. The Stockholder hereby represents and warrants to Merger Partner as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) The Stockholder is the
beneficial or record owner of the shares of Public Company Common Stock indicated in <U>Appendix A</U> (each of which shall be deemed to be &#147;held&#148; by the Stockholder for purposes of <U>Section</U><U></U><U>&nbsp;3</U> unless otherwise
expressly stated with respect to any shares in <U>Appendix A</U>), free and clear of any and all Liens; and (ii)&nbsp;the Stockholder does not beneficially own any securities of Public Company other than the shares of Public Company Common Stock and
rights to purchase shares of Public Company Common Stock set forth in <U>Appendix A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise provided in this
Agreement, the Stockholder has full power and authority to (i)&nbsp;make, enter into and carry out the terms of this Agreement and (ii)&nbsp;vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any
other action on the part of, any other person or entity (including any Governmental Entity). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with
respect to any of the Stockholder&#146;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#146;s Shares, deposited any of the Stockholder&#146;s Shares in a voting trust or
entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#146;s legal power, authority or right to vote the Stockholder&#146;s Shares on any matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and
delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Bankruptcy and Equity Exception. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not
result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder
is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#146;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not
reasonably be expected to materially impair or adversely affect the Stockholder&#146;s ability to perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with the Stockholder&#146;s legal counsel. The
Stockholder understands and acknowledges that Merger Partner is entering into the Merger Agreement in reliance upon the Stockholder&#146;s execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval,
authorization or permit of, action by, filing with or notification to, any Governmental Entity, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in
the aggregate, has not and would not materially impair the Stockholder&#146;s ability to perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the
knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#146;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder
to perform its obligations hereunder or to consummate the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the Stockholder nor any of its
Representatives or Affiliates has employed or made any agreement with any broker, finder or similar agent or any Person which will result in the obligation of such Stockholder, Public Company, Merger Partner, or any of their respective Affiliates to
pay any finder&#146;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Termination</U>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earlier of (a)&nbsp;such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof or (b)&nbsp;the
date on which the Public Company Voting Proposals shall have been approved by the requisite holders of Public Company Common Stock (the &#147;<B><I>Expiration Date</I></B>&#148;); <U>provided</U><I>, </I><U>however</U><I>,</I> that
(i)<U>&nbsp;Section</U><U></U><U>&nbsp;10</U> shall survive the termination of this Agreement, and (ii)&nbsp;the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this
Agreement prior to the Expiration Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous Provisions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendments</U>. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of
the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties to this Agreement
and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governing Law</U>. All matters arising out of or relating to this Agreement and the transactions contemplated hereby (including its
interpretation, construction, performance and enforcement) shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the
State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Jurisdiction</U>. Each of the parties to this Agreement (i)&nbsp;consents to submit
itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington, Delaware in any action or proceeding arising out
of or relating to this Agreement or any of the transactions contemplated by this Agreement, (ii)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court, (iii)&nbsp;agrees that it shall not
attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (iv)&nbsp;agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the transactions
contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of
any other party with respect thereto. Any party may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in
<U>Section</U><U></U><U>&nbsp;10(j)</U>. Nothing in this <U>Section</U><U></U><U>&nbsp;10(d)</U>, however, shall affect the right of any party to serve legal process in any other manner permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>WAIVER OF JURY TRIAL</U>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY TO THIS AGREEMENT IN THE NEGOTIATION, ADMINISTRATION,
PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment</U>. Except as otherwise provided in
<U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, no party may assign any of its rights or delegate any of its performance obligations under this Agreement, in whole or in part, by operation of law or otherwise, without the prior written consent of the
other parties hereto, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and
their respective successors and permitted assigns. Any purported assignment of rights or delegation of performance obligations in violation of this <U>Section</U><U></U><U>&nbsp;10(f)</U> is void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>No Third Party Rights</U>. This Agreement is not intended to, and shall not, confer upon any other person any rights or remedies
hereunder other than the parties hereto to the extent expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. Any term or provision of this
Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any
other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall
have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such
invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce
specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i)&nbsp;three
Business Days after being sent by registered or certified mail, return receipt requested, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
postage prepaid, or (ii)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable overnight courier service, in each case to the intended recipient as
follows: (A)&nbsp;if to Merger Partner or Public Company, to the address, electronic mail address or facsimile provided in the Merger Agreement, including to the persons designated therein to receive copies; and/or (B)&nbsp;if to the Stockholder, to
the Stockholder&#146;s address, electronic mail address or facsimile shown below Stockholder&#146;s signature to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts (including by facsimile, by an electronic scan delivered by electronic mail or any electronic signature), each of which shall be deemed an original but all of which
together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same
counterpart. This Agreement may be executed and delivered by facsimile, by an electronic scan delivered by electronic mail or by delivery of any electronic signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Interpretation</U>. When reference is made in this Agreement to a Section or Appendix, such reference shall be to a Section of or
Appendix to this Agreement, unless otherwise indicated. The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. The language used in this
Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Whenever the context may require, any pronouns used in this Agreement
shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or foreign statute or law shall be deemed also to
refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed
by the words &#147;without limitation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Left Intentionally Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGER PARTNER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEMPEST THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PUBLIC COMPANY: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MILLENDO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER], </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in his/her capacity as the Stockholder: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Appendix A</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_204"></A>ANNEX D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> &#150; FORM OF MERGER PARTNER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Support Agreement (this &#147;<U>Agreement</U>&#148;) is made and entered into as of [&#9679;], 2021, by and among Tempest Therapeutics,
Inc. a Delaware corporation (&#147;<U>Merger Partner</U>&#148;), Millendo Therapeutics, Inc., a Delaware corporation (&#147;<U>Public Company</U>&#148;), and the undersigned stockholder (the &#147;<U>Stockholder</U>&#148;) of Merger Partner. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery hereof, Public Company, Merger Partner and Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company (the &#147;<U>Merger Sub</U>&#148;), have entered into an agreement and
plan of merger (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#147;<U>Merger Agreement</U>&#148;), pursuant to which Merger Sub will merge with and into Merger Partner, with Merger Partner
surviving the merger as the surviving corporation and a wholly owned subsidiary of Public Company (the &#147;<U>Merger</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Stockholder is the beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-1</FONT> under the Exchange Act) of
such number of shares of Merger Partner Capital Stock as indicated in <U>Appendix A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as an inducement to the willingness of
Public Company to enter into the Merger Agreement, Public Company has required that the Stockholder enter into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, intending to be legally bound, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Certain Definitions</U>. Capitalized terms used but
not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Constructive Sale</U>&#148; means, with respect to any security, a short sale with respect to such security, entering into or
acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either
directly or indirectly materially changing the economic benefits or risks of ownership of such security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Shares</U>&#148;
means (i)&nbsp;all shares of Merger Partner Capital Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii)&nbsp;all additional shares of Merger Partner Capital Stock acquired by the Stockholder, beneficially or of
record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
&#147;<U>Transfer</U>&#148; or &#147;<U>Transferred</U>&#148; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security
interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court
order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or
beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Transfer and Voting Restrictions</U>. The Stockholder covenants to Public Company as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as
defined below), the Stockholder shall not Transfer any of the Stockholder&#146;s Shares, or publicly announce its intention to Transfer any of its Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise permitted by this Agreement or by order of a court of competent jurisdiction, the Stockholder will not commit any act
that would restrict the Stockholder&#146;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement.
Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the
Stockholder&#146;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any
person or entity limiting or affecting the Stockholder&#146;s legal power, authority or right to vote the Stockholder&#146;s Shares in favor of the Merger Partner Voting Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i)&nbsp;by will or other
testamentary document or by intestacy, (ii)&nbsp;to any investment fund or other entity controlled or managed by the Stockholder, (iii)&nbsp;to any member of the Stockholder&#146;s immediate family or (iv)&nbsp;to any trust for the direct or
indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes; <U>provided</U>, that (x)&nbsp;such Transferred Shares shall continue to be bound by this Agreement and (y)&nbsp;the applicable
transferee shall have executed and delivered to Public Company and Merger Partner a support agreement substantially identical to this Agreement upon consummation of such Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Agreement to Vote Shares</U>. The Stockholder covenants to Public Company as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Until the Expiration Date (as defined below), at any meeting of the stockholders of Merger Partner, however called, and at every
adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Merger Partner, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all
Shares held by the Stockholder (A)&nbsp;in favor of the Merger Partner Voting Proposal and (B)&nbsp;against any Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder shall cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#146;s Shares in accordance with this
<U>Section</U><U></U><U>&nbsp;3.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a stock split, stock dividend or distribution, or any change in the capital
stock of Public Company by reason of any <FONT STYLE="white-space:nowrap">split-up,</FONT> reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#147;Shares&#148; shall be
deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Stockholder hereby waives and agrees not to exercise any rights of appraisal or any dissenters&#146; rights (including under
Section&nbsp;262 of the DGCL) that the Stockholder may have (whether under applicable law or otherwise) or could potentially have or acquire in connection with the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Action in Stockholder Capacity Only</U>. The Stockholder is entering into this Agreement solely in the Stockholder&#146;s capacity as a
record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#146;s capacity as a director or officer of Merger Partner. Nothing herein shall limit or affect the Stockholder&#146;s ability to act as an officer or
director of Merger Partner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Documentation and Information</U>. The Stockholder shall permit and hereby authorizes
Public Company and Merger Partner to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Public Company or Merger Partner reasonably determines to be necessary in connection
with the transactions contemplated by the Merger Agreement, such Stockholder&#146;s identity and ownership of the Share and the nature of such Stockholder&#146;s commitments and obligations under this Agreement. Each of Public Company and Merger
Partner is an intended third-party beneficiary of this Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Irrevocable Proxy</U>. The Stockholder hereby revokes (or
agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <U>Section</U><U></U><U>&nbsp;3</U> at
any applicable meeting of the stockholders of Merger Partner or pursuant to any applicable written consent of the stockholders of Merger Partner, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Public Company, and any
individual designated in writing by Public Company, and each of them individually, as his, her or its proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with full power of substitution), for
and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Merger Partner stockholders or at any meeting of the Merger Partner stockholders called with respect to any of the matters specified in, and in
accordance and consistent with, <U>Section</U><U></U><U>&nbsp;3</U> of this Agreement. Public Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided
for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other
provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Solicitation</U>. Subject to <U>Section</U><U></U><U>&nbsp;4</U>, the Stockholder agrees not to, directly or indirectly, including
through any of its officers, directors or agents, (a)&nbsp;solicit, seek or initiate or knowingly take any action to facilitate or encourage, any offers, inquiries or the making of any proposal or offer that constitutes, or could reasonably be
expected to lead to, any Acquisition Proposal or (b)&nbsp;enter into, continue or otherwise participate or engage in any discussions or negotiations regarding any Acquisition Proposal, or furnish to any person any
<FONT STYLE="white-space:nowrap">non-public</FONT> information or afford any person, other than Public Company or Merger Partner, as applicable, access to such party&#146;s property, books or records (except pursuant to a request by a Governmental
Entity) in connection with, any Acquisition Proposal; <U>provided</U>, <U>however</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;7</U> shall prevent the Stockholder from referring a person to this <U>Section</U><U></U><U>&nbsp;6</U> or to
the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Representations and Warranties of the Stockholder</U>. The Stockholder hereby represents and warrants to
Public Company as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(i) The Stockholder is the beneficial or record owner of the shares of Merger Partner Capital Stock
indicated in <U>Appendix A</U> (each of which shall be deemed to be &#147;held&#148; by the Stockholder for purposes of <U>Section</U><U></U><U>&nbsp;3</U> unless otherwise expressly stated with respect to any shares in <U>Appendix A</U>), free and
clear of any and all Liens; and (ii)&nbsp;the Stockholder does not beneficially own any securities of Merger Partner other than the shares of Merger Partner Capital Stock and rights to purchase shares of Merger Partner Capital Stock set forth in
<U>Appendix A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i)&nbsp;make,
enter into and carry out the terms of this Agreement and (ii)&nbsp;vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any
Governmental Entity). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#146;s Shares, granted any person
any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#146;s Shares, deposited any of the Stockholder&#146;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or
affecting the Stockholder&#146;s legal power, authority or right to vote the Stockholder&#146;s Shares on any matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement has been duly and validly executed and delivered by the Stockholder and
(assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Bankruptcy and Equity
Exception. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a
default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any
of the Stockholder&#146;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the
Stockholder&#146;s ability to perform its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Stockholder has had the opportunity to review the
Merger Agreement and this Agreement with the Stockholder&#146;s legal counsel. The Stockholder understands and acknowledges that Public Company is entering into the Merger Agreement in reliance upon the Stockholder&#146;s execution, delivery and
performance of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The execution, delivery and performance of this Agreement by the Stockholder do not and will not
require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Entity, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make
or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#146;s ability to perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the
knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#146;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder
to perform its obligations hereunder or to consummate the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the Stockholder nor any of its
Representatives or Affiliates has employed or made any agreement with any broker, finder or similar agent or any Person which will result in the obligation of such Stockholder, Public Company, Merger Partner, or any of their respective Affiliates to
pay any finder&#146;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Termination</U>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earlier of (a)&nbsp;such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof or (b)&nbsp;the
date on which the Merger Partner Voting Proposal shall have been approved by the requisite holders of Merger Partner Capital Stock (the &#147;<B><I>Expiration Date</I></B>&#148;); <U>provided</U><I>, </I><U>however</U><I>,</I> that
(i)<U>&nbsp;Section</U><U></U><U>&nbsp;10</U> shall survive the termination of this Agreement, and (ii)&nbsp;the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this
Agreement prior to the Expiration Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous Provisions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendments</U>. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of
the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the parties to this Agreement
and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governing Law</U>. All matters arising out of or relating to this Agreement and the transactions contemplated hereby (including its
interpretation, construction, performance and enforcement) shall be governed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any
other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Jurisdiction</U>. Each of the parties to this Agreement (i)&nbsp;consents to submit itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction,
a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, (ii)&nbsp;agrees that all claims in respect of such action or
proceeding shall be heard and determined in any such court, (iii)&nbsp;agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (iv)&nbsp;agrees not to bring any
action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or
proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto. Any party may make service on another party by sending or delivering a copy of the process to the party to be served
at the address and in the manner provided for the giving of notices in <U>Section</U><U></U><U>&nbsp;10(j)</U>. Nothing in this <U>Section</U><U></U><U>&nbsp;10(d)</U>, however, shall affect the right of any party to serve legal process in any other
manner permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>WAIVER OF JURY TRIAL</U>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY TO THIS AGREEMENT IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment</U>. Except as otherwise provided in
<U>Section</U><U></U><U>&nbsp;2(c)</U> hereof, no party may assign any of its rights or delegate any of its performance obligations under this Agreement, in whole or in part, by operation of law or otherwise, without the prior written consent of the
other parties hereto, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and
their respective successors and permitted assigns. Any purported assignment of rights or delegation of performance obligations in violation of this <U>Section</U><U></U><U>&nbsp;10(f)</U> is void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>No Third Party Rights</U>. This Agreement is not intended to, and shall not, confer upon any other person any rights or remedies
hereunder other than the parties hereto to the extent expressly set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. Any term or provision of this
Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any
other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall
have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the
intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such
invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in
equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered
(i)&nbsp;three Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, or (ii)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable overnight courier
service, in each case to the intended recipient as follows: (A)&nbsp;if to Merger Partner or Public Company, to the address, electronic mail address or facsimile provided in the Merger Agreement, including to the persons designated therein to
receive copies; and/or (B)&nbsp;if to the Stockholder, to the Stockholder&#146;s address, electronic mail address or facsimile shown below Stockholder&#146;s signature to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Counterparts</U>. This Agreement may be executed in two or more counterparts (including by facsimile, by an electronic scan delivered
by electronic mail or any electronic signature), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties
hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile, by an electronic scan delivered by electronic mail or by delivery of any
electronic signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Interpretation</U>. When reference is made in this Agreement to a Section or Appendix, such reference shall
be to a Section of or Appendix to this Agreement, unless otherwise indicated. The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. The
language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Whenever the context may require, any pronouns
used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or foreign </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Whenever the words
&#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Left Intentionally Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGER PARTNER:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEMPEST THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PUBLIC COMPANY:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MILLENDO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER], </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in his/her capacity as the Stockholder: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Appendix A</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_205"></A>ANNEX E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> &#150; FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">110 Miller Avenue, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ann Arbor, Michigan </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned signatory of this <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement (this &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;) understands that Millendo Therapeutics, Inc., a Delaware corporation (&#147;<U>Public Company</U>&#148;), has
entered into an Agreement and Plan of Merger, dated as of [&#9679;], 2021 (as the same may be amended from time to time, the &#147;<U>Merger Agreement</U>&#148;) with Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public
Company, and Tempest Therapeutics, Inc., a Delaware corporation. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a condition and inducement to Public Company to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Public Company, the
undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#147;<U>Restricted Period</U>&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Public Company Common Stock or any securities convertible into or exercisable or exchangeable for shares of Public Company Common Stock
(including without limitation, shares of Public Company Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Public Company
which may be issued upon exercise of an option to purchase shares of Public Company Common Stock or a warrant to purchase shares of Public Company Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below
(collectively, the &#147;<U>Undersigned&#146;s Shares</U>&#148;), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Undersigned&#146;s Shares regardless of whether any such transaction described in clause (1)&nbsp;above or this clause (2)&nbsp;is to be settled by delivery of shares of Public Company Common Stock or other securities, in cash or
otherwise; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) make any demand for, or exercise any right with respect to, the registration of any shares of Public Company Common
Stock or any security convertible into or exercisable or exchangeable for shares of Public Company Common Stock (other than such rights set forth in the Merger Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions and obligations contemplated by this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall not apply to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of the Undersigned&#146;s Shares: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) if the undersigned is a <U>natural person</U>, (A)&nbsp;to any person related to the undersigned by blood or adoption who is an immediate
family member of the undersigned, or by marriage or domestic partnership (a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<U>Family Member</U>&#148;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#146;s Family Members, (B)&nbsp;to the undersigned&#146;s estate, following
the death of the undersigned, by will, intestacy or other operation of Law, (C)&nbsp;as a bona fide gift or a charitable contribution, (D)&nbsp;by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or
(E)&nbsp;to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) if the undersigned is a <U>corporation, partnership or other entity</U>, (A)&nbsp;to another corporation, partnership, or other entity
that is an affiliate (as defined under Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act) of the undersigned, including investment funds or other entities under common control or management with the undersigned, (B)&nbsp;as a
distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the
undersigned pursuant to a plan of liquidation approved by the undersigned&#146;s equity holders), (C) as a bona fide gift or a charitable contribution or (D)&nbsp;transfers or dispositions not involving a change in beneficial ownership; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) if the undersigned is a <U>trust</U>, to any grantors or beneficiaries of the trust; <U> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir,
beneficiary or other transferee or distributee shall sign and deliver to Public Company a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement in the form of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with respect to the
shares of Public Company Common Stock or such other securities that have been so transferred or distributed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the exercise of an
option to purchase shares of Public Company Common Stock (including a net or cashless exercise of an option to purchase shares of Public Company Common Stock ), and any related transfer of shares of Public Company Common Stock to Public Company for
the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; <U>provided</U> that, for the avoidance of doubt, the underlying shares of Public Company
Common Stock shall continue to be subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) transfers to Public Company in connection with the net settlement of any other equity award that represents the right to receive in the
future shares of Public Company Common Stock, settled in shares of Public Company Common Stock, to pay any tax withholding obligations; <U>provided</U> that, for the avoidance of doubt, the underlying shares of Public Company Common Stock shall
continue to be subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Public Company Common Stock; <U>provided</U> that such plan does not provide for any transfers
of shares of Public Company Common Stock during the Restricted Period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) transfers by the undersigned of shares of Public Company
Common Stock purchased by the undersigned on the open market or in a public offering by Public Company, in each case following the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Public
Company&#146;s capital stock involving a change of control of Public Company, <U>provided</U> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#146;s Shares shall remain
subject to the restrictions contained in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) pursuant to an order of a
court or regulatory agency; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and <U>provided</U>, further, that, with respect to each of (a), (b), (c), and (d)&nbsp;above, no filing by any party
(including any donor, donee, transferor, transferee, distributor or distributee) under Section&nbsp;16 of the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disposition during the Restricted Period (other than (x)&nbsp;any exit filings or public announcements that may be required under applicable federal and state securities Laws or (y)&nbsp;in
respect of a required filing under the Exchange Act in connection with the exercise of an option to purchase shares of Public Company Common Stock or in connection with the net settlement of any other equity award that represents the right to
receive in the future shares of Public Company Common Stock, settled in shares of Public Company Common Stock, that would otherwise expire during the Restricted Period, <U>provided</U> that reasonable notice shall be provided to Public Company prior
to any such filing). For the avoidance of doubt, the Undersigned&#146;s Shares shall not include any securities acquired by the undersigned pursuant to any Funding Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any attempted transfer in violation of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will be of no effect and null and void, regardless of
whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and will not be recorded on the share register of Public Company. In
furtherance of the foregoing, the undersigned agrees that Public Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if
such transfer would constitute a violation or breach of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. Public Company may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any
certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#146;s ownership of shares of Public Company Common Stock: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; margin-right:11%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY&nbsp;BE TRANSFERRED IN COMPLIANCE WITH A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be
binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned understands that if the Merger Agreement is
terminated for any reason, the undersigned shall be released from all obligations under this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. The undersigned understands that Public Company is proceeding with the transactions contemplated
by the Merger Agreement in reliance upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any and all remedies herein expressly conferred
upon Public Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Public Company of any one remedy will not preclude the exercise of any other remedy. The undersigned
agrees that irreparable damage would occur to Public Company in the event that any provision of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement was not performed in accordance with its specific terms or were otherwise breached. It is
accordingly agreed that Public Company shall be entitled to an injunction or injunctions to prevent breaches of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and to enforce specifically the terms and provisions hereof in any court
of the United States or any state having jurisdiction, this being in addition to any other remedy to which Public Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Public
Company with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any holder of Public Company&#146;s securities that are subject to a substantially similar agreement
entered into by such holder, other than the undersigned, is permitted by Public Company to sell or otherwise transfer or dispose of shares of Public Company Common Stock for value other than as permitted by this or a substantially similar agreement
entered into by such holder, the same percentage of shares of Public Company Common Stock held by the undersigned shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#147;<U><FONT
STYLE="white-space:nowrap">Pro-Rata</FONT> Release</U>&#148;); <U>provided</U>, <U>however</U>, that such <FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Release shall not be applied unless and until permission has been granted by Public Company to
an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders&#146; shares of Public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company Common Stock in an aggregate amount in excess of 1% of the number of shares of Public Company Common Stock originally subject to a substantially similar agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the release of any of the Undersigned&#146;s Shares from this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, Public Company will cooperate
with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and any claim, controversy or dispute
arising under or related to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be governed by and construed in accordance with the Laws of the state of Delaware, without regard to the conflict of Laws principles thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement may be executed in several counterparts, each of which shall be deemed an original and all of
which shall constitute one and the same instrument. The exchange of a fully executed <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (in counterparts or otherwise) by Public Company and the undersigned by facsimile or electronic
transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[SIGNATURE PAGE FOLLOWS] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and Agreed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">by Millendo Therapeutics,
Inc.:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">By:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_206"></A>ANNEX F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT TO THE RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION OF MILLENDO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Section&nbsp;242 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo Therapeutics, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the
General Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law
proposing this Amendment of the Corporation&#146;s Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Restated Certificate of Incorporation, as amended, and authorizing the appropriate officers of the
Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RESOLVED, that Section C of Article FOURTH of the Restated Certificate of Incorporation of the Corporation, as amended, be and hereby is
deleted in its entirety and the following paragraphs are inserted in lieu thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;C. Effective immediately upon the filing of this
Certificate of Amendment to the Restated Certificate of Incorporation, as amended (the &#147;Effective Time&#148;), a <FONT STYLE="white-space:nowrap">one-for-[&#9679;]</FONT><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> reverse stock split
of the Corporation&#146;s common stock, par value $0.001 per share (the &#147;Common Stock&#148;), shall become effective, pursuant to which each six shares of Common Stock outstanding and held of record by each stockholder of the Corporation
(including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the
Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the &#147;Reverse Stock Split&#148;). The par value of the Common Stock following the Reverse Stock
Split shall remain at $0.001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate which formerly represented shares of
Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be
entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Effective Time as determined by
the Board of Directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stock certificate that, immediately prior to the Effective Time, represented shares of
Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of
Common Stock after the Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time);
<U>provided</U>, <U>however</U>, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a
new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.&#148; </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be a number between ten and fifteen (inclusive)
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Certificate of Amendment of the Restated Certificate of Incorporation has been duly
adopted by the stockholders of the Corporation in accordance with the provisions of Section&nbsp;242 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Certificate of Amendment of the
Restated Certificate of Incorporation to be signed by its President and Chief Executive Officer this [&#9679;] day of [&#9679;], 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Arcudi III</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc150774_207"></A>ANNEX G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Section&nbsp;262 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>&#167;262 Appraisal rights. </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any stockholder
of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&nbsp;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger
or consolidation, who has otherwise complied with subsection (d)&nbsp;of this section and who has neither voted in favor of the merger or consolidation nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an
appraisal by the Court of Chancery of the fair value of the stockholder&#146;s shares of stock under the circumstances described in subsections (b)&nbsp;and (c) of this section. As used in this section, the word &#147;stockholder&#148; means a
holder of record of stock in a corporation; the words &#147;stock&#148; and &#147;share&#148; mean and include what is ordinarily meant by those words; and the words &#147;depository receipt&#148; mean a receipt or other instrument issued by a
depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent corporation in a merger or consolidation to be
effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263 or &#167; 264 of this title: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Provided, however, that, except as expressly provided in &#167; 363(b) of this title, no appraisal rights under this section shall be available for the
shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders to act upon the agreement of merger or
consolidation (or, in the case of a merger pursuant to &#167; 251(h), as of immediately prior to the execution of the agreement of merger), were either: (i)&nbsp;listed on a national securities exchange or (ii)&nbsp;held of record by more than 2,000
holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving
corporation as provided in &#167; 251(f) of this title. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall
be available for the shares of any class or series of stock of a constituent corporation if the holders thereof are required by the terms of an agreement of merger or consolidation pursuant to &#167;&#167; 251, 252, 254, 255, 256, 257, 258, 263 and
264 of this title to accept for such stock anything except: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting from such merger or
consolidation, or depository receipts in respect thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which
shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger or consolidation will be either listed on a national securities exchange or held of record by more than 2,000 holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the
foregoing paragraphs (b)(2)a., b. and c. of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger
effected under &#167; 253 or &#167;&nbsp;267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) In the event of an amendment to a corporation&#146;s certificate of incorporation contemplated by &#167;
363(a) of this title, appraisal rights shall be available as contemplated by &#167; 363(b) of this title, and the procedures of this section, including those set forth in subsections (d)&nbsp;and (e) of this section, shall apply as nearly as
practicable, with the word &#147;amendment&#148; substituted for the words &#147;merger or consolidation,&#148; and the word &#147;corporation&#148; substituted for the words &#147;constituent corporation&#148; and/or &#147;surviving or resulting
corporation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for
the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation or the sale of all or substantially all of the assets
of the corporation. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d),(e), and (g)&nbsp;of this section, shall apply as nearly as is practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) If a
proposed merger or consolidation for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its
stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection
(b)&nbsp;or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations, and shall include in such notice a copy of this section and, if 1 of the constituent corporations is a nonstock
corporation, a copy of &#167; 114 of this title. Each stockholder electing to demand the appraisal of such stockholder&#146;s shares shall deliver to the corporation, before the taking of the vote on the merger or consolidation, a written demand for
appraisal of such stockholder&#146;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such
demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#146;s shares. A proxy or vote against the merger or
consolidation shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger or consolidation, the surviving or
resulting corporation shall notify each stockholder of each constituent corporation who has complied with this subsection and has not voted in favor of or consented to the merger or consolidation of the date that the merger or consolidation has
become effective; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) If the merger or consolidation was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then
either a constituent corporation before the effective date of the merger or consolidation or the surviving or resulting corporation within 10 days thereafter shall notify each of the holders of any class or series of stock of such constituent
corporation who are entitled to appraisal rights of the approval of the merger or consolidation and that appraisal rights are available for any or all shares of such class or series of stock of such constituent corporation, and shall include in such
notice a copy of this section and, if 1 of the constituent corporations is a nonstock corporation, a copy of &#167; 114 of this title. Such notice may, and, if given on or after the effective date of the merger or consolidation, shall, also notify
such stockholders of the effective date of the merger or consolidation. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this
title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving or resulting corporation the appraisal of such holder&#146;s
shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it
reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#146;s shares. If such notice did not notify stockholders of the effective date of the merger or
consolidation, either (i)&nbsp;each such constituent corporation shall send a second notice before the effective date of the merger or consolidation notifying each of the holders of any class or series of stock of such constituent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation that are entitled to appraisal rights of the effective date of the merger or consolidation or (ii)&nbsp;the surviving or resulting corporation shall send such a second notice to all
such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this
title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal
rights and who has demanded appraisal of such holder&#146;s shares in accordance with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required to give either notice that such
notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation may fix, in advance, a record
date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record date is
fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Within 120 days after the effective date of the merger or consolidation, the surviving or resulting corporation or any stockholder who has complied with
subsections (a)&nbsp;and (d) of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such
stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger or consolidation, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the
right to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon the merger or consolidation. Within 120 days after the effective date of the merger or consolidation, any stockholder who has complied with the
requirements of subsections (a)&nbsp;and (d) of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of
appraisal), shall be entitled to receive from the corporation surviving the merger or resulting from the consolidation a statement setting forth the aggregate number of shares not voted in favor of the merger or consolidation (or, in the case of a
merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase
or exchange in, the offer referred to in &#167; 251(h)(2)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of holders of such shares. Such statement shall be given to the stockholder
within 10 days after such stockholder&#146;s request for such a statement is received by the surviving or resulting corporation or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&nbsp;of this
section hereof, whichever is later. Notwithstanding subsection (a)&nbsp;of this section, a person who is the beneficial owner of shares of such stock held either in a voting trust or by a nominee on behalf of such person may, in such person&#146;s
own name, file a petition or request from the corporation the statement described in this subsection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) Upon the filing of any such petition by a
stockholder, service of a copy thereof shall be made upon the surviving or resulting corporation, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list
containing the names and addresses of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been reached by the surviving or resulting corporation. If the petition shall be
filed by the surviving or resulting corporation, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by
registered or certified mail to the surviving or resulting corporation and to the stockholders shown on the list at the addresses therein stated. Such notice shall also be given by 1 or more publications at least 1 week before the day of the
hearing, in a newspaper of general circulation published in the City of Wilmington, Delaware or such publication as the Court deems advisable. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof
shall be borne by the surviving or resulting corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the Court shall determine the stockholders who have complied with this
section and who have become entitled to appraisal rights. The Court may require the stockholders who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in
Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with such direction, the Court may dismiss the proceedings as to such stockholder. If immediately before the merger or consolidation
the shares of the class or series of stock of the constituent corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are
otherwise entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&nbsp;the value of the consideration provided in the
merger or consolidation for such total number of shares exceeds $1&nbsp;million, or (3)&nbsp;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the stockholders entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the
Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of
the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion
determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal
Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the
surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the
fair value of the shares as determined by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving or resulting corporation or by any stockholder entitled to participate in the appraisal
proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an appraisal. Any stockholder whose name appears on the list filed by the surviving or resulting
corporation pursuant to subsection (f)&nbsp;of this section and who has submitted such stockholder&#146;s certificates of stock to the Register in Chancery, if such is required, may participate fully in all proceedings until it is finally determined
that such stockholder is not entitled to appraisal rights under this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Court shall direct the payment of the fair value of the shares,
together with interest, if any, by the surviving or resulting corporation to the stockholders entitled thereto. Payment shall be so made to each such stockholder, in the case of holders of uncertificated stock forthwith, and the case of holders of
shares represented by certificates upon the surrender to the corporation of the certificates representing such stock. The Court&#146;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving or
resulting corporation be a corporation of this State or of any state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by the Court and taxed upon the
parties as the Court deems equitable in the circumstances. Upon application of a stockholder, the Court may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without
limitation, reasonable attorney&#146;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) From and after the effective date of the merger or consolidation, no stockholder who has demanded appraisal rights as provided in subsection (d)&nbsp;of
this section shall be entitled to vote such stock for any purpose or to receive payment of dividends or other distributions on the stock (except dividends or other distributions payable to stockholders of record at a date which is prior to the
effective date of the merger or consolidation); provided, however, that if no petition for an appraisal shall be filed within the time provided in subsection (e)&nbsp;of this section, or if such stockholder shall deliver to the surviving or
resulting corporation a written withdrawal of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder&#146;s demand for an appraisal and an acceptance of the merger or consolidation, either within 60 days after the effective date of the merger or consolidation as provided in
subsection (e)&nbsp;of this section or thereafter with the written approval of the corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be
dismissed as to any stockholder without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just; provided, however that this provision shall not affect the right of any stockholder who has not
commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such stockholder&#146;s demand for appraisal and to accept the terms offered upon the merger or consolidation within 60 days after the effective date of the
merger or consolidation, as set forth in subsection (e)&nbsp;of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l) The shares of the surviving or resulting corporation to which the
shares of such objecting stockholders would have been converted had they assented to the merger or consolidation shall have the status of authorized and unissued shares of the surviving or resulting corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc150774_113"></A>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROXY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT/PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_114">
</A>Item&nbsp;20. </B><B><I>Indemnification of Directors and Officers</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection&nbsp;(a) of Section&nbsp;145 of the DGCL
empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an
action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such
action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe the person&#146;s conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsection&nbsp;(b) of Section&nbsp;145 empowers a corporation to indemnify any
person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of
the capacities set forth above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner
the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to
the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the
case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in
the defense of any action, suit or proceeding referred to in subsections&nbsp;(a) and (b)&nbsp;of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146;
fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the
indemnification provided for by Section&nbsp;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#146;s
heirs, executors and administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the
request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity,
or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides that a corporation&#146;s certificate of incorporation may contain a provision eliminating or
limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for
any breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of
the DGCL, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo&#146;s certificate of incorporation contains provisions that eliminate, to the
maximum extent permitted by the DGCL, the personal liability of directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. Millendo&#146;s certificate of incorporation and bylaws provide that
Millendo shall indemnify its directors and officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL. However, the DGCL prohibits Millendo from limiting the liability of directors for (i)&nbsp;any breach
of a director&#146;s duty of loyalty to Millendo or to Millendo&#146;s stockholders, (ii)&nbsp;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii)&nbsp;unlawful payment of dividends or
unlawful stock repurchases or redemptions, and (iv)&nbsp;any transaction from which a director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of Millendo&#146;s directors will be eliminated or limited to the fullest extent permitted by Delaware
law, as so amended. Millendo&#146;s certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of nonmonetary relief, remain available under
Delaware law. It also does not affect a director&#146;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under Millendo&#146;s bylaws, Millendo will also be empowered to enter into
indemnification agreements with its directors, officers, employees and other agents and to purchase insurance on behalf of any person whom Millendo is required or permitted to indemnify. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in
its certificate of incorporation and bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future. These agreements provide for the indemnification of such persons for all reasonable
expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were serving in such capacity. Millendo believes that these certificate of incorporation and bylaws provisions
and indemnification agreements are necessary to attract and retain qualified persons as directors, officers and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Millendo has
purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of Millendo against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to
certain exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in Millendo&#146;s certificate of incorporation and bylaws
may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might
benefit Millendo and its stockholders. A stockholder&#146;s investment may be harmed to the extent Millendo pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as amended, the Securities Act, may be permitted to Millendo&#146;s directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, Millendo
has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of Millendo&#146;s
directors or officers as to which indemnification is being sought, nor is Millendo aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the closing of the merger through the sixth anniversary of the closing, Millendo and the surviving
corporation agree that all rights to indemnification, exculpation or advancement of expenses now existing in favor of, and all limitations on the personal liability of, each present and former director or officer, of Millendo or Tempest provided for
in the respective organizational documents of Millendo and Tempest in effect as of March&nbsp;29, 2021, the date of the Merger Agreement, shall continue to be honored and in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, the certificate of incorporation and bylaws of the surviving
corporation in the merger will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Millendo than are presently set forth in Millendo&#146;s
amended and restated certificate of incorporation and amended and restated bylaws, which provisions shall not be amended, modified or repealed for a period of six years&#146; time from the closing of the merger in a manner that would materially and
adversely affect the rights thereunder of individuals who, at or prior to the closing, were officers or directors of Millendo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger
Agreement also provides that Millendo shall purchase an insurance policy in effect for six years from the closing, providing at least the same coverage as the current directors&#146; and officers&#146; liability insurance policies maintained by
Millendo and containing terms and conditions that are not materially less favorable to current and former officers and directors of Millendo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_115">
</A>Item&nbsp;21. </B><B><I>Exhibits and Financial Statement Schedules</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)<I>&nbsp;Exhibit Index</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A list of exhibits filed with this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> is set forth on the Exhibit Index and is
incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)<I>&nbsp;Financial Statements</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements filed with this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> are set forth on the Financial
Statement Index and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc150774_116"></A>Item&nbsp;22. </B><B><I>Undertakings</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)&nbsp;The undersigned registrant hereby undertakes as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1)&nbsp;That, for purposes of determining liability under the Securities Act to any purchaser, each filing of the Registrant&#146;s annual report pursuant to
Section&nbsp;13(a) or 15 (d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15 (d) of the Exchange Act) that is incorporated by reference in this registration
statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona&nbsp;fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2)&nbsp;That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration
statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&nbsp;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with
respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3)&nbsp;That every prospectus (i)&nbsp;that is filed pursuant to paragraph&nbsp;(a)(5) immediately preceding, or (ii)&nbsp;that purports to meet the
requirements of Section&nbsp;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule&nbsp;415, will be filed as a part of an amendment to the registration statement and will not be used until such
amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona&nbsp;fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4)&nbsp;To respond to requests for information that
is incorporated by reference into this proxy statement/prospectus pursuant to Item&nbsp;4, 10(b), 11, or 13 of <FONT STYLE="white-space:nowrap">Form&nbsp;S-4,</FONT> within one business day of receipt of such request, and to send
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement
through the date of responding to the request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5)&nbsp;To supply by means of a post-effective amendment all information concerning a transaction, and
the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of
expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by Reference (if
applicable)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465921042768/tm2111026d1_ex2-1.htm">Agreement and Plan of Merger, dated March&nbsp;
29, 2021, by and among Millendo Therapeutics, Inc., Mars Merger Corp., and Tempest Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March&nbsp;29,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465921042768/tm2111026d1_ex10-1.htm">Form of Support Agreement by and between Millendo Therapeutics, Inc. and certain stockholders of Tempest Therapeutics, Inc. </A></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March&nbsp;29,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465921042768/tm2111026d1_ex10-2.htm">Form of Support Agreement by and between Tempest Therapeutics, Inc. and certain stockholders of Millendo Therapeutics, Inc. </A></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March&nbsp;29,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465921042768/tm2111026d1_ex10-3.htm">Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March&nbsp;29,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/mlnd-20190331ex31b53fa83.htm">Restated Certificate of Incorporation of Millendo Therapeutics, Inc., as amended </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">May&nbsp;15, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000110465918050995/a18-18482_1ex3d1.htm">Amended and Restated Bylaws of Millendo Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">001-35890</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;9,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000104746912008575/a2210793zex-4_1.htm">Specimen Stock Certificate evidencing shares of Common Stock of Millendo Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">333-183602</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">August&nbsp;29,&nbsp;2012</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex42.htm">Form of Tempest Therapeutics, Inc. Warrant to Purchase Stock </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP as to the validity of the shares of common stock of Millendo Therapeutics, Inc. being
 issued in the merger </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex101.htm">Lease Agreement, dated February&nbsp;22, 2019, by and between <FONT STYLE="white-space:nowrap">ARE-San</FONT> Francisco No.&nbsp;
17, LLC and Tempest Therapeutics, Inc.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex102.htm">First Amendment to Lease, dated June&nbsp;
28, 2019, by and between <FONT STYLE="white-space:nowrap">ARE-San</FONT> Francisco No, 17, LLC and Tempest Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex103.htm">Loan and Security Agreement, dated January&nbsp;
15, 2021, by and among Oxford Finance LLC, the Lenders party thereto, and Tempest Therapeutics, Inc.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d150774dex231.htm">Consent of Ernst&nbsp;&amp; Young LLP </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d150774dex232.htm">Consent of Deloitte&nbsp;&amp; Touche LLP </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.3&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex233.htm">Consent of SVB Leerink LLC</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.4&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001544227/000119312521148605/d150774dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in the opinion filed as Exhibit 5.1 and incorporated by reference)
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774ds4.htm#sig">Power of Attorney (included in the signature page hereto)</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d150774dex991.htm">Form of Preliminary Proxy Card of Millendo Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.2&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex992.htm">Consent of Stephen Brady to be named as director </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.3&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex993.htm">Consent of Thomas Dubensky to be named as director </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by Reference (if
applicable)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.4&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex994.htm">Consent of Mike Raab to be named as director </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.5&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex995.htm">Consent of Stella Xu to be named as director </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.6&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1544227/000119312521114415/d150774dex996.htm">Consent of Tom Woiwode to be named as director </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.INS&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.SCH&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.CAL&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.DEF&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.LAB&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.PRE&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the city of Ann Arbor, State of Michigan, on the 10th&nbsp;day of May, 2021. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Millendo Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Louis Arcudi III</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Louis Arcudi III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this report has been signed by the following persons on behalf of
the Registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Louis Arcudi III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director<I>&nbsp;(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Louis Arcudi III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer <I>(Principal Financial Officer and Principal Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jennifer <FONT STYLE="white-space:nowrap">Minai-Azary</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson of the Board of Directors,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Julia C. Owens, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Carol Gallagher, Pharm.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James Hindman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John P. Howe, III, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Geoff Nichol, M.B., Ch.B., M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;10, 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carole Nuechterlein, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="33%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Louis Arcudi III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Louis Arcudi III</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d150774dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consent of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;29, 2021, included in the Proxy
Statement of Millendo Therapeutics, Inc. that is made a part of Amendment No. 2 to the Registration Statement <FONT STYLE="white-space:nowrap">(Form&nbsp;S-4</FONT> No. 333-255198) and Prospectus of Millendo Therapeutics, Inc. for the registration
of its common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grand Rapids, Michigan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">May&nbsp;10, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d150774dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No. 333-255198 on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of our report dated May&nbsp;10,
2021, relating to the financial statements of Tempest Therapeutics Inc. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d150774dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g12t85.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">VOTE BY INTERNET&#151;www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of
information. Vote by 11:59 P.M. ET on 06/21/2021. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting&#151;Go to
www.virtualshareholdermeeting.com/MLND2021SM You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PHONE&#151;1-800-690-6903</FONT></FONT></FONT> Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 06/21/2021. Have
your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717.&nbsp;&nbsp;&nbsp;&nbsp;MILLENDO THERAPEUTICS, INC. 110 MILLER AVENUE, SUITE 100 ANN ARBOR, MI 48104&nbsp;&nbsp;&nbsp;&nbsp;TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND
RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors recommends you vote FOR proposals 1 through 4. For Against Abstain 1. Approve the issuance of shares of common stock of
Millendo to stockholders of Tempest, pursuant to the terms&nbsp;&nbsp;&nbsp;&nbsp;0 0 0&nbsp;&nbsp;&nbsp;&nbsp;of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy&nbsp;&nbsp;&nbsp;&nbsp;statement/prospectus, and
the change of control resulting from the merger. 2. Approve an amendment to the amended and restated certificate of incorporation of Millendo to effect a reverse&nbsp;&nbsp;&nbsp;&nbsp;0 0 0&nbsp;&nbsp;&nbsp;&nbsp;stock split of Millendo&#146;s
issued and outstanding common stock within a range, as determined by the Millendo&nbsp;&nbsp;&nbsp;&nbsp;board of directors and agreed to by Tempest, of one new share of Millendo common stock for every 10 to 15&nbsp;&nbsp;&nbsp;&nbsp;shares (or any
number in between) of outstanding Millendo common stock in the form attached as Annex F to the&nbsp;&nbsp;&nbsp;&nbsp;accompanying proxy statement/prospectus. 3. Approve, on a nonbinding, advisory basis, the compensation that will or may become
payable by Millendo to its&nbsp;&nbsp;&nbsp;&nbsp;0 0 0&nbsp;&nbsp;&nbsp;&nbsp;named executive officers in connection with the merger. 4. Consider and vote upon an adjournment of the Millendo special meeting, if necessary, to solicit
additional&nbsp;&nbsp;&nbsp;&nbsp;0 0 0&nbsp;&nbsp;&nbsp;&nbsp;proxies if there are not sufficient votes in favor of Proposal Nos. 1 and 2. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or
other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN
BOX] Date Signature (Joint Owners) Date&nbsp;&nbsp;&nbsp;&nbsp;0000515548_1&nbsp;&nbsp;&nbsp;&nbsp;R1.0.0.177 </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g150774g13b07.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Special Meeting: The Notice and Proxy Statement/Prospectus is
available at www.proxyvote.com MILLENDO THERAPEUTICS, INC. Special Meeting of Stockholders To be held on June&nbsp;22, 2021 at 11:00 AM ET This proxy is solicited by the Board of Directors The undersigned hereby appoints Louis J. Arcudi III and
Jennifer <FONT STYLE="white-space:nowrap">Minai-Azary,</FONT> or either of them, as proxies, each with the power to appoint their substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all
of the shares of common stock of MILLENDO THERAPEUTICS, INC. that the undersigned is entitled to vote at the Special Meeting of Stockholders to be held at 8:00 AM, PT or 11:00 AM ET on June&nbsp;22, 2021, online at
www.virtualshareholdermeeting.com/MLND2021SM, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the
Board of Directors&#146; recommendations.&nbsp;&nbsp;&nbsp;&nbsp;Continued and to be signed on reverse side&nbsp;&nbsp;&nbsp;&nbsp;0000515548_2&nbsp;&nbsp;&nbsp;&nbsp;R1.0.0.177 </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g150774g02o42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g02o42.jpg
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M! 8' 0(("1$3%!4 $A8A"A<Q41DB06%QL?#_Q  < 0 !!0$! 0
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MF,H23& VHQX)T >KDO\ S_\ ?^_R?ZKG0#<S=3V'<W77?] 2H%#AL/Y1E=$
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M\_.^HQB_C*CD8EL6ENW:GDDDRD5D822HQZ7]FV&?B1M8&3:E$Q,FC[A#1H:
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M[+-#%=KL_>RD=X(!*C-)Q71C544\V*D'QY'@&+:UY<M>EI[P5;[RLH(Z! !
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KX3OI_:G%FO8]S.*;=HO'#3R45FC/(G#A N.B>1ZX8@%6[@BB(WV]  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g150774g11a65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g11a65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &9J^950X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <KK3
MX         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              .B   &@P         !
M                  $             !H,   .B
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   .B     %)G:'1L;VYG   &
M@P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #H@    !29VAT;&]N9P  !H,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     #ST
M   !    H    %D   '@  "FX   #R$ &  !_]C_[0 ,061O8F5?0TT  O_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( %D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M_P#SMV?#[0S_ -))?\Z/K%_\[%__ &Z/_2*AT;ZE=+VXV3G=*;AYE9]5
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\24R-4)$8V1TA*.DY$978F5F=8.SQ.+E)C9S@K3#)W*%HJ:RPL7_V@ , P$
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MSZ7(!S.-O9'?YQ2#TI2[EYU YG&WLCO\XI!Z4I=R\Z_2!S.-O9'?YQ2#TI5
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MX;EC )3<T5[[0B++L&U[#%O6TSACOV3TZ3LQ-G5B7W8M=?O=S-O_ -\9O/\
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MTVF<,=^R>G2=F&SJQ/BUW1F]:90MW]T*<L%A"ES9RM<DZY@[X\;.2A/L,BQ
M !M,-[<L0+J+F"O?:$02K!M>PA7IM,X8[]D].D[,-G5B?%KNC-ZWD,WG_F@[
ML&;_ !=-?KE3:9PQW[)Z=)V8;.K$^+7=&;UHY_YH.[!F_P 737ZY4VF<,=^R
M>G2=F&SJQ/BUW1F]:.?^:#NP9O\ %TU^N5-IG#'?LGITG9ALZL3XM=T9O6CG
M_F@[K$9O\737^#W8V^+XZ;3.&._9/3I.S#9U8GQ:[HS>M,DG=_="MPCY82YK
M .QQX06+QZV#M<@)P[)QBWTP#<)@R;%B,#;;8)EQ!M>]K6O3:9PQW[)Z=)V8
M;.K$^+7<7VLWKC.Y_P":#NP9O\737ZY4VF<,=^R>G2=F&SJQ/BUW1F]:.?\
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MUT&M->V5S97I>R.1-;1D*.5K$8JHC<;%3MI68GM"@% 0I+U%5_=H_+DU 7:
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MB:WBXWP[L?X1N6,P:(PU3(UD784#(HEKP!^D(T(!EA<74MM0,Y:H10AB*3V
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M-B:%1"Z!6]-[XH6O;9/,KR!R4"5(=YO4I*&3-*Q"G.(+,06?%;4(U6<VGJ3
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M"B@% 0I-U$7?$G\J(H%W%+M * 4 H"*=[HF[O*]>7,%,]W+ZKOI&FG,6J 4
MH!0$9BZ44]^7_P ^.% 6: 4 H"%)>HJO[M'Y<FH"[0$9?U10_(G+].U4&FFF
M<U#7TL;WQ>/.RV@*- * 4 H!0&P<FS<6/8>KDA+8%Y7C=8O'&5K-6\&I5TAF
MDH9H='2'!SLE77;&L3V^H+NCD!"N-0-UE*HE"M.* E. ZZ2+5!(H'D]-CJ<0
M9@*NEB1<JD"Z*RB1O9R=*-ARW)C3F8MQ@+$U.)*%HQ<&ZQ&X/3.\&*GP8&I
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MH"S0"@% 0I+U%5_=H_+DU 7: C+^J*'Y$Y?IVN@-0U]+&]\7CSLMH"C0"@%
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M"%)NH:[XD_E1% 7: 4 H!0$4[W1-W>5Z\N8*#33UEJ@% * 4!&8NE%/?E_\
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M_H::_'\LSYQOTC6W_)+\WY/BC@!W[2N?XO5_0TU^/Y9GSC?I&MO3\$OS>_\
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M0HH!0"@(IWNB;N\KUY<P4S\_N\NF7,"U0"@% * C,72BGOS(//CA0%F@% *
MA27J*K^[1^7)J NT!&7]44/R)R_3M5"9]W,N3FR^3WFH:^EC>^+QYV6T*4:
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M<KXE^'K3+[U9?^U2Z^[+=>O>4LLLDL!10 %%% "6666&P %@!:P0   -K!"
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M\<DD"2XSXU<K%UR:25+E<UKLB/1%O:F5%NR';ZL9/6(<EZ@.OR,W]5 7* 4
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M/3<R$/DRE3W'VZ,Q5I-<E"8#A(I X""B9F=*(UP<E5[$(TYQGV- ;&U :I<
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M0M8)VFGR9)D*07>'<$D?'0]+P,JDMT3658HXQ4-M $P1)8&PTFD*1,;ZZ/\
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M%V@% * 4!%.]T3=WE>O+F"F?GR\WM]P+5 * 4 H",Q=**>_+_P"?'"@+- *
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MS9'QF/95@A,.7/I\;CL2:7!L.?[K5,->28PQV>&!S*=!H2EC@L#0'KU0"@%
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M:?Z.@'!37VM0>!I_HZ <%-?:U!X&G^CH!P4U]K4'@:?Z.@'!37VM0>!I_HZ
M<%-?:U!X&G^CH!P4U]K4'@:?Z.@'!37VM0>!I_HZ <%-?:U!X&G^CH!P4U]K
M4'@:?Z.@'!37VM0>!I_HZ S2D"$@=S"$:0D=PW!<92<DL=P7N$5PW$  ;[V]
0PAO<.W9>X0WO;;:VP#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g150774g12b68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g12b68.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2*J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (HZ^B$8X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              (3   "R@         !
M                  $              LH   (3
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (3     %)G:'1L;VYG   "
MR@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "$P    !29VAT;&]N9P   LH    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &#$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MM_2OG7^VA_:,N8^T7?\ ;K__ ":F&#T@SCLT?!0V.;R" E2;5Z^7_P!R+O\
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MW!.0&\N"[%O0NDMU^R@GS<\_]_5BK PJ?YK'J8?$,;/^<Z4N IXWAVTV6'V
MO/D"?^IW*Q7TOJ3A+,:YP\F._P"_0NX&X: D#P&B?DSR4N!7N/#OZ3U:!.'=
M \&DH+\+.I&ZW&N8WN2QP'Y%W_IDZGVCQ*(V&@;'O8?$:)< 5Q^#YMHX<S'Y
MW?\ M(F-N;E8\B1ZU<$<_3:NZSNF8F8"[)J8\][0-MC?^N5[7/\ [2P;OJW;
M3DU/Q7>JUMM9-;H#P-[3[7?0M0,"N$@__]&AT/IHS,ZP6"::WNLN\_<[TZ?[
M7YZ[-C9^7AI 69T?!95A@/:#9=8^YQX(+G'9M<WW-VUK6KJNJ&YI%S?W7&'?
MV;?H/_ZZW_KREB.$;?9_WJ)5+]*CVEZ1_C_]_P "5M7!?K'#?[U(G[O#LH,N
M8]VS5MG)K>-K_P#-_/\ Z]>]2*>"#MJLD"#1%+%1<4Y*#FYN#TS&^UY[I!.V
MG';!?8\?FL'[K?SWN]C$5J:NJVW^;:7>?95<VW'HJ]>ZUC:&0'722R2=OTFS
MN]RY'JWUAZCU4N;:\T8GYN)42&1_PKV^ZYW];V?Z.M$/UBROV..E^E66FL4M
MR!.E8_-=5]'?_+3>()X2]-1D=/R(]#(9;Y->"?\ -^DCAC02&D?Q7%Y73Z1T
M_ NKH-5[SLM<Y^X6D^^M[=OT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X   $$ P$! 0            <%!@@) P0* @$ _\0 1A
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M32>"H2:]230& S.K]08''9[5\%C&492D2V7Y,M,*8*C:%*4M$-"EK=:D$I4
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MQ_/'ZAP?[D<\^?)XX;[_ +>!R/3?NZ;*54 $N35QV>I '[I@?%4Y<@@F['U
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M???>STLJ8S1UK4$JP:>TUJ?/V"1TBQ>,MW78GR.(Z<$S>0?W\'GC_0-1+ J
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MUY[79D/9>?,;)X##@!E'@^ 1X]2Q-2H;AG]2#85N&Y:P;""IW<.#4E@U-_\
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M:3R#_P"H D'D^./34H ^*A?Y@[]QVW!.$K65%[?W?V<L?7>IQK69YW(#6)%
M Y),B_BOGD\E@?/CGD@CA0?'/HF8,*"E/]OGZ8 F[_MN>:/A#L32!_\ BLQ8
M!B%=CSYY5D;N"!P#R#SUXY;D$>H4"1Z D,&-=C2QINU=L+)J"=[V:MJ-NSL:
MV#AGPDVJ\-I?]XKQS+(OY.T8Y(\_LG!/T!X)XY//'WZ0P?S!^:#]_7 N4EG!
M;BW+' SU-I]<<J6::L*\I_)0&*HR'L4Y7QPPX/\ J&7D\\\*7# !8_/>M-OT
M/TP:5:JNUP16H#\U%;]V=L,=U1P2!"IZMW61@K$G@%!X_H(X9E^QR?'D@(*$
MFMJ%W&U]V+6_4 OB-: ^S@BFZB[, UN'Y8;8Q?"0OXE"5(Y"2EPH?@*58DEE
M[< * 0I\$@GCUQ2& !9NS.?6PLWR!O@-1.[C]C]\'N^-NOCS98 0REP%+CJP
M)(0\ER 0 "&4_P#JX_\ >N07) KP:/87!J+VWOMASA.AT#X;DT!<C:C$ 4MA
M7BTQ;="\=9YH^Q5S ))/!_%2>!P.!Y(YYX''CZ"_"Y8:BU#9]AL6_1PV&!22
M[D L7JU XMVL+G"))BYHI?CDA=7'54#+\;!U!X_)DY'G@DD<DJ.!]^CT)5L:
M%JFAN26:[<@?3#-A6[<>M*?I;C&!L8SD!HI> K$,> 00>0"RD=NQ//;C]_'(
M"CTHH3L7J PO6Y+@GB@)?W..(_(A_P!_3'U,4P4RA7X5PI#,1SV!'UUX_P"5
MO((((5N"/0%!KJ:FQ[;]F&S/LV#"B&!J*@OWYN_]V%:??Y8[M\I;RP;KY#$
M,>.00.0.1SSX'WP?Z2O0+FCD$;,.S6I</N"-L-']A2@]OZGVMC;%(=@6!ZJ
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M_MA2>"[; !W[VJU=C;LQ4,9@<WE2JT,=:EC9@HDZ-\/9N" 'Y0$_MU['GL>
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MOIC464S<VP-VUI)+5*]@[LN7?$M-0-:NXGR2K1O5U-B5Y)/@6Q#\0<0RCNC
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MB]C</4J-7M2JQ>K JU:Q:E902O)^I657/4KJ3"$S"T&&G4A*4I)#$I8D@7<
M) #5<AZ-C%@QON\"+#BJ\.+KB+0D@@$7<$$ N=5 ' ;%@7O V&R>HMIL?HG;
MC PQY')_HL'22%*U7%5DE;O:O7"69X(JT7:1$@J332R<A63P3=4E,. M(0$N
MDI 3=1(:K,'-WN3N'QE2\R?O*(L6(I@H7JR18?H--MZ8(_M+]@&WVP^E<?9R
MRQ9G7F3IH<YJ&POQRN\A69Z>/=A))2QZ?BJ0P$&8I\DQDD(ZYL" (9"U$*5L
MHAPGNEZBER0[>IQ9G,Q5,*,--(.R7-2*:ED4(#4%6=W!M,6[M3B#&R8U/D"
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MD>RR98B95)1'(:"@&Q/D\OSX?9G[9N9H:;C@4\R5#=W0#VN[VP7J5IBT4B2
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M)8&IZ+RN K([?B7-O7$>DZ4T;H8RDL=B2'APX=T+$55]4P8J_P#R&3]29D]
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M.XZWD+%JU9AB=#&I^&" M(?GGG=DCBC*]VD(55ZAB+"25 ))  J7(\H N34
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MJIY\/C\S)G:>EV@*XU)+,S31XN)FEFFGB20".)/HJ[DE>"3CQY!*S&B!9"%
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MY6KC1^G@LW&0M#AHY6)6*%4>-+4@61XHNX4+(?&@$, 4T!!TBY;8;6:GS<U
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MXP,3-_LN3%6N;5,MJCS?V=JFHT6/U%ED4O&_X:,>+U/E.LRTK!SW+H"\S@Q
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MD2UE,GD(^E>]J"W!/)"T]<&CAZLLF*Q)E67(9+*(RW+9J8F(6:9T$B/ *_\
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MIS0 S4U='CKTY'$ULS*)(5C8% R]?5V%$2"E0("07X!8%6DV=V8AVV+/C,5
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MOI "4H0&_P!1-Q=Z/R22_%"X>RF[VI;<,]+&25=-XV8%9:FGJPQQF0'Q';R
M>3+7U X'^^WK \_ZD>JT2*5N D)V=+N233S%U!@]00X)%CAZ8: U"LBQ)IZ
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4WQ_-+TX^1^5J)(#E_7_I3CL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g150774g12b69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g12b69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1]24&AO=&]S:&]P(#,N,  X0DE-! 0
M    'S:^>9 X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              (2   "ZP         !
M                  $              NL   (2
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (2     %)G:'1L;VYG   "
MZP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "$@    !29VAT;&]N9P   NL    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     %-H
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@ , P$  A$#$0 _ .=SLW/&?E@9>0 ,BX "ZS@6/_EH/V[J'_<O(_[>L_\
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M((D'CXHGHM/>/$)*:[ZJLEOZ>EEHX(>UI^XE8O4/JOAVC?BDT./YI
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "J .\# 1$
M A$! Q$!_\0 '@   04! 0$! 0          !P0%!@@) PH" 0#_Q !%$  "
M @$$ 0,# @4 !P0'"0 ! @,$!08'$1(3  @A%"(Q"3(5%B-!41<8)$)A<8$H
M,U*1)B<U-T-EH24X1DA66&9UI?_$ !H!  ,! 0$!              $" P0
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M>?&';:T;S]M)V]\OOA0_=[TO=Y\ <?\ :8WL!8G\'C^>?P>3S_O?^?KO\_\
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MALCG<EB(/6;I]*$GUR",=SN(W;@'CS>'QFKT=7JL?R192D@U%EV&%91O-BQ
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M^U%#G;^>^C#ICV]ZRS^(7+Q-B:5>2+R00V[A\TZ\,6*I%',(RI7JPD92'/4
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MQ:X_;8SGR#I]>74M[2';*5VC@VW-_P#G&FFKB:EE@*.F[MF;L L2369XB?D
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MG;%8;LVR/SJPW@<.?>_Z _&V^JT;C^WC:C="O<_FK1N.-^9F7^-XPC$YP'J
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M(Z.R !6XY^QH"X"'F)BWQPS>I,ZSV2#N9!D!H0]_5:WP@:8B/(6 7ZG!@-[
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M(IVK5MA61SXQJA)S=!$Q5\-E/!CVPN^VAIJ]+,]E692L,$0CKNJ=N1,.9@C
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MT@>_ME'6OI_APBQ@B#;3W+):M\JCGYK&H0,S-M[FM&9_14ZSY;!K];#G!!+
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MVE@X)Y^&;ERW8A G+% 0S)&R@ERL8 X5F8=% &- HC14@MSSMVE;-_.K1[*
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ME]K_ $TV6) 3+]RLK L6;A6(',K\!6**I*QE1PQ(^UU4*6]=!C*4Y=LHE1E
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M>*ZD];Z6> ]@40L@CCAG2146(!4*$*JLW'48G&<OL5[77/SJ\0[1,GO7-_\
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M]1&7HE% %'#W9IWO;%51OAO.M#K0EB/+&%"R ,\W?J5Y<?:9$"I_<=C-&H)
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M=.S+(1))5R&0I2S4JK52X62L\[W8S&'$488<J/=3'&XW=GV]ZW7CG5O[_O\
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M:7^OOI958\&]EU\<_O\ UTVS:/B@R+VG6W!;5WLFOX6A)9#(">!''V5G(8J
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MRFD-9:"M37MN=L+%:WIK5FL,CD#C+-BT^0K4:^*PV1FCK4R;EN6J/JI76G-
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M@DDBZA@)"0\9+*5(4#\J22?@<-*4:C(N+VCRW3>+*5H"5W9B[K7!;(I<%6
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M<7CXP[G[-<H9QJ&YG49C\KV&#W95F$2Q,TR8]2"(CU8*[3?UU;GJ9.(BH/\
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M+#X*IP6X-7"XR*ICXWX/'E,!G< >69VY8W(!@HBQIP=S11<J57&5SSC3Q M
M+=ZRAY7->W'[ZB^"T[J/5-Y:& QF0RULCR/'4AD<Q1KP#-8E[B*O I/,D\[1
MQ)Q]SJ/CTTI1@6H'C'\#)^VKD>T[EHJV\ U[N[O@NAV-75VP]@N[NN*JYG-0
M0::TTD8LW<[D9DH8:K".[%[&H\K+1P**K1E7:I<RC*3V\+<A6S3ZA-(P;FM=
MD4E.@M7M'M'<)5*KPUHO4C"*UW0:[F^T,W\J[A5OMHU1::]COMV"RZGU=/OA
MK.F$#Z?VV>'*XF.S&S%H<AKK,P5L7'$#QWDTYAC;B"E$LMP#ZYZ;%DSE'I@%
M6?B35[K]!VQ-HTLL"RK :?IRZG5#MZ=1D9DK&)6"L*HV;9C28=:$?I-^Z?=#
M=WW\;,Z2VHVIPFV^T%8;EV=8QZ<Q$F>RDT,.SVX$F&_FK7F6@GR+B3/IB&@K
MQ35$EMB&,I)&>GI.G+I0Z_3B1&3^)4I%SD4O<QCB+$N-@8:O.%ZO0[>AU)RD
MSD$.VL=MSB+N6)@DU96+SJ->]+<SWQ^V+W#[\W,KD(]Q-F,]O1N9DL##J7%T
MM?Z+JXG)ZUS=^C@I[EFL]W3]FC3L14VQSW*PK^/I CHD1]>I+J_4] 9,?Q8.
M8V8(M-82@-]URKR1Z?\ E^K")1T^I C_ .FT,O<T9YK*9;YK!6]WOMGW*B%#
M>#8W):%OS1.D^;VVO5\UA!-RQ#_R;J-'@K1LQYZ8Z<2(/M1@2&#0^I^EZYV]
M2$NBT#VU**<V-.[:4O!XTK]-U(>KHSK=[5ILO;%>#:R_MKN_MN]JF[B))M!O
M9HVGDKC@08'4F3LZ!U 97C["'^'9X9#&V).Y*!*4U.)R"(W7\>I2^F^FZGY)
MQR6(]JE>)-9=SQNY+Z/5^JC1*(E$F27=6.0&Z-[S?FC0DUW^GOO)I:-[-"G9
MR6. #PV_X;8LT)H_WF1,K@3FZ7C((82V'J(5'9NH'/K'+_#IQ>XE<54$KR.3
MW<71><WJL/K8..I&4;%'%/:>Z7BMN,5MJGFL-MM;Z!F6/4V$N8Z.0_[/<^V>
MC9X9U(KW:QDK.RE6+1"7RI\B1%(ZB4NE+IX8(;=U>E:\\W^_ZZK'J=/J"Q<I
MM8*UG%WO9B]^6G4*$TJ<CCDGGECV_M\E>>0.>>/^?'_(^D7^OEQX/GGC^#]U
MC:/[/'S_  K#YL<<3J;-8.9;6*RV0QEA.#Y<=:GIS#\@<R5Y8G XX!^[C@GX
MX/RA-,QJ+BLU^VV,;^.=M)*DI[9"&$$HQ7MSX:K9QHZ87W.[A5%CJ:D&!W H
M1 =*VM<+6REU!\$)7U#3%#4]8CK^8,TBKR3Q\L"SUIPJS\3..Y^U\R/ =V7>
MW2'1Z2O;<.;@IS[W?'%)N<:LKH/WO5L%XH8,CN?MB "WCTSGJ^X6DPX;GD:3
MUF8GJ0GAN8XLI<9$'VGDD^N_S!D20V9CFOLYRIM5X!\3?II4VQF9K\2/;(YQ
M*+[9&J\8S;C2?OWMWEA7^=MF-:HI"B'4467VHU((_P"W>:Y!-IA9U0GLT+O7
M'!56,8'-?Q3%)3\C0\VU\?=^,TOITJXSJ\RCZBO8H;3W=]6'Q/NTKY2 M<VM
MU>\ 4%;FA,WI7<7%$?N#%<%<ISM$Q^%!A# CLW+'@MW=V*LO*2&DMX>[^%[:
MF],QZF/_ +XL1^&OUOCXU)(_=CM+&4BOYC4NE;'Y+ZCT=J;&3UWY5)HI9JV/
MOP]HRB$.)RRE6_J GD\3(LB9;>U46;--?*&/TTC%VP_#2<>?/\MLFI71]TNU
M5]HVJ[S:/C9UZ\6]1RX^8./G^K!D_IVZMU (E"@-P3P_4^G5L:#'D 6N;Q6]
M^[\*3C+M3.3?+_#DW\XM\ZD,.].F,HJM5W*T9?,D9X6MK? EG*@<(T,>0/C#
M@#HDD?<@@'Y)!6<DR1 JKN[ODIO/GP'B]3[9W?)SQ]K=O;3O#N+!93^EJ/3\
MZ%XY0PSN%FEY[$!2BW2'0CY6/J #]Q8<JQBS4&L;H[M7;C-O!XVXUU2V>ZJP
M.*:+'X;W^S@TFCU9C>'F:_CFF%B9D$67Q]6-F,C,S*/J&4'IWX92H^SKY 2Q
M5/Q642FEJKBU>:XO]=]LZ((KVNVQG._V/.*UPN;J8?'PR17=88.I7(<>*]J[
M&TT5& 8H\K78F0<\@_O^0O)Z\^EE-B53?#5W^A5[#QOH$924M.;\-8^X>=N7
MS!\O[@]J\6_6[NGH:BY5"Y&M*%HL0K,P9<=8LR'Y 55C4@-]I7]Q]*,ZV<[W
M%*C;M;1CC->-%A:5F_;QY\K^^=#?(^ZK9U.]6EJ;(ZGM2$^&#2VFM2ZA:8DJ
M%$4K8Z&LP(4JJM.P)8=NP5?4WI]24L%'$E*$]KOB_/&F(AYYW]Z^/&H%G_=U
M0Q5=9*.W^JHH@BE;>O<MIC;'%=>3VD\F7O6[?QT! 2N'8CJ%#CCT\>E(:9&W
M$92^-JKG8OQ[MC[\?SU6;6WZ@%BEY$AUUM9I4*Q/TVBL=G-T\]&5!X*WK9QN
MDWE  16<2P*5))''+4/I;7T=24N%EV0K%Y&PY,R=O&F(WY_AGW<_P_35-=PO
M>NFI?*EE]R-R6!8(->:H_EC2[DL?N&A]"-4K-#R"5CFSC]N6$JDGCU6/TKC\
ML'_T6R/F4LVC7Y<>:QJA%[4:_P#3<2W.]U93>-G/F]5LSWN.W5S567%8C+5M
M&X*=65\/H;$U-,12QN&5TMW\=%_&,@I#,C#(92UV!)8<GGUH/INC%)RCW2Q3
M-5,N2Z"^0K;!Y8/ KB^=O9O&<\)P-W!M+;<[E;BY$0:1T=JG5^1M..1AL/?S
M4\CR..TDKU8)B"2P[22LH!/)8?@]U.MT>D>KJ0AO^:3&Z%:S>POBA??3=JU)
MHCNI54"Y/>ER?;;5N]-_IQ[_ %RK'F]PAHW9;3?"2S9G=/5>-TX8XV9%_P#9
M[R37A+]RGQ2I"W/V<A^!ZS'^(0E7X,>IUW)73A)R"Y:(U1LOC?&FJ"I>8A*O
M(WDY?E^W%2@[3>P;:%_)N5OOJC?/.U!))+IK9O$#&X.:9.>E6;5.6E$4T#2<
M"2Q1G0A>2!R058G]9U>TC#I]#NA:]3_J,6RJ(AGM)%+S[.F5BA'IYWD.*;HB
MM&-U:VVUPM^^_26W]=\/[;O;MM_MK1B1XX,[JN2QKO4SRN24O3_Q%H\2U^+L
M3%-=JY-HN (Y @Z>G_RD>]EU)]7JJ]U*D+*"@1[3M4BR8&]=P.FDRG&I2^.T
M(IFP%''+8VF&G53MRO<-O%O'<6UN1N)J;57!40T;V0>/#U%/ 6.IA:GTV)J1
M1\#JE>G& /P/[^K]_:=O3"$<410XSL7FW=L^SJL8].+=1MSE5N_*V;M5YV\%
M/;C8+&U]-5MV]_<\^U^U*N9,="\!?7&X31,Q.-T/@IPDMF*?JT,N:L^+&4U;
MRF20J4]9:ZG6DQZ4;C'/4ZTKCTXX%.ZO7-,Q(\V+6M!UHP.T&4TQ&+M1NX0
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M[;?IIC\K\?\ VC_'/SJZ/M']O.P.3UG67);&[/9!592JWML]%VPI_/($^$D
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%^/.O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g150774g12r65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g12r65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '/R^=" X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              .X   &?0         !
M                  $             !GT   .X
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   .X     %)G:'1L;VYG   &
M?0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #N     !29VAT;&]N9P  !GT    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     $J
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M&SZ>#C'VMKCU+XVM9Z#6GW?Z)K/Z_I4_Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.[CY#T3-@*X_ZHQ[_P#M37V<_P#P/L>_VQQD;P\RF=W'R'HGN@*_5&,^K/\
MM37O>_\ VO;'VL]_;Z_9GC(WAYG?\4SNX^0]$]T!3U_PC&?5W]3+7V?_ (OO
M]NV/A][O[<,C>'F>?DF=W'R'HGN@*?5">_L];36/7_\ 8SV[]^^,>O/\_&1O
M#S/JF=W'R'HJ8L!7WY">W;U?O37K[^S_ *3V_!C&,_9^S<C=P/;MT\_1,[N/
MD/15S8"OU2G';V]VFL?:]?B>_G^O?';DR-X>9^*9W<?(>B>Z K]48^]-=O9_
MV&>V/M\9&\/,_A?X)G=Q\AZ*N#Y;.>V'_&S\"66\YS[_ &QCQ.^?5[^/MYQC
M&,\9&\/,IF=Q\AZ*N#Q96>V'^^>^<=DLMYSZOL8;[^KW_@]??V9XR-X>9]4S
MNX^0]%\^Z K[/.,=^V>_[TU[>V/A1CU>OX?]/:Y&\#;O/S3.[CY#T3W0%?7_
M  C'O>KR+7?&._K]B?7[_;_3R9&\/,IG=Q\AZ+Z4=,)PK.7LX\7MXW=AO'B^
M-_:^-W1ZN_O=^W?' 8WA;Q3,[CY#T7SBP%??D8QW[=OWIKW_ /ZGMQ[_ -CU
M_:9&\/,^J9W<?(>B>Z I]48[?]J9[9Q]OQ?X_M=^W+D;P\SILV_+O\V=W'R'
MHJ^GROU1C[TU^9R9&\/,^J9W<?(>B>Z I]4X^#_66O;V[_\ P.,C>'F?5,[N
M/D/1,'RO?&,2,9SGOC&,,M9SG.?9C&,(SG.?@QC'KSC^++(WAYGU3.[CY#T3
M)\KCQL9D8QG&<XSW9;QE.<>W&<>)ZOL]\>SC(WAYGU3.[CY#T5/= 5[_ $1C
MWNW[TUW]_P!O[CU?8XR-X?/U3.[CY#T3W0%<X^B<=_5Z_(M=OA]7[C&?Z_8S
MQD;P\RF=W'R'HGN@*_5&/O37YGVOZXSQD;P\SZ\\=4SNX^0]%7%@*>_(3ZO;
M^]-=O9_V'\?M]7&1O#S*9W<?(>BI[H2OU1C[TSVSC^)/OXQZO9_)C.<,C>''
M>?5,[N/D/15R?+8QXWE\>+W[8SEEOLK/J]7?R?;O]COW]_/;'KRR-ML\SZ\]
MNYF=Q\AZ)Z?*_5"?O37YG&1O#S/JF=W'R'HJ>Z$IG.<8D8]7_P DU[?7ZO[3
M['V>,C>'F?5,[N/D/1/= 5[]O.$Y_P#!-8[8^S^YSWS[/9C'V?;CC(WAYGU\
MTSNX^0]%7-@*^](Q]Z:]7_\ 1]G[>>WJ]_C(WAYGU\]R9W<?(>B8/EE9RE+^
M,J]Y.&6LYS_(CVY^#WO7[<<9&\/,IF=Q\AZ*GI\K[,R4XS[W[RU_'ZO$Q^/U
M=_7\.61O#S*9W<?(>BYHMHE,S1[,U67FR$QJ C"6VTY0Z\V\XE><I3C/BIPP
MKW\^WF+V@ $#?;R/'N637$DWUTON_#S60N:UL6/Y-BFK?>S&=\DREUUI",MM
MJSC++JV5=U91G.>ZT9SC[&>;&M!O<:@VW_GSQNM1>=QW [!OUY[;]BZ_N@+>
MO^$)]7P--9SGX/\ I,Y[_#VQ\';W^99&Z:>9Y_(J9W<?(>B^\G2Z?[9W*>_L
M\:.A.,^_ZN[>._V?@XRMX>9]4S.X^0]%\8L!7.._G.,_::9_D_M<X[\9&\/,
MIG=Q\AZ)[H"OO2<?8SY%K/XD?U]7O^KC(WAYGGG<F=W'R'HGN@*]_HA/;U_[
M4U_H1\/?^;V^S+(WAYGU3.[CY#T3W0%?JC&/_ M9_$C^7WOL_"R-X>93.[CY
M#T3W0%>_T0GMWSCOY)KV^]C^T]OMQZO5ZOAXR-X?/U3.[CY#T3W0%<X[^<)[
M=N_^M-?C\3M[WV,X]_X,,C>'F?5,[N/D/1?6#Y97?.'\=L8[Y[,MY[8[]LYS
M^X]6/9VSG/MS_%QD;P\SZIF=Q\AZ(@Z77_:/97C';OXK#>>W?UX[]D=_7CV?
MQ_Q,C>'F4S.X^0]$P=,*SG"7LJSCVXPPWE6/9[<>3]7;U]\9]?XN,C>'F?5,
MS^W9?8-G'9L3!TQE7B8=SE>.W=&6$85\.?W/D_&]GL]6/?SQD;P\SZIF=Q\A
MZ(DZ85G.,.YSG&.^4I8;SG';MC/?LC/O^K/?MCU^K[#*WAYGX)F=Q\AZ(HZ7
M1GLM[Q<]L9[*8;QGM]K+>,]L^]\/&1O#S/JF=W'R'HOG%@*_5&,^O^XMX]7_
M -C^?U8^SCC(WAYE,[N/D/1/= 5]?\(Q]KR37V/@1GO[_P#'[/5QD;P\RF=W
M'R'HGN@*]N_G&,>W_:6OY^Z,?Z/]/&1O#S/JF=W'R'HJ^Z IGV2,?Q--?S9R
MC_3QD;P\RF=W'R'HJ>Z K]48]N._[TSZL=O;_:>]]CO[,_Q,C>'F>?DF=W'R
M'HGN@*_W?&?L^2:]7K^#Q,?R^OU9XR-X>9]4SNX^0]$Q8"OU1C[TUV^UG.$>
MWU>OM[._O^_<C=X\S?L//DF=W'R'HJ^Z I]4)][V--?9_P#B>_\ C]6,\F1O
M#S/JF=W'R'HJ>Z KCVR,>W^Y,^SX?[7/P9]?J]GLXR-X>93.[CY#T3W0%?JC
M'\;37?V_]A[_ -O[7&1O#S/JF=W'R'HJ^GROU3C[TU^9QD;P\SZIG=Q\AZ)D
M^6QV[O=O&QC..[+6.Z<^S..Z,>K/P]L^S/;'&1O#Y^J9G<?(>BI[H"OL\XQW
M]?K\DU^;G[6>V._?VXQW]=R-X6V;S?OW?#ZZIG=Q\AZ)[H"N?^J,8_\ !->O
MU>W'[C[/M_FQR9&\/,^J9W<?(>BF $J@V*BDD(RC#Z5XRE7;OXS3BFE9]7J_
M=*1G/;'JQW[<TK:/DH;8/]G)?L^@QWXYO]?M]N;&;_A]5K?M^)^35:/9ZN_K
M]7MSZ_;_ %[?9YL6"\4? J6COHKK'>,%I!&7!\)/UJ-1HLB:J<37"AW -F'
M'QI#ZGUX[)4S B,]F\N*PVRG&<]N:V$"_EKJ=NG(6;]2.[PUWG@L3Z \)SU0
M7N'T(=0=Z$Z/(:$\(1U$V+I_J6CZ37K>QNG1F(D_8D$!<#VPIMQ*!-AJ%YH2
MW-J"V]<TR/5V"D9Z#+SAIQ"V8@ Z:[N[D>FU,HU&MP-NRYMV[!S?8L1]*OA8
M>L>X!_!\;6W6)T?9M9];+O6#5)-'UK0KG7MA5$[TO#K\8@V2)92>P+$&-JN;
MU*=$>Y9JJ0L"X[\1]HN2G/O89F=UMVM]V\?G;Y@K+(+VUTL=NV_P[//<I1TY
M>%#ZOK]MCP;S^R&=$FM6]?FO.J+=:J#J2BW*1M+7%8TOKJPV*M:[ADR=^-1K
MQ8)I4:-0\?CURNN$#C=BJ;()O,2(23,[N/D-_P %"T6-MHL+DZ:GF_D%U=O=
M7O49O7PDO@OFM23NH/I@U!:S'5-$N.C^H[IVO&M+1?"&G]2#;I;#Q2GSM@@<
M7RO6>D7%JGZJ*28+<'7>Q!5AM>6+B\RV @TN-Q:^EMVT\;7W@H ,IO8Z[CLO
M;?;2VTK[Z6O"M]9^^XE.V]*T;"DZ(W91^IVPAUB]-;&KD7IZF:;$VZ9KJ0?W
M"=MY"J[W'VR=5?<]>FJW4Z&Y4[,4C1F7%QF'&7V<ZZ#9X:[3QV[^SN3(-!?6
MXOV]G9I<CFT.T7X0GPFVW"_@S@A*W=(U=E>$CUWO2U@Y$?2^R#+.IH^F]<!+
M.R6+1_FR!G+B0L<A!4B@%"DUL>'=+QAKI4K&%9>G YQL+[^ W_!7*W70FP[>
M%_S^2G_1[X4KJ]W 5\&E=-L!M"8UEUZ6WJ2U 0I]$J=W%6^DVOIVC7!A6PV+
M>;OQD9/@7,W2YV%TKW*MXKXB5&\G9B\[+KC(.-Q<W!W>7XJ%H]ZUP1K]?#2W
M';P"V[\)3U;=6_3+;]=/:;J=<&:(1KZ_7W<>["&F;YU'/4>=3Y UR$,MFK]6
M7NGWVHZQ6!=*%K1MP6*N\<"J*S%>"14MKD2*YQ!T-M.=RC6@@WV_+GD<=$S_
M %G;JK?A#-[;P8ZM]1.]*-1\%G0.IRGA;76MEMZ.=$;%L,P+4B;+H"R&;'%-
MD]C^@CL^ZB]<&+I:*0\/U6.IPLVI%AYC<EUR;V&T[-!LW=P\5D6@@:6U'?H=
ME^W=?0FU]JUNZR>O+J'W!T;>%QZ;]Q/!99;1VA^FG:E#V76=17KIRL1,'M[9
M%4E.BS>L+GL"_P!E"X@M,PW*^2F%0Y8H(E9DEP,)V4VRT))VZVV'GCIX*AH%
MK?'?N/#0:[?B+[CWO"2]7/47,Z6.N;I+W"7U=:2%&T;T&]1^O]K:*%VFHPA%
M9VGU/:LK4G6EK8,6^WO3CL-<#),#:(943[K*O)65D5X8F6W"BPDZ F]AH@ %
MK"UR=+\ ;<]VNFN[-%\)]U=;*ZH[8)H>C%V3I_HO7:3Z*;53X.F=B.V@)5ZY
MYH)LF^"F_<VYNA1#HDS+0?>TTK7BYON#[3,63,Q6)V<@_4;FC<-NSCMY[U,H
MMKMM<ZV^MOIHMW^L'JBWM1>JKHWZ1]!O:MJ-CZD(.\;Q8-H[CK=BMU9$5K1%
M8$6.53P%9KMLHSY&QVYTLAF42=LK2:R%C2"K8PHZMME&9)N "!I>_P!/7F^
M L20;7M8;NV_/FO!3P>>][Y5=6>!*"AJ-KO9MUV-.\,<4%F;H3-(-C['KPEM
M&PUT/4;RX<CBJX&MQ),.NV(U80-A;9KGD7830QR,IY6L?S=-^AXG1;- 7'N.
MG/X66\6O/"X=0NN>G[JLNW517*FWU(:5Z:8'4<"Z8,:*VOI*Q0Q<ZQ(I4HM
MNAZX['HNZM(#;B3$CVMJ:[/Q9C\2,4?(!!ZUM)AY!YL23>VP6[@/@/%8EHN
M!OU-^'UT.[:I54/"6=6-5HFTL=0(FAT=V36]"E-%=0-MZ<=]:^I=@O&Z;C#K
M1/3\'1 ^R[#V7MBYAHDS!G5RJ@?K\':$-'<O)I\,>;+CP>;&Y[1P[O3XZH6C
MX:WU&FFAUMWGT4$K7A+?"$W#4N\0--U75[KM_0'6R Z=M@W6NZ+M+UJ'Z;,T
M#%NE[(%])"]TIM5GV.%,.10T[7@+:TJ<F#,3,P.6]"(9CS.ZQ[]NGA9"UMQN
M%OAIQ/;<</-7FS^%IWA=A_2!K?IVG4&];-W9KG>M\V5M&L]-6][R$''M"V5B
MIF-9 >GB5;:1M"LV%T_(\WV!-M=DD>X,8QDL/'GXQ80_AG-AQW_2R9-M^.FN
MZ_<=VSS6]6Q>H78]]\$-N7J/VEI<?K[:,CHYW7<[GI6[,DR%?A6>M42X-SP1
M2/&GBB\VHGY C,V(TR6A$9%;*Q4))HDK\\YD3=A-MUM1W:C;\% +. !OKNU\
M?KP7D'%\*CUGT;2_4E:-8A^FL%K/H4Z2?!K[GS12^O+X0(7(5U(Z+HU@L^NP
M)F%M <W51XHA.-R 1\A$M$Z# A P;L&8MP@=Q@'.X[!P'=]5EE:=NTD^1/IP
M.J]*/#>[1W54/!3;=W!H79A#3=EB8TF4-&PS!3%NDTZ][(I%4)UNJ68-8:],
MIQ9^;;A,@A9&D&/.JT-L%8:%QGK*R>!Y$DBX-@-#QW<[EBT"]B+G7N'?S;5:
MA]0_A3.L/I%OMMZ=[W$U9M?;^LMJZ;VL?M #7AJAAK5X/UW2AR_=0&T!=1FW
M^T2!-BH]UHMMIK!+W2%X,*60"1Y,&6_E+LN9S;B;\-+?#M0-!UV BPUUO?NM
MK;9JLI4_PD/53O$UTOT+5BM,T67UZ[NZS"&@-NWNCV:T5.E=,/3)G,.G.2*>
M+O51?V3M;;*A\NS#'46RK!X-6(QY.!,S*&W>,QOH18[+VTUW\G17*VQVW&W7
M4Z7[@//;\=X.C#K?,;QZ4=T;LW/"H5'/]-^RNH75.R+D+G&AFEK,YT]SIS)7
M:58)3VCYL;KHN/C)F35Y59)065".06'B[D!MM[,.)!.^QUMIOY-MFY8D6('&
MVF_X[!YKR%LOALNIW3C6\9UI :QW8&C] H7K2TI8@.DMN:%#.3+/O;7>D!0U
M C8EV/76_P"H6,[#:N4;8$ZOZR-GPX&:XR$%PY3<QG7G=Q\N?/59Y1IIV&Y[
M.P[=GCLX6A6V^M/4'6UX378T2WZ@VWO[2G0'TN[15'IM.M([6ENK8"Q+O%[$
MC]?3;]82@*U$M<9L< #,B6N?Z4GMUNQ8@L1BZJ_#7-[WUUUTW#LTV*BUAH0+
MD6\1K\SP^"WT(>$8V;9:!N+;%,V!IBK:WV+U@4KI9Z'SY366S=N&]BQH=3@M
M;%/UBB:L)Y,[FMAO8L>Y *.#8*ZYJHN-42DZR6YN+%Q@AD7G6VFRWU TMX_E
MB&C@3H#KIMOX=NT[.V^H^FO"Q=;6]K]TKZ$K\31E+V;M/JRZ_P#I/V!?+7JV
MXR0*'NE+6>N=B578<+64+:[)0"6DP;87@'Z,[L,G#>-1HC:+%$@M/I>F=VFP
M<3;SV&WP[>Y,@UU/&VFGC^"R9H#PH?5EU6 NB[5-(8T/I_>/4!7>KNR[#VS<
MJ5<;EK"&QTG;'G:\=$T'7L;850*R"UX<9CGS"RM^DII8)$R2S!,9?C*C,Y-A
M<#B>//SX*%H OJ?IWFQ^BZ.XO"F]9$?8 K46AZUHO:-ZH/1Z-ZG;Q9-*T39W
M4EJ+>]J(6VQU.'2-7W.LVZD8UIK.2[7)#!7;-FQ;FJ[;IN*O)@26 DXH0I<1
M87&S:.\_#=P5#0;[1K87VG0=G&ZP#X2?K=ZF^H/IO\)E0P F@:#UITT=+_2J
M9V+1;\(M+^\+1<.J*OUJ_OL5^WCK57@]';UC(<Q4F67Z?:O=B>CS8*I -<^,
M^,CG$W&P;QO\>_N[56M L=I-]FS?]%^G74*E.:FU>M:E+6O7=*6M:LY4M2U5
MH9E2UJ5G*E+4K.5*5G.?&SG/C=^;&_JCN"UNVGO/S4V?_P!DJSV]7^J2%W_Q
M.?ZOY/L8S[_;F,FSX^JK-OA__P!!9OYJ6Y8<Q_;/?]V3\_R3Y&?XNWO]_9GV
M_!G:S>>)._\ $_,[EH.WX-^045OJLIHUS5C.4J34[$I*DYSA258$3.V4Y]6>
M^,Y]6<9QG&>W;MZN9.V'N/R0;1WCYK\;'2[J[7W3_P"#^\$OUE:*)VRN=9>Y
M.JK16O+@D=N#8<S._:E>=Q72GWZA6O7)BW%:C.#NT>(B4]+'5:&[7\BF3.),
M=Q+C[NG2W;?R6W:7 \@@;..MUZ1:A\+)U<;(V0O8T#IZ)6WIH?Z@=V:2,TBJ
MZ6V+%N6N*MJ/-L@0]F3MZD+5)HMRLY(Y6F6K?JP=K\3+K(PQ&=C&YCPX@ZO(
M/-]FG ;E,K1M\S;ZJ=:PZ_NKZS=(QOK'M>Q.BJ.&V?T1=2_5!IS0H^+;@6Y:
M38]24P]9:H,AH)WHXQONJ"%BV(NW",(-K&57B3Z6(*<,9PVJYC8FX[!O&O#\
MU,HN!8[=21I:W9SMNL01O"3>$&35NAFN%8FFWMF]=FJ;#U'UHWK7IPV_MN%K
M;6-8UW1;'!U]\SL)M,0>V'>+*6M7I&T6J$;KH>A5[+OD !]Q466S,SK#7;V#
MNX<W5RMN1LMV]E[^?:%VMY>%FZK0/3Q7M@UX!J_474!0^E"Q=3.]>FJS::V[
MN"U1$UBZV.GI=/60);=?4C1^IK:U6TFJM9[+:[E>BN+!"@P*A(C#<%S8O.EM
M--18'XZC\O- P7.A/:3V?"YO\.V^BR7</":]3E3W5J.X;' :_P!!]%=YI'27
M:8NSC^H=E;AK5C?Z@ZJ'+W$#=MPZYNK$;ISL5<M1F+2]?XV)K:?6;3C*[*6L
M$&!AF(_2\@C<#8VVW'-[;%,@L;$DBXX"X^'U76UIX3[J[VMU/FH%(T9[H>GN
MN]=U@Z*[/4H&G=A9LU3J]5(*KA[?1OJ!<MJ:$DX*.>3.D]-(U[Y]$HKF)2;*
MY,9=F\9S?9IPWGGL[DR"QOMM>^[PV[-MQW+4.9U;=175YM/P2/4#?2NKJIJ[
M:WA(=M ]>Z?J(JU!MG4,)J./LK6V1VRCQ*W$AE\DFT"L'CK<:I5!NJ3Y@..A
MDJP;:2)Q<2=3Q-APV=G:%0  X6UMJ>-P=BSSX:FFRME=<O@M-=?.]'^J\99
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M/[;-(!VZ\->*ESKV[5Q;,U3J._3Z#>-I5:N&IFC;.[M"@V.QK5'1KZS#Q,^
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MK35FYK[LJGLR"T*QR=W;;T4#UIHBNRH#5,5 Z?1,DY4RKLM];0X1%!!YK,0
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M -<FY]7MSG'\#Q_%[WP^_P!V8<1Y<_5,IX'P3YYC0?\ ?2K'J]G[Y-]OK_\
MF?V^WP_8XS-XC\N?CN3*[@?SY^&]/GF-"?WTZSZ_9CRDW^;/F7?V^]Z_]'&9
MO$)E=P/S^5UBZN6CH:IUT.[(J$/0]5V+:,.XLU_K5"KX*[6-+ZTN/X/VH77(
MITQA]U*7'4D9\E+BTI4K&58QGD#F;;-T[#^?.JMG[#?QT]$59NAE>QD[A<A:
M'<VXAE,=&TUT&OYV.B/AC$7$=-XS7,V=+&(N$Q\-8*>3\AC#7B^3QA/'N_\
M;Y)[UK>];XKNC+UT5!*K:J*&7I032+W,LA"\4T930T"J7,A<D+:M\ZV5V)7V
M0]BF6MIQ:++*,0ICYY"U(*KEI4K&5VG>->[S!2S@=AT[_F%K[U@TOI"ZL^DF
MV]'\G<==U+KNRQM<#Q[NOP\**W4Q&LKW3[P"#5VOJ%,@X(I*Z; !MP(\5F+!
M&/+1#::RRRE,);:UP.[7MV! '7O8D]O=Q*R]B3X/[-./:[56NG)R@6PSFR6N
MD+UC4\U"T61;K;[EAL59S5U!#9QQ]II]98E"DSUO-H=5(RM"58 L MH;>&N_
MO^/@ EG[=?'7C;BN)_\ ][TD@Y]8D5#IID5HK:QU[*5U_5=/<!$KN(@1!8FY
M$!"ZFH?-M8L9!A#AMBDQW3$&!#BQ(LUJ/'9;1;L_[?#G47T^6U+/[;[-O.GD
MN4I(\'V;K!VDF:MTWEZ99KB0V)9*B4U?4B%7L6P"_B^EKT>K\NK.B2]R*>*G
MTC:"$22;G92GSF<[XJ>R[-]K<!;\?DI9VX.V=V@UMK;PXJ_Q[ET2Q"(0O%;T
M=&+UFFS]=UPI'I -DE7]?DUMNDJ*#G-UU,L332#C+2YU7@/, Y:VFUR(+BFT
MYPNSLW#9S^"MG]N\[>=?,JUQBW03#8U[&A@^GF+'U(W-9U1'C:WK#$?6#))"
MFR#6O&FJPANE-SVU*;FHK2!:93>5(?PXG.>Z[/\ MMV6^/';;G0)[Y_YO/NW
MKN:\M'0UJ%XY)U+"T-JV39Y#<NRR=<T*OT=^Q2FE+4U*/.UBN"W"\EO+B_$?
M(+D.HRXO*5XRI7>@M&HR[QN'/R/:$(=O!/B5E'/4OH/OGOM.L^W'^V3>_J_P
M/U?:Q\.?7Z^,PXCQ4L[_ )2?AZV3YY?0?O[2K'O^ORDWU=^^?>AX^W]O'?VX
M[\9AQ''PYV;TRNX'P3YY?0>?;M.L=NW]TFYS_/#[?#Z\]_Y\\9AQ'B$L>!\"
MJXZE]"9__6E6<_\ A)OKQZ\=^WF>/^#^3C,WB/%+.X'P5/GE]!]O^>E6?@_U
MR;ZN_O8SYGZO7C^+WO9VX#F\1\?Q3*X;C\_DGSS&@^_?YJ58]['?RDW[/;_J
M/[?&8<1XCGGO3*>!\$^>8T'_ 'TZSZO9^^3?@S[?X'_R_BXS-XCQ3*[_ )3S
MY>:9ZE]"?WTZQC./;CRDWU^S'M\S[X]7LS]G'P>L7-X_7Y?-,KN!3YYC0GJS
M\U*L=O\ MDW\?F?^C'V^,S>(\4RNX%/GE]"?WTJQV[>^Y-S]K_J+U]_L^WC,
M.(OQ_'9SW)E=ML>>S:GSR^@_[Z=9[>K_ &V=]G/M\S_DQZOM]N X;;CX^A3*
M[98\]NQ4^>7T)C&/^:G6<>SM^^3>WLQW_P"H\_Q=^_M[_!V9AQ'SY/F4RNX'
MGGNXJ_UC;VLK[8JZ*IMS#6(BR<C2W(@]<A3R(S<6:A;ZL.L-XPA*G$)SG*LY
M[KQV[\P>018&^OT*R:TWV$;/F#O[MWX';7FM;5J;9MU:HI9:8$M=Z" BS$N8
MIZ!-7)P^VEV9(<;RK#<=Q'[I.4JQ^ZSZL^]S8T@ ZC;W7&[Z]RTEI-B!>X'D
M H]\\QH3^^G6/?S_ *Y-^'_N/V?#GX>_,\S;;1YW\-O@F5VRW/?L5/GE]!^W
MYJ=9][V.3O;COZOH3V9^#[?MY,S>///PX)E=P^2KGJ8T'[VU*S[<9_UR;C^+
MZ#S_ .W^3C,WC\TRNX?+M[>SY)\\QH3^^G6,Y_[9-Q_^9Y_KZ_M,S>/S3*[A
M\DSU,:$]?_-3K'KQC'^N3?X_5YG_ %]7J][ES-XC;S\/Q3*[@J?/+Z#[YS\U
M.L]L]O\ ;)OJ^U_ ^W?/;OV^Q[_)G;Q\CZ)E=P^2K\\OH/'LVE6/L=W)OVOJ
M/UX]6/5\/V<=^4.;QV_#Y[#Y_!3*[@4^>7T'GV[3K&<>_P!G)OP?]R>WO_)]
MO/J9FC>/GSLYNF5W \\\V*B;VVNDJ3=8.RI!_5DC8PVNRJ@.V _7X;UW'U.=
M/;*S:O!M:PRCT6NS2;+)*6#8GMBY!!EJ6]%7(;0XF9F WT&^]OKSVJY76M8V
MX7_%6>[7KHKV60K9;8Z]*; *4Z6]/J!.[TT/;"%4GR<-ID3JU,/ )\@%+?0T
MTEZ2+<B/O):;2XXK#:>PN8=MM+;O47/T[MC*X; =>!^>JBR\^#T<A5L<NH=-
M*Q],JQ^C4V K55/5"J5)M<.:/M-.K,554RP JMF@DB$&P5T2W##F8<^;&)0Y
M3,I]MQ=G9PV?'9;9]>U+/[>.WAIX_3L7,=D^#\M ZC![-5^F^Q"-7PH0W68H
M[K"IEQNNAPUF-&'0*'!(55^+3X4"-#BQX,6O-#F(C$6.RPVVTRVE,S,[/#\%
M;/[?$>J[AHUT&V./>8EA#=/9^+L\G7S6RHQO7-9*Q]B&*EB*FJ%KVQ.K+[=N
M)UA$&$BO3[ DC+"IAQ$C'HN(S.$6[/\ MW[OP\/)2S^T;-_X_DI)!V9T>#+V
M9VD-):A';-L8>)7K%L6#5QT2^'@ _,=0\$:N$<(W82@:"J)%5#%SB#\&*J,P
MIAA&66O$79?=?CN\;?5+.ML-N=VU=LOMKI)/VFIWDZ>U8;NU"0=;HMQ,5^&2
MM5*;M$-D?945*PS0SY>MHL0^/'@G4AID-)>%'8BD,2&&D(2NPZZ=]OAY6^"9
M7;+'7M&[CKX;_-4@;:Z215PL.PA9W50V_6T>($VJ\#Z_#AW"S"J^EY $98;-
M&#-&S8\&B0^@/")3I,88E]Y,)MC#KF%+MVW%^.E^"6=;?;A^"M=WOW1=LR96
MB.QWM+[!GTLGZ:ITZ[T\1:YE3,^,TKTO691X"0? E,*CQU8GBEQ)>,LMY\MW
M;1V7:;:B_;SIL^7Q6<+Z'MYW[56R7_HON5IJUXN#^E[5=:*[E^DW"RT\2=M5
M.?4YAY3U5L)0#*+UUU3O[XIT1,AK4YV7G.5<79MT\-?E=+/V:V[]/G\U<C^V
M.D>UG:C:;2<U39;-K^<0*T.Q'Z]"-'J03*PO1I0E4#!(-)(5F<3'?V/(3 DB
M#(FP>T22Z['_ 'KB[>SCX_7COXI9]M_"U^'8#V?'XJ7?/,:$_OIUC./ARY-_
M0^W+F;Q'#?S\=BF5W [+[N;]B?/,:#_OIUC.._ON3?M_4?O9]GP8XS-X_/Y;
M?Q\%<KN'R3YYC0?J_P":E6/>_P!LF^K[7\#_ .#O[.,S>/.G/Y%3*[@?+M[>
MSY6VA/GF-!_WTZQW[_W2;^A_Z/Y^3,WC\U<KN'R5/GF-"?WTZQ]]FX_%#]GM
M]O?[.>7,VVWGNVJ97<"J_/,:#_OIUG[Y-_0_M_R8^'/)F;Q^?.[G17*[A\E3
MYYC0G?O\U.L=O7_MD[^+_J/M[.W?^7'&9O'YIE=P^2?/+Z#SCU[3K'O]L^4G
M=O9[^,Q/7[WJSG/?OG[66=O'@=_PY[.Q,KN'9SZ[%]M]2FAW5H;1M&L+<6K"
M4IP[-QE2LY[8QCO#QCOG.?AXS-X_-,KAN^OR6RVM7FI-,#R6%X=8D(D/LN)Q
MG"7&7I+SC3B?&QC/BK0I*D]\8SVSCU<TK<HG=]8TK9EL1#NHJ46BBZ[#DP6&
M#MA"MM2)1,BT^ZY@"5&>=+4W&90C,KR_D4I5AGR?E7?'(HY\ZAH7XESOESL+
M]J^$3YU#0OQ+G?+G87[5\(GSI^A?B7.^7.POVKX1/G4-"_$N=\N=A?M7PB?.
MH:%^)<[Y<["_:OA$^=0T+\2YWRYV%^U?")\ZAH7XESOESL+]J^+<W*)\ZAH7
MXESOESL+]J^+<W*)\ZAH7XESOESL+]J^$3YU#0OQ+G?+G87[5\(GSJ&A?B7.
M^7.POVKXMS<HGSJ&A?B7.^7.POVKXMS<HGSJ&A?B7.^7.POVKY+=_B>%N>W7
M:B?.GZ%^)<[Y<["_:OE1/G4-"_$N=\N=A?M7R6MQ\2?F43YU#0OQ+G?+G87[
M5\J)\ZAH7XESOESL+]J^$3YU#0OQ+G?+G87[5\(GSJ&A?B7.^7.POVKXMS<H
MGSJ&A?B7.^7.POVKX1/G4-"_$N=\N=A?M7R6[_$HGSJ&A?B7.^7.POVKY43Y
MU#0OQ+G?+G87[5\6YN3\T3YU#0OQ+G?+G87[5\(GSJ&A?B7.^7.POVKX1/G4
M-"_$N=\N=A?M7PB?.H:%^)<[Y<["_:OA$^=0T+\2YWRYV%^U?")\Z?H7XESO
MESL+]J^$3YU#0OQ+G?+G87[5\(GSJ&A?B7.^7.POVKY+=^RVT\W[=J)\ZAH7
MXESOESL+]J^5$^=0T+\2YWRYV%^U?")\ZAH7XESOESL+]J^$4@J>C=7Z]L4$
MQ4JY(&D'6)D=;TBQVDPWY/*6G,93%-FR41MU*VT^)(;83(0G+C:7<-NNH63;
MSSSVK-7"+7-W0>K+_--V*VUV06+OV2R,.2E'['%3AB(:FQHS+<:&5CQ66V8[
M3;2$,LMIPE..^,J[JS?@#WW^A"EMMC:VX6X \.WM5/G3="_$I[Y3VS]=\? ;
MN.[N(V[TMVGR]$^=-T+\2GOE/;/UWQ<<!Y^J6/$^7HGSINA?B4]\I[9^N^+]
M@\_7FW>ECQ/EZ)\Z;H7XE._*:U_KOBXX#S]4L>)\O14^=,T+\2GOE/;/UWQ<
M<!Y^J6/$^7HJ_.FZ%^)3ORFM?Z[X^ \_7FW?=8\3Y>B?.FZ%^)3WRGMGZ[XO
MV#S]4L>)\O14^=,T+\2GOE/;/UWQ<<!Y^J6/$^7HGSIFA?B4]\I[9^O.+C@/
M/U2QXGR]$^=,T+\2GOE/;/UWQ<<!Y^J6/$^7HGSIFA?B4]\I[9^N^+]@\_';
M^'8ECQ/EZ)\Z9H7XE/?*>V?KOBXX#S]4L>)\O1/G3-"_$I[Y3VS/XS?%^P>?
MJECQ/EZ)\Z9H7XE/?*>V?KOU?Q<7[!Y^J6/$^7HJ_.FZ%^)3ORFM?Z[XN. \
M_5+'B?+T3YTW0OQ*>^4]L_7?%QP'GZI8\3Y>BI\Z9H7XE/?*>V?KOCX#S]4L
M>)\O1/G3-"_$I[Y3VS]><? >?KS?NLL>)\O1/G3-"_$I[Y3VSW__ !W_ .SW
MN/@//ZD\CO2QXGR]$^=,T+\2GOE/;/UYQ?L'GZI8\3Y>B?.F:%^)3WK_ /XG
MMGZ[]7\7%QP'GZI8\3Y>B?.F:%^)3WRGMGV_KW_7V>SBXX#S]?G<)8\3Y>B?
M.F:%^)3WRGMGZ[XOV#S]4L>)\O15^=-T+[/<4[\IK7^/TWWXOV#S]4L>)\O1
M4^=,T+\2GOE/;/UYQ<<!Y^J6/$^7HGSIFA?B4]\I[9^N^+C@//U2QXGR]%7Y
MTW0OQ*>]G;Z9[9^N^+C@//U2QXGR]%5/2?H=M6'$4MY*T9\=*L6>V>I2?7C.
M/[.>]GWN/@//U2QXGR]%EW7[#<:BT]EK&<(160?K4M;BU*R-C96MQQ:E+<<<
M5G*W'%J4M:U*6M659SG,57,U].TW[EA?Y6,<(I3PB<(G")PB<(G")PB<(G")
MPB<(M6.IO9>TM61J99Z4-BR*7!)^=;&(.C(Y9YF W8:A$:$^;K*CYT1DK7)]
MSDPIH2&;-R;2)J]?&")\LZU F]E)##,9&2$B0C[H VN<KR2-"+AP8#F+6ACG
MN<0&DCGG?)'D<T>[<YS8&PS, &ITN"X@@$Y@T $FQQ (ZE+OL:#K.J4>TU0)
ML/;NRK0,)32=8)&!VI*B&I%AOH\2-&R)%=C[$/SPP,>.C6J&7DTPH7F6LV"F
M& M<C"7-[J2.(S/D8]T4$+'- >&FH>Z1D3G$V>8F![C=F7K&M# \->\E:Q.]
MXC:US6OED<+EI(C:&.D  ]T/<6MM>]KEQ%PT!7PEOK:&IMM&J;L& O953 T+
MIS>L=QJPROTP?7CNV]M[8URNPXK9$^7L!%1!P;2LD \(G.@CX 8X6'N1I<A@
M(1P%/#-"V2+[I[Y*D,8\NDS-ABAER%P:UK;!TEG%MW$M:0!=P=;)'(6OM(T-
M@!+;-L9))&9LI))'ZEP#I8FYT"YI_7#6!U@V#6O<7,/%J<FNR!$6FW&F6?-F
MCG]M!M-^9.36"L0)7;% M)X:[,#$B[C$>$^MN85ADHA&!"-P][F1OZP,#R\.
MZQCV9"V!U0#8C,YKF,=9P;8FUK@@K(U30YX#2[+8#(YKB29!'8Z@-(<X7!)L
M#?B%9+IUY"J5&BBR&L"N-AI+[ "E*)*N-7@OK):].4<),#T\JMQY%]LE@^:+
M5BE9K@*!@H0&.%<OM1" U(^7E'AQ?=W7#JLL;A((WNL)&R.!D:/_  F@0R!S
MG&P('_,%'58;9N0]9=X+"X W86MLT['..=I:T:D9K?JD+*5-ZK:[==R3-2#:
MF=\6+8;E3,VAEZ-.BL6R@1'W[-'+BXJ5RP=>Q*@%PP:QD'6VBQH8J'YE$9*
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M@&@ '4!8KW/T6B=DW!NYTV[SM8%I8Z[13$\2S:G331F]2JI)*7:J':_?Z;-
M6Z,BG!F1_I3%HJ4945F0FI>65/40WT]>Z&,QOC$H#HRVY9ERQAP#)&/BD:]A
M#W9K9'F]L]K!82TH>[,UQC)#P2,U[ORW<"'MLX91:^9NGZJV)KVEZ'5KD3OH
M-BR0+":>E33##-[O"*B2+D(L:(3L$C7*;%C7:;&4;B-.$3[%5:+S)67YCTQ4
MN5)>=Y7SR/C;$XL+&V#?NX\[6M)+6B7+UN1I.C2\M L+6 "W-B8UY> X..I]
M]V4DBQ=DODS'><MR==J7?26L]B2CD^V5YZ:2L0>F R12 ?L@ LF#KNV$+W2%
MBRE>+BR $G6;>4FGQ9L%)'&6)[C:LSUMQHK;*.HFBRB-Y 8Z1P:0US;RL$<E
MVN!:X/8T-<UP+2!LNH^&.3,7-U<&M)!()#'%S=0006N)<"""#OLHPQTUZL"U
M@W7J<'D5645HNQ*#&L""A:R%1PS:!V=;;7+7[KYYV.:(3[>0?LK\@\T2<?G*
M7'=6J \]%7D:J9SVOD=G#9(I"TAK6DPM#&"S VP#!D%K6'<%.HC#7-:W+F8]
ME[EQ D)+OUB;W<<VM]>Q8KUGT:5VK5HC6;W;#5S'^DZB6J<2N'-GT-C7Q>H!
MS -NR4<JK:EKN]5M-B''9\"UDZW<PP\R*\F,6%9CR3&2VZ6N>]X?&QK'6>UY
M>V&8RM>YK\DC3"R-[&%H+&NC<6GWLWZH;KCI6M:6O<7W+2+&1N4L%@6GK'.:
M3<WRN (L+6O?84#J&BUJTP;J(AGFK-"I(S7BBDR[7<LHM5@L\@3#Q[-&+6*=
M#MI85-+F'AUGL\<O9X?IDPW',-M%9Z)',Z:1S#&XM+#(9;".-N5[@ XL+6 L
M!  +&%K3E;=I+01N$;6N#AFN&AERYQNT; ZY.8BYLYUW:G56^S:*U=;F+JR<
MKCZW-@V.JV^SD!MBLX R_::/" CJE81!T 9&&:N7 PZP#:@SJO.#R$*@X=<6
MX](E./UE1,PQEKQ]TQ[&!S6.:&2.<Y[7-<TM>'%SB0\.VVV6".AC=GNW]=S7
M.(+FDN: UI#FD.! :+$$$64>&=+VB0]>)50=0H[  Q6R=2)P%';1(\\KYFY&
MM@E(+TN2;>G97-N5B-'7IV).".9$]QC$O$-#49O-U74.>'F4EP>V0'*P6>QC
M8VD - &6-K6@6RV&Q8B"$-+0P %KFG4ZASBYPO>^KB7$WO?5=BU]-6F;G,*$
MS57(LES5C)VHH;KETO=-/3"IRL5NFGF7#M0LP(ND$?K5/JPP[5FIJ*P9P!&2
MR0B5.B-2DQE5/& &O!:U@C#7LCD:&M>Z1ONR-<W,U[WN:\C.TN.5P1T$3B26
M:EQ<2"YI)+0TW+2"0YK6@M)RG*"1<75S=T)JW 2Q5X8#*587:BP V9;HMQNM
M EKGU>J5ZC@_1Y2E6$"4!PH-1JH !Z*"3!PN2/@8;F0I"I,M<B>T39F/<X/<
MQKFMZR..4 /<][KMD:YKB7O>[,X$@N)!&BO4QV<T M#B"<KG,-PT-!!:019H
M T(%@LC5FM J;7052JXR*%K=9$#@($1"3E$08'$Q&H(Z!&2I2E89BQ&&F6_'
M4M>4HQE:U*SE6=3WND>Y[W%SWN<]SCJ7.<223WDDK8UK6M#6@-:T - %@ -
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M=R<D$9 @*7D#"3<T8[4Y >8/;E1S7;R_D\N-1E;!63&!LHIB'O<X")T@) ;
MZ8YC&UY:X.:8BTMN']A"ZF]*L3DP6'%68 X5$U1+$R@?6W<V*+"*C$R^>2GI
M*E]/,V:!V&OII8&R1U0N_+F9&Z+6'<6[',6>;6*./CQJI439(G%FPIA1ETK!
M=V9!A*%$5D*]/*.2I]7J3D<1'K_9V&:(JE%(2,#93NF2KK3UKHX&@0PR/+2U
MS[O;[4UN5V:-S[NAA(8V/5KW>^!E<N&MZ1]*"*^6@PF)C,/PVLJ)XYHY)VNG
MA./PQ&FF,]%+4F2;#L-='3,I!FAJYC)41CJ'NO=@V5M4/\T0.W$%S3H?7SUA
MJN88;+Z&"D:&#3(9MB8)LMD<7=(%I3H0-!BE!9H7"\O'/>>0RT!C8^HJF>T-
MR-<]D!DA+6W;F#8[MFRO<6R9GDL8W,Q[&W:_,'-'368WT@IAC5,R&GEK*;!G
MUN']73E[65#(J0/9B0AJJ@P5+IZF1]+2Q1SP55-#G96&6*IA9UBG4!=@4%2W
M]8/%)S0@T1CPXI<IB:42*SL%EAUI"*<EE*%/4: X?4VCL&;NM>Q$9)N/1F2$
M?73,!/LQ<0U[@ \AQRFH#3;JMEX&Y[:M$T=LQ%G8U'2_$Z2)Q?@+YYF4M7.R
M*.IJ.LJ!3_;38W- PW*&EV$P&K('\E;BM'U8J'.B9/EO7=]L-L)6 58:GBN2
M J,.L2(T^:1@D&\6V\U)S#;\T&$4EW+E)R:0VAM['HD^&<4O"G,J<ZJ>>25T
MC9(NK+-00YS@X=;/%M=''K>#/H#[DC#ON?OX-B]9B$]93UF'>POI?>:]DTL\
M,[?M'%\.]V26EI2'9L)]JRAK_P"3UM*;W-W96YTKT"<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G"*WR?H\;_ (9_D4\(KAPBBU2^@BOW4VS_
M #@(<*#?W_0<_@I3PJG")PB<(G"+IL#X$:7-GQX,./.)9CY(S&8S#4N?F(UY
M")F;(;0EZ5F*QW9CY?6YEAK.6VO%1^YX16S-4J^79CZJV 4^1:(L$'LAQ^79
MS)?$;!9F8YF/E<EHIB%#P1;>RM$W$2+B3AW$=K""*BJE55QD0UUFOJB-DFS+
M<508<J,@NSAO#)5#&8V6D$FL--8;G)3B4CR;?BNX\1/8B[*  %N0B6V$$-RF
MY\LHW)0-AID()D(V8<\BAY+.'$SYL3.8LN8E6)$F-G+#SBVL^+PB9KX'(IL'
MD((R$9\EY$/D;"R*:\@]B0SY,?EGS1OR,A*7VO%9QY-Y.'4=EXPKA%VE#1RY
M[154"$HHQ%=@L$E16,SV83SC;ST-J9EO,AN*ZZTTZ['0YAEQQMM:T94A.<$7
MU$'P(&968,*)#S-ENSYOFL=F/F9/?2VE^;*RTA&9$MY+3:79+OCO.80C"UJ\
M5/8BZ;E? O1S$1T*)=BV%;KA^,X.AKCG''XC(]]PNRIG+9);T"-'A.KFI?4Y
M$CL1UYRTTVA)%VY8^ 0@OC)\&).&R6%19(^9&9DPI$92?$7'?BO(6P\PI'[E
M3+C:FU)_<Y3G'JX1?"Q0MR1 EN#8"Y0I#K8N2N''5(&MOMI9?;@/*;RY#0\R
MA#3J(ZFTN-I2VO&4IQC!%]-#1S,F=-9@0FIA-,=)*6U%8;DD$Q&E,14SGTMX
M=EIC,K6S'Q(6YAEI2FV_%0K.,D6**%T^Z<UM5:93:O0*\@)KP;%"TCTQ 8L)
M.L!!DV1-!A0YHXB>6AB:YE_$2N06YF& @^/#@CDL1HK"$$64/087R95KT.+\
MD=6MPVWZ/B>3,N.QT1'%E4>1\4@MR(VW%6J7AY2X[:&59RVA*<$77?K%:DX1
MB37@<C#<!@4WA\3 >P@7%DLS8PU&'(ZO%@1YD:/+8AX[1V93#,AMM+K2%I(M
M>=_]&^A.IF",$[8 6J6$@XM#!"OT[9VR]:5VX#+NAAJXA=@U_75LJX>_";,S
M'Q'+1;;"+J>B2BL)MUF&<-L$2+/AFETZQQ8$&PU2MGH0M.4#(AL&,*QAZ<MM
MLY3"9GQ9#<7&6FFFE>02CNVVA&>Z4)Q@EM_'Z+ZG4VHDXSD,E5:X0B.P(0IV
M+."#)49T8,DJF#AKC#\5QIR /EK7*A0UHS'B25K?8;;=4I62**']-:ULKNM%
MDZH.3&U#>$['H(H<A0D(&N3-:M%4B&%AABHHV>Y %W X\/CSXTB+"+NPSD=E
MLN,'3(I%D_A$X1.$3A%17LS]K/XN$47HWTEU+[F@?Y,C<(C7T[3?N6%_E8QP
MBE/")PB<(G")PBQKLO8>-=P!4_(*>>P0F%FG8PU:,2V(8*HV6Y$I#+&4.N3I
M2AM8EQ!PYA&'9Q25"C*>C,N.R6>>HGZAK79'/S9]&:D".*28FVUQ+8RUK0"7
M/+1H"2/BXWC(P6&GF-)-6":6I:YD!'6,BI,-KL4GD:RSG32&"@DB@@C&::HD
MAC+F,<Z1F'7.I^(R"68<J+B'6H >1Z/59!RGY+QVUS:P.DPLLPW5R*WXT)4R
M;8%L1\P5R88UX9@@N0U%Y3B%FYNI-[,.7K!<F25T3"VP-XSESF2PR@AKFAU\
MOG'=.HFTCJEV&N:YL5*\0FMA+I'5F(RX?!)$61N<^AO$99:US&=49(X'0=>9
M&1].3N0;=;/10A#6 J0T0O6!<:;<I0J4X&8CXO\ "D%8"6H!2-$.M'J*W"A1
MFYGDIR245#!)M]QK&(:MLTD#'4S2'3E@,Q82P-%0,[0&O:']9!E#0[4/:0^^
MBU/Z2PXG7812S8#3O$^+^S,DQ.2![J5K!C<3ZF$,AJ61U;:S"&111B4MF$\8
M9.V3*IE\VUMG8#E6=F5:2!1>(U*?/H(^89'&%T^]6:<$D-2Y#C<J<,=K0"$Z
M196Q!D3SY$(TPDK6YR7-IJ[3F(F/J^M;"9,X;E>8IY',()-W-,<;;Z-)D<T7
M=&X+Z?\ "=K<8- Z2ADHQBD>%OK&S&(P53L-Q>NFI)&R.+9):<T%'&Z=CFPO
MFK)Z1K!4T$P,3E]0)6 U%G*36I3)*O%;R@5(<?%% M(E6KT92#1-YZ6ZTO-B
M!*Q/S!Q%8?:=B%I:GTPQSC2M1KG"Q^[(=&^?*;M<R RY()'$N(^\9[UK BSS
MH&V7SI.F$\+8Y2VBE9/15&*BG>Y]-/2X5+B/L^$U<[GO<T^W4AZWJ>K:YKH:
MI^<1P.!R0=W0.$#;^48 F)L.BQ!$W)%;>8@4[%+8CJ\\#E?(R&YL:(R_F2Y@
M<R2G36&E($0"$UV+!D=$E6UC9W9'N$#6NS6LQX< ;L=KF O<Y0YQ .1KG$-/
MVJOI-!308O.VDJ98L)BIIC.6F.EJXZ@1GK::HRO$T<37F1X@;/-(QMJ:&>5\
M<3\:?/3#QD(A(L-<SB0T2MK8J" *MD)Q856S=FA(4R/G1!LO!E8H#&*R1B$/
M8:C&!<G,A#,YK">?[2:UKC)'[P=-E;&\.+V1R2M;8.R.#W1QAY;:P#VZV*^(
M>GL-/%,^MHB'LGQ(00T=0)YJFGH:NOA!;#+'!)[4:>C94R4S0[*RJIGYPV5H
M76&=3LM4^+#(UE@@Z4-M"H#=;(Q)0Y#*KGL>N+DLV:3*0.+R'(-*CRX4+S4.
MF7E<M[SII.511\;B)N Z*Y=)E 806AO6U+,W6%V5UVP!P&5FI.NX84_3I[IH
MHIJ!LSZFJ%/"**>*2 -&*8W0E[:]\H@J'NBPMDL,/5TQDS2OSM%XX=@];7F-
ML:H#[7&AK')FR"<5X>X_B2Y"E"B<L7+BN24,,,27&9$-U#C\+S@<ZO"ECIQ&
M#F/.D=U/,)XFRAN7,7 M))+2UQ80387(+2+B[3M8YS2''U^"8JS&L.@Q".(P
MB5T\;X7.SNBEIYY:>6-SPQC'N8^(ASXL\#G F"6:')-).^;E]5.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5OD_1XW_#/\BGA%<.$46J7T$4^
MZFV?YPD.!Z_-0;^_Z#GO4IX53A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X145[,_:S^+A%%Z-])=2^YH'^3(W"(U].TW[E
MA?Y6,<(I3PB<(H+<MAUZB2 ;-A<=BLG79C31!;HV*.A^8IC*=S,DDB$#"WWL
MRFD01HY,\N17AU, =(RP[XA%V:7=Q-Y@3IPN.1A."R.!10:6CM1B ^:X+&'(
MS4A$>1,C9\Z"FA)-G+$I[Q8\]IN1Y"6W(C,$5^R;#8SG&2XS&<9SC.,SXN,X
MSC/;.,XR[ZLXSZL_9X1?"C()64Y46%*RG.<ISF?$SXN<XRG.<?OWJSE*LXSG
M'K[9SCA0@':.>;_ D;"5P>?UK*<(\^">)A&6\(\[@^+AOQL+RWXOE.WB>-C"
MLH[>+WQW[=^2PX!8]7':V1MK9;91;*3<MM:UB=2-YMV*#7;<6HM=M/R+M=JR
M :C!"=H=7.F(5XH4),&129%"6$O*<1!EF1N'4-86_C,I+R&E-H><;YJFLI:1
MI=4S1PAL<DQ+S8".(L#WZ Z-,C+[_>%@=5\?%^D&!8$QS\9Q&DP]K*2IKR:A
MV4^R4<E.RIJ&@ N<V"2KIP\-!>#*'!I <X1TAOKI^Q+)A"5\IRI35FJE)*P)
M"L.][-?A_I"J!I*<QE-NOGA[RGXV<J7'2TM29+K"E93S6[$* .?&^HA#A-!3
M/83J)ZIH?3Q'3]:9K@6<0=R^?-TKZ)-FGHY\4P_K68CAF#U$,MW$XCC<'M&%
MT;P8W!TM=3NZR$&[2T^\6FX7# Z@>GI]8D; OU-RJ=,N59#Q6<^(A<G6L13]
MQ$QT^:H0TBMPVE9DMY\G'RTCQ(F7O4GD;B&'DL8RHB)>^IA8!?5](":F,::&
M$-)D&EK$\4AZ6]$7FF@AQ;#R9Y<6H*6)@+0^7H_$7XM31MZL ##H6DS-T8U@
MLS,+!==SJ?Z=$"%DW=H5' 9NA0=F+?R^_F.F@D"V 4&Q^2\USGS!\MV@MM8;
MS*P]C&51DMX\?&/VKAO5]9[7#U?LC:[-<Y?8W/R,GM;_ ,,O!:#;:#IH5K=T
MZZ'"E=5.QV@]D;@L'2%TMW]6,#J*D44&(D=7_P"6?5$0-TSY[#):Q69(QNJS
M6FIL8N$?:D(2^U(1.AJPXAU*.R\*\KW[K2E&%=^RNR<)7C]SVQ] $$7%B#K<
M=MOP7JHG0RL9+$8Y&2-SLD9E<'!UAF#A>]\H!-]K;'8N;!"MXPA." ;"490I
M&,3(79.6\YRA2<>5[8RC.593G'K3E2NV<=\]UAP'@L\C+ 96@ BPL  1^K;A
M8FXML)N-5RMEP+2<(:*"6T8[]D(G0TIQZ\YSV3AWMCUYSG/;'KSG.<\JH :+
M  #@  / +[].!?KP+_"$3^FX53TX%^NXO\(1/Z;A$]-A?KN+_"$3^FX1/387
MZ[B_@^CXGM^#_7>$3TX%^NXO\(1/Z;A$].!?KN+_  A$_IN$3TX%^O O\(1/
MZ;A$].!?KN+_  A$_IN$3TX%^O O\(1/Z;A$]-A?KN+_ ,?B?TO")Z<"_7@7
M^$(G]-PB>FPOUW%_A")_3<(GIP+]=Q?X0B?TW")Z<"_7@7^$(G]-PB>G OUW
M%_A")_3<(J^FPOUW%_X_$_I>$5/3@7Z[B_PA$_IN$3TX%^O O\(1/Z;A%<D+
M0XA+C:TK;6G"T+0K"D+0K&,I4E2<Y2I*L9QG"L9SC.,XSC/;A%]<(K?)^CQO
M^&?Y%/"*X<(HM4OH$I]U-L_SA(\*#?W_ $"E/"J<(G")PB<(G")PBT>\'7;;
M3=^EL58+G9#ML/.;IZKA3AJR%IYLJL97.JS=-=KXY9 D_)EJ@@Z^*&!!,7+N
M6!PD="'1$,Q(K#2"+>'A$X1.$6+]O;MT]H"GN;!WEM"A:AHK1*"'=N&Q[4&I
MU:;*D\NX'#5F3TR# 3-G99>Q$C9?P\_EIS#2%>*KL1:K?^^I^#1_W?/2%_O@
MM8?M+PBP/U!^$3Z*MIUS66O](=9O3W>MDVCJ@Z0A@6I:XW=1C=N/0G>J'4F;
M"/'B0=M8)D(SU<25P7B,8D-O!_/VY421$4^WDAV%>N/")PB<(G")PB<(G")P
MB<(G")PB<(G"*BO9G[6?Q<(HO1OI+J7W- _R9&X1&OIVF_<L+_*QCCGGG\2E
M/")PBCMAJ=?M:(#5A'^E(PZ:P08@ORIJ1KTJ*^Q+BK)#&9+0\PW$F18LZ)'+
M1IL>+.BQIK#3<IAIY!%6LU2OTX;Z)K@Y Z"I]4IU/EY4R1(D*:9C^7ESI[\J
M=,=;BQHL)A<J2\J/ B0X#&6X<2,PT16J@18RJ+35*CL*4JK@5*4IIO*E*R,C
M9SG.<I[YSG/KSG/KSGUYX12[S2)]31_O+?YO")YI$^IH_P!Y;_-X1:Z[ :KR
M]_Z/%SU:_P 2R%?VEF&)-T"6;N!)F.+#+F*JMR:CN"ZE!C)6VNPP2*T.6*.J
M+'AI6Y%7V^94EAQ*@8XTQ+HJS*R2F?).X!D>;J:@?=P-&G6M?K*,K6Z@KQF,
M&E=TOZ*0SOP@RRT72'JJ>LPB6KQ.9C(*,S'#L5#3!AL48+#70SD&N8Z)D8<8
MW6S_ )"!E*4M0D:I:GF9"E9@Q<J4_'3XL=Y2LM=\NL)_<LKSGQFD^I&4X]7/
MHEC3<EK2202;"Y(V$G;<;CM&Y>M]G@N3U,1)<QY)C827QC+&\DBY<P:,=M:-
M 0J)!A4Y3E(@:G*%ON(SB#&QE"Y6,IDK3GR7=*Y&,YP^K';+N,YPO*L<96C8
MUHL21H-KOUCLVG?QWH*> 6(@A!!>X$1L%G2:2.'NZ&0:/.UW\ZZ^% 0?DU(]
M#"LH\VQ%RCT?$\3,5"O*(C93Y'Q<QTN?NTL]O)X7^ZPCQO7QD9LR-MERVRC]
M4&X;L_5OK;9?6RAIJ8BQIX".K$5NIC(ZH.S".V6W5AWO!GZH.MKZK W2L-KT
M;2599!C=;1!B2MVRQ'U<?*6^E(6J]654G(P\>RZ3E2ER<O*-L/+RV/.9)#XN
M$Q8K*4_/P@,&'PB,4H9GJ,HHI7S4P_E,U\DLGO.=>YE!T9+G8-&A>2_1]'2Q
M=%,/911X+%3BHQ8LCZ/5U1B6$ASL7KW2&GK*O[^21TA>ZK8\EL-89X([1QM"
MV(\TB?4T?[RW^;SZ2]HGFD3ZFC_>6_S>$3S2)]31_O+?YO")YI$^IH_WEO\
M-X1/-(GU-'^\M_F\(GFD3ZFC_>6_S>$3S2)]31_O+?YO")YI$^IH_P!Y;_-X
M1/-(GU-'^\M_F\(GFD3ZFC_>6_S>$3S2)]31_O+?YO")YI$^IH_WEO\ -X1/
M-(GU-'^\M_F\(GFD3ZFC_>6_S>$3S2)]31_O+?YO")YI$^IH_P!Y;_-X1/-(
MGU-'^\M_F\(GFD3ZFC_>6_S>$3S2)]31_O+?YO")YI$^IH_WEO\ -X1<^,8Q
MC&,8QC&,8QC&,=L8QCU8QC&/5C&,>K&,>SA%7A%;Y/T>-_PS_(IX17#A%%JE
M] E/NIMG^<)'A0;7=_T"E/"J<(O.#PE-\V=1:%HI=3M^T]::FLG4/6*WU/;5
MTI6I5GV7KO24FF7R?Z7"-#ZI=2E?&E=D#]?5FRW 57IA"M@34V4RY"0X[.C$
M6CT!SK(M5QZ$!6K.IOJ0G:*ZJ8)RO[DL^[M4QZ)NZJ5[I[L1S902Z!80BO#!
M^LSG4'08C6ICY X,$R2P)=>OT 3!NQ FVHBUMTA \+^5Z+NI[J++]0=THS,O
MI2W6?U\$N?FVZ-MEMLT6W7PV*.4/7\G5VN)6E9!.BUYJAA@<JR;75)+&!=RB
MBWYD&%#419PO_6%UL@^M+IZ/5NA;R+](FEPW3MISJG(0Z8&?IMHOO4E4VI5P
MV(7<ED8=_F/Z0*VC24O$NE5,\ A();7C6<B$6)2ATGEW;EMETYW+P@XN)U>A
MGF:-U*[ IO6P=JM:)[D/6'IDH\33C^A]-6F C6<:J:QW.], A[B>,AA\:1F=
MF8Y@T1)VV::9E1WR<[O$_AQV<,J^"A?/R>B>H2+2.%B+(]N7JY=/"PA62<#C
MR[G5WO)9*$,,S!0.64@19F7V(9"2&%/S([;<AT?#<<5&;(O1OA$X1?F6\,#U
M'^&GU%U @@?@U=9V[8>N905EZ[/AM2"MHL"3&!==7 C);.5Y^.#C2/.2TA$D
M>7ENEI?I!B9 @X"Q'IY%F?PK1#J+M.B^C49M/36C4P2WA!NA9J<.3N.VV-HZ
M=E[,@H37;( *=/ 8?  F)+K\(](0\;4,BN.X9!&\8\V6184ZS*SX2>I=7NA*
MET^>#>Z+9_3 =J!*3MZR *M3KP-A3T2C:#\@]L0WJ>D6>@DJ[7V1!2GP 6N[
M&@Z6?6RART/N/ !!%Z2[QTCJ.N=.^@;@+TUK:MWQO>_0-,DV$'K:M +/$*D.
MIO1*##OGP,#&)P9$A4F8Q.2VIA&4O/,/X0TI:.$/)X+U(X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X145[,_:S^+A%%Z-])=2^YH'^3(W"(U].TW[EA?Y6,<;_#Z
M\_DBE/")PBP[N"A7:^0ZRQ3;PBF. [**.S<YADWED4P28]S*?.AAH7G"(PU)
M?#8PA$*"R4^5 <F,L8@-O<(KAJ2H6.F5V</LLV(]*F&,D(8T<4*&QP&'@,&'
M.P(1<S$'D9Z2)4<3L\IR1 BY8(6"9$0F0B.F;)(NU1(9I5)J"FC+#32JR#4V
MTH4AU3:,C8V4HR[F6C+GBI[)RK*$Y5V[]L=^W"*6>9'?K['_  .W^F_R?S]^
M->1^*ECQ/EZ;]_E94\R/?7V/]KT,W]C_ .>_;S_']CA/C\OPY[=5A>W1[BC<
MVIFHQK8JA;H?8.22J]7 [NLDNH@"_,<;#F2)F2L0EXZG?<>@;G#4J9Y^F=W;
M0WVX)C)[=1AIJ^KZNJZSJV1FD)RQY?:7N'6,D&O4",@.)=FN  O,8B:K^%'1
MML;L=%(:;&_:6T<%,_ G/$%-U!QJ>3^40SM=F.&-IQEEEZ\36#!?-'F1WZ^Q
M_P #M_R_1OO\[UZCX_+T3S(]]?8_X';]?V_X;^+M_'[.%+'77NV:<_+MU5,P
M3N<9[G6.WV S??V?8F=^_O\ J]?P<:\Z>N[?;ML=BOB>S3GL'FL'=./IHCJ,
M!*;M*YZ5D[>CSN=J&/JF0YY&YV!K*549IZ,V*2SXGD&Y?D<9.M-HL"U+644K
M/S\,)-%$2]TAS3@O?1F@<2*B4?\ E2!U8%LH-OO0!-_ZFODN@\CI>C5%(ZHD
MJB:C%!UTN!,Z-/?EQ6M: <'8UK:<1VZMLH:/;0T5QN:@DYR\R/=O]G8_V_0[
M?Z;VYWZWW6[M?&_T7K?C\-/2_FGF)[Z_1^__ /)F_P!-Y45?,COU\C_@='Z;
MPI8\3Y>BIYD=^OL?\#M_IO\ 7U>SU]ROQ_!,PCWK_L['Q\']AF_5_P">_P!>
M_)KV=NGXZ>:?'Y>B8@GO?.Q\_P#B9O'_ .>_U_'43S(]]?8_X&;^SZOHW[7O
M^]QK\.[ZW^BGQ/EZ*OF1WZ^Q_P #M]O_ $WO_/PENT^7HJ>9'?K['Q_XG;_3
M?Z_R]VN_Y?B5?C\O3F_<GF)[Z^Q_P.W^FY]OMX3X\_@GF1[U?V=C_9_L.WZ_
M_/??]_\ F[>^3X_+T5?,COU\C_@=O]-Y->SP_%2W:?+T5/,CWU]C_@=O]-_K
MZ_;ZNS7L\/Q2QX[NS;QY\M;U\R._7V/^!V_5_P">_C[\&^ZWQ%_J%?C\O1/,
MCOU]C_@=O]-]_EUY'XJ?'Y=O/P[U3S(]W_V=C_:]#-_IW]?Q%?C\O3X?CJF8
M)[WCL?'_ (F;^'_NWX/^'['"?&_A] $\R/>O^SL?['8.W_IFY_%PI\?EX?!/
M,CWU]C_@9O\ 3?9_)G[/"6[3Y>.S\.Q/,CW?_9V/V^#T.W^F_P!?L^SA+'B?
M+TW_ ![+*]-X6EM"7%X<<2A.%N83XF%KPG&%+PC&581A2NZL)\97B]^W?/;O
MPJOOA%;Y/T>-_P ,_P BGA%<.$46J7T"4^ZFV?YPD>%!_.[_ *!2GA5.$3A$
MX1.$3MCX/L?Q?!PB<(O/[P8G_0B!_P#O[]8_L_\ IB;W_KG[/"+T!X1.$3A%
MKGU0]*.CNLC6C&HNH&KD[71XEMK=[A0@MQN5#*P+949#TNNFH%EH9ZMV.%*%
MR7W'X^8I1I'EO$<6A2VV\I(M',^! \'UG/?W+=0>/M=:76'V_P#\X_CX181W
MIX++HPZ<A^G-O:X";<'7FK]6?1NFN2+?U2]1=[!YE%NJ74@B2U)J&Q=H6FI'
M'%C9LWS>.1!3'([R43X68\R(Q)9(O=WA$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M%17LS]K/XN$47HWTEU+[F@?Y,C<(C7T[3?N6%_E8QR;SW#OW\CXHI3RHG"+$
MNVMFNZP@5XB@.R=07L8D+('MDVXA?S<H3@"\R0X[+$B08D1G2#*EQ(S?J4IE
M,ER)%>>(0R+MZHV&YLD!/,.CX$)0\QZ*Q(#EE'0)1"PH4VB:%,*@CLSXT=)K
M ><O$1M,<X*+0TJ7B-A>2<\^2[%#.16:14&E13"E-UD&VI30$R\TK*!D9.<M
MO-05M.HSG'=+C:U(6GLI*LXSC/"*5^Z"']2'/DZ=_5_")[H(?U(<^3IW]7\(
MM?;P3#/=0&D)CP)#\R&!V@F(2FV>S@#\!$@8'1(:!ZV;BHBW]B6E*$%",EEU
M52;0S+94VJ<K.?G3AIQ&@)9&7-CK,KW59BD;=D=Q'27#:H.'Z[W7, %VZOU\
MABD<3NF'161T%(^6.DQ\13RXW+25D ?!2AXI<#:X18RR4 "HGD:XX8T,D9;K
MB5L%[H(?U(<^3IW]7\^BO7I[H(?U(<^3IW]7\(J9L$/MG^"'/9[]=._J_'"'
MQV?/Z;5A/IX*2H.J ,8V*VC"(H)6U3T;81:3L:UMH=N!YV-F?;0\)R 0C.15
MLN"(S2LN" ZH :1VD#W<<X<-$C:.(2MJ6/#IKMJYV54X'7R%N>>,EKP6V,8!
MNR,LC.K"O+="V5,?1VC;5Q8M!/U^)%T>.8I!C6)M!Q2M<PSXC3DPS1N86NI8
MVF]-2&&F?[\+@,V^Z"']2'/DZ=_5_.Y>I3W00_J0Y\G3OZOX1/=!#^I#GR=.
M_J_A$]T$/ZD.?)T[^K^$3W00_J0Y\G3OZOX1/=!#^I#GR=._J_A$]T$/ZD.?
M)T[^K^$3W00_J0Y\G3OZOX1/=!#^I#GR=._J_A$]T$/ZD.?)T[^K^$3W00_J
M0Y\G3OZOX1/=!#^I#GR=._J_A$]T$/ZD.?)T[^K^$3W00_J0Y\G3OZOX1/=!
M#^I#GR=._J_A$]T$/ZD.?)T[^K^$3W00_J0Y\G3OZOX1/=!#^I#GR=._J_A$
M]T$/ZD.?)T[^K^$3W00_J0Y\G3OZOX17EM>'&T.)PM.'$)7A+B%MN8PI.%8P
MMMS"5MKQC/92%I2M"NZ58QG&<<(OOA%;Y/T>-_PS_(IX17#A%%JE] E/NIMG
M^<)'A0;3W_0*4\*IPB<(O#N\]7^TX?7OL;4UHZKQ>@(5&W5I;76F>EE_18C8
MI?J>UM>M3";A:MD,EVXN-E08V;H2LU7;V/5B\36FIDZ]DO;$$EL3)F,E-HX]
MQ^MQ\UH)1^I/PO1KP<VX.M.Z;ULNOZZ&Z9=;[PU39#>M^DHQ9;SL:1[I,70$
M(K%0IAT<*T>2#E*D3'*O(L-MU@^-\V1(B"G2<>256U_6_P!2_75TB$-I5P;O
MP)<@55\&3U.[YH%JGZMHC&P2>Y]3W+24 =?-@9AUR%0E9BM[&,A0-,JE1$UG
M(F @K9&CY>:W@.12/P>/7?U8[6HG4,HE4"_6R;UONZGU:KD];W[I:B18="M6
MH0%N?ERMP5*7JO1VP)HNX>F1A '4@T6U5!LB)@V5!!;F)K93G?SQ\ENIX*,@
M2*]%%0)& 4JL%9^YNKJ81KLZ8,(S <Z3U=[S>E"94\-*G"9D@<^MR&]*&S)4
M&0XRIZ+(>86VXHJO1GA$X1.$6F'43O;<FJ;N0'ZKT]8-ZOP^G':VR1^O*T4J
M *>7NU0,5EBLP7"MD)0".6C:B,@*W$ 134W+TO$A(B5(:BMN$YYY[UIEX,7K
MZZY>K301S8W4MT WK4=S&[&L-6$PQ+XO7@ZQ5T=$%R8Y9BI;PMU=ND1R%-FS
M0,L@VDB$*RQ3\@?+CO)FC8)37OY/X#U5?"6;)V7/U_TN((=/5^ (C^$(Z'YL
M9^=<]/243YT3?-9>AA6,"=EO.LRRSR<1(LF6Y%&L/.)<(3(\;"U\)N-].X^=
M[!>@I[<>Y!P,T0A=+6R')D 21F1&W+MI&0VY)BPWGV$+8B;15*?0MU"$J9C)
MS(<3G*&<9<4G'":]GC^"\'?!T^%C\)-U247JB+=271V_IA_5L+6#M#LP?7-G
MUL/8Q;#=C@V0B<@;NN#LFW1AD46-<1&I(XE,@^</*G1LJF#,**K]/'")PB<(
MG")PB<(G")PB<(G")PBHKV9^UG\7"*+T;Z2ZE]S0/\F1N$1KZ=IOW+"_RL8X
MYY\44IX1.$5F*EJ\,D"FC9(./E$)OF@1!27#BOS2"T>+YL,3*<0Y(F+0OQ?)
M1<*>4E>$^+G"L8R1 )>OG!K1"L$Q!<0MQYIF:#F0YPY3K3JDR&VI$!QV,IQM
M[QTO)0O*DN>-A>,*[\)W<\^2M.OOI$IGW+ /R7%X12_A$X1:]7F4/:Z@]&Q'
MR%89(R0&T5P!Q'7TTY:)S3 L.J6Y7-A--+A46-%3EM9F!*=:7:F5QXK"7%0U
M8Y\V=S1B5 TO@#C%696/I723O 9'F,54"&TS6Z=8UP/7@AHL6E>/Q62%O3'H
MI&^:@9/)1](#!#/@TM57RAE/2=8:+&FM,6$LC!::J&1S3B+#'&P$PE;"\^DO
M8)PBIGV9]_\ G_X.$6NW2HT'9TC6FP+6MF1>"]XRPWJ0H:-43#BKW952LBR-
M@4HJ]-S+R_D^A_/DHU@])QHG\$:8Y\W"!&*"'JA2!F>H-J)[Y*8.-3-FR/D]
M\NS7ZT'1LW6-;[H"\7^C]M,WHK0-HVX$VG%3BV0=&ZFJJ\'#CC%>9/9YZT"I
M?*9"XUH?[K*TU#(ONVM6Q7/I+VB<(G")PB<(K18)"8@$W*7*+041A!*0N:!&
MK-'(:68;SBI08.T+-N%BT?"<O#AK88NN?,0S%0+GJ=Q$=SC%Y(QE8Z[V#+(_
MJXW7<!E>_/'D8=CG]8S*VYSMMF&+_P!5VKA[IU:+N&AU:+.NX;0+&YW'8O)G
M2&\NI*1"Z'I-R'=2EAL-@I>[8&\ZL=T/9JI!)VD/%))US)NIXKJVMB:(8,%X
ML> ,FF+'5JB[&7'(OL-07UD7O6UM!A@=CC87X9&QD]"^AF9B$<KF1/#35-@B
M95R&9C&DN<UL,L^>[ XN :/GQ2S_ ,ES=>YQ9*)&.B<UI<-8RYQC&4G9<N#
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MJ;$5&RUWQGRBXBK+F*Y+[XQ_#7&52^W=/EO%SG&?D.Z&X:Z@GPXXETL$-1B
MQ-\S>FG2ME>R<1F,008DS%VU]/AP!+OLN&H9AW66D-*7M:X=8Q:H$S)_9\++
MHX/9VL.$8882RX.=\!I>IDGTM[1(QT]KCK+%<"-2U]MF$SBP[/4F _F0RMS;
MFRW7G5Y6I?BS7W+2IX@QC*LIQ&G+D1\(\5'DO%0WA/;-T;HIZO%:UU=T@;)B
M]$:"HBAZ38_!24T1CBBZ["J*'$64N#UN6%KA7X7%25@D=+*)^LFE<_2S$)F1
M4T(AH"VEFZ^-[\.H7RR.S/=DJ9GTYEJX;R'[BJ?-" &-# UC0-4]]E-<Z=V-
MK)ZYWWJ*%@;3$O33@ZK;)NI@0>-,P!B@P7(.$=G;$F6&2]EU%3$ZZA^+(DYG
M+-M*B-H6CNP;H565U;@]'A(Z2U4.%0S.EJY\>Q&;#X8HR9&3=(\1Q&O=UX+I
M7ADV(SRB4-;'*Y[8X6-\/TCQE]/TIP"HJ'8I#3U-/CC9X<+I,-9@4LKZ>D;$
MS$**.'VKVJ[+X2S#8FM9,:ITH >;YSUM\R;;@9NZ:^V!?3X_R;H68PC:.RHD
MT&0CJQB8(L=9GV"-.K]I'N_O<^&;&PSL1?=M]"4*3C/)BGZ-V83#+@>)5/2^
MG$M>,7;/_#3I4:F5SXNKC-%C$6,FHDP>1AZR.AI:LX2^3[T0&077LZ/I$*US
M*ZE9A4N6 TI9]D8:(V6=F<)Z-]((VUC3[KY98A5-'NEX!UG2-35]MJ RFP[.
MR@>]E]E2]N;,==>6I:EY3.?<M2WB#'=64XC3G'X^$>*WAK"$(PG7-T:HIZK%
MJMU=T@;)C%&**ICAZ38_!2TT09"P2X3218BRFP:LM"TFNPJ*CK"]TLAG+YI7
M/VLQ"9D5+$(:$MI)>NC<_#J%\LCLSGY*J9U.9*R*[B.IJG2QY0UF7*UH!S4U
M?<9G,YL.SDIGNI>>4C;>RFW&E(SWPF"ZBTI6-:SVQA34!45M>.^%)SXRN\AZ
M,T,$^$5#:[I$Y^"PO@I63=)^D$\-4QX>"[&*>;$GPXY,,[LD^,1ULT9#"Q[2
MQA:?B$SVU;3#0-%8]KY"S#J!CXB+6%(]M.'4;#89HZ4Q,=<W:22L)=..NAA#
M5@$I-N&W2LUQ^WP%RC<J]:DE+9:NA]#>7M;P[&D8*D1VVT1XAI+&9I^$VT=<
M?RHHOO\ %P[H=ATF!C#W8KTP=#)BE1BAJ']*NE=#B8GS2P"G%6W%Q7Q8:&6<
MW#&U PY\O\K]FZV0N7F>A&,ULF!4-7+[-53@8G2&2MZ&81T<,D;<6K<KY.C\
M=&VE@G8T".*NZGVJLA8RK=*34&^;4:FK[;<!M-@V=E(YU3S.5[;V6XX\M:E+
MSB>\Y:5/$FL97G"6)[DAE*<)0EO"$(2G[4W1FAGJ<7J7UW2%K\:I6TE3'#TG
MZ0P4U+&V.*,2812PXE'3X)5%L32ZKPF.CJ72.ED=*9)I7/\ 3LQ&9D=+$(:
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MEM[R(]+DA:<8(HKTNUA^G:O]STP>D21@6BQH(B4PQ8WT7)5+0I _ P/L_;L
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M/><_WC7B1[2YCIA(6.+;%?,_1T*>;HEAS\/9@CJ4U&*Y/X,LK?L<..+5QD$
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M_'8W])Q]IX;^T:'^]T_[Q/9JC_H3?V3_ /2GI85]<Q_^.QOZ3C[3PW]HT/\
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M(G"+ ENZ8-#7QC>D:VZY%F&.I>OU^J;U;<GG(WS2*W5PLJN PQQ4$K%4U B
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MG8%B!.W+U&*]12R.M8 05TP)O8V"AQF6GTQ'"J^C&@,T$?VE3"XU)DHQ)*P
MWUEIX["Q-B;++-#WMK79S;N:'NK5MED1FUNS1T!QC!L:AM.5.X*@9%I9,BEM
M8QG+S9&!%=9\7.'4)SC/;Y%?T?QS"R/M#":^E:X@,EDII>HE+K9>IJ&M=!,#
M?0Q2/#KBQX]U-B>'UE_9JVFF(OF8V5G6,MMSQ$B1A%KD/:TC>.%FM?4SIBE2
M5#['U Z>AEDJRWZ"C3HA:Q+<2I2,MLUT/:2!Q]W"DJQEI@>XYW0YC"?W*O%W
MTG17I+7-#Z; \3?$1?KW4<T-.!IJ:F=L<#1KM=(!J->.N?&<)IR6RXC2!_\
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M'ZLX1/= /_N1?Y/6#]6<(GN@'_W(O\GK!^K.$3W0#_[D7^3U@_5G")[H!_\
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M]CNPEI:/O6RON]9.JX7"J PVA;[06]46NKPZBRWN*4FN.8.)N[VL51V %K0
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M4G$5,=Y*6\NMN<=104U5-2U$K7B>CD,D$D<CXW-S6SQN+'#/%)E:)(W7:\-
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M2G&<YSVQPB@[YS0T9F'(D%=;LM$($\I!R[+!H5+'"R\*ODI<=I2\.NLP#Q*
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MHK6T28A0H#!!)V>^'@%5RTBY[]/R+#'N55&T^$NJFU@B<.L%9LL<?@5/6D^
M0E1'+%.2::*G;7=&8U;CQX4R+[BG!3I.?+7(E9*;OASL^B@478W4@&8=)/U
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M,1/4<Q%60BBY<4I(B)=4^R,D,$%MIANH>5;LM?W=-NG.G.Y6S^W7M_%7&9U
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M?171AZ"J /BD8<^9$+"W);,/^4;+[1S\-O8@!(OF/Q)MSV[SIMV\>ONJ$9L
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M3+1U<Z(OW01502@\?,PV_AC+2LG-N-U^=%BUUK[=GGQ6"Z_T/-UR&2&";\!
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M^'KZ;M^0=-Z!/:LO!Z]D]AP;:1N0H\S<XS=)57H\LP0V=<-DA)];RBV%\@!
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M,-@02)/AS;Y[MZZ]NZK-X#RZ(0[5)B#!:V'= C5B3K_8EB!MT$>5H(FJ[%L
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M\M_F\7/$^)2PX#P">:QOJ=C[RW^;Q<\3XI8<!X)YK&^IV/O+?YO%SQ/B4L.
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MDOG857:!!YQN(3G19C"[OT2L;+V@!U@49LT?893306/&H%<&[#L=@9:,W$C
M#2'IT3S(9Z-EVNXF&+(;K\H*EJT+M T0>3/'K)]5A:H;GZ5KD4T-?6] *7M;
M8T0^]3@X"FUDA,#6<Z0I]WNJIDA^:"$8.Q+6 D2UW<M"BDHA37U]F0R0YI)%
M9<IQ\.?KX;EWJWU0],!"S"68.DGG+O<X)%VFS &NJ:^O8F7(5,VL;%UFPS9
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M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X18T
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LPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g150774g12t85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g12t85.jpg
M_]C_X1 Y17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-3HP." P.3HQ-3HQ,P   Z !
M  ,    !__\  * "  0    !   "YJ #  0    !   #P          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M]-SG-;<[V_I-MO[_ /A%J[AZ6Z--LQ\N$&['L?G49 (V55VL<#S+S26;=/\
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MFXM>0*JG![BRP^NT,:036W],6[7[GC9_75] C"]"(J^S[N/;LW;_ /,W^O\
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ML<-^\_W)]GZ/9/:)^22G_]G_[1@H4&AO=&]S:&]P(#,N,  X0DE-! 0
M  \< 5H  QLE1QP"   "YH  .$))300E       0G((_CO'5'93"!:35(C7,
M[#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 2P    !  (!+     $  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #40    8
M         \    +F    #@!% %@ 2 !) $( 20!4 "  .0 Y %\ ,0 M #$
M   !                          $              N8   /
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   /      %)G
M:'1L;VYG   "Y@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #P     !29VAT;&]N9P   N8    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M3NJ:UWT?^NJ%F("W:,1X<UFY@:>/:?4:QQH->YUGYO\ A+/TJ2DPZ;F#:_\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" /
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MJ+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,!  (1 Q$
M/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]'?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=?_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=?_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0,=M=_]7='YSI; =EY
MVHV]5?(#MK']&]9U9Q.3KL5D^S\SM3=N\L#MG*9.@I:BDV_+N#%;)KXJ*>M:
M&GJ*Y8J57\\\*/[KW1'X/YRG\O\ J*KK_P ?:N[6P&_J;:F2E[ 3ICN&;J[K
M/;W9/:6X^F.G=V=Z]FP;(EV/T7M+N_L3:M71[0R6ZJ[%4N<IO%70O]A/#4O[
MKW2>?^=)\-H#V3!6[>^6>-R_5?:&R^C]R;;R?PR^2M!NBO[K[#K*6+9?4.T-
MO577$>4WIV3N'#Y"FS--A\9'4UDF#JH:\)]O(KGW7NA][,_F&=']1].=(]R;
MTV7\F((OD/NJ39'5?4F(^+7>^X?D9F]U4^VMX[RKL+7?'S";&KNU\%5XS:>P
M<ID:G[S%PK!1TXE8A7C+>Z]TE-M?S5_A/O+*=>X+:?9.>S^>[?/QJJ>H,%1=
M<;_CS/:FW_E?1;@KNJ=Y[&QM=MVDJ\MLJBCV7N%-TY-EBI=ES[<RD6<:@DI'
M7W[KW2@WK_,Q^'/7O<N3Z!W;V5D\7VGB\]V]M:7;W]P]\U4-7N3HSX_;(^47
M8V#QN7I-OSXC(Y+&=)]@XW+TT<4['(L9J:E\M53S0I[KW0&97^=;\','E-YT
M.7J?D-CL9L/HO$_)C/;RJ_BM\@(=@'HC<N!&=V9V;BM[OL ;;S&V=_2K+C,%
M-35$G\6S=--CZ</51-&/=>Z=NPOYQ'Q,ZEVCM;>':&S/F)L"#<^%[@WE)MG<
M_P (/E/0=@;0ZNZ#_N0>VNZ.P>O1U9+O'8_36SH^P\8T^Y<C1P8R022"*1VA
ME">Z]T,*_P R_P"&3UN]*"'MR"IJ>ONUMU=-;M%)M[<=9'BMX;1^+VZ_F36U
M1EI<7-'4[.ROQYV1E<YBL[$7Q&5>BEHZ6HEK$: >Z]T!F6_G,_%# =1[6[RS
MO6WS>PW6V^=X;7V-LK.Y/X'_ "LI&W;G=^T&#J^NFV[0R]7"LRV*[)K-R4./
MV]6PHU+F,I4+2TSR374>Z]U:+M_<E#N':N$W?'2Y?"8W.;?QNY$H]V8;([4S
M^(H<GCH<FM+N7;^?IZ#+[:R]!!/HK:.MBAJ:.9'CF1'1@/=>Z#Z/Y#] 328:
M*'O+IZ67<>8V7MW;T<?9FRGDSNX.R,!#NOKO!89%S9;*9C?NUJB/)86E@USY
M3'NM13++"P<^Z]U$;Y+?')(_,W?_ $FL0VG4;],K=J[$$8V+2;C?9U5O36<\
M%_NG3;NC;%29&_V:9(&F,@F&CW[KW4G>WR*^/O6NVCO3L;O7IS8&SEW-FME-
MNS>W9VR=J[:&\MMUV2Q>XMI'.YW-T&+&YL!D\-64];0>7[JEGI9HY8U>)PON
MO=-FY_E'\9=DS[QI=Y_(KHG:-5UWG]H[4[ IMS]N=?X"?8NZ.P'\>PMM[QAR
MNX*23;&?WO(-.(HZT05&2;BG20^_=>Z>&^070R;AHMI/W9U(NZLENG*['Q^V
M6['V>NX*[>N"R5!ALUM"DPQS R-1NC$9C*4M)4X](S5P5-3%$\:O(BGW7NL>
M&^1'Q_W%CHLQM_O+I_.XF?.;FVQ#E,/V7LO)XZ;<NRMMU6\=X[?BK:+-34TF
M;VGM"AFRN3I58ST&-A>IG5($9Q[KW07TGSO^&F1W)@ML8WY-]*Y.IW+T5N[Y
M-8/.8WL#;N0V+DN@]A[EIMH;O[4INQZ2NFV ^TL!N&H-/4U'\2_;%/42$>*F
MG>/W7NA:WCWUT9UWL'!]K]@=T=3[%ZMW/+MR#;79.\>Q=G[8V#N&?>*1R;1A
MP>\<WF*';N6EW4DR'&K3U,AK@X,.NX]^Z]TUYKY+?'+;=3V91[A[_P"D\#6=
M+/MF+N.DS7:NQ,74]32;U"MLV/LR"NST$NPWW:K@XP944IKP1X/)?W[KW2EZ
M\[CZB[>3.R=3]J=<=GQ[7K,=C]RR=>;XVQO5-NU^8P]%N+$T.=;;>4R:XFLR
MFW\G35U-%4>-YZ.HCF0-&ZL?=>Z$?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__UM_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=$L^?OQEV?\ ,+XX9SX^;A[5JNC=T[TW/L_(]-=O
M8.6@3?777<^QLU!O_9&Z^N(:S*8:>MWEB&VQ42I#2U,-4]"M5I=%#NONO=5V
M;U_DP]4]M7QG17RNW;UY\.>Y.L/CKTS\JN@MC[>Z\[!P'R)V1\.\;2;&ZGQV
MS^XJYJC<W2-;%@MNQX#=4F"-4,M1TNB-*"N$M8_NO=+3YH_RL.O._-H=Z;5S
M_P D-N]>9CY(?.CH'YAX:+LWK?9G8^QDWEU%U[TWTC@^HLKUGN?=NV*'M79^
M^&V/1)44DU73RRUN6C@1&(B$GNO=>^0'\GZ7Y ?"OX??%+/]P].4^;^(F^Z#
M?&'S61^&^P=Q?'W>XQNQ^R>O*+;&7^)U3O\ HMH8O;&/VYV)_DM/#FY?!5T$
M<]V9V ]U[H3_ (V?R^^D.G%_E\=O8?OV3MNC^#OQC[4^,^R>S]U'8^<;LO$=
MPY/JK&4N:;?6-E6FP-'LNJZ]GPNW<3CY)J>DH,Q)0+(Q0M-[KW0=?(?^2SU;
M\C^R?D/V/NWM_=V.R'>4_>&?P(Q.WJ&ERW3G8?;7Q\^-O0NW>R>O]S4>9H<M
M2;LZP@^.<62H9@8C6)G:Z@G/VS-Y?=>ZG]S?REM@[VZ.[9ZXSG?^6V9AM^?R
MR^COY<]?NF7:N I\5MG;G16?[ W!B^VI*&JSM#1RU6<J]_-#5X:2IAHUIJ81
MK4'R$K[KW1:\I_("Z4[;ZRVGT[WSVOUAN[*](;,^2=/T]3=%_&S97QRVUTQO
MWY,;PZ@WSMKNV@ZLVEOW<N/R&\-G;BZ3G22++35.%W=C<E5T&0I'I8VC?W7N
MA8JOY*O7&X.\JONW)?(_='^F/([M^56]NW)=J[8PF I-_8_Y>_&3/?'>FHMR
M;;3<.3J*->I\OD<UG]E9">:HJ*"+(Y'$1L:24M'[KW63XM_R7F^/GQNB^-V:
M[YZ]S6W\3\A_A[W_ (#.]/\ Q-V-\>:ZIR7Q)W3UEN:"E[!I-O;\W9%V+NGL
MYNK:*#*9^JDIZF%9'>.!V^ONO=6Y9KI?;^<[IV5WG4[K[4H]Q[%VCN/9N.V?
MB.T]\8CJ+,4.Y9HYJK+;NZDH,S!L/=NZ,<4*T&3KZ*:LHE8B)ULNGW7NJ,MD
M?R /C%B:[OV+:/?^]ZNJ[%ZJ^1?7>+H1'1Y&MZ0WMVOOVGJ^A.XMH*VX#D</
MOCXD]=[1IMD[*D4TJ_P:AD$3TZDQ)[KW2A_Z!X/C(W6K]6R]D[WDV]/\AZ?M
MBJG;&TYRM1TY_H1?K/*_%?[Y\N\D/4>9[%JJC?\ -''I!W)-Y/"67S'W7NN/
M=?\ )M[AW+TW\*OC=UC\D=HCK;XY9;)R[DWEVOT]@NQMV')[T^,OR7ZM[V[:
MJ-K[LKMPX/MSL7Y"=I]YQ9VLAS-9CH=M3K-64D]7-JAG]U[J3V/_ "(^H5Z?
MR6S=H_(K-]?5-'W#O3L&@W_V-UYL+M>DIMA=F?$+9GPAW?L3>>$WM546!W=N
M*#J7;+3[?W/4-3SX/-UA9*2>A:HQU7[KW2&[,_DL[IQ&VOE'OSXI][/N3MOY
M'[+Z$ZQV76=@QX/:%#T3FOBAN_JO%?%?O_:W;.(VEOCMBM[.^-FVMA92MW!$
M\COVEG)X/NYL,*6!XO=>Z'7?7\D#XR[BS6[MNX_L3=6PME]B?!F?XE8CJ_;6
M*V]'C<'O+'[>P&P,]\I<(N3CR%)4]IYKJ3"8C:>:IYJ1Z#+X.*6"M$ZUE0']
MU[H)=Y?R'ME9W9N0H]Z?*Z;%]@=G8CM_'=F;SPW2_7FS-K[N[;[5^1W0_P E
M^O,MU[UW#GVH>N-G[-['Z"QU+5[0HZ^M;=V.KZQ:JOCKI?OA[KW0N;G_ )-=
M?6]0?&[JC9?R0V[LRB^)B4DO2='E/C)L?L_KS#Y#?/7&_P#K[Y+U6XNK.R]Y
M[DV_O"G[;G[ J,MMZ&NED.Q:N!:>!\CCYJFDF]U[I.T?\E;I7*=WY_<.5[^D
MW=A,)W;AN[-F]4U/5O5YR.)AR/RTZV^8W=6S>\=X8R&#.]_8[>O9.RL?1;=.
MX(H?[DX&K\%/!6OX9T]U[HW_ /+Z_EK=>_R^%W(NP=X2[F7=?2_074F:#;,P
M&T?XC6=%;C[ZS\._,D<%-*<GN/=R=Y-2U;3ZWB@P],!*X8A/=>ZLI]^Z]TS9
MG<6W]N+C7W#G<-@4S.9QVW<.^9R=%BURNX,Q-]OB,%C6KIX!79G*U T4U+%J
MGG?THK'CW[KW47 [PVINFJW)1;:W'A=P56SL]+M7=<&&R5)DGVYN:"@H,I4;
M>S(I)91CLW38[*TTTM++IFBCJ(RR@.M_=>Z>ZRLI,?255?7U5-0T%#33UE;6
MUD\5-24=)31--4U554S,D-/34\*,[N[!44$D@#W[KW6'%Y3&9O&8[-87(T.7
MP^7H:3*8G+8NKI\AC,IC,A3QU=!D<=7TDDM+6T-;2RI+#-$[1R1L&4D$'W[K
MW7=#DL=DTJ),;7T60CI*VKQM4]#505:4V1Q\[TM?05#022+#6T53&T<T36>-
MU*L 1;W[KW75=D\?C!2'(5D%&*^OIL91>=PGW.0K"RTM'#?]<\Y4A5_-O?NO
M==93*8S!XS(YO-Y&@P^&P]!693+Y?*5E/C\9B\9CZ>2KK\CD:^KDAI:&@H:6
M%Y9II76.*-2S$ $^_=>Z9\IO79^%H\/D,MNC 8^BW%)'%MZIJLM0Q19^66AF
MRD<6#9I_]R\CXNGDJ0M/Y#]O&\OZ%9A[KW2G]^Z]U[W[KW2<RF[]JX3/;8VM
ME]QX7&;EWK+EX=H;?KLE24V9W-)@,<V7SBX+&RRK69,8;%KYZHPHX@B(9RH(
MO[KW2C]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U__]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17?E-U?OCL
M?"]397J_<>Q,%V9U+W1MWM;8^/[+@RDFS-Y9+%[4WMM/+[/R]5@91G\0<CM/
M>61GIZZB@K9:2IIHY&IIX1*A]U[JK/(_RNNZ::>KV=MOY&;*IH\U\>-J[3WW
MMJ7,]HXC(=I5> [1_P!(VX=FXO&8G=KGH#H?=NYLG6T6<J]K15.6SE)6QQUH
M>HCGGK_=>Z&[L'^5[/V1C_A'BMV[WQV\XOCEL%NMNTL]O_*;^W5OC>NS:GLC
MHOLW)[?VWN^3.T>4G@RU1TXV$JJO+F:NFQE7')Y5FBD2?W7NG/XM?R_NU/CM
MWY@^Y^POD?GNP]O[1Z<EV&9J_>W8M&*K$4F*P>&PVQ-P[.S>>RFQZ_8'7-#M
MY\MBLS4R/N!\GD*IJIWU23S>Z]T"7_#06X*C8>U\8W<6!W#G,&FW:61<JO83
M]?[DVCLJ3K+=_7VU*K:-!O1,%2XG;O;FQZG=4,T5*[_Q.M$["1_+Y/=>ZRX7
M^5%V+!M+>>UMZ_)G/97<FZ,KW%EMJY:L['[CRKU6^]Z8?8N#I>Z?X?D=YT4^
M [!RNWL-GI\YC<:\^,I:W+"HH9(Y$:4^Z]TGNQ/Y06].Q:OMO$X[O^/+=.[Y
MZP[5ZTZVV7D]Y=LS;9ZOV?F<UONHVOTA5;3Q^[:G =B]192NW!CJS<,U=409
MJBK\!318YDCAIC2^Z]T-'RX_ER=D=X]H;U[5V#V%UWL#(]E[#Z6V?NK'92J[
M2H(ZC<?6U!VYM_;&X$R>R]U;:DR,W3^1[4CW3LF)X8G;<V."U+1K+!4T7NO=
M+?LS^7AO#=_R/E[UP/9^!HZRJZ>V1MG+9S<&.WE/NO=7:?576O>NQ>L]S;WQ
M^U-W;3VUN7:&WMP]PP[G- %I9ERV/;PO&7AFIO=>Z _I?^5UVMLO';1R.]OD
M92S;PV)N;(UG7:[&W1W/BMN=7TF\^Q,KNCM#8VR?-V/29)<7N7:F7JL+3F31
M4X^*<M3^(QQD>Z]TC]I_RSUQNT,/L3O/Y,;'K-P=3[%-#2;=P'879^WH.O\
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M[^PW8^W\WOROWA+6YO;6S]IXO)8M\)GL70?<T/V,=:E!XEI::GC@0>Z]T1W
M_#O^9-6[?RB9SY.;IV[G=MIDLQL^"G^0N^-PTFZ>Y,9#UU2'LO<F6.PL?41=
M0=CU>*S=?'UK/2U. VP)EIX(I8ZEUI_=>Z4/RE^!/=_<7=W<V\MF4>Q,-C]V
MQIO'']HT>\9-O]J[]P*===1;"J?B#N"5-C9%=L]89#,=9UVX$R\L^:Q]/69=
M#_"7G%5-)[KW0;[I_E\=[5_6?5NT\UTYTKV-/%D-H[+S=:N_,1B-^] =&;/:
MHWA%C>C=Q9CJ:; 'MK?V^<[-0;EW-30826CQ5-/68J'[VIIEH_=>Z'OL_P"$
M?9-"WR6K.N.M>D>U,%V%WAV9\H=H].]P;RW1'U]V7W-O#I?H[K/;</<4]9M7
M=]70[6V_NC;FZ,Y+24<=73O"N.HJ=*6-V:D]U[HN>,_EZ]][9I(JS#=&]%[]
MK,?U5-58O']P=A4M!+ELY2=8=C[!K?BMN[^X_6^3PV(^.?8G9>_(-]U]+@(X
M,#1P8\8E,*THAK$]U[HT71WPPWMU1N/XI=PT.T,12;XZ3Z0^5/7^^MK5V]Z"
M&3,Y?N_LK9/9&)P^S:+:6VL9U9L_9]3NO"Y"M%/CL=1)A,>U%CXEJXZ<%?=>
MZ?N^_AAW-V9VUWWV1L[LNCVWB]^_[);5[9V%+4X1=H[RR?QP[4S>_=R#M>>N
MZTW-O3$T,M+7P1X\[;R]"\[1?OJ"-3^Z]T$74/Q8_F2T>-K(M^?*"JP@W)V;
MDZG(TE1V'N'L?(;)ZOJ^GL5F(Z79F6R&WL9)7;AI/E9L^$P'(/+%+UON"OH[
M4=4D=*GNO=2,;U?_ #!^DO@QN2#)]K=B]X_,#']J[)W#U5!5YO';CH,KFJM]
MC[*RNW=_9O;^T\!3IT-N#<;YS<];3U<0;;N&K%B-3:CBIH_=>ZA2_&_^9-LC
M=NZ<WLKN:O["H=NY6JBQU'V%W[N&GQO>^"S& S.V-F3M@AUQE*#X]9/INGRZ
M5V77&?Q5-\5],)YVBGC@F3W7NE1N[HKYI;'^+^;V\W8?8G<?>F_?D]T=ELY+
MM3O+?^SXHNFL=NGK#"[SVCMG?]-BJ?-=-;8R&T-O927*5N(QS5K25]1422/4
M3&:+W7ND.?B1_,AH</LRMJ?DWN'=6^Y=TPP9G(TG=VZMK[8V714.TNH:/KW?
M=1M)-BU&$[/H>N\AMW=E-N':M5%14O8-1F8<GD*A)0*>D]U[J3L_I3^81M3M
M3K';.\^X-Y[BP'9?R'[!W1OO+X/=N[\]M;JWX@X1,?V9U_U')N:NH\1%1]N[
M-WAA<7L-<^L+9'?^W=PYNOK6BEH(/![KW4SY"?&_^8YNW+_)>GZL[7FQX[&W
M705/6'8L'R,[!V)-LK84^.2':FT]F]-8'9]1LK:.6ZOW%3?<Y_-'(25N]<=4
M.DRO((X(O=>Z9]U_"WYR[LRO5TV\^Y:KL.FKNYM@]A]I8FO[TWM@NOMJ2]:=
MQ]);[Q^;P6Q*+97\)WU@<WL#KS+XJ+:,M-BL719ZMCRQF-1.]11^Z]T.N8^,
M7R^K_DA5]K8_O>NP77V)[:VGNG:VP<!V!N#";;RVR*SLK:D_9^*["V3C]IQX
M'>.4K^H\=7X_%M7RU;4E;+&T4U.ZI41^Z]T!V^?A'\S]LCY&93HCM^IP-3\A
M>[^UM[9S"8SN;>>TX-L[=W3V%U/E-@[MZYCH]LK1[3[%PNU\!GDSD$$]-2YJ
M.L$%14SDQ-%[KW4-/B'_ #':38C5VY?D9N#L3?>Y<E/_ *7]HX7Y";WZ^P&\
M=I[?R?5]/M#;/4VYZ+8*MT/E<K08S<5;F<OA\?#4UWF2BG$R5334ONO=#-D?
MBU\V]H],_$W9'17?NU=A;CZ>Z"ZSZ][7Q64J<KF-B[HWQU=M_ XK%U6"4;8@
MKY\%N.;)9Q<Y4R04-7D8Z/$,L5.8I4]^Z]T72N_E_P#SSZYV<VR.B/E;O7;6
MTJK.;ISFXX*'LVLJ-ZYS<&7[J[SSVVMS;7R.\]H9K;/7:Q[2WYMS-[NH*& T
MNY\KC*NFDCD+FHK/=>Z/+\3>B/E1U)OS<>=[P[QR';&"WAL>K.XZ3*;RS^Y*
M2'M>F[A[(R6*W#L;;N7P6.Q/76U*SIW-82BJ,5B#2T*UU&5^V<Q"KF]U[H_G
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]'?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW1,/FUO?NK8>R^JZWH7(3?W\W=WIU_U6=N+
M@TS,>=V[VBV2VAN7/K/+ALI286MZ=PU?-ON&HK9:3&U(VP]!52%*P(WNO=$.
MJ$_G$[5EWE-BX*SL-$PO<.V!!6U_QQQDF9[?RVW-^87HSLSJ=*G^'TV!^-&W
M$H=M9+/T&Y9!O$;BJZH0T-=C8Y(W]U[H8/E$G\T2?O;&I\7<=M>#J^AZSCQ5
M;FMV;EV(=NY3=&7V5V5+G<Q'MBJQ4.YJ+=6"WE0[:BQ,DE34XWRU'DGA:A%?
M$WNO=!1GL?\ S5EI]TC8$/:HA.Q=L8[K"/MC=?Q5J,G!LZ*NI/\ 2;4]T-U[
MCJ2&L^862:*I_N@=L5$77M'C):?^*ULU='4>;W7ND[G</_.6CP>X*&ER293,
M97I+JUJ7<&+GZ;V^NVNS,!EL35;LP&$VW4YO,#-MO[$S5=+G,Q492AFP,\;S
MXN+*Q-2P1>Z]T*7?_0_SB[>[;^+F\L)O+L[JVDH^INNZCMVBZW[1ZZK]E]?=
MP[8J\WN;=5:^W]V;;@Q.^LM7UF7BP]'D4PE3C*VBBE6IH*>,QE?=>Z7GQPPO
M\S#-]J=V4_R5W)M?9.PL]U+%B^M<KLS&[.SM%M?L*LVYL:#;^YL/3?QRIR4V
MXMO9&7<<NXZ"KH_X)6Y!:3[&H>C50?=>Z!/=M+_.FR>V\/DZ.;K' YYMY0-F
M=O[2DV#EWI<!N7;F7W1A9<7+FZ[;]'6XWJ7LRCQ>WLU#55GW&X]K5-550'[M
M5#>Z]TK>D.O?YC6R^NOE%M+*9C<6,R<FR.T*[IS)[@R74&]:NG[QW/VWVWN7
M;V1Z-1<Q$R].KU_F<%JH.Q<@F6I<L?M8I(Z2GDD?W7N@9W#UK_-ER5!LGL7$
M4M3M;LK"X7^[^<VSA.T=@UVW]V4=;UGL_ [CWKO:GEI]NTVXNPXWP63_ +K0
MU&NCP&<R">26HIVGKF]U[H?.U8OYJ%-T5\0*7K>CP.XN\Z+(4&3^263&:Z[V
MC@7BQN[=EM'B<[ALG-GHLM%E=@5.;6L&%RL47\4ID*.1- T/NO= CW/U)_-:
MS_4NZ=@Q[SW]O@[[H<5E_P"([4W+\<]D[XV_V'FX*N2KV?69:;$X'"XWXV[9
M;&1"O&+=MZO4541HZVI@:J2+W7NA;[BZ4^<6W_E7WAW5TEE=[U^W.T\ITEMS
M:E%2[XZRJ\3MZBZVZ]<X*FRNVNQJ6I7:?Q[J.S,_G:KL"#;OCWOFFJ*23&F1
M(@L7NO=!+L/I'^:!UK'M3:&U,[F=OXK-9N>HJL]'O#KCL/"[=W3E-Q;7P6Y-
MS=M1]C9/);TS'4V%Z=3(U6U\1M2J3,R;TIXAD@M%,*A/=>Z,=C=G?S'NPNJ/
MEC@NW=QT.Q<_N'H/?V"^/D74.X-FXW=-+V3OW;^;3%M%O#[!(MN9SJVNPM!3
MXO*3$PUDF>GGFL:*)A[KW18ZWJC^;7UUU=4XGIG<V8KWWA4[DWAF\7V-N;JC
M=._.N,UD^XNVZ[;. Z]R8K,7CLE'6[/RFU<ANV',9>MI&2&MAQ%32LWVA]U[
MHT7?&Q/YAV<[$V/D.I-T8_:N&@^/<-3V/N#:0ZOHZG=??6S=I=F9G:VREI>P
M\?NNMQ776Y.S\AATKVHUCE_ALTL7WL2^25?=>Z+=ENN/YL.ZL[/ELEN#?.V\
MIMSLON6GV)N/:._^F\9CIMH]J87;V,PE9NSJBOAS.T,EA>HL=C:]-NU-3D,K
M6R9&LAK)\=%*M0K>Z]T*><7^:&.P<-A4H>P*CI78V8W)A-R[@V9F_BM0=P]L
MR4_<79N0Z;W7LFJWE#D-J8K9D?5IVC2=B?QS'X[*5$?WAPV.DJXY6J_=>Z";
M8/57\U+KG%83"X_)[JS=9097!04^Z-P;XZ@W1F-T[[I-ZU=579'O7<FX5FW#
MF_BA2['RM?3TD&WXH.PHITQ\"0)3Q7I_=>Z$:';'\V#:.=ZEJ8MRY'M;$Q]E
M]1;L[)Q&Y,OT7M&/(83=.TJ:G[QV?5[CVG@$J=N;.ZTW"DM1MZGH,-F*C)N\
MD$]7H--5T_NO=.G:FPOYD.W_ )$]JY;H_<&]<GUKO/NC96\=BG<F[NI\EL'"
M:=D=";8RN#W;A=QC^^V ^-=!@]O[XFR6,VU&N[ZC>571U=,9*.=YH?=>Z;?D
MCL;^9'O7M_?M%M>HWR.DZ;LGK[<F.7K#<G0V!K3U%L[<_3>X\#%T4^^YJ3<,
M/R47.T.[VW2F^9AL:OP?VL%%Y)Y(HX/=>Z"FIV?_ #A=MSC,[7CSFY-\[S[$
MZ3WWO&KW)V=U _6V#VUA=L=4[0W7U_@-G_8T\N+)VOB]QUVY8L?)18^NW?(:
MG&R205$+P^Z]T9_XY;"^?FU]V5A[GWNV#ZOR.%[QVC%AJ$]05>#ZEV[@\/U5
M)T)OC:<6&PXW+E=V9'*U6\GRIRU9E*5H8J9)J>!8Z=G]U[H NO\ =/\ -5[D
MV9U=V=@:RKVU/V!MC<%5L^DK,?UKMOK;;#8[+939./WC\@=M;OV\G;^0QW:/
M7&!H=\;7I=M4ZS8O<NX'HLI3)CJ55?W7NC/]%I_,$W;VG4[W[FI<WUQUIANH
MMQP;7ZKK\IT=D*C<';\V#ZXPU'DM[UVPUSU8,8N8Q>XLCC*>DRL=)"N27[LN
M4IZ>F]U[HM$.U/YRN(RDF/.\\-N+#Q_'#9DDV:K1U*<_D^ULMM/!9'N?&T<M
M NW]N8+M3#]@5&8AV1-_"*O9RXZ.@BR,WC^XE'NO=*G&[:_FEYK=F,Q46X^Q
MMF[,RT&"P64W#NW+_%W,YS;?3LV:Z\IJ+,0)MC!55+4?-"EA;<]1NN<455UX
MF'-,F&-7DEC(]U[H,(MB_P VC;N^J_?^!CW=N3.UO9?3N,WUM[=F_>A\=L#?
M>U=E57;%-NH]=93!44^:ZWZD^PW#B*ZAFK\#6[MRU;Y:?)0+ D<L/NO=&&[_
M ,9_,ZS_ ,J-T8OI&H_N=\9\GLZAVS2;U@W!U%D,QB*RN'6-;5[MVCM3=>#G
MJZ+=.,JGW72.^47)P&%()$A8/ D7NO=-?6/7/\P6J^47QQRW=F2WCFNL^K)^
MRXL[G,9NOINAZ]SNSZOKKL/9FSLSV)MW TV+[$W+W[F=S3XNLJSCX1LV#&SI
M-%3TM>D\2>Z]U"^''7G\Q'K;?G36T.X<[V3N'KC;6-W7C>P,]O[?746]\!F]
ML24'85935N0R6/2;M[*=WUO;-3A9<741RQ[8I^OM5//''E4,(]U[I)R;9_FY
MY#9N]YL;N;*X7LS;V'[6W#2T^YLMT!4]5=@=I5&X]JXS9&V.JX-N[?F["V_T
M71]9U&:J\4NYZRFSTVZTIOXC+3441:H]U[H.^Q-A?S?^P,5B]B55;N?#;.R/
M1.6P>]=X;![&ZHV%V34;CJ*/=6X<!/M?PSY)-L]PX[)8K"86KR(RM9A*LU$T
MX$-//.(/=>Z/]\,*?YT)NSOBJ^8%1MT;>K-RPS=48[!P;<>CI:0[HW\?)@*_
M"9JMRO\ =U^NCM2.>FRU+3546>BR+Q-)#(&]^Z]T?OW[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__TM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=$B^?O9OR0ZLZ)_CGQ7V!N_L#M6NW*F.H:+9^R<)V!/C8*7:NZ]P
MT$N<P&:W)MS1MK<&Z,%C<'6UE.U144<65\JK"%-73^Z]T _5';G\QZHV_P!Q
M[GW_ -2[>RNX<Q\;MY=K=,]:/M)MD46R^[MO;LWYMW:O0^8W5)O/,2;O7>>!
MQ>&RKUE2<:\+53@210R#[?W7NBEMWA_-DH]I;-WY3=?[FR63W104VV<_EJOI
M#<*?W;I<!NSM3([&R^6^.29RGW-BMS=G9(8O [OR5))+38+;JTN2A6+R>:'W
M7NE3NSM[^:AF=P4V4PVUMX;.S>W-^]N[<SFR*#X^4&Y.J<77[FVD^VNH:.BW
MS/V/B]Q=Y=;[:2E;>+[FHJ+;]/%F)X\372)K?'T?NO=*&L[A_FNY/='96S=N
M;0AQU!MW-=A/#V)GN@47&T62ZZV_VY6[#V)L2AE[%QD/:>U.^J#9.ULC4;LA
MT18/([GFQ*11U0$.+]U[H:?CQW#\Y=Q_(?;6U^Y^L-U=?=69S:FYLW3TM+UF
M^X]ORSY2MW7FJW)[N[DRG8;U776=V-FZ?';?PVVSBLA)F\;5"O2)*?7-C_=>
MZ#/<_?O\T>BS.RZ6CZ1H*<G?^;ZZ:AQ76]9N;$[]W%U[NK:VP\ENG=&Z8MVT
MU-U!T/W-M?-YG?NW-P5$;5>,7!18BMC:IGBI\A[KW07; [;_ )K6T=CXK)5V
MV\EN^GZKZIP>Z]VY+N/JVFVAN;Y";ZAW!LO8^YL!FJRBWNF#Z5Q^(Q-3F=PR
M5.)Q<]/)!CXZE8VBDE2?W7NEATK\M?F-W;\2MW=G]>XQ>Y^P=H_);![3VIDZ
M/J^OZSBW3L:#IO8&^=RODMHXCLJOI<QAMM=I;GR.!%=2Y44V2H:&,20B<2RM
M[KW3=V5V?_-9QF.J.KZ'$;BSV:RG7WR7VI1]O=7?'[ 8NNH=WIU]0[HZB[FR
M8W=V#EMBX[$[4S60GP-%MJE9\QGLK315*I50M-##[KW2^QWR"_F2[<7:]+4=
M(9GL?(=J4]+5[!IINJEVAB]@IM+M3=>W,OANZMQG?E0=F9#?74./P6?6KKH8
M(X\ME:J"EBT4QIXO=>Z!>#N;^:EJIM_8#9/9O8-75]+XW^&;#WO\?<?TQ@Z/
M?> W'VXO8>Z:W 4/;&2RTVY<90Y'$4V#PN3R-)3;LI<932T]-"\ZUTWNO=&&
MZ$[=_F0;D[.ZYK.Q]CJG2*;KVWL3)-F>GGV#OKL78&Y-M=X90?(K=U%4[NJ:
MSIO<N'R^RMJ4M9LTX^1J49Q_N!!+410X_P!U[HN5?V%_-HZ>S78.V]G[8W=W
M/7[B[+[WW=LC*[XZO&9V]5;(W5VEVCCL955NXJ#?F*Q'7-%\>MD;:VF=H;.A
M6*IW]29B:;R&:2HEQONO=&9V]O/^9CC.W(FW*=N9_J/"=J)C,ECH>C#09S<G
M5^+[E;J>MS5-N/']BRM3Y/+]95+=A*:;&2'S4L=%! U/*Z'W7NK7L77IE<9C
MLG'35U$F2H:2O2CRE'-C\G2)64\=0M-D<?4JE10UT DTS0R /%("K"X/OW7N
MIWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_T]_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW4/'X['XFDCH,704>-H86E:&BQ]+!1TD35$TE3.T=/3I'"C35$SR.0!
MJ=BQN23[]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__U-_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%VROR]^)^#V
MX^\,Q\F_C]C-IQP[+J'W-6]Q]>4^WU@[)W#N3:/74IS$FXEQ_CW]NS9V7Q>$
M/DME<CBZNFI?+-33(GNO="*W;W4Z4R5C]G=?+22]B?Z(8JIMY[=%/+VP,H^$
M/6,4QR(CD["7-1M1G"@G)"J4Q>'R J/=>Z169^4_QFV[OW<?5FX/D-TE@^RM
MG4&.RF[]A9?M+9.-W?M3'9BHV]28BMW-MZLS<.4P%-EJK=V)CIGJXH14/E*1
M8]1J80_NO=2U^3'QR;?&3ZQ7OWI8]D87;6?WGF=@#M'9']\\3M#:F3RN%W1N
MG)[8_CG\:H=N[;R^"K:6OK984IZ.HHYXY71HG"^Z]TKME]L]6]C]=X[M[KSL
MC8>_.J,OB:[/8GLS9N[<#N?8.4P>+DJX<EF,=N_"U];M^MQF/FQ\Z33Q5#11
M-#(&8%& ]U[H*]D_,SXA]DXO(9SKSY2?'C?.$Q1J1DLQM'N;KO<.*H#1-@$K
MEJ\AB=Q5=) U!+NO%QSAG!@ER5*CZ7J(@_NO=0*KYP?#"AI,Y7UWRU^-=#C]
ML[ZI^K]Q9"M[OZUI,?A.R:JHS5)3[ RE=4;ECI*+><E5MO(Q_P ,D=:P/05
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M).H2:2*0KKC>9  Q!!8"Q]^Z]UU%0T4*&*&CI8HF:H=HXJ>*-&>LF-15N41
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M^[]E1=J]@;1QU1C]K[P[/7:6_,MCERU52,Z4M6JHB_;TI@]U[I2]>?#;X_\
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M?VMV]M*CV!_>.NW[1U-9GJ9VILIF,2N!JX)EH37H!%[KW17=G_R/_E#T;N;
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M%:]5X,1BIZR!XH*M6G]U[H7,UT+O[._S%>V-V]F]2;KWQTMV%B^L,%L/=O\
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MR[8P.,SU5E<_M^II,/5RQUE)%+3/'2S,'*Q.5]U[KO<_R6^.6R=]#J[>??\
MTGM+LQJ:"L7KO<_:NQ<#OIJ2JH:C)TU4-HY7/4F?--48VDEJ(W^WTO!$\@)1
M21[KW4K/_(CX_P"TY,%#NGO/IW;4VZ,_MW:FV8L_V;LK#2;BW1N_$T^>VGMO
M!)D<W3-E\_NC!U<5;CJ.G$E16TDB30H\;!C[KW3UMCN/J+>V]-Y]<;-[3ZYW
M;V'UQ)31=A;$VSO;;6=WEL26M++21[QVQB\G59K;+U3(PC%;!"7*D"Y!]^Z]
MTD:KY2?&6AD[*AK?D5T523=,15$_<,-3VYL"&;JB"DR386JF[)BDW LFQHZ?
M,*:1VR@I0E2/$;/Z??NO=<:KY3?&.AKUQ==\C.B*/)MLBF[-7&U?;O7]-7GK
M>MPYW#1]@BCFW"E0=D5> 'WT65T_8/1_O+*8_5[]U[J'0_+CXI9/#X'<6-^3
MGQ[R&W]U;XAZQVOG:'NCK>KP^Y.R:BEI*^GZ]P.3@W+)19C?$]#7P3)B:=Y*
M]HIHW$15U)]U[I4XWO[HC,[BSVT<1W5U+E=U[6WMC.M=S;8QW8VSZW<.W>QL
MU29*OPVP<YAJ;,29'$[URU#AJR:FQ4\<==/%23.D3+$Y7W7NI^Y>ZNF]F;%I
M.T-X=M=9[4ZTKY\=34/8FY=^;6P6Q:VIS%6*#$4])NW*96EP%3/E:YA#3(E0
M6GE.A S<>_=>Z3&/^3_QJRU3!1XKY#='9.JJNN:[N&FI\?VQL*MFJ.I,8U0F
M2[1@CIL_(\O7>/:CF$^:4'&Q&)]4PTM;W7NG["=[=(;EZ^R7;>W.X^J]P=58
M9J],OV9@^PMI9;K[%/BI4@RB9+>=!EZC;E"V-GD5*@2U*F%B ]B??NO=>W%W
MKTCM#<N-V9NON+JW;.\,QNS;VPL1M3<'8&T\-N3*;ZW;0?Q3:NS,=@\CEJ?)
MUNZ]RXS_ "G'XZ.)JRL@(DBC=#?W[KW37N?Y(_';9.&@W'O/OOI;:.WJFFAK
M:;/;G[2V-@,-44=1D\AA(*N#*97.TE#+33YG$U5(DBN4:JII8@2\;J/=>Z?]
MY]S=/]<;,QW8_8?:_6NP^O,PV*3$[\WGOK:^U]F91\[3-68-,=NC.92AP=:V
M9I$,M((IV-1&"T>I>??NO=,,/R0^/%1N_'=?4_?72\^_LQMFGWKB=D0]H['E
MW?E-FUF K-U4F[<=MI,ZV:K=LU6U\=49*.OBA:E>@@DJ YA1G'NO=-N%^5/Q
MAW'1=?9+;_R-Z)SF/[9W+D-E]65N([;V#D:7LK>&):),IM38-129^:+>&Y,:
MT\8GH<>:BJA,BZT&H7]U[IO?Y@?$J/;F:WC)\H_CK'M';>XJ#9^XMTOW;UHN
MW,!NW*QULV,VMFLXVYAC,7N+(Q8RI:"AGECJ9EIY"B$(UO=>Z7M!W7TWE.Q9
M.H,9VSUID>V8=N4V\)>L*'?6UZOL*+:59'3RTFZ)-F4^4DW&FWJF*LA>.M--
M]LZRH0Y#J3[KW0F^_=>Z][]U[KWOW7NO_]+?X]^Z]U[W[KW4#*97%X.@J,KF
MLEC\/BZ-5>KR64K*?'T%*CR)"C5%95R0T\"O+(J@LP!9@/J1[]U[I'_Z5^K?
M^?E; _\ 0RV[_P#7'W[KW3ZF[]IO@I-TINC;K[9BU>7<29O&M@H]%0*1_)EQ
M4G'IHJSXC>06D]/UX]^Z]TQ?Z5^K?^?E; _]#+;O_P!<??NO=/J;OVG)@I-T
MQ[HVZ^V8M?EW$F;QK8*+QU I'\F76I./315GQ&\@M)Z?KQ[]U[IA':W5:BR]
MD]?@<\#>.W .3<\#(_DGW[KW3\F[]IR8*3=,>Z-NOMF+7Y=Q)F\:V"B\=0*1
M_)EUJ3CTT59\1O(+2>GZ\>_=>Z8O]*_5O_/RM@?^AEMW_P"N/OW7NGU-W[3D
MP4FZ8]T;=?;,6OR[B3-XUL%%XZ@4C^3+K4G'IHJSXC>06D]/UX]^Z]TQ?Z5^
MK?\ GY6P/_0RV[_]<??NO=/J;OVG)@I-T1[HVZ^V8=?EW$F;QK8*+QU I'\F
M76I./315'Q&\@M)Z?KQ[]U[IB_TK]6_\_*V!_P"AEMW_ .N/OW7NGU-W[3DP
M4FZ(]T;=?;,.OR[B3-XUL%%XZ@4C^3+K4G'IHJCXC>06D]/UX]^Z]TQ?Z5^K
M?^?E; _]#+;O_P!<??NO=/J;OVG)@I-T1[HV[)MF'7Y=Q)F\:V"B\=0*23R9
M=:DX]-%4?$;R"TGI^O'OW7NF+_2OU;_S\K8'_H9;=_\ KC[]U[I]3=^TY,%)
MNB/=&W9-LPZ_+N),WC6P47CJ!22>3+K4G'IHJCXC>06D]/UX]^Z]TQ?Z5^K?
M^?E; _\ 0RV[_P#7'W[KW3ZF[]I28*3=$>Z-NR;9AU^;<29O&M@HO'4"DD\F
M76I./315'QF\@M)Z3SQ[]U[IB_TK]6_\_*V!_P"AEMW_ .N/OW7NGU-X;2DP
M4FZ8]T;=DVS#K\VXDS>,;!1>.H%))Y,NM2<>FBJ/B-Y!:3TGGCW[KW3%_I7Z
MM_Y^5L#_ -#+;O\ ]<??NO=/J;OVE)@I=T1[HVZ^V8=8FW$F;QK8*+QU I)/
M+EUJ3CX_'5'Q->06D])YX]^Z]TQ?Z5^K?^?E; _]#+;O_P!<??NO=/J;OVG)
M@I=T1[HV[)MF'7YMQ)F\:V"B\=1]I)Y<NM2<?'XZH^)KR"TGI//'OW7NF+_2
MOU;_ ,_*V!_Z&6W?_KC[]U[I]3=^TY,%+NB/=&W9-LPZ_-N),WC6P47CJ/M)
M/+EUJ3CX_'5'Q->06D])YX]^Z]TQ?Z5^K?\ GY6P/_0RV[_]<??NO=/J;OVE
M)@I=T1[HV[)MF#6)MQ)F\:^"A\=0*63RY=:DX^/QU1\;7D%I/2>>/?NO=,7^
ME?JW_GY6P/\ T,MN_P#UQ]^Z]T^IN_:4F"EW1'NC;LFV8-8FW$F;QKX*'QU
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M:?J"N>IW)#O"H>JZ^BQ2[8G>;==.F28M3$FN19O\X WOW7NBY?\ #.O\I_\
M[UN_"+_TF;J'_P"Q/W[KW1C*'X:_$O%] U_Q3QOQKZ/H?C-E'GDR70-)UEM"
MGZ@KI*G<<.\*AZKKZ+%+MB=YMUT\>28M3$FM19O\X WOW7NBY_\ #.O\I_\
M[UN_"+_TF;J'_P"Q/W[KW1C*#X:_$O%] U_Q3QOQKZ/H/C-E7GDR705)UEM"
MGZ@KY*G<<.\*AZOKZ+%+MB=YMUT\>28M3$FM19O\X WOW7NBY_\ #.O\I_\
M[UN_"+_TF;J'_P"Q/W[KW1C*#X:_$O%] U_Q4QOQKZ/H/C/E7GDR705'UEM"
MGZ@KY*G<<.[ZAZOKZ+%+MB=YMU4\>18M3$FM19O\X WOW7NBY_\ #.O\I_\
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MY(K-3AVJ_'-;7I;W[KW1?%_E#?RD'EI($_EU?!9YJ^FDK*&%?C?TVTM;21>
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MHG^4;55E5CZ;^7;\%*BOH4@DK:&#XX]-35E''4J6IGJJ:/:[34Z5"J2A=0'
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M\;DW;U-VAF\%GM\8'>>3R-:O]XZO-UFVZ-&K9T-7%3Q>*.149@?=>Z!'9?\
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M_/-F?_J'W[KW7O\ 9B^I/^>DF_\ /-F?_J'W[KW7O]F+ZD_YZ2;_ ,\V9_\
MJ'W[KW7O]F+ZD_YZ2;_SS9G_ .H??NO=>_V8OJ3_ )Z2;_SS9G_ZA]^Z]U[_
M &8OJ3_GI)O_ #S9G_ZA]^Z]U[_9B^I/^>DF_P#/-F?_ *A]^Z]U[_9B^I/^
M>DF_\\V9_P#J'W[KW7O]F+ZD_P">DF_\\V9_^H??NO=>_P!F+ZD_YZ2;_P \
MV9_^H??NO=>_V8OJ3_GI)O\ SS9G_P"H??NO=>_V8OJ3_GI)O_/-F?\ ZA]^
MZ]U[_9B^I/\ GI)O_/-F?_J'W[KW7O\ 9B^I/^>DF_\ /-F?_J'W[KW7O]F+
MZD_YZ2;_ ,\V9_\ J'W[KW7O]F+ZD_YZ2;_SS9G_ .H??NO=>_V8OJ3_ )Z2
M;_SS9G_ZA]^Z]U[_ &8OJ3_GI)O_ #S9G_ZA]^Z]U[_9B^I/^>DF_P#/-F?_
M *A]^Z]U[_9B^I/^>DF_\\V9_P#J'W[KW7O]F+ZD_P">DF_\\V9_^H??NO=>
M_P!F+ZD_YZ2;_P \V9_^H??NO=>_V8OJ3_GI)O\ SS9G_P"H??NO=>_V8OJ3
M_GI)O_/-F?\ ZA]^Z]U[_9B^I/\ GI)O_/-F?_J'W[KW7O\ 9B^I/^>DF_\
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MV8OJ3_GI)O\ SS9G_P"H??NO=>_V8OJ3_GI)O_/-F?\ ZA]^Z]U[_9B^I/\
MGI)O_/-F?_J'W[KW7O\ 9B^I/^>DF_\ /-F?_J'W[KW7O]F+ZD_YZ2;_ ,\V
M9_\ J'W[KW7O]F+ZD_YZ2;_SS9G_ .H??NO=>_V8OJ3_ )Z2;_SS9G_ZA]^Z
M]U[_ &8OJ3_GI)O_ #S9G_ZA]^Z]U[_9B^I/^>DF_P#/-F?_ *A]^Z]U[_9B
M^I/^>DF_\\V9_P#J'W[KW7O]F+ZD_P">DF_\\V9_^H??NO=>_P!F+ZD_YZ2;
M_P \V9_^H??NO=>_V8OJ3_GI)O\ SS9G_P"H??NO=>_V8OJ3_GI)O_/-F?\
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M>_A6+_YUM!_YQT__ %[]^Z]U[^%8O_G6T'_G'3_]>_?NO=>_A6+_ .=;0?\
MG'3_ /7OW[KW7OX5B_\ G6T'_G'3_P#7OW[KW7OX5B_^=;0?^<=/_P!>_?NO
M=>_A6+_YUM!_YQT__7OW[KW7OX5B_P#G6T'_ )QT_P#U[]^Z]U[^%8O_ )UM
M!_YQT_\ U[]^Z]U[^%8O_G6T'_G'3_\ 7OW[KW7OX5B_^=;0?^<=/_U[]^Z]
MU[^%8O\ YUM!_P"<=/\ ]>_?NO=>_A6+_P"=;0?^<=/_ ->_?NO=>_A6+_YU
MM!_YQT__ %[]^Z]U[^%8O_G6T'_G'3_]>_?NO=>_A6+_ .=;0?\ G'3_ /7O
MW[KW7OX5B_\ G6T'_G'3_P#7OW[KW7OX5B_^=;0?^<=/_P!>_?NO=>_A6+_Y
MUM!_YQT__7OW[KW7OX5B_P#G6T'_ )QT_P#U[]^Z]U[^%8O_ )UM!_YQT_\
MU[]^Z]U[^%8O_G6T'_G'3_\ 7OW[KW7OX5B_^=;0?^<=/_U[]^Z]U[^%8O\
MYUM!_P"<=/\ ]>_?NO=>_A6+_P"=;0?^<=/_ ->_?NO=>_A6+_YUM!_YQT__
M %[]^Z]U[^%8O_G6T'_G'3_]>_?NO=>_A6+_ .=;0?\ G'3_ /7OW[KW7OX5
MB_\ G6T'_G'3_P#7OW[KW7OX5B_^=;0?^<=/_P!>_?NO=>_A6+_YUM!_YQT_
M_7OW[KW7OX5B_P#G6T'_ )QT_P#U[]^Z]U[^%8O_ )UM!_YQT_\ U[]^Z]U[
M^%8O_G6T'_G'3_\ 7OW[KW7OX5B_^=;0?^<=/_U[]^Z]U[^%8O\ YUM!_P"<
M=/\ ]>_?NO=>_A6+_P"=;0?^<=/_ ->_?NO=>_A6+_YUM!_YQT__ %[]^Z]U
M[^%8O_G6T'_G'3_]>_?NO=>_A6+_ .=;0?\ G'3_ /7OW[KW7OX5B_\ G6T'
M_G'3_P#7OW[KW7OX5B_^=;0?^<=/_P!>_?NO=>_A6+_YUM!_YQT__7OW[KW7
MOX5B_P#G6T'_ )QT_P#U[]^Z]U[^%8O_ )UM!_YQT_\ U[]^Z]U[^%8O_G6T
M'_G'3_\ 7OW[KW7OX5B_^=;0?^<=/_U[]^Z]U[^%8O\ YUM!_P"<=/\ ]>_?
MNO=>_A6+_P"=;0?^<=/_ ->_?NO=>_A6+_YUM!_YQT__ %[]^Z]U[^%8O_G6
MT'_G'3_]>_?NO=>_A6+_ .=;0?\ G'3_ /7OW[KW0(_(?!X@]5[@R2XZCBR&
M%-!D<760T\4-315:Y&DB\L$T:+(FI)"" ;'@_4"WNO=#7AI9*C$8J>9S)--C
M:&661OJ\DE+$[N?\69B??NO=.7OW7NO>_=>Z_]??X]^Z]U[W[KW0._(#_F3N
M^_\ M5T__NSH??NO="-MC_CVMO?]J/$_^X%/[]U[I\]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_P A?^9/;T_Z@Z+_
M -VM#[]U[H4L!_Q8L+_VJ<=_[AP^_=>Z=O?NO=>]^Z]U_]#?X]^Z]U[W[KW0
M._(#_F3N^_\ M5T__NSH??NO="-MC_CVMO?]J/$_^X%/[]U[I\]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=)'L#+;HP.PM[YW9&W$WAO3"[1W)EMH[2DK8L<FZ=T8[#5M9@-
MN/D)V2&@3-Y6&*F,SD+$)=1( ]^Z]UK*Q?S.?^%&ICC+_P A#;+.40LP^6'7
MD(9BHU$0R;B>2($_V6)*_0DGW[KW7/\ X<X_X49_]Z#]M?\ I6O7/_V0>_=>
MZ]_PYQ_PHS_[T'[:_P#2M>N?_L@]^Z]U[_ASC_A1G_WH/VU_Z5KUS_\ 9![]
MU[HVG\G_ /FK_)7Y^]V_.7X]_*?XI[3^*O:OPHS'4VW-T[5VYV6.RJF;</83
M]D#*8S(Y2AIFV\ZX:/8\+PST%95PU JS9K("WNO=7P^_=>Z!?Y"_\R>WI_U!
MT7_NUH??NO="E@/^+%A?^U3CO_<.'W[KW3M[]U[KWOW7NO_1W^/?NO=>]^Z]
MT#OR _YD[OO_ +5=/_[LZ'W[KW0C;8_X]K;W_:CQ/_N!3^_=>Z?/?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJU_R7/^WTO_  HV_P#$
MZ?&K_P!P^]/?NO=;2GOW7N@7^0O_ #)[>G_4'1?^[6A]^Z]T*6 _XL6%_P"U
M3CO_ '#A]^Z]T[>_=>Z][]U[K__2W^/?NO=>]^Z]T#OR _YD[OO_ +5=/_[L
MZ'W[KW0C;8_X]K;W_:CQ/_N!3^_=>Z?/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UJU_R7/^WTO_  HV_P#$Z?&K_P!P^]/?NO=;2GOW
M7N@7^0O_ #)[>G_4'1?^[6A]^Z]T*6 _XL6%_P"U3CO_ '#A]^Z]T[>_=>Z]
M[]U[K__3W^/?NO=>]^Z]T#OR _YD[OO_ +5=/_[LZ'W[KW0C;8_X]K;W_:CQ
M/_N!3^_=>Z?/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MUJU_R7/^WTO_  HV_P#$Z?&K_P!P^]/?NO=;2GOW7N@7^0O_ #)[>G_4'1?^
M[6A]^Z]T*6 _XL6%_P"U3CO_ '#A]^Z]T[>_=>Z][]U[K__4W^/?NO=>]^Z]
MT#OR _YD[OO_ +5=/_[LZ'W[KW0C;8_X]K;W_:CQ/_N!3^_=>Z?/?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKM?RH_C5W[U!_-?_GL=
MO]G=2;VV/U=W]W%T'E^EM^;BQ+4&W.S<9MZ@[:DSE=M"MD>^7I,6-PT8FEC7
MQH\X0MK#*ONO=;$OOW7N@7^0O_,GMZ?]0=%_[M:'W[KW0I8#_BQ87_M4X[_W
M#A]^Z]T[>_=>Z][]U[K_U=_CW[KW7O?NO= [\@/^9.[[_P"U73_^[.A]^Z]T
M(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW0+_ "%_YD]O3_J#HO\ W:T/OW7NA2P'_%BP
MO_:IQW_N'#[]U[IV]^Z]U[W[KW7_UM_CW[KW7O?NO= [\@/^9.[[_P"U73_^
M[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0+_ "%_YD]O3_J#HO\ W:T/OW7N
MA2P'_%BPO_:IQW_N'#[]U[IV]^Z]U[W[KW7_U]_CW[KW7O?NO= [\@/^9.[[
M_P"U73_^[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0+_ "%_YD]O3_J#HO\
MW:T/OW7NA2P'_%BPO_:IQW_N'#[]U[IV]^Z]U[W[KW7_T-_CW[KW7O?NO= [
M\@/^9.[[_P"U73_^[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0+_ "%_YD]O
M3_J#HO\ W:T/OW7NA2P'_%BPO_:IQW_N'#[]U[IV]^Z]U[W[KW7_T=_CW[KW
M7O?NO= [\@/^9.[[_P"U73_^[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[K
MW6N=W1@OEGUW\P_E_N'IKY"?)3(31=W_ ,L[%=.[%[.WEO'>WQMVK!\H_D!2
MXKOV ;!Q<.)GKMAX#;FV8E>DH\C!-B,?4U4$552)5M,GNO=#'\2OYE/RN[S^
M5G1'0_9'0G7NQ=K;W^/(WUO_ "4$?9&.W;4[RP\._J'=78_7M/EH*_!4W3=)
MOG9M)MW^$965LS25N9@D?(S:%@G]U[H%_GU\G_DKTG_-CZ.PW5E?W-OO;T'0
M>U,]@OC!UUNO=*4G>%3D*'YAR[_ITZJCZFW7UYN>@Q6:V=L>7<.],ANK YW8
MF-BA&(Q.X)\H:,^Z]U.ZX_FR_*'=E!\.I!L_I7>]/WC\IZ;J/<F^]I]/?)?9
M&PNV^G:_>W0&Q<]V!T0G8M=#N#8.Z^FMQ]RY>BSN/W-%EX<PFRLE7T34U$)W
MH?=>Z!/Y2?S(?YC6-^(NVMSY#!=3=,[I^3& [MRW4.6V#U=\B,YOG"UG7&]-
MI[+VU\?L7)C\IGAC?D-V!B,GD]V8S<61H:7;ZXK$5=$N*J&IY<DONO=6X_S0
MOEYVW\,.@MN=G=0[5VIFLOF>R*':66W!O[9O9F_]E[7HYMH;RW%@<7DMK=/2
MIOV?/=O[WVYBMAX"MCMC<9G]T4=56B>.):*L]U[I!_#/=ORC[+^='SDW;WAF
M]R[<ZOV]UI\-\%TGT/5XO,XC!=8S[[ZIK^T^SX,C.N<K-L;S[%QV\=P-B,MF
MX(/)+'CX(8A20Q^"3W7NB3[J[O\ E!'_ #/_ )=]<]0]P]OYG<&-V5V[2YKI
M3>6#W5N'XR=,=08;X4=([W^-?>N'I<=C=MMB]Y[T^5&9W'A*NGPFZJ?)[@HW
MK0\$9Q<=3![KW0X[?^8GSDPW6FW-P;%Z=VMO[:74/\KKH/Y6[XVKOBE[1S7R
M [@[A[(ZV[;4=4[7W='6T6#I<]MC<O6>/K\U45N,RV8RJ9&6E2DIJF:&I]^Z
M]TDNC_YH'R4['WG\(-J;UVYT;M3'?)2'?NG>>W.L/DQOO:_R%;;_ &GNWK^E
MJ/C[D-L4N5I.GUVAM#!4>\\\F_)JVD?$UZQI6TM(#F![KW0*],?S._FUMKH/
MX&TG8N.V!W!WAVOW_P!M=(?(JJJ>D.UMEU\W9&Q>^]K=?T_QFVGA-N9FIQ/5
MW>*]:[NR>\!N/=4<&TGP>S:M4IY!4O7TGNO=#!O_ /F.?.GK/XQ]=_([<76'
M1&2A[?\ E?E>L-K[(VSUYWUDMY[7Z8V_NSL79T;R;>.X1_I+[CW_ %6S:.NQ
M-'35>WHEI:]X:*CS53%&E1[KW5E?SF[H[WZ6ZUZVE^.&V-B[D[1[4^0O3/1V
M-JNR\/O'/;$V9C.T=RG!9CL#<V(V)D\+N+(8S9]'>K>&.MHHYRHC>HIU?S)[
MKW576_OYIOS(V#V'\S]A[BZ<Z=VUB_C)!UUBY-]Y':?=.<_N'@LUNWJ/:>Y?
ME=V7L+ 9%\MO+XYYG%;VW%N7#XG;F0@S]%B]JSQ5=9-#][D\=[KW24[I_F\_
M+GKO']FU6R>F.M.Q*W9O\OZ+Y-[3PU+U)\GL#D>P=R_Z,\!O2D[RQ<6\J#:3
M8KX[[H["R51L&BV37BD[&ILY3FKFG>F_9;W7N@SP?\Y/^8[)V)AMOU7PMV'O
M##TM1@-J9_;^S=K]U8W=^Z-Z9_KK?6]8:[8V6RE5EL11[>@KZ##T<E-54555
MADK%2626>FCB]U[H?^L_YG'SCW[M#XZ[WQ_2W1N[L+N?!9+=':3;$PG;DL79
MV%KOE[L7XN['BZ%R&8SL%/L3.9>#>LN:JZ?<BYF&"/$RZ9VIY_N*?W7NBM=3
M?S7OFW35>0[4SVV]K]@8'N'Y2= ]:3;3QO5??D4?7&&RWQ^Z>RW8?5W1'5>9
MEQVY=Y=E;*[%W+G<?NJI.:G=\EB9ZN@PM1%'D*;&^Z]U==_,.^47<WQ*Z_ZW
M["ZIV'MOL:FWGV11='UFW<EC=P9#.IV=W-C:W9'QLKZ'^#9C$T\.SI^_LA@L
M;NEI==1%A,C+/2E9H?5[KW1#MR?S7._>NN[/D5MKL'JK:5+U!\>^ZNK=A=C;
MCQG5G?S;FZ>Z_P!Q[VK^O(]]=A5!IZO;^]4[]A:@WGLM]J)6P;=V[5BCRXK:
MAEKA[KW5@.Y?DWW)@/Y>&S?F''UC25W9=%T-TS\A>U^I8<+N=:ZFVQ-A]F;^
M^0^U=G;=-4^ZSOC;_7DVX%V[CYONZJ7-4M)3315#.\;^Z]U6QD/YDWSHWGV3
MA^C-I=5[%VAOOMWXF;H[8ZPQJ]0=W9O?-+D-[]%]S=P=9=X4U=DJJ'KB7K[J
M#<VW=G]=[LVED"F?RF]MP-)3U-'$*/&5_NO=//17\R[Y4;DWK_*YZTDVCUKV
M[MSY1_'7K_=?=7<!VIV/USFMR]GR-N[;_=>-ZRP &:P.V<S\<\EL^*MWAB\N
MODJQED6$8A517]U[H>?FM@?E/V/\]?C%L/I+<'8M#USL[X_=N=V[UP>V?D'O
M?X[;3S.]-G]N]'T.RH-S56T.L>PZ'NMLA2UE=02;+S-;M;&U.,JZN9\K&1I'
MNO=4'5_R9^?&ZNG]D;HZX^0_S-W'B<3W%2]H=\]D9:/<NR-T]$]O;<^.V/W;
M\U-I?Z.AU*^1[B^./Q&[8R:U<'45-B329DK5X2AS*K1WC]U[K=XAFAJ88JBG
MEBGIYXHYH)X9%EAFAE4/%+%*A9)(I$8%6!((-Q[]U[K)[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[H%_D+_P R>WI_U!T7_NUH??NO="E@/^+%A?\ M4X[_P!PX??N
MO=.WOW7NO>_=>Z__TM_CW[KW7O?NO= [\@/^9.[[_P"U73_^[.A]^Z]T(VV/
M^/:V]_VH\3_[@4_OW7NGSW[KW6OQOO\ G*=F[2[+^>&SL-T]TOO"'XI#M+$;
M3VO1]O;AQW9+[DZS[#^,^Q<37=VX<;(RM+L#9G<H^20GVI64(R$U6=K9-1'+
MIE^S]U[K/\@OYM'R,^+F].V^N^T>F.A<SO+HOXMR]I;[P>T.P>R:?)9;>\.S
M'W[6=P[5Q^<V#'./@]MXK'M#+[NJB,W1[WG%#'CZ@*HF]U[IIZ^_G+]L[H[>
MZGZUKNI.B,G1YVMWSM+.Y3:G;>Y)V[XK,1E>[,=C/D/\.II-HU]'V%\..ODZ
M;CD[#W?D/%+MI<X&CAJ(Z2DDS7NO=8MH?SI=_9SK7X([QR76O5\.Y?DAW[E^
MJ>W=I0Y/?]'#B-MTG<?4G3-1GND]VSX>MV1O^HVKEN[\1D*FH3)U=#E\?13O
M1%$>HEQGNO=,=5_,J[T^)77^TL+O&H3OZBJ_YB7R_P#CUF.PNT,E >T\=TOU
M#W2FWMJ4N"V-U;LW#9/L[<M-A-Q14S5N,QU7745)0)--C<B))IZ?W7NK)_YH
M?:'?72_Q1KNSOC_O?";!SNUNW?CZ=ZY>OVG!N[/97K3<'>&P-I;PVALJ#)3_
M -W]N[BW70[@%))F:^BRT=!C7JOMZ/[V2FK*+W7NIG\TWO'OSXU_ WO[O3XS
MR[#I>W.M<3M/<&)R/9N-RF6V1A]NC?\ M2BW[G=P4>(CDJ5Q^"V+69&KEG?3
M3T<<+5$S".)C[]U[JOC?/\SKY$=(=H?,_*R[8ZQ[WZ6VUMC>6\/CM-BM[5N'
MJJG>75/Q>^#7:&Y-I4^;PFQ,EA:GHW?M?\CJZNPNXON,SFDJE=7IWHVA$/NO
M=<?D=_-K^4'Q3[,R?4G9?0/2&Z=];#Z5QN[]\;7V#V!V*-T[RSNX-M=@[YK.
M[>E-M9S8T&2W3\/.B\!UZ^.[$W+6?:U^&SE>L0A58:=<E[KW2$[5_G8[TR61
M[)P?6.W>I<5L.'LOM;I'K3L^+?V1RF\N[5_B.]=H[4[O^+.,CVCG-@=G;<Z:
MR.U1D-XK55;8\O7T,*30P3PU%7[KW5BG\L[Y5=T_(/I3<5)\C-M;:HNWNG<1
MT=3[ESO7N2RFXL5V%0=I?%[IKOS%[F-)5[6VE48_>4P[(FH\ICJ.A- E;37H
MW:.01Q>Z]T#/\KWYS]I]_8SY>;B^6T>[NG,WB_FCB-A=4=:]Q=7Y7I&LZMV3
MVMU=U#DNF_C[%+NW![;KNPNR(<EFIJC)5I\TU=ELX%I!]@V/+^Z]U<U[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#7?W3O5_:69ZTS_8NR,#O/+=.;ZA[-ZP
MJ<_2??ILOL*FP6:VU1;RP])*YHX]PXW"[BK8:6J>-Y*0U#/"4DLX]U[H2O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW6I'\>/YNOS7ZQZ0^,N\>Z\)1]L[G^47;G<&\:'(=O[LV-@JWMCJW:/R-V3
M\>]M]"?!W8_274>RON?D-G:??46YL;L[=E3G<J</@\A-+7S1SR28CW7NM@OX
M!?(/M/Y4_&K;??W:VSMD;"K.P]T;_K-D[5V3E\UG5QW6N%WCE]L[.EW5DLS2
M48DWIDZ3"/5U\=&AH83.D<3/I9C[KW1T??NO=:Q':O\ .-[WZL^8GSI3#[0W
M7O+XY[!ZS[3ZM^+V.W=U9DMK=09SY3_%.;K^?O++1]Z8+!9+-[NP4</86ZZC
M<F.@-2^%PO4F2GI8TFDJ"?=>Z178O\]?LRLV#L; P83J*OW%V#M'YA[$WSD.
MBMV[X@K:;='4^9^2VTNI>_OCCV9N_;=3@MQ=5[R_V72LKYHIL%E*O$?Q6C:>
MI!^WAR'NO="?O;^=5\B.M<QNB/=G3O1V ZU.^-N)LWL&OWIO?<6Y=K='[*^;
M.X_ACWCOWL/8,.*VQD.R^S:W*X.#,;7V?LNHJ,O54U5*1%72TXIIO=>ZM9_E
MN_(/N+Y&=,]J[B[ZS74.2[,Z[^6GRHZ.RV)Z@&9IJ/9^)ZA[CW+M#:>V=ZXC
M<#?QG";W7:E%15[Q5"12U.*KZ"L9%:J(]^Z]T37^9[_,.[3^+GRI^'G6750W
MV=@;<RV [Y^<=?M;I_\ TD;<P?Q>W?VCMKX_8AM^;K^RK).IL)!D]R[DW@,Q
M"U/,T?7TU.7,$M0I]U[JOCXR?SH/DYM^CPW5&_'Z/[AH\=\J<3U9NWY!MO'.
M;JWCUWM3L[YA_(OHC:G779W4FW8=OYW<WR%K9]@X.HQ6!VHV0FQ6P\K%N2MI
M:G'4DDM1[KW7=%_.T^2-'U+L'KKMI.H-Q=X;OZA^:E!W>G1V0W'LW??4':76
ME3\J:GJA-KY3,4FZ=OT&4VOA?CK/C=V8^;$5]9@\K6453.\;3T]!6>Z]U:U\
M(OY@7<WR$^478O1'9G5FPMJ[$7KSM'L'H[=FUMV[FSV]<EM_H;Y-[K^+&]QV
MY19G;F%P5'G-X;DP4&9Q*8F22.EH6EBJ"\C(P]U[JQ+Y"_\ ,GMZ?]0=%_[M
M:'W[KW0I8#_BQ87_ +5.._\ <.'W[KW3M[]U[KWOW7NO_]/?X]^Z]U[W[KW0
M._(#_F3N^_\ M5T__NSH??NO="-MC_CVMO?]J/$_^X%/[]U[I\]^Z]T'.P>I
M.N>KCOMMA[6H=O'LWL/<7:^^_!-75?\ >+L+=<6,AW#N:J&1JZP0562BPU*&
MB@\5.OA71&O-_=>ZX]J]0];]W[&W-UMVIM/'[PV3O'&PX?<N$KI*RD7*XNGR
M-)EXJ&:OQ=5092*G3)4$,VF*=+N@O<7!]U[H032TQFBJ#3P&H@6=8)S%&9H5
MJF1ZE8I2NN-:AHE+@$:RHO>P]^Z]U&BQ&)ACIH8<9CHHJ(SM1Q145-''2-5%
MS4FF1(@L!J#(WDT :]1O>Y]^Z]UEGH*"J\/W-%25'VU7'7T_GIH9OMZ^(L8J
MV'R(WBJXRYTR+9Q<V//OW7NI+HDBE)%5U-B5=0RFQ#"X((-F%Q_C[]U[KJ6*
M*>*2&:..:&:-XI8I462*6*12DD<D;@J\;J2""""#[]U[K#'14<,,=/#24L5/
M#$D$,$<$4<,4$<<<*0QQ*@1(DBB50H  50/H![]U[KD]+2R3"HDIH))Q!+2B
M=X8VF%-.T;S4XD92X@F>)2R7TL5!(X'OW7NB[;[^(OQW[-[DZU[]WSUQ39_M
M/J&EQE)U]G)MQ;OI,/@X\%D<EE]O33['QVX*/8>>K]LY?,5-7BZG)8RKJ<95
M2^6E>&0*P]U[HQJQHERB(A;3JTJ%U:5"+>P%]** /Z 6]^Z]UP>FIY;>6"&2
MTT=0-<2/:HA*F&<:E/[T10:6_4MA8\>_=>ZS>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z@3XO&5/V/W..H*C^&5:Y#&^>CIY?X?7I%/ M;0^
M2-OM*M8*J5!)'I<)(PO9C?W7NIB(D2!(T2-%X5$4(BCZV"J !R??NO=<_?NO
M=(W>VPML=A;+W'L#<E+7C;6Z<3D\+E8]O9[/;-S$='EX9X*Z7#;GVAD\'N;;
MF39:EVCK<?64M9#(VN.57Y]^Z]TC>E/C]T_\=^M=G=1=/[(Q^U-A[#H,QC]M
M8R2KRFXLE3Q[DSM7NG<]7D=S[IK\UNG/9?=.Z*^?)Y2NKZVIK,CD)GJ*B629
MBY]U[H4JO#8?("F6OQ6-K5HJZER=&*NAI:D4F2HIVJJ/(4PFB<05U)4N9(I5
MM)&Y+*0>??NO=2*:BHJ-JIZ2DI:5ZZJ:MK7IJ>*!JRM>*&!ZNJ:)%-15-!3Q
MH9'NY1%%[*+>Z]US:FIG,Y>G@<U42P5):*-C40J)%6&<E3Y8E65@%:X 8_U/
MOW7NFQ]M[=DEBJ),!A7G@R=/FH)GQ="TL.8I*)\;2Y:*1H"\>3IL<[4\<X(E
M2 E P4V]^Z]UDAP.#IZF2M@PN)@K)OO/+5PXZCCJ9?XA4)65_DG2%97^^JXU
MEFN3Y9%#-=@#[]U[IQ2""-M:0Q(^EEUI&BMI=_*ZZ@ =+R'41^6Y^OOW7N@<
M^0O_ #)[>G_4'1?^[6A]^Z]T*6 _XL6%_P"U3CO_ '#A]^Z]T[>_=>Z][]U[
MK__4W^/?NO=>]^Z]T#OR _YD[OO_ +5=/_[LZ'W[KW0C;8_X]K;W_:CQ/_N!
M3^_=>Z?/?NO=$5ZG[\[LS?S7^8G2/;.%ZRVET_U#U5\<NR>D,AMW,9;)[KS.
MVNQLAWEA]][L[6R^6IL3@\#42YWK%(\;B:"*>.AH*9JBHKII*KPTONO='H5E
M=5=&5T=0RLI#*RL+JRL+AE8&X(^OOW7NJK?E'_,%R?QZ^976O3,>-PN8ZKCZ
M([2WMVRR8W-2[H;M"MVKO/?'Q^V3A-WKX]@[1JMSX'H;>D4U)FYX*G(5%?BW
MI;1I,6]U[J7MO^9<,ON3K?:F6Z%S6'S&>R>*Q_:*T79FRMRT?6<>ZNS>D^KM
ME5.#JL.C_P"E-\SF?D!MZ:L@QJT\^,C^ZC=9*A*6&L]U[IO3^9Q54O6VQ.T]
MR?&_<FUMN=@9#L;=^)I\MVMUHN6I?C?U#5;/Q78O=%= E::"7<>.S>]:2.@V
M?25-5D,C3:IQ4Q$>(>Z]U&WO_-6VKMC9V\<Y@>D=[[UW5L+M1.C-T;*PV>PX
MGQ7<N V;W#VQVCUM4YB*DKJ9=R]?=,]409\H(C'6-N?$TSO2B2IJ*?W7NC(?
M+?Y-;YZ4^(F1^2'3O7.)W_N5ATY68/8N_P#<?]QJ:3%]H[_V-M:J_C.6I(,Q
M'C\EAL5NYIC$K-']Q#I\C*+-[KW1:][_ ,R+/=*=D_)[;?9_4M9G]C]8YO=-
M!U-O'9>:QB5.[MQ;1ZH^->[<QUAEMM5ADS5!41;G[T,,.XV04T\,++]DI2$U
M7NO='FZ:[KS?=?Q_Q7<>!ZVR> W;E\+N_P"VZMW7G*/&546]-G9G<&UJK;%9
MN>GHJV"DQ>1W-MZ2.GR+T0D%%-'/-212:Z9/=>Z*1US_ #!HZ^3X4;:W/L+.
MS3_*KJBCWC4]CY?+;0VKM[#;ZK\)DJW"=5T=!3U^2HZ[L#=.5PM9!04]34XB
M@K88&>BJ:N:.HI8/=>Z9MF_S2=E[AZSH-_[@ZKS^TLM,N^/XYL*HW5A:W<VS
M:_:7:/QOZYI-L;MAEH\9_#-Y9BC^3.&RHHE26 TT+/25-=255%6U'NO=)NN_
MFO8G[G?V/VST5E=ZUNP=\[VHJFIVYVCLJ;;F8ZDV5U!G^ZY^TL1N:H@@Q]=6
M9+:FV:N"GQ4/FI)J\PK#E):5Y*J'W7NE-O;^9O1[3V7O'?-#T5N'<N)G[2QW
M5G0U'C=_;6?<7<^0&].Q-@[FS>:V;2TV0WMU%A,'N'JO,K!)E<94&N58(_V:
MMZBEI?=>Z-'V/\HZ/9OQXZ[[RV_L'.[FS'<,O3&%ZPZURF5Q.T\ED]Z=\9';
MF(V-MG=>YW;-;?VA%3Y#<L29&MU5L4/B=:=:N9H(9O=>Z+A\?/F'VA\FOD_L
M3'[3V[CMI?&G(_#G"=\5#U-=B,MO7-=D[R[0W9UQ-M+.VBT8W$;$J>O<A]K5
MX>6KH\N9A.U28FAB'NO=/7RX^=N0^/V^MS]18?KV09ZH^.G:?9NQ.S=Q9O%P
M[.R_:6U^N.TM\[3ZIQ. A<U>X-V5U'U?5UE1CZNNPM5/CV$V/2NAAR$M![KW
M2*P?\RVHHY^C-I=B])S[6[-WWW#2=)]K;/INR]IYFNZVS&3WCU7UW@=[X-,9
M2U$6^-CYK=_<.&ADJ&DQ0I&^YIT-36PQ4U1[KW3=_P .D5%!L[H;>.XOB]V/
MAD^0^YL[D=C8&EW;M7<>>@Z(VQD>ML!G>W<U'M^.NQ>/S5)N+M"@C7;9JBYH
MTDJ'KXV\<#^Z]T;+XT_*J@^16Z^_MG'9-;U]GNB>QZC95;@LYN'%97<68P$M
M=GL=MO?E3BL7%]OBL!O63;%;48F:FJLG05M(EXZQJF*LI:3W7NB2_)3^9?OW
M:VP/E+1=)].4LG8W65!N6EZ;SF[]][1FPF^7Z_\ D)L_XR]Q;CR^V<=4U.7V
M;4==;[WBE3A\=EM"[EIH QDI 6C]^Z]U8=W!VU6?'GH6H[$W+C<AV)N7 4FP
M-L1XNFK-N[8J=Y=A;XW+MCKK;M/5Y2K:@VQMBBSF]]S4OWE7I%+04\DDJ1.(
MUB;W7NB-]H_S3L;U)CMQ9#<W0NX*M-E=;8/)[S&W>S>O<_%BN[]V;?W=NC:G
M36*K,;53T>YL'D<-L+*M5;PHW;%8VHCC@J84D6N%#[KW2 Q?\Y?9L^\-@;8S
MGQV['P%%N;-;YV_O'.'>'7^63KW); HMPYG+>?&XW*25>ZJ6LP&)I:BEDQQD
M9I:TPR+$8'9O=>Z6U#_-3IO%MF/._'?=.(RBS8?+]K45%V-LC<%)UKU_O#-?
M'2AV!NS'9C&!L?V#DMQXGY.[>KJC$T3038U:>N225PM#)7^Z]T:GY>_+W$_$
M;'=89K/[&R>Y=N[[WU%MO=.[_P"\.$VUM+JG:\$"U.7WUO?)5YK<C2XFG,T5
M/!**,8M*N:-<CD,9"Z5#>Z]T7%/Y@W9N VQ\A<YN[H##9'*=>_,_LOXP=.;>
MVWVOM_#?Z1-L=<[!R7:=?O?>.?WG3X[";%R?^C[;&5K8Z'75/5U:4]'&J&7S
M^_=>Z1O:O\T@X/KG='<>S.K-SR]4;+[-Z=Q%)F*"#%]B=H=K;6R^^-D;;[CP
MFU.@MKY:+LC;^X]LP;XI4H*ZHBJL?(ODJ:EJ6(0"I]U[H\F_ODYA.NOBG#\H
M\M@H,YCJKK_8F[\?MK9F\-M[CQN7RO8[[=Q^T\-A>PUGH]HY+!9#/;IHX?X\
MCC'&C<UBZH0 WNO=%HZU^6G=W=WRDZ,Z[PNP<?UIU=+T[\@-\=U&KW'MK>.X
M1VUTGW6?CMN7JK'U%-31P5.S=N[SBFK:;<6-=9<M>%)(*,0U5._NO=)+Y7?+
M+Y8=6?-[HGHSJ#9/7.?Z*WIB^@<EW1OS<HK$SW4\'87R@Q_555/%30YFEDW$
MW9N GDP>"CIJ:3^$YL"MK6:D'C/NO=*.G^47=.6H_C)N\38S:!W5\ZNVOBYW
M-UCE,1AMSPR8K$9'NC;V+I]N;YQ-7C9(ZG:&4ZXHZFER*4R_Q.GGDCJZ2.3F
M/W7N@UR'\Q+>O0>V.R*#M#;&3^0.^L5\Q?D'TYL*BV'A:'8E95]5=2=;Q]\Y
M6NS9UYC"R[GV;UL]514P44<>>K*: RFA22IJ8/=>Z6V\?YE&7QLG8^VML_'W
M.56]%R>?V_T!'G.Q-D8+ ]KY#;78V_.K-Q9/<N4R4T$'5E%@]P;!JZE*?(&H
MJJZFTHB1SDQCW7NEA\3/GK4=[[MV'UCNGK^IQ6:W!U-C,S_I'QF6Q=1MO<_:
M^TNM>D]]=V;6HMGTLU=G=K8#;"]ZX;^%96IJ*B@RX:<0RB,4,V0]U[J9WC\W
M]X="=[]Y;3W;U1B,ATET_P#$[97?M%O;$[W@3?>Z=\[S[/W3UMC-A+M6OH*?
M%8?#5F1PL*'*U-;'345WGJ'$1"I[KW1A^G/D0G:/2NYNT\GL;*;6W%U]F>U=
MG]A]=4V=P.=J,1OWIG<&?VOO3;>W]Y551MS:>Y**3,;>E6AR4LV/I721/N_L
MY4J(H/=>Z)=UM_,CW5V[O/X@T.U.G,#AMK]VYCY/8'OJ@W'V!++V'T'F>@MH
M;>W?C]O-MB@VVE?G=X9/&Y^)\CBGI89J;4I@>HI7@K:CW7NG'8G\SF'L"'9]
M'BN@\W1[HW9NC$9/^!9?MCK#$8[%_'_.]<;4[AQW<E3O'*9.AVL^X).MMZ4%
M5)M+[A*R"L,D4M7'2B*NF]U[H"]M_P T/MK</6]-G]I]24G8.]NNODIV3U%V
MQM:MJZ/J2NW?LW9/7_RJ[)GWKL'';UKIZ[$;*&UNDL=)@]QU23X_>-9#DZ:A
M6*.GDJ8_=>Z$'M#^8KN7>W6/?E?T9A*CK3+[&Z;W3WUTUV/N\;-WS0=C;<Z6
MW+LG%]N[<W=U?29ZCW+UY))E]U08>D>KF\]33U$E="T3P+#)[KW3O\C/YDF<
MZ5[WS>V:'K67)=/=58;M_';^STF0Q[;K[ [8VEL+HC=>U^O]D;=2H&<V[BXY
MN_,-]YG:VDJ*29'D\4944TE5[KW0C;,_F!;GWRN=KL+\6^P?X+UW\?Y^Z>W*
MFNWUU_B,MM;<,LW<6)P756U<%G,ABI]YYW<.Y>E<A30Y">7#4$%/7T,U0T4C
MU5-2>Z]T/_Q_^5&V>[?CC+\AJW$?W4I\!3;_ %[!V;0927=F:V+GNL\AF:#>
M.TLM#_!]OYVGW9@Y,-(E5C*[&8_)4U3>&6G5@"WNO=$NQ7SR[N[VR_Q<V]U'
MU/3]9'LWY%8[9_<&1W%N_:&\LCM7JJL^.D?RNV+D-K+1P-MS/Y#M#JFOI&R4
M:5"UNW)%J*>..I::BKW]U[HR?SMW/W]M+:73-9T#V]M_J3+;J^0W4?5&Z*W<
M/56-[3@R6W^W-W8S8K5%!19'<^V%Q&5VU/EAD()-<\=0\/AEB*,2/=>Z)]V?
M_.-P/5N&[?RP^.79N]\;U9OQ]BX/,T.>VQMB+LQ<%V-OOIO>6<H8=S#&TVVZ
MW#=D=>U@3&RS5#38F6.I,T4XDH4]U[H1LQ_-1P6*CWK4+T9NNKI:2NI-J]4R
M4^[]OU51V5V$^9Z"VSDMLYK&XJCRF2ZUQ>/W'\C<#"F3K8JI:J&&I:. SM04
MU?[KW3+NK^:C/%MS<K;8Z)K\!O"H^%V^?DYU;0]M;WPFU<;O[L#9&Q<[OC/=
M-T*8NGRTL]9M#'8*27,2M/2Y.*G>&JCQYQTW\1B]U[JR[J/?&7WSUGU?NK>6
M*PNTMZ[ZZ_V[O#+;/Q6XH-QTF*KLGAL5D<Q18?,+3T+9[&XFJRD<7W<<*HP=
M"?UK?W7NBV?)GYL8GXT]A;:V=ENM\]N["5.P*WLW?.Z<-GL-1U.SMJ)V1L+J
M;%-BMJUH.8WSF,IO7L;'QFDHC&T-,)'U/,U/3U'NO=!OA_YA\F]]T]5[&ZNZ
M)S^^-U=G;BZ^QKPOV%LS!83:. W7\>]@?)+<NY,[FIS6O4-M38O8%/#3T-'3
MU$^5K4708*>5)Q[KW3%B/YG^S:FI[1HMP=6YO:N2ZYWSVEMV/;^2WCMF3<F1
MV?UOT]WCV[C^R<G01JN.Q>V>P\?T-E(<)4459EL=4QRAS6B>ER%)1^Z]TS)_
M-'QV:W3G]D[#Z1K]];FG3I!NL*;%=H;/AQF]Y>X-V5VP\C0;ASLE))C=C93K
M[=N,J(,C CY<^.)D<P5R2T,?NO=#1\5?E]O/Y+=R=R;='66(VITWM;J7XK]J
M]7;QGW9#5[\W+3_(KK"?L*LQ&\-F4T%11X";;<D+TL<T-;+',8&*^0->/W7N
MFWM_YH[NZ3^0G>&R]W=8X:?HGICX;8SY-3;_ ,5NYIM_9_<];OG>>TAL2EV7
M+C$H*/'U8VNH3(U-9#24KL9:F:.$_M^Z]T8/X[]ZUG?76F7W94;%J-B;YVCO
M/?W6.^NOJ_<5#N"CV_V1UOG*W;NXL+C][XBC7&;CP9R-(#!DH*9+QR:98(IX
MY8$]U[JM+K+^9MW7E,)\1=_]H=([7Q.V^[NI]T[Q[IV]L7>$><GZ=9_DYU3T
M#L/>F*S.0BAJM]XNN;L02UV#H:,U\ 21UF>2)*:?W7NCN_#/YG8KYB8K?^7Q
M?6.\.N:3:&4V_-@JG<U305E)O79&],949G9NZL9-2"GFI*VLH*.05]"T4D5%
M-I2*KJP6=?=>Z+)FOYE6_>O=D_(#=O8/Q[BS-?L+YM[^^)W3>U^N-])E<EV/
MB=E;(K^R)-W;HEJ\')_<[*2;+V]D:E:-(JMIJD00E8(F>J7W7NE'OS^9A4[-
MVQVMV!3?&K?.8V!L'LWI[I;:V8FWYL3#9OL+M#M>DZUS4^#@VW4552VUL3M#
M;O9M-)4Y"NJ=%37T5330QF,0U4WNO=+/H#^8IMGOCMWK#J]>L<[UY3]M](4W
M:^RMP[RW7MI9=S[AHJ=*K?77VTL3BVKJ?<E=UO&67+2)70Y&(>.J&-.,GAR#
M^Z]U8W[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZI0Q!^;'S,^57SLPG7?SVW_\0>JOBEWIL'XZ[)ZYZEZ$^,?8
MDVYFG^./3?>&[>Q]Y[R[\ZL[.SM1N3.9WN4T%'1X\8[%X['8J$-!55$TU0?=
M>Z-I_+#[V[5^1WPJZQ[*[OS6$W1VK1[M[ZZHWIO#;^W8=H8W?.3^/_R%[5Z%
MBW\=J4E76X_;63WU0]:PY>NH*23[&EKJR:.E6.G6*-?=>Z/W[]U[KWOW7NJ5
M-Q[F^8ORU_F"?,CX[]2_,_>/PWZN^&^Q/BO'CZ'JOI7X\]GY_M3='R%VKOK?
MFX-R[RSO?_6_99P\.VJ+;E+C<90X>"ABL9:BI>H9T2+W7NC$?RP^\^YNY>HN
M\]L]];TI.T.Q/C-\Q/DE\4JGMN+:V!V/D^U\'TOO*/&[;W[N?9^TZ:AV?M[=
MN4PN2AAR,.(IJ7&R5%.TT%/ LOA3W7NK(_?NO=>]^Z]U3Q\F-_\ RK[F_F.[
M5^#?1/RASOQ#V5MCX3U_RPW7V!U_U/TUVIOW?^Y\YWE_H?P6RZQ.]=F]@;3V
M[L[;>.Q%57L:#&QY*MK*M%:JCA@\<ONO="+_ "^NU/D#4=Q?/'XI?(/N2I^1
MN7^(G;W4>%V;WIG=A;!ZTWQO'9W=W06Q>Z*?![VVKU7@MK]=-E-C9;<M5CZ?
M(8S&8X5U L)G@\Z233>Z]U:%[]U[H%_D+_S)[>G_ %!T7_NUH??NO="E@/\
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M(XFKABI9F29Y*690MXI-/NO=9,U\E_CSM^F[-JLOW?U/0Q],102=KBH["VE
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MG5^Y*#LZOS6*ZYK<%OK;65I-]93;;F/<&.VG4462FBS]=A)1HJHJ4RO Y"N
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MOQUH\#0T,FTO]'F\J_*MD:K9M'O)LCN3,;>FIHJ7<>:KHY:V9DH:..+W7NK
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M9F3VWB,_2Y%LAUS3;9W5TSCON]P8H&JA?,QTK&&H_A]1#[KW1DOA_P!3=/\
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MQTZ%[/\ D=D\!V]M;Y)?Z3GV[O+9O3>W-X;RVK0YW9^XQ/C<I5T"8NJEHZF
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MZ.QZ.CP&W?D7MFAVKUADMBYK/;BVCUW38+OR>?+8#&83+SY+)8<20_;15E3
MONO=/&X>C>GOGSOGK;Y3[ [5B7K#>VRL-A(&SO4&XML=IY;$==3=IS8W)]+;
MG[-IMK;GV#M7> [;J5W*5P-?2;BQ5'0FFE@1Y9Y_=>ZR]7_!'-[&W-T#V5N;
MO#K+?/9'4_=%?N*@R4O5$6*VY7;)S/QFZQ^,N1V)L^CJ.Q,[G\#OK^Y?4&.R
M\>73)5,3Y&2I67'/3&-8O=>Z1W6_\N"GZOV=M3!XKNGK"N/7/S%V'W[U=MS)
M=68Y^L]F9G:NV<QU[G=AX##U&]ZO>N,W!NW"[AK:V #<-13X#.B 8VAAQT1Q
MS>Z]TS;0_E[[ [=[<[U[#RGR)V#W71MV+N[:&[=K4W6FTLNFVM[XBJ^2^2IL
M1V&N.W$FW)^P-B4WRG2G>-,10,J82&>2/[K(U4R^Z]TH\;_*WPN#A[N@W3VI
ML?)[0[&^,F_NB%R^6Z9PB;VI:WL&FZVK<GO[L3?5=O"0;WQVP,_UM#-M7%RP
MT9PU#,('KII*>.I/NO=)3Y*?&KJ7>/>7;&V=H;XP^[/E=OO8&Y^XUZDQ.SL5
M!NG<O74G3_3G0V%V]O7L#*5,FUZ/8F3W5U!]ZM!N&HHZ7/)6UN/A$(CER,?N
MO=&B^/?QOW/3? V3XM=POM7K3?W9>R>_:;=>&ZHH\)AL/L*/N[?/8.Y:JEV5
MMW'5N1PU-C]DTW8<%**:&HKL>LD0A-14Q-Y9?=>Z!9_Y>5/NFIZDRV5[6Z5Q
M5=CJ/<^(K8.H^B]N[ V_14T&^H^RL+6_&[&4&],C-U/NZ3,8W[/>&7^XSE=N
M3"^2G=J.2.*HB]U[HMN(_D5];;2H=F8[_3EMZCCV[5=(G;\;=);>QT*[NZHF
MQ57+G<'!_?T?PW<F]3M^$RRTI%7%X$/DG\*V]U[H:Y/Y46SMSTF[<7F^U]GY
M*B)[2VUB*3%]3;>$2P;KZN[UZ]PF]>SJ=-S^#>WR'VS4?(.HK,CNHI02U]/C
MZ:FBI*$S35#>Z]T;7Y@?%BB^1?QIP/4&1WWMK;D^U,OL+<..[%WA@:O,KC\W
MM*EDQN.W1B9J/=^V*W ;L6JK14T-<*ZHB6H_9J:>MI9IX)?=>Z+10?#_ &GO
MJO\ E#4[5[PZZW5+N"B^->S>W<KOKIS'SU8[Z^%M/L?)TC]I4&*S.QMK[RZ?
MWGMS&8]=P[;@I**&-*N<4&2IHS''3>Z]TSU_\K;!9#9^8Z[7N;:"[6[$^.^(
MZNW%N&?K#'2=J8Y,)A<[A*\]*]BXC>N S'4_3E?B]Y3-_!<0?XCC72G^TS,"
M/,)?=>Z.+L[XMIB_ASN/XITW8M-D]N9#9G8FQ>L.Q*/;&+DR^UMF;EGSDW5F
M6RM/#7?PS?>]^NL?DJ%JC.2/3S[EK\?_ !&KM5U51*WNO=$UZ:^)OQ]^$6/^
M)VS=P_(B@W)N1?ECO?=?2%35[(BRF]M]Y/>W26]>M\]U-M?^[F1W!GJ7;."7
M-UN=R>2O+04*1F*L$$;),ONO= U\B?B[\0/CMUKLKJGY+_(7IOJK;F$Q/SKS
M_P ?Y<UTY U?2;=[9S77^Y]P;LDIX\O68[,=J],YC<<,<%;B8,94Y6CKZ=:>
ME@E@GD?W7NC(?(+H_P",\N"[EW'V!V%A\7L',?,&KW3NZ-.CLOO3:NUNX.XO
MB53?#S&8W-1X6CK\;4SQ;A['H<_7;FGCCHJ7)R_8UTU/*LE5%[KW0C;UV#M'
MO#H?(?$'8W=U-@=Y?$ZOZ$VSVYE][]69-,=D*3:FVL#G:&GR=!N]<'JVYV+M
MVF%1%FMN9B3[>0/%#7EXJA/?NO=+[._$3![@^"6-^!F;[(H:V#'] [(Z?RN\
MJ[;-!5/EMN;0QN$P%1GZW8%1GVIXL3G:;!-$]&:UJ6%96B61E0 ^Z]T4GLWX
M&]>?,7=E)V+U7WQL?;?2==L7>/7VS>O]K=.X2*FP>/QVTN[^@.R,9M^3&Y?9
M+5FS\AG^R:JIK%JZ.JU5= *:GG2BK'#>Z]TF^V/@%OG$_(/IN'JW#;'R6P]R
M]Y[C[,W;O'+XO8>W\ATCM.7MANX:W;W0V/DS2;OVAV!--/41R9K"4=?3Y(&$
MU--C&IS5S^Z]T:;X<?$?,?#S8F#V/LGLW86ZZ?.=FX*;?.67;F4P@W#U[UWT
MW0]/8BBQU!4;YW8@[4J\OLW"UV<R<<L=%45'W4,=#3+X@ONO=/WSR^*51\R=
M@;<V)CNYL!UEB:.LW=B<\V2V9@]\09C^_P!LO+[(Q;44DV:V]F,5N#;N0RRU
MM!#3U\5/D)T$%7%/'I5?=>Z47QR^+'^@WO?Y-=FT/8F&RF,[MW'1;DKNM]O;
M7I,-28#<59E,_N/(;NW#65F8W'F)MX[C7</BJS0R8C#5ZTRUS8U:^HJJF7W7
MNB7_ "*^ 77<>Z?D/W5O3Y(=<=:[0KZJO[#R6:W=LW'4VXL#N#>?8WQXWU38
M#N_L^+?NW:S=W0D6X/CY1T&(VU]MB:B.ERKJF1>:BHW7W7NE/7?RQ-NS=?97
MJK&]N[8P&,W=\*-M_&W=^;P6S7Q^_4AV!V-N/LK9F\-K;EFWQ7Y.@ZQJ\WO&
MOH,]@*TUQR&+BI(H,G221R22>Z]TX=7?!?I"CRF[]H5V_.L-R]J4?Q6J>I_N
M<1U7'3P==TOR&[0^1W9M%O;KW(;EW7N?*1XC<-9O3,45)BX<O/4/2877-5?Y
M1I7W7ND/UO\ "+H'X48/XI]*[@[TV[1;TJ>].\*SI.FQW4D.*W/O7/=O?'G<
M/66[=M;8V_MC,9K(83$[>HZN/<>8RH84 -'"M:U.&BJ![KW7'(_RDMB_P3K3
M'[?[@VQ38;8.?ZIQDN"JM@+3;'R+[ Z>ZIZ/W%4QX#;78&"\?9F?K.HZ2JHZ
MN6KE2BDJ9:*II:\)%(GNO=&\^+GP^I_BQV!W+V#7[_VQG,=V-2X#;F*>#8M)
MLW=$V/H.T^Y>QJ3.=O;Z.Y<E_I9[+RF:[OFQO\5:BQ0--00Z8&GJ:AV]U[HC
M_?W\N3L.BQO?V[.J>R=HTO8O;O:53F^OMY;6V3L?J[-=+TW9_P CZ;L_L/M_
MM;>&<W3E&[:S74.VLGE\+@9*:CI:[^&UT](M,\]6U1![KW5H/;?Q[ZX[(^-&
M[_B1"V*VQLK<G3=1U-@,=)14&>3;.W8<##M7;%9#@<S*T>8IMNS0TACCF8"9
MX50R*[!A[KW1*>TOY;^R=_8SM#L3LCM'9>PMT[VV!A,-O[LG8'7V'V11;%VQ
MM#XJ=G?'O=6*V3G\SNK)5^RNKIZK?,FX9<755M12TE)0R8^>299FK8O=>ZA?
M'[,?&':GQFVO\:MN_)'8M?G?FWM/M3L'K#>NP-G[QQ6R,E2_(9MRU. W1M'%
MYS/;HCVQ@LO45T@VW3YG<%-)N2LI)HZ!Y)=<<?NO=+#K?X7?'_XV[O\ CGU]
MB>P.N=EY_#=P+VGTMU]1[-VSM++;BCV#\0H^A>U-L;$QD&<%9X<_45S[VSU3
M1QRL*FJ,=3%*6^\/NO="W0_#[%U.#S^'H^SUK5K?G12?,&JJ:;;M-/\ P_*8
M;L3 [ZJ.L)HXMQ. RRX04DF19EEC\NLTEUT'W7NJQLC\:/ASL?>7R%S.]/DC
M@^S(\)\@<_U7N3:V&Z2WYWOV#C^W/D'M;Y#;NVQUMOC [3K]_5/8W:NUZCY6
MG(XUL1@:6JQ^%Q4$5;%')-/5Q>Z]T9.H_E:5M?ELKN2A[6V#5B7!;7K]M_WQ
M^/IR.9W7NG%YSX][MFPOR"K).P,-ENSNDDRO05-#0[,D7&5.,I<CI.1>IH*6
M8>Z]U97\>^GZ/H#I'K#I>@S^2W12=;;0Q6UHL]E8X:>IR/V$1$DD-#3EJ;$X
MN*5VCH:&)FBH*)(J=&98@Q]U[H8_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_R%_YD]O3_ *@Z+_W:T/OW
M7NA2P'_%BPO_ &J<=_[AP^_=>Z=O?NO=>]^Z]U__U=_CW[KW7O?NO= [\@/^
M9.[[_P"U73_^[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>]^Z]
MU5G\G?A?D-\_)')_*'(]E[#ZPV'A.G<?C-U]D+A<O1]X]=8[K?:?R&IZNGV9
MO^GRE+B</U?N:'NDU^Y:*2..6H3"!?(S2PS4/NO= ML_^7%VG48GXRY7&=A]
M"8? ]?=KX?N^HPO6>R=RX/9VUS1=E?'O?%)#T::W(97(XO;_ &9LSI:IAW#0
M22T--49K=-9DBU1&)*.J]U[J3V1_*=ERWQVZFZ3Z\R'1U!78"MWQ)VCE=Z];
MYO+8K=&X=^[DVCG&[[P]-B=PX_)U'R%V'C]EQXK!Y?*5%2\6.RE9")X8A%&?
M=>Z.;\[?BSN?Y5];;6VKM/,[#ILEMG=64S,FWNV,!D]T]99^EW%L'>/7DN3S
M."P]70U\N[.O#O$;DVQ4"0QTN>Q=.Q$;F.KI?=>ZC_&;XZ;.Z'[U^0N6CWE@
M-Z]F=H[2^.N3W7E:C#4\?:F0Q'776%/U'1[N[-W,IFK=Q9'?N>V3D*Y)9Y-3
M3)/;65=_?NO= /V5_+HW!V-\H>U.XLKN3JW)['['ZQ[RV=+_ 'DV3D\WVK4I
MW=TUL#J&JZQW'G9LDNW,QT/M*38(SE#AVI"6K\G.I17$E35>Z]T^Y;^7#0[E
MVQV#%G=[45/V?N#X4=2_$[8'<V#PTU/V%U7E-C[1[1VUO/>VS<_4U<N2P$?8
M']_X5K102TN0J**F>GFJF4Q>+W7NDGTY_+RWWUCO;HC==1D^D\[0[,FW36[L
MPN\,'O[LBMZAES'9>\^QCC/B?N/,;@V_-LJAW52[O&"S)K:6.F&/HHVBHW@(
MH$]U[H.]L_RMM^[8Z^^,'6^)W1T=@L+\=-V[TP^.FVQL3-X),/L++]T;([9V
MYW+U5BJ.ICI>O?E5%C-C?P"OR1DK<>]+F:V2*58C)1U7NO=*#L/^5M5Y/X\]
M6]5]9YGJO9O8.U>ZMX]P[SW^VUL]'2[IW/O.MW@@WAGL)3Y*JQ79V9VOA-T)
M21X_=-)7Q5=+3)!25N&:.GJH?=>Z-3\P>G:[YM?'8[*Z=WSUR])5[]E7(Y;<
M^)FW)M[(4^TJ[=6QMW8G'5U"*F7;^Z=L;E$LL%8M-5F.NQ34I6(S&JI_=>Z*
M2?Y6FZ,?MJKJ*+?O76Y.PZW)OGMW5^\=GY>KVYWBV#SOQ@RFSMA=XC^(U^=W
M7UFM'T1E(*JAEFJ?#)G5DB61$JX:SW7NC#[?^..5VC\',9\ MO=A[!3N##?'
M5,!0Y/([%RU?UVU!%7_PN67^ZE3DIY*?9LM8[8N""2NJJNCIF24Q5/B,<GNO
M=5SYCX#=I=3=@=3T^?EVM7=?[,VUVYOC?WR!S6,";<^.>QJG:OS%^\VKU/NF
M;=-!N+;.&QT7>N&.;QKX>"GW",?][3R4*4W@QONO=&TK_P"69CY<I\-,AU7O
M+";+Z^Z'Z_VUMW,;>V5-GMC8G^/TNY^O^P<OWMUWC]K,*&N[6W[7['7&Y*KS
M+/\ =XW(R25<M8!/1UGNO=%IP_\ *8WAN3IVDVSM[NOI_L/'Y/>\=+6Y?>']
M]NVMHT&.VK6]8XRI[VZZAEW%3P;1^5%?DNGY8<K54TK4BR96LAEJ9Y8I):KW
M7NK4_F=\:JGY+[%ZTH,-2=:5^[NG>^NJ.^MG4/;6V)-S;)R.8ZYS<LU5BLDE
M(DN3PLV2P.2K(J?(4L<TM+4F-FBECUH?=>Z"/J7XT5'QP^2'<OR+W[V%UW0;
M*["RFY<!A*_'X+,X'>F\LQWIW%@MU8).]=SY#-UF$W!D.KLW/!LO8;00QI38
M*N-/> R" ^Z]T6CO;X$]JX?>/S,[]V'_ '=W-NCLS![TW7T]BNMMMKB^Z\UW
M1GL/T%0=1#L_<^YMV8':6X=A=!=C=%XS<N&B$]*U.D]190T<RY'W7NC_ '55
M%L3H?K[ICXF9O>F#';^YNM]Q5$>-QJ9BNGW7N*DI&S7;784=.T5158G;V1WQ
MN*IJA45[TT+5%='2QL9G2(^Z]T3;<O\ +2WEFMV?&C-IVU$U!TK\4]I?'C+T
MRY'>6$IH<UL?8/8>TQNG:^ PV03&9/&=FS]A"'<E%DY0DF.P])&XK?3'#[KW
M13-B?RL-_=)[C^+72.*["ZH7;^/P.[ZW)]BOC_[O[XV3GMNY_P"-&X,CFOC7
MAZG<-5E,7W5N?&]551FS9I*REH<2LOW)_3#6>Z]T(66_E:;VVYU[@-I-WQL3
M#[TJ?D_B-[[*W5O3.;\SU+6U%'LC);=CW%3[,W+G7VKNSM3=>-II\CE]NU%%
M5T]<]&DU/E:2KIQD%]U[H_/5'QP[/^.>1^7V7ZAQ_1E76=_?(BE[\VE55VW<
MOMO*SUV^I]L4_;F.[5GP)@7/UV)I<;75&W\A3S&6>6J"U<2E':?W7NG;YS[1
MP?;W5=?U1'OK8&'W=@!A/D')L'LRBR.X.NNQ]@]-;OP&5W1MWMK9^$67,[DZ
MERE55TM+DXH(JC14RTSM!4A33R^Z]TR?%GX2XCX^[VV]V35YK;V^=W4?Q3Z:
M^/5?OBJVM3T^]\M4=<[F["W%79+^\U2]7FQM*JQ^\,?C<;C9ZF>6CH,-312S
M3>)&'NO= !\W/A3-V%V#VK\A]V]S["ZXZDI?CWO2CWMO3>V/RW][.KL%M_J/
MMW:.>V]A=WPY6AQ.W?CGO#&]C2;AWUCW59JJLP$$JOK:&HQ_NO=!5@/B%UWO
M#OSJ3>74/?VPZ_8'6WR?[C@Q77/7^6W3B]K]>9O"[ZV!W=G=I;+P^QY?[ITN
M^Z)=CU&&ST-9+1X^?#Y.0%*C]ZBJ_=>Z&SY%T_QZ^7>XOC'OS;/>&P*6MW(>
MV^M?CMELUMO-5=3/W9MKM_I+L/<TVUJ^LHZ/^Z'86T<-\;=P8GPU I,J35U"
MTY*QU$<GNO=%BWG_ ":>RMS[,W3A,+\DY]J;PJ^WMU[ZQ._:NHWSO/)[@QE3
MB]ZU^T,[NZCR.?Q%%CM[T6^]Q8RLKTQZ-3U5-@XDDGG+PK1^Z]T?#YH?'G;/
MR(Z9P_P_Z_W?LS:_86U,;LOL;9>V=R9;<=/+0;.V+5-L[&YV2FV_52??8K&U
MM9'$8LMC<YA:]XS25="XF6>G]U[H"L[_ "S=VKENQM];?WMU+D.R.R:G=T^_
M<GG^L6H,3VMB\QB?BIC,/M#>5/1UV6&+V]B5^/61.,00Y:FVZV9B>DI)S#.M
M3[KW4#:_\JFLH>C>P=B;C[1QU3W!N3XH=;?&C9G>^#PN1H]_=?46RJOM&ISZ
M;:W/7Y"MW%@-L[WQV_:;$Y&#'3TL]5C*,QRLRK3QP>Z]T<WJ#XQ9C8?Q#SOQ
MPK-W3[9SF[-M]PXV7<.R\UN7,T?6]?V[E=WY9*?KG([DJ:+/KA^O9-UB/$*Q
MH51:1/##1Q>."'W7NBV=#_RZ:S8>;^..\>P5Z)ESO1/</9_:.,VOUQUM6XS8
MFSX-[="[>Z3IL5U+3[FR.5R.SZG,YG:5-O//3Q^(5FXZ^LD52Y%0_NO="A\[
M/@;MSYMR=;R[FGVNLO4F [2R?7<FX\)5Y=]J=S[G&Q%ZZ[2Q34==1,M5L%=M
MY &G?7%5?Q :E/C]^Z]UCW7\3\3V/UY\PMA]?[]V)CJ;O;Y(;0[.J1MO&4M3
MC=D;KV7!T4^_,+N:@P==''/O7<>=ZNJZW(2MX:HU.562I5Y [/[KW04?+SX>
MOO2O[KW'7]T;?V5_LP?</P_GV=M/.Y',[7VYOC<O3'\0Q]%TSOW,XC[_ "&4
MVUVS752HT-)22R*T*:H9P"A]U[I$YO\ EDU^VMKYS,T'9^V5SM-L/(8+<VZ-
MU8+<N<J]_;/V]T-\;]AX+KWM;.29FNWEO/JO^\_0-759/&SUD\M1B\U(JEJO
MS2S^Z]U(^,'\O7=/7_8WQU[BIM[=/#:&T=K2;H,/7&Q]S[<R>#?.KW)6T?47
M2TV8RLR;/^-.YX.ZXLOF,-60R557F\!25'C1GA..]U[HP/R6^/9WC\D>O.XZ
MW?O3V$PF%ZEW/@\M%V1AJ[*]G=58;:&1K]RY[N?XNY*/<%#0;*['5-T4M#F<
MW-1SQT-+3XZ25:I$^RG]U[JO'!?R@=R;^VEUCO+']V]1P#&8C:^9V#+UQLK<
M=-U[C*;'9CK#/8GM+8U/4[CFJZ#?/=.*V#!G]XURN5R>X:Q9PTIC>IJ?=>Z8
M^P_Y7M)\?.L=^9C<7>?36W=J[R[URVXWHMY;$W=7[73(]P8?</6.W<U@]L8'
M+5.:W#W]U=5[N@K^O9J6-Y*;+^98Q 95J:?W7NK1OC9\,I?C[V_N3L^BW?C<
MO!O/:78>)WB8,.U#N/?^ZMU_(C?_ '!M[L#?F9BF6+<VY\+L_>:85ZF>,N&C
MD^W\-,R0)[KW1;.VOY8F=[7WQ\YJ_);NZX78GRQZSK<#0;<SVULUOA1V#_$.
MNLWM?<.[*#=^1RO\*V_M3)==+'4XS#5R8S+_ 'XJX*+$5E(SUWNO=8^Y_P"7
M_P!A;^W%V%V7N#LGIGJNAW#T#0XK/YC!8?=%'-LO-;?ZNQ>R<]TS3;GJLW@Z
M&+X0Y0X>;-9;!2T]'5SU%1.Q,+.9U]U[ISZY^$N:VW\EOCWWOC.T>C<#O3K[
MJC;FWZ_XX=:8;(X;H&FZQR>X.ZJW>^\^INM)<]75^$WCA*[M3%X[;&\0(XH<
M=_&<<]+!2YOP4GNO=&[^0OQIVWVUV]\>>\L_DL!@E^-U+WA7#/5.#H*C=N'I
M^S.M)]HMFMF;IK8*D[1R6VZF*+(_<!'!>F0Z;J#[]U[HCGQE_EKX&+&]#;PW
M]G>CNV>OMJ;TSW;>W\#M/9.2;KG=M+GNBMC]8]>]L8_$[@RF6H_]*N\Y=N#>
MVX\S)]Q]QN+(?<TK?=1-7U'NO=&<^>/QZ;Y@[6PG2NT.S,;MO?G7^<Q?:68V
M;7;@W#A<?F=I[QVKVAU9BLIN*3:1&X:;^#9+(UV9P,T=XSG=OQ"\,BI64ONO
M=%N[$_E=;QS^ [JPVWNXJ2?%[D[%Z9W1U-M'*Q[CP.-QO7>QJK^__9_2?86Z
M\;6YW<&7V3V]WWG<UNVLEA@FF262B@G2J^T$C>Z]TV]T?"_#?';XS?+WN$93
M$YGM_&=%=0/UIW?4C%4.]NI:SXQ]/=8X;;F^=Q]D]I;NBDH=@;<[(ZLI][[G
M,^9C$^)I:AJC[RK6\ONO=68?';KS:^R?COU5L+%U6W=V8"+K["/7YK$.V5VQ
MOBOW'0+G=S[LH7KI*L5^*WMG<M5Y)2Y9'2LX 4@#W7NB-;,_E[]C;.J_C'AJ
M?M/9U3L7J[;G16+[8ICM;,P;DSM?\7^R^P>V.I)>NJI,PV-P^/S^X>R*JCW!
M'712O]A1P?;-K9PONO=&8^07QEJ^U^^_B1WW@8.MY=P_'#=O88K1OK;!R>87
M9/:VSTVSN3(==[EIXJJIVQOO U>-HJJA\L$M%5J)8IC$2DB^Z]T4O^5!@^KL
M50=_'K#O/K'N2DQN?V'L++OU!M'>>U=KS5G6^+W'MD=I[RJ-US5%#N[O3N&>
M.>JWEF<7-4T=;78Z+_*)V7R'W7NGWO7X2U7>$GR?KNM=R_'?<U;VIW1UWN*;
M#=B;1S&[,1UUN38G2%9T_NBMBK]C[KPF9VEW5@Y-PKN#%96$BKI:B&.GE2,U
M K:?W7NK',%'C.INL]M8_>F^VK:#8NT]MX#-]B[^S--1U69GQ./Q^$?<FZ,W
MDZI*?^+9^MC$M1++*3+53GDLPO[KW3_B=V;:SN8W3M_#YO'9+-[(R..Q.[L7
M25"2UFWLGEL'C=RXVARL*^JEJ:W 9BEK(U;EH)T;Z,/?NO=*'W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= O
M\A?^9/;T_P"H.B_]VM#[]U[H4L!_Q8L+_P!JG'?^X</OW7NG;W[KW7O?NO=?
M_];?X]^Z]U[W[KW0._(#_F3N^_\ M5T__NSH??NO="-MC_CVMO?]J/$_^X%/
M[]U[I\]^Z]U[W[KW7O?NO=5?_+7X6=M=\_(?#]I[*W7L_!;97X[=I=)9V+=>
MX]YU\II^P=B=N[:F@VWL>CP\^#VQFZS-[XQ%1+NJAR<%3]ACYJ2NQ.6\>+EH
M/=>Z!-/Y;';VS<I\>=O=6;DZSP?4W1G>6U^U-N8>KW1V:-S[%Q>-W#\9\AN[
M#;)R591;@BGQ.]<#UKO6BJ,.QH(7GW-Y)JV2CJ:_'M[KW4'<O\KOLV#K+XV[
M1V#V53XK/[&[2W5VIWMDAVAVAAZOL#LG/Y';0VSW-1[OFQ>Z]PY;>76>WMOS
M4./QU1#CHJB#(/%'7T*1?N^Z]T=3XC?&SL?H7LCY7[FW?G]N97:_=_;]7V+L
MJAH<YN?=>Z:$5V8W=69.KW/N3<F.Q,T5)5XW+8RGQV%ME7P,=%+31Y:KH/L*
M6@]U[H N^/BCVUVWV!\LL-B\?AJG ]E[O^*'9^*QV\,]NC;77/=.QNM]N9':
M6^OCYOG=^R\?E=S;0QG\7PARTKP4.2#_ ,3@O33Q252)[KW0H_%3XG4W3';F
MYMZ]H=AX_M/O5^H^D]G87<%3O;>&3W30;%VAU-L7KW>M=+M+/Y:>EQ&#WWVA
ML>MR?F2.I>MG"S5=3+7"9_?NO= _\S/@_P#(_P"1/?#]@]?]@]>;)VO'UED>
MN\;F%W%V-MCL&CP>ZNO.X-I;[VMD&P%#EZ+)X//[AWK@LI!)25>*2E.)9Y*6
MIK8Z*L@]U[I-;'^(_;>Q?ESU#LG$5NX*7XZ;5R'=/=&]8,?4[P_N"F$PG;>2
MW'\->K-M;CKJJ#[3=NQ,OV/NNISN"B2;&U&&IZ#7+IAIHYO=>Z-/\O/BAO'Y
M%;OZTW7MC=]%M>KZLVYGI=H551G-U8FJP/9&2[@^/>\L=O:@@V^K4=55XS8?
M66X<5')4K(\1S7B11!4U3#W7NB$=D_RSOEAVY#L+'[H[<Z]PF*ZRW[M&;"T^
MV>Q.Z*1MS[,Z[Z6[%ZWV]N#</VN+QKT>[,[NG=E#EZK$"2LQ]&*0C[VMD5&;
MW7NF_(?RM/D54[ [JVQ2[\Z\Q,O8_8.$WGN3"X#LKM#%XGY#5D7=?;?:F:W-
MVQF:O8^7_P!&VYYL1V%C<9X,/B<]0U;817F B-%%C_=>ZL5^*WQ6H^F=\=K]
MD[TW+'V+W-NJ79VV9M[U.]-Y[HSF.Z\P7473VW8-HY>EW+DI:3'2U>\MCU^:
MUQ4Z2UK9$UDTCU555%O=>Z#?Y/?#K>?='8O?&X.M]][;V5/W%\5-J]([EHH]
MP;IP>9JL_B.V9=SXK=><3;$+24],NQ)LOAZ3(Q,,B/,T*D0I=/=>Z%*D^,&Y
M,9\.>]_B_C,Y@XI-^87Y4[3ZQEGKMQS[?V9LWN3/]DU75^V:VKTKN&#%[$VY
MN^AH)(Z5G-)#2&*D<QQP^_=>Z)!LC^7!WSMK<GQ.S2[OV5MC:?1_8&X=S/T[
MLOM;MA=E=.8K*=F]8;O,75.>SNTZ_</9"YK9NR,S@*[&Y9-M4:4FZJR))7HV
MJ:6M]U[H-5_EG=A[.VI\<]L=7=Q]1]+]:=1=[=F29*DVKO3=^/P7=^VM\_)*
M@WWL''5V+H\9C*'"[ZJ=M[WWKM7(8A:S+F:NJ,:T%>Z1FF@]U[KVY/Y5?R7R
MFR^S-LCN;'YR7=W>F7[&KSD^Y>S,+%VA!6XONO'[6[$W+5T77>9K.L.Q^MJ_
ML7;V0H:/&#.1U\^T:3RY2"2#%SXOW7NA:[7^!W;&"PWR-W!M3))OO<'R!V[O
MO9=?B8-Q[NK:W*[MWS\BMD9WISL?<%/GM>W<:G1_7D5;+55$1C^ST2I2B17N
M?=>ZLE^4W5>Y^Z^B-]=9[0K<12YK<9VP_P!CN'+;CP.VMUX?![QV_N+<O7FZ
M,YM G<^&VOV9MO$U>WLE5T*3ST]#DY9!!4!3!)[KW12?C3\',YTCW'U=WQV)
MN#9>X-R=>?#W.?'7)YV'(;IK<IAZ2J[KK^UL%MO%9K=!DJ,GUYUOM6O.!H*[
M(31Y&:GI$DDAA61D3W7NG#Y)?$'LSOGY$[&[8VGO_;N$V72; QFV:?=$FX]\
M+O+K2 0=HKO->MMI;?EI=A;QQG>V)WUB*'-SY6KI9J&GV]#)']\&IXJ/W7N@
MDZ]^"7>I[*^+G>'=2=&[V[%^/O<>X<K1XZ#<^_\ ,46V^L=S?%'J3XZ5V;V9
MNO/[,AK*C?\ %N;JMMSOBY\72X^HERTL:Y"GJ(_NY?=>Z#_8G\L[MS ;2Z\Q
MV\FZ4[%J.H/GALKY9]>[?W?NCL3<N2AQ=/L_-;+[ FS_ ')FMK3[AW'O*OJM
MPMF\1]]@:BH7^'T^.RN5RCG^+1^Z]TX5O\M?NG?';/>&Y.S-V=8U777:V\*S
M=U9M7:NX^SL+1[ISV+;Y0T^R-V[EV[%31KBLWC,-VYM"FJ8QE\MY9-LNXG%/
M!C*.E]U[J+3?RR^XLUN#Y 93L/='6NZ<UVE\5=T=08WM6KWIVU7]A[B[,R%3
MU)N?K3-[OH*ZD.'VSM_HG=O7$JX>NQ$\U?D(Y(JMZ:DG,T+>Z]TOODY\,.SZ
M[<??O?FV-Q93)9S>>WMTXC+8+:F4[ RVZ]V=6'H;IG9M-U32;6QN1Q5++0Y;
MLCK_ #>0JH<7-#6K39IZFD^XR!-*_NO="!T7\?NR-W_RO,G\>=Q;1QO4F]NS
M>M>_-M8[8&[,AN/<.$Z_V[VOO;L>OV1LO.3;ACR>Z*C!8#8>Z*"@EI*R#[J"
MEC--+31,AIT]U[IH^.?\N5/C5O;J"7KFIVGMGK'ICO\ ^5F^-H;4Q.9WI4UV
M.Z<^1.R*.EI]@R5&56H?/Y&F[(QE)EZTY.HJE44L3Q5#R(%]^Z]T*Z_$K? H
M.NJ5MR;5:39WS_[(^6N0<OERM5L?>6Y.X\QC=MT=\;J.ZJ.D[&HTE5]-&'IY
M=,S (6]U[HBFV_Y57?HV/O/:&^NY\?NRJS._NT]_-F<EV;VC6P[TWYG>FNY]
ME]=]P9G$Q8+%G9>]<-OGL'"5]514]5F1$N @JA7U532T$5-[KW3GNK^63WSG
M][=T;RR>:Z>WW6[\QVW,=E:K=6_^Y<%D?D/0T';FZNQ8<)W'4;<Q$G^B[";#
MQ>XZ&CQ,&V/XE35TNW:4RT])!*L-'[KW5B':WQ][&WI\.,+\?XM[4F\=_8G9
MW3F!W5G]WYG=6W<+W)_H\RNRZ[L';V]MP8&3,[UPF![JQ6W*_&9.KIVK:N"#
M+2/(E8@E@G]U[JO_ +8_EK?(GL3#[BQN [ ZYZ^JMP_&7!=.XJOV_P!@=Y,O
M75!CMMUNW<I\?MKQ9"7(5.6Z2SF6J:;<DVY:Z;^\RY7&QPQ444;03T7NO=)'
M ?RH?D=@^Q]A;PQ?R(HMN4VP=S98;;R&,W[W%E<OMG9&6VSO/'+C*+%9*HIL
M9N"?%;DWK59*GIJ^H"))(QBJ8'\;1^Z]TNMG_P M+N_&T?7]=5;UV%LRKZTK
M:+.=;[&V=V!W!N#9W5&YU[?^->Z]V9W:6=W11PYS-5?9.T^I-TS9'[VEBBI:
M_=]30PQO35%?657NO=&Z^=GQ@[;^1TWQ_P CU#NC;&UL_P!/]I0[_P#OMZ;D
MWM#M>">G_API,AD^N]M4L^&[,DH(J>H%-3U55@\ECJJ6.KQN8H9$GCJO=>Z*
MWO7^6WV))LCY+;'V%1=.4^.[C^:6_OE9''5[Q[(V93=C1]J[$S^)GI^T)=F;
M9DSN#W+TOV5F*+=. ^QKLIC\S682F$T>+FD%13>Z]U@WA_+7[XWSA^T]IU_=
MM#M7/;X[+Z6WG+\JMG;NW]%\B-V4G6F[*3<%/4Y?;.?H,WU?L/,;-PL$V%Q@
MQ$=1+7X^MG6.LPVMM7NO=6'U?3&;WU\/ZGX_]C8+KB@W'N#H*;JG<6%V=)N*
M;JS'YR79#;75MJ/G(Y-VT6TZ'((D] *AILE10)&#--/'YG]U[HJ'6/P8[8VA
MWCUAW=N7L?$9W<>R,7\>-K97)#<^^ZS(5^S>M_C5VAU;VI@*>DKX$Q513]@=
MJ[OQ>?85"7K!C8ZFI9:NFI0ONO="W\D_B9D.VOD+TGW[M/$=>G=/7_3_ ,E>
ME<AN?=5;FZ#=.U,1W?M7!4V!W1LC^&87,T&9K,#G=ORTM7CZTT,<N/S-1/'4
M^6G2GJ/=>Z()A_Y3?<&S*CHG";'[2PV!ZVZFR/4U;0;+P?8O9FVTV/NO:VSO
MCSC.P.X]G9#^ YZOS>[=TY+JK<6/.&FEQ-)5XW<TU1+7P2U63I:OW7NK./EK
M\9Z/Y,47Q^I*NEVO4CI;Y1]-_(&VYTKG3[;K7(9*;(P8?["GG8YNMH,G)#"D
MVBED#LLK!??NO=$2K/Y:O:&\=\]FMV/O+:>9ZV[([QV?OGL*AH]]]J09GOC9
MN'[C[&[&F?LO$4M-B\)MK,;>Z[W3B=ATF$Q<U3A\GAL4'J)Z:E6DQ=-[KW0K
M_'?X-]M].?-?OCY,9OLS&YC9/:NYMVG!;/IMU;^R-3AM@U>T^L<'LK;$V S4
M0VGC&V[D-C5$S?9?43JWD=GD ]U[I$?*7^7_ -V?)#Y)=A[TGW=U=C>E-_?'
MOMCHG(8JIJM]/NG,;>[-Z,W-L2/;V]-KQ4\NW-SX+ =K9"BW+3F+)T$$*4ZF
M.B&1C^_E]U[I^P_P6[!PN^NGNV\!M/H#:G8FS_Y=VZ?A3.:;.[_RV+ZKS5**
M3+]?9O8&2I-N;6SF]=B29N*>ER5)*VULO2T4WEIZV675&WNO= SU%_+C^2.P
MX.K$W!N#IO-P['W3W-E=N81^P.WVP?1$G96X]F[AH=Z]5T6(VYM:CW9N./%X
MK,X*7"UT&'PU+1Y3R))4P2Y+'9#W7NF"E_E0]P;1V?TSL38/9.!Q&QNLM[]0
M[O?8F)[*[.VEBZ;<^VND>JM@;W[.Q&X*?;NXLLVZH][["R.3H<>L-''D%S,M
M0U=C:MZDU'NO='.^&?Q"[$^/7<OR*[)WYE-DYN7MJEVWCANS;^?WCF-X]F9#
M =H]\;Y_TA=EXK<F+H\)LS<!VUVKB\+%B\'4UM#''B&83"#[2FIO=>Z*MVC_
M "Y_DOV%NSYH9D[XZVH<'\AH-N0[6P6W]_\ 9&TZ?,UVTN^ZGL+:FXNRZ*;9
M>[L4]=@NKZE,!744\6XL9GQ#)2O#0XR6GIZ+W7NCW]\?'+L7NOXB;?\ C-6;
MOVMC\IN3$]/;*[IW=08NIAQ>0V3M[);7J>WH]E;:W)3[XIJA]Z8G"5>.H\=G
M&KZ3[3(,E9+.%;R>Z]T0V;^6+WY4;&W!05/<>V)>SWZYVWT+@^Q\?N+L':TE
M;TEMGH?L_IZ3&5^"VU0T>%VKE-VY+<.W\ODJ?%4Y@6MQ9JH9140TI7W7NEB/
MY=/<>'[TZ@WWA.PL+/U;U/V%W!G=J];1;_WUMO&[*V-O'LW=._,;LK$XN/:V
MX*'<^'WYMG/Q;7SV.J9L?18W&P:86R=((\?'[KW1M?Y?_P ;.S/BIT77]6=L
M;YQW9NZG["W/NU-_4N7WEE\AF,)N6FP]5A<!F)-ZU^2K:<=7T40V?B!32+3U
M.VMOXRJDCAK*BKAC]U[I\^#?Q<KOB5T/M[K'-;ZW?OK<B>>OW'69[L/>V^MM
M8[*5-96U#XWKFBWI4,VRMG4\-0J08JAIZ.CAT^F(&Y/NO=$BWU_+:W]+M/Y1
M;/Z]H.FZ?&=W?,7<?RFCCK-W=E;(@[%7L+K3*[9K<1VE)LK 3YK!YGIOLFMH
M]V[?EQ];DJ'-5N)ITGI\7*WW,7NO='!^4_Q,R?R0^"N[_B=N3<>(WUN?.]9[
M)VY/NWL.ER Q&\]Z[ J]L;@H\]NV/'S9+*X^#=.Y=K)+630M63T@J7D5*AD\
M<GNO=%-[E_EN]C]A[J[K[4Z^W5M+ICLSNW;#[0S=1M7>._I*6BZ_@^-O5O6^
M/Z@%728;#8RJVK%V1L:N=<@N'@GI\97K6I2M4JU ?=>ZL'^)?4>X^B?CWUSU
M1NNNBKLWM*DST,RTV[,[OFAQ-%E=UYW.X?;.+W7N3#;=S&8P^TL-E*?%T;OC
ML?%'2TD<<-+3P)'"GNO=&+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T"_R%_YD]O3_J#HO_=K0^_=>Z%+ ?\ %BPO
M_:IQW_N'#[]U[IV]^Z]U[W[KW7__U]_CW[KW7O?NO= [\@/^9.[[_P"U73_^
M[.A]^Z]T(VV/^/:V]_VH\3_[@4_OW7NGSW[KW7O?NO=>]^Z]U6/\I>AOESV7
M\H>JM[]+[KQNP=C;2P$>/J-Z)OG/15.+BRVU>Z\%O;'9#K65:C;N<JZ[/;IV
M9DJ":.GO.F#G%541/2X^.;W7N@AV1\6OE/BZSXO5<^SI=N;>V'D]Q19S8<WS
M0[IWI_HPWS5[IVEE*GY'93<^1HJ;(=W)N? XK.4D?75:5V[1?Q2-2RKDLH]%
M[KW0#9'X!?S =PTNR(H>WLMLU=M=U8;=.?H8OE%W%7Q[N;%X;#T/9/:>1S./
MHJ7)SXWO?=^.&>39,R-B=L(CT],@%7/%[]U[INH_C)\_>SNE.Y9L*NXML93L
MKL/LZGQV&[#[T[.Q6\*_<N-WW\E1UY\BHUR,%$W6N*Q51N#8\,6SH%K<9_ ,
M'%D:*.6KH\=#-[KW0H]Y]$_,_J+:?:O<VPMX;JWCW=NK+5.1V'@<;OSM;>^&
MSG<LO;/3U#\>\+E-ETL+;;VQU'B=K5.[J7<ICIL=AZ+'9!JBN+0Q>6G]U[H>
MNP_A'V^]9O;%]==E[H7#;T^.OQ-Z?W'NNL[:[ V_O;=FXNE^ZSD^Q]TUE;CZ
MRNFVYE]Y]+U-30U-=C9X:K)SU3P5+:0DR^Z]T7W;O4OR5Z]^;OQ>V555':V[
M-L[7J<A7'=-!V)W+/U_UMT5B(/E)#_<'<PRE&-A=Q3;H.>V)]Q5YS(2Y["5]
M'04T"5,--!4-[KW1D^]NO?D-O?\ F$=1U_7^/WAC^M-I=,;2W%DNR:CL+>V"
MZXV7EL=W)EI]^[9I^M:&CFV)VEOGMKKE1@Y!7RPSX7'NM8K K#J]U[H*,Y\'
M_D_MS9'Q)V_UMV3NBLW+M>BP.9[IW=NCO_M'/9#:7R+JZOJ>OW;\D;;IK\N.
M]L*N"VAN7!IL;)_88"=]Q"H%-'YJN2+W7N@<RGQV^<VP=N8[8U3OS?55O?N_
MYD246T,WM;L;LK?V.ZA^'?<6W\]C>S.L=RY2>@H:#'Y/XK=64-0^T]UY.LIW
MSNYI:1H@E?)$LGNO=6._/OI;M_NCX[G8O0V6R^)WKC=W;4SM)!C=_P VQDRV
M.P0K53$YVL>@J_[S[=_B$U+45V+>NPTU5!3&6GR,%9#3B3W7NBBR_#OY"[9S
M'S!S6)V+L[-[J^4<'PWW-OC>&W>[>Q,7!NV?K+;>Q]@]]]?XC$Y[(T&0VO72
M8S:E?7X6NEJ?LMPTF7^RRSPE)=?NO=(S;OP7^7&W]O;]R]#GL3AOD]V]_+TZ
MKZ#W5\H*#M3<.YZ[!]S=-[EW8U7C6V=N7'46+RF.[/V?N:BIZ;=L--%D\14X
MN:66F>6I,DONO=,F'^"_\P&/L+:F^,-W]N/8U#B-DXO;>U,-ENZ=S[GAZQQ6
M0Q7>%+/MO,;+Q6'H>M]_UNR/[]8**FR$U/43SC'(34SFBII&]U[I>]*_"OY=
M8%^EMP[X[(W4M7U?4[?R6,VO7=W[@JZ?!U53\G^MMT]E4];3;2QV'VQO6GW-
MT+@]R4%)_%8\A)3KGI*$RJDK/3^Z]T)_QA^&.\.G.L^C^@\CL/$87K[ICY<]
MQ]PU69I.S,SNX;LVZU;V#O7J#=5#1;C:LS.'FK=V;ZH4KL++*XQ]3A))DEE2
M9)7]U[HNWQV^)WRI[7V-CCW!E>TMA=?[F^1*;B[)V=FOD1W?BNQNR=H;1WC\
MI8LUO3*U$+[=W-L#&[^Q^Z]@TE+M"AKTQZX[;4%4)ETQ))[KW2J[F^'OS/WC
M6_*&3;^Y,O31;TW329K;V2POR!W#'+V_00=L4V[>MZ"HV9N/#_W7ZJPO2O54
M1VEEL-CJG'#?&HUDF2IJB**=O=>Z1O\ LN7SY[(W5\IZK';ESG7>5^PBV(=V
MU':/8]1@NZ?L^M?BQ+4['ZMV;V!1UM'UUL'%YK:^]J:@WA%45%=DZO/5!JB)
M*BODB]U[H0\5\)OD]N*F.PNULK6;XVIOCX>[MZ-K-Y9_Y"[VQDG4D6[MA=G[
M9W!UME>N=BX7#;7[IJMP;@W;@*P[GJDIJJ@I<,T4,K/0T#UONO=*'87QP^8V
MU,3\1-D;7P>*ZXZZV9U9\<]C]KX"#Y&;NR;=<5/QTK^V8]QTFV?%MO(/V'3]
MVXS>^&CBKI9J66C@PL8KX)?!3P^_=>Z,7\%^L/DOT1T=MCKSN"GQV[LR>U-R
MK593+=FY3<>Z-M=75&VY*FBSV=R]1C*[#[RWKDM^X]_+38N+ X^>ARHR#0TE
M8M50O[KW1_\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_P A?^9/
M;T_Z@Z+_ -VM#[]U[H4L!_Q8L+_VJ<=_[AP^_=>Z=O?NO=>]^Z]U_]#?X]^Z
M]U[W[KW0._(#_F3N^_\ M5T__NSH??NO="-MC_CVMO?]J/$_^X%/[]U[I\]^
MZ]UB6>!YI:=)HGG@6)YH%D1IH4FU^%I8P2\:R^)M)( ;2;?0^_=>ZR^_=>ZZ
M+*&"EE#,&*J2-3!;:B!]2%U"_P#2_OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UQ+*"JEE#-?2I(!;2+G2/J;#Z^_=>ZXK-$[RQI+&\D
M!59HU=6>%G02()4!+1EXV#"]K@W]^Z]UZ2:*%7:66.)8XWF=I'5%2*,7DE<L
M0%CC!]3'@?GW[KW7,$, RD$$ @@W!!Y!!'!!'OW7NN_?NO=>]^Z]UQ#*2RAE
M++;4H()74+C4/J+CZ>_=>ZXQS12F012QR&&0PRB-U<Q2A5<Q2!2=$@1P=)L;
M$'\^_=>ZR>_=>Z][]U[KB&4LRAE++;4H(++J%UU#ZBX^GOW7NN7OW7NL<4T4
MZ"2&6.:,LZB2)UD0M&[1R*&0E2R2(5(_!!!Y]^Z]UD]^Z]UT65;:F U'2MR!
MJ:Q.D7^IL#Q_A[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UC6:%Y)8D
MEC>6 H)HU=6DA,BZXQ*@):,NG(N!<<CW[KW63W[KW7%F5%+.RJHY+,0JC_7)
ML![]U[KE[]U[KWOW7NL<DT,.@S2QQ"21(8_(ZIY)I#:.)-1&J20\!1R?Q[]U
M[IK&XMOF..49W#F*;+M@(91DZ(QRYY)I*=\)&_GTOETJ(7C-,"9@ZE=-P1[]
MU[IX]^Z]U[W[KW7O?NO=>]^Z]UUJ74%N-1!8+<:BH(!('UL"1_M_?NO==^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KCJ75HU+KTZM%QJTWMJT_73?B_OW7NHN/R&/
MRU'!D<774>2Q]4GDI:['U,-91U,89D+P5-.\D$R!E(NK$7!]^Z]U++*"H) +
M$A02 6(!8A1^2%!/^M[]U[KOW[KW6)IX$#%YHD""0N6D10@B4/*6)("B-#=K
M_0<GW[KW3<^>P49KUDS6)C;%8Z/+Y-7R-&AQV)F2HEARE>&F!H\=+'2RLL\F
MF-EC<AK*;>Z]TY0S0U,,513RQ3T\\4<T$\,BRPS0RJ'BEBE0LDD4B,"K D$&
MX]^Z]UR9E0:F956X%V( N2 !<V%R3;_7]^Z]UR]^Z]U[W[KW7"22.*-Y972.
M*-&DDDD8)''&@+.[NQ"HB*+DG@#W[KW7($, RD$$ @@W!!Y!!'!!'OW7NN_?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW1>^W/EQ\4N@,Y1;8[X^3GQZZ3W+DL.=Q8[;W;G='6_6^<K]OBIGHCG:
M+$[RW+AJ^JPXK*:2'[I(V@\L;+JU*0/=>Z'/#YC$;AQ&+S^ RF.SF!SF.H<Q
MA,WAZZFR>(S&(R=-%6XW*8O)44L]'D,=D*.=)H)X7>*6)U96*D'W[KW3C[]U
M[KWOW7N@+[>^47QG^/E;A,;WW\B>BND,AN6DKJ_;E!V]VYL#K6MS]#C)(8LE
M682EWGN#"SY6DQ\M1&L\D"R)$TBAB"PO[KW0H[0WCM'L':^"WOL'=.W-[[+W
M3C*7-;8W?M#.8S<NU]QX>NC$M%EL%G\+55N)R^,JXB&BGIY9(I%-U8CW[KW2
MC]^Z]U[W[KW01]N_(#H;X_XW#9GOGNWJ/I+$;BR,N(V_E>W>R=F];8W.Y:"E
M>MGQ>&KMY9G"TN4R,-'&TSP0,\JQ*6*Z03[]U[I0];=I=9=R[0QW8/4'8NQ.
MUMA9B2LBQ&]^MMW;?WSM#*2XZKFH,A%CMR[8R&4PU=)05U/)!,L4S&*9&1K,
MI ]U[I=^_=>Z!?Y"_P#,GMZ?]0=%_P"[6A]^Z]T*6 _XL6%_[5.._P#<.'W[
MKW3M[]U[KWOW7NO_T=_CW[KW7O?NO= [\@/^9.[[_P"U73_^[.A]^Z]T(VV/
M^/:V]_VH\3_[@4_OW7NGSW[KW5.FTNG>S^O?YH?R2^4&V_BQO+ ;&J_C5N/;
MV^-Y8G=O6.=7Y3;KH*OK;='5.2ZX>;=N-[ K.R:2@V]F-I5.W=ZPX?:FSZ7&
MT=1@<AIW#EVD]U[JX2FF:HIJ>=Z>:D>>"*9Z6I\7W%,TD:NU//X)9H?-"6TM
MH=UU V8CGW[KW5*?SAV+\MH?EA%\N.M-N_PSK/XM_&_M'KK&9D[DQJ;CKZ;N
MOKGL#=':O9>SMLUN2FVSDXNL]X]?=:S24F:HI*RM.*JXZ&.179)O=>Z#/K#L
M#YO9OL[XH[*Q^9^2,M'G=DKW'28GL3(=,_QN'K^H[BZ&Q>[\S\L\ABW2DR-'
M5['S.]H]JXO:TU7D:9*B@^[BBJ88Y*;W7NA5RVR/YBFU.G>C*ZFWI\@-_P#;
M>ZMW;[WOV/1QYKHJE3:7:TU;M.AZ7V9O:GH\;B=O8_XC4N Q^9DW718)ZW,-
M63TTL,C,[JONO=1NU\-_-!_T9]HTFV:[>--D=M=_KUOL*OP%;L#,[_WYT7MC
M9G:.YMD][T%'29W;N.H,GO3NS?NTL)N'$UE;1RQ;4V;4220E*RI:;W7NK5^L
M=Y[HS-1E=E;TVON+'[JV'MKKK^\N\:G%4./V3O;<FYMLC(Y]]BSTF3KWJ8,#
ME::2&MC=8UIY)8U1I5.OW[KW5<G<FWOY@^;^0/=F/Z_S?9F Z^SF(P.'VKG=
MO9+JN/KW"]>5N>Z4IL7DNK:3/)4;IHOD-C*X]@3;HJ,W$^)_N\U(:'RU0Q\4
M?NO=&CP,/R8VG\+M[4-92;LWW\B]M[=[OQ&QDK]P[&H=\;J3$;RWUC.F<E5[
MF7$U6R3NC*;"I\+5/4U-$5FJF)JHEF>51[KW2>^,<?RIH/B;V)1=G4^ZI.Y<
M7F>^Z7IN3?%9MZNWKE-E1YG<<W0=9NFMCRF1HYL[5X"7'B;^*SBNC8:,A^^L
MS'W7NB31[,_FA;7HNIL,NZ^W=W24.YMC9.GSN0SG4%1/5=D9S87QUS>^8/D/
M-C:3&&J^+V%S=9V=01TFWJ?^-P91*5(!)3)B9D]U[H/NRNC/YABS],[Q@R/R
M'WSV%L[+UN[MK;JQ^X_CZ<WLGM+M/X^;MV[E=L[MHLH,?M[_ &7/&=JT6$BS
MU'24U=64M*\DU%(\32V]U[HTF]^D_F*^\.[<3LG>?9&U]O=G_*'K3>%1OW:&
M<ZVAW53]5#XO5L6^<!M#.;CQE;F\/LK%=Z8?'4-!3UD-3E:.GF=*=S1,Q3W7
MNB]5G1OSG[9W%W]F.S:;NW&]AU_PE[?V)M'.8K</2V,ZHAWQN;&_'7=756RN
MLL:LM7EUWANG<.R=Q4O8IRM*^V9YAX()1134MO=>Z%_OJ/YQ["R7=O;>)WUN
M7:?7.'Z]K-NXG!3Y3J_'];[*VA1_&W9^:S6^MOXV/'OGZ7L:D[PCRU#B*RIF
MGI*:J\(J8!A1+*ONO=&9^!/<>Y]_]$=/?WFI^Z=V-O6E^0.Y=O=D=K4.S9-R
MIU[LKO?+;7ZJQW9^7V1+3;;J=];GZXS&-J:.HQL$]%E*7'5-3]Q(Q$D_NO=)
M;YB2_,R;O/X\TOQNP>[3LW'Y;;V7W=GZ+<>UZ?KNIDG[/V9AMZ8/M#;=:M%N
M*KP6/ZCKLQD8I8:F=IGB:/'TXRJ4LH]U[HE/2'4W\Q7;>^MS[O6C[?H,KWOW
MOTKL/O\ W-V1N#H:3);7V9M+J' 5_8W>?5%+MAIZ6JV-@.Q]CU^S]NXR:!:^
MNPF[EKI*0_8QS1^Z]T,G;76OS:V)U-WG#TM5=GUF\<M\]MR]F[*BQ&0Z[DSN
M]>E<]L?$97#;6SFZVGH\KMO8B=FE,1%DI*;+YC%XN@IH\A19##QU2M[KW63<
M>S_YA6[^R^VMMX_=_=.Q=K;L[;V'C-R;JQ&8Z=.WML]4UW=.*^TJ?BG5Y#$5
M>6Q9Q?QO:NIMZUVX,?\ Q-MR&.IQ<!G *^Z]T.?3&X.[LK\Z.]NJ*OL?-[OZ
M#Z!V)UYG8<M5UV!J,QD>T^YMI82D?JC>XHMN8P/)UMMWKN3>,1I3%)*>QJ;S
MMXX8(C[KW1=.Y>OOFALWYA?*;M3H7:7:^0P^_>K-B38B''[GZDQ?4N]<7LSI
MGL3;>0H<3)FX\SOK _(O$=FY;!2X*2HHEP53C8)5J"T>L^_=>ZS]0X[^8?C^
MQ?B>-ZP=M9K8%-E^^-I=FX?<NX=F8FGBZPK.R>PAU;V9OS=V)RV?W1E^R,?U
M4^V5BPM=3"><DR+DJ3+0Y2*I]U[KG@.O/G3U9L+X([6VM_I(SD^QNW^U:#O#
M!RY7K;'TF]=D5_=S#:.Z.UM[8(:Z?)?Z'ZO)9EOM</7T6;R$KQ5WV&7EQ]7'
M[KW5M6R=WS;RI<_53;4W5M(X+>>[-H1T^[*"GQ\^<AVOF:G$1;KPBTU96+5[
M5W*E/]UCJAC')-3.K-&C74>Z]U2[N#XF?)G/9/O#:=%NOY+X?*+_ #$M[_*'
M8_9$6_\ 8U=18?K7<_QL[:BZ_P +TOE-SIEH\!M_$]EU6.P.8PE3C5DHXZP+
M&KTCO5#W7NC-?$"+YYR?(CM')?)R;(0==UVP,)+B\5!1;>&QJ?<<N.Z\EVNN
MTJNDW'5Y*GW+14YW3%NJ"EQT.-?(F!DGFC6D)]U[IG[LH_FS)VM\GFZZ;NR]
M3UF8NBZG;N4Z=INA:7928;KI\O38O&YV.;L)_EO4[G7>2X6JK#%MV)'Q35KM
M1CQI[KW1)]\S_P U[8<F_>U?[W=OXCI+K[HB2NV;B]TU70^0W<-LTNU.]*N;
M/]NT-/1UU9D_D7MG%G:TN2EH9)<))EHH+1U*+7E_=>Z&O&TO\RN;*?'JOVE4
M]I4_7C5?:61QM'V>VP,WVBE!5;VQ=5M.A^5$F%W/A]GF.IZG_B\>+DQ3Y22D
MR$M$)4^^16'NO=<MO;4_F7[1JNA8,KGNW]]TF*[?Z+SV^J?.Y_JR*+=>,W5U
M'U.>]\5OG=6U#%D-K[.V)V#_ 'NJ<;24V&R>,JYB]"/ K86MIO=>Z#K)=?\
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MQ$LZI,"CQZO=>Z$FJ^5_RA[#Q7RIV5+!MWJOLO9WQFW3N_9W6F(ZB[EW)N?
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MJ)ZYJ158TRR,\?NO=5XU?\R7Y([YV_FL/L/K[KG:?8.?^*F_]Z[/VW58_?\
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MB'<^P7^.6Y/D8>JL'NNN7[S![YZQW!@SM#L.FEI1'+FZ/[0MCS+78Z#W7NC
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M-3PLQA:F+-%&2:=B"U.25OX6(Y3])_I[]U[K(B)&JHBJB*H5410JJJ@*JJH
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MT-AU6YLRVQ]T[Y['K1E<5!2]<8GK'=^<-74-+(89I:>2**>98HG]U[HL6<^
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MVX^R,7NVEH<_CMG?'KIFFWK\G=Q3]5[(S=/E8\-2'<^,[5VQ09+"5M"GW/\
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M;-5C^K>P,MN:EIY)]R[#ZJWM+'EL]M1C+3[DHP(9J3(+']G-[KW1)=J_$?\
MF+Y3?'86.[<[]WYF>JZKL[&U&S#M+O3<>T,_6[!PE5W5AUER,NWWQV3P46Y,
M'CMAY*KQU+6:X\A75T?ED6%Y)?=>ZY83XS?S)\M7=VTV^.\NTXVWOM7IW$;?
MR6WNU=K;=V_B\?!N_P".M1NJDV6^%1]T[8W_ +5V;M+?U+ELO'38R+-R[@5X
MYJZ5X9,=[KW1M]I]-_)79OSCQ>XL7N/>V=^)V+Z+Q>R%I>P.YLKN:#'9O!8J
MBHL96X+!R5,^Z-V[\SF7BDESM=NY,G*\"K64F<6::;$CW7N@T^9?07RV[9[O
MS'^BW+[FJNEMZ?%KMOJ;<6WJ_M+';;Z[QNX]W];=Q;?H\[0[1HEH\MD>Q:S=
M&Y]O)&,Q19_ RT%*:E:K#56/2+*>Z]T@E^,7S@V;NSJK:>P.P>PZCK+9O86>
MHMI[FW%\@,UG:OK?9CYWJK,-N/LS$9NNFS7R&PF9V+C-U;9Q>W\K/5-A*^OA
MJH32IX*W'>Z]U@V#\=?FSOJHZJS'?6-1*KJGY*?$C=V'Q^Y.V:#L2I@VUTMT
M5G>O.Y.RL+DH8/'09#LW?.7GR"4MHLC6T]09:Q8II)8$]U[H:_@GT?\ (3JW
MM?Y%[W^1?\4JMR=AXOJ_:E+O/-]OKV3%VCFNOMW_ " SN4WGLC;#4M'_ *']
MAU.U^PL+!0[8BCIXJ22DJ"M+#9IJGW7NBZ[UZ)_F%5NY_F<,9V7OO>V/WOV!
MM\==[9Q/=6!V/2;<ZYS/9DNX-OY+K#^!9;;^ZMI;JZWZTBAQ>4QN3KMLX[<8
M:HD,V4D6*63W7NNQ\3_F;V5A<UUYWS6[]W&-U;9^,(W%VABOD]DL/MVEQ>R]
MT?%W/[ZV7MCJK#T<%-B>U]O;BZYWKE9=]T(Q%=6+EXFIJFH>HCQ^(]U[H\.%
MV3WIM3X,[SV)O/L+/4?<^+Z_[HQ&*[(G[&Q";IP](^:WM_HTSTW:.[\-G\3'
MN+!;)EQ1;+9BEJ]-5!Y*YY'\LQ]U[HK>Q.C/F%!L+XR;YRNZZ_%]C=?=$_+C
M:.[MQ5G8FXNV)EEWYCDR7Q]W97;4J<UV)A]T;\I*R@HZC(C$5&<:FT-C:3(Y
M#'^)9/=>Z+9\;]@_-/N7K#&;^V5O'N[;5#LO?V\)]@T/9/R#["W#)N+<%'OC
MX8'([DR62W33X2KW_P!=U^&V=VM#CL/FZ.HQV*ER]51BF#M3_;^Z]T=7^8%C
M?D9N3M'XH[/Z!H^S*EMQ3=[IGJ_97:&:ZIVELW<%'LC OUSV/V?E<91U='NK
M;FQ]PS2546W:I)X\S*S1?:U*B1![KW0+4WQJ^;^2W'VO2=J=\=NTNP]T?)KK
MC-9;-X;NB@ZTP^0Z4H^RNX\]N)NJJW9NX&[ ZLQ-5UGN#9NV*W#K68NJFK,7
M+)3M+,IR]=[KW3SV)T9\ZI.Q?E96[>RG8^Z>J=R[CZ1S.P]M1_(^HV;O#<^P
M=I;JVZ_8W3W46X\%E-M1]7C=VQJ*K\^X<DN$W-!E"]'_ !O(4];_ !;'>Z]T
MT4OQU_F";;VAD=T93L;=&_\ LBHZFW'LG<6#JOD'GMM;4RE)%\<.LL5M[^[E
M13+08S:V^J'NC'9NIDW-3TF,R&3K8S//5X^BR$C4_NO=#K\4^A>]\%7?%??W
M==7!N?=FP^F?ECU]O?=V7W7CMX;LK<%V5WEUON_HK#9#<E+-D7W/!0]9;3T5
M,@KJ^.GJH@K5-4[_ '4ONO=%DZXZQ^0'0V[OY=_QOIM\Y?8V%DVCN.+Y'8/"
M9RLBZ_VOM#JOM/\ TB=74VT<E'14>TANWN/>N:H=E5]!%5QY+);9J*I(*:6"
MBG*>Z]U<7C-YY3^%01[IP>)VKOS+5F^H=L; GWEA:_(;GH]JY7+1XBLQ5>J4
ML<[9_;5-19.HB2)SB5KO%.2T3.WNO=4W?&SX5]\;;ZC[!VSN#-=0=C?Z2/DC
M\7?F%+G-EG&TM'@?D!1]]X/>/S"Q.6RC[BW6^X-XX==H"1-P4K4,6:GFF@6@
MQ\BO')[KW5E'3G4&Z-C?)'Y@=FY.@Q5)M;NS/=)Y?:=10U4#UV1EV1U/CME[
MCJ\Q1PQI)2529"@2*-I"SS0QJ0=*@>_=>Z(3N7XD?+?;&^OD7OOJ_/[MBQ'<
M';W<._=S; V_WQG=DP[XV)42_%:/9^UM@2P5L.'Z5[*W?MKKW>M -T8]*+)4
MM3E-576HLM+44'NO=.$WQ<^;#[7PF\(=U8J'Y TOP/WYTE5[_.\**3>0WIE^
MZ]F[]VOL:7?_ / DK:O,4'6^,K<,-W&!C#FW;*"\TAE;W7N@ZZ@^*_SPV/OK
MJW)XK</8'7/6<$WR W?5=7+W)MS?<&VLGV#V-\DM[?W?[QWCG,A7[D[?W=O.
ME[!V6E'GJ3^*U6(FPDR&OIFC>MRGNO=#$_QK^8&R*?X TNR.P^W-YU6P,C@L
MU\JI-^?(K.9G![HW)E:;KENQ\ON_(9.OCWIF\?2)ALX^W\9B),CML5U:U'-@
MJ:CJQDL=[KW0E?S!^EOESVYGOC'7?%S?^ZMDXS878N=W!V_0[:[1KNN(MU[:
M;'8HX3#YFGI)8H]U8X92CD+4LA"A787"R-?W7NBI]A='?S/-Q[$[$P=!N7?=
M#N#:U9MS%; R.V_D#B:&+MROH^X_D1N^?<^9+U.WLWM#KJJV5O;9N,R4--E,
M+NBEAQ-Z,5L6,AQ^4]U[H^/Q?Z9WUU-WG\M\_NG9>1H<;WCO'K'MFAWS!W-N
M'L#:>4SW^AS8NQ-Z[,PFR-TUT.1V7+M;=^SJZICK8<;1TV5QF1HAZ'IC2TWN
MO='E]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW0+_(7_F3V]/^H.B_]VM#[]U[H4L!_P 6+"_]JG'?^X</OW7N
MG;W[KW7O?NO=?__4W^/?NO=$<^?U._\ H9VUDZ#.?(';.Y<7VMM&GV?N'XV]
M6X_M_?\ A]Q[RH-P=;0U=9M/+XO)XJDVP<;O:JCJ<O4FEAPLSP5K5,(AU>_=
M>Z KIKK;KC8W2/R!KNL^INYNE,/D,'U-M6MV3VKL# ];8_(U_76VL9M]-^;<
MP.WIYZ/(Y?=5!+#'F\F^F6KJ:&)"-,*D^Z]U9YMC_CVMO?\ :CQ/_N!3^_=>
MZ?/?NO=5'=G=4_,[L#LCY^[3CRG:+=4=C?'[/X_H+)'?>R=M4>W>S*#;FWAL
M?;'7F*Q]56X^MP>Z,X<NV9KL]2X>IB :AR7\7H*FCGH_=>Z+MV[OGYBS?*;)
M=$]:[Z[.H>S\E\6-Q1;6V7L/*==T/4.PJ3_9=\9%1YS<V&R>"2+#=N)\AZFK
MDP.=,TVVCCUIJ)IRT4E#[]U[JU3XX4/=VQMOP]=]KT.[]XI1[\[[CV]V?N3<
MVTL[EH>LL)V5(.D:?>M719*#,9W<>Z]@9E&BJ8Z-Y8H\4XR9AJI$\WNO=!K\
MGNM,EN_Y3?R^-\TW1=7VABNINU^X\YN#L*GQW7-;%TE2;IZ+W9LO$[DJ)MX;
MCP^Z:5,WN;,T,&K;M)DJM5@,D\<<<:L?=>Z>O@[\<\K\<ME=QXO<55NO);@[
M&^3OR$[1GS.]MRXS>.Y<OMS=79NX)=@5U;N.AC^\JX:C8<..>*"MDDJJ)7\#
M"+1XD]U[H//A/C_F'3=J?)/*?)#$;RP>P]RY';^3ZVQ&[-^;4W[18K<E+O;M
MW';KI]D5F FIJW&[/K.OX-FU,4+XW%4)J))13TJ5"5\U3[KW0$]B[.^==9F/
MDP*:?Y*ST>;[6P=1%4]<]D]*8?%UOQOI=]0/@]O?$7'YFIQ.5V5WS#U\XCW)
M7;FJ,7C:F:.K6*>HJ9J&JIO=>Z2?9^&^<?6G1W??=7:_9O>%=ORDZ_\ BEUG
MLW874FYNL*;$RU&YS\?,5\B-T==XR##4U'%VM7[X?<='CLQF9J:GIONIFI$I
M:&2)HO=>ZE5FR?YFT.>V])B,QVE#-0= [[Q&V9*O?/361V]0-+L_O2+!XSN:
MFK)Y*?=7RLCWM5];-B\[C8:C::TU!DS5U.@U@RGNO=+?='6GSIV1VA\+=H==
MY_NKL+KW:E5M;)]^]E[R[8V)6R9^BWON;<P[TP._L*(]K39-]J8*NQTFV)Z"
M&OEIE80XM*-J*66H]U[IK^-OQK^1&P^AO@9L[+GNB?>WQN^1V[Z/N1>U^S-J
M[]3>'7.3P_;&.K=^OE,AELPF[L!#7Y?#3;6FC%)N'&02LGV\'^5(?=>Z#BFZ
MF_F=[@V1E*.;??=VW-PT.3[7W95SU/9/3R9C-]QXOHS.-MJDVE745(N(HOBY
MNGON3%R;9PE5%'70T<%0F7@HZ%_'+[KW5@OS0Q'R!W#T?@*/IANQ:7<4F[]M
M5'95%TGN396TNVZK9BX7-M6T/6NXNP7;:F.R4._&PTM::BJ@:7!0UT4<KR.L
M4ONO=8OB_P!:?(W%;R[,[*^2796\LQN/)_W1VCM?K[';AVU-TG08'']4=0U.
MYMW[2VQA\%0Y>DSN4[AI]U?Y5DZ@51I9S&E/#1BC2/W7NB=]H[A^9N?^5?S(
MQW2D?;^?P76W76W,5MS;[[YZ_P!H]35M+O7H1\E18+KR+(4-7N^D[WC[5J(<
MNN9FII,5#BZ>2B>L@DJ8XU]U[I;?&[H[YF;FEPL_R([5[RVC@MH=-;XV?M?;
MD'86R(VW/N7<W:?R%P."W+V;E-L_WHW?G-WX/H?)['J::JERCFARD"S/)/E(
MJV1_=>Z"WI_HKYU[4Z_^)>WMO;H[PVW1]$=*]9[1W1M[LWLW8FX9M[]R8CY&
M;/V]VMENU,K3Y3/9?L'K>IZ,ILW7X#P5D<XPLT 2.GS:000^Z]U-^/G3/\P[
M<M1U3B._^T^[MK;>QO=^Z-X]N5>%WEUMC,IE(]O]6;+JZ3!8K-8^NW=G,AT3
MO/O>/+2XS'T8Q56F'7[:>DHJ"2.#W[KW0?;H^/?\P3M"AWFN9RO;>%W'L/Y,
M=R=N=)]DKV1UG@^P*"DR'QP^1&V=C[0Q&-@J,YM+#=8MO[-;1Q=J66"/-8^J
M=ZW&8MX\M-5^Z]TY=Z8'Y<]:Y3>&:F/=E/1_([Y,?"K&?:=(;TZRI.S9H<ET
MUF,-WELW8.Z]X9,T^S-G8SL' TU0L>7RE+1TD,M9_#JB."81GW7NK9.D,]V:
M=M[5V+W!A<C)V3M;I[J/*=A[]IHL6-F;I[%S^*S%#OC%;<J,<\/GKL!FMMM/
M5E:2EIC#DZ9H456,<?NO=$5J#WWV7_,.[>V(X[!SWQWVAA^L,'OO;>XZSK^I
M^.^1ZP[%Z+[4EW;M279&6:+>>Y^TL[V@FWIUJXZ>JQ=-ATJ(9ZF)7>BJ_=>Z
M"_:O4OS]ZSSOP7VML>GS^%ZMZB^*_6^TMZ[%P>X]@Q;2;LS:>S]\8[L7:'8U
M95YFIACQV9IJ3:6/VME<?C-QPXNJBJYDABC$C5'NO=)?J?9_\S:DHOCG7;M7
MN%EPOR>W!FMV;0W5V;L*>EK^F]Q[=Z5E>/M3>^(W!F]X2XO9NX:G?TF&H5H<
MU#7Q11TE11X_S82KQWNO='"_E\[<^8^W<3W!'\O,]N?-92LWAB*C;(W+-M*K
MI$RXQ=0O8F0V'4[;S^=K8NK\OGC#+@Z2M7&FDIU9(J"E0E6]U[HLFX.GOGEO
M3:WS3VOEINR\N^2[EZT[!^/.5W/V%U_CYJVFVWW?6YG+]<T&SJ>JR_7=1U#'
MU/08M9)JPXE\S#*T%7AX,S3U.0J_=>Z0M/NCY5=N?,'Y,](;0[7[P6FQ^\-C
MC?M=M3=&S<1UWUOU3_LR_7BXO&=25%;@:3/["[.?XW0YJ/<GW>JIRTSRU>)-
M6_@JHO=>ZLHVOL?O'>?P?INN>W\ON/%_(#.]"9+:&[,]MS<.$QF[8M_S;6K,
M3%F:'<V"EEVY3Y^HKQ%.]3"31&H=B4$1*#W7NBL=6]7_ #NP7:'0VX=PYS=.
M/V+L_:'Q2V+O+K^BW/UK3]='%0=!]L47R/RM;M7#LCUN=QO;W]TXZ2:C9!$M
M.AQJ&C-<)/=>Z&KY1?';L/MCY/?#KM7:%3F4PO1N-^359DUFW114FQ<=O7?7
M5E'MCJW<>YMFU8JJC<61PNX6G:AK*.FFJ<9KE)(CE97]U[HJVQ>H/F5VSF.A
M-Z]]=<9B'-],?)CXW;EPU3O?/]39#<NW]M[5^*68Z[^1F_-O5FU,]DVH<+OG
MN3*U96E2=<CE*.5:@TD4#^*+W7NCS?$3IK.=,2?*&CR>TL7L[#]B?+?M7MG9
M=#AVP:4.3VOO;"['F;<0HL%-)#CJO.[EHLE/4QU"0U<E2TDTJ:I=;>Z]T2K?
M>S?G554OR&A@F^4,M5ENXJ&OR%9L#M#HW#4N:Z>@WKOT[&P_PWH,PBUG7FX,
M?L>?:9WG+NJLH4K&ILG%3K5U4BU4ONO=<^SMK_,'875';O;7:?:/?&7WYF]W
M_$'JO!=<=%;HZZQV*.R]RU_Q0PG>^:Z;H,AC,+1X;L?</8-=ONFI<KGJZB,%
M+.RTYHJ0T4L/NO=,-3L;^9VI@6CW+V+%O'_95,Y@\1DXMY=1U77>/W#+U7V%
M%B:+=6+R](\^4^7%'W1+M*HCST4$NRWQ=-7B6H:G=Z:I]U[H2-_=3_,G:_?7
MQFV)UCN?OG>G1VV%QF,[:[5W1W%M2JK]R[0WRG<J=L-O3'%-HY.3>.T*ZIV>
M=N5U!35];3PM_D!HDHZX5GNO= +UMTW_ #"=A;"^ ?7&SZ_NO [<ZCQQV?W1
M4[VW]L_?F\\MV-@NW-BPYW=G:.?K]^K1;Y^/6X.EJ?=<>W$HOOLO3S5- 9L;
M!7)324WNO='I^<6!^5F<DZ=_V6JOWM204&>W%5;@786X]C[<GCWV(<#_ *)<
MKV:V]Z6=<[\?L56+ECO#&8WRY6LBEI1!2U)5A'[KW0M?&OK;M39Y[6W;W!V/
MV+N_=/8/:_9M;BMJ[ISNV\CLK8/7.([3[!INHL=USB-NXRF7!4-?U5589ZS[
MNIJ\C4R1HU<_WBS7]U[HS_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H%_D+_P R>WI_U!T7_NUH??NO
M="E@/^+%A?\ M4X[_P!PX??NO=.WOW7NO>_=>Z__U=_CW[KW1.OFSNSL;9/6
M.T]P=4=A8+8F^XNR\/CL%0Y_:V_]\4W8%9G=L[OP<&RZ/9W6.)SV\=RY2GJ<
MBF=@I8:.>F+8376>.C2>:+W7NBJ=$I_#^G/DIM^'L_MO=,6&Q?4ZYCKOOJE[
M'I>V-B[ZJ,' N^-Y9"#M2>NW)2[2[HR=,F9Q=/254^#IIHZQ*,0N*FGA]U[J
MU3;'_'M;>_[4>)_]P*?W[KW3Y[]U[JC[-=Y?,[<_<WS$Q&P).[MQ=>=;]F9?
MK*IJMH;(ZT?&[&P3TWQNK=K571M2=N93=&^]]8+';OWE7;P@KZ7*5J8_Q)C(
M36P4"5'NO="%U]M;^8-W1TYV.O;F]^S.K-YY#X+;7V=M79FV<=U/M!<I\C]]
M;![9Q&_=XS[L;"YO<>!WWMW<%'M:JQ[TV6HL1B:F6=O#*DY6F]U[IAV16?S
MZ;;'0N4V-)V]/C]K=%_''9L^R>\]M[%I,EN3L'(=?_(K$=T;H[UKXL;0;OJ=
MQ[>WMM[88:?'9"CH!&_W4?W4=?4R^_=>Z6GQ.I_G[OZ;H>;OSL/?VS=LX6'M
M_=N_VI.LMB[.SN^,U@\ST/2;'Z[W_3;NQ&Y,WB=L5%;D]_"FJ,1!B*K*XJ"E
MD6:(4U-65ONO=%9QF%_F6[TI-O=CYE^VZ7MCH'<?R3RVT\U5;(Z^VMBNWX]P
M;6Z0& ZXRG6^7I\U#@=B3;CI,]12&&NKYJJ6E:HP6XOL3!(ONO=#/\A-P_)3
MH':?85+M')=XIG.XOYA^Y\=U[5=:[.ZIW=V5O+8^Z/B?EMZ;*PE!!N;#1X6+
M8>%[FVA3XJLR,T(S-)M;"RQRU+A9*MO=>Z.WW=3_ "DS?3_Q\PNSLS7;([/W
M/V5TCB?D/N'K'';4RTFUMDUM(\W=%5M%]^8_<6+Q^/BKX33TU:::KJZ:"19(
MU9Q?W[KW5:F\NP_YM-;'FZ39VV^T,)NX_%*HCK:BIV-U-7[7I.[<?L'IK-[4
MW5L$U&-GP,F9W9OFJWEC\KB,A49&6D\!5Z6AI_X7-)[KW0Q?'_<G\S.3NSXX
MX;N&7*KUZ_7>';LF7,=;X.2+<E7%3]PIV;E-^;HVI)BL!L;?>/W%!L<;9HZ-
M%AJ\9-5$4U5KK)Z+W7NEM\E<+\EL5\ZME;PZDF[6V_LG=?0>T.N<UO3$X'KC
M,]%[;IJ+M+?>;[2W-VSD-X5:9S;FX=@]=9:+,;7;'_:QY/,1QT=2U73O-3#W
M7NA^_EZ]K=P]]?'#"=X]R3TZ5_9V9R.5V1BJ2EQ<%)2==;;IL=L+ ;DI*K$0
MI196@[=KMI5F^J.HCDFB&/W13PPN((8D7W7NJ[\/W5_-'PFV>S\]4]7]ZYHU
M.Z-_X3K_ &]7=>=4Y/>^.W5NGHC>:;+3)+''A-NU'6FP^_L'CT&6HUEQGVE;
M&[U.0Q\IFC]U[I6;FZ(^5^;W9V]L[&]@_)^BK\?_ #%\%W_LWL3(+UYG\'MW
MI#.?'O=S8;%]-Y'<>UJO;IV_C^PJ)</F<'D:&O\ X2U1$R4Z_<K52>Z]U(I-
MW?S0=RU79F-:F[,V9N7);0ZX@;)1]?\ 4K]=;/.=WI\<:#%YOI1\M3Y7*9_?
M[;!R?9=3OJES4M=C\1D:2B-'#3I%2PUWNO=#=W3MWO\ ZB[&[<[#V[B_D!W]
MA,/\"*/:VVZG8D'5=#V[NGNC;'9-<<?A]FYA=KX7#8C>6_,/DXJW-RO0/AHF
MI154=%3E#32^Z]T!NV=P_P T"DS'1.)P&X]T[WH%^/554YG/=J]+X_:C[_[=
MIL#WD_8;=FK1XO8=%U378K>M-L.EV/2U$,"Y'%/--4_>-/D)Z'W7NC5_R]<#
MW)B.HN]\YO\ HNW(=U;^^0_9^_-D/\E<%M#9_8>2PN6VOLFBQ%5N[;G62?W<
MV_B#N3%5D-/%0TE,PQ\2.(2S!Y/=>Z)WM/JGYE_):B^/D?R33NVFVQUK\V>L
M>PMU8'<F-ZOV=7[A@VGTMO//=DT6[<%M7%5>$W-\<=I_)&AH*;8TB:<G68R:
M.:HJ*UHJ/(#W7NA%P'QA[OVUL[Y9[KAJNU,YV/V/_,LV=W#BZ+<U5LC/_P!\
M^B=L]M=64&'VN%K<$)8NHMJ]=C)5>-H$J*:OH'Q<;P3(WD2?W7NL';&\OY@E
M)3_)@;'IN\*7<&*[JVU1TU3/UIUQGNM,#\<:CLG*)C<]\6J?:HK.S>Q^W*SJ
M=,=+N*FRR9&DHZV2M\4,-4E-3'W7NC2="?[-?09'M'M/Y#[DWWG(MK; Z[HM
MM=(;,V5UMC-M;HR]/T#UENKLK.[3@C2IWC6[VR7<[;@QU#2U>Y1C*4.:+]^.
M."M7W7NCTXFO;*XK&9-\?D,2^2Q]%7OB\M#%3Y7&M64T=0V/R<$$]5!!D*,R
M>.9$ED19%(#,!<^Z]TX>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[H%_D+_S)[>G_4'1?^[6A]^Z]T*6 _XL6%_[5.._]PX??NO=.WOW
M7NO>_=>Z_];?X]^Z]T17^8@E8GQY7(Q8G'5&)P?8NQ,UN?=?VN/KMY=7[?H<
ME*9^RNJ*'(;MV0M7VAMW(24T>,2'(BIT5,QAILA(%Q]5[KW13?B?539CX]?*
M;<U!-5[RVAG-S[9&WNZ]\XVBPW>/:=9C<-@Z//1=K8JGW5NBNI(=DRB"AP7W
M:8:5L=(=&-CB"5M?[KW5P&V/^/:V]_VH\3_[@4_OW7NGSW[KW6*."&$RF&&*
M(SRF>8QQHAFF951II2H'DE9$4%C<D #\>_=>ZR^_=>Z][]U[KWOW7NO>_=>Z
MQR0Q2F)I8HY&@D\T+2(KF&70\?EB+ F.3QR,NH6.EB/H3[]U[K)[]U[KWOW7
MNO>_=>ZQ3P0U,,U-4PQ5%/41203P3QI+#/#*ACEAFBD#))%(C%65@00;'W[K
MW7&FIJ:BIJ>CHZ>"DI*2"*FI:6FBC@IJ:F@C6*"GIX(E2*&"&) J(H"JH  M
M[]U[K/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H%
M_D+_ ,R>WI_U!T7_ +M:'W[KW0I8#_BQ87_M4X[_ -PX??NO=.WOW7NO>_=>
MZ__7W^/?NO=$*_F)5$.-Z5V=GXV&%W!MON[K7,[+[+RDJQ;%Z7WBE3DZ'#=I
M]HB?:^\Z&;K["FNDHZI*C'-$U5D*>U3CGT9*C]U[HK?QLRN0W-UU\U=U;MW)
M@>V.R<EN'K?&[W^0/6LD(Z1[.&$VQBXMO8+KJAH]O;=H<?E.ML55?99Q V8G
M^XJ8?+E)K)18_P!U[JWW;'_'M;>_[4>)_P#<"G]^Z]T^>_=>Z+;NG;E#O;O^
M';^X:W<<N"QO3J9BCP^+W;NG;F/CR]9O6>BJ,G)!MO,8G[FN>CI(XA)*7*1@
MJM@S:O=>Z6'^@;K?_E6WA_Z-+M+_ .S/W[KW7O\ 0-UO_P JV\/_ $:7:7_V
M9^_=>Z]_H&ZW_P"5;>'_ *-+M+_[,_?NO=>_T#=;_P#*MO#_ -&EVE_]F?OW
M7NO?Z!NM_P#E6WA_Z-+M+_[,_?NO=>_T#=;_ /*MO#_T:7:7_P!F?OW7NO?Z
M!NM_^5;>'_HTNTO_ +,_?NO=>_T#=;_\JV\/_1I=I?\ V9^_=>Z]_H&ZW_Y5
MMX?^C2[2_P#LS]^Z]U[_ $#=;_\ *MO#_P!&EVE_]F?OW7NO?Z!NM_\ E6WA
M_P"C2[2_^S/W[KW7O] W6_\ RK;P_P#1I=I?_9G[]U[KW^@;K?\ Y5MX?^C2
M[2_^S/W[KW7O] W6_P#RK;P_]&EVE_\ 9G[]U[KW^@;K?_E6WA_Z-+M+_P"S
M/W[KW7O] W6__*MO#_T:7:7_ -F?OW7NO?Z!NM_^5;>'_HTNTO\ [,_?NO=>
M_P! W6__ "K;P_\ 1I=I?_9G[]U[KW^@;K?_ )5MX?\ HTNTO_LS]^Z]U[_0
M-UO_ ,JV\/\ T:7:7_V9^_=>Z]_H&ZW_ .5;>'_HTNTO_LS]^Z]T$G;74^TM
MOCK+^"5.^,;_ !GM_9&"RWV_:'9A_B.$R#9(5^)JO+NZ770UHC7RH+!](O\
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M-UO_ ,JV\/\ T:7:7_V9^_=>Z]_H&ZW_ .5;>'_HTNTO_LS]^Z]U[_0-UO\
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M&^=R[8V)FMM]:;,@W7OC$X]\QN.KQ6,6JKHT,]]6GW7ND7!/\RY]X[BV(?\
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M]U[I:_[(+_.'_P"]^>]?_3:GPD_^M7OW7NO?[(+_ #A_^]^>]?\ TVI\)/\
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MZ][]U[KWOW7NO>_=>Z][]U[H%_D+_P R>WI_U!T7_NUH??NO="E@/^+%A?\
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M]U[IJSLM)EL'F<729W%X^KR6*R./I:^:/'96&AJ*RDFIX:R7%ULGV>2BII)
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M_G94'_G93_\ 7SW[KW7OXKB_^=E0?^=E/_U\]^Z]U[^*XO\ YV5!_P"=E/\
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MV73J3_GFYO\ S\YG_P"KO?NO=>_V73J3_GFYO_/SF?\ ZN]^Z]U[_9=.I/\
MGFYO_/SF?_J[W[KW7O\ 9=.I/^>;F_\ /SF?_J[W[KW7O]ETZD_YYN;_ ,_.
M9_\ J[W[KW7O]ETZD_YYN;_S\YG_ .KO?NO=>_V73J3_ )YN;_S\YG_ZN]^Z
M]U[_ &73J3_GFYO_ #\YG_ZN]^Z]U[_9=.I/^>;F_P#/SF?_ *N]^Z]U[_9=
M.I/^>;F_\_.9_P#J[W[KW7O]ETZD_P">;F_\_.9_^KO?NO=>_P!ETZD_YYN;
M_P _.9_^KO?NO=>_V73J3_GFYO\ S\YG_P"KO?NO=>_V73J3_GFYO_/SF?\
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M_P">;F_\_.9_^KO?NO=>_P!ETZD_YYN;_P _.9_^KO?NO=>_V73J3_GFYO\
MS\YG_P"KO?NO=>_V73J3_GFYO_/SF?\ ZN]^Z]U[_9=.I/\ GFYO_/SF?_J[
MW[KW7O\ 9=.I/^>;F_\ /SF?_J[W[KW7O]ETZD_YYN;_ ,_.9_\ J[W[KW7O
M]ETZD_YYN;_S\YG_ .KO?NO=>_V73J3_ )YN;_S\YG_ZN]^Z]U[_ &73J3_G
MFYO_ #\YG_ZN]^Z]U[_9=.I/^>;F_P#/SF?_ *N]^Z]U[_9=.I/^>;F_\_.9
M_P#J[W[KW7O]ETZD_P">;F_\_.9_^KO?NO=>_P!ETZD_YYN;_P _.9_^KO?N
MO=>_V73J3_GFYO\ S\YG_P"KO?NO=>_V73J3_GFYO_/SF?\ ZN]^Z]U[_9=.
MI/\ GFYO_/SF?_J[W[KW7O\ 9=.I/^>;F_\ /SF?_J[W[KW7O]ETZD_YYN;_
M ,_.9_\ J[W[KW7O]ETZD_YYN;_S\YG_ .KO?NO=>_V73J3_ )YN;_S\YG_Z
MN]^Z]U[_ &73J3_GFYO_ #\YG_ZN]^Z]U[_9=.I/^>;F_P#/SF?_ *N]^Z]U
M[_9=.I/^>;F_\_.9_P#J[W[KW7O]ETZD_P">;F_\_.9_^KO?NO=>_P!ETZD_
MYYN;_P _.9_^KO?NO=>_V73J3_GFYO\ S\YG_P"KO?NO=>_V73J3_GFYO_/S
MF?\ ZN]^Z]U[_9=.I/\ GFYO_/SF?_J[W[KW7O\ 9=.I/^>;F_\ /SF?_J[W
M[KW7O]ETZD_YYN;_ ,_.9_\ J[W[KW3UM_I+K+;&4I\UBMLP#)4;B2CJ:RJK
ML@:25?TST\5;4SPQ3J>5<+J4\@@^_=>Z%;W[KW7O?NO=>]^Z]U__U=_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__UM_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
<[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g150774g13b07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g13b07.jpg
M_]C_X0Y+17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-3HP." P.3HQ-3HT-@   Z !
M  ,    !__\  * "  0    !   "YJ #  0    !   #P          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M-81H>2!]IR.2!^>9=]*NO_P;_36)AA=1 (AFH:T3E9)T80:_ZK]/TMGT[?\
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M&UL=N_D,8J/_ *RW_H!_Z)6@]NS'<R2=K")<9)@?G.6?_P"LM_Z ?^B4E/\
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MV;MV[:[U'IST;IA$&@$ N(!+C!>&LLVR[V[FL5U))2)S&UXQK8(8QFUH\ !
M6?\ ^LM_Z ?^B5I7?S3_ .J?R+-_]9;_ - /_1*2G__7]&8Z>MV"/HXS/Q>]
M7UG5%G[>OVF7?9Z]XTT]S]HT_P"_+124I))))2DDDDE*22224I))))2DDDDE
M*22224PN_FG_ -4_D6;_ .LM_P"@'_HE:5W\T_\ JG\BS?\ UEO_ $ _]$I*
M?__0]#I#AU_)); -%>T^/N?*TE2R,?-;FC*Q?2?NJ])[+2YL0[>US7,;9N^D
MY+=UK_1XW_;EG_I%)3=25+=UK_1XW_;EG_I%+=UK_1XW_;EG_I%)3=0OM.-,
M>JR9+8W#Z0^DW^LU5]W6O]'C?]N6?^D54LZ9=:\V6]/Z>]Y.XN<"22==VXX_
MFDIU#DXXF;6"#!]PT.FG_22&10>+&'C\X=]6_P"<LIO2K&[=O3>G-],[F0"-
MI):=S?U?V_S=?^8D[I+W,=6[IO3BQ[0QS8,%K9VL_H_T6[W;4E.J,B@F!8PG
MP#AW_P#.4AD4'BQAD2/<..5ELZ7:R-G3NG-@[A (@QMW?T?]U,WI5C2"WIO3
MFD<0([%G_<?]QVQ)3KUVUV FM[7@&"6D$2.VBDLS'Q^H8K7,Q<7"H8YQ>YM;
MG,!<="]P90WW>U&W=:_T>-_VY9_Z124W4E2W=:_T>-_VY9_Z12W=:_T>-_VY
M9_Z124VKOYI_]4_D6;_ZRW_H!_Z)1GGK3F.;Z>+[@1_.6=Q_Q2)]A_R5^SM_
M^ ^S^I'\CTM^R?\ H[DE/__9_^T6.E!H;W1O<VAO<" S+C  .$))300$
M   /' %:  ,;)4<< @   N:  #A"24T$)0      $)R"/X[QU1V4P@6DU2(U
MS.PX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ $L     0 " 2P    !  (X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      U$    &
M          /    "Y@    X 10!8 $@ 20!" $D 5  @ #D .0!? #$ +0 R
M     0                         !              +F   #P
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #P     !2
M9VAT;&]N9P   N8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   \      4F=H=&QO;F<   +F
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "@ 'P# 2(  A$! Q$!_]T
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M-P=!->,7L,[]3]M94[TV.V_S?T$S<CK982YSVF'B/2QY! ;M/MSWM]OJ;_\
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MR28@O]V8WV6?R_TO_!*/[6M=JUF/:US=Y<QE3@&N ^G^O_G*VWI&6"7&UAL
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M=(?=76#,M:XLNHR'>QWO8]G_ %S]&CC_ )9=_P"%F_\ GQZ691EV7L?0&E@
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M)D<=09=<#39:LGQ@G::>2-O=>Z'WYE?"[>&Q_P":7B?Y7/3>T,5B_@I_-=[
M^*?RU[+VMMZKDI<-U1MGX%RF;Y$[#IMK40,M!M[NF@V/LQQD)9H8(<L:2&!7
M6*6(>Z]U:Q_-GZK[VV/\W?Y7W\RGKKH;MKY6]7_"K<'R-VUW;T3T5@Z/>7<&
M.V_W_P!:KL?"=M=;[ J,C2578&3VC7B]9C:&-L@P2 QM''YJBG]U[HE'\P#/
M[P^9_:/P1^6OR'_EA?S!NY_Y>&R*/Y,;7["^$M3TS5Y3Y!T/;V0IMOXCIGY
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MWEL#:?5V^]XX';U?]]5X'9_=>%RFX^J-Q5;I&*9L7OS!86JJ\?)&[B6"$L;
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MIMP[UHJO'S4]?F99*E8IJ.>O4I[KW2JZ>^ GR"2C^,NY>X/B1\L=S=>_&O\
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MA?2QVOAVMM#!HD9;BX1I)%-M8;E;0SP&QB:.6NL!DC#*5*Z0$C[>.HM5B3C
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M-Z]^]%=:X#:VZ^Q>ZNI=@[6WP(6V5N3>O8^SMJX#> J,;_&H#M;,9W,T&.W
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MAW)52Y'JNGVW'L6NDJ=Q4T=?(TM Q>MC6<WE4,/=>Z O_AJK^5]_WK>^!/\
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M5N)CR$6*K-K]:Y3;55LS;]5C(LO5K3R4E%"\*U4H0@2/J]U[H$/^&J?Y7O\
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M/7=B"/?NO=#CO[XB_%#M;KC8W3O:/QB^//9/476"XE.M>K-_=+=;[QZXZ\3
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MW[KW7O\ H*V_DB?]Y.[T_P#2=.__ /[77OW7NO?]!6W\D3_O)W>G_I.G?_\
M]KKW[KW7O^@K;^2)_P!Y.[T_])T[_P#_ +77OW7NO?\ 05M_)$_[R=WI_P"D
MZ=__ /VNO?NO=>_Z"MOY(G_>3N]/_2=._P#_ .UU[]U[KW_05M_)$_[R=WI_
MZ3IW_P#_ &NO?NO=>_Z"MOY(G_>3N]/_ $G3O_\ ^UU[]U[KW_05M_)$_P"\
MG=Z?^DZ=_P#_ -KKW[KW7O\ H*V_DB?]Y.[T_P#2=.__ /[77OW7NO?]!6W\
MD3_O)W>G_I.G?_\ ]KKW[KW7O^@K;^2)_P!Y.[T_])T[_P#_ +77OW7NO?\
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M[]U[KW_05M_)$_[R=WI_Z3IW_P#_ &NO?NO=>_Z"MOY(G_>3N]/_ $G3O_\
M^UU[]U[KW_05M_)$_P"\G=Z?^DZ=_P#_ -KKW[KW7O\ H*V_DB?]Y.[T_P#2
M=.__ /[77OW7NO?]!6W\D3_O)W>G_I.G?_\ ]KKW[KW7O^@K;^2)_P!Y.[T_
M])T[_P#_ +77OW7NO?\ 05M_)$_[R=WI_P"DZ=__ /VNO?NO=>_Z"MOY(G_>
M3N]/_2=._P#_ .UU[]U[KW_05M_)$_[R=WI_Z3IW_P#_ &NO?NO=>_Z"MOY(
MG_>3N]/_ $G3O_\ ^UU[]U[KW_05M_)$_P"\G=Z?^DZ=_P#_ -KKW[KW7O\
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M -9/?NO=>_V7;X_?\^+Z<_\ 18[)_P#K)[]U[KW^R[?'[_GQ?3G_ *+'9/\
M]9/?NO=>_P!EV^/W_/B^G/\ T6.R?_K)[]U[KW^R[?'[_GQ?3G_HL=D__63W
M[KW7O]EV^/W_ #XOIS_T6.R?_K)[]U[KW^R[?'[_ )\7TY_Z+'9/_P!9/?NO
M=>_V7;X_?\^+Z<_]%CLG_P"LGOW7NO?[+M\?O^?%].?^BQV3_P#63W[KW7O]
MEV^/W_/B^G/_ $6.R?\ ZR>_=>Z]_LNWQ^_Y\7TY_P"BQV3_ /63W[KW7O\
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MEZ]QN>Q68FV]D\)D-Z3B/;='E\;N"FDH9Z:2I6:&LC:%U$BE1[KW2;W!N_\
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M>_=>Z][]U[K7B_X53?\ ;CGY=_\ :_\ C=_\$WU#[]U[JYWXF_\ 9+'QH_\
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M]3=7]:5^_*C8?66TJCO:JJ-RY'!8/'T.'RM;4RQU=--2L*<>Z]T&.W_Y9O\
M*LWST;FLIM?9>UMR] ;N^/F?Z*DW7M_O7L"IV'!\;<?W_N;Y*U6RMN[RQ78:
MT&#V+LON*OR%;05%%5Q'"X^%<93SPXNEAI(O=>Z3>6^*/\H/?+)W5E9]B9S
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M#0;MW?O^<2;KV#6X.8+3TL$;14^0=I9/P5]U[JP_9/QR[ND_FLT/S(W!M*#
M=3Y/^5ML#XY9)J_>.#S^Y\/W=0_(_<7:><VE708^4SYB#%[:RZ:\S"GV-54*
MPC8DV]^Z]U:3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZUXO^%4W_;CGY=_]K_XW?_!-]0^_=>ZN=^)O_9+'QH_\5_Z:_P#?=;<]^Z]T
M8#W[KW7O?NO=?__3W^/?NO=>]^Z]U1-_PIB_[<>?/#_PVNF?_@D^FO?NO=67
M_!/_ +(A^&__ (JK\>?_ 'T>T/?NO=&J]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U4Y_.A[$^470WP4[=^4'Q7^1!Z(W?\ &;:>Y^V\YAY^I.N^U<1W
M%B<3AIZ.DZ]SG]_J.LFVAC#E*R*L;(XK17ZZ=8[F)G1O=>ZKP[I_F3?,3^7)
M\A!UIW9NJB^<?4G4'\N[J?Y2?(#?E?@>O/CEV"V5[:^>.4Z+GWEL_;6P]C[A
MV[N3,;5ZZS--3T.U_+@\?718&>HJ,I'7542S>Z]T+.2_G'[XZEKI1NKJ.LW3
MUE4?-OYI=!;Q^2';V]$ZMZ-Z8QO0?R_P_P >=K[$W!V+UCT1OK:NR\]F<!N%
MLQ@:CL5MI8;)4F-^QEW-59:H&GW7NC;?S!/YD^]_ACV-B^N]A_'; =UU,'Q'
M^3_S.WIE-R=Y)T[3X/J[XGR[!JM_X/ 0/U=V$NZ-[9_";U9L1 \N/I?O*=$J
MYJ:EDFK:7W7NBY1?SJ-Z;ER^^EZ^^)>&RNS\K\RN@O@/\8=X;M^053L^7M_Y
M#][=2;/[^:?M/:_^A#+Y+H;K+K;IO=8R.5R,<NZLK791(L5C,965,Y:'W7NF
M7)_SQ]QTU9\+,%1_$NB_O)\W.XNS?BCL^FS/R)VK@\/US\L>A?DC3=%=W;8W
M;F*G9;MO#H[%[<I\GN+;6\MJP9BNW#64=+@IL'C*_)0R0^Z]T:3X8?S.\I\O
MN_<E\>(/C_/L+>/4NR>]*WY6SOV1#NFEZ [6ZQ^2F9Z!ZXZAG2FV7B&W-E>\
M-N[1S.^L96.V-2EVS3TKB&J^]CD3W7NBD8[^<COKKV38R[TZ@KL[UGO/Y7_+
M/IS=GR;[BWFO5_2?5<'4'S>R7QHVUUSDNP^L.AMY;#VKN^7;,T68PH[#GV3C
M,S24T6/7<-?F*AC[]U[HZ_SI_F)[H^&/<?1.P:CH5,IU7VHM ^\OD_V5O;=?
M6OQ]ZQKLCV=L7KFCV5N;L7:G4';^"V9O?(TN\Y,O02[VEV;M;(1T'V$.:_B%
M3'"GNO=$,[Z_G9;ZI.I/D3FMA=-4_6V,W-T)_->ROPB[LGWK0;\W/G^V?Y8>
MUMW0]@Y7N7HC)[$Q%+UCM/.[GVQ656VVES.?>M@QZ19:DQLM?1PS>Z]TI\9_
M-O[EQ^_=Z]%=?=*T_P C/D+4]J]Q4NV=L=A=P; ^./65!UW\:_A#\./D)VW)
MB.RXNM=P0T.2W-O7Y'T]%MO&YVGJO'/75%3EL[CL31QO'[KW2?[0_FU=S]3?
M+2+:*X'#Y_X[;;^4/RNVIWE-N:JPK=@[:ZU^-_\ *VZA^;M=M[I2#96VZ?%9
MC[2NWS75(GS-;E*C-Y*G2BAR-#C*A*NF]U[I9]0?SKNT.V]C=*U=/\#MY[.[
M,^2_>?QYZP^/^-[ [!W=L3I3?6S?D#T%N[Y,#?<W=.[.A,3F/XAU7UML'*4.
M?QV&VGG:.KW$U##ALCE,=6_Q.#W7N@3V)_,S^9NZOY2_\M#Y;8[)[*SOR)^3
MWS^Z3Z%W_B*_%;;PFU-W;.W[\P^Q.GLGUU%F\3@L]A-G"KVK@J/&?WGH,?5O
M&T35M/#+)*J-[KW0J[J_GKYS9.WZ(;A^(,DG9&Z:/Y$=1]9]>X'O>BRJ=E_/
M'XR?+W:OQ+W]\2MG[BJ>K<6^7Q>=EW]B-X8#>"8\'(;;CRIEP]//B:E/?NO=
M3OYK/\Q7Y9_%?L[O+K/I>FZNP.WMB_RA/D[\U\=O?+05F<WGA^Z^K>W.KNO=
MN?8X3)X7([7SFUL;#O&*-:"LCIQ6MDIZF69/X=#1U_NO=/\ V#_..[6ZNHLM
MU9G_ (:SY_Y?X;Y1U/QEI^FMC]I[P[!V=N%\=\+=N?.67>U'OKKSX];FWD*_
M)=4[ABQRX6EV=6QTFX"ZS5ZXJ"HRL7NO=,O\R'YT_*6EZ._EE[K^*E)\A^CM
MT_-[LW'T>\=@[-Z!Z?[9^5>U-MU_QG[$[FGV)C>J._LM@NLZ?>.UL[MJ"'.R
MUF1@CI*2EJIH'G"I'-[KW05]'_SB_DAA/B/TM6[XZ>V]\B?E%2];_P PSMGO
MU=Q[HQGQ,CVEU=_+H[9/7W8V*WC@4VWVIM_$_+/,4.X=OTU5M#%R+M*'-SU=
M4<W0804U2_NO=*_L?_A0/LO96\<O+MWX_3]B],5_QB[T[[Z_W_M[L;-T>Y3O
M'HGX3[8^;^>Z.[FV]DNH8]B=3]DUNQ-R#'5&(H-U[IW!@IHX:S)XRGI:VG/O
MW7ND!\F/YQORWI>F=ST_77QQV5T;VUU;@?Y;G8/R*W-D>YJ;M?&]/8KY]?*;
M"[(ZXZ_Z_P!OY+I#;M%WME\OT_A\C'NC)))@8-KYC)+#C?XT*1J\>Z]T?WYW
M?S0JOX?]J;CZMV=T1_IDK^GOA[OWY^_(>NRG9]!U<-J_&#KG?%%L7/'JB"MV
MENN#M?NBKJQD:NDV]5S[;Q?@QR1SYB"HKZ**3W7N@D^-'S%^5W96 _G1]S;]
MW#M%-D_%;N/M;J[XH['PF&H$IMM8'J3XW[8[GQ>YMVO7[1PV[<GN3?-!V9@J
MW*TV3KJJ*@KDJ:&GIZ>.G\M5[KW5:.V?YE'SM^//Q]VCOGO_ .5-#\CI_DA_
M*/VI_,HVY6;;Z3Z3ZK[7^-V[1OOXM[6R&P\?%B<+DNN]Z=9[W3Y#U-/CJ_/[
M>ER*5^#D2.5O(1#[KW1X]W?SN^SL-F=^[>VW\'JW=&:K/G#\G?A-\:,9B.W]
MX;IS'>.:^&F.[-S??W8.ZMM=;_'/?FY>K,.<?U['2;7Q]'2[KJ\IDJR9LB</
MBZ&3*2^Z]T+6Q?YK7<O>.=[)BZ;^'?\ =W9/4^U\1@>S<]\A.XZ#JKM/K7O_
M '=\-:CY=;?V+E?C[+LVMSF\=G[;2OQ&U\]6XG/'-_Q*MJ:O'8JNQ6/J:\>Z
M]T7CIO\ G:=L1]$=#[][:^/VU=VO@/C%_+K[[^;78>T.RLCM>/9%-_,BWLNQ
M.C9>ANK\AUGD:WMG*TRJ<SN;#R9;#PX2-CC,=D<]7(IG]U[I2;D_G8=[;>Z)
MC^1E9\"J>AZAS7R&^3'3VW>SI>]]^[FZUV[LKXM[JWQU]NKM;Y ;AZW^*N^-
MQ_'O!;\[$V)6XK"561PF0VWCTIZBNW!FL-1I3R5?NO=7][6W%C-W[8VYNS"9
M#$Y;#;HP.(W%B<I@,O0[@P62QF:Q]/DJ#(87/XR27&YS$UE+4I)35E.S05,+
M+)&2C ^_=>Z?O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\7_"J;_MQ
MS\N_^U_\;O\ X)OJ'W[KW5SOQ-_[)8^-'_BO_37_ +[K;GOW7NC >_=>Z][]
MU[K_U-_CW[KW7O?NO=43?\*8O^W'GSP_\-KIG_X)/IKW[KW5E_P3_P"R(?AO
M_P"*J_'G_P!]'M#W[KW1JO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(
M/M#J_KSNOKW=W5';.SL#V#UMOW"U6W=Y[*W/0QY/;^Y<'6A15XO+4$W[=51S
MZ1J0\&WOW7N@N[+^(?QA[DRVYL[VIT5UKO[,[SZOV_TINO)[GVS0Y2LS_4NU
M-[MV5MOKS)SSH7JMJX3?SG+TU(W[<5>?*!JY]^Z]T@=X?R\?@_V!F,)GMZ_%
MWI[<N4V_OS?_ &90S97:='40U6]>T]\T?9_8N6SU$;4.Z8-X]E8VEW#7463B
MJZ";.4E/7&'[J"*5/=>Z17R6_EM_&OY??(?J?OCY%[3Q?;.+ZEZC[*ZIQ73^
M]\#A=P];Y<=D;VZOWK4[JR]!D*66IGRV)FZQBHD@U&CJZ&OJ8:F.6-RA]U[H
M:MY_#?XL=A[$[=ZSWOT-UMN78O?/8#=L]O;<R>W:6:DWSVG_  _:^+@[)RDJ
MZ*R'?N.H]DX<4>7II(,A0OC*:2GECDA1A[KW2"R?\N7X)YG;M!M+(_%'I*?;
M.(ZCV]T1A,$FR,738S ]1[4[#H>V]O[(V_2TL<,6!QF.[1Q=)N(/1B"IDS5'
M3UDDC5$$4B>Z]UP^)'PNP/Q=W?\ *'M?(;^S?;?=?R\[G/;G;W9&<VWM+9WD
MHMO[>Q^QNJ^NMN[8V3C,9A\=M/K'86)AHH)ZC[S*Y.NFK*^NJIIJHK'[KW4K
M<G\N_P"#F\,QM//;G^+?3F;RFR-W;TWUM^:OVC130Q[H[#[#';N\Z_+T7%#N
M:#.]KJFYI*3)Q5E&FX(HLA'$E7%',ONO=+;NSX;_ !9^1^[MC;\[VZ'ZW[4W
M?UPI@VCG-X[=I<K5T6-.9Q>Y?X!D5DTT^Y-K)N?!T.47$Y-*S&)E**GK%@%3
M!%*ONO=)P? CX7+O?OGLA/C)T['OKY/[+W1UUW]N:+9F+BR7:6R=]4T=)O[;
MFYY(XECFQ_84<$+;A$2Q-GIJ:"6O:HE@A>/W7NF_LO\ EY_!_N3;N0VEVC\7
M.F]\;=RW9=-W#DL5G]G8^K@KNRJ?8^VNL9-U5+Z4GEK,GUML[&;?R$1;[;)8
M2C2AJXYJ4M$WNO=+;)_#SXO9C-8W<>0Z,Z[ESN'[<QW>^*RT6!@I*[']MXOK
M7#=-4F]J2>C,#PY'_1-MV@VW+&+4M1A:.*DEB>!%0>Z]T%N-_EF_ '#=3[GZ
M,Q7Q'Z0Q_4V\-_X7M+/;(I-ET$&*GW_M@TJ[3W/02(!78.OV=244=)AEH9J:
M+#X]?M*-(*4M"?=>Z7^3^$/Q$S'1&UOC!DOCIU-5?'C8V8I]P;,Z:.T,9'U]
MM7-T>8RNX*#*;>VY#%'08BMQN=S=564LD"HU-4RF2+0X4CW7N@(SW\LWHW(]
MD_"+);;%%UU\?/@/E=S[^Z4^+>PMC[+PFP9.Z<QB<Y@<#V?N#=)Q=1O:23:5
M%NS+5T>-I*JEARFX:M,IDI*R>$*WNO=&5[J^)7QI^1F4QV;[SZ4V!VAE\5LK
M??6]'D=V8.'(58Z^[.HZ.AW_ +(JIKQMD-J[J@QU.:N@J/+3/+!'*$$J*X]U
M[I-=M_!KXA=\8CL'!=P?'GK+?^-[5WUM3L[?\>?V_%-4[C[$V/L7'=7[5WK4
M9"%X,C2;EP_6N*AV\E732PS/@S)0R,]+--%)[KW6;OOX0_$;Y0]:;*Z;[^^/
M76'9_5G6U5BZSKW8FX=MTR[<V/483"3;:P[[3Q^.-#'M],9MZH>B@2E\214I
M\:@+8>_=>Z1&X?Y:OP"W7U#U5T%N'X@=!93IGI#*UN9ZHZXGZZP"[7V1D,O5
M2UNY7Q%!#2Q TV]:JHD?<-/,9:?<)E?^))5!VO[KW4_>7\NOX,=A=B;X[9WM
M\5NEMS=D=E8O/X7?6\,MLO&U.8W-C-V[ J>J]X4V1E*"-O[Y=;U/\$S#HJ29
M;&PP05;3)34XB]U[IX[.^!7PQ[HW=L#?O:OQGZ@WYO/JW;&%V5L#<NXMGXVM
MRVV=I[8SU!NG:N H:HQJ\F-VCN7&QY##QS>08FL:6:D\,D\[2>Z]TIN^OA[\
M6OE'E.O,W\BN@^KNYLMU3F7SW7U?V#M+%[BJ-MULU1CZRKIJ=ZV%_N\%D:[$
M4515XRI\V-JZFAI9IH))::!X_=>Z7>W>C.GMI8_MG$[:ZXVEA<9WMN[<N_>Y
M*&@Q%/#3=E;SWEMS#;1W5N7=T04KF,MG]L;=H:"JEEN9::EC0\*/?NO=%<ZU
M_E9?RZ>GMB]H=:=9_#3H+:&Q^ZJ;#4';& QFP\6T&_L7MW(TV7P&%W)55:U.
M0K\#A,M21U5)0&84=/4@RQQ*[,Q]U[H2.PO@I\/.UNM]Q]0]A_'3JW=77&[.
MV=T=[Y[:V2VW3BCK.YM[Y?+9S>79T533&#(X_>NZJ_<&0_B-?330SUE/D*JG
ME9Z>IGB?W7NL\/P:^'=-W5L[Y%TGQIZ:HN[>O=FX[8&R>Q*+8N#HL[MG:6&V
M_5;1P>*Q(I:6&AIGV_LZOJ,+CJD0_=X_#54]!3RQ4D\L+^Z]TD</_+>^!V R
M?0V:Q'Q0Z5HLK\7Y*N3X_P!<NS,?+/U6E3NW);]I:7:S3B44^.V]OC+U&9PM
M+():; Y23[K')2SJKCW7NG#>_P#+V^$G9'7VR^JM\?&3J7<77G7FY]_[OV5M
M2MVU F,V]F^V<YF]R=KM1"F>"H.)[3S.Y:^7<V-D=\=N!:N2.O@J(FT>_=>Z
M-WC<;CL-CL?A\/CZ+$XC$T5+C<7B\;2P4..QN.H8(Z6AQ^/H:6.*FHZ*CIHE
MCBBC58XXU"J  ![]U[J;[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7B
M_P"%4W_;CGY=_P#:_P#C=_\ !-]0^_=>ZN=^)O\ V2Q\:/\ Q7_IK_WW6W/?
MNO=& ]^Z]U[W[KW7_]7?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]
MU9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";
MZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_];?X]^Z]U[W
M[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0
M]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^
MZVY[]U[HP'OW7NO>_=>Z_]??X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:
M]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_
M .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]#?X]^Z
M]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\
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M:*LIZ;,-$V"JGK:?W7NF?L3^;=W-U;MS=]=VAT/M3%=M=*4>=WSN3JSI[O?
M]B=5]H[-W;\,^V/DKT[@/]+^=ZAQ>=V_N67+=?38C*)3XFC@IZB*ERE-5Y/$
MUA@]^Z]TJ-S?S$_F+MWO?';$SG1O4=)/TKM[YR5'R$ZIV1VU6;DJ>T,YT_\
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M@=7;RH.L/E5#W/L3K/YG]/=3=K9GMO<6U>W?X7V73_%/>F?SN\]F=L_)7O\
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MG7._YNK_ )4XRLZ9Q6>VS\5NK<'\=-I;/Z.P_8TC]']O]#[VW#14T>X<QMG
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUXO\
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M>/5F0Q_Q5J=G==_*_P";_P 6L)U;1S[VH_DMB,-\8/B!FOE)M/Y,[NH*K?\
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M5@L/C<KN%\?)G\GC\914>0SDF)H8\7BY,Q6TT$=3DWQN-A2GIS,SF&!!&ED
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MYEHO*_A9-1O[KW2=K>D>E\D< <CU%UA7G:L6<@VN:W8.U*H[;AW-DH,SN2'
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MK6;K^YGIL&<5#0&.OC]U[J%UCV'_ #),%WE\6=E];U?S(K=IX/'?R^=F=.;
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M7NO>_=>Z_]#?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\
MLB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<
M[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]'?X]^Z]U[W[KW5$W_"
MF+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6
MO%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[H
MP'OW7NO>_=>Z_]+?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\
M$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^
MZ]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]/?X]^Z]U[W[KW5
M$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]
MT:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[
M]U[HP'OW7NO>_=>Z_]3?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]
MU9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";
MZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]7?X]^Z]U[W
M[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0
M]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^
MZVY[]U[HP'OW7NO>_=>Z_];?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:
M]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_
M .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]??X]^Z
M]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\
M?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU
M_P"^ZVY[]U[HP'OW7NO>_=>Z_]#?X]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^
M"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?
M_&[_ .";ZA]^Z]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]'?
MX]^Z]U[W[KW5$W_"F+_MQY\\/_#:Z9_^"3Z:]^Z]U9?\$_\ LB'X;_\ BJOQ
MY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^Z]U<[\3?^R6/C1_X
MK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]+?X]^Z]T!/?7==5TEB-AU^.ZXW5VGE
MM^]EX+KG&;4V;DMI8O/-)E,1N'<-?E:63>V?VQ@:PXK";8JI12M6P2U4@6*(
MZV ]^Z]U1W_PH![SV%W?_(K_ )AE5L]MS8W+[2Q?1N%WOLS?.SMS[!WQLG/5
MW?O1V:@PVY-L;LQ>*R%//)CJZ.6*HA$]#51G73SS1V<^Z]U<A\$_^R(?AO\
M^*J_'G_WT>T/?NO=&J]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UKQ?\ "J;_ +<<_+O_ +7_ ,;O_@F^H??NO=7._$W_
M +)8^-'_ (K_ --?^^ZVY[]U[HP'OW7NO>_=>Z__T]_CW[KW15/EOA7S.S^N
M_N.^$^.NW,3W#M+-;O[ BWW@^N\O-@:#%;E^WVY@,_N7%YC 5&3R^Y)<>7H*
MR%J>OHXIX9 R,T;^Z]U1Q_/)W9N'<O\ (@_F-4>9^0_3OR7H=O4O1^/P?8'5
M])@L;GEHJCY!=*UTF,[0QVTMS;AV:F[('G#1U&+BQ--54C(_V$#7+^Z]U>1\
M$_\ LB'X;_\ BJOQY_\ ?1[0]^Z]T:KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O%_PJF_[<<_+O_M?_&[_ .";ZA]^
MZ]U<[\3?^R6/C1_XK_TU_P"^ZVY[]U[HP'OW7NO>_=>Z_]3?X]^Z]T6?Y3Y;
MIO';(V=0]Q]44W=L6X>VNOL1UEUM)M;:VZ:_.=PT^3FW#L6KPB[WK<1M+;V7
MV[-@I\FF5KZ^@AH8J.1Q.'*1R>Z]U07_ #S]][8SW\F;^:OLC$=7X_I#<.P,
M;\8&W7U2VR]H8'<F(FW9W;T]E<3N3,;LZWWGO/KW?F+W114Y&/FHI::LH!1S
M4]9"'"$^Z]U?%\$_^R(?AO\ ^*J_'G_WT>T/?NO=&J]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKQ?\ "J;_ +<<_+O_
M +7_ ,;O_@F^H??NO=7._$W_ +)8^-'_ (K_ --?^^ZVY[]U[HP'OW7NO>_=
M>Z__U=_CW[KW12OFEO?9&R^FHH.P^M=E]G;7WQOK9NP:K'=HY2@VWU'MJJS^
M2:7';U[3WEDL)N6'96T]O5V/1H\BE!55*Y62BA@59IXY$]U[K73_ )MVX]C5
MG\CO^:]LWK[9O7.T\+L>H^-T%=/T/N';G8/06XL[G>YND<GD<IL_M'';%V/N
MK=.]X81!3[EHLZ*^JQ#Q420U!IIHT7W7NMC?X)_]D0_#?_Q57X\_^^CVA[]U
M[HU7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NM>+_ (53?]N.?EW_ -K_ .-W_P $WU#[]U[JYWXF_P#9+'QH_P#%?^FO
M_?=;<]^Z]T8#W[KW7O?NO=?_UM_CW[KW0,=[[WWQL/8T63V!T;N#Y!YK+;FV
MWM2JV%M_<&R]M/3X7<^2CQ.5W5FLCOK)XS$G:^V8*C[C)1PBJK&I YAIIBI3
MW[KW6O[_ #WJS>61_D>?S)ZO>O3&1Z)KH\3\?*#&[&;M?;?8FW_X12=_=.R0
MY;;N!VA5/M_8<=;5U4Z5,,=/3RU\T7GDU^DCW7NKO_@G_P!D0_#?_P 55^//
M_OH]H>_=>Z-5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K7B_X53?]N.?EW_VO_C=_P#!-]0^_=>ZN=^)O_9+'QH_\5_Z
M:_\ ?=;<]^Z]T8#W[KW7O?NO=?_7W^/?NO=%I^5'Q]J?DGUWB-A0[LQFUX,;
MOC ;QKH-Q;2J=][2W138*GRD<6W=U;2I=V[)DS&,3(5\&1IPU>B09/'TL[1R
MB+QM[KW5"'\ZSXUUOQD_D _/[:&4W9MK?^8R6 ^/U7FNP*'8F6VOOK?F8QG>
M?16%R&\.VMT;B[$[)W#V1OS/U%$9Y\E4UD"0QLM/!3Q01(H]U[J]OX)_]D0_
M#?\ \55^//\ [Z/:'OW7NC5>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZUXO^%4W_ &XY^7?_ &O_ (W?_!-]0^_=>ZN=
M^)O_ &2Q\:/_ !7_ *:_]]UMSW[KW1@/?NO=>]^Z]U__T-_CW[KW7O?NO=43
M?\*8O^W'GSP_\-KIG_X)/IKW[KW5E_P3_P"R(?AO_P"*J_'G_P!]'M#W[KW1
MJO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:\7_"J;_MQS\N_^U_\;O\ X)OJ'W[KW5SOQ-_[)8^-'_BO_37_ +[K;GOW
M7NC >_=>Z][]U[K_T=_CW[KW0']\]293NC;FU=HT^]-R[.V[3[_V]N#?T.T=
MT;OV-GMX;,Q$&3>KV?1[TV#G=M;RVS]YF9J&K:>@KJ=Y5HOMY"T$TJ-[KW6M
MU_/=VKVSU'_*G_F>]<=J=S9SNK#[FZJ^-VX>E<OG*-J;<F Z_P"O?DATCM?.
MT/9D\-?#M[.=C9+<6[HF?,8C%XZ++T-+%)6PI6QO+4^Z]UL%_!/_ +(A^&__
M (JK\>?_ 'T>T/?NO=&J]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UKQ?\*IO^W'/R[_[7_QN_P#@F^H??NO=7._$W_LE
MCXT?^*_]-?\ ONMN>_=>Z,![]U[KWOW7NO_2W^/?NO=$B^?>X\WMCI3 5V#[
MKVUT;45?;77>)ES>Y.TJ3IH[N;)9"JI\3L#!;]J-L[NJ*;.YS<9HJA,724,E
M7N.GHIL/&\7WYE3W7NM;/^97F=U;V_D4_P U?=.]^Z-L=Z9_;-9T5UCDMR8O
M?=1V978WL';G?/18[IRF(RV4VWM_(]:[$[+WG%397%[#IPV.VW# J0K'K\<?
MNO=;/_P3_P"R(?AO_P"*J_'G_P!]'M#W[KW1JO?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\7_"J;_MQS\N_^U_\;O\
MX)OJ'W[KW5SOQ-_[)8^-'_BO_37_ +[K;GOW7NC >_=>Z][]U[K_T]_CW[KW
M16?E_NS(;1ZF6I7H;<7R,VOEMP1X7?W7&T=N5&[-T3;9J-N[DK,?D\%@Z2:.
MLEK8=\4&'IS50K+)C(JIZU5O3:E]U[K6_P#YJ]+V+MW^05_,RV7O9,1GJ"E;
MH[?])V+A]R9S='\7WMVK\D.K-U=M=:YO+[CW5O3,93<72&^O/@I*V?(&:HHA
M2K/#%4Q3ZO=>ZV//@G_V1#\-_P#Q57X\_P#OH]H>_=>Z-5[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7B_X53?\ ;CGY
M=_\ :_\ C=_\$WU#[]U[JYWXF_\ 9+'QH_\ %?\ IK_WW6W/?NO=& ]^Z]U[
MW[KW7__4W^/?NO=$<^?U._\ H9VUDZ#.?(';.Y<7VMM&GV?N'XV]6X_M_?\
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M?;6\,-']UB=JY'.4NX<E \;TU'(LL9;W7N@>J_YL_P 5.K^ML'OSY0]J=/\
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M3N6@1H8E9Y#.YI_=>Z+94_R./G/!B^M.U*C??QOW?W]LOY'?S*>R]S;"V_\
M(CYF_&/JO=FT/G]E-L;NH,GB.Z?CWC\'W;M',==[UVI"N5VPU%DL1NG;U1)C
MZC(Q-''4'W7NA$[._DM_,39'6W9?5?Q%S_PZIMG_ ">_E:=:?R_^\,'VWFOD
M#18OI?=_5N*WY1T^\_C=/58[NG>&?ZXW9%V=EX%Q.Z<R,I@ZZ.CR?WV2$1QG
MOW7NK*/D9\/?F%N#^7E\7_C-\:>YMM]<]N])K\4<9VJ8^Q.R.J\!W9UMTQA<
M%A^V.GL+\@NMMI93NOI"+L,8M9*+>&W,5'N&C%,B(M.*F9H_=>ZKP^)'\E;Y
M.=';K^,V<WUO'H:NHNF?YK7RI^>FZ:#";_[HWW+5=;_(+H,;)VYMK!;E[4VE
MDM][N[%V9V#*T=15[FRU14UV.@3)3Y:HKY9*8>Z]T\=7?RG?GC\<,MT/VUTK
MNOX@[J[=ZVW=_,MV9NW:/;><[<_T7UO2'SJ[X3NS9.]ML9;;O7$^;INUNL\G
MB**+-8&7%QXO/X^>>@BR]'XDK9O=>Z,UU!_*V[;VA_(=KOY4^ZNP.O8.Y*[X
MR=Q=+GL+ 5&Y<UUK%NG?>X-\Y[;^1^YR6WL!NA]NH^X:6.L/\-6HIT\OBBGT
M)Y/=>Z*]V%_*M_F&97&]]3[!W%\,:+-?S!_@#TO\(/F51;^W9W1NC&]"Y7J3
M9VY^H9NVOBSDJ/JS&U79N#W)U?OO*5G]TMR4VT_MMT0T<[Y>J@$RGW7NCE_.
MG^6WV]VQ\'OA%\6_BYOKKN+>'PK[P^&'8NU]U?(J?<]1MS=& ^)&.BH*0[MI
M-F83-Y/<&7W&<=2R5-)_DD%47F!JH3I8^Z]T0K??\EWYA=E[IK_E_O#=W2%-
M\N\[\\<]\J,WT3U;\D/E5T-T#%UADOCAC/B]C]A;8^5'3FT-H?)+:7:]'M7#
MQ;@JMUXW;M'!DJ^67%U% :!Y)I?=>ZLIZ3_EXY[JG^4_FO@C+M#XO5W8&[.K
M^V:+=&SLO1_(7L;XF5_97;FX=T;TW%CJBG[#[;R7R'K]@5>Y-RR&6N_O-39F
M.I9\C21TDGBHX_=>Z(+L_P#E1_S J[J+=NP^Q>W.L(L!%\MOY=/>O1_16X_D
M_P#)/Y4;-Z-VY\3.Q-M;R[VFV[\A.]NJ,;WGF:;MNGPBQ[:V3DH*S#[8BI(H
M5RK-4U%0GNO=5S=A]8?(.K^:G3OPKZUV5G^Q-A[5_P"%#>V?YEF8J\E\8/E-
MU_VYL_8M;V5N_L;M7=N^^T-Y=9#XIY'I?857E:^FP>[\)OO+9C?E+7XVEI\9
M0,M0)/=>ZL-ZW_D@=\XSIS^7OU!OOL7J2FI/C=VS_-&W%WGN#8VX=Y_QG*;+
M^=NTOD1L[8>1ZQGRG75 ,WO/:M#VUC),M3988JCC^TFCAJ*M8XS-[KW0-=9?
M\)\>[\Q\=.]>A.[-S](;0W#DOY>VW_@9TUWQL?OSYL_(3?N;HMK]C;8[$AW%
MN?9?R"WA1=2= =.[CR/66VY*CK?8V%K*3%ULN2DQV5@II8Z1O=>ZLU^$7P\^
M<.T?GGW=\W?F*_Q,PE9VI\3.COCQB]B_%_<W:6XZ+#YGJ3=>YLQDLSDZWL;K
M38+9#'[@3,FJI9$5)L?%,F,,4Z40R-9[KW18,]_*)^6![$[IZ4VQV/\ 'C_9
M'_D5_-'VM_-&[![)SC=AI\O-J;EHM^[([8W?T3LG:N+VW'UO6T>6WKUEB*##
M;UJ]RPU^%V_/50RXFO>.G4>Z]T^[ _E(_(S;;?#VKR^[>BUK^BOYN_RE_F"=
MCG#YO>\L>8ZN[ORW<]=M;;^UYJGKVCGR?8V/I-^XR&NIJT4..A6"415U0(8O
M-[KW1V^SO@EOGLG^:/MGYF5VX-H4_2V/_EU]M?#[)8>#)YNF[9Q^_P#L;N#!
M;RAW5MBF&VJC;=+A(=G4]93/7-E(ZZ*K9$6DEB=Y$]U[JK[X+_R&NP.HH#U'
M\K)>G=_=-;(^'/R(^&VT>R-D_(?YN;X[3[#VA\@LU/A\]EH>DNV]\_[+?\5=
MN5/5T=*N3VSM2BW+#5;KA&3I:^C6-8G]U[I.[<_D(_)*N^!&_NO^X/D%L#L7
MY\[F^5?QO^1M5W'3;@[-V7L;L7;'PFVWM;JCXS],[S[#V!A=G=Q[-Q/^B3:D
MDU9GL'!)G-O[GS5374,M9)!'--[KW0U]!?R@._MA=T_"SNK<T'QVVA+U/\ZO
MEU\P/D#LW:W=ORS[\K\W'W1\=:/HGJ:IQ_;WRBEWMV!W)W)A(-O8R;<^>KQL
MG'5KQ_<4^/-1"#4>Z]TZ[7_E5?+VD^6V_P#/4.^.F_C[\2^T.Q?E?N#NK;GQ
MT[R^3U9B_D-L/Y$;)K=N8;'YCX6]OXW>7070'>^,SV0;*Y_L/8^[(9,Q/ /%
MB:<5,ZCW7NG#^5#_ "D>[/A7W#L3?'>Z=(9^#X_?%.7XK=1]C['^1/S<[?['
MWUC:G?-#ELCN/)=>][[SAZ)^-W7V5VIM?#NVP-H8?,45'N3[JKH\K3TI6DD]
MU[I4=J_RYOFCD?YA<_R.^/\ O'H[X]=;;J^171O;G9W8_5_=/R;VIO+M?K'K
M_:L.WNR>K>]_A5E\;V!\2.[.Q]ZTE+'C<3V-#DMIY?#8_3.U'/5P1LWNO=!/
MLK^5=\Y^@MZ=+=W=#[B^(>;[/ZX[0_F?87-;![>W!V_4]92]"_/?OY^[MA[H
MV_N3!=>5.X(NV.JJ[%T$&:PTV*&-W%0S5%#'F*/QI6S>Z]T3'%?\)X?E;L3J
M#XRXW![Q^/O:/8NR_P"7IVE_+Q[NV'NCY'?,_P"/W3%;M/>/R&[$[LP78-)N
M3XO4VQ>R.]MIU^/[&J\7NCK;=4>(V]FHHH#]VLD*3>_=>ZVS.E.L<+TGTWU+
MTUMNEH:+;O4O6FQ.L\#18PYHXRCPVQ-KXO:^+I<=_>3-[EW#_#Z>BQ:)"*[(
MU]8(E435,\FJ5O=>Z$WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\7_"J;_MQS\N_^
MU_\ &[_X)OJ'W[KW5SOQ-_[)8^-'_BO_ $U_[[K;GOW7NC >_=>Z][]U[K__
MTM_CW[KW7O?NO=43?\*8O^W'GSP_\-KIG_X)/IKW[KW5E_P3_P"R(?AO_P"*
MJ_'G_P!]'M#W[KW1JO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=:\7_"J;_MQS\N_^U_\;O\ X)OJ'W[KW5SOQ-_[)8^-
M'_BO_37_ +[K;GOW7NC >_=>Z][]U[K_T]_CW[KW7O?NO=4A?\*0=M9_=?\
M)+^>^+VWB:[-9&EZ^Z_W+44>/A:>>' ;,[OZPWANO+2(O*T. VO@JROJ7^D=
M-32.>%]^Z]T8/^6Y\POBQV)\ OAQN7:?R#Z?K\9%\;NF=MUZS]A;6QV0P^YM
MI]>;<V[NG;6;Q>1RE+D,1G]N9W'STE925$4<T,T9!6UB?=>Z.O\ [,3\?O\
MG^G3G_HSMD__ %[]^Z]U[_9B?C]_S_3IS_T9VR?_ *]^_=>Z]_LQ/Q^_Y_IT
MY_Z,[9/_ ->_?NO=>_V8GX_?\_TZ<_\ 1G;)_P#KW[]U[KW^S$_'[_G^G3G_
M *,[9/\ ]>_?NO=>_P!F)^/W_/\ 3IS_ -&=LG_Z]^_=>Z]_LQ/Q^_Y_ITY_
MZ,[9/_U[]^Z]U[_9B?C]_P _TZ<_]&=LG_Z]^_=>Z]_LQ/Q^_P"?Z=.?^C.V
M3_\ 7OW[KW7O]F)^/W_/].G/_1G;)_\ KW[]U[KW^S$_'[_G^G3G_HSMD_\
MU[]^Z]U[_9B?C]_S_3IS_P!&=LG_ .O?OW7NO?[,3\?O^?Z=.?\ HSMD_P#U
M[]^Z]U[_ &8GX_?\_P!.G/\ T9VR?_KW[]U[KW^S$_'[_G^G3G_HSMD__7OW
M[KW7O]F)^/W_ #_3IS_T9VR?_KW[]U[KW^S$_'[_ )_ITY_Z,[9/_P!>_?NO
M=>_V8GX_?\_TZ<_]&=LG_P"O?OW7NO?[,3\?O^?Z=.?^C.V3_P#7OW[KW7O]
MF)^/W_/].G/_ $9VR?\ Z]^_=>Z]_LQ/Q^_Y_ITY_P"C.V3_ /7OW[KW7O\
M9B?C]_S_ $Z<_P#1G;)_^O?OW7NO?[,3\?O^?Z=.?^C.V3_]>_?NO=>_V8GX
M_?\ /].G/_1G;)_^O?OW7NO?[,3\?O\ G^G3G_HSMD__ %[]^Z]U[_9B?C]_
MS_3IS_T9VR?_ *]^_=>Z]_LQ/Q^_Y_ITY_Z,[9/_ ->_?NO=>_V8GX_?\_TZ
M<_\ 1G;)_P#KW[]U[KW^S$_'[_G^G3G_ *,[9/\ ]>_?NO=>_P!F)^/W_/\
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M[KW_ $"D_P D3_O&+>G_ *47W_\ _;%]^Z]U[_H%)_DB?]XQ;T_]*+[_ /\
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M7NO?] I/\D3_ +QBWI_Z47W_ /\ VQ??NO=>_P"@4G^2)_WC%O3_ -*+[_\
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M7W[KW7O^@4G^2)_WC%O3_P!*+[__ /MB^_=>Z]_T"D_R1/\ O&+>G_I1??\
M_P#;%]^Z]U[_ *!2?Y(G_>,6]/\ THOO_P#^V+[]U[KW_0*3_)$_[QBWI_Z4
M7W__ /;%]^Z]U[_H%)_DB?\ >,6]/_2B^_\ _P"V+[]U[KW_ $"D_P D3_O&
M+>G_ *47W_\ _;%]^Z]U[_H%)_DB?]XQ;T_]*+[_ /\ [8OOW7NO?] I/\D3
M_O&+>G_I1??_ /\ ;%]^Z]U[_H%)_DB?]XQ;T_\ 2B^__P#[8OOW7NO?] I/
M\D3_ +QBWI_Z47W_ /\ VQ??NO=>_P"@4G^2)_WC%O3_ -*+[_\ _MB^_=>Z
M]_T"D_R1/^\8MZ?^E%]__P#VQ??NO=>_Z!2?Y(G_ 'C%O3_THOO_ /\ MB^_
M=>Z]_P! I/\ )$_[QBWI_P"E%]__ /VQ??NO=>_Z!2?Y(G_>,6]/_2B^_P#_
M .V+[]U[KW_0*3_)$_[QBWI_Z47W_P#_ &Q??NO=>_Z!2?Y(G_>,6]/_ $HO
MO_\ ^V+[]U[KW_0*3_)$_P"\8MZ?^E%]_P#_ -L7W[KW7O\ H%)_DB?]XQ;T
M_P#2B^__ /[8OOW7NO?] I/\D3_O&+>G_I1??_\ ]L7W[KW7O^@4G^2)_P!X
MQ;T_]*+[_P#_ +8OOW7NO?\ 0*3_ "1/^\8MZ?\ I1??_P#]L7W[KW7O^@4G
M^2)_WC%O3_THOO\ _P#MB^_=>Z]_T"D_R1/^\8MZ?^E%]_\ _P!L7W[KW7O^
M@4G^2)_WC%O3_P!*+[__ /MB^_=>Z]_T"D_R1/\ O&+>G_I1??\ _P#;%]^Z
M]U[_ *!2?Y(G_>,6]/\ THOO_P#^V+[]U[KW_0*3_)$_[QBWI_Z47W__ /;%
M]^Z]U[_H%)_DB?\ >,6]/_2B^_\ _P"V+[]U[KW_ $"D_P D3_O&+>G_ *47
MW_\ _;%]^Z]U[_H%)_DB?]XQ;T_]*+[_ /\ [8OOW7NO?] I/\D3_O&+>G_I
M1??_ /\ ;%]^Z]U[_H%)_DB?]XQ;T_\ 2B^__P#[8OOW7NO?] I/\D3_ +QB
MWI_Z47W_ /\ VQ??NO=>_P"@4G^2)_WC%O3_ -*+[_\ _MB^_=>Z]_T"D_R1
M/^\8MZ?^E%]__P#VQ??NO=>_Z!2?Y(G_ 'C%O3_THOO_ /\ MB^_=>Z]_P!
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..^Z]U[W[KW7O?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g150774g13k66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g13k66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %SZ^65 X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ,S   '90         !
M                  $             !V4   ,S
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ,S     %)G:'1L;VYG   '
M90    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #,P    !29VAT;&]N9P  !V4    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     #.$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MN(;D,/;GW;%?80
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4['D\\W7K(WB_P!$_C^7QZ&0'^#C''@&Z_YWAV=7531\]S](^X4['D\\W/K
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M=M5+/DCS1WV#5+)$KG!?4-*4A.B7:BP32P1XCG8XTDQ7O6[ZK*W-F76Q /1
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M#;CQ^H$\ :^&UW*1VHW<N-Q\?QC(@H+S;#-,FPZ^J;:TH1[(QF*C4I-AE],
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M2#P4V87 92P)1P"0&0JP!(O4'C22VM;VVXD7!()! (# D"X-QMPKZX=MG@^
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M"+P[UX[@8_F]S9;G&1BVA+;0R$;:;?=]5:Q ]]@;[8<GB;_O@';PW^RM^^Q
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MK\@K,5CX<$[R>4#AK9><OA5%0:+FIW<U4<O?SN[=!_WO8?\ 35/_ .0]OO\
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M_LHWZ9TNG=;TA[%+2=J>!]=.BO\ Y]3^RC?IG2Z=UO2'L5BTG>3P/KIT5_\
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M:\?[*FYW^47.?^5E[[_JO]*>5/\ G-RA_P"^LQ_]15WZ)<D_\U^3O_<N7?\
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MS!8#DMF[6:4*??>2#6L>5#,0XU9F"!)C2<E74 RX\&9U&76QIKT$/C+BX_\
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MG_B]RJW^=F7^7_%.=;7\EO-V6WKO.;<5%835!V5I75Y=X<^LI!33AA";BRC
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M8_.,KP,QY59G((<9F&$PLIC;+<F59!'/-&[(65U#@:249;W4BN>7Q(S/@O\
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MPR<Y(JL)1*90J@L&01*UUN "I*Z^DNI0UZX[&1F:1%$<[%4+*T>@)<FQ!+L
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M6X'S'[*_S<,S_NPRK_C'=_\ I,G7Z0X4_N;#_P A#_Y:^JO,O:0"+EB;6O\
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M874$6 OK;5Q-OBB$_I#7*O\ \JVP*+\O;6X?=_\ P[\?'OU?_9\Y)_Y(S_\
M89;_ /4:K/N;YQU8S+_VN*'_ /K'CPKNC\'/R6,]Y(&P!NU&XM[B>17Y&X61
MY:RPPTFW*J$K[BMQ\,8=TMU44AO7(I:DATS4"6%&20JR:1RO:SX3[H_*O \L
M>4,>;9=A\7AL,N6X;!F/&K"DW.PS8F1F"P33IH*S+I.L&X8%0+$_1>2V3XG(
M\L;!8J2&65L5+.&@:1DT2)$H!,B1L6!C)/1MN-[WKST:*OPHFY+D[T9R$MH&
MO5._F.DW[WE<QKN[N5[6.5$5>]&*J)P15UTX_P!ST_ZW(//\#'Y>J_9V[US@
M_MINSF%'T\XQ^PBM_-:=;%-*4TI32E-*4TI32E-*4TI32E-*4TI7,3X7C_87
MY-_QYV__ /3::Z=R[_O<Q/\ +X3_ ,]*^!?E*?\ %9F?_:>3?_.5_)DOZ\/U
M77PL$>>P\.NP[""=B>)-@1U_FX/-]'^P_CZAT<^"A_V;VV/=_ VX??\ )_6'
MD'Z_Z^''CV[D-_?)A.KX'&=5O\'>U_Q])ZONGY.'_&SD>W^!9W]'^]6*&^QM
MOMU&OZ[-?=Z_2RHMWUZB^7LN?\K'U/\ @SV:Q]A_KJ/R_P";]]2,C5<QS4_O
MFJWC\B.14X\.[CP^34.SR$'P(/\ MK)%P1VBU?SGV_\ [GWH;:UL[63E.V\+
M[*P-L'Q,VM#<R)QA,I#HVN=F_%6L63FHJHG%&\>"<>[T9'^4#+''%'^BT;<W
M&B7_ #LPOH4+>WO#KM>V_P!/7\R/N<F[$9QL2;#WA<@$D@$^^Q<B_';?J'"H
M_P#][S8__OHKG_FL"_\ ;?4_]T)-_FJG_>Q_]!3^QRW^6?\ ] /J_=>U9CY/
M?P(E-L'O;MCO*+RAK3)9]N,NJ\I90S[="5L5JM;*LBA//CR\MXB3(JM2=HI'
M1K]5T+^'-7B.4'NWRY[DF:9,>3:889E@Y<(<1^<S*81,NGG!'[R4.5XZ=:7X
M!AO6YEW(0X#'X3&G->=]ZSI-S?O/F^<T&^G7[Z?3?A<*?,=[]N,MP?"L^KH:
MC.L/Q?-*D<N.P'J\MQ^IR.N@/BBF@B-A"N!#!HBXX""(8R61-F9%/-&UZ,E>
MCOB6#Q^.R^1ILOQN+P,S(8FEP>)FPTC1LRL8VDA=&*%E5BA)4LJDBX%N]SX;
M#8I!'B</!B$5@ZI/%',@< J&"R*P# ,P# 7LQ%[$UYCMN]O[.HJ*"RP7#K"B
MQ^8<BAI3L8I"ZBD($7B+/45I ,@=;,,O>/*%#"^%>^-S=2CS+,8IIL3%C\;%
MB,2K+B)X\5.DTZO\=9I5D#RJWR@[,&Z[U%\'@Y(XX7PN&>&$@Q1/!$T<17@8
MT*%4(ZBH%NJIF;'J AEQ'/1T\\>0CM#OV35@4C+P1@C@&"W#7P.;9CM <X)L
M!J3Q-$<X9&I"JLU0N)Q"& K/,IPS%\,5E<'#N7$A> AAS3&0!RT>DZP&OJ%Z
MM,,+"4-%&PF73,#&I$JZ=&F4$?"+HZ-GN-/1M;:I2*&&"*.&"**&&&-L4444
M;8XHHF-1K(XXV(UK(V-:C6L:B-:U$1$1$1-5,2Q+,2S,2S,QN2QW+$G<DG<D
M[FI@         6  V  &P ' 5Y5K*UUC%;NKP5MH0IZV&T40=;&*N)G')) B
M-6/K,81!(@I$XK)4@EG&'EDC=)#&YLN<DYHP\X_,LZRM#K;FFD165)#'?075
M7=5<C4JNP! 8@XT)K$FA><"E ^D:PC%69 UM05F525!L2JDBX%8]LMC]EKDT
M.RN-H-KK6QKXHH0#[+ ,3.-!AA)F-AB#**J99QHHC"""XHX9&-C)GFG8B2RO
M>[DXL^SR"-XH,YS:&*4DR1Q9CC(XY"R+&2Z),%<E%5"6!)154[ "M1\LRV1E
M>3+\$[I8([X2!F0!BP"LT9*V8EA8BS$GB2:N:;!<((O2\HGPW%9\FL*V2F/R
M*;'JB2]-IY8^AEJB[=X;K FMDA_:I 9B'BOC^H=$K>[6H,?CEPZ81<;BUPD<
MHGCPHQ,PP\<X;4)DA#\VDH;I"15#AMPUZN.%PIE:<X: SNAC>8PQF5HR+&-I
M"NMD(V*DE2-K55<'PI;JJR1</Q9<AHJ]:BDOEQ^I6ZIZI6=&M956G5.O5]>K
M/J%"$GA&YGU/1<.[3W_CN8FPOOW%^]L1+SV(P_OF;F)YKWYV:'7S<LM]^<=6
M:^]Z>]<-SL<WO>#GHDYN*7FH^=CCX:(Y-.M$MMI4A?)4X-6UP1-@8& $(7;D
MQ&6I0PL$!-F7 &-70%6$\4;)328:\(,&*<ETLL88@PK')!!$QFNTLCK$CR.Z
M0H8X49V98D9WE9(E)(C1I9))"J  N[N1J8DV+&B,[*B*TC!I&50&D8*J!G(
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MZ.$H9"P<<&-'Z6-5;THQ$,S$7BR1J]^N4R3E=GV-S?+L)B,6CP8C%1Q2J,-
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MOIM3MP/R%M["N?</U_"FF@]J^FGM4UBUSJ'5\5ON%J=N!]W[1;=__ =S_+P
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M ,!7/\?]H?R>'[6F@]J^FGM;?336O8W"_P 5O/V>;R;BG;@?D+?Q?P%=>/\
MT#Q>/30>U?33VJSK'8W7\ENHV[/QUVIVX'Y"V]A7/V_\P^U^?30>U?33VJ:A
MV-YM+7^SJZ_ZQ=VX'Y"V\''ZQ7/N'A^UX=9T'M3A?]\3VN/DXUC6.L,/.C>K
M\7IVX'Y"V]A77V_\P^U]SP:QH/:OII[5-8[&![-+=7&VUC3MP/R%M["NE_F
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M?CKW(+?*L>N]KVVO:J%8<_*;-^]Q=1OLTM]K;?3;A;CM6^7;@?D+?V%==_\
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MC@MHJ<.0=I0DLP\S6D-2>&5\#D<DBM6_#Y-EF#D$^%R_ 8>900LL&'PT<H#
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M_2P%N/DV->S;W=7%-S&&NQMUK&\.OH+QD%S5%5!)V-Y8*2;BV3 P%M;)+2Y
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MO#AV6%P_[PS\VG.2=XUC0G='UT[ I?-87H&?FTYQ^\:SH7L^L^NG8%+YK"]
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M&Y<W;90VFYN^Y)(V%S:YM8$U@, $U.09+!18&[$%K"ZFVP/$V^DU7#,]Q7<
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M6/FV-C-J/. !A/&L;!0$)4J%!4DMTKW!!L,O$S,6U ;);HWL8W+K?I;W)-P
M-NL==TX/MD#MCC#ZX>YNKLZUR=E_>&V-C8OKI[[(LW)R>\*I,=G/,J\8!+NK
MVQFCKJEK$; X=AI5@3 IDF&E,KW("@1NJ@ 7"K"44,U@7(50+MOQM86 R(]"
MVN6)<,22;$M)J-@20HN38#Z;G>O%<;7Y6=N%F^<@9E0A195MG6[=5U27A9Y[
MZ=*JPN[0>W+L8LVKTMUD,R6X28"$"H11NSHF&,D$)GL,"5!%'$8V(24RW#@7
M)" J!S9L+(MC<[WN"+ "C%V?4HU($ T$D6+$$G6+[L;@ 7L-Q7LQ#;U^W6W0
M=$5?'9!8U.)8[C1!ZSW0=,0/B]</3UQ57BI]]>UV.SD CP.M.RYF)8G)(80J
MN>R.*1E,L^K2J RLX "ZAK;40SA5+6).DMP%O+6- CBL239%4[FW1 %PI)"W
MXG?C7WN]OLF/W7I]RZS*Z6O'I-OLMP<.A-Q(VSE?-E5ECMS);DV\.75;'Q!6
M6)TJLK8JJ)\P:V8SK".8P4RN@LBB%HF1CJD20L' V0.ND HW$.VY) -C8V(,
MBA+APP%D90"I.[6-[ZAP(&UMQ<=A$3MIM3+M7MP!CAV3%Y*?CF&$8Q&=!VW2
MT9%:&I9 1"8<1DE]3AW",E2$VW&<TLUK48KH1^8-'.2833:P@0-('MLQ!-@0
M'"J=/8IV'545CYN,J6+60CK"V%[=&YL=]R#<_0+?+=#9XW=2RH'E9.'58L+B
M&=8G=4K,>G+N;0+<+'W8[;SU^0ID(@M/.,!T3P.FQZW:PELDD[9HY&PQ8BF$
M.NR78R1R*VH  Q.6 *Z26!X'I#:UN%'BYP+T@!H92--R0Z@$@ZA8CJV.]?O!
M]HGX1/FF6W>56>3YAEK6$79(;K/&\4>RKQ*@Q*M8)A$=Y:U#"XZK& 9B+4Z6
MPLI+ JR<(2!5S"U(1I@_-(J*D<9Z.RL_2D:0DR:5/%R+"PTA;W-R<"+2'8LS
M,RFX!(390HLERH-@+WON34WD>"7N29AM9EP&25=77X ^U.GIB\:*M"[J6]Q\
MJ@(;%;Q9+5PU<<()LCXD?3V3NM,9(]SHN,*Q61529"A8R:1JU !=+A_BZ3<W
M4"]Q8$\;FIZ"3&P(&FYMIN3=2O&XMQOP/ 5Y-K=K;' A#.W<J?D=E+D^X.1C
MOIQK[%*&-FXF6VF;6@AF+29?D539E 7-U80UEP2U#1JOJHC>$T9!1>9IA(1I
M32 D:'45=O@D6,6;0I ( ) V)OY!6(XRE[L6)9VVNJ]-BQNMR";G8\0-NV_P
MRC;ZZS=FS%I69+74,.W>35N;SB&XX1>2W<T>*W.,MKXBH<CI&54:UN2VKU(>
M+:.ZZ@$W1=",0,;D2+&V)!4MSH:,$/ITCG ]_BMJW1>L;7!O<$8*%Q$00NA@
MY!4F^Q%ATEM\8[D'ML.!\NW6R<.$Y-DN7&7[B+3([8>VGJ<0%ML$PMYD%;/6
M36]KB(N26X%_DUN/-%VU=6DLHY#JND?7U57+7+*1B2?6BH% "@@%[2/8D'2'
M*@J@-]*K8B[79KFLI$%9FU&[&Y"W1.%KE03=CUDG>PL!:O3E>W]SG=;M,15Y
M)6T$6#Y739N1"?CA-\^XDKJNQK8JZ*:#(Z%*MCQK<YTA3HK)W3(*]L",AEB)
MD)%C?$!D+<X'C!#A=-WU$D%&U?%%A<=?D(P4+K$0;:2K$6OJLI%N(VW/W;U
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M:A96=0R\ZY*+9+BT5U! LM]P++M]53(-[*;'18,>E8WXFYW(X[G>L*UG)[R
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M%5=PMCQ!-R>!)/'86O3#:3&]O<4P'"JK(NU0,6DZHPZP."D)4?LZXX.>P5L
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MHU>&'55556""Q.D<@X+)BIR3)B29HR%Y&7H%51 B* 3I4%CN2+DEF8DGB38
M6K*:4!!>[,Q9B=KM8#8<     .P<2=Y6)^-V^*ATUK;)!#(&$TAH&0G4-A&\
M=T4S6LL*:PKK,54EB:DK82HNFCY\$R/@DDC>8.LK,JD])R#I#@@DC@00=CM<
M;;$;V- 49%4GJ4&Q8;@#:ZV/UUBO:O9O;S:;+,IRF@R<=SLD2VC6N8VBK86P
MW.776:$S71-=".5E-J)9WA==3W%U),968]%!5Q+)+)8''62S33(J,A 72;V9
MC=(Q& NH'0I506539GNW4 ((D<;,P;B#M:VS,7)8@78W-@3P MUDG+,1..V=
M"94V-M%".=/;13H)>$TQR0$69DC7#V-6:#9!/?&YCXR RAYD8Y'1R(CN*UN&
M$@*J20J$='4-D4;@@@V.QN#O4E9-%F.UV!W(XL3Q'CL:QQC>UFW>-[I66ZX]
MM2-NR*2WQ^O'!&J:Z,8'(3<=L<@-MSV23VF27UL7BE&XFXLC$>Y@CG/'D+))
M+EF\LK0K"4;2&5B3J))4,J*!8*JJ'-@ =SQ  %85(UD,EP"00+*%L&*EB3:Y
M)*BY)'E[:R GQ=L7M))N4&*K+RSL*QX]^=7CK-,CX8Y3@0+(,2[#YK^>P*UB
M,"5Z-E9$V5K9&P8.+64D%%4]$$[ $@$@E3?K%CU5(%3O<_&)!!/6+=6QZ]C<
M7ZKUKY4\F[ !R,0MKK<:XM<DPO-K',*RWKKR7'!9X;3/+O<@S'C\?K[62E(K
MI\HR ^2<GJK+$NL'J:XXHIE6/+K8;$RD.HA 1XUC*LI<C3$D*N'8:M01 !O8
M,690"QO5S2$JQD8LCEKBX!NYDTE1T;:FXVO8"MA5=C5JLK;&V2) \E;<!*%D
M1].LDXL4/5W3NJK %UB ]5?TU<:I-87S40D6=(V\VA@ZZ;*=X@#=0VQ)OL0;
M'A8[, 1PO5H*'B>#ZA8D>:]N/7L?"L &; XY<CD"9!N36V;2MP[C<-MC'C6*
MB9'2V%U<T]Z5#B.2/>9:8H1UNFA@2VJ98SW!2O9SVF0!'"W#$.&4K$P*Q"+3
MJDT,%5E!=.#@!MU;HDWVLQ!JYI;$:S8N7^*+J6()T-:Z\"+C< ]MC6R8%W3L
M-NWOM*]K)K =\+G%P(V5C:FNB<Z-ROX/:V2.1BJU51'L<U>]%36LR/9.BWQ2
M.!V.IC8[=A!\Q%7!UNQN+&P'EVK3C8NO/IN67R[LLMPC*O%\S_H8/BAD5@-,
M'1Y1\7-J[BMR#XOVI#(PKCL2QEC!MNSYB.SRY&#E]%,Y&:V9@3A<&H%V4X@L
M +LNIU*Z@!M<#:_&Q[*JC8":=B;!C& 2#8Z4-['KMU]E;:ERXY=P9=3V5K"R
MMO1G5I$@=S)6%/#-IXP2U"L@"AC@B&L?*R(T$F H69$E'FBGC:]M%G C(4W6
MY^+>Q#$BX((/F(L>RU6ED(8$[&X.Y!M8 [C<=8OMP-N%8"J>3]B&-.QP+&]S
M[.'%J'<,W<>3$LAL(LJJK"Z=%3P4<4LUC8QGL%Q%M2I6-"R$DUX-T1#D$X!5
MS44AM=<<1(VK5"-31"+4JE&"](OP%KR%NF;7(!4$*S U"-!;3(=(<N%(+#5L
M -^I #8=MF-RHML:EO326MFK[4)L$]56CI-&?'#Q<TBXZ9L4\<K7LEC;-&[G
M1O22)7L<BM56KJC2W-K93\=SPOQ"6N.PV-K\;5;K6YWZAV]1:_A]5:I1<E':
MVGCR2'$=QLEQV#*![NC/C)R&#*5$PW)\!PS;_(,;JILHELYPY2@,$H+0.[EE
M*."M!FI*TVN:T#6T<7,VGG(@^DAA9-%Y$DDD1R% !L9&!4 :EZP;$4&",!K.
MPU:@2;M96148=*_$*#<WZ6YOPK::N/Q^N,406Q A!$HJ:O#53(71M8#+9QMA
M21TG[8^&%T*O17*[@YKG+]4BZUF5V0$JUS)(3L;]()O;C8D'?R5?J4&]Q;38
M<>HG[+;WK6RUY.N)9-A^38EF6X-/E,F89/<Y%D&766-8Q)F)'QAI)L:M6A6D
M\Q(=98,QIPF-5%@'6,%I\=K0*@6J46!B)L#$R+(CQQ,G-HJK&&<Q@JVI3I 4
MD:KL03TF)8FY-4&)"K*SZ@Q+,Q0:ND+&S6V.GH@[V4"PVO6R8Q] !8U@XEA7
MQ  T,]?!S3(5BA9#/6L'@Z1TB_5)# O-1SE>YL;G+QX*NM>SE&N&+&0$[&_Q
M6N;?3V=8X==X90PL;#38<>KJ[>%:_P!WL#A>8C;@C9UN/8Y#)G-])D$-N#:O
MQB^HI8*J]HL?K(+"CMH![#'\3I[TB#'Z H!M3#8H1DIHIV46-A<D7+/*AB,<
M07FP%(*ZU8!D=C9EZ+NR LURU@%!" **C&CA]3DZR3<74C8A1<<54,0H(M?I
M&[;UG*F6@QT3$:(2\C,"QZB[&C-/M&&&2Q !5P8\QYDLKI)RR(Q^DEFE>KYI
M.D>JJO'5)#L)6*D%F#6 (ZV)L/)?@/-5BE5"C5<*MKF]]K<>N^U_-]%87M=C
M,.RLC/Y<WW%/R%V;WP5\.:%:R8Q>8\M'!:"XK3"6M#;BH9CF)06Q,])1$!LK
MVW<Q>4'0FY-8&6TUPQ$D8BYN+1S:E"&&M6U6UL0R[/)I&I@UP $'0%JJ,:,7
MU.27(:XNI4@64"WR5!V!N+DGB;G,&.#8]B-/@V+@7S3Z_%*(>@@/LK2,PZ<>
MKJAJX8BP,DD<Z4HA@[72RO5.DE5W-\2:J.MA,Q0@NP;2%( NQ) '8+]7#:K0
M54(-1(4:;F]SM87[2?)5@;M[1[<[MQUTUK?"1655D(>2!+:DBY?C2FB8UDF(
M+$3A&3$GXNZ"6CRRX1RA  $.M$K[0B<B8!D<DX)IH-6E&(*E3IU1MNR/^^(
M_P 9%XDBUP +U"1(Y+$G=6# D%@"%9?BFX&SF]K&]B3L*R#30X[BU%@F,5]\
MMD#BHU92PV%I;16-I.'48X75P&VQRN:I)I/1PN,+>V-)RIG.YK5D1NJR)':5
MRA!>[&RD+=G#$*.JV]AV5(%;(H8'3I&^YV%KDGR<3VGMM6,L[V9V\SL['YB\
MGC"%I+=+I"HSH['-824N0;R<;&=QK0\S+\*J[6<"&NO*W'+ 08RC=-5A-JVS
M23.LCFEC#6C)+*%W6R6L5&N,+HD(!.DL"=6Y)J+I&Y'3( -]KEKWN=+F[*#P
M(4@6VJ7VPVPPK:> BAPJ[M+0"]SAF2(!:9 3?OIHH</!QN"NK93""28:H0*A
M"Z-DDCW,DE>U9.8D36'EDE)>10I$134$"ZB7+:FL "Q+'?LML>L$5;*A)O*K
M6)-P H6P)Z@%'EX_1G[6K6Q46[Z]1?>N?\K'U/\ @S^N/]5JC\O^;]]2FH5*
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2HJ ,L5Y:P3CJPDN8OA+!
M*Y['3(Q%9SF$,14;S$X+S474RRL%NK750NS 7M?JTG[:C9A>Q&YONI/4!U,.
MR_TUZ.;8^6"]7G]ZUBZ=UO2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/WE]$
M^W3FV/E@O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.
M;8^6"]7G]ZTNG=;TA[%+/WE]$^W3FV/E@O5Y_>M+IW6](>Q2S]Y?1/MTYMCY
M8+U>?WK2Z=UO2'L4L_>7T3[=.;8^5"]7G]ZTNG=;TA[%+/WE]$^W3FV/E@O5
MY_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"]7G]Z
MTNG=;TA[%+/WE]$^W3FV/E0O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=
MUO2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/WE]$^W3FV/E0O5Y_>M+IW6](
M>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+
M/WE]$^W3FV/E0O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7
MT3[=.;8^6"]7G]ZTNG=;TA[%+/WE]$^W3FV/E0O5Y_>M+IW6](>Q2S]Y?1/M
MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.;8^5"]7G]ZTNG=;TA[%+/WE]$^W3FV
M/E@O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"
M]7G]ZTNG=;TA[%+/WE]$^W3FV/E0O5Y_>=+IW6](>Q2S=J^B?:IS;'RP7J\_
MO6ET[K>D/8I9^U?0/MTYMCY4+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"]7G]ZTN
MG=;TA[%+/WE]$^W3FV/E0O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO
M2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/WE]$^W3FV/E@O5Y_>M+IW6](>Q
M2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/W
ME]$^W3FV/E0O5Y_>=+IW6](>Q2S=J^B?:IS;'RP7J\_O6ET[K>D/8I9^\OHG
MVZ<VQ\L%ZO/[UI=.ZWI#V*6?O+Z)]NG-L?+!>KS^]:73NMZ0]BEG[R^B?;IS
M;'RP7J\_O6ET[K>D/8I9^\OHGVZ<VQ\L%ZO/[UI=.ZWI#V*6?O+Z)]NG-L?+
M!>KS^]:73NMZ0]BEG[R^B?;IS;'RH7J\_O6ET[K>D/8I9^\OHGVZ<VQ\L%ZO
M/[UI=.ZWI#V*6?O+Z)]NG-L?+!>KS^]:73NMZ0]BEG[R^B?;IS;'RP7J\_O6
MET[K>D/8I9^\OHGVZ<VQ\L%ZO/[UI=.ZWI#V*6?O+Z)]NG-L?+!>KS^]:73N
MMZ0]BEG[R^B?;IS;'RH7J\_O6ET[K>D/8I9NU?1/M4YMCY4+U>?WK2Z=UO2'
ML4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/WE]$^W3FV/E@O5Y_>M+IW6](>Q2S
M]Y?1/MTYMCY4+U>?WK2Z=UO2'L4L_>7T3[=.;8^6"]7G]ZTNG=;TA[%+/WE]
M$^W3FV/E@O5Y_>M+IW6](>Q2S]Y?1/MTYMCY8+U>?WK2Z=UO2'L4L_>7T3[=
M.;8^6"]7G]ZTNG=;TA[%+/WE]$^W7XB%GZXAA$L+E:,\9K(8GQIP?+'*KW*^
M61>*+'P1$X(J.55\&LEAITA2.EJN2#U6MLHH ;W)!VML".ORDU(:A4J:4II2
=FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g150774g14a65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g14a65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (@*^AP8X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ,U   "[P         !
M                  $              N\   ,U
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ,U     %)G:'1L;VYG   "
M[P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #-0    !29VAT;&]N9P   N\    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     %Z8
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MXN3;ZE;O4K_TE-?HH>#C.RLAM6/UFRRW$K#=&/ D?H_5<Q[_ $'_ +OT7_\
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M-ZM=T;,JS\=C\:BYY;F81$,+6^GNL95LI;7[+M]7Z/V6,_T%GI(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/Q05;\M90_;3E_\ ?CAXRY\6W_9+3[FG4)^.]\^[_/1^*"K?EK*'[:<O^?\
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MA:51ZG$-7-EL-T>R2+B.5JS*+-,Q3QC*)S36,+$R9V8J  ).#@'4>KV_3VT
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MQT14P()S[*?5\4O:H9H<Q%9J&G7$D_!@0RT [;N&XQLG\NZ?^!O8VV+.XO\
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M&E(0.Q()R:VX\?,:]A1PI1PI2[RA]&XO[1,1?>M2^-]OZ17R%U]F>K4_Z/\
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M_P 3_P!_5?=7Q?7(_P"AL]F8;'[JX&AWOJ(9SO6MZ^B^)1_7K'G#K6?S=O\
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MIKJ.^_GY;WU'8; >+]53&3V$2,1DSZ^V<F1(- !H-[#^KRWYAY:[>8?5TX4
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M,:R3)YFCO]70/T" !Y (=PZ>@AKW IKW8'J( X C48Y$1V#D0[CO8B CU#T
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MNOLSU:GO1_WC7&/[5'X[=*H\1?1B;^U#-'WO7?B;KTB?T>T^RLU#'FK^6?\
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M]@B#.DR3R[CW#74!]  WGK8^6_7RWPJ.&IU$9!Y *XQ)X3SX34@K/^54A_\
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M0Q]1F\-0(]K7P?$:O04F;#.)P#QW!5M.L)C+P))D@") S)X=@@'D>('*LL#
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M"Z^S/5J>\P9CX1G/]ZCNJCQ%]&)O[4,T?>]=^)NO2(_1[3[*S4,>:L?^L_\
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M68)<W0 E0"()"RF$-J45*!);).X%)2"=Y165@Q.Z9A(43.21! #(>1)DQ\9
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MTR^*=6:.%*.%*IW3MJQ;JNWKA%HU0+XUG#A0B**9=@'B.H<2E*&Q  V/41
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M4/$8!54,=4QSF[B&FK="6VD;J0).?*,'4J\Y2LC)SP$"(YRUK=7+AG&> P-
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M=<2LS,6J:>V">>*R,K*.3.7;I7N<YM 5-,A0 B*"*8%1003 J2"*9$DR%(4
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M.ZE9,3QW>($9S.*@B(*B$CCO%*1ZYS]/MKM201?-BO&*S>0:'V)73%PB];F
M.X@LU452$/71M!KJ(<1O02#*5?%((/(#R@"3WSPP3@(,2((G4*D1WB<YT^FK
M"_9E,4Q1#>^V^OO]_D/0>G3ZN-J3H>/LYCV]F>V1KB9S&>>3(GL[CS%*V;8
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M9N_=<=3U3#RG-R 5=4%+WT@A()@"4J@$C7(FK+B%J:2D05#=F3$P"#!D9GM
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M4('/=("MU2@%$82J 2"> P8X'4'CRJXPDQO!)(!B0)&)G,$<C'=V&LO8=4"
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M36PV/EKZ]:XZ+B-X3[>R./XX<JH#@<SJ.6L* F #V1B-<TVX:0\/@$!#R'N
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M8S[?[;_5Q'4L_G;,?)W&OS/?4]8[^;K]:VOW+/XGLD^7%Z_H8N';_67&??\
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B(RH$DJ  G4Q,*+C@"2RI(WVR25M& E:5$X42="! GC7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g150774g14b44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g14b44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '*Z^<T(X0DE-! 0      #T< 5H  QLE1QP"   "19T< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $( EHOO@JMZ@2O_E?#$%"&,X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +C   %I          !
M                  $             !:0   +C
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +C     %)G:'1L;VYG   %
MI     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "XP    !29VAT;&]N9P  !:0    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     $E$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MKFMM;5O]'VV,?ZEWIU5L?OL5+"ZG6++*K'6WY3W.=@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_^6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$              0(#! 4&!P@)_\0 6A$  @(" 0(#!0,'!@@)!PT! 0(
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M1(96M6?M^24I7G*L^6,Y\L8SGXN0&4^C*?P(,N-CWHI9Z+E4>K-6ZJ/AW)4
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MF7&9=0CUG<<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$]#_ ,3$G_JG,_\
M\7E_JY4GZ:_TE_B);M_DW_HF?/#WSVUV4I>]@%:UH7[!U'6$G7;YV99M!=6Z
MMV#FS;VNT38#X.T$KKB8,KT6+7H\(@+A!AV9[[S\Z06G-1E"8[V[=K P"EPN
M@=I4+#L^J^\0  /4 @^IF#6%*$D)U;(]^PII?F- D[[:&B/7YS8!4'WY("-(
ME.S)$E^J2GWWR,-H<0>>=KSZW7IP^/A+$"8XYE:Y,)G&&HKRG&&\80A/+F3_
M )M9\_+._F3\R/@?F!VW+5(U=7_38  [ T?3OW^?<]R-2].KOXNZ9_@Z,_S9
M']?BYSTVP^/XGX:^OQ,C"H?=4[X_(MUK_2SLKQ)FLGNT[L;'?OK7(J52V]&"
M1#^I(D^V50UV&9HI]V9M.M9L0J]0*,!(4%VL5^EN$YL&$\=JC#MIEYE7,@4J
MRS@K")L6[J[0W1IWKI=+]U^J$2\;4%$*A%  )]1MUZ@.12]O""CLV96:&^Q:
MY[(X%,(S,."<2%PW6FYDN,[!8E8PB4? =@NT>V]6,?9ST$2I^6>Z/5T"@FS7
M)6MHM*"P.RV@2+ HP$OEN*G=AR(YB0\%;O\ KUF53SSKBG83$1@;*D/HFXOB
M(XB.(CB(XB.(CB(XB1]LBZ/TP)'R)'M&[=8R#5;H]><E>II.6B;'DR8S,F2E
MI]R((&08<\_9)[,>4^-K8@M/CPYC\=J(_@\AF'#I4UUB[*R+%Q\/'ZNGSLFQ
M690S:)2JM$LOR+ &->/5:X5BH4]%X9X-.<S[!F9#X'"\9BV<IX@Y-*O/;CN(
MQ[*JK;*J2U:7YN7D7XW&\7C/;37E<KG86-9?17:]]?C75!BT45+P]*4:M5AF
MJ/7:V2FL-D;199++;4J>^GTG/51\1EID97PS3BH5> 0QP0>E$2"WYS@X2X=3
M N;LF]S=F93 "S)R&&F<COT5J *Z*02F/0E=->E0;>)?$5WB'+I9:1@<1QN.
M./X#AJG+8W#\54[O5C(=+YV5<[OE\GGN@R.3Y*_*Y#))NR&U(7,V<['$1Q$<
M1'$2LE5=:8[;[_??<;999Z^=8'7GG5I;:::;O7:Y;CCCB\I0VVVC&5+6K.$I
M3C*E9QC&<\1,T]H_KQ\O.F/G1H_U[Q$>T?UX^7G3'SHT?Z\XB/:/Z\?+SICY
MT:/]><1'M']>/EYTQ\Z-'^O.(CVC^O'R\Z8^=&C_ %YQ$>T?UX^7G3'SHT?Z
M\XB/:/Z\?+SICYT:/]><1'M']>/EYTQ\Z-'^O.(CVC^O'R\Z8^=&C_7G$1[1
M_7CY>=,?.C1_KSB(]H_KQ\O.F/G1H_UYQ$>T?UX^7G3'SHT?Z\XB/:/Z\?+S
MICYT:/\ 7G$1[1_7CY>=,?.C1_KSB(]H_KQ\O.F/G1H_UYQ$>T?UX^7G3'SH
MT?Z\XB/:/Z\?+SICYT:/]><1'M']>/EYTQ\Z-'^O.(CVC^O'R\Z8^=&C_7G$
M1[1_7CY>=,?.C1_KSB(]H_KQ\O.F/G1H_P!><1'M']>/EYTQ\Z-'^O.(CVC^
MO'R\Z8^=&C_7G$1[1_7CY>=,?.C1_KSB(]H_KQ\O.F/G1H_UYQ$>T?UX^7G3
M'SHT?Z\XB/:/Z\?+SICYT:/]><1'M']>/EYTQ\Z-'^O.(CVC^O'R\Z8^=&C_
M %YQ$>T?UX^7G3'SHT?Z\XB/:/Z\?+SICYT:/]><1'M']>/EYTQ\Z-'^O.(C
MVC^O'R\Z8^=&C_7G$3+ZELW6U_>FQZ)L*CW5\:TR\18J5L V1Z S(6XW'=FM
M!I\U<5I];3J&7'TMI=6VXE&590K&$3,9'_02?^J=_P#*SRI/TU_I+_$2W;_)
M/_1,^3+QB=1U3;NY@P%K5MPVOL].FYZJNQ+"Z;+ZUHHJ5:#P$C9VHVWM^:$]
M\K7.B6 FA^'33DL@*+@]66DW)AP@D$/:-M>H<@!69^CL"*R@^!/OO6>H@^@V
M=A2=C8.)0Q53L@+U? /U$ZW_ #0VAH=R1\P.Y&MTM!CXB5(5$2P[&3%I>8Z8
MSZ!;3\?#-8<:2P\T#RH(TZUZ.&W&PZLBT+3E(_.8GN.<Y.1VQ[!_S-=]#X;T
M==NWQUV^7;4QZC^?4GOIB=[/ILC8WW^?8_CK>]WSU=_%W2_\'1G^;(YSTVP_
MG?C]WR'R_P#'Y]Y&%0^ZIWQ^1;K7^EG97B3-4G?9NN)\2#IW-G['$Q"&9=#&
M1JY8A?6FZ1Q<W[+56E,!*X V37&MFTTU:T/L3WKM3["4,YQ%A,5^(%FQ(RR2
M)M[[![^USUDU::V]M.=-@U$)/ "GO>V*U,(S"EG.0*Z%@0V)$F%%]UE$B4="
MWIDV'#BQ\/2I4IEAE:\(E0KQW T+OS7(:+1;G%8(-]M.J57!B;.N+7"]W4+[
M1Z+-*/4060EIG6FN2Q+V2,8B.86ZB&R^]-BPT(QE2)LHXB.(CB(XB.(CB(XB
M,YQC'GGXL8XB:[-'W;M-LWNOO8CL+4-4#]2Z!46JQULV\.M+4DM<+*[8&H6P
MTN5?)F3.>S*D!G6'[)-KM=A0(H(<+K+UA'&"5@*ZC$_RW,NY$DFFCS<' &R5
M94MUFY0!&MWWU#'K/O\ YC%6VIU3*=)W/.'_ !?X#C_"M>EY#D?8_$GB9_+"
MVUV9&(;/#W"LY+.:^.XS+?DLI!Y7_G+F;,/*H:[AJ+!L3YMYPT<1'$1Q$<1'
M$2DMO_CD[E?F>Z2_TOW XB=!U!ZX=>274SJ\1(Z&TQ/(3^NVE)LZ=,U=1Y4R
M;,E:UK+\F7+DO@EOR),E]Q;S[[RUNO.K6XXI2U9SE$L3[,G6W\7O1_S3T+Z@
MXB/9DZV_B]Z/^:>A?4'$1[,G6W\7O1_S3T+Z@XB/9DZV_B]Z/^:>A?4'$1[,
MG6W\7O1_S3T+Z@XB/9DZV_B]Z/\ FGH7U!Q$>S)UM_%[T?\ -/0OJ#B(]F3K
M;^+WH_YIZ%]0<1'LR=;?Q>]'_-/0OJ#B(]F3K;^+WH_YIZ%]0<1'LR=;?Q>]
M'_-/0OJ#B(]F3K;^+WH_YIZ%]0<1'LR=;?Q>]'_-/0OJ#B(]F3K;^+WH_P":
M>A?4'$1[,G6W\7O1_P T]"^H.(CV9.MOXO>C_FGH7U!Q$>S)UM_%[T?\T]"^
MH.(CV9.MOXO>C_FGH7U!Q$>S)UM_%[T?\T]"^H.(CV9.MOXO>C_FGH7U!Q$>
MS)UM_%[T?\T]"^H.(CV9.MOXO>C_ )IZ%]0<1'LR=;?Q>]'_ #3T+Z@XB/9D
MZV_B]Z/^:>A?4'$1[,G6W\7O1_S3T+Z@XB/9DZV_B]Z/^:>A?4'$1[,G6W\7
MO1_S3T+Z@XB/9DZV_B]Z/^:>A?4'$1[,G6W\7O1_S3T+Z@XB/9DZV_B]Z/\
MFGH7U!Q$>S)UM_%[T?\ -/0OJ#B(]F3K;^+WH_YIZ%]0<1*N:YU_0M>>(_LH
M;0*14:,.G=)-039L"GUH-684R;]G?=K'K<J*%A0F)$KW%IMGUAUM;ON3:&_3
M]!"<81-ADC_H)/\ U3O_ )6>5)^FO])?XB6[?Y)_Z)GRI>+3JV<3W>*V\]IL
MQM6KT[212'89$_I5I_MM2ZP/%V8]9B9-M[9_8W4,^IGV![:G9\6LU@CDB(Q%
M=(%Y[C(Z 'W%J^]UA"X5.Y\E+0->\Q]^Q"/GL ^DPJ6/25V 2Y(]]D)^  *@
MCT^9]9N!UZIIRG!5,-LM,+HZ5,-1H40;';:55EY:;8&P)A&".9;1E*6H,(A.
MB1$)2Q&F2F4(?<O9';&?T_D_3T'IZ  D:^X'0^![ RS43YZD[UUGN23\1OU
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MV4G99$9K@"#"]@BD)ZRRXDP #N)*[#]342S5TW534*M"H.TP]<,Y=++$S3.
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M>[GIC0SX@79P>.V3):ZRW!N2-UQJ&W:Z:3I[8I3W0Q>HFO,6$+?X:K0$("3
MTO:SL15=&QULAQP%R=$MEU)1#0(9GU>#>!>SCU//8_3;G\GC9I/)X-?YC#.;
MY%N(_D7(Z6)CTL;G)-CV]#8^*C56O2V3:.O\RW9$9=(Q!9M;#:.QHG72!O0)
M!)! M+U*[.;4[ 7+95=NNLQU"@:P!T5PU,:=*N/3[7M +'V-7JY 3/RVMEZH
M:S,UAJ]-S(S4MNXEUQH\<?'BNP\<]XAX+C^'QL*[%SK<M\Z[+6I6%85,? M.
M%?<Y4>\,C.KO.(48K[+6"Y=F#F]3:]A8,H4*%/Q[EQU ?J775_SCKX&7KYRD
MOQQ$<1'$1Q$<1'$1Q$<1'$1Q$<1*-"?Y2O8'YC6H/U^;PXB7>D?]!)_ZIW_R
ML\J3]-?Z2_Q$MV_R;_T3_"?%[XG%BTS=N]5:H.U>WW4,:*5"OX*PB]E:S,&"
M>A!]6#5JRUNFWU(WL93 ML5L0I9S;\3-@KP7SB-J@YB%HN,I3M+2C6A6LK"]
MPP92>C0&E(#@'J)/KW.COY3%JZA62$<]QK3#WR2P9@>G:].AV'I\#/H@I*HZ
MJU!5%F#R$551>5&GBHK4$7.CJK;N69@V$T[(9ACY3>4OPXS<A]J/&6VTAYU"
M$K5EY&O9W[[]SU] ?O ^1&M#1[GTF+5_+KV(/6>Q[L/CWT!W^\=_A\MWMU=_
M%W3/\'1G^+_BR/\ _O\ CYSTVX^/XG]?_AZ?JD85#[JG?'Y%NM?Z6=E>),UA
M^([31VPNZ/3 ;8&W&8-:L=%E"XUFI6@RM/M\>S;=KT&\ P=FV'M.EWUFQ)KH
MJ/ /A  "Q15 #3#X@.;LTT="PCZ^OK^$V4]P.NLWM#UHVCUY";"+ZE1L6IS*
MOFR5R#%DX9@/1EMX!D("LQW'JL3REB!8QHV:+EDP"IP=N?&C3G\*1*,C>F%I
MZU:Y<?([UL%C:L7=WK/L&>%K57K-7K]VP?[-Z$$MD-GM%X-N/F;TJ1%49,V:
MGV.CQ3))$'$P2]#B>K.HFX3B(XB.(CB(XB.(F";1O+>L-9[$V4\!.VIK7M%M
MMX=K%8BMS;+8VZF ('E@J]#==8:EFRR8&8 J,X^RA^=(8:6ZVE658AF"JS,0
MJJ"S,Q"J !LEB>P  V2>P'>5UUV76)54CV6VNM===:E[++'8*B(B@LSNQ"JJ
M@EF( !)E9.E^URG:C7HCM?9M<VO4\Z]CB%:J.L[O'D,6.BU8 >E03&">'FH\
M:45M]F%/%I)89';%D:X-IK,-R<V.R3GZGCP^7;9RMJD+<GD\<AZ@:^/VKBYD
M;71;GV!<AQTJPQZ\.JU5MI<3M_%35\#AXO@?%</;QN0<_P 57HU-B97BDU-0
M^!5=266["\,XSV<7CL++JWY._GLW%N?#S\8)=;FWG"QQ$<1'$1Q$<1'$2DMN
M_CE[E?F>Z1_TOW XB21TU^Y!ZJ?S?\FW1GQ?>_L85?B)+>R-CTO45&LFR=B'
M&:W2ZE ]\CYI^/-F(A1<OLQ6O0ACHTPA,D29<B/$B0X461+E2GV8\=EQUQ*<
MY6#A97(Y=&#A5&_*R7\NFH,BEVT3^D[*B@*"S,[*JJ"6( )E+,J*68Z51LG1
M/[@"3^H2O&>^/59$Q,%W9KK#RL@%Y=D4?8<>&W!LLM(H49>GO51$)FO_  A<
M;J1$^Z^@0%N3K51,3(-B<0.5N1X2\0%.M< ,NKNR9>$[=6."]M01<DN;Q4#D
M+0%-MF-_E-:/1^<EOVBG9'7Z:WV;T;T.]:UOL6]%/8D'M,NUUVWZ_;3*30U/
MOF72 P45+$VS]8M]-9&- #8FN6 >1F7  "A03X Q8*]%-UN3(:/"T6(!+F#F
MH9D=(D8^;X=YC K2S)P]);8E=7DY&+E-8;:K+JGK3%NN=Z;:Z;C5D*IHL-%R
M+87JL596ZIR0K=P"3L,H&B >[ #8+ $;V-C8[RQR%H<0EQM25H6G"D+3G"DJ
M2K&%)4E6//"DJQG&<*QG.,XSC.,^7-)^[X=^WI+L_7$1Q$<1'$1Q$KGV2KVU
M#U>H;>I;==:D5:VUK>/:G:4FGKD2M=D[6,'WQV>FWUVPQDQQE:>($&GH#4>=
M'?92\UF3Z&(Z]SPMW'TW9AY'&Q,A#QV:<<9?M/2N8E#OBA!CW4DL]H52')5E
M)7MO<MV!B%Z&93UKOI"G:EAU;Z@1H#9W\/O])K^H@WQ0[F?U4,M5BCZ^CL:Q
MU\9MY_+E4P%^%D,9KQVU1[./5K4_,.6<F^]=8QBC@9-0KBYN7'@VPP[(V$B9
MUV6W@/&ISWQZ&S"<S,IHJ_/FYJ6LS%QVHL&?CBK'0+BO7E6KE7! %LQ+#82N
M,!E%DVW3[JDGL1L!=A@4))]=@=(W_.'H9:VE9>^%0ZN&HU"$2+YO@CM+L36D
M6E51K"RH:@QR&YY.D[37J?'LE; ->^BQ>J0 N:6E69%?&'T'K6"M.8192L#C
M:/".3S]39KC#XA,#AKSC>U7K7;F%.,')XU^2U-US&M;,^VRNI<;SK*C5CWXP
M:O5QC>M1Z06L+V#?2-A=OT$ $ ;T@!.] [*F81=-_P#B.$!RPM4ZQQ <R7!N
MX0M9,P8SLH46BT06@"<IRWM@%Q[WH;!)3E#'[ #GA3(4(YE7N6%M2)V1A\/X
M)5Q;D\XURBW%NKQ_,TKU/E.;J\O6'4P/LB(KKCW+;5;<#\"$H-N3K0IT='9(
MWW"C6O>U^D3K8T=?>)+^\-N]WJ<0/C]-:0K=YCCZ'29U?GV$7-?B$[)/-5F)
M;9A8R'V &DY=&0YMBC,4<33<STX&-V]=L6.4U6)>!Q/&^$\I:7Y/EKL,V9F2
MEJ4V*K)0E60^,*ZK,&Y=.R4,<RS(":<XRT"S\^E=CY"D]%8;2@C8[$[ .R&'
MIWTH'WDZ["- ^P>\E:V.))WC4,6[Z^QM*XRBKLT$%+V.@4MN^[1'"B6MIPHG
M68Z9#>K)X9$@O8LRII(!%:&PH4VRV!X64SGPO"5^#;7B\FV)F>P8J5HEUM5&
M;E-BX#V)GI;7=[GMZ.XJJ*K5<S6,RTT"RN@-D*^W0-6&;OT[91MM%='XKVV?
M70 &SWLOO!?8V;/;,Z4/&@P9W0.UK5$!.5"G$'7MO@<TU_5M6GKL41TE$S;F
M3]I9+0$OMMM.5:,AJ>+6J4J?I.('!(IJY6JJV[\M<;C-<,K)0#C+O:EY#(04
ML$<8QHQS6^CL9!)5P%Z;MAM]:]_R3D*57^4'24!WW][9!&_AV[]Y"*+_ -Z@
MKF_!*J"6N,$(W6(6C;@NMZ_#$BXQ")[6RK8>$-6Z*P;L8HU%D1:'5HP>LQ#]
M><K!IV.2=(FTCMF<+PC:>'L&97BM:;K.5QA?F6UUN36<''IM]F8U4V5OU9F0
M;,@TW"^GJK"5%Z>J\>8.DD #RVZ5!]#U$CJ()!'NKH @@[]=1G7=O>(_E^N-
M7W64@!(G2==9-KKVL@EL!AG'!1V?L2(I8K8\DE.@9%0ZTR%2PJ-[CM"U/#Y=
MKBTFHF/6\^[C/ P6\X>>+>A<WR1?R%N-==JVE,)CYF *T?K>\V[ZP<''6Q<9
MLK*JZ;8?*)'4O2"1Z)U =CU;][9]%(]/>;75TJ=8U*VQXK>4AI=<U55C(V6,
M%$Y$6Q5R+7K$R]-(2(XJK&&'9L0<S8FWU*8V&<'+Q5E"QJ)%>12(I*!;2.0.
M-^SH"U;N0R*K$>ZM6HN>ZE@B*6R*B%-GD,#U8=+_ .4>8[)><ID?'2"^9VZ5
M4@A3[RZ8$MZ'L!L#LW<#ML:!!.P?JH4V\=UR;-[SU1 T[L8KLK84TA51R:DX
MRZ&=L,C-5(.DZA8[-"L4S%:P*$S[/-FPB-BG"9!=083!EP(B.,Y].-JS:J>)
MY"SD\&K!PZZ\FPY /F+4!>@KR*J7H0W^9:F.J,E"VBKS'=78Y%)L*DVH$8NQ
MZ1KL-CIV5)#'78MOOKTU++\TDO1Q$<1'$3T.R8[&4I??99RO&<IPZXAO*L)\
MO/./3SCS\O/'$D*S?HJS:^0)_@)^VGFGT>FRXAU'GG'IMJPM/GC[>,*3G.,Y
MQ_/Y9^+B""#H@@_(C1_89[.)$<1'$1Q$<1'$2C0G^4KV!^8UJ#]?F\.(EG]D
M[&KFN ,@D<DH]8E8=CBAB'$IEDY7N./X#2<^?H,,XSA<J4M/N;#?EC&''ELL
MNWJ*VLL4#T!!9O@H]>_XZ[?,RU<RK6P;^<"%&]$G7[NY^/;XGMN:VREY&&)\
MDC-C#U2)3N7%_P#!1U83YY_@H3E>%KRE"?)*<K6I6<8\U*RKSSS=>O?T/W:'
M[AV]!K?[)KM$=M@_^\-?/XGYD_#M\)F51M0LKF?";?:;F8$&E-1\J2GW9"1$
MWS]PQC.,9RC&,Y4WC^'Z.,K2G*<*]"G(?JHL!'?H;T^/K^L'N._>36A%J'>Q
MO7<@Z/;?X_>#VE_-7_Q=TO\ P=&?YLCFA'H/_#]WPFT'Q_'^H2,*A]U3OC\B
MW6O]+.RO$F4/[N0+5'[H]3;559=?A0!.*<.V),7L'9U2+CZG8=_:[K@AT^'I
MMA% +%72EA.-UZMC3 BQ9FV@O(=-L#Z2*LDI:)>?MS>]F:WT'=;9IT58S>RH
M:P,2J":OK4SM8G-(%+ ,&^@]5@3B9S(5IF4[(L=D1%+JJU?9)G8M>LD^#$ D
M42BH+:O;R_ZE;5V!U@(#*B]T^K0=17(:S:NR& Q>RV@YC":O5;3!+E-@ L'G
M71PVVN$P3$Z$^M]"R$@;)94CX_L_#X_1_5-OW$1Q$<1'$1Q$P#8FU]8:B%BC
M>U-ATK6X<[81=2"E+S9PM5'EK0;6Z@/7ALLW-A,33))3+^88V.XY+?0P^XAK
M+;+JT4665U(]MKK776I9['8*B*.Y9F8@*H'<DD #N3+^-BY.;D4XF'CW965D
M6)3CXV-4]]]]MC!:ZJ::U:RRQV(5$169F("@D@2H^RNR.G;58150OE]#474T
MX8BR+9L#A :>W8)3,=@QTB1#+7OI$U HA&>23-$X\1O8KD7 <9'F4EXE,L.C
M+-SI"JKIP@]ZRQU>M^7(]*:D/2XXS?O7.X4Y^EJK5L)['R/2!35]FJO;=?1?
M]HC!JL7%QWIRJ/ RD:MS<R]19CV^+^DFO!Q<9[1X99GS,FVKQ%3C8_%28GN[
MU-;;^+>-+2TVEOSS[J0PA"'/B:\\^]^$I2O'Q-^><85CXL<Z#1V!TG9V -?+
ML=?#M\?E\>_:>8?$[.SW)).S^))]?Q[D_?/>GNOU55Y^CNRH*]%64J]')17H
MJ3_SDJ\AV?)6/Y\9\LXY'X@CZ^!]#^HD1./+[Q=2X#2'YV]:3"8<DPH3;TM\
MA&:7,)3&!PZ(AQZ A"I,\A*C083"<Y=E3)#$5A#C[S:%(G(QW8ZJJ7EO&[*A
ME>$X7E'I$_3PE6<X2K*?>[TL85G&<8SG&//.,XQ]K/'_ (?K^7XZ[Z]==]:B
M?C/=SJEA.%YW?3<)SA.<*RX2QCR4K"$_'[W^7\)>?13_ &ROBQYYX[_(_'X'
MX>O?T[ $_AWB?M7=?JLC'I+W94$)QE*<Y6HHG'I*SZ*<>:AV,>:E9PG&/MY5
MG&,?'G&./P!/X D_N_>?@.Y[1/SCNUU3SG"<;NI^594M&,863SG*T8\UI\L#
MLY])&/\ G8^WC^?COZZ/P^![ G0)^0^\Q]>H_M_=Z_,#1U/E)O%1V/6!ESHE
M@&6FJF?7<##@B1B3 EJ'$)8D@VV[C&,X>@%($T?,8<2AZ+-B2(SZ$/,K0E$J
M?;_XY.Y7YGNDO]+]P.(DD=-?N0>JGYMNC/U85?B),=]I53V+3SM,O(ULM5#L
M1+!B$Y,F#LJ9C2&9S$E@D.E0B(R9 F18\^"3'S8<\=-C,38<J/)8:>1D8F7D
MX.15E8EAJR:6ZJG5$L(8@J0:[%>NQ65BK5V(Z.K%75E)!I9592K#:GU[D??Z
MC1'X[E98?3/IM!=@1H>M:FWB NK"((M-F/J@M1JU#24K-80&58E0' ;2V6K?
MFIKB+"%K%'9O1 7.L;#9I&\/B?Q*ZN3FY&K%R+'M]FQPY]H<UY&1YOD=8M.S
MB^U!A?52QPTL2@FJ6O)H!'NJ""H ZCZ@;4:WKX;Z=:)]X@GO.%+ZJ:/#4C84
M'1]"H9&[W'7%@K<5%MO5F(@R<:Y$(\V=8+ 0GM[%D.3RQH,**D[A\&R]AL<N
MI5Z 0*/, ABQ=:^(.5MRL-N5R\RO%Q<ZJYFQL+&2ZI\9"@HI1#@ +55:]:8O
MM%5%"Y-UE=8:ZP6P::PK>6JEV0@=3,003O9)ZSW.B6Z23TJ-^ZNK.ZS@VD50
M*B)NHX *LX@'!$E857/D+0";<%M8@,/#SA6LTXA-1+B1V);N)-<&JBR'WH:,
M2FXZ)TG19KT69>19C/;919:]E;WTI1:0YZR'JKOR40JS%1J]]@!NQ/2+R A5
M#:!  .B2.W;L2 ?W"9SS%E4<1'$1Q$<1'$1Y8^]_<_Q?>XT/E$>6/O<1'EC[
MV.(GCRQC[6,8_P 7&A\HGGD:'R$1R8CB(\L>?GY8\_O_ ,_&A\HCRQ][^N/M
M<:'R^[]7RB.(CB(XB.(CB)I'\63PN-K>(3<--6/76VZAK6+K2MVP(3C6:+8Y
M#I5^PDQ$Z._$R";<;2W&;&N-N^L>2\J=1Z&,XPK.)!(! V-_(Z^N_<_@)[%]
MF'VE<=X#Q>6HSN,R^0;D;\6ZML:RA!6**[497%Q!)8V;!7L-$'U[7 \-CJ-<
M>D?5T)H:]7,+?3XJWW&Q.V( R48'/1;(21-BQ4-F$HFX=BH3EMW*D^YY5Y9;
M^+@DG6^Y^9[[[D_USE/M"\58OC+Q)=S>)B785-F+BXXHO:M[ V.C*6)J]W3
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MB,2&'4_&EQI]IM+K:T_S*0M.<?'\?Q\@V.007<@]B"QT1\CWD]";WTC8UK0
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MLO+6#5O*4U _I>Q<<E+^H[!LO)Y!=!1TG=9))+!@ JBU^6O N*Y?"\#Y^:0
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M[@(L53#Q*,TT<?7-B'R[0^?-PW78<\IG Z.M4K.6HRV\81G+RD(\U8  GO\
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M^"1/C20!E-LU9:+:@38QQ.8/.10UM$8PEQ!(,H0=88+-HEU)LV$.C.S2,N+
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M"Q.'&/U8E[ICO;5:!CY&'0M]%W%*3CXHSJ?(9GSG60K5'S/S0&JG)(9[.K3
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MB.(CB(XB.(CB(XB.(GQW?NGS^-7J7^3_ &?]_P#"*K?XOZ>3\#^(_@T^K?\
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M="_P+JW^@X/."S?\\R_]9O\ ]Z\RT_07^BO\!,TYC2J.(CB)IR[J?R57</\
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MFZL5>E[BZM7E[NE3[Y<Q1'7@>K/DKZJ9;MVUK1O6[;^D=P5&LL.7PAFTX+[
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MBVVB@ID]5N,SM19===B7MQ04X^(N.K5D-E6:*MFGW<I_--[HL-A7;;'8ZV
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M_G'6P?13/$TYV20-GN#]:Z8D%VZ75I@R'+W)<XH^5L*3-91= $X@UI*7(@U
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M/&%82M>%>6<ISC&?+RSG&?+/Q<G1/H"?U2"P'J?XSA_">NY^T<%9_P#QT?\
M_LXT?D?V&1U+\_XSQ\)Z[C_Y;%__ *UC_P#S_P G&C\C^PR0P/Q^Z=TVXV\V
MAUI:'6G$X6VXVK"T+0K'FE25)SG"DYQ\>,XSG&<<B3*_5+[J#>7Y'>N?Z4=C
M.(E!^\\(BKN=TM(-BCQN @V"@)%O!+H9!/396VJ1B00I[->FL@<WFMCLNV:U
MNV=X+!#ZS%%['F18TB/>1E$DSNGNSN]JBYJ8Z\ZR%7NAR=5D3<:=!U;>]AV
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MF9#BG<;9O&'B"RM5NS?/M72>TWU4W9!I6S&NKI-EM;'I2_$JN+@^98XT[LH
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MP>D8G#=8;,L-6.@WR0#V.ZV*U:%GJ--_FJGL]_EC?8 &)QM'JT?,L_FC;?\
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M0.=1KK[<W#]GJP,9>DKDJXR;!DU9/YZK!2SV3(S+\<K30:LC&OMP7S0BY+%
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JB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g150774g14u85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g14u85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2944&AO=&]S:&]P(#,N,  X0DE-! 0
M    )CB^EX0X0DE-! 0      #T< 5H  QLE1QP"   "=1,< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $#FQ 5G.QC%"#3X'85K[,WHX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 85V9
MH         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              %>   #;          !
M                  $              VP   %>
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   %>     %)G:'1L;VYG   #
M;     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !7@    !29VAT;&]N9P   VP    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &]P
M   !    H    $    '@  !X    &\  &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9W>"AY66\2EH<G5VA(:8MK?"QCE%66-XIJ?#Q,7'_\0 ' $!  (# 0$!
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M_P U'T17$)]G;,_WS;O_ "[I\$[/^98_LVOS4\=N_G!WK_-1]$5Q"?9VS/\
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M29$ HF=JP!78RQ&P 8-USM 3V'F?5#;;%0R'RW9;C=[L*6AF-X<XQ F3KII
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M<0GV=LS_ 'S;O_+NGP3L_P"98_LVOS4\=N_G!WK_ #4?1%<0GV=LS_?-N_\
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M7(3I.L'N-1J)R[Q2=8HAON&WI_/S;<Q'NVU*D*20%)(DP/3,?KLSTH.MI!S
MU&I,#O-+N'/VN_?EZ0\_N#MZ0 1[N>HPF"8("=2<A[8GU4X@><2!GJ1KW4G6
M#T]W(>0\A]'=JQ0H89$8_)S&?M^^@,JP_O<O5/HTK)143(S:Z[:*:J/%VL;*
MRZZ28D*9*-A(YS+RKLW:&('9LXYFY=*  B<Q$3%3*=02D-174\K+K)1_G+,)
M$C+,Y3IS-2$J5) )"02>P")/JG\=*QPF !VY[^C8=PV[P'ER$/0//5]VO/(0
M 225) @:F28R]/;I520)G*#!]/Z/ZBCK 'G](=P]Y=MP]K;<-]_Q#JJDJ28(
M,SAR!.9T$B1G0$*$@Y:R<A[8I.L7T_AT*5#%*2, E61R'/M]4U(ST([QV]O8
M:!,4//\ C_!I!Y'N-3'H[Q[Z4# /=^ ?DT@B,CF8&1UJ%0D8E$ 2!,@YDP-)
MU-)U@]/?[0]^^VW=R'<0 0'F B&X<PU)0H*"2DXCH/;KIIVU$B 9R,D>HQIK
MKE64&'DPA26(6B@0JLHI"IR B3L32B35%\HS O6[7M"-7"*PB*?9]50"@?K@
M8H4D8L/[W+^.GMJ>$\(G]#6>S6L6!BCOL/=OOW^;D.KE"@0"()T&6<TX3PY^
MW\*RD'#2UEFHBN5Z-?34]/R;&%A(>,;+/)&6EI-RFSCHV/:($.LZ>OG:J39J
MW1(95==0B293', #19#:5J<(0EM*E+)( 2E*2I1USA()RDY5(25%*0)*CA2!
MJ3R[/74BO,"9K8.@:/L3W]HZ-#PMA*BYJ\P@J:"L<\VJL!+E*HU*(QTO9'C2
M"CG8;HNI5P@Q2.9PJ0@X47]JH2FY;(!(R*8!""X09(T0DJ,\L\ZR>+O3A+:@
M8GU3AGT3E(XZ5XLD8;RSAYS',LJXWNN.W<NBLO%M[C6Y6OJR*+<Y$W"C(LDU
M;BY*@=0A%NRZXI&.4#@43!O9FZ:NTJ4PZEY*",6[!,$S&0$GCH#4+9<:/724
M&)A2AIGG!5V'N-1GUB^D/S';6? J8B#$P2 8(G0F1]_#6L6(=W82.^*7K!Z0
M_/E^/0(43 &>L2)^^H"DD@ YDP,CKW5E)&%E(AK!O9)FJT:V6*5FX-902"61
MBD9J7KRCU(I#F.1(LS R['98J:AE&2BA2"@=%52J2%SA,X5EL\(6 E6'.."D
MF=,]:N4J !(@'3V^XU@Q 1$# &P!N COOOMZX ]T-QV]([[<QV'8;"86B05R
M1$@&"(R,\I)@Y#(QG52$H($Z@&.1/,\N6GKUJHNW/8?3ML.X;CL(;=4=M_=#
MF(<N8ZMB;.%F "GK*!S$@B 3F#.1UB8U@35>+"5 S"T@YP0DB?7 RRF?50 [
MB @;GSY^?VN?N[>?D(;\MM6E6\+A022F%" <@,B8!Q=GI@15PD;R J4!,A4G
M-43I,@Z:Y>GB!L %VV  WY &W?N.W</R<PW\^]&,]RE28#*5'-,#$N(C*93&
M0SPSD09J&T@%>(@0.8,:P<C//AG0 AUMS;=W6'?T&$2@.WH$?6@/G'ES'5%H
MF%81U4XUD >1C.$F,SH>>?"JA02(DC,\\X)@Y:U04#!W@.X;AOWB!1 -PW#S
M#ML(!RUE4 2E<#"&U%)/LC*1/HJ5#(<)4--9T^ZLS*0DO#)Q"LHR5:$G8E&=
MB#G%(P/8APZ=LD7R()G.)4E'4>[1 #]13= 1$@%%,QL++B'#@*8AE2<L@5C\
M0-,B.,FH*5)$DD9@',P,N^=.^.!-8D3 !0Y!L&^X;;[^D0Y#N([B(  =_F'4
MD KW)S2I.-)41A*8$< -#Q,ZZYU(2DYC./3EPT/+AV0:JV$-^\0 .?(?J0$V
M_N '5'?T!WB&K-G ",(*58<"XD J)2D:9'+70:D1G4*5O,Y"2,AP$1^N?'A%
M4[]X; (#RY^C[7+W?3JH9PJ5.6(PDB,Y/6 $S$3RY'E5U$+0(/DA1.><A)B.
M.9 B,NV,Z7F._,1$  >[?;S]X_&&WI]&^KAQ"C"FPLLR$G(S/ >D<-!KGH8P
MX-R4GR_+@Q'MUR[?1E2!W[^MW'</,(&$P<^[D.X;<^X2[?X.VB6V\*GFTD+5
MFN(!&<F9(DQ(RDG36*@"5%$R@9DR<C$SF>>7I]IL " ]XA[NX>M$FWFY 4>K
ML AR$2]PCH%N%381& X\1]">1!UTTC\&82"%802$I&?6RF1ZQF>(]N7"!ESP
M:UE*Q5-!H2S>#6D0%/L22SMHY?MV1B]<%>T5:,W*Q3 F*752, J 82E-A4ID
M%"0%!PM*5Y1.>(#%RSS C,3&0RJ4DPI12>JK=E4@PH@Y'G.HU&L]F+]> @/,
M=@ /M;!R#T^@>_X@UF"DE!25 3.8X0<IGT#3B)JH1"BJ3)(.1@9&?[XB8J@
M >0B&_,0 1W$!#O >8]7;SARVW[N>L90E841!P0">K)@R#&1,Y>L:T4Y"H/[
MQ$1/\=- .65'<.W,.0<O1R[]MPVW#S#W<PV =]6Q*2E*@GR"0"<I4YEK,@J,
M3,3J15YQ93,ZB<HUG7+/CZ/2#< YCS[]_<'O#N_!YAY;:L4A"7)@*&%2AD2G
M%';G))X\S58$E$C"/)@ZY \#Z@(U]4W1, ;[CMMN \AY"&X" \N_D/+OV 1#
MD CK I)2 5" =#(COJPA4P08,',#/UTH" ]V_?MS 0'</:$ '4$$1,9@$00<
MCZ">[6E9>$@Y:QR)(F$9*R$BHVD7A&J(IE.+6)CG<M(K=94Z9 (TCF+MVIN<
M![- X% Q^J4:E02))@2!ZSD*D G3E/J%8C<  1'<-O2 A\6V^K$$ $Z$2-,Q
M520)G@8/I_1JV4!ZVX@/(>8^V.X=_N\O=VW[PUL8%*05)$@@QF!QPZ$@^5EI
M4R)B1.L3GG5SK!OMOS] [@/GY" ]P[@("'F$-AY\M8 A1,!))*L,#/K<LO[J
M#,D99:YCW_=1U@[M_-O^'Y!#;OWY=^H(()!U20")$@G00.)J8/9WCWT;A\>W
M</>/=YN6_F]//T:M@6" 4D$G")YG0>FJD@:F/U^OT12=8/3\0^W\8;#N'>&W
M=J,"^OU3\GY?9[_5- H$$R(&LY??2]8O/F&P>??E[_=YP]_0)4<1PGJ %4@B
M <AKS[*D9Z0?6/?VTG7*(;@/+[?GU);6,4I/5 *LI@'33\*1IF,],Q[Z.L7T
M_G^?Y\PU4 D @&"HI&1\H:CL]="($F .9('XT=8OI]KN'Y/;#GW;B =XAJ<"
M@,1$")G+22--=01I3\<]9HZP=^_=[0_G^?M:@ F(SG3,?K]=HII67BX25FDI
M9>+9*O$H*+4FI8Z0I@#*+1=-&2CQ7KG()DR.GS1$2I@=3K+%$""4#B6#U2 <
MB3$:F?54A)4 H"0>-8CK%Y<^\=@[^_4@$S'#73+OJN(03.0RI>L ]P[[\]O/
MWB'=W]X;>[MZ0U;=K)@)DQ, @Y>H_P!])']X(^^DZY>_?EMOOSVVU4)420 2
M02#D<B,B/4<JGA,CO'#7C2B8 #<1#;\/N>G[6IP*SZIRURH,]".\=ON-)UB[
M;[\MM]PW'EZ>7F#S^CGOW#LPJ !(@&8F!Y(DZ\A09DI&J2 1R*C '+,T=8OI
M\PCRY\@$0$>7FY#[PCW .TX%$8H$$3,C3GK43J> D200,M<S2[AZ?:^WZ/=#
MSAW@ "/< [5"202!(&IX#UTD1/#GIQCCVT@&*/</=L(\AY /<(\N7XO/WZ%)
M!@C/"5Y9]41)RGF.^=* @Z$?W53_ +)^?F#;\(:R@$!J1$XR)Y$"#4GR%>K[
ME5V>Z(?ZGB"_\U'X<EZ\MTJ\JT_KWG_G8KJ['UNO2U][M?8-KYU7JZ-*4:4H
MTI1I2C2E&E*-*5;'ZLO_ ,(W^;U'$>@_>FE?)]T^O^N/PU_XE$__ +;VS7O.
MAW^*[1_[UG[U5YG;?\^U_P!V?_-7"(P[!O\ :UZX"9/(3]H#\:XH$D#F2.X$
M_A79BY=&QCN63A7E.R4XI,O;*"A8*O4YB'6F8)5[5\>8VLUQ?S]N>3C=Q%-7
MSJ[*.6J9(MZDW*04^L@@0!#SC?2&[;4XEQ@.)0XI$@@$ O.-(A,'$>J#$CT0
M1777LQA002L J3,&),)2HF9XSR,".VI><]%9C%2CP=6B9BS-+_(2$A%/[Y=H
M>>JSSKQ64).M.7D1C[QPZ:R2$C"0KQ&H&.[(G9T7L$_1*T5D=D]%'26]65/+
M00D+PH0C"F.JL];7*0"50 !)C@<JMEM) A:9((F!S G749SQX995K?7.C'2L
M,!EZUC?[O"P>.F!Y6(3LV+C5V:D&L?CZ&R/,1ECA9*S%DJ],MX>8(R;D0:2L
M<J_(0YGX-UTC'W7>D3R"PC=]=\=;KI*028R,0H8M1EI6JWLQLESY084R23 [
M2 )D&,P<QH,N$VWKHPL6O7\I&4.?OL'"UJT6KPZ2=UF3MN0[1 1]:P^6,:56
MEL)%I'SR1)S(#R5<ST?X"7Q,G).#HE;1B1QP(Z072 E3C2<2MSDDI2GJ*?$E
M76U"1PD$QR)S'93)!*7,I4.$DRG* =<X '#CI3,@^BRJ,;=(*N67-7E#,QTI
M 6*VUZ%KP,(B2QV?+4ECB6)$6Q297<MK(^&(6\%8GAU09N554#KK+H)E5R'I
M)<N)<*65 %#I0HN))"D,[T$B.$\\O3G5!LMI!2-X,UM99"(="-0J3Z8Y\3-8
M*K='E2WJ?#KDB1FIB1I'$)=6M2?4Y"*=P@X]#)-?LAJ49K+/YX;'-N*B_;LW
MCE9Q"EAYDD<8B<DY9N53'D[<N7F[EA22DL--KQ2E6/K(Q#JY F>9URTRH=GI
M1@4A045%8'8"3'',3D2  1/& >/RZ1FZSAN8Y%3(K*(BH00,F84SG()DQ#UH
MD$2B)!+ZT0$!#EMKU*'%*1;%1Q84QGE)!PG[NR1!RKG*!2]G,D$Q.D)"O;Q]
M-2?AX-['8N[GBG,G> #_ +EEO#N, A\7Q=^M>*E"%?\ ;K41Z' =?7[/56Q;
MC%C3S0LSZ,)J1>#?'%,R]Q+XHQWD)FJ_IMGEIE&PMD9%[%&49Q];FI5,HR,<
M8C]H0J\>B)U&@G6[!-4A4SF,!3QM;>,V3BV"0XAAS/R@1.1P1$DF-<^>M4M6
MD.W2PY&#$!$Q((2/QB>V2373*Q=&QB/*]YJ37#]E/0ZS)83B,@R,A6W,[E&I
M3\Q8;Y(5>*/2Y.U*5JQ.6,"U30<9&0<)&D:^X5:MFL0L]<@V'S#/2&\MVW$O
M(6\=^8*X;6(2%0J I(,#(#(@Z0":ZKEA;N$!M24I(!RS&1SC,&.'&-!V197.
MBR--5W"L\?*LDX+DJ4L+&Q$B:6W$($D+1L@W)JG!-YVRP<K/N9+R!<Q[5=:/
MCH=P5\D\0DSHI 57>=Z2NXKL!@]1IHI^43!+BF4J!(!@C>>GJD9$]7#\%M$2
M'.9U!(.<92"=,L@! SUE6G142"M<L<PXRFLFM"YDCL;LUTZ@ 0LK!/,H5G&2
M\\FX7G4Y9M*M'ED(]4B74.BS'P!VV2E%A(*VJ_M,XIQ"!;$%24E76!(4I)5A
M@)STUG23$14)V4WA*BX" 2!GR,3.+V=H$R::Y>C_ *$G%2=QA,G7&\5B$RC+
M481:8OD6T4L%#L]/KEW1N%@C9U\6B&EG5E=$I*KPBAIEE'.GJPL5$P0U*MNW
M+A0P60VMQA3OE@1&(PD*"2LD(S.42(C4U\0:"5G&"@+2DQG!!!),DA,Y<SEP
MG.$N-SAKHV [/&2V,K/)3M&N%MRQ QD9,12D?(U=[C.YGJLC$^&*RLLK,L@5
M,D,?++J-'+Q),5G#%L<Q2!O['VC<7B%H?04K;2W)\K$%M;S%,)"<\@(4#P)C
M/6O[9M!2ILY)+@(RR.\C@>WLGE%:]K[^H)'\Q#?,,R&X#S#K4J ]<&^X=8/V
M0!Y^6VMM*OY2.T_BK6.P1Z#6%4;LGB <^/'B(XF:8-1J5BOEI@:53XAS/6FU
M2[&!K\*R%('<K,22Y&K%BV[8R2(+N7*B:28J*$(!CAN8H<PW'WFV6%OND(#6
M(R3HD $F?1GZLR*QM(6XM#:3)4!&0@DY $]O/NK8ZJT'(7"AQ X,MV:*'8()
MM5<C47(CN*CSQ$S,/Z]3[E&R<J,>WCI99F9\)(UPW:MGK]@19WU2G<() =8O
M-7<,[5LKANU<0''FW&D[Z$ K4V4ZF-0L$1BTX<-M##]M=H24E>$H=4!GA0DR
ML\A TS[,IKJLCT@%#S-"*8NKF'\AV"?CZ?BY;'TXRKD A84XG%E[K^8,W1,@
M)K4FW=5Y&N8V\HZ\NDY<.?&B+YJX:-$ET5R^73L6[M I]QRV"$+6RZ@N@PX^
MTIEK(C0*="3 R&9.1KKF]0^3NVR 0"A029EMS$X.!,I1.L@F!D:@[,^4*=D'
M'KJSTO!>4LWXE#,N?<U6*9S"=G04*S*6A:BPKFM5A"F7*Q2YXZH/[A5EWYCK
MI^.7LY#_ .AJ1$%E2[6SK9=H]A<OF[%]#;"0TQ+A='RAE4 I!4-<B,XD2*UK
MIQMT8TVZUIS.,XD@J4,P$CK C(^J3E7'E:.?+.5RHQCU$1,9<K0C9P8S=!8_
M61)L<@JF3V.!2*&( * !3%$1-R]<A=N@]=PN*.96HA.9,P),Y9Z@1GIH.5"S
M!;0I*<LE:Y0#P':4ZQI6/ ! 1Y=VX\P[A*.P@("'I 0$.8>?GK,C=F5HSR/$
MZ1J,Y]W+2L2BJ4!20.LDY&.W@ ?UZ14S95#:G\.X>;U&)+_[]LV_CUHVAD.G
M_MI_^DQ[*V',T-GFG_6768X5:%6<J<26#<;7)NN[JEXR=4*Q86K5XX8.7$1,
M2[9F^10>M#)N6JBB*ABD71.15,P@8IP'UP5VNMZTLG+JW$+0E1*@VDQZ>L9&
M>9C3API:,-N7 WBLBI(PR"8/I[8RSCLB:Z<DX2^!_+3FWP.-;?(5NP,'N#:*
MZDJ=(W#(U0J61\GY?G:(Q9QZMS;TF6FFDLS)"A8W3Y)TA6E <.HHCQP)DEO*
MHVSM:V+;KS<H6'"<:$(*TMH"SG,3F8P@3KE7779V;Z5)0I,AP)URF8!C(QF
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MH>&*$H0O,8=3BR&<1RSJAV8TX\J%]4@%)PQ$D@@G%K F1/:!PC"N=%HZGXW
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M:ME._/W-XN^,T*7,)8^6<1U5J5JMF::?/!:82/F922/M-8G>)QLZH\(V3!6
M;ND2KV-XK$9F^DEX%2IE"MW;.H69"2I0W2DJ!C.08,B9,CD:G9C '5< )T]'
M6F>MS B#SD&*YN\4^!U>&O-EEQ.:8<6%M#,Z_)QTRZ:Q[%Q(1UB@F$VV569Q
MDM.,VYTP?&;B5.27$X(@J<J)E!1)Z;9]X=H6K5P4X"%J:B9T5AG0<!IS[!7*
MNF?%E*;D*D!4@R.M(UD\YB>ZNC/1#_4\07_FH_#DO7!Z5>5:?U[S_P [%;^Q
M];KTM?>[7V#:^=5ZNC2E&E*-*4:4HTI1I2C2E6S&YCZW?J]X@)0$!$OMCO\
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M(RY_QKP"7;F [>G<=@V]T-OS]S5U!80H%O*($O#J\HD\!P^X34)2ZHB4@@<
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M3IHR3V91(:RSAB)2\B*YI"43*+P0)(OA<N1>/2@#ER+A?ME#]LIUJ^*6N?\
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M^EW'UC^>F!GYE'</=1Z@O#/^YEP)]ZB@_P V]-X__2[CZQ_/3 S\RCN'NH'
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M3>]!*0@$J23BBKJV%LM]%LRS>[BZ=4O>./K06$I2VV2'(<^3Q**\"E3(U (
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M5+N7G&DMH082">L0,ZS/;!V62VEK:B$%090A1"#B=7;I65. O@)3C*B2)"2
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MFGL@Q$9B25D"4^LHY[LZ9AJC2;L\PXQ-:V;.#1<(O"1DRH<"=!ISSY9&<N4
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M_=/M [*/T/[TC@=U.QAW\P]52O;<MMMMB[AML'<([^X(Z?&WT2"8#FT)R/\
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M_K!UAK\<O0CC<;0CB/@]V(S/G3$YP3&7J%SX.>E!S2W:@Q 4+UO(RGK   2
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M#H2"ONRT&E*KQT\<Z)SI*<9W%J14AS%.D?B+S"50B@")12.0UP Q3E-R$H@
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MVC9!N@DV<-F11.1-^1VEK\R]+^AU]T3VB+:Y;+ULZ9L[I *6;ADJ,*)@!+R
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MM'FBF,^<./+AKW<:0924#OD'P>ZY7#_\>F[1YHJ<9.AGNJDTG(F 2F?NS%,
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MA02EL)D)0(R].<S9JS9M[9-FS*&(<#A(2MQP.$E0)4#EG&NGH%0EAC@)X4<
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M6Z&$*<MDVL(2^IG#XQ!6=X%J(-+MDI(W00$J"DJD84IS(!)R(Q"!(*4SA!)
M-8ZY<1/1NG=R$>7%4?/O(3)$(W8RBU&4FH21H59NE//',ZX<'[-RTJ\?68RZ
M(+0Z$G$LK#%6)JQ=1$HJ+5:#BUV3TN#-NIR]6%/6[I'RH0IHK;<<<3<%0AQU
MUQQ)0X4+6T03B20#5UO6:5*6AK",<D9#$D  2)&'@"E6IPY@@4RN$JR8BMO2
MZ\-=BP?&^*<?2.6*"9JR3K["L-4IA*KE;V$[*'C&D8P;LUYM%ZX25:PM?2=B
MJ9V6!BP7\%3W]OLWEOX.]LHOSO+A%H[O%;UQX@&X04!3BUKQ*2,B M0TZRO*
M.39F[.V+,MG$G>@CAA!&0 [ >$\1)BNL?&_(UZ&Z2BV2MN39KU:+MV(7T^E(
M-CO6"D0TQ[1%I CQHBDLLX;*M2*E62*@H91/<H% 1Y]/P=,W#_@OMV+/$BZ=
M8VLU;K0H(<2\N]NTMK0HJ2$J"B"%2,P=:\#TR=8:Z97+EP,325VY<;*2I+B!
M;VY(5&2@ "(DR"8&E8^;?\$,U7RQC=\BP.6R6"S]MX!:HIZUC;@C$2Z\0U=1
MT(Z%_(4<BIJA6HU^=*"?.H:2D'ITD)!LJMD9'A#MWP^IDO1;L6JFB[9K0M5H
M74)?"5/)#:+P@/W#J27TH<;2A*BV0G6>_9ARU6PEPI_E#KR24+2H)=1*F$F#
M.ZS#8R0M0)D!0)BP[+@\>(K +J2BEV-8GVZ)DY2WN1F9YM$4IU#R1B+1;@B+
M][+/+BQ1C4Q9PXH1K8SQ9J'8NW?86]TY3@*&F7PXXEPA:+-O<)*[A.X*D.A2
MVD(W"UO]9T$K*$J)"!HI1L D@)=:ZHG"ZZH+40 73*<EJDI#9^3!&H,2_;'*
M<&-EFZZR=-V4##MG9'CJ2IZ=N:'\6OK(],I7GK-U&;&20C'#9T\D$ 5>M2%4
M;1;HP(@@MS[='3NW9>6DE]Y22A+=V+-0QH9 #Z5I>U*TJ"&SA0M12IT2HJ3G
M?/1UQ2%K;P-!P$EM3H@@),%!&<#4P<,$)Q81-%?B.!%:P2,=,3CIO"F=R2J$
MRY?7]1=%LNI"HMFK%-DP1*8D<=:=>,7+MF[<ND$&J3M-<4A%6'[OPC)MV7&[
M1M;Y6T'66T;/$(0E:W'%XWS)<.!I2&U@((*D1BHU;=%Y=Q3@2D*94X7RE2E*
M3\F@-I*PK#*E.+20I)"5$DY^5UC;AA(K'LC+F!2#QHG>+>ZA;%//.S78P%!L
M 14D>53;QZ,Y;I%]<*DP:5U=Z@Q7<P2ZA2NVZX',[7Z:E)<-N(N-I*M+=%PS
M;MJPK=NFR6@S*UL6C2&'G'+G<K6&GHQ)6@59^SZ,MJ#0?7C3:BX(075)87"%
M(:"EH"2XXXK"$() W@F<X95,B>#]Q3<>N[?-3C.R+2$J?([1NO8Q>,(M1K;#
MHIPB+2+7C5'+)9&H##*+.$TGKA]*)S)BMR%,QZ5_<=-T7^U$6-LRY:"V:.S'
M2+8MK?"[8*#Y<=0Z,2/&2\D)( #1:*E$I5JLM=']U9&Y==2X7'$W;:4K"RE2
M>JMH9H)"@C <04 %E8$924]I/!?#SM(2FYV,2CGD2E.2GBF7R++,Y!K(1KDZ
M:4P=1@R>Q!R+&C3P:4>X(],D5^6Q-45R(-1XZ=I>$%ZVOE,6*P\AU+3)=1LU
M"D%#C86IA.]4AT8=^+@NJ*<0;-JM:2I0Z)L^C+3C>.Z26\(+F%=U!49.%8@%
MO!"<.Z!21.]"2$@8\\5P)JW5]'(2+I"I1Z,Y'1\XM)Y"5"56.QI:T785VI(I
M!UVK9RZN3=**2-%-EDF+9=R514K--_M+?\(B;,.)8;<NG0TX6$-;/0;<X[A#
MK!4I\H6G"+=PN_*$2I(.9*-=2.BXN4@K4VPD*2I:R^L.@$*2LC 2A>9"4'""
MD!4998B>0X.CKLY8DD,XJFB\4>L4E;="K2S]"IVWP1BZ9L(1BRCH<\PRI231
M]&. EG+Z3F1D3$:$\*2R,.=/1B:5;):0L-X72+-[<A3UN7""NX4M;H!N0I"T
MJ:2V&0B2DIK&Y^S("%H4HE(<("=\DR0J""4!$ !($DF<8(@U&N?HWAJ;U^I.
M\%2"JDTX=._*:-7=6I\LBV6:HN4#&=3S./9IHL72BT:W;M6RSA1$@+KOGHB*
MH]?HT_TK5=;0:V^P!;MA L[C#9HWIWBDJZELI2Q+80HER #D ").GM5&R$L6
MSEB\LJ)EU*L:B$*!4#*D@&3ADID1$\(U9V .0>;E]OSA]H>6O7D"8*HC+0G\
M3SBN-C$ G(D3H1D=#! @'6@=PYB4P &^X_:]K?O[O1SYCMH!A,SR&ASS&68'
MZX5!(4(!$D&),08R@D:\M,^-;[='M0<ZV3-\98L1R*E;B*\H@6\69\V,O7#P
M*ZB1W$ ]:'.FG*/Y5( !DQ2.5R@8 D 6:E0!4WSCPG;4Z/V?1]ZVVV$//775
MV=;H4D7!N1(0ZVKRFT-G)Q>0(.&%$D5ZWH99[2NMJ6K^RUNH2RJ;QPD@(:21
MC2X@@A>,1"9*HA2<A-?3\8X" @&_/N[MN_W1_'[NOR(=3Z3KKZZ_124D$&01
MS$B9&H! (]!@BK>HK)1I2C2E&E*-*4:4HTI1I2C2E&E*-*54  (<S 'Y^[J<
MN)/<#^(JI)!R23^O15(]X^?458:#A1I2C2E&E*-*4:4HTI1MO^?=[>E03'Z_
M7OK2#CS/@>.QG09S/O#^YX@J\TS-C6 @(I"-8O$*+8\@V:/H#/(,B_D9"/;P
M<?"$LBB:\@W.K*+^%%C(MNX=OB%)!TC,\?0<\]1["#G&E6 $@DC,1SRRG@?4
M>VN>>6>)S@!O:]@Q9,\($1E>8Q[+\7$Y:*E+I4ZM1%0#&^;,=(90N,K9+J_K
M]73C\A6-Q#Y1>N(Z6DI1,*<FFX8*SXQ<<O3$F<TYC,Y#734F2=>?,\*MA4<P
MKT9F8GT'.(GAEPK:'&N=^'^[7JO8V=<*%VI[>1X1L0WJ!D'D#%6:=:X>+)8_
MEJ1CZ>J%+EK'>ZHE7K??5F\+'V1DQ.\FJ+D:1:M31%>4EI"003IF .V.S+34
M^K7L$*&J^!@R=<\^'9P'MBM>LV=)%PP8KRKQ'X>FN%Y>T.<5WZ3RW<G<7-4L
MJ<_D+%</C"U,,G62+=G1=5ILR?R='C82Z2!W*:5@C8YLNW;@5!0]5*2,L),>
M@DF<\]1$ SZIJR<4 X@1S U'K'MF:F"M=(AC1LK3\PMN%V\PDGQ!M<@0TQ;6
M,OC][(39^'AGDE5LJD5C.^45NH#6'JL@_BLB1\*2H1L;<*N4[Y1W-G;-IW@U
MP*]6',">WT\ZQEDZRF-8(F2>.8F,LXY<*EB@])7BN1Q/D_*N9*;<\(-,41.'
M[):(=XFEDAXXJN>J\VLF,IN(/CI*:6>%F6ZSII),563=Y!/(]R>1*DS%)XI8
M.)Y$>G@,LH!)$@\3H>=-R9&8[R3.LR1[ !)YZ4YE>DPX.VLX[KYLB6%Q(E:0
M*T,5CBS*4FWN,C9FV+GD!6Z*XCZ>Y1NEND$,T8Q5)4Z\=_/H%MT<9VP;@#CL
M6,<)SC*,\_[^'">%2IHG(D"/2#GJ,QV_CF*;,STBL4KC7 MWQUA"^Y)LF?<<
M9$R_"8_;356J$M 8XQ8T:N;C-3<I;'\1'DD4U)*)8Q< F49!Y)R9$'(,$6CY
MVW8P.!.4Z ZCCKIV^KG0LDDR0<AEGE(![8,:Z2,ZU?F.G&PNRG,A1T)B"]6:
M+H]+D[TW?Q]BK#>2?P,?C&D9/-,35<='3D*M7%V=^@JXG//E7:!;.JG'JMTD
MUD%U*[T#/">V8X\(Q:\AD<]=*KN3YPSU_@.&67'(D5T;X1>)Z#XO,1FR[7*K
M*U2))<K92TDG\E&3<=,+U!^6,?3M8GX@_@$[6W+WPAFTDDTFIS/&$@W5:IG;
M&$V1)QB0DIS@@D=F8DSQ]1RFJD*1E&+*9'#LT[*V?$FP;[[_ &M6(R.>GH_
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M>\=O1Y_/JW#28)F9RTY$:]M4$*G$=--!SJV.XB(C^?\ [.6H,\O[AE_"L@@
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MD=T7 S.A5K RT%1\#JT\?V<<)^?62-('DG+*8TG.)-'TIF?Y]7I NBYYB/\
MOO51]/?_ %N.8[<M^_8/1JOQC6XF.C72T3J?@T$^N;C/E.L958;'5IXYLTCD
M7% <#Q1 @B1P!F*I'HFK 80$>D#Z+<1#<1'Z+M3<-_/RQQOW\]]^_G[LGPCL
M*PST:Z6$I)5(V6F9B)D/R(F9[ZGX'(TO-F@=CZN'9@SRRB.?.CZ4U/?_ +0#
MHM1W[NMQ>'\P 7D XU[]@ /;  \W+4'PD6F<]&.E$Z?\%HR,1(_E&L#76JG9
M"I_Q_9H/&'E=I\V,I]7'C2#T34]L(#T@'1;F /\ !+Q>',;F(!L >IL [#L
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M[<IXP-/X^&04(>-D.J(#NS5V$H@;D)##R$!VZH]40WWV -A'UO/5T)*5HUU
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M(A4ZT4Z\-9(.?"(U54 448K=KVC4ZGZ89 Q!.(F$1'("2 2() D<OURX:50
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M_%!JB#^&3EY-F#$''@Y3)MRJ<C9SYL]A-/M;03LTO;;O&'W/%_&-ZPU;63F
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M%=_;_P"%$^33>N\OLTP(\X_7H\05W]O_ (43Y--Z[R^S3 CSC]>CQ!7?V_\
MA1/DTWKO+[-,"/./UZ/$%=_;_P"%$^33>N\OLTP(\X_7JRXA(!)!51-8!4*F
MH) %T0=S@0PE#;8-Q$VVP;ZD..D@1Q\WAQJ"A $XC(TE4YZ:=LQ4?J?5!Z!
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M/O1&<_$17C5YV3]*.KB5C*^E6;M$A8I\X?$5017 QE*XG2WN=\=T%*=2B58
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M96TE*19WS+ZD JP(6D*P@ J4$&"I*9&)0!"22%&:L_:WUFL%5JIC>8>NZ%8
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ME<E'M&&/:*M"!^[<1 .[G^ -^6I()X@C.)(X^DSG5L2.,3VB?;&=&Q_;]_\
MIU$'L[Q[Z2CL[OX4;']OW_Z=(/9WCWTE'9W?PHV/[?O_ -.D'L[Q[Z2CL[OX
M4;']OW_Z=(/9WCWTE'9W?PHV/[?O_P!.D'L[Q[Z2CL[OX4;']OW_ .G2#V=X
M]])1V=W\*-C^W[_].D'L[Q[Z2CL[OX560!Y@<3  <^0\Q] ;^_[_ )M(C6.&
M4C\/NUSGA5%$ =4 R3J( R XZ\\NS*G97#@47O,.8-_,/F.Z#EM[>_XM8'DA
M13!B!'L3V_WU=LF"9/?R]'#EZ?33T&'BS")A8MA$1$1$4PW$1'<1'W1U@WBQ
M^\:V-V@_NBD\317L!M]S#3>+\XTW:/-%'B:*]@-ON8:;Q?G&F[1YHH\317L!
MM]S#3>+\XTW:/-%'B:*]@-ON8:;Q?G&F[1YHH\317L!M]S#3>+\XTW:/-%'B
M:*]@-ON8:;Q?G&F[1YHH\317L!M]S#3>+\XTW:/-%4^*&!# =)DV(*8E,003
M*!@, [[@(\B[=_,/EU52U'567&?[X]GWU(2E,P "?PY_WBM=,S\&G"UQ%V&*
MMF=,&X[RE8H*&"NQ$Q;X%*5?Q\(#QS(EC&RZANN5H#YX\<@D ]4%5U3!]5KH
M[.VUMC927$;.VC<V;;J@M:+=PMA2P,(4J(DA( K6?M+2Z*5.LH=*1 *\X'K&
M7'GQJ'QZ+CH[0Y?0@8/[N7ZS6VX=_P"R4_%KI_METI$#X>VE T_E"LH_67*L
M(V3LX?Y&Q]7ARRC+U57]*XZ.X0V^A P?MRY>1;?\K4_MGTLT_:#:4<O&%^^G
MP5L_3Q)B/0?NI0Z+CH[0W_L0,'\_^\QM^,PZC]LNE?\ T_M+U/J_&:#96SQI
M96_U?X4#T7/1WCR'A"P@(>@:8VV]KN$.[5OVTZ5Q'P_M/_25?W4.RMG'_(;;
MZO\ "J/I6W1V_N0,(=X?]QC?N\X?5>?W@$-]M5/3'I28G;VTC&8_E"OU^NVH
M^"=GC_(K?4'R3PTX<_=1]*YZ.X!V^A!P@&PB(!Y&M>0CY_JP]K;?WM1^V/2K
MJQM[:0PJQ#^4+R5,SJ*GX)V;E_(F-9\G0\]:0.BXZ.X0V^A!P?MS$=J6UY[[
M>8#C\8#^#3]L>E1$';VT2,S'C"]29YFAV3LTB/$F(R_<RR]8/MJ@W1;='=N'
M]B%@_P!;OR&F-N8^;<>T#N]L!W[]/VPZ4$ ';NTH!!2/&% ".SCZ^VH^"-G8
MDGQ*W(&HPD$GLS.G#[Z\2O1_\%N(IJD9%Q?PU8GI-ZK>2,=.8"T0%:;LI>*7
M>7&%C'*K-T0_61.JR>N6R@ &QT5E"" ;\\3_ $GZ0WK#]O>;7O;AAYI8=9=>
M*VUC#,*2<CF->>?*K)V;8M+;<:M&D+2M)"DI((UD@@\!6PUQX3^'+(]CD+G>
M<.T6T6F8\%&4GI>%2=23\6+)M&,_"7!C 8_@S!FU:);_ %*#=(@<@TV?TNZ2
M;)M46>S]M[0L[9*BM###RD-H*R5+PI&0Q*))[=9DSJW?1[8E^\JXO-F6C[JQ
M"UN-DJ4  $R01,  "9CASIK_ $"_",(\^'W&7?N.U>1W_P O6Y\8'3+*.DNU
M1&G\I6=,LQA$Y<R:U_V2Z-9?X&LNJ04_)GJD3$=;+7A50<"_"( ?ZWW&7F_[
MG4-@V]H3#YO, AZ1W[M3\8'3&0?VEVK(_P"T+Y9Y1Q]=/V3Z.9_X'LI)Q$EH
MG,'+][@,M?3RH^@7X1.8#P^8RV'_ +WD>7M;]II\8'3*(_:;:O\ I"LN4##P
MX??3]D^C<XO@>RGGNS^:@>!?A%WW#A]QF AW?K=1V#W0Z_/^G0>$#IE$?M-M
M72,KA0/JR@1Z*'HET;5KL:R/'-L_FI/H&.$8I1_L?L9^?_N=0#OW_P".//GM
MOW!Z.[9\8/3+_K-M6001%PL:1V=\FG[)=&O^AK+C'R9R)$>=[*8B?!1PI#DA
M:)]0;&_B\M&;2 -/)]'L0>'G7;4SD"=</TTZ!"IB._U)0 -MQZV4^$'IF&X/
M23:DA95B\85B@@  F.8D=LY<:I^R/1S% V19@8  -VJ!!.?EQH8TT&M/P.!?
MA$ /];[C(1'S^3J(=_?W* /=R[_,&L?Q@=,AE^TVU1&4>,*]O5X5?]DNC>OP
M/9:SY"M=9\J@.!?A% /];[C(?=KJ7SOQCSYZ@>$#ID/_ %FVMJ3_ (PKNTT%
M/V2Z-3/P-9?V9&?$Y*&OZ)I?H&.$3O\ H?,9[[; (5Y'ES\VYQ'[6^WM:GXP
M>F?_ %FVJ>4W"M.X?A5?V0Z,Y_X%L<]?DSGZ>MG5)N!?A%, @/#_ (VV'OV@
M4RF]K8Q50$! 0 =]!X0>F0_]9MJ?VZH[B"#4?L=T8X;$L1VAH@]X55GZ!3A!
M*(A]#_CG[4+R_P _W^D?.//5_C#Z9Y?^DNT^SY4<S]">_P!5#T/Z,J!!V/:&
M?HK_ #\*NMN"#A-8NVCYE@7';=VQ=(.VJQ84IA17;J%614*4ZIBF$BA2F #@
M8H[" @("(:QN^$#I@\VMEWI%M)QMQ)0M"G1"DJ$*!ZH,1R.1SBI'1#HVE8<&
MR+4*"PL&%^4D@C51D2!(.1'?4ITYDC(SN3HYZ!3LZW>(Z$@T"@*'@46MC/'=
MA.U 6YTSKE\:SLJY!5R958@. ;$4*U;MD4O+J?<S65DD]8J,*)423)D9\.,>
MBO0):0A&[0 &R(P#()$0$C0 ")B#F3GGD_ KL*'^TC#MY^W< /O^$_BU3?JX
MK,\<C[JM@1YJ>X'[ZJ\GH7V$?X0X_C&F_/GGV^ZF!'FI^J/=1Y/0OL(_PAQ_
M&--^?//M]U,"/-3]4>ZCR>A?81_A#C^,:;\^>?;[J8$>:GZH]U'D]"^PC_"'
M'\8TWY\\^WW4P(\U/U1[JI-7X7EU6G/?V0Y$>6X\OTX>_80'X]PW 9WJ\X4<
MN>7WC]=FM"EL:I2!(_=&OZG[N-,>F-4I9S>4WY 6)#7E]#QY0#L?!X]O"P;M
M- PH=D*W5<O'!Q46%10W: 4QA*0 U9;CB0F%8BH2!DG69$P9B->Z*A*1G*8Y
M9S.?9IS]AXT_O)J&]B#\(<_/:C>+\XU.!'FI^J/=1Y-0WL0?A#GY[3>+\XTP
M(\U/U1[J/)J&]B#\(<_/:;Q?G&F!'FI^J/=1Y-0WL0?A#GY[3>+\XTP(\U/U
M1[J/)J&]B#\(<_/:;Q?G&F!'FI^J/=1Y-PN^W@@[^CPESO[W;:;Q?G&F!'FI
M^J/=3$.T1+DIG7^K_H0K2)*8,U QP$7[:>C&22PN -X3L5NY7)V0*]B;M!,=
M,QP*8MMXO"3BT($0)S!SF.ST]M04B1U01Q/#,_K+CZLGWY-0WL0?A#GY[5=X
MOSC4X$>:GZH]U'DU#>Q!^$.?GM-XOSC3 CS4_5'NH\FH;V(/PAS\]IO%^<:8
M$>:GZH]U'DU#>Q!^$.?GM-XOSC3 CS4_5'NH\FH;V(/PAS\]IO%^<:8$>:GZ
MH]U'DU#>Q!^$.?GM-XOSC3 CS4_5'NIBY&:(0%9)(Q)!:/#6BB1HK=<Z_P"H
MYJ\UV&DTNS<&52_5$:_=M^N).NEVO:I&(J0ARY&E+4L)Q'.>$Z G3U<*A2$Q
MDD Y9@0=1R@T]PK<7W@@(<^L =JN( (]^P=MYP$>MMMS,80ZH', X@ZLCRCP
MY<@>7;ZZG -($9<_?W<N?"D\F(D!#9 >J " @*S@=]]MQ'=?;?<.7+8-QV#U
MQM[;USSNS0>ZHW:#J)]9XZ\?[J7R9BMC;(" COL(*N.0#OW;KCMMN(@(" @(
MCL( .VF]</[WL ^X4P)&@U))S.O?E57DU$]_@XB/[(5G(COSY["MU0[Q[@#V
MM@Y:C>N9];N 'M_NJT",/"(XZ1&NOXU0%8B0[FX@/?OVSGS[<M@7 -M@ .K]
M3RWV\VIWKGG=N@]U4W2/-]I]//VU6%:A@  \$'D&P?JAR'(.0!MVWF#EJ-XO
MSC[*M@1YJ?6 ?OI?)J&]B#\(<_/:;Q?G&F!'FI^J/=1Y-0WL0?A#GY[3>+\X
MTP(\U/U1[J/)J&]B#\(<_/:;Q?G&F!'FI^J/=1Y-0WL0?A#GY[3>+\XTP(\U
M/U1[J/)N%#O:"'F_TPY[_1_;M-XOSC3 CS4_5'NIB71HC$O:.C'%%NG-7-A$
M2).L97PA@K$S;I1 #+&.9$3+M&Y^U0,DL )B0%.S45(>0M9GK'($\#3"D:)&
MN< =^0SI]^34-YV@[^?]4.>_[MJ-XOSC3 CS$_5%'DU#>Q!^$.?GM-XOSC3
MCS4_5'NH\FH;V(/PAS\]IO%^<:8$>:GZH]U'DU#>Q!^$.?GM-XOSC3 CS4_5
M'NH\FH;V(/PAS\]IO%^<:8$>:GZH]U'DU#>Q!^$.?GM-XOSC3 CS4_5'NH\F
MH;V(/PAS\]IO%^<:8$>:GZH]U'DU#>Q!^$.?GM-XOSC3 CS4_5'NH\FH7V(/
MPAS\]J0ZX#(4:8$D1A$>@5?0A6#7K>#I&2Z_5Z_Z<X-UNH @7D*WK=NL8=@[
MQ$1'GSU4K43))^Z@2D "! [.\^NL6:U1A3&)X.^$2&$H[)H[;@(@/>Y =N7+
M< 'VM9 PX0#U<_I)]]4+R4F"% ]H ^\U3Y6Q7[0^^YH?QK3<.?1^LGWT#H.B
M%GT)G\:/*R+]COON:'\:TW#GT?K)]]-Z/-7W#WT>5D7['??<T/XUIN%_1^NG
MWTWR?-7W#WT>5D7['??<T/XUIN%C7"/\]/OIODC5*QZA[Z/*R+]COON:'\:T
MW#GT?K)]]1OD\E=P]]'E9%^QWWW-#^-:;ASZ/UD^^F_1R5W#WT>5D7['??<T
M/XUIN%_1^NGWTWZ.2NX>^E2LS!=9-)-)V45CE3 %") 3K&$I2B807-L B;8/
M,(AL/<.JJ9*4**L.6<3)YF(XQV\YJP6%%,3!/6TRS@3F2)]HTKFWQO\ 2T</
M7 'D>JXRS#3,SV:=MM,)=XUUC6O4N8BD(E6;E8($'R]FR!4724@5Y#N5#(HL
MG+86ZJ!RNA4%5)+U'1SH5MCI2P]<[,5;)1;KW3@N7%-G$4I<R"&G01A(F8(T
MKFW^V+?9[H;=0LE2<0P80(S \H@QD?4!RK2[]$K<#@[;XGXJ]QY!O1\2[CRW
MY?UZQ\P[_'KT9\$72G*7=F@G3^5/9\<L-I!RS]'96C^TUF1(;= [<!]<A41P
M]-+^B5>![?\ O4\5ON#1\2\__P"M6K#P0]*<AOMF2=!XQ<2?_P#2S[=:G]IK
M,Z-K]( _.:/T2OP._8IXJ_\ U(Q-_P!=>H^*+I3,;[9A/_\ 4/\ XV8-1^TM
MIYCG<G\U)^B5N!W[%7%9Z=O(C$O=]^K?;V_CU(\$72DF ]LPD"2D7#Y( U)'
MB6@XG2I'2:S)@-K)Y ">(TQ\P>&H-+^B5^!W[%/%7W;_ .HC$W=MOO\ WZ^[
M;GOW;<]5^*/I2-7MF:8O\8>\GSO\3T[=*C]IK,9E#D9YPG@8/[_ Y'MI0_JE
M3@=-S#$_%6/+?_41B41VVWW_ +]>^VP@._H$!\^K?%#TJ.6\V=F)R??T@&1%
MGI!!GM!H>DUF,BT\#I)P 3IH53KPUJG]$J\#NVX8IXJP#TA1\2[>_P"K4(>G
MX]1\4'2F)W^S8Y^,W,=_B=3^TMF#!;<GD0)]BQ1^B5.!TP@'J5<5FX\@_6/B
M7SCM]FGT^C0>"+I1D _LS/(?RBXS]9LJ?M/9 9M.=NGYS3QQ?TYG"=Q696Q7
M@#'>/N(6'N&0,GT-C$2=PJF.V%<:+15DCY]<TF[ALJ3TFBDHTBG"21FL2[.+
MA1$IB$(8ZA-#:7@XV_L>QO=HW3M@MBP967@T\ZMTI)"9"7+9L>4H?O \0":N
MQMZUN+AEA#;H4^X ) PI)XGK:9CAJ<\A-;F9PZ3?!W#]E&T8CN56RE)V2IFB
M0D7E=A:NZB%@FH**L+462\A<(IVIV;*6;$<"LP0ZCDJR:8*)$(LIFZ.^"[I%
MTDV4QM:Q?V8W:W"GD-BYN'D.RPZME9*&[9X)&)!B520)(&IY6U^G6R-C7SUA
M=-72GF2W):0@H.\0%I 4IQ))((RB>(D5$WTYKAF#_N*S9_Z I?X\@Z[?Q']+
MOZ9L7G_C5UIS_P 0KF#PG;!(D,7Y$D2&VHD9D3O8D#,C6@>F<X9//2LV[[;\
MH"EAR^UD ??U/Q(=+A_E>Q#Z;J['9PL.?MJ1X3-B$2FWOH)(G=-9D9D [X:
MBD^G.<,?+]9.;N?=_H#3/<^R!SY\N7GU!\"'2[.;K8@]%W=S[; "I^,O8GS%
M[F)G=-:<\GM.VE^G.<,GFI6; #_C0%+[_/WY #3XD.EO],V*/_%7/X6!H?"9
ML,1-O?&="&FX_P#JT@],YPRAS\BLUC[7B"ECON.VVWJ@[=_+S 'I#0^!#I<
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MG.&S_@)F?_T'3OY^:?$=TI_IVQO](N/]VI\9^Q_Z'>]S?YJ/ISG#9_P$S/\
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M[(V4#5V[6JKT_&^'H*3(NPC)>0F6C)*/:$BY20/$M114>M6R+YWKH+V7LO\
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M/>Q\,@FKHTB*[>'=^#-_"HU)0C1<4$>U2/V2?5P>+=&BE;>YV1@<<WJT);L
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M0L6X_P 7*716@UY&O*9$O4_DNZ"@\DG0SUXM!T%)Z?7&0>._!EGQVZ1A:L/
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M0I6(\5#C.?LF/55.E31I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E*
M"/=I^%02!K6M'$7Q+Q?#@KC T]CR\7&,R7?Z]CQ.6J"M2,2!F;3.PU=A4EXF
M<LT-8+$[=NYD9$8JG1,_(MJ]!V2<>H-6,2<ZL$QK^NSG4IA4P?O YDG+]36C
MR?3'8'E8"U3E/QQDF[C0*&-_R%'0,C0&;REL$\@6S'RL5)'L]KKS.1GEY"J]
M>&B*^XEY"P/K#6H*';.9.14(VIC)T'ZGCF,XX#4UE" 1F2#$_K+]>FMTL><6
M52OV1<M8Z+C_ "I6WV)WV%X]X]GZ<^-Y1*9M93#BO2,-%0X2TPUK\4YAG;*<
ML,VSC(IFHDX>&<>*6XR"EDF9[/N.GZRJJD$'+,<>/=I&O*3ZJT-M?318;JUE
MRQ65<3W1\YQ7<'-/E9)&\8I:0C%VCFZ'P2V?7J2D;<U3Q2QF[)+*35:7OI(I
M">K<///F2_7BEDS54X$D#F8SXGC'H_N'.F$Y"8)YCVZ<=.S.0*D*6Z5F@0]1
MK]S=X%S4E$VGAYO/$'!F66QR"[J*Q]&OW\_!JL&MW=S+-J*K-K&15\>Q3>@S
M<I/5^/C9]9U)%(D"SRS]&7'F>(B.9/(S5MVN=1''UZ'0<^[MB9<;=(M@VN8L
MO.3LX1]PP63%V41Q%D: L<2>[.ZQ:C52%O;=VK(8P\L(MS6'5*L$59@L0.D6
M+1FN=M(^!/DO!CV"T@9C/D9[LNWT:54H6.9[0.',2.S/TD#05Z[+TD_"/6E+
MRQ6NUE?S]&>2L4I6HW&F27DM:YF$E[/7YF.H*:%34)>"P<O3K&VL,C6!E(RN
M%BW:\XZ8MVSA9$5ID#(<<IT]!G\/NF0E7;IQ$9_K*/XTSLI=))2,;U;'MLC\
M-Y3O[*S\,\1Q=7AO5W%)0<XLP=)$B0/.SA9^S1 3\T@XDW":==K 23MVA!R[
ME)4@$9D=L8(R!.6?,<9,D>C*>^IP*Y@9]XY<??Z.&NLWTV^#XB4R;&HXGO4J
MGC>P/X!Y*,;CC$L8AX'FJ P<TE;LJYM"#G%\78;#/>.:N[N[6,1GJ_$3SMFH
M*L6LAJN]1.LB<\QIWU.[5GF-/;SY'T >RNF7#1GN"XG<*4K-]9KU@K$#=T)1
MQ&1EC&+6>*-HR:D(8LHQ?PC^3AIF F1CQE:Y/13YS'SD&[82C0_8NB %TJ"A
M*=/QJD%)()GU1EV5.^II1I2I4K/]QTO^4*?YXNM-W^<5ZO\ RBLC7DG^LK[Z
M<FL4B8XZUDK&RL:QE(Z0CI)HW?Q\BT<L7[%ZW1=LWC-XF9!RU=M7!#H.6RR)
MSI+(+$.DHD<Z:A3D$2ZD**"%"24D$1K(,B/?3/@0#S(D#U<:^6OB P"GPA9Z
M64=O,KX/QA.R2\G6LVX<L83^$XIK(K+F80V6\,6UP>$Q<_1<'/',Y:OVRKTR
MPI-1=PT,V=$>1D?]@Z-[57M#9I9:N=FOW;:4XK#:;):?=*<0*;*Z"BVI6$2I
M*F21\F%%15->(VK9(1=.//VKL*.(7+#QD#*#N@ <6<$8AGI/DUIYQ4TCAWNQ
M&<UE;CMG)Y@<QE&KJE</#.;66*=)0P]5^RR?(,#]JF)@(=, 3-U@$H=4>?N]
MD7/2YIHM6FP-E*09,+N&PYGJE13; I.>H4#GD0=/)W:=A.O0_?7R52"4KM7!
MG,89WD:R,],7KJ6^C*Z+7H]>*>P.LO5/-N:,JAA2[5U>QTBTTZ"QNU5E>N>;
MKBL@FU5G7SZ!DEHY<QTXZ6:KK"R<LW"J ")5/GG2[I-TAL%NV5Y86EHJZ0M*
MPT0X$C%!"584GD(SYG6*]IL39VSW6FW+9Q:D-PH8DX"H$F!&9CM)Y]E?8,EU
M=NJ(_4CR*/+D'<(]P;[^CWO1\FC,GB3)]->N[!PR_7JKT:FIK%RW]SI'_D:_
M^;U9'EI_K)^\55?D*_JJ^XTT*S]4_P#<:_Y;O69_]S_._P!6L;7'^JC_ %J9
MRW]M5_QA_P#*'6Q4*U/I/WU;TJ*U?XUYRV5OAIO<I1Y"8B;0::QA%Q;V!G%J
MQ+[3V6J- 2#-E84$'"T,I)1LD\C3OTT%3MT72B@)'ZHE'N='T6SVUV$76Z+&
M[NU+WR<;84BR?<;*D:JAQ""!$%02#E7*VF7A9N;DK2Z"T!@(2O-Y(*0I1 &)
M)PR3 !F:T;M-4XL("S8EH$E.7]YY>WC,<U T6-XD)MG/Q%4K^-:66,:6?-)*
M>A)S";6VFG[ E#&@Y C-O)I,DI%Z5!--/ML+V*MNY<;7;)W#316^Y8E2+AS>
M +;:MQ);PIE.-13C.9",A7)<3?MBW0E-R0M9"F=\U*( E96%A*N8$J.0$D3%
MNFYJXCL?YAQZZR9*W"WXIQ8O1N&S-USBU:LZQJIDZ\,_"']ND':\M$7*8L%:
MO=LQ+0#33&E-X5..6MTA('CGRR[5CE>M-C/V-UNBPQ>76_O[5"TJWB6F5-[I
MA*4)6E"7V@^L!2B H- F)%9&W[]F[:S>7:,H+#I*@=XXH$*5J,Y,R=(C4B==
M*]Q*\2^#*!7<PV!]89@9SA^NMTKB-^R3:<ET?*MA2M$&T6>N($(B(=8\=XFK
MSB2OUE@H&8.]L5.)((Q3I8D1(O8KJO;+V-?/7%M;AD(3?LLJ#++;5U;HW)4"
MVZ0I+R+I8+0)1A;6 5 8Y.BU>;2MTMO+25A;3CR Z=XA1Q !)PDQR@F,X!&M
M=2>!KB*MO$OC6^6ZX/<:RCNIY>N&.HN8Q2WL;2JV&$K#2%&.M39&T2,K) E;
M2/AM,.7PH6R5=EX5!%Q(B0TM(>/Z1[)MMC7=M;VX?0EZT:N2T^ME;K*G%'Y%
M:F4H1C0(2XG"%!05(,9^@V9>7-^VL.(MTX'0H%A+@.;:5D*Q" 1)R$  ',08
MW,$HAS'80$1 ! 0'NV]'NZ\]^OU^O9$]2<R,\M?UVZU[X[?PMER_VVWV]([+
M)]WG\^WOC[857 !.LI4G#!U(,::9<3D.,14SB(!) 3KD>,1)XCU_=7RG?U1-
MAO,&1^*O#$KCO%63;]$M, M&#N2I%#M-KCV;\F0KNX,Q=/(&*?MVSP$'""XM
MEU"+@@LBKU.S4(8?M/@AVGL_9^S-JMWFT+:T4N]0I"+BX9:*T[J,2=X4R 1&
M4P?1EY/I(P\[=,J;0I8W, )23HHR9 CE,_C7 -MPP<5;-<CECPZ\0[1PGUP3
M<ML09*073[1,R2@$61KI5" HD<Z9P*8.L0YB&W*80'ZZKI#L%0PJVQLPC+RK
MVU.AG(;R-<^'&O-&SNIGQ=X]@;41SG2)]=96.X?>,B(435B,'<3,4JDR/&I*
MQN,\K,#DCE%%5U&!#-(-(Y&2JRRRQVI=D#*JJ*&3ZQS&'$K;/1QPC>;3V,K.
M>M=VQZP$ R5D2!D#[:D6UWKN;CL&[5(T(U T(&I.G$T(</W&0SC4H=M@_B:;
M12#A1XA%M\9970CD':P'*JZ29)096J2ZA55046(D"IP54 PB"AP&?AKHV%[P
M[4V*'2(*_'+0*(Y8MY.0CB1.<"I-M>$8=Q<J3J0&UJ',#R2,U9QEI,S%>8G#
M=Q=D$YT\!<2*9E6K)DH=/%642G491QD#QS0XE@@$[9@=JV,R0-NDU,W0,@1,
M44Q*.W>CBH2=J[$(!)2#=VL))F2#C@$@F2()D\ZCQ:\'_)7/"1NU\,A("9D>
MRLF&">-7QLM/!AKBE\=N&H,7$QZG.70E%V/5 HLEI'Q,#M5H!2E)X.=4R6Q0
M ";=U?AGHP$A/PEL/!,X!>6A3.IA(6 ,^( SSSFI\7N^#%S,&/DE#,'(R1J<
MSPY'(5YF?#YQDQZ[EU'X-XFF3EZQ)%O'#3&>5FR[N,32(BG'.5484AUV!$4T
MT2,U3';E23*0$P*4H!*]N]&UE./:NQEX5!0*[NU5A(PPI(4X84(B1GEK51:7
M21"6'TC,P&B!))),!.I)*B>)-"'#YQD-H]O$H8/XG6\4T477:1;?&>5TH]LL
MZ26;NE6[(D&#5%1P@X717433*99)PLFH)BJJ%,^&NC2E;P[3V.5D %0N[0J,
M&0"HKF 0" #D?54^+78RW%QQ!.[5I&><?O201&?HK%J\,'%6N@V;+<.W$2HV
M8E6*R;JXAR6HW9D<*]NX*U1-7C)MRKK"*RP(E("JHBJIUC\]73M[H^E2E(VO
MLM"ED8E"\M1,"$R0X"8  $S R&5#;7< %BX4!P*%GF3E$<3ISK=CHTN'[/=-
MX]N%2RV_!V9*K78O+]>-)V"S8PN\%",$U2.D$E7LM*035@T*HNJD@D=PNF4Z
MRJ:11%10I3>:Z:[;V1<]%=NL6NT[)]]RS*0RB[8<6X=XVI2D(0LJ) 2HD@0!
M,Y&M_95N^C:%FXJW=0@/).:%0!!G4>OL[#IV'Z1?%&6++QE9?GZOC;(<]$.C
MT0S&:@:;9).-<F;8VIS9P+218QJ[9;P=V@JW5%%8W9N$%$C""B9BEV_!9MK8
M]IT)V7;7FU=FVSZ%7X=8?O;5EP%5_<J3C0ZX%)"D*2I)*8*5),Z3X3IQLS:#
MO22_N&;&\N&G$VY0ZU:/K3*6&T'"M"")2I!XY&9TK3M?%7$LY.Y4<8WSBN=V
MW39NCJU&]JJ.FJ)A,DW<&/'"*R"9O7)HJ=9,@F,)2@(CKW8VST62$I&U=@!*
M5*6D"]V?A0M0@J2G> )4H$A1&HU,P*\J=F;7423L_:9)2$DFRN@2D'))5NYP
M\8Y^B:H1Q-Q)("J=#&N;T3JD425,2GWM,ZJ:QECK)J"2. 5$U#N'!SD.(E.=
M=<P@)E5!-*MM]&%1BVML)020H WVSX!3&$CY4@$81!&8A.D U V7M9(,;-VD
M"1$^)72C'$>1(!'#0U2GB+B00.@LCC3-R2K4J1&RA*=>BG;D0/UT2(F+&]9(
MB)_7I%3ZH)F#K$ H\]6.V^C!"DG;&P2E<XTF]V?"L0(5B^4@R"021G,'6*J-
ME;5D$;-VD"G-)-G=Y$9B);$08.68U&8KT#B[B:,H*PX]SL*IG)79E1J=][0S
MHI$TR.1.,>!Q6(FBBF541%0I4DRE$"D* 8OA?HK&'X4Z/A.$IP^.[/PX222F
M-X1!))(T)))S)JYV;MB9.SMIDR"3XG=22 .MY!T@ '6 .58YQAKB%<E4(ZQ5
MF9P10PG6*O1KJH10W;*.3&.!XLP&$7"JJ^X[F%94ZG-0YA'.G;W1E,8=L[%3
M @%-_L\0,(3 PN!480$Z>2 "(%55LK:L=;9E^H S"K*Y4F2<S!;XDD\YYFK@
M8PXB2N.Q+C[- /.S,Y*D%5O/A (J'$AEP)XO!4$SJ )3J@'5,H'5,<3:Q_#/
M14),;4V&$F ?Y;L\ E(ZH(#D9" )&67IJ#8;7*@#87\HG"DV=S(Q'.$X<4'T
M1S.=76^)N)%L[3D&F,\UHO$P6!)VC3;PFY(#HPG<]1P2-*J7PDYSG7$I@%8Y
MC&4ZPB(C*MM]%UM%M6UMA*2<)4A5_L\H44QAE)=*2$_NR)$910;,VN%XT[.V
MDE6?719W84 ?* (;&N8,&"-9SE/4DXD"K"Y#&6;BKB<RG;%IUZ%7M#@X YQ4
M&.Z_7,#MT!C];<2N7 "(@LKUPVUT7"0D[6V$4P(2+[9Y @@C(N81&%,1Q2"-
M!%O@S:\R-F[1! /6\2NDJ.($*D[N3,F><F9DUY%,(Y^7*<J^)<PK%4<'=G(K
M0[DH!W2A>JHY.!XH0%<Y0 IUA 5#%Y";EK(.D'1T&4[;V,F$A (VC8 A _<$
M/:3F!D!5?@G:F<[+VB9,D&QNB">WY(@UZ)##W$7+"B,KB[-,EX,EV+<7]*O#
MT4$^7Z6CX3&K=DEZT/6DZH<@Y<@U1O;G1EG%NMK[$:QDJ7NMH;/;QJ\Y>%Q.
M(GFJ35E;*VHY 7LW:"@D98["ZZL9 )EM4) T2-.=5M<0\1K%P=ZQQCFIF]62
M\&5=-Z5>&[E1OL0O9*+)1A%3I%*FF4$CF$G53* %V*74+VYT8< 0YMC8BT X
M@E=_L]0"\\P%.D3UB9$:G.9J$[+VLTHEO9NT$J(@J197:21VE+0)B!D8&0JZ
MGBKB50! $L<9M0!LT/'M^SJ-]2!%@N8!69IB2/#LVA]Q,HW+U4C"7<2".V]%
M;9Z+*Q8MJ;!5C4%J)OMGJQ+2.JI7RF:DP %&2.!TJ1L[;"!EL[:41A@6-TD!
M).:1U?)))R$9YQK6/#%/$!(+" 8YS"\<0Z98@X>2%T=+1:9VB3@L4.\<91DF
M9@^;N 9""93-7J2P)"BX()[C;G1EM*@-L;#0E:L:DIOK!*5JD0M0#N$JD"%$
M$@@0<LBMG;340?@S:"E@%(5XG=%029E(&[R!!D@ZSGD:]R>)^)-!P#U'&V;T
M7A3=H5V2G7DK@I^Q,W X+$C@5 W8'.AU@-N")S)[]0PE&5;:Z+*;+:MK;!6@
MC^;5>[.*#F%>25QDH!0D>4 =14#9FU@0H;.VDE0T5XE= IRB)W8C+JZC++3*
MLC"X^XH("68S\7CS-+>6C'!G+)TK1+B](150Q3*@HV?Q#AFX37$I?"&[ENN@
MZ#8JR9@ 1UKW.TNB-VPY;/[3V$XPXG"XW\(V204@1 4AU*TJ DA2%)*2)2>%
M6:L=ML.H=:V?M!"IP[Q-C<$I48(40$DD2"2""#Q$"N@7"-P+9"SO=G>:N)2&
ML32OA*F=!7K'%KQ<W=Y5N7LP)(QJC-NM&UI@":296Z;9L5TD@E'L$$8]$Q@^
M;=-?"'LSH[LUO8?15VU=N2R&DO6SH=8L6,QU'0I0<N5 &%8E096M148/M.C/
M0^]VM<KO=L%]E"'2XH/IW:KE6N%*5B4ME1$R!EU1A@D=]V,*$<T:QS"+,R8L
MFZ39HS:M/!VS9NB0J:2"+=-,J2*21"@0B20%2*4 ZA"^?\V.7"W7%OW#Y<>>
M45K6XK&2X223B)S))DD]IF<J^V)8:MV&6;8#J)P]70 :#+R0 ([\S)JZ:/?"
M(B#1QM_BC_C#WO:U0$#585QF1G.?XQ68F#"B,0US&OJI2L7I-]VB_/EN*1QV
M]P *.X^]Y^8:8TC(D9D<>(!RJI3C\D@QZ.,=M6T$CKF7*V(*YVJQFKDJ0=H*
M#@B9%#(+@GUA17(FJF<4U *<"J$$2[&*.IQ)&I$&#J!Z#-%HG" 23D,@3RF<
MO;E.?9"^ /O8;G[@I^3J)',=XIB^BKNH\ ?>PW/W!3\G21S'>*8OHJ[J/ 'W
ML-S]P4_)TD<QWBF+Z*NZCP!][#<_<%/R=)',=XIB^BKNH\ ?>PW/W!3\G21S
M'>*8OHJ[JN$CWVP_J1T'/]H/[7I(.A<"<L4<=?=5@C>9X=,LR$GN)%6S)* O
MX&)# [,B=<K42B#DS<AB)G7*@( J9 JBA$S+%**95#%()@,(!JP6#GB$$'CS
M&6O]^58L)2=# 5Z3D?UV4> /O8;G[@I^3JLCF.\5?%]%7=1X ^]AN?N"GY.D
MCF.\4Q?15W4> /O8;G[@I^3I(YCO%,7T5=U'@#[V&Y^X*?DZ2.8[Q3%]%7=1
MX ^]AN?N"GY.DCF.\4Q?15W4> /O8;G[@I^3I(YCO%,7T5=U6UDCLR=N]*=H
MAVB"/;. %%+MW2Z;9JEUU.J05'#E9%N@GOUEEU4T4P,H<I1D*&>8DB!!]QY3
M4*),0DZC5.7Z[:A+*O#AAO-MDQM<,G51W/V7$,XZLF-Y=I;+G7%JQ..BH-W<
MBU3JED@F[Q=PV;BQ<$E$GR*K%1W&K)F8OWJ2J 3J)!'&-1)Y:93KKWR'" !H
M,P1''+L]ATTJ)+=T?7!]>8RNP]CPVQ685)I&L:X2+MV0JXYBFT+;9F]Q";>0
MK=KAGXGC+A/R]C8KJ.#KMI5V1TD=,[5IX,W:?TJ(B8,@R,R) )X]DBM4F),]
MFN8YCD#GR,1E4[)X3QBC.35F;UP[>Q6(V.1GIIM/65O(S(8F.^-04Y)TC+IK
M/4(+QB_(+9P<Z$ND^73GB2I%%2"P)!D0/QUY$Q$Y3/&.51*\\U'E).6GG <N
M'WYB,Y+@MX7)>=@[*^P[6U)VO3<K8XV23<3;5<TQ,Y+9YB>.)4&DJW3GD4\G
M1[:Y1K";)(1\++*OCP[5DA(R39]&!/I/ YYSF>7><]-=1)*\X&O'*9[S,C(_
M=E27[@PX:<H7NW9*O6-QG;C?<<+XCN$@:XW^.9SV-UX]Y'GJ#R!B;4QKP194
MI!\LV[*+3<,Y)RK+-7"$D?PHHH23),Z\_5ED/1GH3.=)6! T[8GOUX#B)(!R
MSIMV7H_^#ZX8Q1P[9\+1$W0$;5*7=6-?6&ZK2\G;9N%=5F;GIRXC92W.P2$Q
M6WSJ DEIZ?DO#8-4L0Y34CT&[=-@3! TF9$C/MD3F!'9SI*\M00",B,QEVY=
MT=G"O;9N!#A)M[=5O/X9A'9E#SBQ7J$W<(Z5;JVBW3MZLBC"9B[&QE8U2;M-
MFL,A)*1[QL=VWFY*(54/"NE8XT8$^CAPX'G$@9G0D^J*2J,YUG43IK((S[>'
M?63O_!1PLY2B\>0M]PY7;!%8LJ3.@4MBLZGFB+*@L$XHB%"E_%\NV-;J,?Q%
M#J.JC;S3=??+Q[9P_C7*Y3K* A.D#*(G^'+7,<XX"I)4"8G,<_3VY:YD<0<L
MYI'O!/PKR$K SCG#-9&6K4_-V:*?(.9]DL68L&2V&9)-Q(BSF$0G6QLHQS6Y
MLHN="1B8:6!PM"L6"3U\V<3NTY9#O$ZDP3/."-?3K+>GF1/&-(B,N1T,?QJ9
M,<8NH>'ZJWHV,JVUJ-/9R$U*1]<CG#U2)BW-@EGDY*(0[5ZZ=%B(H\F_=KL8
M.-%M#Q"*H,HIDS9)(MTY" G),1Z1[Z@N3F9]FGL_'TT^^H;T?&'RZF#V>H@G
MV30+!Y^N(]>=(("'?H%$9 _<:D$'2I3K/]QTO^4*?YXNM)W^<5ZO_**RM>2?
MZROOIR:QUDJA3F0P>US[N[<-^_EW?F&H)CF?1K3]=U:9<8N)5[K0%+]5+2ZH
M.1\9M7LK!V@C5Q*5][7USMCVBL9#K+9PV\K:"_CFYGLG%G.J[C7#%":B45WS
M(K%[V-C;0\3ND-.--W#-T2A5NXHI!4!"5H6D@MNI"S@6" "3)C,<^_M/&6RI
M"BRZT)2[$I R)"@3!!@3.F8'*OGQS10,YRBS56)Z*/A8S0L_>(K&O&.:-3K5
M6K.V6$=Y!"QXRLN/;)'F>]8IU#6BM1S]J545'2 "&X_5[*YZ.,M.EW;_ $CV
M4ZEE12A3V#"_AE" EU"RX@+ R;6H% @$"O%W#>TUNH+=CLR_0I:0XJ4[TIQ8
M5*4$K2$D@&3 @G21!^DGA?X>L/\ #WCYI$8HPQ3<**6II$V*Z5NIM$]SV96-
M0*[0D9<ZCA],C$+*.8]FNZ=N$T42F*U[--0P&^0;1O[J_NG5W-Z_?!MQ:&7K
MA6)9:"CA,#(%0@F!/ D\/=6ENS;M)#3"&"I*5+2V.J%0)'/(Z<!PS)K938/0
M'O:T*VJ72E8N6_N=(_\ (U_\WJR/+3_63]XJJ_(5_55]QIH5GZI_[C;XCN]9
MKC]SU^W#6-KC_51_K4SEO[:K_C#_ .4.MBH5J?2?OJGUA4SJ*' A4RF.<YA
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MO8R4!<SO6D@P=))S%<_:FV1LYUMLM!W$@J)Q$$2=!"5#/4C+GGPYS?HG[?\
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M)P*RBOEKUS+BN@BN*QC=IVR22H"!TTQ+*/"-X.D)"4;8L4H  "$;/O4I "<
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M</S[_CU41 RCLB(GLX=O*K?K]356P>@/>#0@'4 ^FE)U"?L2_O0^34TI=@]
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J !V$0 1 !V$0#<-Q* [?:TI5S2E&E*-*4:4HTI1I2C2E&E*-*4:4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g150774g15d63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g15d63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )<2^EF@X0DE-! 0      #T< 5H  QLE1QP"   "=1,< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $#FQ 5G.QC%"#3X'85K[,WHX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ,8   $D0         !
M                  $             !)$   ,8
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ,8     %)G:'1L;VYG   $
MD0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #&     !29VAT;&]N9P  !)$    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &V<
M   !    H    &P   '@  #*@   &TL &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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MS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         /_A
M/_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU
M-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#0M,3!4,30Z-3(Z-#0K,#4Z,S \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!3
M8W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3$P5#$U.C W.C4P*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP-"TQ,%0Q-3HP-SHU,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D
M9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @
M(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:3YR<C$W-C,V,CPO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @
M/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R
M9" M(%1E;7!E<W0@4RTT/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.C5$,C0W0D5!1$8Y.45",3$X,3DX0S0S0S@U,T0Y.3 T/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.C5",C0W0D5!1$8Y.45",3$X,3DX0S0S0S@U,T0Y.3 T/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z-4(R-#="14%$1CDY14(Q,3@Q.3A#-#-#.#4S1#DY,#0\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C5",C0W
M0D5!1$8Y.45",3$X,3DX0S0S0S@U,T0Y.3 T/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$P5#$U
M.C W.C,Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-4,R-#="14%$1CDY14(Q,3@Q.3A#
M-#-#.#4S1#DY,#0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C$M,#0M,3!4,34Z,#<Z-3 K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C5$,C0W
M0D5!1$8Y.45",3$X,3DX0S0S0S@U,T0Y.3 T/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$P5#$U
M.C W.C4P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C5#,C0W0D5!1$8Y.45",3$X,3DX0S0S0S@U
M,T0Y.3 T/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.C5",C0W0D5!1$8Y.45",3$X,3DX0S0S0S@U
M,T0Y.3 T/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-4(R-#="14%$1CDY14(Q,3@Q
M.3A#-#-#.#4S1#DY,#0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M"2'MU9Y8YG;D3M(RM&S ;#;N  >_/T;$SZAJM:>0NU:[$\/(#=:UF))(D&P
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M6WD;]M$=_(7Q3/;'Q=+Z*?UNUF,/QECYT?51Y.&5<GQC&,8QC&,8QC&1D?\
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M%J[$5N+MX!D>E+<9<:3/[VY#6B)0G6F].B+5]1601GU2%,"MGMMLQ$_!*?\
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MQZI5R.,B9J'+5&H(:$<-99F8Z/60.T2^PPZX/IQ+3CS27/;MQ'NQ>"6-0[J
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M\CL=CV.<*+GSYRM0-P:\GK2[6+/7K-:X";;,YTL"4KU- 7*6J5%>3SC?N&@
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ML35+=:4 @2068'CFB?8D<HW4[$C?8D9%,YXZ<1G(Y^-7S&D1;96JPR61!U6
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MJ C!(#0>S S$D*HEJR25Y-CLTC[J P U":=.DL4BM&%](NS3(267E*+2P2
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MR%\4SVQ\72^BG];M9Y#\98^='U4>3AE7)\8QC&,8QC&,8QD9'_E+O_VZ=_\
M[^_?X<MI\0W\AS^7D>^0/\8O\M!^3MVSXK\JMZ_8^L-?@_8_W36>CX@?-L?R
M^L/[,\_VG_B?W9)V4\L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9"W'_[
M9=I^V>;_ $/H^6K/P:GT5?K9LAA\YOGF_03.0K\X2"^QJV?IO3,#[2?Z5%]3
M-@_;"_,M^FF3+E7)L8QC&,8QD:<@_N>P?_MYW](97+-OX]OY$/U,>1Q? _\
MRD^L;*;WN^S/,..]"OU>!'D)BKUTJ2!:,;<> &<2MMI<K)LLOC/.Q,(RZY,R
MK3)##KD< 4AIYMS:5ZRH0):N5Z\C%$ED"L00&(V)X*3N.<FW!>Q]9AD=J5H:
M\TJ %D0L-_(>SDW<>JF_-NX]53WS&:U]!OW/X4.%'\EZM?3;I?N=55^[F5:@
M,&\<AKHY8%.6:2$K\D#7S8N?(B0ZQ1]6")TD>PR [LA(V5C:PD;.&O7L2,[:
M7/76"O:E%<2V2+LD BVA5I$,@>,.TLYC/>-2$2,]S1DFFA0*+T<S2RPIU6CA
M'HZ2E_LA5"%96XA(N0^$1R9QN<LNR]\ZY2J9TE,!= NQ6WDG6JE4:@X%7X-A
MWO.[+2H^;F.<&"544Q@.VTY$K(V(Z6IP,2T.'70]R<>T$F>:7+'I]2>:L9('
MI0W*<TTX,CD4.E,T:609BK-%/P6,1SLYWD)5_B\P>W/%'+QD%F2O8CCC(11Z
M5SBY-"1&" \?(N6C 'J+R !;+RD.C=+U.^/ E/[M 7AVXPG/)0^#9J=9'8O=
M<.E];Z3TFS2NFF':C I@B1P^<Q5<^1.)N6AX@]$\TL[04:5:W3U(S4)(1 ]A
M%D,TI,$JI_!JT2=Q/(9%+6'DW58"SKP(4G-IIP],1VDE$J1$KP1>JC-]FF=N
MQC0(0L*Q[,9-E;EN2,A_'>[370N:)LL^2^7(;OG78'3Q'U=\3Y&H]9NU3BFO
M_-<7#"?#8BX4-AK?R.B=M-HV<7(G?,2)6NU"!*]D1Q@*IK4I=@6^%/3@F<^N
MSD$O(VXY; ]E"KL!=J2M-#S8DGK6$[[>45B6)?@J@^"@_B[_ "DG<GO>0P8D
MCPSK4?("C' '4"S!FA&,-DB&"$Q9#)(I0SR5LD#$,K6R^PZA;3S2UMN)4A6]
M;QTYBMZHRDAEL1$$$@@AP001L00>X(/GF5D UY@>X,;@CV$;'<$>T'R(]HR@
M?[$SQ9_>V\%_B@Y[_-W//?"_]_7?^+L?M,\]$J_>U?\ ,Q_Y<?[$SQ9_>V\%
M_B@Y[_-W'OA?^_KO_%V/VF/1*GWM7_,Q_P"7-5?<^9\XYE]+'X$1W-Z!2Z!'
MR52OYLB#2JM!U80\Q$->F$%&#08(+))"&4):0^\A;J6]:1I6DZUK.DIS33^&
M]9:>::9EE@53-(\A4=2 [ NS$#<[[;[?)[<U<\<<6JT%BCCC!60D(BH"0L@W
M(4 $[>TYH*^D:_/D\F_M1F/] )G3Z-_T3IWT6/\ OS37_MRS\ZW]N6-5?*[J
M//\ @+/".=S]MY\C?6IGJ,G=*3>K#5I699F:=!U)53D@H-V/^9BQOJ1N50\1
M(/Z62[\+Y)&FDOKGDH5IK7I<RQS$5EKK%+"DBH5E>7J*S D,2Y7L!V /+?,%
MLR1PB&-G0=1I"R2,I;= G%E  *C;?N3N?9D^<'^D.F>.5;G<;.\>K_1[IQAR
MS)Y%T=^_7ZBSL#%6J:7:)2KW$:F28#/2JB]:%[F7*[8WD!$J4X*9M]I?JFK<
MTB.T\S):>O%:$?I-<00S([1)TT>(RJ>C((_4YIL1Y@_+-!>:%4!B5WA+]%^<
MB,H=N;*W!EYJS=RK';\/?/Q$>>4 7R.N<RZ;P0F^&5T_JDFW98+OG4.5#FD]
M9N<O=9U)]5HVQ8J1&&/E/E16)<F23H1A3:5--EDM*R.E,+,D]>Z(NHM90CTJ
M]G;T:%(4VDF7=20F[%54!CWW"@X%Q3$(I82^QE.ZSRQ ]5RS<E0'<=]@#OL.
MP\\@3R<,YB3,\_8YH_S620%1AD6R9Y= 3E4KYED+D3I!V-U 3T4!((16 RQJ
MT%.R1\]/6L6,189Z2;-.T ':I"<1SFQUQRE^Q+/(DK! H 821LRGJ,#(458T
MBY!$4@%L@F,9Z?3X'U/7,:,BEB2=@K =E!"AB69]BS'<@#8/]![79JR^2O3
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M&E2;IE4$EF5PSR<I;E\2P4II=I%>-)+!=6J3&*&/2+R],J(T9Y3J"59BB0N
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ME-O#DL..,O-+2I#C:U(5K:5;UE96*L&4E64AE8'8@@[@@CN"#W!'D<F(!!!
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M\7^^/Z_\,??PY9_?8Q_V9-_ZLQZ-/]S/\Z_XXZ\7^^/Z_P##'W\.6?WV,?\
M9DW_ *LQZ-/]S/\ .O\ CCKQ?[X_K_PR.CNS\RW8-NZM3&T?,)_7?5\QK7I[
MM[_#K<=K?KZ_X,N)5GZ##IMR*L.Q3;S)_P![Y/ZLK/8BZH',;!E)['V;$^SY
M,^*[-S+=E^-NU,>S9VE^[ZNF?['W>OXOJ[W?_+_+@5I^A\620I'FNVQ)'^]W
M[G_GSQUXNKMS&W+?R/R?B\MN^2-]_#EG]]C'_9DW_JW*?HT_W,_SK_CEGKQ?
M[X_K_P ,N^JW2K7<0TVJ30<T-&R"HF16)MS2P)) 8<@H$QEYMI\8KY"1 -TR
M\VA:A3!B$ZVT\VI4<D;Q$+(I4LO)0?:NY&X^4;@C?Y1F22))N48-Q/$[>P[
M['Y#L0?Q'+HS#,\8QC&,8QC&,8QC&,;_ !;_ &<8S'S@WDURWR.7T=OF9LP8
MOEET,H-MU+0Y$1\"Q ;=T0T%M]:_G1=;97[26_:E7X/UOX=9=N4+%$0&P$'I
M,0FCXN&]0_[VWD>_EW_'D$%F*P91&6/2<QONNWK#Y/E'X<R#RED^,8QC&,8R
M%N/_ -LNT_;/-_H?1\M6?@U/HJ_6S9##YS?/-^@F<A7YPD%]C5L_3>F8'VD_
MTJ+ZF;!^V%^9;]-,F7*N38QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC(5'_.+F/L5KGZ<VK++?:47TN7ZB/(A\>WS4?Z<F</)ORV\C?MHC
MOY"^*9[8^+I?13^MVLQA^,L?.CZJ/)PRKD^,8R$.2?EAY%?;6)_(IQO+5CXN
ME]%/ZW:R&+X=CYY?U>#)ORKDV,8QC&8J]4\@.&\BMXP'4NQ<TY[(&[;(%CKC
M=J]7I$@92UZ22U'R<@,8L9:FUMH(2SME:T+0A:E)5K71:5X?UW6*SR:7H^IZ
MA&G)&EITK%B)7)WXF2*-T#;'X/+EW\LU%[5=,H3(EV_3JR'BX2>Q#$Y3RY!7
M=6*D[C?;8GMOF-7;OI"_&^@T#I/1>=]HXQTJV52#DY:L4F+Z57"3;+.,_#;C
MHIL2.DGI-QMTI]G9.@AW"$#(?6C6O9M2>FT7W//$FH:GING:AHNM:94M6(X;
M5V73+*I6A)9I)2\L:Q J@(4NP7GL#[-]-J/BO1ZM.Y;J:AI]RQ!&TL-=+D):
M9P $C 1S(06(+!%)X@]O:-BM5LS$]$P+A;T8-8).LP]B.A!#VBG1&9(9I2WF
M4;V@EZ-29MX4<]3"&GU-;UK>G-*1K@+-<P2SA%E:O%9FKI.\;(KF-CLK'8JL
MI3B[1\BRAAN-MB>I@F$L<18HLLD$<S1*X8J'4;D>TH&W4/ML=OE[9'_*_P L
M_(?>_P!CL,;^'_!KB?'OP?\ !_@S&P?5J?)Z(3_ZJS[,RC^'/\Z/J8<EF)EX
MN>CA)>%D Y6*/920#(@$-%!EL+]?:Z.0RI;3J-[UM.]I5OT4E2=^BM;UD+*R
MDJRE6'FK#8@_A&2 A@"I!![@@@@CY01V.4&^@2<C3["-#6*9JDI]5DO S]?9
MA"9>/(%UHI"PV+'#6"&=4_\  V*Z@V'-3MA]WX*6B?@D-5;J2/5G6*>6M)TV
M9)X!"TL;*.0*"Q#/">7'B0\3CBQV ;9ANO#T]2MK>F2WM,HZQ3%N*.QINI2:
MA%2LQS'HL)Y-+OZ9?01]3K(U>]7(EC3F7BYQO@,3Y1]%Y#SFHB349,=1NTQQ
MNG]-:D;,*U%2,[*3]'ZG;K1$I8IE0B88*/JDG3:K!)TB/V>.S;X]J2<*D7 G
M#^&_=+J&EZ=26>*74[LVCT]3ZE@"&2:6Q2U2W:CXU*<<,<=66G5@'V,.HMQA
M^<A3J?HN'W(_#'C3Q1K<VGW*/A'0*7CK6_"3U=*F>Y5TZIIOB#P=HFCW.IKV
MN7+]FSK-/7=8U%B;1KRR:):>JL-9)TK56R>778JG(;BIOE=*&T]*W6';LJ+%
M=2*S#NT*9E8LP^Q.#T=V0$!MY8\- T_0@Q+CL_-@ME+6V4PQN6QXIU>M)TY=
M+IJ#+;A](])N-6B-&>6%Y)RM%G5+;+!!3"*Y:Q.@8D$ U-+]QCP/K-47-/\
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MTW]\CTK^"7$_Z+LD](K_ 'C!^=M_ZC,.E-]]2?FX/V>/O7=-_?(]*_@EQ/\
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M/*'PPZCX_P#3#/,_P$91$7ACXIG6^#B,N*J_4H;;VS9=V'@Q]H:5)%;3M\R
M$^5>?(3]:U=\.?;T+);NCJL%RN-+UD\X3L*UP_&UVV"KS<^P>0D(.P)60,IY
M+K[5.2"3TRCNK@DRP#NLBGN>*_A/<H-COW0J1L<X?#GS/Y?YBT#=BJ#JX"[0
M"60NA\TEWD:LE-F/PM.Z=:VEIP^#)(;=U%S;3#;1.D+'+9!DF"P!]3J>EV-,
MFX2[/$^YAG4'IRKY]C[' [LI[CS&XV.7:ER*W'S3U7'9XR?60_U$C?R.WX"
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MK2DEE;Y8C*'6=K;4Z4.WI6UO-Z5$+%@E@*U<E3LP%" E3L3LPZ.ZG8$['8[
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4&,8QC&,8QC&,8QC&,8QC&,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g150774g16q32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g16q32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (PJ^B7 X0DE-! 0      #T< 5H  QLE1QP"   "=1,< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $#FQ 5G.QC%"#3X'85K[,WHX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              &@   &(P         !
M                  $             !B,   &@
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   &@     %)G:'1L;VYG   &
M(P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !H     !29VAT;&]N9P  !B,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &*T
M   !    H    "H   '@  !.P   &)$ &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
M0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N
M +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!
M*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0')
M =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"
MF *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.*
M Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$
MM@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&
M!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'
MF0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/
M"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+
M40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT
M#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/
M[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$
M$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585
M>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*
M&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<
M APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4
M'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8C
ME"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K
M)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L
M.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;
M,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U
M_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM
M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
MYT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42154
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?)4D1MKJS::(:/:[K6[;+69^W*!*M033=\L'X-12M;#1H^,7K890<R0M)G7
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M8?T#4PE'@M-HE2&X7]E2XYC*L,?U>,^W[<(L)3T9Z=I%8")ZUZ=P(QK^)JK
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M4,^3A,E9+:L.J2Y''N/IEO(REE[.%MLJ3G#3N<9_JU^,!6:P3#7*Q -@V["
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M?"BQ!A,A(>;@CILA@BUZ=^]R=E--]L^OH'5FV]U+I^T900H=U;5*]K>:%EC
MMZH%*+5>D.YZL;?M1"U'F+5/N!S\];*UK68-<"&,A[:-=2IP.1;'>S51WM;J
MQ0,: O;])M +;NO3MF1G )(JSZ^B&<,W("?<+""<W(O\)D.%<0Z\^',$IHR&
M/_$OP^3.A3"+5]K74?JJUP-9)N[=QUQZL1NLVTAQ3\W2A6S13-N?LY(@-CF*
MU5,ZY*G;4JJ)DYA7*!;!H42%EC@DP47GC9"9)%MVZ]^[&@M'^_.%*QJ#6GNR
ME.4IRK\F!?.4ISE6<8SG],>Y6<?IYSGA%KYQM7M16.UG:T73=54MG6Z+'K)X
M?<RX_8%\F$"F=:!(DIB8'UC%GE0;#8R(%),(>$$?ER6=2]*CK@NMYIU;0BH[
MG)!.GHS"=W/,[%6E+;BC)\:B+1N-9I;/GT+&74#@PF+L7[W79]/C4^YP7X9S
MU]GC52>+#Y#$.=L;E7&N3B/-.0%Z\,FI\KF/$_F\8L^@,Q'%(WI?N><4[%W9
MV%LG:[JP"@5'3-JM+JMD/Q2@K86W*,$U_ENN81C\_4VR"1=HSBQ>Y^!&>'U4
MKE[#&(A9+<)2,\]GU<VYN8D4&G)'*3W"DHO9LTCD:.!SB^8SY2KR$WGW_KH"
M8O%@=G9NDH\1Y+B\!YU<T>*UK%0!QAI[[9>9N05SM7A@N-G<AJ!>@C=ZK"[M
M4O?LG)YA\#=S5W[8<[\IJMF0-UIU&ESE@3"!LJ3NO<$.+'F*&RL19$R C0TU
MR5&8?RVX_%9(1')+32VFY<5;N'FK7/\ ZB7^,9-_-O[_ &_!<CH?[=2_'_2Z
MW_K!]?JL6T';>ZX_26IF"&BNO5@7'US3&TE!'8V[@\E&$5X>F--R#)=<R"1#
M\F-AIU\=^/EFXDA3D=!*6VVE]>AA_P"Y<CKOK[,H==]=NWRL7N_7MV_U?^/Y
M*?YWW_3?F/?7?]*>0=]?3_>UOZ?7V;Z-W[NJP=0-F=XP6\N^D[9G5[%EKML[
M%!++4!^OMA4&'(JC,32NKZBH#-*WLQ346EV57:S4C:"#<,1E#Y"<]\'P3HT,
M=[1U(K]B_6CKW(3SK#5IRLQ!&!2E#%89HG&61S9X9X9>^A;QD'_YNV;S?XG:
MX]G<?TK.EC7(N29YZ="'-MS6;$=,+5BB4EN.2K ,#M>IW*C@QF7K5979GC>.
M0\A[3=S>PM!V#U;#0]/=@=%B-D[T9UI9(\NN]6-HL[$B3*#>+I& 4M8K>IVR
ML6YR32&XL=E@$S&="$#3_P V344+%D2?Z_7Z_P"BJRL5M3O2"IVK;U:Q>M]U
MU>XU6O$S4(7MOKEV(#5!:Q4=<^0T9NM-UK;0$*&Y!8DX24BE9<*(_P#$[/>8
MC)>=;(LCT)WDT#M*H41-EWSU[%[8L]>"%RVO NSQ+,^#-/1VYD,<,#6UT#;9
MWAB3'8PZ\$:S)E)=^F2XUEM2B+%=&P]=J[V=QU5RSR"ME"4+KM,,@,;&LUA@
MUV3L!C9!@G(:ILZR$ %;=L48#69J'1X8?ER)&C9BY1'DO)??K]?K_N5B]G[\
M":KOFHM?%:3L>PDMT6:34JJ7J-?@%JZ/,P1!.QSFK*0DFASPEF)6@9RPO/HA
MS$?A8:?EO*YF(T2013MPB<(G")PB<(L)V74IE^US?J*/LIBF3[I3+/5(5PKZ
MTMGJK+L06:(CV,(XK.$ME@CTQ!(<O*DX3+C,J]R?'NP1:[.C^C[W3-F[7FW?
M;NJ#);66K]2]426OM"1MEBP->>U]6F+G6K;=V-DVJSKC[(FT:^UQ4%@+AYF#
M7Y["2E@LLIYE8\BJ%Z2VFI.O>T_;XF=9V#(M(PUL.G3S6PZC8!%E+PE[NLAL
M>>LEK@]:M*ZZNA>ZCOP^XP9PNY[!)Q0I.,U 5$$*D.+(OH =CL/9QEYAEW.$
M.-XRZVAS.&WL8PZWC*DYSA#N$IPXC_<KPG&%8SXQPBJ>:99C]X=1L,--LLL]
M4M\MLLM(2VTTVC:_7-"&VVT82A"$)QA*$)QA*4XQA.,8QC'"*VW")PB<(G")
MPB<(G"*!K*'$O=B-7DWA0YXBUK/;"FY[L*,Y-0J,?U0AC*)2FLOHRPB7*0UE
M+F,MHDOI3X2\YA4#9AA+D>5*\492ME;'4C@+R#XV<?QZ/KR;KR)F]VZ\B9OJ
M_?0LR[<#X9<NJA;M!5+EG#&*L%B48#:3-YF4C% Q>!,90PD?8_?**)R[<!ZB
M?NZ0KEATO>]4RJY'NIRQU24:R%?QE4"M" \IJ4W>;$ZAYAR(/%$XC6 \=EUN
M=8#;30N!EME!,@-A^='6LX>ADG5&_/:IG-Z)?ZJI%"7F.A9)G8HXX90;T!']
MK9G9HHNA::2*X_ .#4S.><=YA#J2X&?E;,-!K\?M9UKMZ$H3X[F 4<@36;M2
M>1[TL@'6S<\CN66(RJUK4]:PU+7-:#,?2968L<L? @F+40:922GQAK.&( R&
MRTG$4'6Q32<,A:R(;BAQC.,K:CN37Y<V38<S(K9D?4?[6P<<<<]J06]608Q8
M8X@9N@@JQ,WC!5A8(8F[=A<RD,^<\KYCI\KL]V&&EF0V+-BCCUC-ZE:6U(\E
MFW.9N\VAJW#?U-#6NE->MR="4HUXX((>MTK'888V?\++3/R[EV Z[\3:&_D<
M5-B^YQ>$83[G%8QCW+5Y4KQCSG/,6*(BVJPBPL^UH.[,S-V[E&[N_7U=W]W?
MZN_U6[SJ220^)>H9GX<&XV ^9$7B#0S= /D[^(MV_0MTS=^S*:>32HJ<(G")
MPB<(G")PBUC=F.Z&R]9]H*GUOUI,ZWP"UGK=$(,KWG8=FUN5,,WQG>Q8='&3
MJ=5CX1L6R T%;WI4PK)A9BDU"X#N<NFAJ'"*F7K=:V:N"NK1BRE;;BL%"MWH
M!:!""S;9KN 9LP,>L5)R'K_6KL'=(UXLKS<D!4SX9FKO1&&7T19R"CD9U!%O
MR",)C!1$9*%(1'%CV$MKP][T):B,MI0O$EMF1[DX3C"OJ&FG_.,_*VASW)P1
M=%<H,%FH6IYJ'%:>:J)^*TZW':0ZW&R-DN9CMN)1A:&,N(0O+*<X;RM*593Y
MQC."*+NIG^]9ZV_^P74'_P OJ]PBL%PB<(G")PB<(HYN&R(=-LE&K,JNV@K)
MOYAX&(GA80^2+AD(X^:7?07?E%(3\1MH0,)E%.LQI6,Q1\A*,*DY88>C;FD%
M*S0JG7M2EHS%7AD@CC.()0C.<FF(YHR!F@BFE[$#^[&73.70O9L7C%C;R^0:
ML.GD4XN-TH]"[7OV+45N>M+:KT8BI1PT[$<Q'>MTZC!)-"[2V8W=VB:22.&N
MSNWC=1H5^ ZYK$Z\WF!035A+P!L%XHU5JXN#.922(1([\1P@7*J8E1ZQ66)D
M6<:>BSIBG8XD60EM0O*=F>EGZ,&94DT+\>=/9FCA!Y6JU?3D9Y9 $@>2:7Q,
M:E43"2P0R'V$4,AM=_A/PS/V^1\;T.3Z]?CW'K/)*&92LVK$=0]?5&Q!(]2K
M-+',%:E3:2&37UI()J]".:O P2W;E:$LBZO  ,33-#LD"NGPIFY5&L&K([=$
MJ<O$XBL-%0G%CE.J<>]T1&,LCA[66!PN!EF&-@P(J4QD;/%:\ 8F?:CK6:\]
MZG4L6GO=OH22O #-\V3^_D#-XQQCXQ11^(11Q@S T9\6=#1GYUR/+M:>;?HX
M6YL9^4&"[#Q^O6&_,1?940,(=3']^U9/U+5RRTD]NQ8F=Y2D>HZZ@4^P7.Q1
M#UG*2KT59-&(AHA&ECH\^/ A"6'!<=F!&<AH:$C!HQ+:GWDYBP(^5^Z1EY]V
M2IYP4[%VR%BU,=^9IY@GD$XQD&..$7A$8P>,6AABB8?(F\8Q=^S\B*L;/);&
MUFX69-G9-2'CU(Z%*:A6FALRUI;-B[(-N62S,,Y'=MV[9&T8.TUB1AZB8(PD
M+DBJXG")PB<(G")PB^9GU+WU5#U(NMA+9.QA6 UK.:P=UI6IL:CEI58K\'8N
MO(YN*AL_ULME@C,V/806$89%U?9),B[+%I).?EA3H]*R+.?5%,V0'Z@W4"-F
M\:ZJK5BICD&IDR%XFZBNHJ(SN;5WYQ'1SY'N!H&M[2_,#RPOX9K]5%V*XWB/
M)??JQEW,5*B+Z(Y4E,*%)F+:D/IB1GY*F8C#LJ4\EAM;N6HT5E*WI,AS"?8R
MPRA;KSF4MMI4I2<9(M<T_P!13JIM2O;%UZ&O<^N6U_0VR]AO"MC5DYK=8ZKA
M;-:-1RII-VZ0PS4)Q^_A" $='=5AP@XVQ(B?+&G0'9)%<3KYG"M!:0SC.,X5
MJ#6N<*QG&<9QFF!?&<9_3.,X_CC]<?IGA%6_KG^1U=GNXD8$-V?&L0NW4Q!Z
M=;+!>"%0GH+U$7)\5X<<L9,$T_'(0)F8;D(5 =A5R2)@"UH XBPX]1PM*&UR
M'F%,(+4<E.]FO++- \<$KGEUHA]"3M_4=F@<G9V9_3.,Q[ F=NQ\^XS=R?AQ
M\&=J>_DV:VSA<E"K5IWAGO56BY5I7#>[68!]%G;0"-G8Y/&Q#9@-@DB=BZ_L
MEK:N7OLYU??LNE,[%&B\W:,Y8)MGK\< )9G#5?4MDZ>6*L/G?PC##!S&6A<O
M#^%-QHF7YC6&$8]_!R=7?XU9T:@6I*WVF$03$10N)5A/J2!W]*7HV8F\P+IV
M[^@MUL?#SGO+N)_#SXH9W'->SDP:;<6DL2THPCN-(&J4)%!? /FJKE7,HS]*
M8&<"=O9R=WSC=VK4Z^U'L6PT#;&P=3@PE,L)8O %_-? \<:/'OSYCP('8,%#
M &:U'8<;A-50H,'M>]69 F8G&$IS:=$<;/NZ%"_:HUZE2Q//3D&73I'''"1$
MT=60WM0DPC]P:-FN#/\ O1']%H<6WI.;\CPN/<@X]E;VGM;.9G4-FK)5XMO0
MV[=R*" IM6K V5> I#%[$F]EZ,YBSM':@)_)8GTVW0'1H320BX.6\0DW51$2
MI7.]RF)P6WN.Y<CQ XZT1PM>C0B4=QI8L16[ '"EI<2(PD([:HK>#<O4XGR.
MO:P\-[4$F>-FC3AIV)N_DKA#&T(!#8(8WCL&<9,-:S'#+(3.]?YF/J4ICXM_
M#70R^<\\^Q[]3D)9N]L7-G.I> [F+'-:.[)-;RXYK/S&=#%8!ST\RQ>JU0<1
MU'S+3E4CDGK_ *QUY1]D=F3-/IX&NE3NUA[9B>*@-1)))#FM:!8G$RW$8PIY
M*CMA.%585Y_MI68]^KV>362S-?Y&[?\ F\/T_P"28[>_\6\6;^S\U1^7D3X7
MPT9W?H>%6V;Z],W].N:%U_,G?^IV4-]V]'&=M;,Z8GAZ:2Y^S;L&Q9@[EL"P
M"DT5:F*9:)T(P#>F5PTN'(C!1)UI"FY$9*"SP0@EG,X; *",>V]P;6$U70M4
MPLZWRMF. *9C/ ]"]:\3^:J6#%VDJ /E$<3^F<K._GZ9Q['!AQY,OGQZG'LO
M:GS>(OK95B_/LQ29]X=_"R?4B'+U\V&8'K:]B1X[<5D?F8:I-U$,\,]DNS^M
MBNX>NVX]3!Z^!M4_96O+-1/P"T7&PT&ODHMK'/!9[):VU0+8K")A(@39+SGX
M8&F/3<-_ASGT[$MV2S85SM=)IC1003UMU+I;;6M=>$FZ)KBM4(C3Y,^3M^GL
MQZT)C@68\([L"M"2QZ%(@P(SJG# &(^C+JHBTR$1TR7B*CNLNB&H1_</LA;Z
M[UCO'7$!8*;JX33=O::N(O2@:SD:FJVL6=+ O2^SH!DBS.R=KDP9&O=&P-?P
M"EJEQ(SK,9@@18GV>I?<S4?8/H:.U#LI[L/7#N_[\B5CL3!H0]>O/CZ];883
MA-LUF.UW9;!!DUV;:7\*GU>WF(2@[$IV85F*CAC)%;>Y=DKO2ZA9!?973&TM
M*0<UXO@GO#1L_P#;=K2N16Q[KDJQQK!7:XSLZH8%,)=GO&;QI,56P^(^7YAB
M3':6]DBRGT_;^WM?IGUWVBG:!C<;^Q-9URW$]@&R PE.+G2\)MVPQ\NB!@>#
M':$'4D1*1R![#HQ4)8^1C+\=S/"*XO")PB<(L"VHW*>UCL5F"5M &:[1K8U#
M.4@6LY<PTIP%/1'*U(*VS)<+V8<]E$L$+1'?7/*,Q8J67,NX1DBTN>CH(NA&
MP;?VR<W+O/:]?VD!KY@&7O\ H??NI*3;8<8G.A5ZXQBF[MC;#BF+J)J$8'KY
MZ#2E!,-5FM#9EQ?M=E6Z:;(O?].359VF=W.W%DGZEV]3815&S67K#=J2U4:R
MR4,]H-G6F$&A7%&H-?*W_(ME4GU_8=<V NZ;170@!69KE1J*VPQ*-D5M^^O8
M'MMHZ;K;'6#3&-Q-G:WN"=:!4>BWRW$L6"M5.,2UY C$:VZ-K%<'3C*IJSBK
M0>@%CL.,V(HT S8G405D6&===C[PV=V/Z\V?>&L&=>64KTNW(2DN8R1!R2\Z
M5MSK^F2_*UN?;=L^NG'(K, C^6[$7*EAN2:ADYU$N _[B+:;PB<(G")PB<(G
M")PBJUN2[_DK<.K'8 Y9^TG*!M@!3:RRYEEX_9)IS5#\6*[(PV[B +AQ8LPN
M=*N-K:% QQ&>I#RV$1W:KLW_ )'9RO3C>Q;L9VQ7I51=Q>Q9.?',!<_$FCB
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M/$P\Q$O"0?"0>V9_$Q?OQ)OH3?@_?O\ BN2V8?EK$]?U89_0E.+UJTC2UY?
MG'U()>A:2(^O(#9F\A=G9O?I1#I4<:&LWO!BRT>QY+WDS96%4IZ4\@9^..8?
M='$\R9LS^TLY:1AM3?PX4CWY4WC./M%Y-2[4:ZUV2K(]F]/;C^6"4& 9W9W
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ML"TU+*CFP\RKDQL$5@Z=66W.T,VK;K1R[W!O&Q=8]<-J[*U6:K0.Y4"KS[;
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M >R\>V]F<N_N]/F^"/PMY$?Q*P'Y?QCG6#A@&L4^E%Q#:G]*9\>\%>,V>B3
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M+V<_/KP0] -PZ)/K,$;48D&O$Q@N6L9/G-C2D"56V%/CQT6=)FJV;4J6+=N
M9FFNFTEESM6I@,Q$1$AAFFDBB<0$09H0#H!$.O$69J+J<FU]C-R,F_)2.CA0
M%6S @R<JE-! 9E+)');I4J]NTTDTDD\CVYYW.Q)+.3O-(9EA?:#O/U.F]A.C
MC0_LZ<%X+;IM$ @$J&+8D44%P=/;),PYDJ#&JDQR>\1MD6K4Q3D53RIH6UE
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M665=6*X_L^Q:7WSMLN3V*$,/R*X;L\1L+.GUY^27HYTZB(Z]#\_B_P!>O?\
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M2EE_5.UF\1Y"FL2'G,@!V4_1HQ@_#]WT9#ZWJMR[F3U:(5CGF>)O]*GEKQ,
M2A(1.<-:T;DS S"+1MY._N8]>^/X?ZV+A<JSM??FTXL^D-HW^R:%71MR32U9
M:\<;06]+*A&-_6(SE^9(A\&$83\G<+HZH=$V'4>O[#&EM'VS5&K9ANQS1T*+
M,-)(!(<S!J9'34Z.PQ*(Y=^ND-_DVJ-MNO+Q^7@R4_A\>4C>1XP>40"5Q%S
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M&K4I!+,;-YR?+4H*]6,Y';SD>.$/4D<Y3\I#,BA/K)J:YT/LWW?V%8*5LX
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MZX_AX_RX1<\(G")XQC],8QPB<(G")PB<(G")PB<(G"+CQCSY\8\_S\??^/\
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M?PZH<$MRUJGQ#X1S)XWI,P<9NW[=AVMU6L%(3OG_ &:T5<OV4GAJ23=G$[P
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9<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g150774g17p79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g17p79.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2\:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +OZ^$@,#A"24T$!       /1P!6@ #&R5'' (   )U$QP"4  (<G(Q-S
M8S-C(< @4 '$UI8W)O<V]F="!7;W)D("T@5&5M<&5S="!3+30 .$))300E
M     0.;$!6<[&,4(-/@=A6OLS>CA"24T$.@      Y0   !     !
M +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M!);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G
M1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $
M)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M    (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $
M-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V
M]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M!%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %
M)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M        !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M       $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M          "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M   %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4F
MQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H96
MY0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W
M)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M  "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  (!+
M    $  CA"24T$)@      #@             _@   .$))300-       $
M  >#A"24T$&0      !    !XX0DE- _,       D           $ .$))32
M<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M   0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0
M M    !@       3A"24T#^       <   __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M X0DE-! @      !     !   "0    D      .$))300>       $     #
MA"24T$&@     #-0    8              O$   5I          $
M                   0             %:0   O$
M   0                         0     0       &YU;&P    "    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P   O$     4F=H=&QO;F<
M5I    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6
MYE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&
M5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M      0G1O;6QO;F<   +Q     %)G:'1L;VYG   %:0    -U<FQ415A4
M   0       &YU;&Q415A4     0       $US9V5415A4     0      !F
M%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96
MQL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W
M)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC95
M9E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4V
MQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M  "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M    MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M   #A"24T$$0       0$ .$))3004       $    !#A"24T$#      DH0
M    $   "@    5P   >   *,@   DA0 8  '_V/_B#%A)0T-?4%)/1DE,10
M ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T
M94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                          $6
M-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M  %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
M)4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6
MD   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&
M=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2
M Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D
M="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M    !865H@        \U$  0    $6S%A96B                      6%
ME:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M     DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F
M-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                               &1E<V,
M  +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U
M)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W
M5R('-P86-E("T@<U)'0@                            !D97-C
M   "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,B
MXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($
ME%0S8Q.38V+3(N,0                                  =FEE=P
M  $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M!7'^=M96%S          $                        "CP    )S:6<@
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MH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J
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M3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M
MQ!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@
ML1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,#
MP,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,#
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M#@?]'E+J]C/W1]RB74!VTEF[B-)1M3R='5_K(&O?E?8#%#P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@EI&@WY2.I.]#2<SC&T@/)+7$\K@ "23H@[WW_'_ #;G?IYTSMHO;=E]K(I
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M6V%IBFNJ#9DBT;[40TV7T-E>&=>FM@GTZ&R>_N[O0M9[CMA[B6,<\?'U'?\
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MWZJWQ>3S _E_ZE0A<M0S&_V[-G:G32ZSK9H/*AE&PB=E((B8CQS5'0U%Y4E
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MW62<A3B3"I%MQ[Y%=LZ;;HN,:9^*9O6N,_$,G2:)%@MEV;3--FY''+5[ZRR
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M(:>X'X8-M%E7JB\3XCP5O+RUGUI(0(8I6ELSBW1)#^9G)"]Q!#?QG,[E 8"
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M.90I*T21.P)5;SEKV$[#VQ<15)*MX]"-'"LXGII9(%%I,\9R,3$Y!N'%D5=
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M5D9<!WEO.X; ) )'0'O4 O9?%8Q\3,CDJ%!\P)A9<MP5GRAI <8VS2,+P"X
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MCFOXFGHEIJFGKC733&-==<8QC&NNO_!UQC7&,8QKCQC7&,8QC&,8QR=@ =
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M7V1S13=KCN'(W ZKX>&7EENL!]K-EK##,Y^@[Q5D$8)82%]">%:P/!YPQ@_
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MN/.2OY,8QCYY\\W!%:  \:;T'\';]M=D0W  /'&]/_XK/6+RP$G&?NG;//\
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M4LZHMT\[>PBEKG.J:>-=-?EKCG:?AF/>]YR&6:7N<[3,A,UK>8DZ:WKIK=Z
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M1KS:TNL!]9>NL9!_5F/T74@B/>76<!6->1- ;C+W.^7><--1/N?]TY4WRO\
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M.''B:&JY0N\SL[(O-UG;G?==7??8BCJ\.N]1=B8XE';6B+0_]&ZN5HM(4%G
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MX?.BTI.XTV5(/\:/WQ'Z"#+$EW[T+#A"Z$8BC=ZH+CH]BPTU2R197(XY'Y>
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M+ZI+).4M5D4U<)N$-\*H+IXWUVQHLBIC"B2NOC=/?&-]-M=L8SPB]WLZ_/\
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M.1*G2#<4/1;CA^2!!SNU'M6K)';1LV13T(J^6%_#QZN_XNG;C_7/JMR24O\
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M,BH[2W=XF2R_+CMB!%:JX8UW8;="*#KP9^&>T;\*NXO&[>L*#&HW3=KQX0D
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M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*.3/_ 'U>_P#TDO\
MZA/FW#[0?)_^3U@=[=WRC_[6KK>951.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$7: _P#ONW_]&M__ &9YBF]H?E"JWV[?D=_4I$YJ
&+.G"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g150774g18f63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g18f63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (JB^B'(X0DE-! 0      #T< 5H  QLE1QP"   "=1,< E  "')R,3<V
M,S8R' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $#FQ 5G.QC%"#3X'85K[,WHX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q =14F
M\         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              0H   (3P         !
M                  $             "$\   0H
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   0H     %)G:'1L;VYG   (
M3P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $*     !29VAT;&]N9P  "$\    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &$P
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /4R]C3!< 3P"5#)^T?9[/LNS[1M/I>I.S?'L]39[MFY
M8&ZKJ#Z[LOI'[5NJOMH-[64@5>C>^G1N5<U^WV>O[59Q,)[^FEU5=CGW,IAI
MRK:VC8 W]#Z9L9A>FWZ?V5GZPE::;-65UY]A;9T^BIA#X?\ :2\@@.]+=6,=
MO\X_9_A/8Q"&9]9@->F8[B(U&60.P='ZJ[\[=_80'8.>VD!N);8;/;;4[J%I
M#6@^TM>]KOI3^9[U)M'4<7*=?1@66P !NS2[< !4V:K]S&>WWV;7?R_TMB2&
MUE7_ %@;4#BXN.^WUBTM=:Z/1CV6[O29^D<[Z5?YG_"+25?#NRKJB[*Q_LM@
M<1Z>\62!^>'L_-<IG(:,IN-M=N<PV!VFV&EK-O.[=[TE)5BEV/CX=-KL-V1N
M8)]"AMK@8!][?I^Y;2YYEU-MN& UC;<>QM&][HL<"RB]_P!E:W^<K_2[<C>G
M#8J3NR,9C]AZ?=P72,9I:/!NYOMWN4J;<:VXT_8;*B)E]N.UM>G_  ON8[^0
MH9W3>EN%V;DT@O:WU++@3N K;(>W<[TOT;6>S=[%=K>+*V6 DA[0X$Q)W#=+
MMOM_S4=>ZD&75CLQK'#'WG:0!16TVR[V[JA[/<R=ZPVX.375ZIMZF_U*G-8Q
M]#'.8]V]HL=6QV[]"W8YF[^OZWO6UU&['93Z%['V"]K]H:TO$U@6@NV>_P"G
MLVI[NGX>;70[+J%SF, :7%VFX-W_ $'-^EM0U4XHPLNNQY.3U!_JD[#]DJ<U
MLV-=N8T-]-K6MK=5^DK_ )BU7!T'J0!8.KNDDPXXF,2))_>8?8W\U:6&RFN@
M4T1Z5)=6QK0X!H:?YK](Y[G>G]'>I9%S*:MSVEP>]E6UHDDVN;0W^QNL_2?R
M$OJIPFX-[G7-]3J+&!K 2<>O<',<U[[L5SB_^>;2^JRKT[/9D?0348V8R]F5
M9=GVUM</5QW85(:YDO\ T7I,;['.V>^ZK]+[Z_\ !K5QL6E^+?B6XXJI-FTX
MVZ0!LI?MWUG\YWZ13Q<3"P[75XM3*O5:'/AY+SL.UGZ)^_\ 1MWO_2):]U)*
M68UM;;!C"L._,MJ:QX@[?>PM]JJOR\1CW,=T[():2V6XFYI@_28]@<US'+0)
M@$G@ D_+54,%[+,EN75CG';ET>N'N(W6;C0]KK*@7>E94U^Q$D]T,GWXS'AK
MNGW:ZRW&:X1_8W?YG\XE3?CORZ:V8EM%@L^F^@5MT:^0+V^QV[^0_P!Z&_IF
M+AV49&#16R[UV,<][K#%=AV9&SWN_2O;^\K[OIT?\:W_ *FQ+5+_ /_0ZVK)
MQ:R!F=5MZ=8[.RA56UU8%H&0]K6O]:J[VM_F?8[^;6YTB#TS&(,@UM@^.GTM
M%1PV]=KH/V=E3M^9DO>,M]C7"EUKWT>B&LL_,_,=[$;#ZET_$Z74[+RJ:!36
M/6-EC6[3#7^_>6[?:]GTDE.HDL]W7<#[2<2GU,C(V>J&55O<"T.]+^?V_9_I
M_O7(+<KJ]^;D5LJ^S4MKJ-;K6[S+C=ZNUK/1IW^RK_M9D;/]&A8[IH]F_;G8
ME3;'66 >DX5O&I.]S6V,J:QON?:]EC-E;/>J=%F7=U9EUK!12<:P,I<)M^G5
M^DML:[TZ_P#PNUMG_"6_X%-@8-U67E9%P==:ZT&FZ][26M--%;_0JJ9Z>.US
MV/W[/?;_ (2Q7!0XYC<AX:7"IS-P!D2YCMN[?_(_T:'%V!3P^(;"YS$INI<U
MSI:S)RV6L ;N:YOI8M8<^QO]']]3_I_SJZ-8UAQV8./=>;/8UOIUTN<'/>0-
ME;*V.9ZUOM_1_P!M/&Q6HNH]5QATG+RL+(IO-+ 7%K@]K0_V_I/3/M]N]6.E
MY#\KIV/D607V,DEN@T):(_LA86']7>E=(QGX6!@-JZAU$-?=C57WOI:QCG>C
M=EWVV?S6/ZG^#]-^9=[**O\ 1]%BXM.+4*J=P8  &ESG >.SU'/V^XI@C/W>
M*_1P</#?Z?%\U+^*'M<->OCXN+^IP_+;6ZEC9%EM&13MC'KR _<X@18QC?HM
M&Y_T'*U597L96'M]05M/I[AN^B#]#Z2>]E;Z7MM<651-CPXUPUOO<3:"W8S3
M])_P:P6]'Z-7U!_UBMQ+*\BQS:\2QMF0<FUQK^S:X_J^BQUM/Z.EFS]'C_K6
M1;3_ (*0K&[T#J#,ZC(<RH5!M]CB&NW2ZQS[']F_G*WU"BR^AC:QN<R^FTB=
MIVUV-MLV._?V-_MH'2.F585&X4C&NM<7VTUV/>P%Q
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_^6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R
M,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP-"TQ,%0Q
M-#HU,CHT-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#
M<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,#0M
M,3!4,34Z,C(Z,30K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(Q+3 T+3$P5#$U.C(R.C$T*S U.C,P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @
M(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XQ+C$V
M("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,3<V,S8R/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A
M=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B
M/DUI8W)O<V]F="!7;W)D("T@5&5M<&5S="!3+30\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX
M;7!-33I);G-T86YC94E$/GAM<"YI:60Z.31"0S-%0S%%,3DY14(Q,3@Q.3A#
M-#-#.#4S1#DY,#0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/GAM<"YD:60Z.3)"0S-%0S%%,3DY14(Q,3@Q.3A#-#-#
M.#4S1#DY,#0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HY,D)#,T5#,44Q.3E%0C$Q.#$Y
M.$,T,T,X-3-$.3DP-#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z.3)"0S-%0S%%,3DY14(Q,3@Q.3A#-#-#.#4S1#DY,#0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#0M,3!4,34Z,C(Z,#<K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY,T)#,T5#
M,44Q.3E%0C$Q.#$Y.$,T,T,X-3-$.3DP-#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-"TQ,%0Q-3HR
M,CHQ-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z.31"0S-%0S%%,3DY14(Q,3@Q.3A#-#-#.#4S1#DY,#0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#0M,3!4,34Z,C(Z,30K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-
M33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.3-"0S-%0S%%,3DY
M14(Q,3@Q.3A#-#-#.#4S1#DY,#0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3)"0S-%0S%%,3DY
M14(Q,3@Q.3A#-#-#.#4S1#DY,#0\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HY,D)#
M,T5#,44Q.3E%0C$Q.#$Y.$,T,T,X-3-$.3DP-#PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H
M;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME
M="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P  1" $O ET# 1$  A$! Q$!_\0 'P   00# 0$!
M 0            ('" D!!08$"@,+_\0 ;A    8" 0(#! <# PT'#P(7 0(#
M! 4&!Q$($B$ $S$)(C)!%!46&",S41="84-26 HF*#0V-U-B8W&!EM,D)2<U
M.%>1&3E&1U99<G1XDI6SM]CP=8*AL;*XP45(5&9V=X>VT55D9X.8H\+7X?_$
M !T! 0 " @,! 0             ! @,$!08'" G_Q !K$0 ! @0$ P,&!PH)
M!@@, @L! A$  R$Q! 5!41)A<08B@1,RD:&Q\ <4%4)2P=$6(S,T5%5B<N'Q
M""0E-413DY2T-D-%<W1U%R8W8V6"DK48)V1V@X2BLK/#TM5&A:/3XE;"U&:5
MI+;$_]H # ,!  (1 Q$ /P#[^/"$'A"#PA!X0@\(0>$(/"$'A"#PA!X0@\(0
M>$(/"$'A"#PA!X0@\(0>$(/"$'A"#PA!X0@\(0>$(/"$'A"(:<XH2&LN+L?5
MZQ1<=.0$UR,X^QDS#3#)O)14I'.\FP23IA(Q[I-5J]9N4C"FNV<)*(JD$2J$
M,41#QV7LK-FR,?BYTF8N5-EY/FZY<R6HHF(6G!32E2%I(4E0-0H$$&H,<?F2
M$KD2T+ 4E6+P:5)4 4D'$2W!!H0=0:&QCCR\2.*^B[XY8*$3+BG_ 'I:<&]*
M$+TZ"#'OHVM_%W'L!A(!M[Y?SVO\L9JP2X_E#$%RQO\ ?1KT'@[8_B&!_),-
M=OP$O=F\WUDW]$8^Z3Q6\L!^[G@ON?0&_9-3?YJH@&OJ,0W[OQ; !UZ]/6)9
M^7\^?^>,UM;Y0Q%Z4_"OKSIL6A\0P0%<)AMG^+R__IY.]F],*-Q(XK (_P!C
ME@H ^D>7_>FIW^('0/\ O'L1V?XM ;OTB &$H# S_/C_ *8S7S7_ )PQ%ZU_
M"[#H.8M'Q' _DF&\YOP$OT>;Z]O3"3<2.*P;$>.>"P^'UQ-3!UL#"/?ZCUWU
MZCV[; >GJ$)&?Y]^=\TU_P!(XG_]:+6@<#@1_1<*-!]XETO^CRO:CVA9N(_%
M8##_ &.6"P]_IT.)J=_A2EUOZCV/KT^@#W'8=?2 P.T&>F^<9I;\XXC8G^MU
MOKRI$_$,#^28:_\ 42Q1_P!7P?IXI/Q(XK%!01XY8+ "@0>^)Z:.@%$3_P#[
M#[[T)@$=%#0:$4]F\2,_SZCYQFE7_P!(8A_.8?YWPI4O9V$/B.!K_%,-:GWB
M72C_ $;ZMMI>,GXD<5@,</NY8+  * Z_9-3A /Q@((B/U%L0]"Z]0 ?3S-%\
M0,_SXM_+&::O_*.(^B]/OK<VKU8N'Q' O^*8:P('D)>_ZNMFOXP#Q'XK@<0'
MCE@O7EE'0XFIH]_+$W5U?4??TV :Z0UO?E^]X?=!GS?SOFCN?](XBS@?UO@=
M;:TB/B&"-L+AK/\ B\O;]7Q:_A&/ND<5A4 /NY8+UT@.OV34[YG$H#L8/?Z!
MH WKMV/V\/N@SUOYXS3K\HXC;_6>/V@Q/Q#!/^*8:P/XO+_^FG(=7?0^Z1Q6
M P_V.>"] D)Q ,34SMI(#";?U'_'J$![;^?E^\#[H,^;^=\TO^<,39_];X;^
M-(CXC@0:X7#6/]'EW%SYNVG/I"@XC\5_- /NY8+$.D=E_9+3O7S +OJ"#WZ#
MT].M_+NILO@>T&>L?Y8S1]#\HXC;_6]#Z:@1/Q#!/^*8:W]1+WWX?5XTA!.)
M/%<W0/W<\%B I'-_>FIH;T3J W5]1B  &Q'7H/J(@0>KQ)S_ #X/_*^:FH_T
MAB+.0?\ .@UM6M]8?$<"P_BF&M^3HK_[/6ESI"B<2.*PB7^QRP6(&,(?WIJ:
M #[QBB'_ !'U ';].H0#IUU[#Q!S_/JMG&:6_.&(Y?\ .^G2MV:'Q' G^B8;
MI\70^OZ.X.FPZX+Q(XK"0IONY8+'91$1_9-3="()E-Z?4?;N._T[]]$T89.?
MY\Y_EC-#;_2.)W/_ #NMFN&:\1\0P7Y+AG(I]XECVIJU[ZUTB!^?LN^S>XW9
M:K6$LA\295]?+JJLWHC>@<%+ED2&OK]K!*6B4BJ-/5'&\I%6V7K\ BM(V.,@
M7+Y[!MVSD\FBV%NL">)7:3.T*X3G&;DEF;&XLOW7H0L@FYIM8"]AEV#4'&$P
MO/[Q+T+,Q#BVND:&/Y)>R3=9;D<-2>(Z#4[!%92LV$EK5<>)LQ6\5N,P5"LI
M6^P8Q0RK(8]3H25UCZT?ZZ^I'DZT<N&90%L"QEV9'#[I<Y*E(^6LU!#BN.Q8
M'$')#F8 [;U84!)B?D[!T/Q3#,S_ (&54&Q\V@UMZ(XI[R^]E6PQ#)9[<\3+
M>GAB-;1\^GD__J>N2#TF8H4NA-.HG)4182XM&,5Q_(HP3T26%RY:_0P-&FDV
MK$LS$G>U^Z;.F*CF^<</""#\<QC5 [S\;->IH7##=\G8.WQ3"DN7^\RO8WV\
MXF?C:G\%\FX:7SPVXST2@X\91\_.2#K+_&9/%,Y&UZMLCR,G87]8O%-AYQK!
M?5J*LJRESLOH4A' #QHJLW,F<V1/:+/"DJ^5\VX0"75C\4DT>K&8"S"[='+Q
M!P&"=OBF%=V_ 2SM1V8'KO#4X\R)[+;)_'7*?*NLXKPVVP=ANP9"KUZMECX\
MM:R[CW^,%C(6=%O5YNGL[0Y6.L=!O$1X0Y)F5>N&\8UC!E%3,RU3VESM2%+&
M<9KP)"G)S#$@ND T!F@^#5)9K CE^"! ^*85S_S$O4EAYO+>PAA9#F=['EEC
M[&V3$</U&6J61\=2.8E'\!Q$E+ MCC$$/?W&+I/*.76<3172V.Z6VO;&1@/K
M2;*11PNP?NF35PP9.'2<#M/G/=4<YS;A4":8[%%AQ%/$K[XX2%!MZ/6IB?D[
M!EP,)A01O(E;.P[M]?;#^U2Y>SHOW(:T\:*3Q@B[-=J9935*V7"$X=3DIA>L
M6(E :Y,)$SV:&F/U<<Q3MW59**78)R$^W.^>RT3'M 6<R38JED]H\\*@GY8S
M8FKGX]BBEP$J\X3.&@(^=\X;I>#E^"8'XIA1_P"AE%^3,_HK#K0-3]G]9<LY
MHPI'85P6UOV!$,4*Y&:2V&ZI%1D:?-45)36/4(Z9D()".FG4RQAG_4WCEUE&
MKGRVJP NNW(>R>T6>%7"<YS1TD<3YAB?G<7"Q\JQ);2H84NPY?@@'^*8:M1_
M%Y9H&>@3UYWVCLYK#?!.%J(7QQB3C*M572:QHB89T;&;AA8721) R<97GYF2
M;"9E7BD>Z;,F#1T==RZ0.@4H'37 C[H<\"0HYSF;5_TCB&HQ(!\JW@]-[0^3
M\$20,)AGI3XO++5-2R7^QHX#!%<X"<A<)8ZSU4,#X.@:=DK'E-R7&1UUQ?C&
M&L\#6[PW(M7S6N/:$E6$0[>J>8S(5.4>,5WJ*[=B^=BF4QH1VCSQ:0H9QFC&
MM<QQ(+%V!^^]?1<U@<OP0)'Q3#?V$O7GPUZ<^D.\KQSX7(33VMJX7XV)6&/@
MU+"]@5,?8]),LH,IU4AG'<6:,!\WB2JIF3%^LB1GUE$AEP,53IM]T&>4!SG-
M'<$CY1Q#\+AS^%%*[?4#'Q#!?DF&M^3H9^O#ZKQX4L$<&5H!G;$<4\7%:I(K
M-VD?9DZ7C4]>?/73U*,;-6<V1@,8Z=.)$_T!%L@Z456>F%HD0ZPIIFC[H<\X
M>+Y9S,#B9_E'$-JP?RI#Z->EKL^(8)V^)X:Q+>0EVI7S=/KB$YLZ>S3:\0Z1
MS<D>*226#KJRM$B9W#\1VM[L=-AJ>\N#2PV?(,3C2 NC2GU6.^QDLNYLDE*!
M!MD3L =OV[AV9NE3[I<ZX!,^6,V"2:?Q[%&@9R6F*(%[LWH>?D[!N4_%,,2W
M]1*&]G2WARCQ)\C?96H5!A=)[CS#TV*E,+YKY!1C>^<.I>D34IB7 4-3I^_V
M^.A++18V2>1IHJ[PCNKK-T%$;60[P(51T+0P#![2YTS_ "QFP!"E)?'8H$I2
MY)8KJ&(:E="2%-(R[!U_BF%_L)3 D@"P//W:)7W#'_ VA8"L7)>SX)PNTQ)5
ML42&:)F<1P?77D@WH$;5%[D[DTX-I7%91P[3@D3.2QB+4[U18H-@1%7K*&17
M:+/ DK.<9H$@<3_*&)M0V\H]M+UZ148#!$M\4PU_ZB7JX \W?V0T''N\>S#Y
M)DNK>C8?Q-6Y['"=1=7BI9>XWEPS;(&+R'#.[%09Y6"R52JVY>U^X0,9*2M?
MFXHS^.?M&#PX."&1 @U3VDSM?%PYSFH8)+*Q^*264"0>],L0 0U&J]XDY?@P
MSX3"U>TB7NVQMK^PQ)5' O!Y:0CH9/$W%]6:E(4+-'125(QJ:3D:V9-98M@9
M1Y8\SES""BD*H2Z"9X\R9!5!P)"G$MSV@SSB(&<YG9Q_*.(_1K^%-"[@U#$:
ML\?$,%^28:['^+HYAO-I:]G$5R5/EC[-JXX\R5ER&X223C%6.:KR:O">1B\;
ML0+52Z5GBJLR9Y$=U9\ULJZC)W+R2SN.H\5>4*;*3ZD<[=NVL1&JQSU[A^Z?
M.BY&;YNP"BYQ^(KP/Q%O*DAZ," Y&S@6^3<'^2X5W'^9ET<T'F>FKM7:+!ZG
MAG@_;XVCNV.$>/+*2R'3XN]5BK2^.,<L[:\KLM%HRB;LL 1BNZ6*S07(2079
M"[9-G":I/I:B:9E/&7[H<\)#9QFE4@@',<0^E6\J_+[#%?B&":F%PU"Q/Q>7
M4U'T1[BNL.$'$?BOH-\<L%]U0)WQ-30 ?Q"%Z=!!B/H80W\7?T PE 9^7\^_
M/&:>:_\ ..(V)'^='U ,='A\0P0OA,->O\7EZZ!D_:?2(2/$GBL"8F'CG@L-
MF  -^R:F?S5!UH(,0'X>P]@V7?P=8E?+^?/_ #OFFO\ I#$\J?A?<&]A$?$<
M"!7"X9]_B\OGIP\CX0HW$CBN43[XY8+ /.Z WB:G=NY Z1_WCV/<W8==7?0@
M!A* OE_/2W\L9J.[7^4,1=B7_"G0;M0FPB3@<#^28:[?B\L^'FUV]5X2?B1Q
M6#K$>.>"PT!!_O34SML!$1V,)H=@'S[ (=0").H0D9_GWYWS37_2.)^J;I:G
MH)@<#@0Y^*89@S_>)9;T)UINWC"S<1^*P*& >.6"P][6OV34X?50"^OU'U#Z
M]/< $/F'6(!X@=H,^;^=\T__ +CB-G_K3I7]D/B.!_),-_82]V/S:U]&L)'B
M1Q6ZC?V.>"] 5,0 <34WMU)&-Z_4>AWH#?( $.PBGLWA]T&??G?-+G_2.(WI
M_G?#]IH^(8*H^*89Z?T>7KMW:VYM5RT9'B1Q7\Q4/NY8+T4FP#]DU.T72A2B
M._J,3&#T#I$ $/3\SI*(9_GS#^5\TNQ/RAB-02&^^MS]&CF!P&"_),,U/Z.C
M5M>&OAO6,?=(XK=9@^[E@O0) ;0XGIO8?+ ^]_48;[:-KX0'OOR_>\/E_/F_
MG?-'XOSCB+.:?A?#?Q+1'Q' DEL+AK?U$O77S:Z<MXR7B/Q7$XA]W+!0AY?5
MK]DU.#OYW1O_ (CWH/AZ1#?;O^)HHCG^?-_/&:7;^<,19GOY4CF6!N-(GXC@
M7_%,-LWD)=W:_#6[';E&"\2.*P@ _=SP6("01_O34P/Y'KWL(/6OWOT]>X)^
M]X'M!GP-,XS0U_..(^DW];X7])A\0P7Y+A>9\A+V_5H-:\JQDG$?BL(A_8YX
M+'90_P"U-30]3"41_P"(]_PUK^'Q[+X'M!GU?Y8S05_..(V_UITK^R P.!+?
MQ3#'_P!!+Y_HTMKMS@3XD\5C%(/W<L%FV4X_WIJ:&P @FWOZC[:]=!V'N)A
M@@;Q)S_/@2!F^:W'^D,2&JUC-UYOTT@,!@2!_%,,>?D)8>_Z-/M]$8)Q(XKF
M$FN.6"AZE!+_ 'IJ<'4&SEU_Q'U  "'Z=0ZZ0 3;#Q!S_/:MG&:V_.&(Y/\
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MES, YUXFZ$H_\)^2.Q03#6N/V7@_D^W;T_T@ ;+TCXWI/\T]H"?R+ UK^=L
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MVV(/)0UZM^'K_2*@F[)$S*DQ G?ST;!0<C 24Q3RR+LIN%0>F@5W@2H!CPJ
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MD:QQ^Y;WRXXT2J5DE&-AE&2]I?SM!M+N.;UU6?A'<%&C)DG 070(IE2M*B0
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M](;"(]H%!5J8RNSY!T/]B\5C;*$YBR)EXVU/LH&N5@K&+HW-%C72CZ[3(UQ
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M\/78:-A8J*A8U,Y8Z(C8^-;M6C".8>:J#-BW12;-?,5^CI$.HKN_" X90'"
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M1KZ'!#O6\5J1H:FX/0T].OMHH%#:#NGW6T'OJ:#\1,=AT_/8!K]_]0ZNCP8
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M51?[TIB2:O\ ?=]#2I%R1#CTY, 5!_#NDW]G(1T^.^&>?Z3D*J7EQR#P7*!
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MRMB]J$->Z\>LSZ8M<"XV3%PK$NC*F3;..RC1?JZ%TMF* $V'B)=2OSG>Q?\
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MZ6Z7Z(EDF6D$K<)14\526<@DU&HL:U#$1*J*HS.;$4OH.8KK?FTU$Q#9-$2
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MHQAE:S:ZR>+76.S=(N'3X)-/\5N9-N15%05:*X@@%) ;B)X@"[)):C<P2>3
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M]AWW\P1!N$7U^C6SW\/=A N]+Z.[6ZMZ'-32A=(B;8^Z3?EI_P"&WZ)?+?\
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MEQX^YRJ=HBF4W6[+AW)4'/PS\BZK&5AY2H3;*1CGB8F#K;.VRRR"Q-[,F<P
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M><KS@U"/G;,Q;ZMJ0KJP<%QX:U9OJ9^2@Z_-[)I 7H'OU([V*@:#YEUWUO\
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MUJTEF_UP5K-3]F*TL4_&,(%"3*<U?64'%* X2H*+*6"*NQ/$38GD3Q,6X:4
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M@%N+U422 20D@&KT!=AIM=B0XB"[. 'ZOINPJX ;H'UCH \P0#\-+?G!Z&2
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M[_RFS>!X2FZK@6&H+Z-04;U-#O/I;<^RGC;KI"$P4#RP!(G3Y2@; 3CV @
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M%8!\^3/'7_VHP/Z?_'\!]/'8NS7XYCO]RYQ_@9L:.8?@97^V8/\ Q$OI[1'
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MH(#W5V'O&UZFWL3;#UZM^@@<HCX_9M1%;4"=$\MN5]/ B/Q\&GKN/4:^^L(
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M7,DSI:B'1-E+7+6DA25$$&.I\98PP>$(/"$'A"(C\R W1L5AZ[Y,\=>P]O\
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M=23KDY!,)P,1<0%QOL(@(Z%/N&E-[WH!*(]77T@)AV A +LQ2>Z=+7Y-]35
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MVJYMUQD3@BEY\K:Y^7D%012\YT?RR=.+%8W!X&6J=C<7AL')2"53<5/E8>6
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M76>K4,&)Y!X+>[E1F(5-N>[7)!5-6I7.AV!2M2D;)4/-]29M<):P4J<2RP$
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M)-VPTY>7(I2CBO TV9,)6R4@CA9E @E#E*F![P!>HHHAC6,CI2D .3<DD@N
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MR23'(T?4<E\?;FC%K&<.+S$S=3NLQ9(2T)GBHV*AZ=;H*5G!C1H&%2?**#V
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M8K$S%@Q3DU)%$C'S%V:3-9LJKK#!X08@XL87##%$,<2)$H8@C@"&,[A\H1P
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M*8.9.4=(1L<P!=X^?R#ENS9,FC?2KAT\=..ANV:()$.HLNLH1%)(ISF$I"G
M^$_.)*6"/J-27MKT9ZU&44L#=K>#].GA0,*E\T9GOO,:^6GBM@2%C5\7QTHE
M7<O9<D@A[E1UR,G;696C6K6KW:#E9B*>(L7E7LU;^MZ[,HJOF\M*/&<(O28+
M,V%2ES%*0EN%F4MRWS30@@EGJ S7-".*X 2.(N[N WA5Q3D]FI8-85@C N.>
M.F/V6.\=0Q&3 D@I*3LR=G&(SUQL;I%HB_M5K?Q[!F,[89%)JW3?SDB1>2D"
MMTU9!T[=?2'+C)+2$!@S<%=R:AR15Z!]7W+$4)*J][SJ:MTY<Z?5'=7NZ05
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M4C:[$O)V;E5W,I8+++,JM"5VOEGK-.O9"?GG$5!Q39]-R+YZ5HBJX.(9VX:
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M#T\W6WZVE.GCJ[&(+5%=06U8.S]"_-CXJ4$OF'V1P @0OH0^Q 7 >GXP#L!
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M5@FQB(&OQ+2%AHQDBOTIM8^+C2M6+)$HB(%1:H)) 8=%*!A\P,[,&'  ]+,
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MD3') *I.E987D3$JIRCE^"Z(NWD@05T(_=S=>/69Z<5K,SF+,@4R0@*UDUS
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M49M*EI6M* N9,P4U*$!2U)3Q*40$@FII6-#,2!(EJ+LG%812B 20E.(EE2F
M)9(!)+4 >T<>'*'!>B_U[K_G";O5+COIZR=AW5C:+K8_(/70  &*IO\ R'FO
MY*BJ*?QC#7:Q_C Z;^+$8OCN&_K57_JY@V/T!3>QN.48^]!@P2 'VW< (&W_
M '*7#J'15/UJX]A$2^@@(#K9@'1B!D>:.?XJBHO\8P[.6_\ *!0:AK:-2'QW
M#,WE5=?)S'_^'Z_7$,L[5_CWG?+5&OUMSE99>H5ARV%7%TU3;&YK-<?PJR,[
M7;YC):-I\8[@K_\ :-DC$V]W<%+U5[SC*;M./IJL?4KQNB3&KL_FBE G#)(X
M?-^,88)!'$00/+T5H7?B!*2Z32XQV&%!,8W?@F=&)X"&(T!!%[UB98<G<$D*
M)$[JLF43=6DZE<"%$QQ,=0P %8#WC',)CF["8YA,83''K+<9%FGY*C7^D8<G
M2_W^Q]C]#7XYAK^5-K<$SZT7Z^.C?H;E#@L3#J[N ]_?:J7#6O,*/;=7$-:
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MA+^&$'(LU;\51?\ *,-M?\.#3UE^I?'<,_X55!]"8VUN"^M!XLT))RAP8'2
MW=P.DS (C5+B'?H  W_6Q\6_3^(!H0-[_B3D>:5;"H\[7$8<O6_X?W>N@,_'
M<-_6FC_YN97_ -BO)O'GDG*'!8"4!O#@0 WJ-4N/IU"/?^M?6@ =?!KTV70
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M<P@_*#!G0(!=W B.O2J7'8=B>FJP'Z#O8B.]]Q]X3R,BS3B'\50+U&(PW/\
MY]OV1'QW#-^%56OF+>UO,8>JNL*4Y0X+T?5W7'9RB !5;AZ!U]@_K7+V]!$?
M3>NVA*5,,CS6G\50*$$_&,/ZC\8IZ1KXR<;AOZTW_JYGL*+<P#U84PIR@P8(
M'U=W&Q(30!5+CV$!3WT_UK@.Q][8=6P][OV,*A.1YK3^*H#$_P!(PSU!:^(]
M)Z<FCX[AOZU56/F3*6W1Z1UI"C<H<%]9A^V[C7;0!5+AKU5]/ZUP_4/X>@@
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ML5JB]51:JJD7623.A$DO"$'A"#PA!X0@\(0>$(AOR*,!<Z<1Q$1*'VGS#W
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MT$ 1$2!V[(Z]0-H=B.P'W@,/F'GA-2 !3=6[-YUOV'D(<4J:DM;ZM :==Q6
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M:Z="'KOMH!*;0%("22>Z/,:]Z!Q57+KM EA4F[/3F-K4ZP'5(4HB*@AI4 ^
M@CW(D&@_! ==0#W$V]]7?0B90$DMW?FEV)W)KWK5V.T":&I#'EL/57K"E%2
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M\<UNNP6.*1$MZW'N'U;8L!6D(HE9!4M9XB22E1 *ED$<7GEU$ U 8 !K-H6
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MO8.D'-0YTL UCU)#CTL!%(GMASE-(<?P*<3:9Y/'72   &7H.A#1";WKTUV
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M6A$I]8@/YIT:HY#ZVO7UC,+;WO3ZO3[B JINDH@H'=P(; JFA'S";#LH70[
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MJ?-W&B0^@JWV0!L7%26IU8=?W<X#J& OQAKKT&P.';RDPU\8A\@$=%UK0:$
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MBO:I>B4"L5&3LRY'/TDBU@?U^-CG<RL1PNLN5625<G!9=58#@=0QBQP(2[(
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M<$7W=S?>I^<QK52A5A=0 /AST]FH+,+"C'$!5[AKRRB  0-A[J.Q$>COOO\
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MR*RG/5#'U+M54KK+)M%RI6\LT^C9 :O+KABN.8Z&F4(C&T;%,:DQB</D5.
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MP]CDLPYV&IMPGEU^IK&KO2CCEJ".?/4AC?5DF,;N #\P ?<_0#[[BIZ:^?\
M'X=;*<  W.MSJ4\O??4"3Z.AWM5R^EK'H<J";:FA#?G!K9!_4G^6[B.O7JV
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MSD-9(QK-5^6CIR'?%5,SE(EXWD&#H$5E&RWD.VJBJ"HHN45FZP$.(I+I*HJ
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MDDB"LE+I"@#Q.4E@2Q-C3O.2*]!<7!:$@AGJ6I6C%@-=3I5S:&;XM&_X-K<
M'1#^R7Y?>I0'W?O79B-K7D^HEWH-#[O\F78D4I*9K%_OFOZ:V?O7?]Y:DJ+:
MCYHZ=T>@O5S0#T0^UEA6UFK\]7'K@4&4_#R,(\5;>0#I)K+,7+!PHW,X:.4
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M7X;=ZU_:=21ZCQY@BG4BW72D1WY6&#]@=_'S$>GZ-6.VB@._M=7  =^3\Q]
M[?/0FV(J46.XJBQWB-_G5#<5??4TG72NXT8T%*DD>%Z1(;8]0CYB/3Y1QUTA
MZZ4[[\GX>Y?7>O=^'0>7<VJ%44D:W?FKU[>N!2M+,/;=MFI9G+0HIO?^-'I
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MS3RRKB9BLRDT7+15-%ZDI#6!(S0IX&:3:U2M"C0DDI<5N 2[=[J-6(Y$B""
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MK&US:TILVW?3E+1I[:JI242%K3=IQ+-"/+/>SDS%D";G;O;+I0ZE8[%;\1V
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M\A4_$U\J-CRQ&X4R\WJD7'L;Y8,/TV"MLS0"OUXJ[NXO(ME;3AV[1VQ2MK>
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M#[OH&ND1#I3D-L;4Z$GT/N]M=2+[BIK2]+,]3XPHWF:[J)[\TO<-:UUJB/\
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M,0[^)5>/&:4HR>1RSR*?.(N4:IO6SIL=Q%R3-9)W'2*!5?,9/VIDG+-P";A
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M"',]FBDFA[.W@N@BF1)%'B1Q[2223*!")IIXKJQ")D*4  I"% "E*
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M&PZPWO\ !_RP=M;WV#T$>VMI0JUC<:<R?HZ^TL><B]"&'OITU!Y&M$ID#W!
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M,G"81J$B1ZA!6^YQ+)PA&0E>CU22J'&GB#39*-:OS_3;%,J,X$;]DJ60BP#
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M)&53KBTS]'Z+- E!5(6=@C?($&3TH@HD198I#IB<3>.(C/'T^?U(Z #R]Y0
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M\D1'OUF'U]>Q=#V^703P?^$Z_P#P-=J@ZF\MV>NEO_Q)E3&PJW7[?<OX-O\
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M4UW+F[,-]^GOO]'*P ^CX[CK[M&2IDZ2AHO]L?SBCK1R=_S0 -[$?T$-^\(
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M!HQ60 %NF3E(IOY8D="JG\-'^!?CAP_^,+"GB5P_Y,SZ4)?^>^7I(%X^V/\
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MB%I2E#H.HP_'XW-<LRXRTX_'X3"3)P)DRI^(E2YT_AN,/(4H39ZM.&2A:B:
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MVV&87'\JL94ITW:R_*V1ERB5115%R(=8]EFROA+Q&$EXJ?C\;@< P,G"8/\
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M[(8<()4?OF5=G,+E$N>@.0 )JE J54J*E'UC!9!A\OE2Q@T9!-GRP%2YN7?
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M,7]1@H!6CE]#0KIS'L%BQ[.!BY!1BKUS2-9KYY(5$H:%9QUT)8\14DK(/$H
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M7IUH!] T ^BFP27/?%['PO\ O]%6QM9P?3LY%7W]?A"BE3   $3"'4IV$="
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MDA0\GALC[-R!WB3Y\W+<5,#49E"SGB-8YP]H^RZ$@2.P.6<0*3QXG/.T>(-
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MR_?8=^WK\_3>A]/'9LD_FSM!5OO&7;?EZ+@QQ^+_ !C _KS^7^95[\[0Z0=
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M7H^\S1"039W;E*6V=.Z]!6B8CJW6(^U3D UBW=Q"MPCNP-UQAX)G%70EB"5
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ML  #'#B>X\W8&O$HN-/>HK0:@N#>SD[5'UMSK=\FZ!+W(</Q2=A4.'[ZNA^
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MJ-O<Z._[ 1-V&E;CT<V^KP_0W0"IO<4$>W<#G$?S?70$[?J(]("(Z'0&_#&
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MS_4Y!;_>*XX[^@9S^OC^?]'3[\K1*.HB4:Q6! H_\2Q.NZ>O^+T0$=>;\(@
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MA:EJ(*R%$,X )#. S]X.2"3PDL'(>+*4X 'FT% *C1W>G2_C%ABFND?=-^:
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MXB-A8*$B&K2/BX>(BVC=E'1<:P:^6V9LF#-%)JT:MTTT4$$BI)IID+TI[ !
M #  E@ 6:K!AMMI1K#BHX)K=JFAV)!TUJ6UO$5N1W+6K82M-+Q9!C 6;--Y-
M$S$+CF5GVE;D9>D#8BQ4ZM6'DNK'U^>R%+E0?P>+L>.;%!R%]N/T=D@\9Q$?
M,RC*BU\+ D%14EDU!TJ'8.=G!)?1RFP3Q.6# ,_(Z4>G/0/XZ?&7$RHN\FL^
M1.4AD<@9%(YL\_C<MP?3DJOB",O-BL\Z^JD M,HUIXX@$HNQ1Y(FLW*JKR..
MYE&?9U^0:1+B-BJ_7R;GC474]'XNZ%%3I%'(J&!'=L*$0XOF@$ "M!4@)8FI
M8TTN_(Q-8@ET7W1_*./<4Q'8"MV_, =CH.X!_-[#HOFY2[FH\X;_ *-^>W[3
MPU!>M:CPN?7]31E,2:*'2.Q$P=Q3[:!,1W^(';0C_#U[_&)"GW:HT5N6^KU<
MG#0[N:FSU^WG7F6202= >Z("(&["9/>^E3>MG#Y@&M ([UH!'I!23Q/?78[I
M]_3S8& LP%3Z#?FS%NFS0HHD "ATB =1_44@]#)?Y3]!-\P   >^NH4X/$=0
M*"S[*]QSY@.#4O8MK1QL]Z%ZZUBL'EA1^57)>[&XW0M5CL<\?94:[8;9DB<:
MP-@CKQ 5BS%)9ZFQFHJ>DK15K'/-++6;%5XU2E5"0:OL6V=DCD0&-L9R$)AF
M"8M2D>:DARIG'""' 9RZG<!DL4J[Q!)%TJ2 #<VZ%CK8APSZDB@UG;A[#] P
M708C'>.H-"&@(U4ZROE(1[=S*2*A&R+F5?E8),V)%E46[=HS81K-A"0,.SC*
MW6HR'K$/$Q$9D2@(HE@R= 7=C< -<!@P:@   !J234UO<A@!I[O6YUCGN06?
MZ!QSH1KG>96,8J24D2O5",EI=C -K';W<<^=1<.ZL,D8(>JQ2GT)1><M]B59
M5JJ123F:GG[1BU,*A2@GO*(=@!<.2JE2& YNS7,&>@%W=F<%B_CI2(J-,!,^
M9LE3,L\@(FT-*9"25/L#/ -BFYY.&K^7<>1,I"N[A!D8M:=(UE[7K;8KW!MI
M6#M60\?9FIR=9NC9PO'A5WK''P>5 *Q0?,[Q#A)#V#$*>J7"@QU BS\#MU>F
MIKN]*U9J :Q8@QCXZ(8LXJ*CVD;&1S5NPCHV/;M63!@R:H@@U9LF;8$F[5JU
M1331;MT$R)()$(FDF4"D3','8 , +,"-FT].AKU%"SE5SX:.[ZZU?EK2/:IT
M@*GNB/XI?\%H0V0 _E-:T(]A'6@$>H0V8(#TK\TV?F[%MVY\K")+;:BS.>5]
MKNU"8PH(!YONB/N)#H!3_0=Z#KWO>M^O?78IM$$/FU<.=_LTK=OK@=;Z&C7^
MVU#HT*/T J;8#KL'JF!?S-!V\T?E_C: -]Q+LX _#0C6S['D+'7?F&*C\Z>H
MA_4S[AO!(B4#"(@;700>XIA_)#VUU[]?](FT/2!OP_$UW%S8'Z0_;ZQ9S%:$
M_I$7YMONVH#6Y"*1/;#Z^L>/^@$/]QY.^91#\^A:T!3&T(!Z['0@(=.PV(^C
M]@'\GFCE^_A-WMB;NVK^+ORZ[V@OA>D]_P#]%'T8^/&X[;!X0@\(0W.6,44?
M-M%D\;Y'BEIJH2\E5I9_'(24C$JK/J;;(2[5]4'\4Y9ODBM+%78EXHDDX(FZ
M3;G:.2JM5UD5$(;3#G$W!^!<@93R9C2MRD1:\OOW+ZTJR%KM%@BH])_=KQDR
M5B:7!3DL_AZ-!362<F9 OLS#U5G%L9*T6N2D'22A4HY!BA$D?"$0[S9P2X\9
M_4OKB_Q5[;N\FVK$=RNKZD97R3CQ[-3V"V\BEBY95U2K/"+(M*NYD32Z$<W,
MDQ=S["&G7S=Q*PL6Z:(1*E/ZJJ5=2!]*G:PM:ADB.INRS*SE1"-B&12*R<]8
M)IRHX<JD;-S.9.8E7BBZYP6>/7)U#JJBA#>WRCXHY+XND:;8EHZ^XSMCB%=N
ME*W9%?H$FM5+/%V6,,UGZU()JZ96& 8*KE:/@*J+95FY Z*BZ)D(XG%O$#C;
MA/+^4,[XHQ)5:'E#,L:QC,D6*N-#QP64K2VW"].7[F,14"+1FIZVWJP3MIFF
MK1&3L[\\<M-NGPQ,;]&0B0;F6BV3V-C'DE'M)&9.Z3B(]R\;(/951BV,\>DC
M6BJA%WQV;0AW3HK5-4S=L4RZP$2*)@0B%F4.$'$?DHXRN[M,4\GY+(UUCY+)
MLI2LIW" E5+%5L32_'Z5KCA_3K,P=0+&5P_8[%CB\55JHQ:S<+/R19EF>350
M>H(1,</L[3*^W2,K%5JL5V-:,4!<+MHR'AXMBBBR9-_.<*)-FC1LB1!LB!U"
M$(4$TP'T#PA'(Y@Q'1,[8XLV)\F1*TY1K>C'MYZ*;R4E#K.THR7CYQF4DE$.
MF4BV\N2C&:QC-G*1E"IF14$R2BA#(0V>*^(^#L,Y9R3FNA5Z987S*9ID+"YD
MKA:YV%C$+-=IK)5L9T^MS,N]@J<RMN1;'-WBRMJ\P8IRMDD5WRX:!))-")$I
MR4<M(.XE%^R5E6#9D]?1B;I!209,Y)1XE'.W;,J@N6S9^K'2";)=9,B3I1@\
M(@=0S5<"(17W9/9P<1+9*Y4C)Q?*+F?S5DB1SG;69.1N8&\TC<U8*:H=EL=-
M;HWLCVDL)3'^09'%E@;U).*C#X\FXNE&3;Q#2 :LT(L!B8J-@HJ,@X9DWC8B
M&CV45%1S1,$6C"-CFR;-BR:I%]U)NU:HI((IE[$33*4.P>$(8GDAQ@Q;RKJE
M6IN6#WU.'IE_KV3Z\KCW)U_Q7,,[K4TWX5J64G,=V&N2SP(1U('EHUD\>+L6
MDZSBIU%N27AXQXT0CP85XH8HP%?LQY*H#K):EHSS9QN62QN.7,D7V%EK,"2+
M1.8C:Y<++,P5>=-XII'5]H:!81Y6=;B8>O-2HP\4P9MT(DKX0BO2X>RVX89&
M1SLSR9CNR9.C>1-PFLA9 B,C9/R1=8>/OT[6YREN+MCN+L-H?LL76IC2[ _I
ML'.4!&O2$#4R1]=B%V<1&,&C=")W5:LP5*K-<IM7C6\/6:E!1%9KL0T 2M8J
M"@8]O%1$:V*83&*W8Q[1NU1 QC"":10$1'OX0C>^$(/"$0XY$_W].(_8P_US
MY@#1=[_O3R_?L4P]O\P_]/;QV;)/YL[06_ 9=<?^7HYCI>-#%_C.!_7G_P#P
M%>YATR[Z.Q%1[F[#U!KW5/\ )#V[=N^M=7O:V)-;5W3IZB_TNGH].5J-:]G^
ML;DMT!'+)=@!0 BP[<B'8#=M*)AL?P1'6Q#?;>Q*/2 ])5(-S5/F4%*4/.W.
MS:FXGJ->OCZK[-TA/?R@_#7[GT( !MALBVQ_*UTZ ?X=.^X@)C$GYSNFW+0B
MK/X/NW)UA0$_7UV<ZVUM%05^QIR*YIYZD:/F6MWW"_'K'PO9:'J,:M$-9YG?
MVRBBF*\J.+W JNHV[)V*#DK VD8*F7F288ZGJ\_IMZQS+I3U8R>KK,J:H!3)
M2$. "'< \*J&KU 93 @@@^<+AD $$DDG3G4,UN98Z@M2+1<>8^@,85"'J%>)
M).THN-AF<C8)E9-_:[A)Q4)'P:EMN\Z1FW7LURFVD4T6L%DD"F?2SLAG#A0Q
M=>5L) 2 '305)8DFE200Y+ NVFEHQJ)+T)!+4T!>@!L!;9B[O'=' >LP@18?
MQ-:]X/Y8@;_)WO>OD [_ '>K29@J!5)IHU>Z=>*M*>S>)'3?K4UHPIXU %Z1
MA3>E!Z%AT"8Z+U=_]SB/^"[AK]1 .GT,)=J!*?FATF]:?2_6Y<RXH'($1S:X
M\;'UU85WVC*F^M3\-<1Z2^@'WV<%#0?@]S;W\OB^0&TF,)L!Q)N3I7NFOG>K
MD;W@;V-@7;G:WBVO6,&WUCHBHCY11'L?0AY(CZ^5_H_3I'XNGW_ $-=-SM3O
M4^=TIR:](,YU%.EPS6TZN"](!V*@#Y:V^D/D;_"ZUOR?4!]?='WN^@-^'X!@
M&=-SMJ/UO"_I%8G47M6[>QG]%_1@=]1AZ%M^0(_O"'9#>@_"#U^7?73OOTAY
MGB7IYR3WO_XOUC[Z/2(MH30Z78:EKEFUTWA90'S?@6 >GM\8C^=K6P0]=CV[
M;ZN^A-^%X@LUT[^@#]+:EZ\KQ.OA]?3TUT%(Y*Z6=:FT^PVMO5K9<W-?@9*5
M:5"F1Z,G;+,[:M3JM8"O,GCB.CU)>5< DR9GDY2,B4%%BN)64C8Q%S(HPH\(
M40Q8@L&<L10=X5IJU]W #05M<NXZT]G*C5BI[$V,\]<S,K*Y\RK?@I&.*O;6
M\%3L;5**F)RBY$PPO*3KJVT&SMK,Y@7<7<G#M!OA[D'7+Y10D$+#7\AUV4HB
M ,,.V:D8 %3"5*4E(H !YI15P02*_-4%48%V[I%R>&C5UW!Y,.I!NY#7(-O<
M/$QT##Q4)#1Y(R'AHUI$Q,8T2\EJPC(YB@T8,FR)40*BV:-$DD$4R[*1%,A0
M$"@!S;-!0%( :G0N/G:7/H9Z1CJ=ZN27LX]9]+&-EW$"[(L&S'["!]_FF#_
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MEKT%M*0-"2Q.MR=VTYEP+4TC*@B GT18=+!V*!NH1ZDR[#:6]AL-Z+OJ /=
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M,N*']'O%'^IT3_L/#[I<_P#SOC_[Q,^V'R?@?R3#_P!DC[(/N9<4/Z/>*/\
M4Z)_V'A]TN?_ )WQ_P#>)GVP^3\#^28?^R1]D'W,N*']'O%'^IT3_L/#[I<_
M_.^/_O$S[8?)^!_),/\ V2/L@^YEQ0_H]XH_3^X^)]!]0_(\/NES_P#.^/\
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MC_[Q,^V'R?@?R3#_ -DC[(/N9<4/Z/>*/]3HG_8>'W29_P#G?'_WB9]L/D_
M_DF'_LD?9!]S+BA_1[Q1_J=$_P"P\/NDS_\ .^/_ +Q,^V'R?@?R3#_V2/L@
M^YEQ0_H]XH^7_8=$_+T_D/E\OT\/NES_ /.^/_O$S[8?)^!_),/_ &2/L@^Y
MEQ0_H]XH_3^X^)]/T_(\/NDS_P#.^/\ [Q,^V'R?@?R3#_V2/L@^YEQ0_H]X
MH_U/B?\ 8>'W29_^=\?_ 'B9]L/D_ _DF'_LD?9!]S+BA_1[Q1_J=$_[#P^Z
M7/\ \[X_^\3/MA\GX'\DP_\ 9(^R#[F7%#^CWBC_ %.B?]AX?=+G_P"=\?\
MWB9]L/D_ _DF'_LD?9!]S+BA_1[Q1_J?$_[#P^Z3/_SOC_[Q,^V'R?@?R3#_
M -DC[(/N9<4/Z/>*/T_N/B?3]/R/#[I<_P#SOC_[Q,^V'R?@?R3#_P!DC[(/
MN9<4/Z/>*/\ 4Z)_V'A]TN?_ )WQ_P#>)GVP^3\#^28?^R1]D'W,N*']'O%'
M^IT3_L/#[I<__.^/_O$S[8?)^!_),/\ V2/L@^YEQ0_H]XH_U.B?]AX?=+G_
M .=\?_>)GVP^3\#^28?^R1]D'W,N*']'O%'Z_P!Q\3Z_K^1X?=+G_P">,?\
MWF9]L/D[ ?D>'_LD?9!]S+BA_1[Q1_J=$_[#P^Z3/_SOC_[Q,^V'R?@?R3#_
M -DC[(/N9<4/Z/>*/7?]QT3ZZUO\CUUV_P WA]TN?_G?'_WB9]L/D_ _DF'_
M +)'V0?<RXH?T>\4?ZG1/^P\/NDS_P#.^/\ [Q,^V'R?@?R3#_V2/L@^YEQ0
M_H]XH_U/B?\ 8>'W29_^=\?_ 'B9]L/D_ _DF'_LD?9!]S+BC_1[Q1W]?ZSX
MGO\ _P!CP^Z3/_SOC_[Q,^V'R?@?R3#_ -DC[(/N9<4!]>/>*._K_6?$_+T_
MD/EX?=+G_P"=\?\ WB9]L/D_ _DF'_LD?9!]S+BAZ_=[Q1O]?L?$_P"P\/ND
MS_\ .^/_ +Q,^V'R?@?R3#_V2/L@^YEQ0_H]XH_U.B?]AX?=)G_YWQ_]XF?;
M#Y/P/Y)A_P"R1]D)-PNXEG':O'3$"P@&@%>C02XE#]"BLT/T@/S NMZ#>]!J
<?NE[0"V<YB.F*FCV*$/D[ ?D>&/63+/M28__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g150774g20e07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g20e07.jpg
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M 0$! 0$! 0$! 0'_P  1" "Z :,# 1$  A$! Q$!_\0 '@ !   ' 0$!
M          ,$!08'" D""@'_Q !?$   !@(! 00$!PD)"@P$!P ! @,$!08
M!P@1$A,A,0D40<$5%B)187&!(S(S-$)RL='2)"524U1C9(*3"A=#16*#D9*4
MTQ@9&D176'.$EJ'7X2:7HM0X97B5F+?P_\0 '0$!  (" P$!
M  $" P0%!@<("?_$ %81  $# @,$!@8( @4(!P<%  $  @,$$04A,08205$'
M$R)A<9$4,H&AL<$(%4)2<M'A\"-3%B22E,(U5%5B@K+2U!@S0U:5U?$E='6S
MM.+D16-SHM/_V@ , P$  A$#$0 _ /OXPB81,(I1T_9LB]ITX31\.H%,;JH8
M/\E,O50W]4HY8-<[0$_#VG0>U02!J?S\M5;+JWMR=2M&RBP^0**F!$GU@4 .
M<P?0;NQ^KVY1 ?M. \,_R^:H9.0/M_2_R5#7M,JKU[LZ+</F22*(]/I,L*H]
M?G$.S] !Y9D$+!K<^)M\+*I>X\;> _\ 4JEJRDBMU[Q\Z, ^9074*7_4*8I?
M_++AC1HUOD+^:BY.I)]JE#*JG^_44-^<<QOTB.6L!H %"\ (AX@(@/S@(AA+
M#DHQ'3E/H*;A<@AY"150O3ZNR8,BP.H'D$4\C.2R/3L/ES=/8J(+A]7W8#^'
M_P#@RIC8=6CV9?"RG><.)^/Q57;VY\F( X00<%\.HE[2*@_/\H!.3_0F&4,#
M3H2/'/\ +XJP>>-C[C^7N5PM+1&.! JIE&AQ\.BQ>J8C]"I.T !]*@)AF)T+
MQI9WAKY'Y75@\<;CWCW?,#X7N!-1-4@'2.10A@ZE.F8IR&#YP,41 0^H<Q$$
M9$6/(JX(.8-QS"]X1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*1?2+2.3[QTJ!!$!["8
M?*54Z?P$P\1#KX"8>A"_E&#+-:YWJB_?P'B5!(&I]G%6-(6EXY[2;,/4T1ZA
MV@$#.#!\XG^]3Z^?1,.T4?#O!#-EL+1F>T>_3RX^WR6(O)TR^/G_ .BM@YSJ
M&,=0QCG,/4QSF$QC#\YC"(B(_2(YE  R L.055YPB81,(F$3")A$PB81,(IM
MH^=L3]MJNHB(B F H]2'Z>7;3-U(?^L4>GLR'-:[U@"@)&BO..MB2@E2D2 B
M8>@ X2 12$?+JHGXG3Z^TQ1.7J/WI"AUS7?"1FPW[CK[#Q_>I60/Y^?Z?OP5
MX$4(J0JB9RJ$.'4IR& Q3 /M*8HB A](#F @C(BQY%9%ZPB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+SVR=OL=HO;[(G[':#M]@! !-V
M>O7L@(@ FZ=.H@'7KA%ZPB81,(F$3")A$PBITK+Q,"P<RLY*1T-%LR H[DI5
MZVCF#5,3%(!W+QXJBW0()S%*!E5"E$QBEZ]1 ,@D 7)  U)R ]J*C5B]TB[I
M.%Z9<:M;46BG=.U:S8(F=3:J]"CW;@\6[=%04Z&*/85$INABCTZ"&0U['B['
M-<.;7!P\P2EB-1975ED3")A$PBM29LB;03MF/96<AU*=4>ADD!]H 'DHJ'M#
M[P@^!A,(&(&:.+>LYV0X#B?R!\SPX%4<^V0UX]W[\EC]9=9PH99=0ZJAQZF.
M<1,8?H\?( \@ .@ '@  &;(  L  .Y8E"R43")A$PB81,(F$3")A$PB81,(F
M$54C9=W&'ZHG[:(CU4;G$12/\XA[4S]/RR=!\  P&*'9RCV->,]>!&H_,=RD
M$C3RX>7S62HV4:R:7;0-V5"@'>H'$.\3$?G#\H@C]Z<OR1\AZ& 2AJO8YAL=
M.!X']>[Y+*' ^/$<1^G>JEE%9,(F$7D3E#S, 81>!71#S4*'M\\FQ.@)4$@:
MD#Q7@7;8/-9,.G^5BQY'R*;S>8\UX%^S#S<I!]9@#)W7?==Y'\DWFCB/C\%#
M&4CP\W: ?6?)W'G[+O:+?%-YO,+R,O&!YO6X?6?_ -L=6_[I4;S1Q^?P7@9J
M)#S?MP^L_P#[8ZM_W2F\WG\5Y&=AP\Y%J'3^<_\ ;'5O^Z4WV\_<?R7CXPP@
M><FT#_.?^V.K?]TIOMY^X_DO(V2!#SE&@?6IT]V3U,GW'>5_@HWV?>&E^.G/
MP7D;/7P\Y9EX?SH?JQU,OW'>2=8S[P7@;57 \YAB'UJ@'NQU,O\ +=Y%.L9]
MX+R-NK(><VP#V_A@_5EO1YC_ -F[RM\4ZQGW@O W&KAYSD?_ &P?JQZ/-_+=
M[OS3K8_OCGKPYKR-SJH><]'!]:X![L>CS_RW>2CK8OOM\UY&[U(/.P1H?Y\/
MU8]'G_E.\DZV+[[?->!O=/#SL49_M ?JR?1I_P"4_P DZZ+[[?->?C]3 \[)
M%A_W@/U8]&J/Y3_).NB_F-YZC3FO [!I0>=EBO#^D!^K'HU1_*?Y*.NB_F,Y
M^L-.:POL^^H(357F*C--G3B.2D2N!;*=\B9-=5B/JKQ,!*"B#@J1@,01 >I
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MT=)W*)CF<;&-F[*-MTE#Q$A9V+9--M/OHN.=RR3MPR;*)7:UN[ZK19UA9H
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M?YTG[.1U!^\/+]4ZSN]_Z*$:XH%Z_N)8>G3_  I/;_5QU!XN'E?YA.L[O?\
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M>$0/73-+-R.7ZH^C)]&P?2!K-JO2=JZ/9VAV<P\!L,+H*O&ZK%<0AJ&X7/\
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MGV^[,D?'V?-57IFU>OGS5I'(KN'ZZR:;1%L!A7.N)NJ?==GH8#%$.UV^H 0
M$XF*!1$+.<UK7.>0&@$N)T XW_>:EH<2 T$N)R UOW+H356TZSK\8VLCQ)],
MI-RE>.$BB'4>HBFFJIVA!PNDGV$UW)2D!PH4RG9$3"<_5IC&Z5YB:6QDG=!]
M]AP!.@SL,KKG(P\,:)""\#,C]YGF>)5PYB5U1[#88.IP<K9;-+1\#7X-BXDY
MB:E723*-C(]J057+U\[7,1%NV03*)U55#E(0H")A ,@D-!<X@- )))L !J2>
M "LQCI'-8QKGO>X-8QH+G.<XV:UK1<DDD  "Y.06G8^DHX %$2FYB\> $HB
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M>NK* 3T=8R9CG'#:)DKFX5&^2&I8W$_2]SJO_P 95Z/_ /ZXW'C_ .:%7_\
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M8MU73MTJ5%NW1*)U553B %*4H?Z1$>A2E 3&$"@(A=KFL:]SB&M:+DG( 9J
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MFJ*AU3!'34<,D=;-38A! 7]'O^3=<,O^F#DY_P")-3_^C^>R_P!!<+_SJO\
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M<-+6OD;\@LP!:T;QW"UQ-CDXC= L&G,WTS&[]X@+ .U=6;*X15R&CN7C6:Y
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M41'IU$<(M5X8 -SGV:4P 8IN)FCP,40 0$!W!R& 0$!\! 0\! ? 0\\Y%_\
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MR+^#V1VSCU>NV>]3=;6[Y0P'BNL&A\5V@'BJ[ZA&JJ-S6#0"3G<]YMY*I)(
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*$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g150774g20o06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g20o06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#R^8@0X0DE-! 0      ",< 5H  QLE1QP"   "   < E  #TMA=&%R
M>GEN82!2;V)A:P X0DE-!"4      !#N+#3X-#0$K6Z ='=YYZ=5.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             $
M/   !V0          0                         !              =D
M   $/                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   $/     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P  !#P     4F=H=&QO
M;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      WI     0   *    !<   !X   K(    W- !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !< * # 2(
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MK]X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"M*+6D 0;8!*PLM44%A]EI@ 9:(!< VW  VB @(" " @(:" @.P@(;" ["%
M6+BU-CPD\0=FY$YH?&$*OQ->E(5I?&FQ:G<FU1XN?885X9 X(TJY(9U.LG5I
MB%!0V&E676@7] >)F8L#=$W*<ISY_P [9'B#1EUTDSBHG;8OS4\QQ6C> , J
MTH]D3O2<ENO% 6CO\ 627:-MX&=7_5!$?I]AVQLCT]DT,-D4-5)9D<2MHY&6
M5%.U\6V/7&25T3E?])7)>JK===FNN//5=-8#JF5U7+"VH<Y%E1U4^-R.N2Z]
MB2(C<R)H1+_.IK;VM'0@Z_58@VO?[8.0:=_/V?T^+6NUR]LL<G5G0L.I-;<F
M"_'4_/9-:/:S]"#[K,%]'^N%?_?^R#T:_%3+VRQR=6="PZD;DP7XZGY[)K2O
MM9^A"]UF#?Y0K_V<OW0=E,O;+')U9T+#J1N3!?CJ?GK]:4#AGZ$'LRS!>_;B
M%?\ XA^F"F7MECDZLZ%AU(W)@QQU/P?7)-/!^- \-'0@\ARQ!MNSVPD@^]_7
M!OS^*F7MECDZLZ%AU(W)@OQU/SU^M'M:.A"#]]F#?%Q"2 >[ND'H"F7MECDZ
MLZ%AU(W)@OQU/SV36E?:T="%[K,&[_\ ;"R#](-Z9>V6.3JSH6'4C<F"_'4_
M/9-:/:S]"%M^VS!O1_KA)!M_S@VIE[98Y.K.A8=2-R8+\=3\]DUH]K/T(7NL
MP;_*%?\ ](*9>V6.3JSH6'4C<F"_'4_/9-:4]K/T(._[;$%#L'_7"2 -?^<&
M],O;+')U9T+#J1N3!?CJ?GLFM'M9^A!Y>=F"]W^V$?\ TCI],'</R4R]LL<G
M5G0L&I&Y,&..I^>R:TK[6?H0M-/.S!=/_P PC_\ I!3+VRQR=6="PZD;DP7X
MZGYZ_6E/:S]"#[K$%_RA'_W_ +(*9>V6.3JSH6#4C<F"_'4_/9-: X9^A![,
ML077_P#,(_@/_P 0:]M,O;+')U9T+!J1N3!CCJ?GLFM+%-PV="7>J<K%&58-
M:24I*M17#Q R"WPI%R)*8;<%WE!I>%JJ]19J !IU1MWZNM,O;+.?][JS3F_>
M6#1<G\SPWC<F#&==NI^>/N3_ ,I?>UHZ$';]MF"Z=@^V$?\ 3;EOY0:!S^,1
MIE[98Y.K.A8=2-R8,7W;=3W\&[)-[^] <-'0@CRRS!>[_;"/_+?_ (0;ASIE
M[99Y.K.A8=2-R8,)IFI^>2:TH/#3T((#H.6(/J/:'$%(A#?;<;7X0 ._?0 Y
MZ!5R[LLKGR=5]#0)[-I&Y,%^.I^>2?"4^O:T="%R\[,%_P H1_[]_P!T'?S^
M_4R]LL<G5G0L.I&Y,&+OQU/=F_WQ_F_C>WF'M:.A"]UF#?'Q"2#M]^0:#Z?O
MTR]LL<G5G0L.I&Y,%^.I^>OUH]K/T(7NLP;N_P!L*_\ +N^F"F7MECDZLZ%A
MU(W)@OQU/SV36E!X:.A!#]]F#=^W$)(1_ _COM[],O;+')U9T+#J1N3!?CJ?
MGLFM <-'0@]F68,'_K"2 /O#( ^7MIE[98Y.K.A8=2-R8+\=3\]DWO[T#PT=
M"" ;Y9@WO!Q"2 1V[@"0".WO4R]LL<G5G0T&I&Y,%^.I^>R:WQ>PK[6CH0O=
M9@W^4)(.WO\ ZX-0^/E3+VRQR=6="P:D;DP7XZGY[)K?*/:T="%[K,&_RA7_
M /2"F7MECDZLZ%AU(W)@OQU/SV36CVL_0A>ZS!O\H60?I!3+VRQR=6="PZD;
MDP7XZGYZ_6CVM'0A=F68+_E"O_Z0>G7X]:9>V6.3JSH6'4C<F"_'4_/9-:4#
MAHZ$'F&68,'_ *PD@ =O1Y0:^]Z.5,O;+')U9T+!J1N3!?CJ?GLFM+(SALZ$
MNUP1E%Y5@PHS$JZ]29[8&0#U#RS$0)+>OY0:6"988K'JB&MW4YAU=V7MEF_^
M#ZS0N;(L'B_F=[@\:\ W)@OQU/SV36E[[6CH0==/.Q!M0T_^\)(-.W30?*#0
M1#?8!U"F7MECDZLZ&@U(W)@OQU/SV36@>&?H0>W+,%_RA)!\GTP=_9WTR]LL
M<G5G0L.I&Y,%^.I^>R:T!PS]"#V98@O^4(__ !_N@^6F7MECDZLZ%AU(W)@O
MQU/SV36CVL_0@^ZQ!=P^V%?]PV_X0<N7WJ9>V6.3JSH6'4C<F#''4_/9-:/:
MS]""/[[$%[/_ +PC_IZ-!]G].WD'/G3+VRQR=6="P:D;DP8XZGYX_>_O?2/:
MS]""/[[,%';[85_Y?=!RV^]3+VRQR=6="PZD;DP8XZGY[)K2OM9^A"W_ &V(
M+OS_ -<(_P"__."F7MECDZLZ%@U(W)@OQU/SU^M'M:.A"Y>=B"_Y0C_KSUY^
M4&O.F7MECDZLZ%AU(W)@OQU/SV36CVM'0A>ZS!1_]81_'F&GV0=U,O;+')U9
MT+#J1N3!?CJ?GLFM'M9^A"]UF"CW_P"N%?Q]._\ 7!3+VRQR=6="P:D;DP7X
MZGYZ_6E!X:.A![<L0;?_ /$)(!^720#]^F7MECDZLZ%AU(W)@OQU/SV36CVL
M_0@Z:>=B"Z#V>V$D ?>\H*9>V6.3JSH6'4C<F"_'4_/9-:!X:.A![<L0;8?M
MA) /R?UP??IE[98Y.K.A8=2-R8+\=3\]?K2OM:.A"]UF"[?_ (A'_;_G!_0*
M9>V6.3JSH6'4C<F"_'4_/7ZTL5_#9T)911(I,JP8PRY:@+-M]L%(+]$IJLDM
M69H$A#3P:83;^N.H6]770=-*+;VRSR=6;VBQ8-1OZ%W\]^;2-R8+\?3\]?K2
M]]K/T(.W[;$%VY?ZX1__ $@_\1IE[99Y.K.A8-0-R8+\=3\]?O?WI7VM'0A#
MOYV8+W_[85_[>[^N#MIE[98Y.K.A8-2-R8,<=3\\?K2@\-'0@Z_58@VX[Z<0
MD@Y^G20;<^W3G3+VRSR=6="PZD;DP7XZGY[)K1[6?H00_?9@H?\ K"O_ "^Z
M#E_U>BF7MEGDZLZ%AU(W)@QQU/G_ *8_6^,>UGZ$'W6(+_E"/_Z04R]LL<G5
MG0L.I&Y,%^.I^>OUI7VM'0A<_.S!O\H20=OH\H/P4R]LL<G5G0L.I&Y,%^.I
M^>OUI(-'"CT*C^[-3$RY*A[H\OKD@9FAL19_D1ZUR=7562A;F](18_B8>J6K
M%!*9.38 WFG&V66@(W!7"7"+95ACDFEH:J.*&-\LLC['@:R..-JOD>YRPW(U
MC&JYRKH1%4Y-HL&7N:QDL#GO<C6M;62*YSG+<B(B2WJJJMR(FE3M-\QSX$0W
M\W<LU_Y3)Q[WUXKSWW3L+_#J?F%)JC>[G[*\'=Z^;6'Q=T.W =;=:%^/I5;=
M?=U; NR=-[1ONT&[JV +R W#H CI;J.@".F@4^Z?A>EU]?3)?H_<-)G\GWH=
MS]E>#N]?/K#[^8Y\"/+S=RSUF3CLY?V8[.ZGW3L+_#J?F%)JAW/V5HW.[A_'
M3:P[8\-_"5A+A0;)0T868'1A0S%>W.3\6Z2-ZD5ZE6U)E"1%>4:\JU=Z:TLE
M4=;<60-EA@W!=> C: AYRW,)+6PCDIY;5FCF?2LDCA6."*'%;(YKGWI$UJ.5
M5:F==%V;2IO4E#34+7MIHU8V1R.<BO>^]42Y,[W.5,V\;1>,3XZD.08SE1^B
M+.\SZ%M3BS1"2.:8%JR,HG8ZPYSN8[% F)VY<N$NPD]S3$EN(I0O1VJK4IQY
M1FA%:5?!15%G0U4L5%5R1RU4$;L1E0Z)%2-)E;<Z1C+U5L;G+'C7/5JN1JIE
M=30/G94OB:^:)JLC>Y+UC15O7$1<S7+H5R(CKLU]RJB[#K1,Y8.K4V/K:O9G
MIO1NS0Z)#T#DV.*8I8@7HE1=Q*E(L2GV&$J$QY5UQ9Q)MEQ9EEPVWVB B%8Y
MH8JB*2">*.:&9CHY8I6-DCDC<ESF/8Y%:YKD545JHJ*FDXO8R1CHY&-?&]JM
M>Q[4<U[7)<YKFJBHYJHMRHJ*BIF4U*;@K"S$R2BQEQ-CIKL>(ZX-;M8@AS E
MM<FX?!KO$5MI*"RU2E!:B1K+2#NL7:J2IU%MH&DEWV]7%@]8,#9F0V+9<3:B
M-8:AL=!3-;-$KFO6.5$B1'LQV,?BNO3&8UUU[45--EF6<S'Q*"C:DC-KD1M-
M"B/CQFOQ'HC/I-QV-=<MZ8S6KI1%,N@6.H%CMKN1P2'1N(IG"U,H7EQYG0M?
MCQ]A75+.6WI"2C%9A=M]]I=ZBXP2[;KK;!M"X0'9H+*LVRV/CLVAI:%DCD=(
MVF@CAVQR7HBR*QJ*]6HJHU7*N*BW)<AFIZ2EI&N;2T\-.URWN2*-K,94ON5R
MM1%<J7K=??=>J(9W6^; H#7&8E3NAQ%E-;'SEZ=^1XXG"ID/:A46NA#NGC+H
M<VG-MR0+E5J\M983>C%, J 46EB2 F=4* ZP-"CB-QH4* HY'*"W&+Y7RD@B
M*Y=,LH.R<J'1_&#?%\7->1Y(HC+N:X3"2N<I?A7/[6X'-MKC[ M"0Y"SV*@!
M>V:[V$4Q<0F5UCS#4%ZAKDD;D.0$D4(F#!B.<,2Q^*=6>'G7W-T;DC\*9&UP
MQY>I FE[R<^F+26]J%6WLJ\R,R\HA^OMV\0[:??V3R9S$(-G_-B5NX=H>M5*
MI+(I0SQENR0]/&*GM"8F?'5\<XD_%7N 2I/XN\P%R0V*9.7='S6ZZZ]#<L<6
M\N1MI:<"]P=GC.SD]X*@LF+2/ECQ"HL9,Y ^PR01]X>'CV*E)4Z M2*X].@?
MH1(&5O9G1$>V7)U2BQ>K6FMI<@8/%Q?/O]EX/:7F89X>F:LVI%\WFL4F:S-I
M, QNX,;[*&AEA9I>(H"\-4BD5S'UDYD68RG9VFZYF7EJ$,M=%=C!<W.BU6D3
M%"%XEG61XW,LG-\*>5N0%;E*H_:5*WYORVNC^/;I;G6+12R(.4*?9"FC"LYO
MADK>GEI<X"HC2>YCB1+B\)A;'!O<%8&,ROB8SSCYK2A+"8VN42!W=F%H<H]B
MN46K$"J+SZ>1-0<FCBV>'%R95*&2())40W@\L=K&UK')P)/?$:-*6I%1+\VC
MRZ"XXB9]D@['&$9$PR\PF123$LOD!CC 'Z=-C$_Y!]B<<N+ 5&$T%3R,F5+E
MBM4^DPR-R8ISC;P4H4 X@K)L,L,$X>V^GH[)OF+2^9S6[(62TCW*\S,"[V+R
MP9AQGCJZ<6W*YZD5P6Z(-*9C8[%<>DEB8Y2K)+:W]$Z1H$1KJ:H+M;[5JBP#
M?V6(9/XO&,T9D6Y6EB=2;B%$K98"@4&E1Z*SV)DV/R1<QW)CQ6*A<W]&E0'-
MYEYZ=S3+5C?>3<0L,+/ [F6#<-E@WV]6\;;1NMUUZMP@ W6Z]N@ZAKZ* _#%
MT@G^W3XCN\<CK@U =PU;VWL]\-!Y;[=M?K/ /_8^P/[$O_L3'S*V?X4K/SO^
MAIT[#OW$/2(>\/;H/+41$=.X*]:=85 0[._D.VFN_+ERW#T:[ZZT!01YZ:@.
MWX0[^W< T'3;3LH!_L==O2&_9MST#3F.GHUT#;>@&NPB(:=H<N?9V#OH&NN_
M,>[8#Y[]]M--@YAH(@(AMN !KV;<O2!70-NS;L[NT=0$-1[1V'D&W+4"N@"
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M9V?U09#LOP1OZ<GSD6Z]%;P&)2$UY.!DMMQCFU)KQ&?91NU*5N*=.=;H,VT
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M ?6PCR#78>S7T;_)V_>W$!RVV'N#0-=.8ASWVT[.[76@'6TYZ!V!ST'3TZ:
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M * A7WYU1_#3%^5T=.WH!-4 H!0"@% * 4 H!0"@% * 4 H",>_H,[_!B_\
MDIM 7:3YT2_P<G\7;0%Q0"@% * 4!CCK#XD^NS,_/<7CKR^1PV\Z//+JR-K@
MZL)QMUEQAS,XJTQRML-,N++NO,1'$7W7%V#<(C;:( 9'0%HG0(4AZY2D1)$J
MET4EK')0G3$DGN*LI(F0%*EQI=EIBM26@1(T19ZBXPVQ(D3)K;@)(*LL NZ
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MLUA3RHZ.KW;L*^O5K_2VF3,,.1K7Z)GZN,:R/"J7G;-:/*CHZO=NPKZ]6O\
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M35'/UT[M,.C\12-ZY.:T%>QCB<';QYO;OFK;I'+"X+,WV.RK*]Z]HQ[G%_R
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MO,?JCK\]GNQ0"@% * 4 H!0"@% * 4 H!0$*^_.J/X:8?RPBH":H!0"@% *
M4 H!0"@% * 4 H!0$8]_09V^#%_\E-J+H6_1<MX+M)\Z)?X.3^+MJ@N* 4 H
M!0"@% * 4!8-;6V,C<B:&9O1-+2VIBD;<V-J4A"WH$A%H6$)4:--84G3)R;
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M$DCT^@]\+G.3'QL[G*M]Z*IT%6W!_=$FZUIDJ,:^7'DD1V,K4_"1KD1%Q;C
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MGWO_ &3?+W\AING9<XNV.94>H&)@MWU)P_C9?)WVG@X-X>1G09:?1'!&@_\
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MVF_O[!J'=L!4=1&W3;?7?Y- YAN&NP>_0%!#7M$=^6W(>[4>[D.X[;:;T!4
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M*#$:92M6*$Z:\P223U:DTNRV\\VZX"^H"'?X\PRIH6,$F96N0L;A:5:N:'I
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M_?3EOY=;Z=E3*6RWQ=K]%474QN?!>]?ITGC_ '7*GLVX>:+H-M@!ZPB(CIH
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MWP1?%29GX)K<I):X(S/8Q5!B5+:<R&$MSH:98JCQ% >JE@W#98-X %XVVC>
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M8/=KOSU !$* IS[]M0WW[ UUV$-0WTY:^D!UH!J @ :!N/Q:\P ?O:[=X=]
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M9KSY?+H UYCJ&FG/30=A#4._3WNW;4!TH"O,--=!'WNT-1 0T[^>@:Z::\Z
M!H/+WA ?Y^\0UY#VCSU"@*!H([?S:[CRW#33<1$0U]_EJ!4?3L'/74.8#_X#
M\@#W4!\B&^FXZ[CKKMIKW!MKORY]FVP@5 =M^8!K\7:/IWYAKV:Z:T!7T#OJ
M(AKZ--=].WL[-N5 .WLT'EN'(.STZZCMIL',==  "@AST'00VTUT';EV]^F_
M<.G.@*B'/7N#4 $?P#L'+37;M'4.P"@Z:#R'3O[-M==]QVTU[^[L$ &O8 \]
M^MV]@[AKR_F[: =H@/O".@_%RN[=1[N[M"@/T_\ 0+?46SQ_RJLW/77Z3F_O
MKX!LQ?PI8W_UTO\ [3SVV"OU:K_M#?\ *:>\E?'CU0H!0"@% * 4 H"$5?3
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MB92B<97B\;69%D;ZY+98J5Y1FC&I/<K51B:V\]J;9B@0HK_%"$]HE)T:<L0
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M\_NYE^Z.6#[_ /9"F/;7>R>JA3W,08EG<+/6/^;>+!(P\)%RIS!0M9O%[51
M(!&0RD $@4*2XWJC:O"ZX/&Q4:C?K=KUK0'J6V@%Q[9[R3U4/R^<FUV=PL]8
M_P";S>3QE_Y/\'H?[N9=_P#A'+!_Z0'3[U3'MKO9,W\S"GN8EY=KL[A9ZR3Y
MB\;XAPDNJ]&V-QS2K7N"DE&B2E2*5B:H5*#+2B"2P%P !O-,NMLM 1 !$0W"
MN+Y;88USWH]K6HKG.6*&Y$32J_0WBI%9[E1$Q%55N1$DDSJO_,;,]K9AG[$;
MO\?R3\[UJY2K>._\<7R&;<5-Q?\ WR?,/:V89^Q&[N^C\D_._P!_G5RE6\<G
MJXOBSMOWC<5-Q?\ WO\ F'M:\,_8C?\ X_DOYWHEIUJ?QW_BAU?;?&XJ;B_^
M^3YS84,Q_$\?I%J&)-8M:5P4VK%98K5ZX35%A5I%IG7<%2HRP *LMMZA=UA>
MW6ZO6$1'7GJ)JA6NF?CJQN*U<5K;DO5=#&M1<ZZ5SF:*&.%%2-N*CEO5+W+G
MN1+_ *2KO(AF58#(* 4 H!0"@% * A%7TPL_P8^_RAC[/Z??H";H!0"@% *
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M%K@<,;;69I4)FEZ6=<0S'(>."8\Q9GFA[3(6YX0\/V.GF*NQKD_WV69B\?R
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M^^^_+;3?01'GW - =WN'*2\?S/!%J;A>'/WF\NDBX]P#%["^N<>\JKD#5:Y
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MAN7X7_ $W5 H!0"@% * 4 H!0"@% * 4 H"%??G5'\-,/Y814!-4 H!0"@%
M* 4 H!0"@% * 4 H",>OH,[?!B_^2FT70M^C?!=I/G1+_!R?Q=M 7% * 4 H
M!0"@% ?!I19Q9A)Q=AI)MEY1I1MEIA9I9EHVWEF67 -M]E]HC;?9< VW6B("
M @(A0 LLLHNPHJRPHHJRTLLLNVVPLLNRT+;++++0"VRRRT MMMM +;;0
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M * 4 H!0"@(15],#/\&/GX]DJ;Z>1?AV_8";J@4 H!0"@% * 4 H!0"@% *
M4!"OOSJC^&F'\L(J FJ 4 H!0"@% * 4 H!0"@% * 4!&/?T&=^W^IB_;O\
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M\#CUGKR1WXH!0$(V?1.1_"*/\B-E.'MO)VS>^\$W0"@% * 4 H!0"@% * 4
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MMBM0SB@% 0C9]$Y'Z')'^1&L:</;>3MO_!!-T H!0"@% * 4 H!0"@% * 4
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MV>_[WI_YWGGZKZS-XW)_A:GP, K:-<4 H!0"@% * 4 H#:6$_JL0/^,"7_\
MY,K6K?JE3^:7WH9Z;ZQ%_70]=J\@>A% * 4!"-GT3D?PDC_(C73A]GH3XW@F
MZ 4 H!0"@% * 4 H!0"@% * 4!"*OI@9_@Q\_'LE3?3R+\-[M=YP3=4"@% *
M 4 H!0"@% >"W2T\%7$CQ.Y<Q?*,*8\*F+''<<*F!X6&2N&Q\4;J9)G-PL3
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M_IRH";H!0"@% * 4 H!0"@% * 4 H!0$(J^F!G^#'S\>R5-]/(OP_4";J@4
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M "(V4X>V\GH[+O@FZ 4 H!0"@% * 4 H!0"@% * 4!"*OI@9_@Q\_'LE3?\
M,OP[><$W5 H!0"@% * 4 H!0&++(-"G!4>M7Q"+K5BDRXU2K5L#4I4J#;O\
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MK$DKT8LTJ0Q8U]SY7-<YK$6ZY'.1CKKU2]4N3.J(L_6R910$8]_09W^#%_\
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M5S*J+M2Q13-1LL;)&HYKT:]J.;C,6]KKEO15:MRI>F941=*&3
M  &@  ;   &P  <@K7,A6@% * 4 H!0"@% 0C9]$Y'\(H_R(V<_Z<J FZ 4
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M)5%-JU2F3FE$K@17+#%*9.LL/3EK2TRRTKQA,099M5=GTE;N7=,6V)1U<5=
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M8I3DJ+2CB5)5IY19MI:A,9:<G46 9;<%AR<ZRPTDVT ,*,MM,LNMNM 0 YJ
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M 4 H!0$8]_09W^#%_P#)3?>_#1<Z*G""[2?.B7^#D_B[: N* 4 H!0"@% *
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M5R;P74U\)XZ8AOZ_7ZP=7P?B>G5ZMW7\)KK;U?V3MV] +V@% * 4 H!0"@%
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MT:!3(?$B+UK6YGEF7MS<M7$!V]*7^Y3L-0"@% * 4 H!0"@% * 4 H!0 1
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M0.\E * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g150774g21d92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g21d92.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1W04&AO=&]S:&]P(#,N,  X0DE-! 0
M    ';2^=@0X0DE-! 0      #T< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $,KH3TM^MC\Z-(RR30L222(X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              )(   #@@         !
M                  $              X(   )(
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   )(     %)G:'1L;VYG   #
M@@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "2     !29VAT;&]N9P   X(    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     $U@
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MBED?6_/Q#4W*Z6:G7N:VH"Q[B\N?Z/ITM.-6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ NP$? P$1  (1 0,1 ?_$ !\  0 !! (# 0
M   )!P@*"P,& 00% O_$ %\0   & @$! P0($0<'!PT   (#! 4&!P$(  D1
M$A,4%2%V"A8W.7BUM]07&2(Q-#8X05%66'-WE9>SU1AA<8&QMK@:(S*1EM?P
M)$)&5X6TP24F)S-'2519=*'1UN'_Q  = 0$  @(# 0$             !P@!
M!@0%"0,"_\0 3Q$  00! 00$"0@&!P0+      $" P0%$082(3$'$['P-39!
M47%T=;2U%!5A<X&AL\$(%C(T-]$7(B5$4I&R55;"X1@C,T5V@I72T]3Q_]H
M# ,!  (1 Q$ /P#/XX X X X X X X X X X X X X X X X X X X X X X
M X X X X X X X X X!0VQ+YC5;VYK_3KLU/BQ_V*>[$8HFY-Y: ;0S*JWKY
MUL9W-D U*Y.L*(6-#0>C;LMR-P&-Q,* I G3Y&H"!1?;V07@3+M3Z[IB<N]9
MI[BO"5PVS)VQ0B.39UCL'8]=+PL=(<A*ES,_1ID5+IQ"(@U$O#NV*DP1+\(
MIU!ZXDD8$9>J&[NXM@[&ZQ12W7%S5,UIP:#AF<"C%1FQ\M@6+M=W6:2":3)L
ME<)8WYG9EMDM!GD]GP*VIC!V=8M14\]54T2@P<H !,[-+XC4'O&D*&<6E\52
M:]F:V'N,NJ(M )C:DU0-<7=7\I\,/7D+RCW$B5H2VC"%"N ,U.J\L&D!@H9H
M%<> . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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MO)CJH&<\.:F!)"VF2SA0C-LA 4"0KX8U)6E"QL4D5&R]/C[_ +>?I^[7S\>
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M729J<JY3%N^'Q(X1K:VJU[ZE,&:V%M_B-J-&I/4=U<(.0%"P4(P78'.037<
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MS8O<18VTOHQ:U2Q[9!6AI%?O]"[8E$J9(8HJ&H%*Y'31[5''=B25(?)@O!Y
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M'W%*9^'+H3_BXJ+@$B/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M)QP2P!-- 7X0#3,!Q@9@2N^9DL(Q=H@@R8/(,9P'OB[.]D#EX X X X X X
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MQ-8WJE8L4>B*QC%XD@^.S.,=GUNST?T<CLW8< < < < < < < < < < < <
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M X X X X X X!P*OL91^8._=BX,.Y+Z%[#2&S;[<Y=ZSO_QJKX,FSS]C$>]
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MH3:_0^H44,DCB<@6LZ:U(QL^\ EAJ]1@:1>D\P)B$P6;QL*094'IA\X/=/\
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M/5ST:F)**W*LSC./HC0G_:9GS_/_ /%_\?@Y9I>D_8!6Z?K7A]=$3]YX</\
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MVX!\5\B$+5H5C)YFB:5P>FUT1H"CFMI ></*,8#3""/ P>>%+@XLT_P0CR4
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M#%L=NY34:]D:L,J<DV+$5I7OM1>,N1ZI/A#@#FJ )Q)&E$$!:?&?*NPS&<\
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M>@3OM;S!G8BD+]E_6J4K64N2$'$8D3P6J R+N . . . . . . . . . . .
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MSD&<DFF=\??,+[HQ]X7>SGO9[0.7P20%F@ 24$)HAC-"$L& F#,]!@S XQC
MQ&?\\0L9R+[^<\ H_1E45[3U;-=;5Q&4D9@\7=I2DCL=*4+W%&RH#9B^NY36
MW&/"MP5I6AN6KU 61H*4!;&!#A,U,B5O:D2)$G JYE"BSW^U&ESXN!X,[4Y6
M?$P89XIF!_4?5X&;_G!X%VX$9]7GM%Z> 4DD-60"0W56MG/4<3.$WK6+V&F@
MKR>J<>Y',SL<3:I6M1-1:P#*-X=6EG1M'GQ4W*'E"T&.34W+T;>\O"9>!67@
/#@#@#@#@#@#@#@#@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g150774g21j92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g21j92.jpg
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M 0$! ?_  !$( *<!GP,!$0 "$0$#$0'_Q  ?  $  @,! 0$! 0$
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M6)ZC1;><^>+2/9&I(P_M+>6Z$*$(S9#'7EV8# *"O ,(<S2_#*R+!@2K8 7
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M=7>+TI6,)J]B=WP:<;T[-L)CR"/IG5VRC)3H\.3D!!XZM"C3IT@%!Y@$I!)
M2RPD)N2>J2?&MS\*$X1.$3A$X1.$7&^]_P# (Q_A1:)_7BUVY!X>%OI"D<?
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MOJ<(G")PB<(G"*&KKA_!1K_\(&+?H[M+E;.)[G[0K,_N!\H>@J2C6CX.&O\
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MY/182)#RD^$I."\%A*#:YMPON[BC7Z^GQ2^V'Y"OK*TWPJXOPC?#^J5UOO\
MRVX8%K(^S:BD$D=Y]%+3UMD"ABA[K$&62R.NVG9*IEMQQEH<)Z^1J(EJI)4)
M,Y8NY>I SD+"W :(IP3*E!!@2H;:^_<+'>;\;&W"YXVYES1TP-@;&L5CF\$M
MO6Z=5+9:F86[;TSL9U*UC0Q6P12^VWD,#(.1T/9LF=U\]::E4P"/25_D,00
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MNI"=<8(]*W$J%&#208 H--++\(L 1"K9Q/<_:%9G%FCY0/C:2IC=:/@X:_\
MS)53^8C#REW$]T^E7&>X;\EOH"W;R%4G")PBJ"7-_K,,*_KG4?U96/GI/#?[
MMV8._,/_ %#@BY75_&IA?>^3ZNQ%6^^>;%U1.$3A$X1.$3A$X1.$3A%QOO?_
M  ",?X46B?UXM=N0>'A;Z0I''P.]!79')4*,NQ.L7TXZGGLSK"?[%989Q7LG
M?(9+V3%0WN[8:)+&W%0TO3;Y38ZP<F=?E$X)%";*MK<%J _)>3$JH\D0#!?;
MX=R;YXQ>AIL2PW+E?5T-7'M::IC-/LYH]1;K;KF:ZUVD;V@[EH*K-.7Z*HEI
M:K%::"H@=HEB?M-3'6!L;,(O8@[B>*_55_5^Z=ESV'#ZIK78;,CGT^?4,9B3
M"*I;S9<.SVY&=TB0^59!6;4RH,GF?Y&%#FY(T@,YQWAX,9QRG%.3K.V"T%1B
M>*9=KJ*@I&M?45,I@V<37R,B:7:)G.LZ21C!9IWN',II,T8!7U,5)1XI35%3
M,7"*%FTU/+6N>X"[ -S&N<;D;@5(1+I?%8!&7N:3B2,<0B,:;SW602:2NB)E
M8F5M3!\(]<YNK@<G1(DQ>,XP(U0< 'A""#&<B$$.?BEOE@4%V I2SUD<;Z[L
M^&S1;+66=R"/)XV])74QQ:JOD$2BEBG8PD$9A,?"I+/(>Q25O693N+2Z/Z!&
MK2EG#&$LIL>H>;FZO#Q\W56M9#N[JM%CT2=ZN6.DF+F9SD964:&0NY)$?9I7
M)8.ZO;BI9V9>G:&E#+8=*F)0X.IJ-*!:P.F.][I(:8$FD]3M=3J>L+[#YM]K
M1'9)'(JYW%$L.4J00ET:5K<:N>HN6W68H EK98]S9E1.$,BZ>Q%)I),#,D[\
MT8F)BA,&.>4LJ".\)8^GS<?Y[O4*X*Z^GQ2^V'Y"OK*TWPJXOPC?#^J5TGU,
MG$]#IA:"-!"]<[#?97(Z6KJ(P_;.)/<ZU]=YU9UZ5K7D$Q846CT8E[DYD(9C
M)F1QCXLL@FU!*TC$Y/;FP,J-P?FTJ6\1O(M<W'&P!)MO',.KX^"XVZ46ALKU
M$F=F2NP-8]7JWL"Q8NF+EUTTA<)$G>9:X$NS<I!#&JFHEJ_KG5%05LDP4:XH
M4,';SEJI8@:PRDV4.V!R,!2]VJUBXVYB//?4XD\V_F4WG"H3A$X10W='#][^
MI[^.1WW_ #FAO"J=^+\D?M4R/"I3A$X1.$7+&]'P)=Q?P6-@_P!$LNYM\O\
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MO>27UKO*GB2M#&T*8U<]AM:4MB O 0H(E*Q):"D:@+@M7&=\E=)\X-Q BS
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MWA_TW$U\)R;?!F3OM4_1Z57;=:/@X:__ #)53^8C#S@CN)[I]*Z4SW#?DM]
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MI5=MUH^#AK_\R54_F(P\X([B>Z?2NE,]PWY+?0%NWD*I.$5<?]T*?Z-:K_\
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M&;OR9PE+G7PS:U7.9\$-''Q;S*F[-&6^_P#@_P!8TZQ<8)]B<4X;\.K>8?\
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M&A1:@%09ZHA7A0(Y^'#AC91>95UB_<\0]2BBLFV-=BNIQ,J)-<MR,3L+>Q>
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M(YTJ\Q0873OR[T2ZM-?$V44M/'42="]#53I"YCXI0&;5L%WZ00[2T$:B#^6
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M?FGU+6MK]:?HZ6S%4T5<]^VB,)T<M@TU3ND1BE@$NY;W7<P99W%Q8&_5#(D
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MT-\D\E.)$T4%PHU=+R)+A"0V.KGAO0$(&Z'.K&Y*"77R0FDF49\BL5[P_M$
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M(N>CD D,7CQ:2$N('TH9:E]7.;PS)'5./.,1^Q6U^<365S*6A9!''02RTS#
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M(G:C5-$TM53X8R=SHX8*1E88W/IFLDKHZXJ/++Y)VNJG1AGL@UCG3[2,ED]
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M9?D1:TE&]Q^RYBSNR0IQ0J6QP+3.+?"TZQ.!:VK%:!4$HX&#T:I0F-\(DXP
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M5.#BP@$  3!Z^DY;\FP5>*SO@QS16U5/-"&T5,7!D5!24SM8-> UVT@>0 7
MM+3<$D#*GY,\Q2044;9,,U4\$L<EZF8#4^JGF&D]"FXT2MN2![:XM87.!^8V
MW.^[5'^G$D_87FPZ?.2>P8]Y!2_Q!8O2MS+V3"_*IOW5/,;;G?=JC_3B2?L+
MQT^<D]@Q[R"E_B"=*W,O9,+\JF_=5G=E]%K;V73)Q?FMXI@"%4ACR<H*N9R$
ME1@QKCC2TJ?#++A)P,!RJ0G9*S@S.1%9 ,6 "%D <##.6_)M'11T\L&.&1DE
M2XEE#3%MI:J:9EB:]IOHD;?<+&XWVN<JMY,\Q5%2^6.3#-+F0M&JIF!O'#'&
M[<*4[M3#;?PL=W!8)YC;<[[M4?Z<23]A>9_3YR3V#'O(*7^(+%Z5N9>R87Y5
M-^ZK/*LZ+>WL,LVNY>[N],#:HM.(I(G,"*9R$Y8- ROJ!R6!2DF0H@LU1E.F
M,P26,XH S,A"(P&,Y%C78ORWY.KL*Q*BA@QL35=#5TT1DHJ9K!)- ^-A>X5[
MB&ZG#40TD"YL>"RZ#DSS%35U'4R28:8X*J"9^FIF+M$<K'NT@TP!-FFP)%SS
MA8'YC;<[[M4?Z<23]A>;'I\Y)[!CWD%+_$%B=*W,O9,+\JF_=4\QMN=]VJ/]
M.))^PO'3YR3V#'O(*7^()TK<R]DPORJ;]U6=Q#HM;>L<?M)K6O%,"4S*"-\;
M:,D3.0F% <$MG5S+S1+!"A)8B4V6J*.8 F%@.'E8)*3DK!9HSB=?6<M^3:BI
MPF5D&.!M%B$E5-JHJ8$QOPO$J(!@%>=3MM5Q$@EHT![KW :[*I^3/,44-?&Z
M3#-532,ACM4S$:VUU'4'5_119NS@?O%_;:1:Q)&">8VW.^[5'^G$D_87FPZ?
M.2>P8]Y!2_Q!8O2MS+V3"_*IOW5/,;;G?=JC_3B2?L+QT^<D]@Q[R"E_B"=*
MW,O9,+\JF_=5G:KHM;>G5BQ1 #Q3'E5MG<LDB@8IG(<(\M[W'X6UHPEG8A.3
M!*<*6!=D\O)(0 *$G$$T8C! +U[.6_)K<5J*TP8YL9</HZ5HZ"IM>T@J:Z5Y
M+>C[!A;41Z3J))#@0  3ENY,\Q&@AIA)ANTCJZB=QZ)FTZ)8:6-MCT-?5JA?
M<6  +2";D#!/,;;G?=JC_3B2?L+S8=/G)/8,>\@I?X@L3I6YE[)A?E4W[JGF
M-MSONU1_IQ)/V%XZ?.2>P8]Y!2_Q!.E;F7LF%^53?NJSN<=%K;V1$0<M \4P
M$4=@C1&U_C,SD)>!."%P>%1PDV00DW)B;):\G #!X*&(>#,9*#@.!"P*'EOR
M;3.KS)!CA%3B$U5'IH:8VC?% QH?>O%GWC<2!J%B-]R0,JJY,\Q3-I0R3#?O
M-+'"_54S#V[9)7$MM3&[;/%B;&]]RP3S&VYWW:H_TXDG["\S^GSDGL&/>04O
M\06+TK<R]DPORJ;]U3S&VYWW:H_TXDG["\=/G)/8,>\@I?X@G2MS+V3"_*IO
MW59W:71:V]F5G6-+VAXI@#5*YW+Y(V 63.0DK M[Y('!T1!5DEPDXLI2%,J*
MP>6 XX!9N!A":8'&!YU^$\M^3:+"\-HIH,<,U)A]'2REE%3.89*>FCB>6.->
MTEI<PZ26M)%B0."RJ_DSS%4UU941R89LYZNHF9JJ9@[1+,^1NH"E(#M+A< F
MQOO*P3S&VYWW:H_TXDG["\V'3YR3V#'O(*7^(+%Z5N9>R87Y5-^ZK.ZYZ+6W
ML4D#@Z.;Q3 DRJ"6E&RL)9G(33<.$RK&7Q!H$,(X22'"8#J^(AK#,#R,E&$\
MXLHXPL))FOQ/EOR;64T444&.!S,0PBJ.NBI@-G0XK15LP!%>XZS#3R",6LYY
M:TEH)<,JCY,\Q03/D?)AFEU)7PC34S$ZZFAJ*>.]Z4>UVDK=1YFW(!(L<$\Q
MMN=]VJ/].))^PO-AT^<D]@Q[R"E_B"Q>E;F7LF%^53?NJ>8VW.^[5'^G$D_8
M7CI\Y)[!CWD%+_$$Z5N9>R87Y5-^ZK/&7HM;>M]?SJ,'O%,9<I&\0E<WB+F<
MA$E"3'LR3*_"DW,)",LP7E9+XN$!1N#.P[PQ%^ 'P\"?EOR;)B-!5M@QS94T
M%='(#0TP>75/0NST@5Y! V+]1+A;VM@;FV5'R9YC925,!DPS7-+3/814S:;0
M[?7<]"W!^^-M8&^^]K"^!^8VW.^[5'^G$D_87F?T^<D]@Q[R"E_B"Q>E;F7L
MF%^53?NJ>8VW.^[5'^G$D_87CI\Y)[!CWD%+_$$Z5N9>R87Y5-^ZK/7OHM[>
MN-?P.,$.],8<8TZ358X#,F<A"E$3(38^-!A,:&%"&8,.&M3XP$916"\Y*\ 1
MGA"R# @Y;\FQXA7U3H,<V=5%0LC H:8O#J<5 DU@UX !VK=-G&^^]K;\J3DR
MS&ZDIH!)AFN&2I>^]3-IM-L RQZ%N3][=?< +BQ-S; O,;;G?=JC_3B2?L+S
M/Z?.2>P8]Y!2_P 06+TK<R]DPORJ;]U3S&VYWW:H_P!.))^PO'3YR3V#'O(*
M7^()TK<R]DPORJ;]U6=V-T6MO97(6]T;'BF )DT%JZ.&85S.0E&Y<(=6<1B+
ML((00DX.4PW5C6C1F9'@9R01!QA1)@Q$EZ_#.6_)M'320RP8X7NK\5J1HHJ8
MC9UN*5E9""37M.H0SL#Q:S7ZF@N #CE5G)GF*>9DC),,TMI*"$ZJF8'734-/
M3R<*4^UVD3M)YVV) )L,$\QMN=]VJ/\ 3B2?L+S8=/G)/8,>\@I?X@L7I6YE
M[)A?E4W[JL[JWHM;>PVSJYE[N\4P-JBD[B$D<P(YG(3E@F]CD#>Z+0I23(22
M6:I$F2FX(+&<2 PW(0B-+#G(\:_%N6_)M;A>)44,&.":KP^LI8B^BIFL$E13
M21,+W"O<0T.>-1#7$"Y /!95!R9YBIJZCJ)),,V<%73S/TU,Q=HBF9([2#2@
M%VEIL"1<\X6">8VW.^[5'^G$D_87FPZ?.2>P8]Y!2_Q!8O2MS+V3"_*IOW5/
M,;;G?=JC_3B2?L+QT^<D]@Q[R"E_B"=*W,O9,+\JF_=5W3TZ^F)L=JOLJTVW
M9;E62J+(HE+&,XJ+2=Y=';QQ[1%)T8@)%T7:2!$!,!GOQY68$ /9D)8_?QCX
M'E)Y4\M9MRQ+@^%Q8JRK?64E0TU=+!%#H@>YSP7QU<SM5B-(T6.^Y"^JR;D;
M&L!QN/$:Y]"Z!E/41$03R22:I6!K;-=!&+7XG5NZA5@?GG==>3A$X1.$3A$X
'1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g150774g31c55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g31c55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2SD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +,B^$49#A"24T$!       'QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "    .$))300E       0T\F?2SV-ZBB%2#5JA!6<*SA"24T$.@
M  Y0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0F
MET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V
M93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V
M]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F
M]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$
M]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36
M)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M   $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V
M=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M  1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%
M15;G1&(U)L=                $)L9"!5;G1&(U)L=                %
M)S;'15;G1&(U!X;$"/0           "G9E8W1O<D1A=&%B;V]L 0    !09U
M!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M      5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M         08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&
M]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W
M12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M     0 ^@    !  $#Z     $  3A"24T$)@      #@             _@
M  .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
MD           $ .$))32<0       *  $          3A"24T#]0      2
M O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M  !@       0 U     0 M    !@       3A"24T#^       <   ______
M_______________________P/H     /____________________________
M\#Z     #_____________________________ ^@     ______________
M_______________P/H   X0DE-! @      !     !   "0    D      .$
M))300>       $     #A"24T$&@     #-0    8             !2@
M7<          $                          0             %W   !2
M@                      0                         0     0
M   &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M  5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !2
M@     4F=H=&QO;F<   7<    !G-L:6-E<U9L3',    !3V)J8P    $
M    5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;V
MYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V
M5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M    !,969T;&]N9P          0G1O;6QO;F<   4H     %)G:'1L;VYG
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MU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M      #     (_\        #A"24T$$0       0$ .$))3004       $
M  "SA"24T$#      B4@    $   "@    C0   >   0A@   B-@ 8  '_V/
M_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M( "0 & #$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@
M !     -,M2% @(
M                  $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865
MH   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG
M9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M  #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M  0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M!D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-21T
M(@245#-C$Y-C8M,BXQ
M                        !865H@        \U$  0    $6S%A96B
M                  6%E:(        &^B   X]0   Y!865H@        8I
MD  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#(&
MAT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:6
M5C+F-H
M       &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V
M]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&
M5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;V
MX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F
M<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M          =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%
ME:(       3 E6 %    !7'^=M96%S          $
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M0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01#
MP,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0
M@ C0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0
M($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @
M0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4
M,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<
M34Y/2EM<75Y?569G:&EJ:VQM;F]C=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=K:W&24F,U)A<7*U_\0 ' $!  (# 0$!              4& P0' 0((_\0
M01$  @$$ 0,!!00&!P@# 0   0(#  0%$1(&$R$Q!Q0B05$5,F%Q(R1"@9&T
M-E)S=+'!\!8S-6)UH;+1)C22L__:  P# 0 "$0,1 #\ [^.*4XI3BE.*4XI3
MBE.*4XI3BE.*5K[9NV-9:7J4A?-MWZI:XIL6G.3;'<YZ.K\4ASV+6V*T3(D,
M)+/(PA2 XX3#YYKWHP(,^\I+><]M:W-Y*L%K!+<3/]V.&-I'(^9TH.E'JS'2
MJ/+$#S7P\B1J6D=44>K,P4?Q)'\*YN.Y/\27K"G(DJATOHCNU;$C+PV-K;)
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M.6UB50 $)#--(@^%9II>&ET!&XO&+BNI\?:[YS' M-=2;),MU+=7)F<D^3Y
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MFW.KM^)S)2!@F(U_:#E9.C%Z/,:]L2)$V1[I]X?%1OWHL88^WO@D_I-WM&U
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MGD2)7FLN$2%V"AI'[K<4!/Q-HZ'FMZ=M-P]@M(U^EW32/7]_L+!BV(K&VZQ
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MKUVZ7GHJ3%,KU2*V#)PL6);$(/GM7,U"C1K=*U^V74+3FI2JQ*X8_P!?X_\
MJE?#ZLR%I'W-N"JFREMNT;%?G3+%:;G8[:S8:C:)&\'R,+0I>IG;9V+KN;6_
A 21BX>Y:O@Z+#1$#5P:N7 BLN1(02E3_ .*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g150774g34o59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g34o59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2H$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *>B^$'*#A"24T$!       /1P!6@ #&R5'' (   (=S!P"4  (<G(Q-S
M8S-C(< @4 '$UI8W)O<V]F="!7;W)D("T@5&5M<&5S="!3+30 .$))300E
M     0O]%3NBCX%]GYG<O#S_\_[CA"24T$.@      Y0   !     !
M +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M!);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G
M1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $
M)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M    (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $
M-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V
M]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M!%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %
M)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M        !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M       $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M          "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M   %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4F
MQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H96
MY0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W
M)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M  "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  (!+
M    $  CA"24T$)@      #@             _@   .$))300-       $
M  >#A"24T$&0      !    !XX0DE- _,       D           $ .$))32
M<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M   0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0
M M    !@       3A"24T#^       <   __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M X0DE-! @      !     !   "0    D      .$))300>       $     #
MA"24T$&@     #-0    8             ! 4   +\          $
M                   0             "_   ! 4
M   0                         0     0       &YU;&P    "    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P  ! 4     4F=H=&QO;F<
M+\    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6
MYE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&
M5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M      0G1O;6QO;F<   0%     %)G:'1L;VYG   "_     -U<FQ415A4
M   0       &YU;&Q415A4     0       $US9V5415A4     0      !F
M%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96
MQL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W
M)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC95
M9E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4V
MQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M  "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M    MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M   #A"24T$$0       0$ .$))3004       $    !#A"24T$#      ?C
M    $   !W    H    6@  .$    ?<  8  '_V/_M  Q!9&]B95]#30 "_^
MX #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1
M,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@
MT0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,#
MP,# P,# P,# P,# P,_\  $0@ H !W P$B  (1 0,1 ?_=  0 "/_$ 3\
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MW"N_SW_P#I!$$'H@BNJ_Z?]_%_]EO_ "*[;_%_M_9V;ZYH/ZRV-GI1_-MY]
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M9F+>ZZXNZ:^R7V,;:SU T0Z_CT[*V?X2NS]+ZO\S5ZGJ;T!U-A!L/37@6DN
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M]+_,3MZCT\$AU#75[MP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(T)3DJ&QP>$')&*BU>+P)3,U5G*RPC0V0U=C<X*#M+7D\41TLW7_V@ , P$
M A$#$0 _ (=R&<\[KEYT\WHCQ^F7(>5M8+R<O1!8!"[*E[0?&0>]RRT* 9MV
M.DD8LF#'OI(C!3!IIHGIA-)JU0UUTTTQZQRD=&,NZ,=&JC-J?*8&JLERLB6I
MHZ=GFE\'4\DK%N"S.VY=V:Y-RS&YQ\SJ?"-1F.8)325+B*KJ 529U"*9Y%4
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M!UNZ"&.B#C42HZT51V(>SJ:J.>*H-M,E17FI"&YX<8CD%M=@#K:6Q %_Q0)
M%KT)ZZC&OP=&#!T8,'1@P=&#%CKM_P"*_A__ /E]E?\ _*SDMUJLN_Y7GO\
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M,KB(((N""*FQ!&X(V(QB^$\G&QR) >T&I<$>8@QW!\QQ^/\ -"/!2_V("/\
MKY-_5;I_@ETX_P"L&?Z*B^\X/">3_ :?.F^SP?S0CP4O]B C_KY-_5;H_!+I
MQ_U@S_147WG!X3R?X#3YTWV>#^:$>"E_L0$?]?)OZK='X)=./^L&?Z*B^\X/
M">3_  &GSIOL\'\T(\%+_8@(_P"ODW]5NC\$NG'_ %@S_147WG!X3R?X#3YT
MWV>#^:$>"E_L0$?]?)OZK='X)=./^L&?Z*B^\X/">3_ :?.F^SP?S0CP4O\
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MIH^N&OX*!4;/$M1^6QEP.G11!PX**/1:+T-IY,T<-T&('4$V4@%E)&J_N/&
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M9"\H%12J4#<2XFF6,$Z$&DJ.*3':TNZ^.(1XY=L^XF>#,KBZ[2K:=V(XCA.
MR6S S.(!K;8%-7L3BMFPL"((FI5)FL6%1FX%HPO96JL"<$RK9OF. 9"@%DGE
MJ,?D&MI<]Z9U>6T-934@F2K@H96J)*!D*SU%%432)'!"T\DV7K,*/^=".-FX
MTL1D@TF6*Z2CRJ*HFBED*F)YU$:3!CHCF1%+/((PD^GC7C)8#0K!9+Z7B"7%
MGP>T:85(TLJ;H1>0S6O./\T9-'%L-_=<FSLSB[M9\V,3^,DDHX#A[<98I*'-
MH</VLR%L9"*D3YJE)EW(C=MOD'.NE<SU[4=.9X:>JS:G9EH/Q<;T6=FBIHZ2
M93+)4%Z2.H-0_4JEH9(5)@ D#&/5,M181+($>2.F< S>,1-1<:1I8R$6,"5H
MQ&IFC#!B-?BD8_6%\??!CR1P\$RKD-$QX  2M *&>-Y8@*-O1"EPVF-A$A1?
M/P404)=V'#("\R0DZY\HBS.-G3."/XXX?$HHJG-NF4*K)!E-0TLJT4LB& O&
ML@RZ@>IA*K)4! :B2J73!PD+0LIJEF").)394S%7JD"+Q5#!K$_CYQ&P+*A:
MT:Q'QR[68$1LA+)HT_\ ]^W_ ).OI>-!@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#H
MP8.C!CM'\%9_4^.-W]Y6O_Y\VGUYD_E$_P">&;?%0?\ ME'CZ+T=_P!$T_\
MMU'_ *B7&P'KBL;O%+N1[:V]+8I8S7'G%))#54V6\3##"^*M/K%;+K!23/;(
MDL>GL><1Y[&Z\%RHG%G4GC9>,[[;&&;;$B+D$X%**GU:D*WVY@7TF[+?401:
MPN1<$&Q&_(R%K&_\1\0//S[X5'(.2SU>1W  T;WJZ):S> Q>N\U<A:^P"#P>
M2TJ9WVMR5!Z>5;S*6BAT^)64T2%"7++WP36)P *3*1YF&1DX-.3XWNR=2@:=
M5E4K[NR;D7U7L=R -K X!V<N1YVYWY;[ \OB&_;A0N:UY>2QU=HY>P;GCBS!
M6X) &+AVTY8D'[9Y+I@PIJ,1!0A:0F#R0T;KB1"Y,*(11A7 &JIA#@0&V@$I
M\N>^3Q*R'6-3BQ<[7%Q<Z0#K )*D$%0 I4!@3<8-A8[=EQS^/8WM;SWO>XMV
M6AB4FN=B0K*.2_0AM)VE^G@18@Y4D(,;,H\_BEIG98LQ'DW&C<[%@J#8%)8<
M\'Z/@@9!Y'(4BML<C)EZ[F"XT@\]9!W.XLQ.QM<#8J1<"X',' 0.SD #V>8#
MXMSO_'%Y>K<1Q*H-_3E%O\/"_P#QB75<W^:E_P"[?_=.&O,?&/VXBVWW<_V\
M_P"7JS"Q\Z,&%C=A&4AZ;MDM!]%U)F,K6<$(GJU3RLZS)&<9)N N6J&NF^7#
MK4BFWV;-\:_KZ^$T>W7O][$7)".1S"L1;G>QM^O#',7Y7%\:_$XE?LDGLD0C
M4WML7$&(2T)&K.\$YM,8')H7K(J&D_'45!F3>6B'4J/F(+%IU'I.XA)-A(-W
M).:+2DQJ2F$>4-4V<DV+ #4;W8@@%"@6Q!-U!!(WN3<FXO*X'8+[;; @[WOS
M[=QL.SNQ+(U+N385-"-R^.R!K+F=^T'Y ?R1-%1,R 3N0N65MQIKY<JB'+ J
MZI1@1D"Q("U8"4SS;!UX":3!@4PHP7&S7OK6QW(8,?&';LJ=UA<7]U?"V-[<
MK'8]G=O?<D^S&R7J_$<'1@Q;?C#_ $-,_P"[@O\ -ENM?7_]%_YG_!BR/M^3
M]^.=Z_JKY12J7V^\A'*:S(9<,DYR3-,)$6MGU^L+@G&>6<I9'1$=*^9I%ZWN
M#5U'";J+SYO*M$DH:^KLPS;MG"!!OL[4^SY56Y)#3Y>E3DE%4Y?#T9IN+4-1
M58>JSF'(X<TFC\(LIR\B9!-2M3DFI6KC)(9&TCCZJ&L9YVCK*B.9\QDTH)DT
MQ4C5CTRL( PF\5BDHD $9B-@01?%26E5<U348E<Y#>$3D>\3$5D#GX0M(!SR
M/N#),\<Y 1Y ,5'K'GCD$(U+<>I*GO)6^3[K#<\!=N(VW1T-9%;\UO1R.>"E
MDZ(Q<=ZV6EE2%EF$<<4653&6-EB42R&/-X"(6X2ZHI569B8Q)@\*O:-Y1FDF
M@0K*I8LI9F>I32P+G2H:E?QQK)U(2@&HKG7=3\OFA-%MCPB5@R4RVDX82; [
MQ<R#PXTUM_C[5<P\1)%3A;338:YY&PQ^+=;#%]RWD$D34;#]6(YP7I%=D!B+
M?@C1P1&"1XI1-'+I)R[-:^G!A$49(=<HJ$D&M1'KA(9RSK',15AD5/"L[L9
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M)Y."42BJ38@PNARR57,SZMWPO3?+O'DYN(I*/MVR@YHMIE)69?)%)*G293%
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M;+YF2-"7E8H0J2-^,9HJMF32B-I0/'3AF1;H)&/(KIU^<UZDB5'W\3KF&BG
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M%[&P8;AT]G*QOYN5O2=K[^C&RCJ_$,'1@Q;?C#_0TS_NX+_-ENM?7_\ 1?\
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MXJC1 1F"HKM([++$\;+I,<TECTE<'L,QF17FF1!(7U\.*2H0LP5O=_S<DJ%
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MY*[3L>-&IT.C<DM7:!M0>593,Y+(0LP91V.FMUVJA6HK&K!=;L2QCO:,#Q;
MW)M< M:W,MJ '>_/8=_,]OF!YV%_,.=L,*O.=-27<!.V/'N,QY.3PJ)J7R<B
MQ4&.#39X9C8J1QZMA;]-O,-Q4GF9T2*E:,.:.BY%K$'T:3T.NXR10CZBLEC1
MP2&DNHU$:4OV@=EB38VWVMO;;".QM8;[<S;L/??;;%WHAR$'SJ)Q>;1L($?Q
MV8QT+*0#[5<OC5X%D UL6%NL8P2VQC#AB[06QC&VV,8W[,9S]WJP0!@"':Q
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MS6$];[(D@IHB+=:[-W">=\M7BWB5?&-EO%N45DD_-7\H<\=3TMS.:'B-&R4
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MWLO6T_!_)?@VE]7_ !Q1X0KO*ZCUK^W!Z9O*3Y;IO^6MO9>C\'\E^#:7U?\
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M(OFKYDUS<MJJC-IJZ&BZ15CG+Y*>.=Y,HHH48U-.M3$8C+3JSJ8G!)*K8D$
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MN,(^Y"B?C<I.$]^YXS+[?&G>[.SO9UV[.WM[,_<ZA).3&XT 71A?63:ZD<M
M_;ABUQN>8[!W_'C!9J=OG.<^^?'PY[?^!5/TAU/K!]X/TS]3"V[SZ![<?/-.
MW^,^/H53](='6#[P?IGZF#;O/H'MQ"K)X]Q^>5Y.X1(9EA@!E\/DL9,O\"/%
M[,!AP.\&O7VBJY'5%+=DW<J.=%5=M4T]TM=]\XUUSGI-,64J4 # @D/N 1;W
MF#8;W.WF'M/[#BH<<J3BH%G$LGF_)P!M8+6#EB)I 43'# T'4NA&L%9K.H7$
ME2!%V%)S\VSK0TMDJ^E"X@A(@B33#+W]NM)) 3"Y;2+D'\NP75:Y4%#8D@'<
MFWRF\S?8;V[-@;@<KD-RW\V,N)X.<=6QK?$+LY-BQ)6G36Y".#DV[H1H<HAN
M^N" P>.^1O&^1GBRKEC/"[9VN95>B6[D2WU8L5VV@]"07.E /&6X#[>)XP \
M3;<@GF>S881OVZN1[!R-@>W_ .KWY6Q=KS3M_C/CZ%4_2'5O6#[P?IGZF([=
MY] ]N#S3M_C/CZ%4_2'1U@^\'Z9^I@V[SZ![<6#H^*)Q="2:ID\$O+516V<^
M1[,_$^3Z/\8QV;.%_&=_QW;VX[O=[G[/>^##JI#)P[KIMJ_*O>^GS"UK?KQ-
M+;VOV<Q;O\YQS2WYR9=0OD7;R2?'8')SL1NV0QS4_FZN*$+?%0D YN/^0+$B
MK)%L-KK31=ZB6P_2M9/*DXDT+Y1)EX]A^PRCU]ORK)14Y1EQ\+O!%/EL,W"\
M'YY4JDE7T;7*F007.6W4R,QK88#4&.Z1RZ7OCC*JKT552.JAV2H9=7&I(RPB
MS#K()>PJ+'3;A.^C58LMQ;%/8]>,F#Q2,QYSQWC3Q<(*;, KK7D=Q>T3J*4H
MQ:W0C^Z:6U4)JKA;<D4AL.*SPR5-K/DMY'78[?+ERJL#?1+H9<LADGFE&;RJ
M))&:1?!6<WS" ST$JY;F)"A9*"*&DGI8XXU'XFL<:0!*M1@)4LJ*II5)4 (>
ML4OXA^',C3P=JS.\D<K%B1KB&Y\0Q^4]=LY*0&X8<-IU,&ZLF(3^+.WS'DUQ
M>2:6 8F=$534*5FW*T1)(N)!/69ROI5/%G$<> FBQ2U)-IC.%=2KB4N++*=*
MK+ZA\QXJT<]+.JOD^<EJ2.GS2NS$T>7,05BI7CJX*0"99&$=! ;$&-:<:H<Q
MS((&4RI(A(J:6TA>EAI^+/VM(&BDF)0KXTSB_NM:]JJ<V16T7XUCDJZSH[H-
MF?2<Q4-R5XPLJRDDF,,KN9[6EL&<F74@TL5TUL^+"WKY8]EKD="=M%?+T78)
MA&,NNI:2LFSES5@KFK0D3R91G+5L,$3Y:PHN(J"(TBFBG=%6(-KJ01H996GA
M!-+"M+:(WIED&A:BE$3.Z5"\72;MQ#Q8PQ+$$1G8Z@$>4>Y.3QN(HC$GX\Q0
ME+*?CV=G4R$\H*>$RLU8JD4=@9',U)6TM9J:PRM T_?S*R PK:,O#<G=IE2Q
MV0NF>^[_ %LN24QDS/@YM,E/F$H IGR:N>".C%0LL5.(&H6CU442K3T<DG&6
M*!3''%"K^)>M8]J;72J7@6^M:F%9&F*:7EX@E5[2DL\J*4+.06=B-Y/GES.]
MWX/.]$,,Q6+6*O)HQ7VW)GC<M#04=],0AR;:#Q(K>5:LQQ#2)/F52JHMV?N;
MD;&Q#S37R#?W&9T#H_3!92,T;K%12"&>K&49L*B6;\'TR9GDD$.IU,Z-7@EM
M>N:53=_QC2-=(=(ZMXD<A9(NLTYC5.NM5* I:P(0B$@#3I13R\4*%*_KCUB
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M(+*-67TK&P\[$D^<X^@9#)))E5.[NS,9*@%B=R!.X%SVV&-DO>Q^Y-_R9O\
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MM7[V.I-CPJ\Z$ADAB3N.MA&X^#\B9AI3T*(B"#PB[)N"S:4JJ3HRV.A8R<:
MTWT7]P-M-&DA?@>_Z0%K6-B=/+GS!;< V^*^"Q N3R!W!.YV/Q6(V^/SXV1=
M['[DW_)F_P":ZGB%SWGTG!WL?N3?\F;_ )KHP7/>?2<->M<XRD7[-$]?UQE_
M.TDT^W]2Z^[XO77M[/A[.WM[.W/9V=N>L>?\G_Q?NQ-"3>Y)Y<_EQQW\RZ)2
M)W;R;9QZJJ>MR5D+>MR]]^/X2X^8+:RY "-<DI13^MD)1-NV#4T[E!&6[HIO
M8_#98[/M69%/ T/EBGA!+T3T=S/1EF2M-79CE\"9?E^5C-9:#H^U%%+%D\%?
MU,SDRYBL"0 E9JF!82Z'7)J-SP5?3ZJFL"PT\[\>>HZLLU<)F5JMX.+HLM.7
M+D76.0L VRVN!2F3BK9!MY]*I5P:*MV@0*Q-S23/N2E[.FAD'M%S>&SUD;UN
M)=">M6,.4D:+K$<=2'W( *&FK[1FQ4>I;='!)02M20P=)E+2R-%30KD^5JT<
MO'B+*T9RX-2LU0(2O&6'B2B)E+.$.,%UG42L]!LJAY&-54$,I1@&#=8(E C+
M@Z"^E-5[+?$A*1._(MN45>\%9"R<5Z:1@Q'1CR=O5X_BQHLG"8FM'-&PJZ'+
MUDJFUDU> #S1HEA(.P,Q-B>PQ9.Q>FU*5&53\-5Z3QN*N(U2:LFRM5GBC-3.
M)M3Y:%8%H:N6)F-Y'CG>+4RN<3:.I343EY'"81-:KJ&*,PC30 M22/%:)' %
ME5HU>P*C"U.4M((^PEI<UX-@&U&PMD/)'R?GLMETRV:%@;F3LUP;MI:KA&6Y
M4 ,WIA=.**&UFC%F[</-$-6R^=,V/,8I6IXX^F$S/5,ZPIX.H%>\<HA82JU
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M!>MZ^/K[T>#LU_UAJ_F&5?=,''I_(8O75/VN#ST<?/F;P+UO7Q]?>CP=FO\
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M&OX%2W@YV*\4&2ZT0CEXJ'KM&S7XFRB^XZ+@"UE<A&EK3>"NQP(LVEEEPR"
M*(5B4![Q 4:S)BCS,>D*JKA45U4N9=+G6>2GH9542U9HHY*.,//*E'E+4--5
M!Y4:GHJFJES05%797BX,:\:$ !]<L&5CAJ\P)(CXS+*Q$:&:J$TD=D(>5(EI
MN''<AM9.AS>S@$Q7P8SFH0=>OIO$D6[2=NIM%SNI#9]8UBJ;\>8*G[FV>0?$
MX&M7X56SE;!'HQ;$S@8) O' 2F%$D#>I^1Z]Y^F8S"6K6FJ"6IEIIXBFBCI
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MJJV8QPF19ZB01F>J$QA:ID17!4<%.(2Q6+BJY4DJEL4]D,/ND,SD&TCX8R5
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M-CC8SW$?P@'^FP_MW7%[^];]%O9C;V/F](]N%I<M;B[<J>Q*S(KP]RC-H>=
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M^U"89PGD5+=*<ASH*0<$WY9X483#9:=G$#X2+&F@I)Y%=0FZ*;20O@,3V?E
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ME\FI5SRG)9B)$.6T"N'JZB&A99HVI0Z25%1/!!(DJJ[\2/6"A!QJRLR;FCD
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M655]U6'8\9R1>UR-.D"V(=)>7L4E=16)2I/E(&3A]HC(R'EJ[#B9)6)MX.B
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MBWLQ#!Y-_P![%?30CV[HW]ZWZ+>S!AIUPGXM(M^NM5>U1E_0SQH[QKV:N?\
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M5Y-0RQ2%J9EIQ'-G$4@T/4GAQN'6-B@8--6:1(:^:.-GGN"NMECCAJYU9;2
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M1_-]&"Y[SZ3AJUOOMND7[W=^!1EV=W333_DN?N]S77M_^/;V?L?=ZQY_R?\
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MYI\?&1O]&.?S_7&\?^A_6_NXW&(+9]5PK2MY[BR+""Q:OUX?(FDTD9A5./C
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MG7CT;R1+.](SJLT,$L3JAC#:@LADCD=4@3^*E04:AI*<0*154H12(Y55B@D
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g150774g36k70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g36k70.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &H:^9Y X0DE-! 0      ",< 5H  QLE1QP"   "   < E  #TMA=&%R
M>GEN82!2;V)A:P X0DE-!"4      !#N+#3X-#0$K6Z ='=YYZ=5.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
MFP  !D           0                         !              9
M   "FP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "FP    !29VAT;&]N9P  !D     &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   IL     4F=H=&QO
M;F<   9      W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     ! _     0   *    !#   !X   ?:   ! C !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !# * # 2(
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M;6QW7<'<X2_IUC/3AX.S=3ZCQ:QOI_2])@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MA[6W&20R0U1TAI6GLM/Q-$A88FAV.41%4F.$B)*3T=;_Q  < 0$  @,! 0$
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M^3Q3WXH9_?#*?Y;Y/*)NNW^ /NJ.$'5;];^E/D\4]^*&?WPRG^6^.43==O\
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MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X103;GW0.K_P!>$@_1OO\ Y?#W.UY
M?T?SJM_M^E52=M#Y7_*D]?%TKMT!]H1CZX^QGZ0MH<6.Z#Y"K]FA4Q=J_E)O
MK34U\H5B<(O)+'P0'##)PT)"X*DFP87DL19CL$B[W.^&8IAEXLCAX2=YTWPV
M8M_6.E\Z;^J2W]'/D1>>I-8:ENNFK+8RFHU/MHHYT4/"M-V\I>Z)*,XTOKL[
MQLB?=IKH;M@RF-2*^BR6R3;?533.2+TV!H,5<%&HLL,).@CWX-,MF#]J\<""
M/J$77P>41;JJ*,'OLKANY]E=ZI+^H716]7ZM73;8B]/A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$4!=I_O<[G^KZ0?YGM_B_#^3F33]U5_*A]*JG
M[C)\1^CU_7XEV>MGW&XS^ZDX_C_*.1:[N7Q8OJ@2'N8_"?[Y*=.8ZM3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$4$VY]T#J_]>$@_1OO_ )D0]SM_FX_:JRJD[:'RO^5)
MZ^==R@?M#,_1_;D[&?I"VAR+/=![WY"K]EA^GI2'M/\ UR_6FIJY0K4X1:[?
M$.ZTVSVBBE80*NHE21V,)3-9U;Q2R9"_A]AMZZR@T5(Q.EIJRJ.W-H(;G;MH
MT%RZ8M1+$\-BK1TRC#Q@=*,Y#'B+6A-O!R[!R5[-%VTXI??0^&L>LFBI$O+_
M %Q!E9$I[(29+MF933@#CU/9.!:7P/% 8PFX)-"*<7?N4[BC^IAFT$$5PJ,\
M.:W8),+A,%>PLHJ1O*B&K4)*NO!>/XG5DL=+O[,W'M+K=Q9U42,*PDKMKV#%
M1%X,$)R9UMM7;,PE-]!Y;2,"R*R'0:0V$3B786+6+9LQMQ[5/;2YZJC<RGVL
M8Q+',.BN(SN#9%EHA&XF$=+L_A%UC#EN#:J*ZJ8];Z>=<9P17OX1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$74?N]1[%Z_W0=NM&+1R[W;,&RKU\XU;([K;(,F
M:&NR[MVKC3*;9LCKLJNMMHDGKG??&,D6%UQ8X*T0*\CCK"3L!R!<H$SB4QDQ
M%7BST,[5'DLMF)MJT=+MFI%!TPV=IIY;[NFCE-/??U6<Y(L_X10%VG^]SN?Z
M/[7\@]__ /*;?Z_A_![^9-/W5!Y4/I5-CN,GQ7]?7]"[/6SW4W&?W4G'\?Y1
MR+7=R^+%]4"F'N8_"?[Y*=.8ZM3A%\>M3\LY]9IY:[^KSGT]?+"GGC'H9SY^
M6-_/.,>CG^N\\XQY>><<(F5$\>GYJ:8]7C&5//;7'H8SCSQG?SS_ %N,X]^/
M2\O/'OQPFOKZ^?P+[X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%!-N?= ZO\ UX2#]&^_^9$/<[?Y
MN/VJLJI.VA\K_E2?[KMT!]H1CZX^QGZ0MH<BSW0?(5?LL*F+M7\I+]::F%\]
M9C63PB0=(,F ]JX>OGCI71!LT9M4MUW+IPLIG5-%!NBGNJLKOMKHFGIMOMG&
MN,YY0K%K,@?=R^K[F<S5ZRT=1EF51"'XWU[^7]AK.JVW)1%RKHRQ'3*+P4SU
M4)01P+-/8Y(AP'5:VMF2AF/G([*#,0DH8Z&#D5@NWEQV_3$4J.35A'(*1'23
ML1UWK:S7TW+&$W\>@]MW3 *P**0X$$'KMI#*ULS+*354K(00<$B@X,[_ !@6
M0; WI%ICG'B^=FXZ0G#=D IM+4 A84L:-R$7D:BXN90>3]C@,?Z0F=M)^TW6
M["6.PIJ)&0YOV<>6T2EC[(VK"C=< HH17'HKQ'+>E4RNH;*:)FMQ,(>8T09Q
M'K;"QI2>U$14NSLQ6.:^MA&9V8&8/#;.*4;#YP\*(_%PCA:RF6B<3S'W04JH
M131X9LK7G$/[82YS$I= US_>GL(05AT]8#Q<QCVZNL.QD=(1PDL=&LR*6-<;
M*HLR[]'77?3.%]LYSC!%LHX1.$3A$X1.$3A$X1.$3A$X1.$6(2"P8%$X\YET
MIF\0C449;+:O)/()*&#1YILW451<:N31%ZV&H;(*H+I+85<Z92415TW]'9/?
M&"+7[+/%]Z A2KF-02ZU>QLR;))J_$SJ=!IUV=/*9542222VWI>/3 (R4447
M1TQ\*&&">NZR.FZFFRZ.JA%BV>\'=ZU<ZI=;/"]MX8/5U<:_'3NE:]<]8 K?
M?3;;V==&%QE2[[2((.4O5J)HNXE'W&JBGL[GV7*:RJ1%C\MHCQ8[NBTD;6UW
M.HGJQ&B0<ZV)Q'IK0,CM.PL!GHE5LLQ#7!=4D;/$SZ6FZV6!2,U *+Y?935$
MX9NMVF&9%G7A&=8)GU"ZE8IF>7'=%W2!E:=D2'>67;$CD,.MV)\SJNP8 1$C
M)GB^L??-D=)0JHZD)G;XR2.0)Y7;;Z;L6Q%M X10%VH^]RN?YON?2#Y__,]O
M\?X/R^7,FG[JK^5#Z53/W&3H[1^GUZ?!XUV>MGW&XS^ZDX_C_*/P<BUW<OBQ
M?5 IA[F/PG^^2G3F.K5QG/EC.<8SG.,9SY8\O//Y,>><8\\_-CSSC'X<XQPB
M_E3G7A\]F)]!+4=1;I=+*VQ,;#G*[/KV0NFH-(BU?%:%O.M*/OW6<L;UFY*=
MVI K/FL;M:X;$F68Q._:G$?VKF.RXK5@=X5>OI12-(?#Y[=*6?;4GD5/_92B
MKNR=I-<X[%F05+?OG"'?:\5;,'BJ8B02L:/'YIVDFWV/?@BWE84%(*,<1$.\
M?Q5QDADBEF]X1WRZ8]%>OUJC^Y\LA\DHV!=-:FL6C&]?4[8\+DTB.VM6M53E
MP^M":PXS8;];(>8*C<$V1A!)TM'VA-KA!5^Y4W(OZ#N$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%!-N
M?= ZO_7A(/T;[_YD0]SM?FX_:JRJD[:'RO\ E2?Q7;H#[0C'UQ]C/TA;0Y%G
MN@^0J_985,7:OY27ZTU-"B::R>Z2NFBJ2NFR:B:FNNZ:B>^N==]-]-L9UWTW
MUSG7;7;&==M<YQG&<9Y0K%HKG-RFZ]\4D'1T5LN/U?!54NN@%M6 &P.O55:R
MX2J'(MD 6\!)]>+!M"SF ]KJB,#H!K?J]08Q5Q&@ 8,U:-I-(B+>DL@BXUQH
MNBDOIJHBMKHLGHIKJLW5T705QKOC;&%$%TTUD5,8])-73133.N^NN<$73V$"
M=L[[;"QVVRC],HIG9DVSE0FCKIJB1WSE+SW?I:IIZIN]O-PGJGIC53&-=<8(
MNH48OD!,@VB:0,?)7[)^N-=E&"RPE21;,=D1;V0-QJ[ @19)N4VFK_1N];/E
MF*6R#=VW4]4HF14?Z;T-VFHV2W(I<L\H"7P^V[.L"Z5FM8P6Q8S)1,]GCN.>
MN'IOI5.Y*+6B+ >(>Z)M]AWPRH\<-5-B7J$54E2*_G")PB<(G")PB<(G")PB
M<(G"*(K]B5C3ZD[3@U1RX' ;)F,'D,7B$WD@@F=#Q,L>'K"])"X$!RX$D^7$
MH.EGH])L799P11:**J;(Z*)*$6I7I7_4_70/J;!V "<PC3MM,64C=29";]BA
M[*7,A;MTDU\V$:KI?*\!##47J+HGHJL%)G%WQ%VH_-O--6J;<BW/Q*$0N B4
M0$$B$7A0)OY^SA8D %1P2AY[;;Y]2.#M&;-/SWVVVSZ".OGMMMMGWYSG)%E'
M"+YVWTT]'T]M=?2VQIKZ6V-?2WV_\'77SSCSVSY9\M<>><^7NQPB^4UD5?+U
M2J:GGIHKCU:FN_FFIG;&BF/1SGSTWSIOC3?_ ,';.FV,9SG7/D1?IPB@+M/]
M[G<_U?R#_![)MY_XO/F33]U0>5#Z53/KP9-.H_ZN_P"9=GK9[J;C/[J3C^/\
MHY%KNY?%B^J!3#W,?A/]\E.G,=6IPB<(G"+6!XQOW@-D?6SU*_2ZHSD/KWD6
MS_DHG")PB<(G")PB<(G")PB<(J=V?WVZMTY?T(ZP6%/C8:[[&^ LPN',ZQM2
M0(G$I$6:@Q[E&3QR%EHDV9H$GS)$T\>G6S6.IO&KH^L-:KI+;$5Q/G^;A$X1
M.$3A$X1.$7\:7]4-^*EXJ'4E<-7]4U&YZHT\?LT^*A/:R.S2'6.=ND/'!8U^
MT#(@EXT[Q3:BZKUP2<,"JCF02)J-42&O$!; Z@\(K.?U-QXBWB$]WZRE8OM!
M7ZUEU5!24H'".Y!,U'8Z;*RQKK#78^HB$!& QNTM=,1QPP97L,<JDDP;)CP!
MI!R0W1>;D6Q?LS..[\+[<_$.G(U94\J*91:+=BVA40P10C8%3K]$+34L'K<G
M+U13ED ?=AYZ/ZX"Q3)\NH0=AY7;)$7A)(4OG4B@4!W \2&2FX=:JE$&0P./
MU?:.TEK1Y25MB!%F.T+CZF!@3MA'WYI>1UU83".SBY6(%=[([!$OPD$D,LUC
MCMD]=L(H196>[1]X\UC;L095;.HO)-*D[0$:]-[4O=<RGDKF#21]PV4">Q2;
M"VKR%0-U#&E8TF^"1R?@7RD[;69'D8P^9I/(TV-D5K>H_8_M):5VVM6-S4.5
MKV 5^&=)QB<F(C,0+P^^%2)H!!N]I,57=1&=8L>-Y<V!Z,=:19Y L8UBY4:?
M7WW-($6QSA$X1.$3A$X1.$3A$X1.$4$VY]T#J_\ 7A(/T;[_ .9$/<[?YN/V
MJLJI.VA\K_ER+MT!]H1CZX^QGZ0MH<BQW0?(5?LT*F+M7\I+]::FOE"L6BZV
MXS-2?B=C+-=QN;F:DCA*GFP^PF\%L^:5C%-HPF41G2;JPP':^KZYK7(,UA;2
M4LY)1-GM!SY)0J37)KNGT?$D6\_7;7?77?3;7?3?7&VF^N<;:[:[8\]=M=L9
MSC;7;&<9QG&<XSC/GC/EPB^N$7EG,&LA3&(UN+3D619# !0XF[6"Z&LM%L"M
MS"+!5!\J+U?>HV()LET7>[3"VK95-;.F^"*AO2ZYNV=S2:Z\WDVZ[,(=4EJV
M)2.B54"[+:R4M-((ZC6_Q@V<2^0%!:,7?CRS_7V##;X53>IM-O:O486TW(M@
MW")PB<(G")PB<(G")PB<(M>?8KNP<C5\P+I[U;@XB\.T,G< )18PXF3>L*UZ
MWTDL11^&[/NR0AT7;L4_,#M'+"LX$UU3D<T-.&SI+1L%;[N'9%>6;(2]U#I2
MVK\@$%3I>/&$H<2DK-T0CS&3[L%]0;HZQ9*HO'0A$EEMN11:*:N=VF%<(>DI
MZ.N2*)*?!]F!1XJO>$\JV5QS>#5ZP#,8'$34>)H6 /$J8LR0OW9,B\14 R$V
MOC,:#))^N$C&*&SERHY=N$TB*P7")PBBBUZ2KB[&\,:6.#5.MH!.@MC1I%,F
M3&)MY1'TWB0Y=]H-=M=2XS&CY?#P$5P\"D?]BR_8.?4(^@11[2?4&A>O!I&0
M51$WX JA &%8Z.7<JE)_&T-%R(K*A[!9(\7(IN'K<P:(J9-KZJ&W#11N-=D%
MQX\<V:-/1Z^O>169X10#VH^]RN?ZOY!\W_F>W^N?R<R:?NJOY4/I5-CN,GQ7
MZ/7]?B7:ZV?<;C/[J3C^/\HY%KNY?%B^J!3#W,?A/]\EK9GE6V5V([1%V-RL
M>ZU?TR_G$[A4"D=<=OI_1$;B2," JJLI5]C^DH36.K^$SIV%5>BY78MQ6%)'
M1B:Q4=&Q+D2E,!E:XZM6T>G:X(55#$8@]M.R;=;M7[IR&DUKE ,@F#,,X3;X
M9@'4E"1Z.N)(T&[)K;M#<FT,2IWJZVP8/E-DD%-"*4^$3A%K \8W[P&R/K9Z
ME?E_^MU1GT>[A%L_X1.$3A$X1.$3A$X1.$3A$X1:Q[RSG_NK'0#'G[ODU]Z\
M^7T>?PCUE]_EPBV<<(G"+XW]+/\ X/X-O]'E^#_+C/Y<>_.(?7X/'T_H=O&W
MC_U*JU#S>_I3/KCCEKKU&J%JZ4"X4U5KP%-!9,D9*0. V+H2=J224&VJ8M$3
M.-!6[5)O[7L18;.\.=6JWL^N^RU'&5:.&L43OE+DJAW)!M/!PXPBOW\>\8<(
M6-R>6EQ=2?1@/<)G?4EA52NO).-F2L81GN!P8)82UW(I&=W.S.+\TCL^C-SL
MK6<T2S4X18!9E45==,3>P*X:X@EJP<BJW</X=8T2 S6,/'#3?*C5PY!21@2&
M++ME,YW;K*-=E4-\YV2VUSG.>$7H0.OH'5D3#0*LH5$Z[@\=;Y: (=!XZ(BD
M7"-=E-UMVXH ":,!8]'=911;=-JU2UW6445VQG??;;)%E_")PB<(G")PB<(G
M")PB<(G")PB<(G"*";<^Z!U?^O"0?HWW_P R(>YV_P W'[5654G;0^5_RY%V
MZ!^T(Q]<?8SY_G^^%M#Y^18[H/D*OV:%3%VC^4EZ.CNIJ:^4*Q:2KU-=1AOB
M,P"EI=X?=83Z=V0B%D#FYB44#K'S9TP9!LUI2C"=Z[(@I^,BJ974S))\?F3$
MV :Q";+(L-]XN/R:(MVFNNNNN-=<8UUUQC7777&,:ZZXQY8QC&/=C&,>[&,>
M[&/=CA%&<SNJGZY=EV$_M*OH4^ 11*=G&4JF  "[$0MP=0B[:5DFQ-^V69QY
MU)7+>/-2[C1-BY-KI"D%U'RFJ&2+\8A>=+6#)5H;!+;K::2UO%P\V7C,5F\;
MD!U*'2!H,( Y5N*%$G3W6/%V!L*^'%_4^P/&9D0Z07W0)LE%R*K'0KY^Z/\
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MC9O=TZC=]U\O&&P\NLU&J*1S3X2(MVO"+1Y>_B(63#.S%Z4]7-LT>5A]8[U
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ML"*NW<CZ,],Z$"N'C<WV*J2HJ[)NQRJB+T'5C>MQ)VYI!ARAMJX&[9K]@3B
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MV.0GY,',XC?C<?6NA4(%AHJ!% "B:9(E+O@H.G(TV<F0R8>*&8=K"1PZ>$5
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M\OEV&D/L,%-JYD1TF!8Q00Q*PEE =D9$[*;G&BC<BNC;GW0.K_UX2#]&^_\
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MP^GX>C_35;'(/ULZZUE,S%C5M0E+U]84A3)HGYW"*NA$4F)Q$V_1*F4C$F!
MV!HDF7*-VY(GH]>K:OWZ"+QUA5PDFIJ4J:N$5;^RUY2&A8M'Y."K$U9VI>5@
M8JZ8A7SI@L+=2@T,C@)==1N".XW3('3 \8FGNFWVV5<:X1W56RFCM?7QN5R<
MA0XD<2=B.*6Q)'E<F6+C>"O#+/.<4HT[G%*&&*28P<!TCC(A<R;<?5Y6UD*L
M,9XZA#?D*:*.2.:Z=%@"20 X@F%*YOL+EJ8N,;[C/PW.3=C*(.W;^4VCU0WK
M0.P>PRW^SH@'6$,C:Y<T.?1R33!EJ3DSDN2$H#3'P-7<3'RB4RS3V)ND4"1Y
M\%=CG'POJ+=]%L@$M#/096PU(X=FW]E<D0[N0I&%4P!JU>24(&G+(62BHT++
MQ1&$TT5QHVX)"WB_RV?%\&-HJV0N11Q-&TIRQ12FS%. S-'#(8 #2-Q7A!W9
MF)X6=^&HM\(JCI;173>$,I5)6DC1LA,;;L>PQ)'';0$&G\;!%TX\B-+)IM ^
MS!RHNHX2#:^QD7KIV36])XZ6VVRNR'G,AG=L\]/>K8^M'3NR8S'C2 VF.G1_
M(M)D9C$7L7#F&8^(S, 5RA@ 6:%R+#V:I92C4L0Y.:I*)VSEQ_)7G=XZ1Q1;
MD=CC".L_$:0S>/\ )_E&$6;=U>RM!2:.F+7[;I"#H<JJM=L4>)IC2;)]ONST
MZWT&QW=ZZ-EU=LM=7J*K/9QC&4M722C?.V%=-M,8.<KV(<5LH4T$\0^P]H-9
M8I(VWRVBSIL#N8MH;@['NOH^Z0OIH[+>0D+R669V=VF%W9G9WTX$#:Z,^NFK
MZ<_?5K.<TKTX1>2>!!Y0#,1J0C6AD!(!;\*;$OT=7#$F)*-561 >\0W\]56S
MMHNJW73V]VZ:FVOT\JG@AM035K$8306(I(9H9!8HY8I1<)(S%^8A,"<29^EG
M=EF8[(7L3D*.5QEJ:CD<;;KWZ%VL;Q6*ERI,%BM9@D'G"6":,)(S;G$Q9^\O
M0;-F[-NW:-$$FS5JBDV;-FZ>B*#=N@GJDB@BDGC71)))/75--/3773337777
M&,8QCE@B(B(B+"(LPB(LS"(LVC"+-HS,S,S,S-HS<S+'EEEGEDGFD.6::0Y9
M99"(Y)99"<Y))#)W(S,G<C(G<B)W=W=W7[<E5IPB<(G")PB<(G")PB<(G")P
MB<(G"*";<^Z!U?\ KPD'Z-]_\R(>YV_S<?M5952=M#Y7_+D7;H#[0C'UQ]C/
MTA;0XL]T'\WJ_985,7:OY2;ZTU-?,=6)C&,?-C&/?G/N_#GY\_MY^GA$X1.$
M44!KSJ*0VG)*2"6!'25K1$=N5D<):NM]RXMFBVC3U[ZWS2PU6=BV4TACXT.;
M.5R(1C,8D]+M6363 U7Y%5SH5\_=+^_Z[$_^Y#/]/"*_7")PB<(G")PB<(G"
M)PB<(JX7%U2I>ZGC>0R".N(U88W;*P&UZ](.(39H%WKKZ*+IE+ >6[QYA#'O
M38F]2HOSSG.S';/OQSV7V7P^9,;%BN5?(1\\&5Q\A4LG7+O%'<@W9"9M.YS<
M6)_Z4;KZAL1V8MN]@X)<9C,G'E-F;;</);&[2UHL_LGDH7+>.&QA<AQ(('D?
MMK&/>G<YM&L,W,\#$E^Y5##"8R0 Q_=.IL,G+=1^&V'0/L&P#JI9;N&3X#Z"
M<-L-5)KMG1)<8[ '22F5EE],K93UVTKMM;AA*"U'%M=B";AG/'N4<]! ?M#X
ME8!Y)DN&#N^M=Z]F3G=HR/1G[B>/L#]D6&2U4MY#L'[6/'+))CY8[^TW8]R%
M@ .5GQU^ RVCV;EG-G8(9HLC3K$\,=:1NEJ;=3+D\/0;7<E83^E&-*NMK*LE
MQHPO2OR$E?KM"<M*O6#9"4$V,M:L5QH]P@"<@<G&[S0L%,N\,-M\NGBV')D^
MQ7J)1UJ8 -3&TI"R^'R1R1RXO%4,2<0V<K3D=F$J)"$<4VKN!RR $YSLN!A_
MD>;30<6' ; 8[:>,S*<YQ?&VKLD4I&%2U#!F[CY:7'V<?%2NQ7(8GI<.]7UD
M:Q,;/:844\*<[E%)B7ZG:*N4=E-$'Y:' W>FFNN<[860+.1[EFOKC&<^J<:(
M.-,X]VF-L<\1-V*IW8(Y-E-XF?03GIPFS,W/O#+(!@3-WB829_&M%>_DF;:T
M!D*QV!<\X1DP%)4V+MWHW<G9F>*6A4L!*+ZMI)"9AWV+3G4A *'Z!RK#/:,,
M:AD>"'K<L,@K)V+^V^H];Z_+3V"7./:?4^H6];E'T_5^I5]/R]7OY9\&S&P%
MI@>M7Q5EI->&\&1.9CW=6?<X=PM[1V?73731]>AUP>2[ HX=YVR_8TSN*>MN
M<I;(X?:&CR?B;G#X[61BX._Q(]S?W=[?#=UWAUR(OTPZXO(\8W9MI2$24%$M
M$Y&UN.U-T@>?9%]/A9/9S/-QV/@K;_OOT76N6FF6_HN-?4XWUYDOL1LP(%*%
M><=P2(9#R^7.('%G?>,7R+ 0 [:F+NPN+.SNS<ZYT^QG@)3Y'#C\N%N?2""*
M/,[1%/QIFW(!BK^R6\9N9APHA'4RW1%GU9E['3"OPM8T>PAL<LXO:@(1*9FD
M--F2P@VZ&H[R-^HH'U(!T]=%4\N-UC&-7>ZSE/)?*:>VC'5DDGO,)9*SC8-Z
MQ7LC6>2C"=8   K43>I5A=@DD8GCKPQ:$Y;S@X:ZLS$^[P>SV2V8Q=?$Y-LD
M,D!VAKME:AU+0U8K<]:,6"2.,Y(PDKR@TA,3[XR1.7Y+0;7\VRVR@+M1][E<
M_P _W/I!\W_F>W^+\/Y//F33]U5_*A]*IG[C)T]H_1Z]'A\2[/6S[C<9_=2<
M?Q_E'X.1:[N7Q8OJ@4P]S'X3_?):]_$,[G7CT_N2M"$(EW6AU7,QK"3?#U:W
M=([B"'AQJ.2<:N]MUHO2'7BZCP.O8X#)(A9G*)J]#0<<N0%[J*#'B"SHCCJU
M;5H46(GH;$CA?,>V+&8R!+%-HB76D$4V(D131X]S&#SAD-7-Q[+E97(4NN.8
M+$AOLSU1DUW6V03(LFX1.$6L#QC?=T!LC/\ QL]2OTNJ,X1;/^$3A$X1.$3A
M%4"W>^?5*B;K@G7:U;14BUQ6:H!1@D/S!;'-;21:2D78L0DQ.1^(E8WJJHZ8
MN]GJ;DPAN)9H;DBVK(=Y.LD7\W?]47.Y=W^J"PZQZV&'BU4] #;N?]J+/7./
M652EK1?[!(E'^OH%(4P(9G=L0MO(W$JE7DJB KAN[T$&7.TG+IL1I%_0]X?W
M6E;H'T7HGK?/[-%S%Q1T&>#Y38SW&D>CVZQ"0&I0_P!6NY5QC+&-Q]0YN##.
M2:R*Z@<8R</$FJZJC9$BA'P6#H0WX==-:AS HML-EW8%J1T&$6;_ &'NG'8V
MV2*#9[AHLKEJNLP>LWZ**^$U%&3MLZTUV0724W*&T;F[_-^GF9O1T="VI\*4
MX15W[1;8UJP?G;RQZ-T=9MO2V\L:ZXQV3J;TLYSGYO+'GYY]V/+Z<8\^;S9S
M_P T/OL^&VDU\#?_ *[E>=V\VOCY^E46.:-N]^6K\_@_G$7P_K[RP>CGFMXV
M3)^R2V<KPD:B:JGKYIZSUC-_#F!9'%A6JVTSKC3.UE2X*@(CKS799->OX1'#
M8UPFC,"*&^7E7;$XRI@ ;=M3/%E<X6FAM9DA=\?CCZ/:T*LSS3!TC>NSQR-O
M5@TQJA<J,KW3&3/%4\<#%[:?1^<7L$V\/,S\!HG?G)UDG2[7&W3_ *N_1GY/
MU1XQGW>[S@@+W^_'SX\OVOPXSRC:SGVGVA_[UD_MDWA_6LN#N,/DH_W&6=U[
MU\HRI2Q ]5U0UO79LLTR/*EX7#(]&B1(?LY2>[,7ST0/:.'+39XBBZV;JJ;)
M9<))JYU]/37;'.B.[K[>4F?O232R-KT,^DADS.S-IJVG-S+"IX?%8^62:ACJ
M5.65MV62M6BA.07?>=C*,1<FWF8N=^EF4P\]+9)PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB@FW/N@=7_KPD'Z-]_P#,B'N=O\W'[5654G;0^5_RI/\
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M7ZCL%BS+( 209&I2LA(P.+E^1>/VV@2F[/I.-MA<J1R!#;@8-(GCNTK-&9B
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MPS) "A"W00T_L%'K3UYZQ'"KB0;2PBTV@SB*]>Q<E$Q3<#N39262N]W4D>M
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M(8N$^2BBR[%'NRV*\QQ/J->TFQ&8L;-VMIMDMHKMYXZG#R="$(ZD^$R91M#
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MCA1N2VK=N,96C?D\%*O=,9C;GCBD,78O:S'%H1#Z+*@>,?)5X9YXGJ<JC&(
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MAIB'M'#D<Z^++,W')>4;-I%&=!DKB9-$9(X@8"R$2.)-B+*R/3NIE>K=@=5
MC=T!BMCU0]JV33-NV#JSPVLO73"LV5@24KH-:MI1/V $,"W^'"S-39VN%8)K
MIX:(Z(:$]6_5_O\ H7@]0^B])]-JU6K> -RDJ1?N2CTK(IZD!+&U5)&-"MI6
M'$98!!;.-0@Z5$*2!.O C9K#8^])O!L:$"(ZW%!AQ%@'6/PXJ5ZGW7*;5J=
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MIPKWY\OU([^'./UY_)SS['1^^'\WT*>5'U1\_I7/RYK%\_+XIPKY_+]2._\
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MYYY/L=%UY/F_=3E1]4?/Z5S\N6Q?=_8G"O?GR_4COX,Y_7G\G'L=%[Y)T?\
M3T_JZ/%YTY4?5'S^E<?+FL7\4X5\^<?J1WZ-L:_KS^7SY#8Z-V9^(;:M_P!+
M_P &3E1]4?/Z4QWEL7/E_8G"O?CS_4COY/[L_EX]CH_?#^;Z$Y4?5'S^E/ES
M6+Z6-?BG"O?CS\_5'?R_W9_)Q['1^^'\WT)RH^J/G]*Y^7+8OGY?%.%?-C/Z
MD=^GS_NS^3D^QT7ODFO_ *?HT_BG*CZH^?TKCY<MB^[^Q.%>_.<?J1WZ//\
MNS^3CV.B]\D^;Z$Y4?5'S^E/ES6+Y^7Q3A7SXQ^I'?IQG/Z\_DX]CHO?)/F^
MA.5'U1\_I3Y<UB^6<_%.%>[.<?J1WZ/^>>/8Z+KR?K'[J<J/JCY_2N?ERV+Y
M^7Q3A7S9S^I'?H\O[L_EX]CHNO)\W[J<J/JCY_2OG/>:Q<8QGXIPKW^7_BCO
MTX\_UYY'L='[X?S?0G*CZH^?TKZQWEL7/_!.%?/G'ZD=^C/E^O/)]CHO?)/F
M^A.5'U1\_I7&.\UBYSY?%.%?-G/ZD=^C/E^O/'L=%[Y)\WI_5YO.G*CZH^?T
MIGO+8N,9S\4X5[O_ .$=_EGCV.B]\D^;Z$Y4?5'S^E,]YK%QC.?BG"O=GR_4
MCOX?+]>>0V.BY_;R<W-_1\#/U?&G*CZH^?TKC'>:Q<^?]B<*]V,9_4COTX\_
MUYY/L=%[Y)\WT)RH^J/G]*^OERV+Y^7Q3A7S9S^I'?H\O[L_EX]CHNO)\W[J
M<J/JCY_2OG'>:Q<X\_BG"OFSG]2._1_SSQ['1=>3YOW4Y4?5'S^E<Z]YK%VQ
MY_%.%8]_E^I'?Y9Y#XZ)M7WY.9M?Z/W4Y4?5'S^E,=Y;%SY_V)PKW9SC]2._
M1_SSPV.B?1]^3GY]/:^#P[O\$Y4?5'S^E<_+EL7S\OBG"OFQG]2._3Y_W9_)
MQ['1^^'\WT)RH^J/G]*XSWEL7'_!.%?-G/ZD=^CR_NS^7D^QT7ODGC[7T>E.
M5'U1\_I625W>$LO>XJ?%G!\=",X1*Y'.=,B6A)1R27Q5EAPO0?LJ\+JI-$<:
M3-0CLOANXWVV'Z-<)Z8<[+HURUAK03D)$3R $?/HS,W&BDUYFY^YZ:<W3KKS
M:/Z"4II(V=A9A)SYM7UT ATZ>;MM=>?HZ%8F/PFYH4B;#1JR:QP#=S>Q98/1
M.4W*B95FG/9_)9RH->$F%YA&9#<8O(U1VCY 0-U=I-4W&S)ONILEKC$<$CLY
MQ2[PQ1"[C.#"_#B"/5F>N3MO;NNF\6COIJO;/(&\S$&F^;MK&3O[8R+1W:1F
M?37371M? R]WV;L%^R13?\!TV_I#\C2MKIPI^_\ \Q'WM/[MXU._+UH_DR_%
M3V7L'^R13?\  =-OZ0_#M6;^JGZ'?W1'WM/[MXTWY>M'\F7XJ>R]@_V2*;_@
M.FW](?D/R9OZJ?\ I?\ ,1_T?_;=]-^7K1_)E^*GLO8/]DBF_P" Z;?TA^'>
MLS,_"GYV9_=$??U_NOB3?EZT?R9?BI[+V#_9(IO^ Z;?TA^3_-M&?A3\[:^Z
M(_ [_P!F\2;\O6C^3+\5/9NP?[)%-_P'3;^D/PW)G_JI^C7W1'X7;^S>)-^7
MK1_)E^*GLW8/]DBF_P" Z;?TA^-*W/\ DI^9V;W1'W]/[MXTWY>M'\F7XJ>R
M]@_V2*;_ (#IM_2'X_FWM?R4_MFU]T1\W-K_ &9-^7K1_)E^*GLO8/\ 9(IO
M^ Z;?TA^'Y,S._"GYG9O=$??T_NWC3?EZT?R9?BI[-V#_9(IO^ Z;?TA^&:L
M_P#53]#/[HC[^O\ =O$F_+UH_DR_%3V;L'^R13?\!TV_I#\A^3-K^2GYFU]T
M1^'3^S)OR]:/Y,OQ4]E[!_LD4W_ =-OZ0_);DS_U4_1K[HC\+M_9O$F_+UH_
MDR_%3V7L'^R13?\  =-OZ0_'\VT=^%/S-K[HC\#/_9O&F_+UH_DR_%3V;L'^
MR13?\!TV_I#\:5N;\E/S_P!XC\#O_9O$F_+UH_DR_%3V;L'^R13?\!TV_I#\
MG2MKIPY^AW]T1][3^[>--^7K1_)E^*GLO8/]DBF_X#IM_2'Y&E;37A3].GNB
M/PZ?V9-^7K1_)E^*GLO8/]DBF_X#IM_2'Y.E;73AS]#/[HC[^O\ =O$F_+UH
M_DR_%3V;L'[_ .V13?NSY?<.FWX,9_\ M#_EYY_FVCOPI^;3_F(^^S/_ &;Q
MIO2\WMH^=M>YEX7;WWQ)[+V#_9(IO^ Z;?TA^2[5F=FX4_/K_P Q'WO_ &R;
M\O6C^3+\5/9>P?[)%-_P'3;^D/R&Y,[Z<*?I=O=$?>_]LF_+UH_DR_%3V7L'
M^R13?\!TV_I#\].U9OZN?I9O=$???3^S)OR]:/Y,OQ4]F[!_LD4W_ =-OZ0_
M/+<F=G?A3\VO_,1]YM?[,F_+UH_DR_%3V;L'^R13?\!TV_I#\G^;>]3]+-[H
MC[Y./]F\6J;\O6C^3+\58C/H!=UCPR20,W:%5M \L%. A-P*I.7($TF+[7"3
MG9@N[OU\U1=^JSMA!5PR=HI*9UW4;+ZZY3V]1R5X9 D&*9R MX=ZP&FHLQ-J
AS5F=VUZ69V?QLO)<607!S!F+VKNT9:LS^#\KZ]_5?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g150774g44t35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g44t35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )IZ^F(8X0DE-! 0      ",< 5H  QLE1QP"   "   < E  #TMA=&%R
M>GEN82!2;V)A:P X0DE-!"4      !#N+#3X-#0$K6Z ='=YYZ=5.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0')P           *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M80  !E<          0                         !              97
M   "80                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "80    !29VAT;&]N9P  !E<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   F$     4F=H=&QO
M;F<   97     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !Q8     0   *     \   !X   <(   !P\ !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
M@0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P
M /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!
M@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X
M D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#
M(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M
M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%
M=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C
M!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((
ME@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ
M"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,
MC@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2
M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1
M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G
M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT7
M01=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW
M&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>
M%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.
M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E
M]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU
M*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N
M[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X
M,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y
M!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@
M/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$
M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW
M2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0
MNU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$
M5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>
M;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662
M9>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM
M8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H
M=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]
MH7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.
MAG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/
M-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?'+2YC%C(J6=E,9)@2%I''RU 5F&[) WD*O+<$[#@(*#)0E.!X6"PER'P^<
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M=G94VR%H7IVQK7(Q.*)R<3TJPTI$WK&\ UR58I$4G4(P"5$F#(#D> /"&PX
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MDF!!B=(]JDA 2\$@0@9.AWL(DK'8V#21>Q2Z96 3'XH783M<\;S%+QBQ^Z$
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M ' ' (R;B^KM.OVC7WVEP[CZ@<:8^JS1_P Q6_\ ?*> 2<X X X X X X X
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MPU370;I,8<1<=M8A<=Q9 XWC'=PQ"FN&[X19:< _DO$<N/BW@L8*\'X/& <
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M=E.,0*L?QB19QC/ -E< < KUWS_G=T^_I_5A]D]W\ L*X X X X X X X X
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M+.L7C@#,)6JCY]5*64\[(!]\QL44<E15&:DSG_Z0Z_2$1O(?^XEXQW^T"1_
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MZ'OJ%.% \H,*50D@T)9QP @5& &6,;PH+A. . . . . . . . . . . . .
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MDW%]7:=?M&OOM+AW(7N7N[O;W?M!QICZK-'_ #%;_P!\IY()(KT29S0K6Y8
M9B-P2*$2HLLX].8-,K)&0> "A,82I(&(HP00G)S2CRA9P,HP!@0BP!1ZVT5H
M>MV5>*!;^H1MFJF['*VJ/.NLI>V\]\BH)'(8S)I4V0+,["W MLQ<JB\/DSF*
M,%7><\)D+4H(5ED8,3IS@+PT2-.W(DC>D (M(A2IT:4L9IQXP)TI0""0#/4&
M&GG""6 (1&GFF'&9QD9I@QB$+('M< < KTT;_P ;'4K^GNX?[)^J7 +"^ .
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M.^/+ZX*5;DYF@?4+P!P!P"O31O\ QL=2OZ>[A_LGZI< L+X X X X X X X
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M@@7']@$[Z[F$1L"#1::0(X:B&21F1ND:.,8W:-#&T'E_WIG+ ^MS0[M'86'
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MZ85\F!)RR!^"%E$X7Y>">9.:H0,8,)&NB=5P-6+.1'$GDX& HD#/Z[Z<>H4
MD:6>.%7XM^T$PO"XMG8612*^K'PISV]]2BD=I.4F&PC,SGMR1&4[*B+P$!9*
M4HLHH  )PEE%DE@*)+ 446' 2RRP! 6 ./1@( !Q@(0XQZ,8#C&,?DQP#]\
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M:Q%_5][W\8VK^L]"2SW%KWNAG<9)L/-R-6Z*3(SU[I5M?2\A-8+JP@+\(?\
M&Y>B<Q&FB"(9&!!=(W5@THRB3#DQUC+R\B!RTFRVF-+1R2XYD.:OUVJ^7/9J
M%L6'I*Q-W2X_%3KQF2/JK+F656[M1[:$:[*=E#%YC/7:N/J5K4UF]-'7IXK%
MQRV<C=GE=QC@:M=KI72R*J(D%-JO5=T29Z="FC:V!RN3WW07F9TVIC].A;4\
M<JAU2U?$T#9+I:UG2I^FDH8,3!M&]REM%'5.7'RW)PY(>53<K>D E0S4SLK^
M:==ZR\I^H]4XG):;R^IWXUZHVG;258()\@L%^*];I0V',7L'8E\E=KNRBADK
M1R,@:L*L5_Z7^071'D4T-Y*=?8;RN0:(DU1&]+>K<7)=FNW<5@)+6$_L]A\W
M8Q;GP5+K-311V%JU+$UJI;M0);?'99-!#?K&=6*\1OB*:V.MD-Z6(A,PI1S"
MVUQ$A*95>?XPC(?"TZ5! 82 )F1"(%&8R@7 #D(3W!2(/A,^AUM,8]D[+N1?
M8S>0C5',MY9[;"0N[^5.FUD="EUWV6K5CDVV1TCMMSXJRWE?U-/C[&!TO!C/
M)[IBPU8I\'HNO)C'WX4Z(S.9Z2:QJ//JK41)&Y;+6:SG(JQUHFKP22N,8QC&
M,8QC&,8QC&,=F,8QZ,8QC'HQC&/DQS8SRI555557=5ZJJ]ZK[U(:;DRLEC:*
M>0XCD]D*@F]JCG"H,*KZ9S<"&-P">Q]ZDJUP-BK([%(3$S;D1Z)&J&4L=<E'
MEMI"HP@T =0U=92&+$,2O>L.;G,5=>E.A<N]G7HWH)K+Y%J03)&K8UY,:_9T
MO%R1HY6JA[GY#L0^_=UQ87*:=QD4GD\UII^%V>U+@L MC*ZDT[DJ&*KUF9B_
M2?8;+:1(YYX6O@I\XWVI(62,<LPT2LI>C2+B G@)6I2%9(%28]&J 4I* <6%
M2D5%E*4IX0#Q@Y,H**/(,P(HXL!@1!QMK'(]C7HCD1[6N1'-<QR(Y$5$<UR(
MYKMEZM<B.:O1414V/$;$+ZT\U>18W/@EDA>Z&6.>)SXGN8Y8IH7/BFC56JK)
M8GOCD;L]CG-5%7V><CJ' ' ' ' ' ' ' ' ' ' ' ' ' ' (DZ5^K1'/G=>7
MVX65P#R:$^C1K37Z*^O_ /;5$3SR$Z_:OR54!++D@IRZNY[(C9->UTIL>MDL
M73S"<@<Z!L^WKII1AO!4HB91;4\$R^@([+K#.6U$J[9*0SF1IPC"L3K@]T/;
M71(PKR0\>/'U$[=*4;NW:EZ\H'^V#;T>D551-(YVZ<4^%&3Y8G;BRCG[MDX0
M24\LX0/ E+9"'#XO*) N=^UP4*,Y W)(JLK.72R'3R5U["I+-Z\,7G0*7OT7
M97:30LUU* 0Y&Q9\7HCW)A,7DEEEJQMBE,(\  X,R+NX[ ,)4ZQ:WK(U)H:K
MH.FU,1F<N#/Y?&#ZUAQK!)YR%46N#,7]H&SB0.TF"L*+4X?%Q![E@X&!X4]O
M;G($8][BBD\IZ>Y!!19)!._56E$DE "644474MW +**+!@("RRP!P   8P$(
M<8"'&,8QC@%AW ' ' ' .!"" (AC$$  AR(0A9P$(0AQVB$(6>S& XQC.<YS
MG&,8QVY]' ()6+U#:(C<K=:NJ5---JKL:3O%'"I=:6(FPW5@6Y_BA*GLT$O:
MJNK,HLS(<*3)_.(^>4# Q$I%(RQ%< P;X!=0G9'.3+,LJ*Z.5@L'GOUY09S9
M;&P[JUF=O]ZR.\I@Q@K^OEII6<!5I:YKV3N"(T0O)5A8$4!28!O^A=*];M<'
M!QDM<5VG/L=^!C$JN2>.KQ9-TR\W/;DPR2VK.5S[-7 HP8AF8;@NY#.F$8,*
M)N2EB\'P"4XA!"'(A9P$(<9$(0LXP$(<8[<YSG/HQC&/3G.?1C'ISP" ^R/5
M$T%U.,4M]V[.UFQ2@CO%@@4?=A3NPU*K&< +0DPB$DO\B+5J#QE)B0K$"4K)
MYY(##B_"ASD#Y/=H>H_O-UNK5DNK.@-'2Y%KZQ21$SO!4D5IX\U21&0K+\<G
M-_R @MT9F:,HAE&F,%5+UAZ!6I**6/S-8KJ45$FH"XVH.@0PO4.KUCVYV#G$
MFCL+<$LN2:]ZYK7*G*03SX023%TSELG.5/-R7+81RDOOF6A-)@W2,O)9!$>2
M1=H3(F=*!<91NE.J>MYY[C35%P*(R1;@/E2<F-8I'8[V,.!AP:_61*CGN=/9
MO889COND@59"$>0![I>,!P!*+@#@#@#@#@#@#@#@#@$9-Q?5VG7[1K[[2X=P
M#C3'U6:/^8K?^^4\ DYP#YHZ>A$CFW5TL^^CJXOER=HOL;-ZF+N""Z^Z$,5.
MD06-Q)(RE1R8V-+&U'N>>>VI3?@Y(9&R*%RB1B3(AQY<9"%B9$F ^EL0L!#D
M0LX"$.,B$+.>S&,8QVYSG.?1C&,>G.<_)C@%7Z#J\:@N%4%725\=68$OEKI%
M(\M34C/GESEI,<AS[8DQF,98X\V/#JY0.#P*-NTOF$JRE(0L;.4DR?@2UT:D
M:T"1%9[Q:[6]><BU\@,G?'F;L#0Z.Z=X%#90BKN68CB"!NDP:X)8RQL)B,R>
MX2@M"OU$M:F)T5JF;$H2%&A&>A>2FT#5NC?^-CJ5_3W7_P"R?JEP"PO@#@&&
MMEC5Z]ORJ*LT[AKO)T0UA:V.-DG9%[\D,;C,DN!:IG2KC7!.-"=C)2P!J< D
MIF,@/P 6.S@&1.SNTL#:N>GUS;F5G;$QJUR=G9:F;FUO1D R8>K7+UAI*5(F
M)+#D9IYYI918,9$,8<8SG@%6MT]7C7*$)CD5%LTSVRDIC@)D;5%.HTX*G4O_
M (0).&A/>,A,;Z_E[J2</ 5L4IY9:UB$!"9DJ#J1 R#EEC,/D\S,L&-IRVG,
M;SFD;QCKUHT156:W;E='5J0HB+O-9FBCW3;ER5$7IFGAKM1TTC6(J[-1=W/>
M[_=CC:CGR/7ILUC7.7?N/FQ>J0ZF&ZO7+HB=;)-4[H"O7F'8LB.5\QGG3=EJ
MBF*_^"R$0&5DF\;1LYSJJM=RA4H62J1PE&YQ:?N""4Y8VU\A3(D0;&[!5L,Z
M.Z[-:9SL56&2U/CF6[KH)K<,T<*X_>.&NEE^TJ6&/BG9#:A@F1DCFK&DV.EA
M\[7,\WN5^;D8V160HYK',5R3;*]ZL;TX*CF+(Q[F\F-]96_66A^(K5-8I@-0
M09VLJ^YH6%T<V)I<#IC<,V/-$' 99<%FRE:K6,4="<9X3,BGCZC:$Q7A$46;
MU1X$S0/1=4:YMV[$-*9\N4R#(_\ 1VGL7'#7K4H%Z-<E:)(J&(I)OZ]J=(NU
MV=Q6S/LQWI>C/)?>S=&;4-^U3TCHNK+V>3UKJ!9FU)9V(JNI8J%K9,GJC-JU
M%2+%8B*W-$JL=<?1J<K#,L9J#DECNS?-MH'EKFRYO5EN<9II@\9^)>"*RA8&
MD4JT"TI.JM&4HLX"8"3S1)Y/0+,9/C,981AP>;K<."L9"6.[J6:*[)&]):V'
M@Y+AJ+VKNQSHWM:_)VHU1%2U<9PCD3E5K5U1'+L]_P HV*TO3LX#R24;F KV
M87U,MKK)=E_;S44+TXS10V:[I(=(8>=-V.Q&!G\YLP*D>6RV1:JQMTCM92([
M V(H":IZ%M6Q&Z#'G&2J50RT4,.9DK*>VRI$RM*%D46["5!;NRR1>WOKVXH6
M$LQTCAF&<;L\$EF,(;.]G]28W(Z?@Q.*GN8^A>NW[,\=;3DK(WY#$W<,]N^4
ME9<>L44[9'1L:Z!C%[6OO:38[/)_6TC+H3RG5\]KO!Z>S&IL7BL3B\7D:^KY
MK,SL+J/"ZE=:EEPF"R./9!<;3GI5E?:\X6VQ6VH8*CVSNL?Y;'BXX X X X
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MX<VMY<>3=]M]MTW[S#MXZ_01BW:=BJDBN2-9XGQH]6[<D:KD1%5NZ;HG5-S
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MNW*#M4MZ*:"WHX8Z-O.NKK PA2F+FWP1,H/KXB/J%H50LMI;AY2PD7C1@1G
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M.H'V>OT5BC$P/$V>R@F +=Y8YM*!(LD3F7@X[ 5SL<K4AR<=G!F,FF9$!GG
M' ';C/R9^3T9_5G\W ' ' -96G2M.WDR(HS=-5UW;4<;7,#TW,-DPR/39G0O
M!2=0D+=4;;)&]R1IG$M(K5)@+220* $*3R0F8+-,"(#B,TG3<+DX9K#ZGK:*
MS(,3:($&6QV$1IEDV(.P$I4S'#\/K<V)G3X,,Z="B(;&+QKR8A)1I"DR4LM,
M2$ &LMQ?5VG7[1K[[2X=PO<OX=_[ <:8^JS1_P Q6_\ ?*> 2<X X X X X
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MK,M(]05#T^#2:8EU12RMW!J*+"!^=7FOERARC8Y@2V(@+H> . . . . . .
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MU.8W5BN]^4[D7I4BYRNR2HH3WJ;8I=14#:IAEZ2.$'CZTQ$LD<?=&\A+Y*=
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M-@C%7,WT^C%AV).4EB%1T^:B;(7>"IS86^1DRE1'$2M.L8'%<ZF# $H#Z&>
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M?;A97 /WH1ZC6FOT6-?_ +*8I^;_ )_/Z>$_/[_CX]W0$L^ . . . . . .
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MAYM5(*SBT?4S"109$%Y5V<[+B&\I'.8XZJ3\HR:M(,5&83(#0$$84)PFGC+
*8H(+R(T(Y'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g150774g61u20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g61u20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (<:^AD8X0DE-! 0      #T< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $,KH3TM^MC\Z-(RR30L222(X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +A   $G@         !
M                  $             !)X   +A
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +A     %)G:'1L;VYG   $
MG@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "X0    !29VAT;&]N9P  !)X    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     %VD
M   !    H    &0   '@  "[@   %TT &  !_]C_[0 ,061O8F5?0TT  O_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( &0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M<00W9C7/]*_=Z5E65^G]"ZEE=U=63CWU?:%TN7;U!CF#$H9:W<W>Y[]OM/\
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MZ-S/5_.;_A,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( .P!>@,!$0 "$0$#$0'_Q  >  $  @(" P$
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MO&,N5?W8T M)\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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MX_?X#V\ \ _G_G\ QC&,?3&/IC'[L8Q_-C'_ (> > > > > > > > > > >
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ML#],;;9JN0X>PR/5DSW.9!;R_"+46VU-[[;K 2 ^':(2 ];^RW#R8"FP\?\
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MP_6S22ZV.TI"6Q'>VGS.E)C#]J_6B@^:3"*R8ZUJ4M*<#Y.#, 3L!U[-(O\
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M,'J!1D@B\T<YU1U<H?B;8 K^>\']#3:N.L*;A+NN*0KJR/D1*VR0ADWB#\_
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M0D_N/?Z1Z>1E$Q"S^[)UH'//=FZN- (@4C_33=[?V+>'_P#&O2/@+<O / /
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M+<O / / / / / / / / / / / / / / / / / / / / / / / / / / / /
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M:=X\LV#0+;GRJ.5Y[6%_V_4W-\>)V[/;2CTW&W9:C^7X9*E!<1BI,*WK=B+
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M9&:.Y(]\4\U2!KH*WIT;*J1NL/G1TJM=X^[I#J'A<[K&_IC(VL4_2U.SF:.
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MSY3;P>?XOEKO<?0YUW=+C7/_ -> 0.K(SG/_ (_9NS@[A1/_ /;Z;Y^GT_\
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M29W;(RQMK,(DHE^D#7CW H2RBVS%S'57VZ#5JODUANV28Z@2'[2YY=]9\H=
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MZ2?W/+>@B$#8$;7G=.,J E\A)/C!!C(*@8'RTF;PHC%7A%:)*L=C)PJX<N\
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MF \#M:^ > > > > > > > > > > > > > > > > > > > > > > > > > >
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>]^ > > > > > > > > > > > > > > > > > __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g150774g67q07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g67q07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2964&AO=&]S:&]P(#,N,  X0DE-! 0
M    )CJ^EX8X0DE-! 0      #T< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $,KH3TM^MC\Z-(RR30L222(X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +(   $           !
M                  $             !     +(
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +(     %)G:'1L;VYG   $
M      9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "R     !29VAT;&]N9P  !      #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!0       0    $.$))300,     !OL     0   *    !O   !
MX   T"   !O0 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" !O * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M_P 'ZOKUOI4L[ZWX>)7=:VOU,=E55E%I>&ML-CKZW-^BYU%=#<4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  #_XO__24-#7U!23T9)3$4  0F^
MS/[^'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!
M4%!,     $%$0D4                    !  #VU@ !     -,M041"10
M
M"F1E<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P
M  "B!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$
M WYT  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N
M4RX@5V5B($-O871E9" H4U=/4"D@=C(
M
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M*J KGBR=+9HNE2^1,(TQB3*&,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU
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M[USP6_%6\DSS/?0J]1+U]O;6][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\
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M;-)MOFZJ;Y9P@G%L<E9S0'0I=1)U^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-?_2
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M7$ROF8^7:S=-EPJ6Y1XHEE^46  ;D,2 $JCBJ[FO Y>BIWVJN(7"HW*FPW-
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M>JO.?9=\?)7^?<!\CW]3??-\N6?3?C=\]T\>?HU]-#.0?Q)]<@Y!@$A]@],
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M?@<4@?B$*,%4@KV98:[8@@V6_9MU@7J4G8<I@06247(;@+"0+5PU@(2.5$4
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M=S1ZUC5H>"%[/A#.>,)ZK=7B;82#'<&D;QN"9ZRU<)F!PI;,<@"!28 <<UZ
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M^4A5C$5VV3,HBZUWBAC]C0!W@P  @:%^'YT8DA-[3HX0D&)[?7XACL9[IVT
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MMX^@ZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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MI;>.?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
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ML%>21E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
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M@3)ZJPUF@=%Z70  @ "  (=*@%: BWG]@!N HVO"?]^ EER+?Z: ;DQG?WN
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MGBR 5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
M    @ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RL
ME'2%#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,
M=A^+DWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4[SV]
ME2B3K"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:KU)<
MC4)DK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "  %AP
ML&=A?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!V
ML@  @ "  %@(KI)H:$U*K MID$'0J8EJM#4XISAKSB<8I:QLFA8*IG-L? 0Y
MH_-M>   AF=ZW0  @ "  %>NK*=O.DS?JB9O_4%7IZAPN33GI55Q;2;?H[QQ
M[!8*I$YQJP2$H5QR_   A4%^B@  @ "  %=2JOUV'$R*J()VBD$$I?]VZC2*
MHZ9W,R:ZH?5W;18)HEUW*03"GP9XX0  A#Z     @ "  %;_J:U](TQ0IRI]
M2D#5I)U]3C1>HC=]/R:2H'1],Q8;H)=]%@3_G.]^%@  @UZ     @ "  %:Z
MJ*"$+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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MAK&4&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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MC?A[T0  @ "     @ "  %CPDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6
MSAD@CJF ZP=0C!R X   @ "     @ "  %B(DER(8$XOD3J(.T+GC^:'Q#:0
MCH:'-BC<C7Z'!ABWC7.'1P<KBJ.$V0  @ "     @ "  %@WD8Z/Y4X)D'*/
MHT+#CQ6.SC9OC9"-VRCBC%>-PACYC B,H0=RB52%"0  @ "     @ "  %"F
MJF%4349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q
M+@  @ "  $_&J)1;*D7$ILQ=-SJ_I1Y?,BZ%H\%@]R!;HVUB*P['I;)B!P
MG6QE%0  @ !U^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3H0=G
M5@[1HN%G"@  FMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VA
MGTEL !_ GK]LD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP
M3CDSGL5Q$2TKG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7
MH&IV8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
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M<LB!LUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M>WF%RU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
M    @ "  %H[>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB>=F+,@E,
M>RJ&20  @ "     @ "  %2EEMQ0/4J,E?%353^)E4]62C,FE0)8^B3/E7=;
M%A+OF%);J &"E*5=C0  @ !M%   @ "  %.>D_U7/TF\DT19X#[%DJ=<73*(
MDD1>FR1GDHA@3Q+8E.=@F0'4D0IB:0  @ !Q^   @ "  %++D0Q>/TC<D'E@
M9SX*C^QB;3'8CX=D.2/DCZ]EAQ*;D:1EC@(&C<MG9P  @ !VY   @ "  %(
MCD)E0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![
M/   @ "  %$YB\AL54=$BVEMECQKBO=NM3!TBH]OGB+CBHIP/1'^B[YOY@(M
MB'AR6@  @ !_!@  @ "  %""B:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)IB&AU
MUQ'BB1]UB )%AE5X2@  @ "     @ "  $_BA^)ZJ48,A[A[+3M8AU1[=2^
MAM5[ER($AI-[IA&HAN5[BP)PA()]5P  @ "     @ "  $]@AF.!Q$6(AE*!
M\#K8A?:!UR\,A7"!IR&;A1&!IA$OA1B!PP)A@Q&!=0  @ "     @ "  $[X
MA32),T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
M    @ "  $A8HG%.7S[?H3Q10C1IH&=3]BA9H"A63AG#H7-7OPBCHQM890
MD91?Y   @ !P>@  @ "  $='G^94_CWXGNQ7=S-XGAI9Q2>/G:];O!E%GJ%<
MV BGGW-=60  CMQD?@  @ !U40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;
MFOEA)!C#F[UAZ@B7F\YB4   C$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]C
MW#'VF+QE5B9 F$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@   @ "  $5D
ME[AHZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
M    @ "  $3%E9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9
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M] %[?8!K&9S13H58"(X44BY;;WZ$5;)>OFX(61%A\EQO7$-E!DFK7P=G]C6
M8)AJGQVM8#)L=@&+?61OSYK:2:QB/HP[3<!DN7SO49QG(FR*54%I>UL@6*AK
MODB-6XIMZ#2:7/-OVAT.74IQ) &:?4MTXICH13QL9(IK2;-M^7LR3=1OB&L?
M4;EQ#5G:559RA4=^6$YS\#/(685U-!Q_6MIV!@&F?39YBY<*039V>(C+1@IW
M.'F^2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G
M/:F ?H=K0M2 ;'B;1XN 7&C#2]R 2U?O3\: /D7W4MZ 0S*14Z" 6!NK5RF
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M;G=X"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M    @ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<
M>** )P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%
MVQ00;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]
MC?]41!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94
MBS>UBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%
MA?I89T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !V
MB   @ "  $F-@E1?1T 7@LAA3S6K@R-C*RH!@X%DOQP@A#%EJPN(A+=EP@
M@*IJW@  @ !ZZP  @ "  $B;?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5@,%J
M^ L[@6!J_0  @ !P>0  @ !^O@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ
M?7UP(AK[?:9P; L3?H9PAP  @ !V50  @ "     @ "  $;X>3%T73V5>BUU
M'3-<>LMUIR?F>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "     @ "  $9/
M=M![;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M    @ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@
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M6   @ "  #R:BQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP
M@ !T!   @ "     @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1K
MU@*FAP-N,   @ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-
MAK]QM [GAJYQA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=@\]W
M?"=VA&5WKAPNA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "  #H-
M@*I^)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M    @ "     __\  /__  #__P  ;69T,@     $ PD   $
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M,KF P8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J>
M5)?12&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[
M=&N +J-<7BF !YN52 * !Y,[,A> ,(G^XP""O=-4S3>!ULI9MOJ!!\&:H(B
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M=*"!"8 Y7G. _H 92'6!%8 ?,N"!6H!)WU&!08U!RL& V8MNM9: @HFXG\6
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MKYG.8\:5(I7R4^V1GY()1)>. HX ->^*9XG/**F&IH6)HDZCB*UZDQ&?MZC
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M9ZJU!) )6PVN@8W"3J"GUHN80I2@_(F#-TJ9YH=U+0>2C(5[)&B+%H.J@+W
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M:>"F-9UI70.A&YD94%B<"93K1 R6_9#*.(.1SXRU+>*,FXBF),V';83A>1K
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M8\B!>'1_41&!<G:+/H>!C7C=++.!V'N;O$F MG4;J\F AW8 FF. 7W;:B$N
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M*;F!%H(<JG:$G9?QFSF#P)7 BS^"]9->>J^"0Y#=:>B!L8Y862*!/HO32+.
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M1WT,,<R(KWW?)9"&"G[0DON9.H(7A<26KH&U> V4+8%3:>N1M8#_6W"/2H#
M30.,W8"1/PV*88!H,;6'X(!,);F%5( XDCJ8+(G@A0F5IHC:=U*3+8?*:2R0
MO8:V6NB.4(6F3)B+^82F/LV)D8.>,:2'*(*/)=N$MX%YD9J72)&SA&>4T) #
M=K&268XT:)B/Z8Q06F.-@8IK3$&+)XB*/IF(U(:B,96&AH2B)?F$,X*3D166
MH9EC@_64,)<+=C^1LI1T:!R/.I&Y6>F,V8[]2^**BXP]/F>(.(EO,8:%_H:
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M (GH=#]SDXA>8<QU48;B3Z9W*X54/=1Y/H.H+.][DX'"N9)L=9A3J-1M_)8
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MAG^!(WB[=L" Z7EO9I^ OWHO5EJ K7L#1FB JGOF-MN S7SD*&N!%GX!HIN
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M(^^ HX*C?G^& 9L4<V6%(ICD9Y^$%Y826W6# Y+F3T^"'(_!0U>!<8RE. .
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M(VR"SWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J:
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M0*J!I7@\-9J!B7G5*SV!CWN5(DV!KGUJ> >!(GB=;8Z ^GED8IN QWH65T6
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MX7X>1.R$X7Y5.N:#\7ZB,5R#'W[\*)>";G]:(4"!VG^V;%J'A8/R8M2&PH/
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M-'EB,NMVXWLQ)RIZP7TNCZU>Z7DN@UMAZGGK=F9DU7J0:.-GS'LE6QAJ]WO
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MD'[=+&%Z^G]"(WQ]:G^H>+%KMX1T;EIMDX1%8WQO6H/96"IQ+(-+3*]S*8+
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M-[*"*73P+LR"$G=9)J>"''GL']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E>
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M'Y>!#("*6C.$2(=(4H&$)X;K2GF#IH8)0E^"SX3T.F*!^X0.,J"!6H--*WR
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M#(+C,ZYO68(U**MUG8&$C3E&#(^+@4M+DXX0=,M0]HQY9[-69XK86CM<%HE
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M(Q5[ ('_;-)ZS5$58TI[AU4N66U\8EE@3RE]15VO1*1^+6(E.C!_+6;5,%6
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M+[^"+''L*.""/W4E(KZ"<GB!'=""MGO'51%_*6H-3<%_JVPF1CE__FY,/I>
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M'=J!+'^T2?N ?'ZE0Y>!4G[;/56!G7[F-S&!;'[Y,22!#W\P*U2 RG]\)BB
MEG_1(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
M                  $                    !     0(#! 4&!P@)"@L,
M#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3(S-#4V-S@Y
M.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@86)C9&5F
M9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-CH^0D9*3
ME)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_
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M?9MPRW^<;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MS9J$I\V:A*?-FH2GS9J$I\W_H3@B_YY%-_^>2TG_HTI7^J=+9?"K3'/HK4^
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MY-(O0<_D+E6_[S-KK^$[?J#62HV6SEN9D,AIH8S#<ZB)P'NLAKY_KX*\@;*
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M:77L7F]NZ6-T:N=I=V?E;GEEY')[8^-U?&+B=WUAXGE^8.%[?U_A?7]?X'^
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M_YE")O^<1C3_HT5 _ZA%2O^M1U7^L4I?];50:.NY5G#CO5YWV;MJ@,NR<)#
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M;6KK9'%GZ&IT9.=O=V+E='E@Y'AZ7^-[>UWC?GQ<XH%]6^&$?EKAB']9X(R
M6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX'S
MO0T$S,\) ;WE# RL_Q<>GO\D+Y+_+SV'_SU)?_])4GC\5%IP^%I?:?1?9&3R
M96=A\&II7N]N:USN<FU;[79N6NQY;UCL?'!7ZWYP5NN!<57JA')4ZHAS4^F+
M=%/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW3,Q@@
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MG'J/Q96!FKV.B**WB)"IL827KJR G[&H?J>TI7VQM:%]N+:=?KBUFG^YM)F
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MBHN;J(:2H*."FJ6>@**HFWZLJIA^N*N6?L"KE'_ JI. P:B2@,*HDH#"J)*
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MJ4DU\:Q//.FN54/AKUU+U:AD6<NA:V?"F7-SN9-Z?;*-@86LB(F,IH20D:&
MF):=?:":F7RJG)9[MIV4>\2>DGS*G9%]RIR/?<N;CWW,FH]]S)J/?<R:CWW,
MFH]]S)J/?<R:CWW,FH]]S)K_?R(&_X0Q$/^3-A?_GCP>_Z,_)?^H0BSXK4<R
M[[!-.>:T5#_=LUM)T*QB6<:D:F:\G7%RM)=W?*R1?H6FC(:,H(B-D9J%E9:6
M@IZ:DH"GG8]_LIZ-@,&>C(#)GHN RIV*@,N;BH#+FXJ RYN*@,N;BH#+FXJ
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M?U'0X']1T.!_4=#@?U'0X']1T.!_4=#@?U'0X'__E1H#_ZD? _NZ$@+4S0L
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M[FO%7NYKQ5[N:\5>[FO%7NYKQ5[N:\5>[FO_9",$_V$M!O]P,@S_>S@4_X%
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MF6E7J)1P8*&/=V>;BWYNEHB&<Y&%CGB,@I9\B("?@(1_JH*!?[>#@'_(A'^
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M1MSU6T;<]5OMG 0 T:T$ ,*X!0"WPP4 K=$( *3M$ &;[2 %DNTN#HGL.AB
M[$,A=NQ**F[L4#%FZU8W8.M</%OK9$!7ZVM#4^MR1E#K>DE-[(-+2NR,34CL
MEDY%[:%00^VN44+NO%%![\Q20>_E4D#M\5% [?%10.WQ44#M\5% [?%10.WQ
M44#M\5'4I0  Q+(# +:\ P"KR04 H-@( )?T$P&/]20'A_4Q#W[V.QAT]D(@
M;/9()V7V3RU>]U4Q6?=;-57W8CA1]V@[3?AO/4KX=C]'^'Y!1/F'0T+YD45
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M,##_G#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN
MGL4  )#2  "#X   ??\/ 7+_%@)H_QX$8?\G"%K_+PQ4_S<03O\^$TG_1!9%
M_TH80?]/&3[_51L[_UD<.?]?'3;_9!XT_VD?,O]P("__=R$M_W\B*_^'(RC_
MD"0G_YDE)O^A)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR:?P   D<T
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M^E3@4OI5X%+Z5>!2^E7@4OI5X%+Z5>!2^E7_6"8#_U0P!?]=,0?_9S@._VU
M%O]O21[_;E(G_VI<+_]E9C;_87$\_UU]0?]9B$;_5I))_U2<3/]2I$[_4*M0
M_T^S4?].NU+_3<13_TW/5/Y,X%7[3.M5^$ST5?!/]U7I4?A5XE+X5MM4^5?9
M5/E7V53Y5]E4^5?95/E7V53Y5]E4^5?_628#_U<N!?]@+P?_:C8-_W$^%?]S
M2![_<E$F_V]:+O]J8S;_96X\_V%Z0O]=A4?_6H]*_U>83?]5H%#_5*A2_E*O
M4_U1MU7\4,!6^D_+5OA/W%?U3^E7\D_S5^I2]E?A4_=8VE7X6=%6^%K/5OA:
MSU;X6L]6^%K/5OA:SU;X6L]6^%K_628#_UHL!?]D+0?_;C,-_W4]%?]X1AW_
M=T\E_W18+?]P8#7_:FH\_V9V0O]B@4?^7HM+^UN43_E9G5+X5Z14]E:L5O54
MM%?S4[Q8\E/'6?!2U5KL4N9:Z5/R6>%4]5O75O9<SU?W7<A9^%W'6?A=QUGX
M7<=9^%W'6?A=QUGX7<=9^%W_6B4#_UTJ!?]G*@;_<C(,_WD[%/]\11S_?$TD
M_WI5+/]U7C3_;V<\_&IR0OEF?4CV8X=,\U^04/%=F5/O6Z%6[5FH6.M8L%KJ
M5[E;Z%;#7.96T5SC5N1<WU;P7=57]5_,6?9@QEKV8,!;]F&^7/9AOESV8;Y<
M]F&^7/9AOESV8;Y<]F'_6R4#_V H!?]K* ;_=S +_WXZ$_^!0QK_@DLB_W]3
M*O][6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>
MW%G 7]I9SF#56>)@T5GO8<I:]&+"7/1CO%WT9+=>\V2V7_-DME_S9+9?\V2V
M7_-DME_S9+9?\V3_7"0#_V,F!/]O)@7_>R\+_X(Y$?^&01C_ATD@_X51*/B"
M63#R?6 X[7=J0.AR=4?D;G]-X6F(4MUFD5?98YE:U6"A7=)?J&#/7;%BS5R[
M8\M<QV3)7-MEQ5WK9;]=\F:X7_%GLV#Q9Z]A\6>N8O%GKF+Q9ZYB\6>N8O%G
MKF+Q9ZYB\6?_720#_V8D!/]R) 7_?BX*_X<W$/^+/Q;_C$<=^8M/)?*(5BWL
M@UTVYGYG/N!X<4;;<WM-U6Z#4]!JC%C,9Y1=R66<8,9CHV/#8:QEP6"U9[]?
MP6B]7]!INF#F:;5A[VJO8N]JJV/O:J=D[VFF9?!IIF7P::9E\&FF9?!IIF7P
M::9E\&G_7B,#_VDB!/]V(P3_@BP)_XLV#O^//A3]D44;])%,(NV.4RKFBEHR
MWX5E.]=^;470>'9-RW1_5,9PAUK";(]>OVF78KMGGV6X9:=HMF2P:K-CNVNQ
M8\ILKV/A;*MD[6VF9NULHV?M;*!H[FN?:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H
M[FO_7R,#_VL@ _]Y(@3_A2L(_XXT#/^3/!+XED,8[Y9*'N>54";@D5@NUXIA
M.LZ$:D7(?G--PGE[5;YU@UNY<8M@M6Z29+)LFF>O:J-JK&BL;*EGMFZG9\1O
MI6?:;Z)HZV^>:>QOFVKL;IEK[6V8:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6W_
M7R,#_VX> _][(03_B"H'_Y$R"_^7.@_TFD$5ZYM'&N.;32':EE4MSX]>.<B)
M9T3!@V]-NWYW5;9Y?UNQ=H=@K7./9:EPEFBF;I]LHVRH;J!KLG"=:\!QG&O2
M<IILZ7&7;>IPE&WK<))N[&^2;NQNDF[L;I)N[&Z2;NQNDF[L;I)N[&[_82$#
M_W = _]^( /_BRD&_Y4Q"?N;. WPGCX1YZ!$%M^@2AW3FE(KRI-<.,*-9$.[
MAVU-M()T5*]^?%NJ>H1AIG>+9:)TDVF><IMMFG"D<)=OKW*5;[QSDV_-<Y)P
MYG.0<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(;
M _^ 'P/_CB<%_Y<O"/B>-@OMHCL.Y*5 $MJD1AS.GE$JQ9=:-[V18D*UC&I,
MKX=R5*F">5ND?X!@GWR(99MYD&J7=YAMDW6A<)!SK'.-<[ATBW/)=8ITXG2)
M=.ASB'7I<H=UZG&'=>IPAW7J<(=UZG"'=>IPAW7J<(=UZG#_91\#_W0: O^#
M'@+_D"8$_YHM!O2A- GIIC<+X*H]#M2G1!O)H4\IP)M8-KB58$*PD&A+J8MO
M4Z.'=EJ>@WY@F8"%991]C6J0>Y9NC'F?<8EXJ7.&=[5UA'?%=H-XWW6#>.AT
M@GCI<X)XZG&">.IQ@GCJ<8)XZG&">.IQ@GCJ<8)XZG'_9QT#_W<9 O^%' +_
MDR0#_YTK!?&D, ;FJC,(W*XW#,^J0QK%I4XHO)]7-;.97T&KE&9*I)!M4YZ+
M=%J8B'M@DX6#98Z"BVJ*@)-NAGZ<<8)]IW1_?+-U?7S#=GQ]VW9\?>AT?7SH
M<WU\Z7)]?.IQ?7SJ<7U\ZG%]?.IQ?7SJ<7U\ZG'_:1P"_WD8 O^'&P+_E2,#
M^Z I!.ZH+ 3CKR\%U[(T"\NM01G!J$PGMZ-5-*^=74"GF61)GY1K4IF0<EF3
MC7E?CHJ 9(F'B&F$A9%M@(.:<7R"I'1Y@;%V=X' =G:!UG9V@>=T=X'H<WB
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M]85)&^Z"42+G?5HJX7AD,MQS;CK4;G=!T&J 1\QFB4S(9)%0Q6*84\-@H%7
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M73>LBV4_I8=L1Z"#<TV;@'M3EGV"5Y)ZBER.>))@BG:;8X=UI6:$=+%G@G3
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M9FF'\V5JAO-D:H;S9&J&\V1JAO-D:H;S9&J&\V3_;A(!_WX0 /^-$ #WF@X
MVZ<* -.P"P#*M!8 P+0I!+:Q-PZMKD,:I*I,)9NF53"3HUPYC*!C08:=:4B
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M6U&F^EM1IOI;4:;Z6U&F^EO_@ D X9(! -&@! #&JP4 O+0$ +.] P"KQPL
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M&2K_F1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM
MD[\  (;*  !XU@  ;.(  &/\!P!<_P\ 5?\6 4__'@))_R8#1/\N!$#_- 4\
M_SL&.?]!!S;_1@@S_TP(,?]1"2[_5PHL_UT**O]D"RC_; PE_W4-(_]_#B'_
MB@\@_Y40'O^@$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O   AL<
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M./A(L3GW2+DZ]D?"._5'S3OR1]\[[D?L.^M(]COI1_\]YT?_/N%(_S_:2O]
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M6G=V^UEW=OQ8=W;\5W=V_%=W=OQ7=W;\5W=V_%?_9!(!_W,0 /^ $ #_BQ
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M5V&)_5=AB?U788G]5V&)_5?_;PP _W\) -^- P#2F 8 RJ(& ,*I!@"ZKPX
MLK @ :FN+P:AK#P0F*E&&I&G3R.)I%8L@Z)=,WV?9#EWG6L_<IMQ1&Z:>4AI
MF(%,99>*4&&5E%->E:!56Y2M5UJ4O5A9E-17693L5UF3^59;D?Y56Y#^55N0
M_E5;D/Y56Y#^55N0_E7_<PD ]80$ -B1 P#,G 4 PZ4% +NM! "SLPP J[4<
M :.T+ 6;LCD.DK!$%XJM32"#JU0I?:E<,'>G8C9QI6D\;*1O06BB=T5DH7])
M7Y^(3%R>DD]8GIY25IVK4U2=O%13G=%44YWK4U.<^%-4FO]35)G_4U29_U-4
MF?]35)G_4U29_U/_> 8 X8D  -"6 @#&H0, O*D# +.P 0"KN @ I+H8 )RZ
M*0.4N38+C+=!%(2U2AU\LU(E=K%:+'"O8#)KKF<X9JUN/&*K=4!>JGU$6JF&
M2%:HD4I3J)U-4:>J3D^HND].J,]/3J?I3TVF]T]-I?]/3J3_3TZD_T].I/]/
M3J3_3TZD_T_Z?P  V(X  ,F; 0"^I0( M*T! *NU  "AOP0 F\$4 )3!)0*,
MP#,(A+\^$7R]2!EUO% A;[I8)VJY7RUEN&4R8+=L-ERV=#I8M7P^5;2%05&T
MD$1.LYQ&3+.I2$JSN4A)M,Y(2;/I2$BQ]DE(L/]*2+#_2DBP_TI(L/]*2+#_
M2DBP_TKBA@  SI0  ,*A  "VJ0  J[$  *&Z 0"8PP4 D,D0 (K)( &#R2\%
M>\@[#73'111NQDX;:,56(6/$72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S CSQ*
MP)L^1\"H/T; N$!%P,U 1<#H/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\
M_T/6C0  QIL  +BE  "MK@  HK8  )B_ @"-R 8 @]$+ '_2&@!YTBH#<M(W
M"&S10@]FT4L58=!3&ES/6Q]8SV(C5,YI)U'.<2I-SGHM2LZ#,$C.CC)%SIHT
M0\ZH-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*
ME@  O*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>
M/@I=WD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF
M*C[?M2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP
ML:<  *2P  "8N@  C<,  ('- @!VUP< ;N@/ &GH&P%CZ"<"7NDR!5CI.PA4
MZ40,3^I,#TSJ4Q))ZEL51NIB%T3K:AE!ZW(;/^M['3SKAAXZ[)$@..R>(3?M
MK"(V[;LC->[/(S3NYB,TZ_4C-.OX(S3K^",TZ_@C-.OX(S3K^".SI0  IJT
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M"1C_J D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW
M6.,  $WP  !'_P( 0O\, #S_$0 X_Q@!-/\? 3#_)0$L_RL"*?\P B7_-0(C
M_SH"(/\_ Q[_1 ,<_TD#&?]/ Q?_5@05_UX$$O]H!!'_<@4/_WX%#O^*!0[_
ME 4-_YX%#?^B!0W_H@4-_Z(%#?^B!0W_H@7_.2\"_SPP _]!,0/_1#0$_T0Z
M!O]$10C_15$,_T-=$?]!:1;_/G89_SR!'/\ZC![_.98@_SB>(?\WI2/_-ZLC
M_S:R)/\VN27_-L E_S7*)O\UUR;_->4F_S7O)O\U^";_-O\F_C;_)OPV_R;\
M-O\G^C;_*/HV_RCZ-O\H^C;_*/HV_RC_.2\"_SXO _]$+P/_1C($_T@X!O](
M0PC_2$\-_T=;$O]$9Q;_0G,:_S]_'?\]BA__/),A_SN;(_\ZHB3_.:DE_SFP
M)O\XMB;_.+XG_SC')_\XTRC_..,H_SCM*/XX]RC[./XG^3G_)_@X_RGX./\J
M]CC_*O8X_RKV./\J]CC_*O8X_RK_.B\"_T$L _]&+ /_2B\$_TPW!?]-00C_
M3$P-_TM8$O](9!?_1G ;_T-\'O]!AR#_/Y C_SZ8)/\]H"7_/:8F_SRM)_\\
MM"C_.[LI_SO$*?\[SRG^.^ J^SOK*O@[]2GV//XI]#S_*O,[_ROR._\L[SO_
M+>\[_RWO._\M[SO_+>\[_RW_/"T"_T0I O]**0/_3BP$_U$T!?]2/@C_4DH-
M_U!5$O]-81?_2FT;_TAX'_]%@R+_0XTD_T*5)O]!G2?_0*,H_T"J*?X_L2K]
M/[@K_#_!*_H_RROW/]PL]3_I+/$_]"OO/_TL[3__+>P^_R_K/O\PYS__,.<_
M_S#G/_\PYS__,.<__S#_0"H"_T@F O].)@/_4BD#_U8R!?]7/ ?_5T<,_U51
M$O]271?_4&D<_TUT(/]*?R/]2(DF^T>1*/I&F2GX1: J]T2G*_5$K2ST0[4M
M\T.]+?)#R"[P0]<N[$/G+NE$\RWF0_PPY$+_,>-"_S+A0O\SW$/_--Q#_S3<
M0_\TW$/_--Q#_S3_0R<"_TLC O]2(@+_6"<#_UPO!/]=.0?_7D,,_UM.$?]8
M6!?^560<^E)O(/=0>B3T380G\DR-*?!*E2OO29PM[4FC+NQ(JB_J1[$OZ4>Z
M,.='Q3#F1](PXDCE,-]'\C+;1_LTV$;_-=5&_S;21O\WS4C_-\U(_S?-2/\W
MS4C_-\U(_S?_1B0"_T\@ O]6'P+_720#_V$L!/]C-0;_9$ +_V)*$/I>5!;U
M6U\<\5AK(.Y5=27K4W\HZ%&(*^9/D2WD3I@OXDV@,.%,IS'?3*XRW4NW,]M+
MPC392L\UU4OD-=!+\#;-2OLXRDK_.LA*_SK&2_\[P4S_.\%,_SO!3/\[P4S_
M.\%,_SO_2B$"_U,= O];' +_8B("_V<I _]I,@7_:CP)^6A&#_)E4!7M85L:
MZ%YF(.1;<27A6'LIWE:$+-M4C"_84I0RU%&;--)0HS703ZHWSDZR.,Q.O#G*
M3LDZR$[=.L1/[3O!3OD]OD[_/;Q._SZZ3_\^ME#_/K90_SZV4/\^ME#_/K90
M_S[_31X"_U8: ?]?&@'_9R "_VPF O]O+@3Y<#@'\F]"#.ML2Q+E:5<9WV5B
M']IA;"74778JT%M^+\U9AS+*5X\UR%:6-\94G3G$4Z4[P5.M/+]2MSZ]4L,_
MO%+3/[E2Z#^U4O9!LU+_0;%3_T&O4_]!K%3_0:Q4_T&L5/]!K%3_0:Q4_T'_
M4!P!_UH7 ?]D& '_;!T!_W$C OUU*@/S=C,%ZW8]"N-S1P_<;U,7U&M>'\YF
M9R;*8W$KQF!Y,,)>@32_7(DWO5J1.KI9F#RX6* ^ME>H0+16LD*R5KU#L%7,
M0ZU6XT2K5O-$J%?^1*=7_T2E6/]$HEC_1*)8_T2B6/]$HEC_1*)8_T3_4QD!
M_UT4 ?]H%@'_<!H!_W8@ ?=Z)@+M?"X#Y'PX!]QZ1 W2=4\6RW!:'L9L8R;!
M:&PLO69U,;EC?36V880YLU^,/+!=E#^N7)M!JUND0ZE:K46G6KA&I5G'1Z-:
MWD>A6N]'GUO\1YU;_T>;7/]&FES_1II<_T::7/]&FES_1II<_T;_51<!_V 2
M ?]K% '_=!< _WH< ?)_(@'G@2D"WH(S!--_0 S+>DP5Q'96'KYQ8"6Y;F@L
MM&MQ,K%H>3:M9H ZJF2(/:=BCT"E8)=#HE^@19]>J4>=7K1)FUW"2IE=UDJ7
M7NQ*EE_Z295?_TF38/](DF#_1Y)@_T>28/]'DF#_1Y)@_T?_6!4!_V,1 ?]N
M$@#_=Q4 ^WX8 .V#'0#BAR,!UH<N \R#/0O%?TD4O7M3';=V726R<V4LK6]M
M,JEM=3>F:GP[HFB$/I]FC$&<991$F6.<1Y=BIDF48K!+DF&^3)!AT$R/8NA,
MCF/X2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_
M>A( ]X(4 .B'%P#=BQP T(LL \>(.PJ_A$<3N']1'+%[6B2L=V(KIW1J,:-Q
M<C:?;WD[FVV /YAKB$*5:9!%DFB92(]FHDJ,9JU,BF6Z38AES$Z'9N9.AF?V
M3(9G_TN%:/]+A&C_2H1H_TJ$:/]*A&C_2H1H_TK_7!(!_V@/ /]T$ #_?1
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M3&]W_TQO=_],;W?_3&]W_TS_9 T _W(* /!^!@#:B 4 T) ' ,J7" #"FQ
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M#'ZO1A1XKDX;<JQ6(6VK7"=HJ6,L9*AJ,&"G<31<IGDX6*6".U6DC#Y1HYA
M3Z.E0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C
M?0  SXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X
M0Q!QMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD
M/$BNLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P
MQY$  +N<  "OI   I:L  )JR  "0N@$ AL$) ('"& ![PB@"=<(U!F_!0 QI
MP$D29+]1%U^^6!Q;OE\@5[UF)%2\;B=1O'8J3;M_+4J[BC!(NY8R1;NC-$.[
MLC1"N\4U0[OB-$*Y\S5!N/TW0+?_-T"W_S= M_\W0+?_-T"W_S?.BP  OY@
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M&#'HY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0
M>\8  &_.  !CU@$ 6-X% %3N$ !1[QL 3>\F 4GP+P)%\#@#0?$_!#[Q1P4\
M\DX&.O)5!S?R7 @U\V0),_-M"C'T=PPO]((-+?2/#BOUG0\J]JL0*?:\$"CV
MSA$G]^81)_7Q$2?U\1$G]?$1)_7Q$2?U\1&CJ   EK(  (B[  ![Q0  ;\X
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M/)I7_SR96/\[F%C_.YA8_SJ86/\ZF%C_.IA8_SK_4A(!_UP. /]F$ #_;1$
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M,Y1GA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/]
M@F3_/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,
MA!( PX4D ;N#- 6S@$ ,K7Q+%*9Y5!NA=EPAG'-D)IAQ:RN4;W(OD6UY,XYK
M@3:+:HDYB&B2/(5GFS^"9J9!@&:R0WYFP41]9ME$?&?O0WQG_$%\:/] ?&C_
M0'QH_S]\:/\_?&C_/WQH_S__6PP _V<) /=Q!P#>>@4 U( ' ,Z%"0#'AQ$
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M/'-UE3]Q=)]";G.L1&QSNT5K<\Y%:W/I1&MS^$-K<_]";'/_06QS_T!L<_]
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M/U:+LD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P
MUGP  ,B'  "]D0  M)@  *J<  "@H@  F:00 ).E( &,I"X#A:,Y"7^B0P]Y
MH$P6=)]3&V^=6B!JG&$E9IIH*6.9;RU?F'<P6Y> -%B6BC=5E94Y4I6B.U"4
ML#U/E,,]3Y3?/$^3\CQ/DOT\3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=   SX$
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M*C^T[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI
MEJL  (JR  !_N   <[\# &K$# !GQ1H 8\4H 5_%-0-;Q3\%5\5("53$4 Q0
MQ%@/3<1?$DK#9A5(PVX71<-X&D+#@AQ PXX>/L.<'SS#JR [P[PA.L/5(3O"
M[B$YP/DB.+__)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@  C+$
M ("Y  !UOP  :L8$ %[," !9SQ( 5] A %70+@%1T#D"3M!#!$O03 9)T%,(
M1M!;"T/08PU!T&L//M!U$3S1@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70[!8T
MS_<8,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7
M  !JQP  7LT# %34" !,W0T 2MT8 $C>)@!&WC(!1-\\ D+?10,_WTT$/>!5
M!3O@708YX&8(-^!O"37A>@HSX88,,>&4#3#BHPXNXK,.+N/'#BWCXPXMX/(.
M+-_[#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>
MSP  4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M
M50,O[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S
M""+O]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP
M1MT  #_J!0 \]@X .?87 #;W(  S]R@ ,?@P "[Y-@$K^3T!*?I$ 2?Z2@(E
M^U("(_M: B#\8P,>_&X#'/U[ QO^B009_I@$&/^H!!?_MP06_\@$%O_@!!;_
MY 06_^0$%O_D!!;_Y 23K@  A;<  'C   !JR0  7=(  %#9  !$WP  .N0
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M)[1&_RBS1O\HLD;_*+%&_RBQ1O\HL4;_*+%&_RC_1A4 _TT1 /]5$@#_6Q8
M_UX; /E@(P'O8"P!YEXV ]]<1 7865 *T5=;#\Q4913(4FX8Q5!W&\-/?QW
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M,HQ8_S&,6/\QC%C_,8Q8_S'_40P _UL) /]C" #K:@< W6X( -AQ"@#/<A,
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M_S;_6P  ZV<  -EQ  #,>0  PWX" +N" P"TA D K848 *:%* &?A#4%F8)
M"I-_21"-?5(6B7M9&X1Y8!^ =V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)LV
M:V^G.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_
M7@  Y&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$
M1P^)@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E
M.&1SLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80
MX&T  ,]W  #$?P  NX4  +.)  "JBP, HXP3 )R-(P&6C# #D(L\"(J)10Z$
MATX3?X55&'N#7!UW@F,A<X!J)6]_<2EL?7DL:7R"+V9[BS)C>I<U8'FC-UYY
ML3A=><(Y7'G=.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9   W'
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M,DR/[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0
MII8  )R:  "0GP  AZ(& (&C% !\I",!=Z0P W*C.P9MHD0+:*%,#V2@5!-@
MGUH779YA&UF=:!Y6G7 A4YQY)%";@R=-FHXI2IJ;+$B:J2U'F;HM1IK0+4:8
MZRU&E_DN1I;_+D:6_RY&EO\N1I;_+D:6_R[1=P  P80  +:.  "JE0  H)L
M )6?  "*I   ?:D  '>K$ !SJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:J5@3
M5ZA?%E.G9AE0IVX<3:9V'TJE@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&CZB=
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M&C2Y_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0
M8[X  %C$! !0R P 3<@7 $S))0!*RC$ 1\H[ 47*1 )#RDP#0<I4!#[*7 8\
MRF0'.LMN"3C+> HVRX4,-,N2#3++H@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['
M_Q(NQ_\2+L?_$B['_Q*NEP  H9X  )6E  ")K0  ?+0  '"[  !DP0  6<8
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M A#[Z0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0
M)/X* "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -
M_U8 "_]B  G_;P (_W\!!_^0 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_
MQP&#M   =;T  &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0  &O\%
M !?_#  5_Q  $O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0  _T8
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M$=4Q_Q+2,?\3T3'_%- Q_Q30,?\4T#'_%- Q_Q3_-QL!_SL7 /\_%@#_0QP
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M(:)&_R&B1O\AHD;_(:)&_R'_10X _TL* /]3# #_5PT ^5H0 .M;% #?6AP
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M+7!BLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50
MY6   --I  #(<   OW0  +=W 0"P=P< J'@5 *)Y) "<>#("EG8]!I%T1PN,
M<D\/B'!7$X1O7A> ;60:?6QK'7IK<R!W:GHC=&F#)G)HC2EO9Y<L;6>C+FMF
ML2]I9L$P:6;;,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6   X6,
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M+UET["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0
MKX,  *:&  "<A@  E(@, (Z)&0")B2@!@XDT WZ'/@=YAD<+=(5/#W"$5A-M
M@ET7:8%C&F: :AUC?W(@8'YZ(UU]A"9:?(\I6'N<*U9[J2Q4>[DM4WO.+51Z
MZBU4>ODL5'G_*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@  JX<
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M)$.0_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0
M=*(  &ZC"P!JI!< 9J4E &.E,0%?I#L#6Z1$!5BD2PA5HU,+4J-:#4^B81!-
MHF@32J%Q%4>@>QA$H(8:0I^3'$"?HAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;
M_Q\\F_\@/)O_(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I   ;Z@
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M"RC!_PNHE0  G9L  )&B  "$J0  >*\  &NU  !?NP  5+\  $G#   _R 0
M-LT) #/.$0 RSQP ,<\G ##0,0 OT#H +M%# "W13  KTE4 *M)? 2C3:0$G
MTW8!)=.$ B34E (BU*8"(=6Y B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1
M_P2?FP  E*(  (>I  !YL0  ;;@  &"^  !4PP  2<<  #[+   UT $ +=4&
M "7;"P DWA( (]X< "+?)0 AX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH
M&N1X !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6
MH@  B:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K
M"@ <[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I
M  WS>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0
M?;(  &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4
M^@T $OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_
M9@  _W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H
M &/#  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD
M"_\-  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5
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M N\8_P/N&/\$[AC_!.T8_P7M&/\%[1C_!>T8_P7_)R,!_RD@ /\I( #_*",
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M#[\Q_P^_,?\0OS'_$+\Q_Q#_-A, _SD/ /\^$ #_010 _T,: /]"(P#U02X
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M(8!2M")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@
MZ50  -I<  #,80  PV0  +QD @"V8PH KV07 *EE)P"C9#0"GF- !)EA2@>5
M7U(+D5Y:#HY=81&+6V@3B5IO%H99=AB$6'T:@5B&'']7CQY]5ID@>U:D(GE6
ML2-W5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<
M --?  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*
MC&)7#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q
M6K\E<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B
M  #$9P  NVL  +-L  "L:@0 I&L2 )YL(0"9;"\!E&LZ X]I1 :*:$T)AF95
M#8-E7!" 9&(3?6)I%7IB<!AX87@:=6" '7-?BA]P7Y0A;EZ@(VQ>K25K7KPF
M:E[1)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  #
M:P  MVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI
M60][:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/
M)F1BZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@
MLW$  *MS  "B<0  FW(. )5S' "0="H!BG,V H5R0 6!<$@(?6]0"WEM5PYV
M;%X1<VMD%'!J;!=M:7,::VE\'&AHAA]F9Y A9&><(V)FJ25@9KDF7V;-)E]F
MZ"9@9ODD8&;_(V!F_R-A9O\B86;_(F%F_R+H6   TV,  ,1K  "Y<0  L'4
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M(E%T_R%1=/\A473_(5%T_R'88P  Q6T  +AV  "N?0  I8(  )J#  "-@P
MA(0# 'V%$ !YAAX =8<K 7&'-@)MAC\$:85'!V6$3PIB@U8-7X-<#UR"8Q):
M@6L55X!S&%1_?1I1?X@<3WZ4'TU^HB!+?;$A2GW$(DI]X2%+?/0A2WO_($M[
M_R!+>_\@2WO_($M[_R#09P  P'(  +1[  "J@@  H(8  )6(  "'B   ?(H
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M%SB5_Q>[>@  KX4  *2,  "8D0  C94  (&:  !UG0  :*   %ND  !6I0P
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M B>_D0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@
MF)@  (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P H
MR!, )\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-
MB@ ;S9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\
M (*F  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L
M%M<0 !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .
MWY$ #N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N
M  !JM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-
M  [G$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX
M .J4  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>
MO@  4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V
M#@ %]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!
M  #VE0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R
M1,T  #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"
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M N$5_P+@%?\"X!7_ N 5_P+_)1L _R87 /\D%@#_)1P _R8E /\D, #_(3L
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M$I= N!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/
M^40  .1*  #83@  SD\" ,E-!@##2P\ NTT= +5.+0"O3CH!JTU& J=,3P2D
M2U@&H4I@")Y)9PF<2&X+FD=U#9A&? Z61H,/E$6+$9)%E!*019T3CD6H%(Q%
MM!6+1<06BD7<%HA&\!:&1OT6AD;_%H5'_Q6%1_\5A4?_%85'_Q7_/P  [$@
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M''!2Z!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P
MMV(  *]A  "H7@( H5\0 )M@'@"68"P D6 X 8U>0@.)74L%A5Q2!X);60J
M6F ,?5EG#GM8;A!X6'42=E=]%'17AQ9R5I$8;U:<&FY6J1ML5K@<:U;+'6I6
MYAQJ5_<;:E?_&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@  LV4
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M&UQB_QI<8O\:7&+_&EQB_QK@50  RU\  +UG  "R;   J7   )]O  "4;
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M%T=U_Q?)90  NF\  *YW  "D?0  F'\  (M_  !^?P  <X$  &R#"0!HA!,
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M"SB5E0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>
MJH(  )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&
MH"8 1* P $.A.@!!H4(!/Z%) 3VA40([H5D".:%A S>@:P0UH'8%,Z"#!C&@
MD@<PH*((+J"S""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@   HXD
M )>.  "-DP  ?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  ZJA\
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M !#'N0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0
M9*\  %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -
MT1D #=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34
MJP #U<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@
M $R]   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$
M ]T8  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP
MY:X  .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$
M   SR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1
M  #H%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP
M /.M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   G
MT0  '=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q
M#@  \Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:
M  #_I@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0
M_P!1 /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#]
M *8 ^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T
M_P#M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=-
M /\%60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0
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M <P3_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8
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M [0HOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04
M_S   /\S @#V- 8 [S(* .@N$ #<+!@ T2XH ,LO-P#&,$0 P3!/ +XP60&[
M,&(!N#!J K8O<0*U+W@"LR]_ [$OA@.P+XT#KBZ4!*TNG 2K+J0%J2^N!:@O
MN@6F+\H&I##B!J$P\P>?,/\(GC'_")TQ_PB<,?\(G#'_")PQ_PC_,   _S4
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M#X)!Z0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@
MOD\  +A,  "R20D JTD5 *5+(P"@2S$ G$L] 9A*1P*524\#DDE7!)!(7@6.
M1V4&BT=K!XE&<@F(1GD*AD6""X1%B@V"190.@$2?#WY$JQ!\1;D1>T7+$7I%
MYA%Y1O<1>$;_$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P  N%0
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M$V52_Q)E4O\295+_$F52_Q+D2@  SU,  ,!:  "U7@  K&   *)>  ":60
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M$E-A_Q+15@  P%\  +-F  "I:P  G&L  )!J  "%9P  ?6D  '=J#0!S:Q<
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M#D5SE@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P
MLVP  *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7
M?R\ 57\X 5-_0 %0?T@"3GY/ TQ^5@1*?ET%2'UE!D9];@A#?'D*07R&"S][
ME T^>Z,./'NS#CQ[R X\>N8./'GW#CQX_PX\>/\./7?_#CUW_PZ\:   KW(
M *1Y  "6>@  B'H  'QZ  !P?   8W\  %R"  !7A L 4X44 %&&( !/ABH
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M!"B:P 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@
M=HP  &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ M
MI#( +*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^E
MNP$>I=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0
M &.8  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D
M'[ Q !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3
MLLX $['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC
M  !0J   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF
M !&]+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL(
M![[?  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'
MLP  /+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7)
M)  $RBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(
M  #,X@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP
M,+X  ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@
MUB(  -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>
MR   WMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<
M !O+   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<
M .4>  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM
M[L(  .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6
M   +VP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3
M  #R&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT
M /ZO  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_
M &4 _P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4
MK0#S +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_
M .H _P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$
M_P!K /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L
M +( Z@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$
M_P#_%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F
M /8 ;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\
MX0"X -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_
M&!, _Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&
M:@#I!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U
M -(&P #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX
M_QD, /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>
M#6T VPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.
MP #&#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$
M /\?" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@
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M IPI[ .:*OH#F"K_!)<J_P27*O\$EBK_!)8J_P3_*   ]2X  .4S  #:-0
MT#,! ,PM!@#&*A  OBT> +@N+ "S+SH KR]% *PP3P"I+U@ IR]? :4O9@&C
M+VT!H2]S J N>@*>+H$"G2Z) ILND0.9+IH#F"ZD!)8OKP25+[T$DR_/!)$P
MZ 6/,/@%C3'_!8TQ_P6,,?\%C#'_!8PQ_P7_+0  ZC4  -PZ  #./0  QCP
M , W @"[,PT LS09 *XV)P"I-S0 I3=  *(W2@"?-U,!G39: 9LV80&9-F@"
MES5O I4U=0.4-7P#DC6$!) UC02/-98%C36@!8LUJP:*-;D&B#7*!X<VY0>%
M-O8'A#?_!X,W_P>#-_\'@C?_!X(W_P?T,@  XSL  -)!  #&1   O4,  +<_
M  "Q.PD JCL4 *4\(@"@/3  G3T[ )D]10"6/4X!E#Q6 9(\70*0/&,"CCMJ
M XP[<02*.W@$B#J !8<ZB :%.I(&@SJ<!X$ZJ B .K4)?CO&"7T[X0E[//,)
M>SS_"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I
M000 HT$1 )U"'@"80RL E4,W )%#00".0DH!C$)2 8E!60*'05\#A4%F X-
M;02!0'0%@$![!GX_A =\/XX(>C^9"7@_I0IW0+(*=4##"W1 W0MS0?$+<D'_
M"G)!_PIR0?\)<D'_"7)!_PGI/   U44  ,5+  "Z3@  L$X  *=+  "B1@
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M"UM1_PO62@  PU,  +99  "K7   GEH  )-9  "+5   A%8# 'Y6$ !Z5QH
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M"U!=E@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5
MN5P  *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A
M9#( 7F0[ %QD0P%:9$H"6&11 E9D6 -49%\$4F-G!5!C< =.8WH(3&*&"DMB
ME M)8J(,2&*R#4=BQPU'8N0-2&'V#$AA_PQ(8/\+26#_"TE@_PO$6   M6
M *IF  ";9@  C68  ()E  !V9   ;F4  &AF!0!C9Q  8&@: %UI)0!;:B\
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M"#=UP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0
M?G$  '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"
M@#T 08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^
MO08P?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78
M &YW  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@
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M !:<]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP
M1I@  #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4
MJCD $ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI
M\@ -J/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,
M #6G   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\
M"+8Y  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0
MM?$  +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR
M   CM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O
M  ##.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8
M ,3N  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9
MOP  $<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0
M+0  TC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=
M  #8W0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0
M"LP   +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0
MXRH  .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #J
MPP!PJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D
M  #=    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T
M /,G  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_
M"QL _P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\
M<P#] 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X
M .X PP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@
M_PH5 /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U
M '< \P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0
MOP#C ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1
M /\&$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '(
MZ@!Y .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5
M ,@ T@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,
M#0#_"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T
M -T >P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0
MQ@#7 ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_
M$ X _PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%
M=@#,!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4
M +H)Z0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D
M_Q$. /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0#
M#7< OPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1
MZP"K$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10&
M .40#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$
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M H8J_P*&*O\"ABK_ H8J_P+T*   XS$  -$V  #%.   O#8  +8P  "R*PD
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M!65 _P7</@  QT8  +E+  "L3   H$H  )='  "10P  BT,( (9#$@""1!X
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M!EE,E0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2
MO%   *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G
M4#, 95 \ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UE0< 174'H%55"&!E10
MDP=24*$(45"Q"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P  N5,
M *M7  "<5@  CU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B5#$
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M!T)=O@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@
M@UX  'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.
M8T$ 3&-( $MC3P%)8U8!1V-> D5C9P)$8W$#0F-]!$!BBP4_8IH&/F*J!CUB
MO <\8M8'/6'O!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80  ?V$
M '1A  !I80  7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(:3X
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M BIV^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0
M4'4  $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M
M@D@ +()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_
M]P$B?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P
M $.    [@P  ,X8  "V)"@ JBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$(
M(HU* "&-5  @C5X 'XUK !V->0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9
MB?\!&8C_ 1F(_P&==P  C'8  'UV  !R=P  97D  %I\  !0@   1H0  #R)
M   TC   +9   "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA#
M !:830 5F%@ %)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P
M$)3_ !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   M
MEP  )IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD
M10 +I%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[
M  .A^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@
M'J4  !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/
ML$<  +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N
M] "'B0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$
M !"T   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P
M +Y(  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_
MD@  <)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_
M   "P@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\
M  #.20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG
M:*$  %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*
MS@   -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B
M/   XTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP
M %&R  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W
M -\   #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@
M\SP  /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\
M%0#_ !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!]
M /@ @P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L
MZ #A .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_
M !4 _P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\
M?P#M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #:
M -H [ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !(
M_P : /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B
M (  X "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L
MYP#) /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5
M /P ( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L
MT "  ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\
M /( NP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /
M&0#F "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![
M ,$ @0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\
MKP'[ *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#;
M AT T@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%
M? "S!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS]
M *(-_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0
MQ@HB , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H
M#GX IP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84
M_P"5%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(;
M +03*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD
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M 74J_P'E+   T#0  ,$X  "S.   J#4  *(Q  "=+0  F2H. )0K& "0+"0
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M F0YE0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P
MP$(  +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P
M/38 ;CT_ &P]1@!K/4T :3U3 &<]6@!F/6$!9#UH 6,]<0%A/GL"7SZ& EX^
MDP-</J #6S^O!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P  O$8
M *M(  "<1P  D48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J03,
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M!$M+O 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P
MA4X  'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!4
M34$ 4TY( %).3P!03E<!3TY? 4Y.9P%,3G("2TY] DE.BP-(3ID$1T^H!$9/
MN@1&3]$$1D_M!$9._ 1&3O\#1T[_ T=._P.]3   KE(  )Q1  "-40  @5$
M '=0  !N3   9TX  &)/  !=4 T 6E 4 %=1'@!542< 4U$P %%2. !04C\
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M S=<^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@
M5EL  %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \
M8TT .V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A
M^ (Q8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F
M $QB  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD
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M 1MW_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@
M+GT  ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7
MAE8 %H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!
M_P"1;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<
M "&*   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\
M#9%<  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")
M<P  >W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5
M   3EP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4
M  "=8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0
M=GD  &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .
MHP  ":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I
M60  J6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$
M &&$  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP
M +(   "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@
MN%T  +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0
M  !.E@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X
M  "^    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$
M ,EB  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&
MI   .JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
M    S    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4
M  #?9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M
M,K@  "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9
MVP   -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R
M6   \VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ?
M /\ + #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0
M\@") /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B
M /L X@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\
M* #_ #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"%
M .8 B@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /<
MT0#_ -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W
M "\ ]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@
MA0#5 (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^
M ,( _P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D
MYP V ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #&
M (8 Q0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0
M_P"T /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O
M -$ .P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($
MMP"' +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G
M /\ I@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,,
M,P"_ #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@""
M *D B0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\
MF@7_ )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S
M!#< L 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(
MA0";"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_
M (T._P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C
MI0X[ *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0
M$(H CQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5
M_P#M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U
M )86/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8
M@QF0 ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E
M(@  T"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>
M.0")'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&,
M '<AEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0
MR#   +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- "
M)CT ?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XH
ME !L**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8
M *\V  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@
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M E0YN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20
MAC\  'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=
M.T, 6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^
MMP)./LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(
M 'I   !S/0  ;3P  &@]!0!D/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7/D
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M C])]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10
M7D<  %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$
M3$X 0TU6 $)-7P!!36@ 0$UT 3Y-@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-
M]@([3?\!.TS_ 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@2@  64L
M %1,  !0304 3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!11  _44L
M/E%3 #U27  \4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V
M4?\!-E#_ 3=0_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@  5$\  $]1
M  !*4@$ 1E,, $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1
M #A76@ V5V, -5=O #17? $S5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!
M,57_ 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$
M5P  0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=
M5P P76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_
M 2M:_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70
M.E\$ #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I
M9%T *&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A
M_P&<6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8
M "]H"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D
M(&QE !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"5
M7   @UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP
M!  C<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@
M !9U;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8
M?6   &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <
M>P< %WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_
M:  -?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4
M &IE  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A
M$(<(  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "
MB7$  8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K
M  !;;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&
M  :3#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD
M )5Z  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4
M=0  27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">
M"0  GPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q
M  "CA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@
M0H4  #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!
MJPH  *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R
M>0  LHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,
M #"9   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(
M +D(  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;
MQ((  ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH
M   =K0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<
M  #)!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,
M -J*  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5
MNP  #;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
M    VP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z
M  #OCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4
M_P!! /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M
M (\ ZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T
M_P#= /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ]
M /@ 2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H
MW@"0 -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+
M /\ RP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L
M0@#G $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+
M ,L D@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\
MO #_ +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7
M $< T@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P
MC0"Z )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_
M *T _P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $
MP@!* +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M
M (\ JP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *
M_P#_    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !#
M +$ 3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H
MG@"3 )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y
M!0  Z@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0
M10"B $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/
M ) !F0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P
MWA0  ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7
M"4< E0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,
MEP"##*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X
M +T=  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$
MBA!( (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X
M$J  =Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E
M  "E(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=#
M 'X72@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT
M;!NK &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=
M*@  DR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>
M10!R'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H
M &(CN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P
MC"T  (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J
M)4< :"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HI
MM0!:*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(
M '\O  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D,
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M 4<X]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P
M9#8  & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+
M.$X 2CE5 $DY7@!(.F@ 1SIS $8[@ !%.XX 1#R> $,\K@%"/,(!0CW? 4(\
M\P%"//\!0CS_ 4([_P&S/0  GCX  (T^  !_/@  =3X  &P]  !F.@  8#D
M %LZ  !7.@@ 4SL0 %$[& !..R  3#LH $L[+P!)/#8 1SP] $<\1 !&/4L
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M #5&_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P
M1$<* $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T
M3%\ ,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+
M_P"A1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP&
M #M-#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P
M+5%G "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<
M2@  B4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53
M#  S5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D
M "97<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630
MA$X  '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K
M6P\ *EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>
M;@ >7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$
M '!1  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P
M(F,1 "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 6
M97H %66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5
M  !@5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P.
M !AL$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4
M#6Z'  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<
M6@  5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W
M#P .=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>
M  -WE  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@
M3F   $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %
M@1$  X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""
MC0  @:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<
M #]K   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX
M (L3  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0
MCID  (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV
M   O>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</
M  "8$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)
M )NE  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   G
MAP  'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E
M#@  IA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;
M  "KKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@
M%IL  !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"
MM0T  +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]
MI   O;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D
M  FN    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4
M ,8*  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP
MTZD  -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
M    P0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@
M  #:!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL
M .RH  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[
M %( ^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8
ME@#D )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_
M -0 _P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T
M[0!5 .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3
M )D T0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,<
M_P#_    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0
M -D 6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0
MP0"< +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M    _P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,<
M4@#$ %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7
M +  H "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_
M_@   /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T
M %, L@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *(
MFP"@ *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \
M .$   #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T
MI !4 *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3
M *$ D0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'
M  "_!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !.
M )8 5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T
MA0"I (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q
M#@  J T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"
M3@") E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G
M '@&M0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@
MG!,  )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^
M"T\ ?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.
MM0!L#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL
M (L9  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H
M<Q%0 '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B
M%<8 8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@
M  !^'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+
M &@840!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',,
M61W@ %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V
M(P  <R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>
M30!>'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/=
M %$D\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*
M:R4  &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6
M)%  5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI
M\0!**?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H
M &,G 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T
M3BE4 $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%
M+OX 12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL
M  !9+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1
M $<N60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT
M0#+_ $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4
M, 8 43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S
M5P! ,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_
M #LV_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- ,
M2S0, $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [
M.%X .CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y
M_P"B.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@*
M $0Y$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P
M-3QG #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">
M.P  BSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]
M#@ \/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E
M "]!<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0
MASX  '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W
M0A( -4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&
M;P I1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$
M '-"  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!
M+T@6 "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C
M2WP (DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$
M  !D10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3
M "=/&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D
M'%&* !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@
M2   5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5
M%@ ?5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B'
M !18F@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P
M4TL  $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 7
M71D %EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?
ME@ -7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\
M $A0  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0
M#V8;  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $
M9J,  F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5
M   [6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6
M  5P'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX
M &^R  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)
M3$4 ! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P
M"W8$  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4
M>E\  'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;
M  !,7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"
M  """   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<
M (=H  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&
M9   /&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".
M!   C@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?
M  "5<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@
M-70  "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";
MG (  )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F
M:   IGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$
M ".'   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@
M *P   "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7
MN'$  +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7
M   2G0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L
M  "]    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0
M ,UZ  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,
MK    [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
M    S@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K
M  #F@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T
M_P X /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F
M (4 Y "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$
M_P#1 /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S
M /  /@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\
MT@"% -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#
M /\ OP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .
M. #; $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"
M +\ A@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\
MKP#_ +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#&
M #P P@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\
M@ "M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_
M *$ _P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8
ML@ _ *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@">
M (( G "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$
M_P#W    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X
M *  0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P
MCP"% (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
M    TP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ),
M.@"1 $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"
M (  B@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@
MQ L  +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "%
M #L @P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0
MA@!S )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$
M *82  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8
M> 0\ '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H
M")  9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8
M  "0&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW
M &T,/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX
M70^< %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "(
M'@  ?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01
M.0!C$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69
M %,5J0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P
M=R(  ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:
M%SL 61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<
MI@!*'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28
M &HE  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3<
M41T] % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$
M(K8 0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I
M  !@)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y
M $DB0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0
M/2?* #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<
M*P  6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G
M/ !!)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS(
M #<LY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@
M4RL  % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \
M*T  .RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(P
MY0 S,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\
M $LM  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X
M-3!& #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N
M-/8 +S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q
M  !",@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5#
M # U3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4
M*C?_ "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]
M-@  .C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ
M20 J.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_
M "4[_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@
M-3L  #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D
M/U  (T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " _
M_P").0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$
M "U!!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X
M'459 !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$
M/   <ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=&
M 0 D1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5
M !9+8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P
M;T   &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >
M308 &T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!1
M7P /4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0
M %U$  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P
M%%8) !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (
M6&@ !UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(
M  !02   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&
M  Q@#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,
M &!S  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,
M3   14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG
M"P #9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM
M  !I@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P
M05$  #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0
M< T  '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S
M>0  <XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@
M #)<   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H
M 'L.  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0
M@(8  ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE
M   C:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*
M  ")#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX
M (^5  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <
M=P  %'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7
M"   F P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,
M  "?H@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0
M#8L   :0    E    )@   "<    GP   *$   "B    I    *4   "G
MJ 0  *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "R
MF   L:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH
M  "?    I    *@   "L    KP   +$   "Q    LP   +4   "V    N
M +H   "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@
MR)\  ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
M    LP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L
M  #-    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$
M .*B  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W
M $@ \P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X
MC #< ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_
M ,$ _P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $(
MXP!+ .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#(
M (X Q@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8
M_P#_    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!%
M ,H 30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@
MM "0 +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M    _0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +<
M1P"U $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "*
M *, E "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^
M[@   -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D
M $@ H@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0
MC@"2 )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP
M ,<   "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$
ME !( )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "#
M )0 @@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4
M  "J    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!"
M (4 1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\
M=0"< '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";
M!@  DP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D
M0@!W $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8
M &@ I@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@
MA@T  ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L
M $( :P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"
MHP!< [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(
M '81  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT
M8@=# &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3
M"[, 4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7
M  !J%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_
M %@-10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+(
M2A'( $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B
M&@  7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 2
M00!/$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;%
M $(7XP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P
M61P  %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'
M%T, 1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<
MX0 ['?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R
M %$>  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$
M/QU' #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U
M(?, -B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB
M  !)(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$
M #@B3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O(
M,";_ #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$
M)   020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F
M2@ Q)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^
M "PI_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*
M/"@" #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L
M*U$ *RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M
M_P"**P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP
M #0L"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X
M)C!9 "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&
M+0  =2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q
M!@ M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357
M " U8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",
M<3(  &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H
M-@L )3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ
M8  9.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30
M & U  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@
M(#P. !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4
M/VP $T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX
M  !2.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+
M !A#$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D
M#D5Y  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/
M.P  1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*
M#0 12A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT
M  =+AP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@
M1#X  #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +
M41  "E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2
M@0  498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$
M #M"   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X
M E@2  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?
M69   %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='
M   O20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0
M  !A%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL
M &*@  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J
M4   (U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J
M$0  :Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:
M  !LL   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6
M'5P  !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@
M=A$  '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !X
MJ@  >,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<
M !!K   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT
M (01  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@
MA[D  (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY
M   "?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,
M  "5$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+
M )C'  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(
MC    )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F
M"@  J X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ
M  "KRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0
M *$   "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0
MN0<  +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!
MO  ^<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(
M  "V    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP
M ,X%  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M    _P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T
M4@#J %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6
M ,\ H0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_
M_P   /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4
M %, T0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T
MFP"[ *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P
M /@   #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X
MO@!3 +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I
M *  J "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8
M  #7    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!.
M *D 4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D
MEP"F )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
M    MP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D
M30"7 %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@
M (< KP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O
MI@   )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"(
M $P AP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@
MJ0!W +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP
M )   @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8
M>0!+ '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J
M +0 :@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,
M  !_  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!&
M &P 2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\
M7@## %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T
M!   <0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &(
M1@!@ $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^
M %0 V@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#
M9PD# &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7
M 4< 5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&
MU !*!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\
M %T-!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40
M3@E* $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"
M#>X 0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01
M  !4#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y'
M $4.3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?
M.A+] #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,
M$P, 3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T2
M3  \$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\
M #06_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&
M118' $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U
M%U$ -!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;
M_P"*'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH#
M #T:#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\
M+AU9 "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&
M(   =",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>
M"0 U'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6
M "@B8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P
M<24  &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P
M(@T +B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F
M8  A)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<
M & I  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL
M*"<0 "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <
M*VL &RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK
M  !3+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP.
M "(L$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD
M%C!Y !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0
M+@  2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ
M$  ;,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W
M !$UB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,
M13   #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5
M-Q, %#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZ
MA@ ,.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,
M #LS   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A
M$#X5  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %
M/Y0 !#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU
M   T-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03
M  E$&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19
M $2D  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q
M.   *SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+
M%@  2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA
M  !+M0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/
M)SX  ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P
M4Q@  %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2
ML0  4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0
M !U'   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4
M %L:  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0
M6L4  %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/
M   24P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46
M  !F'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<
M &3>  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -
M7   "&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R
M%P  <QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4
M  !P[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':
M &L   !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0
M@A8  (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  "
MY0!*3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D
M  !]    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA
M )06  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$
M50  .5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
M    D0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40
M  "H%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@
M,F,  "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?
MH@   *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[
M$   OA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W
M "!X   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP
M +8   "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."
MTA   -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\
M  #_  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9
M .$ 7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *<
MQ "W ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z
M  $ \P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@
M60#& %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O
M +  P@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F
MW0 ' -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S
M %@ L0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\
MN0"> -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 "
M +H # "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %(
MG@!7 )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"-
M ,8 C #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8
M" "A  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1
M (T 50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P
M? #< 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0
M  P C0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T
M3P!\ %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#,
M &X [0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @
M?@ . 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O
M $\ ;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$
MY !A /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 +
M &\ $ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H
M80!/ &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6
M /$ 5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0
M#0!C !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+
M %8 40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L
M3 #Z $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:
M  X 6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T
M30!+ %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U
M $, _P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L
M40,0 $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#
M!%$ 0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(
M_ ".$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H,
M $D($0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\
M.@M8 #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"(
M$P  =Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-
M#@! #1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7
M #(/8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@
M<AD  &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z
M$!  .! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L3
M7P J%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL
M & =  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T
M,A02 # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D
M&&H (QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?
M  !3(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0
M "H8%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@
M'AUW !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0
M(@  2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=
M$@ C'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U
M !@BAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)
M124  #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >
M(14 '2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,F
MA0 2)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<
M #PF   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q(
M&"<8 !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .
M*I8 #BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH
M   T*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6
M !(L'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y(
M"2^E  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q
M*@  +2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR
M&0 -,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B
M  (SM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+
M*RP  "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (
M.!T !S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   X
MLP  .,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\
M "0P   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH
M #XA   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L
M/<<  #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T
M   ;-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=
M  !%)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0
M $/C  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7
M/   $C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.
M(   3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA
M  !*\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P
M#T8   M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P
M5R,  %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3
M\ !+/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\
M  51    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT
M &(F  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'
M0   /S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M    7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@
M  !O*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1
M/D,  #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G
M:P   &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_
M(@  ?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D
M "],   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0
M 'P   !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0
MDB4  )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6
M   >7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P
M  ".    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL
M *8I  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7
M:0  #W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
M    H@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?
M  "[,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>
M"8    "(    CP   )8   ";    H0   *8   "J    K@   +    "Q
MM    +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2
M)0  TC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P +
M /P $0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X
MU0!C -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z
M .H N0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .<
M#P#B !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!=
M +P 8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X
MI@#Y *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #%
M !( PP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D
M7 "G &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q
M )0 _P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \
MJ@ 6 *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4
M %H DP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (,
M_0"$ /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1
M )0 &0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0
M@@!: ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T
M /\ = #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($
M% "! !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4
M '$ 6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\
M9@#_ &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q
M !8 <  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0
M5 !C %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_
M %H _P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !(
M8P 8 &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7
M %8 5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\
M_P"<    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4
M %< &0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %(
M2P!: $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2
M!   @ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X
M%0!- !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6
M $$ 7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@
M> P  &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!%
M !8 1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D
M7  X &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\
M &00  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q(
M/ (8 #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P
M!F8 +P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3
M  !4%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4
M #4(&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4
M* QS "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1
M%P  2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-
M%@ M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S
M " 0A  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0
M11D  #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H
M$!@ )A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3
M@@ 9%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP
M #P;   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4
M(!,: !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4
M&), $QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=
M   T'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7
M !D8'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')(
M$!RE  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q
M'P  +1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<
M&P 4'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B
M  L@M0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0
M*B   "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0
M(A\ #R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <D
ML0 &),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(
M "0A   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT
M"R<C  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP
M*,4  2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C
M   ?(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA
M  4L*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(
M "S@   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =
M)@  &2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R
M)0  ,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?
M   Q\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@
M%BP  !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@
M."H  #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V
M\ !1*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$
M ! S   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4
M $ O  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-
M+@  0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ
M   )/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J
M  !(-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@
M/C(  #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #
M1    $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2
M,   4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8
M #0U   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30
M $\   !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@
M738  %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X
M   K.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H
M  !<    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX
M &H\  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E
M0   '40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M    :@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU
M  !Y10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@
M%TX  !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W
M>0   'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  ".
M.P  C4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L
M  IA   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@
M (T   "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0
MHT0  *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M    =P   'T   "#    B    (T   "1    E0   )@   ":    G    )\
M  "A    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D
M +A.  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!
MB0   (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
M    M@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$
M  #/6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !<
M]  @ /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+
M &@ R0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\
M_P"E /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ;
M -8 ) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &(
MLP!G +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8
M /\ D@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D
M'P"W "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A
M )X 9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\
MA0#_ (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@
M "( GP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H
M80"( &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_
M '8 _P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P
MB@ C (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X
M &$ =@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D
M_P#     JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  >
M '< ) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L
M9P!C &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
M    F0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &<
M'P!G "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!=
M %@ 9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=
MBP   'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!:
M !\ 60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T
M8@!+ &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@
M '    !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H
M3@ @ $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!!
M &@ 0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&
M  !=!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ;
M $, ( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0
M-P!Q #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6
M#   3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L
M'  Z "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M
M "X ?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@
M20X  $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R
M !T ,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!
M>@ F 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$
M #X1   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD
M*@,> "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?
M!XL '@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3
M   U$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @;
M ",)(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L
M& R> !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q
M%   +1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-
M'0 =#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@
M !$0LP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@
M*A4  "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7
M$"$ %A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3
ML0 -$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<
M "06   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\
M$1,F !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (
M%L$ "!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8
M   ?&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C
M  T8*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\
M QG:  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =
M&0  &AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=
M)P ('2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8
M   =[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P
M&!L  !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "
M(BP  2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A
M[0!5'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT
M !,>   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD
M "<R   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1
M(   12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B
M   /(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO
M   M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@
M020  #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -
M*   "BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S
M-@  ,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8
M #0G   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@
M!C !  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@
M.CX  #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I
M   K*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<
M   Y @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD
M $-'  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J
M*P  )2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M    0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"
M  !,40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0
M(B\  !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*
M3    $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !7
M2P  5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34
M !8X   1/   #$    =$    1P   $H   !-    4    %,   !5    5P
M %D   !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1
M9%<  &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"
M   ,1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4
M  !G    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\
M '1C  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %
M4@   %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M    >@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;
M  "&<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80
M &8   !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*
MC    (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=
M9P  FH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<
M  !]    @@   (8   "+    CP   ),   "5    EP   )H   "=    H
M *,   "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7
MM'0  +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
M    E0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8
M  "Z    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@
M ,N!  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H
M "X X@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$
M< "^ '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_
M (\ _P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@
MQ@ P ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I
M '$ IP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0
M_P#H    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J
M *D ,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D
MDP!R )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
M    S0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0
M*P"1 #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K
M 'X =0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'
MM0   *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^
M "L ?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T
M;@!L 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H
M )    "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4
M:P J &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!<
M ', 6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\
M  !U    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E
M %P *@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T
M3@![ $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M    7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\
M) !. "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U
M $( A@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=
M50   $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$
M "0 0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@
M@  W ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,
M $<#  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\
M.0 D #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N
M (X +0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (
M   [!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @
M #  )  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D
M)@"= "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V
M"P  ,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@
M(  G "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9
M !X K@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0
M+0T  "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A
M "( (  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@
MJ@ 8 ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X
M "8.   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\
M&@4E !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2
M!;P $@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0
M   @#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB
M !0**0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H
M#0K2  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <
M$   &A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -
M*  /#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0
M  <.Z !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@
M%Q$" !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,
M$"T "Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1
MZ !5$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(#
M !,2!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH
M!Q0S  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2
M%   1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3
M!@ 1$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P
M  $8.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@
M0Q@  #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0
M% 8 #A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <
M.   '40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H
M #8;   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0
M#!D%  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0
M(D$  ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=
M   K'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#
M  <?!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX
M "=+   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H
M'P  (QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D
M!   )@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(
M   M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0
M(2   !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @
M+00  "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U
M4P  -&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(
M !PA   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $
M #8$   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@
M/6$  #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE
M   4)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!
M  !  P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL
M $5Q  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1
M+0  #3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M    3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J
M  !0@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0
M"#D   (]    0    $,   !&    20   $P   !.    40   %,   !5
M5P   %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>
M>P  7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40
M  !(    3    $\   !2    50   %@   !;    70   &    !B    9
M &8   !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0
M;8L  &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M    60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<
M  !Z    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$
M '^;  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D
M:0   &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
M    D@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/
M  "5IP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P
M (    "&    B@   (X   "1    DP   )8   "9    G    *    "C
MIP   *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "M
MG  <3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0
M  ":    GP   *(   "D    IP   *H   "N    L0   +0   "X    O
M ,$   #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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M________________________________________
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MW^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ /%?C
M%C#YO2!3ZK@G?,RH1*O&I5VTPJ1PNKZB?[^\H(C#N9N(Q[>8B,JUE8G.LY**
MT+&/B].PC8W5KXJ/UZV(D]FMAIC:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:
MJX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:]\$/%??!%C#X
MOA]3ZK@F?,NI0ZO&IERTPJ1ONKZB?K^[H(C#N9V'R+::A\RSEXC/L92)TK"2
MBM6NCXS7K8V.V:R*DMRKB9G=IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<
MVZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;]L$.%/?!%3#XOQY3
MZKDE?,NI0JO&IUNSPJ5NNKZC?K^[H8C$N)Z'R;6<A\VRF8?1L):(U*Z4B=>M
MDHO:JY"-W*F-DM^HC9K?HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+
MG-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<]L$.%/;"%3#WOQY3ZKHD
M?,NI0:S&IUJSPJ5MNKZC?;^[HXC$MZ"'R;2=A\ZQFX?3KYF(UJV7B=JKE8K<
MJ9.-WZ>2D>*DD9G@H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@
MCIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<]<(.%/7"%##VP!U3ZKHC?,NJ
M0:S&J%FSPJ9MNKZD?;^ZI(?%MZ&'RK.?A\^PG8?4KIN(V*N9B=RIF(O?IYB.
MXJ67DN:@EIG@G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=
MG).;W9R3F]V<DYO=G).;W9R3F]V<DYO=],(-%/7#%##VP!Q3ZKLB?,JJ0*S&
MJ%BSPJ9LNKZD?+^ZI87%MJ.'R[.AA]"PGX?5K9V(VJJ=BMVGFXS@I)J.XI^8
MC^.=FICAF9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;
MW9F7F]V9EYO=F9>;W9F7F]V9EYO=\L,-%/3#$S#UP1M3ZKPA?,JK/ZW&J5>S
MPJ=KNKZE>[^ZIH3%MJ6'R[*CA]&OH8?6JY^(VJ>=B=VDG(K?H)N+X)N:C>*7
MFI/AEYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><
MF]Z7G)O>EYR;WI><F]Z7G)O>\,,-%/3$$R_UPAI2ZKT@?,JK/JS&JE:SPJAK
MNKZG>;^ZJ(/%MJ>'S+*EA]&LHH?6J*"'V:2>B-RAG8C=G)R)WI>;B^"3FX_@
MDIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2
MG9?>DIV7WI*=E]Z2G9?>[<0,$_/%$B_TPAE2ZKT??,JL/*S&JU6SPJAJN;ZI
M=[^ZJH#%M:F'S*^EA]*JHH?6I:"&V*&?AMJ=GH?;F9V'W92=B=Z0G(W>CIV3
MW8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=
MCIV3W8Z=D]V.G9/=ZL4,$_+%$2_SPQA2ZKX=?,NM.JS&K%2SPJEIN;ZL<[^Z
MK7[%LJF'S*REAM&GHX;5HJ&%UYZ@A=B:H(7:EI^&VY&>B-R-GHO<BYZ/W(N>
MC]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/
MW(N>C]R+GH_<YL4+$_'&$2_RQ!=2ZL ;?,NO.*S&K5*RPJMFN;^P;[ZWK7[&
ML*F'S:JFAM&DI(73GZ.$U9NBA-:7H878DZ"%V8^@A]F+GXK:B)^-VHB?C=J(
MGXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?
MC=J(GXW:X<8*$_#'$"[PQA91ZL$9?,NP-:O'KT^RP[!@N+RR;+^RK7['K:F&
MS*>GA<^AI832G*2$TYBCA-24HX35D**%UHVAAM>)H8C8AZ&+V(>AB]B'H8O8
MAZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'
MH8O8V\<)$N[)#R[NR!11Z\06?,RS,*O'L4RQQ+A6M[:Q;L&NK7_'J:J&RZ.H
MA,Z>IX//F::#T96E@]*1I(33CJ2%U(NCAM2(HXC5A:.*U86CBM6%HXK5A:.*
MU86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5
MVL@)$NO+#2WKRA%0Z\<2?,RV*JK(MT2PNK99NJ^Q<,*JK7_'IJN%RJ"JA,R:
MJ(/-EJB#SI*G@\^/IH30C*:%T8FEAM&'I8?2A:6)TH6EB=*%I8G2A:6)TH6E
MB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2V,D)
M$=_-"RSGS0]/Z,L.>\V\(JC"O#RQL;5>O*FQ<L*FKG_%HJV$QYRK@\F7JH/*
MDZJ$RY"IA,R-J83-BZB%S8BHALZ&IX?.A*>)SX2GB<^$IXG/A*>)SX2GB<^$
MIXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/U<D)$-C/
M"BO:TPM.V- +>LW#%JBSND:UJ;1BO:2Q=,&AL'_#GJZ$Q9FMA,>4K(3(D*N$
MR8ZKA,J+JH7+B:J&RX>IA\R%J8C,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,
M@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,TLL)#]31"BG5
MU0M,T- *?KB_):ZHN$^XH;1FO)ZR=;^=L7_!F["$PY:NA,61KH3&CJV%QXNL
MA<>)K(;(AZR'R8:KA\F$JXG)@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*
MRH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*S\P)#=#2"BC.U I2
MQ=$*@ZK#+:B>MU>XF[5HNYJT=;Z9LG^_E[&$P9.PA<*/KX7#C*^%Q(JNAL6(
MKH?%AJZ(QH2MB,:#K8K&@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&M
MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'S,T)#,O3"BW'U I9LM@+
M@)[-*YJ8P5"KEKAGMY6U=;R4M'Z^E+.%OY"RA<",L8;!BK&'PHBPA\*&L(C"
MA;")PX.PBL."KXO#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!
MKXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#Q\\($,74"32XV0I;HN<2=I?:
M)8F0ST68CL==HXW!;JN-O7FQC+J!M(FX@[>&MX6YA+:&NH.UA[N"M8B\@;2)
MO8"TBKU_M(N^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^
M?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^PM$'%KW6"#JG\0Y5F_$;:)'F+7B)
MW4"%A=56CX//9Y>"RW.=?LAXH7O&?*1YQ'^F=\."J'7"A*ETPH6J<\&'JW+!
MB*MRP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+
MK'' BZQQP(NL<<"+K'' BZQQP(NL_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*Q
MQ)MRML*;?[G FXB]OIF)P+R5BL.ZD8O&N(V-R+>*C\JVB)',M863S;2#EL^S
M@9G0LX"=T;)_H]&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MR
MML*;?[G FXB]OIF)P+R5BL.ZD8O&N(V-R+>*C\JVB)',M863S;2#EL^S@9G0
MLX"=T;)_H]&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;
M?[G FXB]OIF)P+R5BL.ZD8O&N(V-R+>*C\JVB)',M863S;2#EL^S@9G0LX"=
MT;)_H]&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MUY&5H->1E:#7_+P0#?V\&2;^NB-&]K0M:MRL.9+'H%NQQ*-FM<&F;KJ^J7C
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MHY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5], -#/?
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MB*V&QH>MA\:%K8C'@ZV)QX&MB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\>
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MFG*TPYQZN,"<@[N^G(F_NY>)P[F3B\>WCHW+M(F0SK*$EM&Q@9W3K("BTZ>
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MD*>$T(FEAM*$I(K3@*20TW^EE])_IJ#0?Z6FSH"@J,N H*C+@*"HRX"@J,N
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M)0__I30E_Z%"/O^?3%7XHDQG[*5->>&F3HO5I%:<S*%AJL:A;+/#HG:WP**
MO;R@A\.WFHC*LI.*TJR+E-N@AY_8FH:DT9>&I\R5AJK(E(>LQ9.'KL.2A[#
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M]KTS:NO*,77<VBF"Q,XXF;+!3ZNGN&.WH;1SO)ZQ?\&8KX3$CZR$R(>JA\J
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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M /^J'@C_LQT1[,D.#\[C#A6^\A@MK_XB0Z'_+566]#EDC.Q%;X3E47E^X%R
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MGVI)[Z=K2.^P;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=L1^ZW;$?NMVQ'[K=LW:\
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M.#/_F#DS_Y@Y,_^8.3/_F#DS_Y@Y,_^8.3/_F#DS_Y@YI\,  )?4  "(Y
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M0/]^94S_>FY6_G9W7_ET@6;U<(IM\6V1<NYKF';L:9YYZV>D?.EEJ7[H8Z^
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M_K,Z*/.[0"WIPT@QX<M1-]+'5DO%P%Y=N+AE;JRQ;'V@JG.*E*1[E8J?AIZ
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M6C[[T5H]^]M:/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:TJT  +VX @"NQ0(
MH=4" );W"P*-_Q@(A/\F$7S_,1IQ_S@B:/\^*6#_12]:_TPS5/]3-U#_6CI,
M_V \2?]F/D;_;4!$_W1"0?][0S__@T4]_XQ&._^51SK_GDDY_Z=*./^Q2C?_
MODLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+O[,  *Z^  "@S0  DMX
M (G_#0&!_QH%=_\C#&W_*A-D_S$97/\X'E7_0")0_T@F3/]/*4C_52M$_ULM
M0O]A+S__9S$]_VTR._]S,SG_>C4W_X(V-?^+-S/_E#@R_YPY,?^D.C#_KSLP
M_[([,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([L+@  *#'  "1V   A.\  'S_
M#0%O_Q$#9O\9!E[_(0I6_RD/4/\R$TO_.A9&_T$90O](&S__3AT\_U,>.?]9
M(#?_7B$U_V0B,_]I(S'_<"0O_W<E+?]^)BS_AR<J_X\H*?^7*2C_H"HH_Z,J
M*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,JH<(  )'1  ""X0  >/\  &S_" %@
M_PT"5_\1 T__& 5(_R &0_\I"#__,0H[_S@,./\^#C7_1 \R_TD0,/].$2[_
M4Q(L_U@3*O]=%"G_8Q4G_VD6)?]O%R3_=Q<B_WX8(?^%&1__CQH?_Y$:'_^1
M&A__D1H?_Y$:'_^1&A__D1H?_Y$:_V@9 O]D(P3_7R\&_UY $/]C2QK_9U0E
M_VA=+_]F9SG_9')!_V)]2/]@AT[_79!2_UN85O]:GEG_6*1;_U>J7?Y6L%_]
M5;5@_%2\8?Q4Q&+[4\UC^5+<8_92YF/Q4^IC[%3M8^96[V+@5_!CX%?P8^!7
M\&/@5_!CX%?P8^!7\&/@5_!C_VD8 O]E(P3_8"X&_U] $/]F21K_:E,E_VM<
M,/]I93K_9W!"_V1[2?]BA4__7XY4_UV66/];G5O_6J-=_5BI7_Q7KV'[5K5B
M^E6\9/I5Q&7Y5,YE]U/=9O-3YF;N5>IFYU;M9>%8[F7;6>]FVUGO9MM9[V;;
M6>]FVUGO9MM9[V;;6>]F_VH8 O]F(@3_82X'_V _$/]I2!O_;5$F_VY;,/]L
M9#K_:6Y#_V=Y2_]D@U'_88Q6_U^56O]=G%W]6Z)@^UJI8OI9KV3Y6+5E^5>\
M9_A6Q6CW5<]H]53@:?!5YFGI5^IHXEGL:-M:[6G36^YITUON:=-;[FG36^YI
MTUON:=-;[FG36^YI_VH8 O]G(@3_8BX'_V,^$/]L1AO_<5 F_W)9,?]P8CO_
M;&M$_VEV3/]G@5+_9(M8_V&37/U?FV#[7:%B^ENH9?E:KF?X6;5H]UB\:?97
MQFKU5M%K\E7A;.Q7YVSD6>EKW%OK:]1<[&S-7>ULS5WM;,U=[6S-7>ULS5WM
M;,U=[6S-7>UL_VL7 O]H(0/_8RT'_V<\$/]P11O_=$XF_W97,?]T8#O_<&E%
M_VUS3?]J?E3_9HA:_F.17OMAF6+Y7Z!E^%VG:/9<K6KU6K1L]%F];?18QV[R
M5]1O[E?B;^99YF_=7.ENTUWJ;\U>ZW#'7^MPQU_K<,=?ZW#'7^MPQU_K<,=?
MZW#'7^MP_VP7 O]I(0/_92T'_VLZ$/]T0QO_>4PF_WI5,?]Y73S_=69%_W!P
M3O]M>U;_:H5<_&:/8?IDEV7W89]H]E^F:_1=K6WS7+1O\EJ]<?%9R7+O6-IS
MZ%KC<]Y=YG+37NASRU_H=,9@Z'3!8>ATP6'H=,%AZ'3!8>ATP6'H=,%AZ'3!
M8>AT_VT6 O]J( /_9BT'_V\X$/]X01K_?4HE_W]2,?]^6SS_>V-&_W9L3_]Q
M=U?^;8)>^VJ,8_AFE6CU9)UL\V&D;_)?K''P7;1S[UR_=>Y;RW;J6]UWX%WC
M=M-@Y7?*8>5XQ&+E>+YCY7BZ9.5XNF3E>+IDY7BZ9.5XNF3E>+IDY7BZ9.5X
M_VX6 O]K( /_:"P'_W,V$/]]/QK_@D<E_X10,/^$6#O_@6!%_WQI3_]V<E?^
M<7U?^6V(9?9JDFKS9IMO\6.C<N]AJW7M7[5X[%W!>>Q<T'KC7=][U&'B>\IB
MXGS"9.%]O&7A?;=FXGRS9^)\LV?B?+-GXGRS9^)\LV?B?+-GXGRS9^)\_W 5
M ?]L'P/_:2P'_W<T#_^!/!G_AT4D_XI-+_^)53K_AUU%_X)E3_]\;EC]=GA@
M^'*$9_5MCFWQ:9AR[V:A=NQCJWGK8+9\Z5[$?N=>V'_88=]^RF/?@,%EWH&Y
M9]Z!M&C>@;!IWX"L:=]_K&G??ZQIWW^L:=]_K&G??ZQIWW^L:=]__W$5 ?]M
M'P/_:RL'_WLR#_^&.AC_C$,B_X]++?^/4SC_C5I#_XEB3?^#:5?]?')@^'9_
M9_1QBF[P;)5T[6B?>>IDJGWH8;> YE_(@MUAVX/,9-R$P&;<A;AHVX6Q:MN%
MK6O<A*ELW8.F;-V"IFS=@J9LW8*F;-V"IFS=@J9LW8*F;-V"_W(4 ?]O'@/_
M;RD'_W\P#O^*.!?_D4$A_Y1*+/^543;_DUA!_Y!@2_N+9U7UA&]?\'UZ9^MW
MA6_G<I!VXVV;?-YHIH':9;.$U6/$AL]DVH?!9]F(MVG8B:]KV(FJ;=F(IF[:
MAZ-NVH:@;]N%H&_;A:!OVX6@;]N%H&_;A:!OVX6@;]N%_W(4 ?]P'@/_<B@'
M_X(N#?^.-A;_E4 ?_YE(*?^93S3_F%4^^I9<2?229%/MC&M=YX5V9N%_@6_;
M>(QWTW*6?LUMH83):JV)Q6B[B\%HT(RV:]6-KFW5C:=OUHRC<-:+GW'8BIUQ
MV8F;<MJ'FW+:AYMRVH>;<MJ'FW+:AYMRVH>;<MJ'_W,4 ?]P'0/_=28&_X8L
M#?^1-A7_F4 =_YQ&)_^=3#'\G5([])Q91>V98$_FE&A9WXYS8]6&?6[-?X=X
MQGB1@,!SFX>[;Z>,MFVTC[-LR)&L;M*1I7#3D*!RU(^<<]6-F736C)=TV(J6
M==F)EG79B99UV8F6==F)EG79B99UV8F6==F)_W03 ?]Q'0/_>"0&_XDK#/^5
M-1/_G#X;_Z!#)/^B22[WHU W[Z)60>>A74K?G6=4U)5O8LN->&[#A8)YNW^,
M@K5YEHFO=:&.JG*ODJ9QP92A<]"4G'31DIAVTI&6=]./E'?5C9)WUHR1>-B*
MD7C8BI%XV(J1>-B*D7C8BI%XV(J1>-B*_W43 ?]R' /_>R,&_XPI"_^8-!+_
MGSP9_Z-!(ONF1BKRJ$TSZJE4/.*I6T37HV-3S)IL8L*3=6ZZBWYYLH6'@ZI_
MD8JD>YR0GGBJE)IVNY:7=\^6E'G0E)%ZT9*/>M.0CGK4CXUZU8V,>M>+C'K7
MBXQZUXN,>M>+C'K7BXQZUXN,>M>+_W43 ?]S' /_?2$%_XXI"O^;-!#_HCD7
M_Z8^'_>J1";NKDHNY;%2-=RO64'/J&%2Q:!I8;N8<FZQD7IYJ8N#@Z&%C8N:
M@9B1E'ZEEI!\MIB-?<V7C'[/E8I^T).*?M*1B7[3CXE]U8V(?=:+B'W6BXA]
MUHN(?=:+B'W6BXA]UHN(?=:+_W82 ?]T' /_@" %_Y$H"?^>,P__I#<5_JH[
M&_.O02+JM$@HXKE0+M2T5D#)K5]1OJ5G8+2>;VVJEW=XH9& @IF,BHN1AY61
MBX2BEH:#LIF#A,N8A(/.EH2#T)2$@M*2A('3D(2!U(Z$@-:,A(#6C(2 UHR$
M@-:,A(#6C(2 UHR$@-:,_W<2 ?]T&P/_@AX$_Y0G"/^@,@W_IS03^JXX&.^U
M/1SFO$8AW+],+,ZY5#_#L5U0MZIE7ZVD;&RCG71WF9A\@9&3AHJ)CY*1@HR?
MEGV*KYAZB\>8?(G.EGV(T)1^AM*2?X73D'^$U(Z @]:,@(/6C("#UHR @]:,
M@(/6C("#UHR @]:,_W@2 ?]U&P/_A1P$_Y<F!_^C+PO_JS 0];,T%.N[.A?B
MQ$08U<1(*\B]4SV\MEM.L;!C7::J:FJ<I'%VDI]Z@(F:@XF!EHZ0>9.<E722
MK)=QDL.8<Y'/EG:.T)1XB]*1>8K3D'J(U8Y[A]:,>X?6C'N'UHQ[A]:,>X?6
MC'N'UHQ[A]:,_W@2 ?]V&P/_B!L#_YHE!O^F*PG^KRP,\;DO#N;#-@_=S3P6
MSLA'*<+"43NVO%E,JK9A6Y^P:&B5JV]TBZ9W?H&B@(9YGXN-<9R9DFR;J95I
MF[^6:YG0E&Z4T9)QD=*1<X_4CW6-U8UVB]:+=HO6BW:+UHMVB]:+=HO6BW:+
MUHMVB]:+_WD1 ?]X&@+_C!D#_YXC!/^J)@;XM"4(Z\ H".'-, ?4TC<4R,U%
M)[O(3SFOPE=*H[U?6)BX9F6-LVUQ@Z]U>WJK?H-QJ(F*:J:6CV6EIY)BIKV2
M8Z/2D6>=TY!JF-2/;975C6Z2UHQPD-B*<)#8BG"0V(IPD-B*<)#8BG"0V(IP
MD-B*_WL1 ?]\%P+_D!<"_Z(A _^N( 3RNQT$Y<H> ]K;) /,V342P--#)+3.
M33:HR55'G,1=59' 9&*&O&MM>[AS=G*U?'YJLX>%8[&5BEZPI8Q;L;R-6Z_5
MC5^GU8UCH=:,9IS7BVB9V(IJEMF(:I;9B&J6V8AJEMF(:I;9B&J6V8AJEMF(
M_WP0 ?^!% +_E14!_Z<= ORU%@+KQA !VML/ ,W@)03#WS8/N-M!(:S52S.@
MT5-#E,U:48G)8EU^QFEG=,-Q<&O!>WADOX9^7;Z4@EB]I856OKN&5;W;AEBS
MVH=<J]J'7Z;:AV&AVX9CG=N%8YW;A6.=VX5CG=N%8YW;A6.=VX5CG=N%_WX0
M ?^'$0'_FA$ _ZT4 -J^"@#1S0H R^00 <'D)0>WXS43K>% (:/>22^7VU(^
MB]=92X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5
MM]^ 6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.
M#@'_H@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%5
M27;@75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W
M4K[D>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=
MJP0 S;@& ,+$!@"ZU D L>\4 Z?N)0V>[C,:E.T])XKL1C. ZTX^=NM51VSJ
M6TYDZF-57>IM6ECJ=UY3ZH-B3NJ194KKH6='[+-I1NW0:4CFZ&E+V>MJ3,_L
M;4['ZV]/P.IP3\#J<$_ ZG!/P.IP3\#J<$_ ZG!/P.IP_XD+ .F@ 0#0L00
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M=ER@YW5?G.=T8)KH=&":Z'1@FNAT8)KH=&":Z'1@FNAT_W(2 ?^&# #[F D
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M5$7/_%1%S_Q41<_\5$7/_%1%S_Q4X94  ,NF  "[L   KKL! *+( @"8U04
MD/@/ 8GX( 2"^"X+>?DW$W#Y/QMH^48B8/I-*%KZ5"U4^EPQ3_ME-4O[;3A'
M_'<[0_R#/3_]D#\\_9]!.OZO0SC_QD0W_^I%-OS]13OR_T0^ZO]$/N;_1C[F
M_T8^YO]&/N;_1C[F_T8^YO]&T)\  +VL  "NM0  HL(  )7/  "*W0, A/\2
M 7O_'@-T_RH);/\S#V3_.Q9=_T,;5_]*(%'_421,_U@G2/]@*D3_:"Q _W$N
M//][,3G_B#(U_Y8T,_^D-C'_MC<O_] X+O_O.2W__SDQ__\Y,_S_.3/\_SDS
M_/\Y,_S_.3/\_SDS_/\YP:@  *^Q  "BO0  E,H  (?8  !]\P< =O\2 6W_
M&@-E_R0%7O\M"EC_-@]2_ST33/]%%DC_3!E#_U,;/_]:'CS_82 X_VDA-?]R
M(S'_?24N_XHF*_^9*"G_IRDG_[DK)O_2+"7_[RPD__\M)/__+23__RTD__\M
M)/__+23__RTD__\ML:X  *.Y  "4Q@  AM,  'GA  !Q_P@ 9_\/ 5__%0)7
M_QX#4?\F!4O_+@=&_S8*0?\]##W_1 XY_TL0-O]1$C+_6!,O_U\5+/]G%BG_
M<1<F_WP8(_^)&B#_F!L?_Z8<'?^W'1S_RAX<_^8?&__P'QO_\!\;__ ?&__P
M'QO_\!\;__ ?I+4  )7"  "&SP  =]X  &OT  !B_P, 6?\+ 5'_$0%*_Q<"
M1/\? S__)@0Z_RT%-O\T!C+_.@<N_T (*_]&""C_3 DE_U()(O]9"B#_8@L=
M_VL,&O]V#1?_A X5_Y(/%/^@$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_
MPQ(3_\,2E[X  (;,  !WVP  :><  %S]  !4_P  2_\% $/_# $]_Q$"-_\7
M C+_'@,N_R0#*O\J!"7_+P0B_S4%'_\Z!1W_/P4:_T4&&/]+!A;_4@84_UH'
M$O]B!Q#_; </_W<(#?^$" S_D @,_YP(#/^B" S_H@@,_Z((#/^B" S_H@@,
M_Z((_U @ O]+*@/_1#8%_T<Z!O]*/PC_3DD/_T]4%_]/8![_36PD_TIY*O](
MA2[_1I R_T2:-/]#HC?_0JHX_T&Q.O] N3O_0,$\_S_+/?\^W#[_/N@^_SWS
M/O\]^S__/O\^_T#_/OI#_SWT1/\^[D;_/^Y&_S_N1O\_[D;_/^Y&_S_N1O\_
M_U @ O]+*@/_134%_THX!O]-/0C_44@/_U)2%_]17A[_3VHE_TUW*_]*@R__
M2(XS_T:8-O]$H3C_0ZDZ_T*P//]"N#W_0<$^_T#+/_] W$#_/^E _S_T0/\^
M_4'_0/] _4+_0/9%_T#P1O]!Z4C_0>E(_T'I2/]!Z4C_0>E(_T'I2/]!_U$?
M O],*0/_1S0%_TTV!O]1.PC_5480_U90&/]57!__4F@F_U!T+/]-@#'_2HPU
M_TB7./]&H#O_1:@\_T2P/O]#N#__0\%!_T+,0?]!WD+_0>M#_T#U0_] _4/_
M0_]#^$;_0O!(_T/J2?]$XTK_1>-*_T7C2O]%XTK_1>-*_T7C2O]%_U(? O]-
M*0/_2C($_U S!O]5.0C_64,0_UI-&/]96"#_5F0G_U-Q+?]0?3/_38DW_TN4
M.O])GCW_1Z8__T:N0?]%MT+_1,%$_T3,1?]#WT7_0NU&_T+W1O]#_4;Y1O]&
M\$G_1NE+_T?B3/](VTW_2-M-_TC;3?](VTW_2-M-_TC;3?](_U,> O].* /_
M3B\$_U0P!O]:-@C_7D 0_V!*&/]>52#_6V H_UAM+_]4>33_484Y_TZ1/?],
MFT#_2J1"_TFM1/](MD;_1\%'_T;-2/]%X4G_1.]*_T7X2OM'_4KQ2O])Z$W_
M2]]._TS73_],SU'_3,]1_TS/4?],SU'_3,]1_TS/4?],_U0= O]0)P/_4BP$
M_UDM!?]?,@C_9#P0_V9'&/]D4B#_85PH_UUH,/]:=3;_5H$[_U*-/_]/F$/_
M3:)%_TRK2/]*M4G_2;]+_TC,3/](X4W_2.Y-_$CY3O)+_$WG3OU/W5#]4-)2
M_E#,4_]1QE3_4<94_U'&5/]1QE3_4<94_U'&5/]1_U4= O]1)P/_5BD$_UXJ
M!?]D+PC_:CH/_VQ%%_]L3R#_:%DH_V1C,/]@<#?_7'P]_UB(0O]5DT;_4YU)
M_U&F2_]/L$W_3KI/_4W&4/I-V5'V3.I1\DWW4>=0^E+;4OM4SE3\5<=6_57!
M5_Y5O%C^5;Q8_E6\6/Y5O%C^5;Q8_E6\6/Y5_U<< O]2)@/_6B8$_V(F!/]J
M+ ?_<3<._W-"%O]S3!__<%8H_VM@,/]F:SC_8W<^_E^#1/M;CDCY6)A,]U:A
M3_55JU'S4[53\5+!5.]1T%7K4>=5YE+V5MI4^5C,5OI9PUC[6KQ:^UJW6_M9
MLUS[6;-<^UFS7/M9LUS[6;-<^UFS7/M9_U@; O]3)0/_7B,#_V<C!/]P*@;_
M=S4-_WI %?]Z2AW_>%,F_W-<+_QN9C?X:7(_]&5^1?%AB4KN7I-.ZUR=4NA9
MIE7F6+!7Y%>\6.)6S%G>5N19V%;T6\I8]UW 6OA>N%SX7K-=^%ZN7OA=JU_Y
M7*M?^5RK7_E<JU_Y7*M?^5RK7_E<_UD; O]6(P/_8B #_VP@ _]U* 7_?3,+
M_X ]$_^!1QO_?U D^7M9+?1V8C;N<6T^ZFQY1>9HA$OB9(Y1WF&85=M>HEG6
M7*Q;TUNX7M!:QE_-6M]@R%KR8;Y<]6*U7O1BKF#U8JIA]6&F8O9AHV/W7Z-C
M]U^C8_=?HV/W7Z-C]U^C8_=?_UH: O]9(0+_9AT"_W > _]Z)@3_@C$)_X8[
M$/^(1!GYADTA\H-6*^M^7C3E>6D]X'1T1=IO?TS3:HE3SV:26,MCG%W'8:9@
MQ%^Q8\%>OV2^7M)ENE_L9K)@\F:K8O)FI63R9:%E\V2?9?1CG&;U8IQF]6*<
M9O5BG&;U8IQF]6*<9O5B_UL: O]<'P+_:1L"_W4< O]^) /_ARX(_XPX#ON.
M0A;RCDH>ZXM2)^2'6S#=@68ZTWIP1<UU>D[(<(-5PVR-6[YIEF"Z9J!DMV2K
M9[1CN&FQ8LIJKF/F:JAD[VJB9N]IG6?P:)IH\6>8:?)FEFGS9)9I\V26:?-D
MEFGS9)9I\V26:?-D_UL9 O]?' +_;!@"_WD; O^#(0/_C"P&_Y$V"_64/Q+L
ME4<9Y)-/(MR.6"W2AV(ZRH%L1<-[=4Z^=G]6N'*(7;1ND6*O:YMFJVFF:JAG
MLVRE9\-NHF?@;IYI[6V9:NYLEFOO:I-L\&F2;/%GD&SR9I!L\F:0;/)FD&SR
M9I!L\F:0;/)F_UP9 ?]B&@+_<!8"_WP9 O^&'P+_D"D$^I8S"?":/ [GFT05
MWYI+'=.452S*C5\YPH=I1;N!<4^U?'M7KWB$7JITC6.E<9=HH6ZB;)ULKF^:
M;+YPF&S9<95MZV^1;NQNCV_M;(UO[VJ,;_!IBV_Q9XMO\6>+;_%GBV_Q9XMO
M\6>+;_%G_UT9 ?]D&0+_<A0!_W\8 ?^*'0'_E"8#]ILP!NN?. KBHC\0V)]'
M',V94BO$DETYNXQF1+2';DZM@G=7IWV 7J)YB62==I-IF'.>;91QJG&0<;IR
MCG'1<XQRZG&*<^MOB'/M;8=S[FN'<^]JAG+P:(9R\&B&<O!HAG+P:(9R\&B&
M<O!H_UX8 ?]G%P'_=1,!_X,6 ?^.&@'^F","\9\L!.>E,P?=J#D,T:-%&\>=
M4"J^EUHXM9)C1*V,;$ZFAW17H(-\7II_AF25?(]JD'F:;HMWIG*(=K9TA7;,
M=(1WZ7*#=^IP@G?L;H)V[6R"=N]J@7;P:8%V\&F!=O!I@7;P:8%V\&F!=O!I
M_UX8 ?]I%0'_>!(!_X84 ?^1& 'ZG!\![:0G N*J+ 36K#0+RZ=#&L&B3BFX
MG%@VKY=A0Z>1:4V@C7%6F8AY7I.%@F2-@8QJB'^7;X-]I')_?+-T?7S(=7Q]
MZ'-\?.IQ?'OL;WUZ[6U]>>YK?7GP:7UY\&E]>?!I?7GP:7UY\&E]>?!I_U\8
M ?]K$P'_>Q$!_XD3 /^5%0#UH!H!Z*D@ =VP) '0L#(*QJQ!&+RF3">SH58U
MJIQ?0:*79TR:DF]5DXYW78R+@&2&B(II@865;GR#H7)W@K!T=8+%=72#YW-U
M@>IQ=G_K;W=^[6UX?>YK>'SP:7A\\&EX?/!I>'SP:7A\\&EX?/!I_V 7 ?]N
M$@'_?A  _XP1 /^9$0#QI!, XZX6 -:V' '+M# (P; _%[>K2R6MIE0SI*%=
M0)R=94J4F&Q3C)5T6X:1?6)_CH=H>8R2;72*GG%PB*UT;8C!=&V)Y'-OA^IQ
M<(3L;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_
M@@X _Y . /6=#0#CJ0P V;4, ,^Y&@#%N"X'N[0]%;&P22.GJU(QGJ=;/I:C
M8TB.GVI1AIMR67^8>F!XE81F<I./;&V1G&]ID*IR9I"^<V61X7)HCNMP:HKL
M;FR([6QMAN]K;H3P:6Z$\&ENA/!I;H3P:6Z$\&ENA/!I_V,5 ?]U#@'_A@T
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M8%6A]F!5H?9@5:'V8%6A]F!5H?9@_W<( .N,  #3FP  QJ@" +NQ @"RNP(
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M? @0_XP(#_^<" [_K D._[L)#?_3"0W_TPD-_],)#?_3"0W_TPD-_],)D;P
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M8'EW^%YY=OE<>77Z6GEU^UIY=?M:>77[6GEU^UIY=?M:_UH5 ?]I#@#_> P
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M6F6&^UEEAOM998;[666&^UEEAOM9_V8- /]W P#CAP  TY,! ,J>! #"IP0
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M3$JK_TQ*J_],Z7\  -&0  #"G@  M:<  *JO  "@N   EL$" (S+!P"$U0T
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MJALL_K\<*__C'2K\^ATJ^O\=*O?_'"KW_QTJ]_\=*O?_'2KW_QTJ]_\=LZ,
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M!0G_J 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP
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M4(AG_TZ':/],AFC_2X5G_TF%9_])A6?_285G_TF%9_])_U(4 ?]?#@#_:PL
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M37%U_TQQ=?],<77_3'%U_TQQ=?],_UL. /]I! #V=P  W8(  -"+ P#)DP4
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M2EN*_TI;BO]*_V@  .5Y  #1AP  Q9(  +N<  "QH@  J:D  *&Q @";LQ4
ME;,H HZR-@F&L$(2?ZY,&WBL5"-RJEPJ;*AD,6>G;#9BI74[7:1_0%FCBD-5
MHI='4:&G24^ANDI.HME)3J#U24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22
M_T=4DO]'_VX  -Y_  #*C0  OI@  +.@  "JIP  H:X  )>V  "1NA  C+HC
M 86Y,@9^N#X.=[9)%W&U4AYKLUHE9;)B*V"Q:C!;L',U5Z]].5.NB3U/K99
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MN"\_R=<O/\?U,#W$_S,[P_\U/+[_-CVX_S<]N/\W/;C_-SVX_S<]N/\WT88
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M$2?V]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP
MA+P  ';&  !ISP  7=@  %'?  !)[@0 1OP. $+]%P ^_B$ ._XJ 3?_,P(T
M_SH",/]" RW_2@,K_U,$*/]<!27_9@4B_W,&(/^#!Q__E @=_Z8('/^\"!O_
MX@D:__D)&O__"1G__PD9__\)&?__"1G__PD9__\)HJ<  ).Q  "%NP  =L8
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M/*%5_SN=5O\ZFE?_.9=7_SB75_\WEU?_-Y=7_S>75_\W_TD4 /]3#@#_7 P
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M,YMH?S>89H@[E661/I%CFT&.8J=#C&&T18EAQT6(8N5%AF+Z0X9C_T*$8_]
M@V/_/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4
M? < T8 ) ,J"% #"@R@"NH$Y![-^1A"L>U$9IG=:(:%T8RB<<FLNF&]S,Y1M
M?#>1:X0[C6J./XIHF$*&9Z-$A&:Q1H%FPT=_9N%'?V?X17YH_T-^:/]!?6?_
M/WQG_SY\9_\]?&?_/7QG_SU\9_\]_U(. /]= P#]:0  X7(  -9Z @#.?P4
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M/VAV_S]H=O\__UL$ /=I  #==@  S8   ,.(  "[C@  M),! *V7"0"GF!H
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ML#U,G,<]3)OJ/$R9_SQ,F/\\397_/$^1_SM0C_\[4(__.U"/_SM0C_\[ZVT
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M(SJ^_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG
MH*(  )2J  "(L0  ?+@  '&^  !FQ0, 6\L( %?-$P!6SB, 4\XR 5#./@--
MST@%2<]2"$;/6PM#SV4.0,]O$#[/>Q,[SXD5.<^9%S?/JQ@VT,,8-L_H&#3-
M^QLRR_\=,<K_'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0  EJD
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M Q/Z_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP
M2=H  #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7
M_SP %/]$ 1+_3@$0_UD!#O]G 0S_=P$+_XH""O^? @G_M0((_]4"!__T @?_
M_P('__\"!___ @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0  .^(
M ##G   G[@  (_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -_RX
M"O\V  ?_/@ $_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$
M__,! /_S 0#_\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H  "/N
M   <_0  &/\  !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F
M  #_+@  _S<  /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@  _\,
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M(K] _R.]0/\CNT#_([9!_R.S0O\BLT+_(K-"_R*S0O\B_ST7 /]$$0#_2@X
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M,(U6_RZ,5_\MC%?_+8Q7_RV,5_\M_TD. /]1!0#_6@$ [F(  -]G P#8:@8
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M,G-F_S)S9O\R_U$$ /]<  #B9P  TG   ,=V  # >@  NGT" +1_# "M@1T
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MKCI;?,$[6WSC.EM\^CA<>_\W77O_-5YY_S1?=_\S7W?_,U]W_S-?=_\S_EP
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M,$F4]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0
ML8\  *:4  ";F0  D9T  (:B  !ZI@, =J<3 '.H) !NJ#(#:J@]!F6G1PMA
MIE /7:58%%FD8!A5HV@<4J-Q'TZB?"-+H8@F2*&6*$6@IBI$H;HK0Z':*D.?
M]2M"G?\K0IS_+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC   JI0
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M%2S!_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@
M:[D  &"_  !4PP  2L@" $#-!P ZT@X .=(; #C3*  WTS4 -M1  #352P$S
MU54!,=9@ B_6; ,MUWH$*]B+!2K8G04HV;$&)]K-!B?7[P8FU/\))=+_"R31
M_PPCT/\-(]#_#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP  8,(
M %3&  !(RP  /M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P FY4H
M).95 "/F80$AYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08
MX_\%&./_!1CC_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H  $?.
M   \TP  ,MH  "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1(
M !7U4@ 3]E\ $O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!
M#?/_ 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   O
MW@  )N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_
M0P )_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__
M  #__P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@
M&>H  !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P
M_ST  /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_
M^@  __H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@
M  [_   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL
M /\V  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP
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M".8D_PKD)?\+XR7_#.,D_PSB)/\,X23_#>$D_PWA)/\-_RX> /\S& #_-18
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M'*E!_QRF0?\;I4'_&Z5!_QNE0?\;_ST0 /]""0#_2 4 _TT( /]0"P#Y40\
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M)(%6_R2!5O\D_T<# /]/  #G6   V6   ,UD  #&9@$ P68$ +MF#@"T:2
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MK#!J9[XQ:6?<,&EG]2YI9_\L:6?_*FIG_REJ9O\H:F;_)VIF_R=J9O\G_U
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M+U=W\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0
MN7H  *^   "FA   G88  )&'  "*B0P AHH; (*+*P%]BC@$>(E""'2(3 UO
MAU02;(5;%FB$8QID@VL>88)T(5V!?21:@(DH5W^6*E5^I"Q2?K8M47[.+5%]
M[RQ2??\K4GS_*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  # =@  M'X
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M(3Z5_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F
M@YT  '>@  !II   8*<( %VH% !;J20 6:DQ 5:I/ )3J44$4*A.!DVH5PE*
MJ%\,1Z=H#D2G<Q%!IG\4/J:-%CRFG1<ZIJ\8.:;'&#FEZA@XH_\:-Z'_&S>@
M_QPWG_\<-Y__'#>?_QPWG_\<Q'@  +6%  "ICP  G94  )*:  "&GP  >J,
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M!AW)_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP
M.<<  "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7
MWV( %N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';
M_P(1V_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=
M "35   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E,
M"N]B  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #
M[?\ E:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@
M   2Y   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0
M  #\80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\
MB:D  'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *
M\0  "/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_
M30  _U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,
M &R\  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P
M /\   #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0
M_TH  /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9
M*0#_&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P",
M ?\ E '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /,
M_P#] /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_
M'"4 _QDG /\3+ #_#C0 _PM  ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"
MD0'_ I@!_P*? ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$ _P#\
M /P!_P#\ O\ _ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_("$
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M",HE_PC*)/\(RB3_",HD_PC*)/\(_RX4 /\Q$ #_,@T _S0. /\U% #_-1P
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M%9=!_Q670?\5_SL& /\_  #Y1@  Y4L  -Q.  #3300 T4H) ,I*% #"32<
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MK2)Y5+TC>%77(W=5\B)V5O\@=E;_'W96_QUV5O\<=E;_&W96_QMV5O\;_T4
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M)F1B["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@
MO6D  +-N  "K<   HG   )EN  "3<!  CW(? (IR+@&&<CL#@G%%!WUP3@MZ
M;E8.=FU>$G-L915P:VT8;6IU&VII?QYG:8HA96B6(V)GI"5@9[0F7V?))EYG
MZB5>9_XC7V?_(5]F_Q]@9O\>8&;_'F!F_QY@9O\>[T\  -I<  #&90  NFT
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M'TYV_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@
MCH(  ("#  !YA0( =(81 '&(( !NB"X!:H@Y F>'0P5CATP(8(93"UV%6PY:
MA&,15X1K%%2#=1=1@H :3H&-'$N!FQY)@:P?2(#!($> XQ]'?_H>2'[_'DA]
M_QU)?/\<27S_'$E\_QQ)?/\<UF$  ,)N  "T>   JH   )^%  "4AP  B(<
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M$S.9_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@
M3Z8  $>I" !$JA( 0ZH? $&K*P! JS< /ZQ! #VL2@$[K%,".:Q< S>L9P0U
MK',%,JR!!C"LD0<NK*,(+:RX"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE
M_PTJI?\-M8   *B+  "<D0  D98  (6<  !XH   :Z4  %^H  !3K   2*\
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M>  ,UHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@
M (Z?  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0
M$=8   S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P
MY7L  .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G
M  !TKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$
M  +E    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@
M /-^  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !F
MN   6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M    ]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I
M  #_@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP
M2\L  #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_
M_P   /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_
M:0  _X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG
M /\&+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )<
M_P"= /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\*
M* #_ #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P":
M /\ H #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\
M^ #_ /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_
M"BP _P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\
MG0#_ *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_
M .\ _P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@
M_PXT /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X
M!I\ ]@:F /0&K0#R!K4 \ 7  .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+
M_P'D"_\!Y O_ >0+_P'D"_\!_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O
M /\3/ #_$4D _Q!5 /P.80#Y#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M#IL
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M!;4E_P6U)?\%_RP- /\M!0#_+@$ _S$% /\Q"P#]+Q  \2L8 .<I)0#?*#,
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ML!*00< 2CD'9$HM!\1*)0O\2B$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@
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M&G%0Z!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5
MP5H  +==  "O7@  IUL  *%8 P";61( EELB ))<,0&.7#T"BEQ'!(=;4 :#
M6E@)@5E@#'Y99PY[6&\0>5=W$W96@!5T5HL7<E66&6]5HQIM5+(;;%3&&VI5
MYAMJ5?L9:E7_%VI5_Q9J5?\5:U7_%&M5_Q1K5?\4\D,  -]/  #+6   O5T
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M&5IA_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0
MDVL  (EI  "#:PD ?VT5 'QN)0!X;C(!=6X] G%N1@1N;4\':VQ6"6AL7@QE
M:V4/8VIM$6!I=A1=:8$66VB-&%AGFQI69ZH;56>]'%1GW!Q49_8:5&;_&%5F
M_Q=59?\65F7_%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<   CF\
M (-N  !]< 4 >'(2 '5S(0!R<R\!;W,Z FQS1 1I<DP&9G)4"&-Q6PM@<&,-
M77!K$%MO=!-8;G\556Z+%U-MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0
M:O\64&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=   B70  'QS
M  !V=0  <7<0 &]X'0!L>2L :7DW 69Y0 -C>4D%8'A1!UUW6 E;=V ,6'9H
M#E5U<1%2=7P34'2(%DUTEQ=+<Z8827.Y&4ASU1E)<O,827'_%TIQ_Q9*</\5
M2W#_%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O
M?   :GT- &=^&0!D?R8 8H R 5^ /0)<@$8#6G].!5=_50=4?ET)4GUE#$]]
M;PY,?'D12GR&$T=[E!5%>Z061'NW%D-[TA9#>O(60WG_%4-X_Q1$=_\41';_
M$T1V_Q-$=O\3S5\  +MK  "N=   I'P  )=^  "*?0  ?WX  ')_  !F@P
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MB ,HI9H#)Z6M!":EQ@,FI.L$):+_!26@_P8DG_\&))[_!R2>_P<DGO\'KWX
M *.(  "7C@  C9,  'Z5  !PF   8YL  %>?  !,H@  0J8  #BI   OK ,
M*JX. "FN&  HKR, )Z\M ":P-P EL$$ )+!+ ".Q5@ BL6, (;%Q !^Q@@ >
MLI0!'+*I 1NRP0$;L><!&Z_^ AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/
M  "1E   A)H  ':?  !HH@  6Z4  $^I  !$K0  .;   "^S   FM@  'KD%
M !B[#@ 7NQ8 %[P@ !:\*@ 5O34 %+U  !.^2P 2OE@ $KYG !&_>  0OXP
M$,"B  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'
MFP  >:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&
M!0 +R@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4
M  #,JP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP
M;JH  &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !
MU D  -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?
MFP  W[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,
M %.Z  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $
M .$)  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0
M\*(  /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$
M   WR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P
M  #N!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT
M /^F  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   J
MT@  '=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M    ^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/
M  #_I@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #(
M_P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_
M *4 _P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X
M_P#^ /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z
M /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$
M_P"G /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U
M /\ ]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\
M0P#_ %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C
M /4 J@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\
MZ@#_ .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_
M $L _P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L
MI@#I *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_
M -T _P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4
M^P-1 /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=
M!*L VP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+
M_P#+"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U*
M .D,5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD
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MM@*M)<8"JR7? J@F\P.E)O\#HR;_ Z(F_P2A)O\#H2;_ Z$F_P.A)O\#_RD
M /\H  #V+0  YS   -\O  #9*P0 UB(* ,XC%@#&)B< P"@V +LJ1 "X*T\
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M"X4\Z N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P
MRD<  +])  "W1P  L4(  *T^"@"F0!< HD(G )Y#-0":1$(!ET1, 91$50*1
M0UT#CT-D!8U#:P:+0G,'B4)["(="A J%08X+@T&9#(%!I0U_0;,.?D'&#GQ!
MY YZ0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #12   PTT
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M$&10_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@
MEU<  )%4  "+50P AE<9 (-8)P" 630 ?5D_ 7I92 -W6% $=%A8!G)77P=O
M5V8);59N"VM6=PUH58$/9E6-$614FA)B5*D38%2Z%%]4TQ1>5/(37E3_$5]4
M_P]?5/\.7U/_#5]3_PU?4_\-YT0  ,]0  "_6   LUT  *A?  "<70  DEL
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M#E!@_PU08/\-V4\  ,-:  "T8P  J6D  )MH  "/9P  A&<  'EE  !S9P
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MB@DZ?IH*.7ZL"S=^PPLW?>8+-WO\"S=Z_PLW>?\*.'C_"CAX_PHX>/\*OF0
M +!O  "E>   EGD  (=Y  ![>0  <'H  &1\  !8@   4(,  $N%"@!(AA0
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M 1^>N0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP
MA8H  '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >
MIQH ':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.K
MM  2J], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(
M &V5  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1
M#K47  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %
MML4 !K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@
M  !7I   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1
M  '!&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4
M ,3:  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/
ML0  0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-
M$0  SA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"
M  #6Z0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@
M-+T  "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P
MW1   -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #J
MS@  Z^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<
M !O+   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<
M .T-  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@
M_-(  /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8
M   (W0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!
M  #["   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8
M /_*  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_
M %8 _P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\
MK0#_ +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_
M /D _P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$
M_P!> /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[
M +  ^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /,
M_P#S /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9
M /\ 8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P
M[@"T .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E
M /\ _Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /<
M7@#T &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P
M -\ N@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\
M_Q40 /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H
M &$ Y0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X
MM@#, ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+
M /\5!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL
MU0)D -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_
M!L$ O0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8
M  #_%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU>
M ,4-9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<
MLA'5 *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z
M'@  ZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<7
M80"T&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/
M *$>Z@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P
MX"H  -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H
M)&0 IB1L *0D<P"C)'H H26" : EBP&>)90!G26> 9LFJ@&9)K<!F";) I4G
MY@*2)_D"D"C_ H\H_P*.)_\"CB?_ HXG_P*.)_\"_R8  /(I  #C,0  TC0
M ,@T  # ,   NRD" +@C#@"Q)AP K"@K *@J. "D*T0 H2Q. )\M5P"=+5\
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M!W(\_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@
MGT$  )L] 0"5/1  D3\= (U!*P"*0C@ AT-" (1#2P&"0U,!@$-; GY"8@-\
M0FD$>D)Q!7A">@9V080'=$&/"')!FPAP0:D);T&Y"FU!T IL0>X):T+_"&I"
M_P=J0?\&:D'_!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@  F$<
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M!UE._P=93O\'WT,  ,=-  "X5   K%D  )U7  "150  B%0  (%0  ![4@0
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MBPE'8IH*1F*J"T1BOPM$8N$+1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(
M +A<  "K9   FV0  (QC  " 8P  =F,  &IB  !C9   7V8& %MG$0!9:!T
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M!3)WN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0
MBW   'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [
M@"T .H V #F!/P X@4@ -H%0 #6!6@$S@60!,8%P 2^!?P(M@8\#+(&A RJ!
MM@,I@=(#*7_S RE]_P,I?/\#*7O_ RE[_P,I>_\#L6H  *5T  "5=@  A74
M 'AU  !M=0  87<  %=Z  !,?@  0X$  #N%   UB D ,HD1 #&)&P PB24
M+XHO "Z*.  MBT$ +(M* "J+5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+LP$A
MC,X!(8KQ 2"(_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z
M  !F?   6W\  %""  !&A@  /(H  #2-   LD0  )I,, "24$P CE!P (I4F
M "&5+P @E3@ 'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D
M%I7N !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?
MA   5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A
M)0 2H2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F
M  R@_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@
M3)(  $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %
MK20 !*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M
M]   K?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\
M #FC   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P
M +HE  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP
MN_X  +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q
M   EM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;
M  #()   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8
M ,W_  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9
MOP  $<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:
M&   W"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X
M  #E_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@
M!\X   #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@
M[!4  .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y
M\P  ^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T
M  #A    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L
M /T1  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@
M_]8 _P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\
M:0#_ '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y
M /\ Q0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\
M_P<8 /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_
M &T _P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4
MOP#T ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4
M /\&$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@
M^0!P /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G
M ,< Y0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)
M#0#_ 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K
M .H <@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,
MT@#3 -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_
M P( _P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L
M; #7 ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+
M ,  Y0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@
M_P@! /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#&
M &X Q !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +(
MX "Q ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T
M .H*  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@
MMP9O +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D
M#?0 H@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6
M  #2$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J
M *D1<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0
ME1;_ )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"
M'0  OA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;
M; ";'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_
M 8@@_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*
ML"(  *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0
M)FX CB9V (TF?P"+)H@!BB>3 8@GG@&&)ZL!A">[ 8,HT0& *.X!?BG_ 7TI
M_P%\*/\!?"C_ 7PH_P%\*/\!]20  .,N  #/-0  P3@  +0V  "K,0  I2P
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M V,[_P)C._\"Y34  ,T_  "]1@  KD<  )]%  "50P  CD   (D\  "$/ H
M@#T4 'T^(@!Z/RX >$ X '5!0@!S04H <D%1 7!!60%N06 ";$%G FI!< -H
M07D#9T&$!&5!D05C09\%84&N!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU
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MB@523I@&4$ZH!TY.NP=-3MD'34[U!DU._P5-3?\$34W_!$Y,_P-.3/\#SD0
M +Q.  "N5   G%,  (Y2  "#40  >E   ')-  !L3P  :% + &51%0!C4B$
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M!C]=M@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70
MD%P  ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,
M8S4 2F,^ $EC1@!'8TX 1F-6 41C7@%"8V@"0&-S SYC@0,\8Y $.F*A!#EB
MM 4X8\T%.&+O!#AA_P0X8/\#.%__ SE>_P,Y7O\#O%4  *U?  "<8   BU\
M 'U?  !R7P  :%\  %U@  !58@  3V0  $MF"@!)9Q( 1V@= $5H)P!$:3$
M0VDY $)J0@! :DH /VI2 #UJ6P$\:F4!.FIP CAJ?@(V:8T#-&F? S-IL@,Q
M:<L#,6CM S%G_P,Q9O\#,F7_ S)D_P,R9/\#MUL  *ED  "69   AF,  'AC
M  !M8P  9&0  %EE  !0:   26L  $-M! ! ;@X /F\8 #UO(@ \<"L .G T
M #EQ/0 X<44 -W%. #9Q5P T<6$!,G%M 3%Q>@$O<8H"+7&< BMQKP(J<<@"
M*G#K BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I
M9P  7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y
M-P O>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI
M 2)W_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;
M6FX  %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C
M@S@ (H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!
M_0 9@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8
M $EY   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC
M%HXY !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /
MB_\ $(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"
M   YA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP
M  J:.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\
M!)?_  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   Q
MD@  *)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F
M,@  IST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_
M  "D_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@
M'Z(  !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*
MM#(  +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T
M_P  M/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K
M  ^T   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<
M ,4R  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P
MQ_\ @Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
M    PP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E
M  #;,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\
M=Y\  &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,
MT    -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M
M)   \#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@
M %NO  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X
M .4   #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@
M_R(  /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\
M%@#_ !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U
M /\ ?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\
M^P#G /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_
M !$ _P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\
M> #] 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@
M .X \@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T
M_P - /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q
M 'D [P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X
MZP#< /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P )
M /\ #P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ',
MX !Z -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #(
M /8 Q@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\
M"P#T !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T
M ,H >@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /
MM0#_ +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H
M  T X  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H
M= "Y 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[
M *8 _P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  <
MSP 1 ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K
M '4 J0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'
M_P"8"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+
M +P % "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$
MG0MX )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+
M$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+
M#0"K#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S
M ) 4? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\
M?QG_ '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@
M%!, FQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>
M=P"#'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_
M '0A_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A
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M'P!X,BL =C,U '0S/@!R-$8 <#1. &\U50!M-5P ;#5D &HU; %H-74!9S6
M 64UC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!
MW#,  ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q
M."< ;SDR &TY.P!K.D, :CI+ &@[4@!G.UD 93MA 6,[:0%B.W(!8#M] 5X[
MB@)<.Y<"6SNG ED[N -8.](#5SOQ E8[_P)6._\"5CK_ 58Z_P%6.?\!U#<
M ,!!  "O1   G4,  )!"  "%0   ?CX  'D[  !T.@  <3H. &T\& !K/20
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M DQ"_P),0O\"RC\  +E(  "F2@  E4D  (=(  !]1P  =44  &Y"  !I0P
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M>P(\5XL".E>; CA7K0(W5\0"-U?G C=6_0(W5?\"-U3_ C=3_P(X4_\"ND\
M *E6  "550  A50  'A4  !M5   9%0  %A4  !25@  3E<  $I9"0!'6A$
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M "1KIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8
M=E\  &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I
M<1X *'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MS
MHP :<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60
M &9D  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q<
M''L? !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0
M?;4 #WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I
M  !7:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887
M !"''P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX
M!8;)  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0
M<@  1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22
M&  "DB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_
M  "1Y0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?
M/X   #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P
MGAH  )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">
MV@  G?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP
M "R1   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,
M *P9  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0
MKN\  *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@
M   :I   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2
M  "[&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,
M ,#Y  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1
MLP  "[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,
M#P  SA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL
M  #9^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0
M ,4   #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P
MX@T  .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P
M[   \/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(
M  #6    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(
M /4*  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0
M_^$ _P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\
M8 #_ &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N
M /P N0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\
M_P 1 /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_
M &, _@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X
MLP#M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P -
M /\ "@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X
M\0!F .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#<
M +D V@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\
M P#_    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@
M -X 9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +,
MQ0#" ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M    _P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@
M80#& &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[
M +$ S@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]
M\@   .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V
M &$ M !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *(
MQ@"A ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0
M -4   #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L
MI0!B *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3
M -P D@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-
M  "[!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%<
M )<!8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@
MA@GP (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L
M$@  J T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-
M7@"+#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T
M '@2_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'
MFQ<  )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@"
M%6  ?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;
M_P!M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"
M (T<  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP
M=!]C ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D
M(_\ 9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D
M  ""( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@
M &HG: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\
M7"G_ %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y
M* , =B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N
M90!A+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__
M %4N_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@
M;BX- &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:
M-&L 635U %<U@@!5-9 !5#6? 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T
M_P%/,_\!RS8  +@]  "C/   DCP  (4[  ![.@  =#<  &\U  !L,P  :#0*
M &4U$P!B-AX 8#<H %XW,0!=.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@
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M>P%%0XD!0T.9 4)#JP% 0\ !/T/A 3]#^0$_0O\!/T'_ 4!!_P% 0/\!OT$
M *I%  "610  AD4  'E$  !O1   9T(  & _  !;00  5T(  %1##0!11!4
M3T4? $Y%* !,1C$ 2T8Y $I'00!)1T@ 2$=0 $9'6 !%1V$ 0TAL $)(> %
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M 3)1I0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30
M>DT  &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z
M52< .54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7
MHP J5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E
M &I0  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R(
M,ELK #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C
M7;4 (EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94
M  !<5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E
M "AB+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+,
M&63. !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !9
M6   4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK
M*  =:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S*
M !%K[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57
M2UX  $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2
M=2D $74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ET
MYP *<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164
M #QH   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R(
M"'\J  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X
M??<  'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q
M   L=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC
M  "++   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,
M (C_  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E
M@   '80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8
M)   F"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_
M  "5_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0
M%)(   Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'
MIR0  *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F
M_P  I?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J
M  >D    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL
M +@D  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P
MN?\ ;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
M    MP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9
M  #-)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\
M9X\  %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##
MQ@   ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C
M%P  YB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX
M %"D  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V
M -L   #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0
M^18  /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\
M#P#_  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L
M /\ <P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,(
M]@#: /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_
M  H _P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D
M;0#W '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#-
M .4 Z0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $
M_P $ /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G
M &X Y@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\
MWP#. /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P
M /T "P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &<
MT !M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z
M .T N0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X
M!0#E  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G
M +L ;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0
MIP#X *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0
M  H R  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H
M9P"H &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q
M )8 _P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0
MN  . +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80":
M &< F !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@
M_0"( /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP )
M *8 $ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &(
MBP!I (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![
M _\ >P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L#
M# "7 !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D
M '\(; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\
M;PW_ &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P".
M"@X B0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40
M: !S$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_
M &43_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@
M?Q$2 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I
M&&T :!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;
M_P!<&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/
M '(:& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D
M7R%S %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4
M(O\ S2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB
M%0!G(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP
M %8H? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\
MR#   + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@
M*1P 7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N
M>@!.+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0
M *LU  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@
M6# B %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(
M-(4 1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X
M  "3.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4?
M %$U* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(,
M03F3 $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/
M.P  ?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ
M)0!*.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1
M #H]HP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@
M?#X  &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$
M/RH 0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"
MH0 T0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$
M &Q!  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"<
M/D0O #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N
M1K, +4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#
M  !?0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL
M #9)-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$
M)TO* "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;
M1@  5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/
M,  O3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#(
M "!0ZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@
M4$H  $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G
M53, )E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6
MZ0 :5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X
M $5/   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X
M'5PW !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 2
M6_X $UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3
M   X5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q
M !-E.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D
M#&+_  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T
M7   +%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN
M-  *;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_
M  )J_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P
M)F<  !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0
M>#<  'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T
M_P  =/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W
M !AT   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#
M (0[  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P
M@/\ =V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_
M   ,@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R
M  "2/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\
M<6L  &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $
MD0   )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B
M-0  HT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$
M %]R  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H
M *0   "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0
MM#D  +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]
M  !)@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0
M  "W    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P
M ,D]  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!
MD0  ,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
M    R0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N
M  #C0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@
M+*D  !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:
MVP   -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y
M,@  ^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P .
M /\ $P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0
M_P!Z /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P
M /X [P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\
M$ #_ !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T
M /$ >@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@
MW0#_ -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_
M !0 _0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\
M= #< 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_
M ,0 _P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !
MZP : .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#%
M ', PP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$
M_P"P /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4
M ,T 'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T
ML !S *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P">
M /\ GP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D
M&0"U ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L
M )T <P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\
MC@#_ (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E
M !T H@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X
M;0"- '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_
M (  _P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !<
ME0 A )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "
M '  ?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ',
M_P!S /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 :
M (8 ) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P
M<P%U '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G
M!_\ WQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%
M'@!Y!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR
M &<,?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\
MU!P  +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P
M#B( ;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2
M>P!<$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(
M + B  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X
M918G &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4
M&H4 4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG
M  "6)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC
M %L>*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8(
M2R*1 $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1
M*P  @BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D
M* !3)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/
M $,HH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P
M?2\  '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-
M*BP 2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TM
MG@ \+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(
M &TR  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH
M1C Q $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V
M,J\ -3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU
M  !@-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N
M #\U-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT
M+S?% "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=
M-P  5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY
M,P Y.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO#
M "D[Y@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@
M4SH  $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S
M/C< ,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1
MY0 D/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST
M $D]  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0
M+$0\ "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?
M1/L 'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9
M   ^00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY
M "1)00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H
M&4C_ !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [
M10  -4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U/
M/0 <4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_
M !--_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@
M,4P  "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 3
M5T( $E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4
M_P .4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$
M "94   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT
M"UY(  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %
M6_\ @4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:
M   ;70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="
M  !G3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\
M>E(  &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   4
M90  $&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q
M2   <58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@
M &57  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P
M"G(   1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0
M?4X  'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<
M  !77   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX
M  ""    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8
M (M6  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !1
M8@  1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
M    D@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,
M  "<7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);
M/7$  #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@
MH0   *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O
M5   KVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\
M "B%   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0
M +,   "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20
MQ%X  ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6
M   4G0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4
M  #&    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU
M .!H  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .
MKP  !;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
M    W0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8
M  #X<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H
M_P F /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\
M ($ ^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L
M_P#= /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A
M /\ + #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L
MZ@"" .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+
M /\ P0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8
M)P#T #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![
M -  @@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\
MM #_ *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#=
M "L VP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H
M>@"X (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_
M *$ _P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4
MOP O +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E
M 'L HP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0
M_P"2 /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I
M *@ ,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0
MD@!] )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"&
M /\ ^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )<
M+ "5 #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W
M ($ @0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\
M[0   -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"&
M "X A  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0
M? !R (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL
M ,(,  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@
M>  P '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G
M (0 90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81
M  "B$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K
M &P!,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$
M7 >/ %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9
M&   BA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,+
M+@!B##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/
M %$.GP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0
M@QX  '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:
M$3$ 6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4
MG !'%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(
M '$B  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T
M41@T $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@!
M&ZP /QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF
M  !C)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ
M $D?-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H
M."+  #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?
M*0  6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D
M- !!)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^
M #$GX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+
M52L  % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \
M*CD .RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LL
MW@ L+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X
M $PN  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8
M-2\^ #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F
M,/< )R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q
M  !$,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[
M "\T0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8
M(C3_ ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  !
M-   .C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY
M0  H.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_
M !TX_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P
M-3@  #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B
M/D8 (#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\
M_P 8//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP
M "X^   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$,
M&D1- !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 3
M0?\ B3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"
M   E1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI*
M !%*5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\
M@SX  '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A
M20  '$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M1
M40 *45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(
M &M#  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P
M%U$  !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83
M6%H  %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'
M  !92   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@
M  U; @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0
M &!C  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !5
M3   3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC
M   "9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=
M  !J;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24
M2D\  #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N
M;P,  ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V
M:   =GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4
M #E8   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?
M 'P#  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P
MA74  (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A
M   G9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L
M  "- 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP
M )6&  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?
M=   %7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
M    GP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ
M  "HF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A
M#HH   >0    E@   )H   "?    HP   *<   "J    JP   *T   "O
ML0   +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^
MBP  OJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP
M  "B    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP
M ,8   #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?
MVIH  -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
M    N0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H
M  #=    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D
M /6E  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_
M #D _P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /<
MB@#U )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_
M +\ _P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #,
M_P ^ /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B
M (L WP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0
M_P"P /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W
M .< 0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0
MQ0"- ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C
M /\ _P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P
M.@#( $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"%
M *T D "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\
M_P   /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P
M #L K0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H
MB "8 )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _
M .P   #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4
MFP \ )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "&
M (P A ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@
M  #"    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V
M (< /0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8
M=0"4 '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
M    H@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D
M-P!X #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ".
M &< G0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"
ME @  (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L
M #@ :@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P
MF0!; *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X
M 'T.  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #,
M8  Y %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1
M *< 4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03
M  !L$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U
M %8'.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8
M1PJZ $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E
M%P  7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.
M. !.#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[
M #T0W  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'
M61L  %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'
M$SL 11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45
MV  U%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\
M % >  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@
M/QD_ #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O
M'/, +QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB
M  !((   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\
M #<?1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?(
M*2'_ "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$
M)   0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D
M00 P)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_
M "4D_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P
M/28  #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K
M*4< *2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I
M_P A*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H
M #4J   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4
M)"Y/ ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;
M+?\ C"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N
M   M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-,
M !TS5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\
MARX  '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H
M-   )34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y
M50 5.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$
M ' R  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0
M(#H" !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0
M/E\ #SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV
M  !=-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\
M !=!!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L
M"41J  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9
M.@  3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-&
M P /20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE
M  !*=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@
M2CX  $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +
M3PD !U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1
M<@  48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$
M $!    Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<
M %<,  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;
M6H$  %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$
M   U10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)
M  !@#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L
M &.3  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O
M3   )T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J
M"@  :PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-
M  !OIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5
M(%@  !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!
M> D  'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^
MH   ?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,
M !%H   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(
M (D'  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP
MC[0  ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW
M   "?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L
M  "=!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL
M *'0  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")
MC@   ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
M    L@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?
M  "WZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0
M *8   "K    L    +,   "W    MP   +H   "\    OP   ,$   #$
MQP   ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2
MTP  TO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@
M  "]    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0
M -\   #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0
M\=@ _P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\
M2 #_ %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7
M .X H@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\
M_P   /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U
M $H \@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4
MF@#1 *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P
M /\   #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0
MV !+ -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z
M )\ MP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\
M  #[    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$
M +H 2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8
MH0"E )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
M    TP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *,
M1 "A $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"<
M (P K0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,
MO    +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0".
M $, C !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H
MI !Y +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J
M )X   "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T
M? !# 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J
M *\ :0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T
M  "&    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ]
M &P 0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@
M70"^ %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M    =    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &
M/0!? $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W
M %$ U@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@
M: <  &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5
M #\ 5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $<
MS !' .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X
M %L,  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L
M3 %! $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]
M!.H /07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1
M  !1#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^
M $,*10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D
M-0W] #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*
M$P  21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/
M0P [$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_
M "X1_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&
M0Q4  $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T
M%$@ ,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5
M_P I%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH
M #T8   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48
M+1I/ "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C
M&O\ C1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;
M   U' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]-
M "8?5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\
MB2   '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P
M( $ +B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D
M50 ?)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(
M '$D  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0
M*24' "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9
M*5\ &"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG
M  !?*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$
M "(K#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET
M$BYL !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;
M*P  4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP
M"0 :,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I
M  TS>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@
M32\  $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4
M-@P $C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X
M=@ %.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$
M $$Q   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D
M#3T.  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@
M/H8  #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT
M   W-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-
M  9$$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($
M $28  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U
M-@  ,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)
M#P  2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4
M  !*K   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0
M+#H  "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0
M41   %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3
MJ   4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T
M "!#   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X
M %L1  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP
M7,$  %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+
M   33@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.
M  !H$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L
M &?G  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .
M60  "%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U
M#0  =Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@
M  !T_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@
M &H   !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P
MB P  (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&
M]P  A?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L
M  !_    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4
M )T,  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@
MFO\ 1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
M    E@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#
M  "T"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P
M/V0  #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E
MJ@   *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
M    S@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$
M "EX   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@
M ,(   #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A
MY0   .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\
M  #_  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3
M /\ 6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H
MY@"\ ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M    _P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P
M4P#H %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R
M ,4 R0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]
M^@   /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #*
M %( R !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X
MO "L .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP
M -L   #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L
MK@!1 *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6
M ,P E0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P
M  "T    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !*
M )8 3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X
M@0#D (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
M    EP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (,
M2 "! $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0
M &\ ]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",
MA0   (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q
M $@ ;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &
MZP!A /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P
M '( !0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $(
M8@!( &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4
M /L 5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8
M 0!C  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!#
M %4 20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /,
M20#_ $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9
M  4 5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L
M10!* $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_
M $  _P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@
M3P(( $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!!
M $@ 0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8
M_P W /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH#
M $<'"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44
M.05. #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N
M!_\ D1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -
M!@! "@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q,
M # ,5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\
MBQ(  '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y
M#P@ . X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H0
M50 H$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0
M ',7  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0
M,A(+ #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B
M%%\ (!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:
M  !?'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<(
M "L6#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T
M&QIK !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<
M'P  4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;
M#  D'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI
M !0?>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0
M32(  $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >
M(0\ '2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C
M>  .(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0
M $$D   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T
M%R81 !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  *
M*(< "2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G
M   W)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0
M !$L%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,
M BV8   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U
M*0  +R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ
M$@ ,,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5
M   QK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P
M+2L  "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %
M-Q0  S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   W
MJ0  -L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT
M "<M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(
M #X7   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP
M/<,  #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P
M   >,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04
M  !%&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,
M $/H  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :
M.   %#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.
M%0  3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG
M  !+_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P
M$$(   Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0
M61<  %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4
M_0  5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL
M  5.    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(
M &<8  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_
M7_\ 24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M    70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42
M  !W&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\
M1D8  $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H
M:P   &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")
M$P  BAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL
M #I,   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?
M ($   "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0
MH10  * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5
M   F6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0
M  "7    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T
M +@6  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >
M:   $W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
M    K0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.
M  #1&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0
M#8$   &+    DP   )L   "B    J    *X   "T    N    +T   #
MP@   ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K
M$0  ZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $
M /\ "P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L
M^@!A /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#;
M /< U@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P
M P#^  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!:
M -\ 7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L
MNP#_ +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J
M  4 YP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\
M6 "] %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[
M )\ _P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(
MP0 * +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C
M %8 H0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T
M_P"& /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ %
M *( #0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\
MC !5 (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W
M /\ <@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L
M"@") !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !.
M '8 5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\
M90#_ &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V
M  P =0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8
M3@!E %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_
M %@ _P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D
M90 . &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7
M $\ 5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T
M_P!- /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  ,
M %< $ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H
M2@!2 $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!#
M /\ G@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T
M#0!, !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!-
M #\ 5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\
ME0,  ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#
M  \ 0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #<
M4@ V %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D
M '@,  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T
M.P 0 #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N
M %H +0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.
M  !C$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08.
M #0%$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD
M)@=E "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>
M$@  4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*
M$  M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE
M !X-=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0
M3A8  $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H
M#A$ )@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0
M=@ 5$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@
M $(9   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\
M(1(4 " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1
M%(< $!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;
M   W&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2
M !H7%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80
M#!F8  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U
M'0  +QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<
M%0 4'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4
M  4=J@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P
M+1\  "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0
M(1@ #B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   B
MJ   (<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$
M "8@   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4
M"B8<  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@
M)K\  "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B
M   A(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8
M  (K'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X
M "KD   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?
M)   &R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q
M'   ,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D
M   O^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P
M&"@  !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&
M."   #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U
M_   -?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T
M !$O   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L
M $ D  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_
M//\ 4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV
M   ).   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>
M  !**   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\
M2C,  #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #
M00   $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5
M(@  5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<
M #PW   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@
M $T   !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P
M8B<  &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[
M   T.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D
M  !<    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B
M '(M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N
M/P  )$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M    ;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D
M  "%-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2
M'4P  !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^
M@0   (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=
M*0  G#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D
M  U@   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0
M )<   ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@
MM3   +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M    >0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P
M  "O    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24
M - [  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$
MC0   )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
M    R    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO
M  #J20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X
M_P 4 /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T
M &@ \@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8
M_P"H /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ .
M /T %@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &
MT@!G ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P":
M /\ D@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L
M$0#: !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!?
M +, 9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\
MA0#_ (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T
M !0 M  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D
M7@"7 &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_
M ', _P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !
MF  6 )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"!
M %X @ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &<
M_P!E /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1
M '\ & "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8
M; !> &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!:
M /\ O0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L
M$P!K !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7
M %H 80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\
MK0   )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !;
M !4 6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T
M6P!+ &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP
M (D   !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$
M3@ 6 $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!
M &  /P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X
M  !N    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2
M $, %P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L
M-0!H #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F
M!0  60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D
M%  Y !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D
M "P <P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@
M4PL  $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q
M !4 ,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0
M;P C (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X
M $4.   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1(
M*0$7 "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  <
M 7\ &P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0
M   Y$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84
M "(&&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T
M%0>1 !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V
M$@  ,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+
M%P <#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2
M  X-IP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%
M+10  "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7
M#QH %@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0
MI0 ($+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8
M "85   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@
M$1,> !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #
M$[L  A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7
M   @%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;
M  T7(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D
M !?=   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >
M&   &Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<
M'P ''"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>
M   :]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@
M&1D  !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !
M(2,  "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >
M^   'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L
M !4;   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B
M "8H   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0
M(_\ 51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>
M   0(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE
M   L+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\
M42(  $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .
M)   "R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S
M*@  ,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4
M #\F   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@
M!RP   ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@
M.S$  #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ
M   R*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30
M   V    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P
M $0Y  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O
M+0  *2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M    00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T
M  !/0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P
M*2X  " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)
M3    $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=
M/   7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,
M !LV   3.0  #CT   A!    10   $D   !,    4    %,   !6    60
M %L   !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-
M;48  &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_
M   .1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L
M  !M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X
M 'Y4  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '
M40   %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M    @P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)
M  "48@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80
M &@   !N    =    'D   !_    A    (D   "-    D0   ),   "6
MF0   )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P
M5@  K',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L
M  ""    B0   (X   "4    F@   )\   "D    I@   *D   "M    L
M +,   "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P
MRF8  ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
M    G@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L
M  #/    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL
M .=Z  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_
M "( _P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X
M<@#L 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_
M )  _P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L
M]0 E /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#(
M '( Q0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (,
M_P"  /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ >
M ,L )P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D
MJ0!S *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T
M /\ X@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T
M( "H "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J
M (P =0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\
MSP   ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0".
M "$ BP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8
M; !T 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@
M +$   "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H
M=  A '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A
M '  7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\
M  "-    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ;
M &$ (0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@
M4 !W $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M    ;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %(
M&P!1 "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P
M $( @0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O
M8P   %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!%
M !P 1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #<
M>@ V (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6
M $\   !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !<
M.0 < #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L
M (@ + "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#
M  !  P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8
M "\ '0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D ((
M(P"9 ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z
M"   -0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "<
M&0 F !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3
M !L K  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P
M, L  "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ?
M !L '@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4
MI@ 4 ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T
M "<-   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@
M&00> !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ /
M +P #P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.
M   @#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D;
M !,)(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![<
M"@;;  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =
M$   &@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,
M'P /#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2
M  (,\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0
M&!$  !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,
M$"0 "A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .
M\P  #O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(
M !01 P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$
M!A,I  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0
M$?\ 6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2
M!  1$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G
M   7,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\
M510  $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0
M$P< #Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;
M+0  &S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418
M $,8   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00
M#18$  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@
M(34  "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;
M   T'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"
M  @< P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(
M "<_   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q
M'P  *!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A
M   !(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[
M   N2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0
M)B$  " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G
M*0   "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V
M10  -5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",
M !\A   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@
M #0    W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0
M/U(  #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C
M   8)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X
M  !     0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP
M $EA  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4
M*@  #BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M    30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:
M  !5=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@
M"C8   ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8
M6@   %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F
M:@  9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(
M  !'    3    %    !4    6    %L   !?    8@   &4   !H    :P
M &X   !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80
M>'\  ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M    6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((
M  "%    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,
M (V5  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H
M;@   ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
M    H0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(
M  "FJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P
M (D   "/    E0   )L   "@    HP   *8   "I    K0   +$   "U
MN0   +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"
MG0  P;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\
M  "E    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP
M -H   #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD
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M_____________________________________________P
M       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S
M-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML
M;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2F
MIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?
MX.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____________________________
M__________________________\                      0,$!08("0H+
M#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%
M1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^
M@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:X
MN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q
M\O3U]O?Y^OO\_O______________________________________________
M________  $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)3
M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
M@8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRM
MKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:
MV]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$
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MJ4(?_[!*+?^T5#W_M%Y._;-G8/&O<'+FJ7B#VY]^D]*7@Z'+CHFLQ(:.M<"
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MF:;"<*6;O76OD;A[MHBU@+R!LH; >["-PW:NEL5SKJ'&<JVMQ'*IL,!RJ;#
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MO)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L?^<&@/_H"0&_[ L"/G
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MFH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@_^C&0+_MAT!Z<P7 <_C'@/"\#,2M?I
M(JG_1#"=_TD]E?]02(O_6U""_657>OEM773V<V%O]'ED:_)^9VCQ@FEF\(9J
M9.^*;&+NCFU@[9)N7>R7<%SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<
MZYMQ7.N;<5SKFW%<ZYMQ7.N;<?^L%0'SPQ  T=H+ ,'O'P:T^S,3J/\\()O_
M0BR0_T@VA_]//W__6D9X_V5+<?]M3VS_<U)I_WE59OY^5V3]@EAB_(998?N*
M6E_ZCEM>^I)<7/F775OXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>
M6_B;7EOXFUY;^)M>6_B;7OJY#@#-RPD P.8- ;+\( BG_S,3FO\Y'8W_/R:"
M_T8N>O].-7/_6#IM_V,_:?]L0F7_<D1B_W=&8/]\1U__@4A=_X5)7/^(2EO_
MC$M:_Y!,6/^535?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^9
M35?_F4U7_YE-5_^93<W!!@"^T < L?8. J7_(0F9_RX2C/\T&8#_.R!V_T,G
M;?],+&;_5#!B_V S7O]I-5S_;S=:_W0X6?]Y.5C_?3I7_X [5O^$.U7_ASQ4
M_XL]4_^0/5+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_
MDSY2_Y,^4O^3/KW%!0"PUP4 H_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?8O])
M(UO_4297_UHH5?]B*E+_:2M1_V\L4/]S+4__=RY._WHN3O]]+TW_@"],_X0P
M2_^(,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+
M_XLP2_^+,/^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3
M>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6V&O"
MF-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SX
MC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6V&O"F-5I
MS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3___XO__24-#
M7U!23T9)3$4 !PF3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^N
MD=MMLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_
MG6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MM
MLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"
M_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:
M;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM
M3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6
MV&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F_^+' 3_B2@(_X4S#O^0.13_F$(<_YY+)_^?5C3_GF%"_YIM4/^5
M=UWWCX%H\8F+<NN#DGOG?9B"XWB=B.!THXS=<JB0VV^MD]INLY;8;+J8UFO"
MF]%IRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<
MRF;*G/^,' /_B2<(_X@R#O^3.!3_FT$<_Z)*)_^D5#3_HE]#_Y]J4?V:=%_U
ME'YL[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5G
MPZ; :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'
MH?^-' /_BB<(_XHQ#?^6-Q/_GD ;_Z5))_^G4S3_IUU#_Z1H4_R@<F+RFGQP
MZI2%?>.+BXC=A)*1V'Z8F--ZGI_0=:2DS7*JJ,MOL*O);;BNPFF\L+QKP*JW
M;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I?^-
M&P/_BR<(_XPP#?^8-Q/_H$ ;_Z=()O^K4C3_JUQ$_ZEF5/JE<&3PGWESYYB"
M@=^/B(W9B(^7TH&5H,Y[FZ?*=J&MQW.HL<5PK[7!;;>WN6NXM;-NO:ZP<,&H
ML'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J/^.&P/_
MBR8(_XXP#?^:-A+_HC\:_ZE()O^N433_KEM$_ZQD5?FJ;F7OI7=VY9U_A=R4
MA9+4C(R=SH22I\E]F*_$>)ZUPG6GN<%TL;NX<+.[L6^VN*QQN[&I<[^KJ7._
MJZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._J_^.&P/_C"8(
M_Y O#?^;-A+_I#\:_ZM')O^Q4#3_L5E$_+!C5?:N;&?MJG5XXZ%\B-F8@Y;1
MD(FCRH>/K<6"E[3"?Z"XOGRHN[MZL+VQ=+*]J7*TNZ9TN;.C=KZMHW:^K:-V
MOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K?^/&P/_C"8'_Y$N
M#/^=-A+_ICX:_ZU')?^S3S3_M%A$^K1A5O.R:FCLKW-ZX:9ZB]:=@)K-E(:G
MQHV-K[^'E+6Z@IRYM7^DO+)]K+ZK>;&_HW:RO:!XN+6>>;VOGGF]KYYYO:^>
M>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]K_^/&P/_C28'_Y,N#/^>
M-1'_J#X9_Z]&)?^V3C/^MU=$][=@5O"V:&GHLW![WJIWC="??)W'EX.GOY"*
MK[B+D;:RAIBZK8.@O:F!J;^E?K# G'FQOYI[M[>8?;NPF'V[L)A]N["8?;NP
MF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L/^0&@/_C28'_Y0M#/^@-1'_
MJ3X9_[%&)/^X33/\NU9$];M?5NV[9VGCM6Y]UJQSC\JC>IW!FX"GN)2'L+&/
MCK:KBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[
MLI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LO^0&@/_CB8'_Y4M#/^A-1'_JST8
M_[-&)/^Z33/ZOE5$\[]=5NJ_96K?N&M^T*]QC\6F>)R[GWZGLIB%KZN3B[:E
MCI.[GXN:OIN)HL&8B*S"D(*OPH^#M;F/A+JSCX2ZLX^$NK./A+JSCX2ZLX^$
MNK./A+JSCX2ZLX^$NK./A+JSCX2ZL_^0&@/_CB4'_Y8L"_^B-1#_K#T8_[5%
M(_^\3#+XP51#\,-<5N?#8VK:NVE^S+)PC\"J=IRVHGRGK9R"KZ67B;:>DY"[
MF8^8OI2-H,&1C*G"BXBNPHJ(M+J*B+FTBHBYM(J(N;2*B+FTBHBYM(J(N;2*
MB+FTBHBYM(J(N;2*B+FTBHBYM/^1&@/_CR4'_Y@L"_^D-!#_KCT8_[=%(_^_
M3#+VQ5-#[LA;5N/&86K4OVA^Q[9NCKNM=)RQIGJFIZ" KY^;AK68EXZ[DY65
MOHZ2G<&*DJ?"AHZNPH2-M+N%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FT
MA8RYM(6,N;2%C+FTA8RYM/^1&@/_CR4'_YDL"_^F- __L#P7_[E$(OS!2S'T
MR5)"Z\U95=_)8&K/PF9]PKELC;:Q<INKJWBFHJ5^KIF@A+62G8NZC)J3OH>8
MF\"$EZ7"@):OPG^2L[R D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&X
MM8"1N+6 D;BU@)&XM?^2&@/_D"4'_YLL"O^G- __LCP6_[M$(?G%2S#QSE%!
MY])85-K.7FG*QF5\O;UKC+"V<)JEL':EG*I\K9.F@K2,HXFYAJ"0O8&>F;]]
MGJ+!>YZOP7F9L[QZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7
MN+5ZE[BU>I>XM?^2&0/_D"4'_YTK"O^J,P[_M3P5_+]$(/3(2B[MTU _X]A6
M4]/276C%RF-[M\)IBZJ[;YB?MG2CE;%ZK(VM@+*%JH>W?Z>.NWJFE[YWIJ"_
M=*:MOW.AM+MTGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5T
MGKBU=)ZXM?^3&0/_D20'_Y\K"?^L,PW_N#L4^,-#'N_-2BSGVD\]W=Y54<W8
M6V>^SV)ZL,AGB:3";9>9O'*AC[AXJ8:U?K!_LH6U>;",N'2OE;MPKY^\;J^L
MO&VKM;ENI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT
M;J>YM/^4&0/_DB0'_Z(J"/^P,@S^O#H2\L="'.C322GAX4P[U.-34<;=6F6W
MU6!XJ<]FAYW):Y21Q7">A\%VIG^^?*QXO(2Q<KJ+M&VYD[9JN)RX9[>GN&>W
MM[9HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[
ML?^5& /_E2,&_Z4I!_^T,0KXP3H0Z\Y"&.#=1R75Y4L[R^=14+WC66.OWE]T
MHMAE@Y;3:H^*SF^9?\ASH77$>*=NP7VK:;Z$KF6]B[%AO).R7[R=LE^\K+%B
MO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K?^6
M& /_F2$%_ZHH!O^Y, CPR#@-X=A $]3C12;*ZTL[P>Q/3[/H5V"FY5]OFN)F
M?([<;(:$U7&/>M!UE7/->IMLRG^?9\>$HF/&BJ1?Q)&F7,29IUK#I*=:Q+"G
M6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PI_^8%P+_
MGB $_Z\F!?C +@;FT#,(U>$\%,GJ12B_\DH[M?%.3*GO5EN=[5]HDNIG<X?C
M;7Q^WG*"=MIXB'#7?8QKU(*09M*'DF/1C)5?SY*67,Z9F%G.HIE8S:N:6,VK
MFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFO^:%P+_I1X#
M_[<C ^W))@/6WBD&R>D[%[[S1"FS^$DZJ/=-2)_V5564]5]@B?%H:(#L;W!X
MZ'5U<N5Z>6WB?WUIX(2 9=^)@F+=CH1?W).&7=N9AUK:H8E8V:B)6-FHB5C9
MJ(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB?^<%@+_K1L"]L$=
M =O:$P')Z"D)O?,[&;+]0RBF_D<VG/U,0Y/]54V*_5]6@?EI77GU<&)S\G9G
M;O!\:FKN@6UG[(9O9.N+<6'JCW)?Z91T7>B9=5KGH'=8YJ9X6.:F>%CFIGA8
MYJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>/^B%0'_MQ4 V,\+ ,KG
M$P*\\RD+L?T[&:3_0":9_T4RC_]+/(?_5$1__U]+>/]I4''_<%1L_798:?M\
M6F;Z@5QC^(9>8?>+7U_VD&%>]I5B7/6:8UKTH&18\Z5E6/.E95CSI658\Z5E
M6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E9?^M$ #6PP@ R-,* +OT%0.O
M_RH-H_\W&)?_/2*+_T,L@?]*-'K_4CIS_UX_;O]H0VG_;T=F_W5)8_][2V'_
M@4Q?_X5.7?^*3US_CU!:_Y-16?^84E?_GE-6_Z-45O^C5%;_HU16_Z-45O^C
M5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5-FZ!0#%QP< N=D( *S_%P6B_RL-
ME?\S%HG_.1Y^_T E=?](*VW_4#!G_UHT8_]E-V#_;3E>_W,[7/]X/5K_?3Y8
M_X(_5_^&0%;_BT!5_X]!5/^40E/_FD-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_
MGT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0\:^!0"WS04 JN0( 9__&0:4_R@,A_\N
M$WO_-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ
M4/^ ,D__A#-._X@S3?^,-$S_DC1+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+
M_Y8U2_^6-4O_EC5+_Y8U2_^6-;?$ P"IU ( G/D+ I/_&P6%_R,*>?\I#V[_
M,11E_SD87?]!&U?_2AY3_U(@4/]9(DW_8"-+_V8D2O]K)4G_;R5(_W,F1_]W
M)D;_>R=%_WXG1?^"*$3_ARA#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI
M0_^+*4/_BRE#_XLI0_^+*?^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_
MDV$Y_Y!M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJ
MN7_G:,"!YF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:
MA]-@VH?38-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y
M_Y!M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G
M:,"!YF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@
MVH?38-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y_Y!M
M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G:,"!
MYF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?3
M8-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y_Y!M1?^+
M>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G:,"!YF?'
M@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'
MTV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y_Y!M1?^+>$__
MAH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G:,"!YF?'@^-E
MSX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:
MA_^#' /_@"<'_WTR#/^(-Q'_D#\8_Y5)(O^75"W_EE\Y_Y-K1?^.=U'_B();
M^H2,9/5_E&OQ>IMR[G:B=^MRIWOI;ZU_YVRR@N5JN(3D:;^'XFC'B>!FSXK6
M8]:,SV+8BL]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BO^$
M&P/_@2<'_X Q#/^+-A'_DSX8_YE'(O^<4BW_FETZ_YAI1_^3=%/^CGY?]XB)
M:?&"D7+M?9AYZ7B??^5TI(3C<*J(X&VPC-YKMX_=:K^1VVG(D]5FSY7+9-&3
MQF74CL9EU([&9=2.QF74CL9EU([&9=2.QF74CL9EU([&9=2.QF74CO^%&P/_
M@B8'_X(P#/^.-1#_ECT8_YQ&(?^@4"W_GUL[_YQF2/^8<5;[DWQB](V&;>Z'
MCG?H@)6 Y'J<A^!UHHS=<JB1VF^OE=AMMYG5:\"<TFG)GLEER9["9\V8OFG1
MD[YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1D_^&&P/_@R8'
M_X4O"_^0-!#_F3T7_Y]&(?^C3RW_HUH[_Z!D2?^=;UCZF'EE\9*#<>J+C'SD
M@Y*&WWV9CMIXH)76=*>:TW"NG]%MMJ//:\"EQV;"I\!HQJ*[:LN;MVS.EK=L
MSI:W;,Z6MVS.EK=LSI:W;,Z6MVS.EK=LSI:W;,Z6MVS.EO^&&P/_@R8'_X<N
M"_^3-!#_FSP7_Z%%(/^G32W_IE@[_Z1B2ORA;%GWG'9H[Y: =>>/B8'@AY",
MVH"6E=5ZGIW1=:6CS7"LJ,MMM:S':[ZMO6B_K+AKPZ:S;<B?L&_,F;!OS)FP
M;\R9L&_,F;!OS)FP;\R9L&_,F;!OS)FP;\R9L&_,F?^'&@/_A"4'_XDM"_^5
M,P__G3P6_Z1$(/^J3"W_JE<[_JA@2_BE:EKSH71J[9Q^>>23AH;<BXV2U8.4
MG,]\FZ7+=Z.JQW2KK<1SM:^_<+RPM6N\L+!NP:FL<,:BJ7+*G*ERRIRI<LJ<
MJ7+*G*ERRIRI<LJ<J7+*G*ERRIRI<LJ<J7+*G/^'&@/_A"4'_XLL"O^7,P__
MGSL6_Z9$'_^L2RS_KE4[^ZQ?2_6J:%SNIG%LYZ!Z?-^7@HK5CHB8S86/H<>
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MS,R96<S,F5G,S)E9S,R96<S,F5G,S)E9S,R96<S,F?^2%@+_G1P#_Z\@ O;
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MP;!H<;:I;WZLHG6)I)U\DIR8@IJ5E(J@CY&2I8J.FZB&C:6K@XRPK(&-OJR
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MPU%/_\-13__#4=JO @#&O 4 N<D% *W;" "C_Q<$FO\K"X[_,1*#_S@:>?]
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M[&[&8.QNQF#L;L9@[&[&8.QNQF#L;O]T' /_<"<&_W8K"/^!+PO_B3@0_XY
M&/^222'_DU0L_Y!@-_^,;$/_AW=-^X.#5_A_CF#V>I=G\W:@;O!RJ'/M;J]X
MZVNX?.AHPG_F9LV"WV+8A-%?W(7*8.!_Q6'C>K]CZ'2^8^EROF/I<KYCZ7*^
M8^EROF/I<KYCZ7*^8^EROF/I<O]T' /_<"8&_WDJ"/^%+@O_C3<0_Y(_%_^6
M2"#_EU(L_Y5>./Z1:43ZC'10]8=_6_*"B67N?9-NZG>;=>=RHWSD;JN!X6JS
MAMYGO8K:9<J-TF+4CLABV(K"8]R$O&7@?K=FY7BV9N9VMF;F=K9FYG:V9N9V
MMF;F=K9FYG:V9N9VMF;F=O]U&P/_<28&_WPH!_^(+0K_D#8/_Y8^%O^:1R#_
MG% K_YI;./F79D7TDG!2[XQ[7^J%A6KE?HUTX'B5?=MRG874;:2+T&JMCLUH
MMY#+:,.1R&?1DK]EU(^Y9]F)M&C=@K!IXGRN:N1YKFKD>:YJY'FN:N1YKFKD
M>:YJY'FN:N1YKFKD>?]V&P/_<B8%_W\G!_^*+ K_DS4._YD]%O^>1A__H4XK
M^Z!9./6<8T;OF&U4Z)!W8N*(?V_:@(=[TGJ/@\UUEXG)<9^-Q6ZHD<)LL9._
M:[R5O6O+E;9IT)2Q:]6-K&S;AJAMX'^G;>)\IVWB?*=MXGRG;>)\IVWB?*=M
MXGRG;>)\IVWB?/]V&P/_<R4%_X$F!_^-+ G_EC0._YT\%?^A1![^I4PJ]Z57
M./"B84?IG&I6X91R9=B,>W//A8-\R7^+A,-ZDXJ_=IN/NG.CD[=PK):T;[>7
ML6_$F*QMS9BI;].0I7#8B:%QWH*@<>!_H''@?Z!QX'^@<>!_H''@?Z!QX'^@
M<>!_H''@?_]W&P/_="4%_X,E!O^0*PG_F3,-_Z [%/^E0QW[J4LI\ZI4..RH
M7D?CH6=7VIEO9\^1>'/'BH!]P82(A;M_CXNU>I>0L7>?E*UTJ)>J<[*9IW*_
MFJ1RRYJA<]"3GG36C)MUW(2:==Z!FG7>@9IUWH&:==Z!FG7>@9IUWH&:==Z!
MFG7>@?]X&@/_=B0%_X8C!O^2*@C_FS(,_Z,Z$_^H0ASXK4HH\*]2-^>L7$?>
MI618T9UM9LB5=7/ CGQ]N8F$A;.#C(RM?Y.1J7N;E:5YI)FA=ZZ;GG:ZG)UW
MRIR9=\^6EWC4CI5XVX:4>-V#E'C=@Y1XW8.4>-V#E'C=@Y1XW8.4>-V#E'C=
M@_]X&@/_>",%_X@C!O^4*@C_GC$+_Z8Z$OZK0AOUL$DG[+50-N.P6D;8J6-7
MS*%K9L*:<G*ZDWI\LXV!A:R(B8RFA)"1H8"8EIU]H9J9>ZJ<EGNVG91[QIZ2
M>\V8D7S3D(]\V8B/?-R%CWS<A8]\W(6/?-R%CWS<A8]\W(6/?-R%CWS<A?]Y
M&@/_>B(%_XHB!?^6*0?_H#$+_Z@Y$?NO01KRM$@FZ;E/--^T6472K6%6QZ5I
M9;V><'*TEW=\K9%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^SGHV PIZ+@,R:
MBX'2DHJ V(F)@-N&B8#;AHF VX:)@-N&B8#;AHF VX:)@-N&B8#;AO]Y&@+_
M>R$$_XLB!?^8* ?_HS *_ZLX$/FR0!CON$<DYKU.,]NX5T3-L&!6PJEG9+BB
M;G&OFW5[IY9\A*"1@XN:C8N1E(J3EH^'FYJ+A:6=B(2PGX6$OY^%A<N;A871
MDX6%V(J$A-J'A(3:AX2$VH>$A-J'A(3:AX2$VH>$A-J'A(3:A_]Z&0+_?2 $
M_XTA!?^;* ;_I2\)_ZXW#O:V/Q?LO$8BX\%.,-6\5D/(M%Y5O:QF8[.F;'"J
MGW-[H9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ.=@8JNGWZ*O)]^BLJ<?XK0E'^)
MUHM_B-F(?XC9B'^(V8A_B-F(?XC9B'^(V8A_B-F(?XC9B/]Z&0+_?QX$_Y A
M!/^=)P7_J"X(_K(V#?.Z/A7IP44?W\5,+]"_5$+$MUU3N+!D8JZJ:F^DI'%Z
MG)]W@Y2;?HJ.F(:0AY6.E8*2EYE]D*"<>H^KGGB/N9]WD<J=>9#/E7F.UHQY
MC=B)>8W8B7F-V(EYC=B)>8W8B7F-V(EYC=B)>8W8B?][&0+_@1T$_Y(@!/^@
M)@7_JRT'^[4U"_"^/1+FQT0<VLE)+LO#4T&^O%M2L[5B8:BO:6Z?JF]XEJ5U
M@8ZA?(F'GH./@9N+E'N9E)AWEYZ;<Y:IG7&6MIYPE\B=<I;/E7.4U8QTD]B)
M=)/8B723V(ETD]B)=)/8B723V(ETD]B)=)/8B?]\& +_A!P#_Y4? _^C)03_
MKRP&][HS">S$.P_BSD(8T\Y(+,;'4D"YP%I1K;IA7Z.T9VR9L&UWD*MT@(BH
M>H>!I8&->J*)DG6@DI9PGIN9;)ZGFVJ>M)QIG\6;;)[0E&V:UHQMF=B);9G8
MB6V9V(EMF=B);9G8B6V9V(EMF=B);9G8B?]]& +_AQH#_Y@> _^F(P/_LRD$
M\\ Q!^?+. O=V#H6S=)&*L#,4#ZSQEA/I\!?79R[96J2MVMTB;-Q?8&O>(1Z
MK7^*=*J'CVZICY-IIYJ69J>EF&.GLIEBJ,.89:?1DV:CUHMGH=F)9Z'9B6>A
MV8EGH=F)9Z'9B6>AV8EGH=F)9Z'9B?]^%P+_BQ@"_YP< O^K(0+[N28#[<<L
M!-_5,0;3WCD4QMA$*+G13CNLS%9,H,==6I7"8V>+OVEQ@KMO>7JX=H!SMGV&
M;;2%BVBSCH]CLIB28+&DDUZRL91<LL*47K+3D%^LV8E@JMJ&8*K:AF"JVH9@
MJMJ&8*K:AF"JVH9@JMJ&8*K:AO]_%P+_D!8"_Z$: ?^Q'0'TP" !X]$@ =/?
M+ ;)XCL4OM]$);+93#BETU1)F<];5X[+86.$R&AL>\5N=7/#=7MLP7R!9\"$
MA6*_CHE>OIB+6KZDC5B^L8Y7O\*-6+_7BUFXW(59MMV#6;;=@UFVW8-9MMV#
M6;;=@UFVW8-9MMV#6;;=@_^!%@+_E10!_Z<6 ?VX%P#IRQ$ T]\6 <CG+ >^
MYCL6L^1$):CA2S6<W5)$D=E94H;58%U\TV9F=-%M;FS/='1FSGQY8<V%?5S,
MCH!9S)F#5LREA%3,LX53S<2%4\W=@U/&X'Y4P^%]5,/A?53#X7U4P^%]5,/A
M?53#X7U4P^%]5,/A??^'$P'_G!(!_ZX1 -K""@#0T@H Q^@8 ;SL+ JRZSP7
MJ.I#)9WH2#.2YE! B.192W[B8%1VX6A<;^!O8FC?=VACWG]L7MZ(<%K>D7-7
MWIMU5-ZG=U+?M'A0W\1X3^#>>$_6Y75/T^=T3]/G=$_3YW1/T^=T3]/G=$_3
MYW1/T^=T3]/G=/^/#P'_I X V[@( ,W%"0#%U0H NO$: [#R+0RF\3L8F_!!
M))'O1R^'[DXZ?NY80W?M84IP[6E0:NQQ567L>5EA[(%<7>R*7UKLDV%7[9UC
M5>VG95+MLV91[L!G3^_4:$[KYFA-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&A-
MZ.AH3>CH:/^9"P#=K@0 S+P& ,')!P"XVPH K?@<!*3X+PV9^#D7C_@_(87X
M1BI\^$TR=?=7.6[W8#]I]VE#9/AQ1V'X>4I=^(%,6OB)3UCXDE%6^9M24_FE
M5%'ZKU50^KM63OK*5TW[XU=,^^E73/OI5TS[Z5=,^^E73/OI5TS[Z5=,^^E7
M3/OI5^6E  #.M 0 O[\% +3.!@"JZPT!H/\?!I?_+PV,_S85@O\]'7C_1"1P
M_TPJ:O]4+V7_7C-A_V<W7?]O.5K_=CQ8_WX^5O^&/U/_CD%1_Y="4/^@0T[_
MJ45-_[-%2_^^1DK_T$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<
M1]&N  "_N0, LL4# *?5!0"<_0\"E/\B!HG_*PQ^_S(2=?\Z&&S_0AUE_TDB
M7_]1)5K_6BA7_V,K5/]K+5+_<B]0_WDP3_^ ,4W_B#)+_Y T2O^8-4C_H35'
M_ZHV1O^S-T3_OSA$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.,&S
M  "RO@( I<P! )G= P"0_Q("AO\?!7O_)PIQ_RX.:/\V$V'_/A=:_T8:5?]-
M'5'_51]._UT@2_]D(DG_:R-'_W$D1O]X)43_?R9#_X8G0?^.*$#_EB@__YXI
M/?^G*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"E
MQ@  E]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_
M3Q=%_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7
M'C+_H!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@
MB=X  '__!P%T_Q ":?\5 U__' 57_R0(4/\L"DK_,PQ%_SL.0?]!#SW_1Q Z
M_TT1./]2$3;_5Q(T_UP3,O]A$S'_9A0O_VL4+O]Q%2W_=Q4L_WT5*O^#%BG_
MBQ8I_XX6*?^.%BG_CA8I_XX6*?^.%BG_CA8I_XX6*?^.%O]F( /_82H%_V$S
M"/]I-@O_;CT/_W%&%?]S41S_<UXC_W!M*?]N?##_:XDU_VF6.?]GH3W_9JI
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M2AS_@E4E_W]C+O][<#;_>'P^_W6)1?]QE$O_;YY0_VRF5/]JKEC]:+=;_&;
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M!>J]-0G@QCP0TL1$(\6]3S6ZMUA&K[%?5*6K9F"<IFUJE*)S<XR>>GJ&FX&
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M/47_S#U$_^8^1/_G/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/LNL  "YM@$
MK,(! *#0 @"5Y0< CO\8 X3_) 9Z_RP+</\T$&C_/!5A_T096_]+'5;_4R!3
M_ULB4/]C)$W_:R9+_W,G2?]Z*4C_@BI&_XHK1/^4+$+_GBU!_Z<N0/^Q+C__
MO"\^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,+NQ  "LO   G\D
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MD(6.>(R"EGR(@*" A'^K@H%_N(-_?\J$@8'A?8&!YG:!@.MO@(#O:H" [VJ
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M8$O4[5Y,T?=<3,SY6DS,^5I,S/E:3,SY6DS,^5I,S/E:3,SY6O^/ P#:H@
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M*#C_W"@X_]PH./_<*#C_W"@X_]PH./_<*+6O  "GN@  FL8  (W4  "!Y@$
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M(@/_62<$_V,F!/]K* ;_<3 (_W0Y#?]U0Q/_=4T9_W59(?]Q9RG_;70P_6J
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M;%BHZ6A:I_1C6Z/X7ERC^5U<H_E=7*/Y75RC^5U<H_E=7*/Y7?]X#0#_BPD
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M1$7>_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0(
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M:&F+Z6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL
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M4%2L_TU4K/]-5*S_352L_TU4K/]-5*S_3?]]  #?CP  SIT  ,.H @"YL (
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M0]C_.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P"
MZ1$ >>D@ G+I+ 5KZ38*9.D_#U[I2!19Z5$95>A:'%'I8B!.Z6LC2^ET)4CI
M?2=&Z8@J0^F3*T'JH"U ZJ\N/NO +CWLVRX]ZN\N/>C\+CWG_RT]Y_\M/>?_
M+3WG_RT]Y_\M/>?_+<6?  "UJ0  J+$  )R\  "0QP  A-(! 'K?!@!T]!,
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M_SNF9?\[IF7_._]5&0'_810!_VP2 ?]V%P'_?1P!_X,C O2&+ 3JB#4'X8=
M#M:"3!G-?5@DQG=B+<!S:S6[;W0\MVQ\0;-IA$:O9XQ)K&643*ECG$^F8J51
MI&&O4Z)@O%6@8,U5GF#F5)YD]TV?9_]'GVG_0YYI_S^=:?\]G6G_/9UI_SV=
M:?\]G6G_/?]7%P'_8Q(!_V\1 ?]Y% '_@1D!^X<@ >^,)P+DCC %VHT]#,^'
M2AC'@E4COWU?+;EX:#6S=' \KW%X0JMN@$:G;(A*I&F03J!HF%&=9J%3FV6K
M59ADN%>69,A8E&3A6)5H]%"6:_]*EVS_199M_T&6;?] EFW_0)9M_T"6;?]
MEFW_0/]9%0'_9A !_W(0 /]]$@#_A18 ]HP; >J1(@'?E"L#TY$Z"\F,1Q?
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M7'AWZEA[>OI1?7S_2WU\_T9]?/]%?7S_17U\_T5]?/]%?7S_1?]A$ '_;PL
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M36:0_TAFC_]'9H__1V:/_T=FC_]'9H__1_]L" #^?   WHH  -"6 @#(GP0
MP*<$ +FN P"RLA0 JK$H Z&O-PR9K$,7D:A-(8FE52J"HUPR?*!C.7>>:CYR
MG'%$;9IY2&B9@4QDEXM08):54UV6HE5:E;!7697!5UB5WE9;EO-079?_3%^7
M_T=@EO]&8);_1F"6_T9@EO]&8);_1O]P P#K@0  UH\  ,J: 0#!HP, N:H"
M +&R 0"JMQ$ H[<D INU- J3LD 4BJ]*'H.M4R=\JUHN=JAA-7"G:#MKI6]
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M/4NT_SU+M/\]2[3_/>*#  #-D@  P9\  +2G  "JKP  H+@  );  P",R@<
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M!1#_D 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0
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M3HEG[$J*:?M#BVO_/HQM_SJ,;O\WC&[_-XQN_S>,;O\WC&[_-_]9$ #_90L
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M<?A&?G/_07]T_SV =?\Z@'7_.H!U_SJ =?\Z@'7_.O]=#@#_:@8 _W8& .2
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M0W1\_SYU??\[=7W_.W5]_SMU??\[=7W_._]A"@#_;P( Z'P  -F& 0#/C@0
MR)4& ,.:!@"[G!8 LYPJ ZJ9.0NBE444FY%.'92.5R:.BU\MB8AF,X2&;3B
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M.UV3_SM=D_\[79/_._]N  #@?@  SHL  ,25  "ZG0  L:,  *FI  "AK@L
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M$2WPP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0
MD[,  (:]  !YQ@  ;,\  &#8  !5W@  3O,* $KW$P!&^!T 0_@G 3_X, ([
M^3@"./E  S7Z1P0S^D\%,/M7!2[[7P8K_&D'*?QT""?\@@DE_9 ))/V@"B/^
ML HB_L0+(?_@"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0  A[L
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M.Y]6\#>?6/XRGUK_+IY;_RN>7/\HGES_*)Y<_RB>7/\HGES_*/]0$0#_60P
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M-X!K_S.!;/\O@6S_+X%L_R^!;/\O@6S_+_]9"P#_8P$ ]&\  -]X  #4?P0
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M,FM\_S)K?/\R:WS_,O]A  #J;P  V7H  ,R$  ##BP  NY$! +25 0"LEPX
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M)CVZR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0
MK)T  *&D  "6JP  BK(  '^Y  !SOP$ :,8% &#*#@!>RAT 6\HL 5?*. -4
MRD,%4,I,"$W)50M*R5T.1\EF$43);Q1!R7D6/\B%&#S(DQHZR*(;.<FS'#C)
MR1PXR.@<-\?Y'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1  "PFP  I*,
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M!1KY\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP
M6M,  $W:  !"WP  ..4  #7[!P Q_P\ +O\6 "O_'P I_R8 )?\M "/_-  @
M_SL!'O]# 1O_2P$9_U,!%O]= A3_:@(2_W@"$?^( A#_F@(0_ZL##O^^ P[_
MU0,._^T##O_P P[_\ ,.__ ##O_P Y.N  "$N   =L(  &?,  !:U0  3-P
M #_A   UY@  +?0  "K_ @ F_PL (_\1 "#_%P =_QT &?\C !;_*0 4_R\
M$O\U !#_/0 ._T4!#/]. 0K_6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_M0$
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M(;Y$]Q^\1?\=ND;_&[E'_QFX1_\8N$?_%[A'_Q>X1_\7N$?_%_]$% #_2Q
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M*9%:_R616_\CD5O_(9%;_R&16_\AD5O_(?]/"P#_5P( _V$" .IH 0#>;00
MV' ( -5P"P#+<AL PG$N KIO/0:T;$D-KFE4$ZEG71FD9&4=H6)M(9UA="6:
M7WPHF%Z#*Y5=BRV26Y0PD%N>,HU:J#2+6;4UBEG&-HA9X3:(7/0PB%W_*XE>
M_RB)7_\EB5__(XE?_R.)7_\CB5__(_]1"0#_6@  ]60  .!L  #7<0, T'0&
M ,UU"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@H
MD&* *XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"
M8_\F@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y
M!P"^>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]
M*X=EA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H
M?&?_)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y
M?A( L7XE :I]-02C>D$*G7=,$9=T51>2<ET<CG!D((IN:R2';'(HA&MZ*X%J
M@BY^:8LQ>V>5-'AGH#9V9JPX=&:\.7-FT3IS9^TV=&G],'5J_RQV:_\I=VO_
M)W=K_R=W:_\G=VO_)_]7  #V8P  WVT  -%U  #(>P  P7\" +N  P"T@1
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M,4N2PC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0
MO(D  +*2  "GEP  G9L  ).?  "&I   ?J8, 'JF&P!UIBH!<*8W!&RE00EG
MHTH-8Z)2$E^A619;H6$96*!H'52?<"!1GGHC3IV$)DN=D2E(G)XJ1IRN+$6<
MP2Q%G-\K19OT*4::_R='FO\E1YK_)$>:_R1'FO\D1YK_)-1W  #"A   MH\
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M$S+ _Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@
M>[0  &Z[  !CP   6,4! $W*!0!$SPP 0] 7 $+0)0! T#( /]$] 3W11P$[
MT5 ".=)9 S;28P0TTFX%,M)Z!S#2B @NTI@)+=.I"2S3O@HLT]\)*]'S"BK/
M_@LISO\,*<W_#2G-_PTIS?\-*<W_#:Z8  "BGP  EJ8  (FN  !\M@  ;[T
M &/#  !7R   3,T  $+2 P YV0D -=\0 #3?&P RX"< ,>$R ##A/0 NXD<
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M 0;_]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@
M)N8  !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &
M_SL  _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_
MU@  _]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT
M !7]   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL
M /\S  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0
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M".0L^@CB+/\)X"S_"=XL_PC>+/\(W2S_"-TL_PC=+/\(W2S_"/\U&@#_.A8
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M&*A&_Q:H1O\5IT?_$Z='_Q.G1_\3IT?_$_]$#@#_2@@ _U & /]5"@#_6 T
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M'(1:_QR$6O\<A%K_'/]. 0#_5P  Y5\  -AF  #.:@  QVP# ,-K!0"\;!(
MM&TE *UL-0.G:D('H6=-#)QE5A&88UX5E&)E&)%@;!N.7W0>C%Y[(8E=@R2&
M7(PFA%N5*(%:H"I_6JPL?5J[+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>
M_QU]7O\=?5[_'?]0  #U60  X6,  -)J  #);@  PG ! +UP P"V<!  KG$B
M *AP,@*A;C\&G&Q*"Y=J4Q"2:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF
M?5^2*7M>G2MX7JDM=EZX+G5>S"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW
M8O\>=V+_'O]2  #L7   W&8  ,YM  #$<@  O70  +=T 0"P= X J74? *)T
M+P*<<CT%EW!'"I%N40^-;%D4B6I@%X5I9QN":&X>?V9U(7UE?21Z9(8G=V.0
M*75CFRQR8J<N<&*V+V]BR2]N8N8N;V3Y*'!E_R1Q9O\A<6;_'W%F_Q]Q9O\?
M<6;_'_]4  #H7P  UVD  ,IP  # =0  N7@  +)X  "K> T I'D= )YX+0&7
M=SH%DG5%"HQR3@Z(<%83A&]>%X!M9!I];&L=>FMS('=J>R-T:8,F<FB-*6]G
MF2QL9J4N:F:S+VEFQC!H9N0O:FCW*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_
M(/]7  #D8@  TFP  ,9S  "]>   M7L  *U\  "E? H GWT: )E\*@&3>S@$
MC7E#"8AW3 Z#=502?W-;%GMR8AEX<&D==6]P(')N>"-O;8$F;&R+*6ILERQG
M:Z,N96NR+V1KQ#!B:^$O9&SV*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99
M  #@90  SF\  ,)V  "Y?   L7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!
M"(-\2@U^>E(1>GA9%79W8!ES=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M
M8'"P+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<
M:0  RG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!
M2 MY?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N
M+EEUP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;
MQ78  +I^  "QA   J(@  )^)  "4B@  C8H1 (B+(0"#BC "?HD[!7F'10IT
MADX.<(15$FR#7!9I@F,:9H%J'6* <B!??WLC7'Z%)EE]D2E7?)XK57RL+%-\
MOBU2?-HM4WSR*55\_R56?/\B5WS_(%=\_R!7?/\@5WS_(.5D  #/<   P7H
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M($*5_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP
MD9L  (6?  !YHP  :J<  &6G#@!CJ!P 8*@K 5VH-@)9IT $5J=)!E.F40E0
MIED,3:5@#DJE:1%'I'(41*1]%D*CB1@_HY<:/:.G&SRCN1P[H](;.Z+O&SN@
M_AH[G_\9/)__&#R?_Q@\G_\8/)__&,1\  "VB0  JI(  )^7  "5G   B:$
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M!R/'_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@
M1\8  #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  A
MW5L (-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:
M_P(7VO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X
M #'3   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X
M$NQ: !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,
MZ_\ #.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=
M   =X0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*
M  3\5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T
M /S] (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3
MZ@  $/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_
M10  _U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E
M '^T  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@
M"?\   ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-
M_T   /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@
M*0'_(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$
M O\)C@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!
M_PCQ ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_
M)20 _R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_#G8"_PZ  O\.
MB@+_#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-T0'_#>,!_PWO
M ?X-^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_ ?\F(P#_*"
M_R@@ /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"_Q-\ O\3A@+_
M$XX"_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']$M\!^1/M ?43
M^ 'S$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P _RP;
M /\K'0#_*20 _R@O ?\E.P'_(D@!_Q]4 O\=80+_&VT"_QIW O\:@0+_&HH"
M_QJ2 O\:F0+]&I\"_!JF OL:K +Y&K0"^!J] O8:R +S&ML"[QKJ NP;]P+I
M&_\"Z!O_ ^<<_P/F'/\#Y1S_ ^4;_P/E&_\#Y1O_ _\M&P#_,!< _S$5 /\P
M%@#_,2  _S J /\N-@'_*T,!_RA/ O\F7 +_)&<"_"-R _DC? /W(H4#]2*-
M _,BE0/R(IL#\"*B ^\BJ0/M(K$#["*Y ^HBQ0/H(M4#Y"/I ^ C]@3>(_\$
MVR3_!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_
M.1L _S@E /\V,0'_,ST!_3%* ?@N5@+T+6(#\"QM ^TK=P/J*X $Z"J(!.8J
MD 3E*I<$XRJ>!>$JI07@*JT%WBJV!=PJP@7:*M(&U2OG!M K]0?-+/\'RRS_
M!\DL_P?(+/\'QRS_!L<L_P;'+/\&QRS_!O\U$@#_.0X _SH- /\^$ #_0!8
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M$)=&_Q"71O\0ET;_$/]"!0#_1P  ]T\  .53  #=50$ UU4& -52"P#+4QD
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M)65BOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P
MRV@  +]O  "V<P  KG4  *9U  "=<P4 EG,4 )%T) "+<S("AG(^!(%P1PA]
M;T\+>6U7#G9L7A%S:V04<&IL%VUJ<QIK:7P<:&B&'V9GD2)C9YXD86:L)6!F
MO29?9]8F7V?Q(F!H_QYA:/\<8FC_&F)H_QEB:/\98FC_&>Q7  #98@  QVL
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M(5!W_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA
MG8<  )*'  "$AP  ?8<) 'B(%@!TB"8 <(@R FR'/01HAD8&985."6&%50Q>
MA%P/6X-C$EF":Q56@7074X!^&E" B1Q.?Y8>3'^E($I_MB%)?\PA27[K'TI^
M_!Q+?O\:2W[_&4Q^_QA,?O\83'[_&-5G  ##<P  MGP  *R$  "BB0  F(L
M (V-  !\C0  =8X$ &^/$@!MD"$ :9 N 66/.0)BCD($7HY+!UN-4@I8C%D,
M5HMA#U.+:!)0BG$438E[%TJ)AQE(B)4;1HBC'42(M!U#B,H=0X?J'$2&^QI$
MAO\818;_%T6%_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@  DI   (:3
M  !YE0  ;)<  &:7#@!CF!L 89@I %Z8-0%:ESX#5Y='!5663P=2EE8)3Y5>
M#$R49@Y*E&\01Y-Y$T23A15"DI,70)*B&#Z2LQD]DLD9/9'I&#V0^A<^C_\6
M/H__%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !S
MG   9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?
M8PE#GVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_
M$3>9_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI
M7Z<  %*J  !-JPX 2ZL: $JK)P!(JS, 1JL] 42K1@%"JTX"0*M6 SZK7P4[
MJV@&.:IS"#>J@ DTJH\+,JJ?##&JL PPJL<,,*GG#"^G^@TOIO\-+Z7_#2^E
M_PTOI?\-+Z7_#;:$  "JC@  GI0  )29  "'G@  >Z,  &^H  !CK   5Z\
M $NR  !!M08 /K81 #VV'@ [MBD .K<T #FW/@ WMT< -K=0 32W6@$RMV0"
M,+=O RZW? 0LMXL%*K><!2FWK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R_P@F
MLO\()K+_"*^-  "BE   EYH  (N@  !^I@  <:L  &6P  !9M   3;<  $*[
M   XO@$ +\() "W#$@ LPQX *\,I "K$,P IQ#T *,5' "?%40 FQ5P )<9H
M "/&=@$BQH8!(,:8 1_&JP$>Q\$!'L;D 1W$^ (<PO\#','_ QS!_P0<P?\$
M','_!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   O
MQP  )LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35
M:P 3UGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_
M 9R:  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT
M'-4  !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (
MYVT !N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A
M  "%J0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\
M  WC   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP
M /)M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !Y
ML@  :KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S
M   #_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:
M  #^;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP
M7<0  $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_
M_P   /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_
M6   _VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD
M /\5)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )(
M_P": /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_
M /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9
M(P#_$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6
M /\"G #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\
M]P+_ /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_
M&"0 _Q4O /\2/ #_$$D _PY6 ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2 ?\*
MF0'_"I\ _PJE /\*JP#_"K( _PJ[ /T*Q@#["M0 ]PKG /,*] #P"O\ [PO_
M .X,_P#M#/\![0S_ >T,_P'M#/\![0S_ ?\E&P#_)A@ _R47 /\A& #_("$
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M!;0L_P6T+/\%M"S_!?\T# #_-@4 _SD# /\\" #_/ T _3L3 /$X'0#H-2D
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M&W-1P!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P
MT%L  ,1@  "Z8P  LV,  *QA  "D7@D G5\7 )A?)P"37S4!CEY  XI=2@6&
M7%('@UM9"H!:8 Q]66<.>UAN$'A8=1)V5WX4=%:(%W)6DQAO5I\:;E6L&VQ5
MO1QK5M4=:U;P&FM7_Q=K6/\4;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@  S%X
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M'%MC_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@
MI'0  )IS  ".;P  AV\- ()O&P!]<"D >6\U 75N/P-R;4@%;FQ0!VML5PII
M:UX,9FIE#F1I;!%A:7437VA_%EQHBAA:9Y8:6&>D'%9GM!U59\H=56?H&U9G
M^QA79_\65VC_%%AG_Q-89_\36&?_$^%8  #+8P  O6L  +)R  "I=@  H'@
M )9W  "(<P  @7,+ 'QT%P!X="8 ='0R 7!S/0)M<T8$:G).!V=Q50ED<%P+
M87!C#E]O:A!<;G,26FY\%5=MB!=5;)094VRC&U%LLQQ0;,@<3VSG&U%L^AA1
M;/\54FS_%%)L_Q-2;/\34FS_$]Q<  #'9P  N6\  *]V  "E>P  G'P  )%\
M  "">   >GD' '5Y% !R>B, ;GHO 6MY.@)H>4,#9'A+!6%W4@A?=UD*7'9@
M#%EU: ]7=' 15'1Z$U)SAA9/<Y,837*A&4QRL1I*<L8:2G+E&DMR^1=,<O\5
M3'+_$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z
M?@  <W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\
M9@U1?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_
M$D=X_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@
M:X8  &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+
MA&P,281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4"
M_Q! @/\00(#_$,9K  "W=@  K'\  **%  "7B0  C(L  (&-  !SC@  98\
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M"+&"  "EBP  FI$  )"6  "#F@  =I\  &JB  !>I@  4JD  $:K   \K0
M-:\, #.P%0 RL"$ ,; K "^P-0 NL3X +;%( "RQ40 KL5L *;%G 2>Q= $F
ML8,!)+&4 B.QI@(BLKL"(;+; B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+
M  "=D0  DY<  (><  !ZH@  ;:<  &"K  !5KP  2;$  #ZT   SMP  *KH#
M "2\#0 BO14 (;T@ "&]*@ @O3, '[X] !Z^1P =OE( '+]> !J_;  9OWP
M&+^. !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6
MF   BIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'
M!0 3RPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#
M  K.EP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@
M?Z4  '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,
MU@4 "-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>
MB   WYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX
M &6U  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0
M .,'  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@
M[HP  .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_
M  !+Q@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L
M  #M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<
M /V-  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \
MSP  +M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M    ^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W
M  #_C0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH
M_P S /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_
M *( _P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P
M_P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P
M /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X
M_P"D /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S
M /\ \P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\)
M.0#_!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A
M /H IP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\
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M .L.BP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H
MSQ+_ ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_
M)1, _R,< /\@* #['#4 ]1I" .\83P#J%UH YA9E .,6;@#@%G< WA9_ -P6
MAP#9%HX UA:5 -06G #2%Z, T!>K ,X8M0#,&,$ RQC2 ,<:Z '#&_@!P!O_
M ;X<_P&]'/\"O!S_ KP;_P*\&_\"O!O_ O\K# #_*P4 _RL# /\M"0#_+ X
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M!XP[_P>,._\'C#O_!_\X  #Q/@  XT4  -1)  #+2@  Q4<  ,%!! "Z/Q$
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M"^Y%  #<4   R5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7(0"+6"\
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M%%Q9LA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60
MOF$  +-F  "I:0  H&H  )=H  "+8@  @V(, 'YC& !Z8R8 =F,R '-C/ %O
M8D4";&%,!&IA5 5G8%H'96!A"&-?:0IA7W$,7UY[#EU>AA%:7I,26%V@%%==
ML!567L0655[C%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(70  NV0
M +!J  "F;0  G6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG.0%K9T("
M:&9* V5F4@5C95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?$U)BKA51
M8L(54&+A%5%B]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN
M  "C<0  FG,  (]Q  !_:P  >&L% ')K$@!N;!\ :VPL &AL-P%F;$ "8VM(
M V!K3P1>:E8&7&I=!UEI90E7:6T+56EW#5-H@@]0:(\13F>=$TUGK!1+:, 4
M2VC>%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@
M=@  EG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ
M30-9<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<
M$D9M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P
MD7P  (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3
M>%$$47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T
M\P] =/\.07/_#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P  C($
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M!BN-_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP
M59D  $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  N
MGUH +9]D 2N?<0$IGG\")YZ0 B:>H0(DGK4"(Y[. B.=[@,CF_X#(IK_!"*9
M_P0BF?\$(IG_!*R!  "@B   E8X  (N2  !_E@  <IH  &6=  !9H   3J,
M $*D   WI@  +J@% "FI#P HJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU,
M(:M> ""K:@ >JWD ':N+ !NKG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8
MIO\"&*;_ J6)  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0  1*P  #FN
M   OL   )K,  !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4
M !*Y8@ 1N7$ $+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT_P .M/\
M#K3_ )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   E
MN@  ';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&
M5P #QF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_
M )66  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q
M$\<   [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520
MUE@  -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=
M  !^I   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(
M  75    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD
M .A9  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !Q
MK0  8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
M    Y0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(
M  #X6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@
M5KX  $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M
M[P   /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_
M1P  _UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP>
M /\$(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L
M_P"2 /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #]
M /L ^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(
M' #_ "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P".
M /\ E #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@
M\P#_ /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_
M!1T _P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@
MD #W )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_
M .8 _P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D
M_PHD /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L
M )$ ZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@
M_P#6 /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$?
M /\.*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P
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M :@=_P&H'?\!J!W_ ?\H  #_)P  _BH  .\J  #G)P$ YR() .0=$ #9&QT
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M!?0W  #E0   TD<  ,5*  "\2P  M4D  *]#  "I/@L HC\7 )U )@"8030
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M#&A(L@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230
MPE,  +=8  "M60  I%@  )Q5  "33@  C$X. (=/&P""3RD ?U U 'M0/P%X
M3T<!=D]/ G-.50-Q3EP$;TUC!6U-:@9K37(':4U\"&=,APIE3),+8TR@#6),
MKPYA3<(.8$WA#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<
M +-;  "J70  H5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!
M<%-, FU24P)K4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;
M4< .6E'>#UI1]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?
M  "F80  G6$  )1>  "(5P  @%8* 'I7%0!V5R( <U@N '!7.0!M5T$!:E=)
M FA64 )F5E<#9%9>!&)5905@56T'7E5W"%Q5@@I:58X,656<#5=5JPY65;X/
M557;#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C
M90  FF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;
M3@)A6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8
M#E!9\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:
MEVD  (QG  !]8   =5\# &]?$ !K7QP :& H &9@,P!C8#P!86!$ 5]?3 )<
M7U,#6U]:!%E?80577FD&55YS"%->?@E178H+3UV9#$U=J U,7KH.2U[4#DM>
M\0Q,7O\+3%W_"DQ=_PE,7?\(3%W_",]4  "^7@  L64  *=J  "=;0  E&T
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M"#MM_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@
M8'@  %9W 0!0=PX 3G@8 $QX) !+>2X 27DW $AY0 !&>4@!1'E/ 4)Y5P)!
M>6 "/WAI SQX= 0Z>((%.'B1!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U
M_P8U=/\&-73_!KEH  "M<0  HGD  )A^  "-@   @H$  ':"  !I@0  6X$
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M J=_  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP
M*J$  "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5
MI7  %*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&
M  "5C   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP
M !FN   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6<
M"+%X  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/
MDP  @I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y
M   -O , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M
M  "_@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@
M>*   &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $
MQP   ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/
M<@  SX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@
M %ZO  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP
M -4   #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P
MXW<  .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y
M  !#O@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(
M  #D    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68
M /5\  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   V
MQP  )\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M    \0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H
M  #_@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0
M_P N /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_
M )H _P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H
M_P#Y /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J
M /\ -P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8
M_0"< /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P
M /\ [P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\
M,P#_ $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7
M /$ G0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\
MX0#_ .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_
M #H _P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4
MF #C )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_
M ,X _P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0
M] !! .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1
M )H SP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#
M_P"_ _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y
M . #1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8
MP0:= +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O
M#O\ KP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,
M/@#+#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!":
M +(0HP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\
MHA7_ /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]
M%D0 N1=. +475P"S&&  L!AG *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:
MG@"C&Z@ H1NT )\<Q0">'-\ FAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__
M ?\F  #T)P  YBT  -HO  #/+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T
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M WPSM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0
MRD,  +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'
M.4P A#E3 8(Y6@& .6$!?CEH GPY;P)Z.7<">3F  W<YBP1U.98$=#FC!7(Y
ML05Q.<0&;SKB!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@  Q$@
M +E+  "O2P  ITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^/T@
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M"%I(\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60
MFE@  )%4  "&3@  ?4L( '=+$@!S3!\ <$PK &U,-0!K3#X :$Q& &9,30%D
M3%,!8DQ: F%,8@)?3&H#7DQS!%Q+?@5:2XH&6$N8!U=,IPA63+D)54S1"51,
M[PA43?\&54S_!E5,_P553/\%54S_!=5(  #"40  M5<  *I;  "@7   EUP
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M!D98_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8
M:%X  &%="0!<71, 6ET> %==*0!67C, 5%X[ %)>0P!17DH!3UY2 4Y>60),
M7F$"2EYJ TA>=01&7H(%1%V0!D->H =!7K$'0%[(!T!>Z = 7?P&05W_!4%=
M_P5!7/\%05S_!<-6  "T7P  J&8  )YJ  "5;0  BFT  ']L  !O9P  9&0
M %MB!0!68A  5&(; %)C)0!08R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&9%\"
M161H D-D<P-!8W\$/V..!3UCG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB_P4\
M8?\$/&'_!+Y;  "P8P  I6H  )MO  "1<@  AG(  'MQ  !L;0  8&L  %5I
M  !/: T 36D7 $MI(0!):BL 2&HT $=J/0!%:T0 1&M, $)K5 %!:UP!/VIE
M CUJ< ([:GT#.6J,!#=JG 0V:JX%-6K$!35JY04U:?D$-6G_!#5H_P0U:/\$
M-6C_!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(
M< H 17 2 $-Q'0!"<2< 0'(P #]R.  ^<D  /7)( #MR4  Z<ED!.')C 39R
M;0(T<GH",W*) S%RF@,O<JP#+G+! RYRXP,N<?@#+G#_ RYO_P,N;_\#+F__
M [-F  "G;P  G78  )-Z  "(?   ?GT  ')]  !D?   5WL  $QZ  !">0,
M/'D. #IZ%P Y>B$ .'HJ #=[,P V>SL -'M$ #-[3  R>U4 ,'M? "][:@$M
M>W<!*WN' 2I[F (H>ZH")WN_ B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL
M  "C=@  F7P  (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A   ,X0)
M #"$$0 OA!H +80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG,
M(X:# "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">
M?0  DX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60
M#  CD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^
M !:2D  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P
MCH@  (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6
MG0P %9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>
MB@ +G9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X
M 'N2  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04
M"ZL-  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0
MJI4  *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:
M  !CG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*
M  "V#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L
M +>@  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8
MIP  2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #"
M"P  PQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4
M  #(J@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0
M/[4  #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P
MT D  -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?
MG   W[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X
M "3!   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0
M .(%  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP
M\Z(  /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,
M   .T   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /
M  #R    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y
M /^C  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_
M $< _P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\
MH0#_ *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_
M /8 _P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $(
M_P!/ /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X
M *, ]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P
M_P#L /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!*
M /\ 50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\
MZP"F .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#=
M /\ W0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4
M4 #R %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A
M -D J0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\
MR #_ /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D
M %0 X != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8
MI #$ *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_
M /\4  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T
MS@!7 ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U
M *@ LP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6
M  #_$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50
M +P&6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4
MI@JP *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W
M&0  ZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\0
M4@"L$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M
M )@3O "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P
MWR@  - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?
M&50 G!I< )H:8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T C1VI (L=
MMP"*'LH B!_G (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E+   TS$
M ,8S  "\,0  MBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B1P"3(T\
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M V@U\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P
MH$0  )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q
M.%< ;SA> &TX90%L.&T!:CAU 6@X@ )G.(P"93B9 V0YJ -B.;D#83K0 V Z
M[@-@.O\#7SK_ E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3   FTH
M ))%  ")/P  @3H) 'LZ% !W.R  =#PK '(\-0!O/3X ;3U& &L]30!I/5,
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M TY'_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@
M<$H  &E(#0!E2!8 8DDA %])*P!=230 6TD\ %E)0P!724H 5DE2 %5*60%4
M2F$!4DIJ 5%*=0)/2H$#3DJ/ TQ+GP1+2[ $2DO%!$E+Y@1)2_H$24O_ TI+
M_P-*2_\#2DO_ \A)  "X40  K%<  *%;  "87   CEP  (-9  !V4P  :TX
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M [Q4  "N7   HV,  )EG  "0:0  A6D  'EG  !K8@  8&   %5=  !.6PP
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M 2ILDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;
MF7,  (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P
M<QH +W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")U
MD  A=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D
M (I\  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10
M)'T< "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7
M?Y\ %G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"
M  ![A   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5
M !B)'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL
M#8JO  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !S
MBP  98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7
M%0 ,EQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H
M  "5O@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@
M794  %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$
MHQ<  *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "B
MM@  H=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX
M $:A   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$
M + 8  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK
ML,8  +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ
M   MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1
M  "^%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@
M ,+7  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   A
MM@  %KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-
M#P  SA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#
M  #9X0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P
M#<0   7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P
MX0P  .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #O
MQ@  []T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M
M  #4    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (
M /()  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0
M_\   /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\
M7 #_ &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K
M /\ M #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\
MZ0#_ /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_
M &$ _P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0
MK@#R +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_
M /\'#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P
M^ !E /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C
M +, X0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)
M"@#_ 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!?
M .< 9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T
MS "X ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_
M P  _P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0
M8 #1 &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R
M +D P "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@
M_P,  /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#
M &$ O@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H
MN@"H ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX
M .8-  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L
MKP!B *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0";
M \8 F07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89
M  #,%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I<
M * *8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4
MC0[B (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_
M(@  N1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),2
M7 "1$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?=
M '\8] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+
MKB<  *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%
M'%X A!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A
M\ !R(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0  I3$
M )XK  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D
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M 5DT_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P
M>34$ ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=
M-V, 7#=K %LW=@%9-X(!6#B/ 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y
M_P%3.?\!4SG_ <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0   <SL
M &PX#0!H.1< 93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V
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M <%'  "R3P  IE0  )Q7  "26   B%@  'Y5  !Q3P  9DH  %Q&!0!71@\
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M 3=3D@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@
MGF   )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _
M5B$ /58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8
MD $O6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4
M )%I  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T
M-UPF #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I
M7Z  *%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN
M  "#;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A
M "YD*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT
M(&:Q !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  "
M=0  =74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M
M)  D;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N
M !9OQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P
M<7L  &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :
M=R8 &7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YX
MPP .=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(
M %V"  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX
M#H,G  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $
M@=L !('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*
M  !)BP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@
M  &/*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\
M (SN  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  !
ME0  -)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<
M(@  G2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH
M  "9^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@
M*9\  !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@
MJB(  *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I
M]   J?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD
M !2K   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D
M +HA  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@
MO/<  +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW
M   #N0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6
M  #,(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T
M -/V '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##
MQ@   ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A
M$P  Y!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE
M &:F  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP
M -D   #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P
M]1(  /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\
M$@#_ !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K
M /\ <P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H
M^@#) /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_
M  T _P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X
M;0#\ '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#!
M .L U0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @
M_P & /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O
M &\ [0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H
MR@#7 .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P
M /\ ! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D
MW0!O -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#"
M -@ P #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\
M  #T  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I
M ,8 ;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L
MKP#G *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
M    WP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4
M:0"S &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#>
M )X \@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!
MS@ % ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D
M &@ H@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )
M[0"/ /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P
M +H""@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V,
ME0-I ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP""
M"_P @0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0
M  "H"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC
M (<-:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\
M=1+_ '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";
M$P, E@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L5
M90!Y%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_
M &H;_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P
MBA<, (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N
M'6< ;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B
M_P!A(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$(
M 'L@$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&,
M8R5K &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9
M*?\ 62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F
M#P!N)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH
M %HK<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\
M4B[_ ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G
M+14 9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q
M;@!2,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_
M ,8Z  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A(
M73(< %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,
M-G< 2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^
M  "R10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8
M %0W(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4
M13N# $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O
M20  HTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\[
M'P!-.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^!
M #\_D0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3
MH5$  )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'
M0"0 1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$
MCP Y1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4
M )18  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"(
M044I #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T
M29X ,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<
M  "(70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF
M #I*+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P
M+4ZO "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&
M8@  >V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10
M*P S4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M
M "93Q0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P
M>&8  &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L
M5B\ *U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9
MP@ ?6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P
M &IK  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH
M(UXR ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  6
M8.( %U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q
M  !8;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M
M !EG-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.
M$&?W !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3
M=@  1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q
M+P 0<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O
M  AO_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@
M0'T  #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &
M?#( !'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y
M^@  >?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<
M "V'   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P
M (DV  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^
MA/\  (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21
M   :D@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N
M  "6.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\
M )+_ (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2
MG0  #)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F
M+P  ICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_
M (:-  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0
M :L   "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)
MMS   +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3
M  !MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<
M  "Z    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20
M ,HR  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !A
MH0  4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
M    RP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D
M  #C-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@
M1K   #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8
MW    -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X
M)0  ^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P .
M /\ $ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8
M_P!\ /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V
M /  ] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\
M"@#_ !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W
M /< ?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@
MY #Z ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_
M  X _P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@
M=P#F 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S
M ,P _P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L
M]@ 3 /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0
M '8 S@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D
M_ "W /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP /
M .$ &0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '
MNP!V +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F
M /\ I0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P
M$P#' !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O
M *D =0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X
ME #_ )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X
M !< LP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H
M;P"8 '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_
M (8 _P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$
MI@ ; *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"*
M '  B !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%
M_P!X!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4
M )4 'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H
M>PAR 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M
M#O\ ;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+
M%P"$#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N
M &X0=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\
M8A3_ -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y
M$AP =A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07
M<@!B%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_
M ,TJ  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@
M;!HB &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9
M'WD 6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O
M  "X-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$=
M &$A)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78
M4"6# $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S
M.P  IS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG
M(@!7)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N
M $@KD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P
MI$,  )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0
M+"< 3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(P
MC0!!,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<
M )9)  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0
M23$K $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \
M-IP .S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-
M  "*3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H
M $$U+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL
M-3JM #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(
M4@  ?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY
M+0 [.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K
M "\_P@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@
M?%4  '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V
M/S$ -3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#
MP  I1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H
M &Y7  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\
M,$0V "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C
M2.  )$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<
M  !?6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS
M "A*.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT
M'DWV !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<
M7@  4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1
M-P A44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T
M !=2_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99
M36$  $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 9
M6#P &%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9
M_P 16/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@
M #YF   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183<
M$&%   ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *
M7_\ "U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO
M   M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\
M  =K1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\
M &C_ )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G
M=P  '78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U
M00  =4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_
M ))U  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0
M%H$  !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P
M@D<  ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\
M  "$@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T
M  F.   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\
M )!-  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  "
MB   <HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
M    G0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#
M  "@5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@
M9Y(  %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H
MJ@   *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q
M2   L5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H
M $V?   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP
M +<   "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/
MQDX  ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H
M   RK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8
M  #(    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT
M .!4  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   E
MM0  %[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
M    W    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&
M  #W7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !,
M_P ? /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_
M (0 _@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /
M_P#P /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ;
M /\ )P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X
M\ "$ .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#=
M /\ V0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P
M(@#Y "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^
M -T A #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\
MQ #_ +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G
M "@ Y  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8
M?0#$ (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_
M +  _P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "(
MS0 M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q
M 'T KP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X
M_P"> /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F
M +< ,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8
MG@!^ )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P",
M /\ C0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *<
M*@"D #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W
M (T @ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\
M?P#_ .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6
M "P DP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\
M>@!] (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_
M .,1  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4
MA0 O (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P
M G\ ;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:
M  #$(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H
M '8(, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H
M8PR' &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\
M*   KRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.
M*@!I#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*#
M %@2D@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@
MJ3(  )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?
M%2T 714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9
MC@!.&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<
M )HX  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD
M51LP %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&
M()P 12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^
M  "-/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L
M $PA,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID
M/B:K #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*
M0@  @#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F
M+P!$)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI
M #<LOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@
M?40  '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^
M*S, /2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(P
MO0 Q,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD
M '!%  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\
M-R\V #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L
M-=L +#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*
M  !B10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T
M #$T/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@
M)SGT "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?
M20  5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY
M.0 K.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S
M "(]_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P
M4TP  $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F
M/S\ )#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"
M_P =0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(
M $A.   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P
M'D5% !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 7
M1O\ %T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14
M   Y40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM"
M !9,3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\
M$4S_ )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U
M6   *U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!3
M2  /4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_
M )M=  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8
M)EX  !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '
M6U$ !EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D
M  ".:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<
M !AF   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P
M &1:  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")
M<0  @'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q
M   -<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4
M  !O9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>
M?7L  '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &
M?0   'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![
M7@  >V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((
M &N#  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@
M (H   ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@
MB6@  (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+
M  !3C0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@
M  "7    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X
M )ES  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(
ME@  .ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
M    I0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG
M  "K@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP
M+:(  ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S
MM    +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  #
M<@  P(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L
M !.M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q
M ,8   #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9
MVWX  -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
M    NP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D
M  #;    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T
M /2(  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_
M #0 _P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H
MBP#Y )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_
M -( _P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\
M_P [ /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I
M (P YP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0
M_P"] /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U
M .X 0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4
MT "- ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P
M /\ K0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H
M.0#3 $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"&
M +D C@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\
MH #_ /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_
M #T NP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *<
MAP"E )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_
M /T   #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8
MJ0 ^ *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4
M (H D0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,
M  #C    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W
M )< /P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (,
M@@"/ '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1
M#   PPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@
M.0"& $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "(
M '$ E0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%
MN!8  *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y
M #D =P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4
MD0!C )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"
M *4?  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3,
M:P$Z &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9
M!YP 5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH
M  "4)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT
M %X+.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH
M3@ZL $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/
M+0  ABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00
M-0!3$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I
M $04O@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-
M@3$  '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+
M%C< 218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;
MNP [&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<
M ',R  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S,
M0ALZ $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U
M(=8 -2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X
M  !G,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V
M #HA/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M(
M+R;R "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C
M.   6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E
M.@ S)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP
M "HK_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0
M5S@  $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N
M*C\ +2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O
M_P E+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T
M $LY  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST
M*"]& "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @
M,_\ (3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_
M   _.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1#
M "$U30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\
M&S?_ *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]
M00  ,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ
M2P :.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_
M *!+  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P
M,$,  "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  4
M0%, $T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0
M  "35@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L
M "-(   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E
M#D=>  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "0
M6P  AV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0
M   73@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:
M  9.:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@
MA&8  'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   2
M5P$ #58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !6
M90  57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P
M '=N  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80
M"6 (  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80
M7G(  %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T
M  !J=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&
M  !K"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T
M &B"  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B
M>P  57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W
M"   =@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\
M  !TD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@
M3((  #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P
M@P@  (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""
MC   @:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL
M #6-   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$
M )('  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@
MDIP  )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6
M   <EP  $9@   F9    FP   )P   ">    H    *    "@    H    *$
M  "A!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(
M *2L  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1
MH0  "*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
M    L@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA
M  "YNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K
M *\   "Q    M    +@   "[    O    +P   "^    OP   ,    #"
MQ    ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5
MJP  U<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L
M  "^    P@   ,<   #*    S    ,P   #.    T    -(   #5    V
M -L   #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG
M\+(  /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\
M1P#_ %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4
M /( G0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\
MO0#_ /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V
M $L \@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\
ME@#= *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_
M /\   #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4
MX !- -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #%
M )H PP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\
M  #_    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !'
M ,4 3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )(
MK@"> *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M    \    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$
M2 "N $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6
M )D HP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K
MW0   ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"=
M $@ FP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@
MG "& *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0
M +X   "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$
MBP!' (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V
M *, =0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)
M  "H!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!!
M 'L 1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T
M9P"N &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=
M$   E0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X
M0 !L $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I
M %D O !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0
MC10  (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@
M $  7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!
MN !. M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T
M 'T8  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L
M5 9! %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$
M"]  1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A
M  !N&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\
M $D-0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$
M.Q'Q #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I
M(P  81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1
M/@! $44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N
M #06_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@
M7"0  %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X
M%D( -Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<
M_P N&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H
M % E  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX
M,1M' "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H
M(/\ *"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK
M  !$)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$
M "HA3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\
M(R3_ *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!
M+   ."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E
M2P C)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_
M *,^  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@
M-2T  "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >
M*E0 '2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!
M  "51P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0
M "HO!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$
M%S!> !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "3
M2P  B4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V
M P ?,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5<
M !$U:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P
MAU,  'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <
M.@@ %C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[
M:  +.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@
M 'Q;  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@,
M$D + ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $
M078  T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@
M  !P8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(
M  M'#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',
M $B&  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N
M9@  968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51
M#0 !4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#
M  !/F   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0
M86L  %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P
M6@\  %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8
ME   5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$
M $QP   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T
M &41  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD
M8:<  &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W
M   X=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.
M  !P$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(
M &R\  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O
M@   (G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^
M#0  ?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV
M  !YV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0
M&(D   ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","
MC0T  (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*
MS0  B>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0
M  :5    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04
M )T+  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@
MG>@  )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
M    HP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!
M  "P"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4
M +/P &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M
ML    +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
M    Q0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB
M %B;  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@
M ,,   #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9
MW0   .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\
M  #_    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4
M /L 6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$
MZ0"M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M    _P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L
M5@#H %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F
M ,\ M #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_
M_P   /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0
M %8 S@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D
MK "V +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0
M .\   #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %
MN !6 +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C
M +0 H #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T
M  #/    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/
M *, 50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P
MC@"_ (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
M    M0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )(
M3@"0 %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U
M 'L SP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O
MJ    *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"
M $T ?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P
MQ !J .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP
M )0   "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $<
M< !, &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!=
M -P 7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@
M  ""  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!&
M &( 3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\
M4 #O %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W
M!@  <0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8
M1@!5 $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I
M $8 ^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$
M: L  &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+
M $@ 20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'
M^  \!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(
M %H- P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$,
M0 A+ #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S
M#?\ - W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04
M  !,#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY'
M #8.4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\
M+1'_ *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'
M%@  0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X2
M30 M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_
M *8Q  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0
M.Q<% #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G
M%U0 )A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T
M  "8.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X!
M # 9"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U(
M(!Q> !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5
M/0  BT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@
M!P G'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%<
M !DA:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300
MB40  ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C
M(@L ("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F
M:  3)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@
M 'U*  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D
M&R<. !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .
M*W< #BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.
M  !S3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT,
M !0L$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0
M"3"(  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q
M5   9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S
M#@ .,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$
M   VF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60
M95@  %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 )
M.A$ "#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \
MEP  /*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT
M %I<  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q
M $,5  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E
M0JH  $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A
M  !)70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3
M  !+&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<
M $G   !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#
M9   -V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5
M%0  5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]
M  !0X@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P
M,&D  "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@
M7Q<  %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:
MWP  6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(
M !UP   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(
M &H9  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV
M9/4  &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z
M   ->@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3
M  !X&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$
M ''_ 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #
MA0   (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "(
M$P  B!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^
M 'B$  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@
M ),   "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0
MF1,  )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*
M  !?C0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$
M  "D    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P
M *X3  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3
ME0  1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
M    M    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+
M  #%%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0
M.*(  "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!
MQ    ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@
M#   X1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P
M /\  0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T
M] !C /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#?
M ,T W #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\
M  #_  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X !=
M -X 8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$
MP@#C ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S
M  $ [0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0
M70#" &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0
M *L \@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@
MU0 ( ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N
M %L K !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )<
MYP"6 /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP #
M +D #0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4
MF0!: )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$
M /8 @@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *<
M"0"B !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3
M (8 60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P
M<0#_ '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3
M  P C@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8
M4@!T %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z
M &$ _P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @
M@0 . 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F
M %( 9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4
M_P!4 /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 +
M '  $ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P
M6 !3 %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!)
M /\ 20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4
M#0!A !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!.
M $L 5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\
M/P#_ +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7
M  X 4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$
M40 _ %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_
M *P@  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H
M2@(/ $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V
M U8 -01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E
M  ";*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+
M #X'$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E,
M+ I> "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8
M+P  C3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-
M#  S#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y<
M ",/:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P
MBC8  ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L
M$ X *A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3
M:  ;$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H
M 'X[  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP
M(Q,0 "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6
M%W8 %!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_
M  !S/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<.
M !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0
M$!R'  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q
M0P  :$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<
M$  5'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%
M  LBF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2
M9T8  %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1
M(1, $"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8F
ME@ $)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L
M %M(  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$
M#2@6  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE
M*ZD  "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-
M  !/2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5
M  8O&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<
M #"_   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.
M4   14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V
M&0  -B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]
M   VX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@
M0%(  #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@
M/AT  #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \
MW@  ._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<
M "]5   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH
M $8B  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W
M0O4  $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<
M   ?6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>
M  !/)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4
M $K_ (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   8
M8@  $&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9
M(@  62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_
M (%L  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P
M"6H   !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'
M92<  &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT
M  !W=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4
M  !U    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B
M '(L  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R
M?@  9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M    @P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C
M  "",@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P
M684  $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1
MD@   )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4
M)P  E#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T
M #^0   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H
M *    "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'
MJ"T  *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9
M   CG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\
M  "P    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\
M , S  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6
MI0  "Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
M    P@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE
M  #>.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  <
M_P 0 /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K
M &D Z0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -
M_P#/ /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P -
M /< %0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &,
MT !I ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X
M /\ M #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$
M$0#< !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B
M +@ : "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\
MH@#_ )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#!
M !4 O0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *,
M80"A &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_
M (L _P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$
MJ  8 *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/
M &  C0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H
M_P!W /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3
M ), &P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D
M>P!@ 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I
M /\ 9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (,
M%@!_ !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9
M &H 80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\
M6@#_ ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q
M !@ ;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P
M6P!: &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_
M +L*  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !,
M8@ 9 %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!.
M %X 3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1
M  "E%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4
M %0 &@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D
M00!C #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?
M&P  DQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H
M%0!' !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!?
M #8 :P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@
MCR0  (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^
M !8 /  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T
M9P K '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH
M ($J  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1(
M,P$7 #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C
M!G0 (@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO
M  !T+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2
M "D'%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'(
M&@R% !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R
M,P  :#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,
M$P A#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$
M !(0F  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.
M9S8  %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9
M#Q4 &! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3
ME@ -$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H
M %LW  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A(
M$Q,8 !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (
M&*@ !AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\
M  !0.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6
M  X8'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8
M 1V\  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !/
M/0  1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=
M&@ *'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z
M   AVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@
M13\  #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $
M)"   B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   F
MV0  )?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4
M #Q"   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX
M "HF   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@
M*O(  "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='
M   M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C
M   Q+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(
M "__ (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H
M2   'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y
M*0  .30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_
M (=5  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P
M&$P  !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@
M03$  $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<
M  !\8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0
M  Q2   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP
M $HY  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y
M9P  <FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M    6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T
M  !40@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@
M<'$  &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E
M90   &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?
M/   7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<
M %UV  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0
M '$   !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0
M;$8  &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]
M  !$?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X
M  !]    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P
M 'Q/  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   Y
MA@  *X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
M    C    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&
M  ".6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP
M'I   !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";
MG    )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C
M3P  HV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH
M  >;    G0   *    "B    I    *@   "J    JP   *H   "K    K
M *T   "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P
MNEL  +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
M    J@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\
M  #     P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T
M -AI  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_
M "  _  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$
M< #? '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_
M +$ _P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L
MZ0 E .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#%
M &\ PP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *,
M_P"< /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ?
M ,@ *0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D
MK !O *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P".
M /\ B@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +(
M(@"N "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H
M )< < "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\
M? #_ /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ":
M "4 EP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0
M:0"" '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_
M -\   #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X
MA0 F (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P
M &L ;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P
M  "\    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ?
M ', )@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0
M7P!N %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
M    I    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4
M( !C "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H
M %  = !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P
MFPP  ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6
M "$ 5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0
M;@!" 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(
M (D1  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L
M20 A $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W
M '@ -@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:
M  !Z%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ;
M #T (0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ',
M+ "% "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U
M'P  ;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0
M'  S "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "!
M "( E0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0
M:2(  %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J
M !T *0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H
MD@ 9 *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@
M %TD  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD
M(0(> " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2
M!Z4 $0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ
M  !1)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@:
M !@((  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4
M# V[  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0
M*P  1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,
M'  1#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X
M  40U  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,
M12P  #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -
M$"  #! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3
MT0  $^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$
M #PN   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\
M!Q4F  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T
M%^T  !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT
M   S,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD
M   :+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T
M !O\ (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S
M-P  *C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @
M*P  (38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\
M (I#  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P
M)3<  !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0
M)C,  "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(
M  !_3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P
M !<Y   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$
M "T]   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]
M4@  =54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_
M   -/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z
M   T1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6
M<UL  &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (
M1    $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \
M1   /%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$
M &EC  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30
M $P   !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0
M15   $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ
M  !=:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8
M  !4    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL
M $Y=  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5
M;0  1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M    7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8
M  !9;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P
M/G,  #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K
M:@   &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F
M9@  97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL
M "5[   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >
M '<   !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P
M=7<  '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$
M   .@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<
M  "'    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T
M (>)  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $
MC@   )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
M    F    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_
M  "<G   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@
M )P   ">    H0   *0   "F    IP   *8   "G    IP   *@   "I
MJ@   *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "T
MC@  M*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D
M  "L    KP   +,   "U    MP   +8   "W    N    +H   "[    O0
M +\   #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,!(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
MP<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/D
MY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^
M_O__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^*!#DE#0U]04D]&24Q%  D)
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________]/__________________________________
M_______KT?_________________________________________WZ?[_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________AS=?_____
M_________________________________]VOEK?T____________________
M_________________\6,:*?G____________________________________
M_\R<B:3G______________________________________K.N\;U________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________<Q;WU____________________________________
M_[^3>H7%____________________________________VY!;/66H]O______
M___________________________^O'4T %2;Z_______________________
M___________3E'Y)+$Z:[/_______________________________]C4RK-^
M96VE^?____________________________________3%KJ_)____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________PUL;L________
M____________________________YKN1=&.K]_______________________
M__________;$FG-%)C1]S/_______________________________[6 53 *
M !E@LO______________________________SW0U"P    I2I___________
M____________________EC0       !/I___________________________
M___V:1T   D,!@E2L?_____________________________+.PX3-4Q;34Q>
MP_____________________________^I8#9@AI^VK*FXV?______________
M_______________@EXV^Y?______________________________________
M[?G_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O9RKS'___________________________________/FH%M
M6D:(ZO_______________________________\1\/B80  !4L/__________
M____________________X(,\       NA^W_________________________
M____K%,0       7;=;____________________________[@#$        )
M8<S____________________________26@(         7<S_____________
M______________^H-0          7-/___________________________]]
M#0          5-;__________________________^Y]10          1-3_
M__________________________RJ9"\"   $(C=)6,[_________________
M___________II&M!*#]C?Y6GNMK______________________________]6R
MK++,Y/K_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^6[EW=BR/__________
M_______________________;GF<V"@ "C/__________________________
M_____\A_/P4     7L______________________________V8$Y
M/*K_____________________________GDP         (Y#_____________
M_______________<;QH         $'WY__________________________^O
M2            &_N__________________________^$$P           &3F
M_________________________^Q1             %?>________________
M_________[@5             $C6_________________________W04
M         #C/________________________^:):$P           "/%____
M_____________________]^;7"P           VZ____________________
M_______OL7U5.2(1!P$"$2*R_______________________________?OZ69
MF)J@K+W:____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________COIV ?/O________________________________RMX17, X
M':S______________________________]**3!4      '+S____________
M________________UG\V         $O)___________________________Z
MD3X          "^K___________________________ 6@           !J5
M__________________________^-)             B$________________
M_________^=>              !W_________________________[0E
M          !J_________________________WT               !;]/__
M_____________________2L               !,Z___________________
M____I0                 \X?______________________, P
M       MV?____________________^9BF$G               GU_______
M________________[;Z)52<            EW/______________________
M___^RIUV74H\,BTL,#E'WO_______________________________>;=UM+0
MT]GD________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^_4N];_____________
M____________________Y[B/:DLO%6______________________________
M_^2A9S0'     #S)____________________________UH([         !*7
M___________________________MA3$           !O________________
M__________^F0@            !0X?_______________________^QI
M           WR?_______________________[,O               BMO__
M_____________________WD                0I___________________
M____\C0                 F?______________________J0
M        C/______________________1@                  ?_______
M_______________?                    =/____________________^7
M                    :O_____________________.
M    8_______________________*2(!                8?__________
M____________N:. 5S<7            :/__________________________
M^M.NE(9\=7%P<G>!E/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________;NIV":6G3
M_______________________________(DV4]&0   !V>________________
M____________VXY,$P        !N___________________________;?"P
M          !%U_________________________^+*@             BM/__
M_____________________\)$               #E___________________
M_____WT!                ?_______________________YS8
M        :O______________________G0                  6/______
M________________1@                  1_C____________________I
M                    ->G___________________^6
M    )=O___________________^\                    &,[_________
M___________K                    #\+_____________________
M                "KG_____________________)P
M"K7_____________________<                   #;G_____________
M________X)R,<%5",R8;% \-#A(:)K_____________________________Y
MY-C2SLS+S,_6X/S_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________KT[SC________________________________
MTJF%94@L$@&%____________________________\:MQ/ \       !/X/__
M_______________________5?S4            ?LO__________________
M_____^-U'0              B?_______________________Y C
M        9_______________________U4,                 2/;_____
M________________B@                  +MW_____________________
M.                   %\C___________________^^
M    !+;___________________^<                     *7_________
M__________^Z                     )/____________________<
M                 (+_____________________
M '3_____________________$P                   &C_____________
M________0@                   &#_____________________>@
M             %W_____________________T0                   &'_
M_____________________R0                  &;_________________
M_____\FLF8E]=G%L:6=F9VMP>HS_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________BQ:J1>6%W____________________
M_________]VF=U L#      QQ/_________________________@DDX3
M        C________________________])P'0              8/______
M________________[F\/                -^+_____________________
MEAP                 %,#_____________________0
M     */___________________^N                     (G_________
M__________^>                     '+___________________^\
M                 %_____________________:
M $W____________________Z                     #O_____________
M________#@                   "KY____________________,P
M             !OI____________________7@                    _;
M____________________CP                    ;0________________
M____T                     #*_____________________RL
M          #(_____________________X                    #+____
M__________________<6 04% P$       $&#1C+____________________
M___\Z^'8S\S-S]#2U-?<XNK_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____\=K&_______________________________QQJ.$:$TR&  5J_______
M____________________N7Q&&           <?______________________
M_]=\+P              .^/_____________________WV0)
M    #+7_____________________= ,                  (W_________
M___________%%0                   &K___________________^9
M                 $O___________________^V
M ##]___________________7                     !GG____________
M_______V                      73____________________#@
M              #!____________________+P                    "O
M____________________4@                    ">________________
M____>0                    ".____________________I0
M          " ____________________V                     !T____
M_________________S8                   !M____________________
M_WP                   !I_____________________]<-
M      !H______________________]P                  !A________
M________________4#Q&3E1976%D:&QP=GZ)________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________OU;NCBW-:E?__________________________^+^.9$$A!0
M    4OS_______________________>=5A@             %\'_________
M____________Y6P6                 (W_____________________8P
M                 %[___________________^=
M #7\__________________^A                     !'9____________
M_______*                      "[___________________N
M              "A____________________#                     "*
M____________________+0                    !V________________
M____30                    !D____________________;P
M          !2____________________E                     ! ____
M________________O                      P____________________
MZ@X                    B_____________________T0
M       5_____________________X$                    +]?______
M_____________\@+                   "[/____________________]>
M                    Y?_____________________)'
M    VO______________________G0$             !PX7Q?__________
M_____________]6YO,''SM7;X>;M]/O_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________C?S___________
M___________________LQJ6(;50[(0< ,M[________________________7
MDEDI             *#______________________XDV
M &?_____________________9@                   #+V____________
M______^5                      /(__________________^G
M              "@___________________7                      !\
M____________________                      !>________________
M____)0                    !#____________________2
M           L____________________:@                     8____
M________________BP                     %\___________________
MKP                      X?__________________U0
M        S____________________R0                     OO______
M_____________U0                     KO___________________XL
M                    G____________________\L.
M    DO____________________]7                    AO__________
M__________^J"@                  >?______________________;0
M                9O______________________]U4
M1?________________________]J(RLU/TI58&IU?H>1G/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z,^VG8-I
M3KG_________________________[+*#7#H= @       'O_____________
M_________\5M*0               $#_____________________@QL
M              ?+__________________^2                      "8
M__________________^D                      !J________________
M___=                      !!____________________#@
M           =____________________.0                      Z/__
M________________8                       SO__________________
MA0                      M___________________J
M        H___________________RP                      D/______
M____________[Q8                     ??___________________SX
M                    ;/___________________VD
M    6O___________________YD                     2?__________
M_________](6                    .?____________________]8
M                *?____________________^B
M&?_____________________U5@                  !/______________
M________NR\                  /C______________________ZLI
M             ,_________________________)1P     '$R N/E)HA.W_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________TU<G____________________________Z
MTK"2=UU"* P  $K________________________%?447             !'8
M____________________Q%                    "?________________
M__^B#                     !H__________________^4
M           V___________________:                       '[/__
M________________%0                      Q/__________________
M2                       HO__________________=0
M        @___________________G0                      :?______
M____________PP                      4O__________________YP\
M                    /O___________________S,
M    *____________________U@                     &/__________
M_________X$                     !?___________________ZP
M                 /___________________]XB
M /+___________________]<                     -______________
M______^?                     ,S____________________H2@
M             +?_____________________H!8                  )S_
M_____________________WH"                 '?_________________
M______]Z"P              !4S_________________________HE=H=("-
MG*N\T.?_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________[>/_________________
M_________]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M          !I___________________D0P                     T____
M______________]Y                        X__________________-
M                        LO__________________$P
M        A?__________________3P                      7?______
M____________@P                      .O__________________L@
M                    '/__________________VP,
M     O___________________RH                      /O_________
M_________T\                      .?__________________W0
M                 -3__________________YL
M ,#__________________\0'                     *W_____________
M______ S                     )K___________________]G
M             (;___________________^C                     '+_
M___________________C1                    %S_________________
M____D08                  $'_____________________ZU\
M         !W______________________\I+                  #_____
M___________________+5P  #!@D,3].8'2+I\?_____________________
M_____]?G\O__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^O4S<?"OKJWL["MJ:BE____________________
MW7Y3/S C&1$) @          V_________________]V
M        I_________________^Z                        =?______
M____________!P                      1O__________________3@
M                    &O__________________C
M     /W_________________P0                       -O_________
M________\1D                      +[__________________T0
M                 *3__________________VL
M (W__________________Y$                      'G_____________
M_____[<                      &;__________________]XA
M             %/___________________]*                     #__
M__________________]W                     "O_________________
M__^L"@                   !;____________________G10
M          #_____________________B@                    #_____
M________________UDT                   #]____________________
M_Z<N                  #5______________________^8*@
M!A@M16#@________________________J&-T@8^<J[O-XOK_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M
M&0H                 ,?__________________
M     ___________________0@                       -S_________
M________C@                       ++_________________S@
M                 (W__________________RD
M &O__________________UH                      $[_____________
M_____X8                      #3__________________ZX
M             ![__________________]07                      K_
M__________________H]                      #_________________
M__]E                      #___________________^.
M          #___________________^\&0                    #O____
M_______________Q3@                    #8____________________
MBP                    "_____________________S$,
M      "A_____________________Y$9                  !Z________
M______________)T"@               !%?_______________________H
M=!,?+#A%4V)RA9NTTO7__________________________]?H]/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^_?S\>[LZ^OL\?__________
M________V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M                 )+_________________B
M &;_________________UP                       #W_____________
M_____S,                      !C__________________VP
M              #__________________YT                       #_
M_________________\D,                      #V________________
M__$U                      #?__________________];
M          #+__________________^"                      "W____
M______________^I!@                    "C___________________3
M+P                    "-____________________7@
M      !W____________________DP<                   !>________
M____________S4,                   ! _____________________X<0
M                   <_____________________]A>
M    ______________________^_3@      #APL/E)JAJ7(____________
M____________PGR,FJ>VQ=;H_?__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________[N'7S\G#OKJVL:VIIZ:FIZ[_____________
M____OH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M              #__________________S0                       #V
M_________________W8                       #2________________
M_[                        "R_________________^$D
M          "6__________________]1                      !\____
M______________]Y                      !F__________________^@
M                      !1___________________'(P
M       \___________________N2P                     G________
M____________=                      0____________________HQ8
M                    ____________________V$P
M    _____________________X@/                    ____________
M_________\M3                    ______________________^E.
M        "1TT3FN,________________________F3E#45]N?8Z@M<OE____
M_________________________^OY________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O,N:RAF9&+AH%\>'1P:VAF9FCQ________________
M_V%%,B,8#@8               ">_________________WX
M          !U_________________\,                       !2____
M______________LW                       R__________________]J
M                       6__________________^6
M        __________________^_&P                      ________
M___________F0@                      ____________________:0
M                    ____________________D (
M    ____________________N2P                     ]/__________
M________Z%P                     V?___________________Y$8
M                O/___________________\I3
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M$0,                     __________________]"
M        __________________]]                        ________
M__________^P"P                      ]O_________________=.0
M                    W/__________________8@
M    Q?__________________B0                      K___________
M________KR(                     F?__________________UD@
M                @O___________________W(
M:?___________________Z$H                    3O______________
M_____]-<                    ,_____________________^6+@
M        %3)2=______________________@<A,   $/'R]"6'"+J,CL____
M____________________RF]N?HZ>L,/8[___________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________YX-+(P+JUL*RHI:*?G9N;G*"G________
M__________^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                    K?_________________,'@
M    B__________________[4@                      ;?__________
M________@                       4?__________________J1L
M                .O__________________T$(
M(___________________]6@                     #/______________
M_____X\4                     /___________________[@^
M             /___________________^5M P                   /__
M__________________^?-P              $"]0=/__________________
M___=<A0     !A<J05IUE+;:________________________O%A$5&1UAIJO
MR./______________________________]+-X?'_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________S[^OO]
M_______________________NN:B=EH^*AH)_>WAV=')S=7A_D/__________
M_______K3SHP*"$;%1 +!P(         (___________________:0
M                 /__________________FPH
M /__________________R#D                      /______________
M____\&,                      /___________________XH.
M             /___________________[ T                     /__
M_________________]5;                     /__________________
M__^%&@                   ^S___________________^Q20
M    &#E=@?_____________________E>QX       PA.%)OC[/9________
M________________NU@I.4E:;("7L,WM____________________________
M_[.>M,77Z___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________KOY^'<V=;4TM#0T-'3V>#K
M]___________________N(I^=W%L:&1A7EM96%=765YE<?______________
M____OS$?%A *!0               /__________________[58
M             .C__________________X($                     ,S_
M_________________ZLO                     +/_________________
M_])7                     )O___________________=\$
M         (7___________________^B-P                 %*Y3_____
M_______________+80(            ,+%!VGM'____________________U
MC3        TC.U=VF;[E________________________PV,8*CM,7W2-I\;G
M_____________________________ZA_EJB[T.?_____________________
M_______________]____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________]W.Q;^\N;:TL[&RLK6YP,G5X___
M_________________Y=L9%Y955%/3$I(1T9(2U!99J'_________________
M_Z<F#@<"                 %;__________________\Y0
M         #K___________________1Y"P                   "'_____
M______________^?,@                    [____________________$
M6                 @Q6H3____________________I?Q\           8G
M2W&:PNG_____________________ITD      A<O2FB*KM7\____________
M____________TW4>)CA*7G6/J\OO_____________________________ZYR
MA9BLPMOV___________________________________?[_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_____
M______________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>
M+@8                   #____________________#5@
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M__\
M
M                                                     /______
M____________________________________________________________
M____________________________________________________________
M____________________________________________     /_A0$EH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C$M,#0M,3!4,30Z-3<Z,30K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U
M+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 T+3$P5#$U.C P.C0X*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R
M,2TP-"TQ,%0Q-3HP,#HT."LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D
M=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD
M8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2!496UP97-T(%,M-#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR
M<C(S,#<R.#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C@R1C U039&1$8Y.45",3$X.30R0T,Y-C@Y1$,Q1D1$/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.CA$1#<P.$,W1#<Y.45",3$X.30R0T,Y-C@Y1$,Q1D1$/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z.$1$-S X0S=$-SDY14(Q,3@Y-#)#0SDV.#E$0S%&1$0\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CA$1#<P.$,W1#<Y
M.45",3$X.30R0T,Y-C@Y1$,Q1D1$/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$P5#$U.C P.C,Y
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z.#%&,#5!-D9$1CDY14(Q,3@Y-#)#0SDV.#E$
M0S%&1$0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C$M,#0M,3!4,34Z,# Z-#@K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@R1C U039&1$8Y
M.45",3$X.30R0T,Y-C@Y1$,Q1D1$/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 T+3$P5#$U.C P.C0X
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C@Q1C U039&1$8Y.45",3$X.30R0T,Y-C@Y1$,Q1D1$
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.CA$1#<P.$,W1#<Y.45",3$X.30R0T,Y-C@Y1$,Q1D1$
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/GAM<"YD:60Z.$1$-S X0S=$-SDY14(Q,3@Y-#)#0SDV
M.#E$0S%&1$0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\
M+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#
M4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T;W-H;W Z
M24-#4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D 4@# 1$  A$!
M Q$!_\0 'P !  (" @,! 0            @)!@<%"@$"! ,+_\0 3A   00#
M  $"! (%" 8' PT !0,$!@<! @@ "1$2$Q0A%3$6%Q@B40HY05EXD9G7&2,D
M,G&W)3-"88&Q\":GM"<I-#948G-VH;7!T?'_Q  : 0$  @,!
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M@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \
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MAUQCWVS^><^V/OG/\<_?P!A)/&/;">F,?%\7MC37&/B]_B^+V]O;XOB^_O\
MG[_?W]_ &4D\^_NGIGWV^//OIKGWWQC&,;9^W^]C&,8^+\_;&,>_@#Y:><:Z
MY3TSKK[9UU^#7VUSK_NYUQ[>V/A_H]O;V_H\ \XUUQG.<:ZXSM[?%G&,8SGV
MQ[8]\XQ[Y]L?;'O^6/ /;P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#
MP!X \ > / '@#P#I,\3P;I5S6D\=T#Z&W*G5='K]!]"ZUG<_2<MY^C-\G@;2
MXIDR=BK/TG#$L?(GHD8;$(JDZ<MA&J(X.T8:-7>&>2;T#M]\X-9*RH6HFDRJ
M&)T#*VT!C:,AI."/@9*&U:6T'(ZO81&2$90;1]X%CZ^-V#!P&01'*H(Z;-4]
M4LZX\ W7X \ > / *Q*E_G<>T/[&'%/_ #)ZP\ L;D4MBT0:HOI7) 499.5\
M-6[R0%V =JNZRFHMALBX(N&R*CC9))57".F^5,II*;_#\.FV<5F4S6&P<,=C
M-9;&XBO+*D$4^3O5:$,DRL=(D3)+4L3'RJQCWI&URN5C'.VV:JI8XW#Y;,S/
MKX?%Y'+6(HUFE@QM&S>FCA1S6+*^*K%*]D:/>QBR.:C4<]K=]W(B]?'I3^4O
M<4<R]'S_ )JDM8WW,Y)7TH&Q9_,8$RJ\M!"[DF/%$4GP4J]LL<\<CDDBR*2R
MRH]#?59!QKA+;&FN=I%2_2OU(K]"Y5NT9V+)#=J6(K%66-JN:Z2*Q"Y\4C$<
MUR*YKU:BM5-]T7;PM4;M&U)1NU+-.["](YJ=J"6O:BD<B*UDD$S&2QO5'-5&
MN8BJCD5$V5"_R-6'!)BLHUBLSBDD>(-M7;EF D(@PZ:MMM]$\+N$!SQRHBC\
MQ31/YN^N$_F;:Z8VSMMKC-=B]3Z;S<TE?"Z@PN7GBCYTL&,RE&_-%%QMCYLD
M56>5[(^8]C.-S4;QN:W?=4)^3TYJ'"Q1SYC!9G%03/Y4,V2QEVC%++PJ_EQR
M68(F/DX&N?P-<KN%JNVV15/LF9DS'8I(CD<BA*='Q0=^^#0T.0""2<H)MVRB
MC$&Q*R0@) #7!%QA-MJ^,$F8]KA3*[E?5-//O>%,50Q#LOJ.R*:HL(T"U#7/
M2W0'8W3W-67SEE([%JVI@7.TIZ'<G3NHQ(U!#=E$VL1H]&/#\Y*PEH=D9W21
M+-1(QNH$\ X")=A=BW;+L\Y5B\H&$] 5 "Z ,WK-I5")O+JVE9*F;?1J># H
M#$Q]@QD[%1]N(+9F1TR6E,H=URV1WC[47*W2NA5,#+XOZP=,$ZZA\\+U#T Y
M8K0?G:4VT:@E>)S.'U"1Z6CD9)5R&*$D#;&02Q8Q(9,UBC=K!(O)C35_KH],
MAQ0EVQ(.@-EMO4WKH@Y>1 3073QF\P\XF4*DO-XN"0MY<,70@,*KFQ)+-3**
M=D_H!K"&\/MZKW[ LPGK]X:)3@#&Q Q[)%EQ3<#4-[^I2^<4[7=S\V(#\1*2
MTVA>QYY:48(,7P6(&;SJBEHD--!M#0Y:.$Y"XE]@F$<OW*FZ*==$454=,X7P
MF_ $C"WJ'5=D/""==5G>EV.[0)3]2K(_5D)"OC=D5]5^@;2;W9%4Y5+HF/4I
MY@0D 0."EI8@*6GA$R"V@ N3C)%'R10#:<8M<]UAS-$;@Y6F[&LW%G#!\AA4
MHMNJB4MP,$HFE&I1M(:U;SJ!$="+MNP?,4D598R6%.54G3ENYV048[@52(]B
M]OQCC1+JFR>BN78^PDO1@?GI @5YZ/1:(U6T2[6SS3);8F!HKT<JT-A&</"'
M)4J!67B;86\?H9=2A9H)55(!W,H#>H1T+H*Z+$5K/^?^X6=8P^B90,Z+YNJZ
M=E:[K]U:-K$('8@.;U]7=DV^0LHU44 8J7:XB]:S=G+"T824$D! ;+D>97=?
M:?\ ,&_:.N;I_HB*V*(JCL'C2>OX23B#]K<<'IJ5%7[#4DPEOZ5U9:7-I&^6
M<CKN3,56<7.QF8OK"QJ;%NBXMQ!F;L;DFX VOZ<-D=+WGSE6O0?0MCU=*]+L
MK:#SR,1*N*A,UOF"*F63M\7'E#96T[!_3'1;5R-29.$A47V9Y9.5%$7?UVB;
M,#[173UMX[LE-!SN 1BMJ( \USBX8[-34H'D9;,'D-LF!1(E+R2(UWN!@L!;
MCI&3R,8%GSR2$-6RIHZA&$$6XU<"*1[U([>UC_:MB!X%"X_7M60CE&4\X$[
MVD(G5Y#NAK+L>KWEZ7AC39NZCU<#LQ-&V$0K!)D58U"P3)G"@HV:?,8V!J^8
M^HOT,$1F5'P^<5;=UPP>^*2A!.]><^>;+N^(_JZMJH;:M1=XZH*O;)DY_2:1
M\C4A"%N$V=J+1W5.31:0E7H3YA0:S MGY*M/>YJ#A,^=6*)M(L05DHV0RH35
MTEI/&DBCTJ- 34;+U+,CTEE< DL/?CEHM)H[(##DDW.B'ZZJ;5-PDU1 DAX
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ME8T(.DA".I/$%##"/F'Q,8(,O!^F^7+4:5(!3+(:[7331?.1!1%KNKN/=X2
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MV]\Y_/.?;\\Y_ISG[^ >,))XQG&--?;.?BSCV^V=O?W]\X_+.??'O[Y^_O\
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M;#&<\@^[?,BW /B!H8CDU'D'+X,_^K $Q)'"C%UC"NB>'F$%,^^JR2NF?A\
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M?;&,9SG.?RQC'WSG/_#PJ[(J_+J._8U@_L#](P,GVI]Q%YU)P+]$(HT7.[-
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MA_8PXI_YD]8> 6=^ / '@#P!X \ > / '@#P!X \ > / '@#P#65P7/5'/\
M7Q^UKKL&*5A7,7126.3"9F68,(QRX6T;,V^7;U5+5=^_=*),QHYMA9^1>K(L
MV+=PY532V Z_'I&=N%Y%Z=JKWDBAI1U980;KCI8#(J_'3NOZETA+&S;;L6[(
MC+YQ(;"+M\C(J2B4N!MTG((+)22IQ9X+1&[J#7JB0%PMRP?M:W(W4GZHKTK[
MD)^X";$;N9[U0-Z+EK0^[:!%T(U7LFDAZ(PI%B%=_I"/(2 S C&YC&19!B.'
M:)N&BP'.VMQ=2MYVM6]PVQM94KD=4H@58?&T+@M",5:UD,;.K2,7,2-51*6
MX*?E*1-73*A*0!2NJ[-F.'N$%F@]HFD!)1M%8RS.D)0TCP-K)2R+5N5D+<2/
M1.$V[)+"#) @63;ZOWJ+1#&$6J3EPKHW2_U:6NFN,8\ Y[P!X!JF[J?K&^ZQ
MDU3W&&WD%<2O07I(Q&DCD42V=ZB3(XX-QB010S'SX_Y)<8P7SE@7:9<82RT<
M96:KKH*@:7Y/XFY-XV92X=RS7C:O1\QR&S)V+*?3Z:,W&0BII<3E!K-9A*4
MN4USQE97\(T'?B"KO=1]]5N@ALB!(D[8D-CDBC\2+'6J$GE*^$ 8%'59Z5>8
MSA3.SS=BR3<.&@Q+Y2F%RKQ-N-0VUSHJZTV]L9Y_):IP&)RF,PE[)P19C,RI
M%CL8Q)+%Z=%1^\[JU=DLL%-O+>DEVPV*I&K5:^9JEY0TWG,GC,EF:>.FDQ.(
MCYF0R+UC@IP+NQ$A2Q8?%'-;?S&+'3@=+;D:O$R%R=3@PXFR2,KDSR9$HNG
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M ,6E*@CK.^44MK%DK%TWKVIAVCG.FCY_8TMCV[1';=SHS<Z);Z^ 5]]H\/\
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M^QAQ3_S)ZP\ L[\ > / '@#P!X \ > / '@#P!X \ > :H1O6FG=INZ,86C
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MIC>5O,UVV?E$QS4C7,8<.,;;I@E4?@QD"Q&EZ"I3G2&LZ^HFJX)4L-9?#MH
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ML#J%SL50C)E15VJ!=X?ZH,"NNWR73IH_0TQC9HIX!=3X \ > / '@#P!X \
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MD>5K2K_"-[U5?39$WWZ=R4SPL\1W]M$ZD3U^WBK4:(G3JJR,8B=_53XM^HZ
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M])+&,)Z)0D!OC7&,9QC&/G,5,YQ]_P LYSC^'M]O;2/PO\.V*CG:+TY.]/\
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M-'423E&[I2XPF6*D@U;X?J!\(.]!FV_TVI)_C7YV0)C_ +-OJ??UG5:?X?\
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M$'BPY-70&)$-6V07I^ / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > /
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<!Y]L>_O_ $^ / '@#P!X \ > / '@#P!X!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g150774g83o77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g83o77.jpg
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M45=987F7LKC7=9;5_\0 ' $!  ,! 0$! 0            8'" 4$ PD"_\0
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M.WNS-X3(X1K!5K]R%Y%05-ZQW\2FH#NC"7$9'T)&NP_VB+67^W^]_P#U&O\
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M<CC:41&<URC$F0>2 )$'D D?$#G4BI],M_)MU7-RU62E6$,9$9>_(R7!D93
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M(0^D"22:IZE;>I[8W*M.)7.K4LTJ^00N+6S]G:7/2R*6LE)H 97#HB3)266
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J=>Y6@ZP9!AEVHM)$ZT8!RI2[9 RB&)G.$CW!<H;6^J1UHW3IIITTU__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g150774g84f41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g84f41.jpg
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M 0$! 0$! 0'_P  1"  L F # 1$  A$! Q$!_\0 '0 !  (# 0$! 0
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M9PQP7$\8+1F2 VSDG[4<RB6,C>BR,@4\ML  =_=LY%I?SS7-K;RD+*L5P+I
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M+(4I4*DIS6,+2X:!5LRQ&_495[-*@08);-97 @V:%*;.QCGCE9DD<2R/#:N
MVHV5'?NR\? 4GMQ_=XY,?'@D7W^1EMY8$$D49ABCN+Q&*;E#R1H88>7W%U7N
M2?9Y*A1^P#U%Y_4*M.E]VI</<'!IK2K.A:9S<2MD+ *I539=\X6)G4MIO#F
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M"QSZ*J3"-3"I1T9<=34_VS_B2_YNUWV,[91/]MEDT76$B\&&*7Y:.3[3Y_\
MC*WQW\<V^3BQ&4AZDQ=CA\]G,E-%?#'7N.STUZG].M.Y_LOK,%&<7)?]C4BK
M<3F7EVV[6]Z8_F*ZRW\M7>'GSN%N.D<UDL_TQTWB8)L:<KC\KTQ;X]_ZM?=K
M60^@ZFF&:BQGU.XG:UMQ"%[R&:'X;O=>OZH=#Y\;;"YE,]GHLQJ>7X 8TFTG
MM)X['94]8D+[:8AL1",HAZC#-%TJV;IR)2-2$0<363<M7!1;H<C_ !?TQWYL
MABK9Y\=CNBKZ7.X\W5Z9,7U+_H\=18C(]SZ@SM8Y 2AD5W-H+RTN+4J4D2%>
M5Q7\S]9"W@Q6:NX[;*Y7^1<=!TSE!98]8LWT@.OCTIG<1VOI1;+DL48665XT
M6^;'WUK>!UDBDN7L@G9VUG>PV6H><A_]1.5]77W?O0"$]+YZI9/<D<8K_F_T
M_P"AZL;*9]?\T[-=1_I+]5CG)\1_;C'\SOCFPG0W^DAU^+7^R;$]-_Z5^JR7
M$==",,;[ZSZCZK^C_P!./]:%M]86[^K(R\#VQWZ]1?R3_KH_Q<;[_<KDAU>>
MM?HL1R;^-#,4&-^@^D%D,^<L/]/F[^@"_2ALB(>X!*>L5^F#JH[/G2Q5I;QJ
M/R>TR5SR&K"E\VXK2YJQ"DM_W3HX5J5"6MX*1Q[E>"!?]>]#+L%5FK9)RV7;
M)?9[^2_U"YT .T&6,1K((8^Z$"\ !)QYC[?&P0?^Z^Z_TRT+$D2LK2F9HC/,
M86D+]PLT//MG[_NT5UL#QJMW9GTW]7+7G$RFTC"V$,1M D.-7! (7;UE0>J;
MD,"L&Z3,I9]<1>2C(O*'W:;1MB^<+,4,R_:7W2_;]95=16$=]<1JBJ4)C!$3
MM%&\D0.]B.1E+*/)T-GCO[=5[+C;65W=ED'=(::-)I4BF8?@RQJP1R-?G0W^
M]UD6W].C62Y):?EIX38,4SF\8C<)M"-59;%A59"+<AT/']AXO&;-A\'/A0<I
M% P??8!ABNU0<I ?MA\G.0]NV0117UQ$JJI1N#,T;21I(\3.=LT;."5+'[C_
M -^?SNO9L=;3.SL)$[B+'*L4LD22H@TJRHC*K@+]HV-\=+O0U5@"NO\ 5I:P
MJ1LU6/Y,Y-KN G47J?$6]=#0T< V("CT;D@WL(T43'/6^8:+A68W!T@IT+P:
M]]LOM=JY]]TB:0)+'RVLQ1I-@$L48LIV?(.V).OSOS60;>)I(92NFMU=8M$@
M*LBJK#B/!'%0!L>/U5=[,^F_JY:\XF4VD86PAB-H$AQJX(!"[>LJ#U3<A@5@
MW29E+/KB+R49%Y0^[3:-L7SA9BAF7[2^Z7[?K*KJ*W1WUQ&J*I0F,$1.T4;R
M1 [V(Y&4LH\G0V>._MU6-+C;65W=ED'=(::-)I4BF8?@RQJP1R-?G0W^]U)$
MMTMUSG#*_!4F@*!$-LK#:\@=I!/SGK8.ZCM4"20>O48X/:+(MXF[BR!-1R)?
M@,&+IH1:#2"*F#D>US3@MU.AA*OHV[.\9T"0TA!<L3_ER(\AM@C8_9JU[*W<
M7 :,$7*1QRKL@%8@1'Q \(4WM2NB" 1Y K/GFO#!QK3']<ZR5:Q\#"Q%-Q6'
M]'GA!\D/BM226$O1[%X_Z3>D7KON/1'%BF[7Q55<OLTE7:N.*BRV.\Z7S<.$
MS\.8NXY9XT@RT<B0!.XTF0Q=]8HRAV1 JS72N_W#4:MQ!;2GF^L^G)^HNE[C
M V,T%M+)<8.6*2Y,G:6/%9K&Y*16,:22%G@LGCC(4@RLG,JO)A)$VIR"6#.:
MBL63CW;N4T=(I'*:\=H$GC-N,,RN'&8(:7>LFZN#8JDO'#Q)JDW?8+)-UU<'
M:6.+A%//'GTE=$E12 LRJKC0.PKAQH_K[E'X_P#I74R0QR/#(X):!F>,[( 9
MD*$D#\_:Q&CX_=5/??3)U*5BA:&@XM,H(&*[%NMJD<ZYLJ;00K'[H=QM_%,Y
M!$C,:,#RD58(!B3M!@!!.F(D;EGAFP:MND4<4\D9"YY!RR.1!]/_ '(U<-%R
M#<6# ACL#9()/[K$.,M.)14>-3<&Z';DDC*S%2G)"C H.)("J0H_0%=#*/I\
M:_3^CY-KU9KRY+8KF52X'-G^%K7E:-BR=D;CV;+(=B"E\MDI60@AF/X7]7 H
M6_;,'&+TEVHCWF_<Y9Q6]G299XQ%'(J%!VXHT4JV][55"D^?R1OP/0J;8^WD
M@:WE[TL3.KD2SRR,&76N+NY91X\A2 =GV:EYCJ[2@W8Q7:MA$<&ET*U0WI;(
M^@^>)CL((U,MS:#5(!BKT(1*)K,VC'$RFUQ(XAVZ8G%?IE_9+*HW$I@^G+;B
M$AEX_OF1QWO\ZULZWK9)_-6BU@%S]6$U/VNSRV==OD&UQWQWX Y:WKQ^*ZFV
M:3KZ[$ZY2L$:\)855;,'NR&],RCX7VQL&NW;I[%B3KMBJEV09M'#Q?)P+=_<
M8O<<NL7*6>../748Y7BY\"!W(WB?8!VCZY#S^"=?D>1^JG+#'-V^X">U*DR:
M)&I(R2A.OR 3^#X/[J*+WTPI;8*8 [(DV=C0FS@$;=PEM9=-6C.:AG+Z"/WN
M1)[!CAZ"FA"YZ*+D,U'V DO@\38NEW2XW-DH]>=N+(;J6!2B\'C+!S'+&DJ<
MQX#@.#Q;0UL:V/!WH:IGLX;AUD;N)*JE.[#*\,AC)V8V:-E+)OSQ;8!V1K9W
MFP?337>M"5!$H#!,8KWK/'+)B]2,AA@SVP#C;<Q$_P#0%RZ3M\Z5E!>1.0S4
MB^.2%<B66**OB2KQ1X^<K*&NIG$P=^7U!C:4D#9,6^ &@.(79 "Z&M#6A7J6
M=M&8"D?'Z994B +: FUW.0)/,L1LLVR22=[)KGX#HEKC64E@,FA,7-!5*LM"
MV;>KD&E*SRL6A4MNV-O(M8:,<CRSQ0<+C!,:0?K,8DU23CP0D]=D0X]DZ<KY
MJ2>\GD5U=@>['%'(>(Y.L+!H^3:V6! !;_(@ $D 5&.PMHFC9$8=J66:->;E
M4>92LG%2=!2"=(/M4DD $U*M,Z]5C0*]E=U:+(QT;:MA&;3DL<[-$7T:9S62
M?TRD1.+A'BZS.+-SBZ23H@*"X-!63I/%=!FAGDI_>N6>2;M]PAC&@C5M ,47
M_$,1Y8C\ G9U^ZMAMXK?N]H%1+(TKKLE>;?Y%5/A0=#870WYUNN*A&M$:6U4
M&:OW4+!6!%WD)?0J;C$<R*88XP?O';E7IFZZZ&%V2J/:Z"[$BUR8$QQ!NB^8
M.&SMN@OAO^J<Y'F^ILGG;))K>.]NQ<0).$[T8$4::D"-)'O:'8#,I!T?V*Y?
MHOIN;IWH[#=-9&2WNYL?9-:W$EL9.Q*3-+)N(R)%*!J0:+(K!@2/P#4+-?IA
M:M9@YN%E*5N64I8,;B<$D4@M*[;*L"4?\SA4P&3P)5HD])) ]>A*\[DX<>_+
M1H5DT;GL&^+0TH^:?_3S3F_N-J5[:<&9U6.)$7N.I0R%5 !?B2 QV1OQ6^_I
M=J5=7$TO<1(V:6>61^TCB18E9F)6/FH)4:#:^[8J4;-T6UEM4LJ:.5TT D'E
M6V;3!=2 N5H&E(*XML>R'RZ/2!O%_P!<@82_\YF_".7J:KH"41_/&+(+9Y]Y
M0CO+B(:5RP$D<HYCGIX]\2"VR/R00/!'@U=+8VTQY-&%/:DA/;)CY12@!T8+
MKD/ *[\J?*Z-=0QU)HD9>$(V,'P_)G;L JSNF0<I;E"*63B 88XX-19QABXZ
M8FW;!/K-)B6(-UB;=!7-OTY[0P132@;F8PO 6W$\G=*Z'^?L'\@']@>*D+2
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3IQ2G%*<4IQ2G%*<4IQ2G%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g150774g97h86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g97h86.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1SN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '-*^<W@X0DE-! 0      #T< 5H  QLE1QP"   " ?\< E  "')R,C,P
M-S(X' (% !Q-:6-R;W-O9G0@5V]R9" M(%1E;7!E<W0@4RTT #A"24T$)0
M    $,KH3TM^MC\Z-(RR30L222(X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ,>   %-0         !
M                  $             !34   ,>
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ,>     %)G:'1L;VYG   %
M-0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #'@    !29VAT;&]N9P  !34    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     $G4
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV+'^R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" #_ :L# 1$  A$! Q$!_\0 'P !  (# 0$! 0$!
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M3',#(AX]9:+MFI-@NKHZ21*#>*+0LGT+I5,\X'O#J9B[-#3L0S<CQ3HMK?\
M:>I%P,8/'I)VQ'KO,+*LF;HB0<MFVR2*[UTKILNHB=$N(CB(XB.(CB(XB.(C
MB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB1?:MF:5
M@)C[_6-&9:^D\M&0T0$!*CD'SDJ69DWC7X*%'3-GJGG Q5+;.[C3X;JIY_\
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M;-;"!-<6? )\: 7(*ZQCS5UL(5.@X9_''JT0$>XY8+%4G)J/:ZZ$TDB?'XD
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M>'1E7X^)5E5^KY%]+/DY561V@JL**RK5AXO9GV26V; =@#ET2T+S:!)!V!W
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M1T3;Y;XU]A55/?LX>65Q,L'&P'./14:GLP<6RP,V5362[O66L)1V&W+=^QU
M(Q*C8ZMU/73,/ ^1Z?5J65<1<.^C6L2*HN#87(YL+<IFGKPF[(-FNB6FFY(B
MZ74?OW:N4=%7+QRX4<N5_4LLKNIOMMGEBYUM[9"*[.=G!K5452Q)/(B@*JC9
M"JH"J.@  $RE?Z%KV "S-D&@H5@F5C]K3./L'J3ITZ6%,$F0G3(A'W7:^C9%
M%-TKC#3TZ^UA?;.--<[_ !ST^)Y.2Z8E=EC%+,+'L92 H=BUAYSI1LG0]KQU
M,0!LZ Z'[A_W*U=A/&'6-@6$_P"Q76>=2SI)VZ6U]Y:]*);L&@>P7":VSE(?
M?U/NL)5[> %=QME1^G)Q[>2+9U1]F4-]6R2>./,I#8KR'WST\)L(%Y5*?:0.
M**O$@\=[YT(.D$OZJ2Q99QHV';VL 2;DYSUK/OO>;)./O%(G!'+_ .H.1\H8
MAVFVR*)UYBDMBD\C@>8P>31^91*0L428"414R.D,=.#7&OJ;D!!H2Y=C23)?
M7_&2=,W*R"F/TZ;YQQ$V'B(XB.(CB(XB.(CB(XB.(CB(XB.(D&W;FX$ +IU6
M<UAL/2RD(8;.SD%?RLVV(DC[0?L_'K[2X4$T;IM7:.N&1&/DMMMTU]_F=?>1
M^6Z/#_43:%R\>^\[=@*\E::RJ5,W*Z]@]A)*GVDM3O'LG1YH._ @?5O[Q*NP
MDE8^EGTPVN"Z6<SD#&^KDA(@2WC$.A(PPC':@G"B9(:+:-UY"X)-FR^=7R:9
MUXQQHOA;9FCGVLZ]C(KQ?5,]L' ;'J;AF!DV.;K\AT-V=C H[L14J%A[)[-6
MV-<QZS'J"O,P)).AT&^A/=W[ WXZDCQSL11SSN]:M&-;1AR]MCZ*J5^\@J9A
MOL:;IA97<),PV4T^/R^"HH5*XV8(!?F,F&@<T/++L=!RV'.-2WA7$5]'\+B3
M8=XP7XCG(N2:SV9-E. M9![^1WIM1;-=FUE;5AN<<L<Z\Y3F'-R@\N^NNOA]
MOP(/<9B.V7D3ZI]/JVE4\L6UH87.@6N^@>KHK*X\8LB6GE--\#P8F,M""Q%O
MARXQKJ],D&S<.%;>X]).T4M-=5+>">BO&N/9=&-B860E=K#M,RZBU,2BH=7L
M>YE"'2]5K5B]ATJ [V(LMKK!+,.G@#LD^6N_[AXRJ?C>\K74'L#UQK@6<M>O
M*4LR!1F-U])ZSM.P8M%C2KZ-A6@EL:BB\@>A-9< ,MF2;U-X';JJBW"R@LJ@
MU<I);NNSZ6>A7'>%<5RFKPLKB&'DVVY5.9A8MUU82VQG-=XJ6SL+:RQ4K80'
M #H2I(6NJ^MU'M*K#H58@'8\M]X/N^'?)O[-][.HU56KT_CLUOJO&!"97$3)
MBU&1]F:&L@;NHK7@S21R(N'4?#(U'7,NE\?!HFCCMB/4</'3G"_T\,<>#>?P
MCT;XYFX7';<?AF4ZX^ B.&J:MVL7/PLEJJJW"O=:**+;376K-RJ!KGLK5\WM
MK4H&8 L>G7?@>I/@-Z&SXGR!(Z/Z;Z*::*)[ZJ)J:Z[IJ:;8WTWTWQC;7?3;
M7.==M=M<XSKMC.<9QG&<9SC//)]W?+9_7$1Q$KOV"_TJA/\ B(@7_1Y9S)?U
MOW3]T2Q',8D.Y[!TEK=6.N>;/AV+RVB?WSBL<EV_W5F+^_A#ZE\C\?3Z\XSA
MU@=[OU3(S_VMAED7C+SF]^3.(?D_\J^IW_D[M_5O7.S/8=MK?)S_ &<VN3G]
MCFY_9F/.O-R<PYM<W+XZ\Y,7-&92B/\ *<]!,!+0DBG:BK&X&F9H-KNRRKPF
M^9,XQ-BSR3LF,;45=CT<%"*F\*E[I;0)@DFS%Q@Z:>J-Q MX^11+Q#B(\P/8
MEA+YF4%%&;4B,)CG*+T>1'O4-'+)\Q>-MU6[MF[;*IN&SENHHBN@IHJEONGO
MKME$^SB)5F^^[/5?J]( <7OVYXQ61V11TE+A;(\W.*XWB@9^V&%Y*^=BQ)!D
M( "WSMLW(ER[EBP996TW<N$TOCOA$U.P_(GTFJG?;2?=BX$ UTD\AA^[C.Y@
MHR3/Q.'5Y8,E;*/PPHBR39A83;%<R=^9W<:A4 \M%.\D/1NM[*-;_E+)O[5K
M<<)@)]Q-8ZH$M,Q' %;%V))N4'3LK+AS@Q&VT5>#-G:!S0P%9O#C1V/W79;
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M7RZBFT-0]H<XW6:HX>*;9V451T4SMUWC%;FJ79=%WVBT6C3 -H+;0X!!T.8
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MN9D0MF1IKQZMXW!YYI'9;+9D>;.PH*,!R[PJU78:.$]D2O/AWB$8B]/W*YC
MD8$9F[@:;-PP7MY5G<4-' ,<K*!1&&0P!-:IAT.%0Z+P>'@0D5B\$.(&9$.
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M.,_JO%$4=YLX5E%,D]>@]7.1S'Z.QU+M@.EBM7[R-I_^UVH^O4S</M/OCTO
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MW=^M@+PZRJ\9.+E66T8]M_/5FUTH_(R!4[-L*XKT;1;M#LC8 WJ8L6&M$:)
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M-+Z,ATK92E5G8+VE)LK#FMFMK4\I/>NW+<K!E#^T!O>\'K#,#MUYSRN%8J&
M4D;\CT YAIM=-ZUJS@<.+CP@6!",&PL*$',A(D8R2U09CA@YLFS8L6J.F,:I
M-VK5%)!%/7'PT33UUQ^C'--F9F9F)9F)9F)V2Q.R2?$DG9,M    &@   .X
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M&/0*>J$QK-QM%;$UL>MKM59NY;H%J<<"M*4R606Y&R98Y%94B=D.R?6WMO\
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M5FOG8:+?G&9F(!(&W+$#KRC2]=$GV%4;_J4I[^JVOO[IB.>2R/TB_P#QK?\
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M3%DW6=O'CM9-LU:-6Z>RSARY<+;:(H-T$M-U5EE=]$TD]=M]]M==<YQ !)
M))(  &R2>@  ZDD]PCN[YR*ZYRF'6/WKO6= I;'I,BVF$7B4*W%%F3U1:)(U
MC9<E/E!Z*2NRSD*ZDI]LW^IHI[,5737&B;A3.VF,=O*KLIX;BU,CH2EEE@92
M!VANJ1 W@&%:?1.B >H[YHU,KY-K!@VF15U^SR6,VO<6/\1T,Z^\X<WIACI
MF,89="0#R2.\+)IX&L7HI@OE/?U>M?Y@P]8,_0E\,>K3+CW=O5CV]-OAM\,E
M )T6"CS()'P]D$_9()UX$^X:^\@?;-+J-&2#8)%XY)HRZCA"+1B- %,KDPQ-
M DN+#MF#MRR4$/GF4VV%VN<IX>:-E]]%--L)8SC?&MEY1K;'1PP>QW&@P(#,
M2 >8#KH^&QT[YC6"$52""JJ#W== #IHGI\=3]Y17BDH,BC.\YF@;8&0P5#L
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M9=!.LD^[$@^T$FB,A=V8&)P^1+L&]@3AA6LGF-= S<:KN>36J61Y"OIA.8&
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M5NV_+)@,S!'KZ31QC,91:U,O9*/.!F%=-:V ,XX';6>2U9RU)/S_ !,K" [
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M+;,/%082>6WL;6_&R'J)0!'0GGY+%#J'53RNN^JN!L<RD$@Z.QK4V5J_79#
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MEQ)E8J\A6D2Q&GDH;+AT&@V4N!JAP:)=E1+-ZBP*OT%T3:_Y-SQV_L$=+?\
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M^2(BFX0H@82=;U[SK^7XRNO83R-]SNIQZQ^M=DZT%9=_M4NJTJK2VJSJ2S]
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M.[BBC6=RPP0(6C&8!.XK$)H@Z=L%@#%H^>IN$;^V1:KX.J>J^F>Q-:]>3B+
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MS*MA]Y5!95$D4V4OEDXAD?&J,+8C,2=IR9\7KXZXUB^Z6#Z81S'9 H/U#2@
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*$<1'$1Q$<1/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g150774g99q79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150774g99q79.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1XP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'A2^=P X0DE-! 0      ",< 5H  QLE1QP"   "   < E  #TMA=&%R
M>GEN82!2;V)A:P X0DE-!"4      !#N+#3X-#0$K6Z ='=YYZ=5.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
M#P  !7X          0                         !              5^
M   ##P                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ##P    !29VAT;&]N9P  !7X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   P\     4F=H=&QO
M;F<   5^     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !/-     0   *    !9   !X   IN   !.Q !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !9 * # 2(
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M-;:JL_(HI8"',K<!)<ZQYW.<'._PW_@=:7$54Z/KO_T%G_0_]*)'(<T%SJ;
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M+L8,+G8]!>_%;27O;9ZCG!M;33>WT=OI>S]]= UV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ ^P'" P$1  (1 0,1 ?_$ !\  0 " @(# 0$
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MT]0D-#="57)T@J'!TN$E=@@X0V1WE:/Q%A=B=1@F)U2U1$968X/_V@ , P$
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M?558_5EO5\9[V:DG'2NIR4VTH;;^8KA]>A41+Q*\I984J(Y3V(O8:RMHK46
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MY-3WXE%U@MYU%?5[$9F0*[:(3M!.H$DS:R;<4B[(3FY"U.*[[*U*<NUNBJP
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M<M2K^I(.Y/9N<O*>_;$<\_:I&NQTCD9=+%!A(>;A&629AZ6];#IV<+QEP[K
MN4;:>'8V;S]Z=[6ODO2.4J\K<.4+&77FDLR-J%V:-.N9<U]:DT[+,J['Y>AY
MRK4'\,G?H=Q4'W@ #+U;=TVN\^>G*QQ$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
MU4=X>PFR>OVZ1;A295XH6I=--_[!;HTS(SBZ%.6FO;!T\!#REAKD9+1;$@;'
M!2TF*"?Z5J0"'/+9%*::)(;=^BX3A49N*:K5 -G%,.GG(J<Y*WHRF=4=E8@,
M44E>H) )!(&G%YV19CW!T.H3#R+-A+<MF6RD LH(!(!(![1J>NA,Z$3MUVFK
MVXWZ3<W]'35:K':C16@[+BN4:ZPDQ-1?8'7D;>(Z3ASI'8TV)#%4!V1;CG%E
MQTPFWI7DE3%:R-Z(S8\-X>^*+JAEK99P[+S*]]U3JC85[4LKA:$+"X+N #*:
MSTU?74:C+RENV/R2JY=&.VU'5F6^L6 J38P!KUT.H.\:D;=-)$@_?#N++48>
M\@+Z\ #S/6;L!V. C7]>[ ,=BP^NMYS5)*KODIVJ,F3)OJ'@GV9-+4>U54+?
M;P%/.,(?)L?<CABVFEN_6*9^%@LPNI 8YU/,6P#O<[13HP*]3;X)UKU($7?V
M65WCO<:XU^0!LL.@HLY90GF=2_0ZZ+LZ@AM).X??JY&S[<$L+6\=*2/;+K+I
MB)KA69)R>7KC=FJ:)?;#,X&S8AB#9N-D;',"0\VP S"MA@L),AS'VGWG:C<'
MJ5"X-[*O#L_*=QMV<[%R;J47780$944LNXMN/1@.DG[_ 'W!=*P6RL6D*2=W
M+OJKL9B-VI8%RH.@&@ZC6167Y0GL54*/$;:M%7U59ZM<]?\ ;V:K-,K$!;H6
M>A)OK/;3(*+E)ZQFVZ?&E(2P"#NDST>% Q;\2,*LT:4=RIP=NR."X-ES8M=N
M17;5=PQ++;'J:MDSZ@[*B"I"KH>B,78,3H4'36(Y^0B"UTK9'3+9$565@<9]
MH+,7;4,-=P"#;IKJ>R7$ZB=CMA;0KVW2]SXHP[&L#( T>[U14%"QTE7INFL6
MJ0]W*A%[/VP55BZVI).6S)&SH;L=>+AYL6."RX4TGB^)8-..^,,7G$WAP:K-
M[,KI::UV6MCXPL%G0Z+7][<,A9M!+F)D66B[G; *BI#KM4%60,=RBRTJ5Z]2
MWA*00!U$U?Z:[Y;3H]QV=NJZ"[SL=5WIIW=^U=;Z_P!D5_8,+K6!MVLC[7?=
M75#4M@L<<BO%05MT4TS(V0JE)>03*PZCG&BW7!%KY_*X/CVU48E1PTLP\K$Q
M[[Z'I:]Z\CET9%F2E9WAZLO5:Q=U"MH"!K.+IS[*WMN?OAEOJOMKKM5Q6KU;
MK*UJ9@%*M2"6*#34:GJ1+'7OL=V+.#T:$%V*ZTR$C+=E] Q=FD]60MK&&$JF
MSJ+8K>%6-A116P9% <&J0@R\,/QMO23=8=(#APM<0/(1LS1IPL(',)PLY57
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M'E<C?F\@#:*=U_*V_!Y>NS3XM-)%MQ=_,VX_,UUYFE>_7S[M-VOQZSO15]>
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M9ZZI$C(].=+) @[6]?(8).:-@2(O!!I\D1<XP;&<,@6I^1E),]ZPBH:EW39
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M=S5WI;W/G^N<:Y,[_A;;WME-*1+,='R[LGM,#9>UB:& W%2V<1<DX79FHUA
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M.<\X7NDX+7W1]S_&^Y^Z]\:KC?"L_A5N14JO90F?C6XS6HCD*SUK8656(!(
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MW&-:]K&VES>-CW32=+L<!<[I(CFR"JZ#C6]H52):<G(:E1(;<2T.6VTQ-MQ
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M71@*+<=CTVJ6PS8/6ZX"PMDGX^#(?K0'9[5;)DNVY)OBC*&'4">XYC#_ *;
MT=)&8:R)'FO,(G?[L[/=:B],[<$$[#:-***UC?1QAA]M4%X@@AZJRS;+##+=
M@4XZ\\XI+;33:5+<6I*$)RK.,91/XS.03?'/]2$_'G/_ "#OM^KX?J,_O^SZ
MGQ^/$3\X#,5C&4B$JQ[?#.&'<XSG&?#./'"?J9\<>&/J_4\>(G](3^A<=UZ:
MUUY+H:N[!VWK*BV#]$+MT[,%<K[5:Q,X"*&J&!C,QDW+!&X%)RT[A@C+'HGL
MMN8;6KS%>")-'E1=ZZ1L>XZ$77MR:JG16-:CCO$PVPZA)CLOXM%C<RPZ\%,/
MMMO8;6AS+:E87A"T*\WS5)SFS00 VI Z^<>:)K,^%75WCA/PDT#SLXSG&/?E
M7/'.,9QC.<8]TO'.,9SC&<_4SG'C\?)M1YQ^41+@=#MTZ<A>TNM9*8VSK**C
MA_?1ZP?)WVJ AL>DJ4VTWETDJ6:8;\]UQ#://<3YRUI2GQ4K&,QVD&MM"/)Y
M?C$SY_MK\7^?XI].=*VWJG9+YXNNMFZ]OQ46RR1)C4JZ5NU/QS!*UMCOGLP4
MD>X&R^XVXVRX0EM#JVUI0I2DJQBI,20N(CB)5/5GTL-<?:'4/R>CN<K?X^[U
MMGTVE.KQ5?JT^B),>J?'WKRGC]DK<W^+X8+UX?O>'*.1XQ?48OZM3+%7O3ZR
M[ZUYZ-TZ[EMM:LNNN(/9E_TW+6V'5%@[-U<=%QM^J+V21R/=&MGS,5- "%.H
M84"0]D#): 2R_<TN,DO5)(2"22#>DG6RV]6-2S^MKM?(C:D_([2OU[=V8/'7
M4&T7(.XR+,G&N[!(O^P=HV29M57!RQ0PI@NZRWK-)JE0:7Z H<EK")<+B)\:
MGE0?[=7Y.G_I/:-^8'H#Q$V+Z(_Y/J7[?_K7W#Z_ZQIC_P#7V_\ 7X<\U>[6
M?_U%]P;_ )QO'Y<K@7MGI'W%_P"3KW=_^4*OU'C\I3W0_P#&'[;_ -$+=O\
MOJ_<]*SS=-K'4_\ LANO_P"Y-:_[_LG/-65_UI.&_P#AU;]=FSTAC?\ 5?XC
M_P")"?JF#-"VJO[/;R^OC_=3]?\ P_\ M[T\/W_B\,9]OU.>E9YOGTQ=4O[)
M'N5_Z[JW_M6;GF?W(/Y7?=V_^\<*^MXK/27NM_R2>X7_ /9^*_4\(GS)_P!#
MT?V)O6#_ *0_>/Y.]:N>F)YMGTT^3EEXJ!ZV6J9G)./AHB.V;:BI"5EC1HZ-
M &;@JGZ0@PXQUD45A'CCSWGW4-I\?TRL<\S?]%+^33/_ .;^+?J'!YZ6_P"E
M5_*1P_\ Y1X7_P#R7&I,N[>S%,@JC?8/7]V$(V4)J24V75"8H!4Y#O0K*7&Q
M9L.:P$=5I!K+S:_1CY,(R[C'CZ!:,XSGN'W2N,<0[G^X+NLXWPF\8W$N&<%S
M,O"R#75<*<BI-4<U7I92^T]=MB,I\H,Z?]S?A'#^/]WG<IP7BM'?7#>)\;PL
M/-QQ;;3SL>ZS;8G-H>NZLD=-U=BL/(1)0Z[VR?O>D=:7"T'8DK#8:N')2QV!
MA0\%&/+=PX[@8)D<5GQPE./,89:;QX>Q&.:>YAQKB7=%[G_<IQSB^0,KB?$^
M$TY6;D"JJD6WNSAGY5"5TIJ%'@UHJ_%-_=,X-P[N>[O>ZK@G",?O7AO#>+78
MV'CFVZ[DTHJ%4YM]EMUFA)\*RQV\YDS\^[GPT\9SA.,J5G"4IQG*E9SC&,8Q
MCQSG.<^S&,8]N<Y]F,<1.AK=KJ]RCLR]1LD#:8E)#HF9.NR\?-1^"F4MK>&R
M9&D$C8(:0ZTIQGTGI$)<;RI.,+3G*)RYJ;AZW%'3M@E(^$A8QA14E+2I; $<
M ,C.,+(,,*6T..RG*L84XZXA&,YQXYQX\1/U#S,188H"<@9,"9AI45HV,E8L
MM@Z.D WT^<R4&8,MQ@D=U.<*;=:<6A>/:E6<<1.RXB.(CB(XB13HCZ2.GON7
MT+\EHKEC+_C63_:+OK&D5'B*?55_062MRO)9&>W/H.8^WC5?YT:=RQC>-/J<
MCS?_ +>WS_\ OYNLBN\7_?J^M229RO)9A='0AR!D$+2E:%W'8Z5H6G"D*3G8
M-HPI*DYQG"L9QXXSC.,XS\6<<3 _S/Z3]OT3+%""K2M"QAU(<RC+B5,MJ2YE
MO&,-Y6G*<X7E&$IPC*L9RG"<83X8QCCVZ_C\_P"&9T'F^+\7FGM2TVA3BDMH
M2IW.,NJ2A*5.92G",9<SC&,KSA.,)QE7CG"<83CV8\.(GI4$&M.$+$&6C"4)
MPA3#2DX2WG.6TX3E&<82C*LY1CP\$YSG*<8\<\?[?X=GY-3I^&/M_G^GK/<A
MM#?G8;0A&%*4M6$)PGSEJSXJ6KS<8\5*S[5*SXYSGVYSGCS?%T'Q#S")Q9*0
M$B(X^5/>0.!&!%2!I#BL)0P($PX20\M2LX2E+;+:UJSG.,8PG.<YQCD&3D4X
M>-D9>0ZU8^+1;D7V,0%KIHK:RUV)T 5$5F))  '6:NRHK.QT5%9F)[ J@DD_
M@ )FK"/?+,%]T)#&4R$N0;.R"5?JDR,Z:1,'H5G./'.4%G/XSX^&<YQGQ]OL
MYY<PVNMQUR,A2N3FV7\0RE)U*Y7$;[<[)4G0:E;\BP$Z#7372?$AF<%G]^Y:
MQM= =]A-C#7KV,S=-?\ '03*Z+)X=V/UM@UJQAR$WWMAYAOQ_39 GNN%[F$/
M^;X^.4.2I$RRE6,83YPSB?'*DJSSM[W,,K=PSC'#R0&P.-7/6FO4X_$<7%SA
M;I\%\VW/0'0 M4XZE23]#P=]:+4/:E[%?ZMB5V:_$.8;%^/;\1FS'G9DY>.(
MCB(XB.(CB)A=6_KYLC[= ?S=T+B)FG$1Q$<1,6-H]+DK$W;Y&I5H^U,PJZVU
M9#8.-*G6Z\X>B47!HE7QG#DQ*I)"#U1Z7\"9,3@GT7IL>?Q$Y?O6K'R<@?O1
M'_-^(GA57K"4Y5[W(+]+C.?ZT1_Q8Q]3^I^([)&],I%;B*U'"4G7E B*RM1T
MC' 9;4TII<Q)%RY[JT8A2L(<+D3C#'4I?<3ATA7F9PCP3A,=?B\O^WX?C[)D
M_O;>]OC3=?Y^M[%_O_\ %W][]_V>U'7IV?'_ +>W_#KT>]M_'Q4[7_\ ]E?U
M_M=_OY_O_P"/B.OF'Y?B_!^ ?@_).F51JDNW5V?GJ%2<6(2+L==@)@$1)10,
M9.KA):? PE^+#:2-)D56">?SYKKF78P;S,H3Z3ST=?Q?X_[_ .'XYG?O6K'R
M<@?;\?\ P1'^W_[OQ,SG!1$3&J<7'1D='K=3A+J@@AA5.)3G.4I<4PTWE:4Y
MSG.,*SG&,YSG'MSQ$[#B(XB53U9]+#7'VAU#\GH[G*7G[_=V^-L\A/\ /;R@
M:2G5XJOU:?1$F+5'T+RGC]DK<WYX+UX?O<I9'C%]1B_JU,L5>]/K+OK7DE<@
MDDA_L#M96C-(;7W&F S:5:SH=ENB:_[I9AF954!&$'I&.FL 2N82,SEG"Y::
MQ%2>8B-07(XCCLC>JNHE&H+RE(<[8^H=<"U6/(F=EZS89NP#0.P6IF5I\A"0
MS$N/%4:*:JC#FSDR$>4!;DE'/:_>9UI-5^\H!(9EV8U")I:[P:*[3[T\I9T\
M[,Z]ZC=BCM4::[OU?>-ZDI&H0<5*A:_B]3=3:D6<##%VI)DF>B9U+<VDQH:5
MDK9$$>QCS3F,91+0Z!F]DFP^AYN+ZV=C9>)UOV8V;-6DZ.U\"\R*U6+'4:+8
M0Q\+L;2RY"'M>N+=#&#,HSX$QGGLN/#D,/+Z7]TSN)X_W3]V/N5<9X3319@]
MRG=%9Q'C-EN370].*V1PJP-56YWY#%,6[P*@6U4 CPAKW-[FW=KP'N9[C_=4
MX-Q6W(KSNZON=3AW!TJQK+J[<I<7BU16ZQ/!H4/ET:/9HO4G713I7KM5KCL/
M:O*RW3O%']5>Q W7</R<EUT>=9Y*F0P<J%>\DW"6<:(KN;0N53$,QYXY#TNA
ME8R$X<3[5MY3SNB=,R^?6ZY;#KNQ]);-,ZR=F":=%=<HZJ/2<?K<(I3\F>;*
M2X:PQL69#[X1 $F&^@K"$H\',ISC"DJQCI:_N)X_9[N>%W=K1CGN=I[CGX/9
M?WS6,@9S6Y3"OO746E-MJ'F@%.I'0B=R4=VG D]P_,[A6NR!W07=V2\:2GO>
MPXYP!CXE9<Y/BA9NJ<<L^%TU[")J7BM+]E=6]FO*K[QO?5G?D!KGM]V5Z[R6
MD)A^J0K[\W@VVW>D184M'BV9\N D9:U[,IL)&C2+3>'BY7"EK:''(>;[IG3<
MWG:'V3>Z!N7L9=+'U>[2,P6R9.")JSPVL BB'V0%3>2,EC-V?T@>4X.'\U+O
MM7YRO#]3GG2GN>=Q/'^YWW0O=3[H>*445\,[JN(X.3P>VK*JNLNJQ[,YK#=2
MA+T$"^LA; "=3Y09W-[H'=KP'NA]S_W+NY[AEV19Q/N5X=GXW&*[<:RFJJV^
MOAZU"FY_ O!./;J4Z+H-??":*/)1:9[)]'M-]8=/]B>K>^ZM?W>ZVX-A1T-%
MU2&L29B DZ%K*R,-Q9D397Q'Y1J!U->I4F/<=9<8%B,9RK+I0S3G=?V^W^?^
M<Z9E_ML5C?5L\EAW!ZI0O5#LH_N'<=7V%%T>+=HD0/#F&6*&K848V=//6G ,
M<EQ^,+2ZX0K"&4I0I><87CPZ4]P7N([H.X'N*RN"=TE%&/GV]T/$.(I7CY-6
M77WKD8G#JJF-M)*!B^/;JFNX  GH1.Z?=W[MN =WO=EB<:[G;LB_ I[G\'AS
MODXUF+8,FC-XE=8HKM 8J*\FHAQX))('53(%ZI5_=6JM3:5ZZW#K+V$$V[0/
M)TPFM[+50Z3&'K%GL2\K"X*9.'LB@"H5<JTX"B49)4UEYM>?,PWC"\_;>Z-P
M3/[I.X7NJX#PM*[>(\5X/EX6'7;:E-;WW+M0/:Y"5J3VLQT$^(]SSC6!W.=W
M'<MQWBCV5\/X5QG#S<QZJVNL2BFP-8R5)X5C =BKU/DF7^4_@.\>[_)G:AZ\
M]0]"=P*EV$J&R=<S%A,KH^-7+34H*#O0EA#:N0%YB\ECN'3$&I<8DK+9JFTO
M9:7D3&4:>YKP+B/<SW!]RW .+5UU<2X5PJG$S*ZK4OK2Y&<L$M0E+% 8>$I(
M,D]T?CG#^Z7NY[I^/<*>RSAW%.*796(]U34V-2ZH%+U/X2$E3X+=1Y9-4[LO
M=UXF^W<5K/2?:M=A:WO2AGF8NKNQ)M>\VI'WU^%DGTVL;U @JI;,H,ZD-AUU
MA\66&2I?K(C[+'S?NU=S7==W5=QJ<+[BK[<?C(XQ@Y1LJXD>%-WG35EK>IRE
MMJ)4M95K5N(?0'0[>GTGN,=TG<EW*]V#\4[L\>K)X.>$9N,*K>&IQ5>_+;L1
MJ6[U>NT A*[@+=NJ D C=H>'WYENZ&X>Z_DRMH]?=(=RX;1>B=AW29[2Q  C
MU*C[#6I0K7[D(/*T]B]!L;$9:9AK%A$>4(>D1+[J,-IP<K#G;* BM%8ZL$4,
M3UU(4 DGR]?RSJ=R"[E>BEF*C33H22.GDZ>2>>M5RVVW"=>YJ Z^=FS*O2-S
M;0.NS\'2F< $#Q4Y7:C(B>KILXWNJ1&6&EVB*)&4RXEM\)>6\K9(:=7U!W?]
MRG=5QSNZ]S'C/!'*\&[G>)YF1W1*.(=ZA\:VWASU XN]>_=%HO\  VOMUTT\
M.=N=P/=5W+<$[B/=,X/QNL/Q?NAX7B8_<\QP.^MF353Q)+",G8W>?AY%'WS<
MN[377P.D3=EK1WEDO* ]@-ZD:L[D ] GNB4U5F*A*I?9I$;MZ(-BYN5M!.I\
M79X,,H2 C)9YVVHAU$992XPEY:G\(5W%.H9>[J]?=RP6T-/F3.B.T8&M6M$U
M.BOX)J./>J%;27HY.9DF,1:EC,Q[ RU$DSJ0E+;$2ZO]-^H5U(G<[W8#W9+N
MZ9LF[_X*;N47AU>+]TW-(XOSJF-@X3S-H;:K:Y/*!\F[J9VP_='W)'W':NYD
M8M([LU[K/NB^5]S*Q>>$<FY>6>+<OF%-[)_!N;IV';TFZ7G;<ZGCB(XB.(D4
MZ(^DCI[[E]"_):*Y8R_XUD_VB[ZQI%1XBGU5?T%DK<KR61GMSZ#F/MXU7^=&
MG<L8WC3UT^\Y'ZO;T_'V2*[Q?]^KZU))G*\ED:TV>CQ(J1'>3)Y<;N>Q,*RS
M!S936<YV#9\X\Q\:/>8<Q[?;EMQ>,9\<9SC.,XQ4LSJ*W9&7*+*="4P<VQ=?
M_ILKQW1A\:L1\<CYBC4:6="1TJM([3V$)H1\8U![03VG*_?-%_\ ,E_P<L/^
MR^:?=''^#F?^7<1_=8YJ^:SYFW_1'OFB_P#F2_X.6'_9?'W1Q_@YG_EW$?W6
M.:OFL^9M_P!$>^6+_P"9+_@[8?\ 9?'W1Q_@YG_EW$?W6.:OFL^9M_T3\+M$
M6C'CZ&<<S[?TK-7LSR\^&,Y_4-1"U8^+PQG.,)\<XQX^.<8SJW$\91J:\]OB
M3A?$W;LU[$Q&/XSH-=!KU$P;5 UTM_%3<3_@D@C;AM_O48[4JQ2Y\:MFJ:]W
MI60:8#)FPT^:[F&"CW'_ %L:/)=PEN6(D4#/DC-O1S(*QC5FM_!=UUO=!Q_&
M;A'#>"YU/"KBIXAEY*U4W9]*D-WC1C-9S:L:Y@%S+,I:K+*D?%3':K(:].-S
MFRLA#13CV"IM.8[@*;%[>6JZ[@I.@L+[2R@H%VL6$%XU3L3&<9]ZDEGV^/\
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MI56R2=4L6UI,.5E*['1\  [)9=L2X/6?R@5+W]2M*628U_<Z(?O.QV2HU$@
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MQX8QC&G;]C&,8Q[,8QCXL<^2K\7=_47ZU)Z*S.N;PK7_ /<Y/ZAE399T]MK
M$G>-<&/Y0Y)%-7^MH=5X(=;=# @K1'!XS[,>H%Q\3,O-X\%.NV,I]&%8:(4C
MG.YG(6NW,P6;0VL,W'!/0ZHE.36@\G+:NJYATW-D.P!T8CJCW;N#6Y.)W/\
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MZ,9+ RVA:TDJ2A><<IQ'N=XYPFNNWB/#,O%JMJ2Y+7KW5BNPA4+V5ETJ9F(
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MBXZO16%W"R$GS$>EL^P)]!)%9PJ(P@<%K5N$8.W05%1H0=A +#=N .H.NA
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M^7\<@KI9G9":]MQ&R]F5+9<DYN:Y&1)=1CV8P6+B#"4JPT\*V (XE$B>V=)
MY>?DE8"?:0D]["/9SG=G]SN^.$GAO#<OAM8X/AI<F78UCVVHIZAC8X)JK*5/
MHM?AJ24&LKX'-VWBVU+3S["I0  *3V= -=3JP)+=#VF71Y\;+T<1'$1Q$<1(
MIT1])'3WW+Z%^2T5RQE_QO*_M%WUC2*CQ%/JJ_H+)6Y7DLC/;GT',?;QJO\
M.C3N3XWC3ZK(_5[?L?BD5WB_[]7UJ23.026.(CB(XB.(CB(XB.(CB(XB.(CB
M(XB.(CB(XB.(CB(XB?S\/Z,D_LE^FWUO@,O'Y?8_>^+QS^WRTW\2I_M65]3B
M30>,;^HGZ;)\<<?G^KP<>&/_ *:-\7C[/Z>CZOCG'M_]W[6.:8O\9Q_7T_6+
M,O[QOZK?H,_K[]Y*M<;"7U%+DJCN#8G6.$N=O)[*T'1Z[F5;YH8S44\#J21F
MZQKF3C+W=J%!;!='>G:U7LR?F3I53L<K#%1%>-+ B?W[?UF_29E>P?@'Z)5M
M&PO*!U2WZ1J>JM8=A:1K@>G]9QZ=K;9D#7-V^ZE3L%JN ?9PGLYV)E9:UV:K
M;3U%KP2M3&MHL>ZBOV>=5%Q9@NQ39B<BZOK,R'JD=Y4RTM=2S=V6KL7ZG'[+
M\G[N#;#U,T_4*G)1SFSM.]A >QFIK1 5:C83/ZXUSM*%T\FU1\G&GRU+7<RK
M#.2@[,77Y*KHG:U/97EAH*D]<C[01M"X[!O>I-7[!/@5]?-9@5DG>-FVK#0.
MT-#;Z.BZ[%G:9UMKW2XR[I#7/!=4GYBZ3EIS[[9?$#6M:E(FTKR=%<V74NFV
MGJ_N".MD3L6/SL/WQ1]X]T/?0/ZWM6\'1'NI[JK</_IT$3&/A>G6K_@YT3T7
M@SZ/&$2[7$1Q$<1'$2J>K/I8:X^T.H?D]'<Y2\#GW=!XVSR#X;2I7XNO^HOT
M1)CU3]"\I]TG<WYX+U_/]KE+(\8OJ,7]6ID]7O3ZR[ZUY)/())(=[ :ESO;3
M=_U$FWSE"S>X5,-FXUK",S\ GUX0M9T1EQYAM!V$"J:8<<7EMI3OI'&GT(4P
MXB<'K_H6K=<J&YKRGSEIGH5<](3[9%M>KSQXI$D."P0&+BLURKQC4>E8."FV
MO<U1&2BC'727<.H0TB3AQ$J;V9^CSI=^ZR'_ -6_L=S!_P Q^G['\/Q1)BW5
MM>O:+U/?]P6P>0+K6NJU(6F;&B4#.23T=&MX<(0$V60(,M_*,^*$O$LH5G'A
ME>,^'CR7".&7<9XGA<+QWJKOSKTQZGN++4COKHUA178*-.I"L?BE?+RJ<+&O
MR\AMM./6UMK=.B(-3IJ1J?,->IZ#K*YT+O!6]OZS@MCZ;TMOO9#5@#"*$C0J
M"Y6@1_76TN>>]<;F=7Z?*A!^=C!QE/F+5E&<*0(.8XG+?.?S>X^_A?$;L#BG
M&.!87(9PUS9XR"P0Z>#C8B7Y5;OVHF33CGRN4'6<;1QNG,HKOX?BYF:MBJRE
M*>34 PUU.1D&JEP.QN2UK#J-NH(G.7;NR-R6]B8JEQUC#.HPEN+U?!42RV].
M<>&?29V%M6RQ5>:0\G.4NA-:AP0,KQR//+SA+O(QA<"Q0IKS<'.M!ZV<0OSJ
M<8_%WEPW%MO.A['/$M&'OJ1-C]U+R>8W>=9'O,1*KKQY_P"%99%77X(P===
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M/9\];_KCX,*W^R>P_P ;NV/XZ\=\6?!H_-<;]C'*7SV?/6_ZX^#"M_LGL/\
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6(XB.(CB(XB.(CB(XB.(CB(XB.(G_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
